<SEC-DOCUMENT>0000896262-21-000104.txt : 20210805
<SEC-HEADER>0000896262-21-000104.hdr.sgml : 20210805
<ACCEPTANCE-DATETIME>20210805080126
ACCESSION NUMBER:		0000896262-21-000104
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		61
CONFORMED PERIOD OF REPORT:	20210630
FILED AS OF DATE:		20210805
DATE AS OF CHANGE:		20210805

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			AMEDISYS INC
		CENTRAL INDEX KEY:			0000896262
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-HOME HEALTH CARE SERVICES [8082]
		IRS NUMBER:				113131700
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-24260
		FILM NUMBER:		211146399

	BUSINESS ADDRESS:	
		STREET 1:		3854 AMERICAN WAY
		STREET 2:		SUITE A
		CITY:			BATON ROUGE
		STATE:			LA
		ZIP:			70816
		BUSINESS PHONE:		2252922031

	MAIL ADDRESS:	
		STREET 1:		3854 AMERICAN WAY
		STREET 2:		SUITE A
		CITY:			BATON ROUGE
		STATE:			LA
		ZIP:			70816

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ANALYTICAL NURSING MANAGEMENT CORP
		DATE OF NAME CHANGE:	19940819

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	M&N CAPITAL CORP
		DATE OF NAME CHANGE:	19930125
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>amed-20210630.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2021 Workiva--><!--r:9b598574-bbed-4d17-bc5e-2b8ec86d1c16,g:311e4854-6196-49e6-97c5-f444b0264a32,d:ccd9c69ecd2c42e5897cfe9ab4e7e0b5--><html xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31" xmlns="http://www.w3.org/1999/xhtml" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:amed="http://www.amedisys.com/20210630" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>amed-20210630</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630" format="ixt:booleanfalse" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV80L2ZyYWc6N2M4Y2M4NWJmM2E3NDA3ODljNWMzYzQ3ZjcxZTE1OWYvdGFibGU6NmYzMjVhNmU3YTg5NGRkNDk2ZjZkOThkNDYwYjRiYzgvdGFibGVyYW5nZTo2ZjMyNWE2ZTdhODk0ZGQ0OTZmNmQ5OGQ0NjBiNGJjOF80LTEtMS0xLTA_5f442d1e-eb01-44eb-ae22-3d97454ba6d0">FALSE</ix:nonNumeric><ix:nonNumeric contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV80L2ZyYWc6N2M4Y2M4NWJmM2E3NDA3ODljNWMzYzQ3ZjcxZTE1OWYvdGFibGU6NmYzMjVhNmU3YTg5NGRkNDk2ZjZkOThkNDYwYjRiYzgvdGFibGVyYW5nZTo2ZjMyNWE2ZTdhODk0ZGQ0OTZmNmQ5OGQ0NjBiNGJjOF82LTEtMS0xLTA_52646e75-5b4e-421f-a8ab-0be4ce6597b8">2021</ix:nonNumeric><ix:nonNumeric contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV80L2ZyYWc6N2M4Y2M4NWJmM2E3NDA3ODljNWMzYzQ3ZjcxZTE1OWYvdGFibGU6NmYzMjVhNmU3YTg5NGRkNDk2ZjZkOThkNDYwYjRiYzgvdGFibGVyYW5nZTo2ZjMyNWE2ZTdhODk0ZGQ0OTZmNmQ5OGQ0NjBiNGJjOF83LTEtMS0xLTA_6068327d-1b75-4a83-8ba1-5a1d722d75a6">Q2</ix:nonNumeric><ix:nonNumeric contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV80L2ZyYWc6N2M4Y2M4NWJmM2E3NDA3ODljNWMzYzQ3ZjcxZTE1OWYvdGFibGU6NmYzMjVhNmU3YTg5NGRkNDk2ZjZkOThkNDYwYjRiYzgvdGFibGVyYW5nZTo2ZjMyNWE2ZTdhODk0ZGQ0OTZmNmQ5OGQ0NjBiNGJjOF85LTEtMS0xLTA_573e8149-a4fa-4b56-8183-20421bf77cd8">AMEDISYS INC</ix:nonNumeric><ix:nonNumeric contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV80L2ZyYWc6N2M4Y2M4NWJmM2E3NDA3ODljNWMzYzQ3ZjcxZTE1OWYvdGFibGU6NmYzMjVhNmU3YTg5NGRkNDk2ZjZkOThkNDYwYjRiYzgvdGFibGVyYW5nZTo2ZjMyNWE2ZTdhODk0ZGQ0OTZmNmQ5OGQ0NjBiNGJjOF8xMC0xLTEtMS0w_c75f1c75-a0a2-414a-bf13-736fe8ace4f6">0000896262</ix:nonNumeric><ix:nonNumeric contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630" name="dei:CurrentFiscalYearEndDate" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV80L2ZyYWc6N2M4Y2M4NWJmM2E3NDA3ODljNWMzYzQ3ZjcxZTE1OWYvdGFibGU6NmYzMjVhNmU3YTg5NGRkNDk2ZjZkOThkNDYwYjRiYzgvdGFibGVyYW5nZTo2ZjMyNWE2ZTdhODk0ZGQ0OTZmNmQ5OGQ0NjBiNGJjOF8xMS0xLTEtMS0w_54c21015-e543-4528-a91e-4b05c0f0beb6">--12-31</ix:nonNumeric><ix:nonFraction unitRef="usd" contextRef="i47cb3be3d5564293b84a6274e71f0a2c_D20200401-20200630" decimals="-5" name="us-gaap:GainLossOnInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV80MC9mcmFnOjFjYzZhMTg2ZGVmMjQzZDg4ZTU2OTg1YzViMzM3OWEwL3RhYmxlOmJiNTZhMTZhNjJiNzQ5NWU4NTg5NjFmYjc1MGUyMGE3L3RhYmxlcmFuZ2U6YmI1NmExNmE2MmI3NDk1ZTg1ODk2MWZiNzUwZTIwYTdfNC0xLTEtMS0xNDE0_1cc13b15-7692-494a-821d-24dd547dcfdf">3.0</ix:nonFraction><ix:nonFraction unitRef="usd" contextRef="i87ceb60dc20d4df1b0a97d3514837910_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV80Ni9mcmFnOjdjZDcwOWVjYjkzOTQ3ZWI5YzA1ZTUyMjU5OGJmMzgxL3RhYmxlOmEwZGFhMjU1NjY4MDRmZThiZDcxYWMwNjE0NWFlZjg3L3RhYmxlcmFuZ2U6YTBkYWEyNTU2NjgwNGZlOGJkNzFhYzA2MTQ1YWVmODdfMy0xLTEtMS0w_19144da3-41aa-45d6-8598-e3e92ce10d52">83,357</ix:nonFraction><ix:nonFraction unitRef="usd" contextRef="ie2776ede445a47be9f24c8e19df8e41a_D20210101-20210630" decimals="-5" sign="-" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV81NS9mcmFnOjkzMzc2ZDZkZTZhZTQ0OTM5Y2I4ZDg0ZWUzM2YxNGQwL3RhYmxlOmFlMGY1OTFhZGVkZDRlZmFiNjMyNGU2ODMxNzg0OGY5L3RhYmxlcmFuZ2U6YWUwZjU5MWFkZWRkNGVmYWI2MzI0ZTY4MzE3ODQ4ZjlfMi0xLTEtMS0w_763eaa52-c8b2-4ac8-ae0f-689ca371dd9f">0.1</ix:nonFraction><ix:nonFraction unitRef="usd" contextRef="id8f72c421ee54ba2a739418940dde57c_D20200401-20200630" decimals="-5" sign="-" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV81NS9mcmFnOjkzMzc2ZDZkZTZhZTQ0OTM5Y2I4ZDg0ZWUzM2YxNGQwL3RhYmxlOmFlMGY1OTFhZGVkZDRlZmFiNjMyNGU2ODMxNzg0OGY5L3RhYmxlcmFuZ2U6YWUwZjU5MWFkZWRkNGVmYWI2MzI0ZTY4MzE3ODQ4ZjlfMi0yLTEtMS0yOTQ4_5e7b9738-69d7-4dcd-aac8-97aff95ff328">3.0</ix:nonFraction><ix:nonFraction unitRef="usd" contextRef="i93266b4b1d884fad8c5cb4456e2def79_D20200101-20200630" decimals="-5" sign="-" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV81NS9mcmFnOjkzMzc2ZDZkZTZhZTQ0OTM5Y2I4ZDg0ZWUzM2YxNGQwL3RhYmxlOmFlMGY1OTFhZGVkZDRlZmFiNjMyNGU2ODMxNzg0OGY5L3RhYmxlcmFuZ2U6YWUwZjU5MWFkZWRkNGVmYWI2MzI0ZTY4MzE3ODQ4ZjlfMi0zLTEtMS0yOTQ4_05062f13-6686-42db-9847-b914ebeabea2">3.0</ix:nonFraction><ix:nonNumeric contextRef="ia2de44b83d484d54a6dcb3b8f754c999_D20190204-20190204" name="us-gaap:DebtInstrumentDescriptionOfVariableRateBasis" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV82MS9mcmFnOjRlOTFjMTdjOGQxYjQxNTg5ZGQzZjdmNTg2ZTQ2MjkzL3RleHRyZWdpb246NGU5MWMxN2M4ZDFiNDE1ODlkZDNmN2Y1ODZlNDYyOTNfODEx_eb308438-7b3e-41e0-9cee-a71bd28e9d3b">Fluctuating rate per annum equal to the highest of (a)&#160;the federal funds rate plus 0.50% per annum, (b)&#160;the prime rate of interest established by the Administrative Agent, and (c)&#160;the Eurodollar Rate for an interest period of one month plus 1% per annum.</ix:nonNumeric><ix:nonNumeric contextRef="i8f72f99e864d4c5192c1e32828587ac2_D20190204-20190204" name="us-gaap:DebtInstrumentDescriptionOfVariableRateBasis" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV82MS9mcmFnOjRlOTFjMTdjOGQxYjQxNTg5ZGQzZjdmNTg2ZTQ2MjkzL3RleHRyZWdpb246NGU5MWMxN2M4ZDFiNDE1ODlkZDNmN2Y1ODZlNDYyOTNfODEy_9d889f6e-a855-45f1-8b1e-b33db838a91f">Rate at which Eurodollar deposits in the London interbank market for an interest period of one, two, three or six months</ix:nonNumeric><ix:nonFraction unitRef="usd" contextRef="i2c8351954d014a1c80a3d8cfc2327ab2_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV83My9mcmFnOmFlZTE3NzNjM2Y4OTQ3NWI4ZDk4ZmIwM2FhOWY4ZDNmL3RhYmxlOjcxZmJkYWZmMDlmZTRmOGJhMzQ5MGIwNmVjNDM4MDQyL3RhYmxlcmFuZ2U6NzFmYmRhZmYwOWZlNGY4YmEzNDkwYjA2ZWM0MzgwNDJfMi0yLTEtMS0yOTky_135700a7-2230-48bb-9fc2-f2e9bfe47cd6">485,059</ix:nonFraction><ix:nonFraction unitRef="usd" contextRef="i2c8351954d014a1c80a3d8cfc2327ab2_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV83My9mcmFnOmFlZTE3NzNjM2Y4OTQ3NWI4ZDk4ZmIwM2FhOWY4ZDNmL3RhYmxlOjcxZmJkYWZmMDlmZTRmOGJhMzQ5MGIwNmVjNDM4MDQyL3RhYmxlcmFuZ2U6NzFmYmRhZmYwOWZlNGY4YmEzNDkwYjA2ZWM0MzgwNDJfMy0yLTEtMS0yOTk2_325745d9-68dd-4f85-b88f-156515892796">295,228</ix:nonFraction><ix:nonFraction unitRef="usd" contextRef="ib87cee58ccf2448a8d4422101bf61fa0_D20210401-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostsAndExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV83My9mcmFnOmFlZTE3NzNjM2Y4OTQ3NWI4ZDk4ZmIwM2FhOWY4ZDNmL3RhYmxlOjcxZmJkYWZmMDlmZTRmOGJhMzQ5MGIwNmVjNDM4MDQyL3RhYmxlcmFuZ2U6NzFmYmRhZmYwOWZlNGY4YmEzNDkwYjA2ZWM0MzgwNDJfNC0xLTEtMS0zMDAz_fe690f40-00ed-4c6e-bc4f-ac7941d65040">490,634</ix:nonFraction></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="amed-20210630.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="ifed7a9d7833f4709ab4d734d7c419fe7_I20210730"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-07-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="i1e833203be6947b4968aba4d20064ec8_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i87ceb60dc20d4df1b0a97d3514837910_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="ib87cee58ccf2448a8d4422101bf61fa0_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2c8351954d014a1c80a3d8cfc2327ab2_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i667fa0996400408f9cb2d7f4d3ee2087_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieb79ce9f481b42d1ab430d3f3d11be5a_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6a51d0190d2c46638e83e1dd687ec01c_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i505af52860ef4f88b5ff9bd288e4b861_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i74fd298667c64003ab51d64eb7694f4f_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idebaf491ed4a4eaa830b4edf82a260af_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2abc69b9d9f54af3a54fc8752ccb2ab0_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1f49d2d5c447470d8ad1b0c00a898651_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia839bd0c1e7440a2be8dd89d587ab038_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i873536f8b14a43938a68d5f9d661e909_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iee63e04ff2174c9686bcc42c3eb46125_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib467ac52451749bfb8cdba39aa1441a7_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6d9970853b6d41799b9af78b866c694b_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3e59fd3d3cfb4bb7ae9ea1d3af94e290_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id0e0b2cc08e747cba20ceed2b5382012_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i01768f8d7ebc4cc18d5eb154976ba4d3_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1302a68dd8ef42e6ab76db142d77aae4_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i90abbd77ace44a6bac4330406a6d4810_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie40ed45ce02a463b81cddfc774673775_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7e0bc5dd338e4f46a448f49e5796b04c_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i50eeb2e1fb1c44a38c21b210240eb586_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i293e823d67b246d381d9224a4d88ecb8_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie0f0ea8548294921ad4f0b1603762e12_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i259a6cf078e54dd1a1db53e0ddaaf3ee_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if8b5cc2263e34d7d829e9025bfd31619_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i74c16b1d1e794dca817c0cabfec5d055_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idfe2bc4b48cf420480bdcedd1afce6c9_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1667f8e90077426897db77b94e7b94d2_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7b84646fd5a5457ea3426c3891522efe_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i513740b0a9e54ee1a6565acc0bdf79f2_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idb32f2bfc5474a4199e7c84d1720275e_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i15586f038620443192b7c904beb4ad54_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6271c5457d114e698b9aa02424c6fba7_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7f5f7a1bdc904b23a1b3496bf1c343ed_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic2e9db201a8c41efacbe6c14b48f08c5_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie2958a3a3c7d4e89970b11fea75ea413_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1f8cee8ab0a8499bb9039cd2b585f4be_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0520e88179174d4c983746db6664ff87_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2f9b5ede983b458f9d589f077a9b9885_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i00022a1a9b074ad09a7448259eb40d7b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3904353da8ce4531bf4ac08cd4d11033_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ida4c2a7ffda04385afb5f441d707b3cc_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i656ece5c7f7e4dff8816621dc7e0455f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic4cd949100864281ac1cb035f36fe501_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4c81959cee2f417b9189bc4e6ad7f42d_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3a5e5c59232b4c58b6e84716db6d8973_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7299a7a0217a4939aebcf1747818528d_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i87f87ab13a114dee919b9d2827a73fab_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5ac6fbdda808429998d8987cf9923712_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifa673cc4c9af455b97f34a55548dfc84_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i34b209949049477791ec23971ce9e445_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia9b5755043594e6fac0445e663b73395_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i441145d29ff346a58266e6fa5735a383_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie9c9163b115847718a0e04afa87d792f_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2f812fe62e9048c1b51562c9b05a841c_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2fef7471e4c74e2cac75b17f8e455e63_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia6768b0ddf76411381a296ae9d695ae6_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i846085ebf1cf4817ac0dd1e9245c242a_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib8af587d580b4f4e9cdf536e3b9b31e6_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i917af374eb6a409ebea5c8abe45a5a8e_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i105f613dfc9b4ea7afdeaf6f08277f25_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i08ad12ef46cf4d2da58b68346a440ca1_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="i85ce6ba1e58b4b7c883aa1e71fb67e40_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amed:MedicareRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib0181bc176d24054b0b4382b5f3a2ef9_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amed:MedicareRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if78f143ce2814015b9ecc0469dc639f1_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amed:MedicareRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9d0cb72c37b145799e408add964d0544_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amed:MedicareRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="care_center"><xbrli:measure>amed:care_center</xbrli:measure></xbrli:unit><xbrli:context id="i30a2e3b95ac74ea890c5478c6d00aa9d_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3e0c07dff3444ff8bdeaaddc51231dfe_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7e884a08e6374bbb9ca4c0909fb43265_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:PersonalCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="state"><xbrli:measure>amed:state</xbrli:measure></xbrli:unit><xbrli:context id="i56460531924447ac8bc770856f36964a_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="amed:TypeofEquityMethodInvestmentAxis">amed:MedalogixMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i47cb3be3d5564293b84a6274e71f0a2c_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="amed:TypeofEquityMethodInvestmentAxis">amed:HeritageHealthcareInnovationFundLPMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i819d1cc0f63448c9bae946092e2d9634_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:HomeHealthMedicareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iab0c4aa1f54048f9bb07ee49f6bb395e_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:HomeHealthMedicareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i72044b2a44e74c5591b023a1c6e1f437_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:HomeHealthMedicareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iec44149de0804e90a0d618b5aab11df1_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:HomeHealthMedicareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iba4b4085e2a44ace9b534d8db3a5cb18_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:HomeHealthNonMedicareEpisodicBasedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i62976d7f48f547f690d30bf5ecdc0c9d_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:HomeHealthNonMedicareEpisodicBasedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2b90bd098db34908919842c129b2c275_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:HomeHealthNonMedicareEpisodicBasedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i986914649c744434996e298aed0a55de_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:HomeHealthNonMedicareEpisodicBasedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id3dfc4a215e346f2b62f7a0031e7a1c0_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:HomeHealthNonMedicareNonEpisodicBasedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1889f1856fd04eb9a83ad415f13bb6e1_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:HomeHealthNonMedicareNonEpisodicBasedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i07bd2c944cf046a189fd4eb6529755d6_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:HomeHealthNonMedicareNonEpisodicBasedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i584d1976fa4740918795b29a298c07f8_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:HomeHealthNonMedicareNonEpisodicBasedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i82e2454c5eed4b28ab058238918f809e_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:HospiceMedicareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i617f99e1213a4f2094c8432f4837db94_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:HospiceMedicareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7a48258931a748a99b37e6058a5916e4_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:HospiceMedicareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iff8b2cf9576146db8b00ff2d1d72091f_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:HospiceMedicareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i575fb5ffd81f408fb483b5911db2264f_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:HospiceNonMedicareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i79540dc5db374f3e8dad988e2d746e13_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:HospiceNonMedicareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i83c28c34df424dba99ce508660059376_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:HospiceNonMedicareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib14de18b4a2d452c831ee77de19f382d_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:HospiceNonMedicareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9459b4ff31494b3a8001d1ad78d69359_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:PersonalCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4720759f4b1249fc9f52ebf7d06b0d2c_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:PersonalCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i913d274664fd48a49b9a53ffbeeb81bd_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:PersonalCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2cd2a132976345f995477e91bea1b7a4_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:PersonalCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="visit"><xbrli:measure>amed:visit</xbrli:measure></xbrli:unit><xbrli:context id="i90c63ef3c03b4a79b0e16bebccfb5aaa_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iea406e6210c24d67b95bd8bba7ed6315_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1e89d4343fef486490e1fcdab10c1010_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id4b15251aa8147bcb0b8c78424ea981c_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i741b04b8cd704e398b27520bf8aea7fc_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i35e97441f2084fc28b554985218499ab_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="amed:CapYearAxis">amed:CapYearTwoThousandSixteenThroughTwoThousandTwentyOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7dc0b5d0b4c04b6ebdca7598a9e533de_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="amed:CapYearAxis">amed:CapYearTwoThousandSixteenThroughTwoThousandTwentyOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:AseraCareHospiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4f2f1eaba6994474b883c637fd8bdd09_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="amed:CapYearAxis">amed:CapYearTwoThousandFourteenThroughTwoThousandTwentyOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iab3b21e1071d46c3a8d7f08560252318_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:AsanaHospiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia1dcbe4b6aa344ddad5971d791de6929_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idd69fb45b72f455583eebe90df674886_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9c7cadad474d42da9b01844212441bf3_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0c4514a4ad16425f82d85ae99b3a59c1_I20200327"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-03-27</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iac8bb77409a847a08a3de53000ce0e86_D20200401-20200430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5e57d112c8b243c6ad6311b3c05c5d43_D20200401-20200430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquityMethodInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id175698a0fde4ea494dd3ebf050a22e3_D20200401-20200430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:AseraCareHospiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic7961b340f674cd8b10f0d54284e1eef_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthAndHospiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia821fd814fc04a678988e6c92ea2a385_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthAndHospiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1c8d3b2b4c064d6a90ebefef21edaeb5_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthAndHospiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibb3ce40344c74f1581b747ba288ae945_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthAndHospiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8f67ab0074b94f94a94986aa649dde19_D20200327-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-03-27</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia6c66b5559184a299f6fd13a6091fd6c_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3800e4dbdd2b4b74be666a6efdf57781_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:UnusualOrInfrequentItemAxis">amed:COVID19DeferralOfSocialSecurityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifc0809f18c444433ac13693a115bb6bf_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:UnusualOrInfrequentItemAxis">amed:COVID19DeferralOfSocialSecurityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifd83ae148acd4a77824ab56405bb1c41_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:PersonalCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i45e11b09cca8443d838df683d0210fd2_D20210501-20210501"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:NC</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-01</xbrli:startDate><xbrli:endDate>2021-05-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i535b766678164627a4ddec7a5f2f5950_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:NC</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8bbf534b5cc84c0e8690bc7618aac045_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">amed:CertificateOfNeedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:NC</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i83f6f6c3fd9a43b9871634c7190f8d34_D20200601-20200601"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:AseraCareHospiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-01</xbrli:startDate><xbrli:endDate>2020-06-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i867c8c481181405cacf65820555c0934_D20200601-20200601"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:AseraCareHospiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-01</xbrli:startDate><xbrli:endDate>2020-06-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifaa721259ce4436aa80fefef62ec970f_D20201001-20201001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:AseraCareHospiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2020-10-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1af2ff078c3a4f71aa611b0e527d319e_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:AseraCareHospiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie2776ede445a47be9f24c8e19df8e41a_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:AseraCareHospiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id89f6008c2694e98ab64e39c65f6ad94_I20200601"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">amed:MedicareLicenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:AseraCareHospiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i529e20e30522490fbfb5f6be349b8c2e_I20200601"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">amed:CertificatesOfNeedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:AseraCareHospiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i012cb8f0777f4308802fe58df675adca_I20200601"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:AseraCareHospiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">amed:AcquiredNamesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3bd9e093562340059df041fec4f9ea9c_I20200601"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:NoncompeteAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:AseraCareHospiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib2a212363aa54dbc9ffb59f71147e64a_D20200601-20200601"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:AseraCareHospiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">amed:AcquiredNamesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-01</xbrli:startDate><xbrli:endDate>2020-06-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i203c1416080945b495a673816a335d4a_D20200601-20200601"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:NoncompeteAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:AseraCareHospiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-01</xbrli:startDate><xbrli:endDate>2020-06-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id2115fff96eb46a78868c96cf8b1c4a1_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:AseraCareHospiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i93266b4b1d884fad8c5cb4456e2def79_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:AseraCareHospiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id8f72c421ee54ba2a739418940dde57c_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:AseraCareHospiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4f3b5acefd614cc18bfcd62fc3a07ded_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:OneHundredSeventyFiveMillionTermLoanFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i47d7f0027dea435bbbef8d4d8e234b83_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:EurodollarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:OneHundredSeventyFiveMillionTermLoanFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i282996a0cb644ac088b44f613c53cdcb_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:OneHundredSeventyFiveMillionTermLoanFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6f0dd8df1d3345b4aa1558de68c7698c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:OneHundredSeventyFiveMillionTermLoanFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9b034d16545343f69ba28f30d62f22c2_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:FiveHundredFiftyMillionRevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i805854b7963a41c7938b322adb3c1278_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:FiveHundredFiftyMillionRevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:EurodollarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if607f3cb243b4973902b1d41f80fb10c_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:FiveHundredFiftyMillionRevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0eccf63206474ddaa2ee2c286f646d71_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:FiveHundredFiftyMillionRevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id1083386f2394412b5f29ff8fd11b397_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:CapitalLeaseObligationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibbcbe46ad8ac4ae8a7fd039b14ce5a80_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:CapitalLeaseObligationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i44c7af72d3a34639b4816895619e7f09_I20190204"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">amed:AmendedCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-02-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i24530ac946f344808f972a08211612f0_I20190204"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:FiveHundredFiftyMillionRevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">amed:AmendedCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-02-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2d0c143d688b41d490b2ea06ad3046d0_I20190204"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">amed:AmendedCreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:OneHundredSeventyFiveMillionTermLoanFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-02-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9ae11ec3a41040829df9de1fe8e7b2bb_D20190204-20190204"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">amed:AmendedCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-02-04</xbrli:startDate><xbrli:endDate>2019-02-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iee6ede9b55994de38f9991f940db59e9_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">amed:AmendedCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i572c716155d248eeb353108705827f98_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:EurodollarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">amed:AmendedCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib51e6cda5b7f4d999f0a54be2194e8fd_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:DebtInstrumentByLeverageRatioTrancheOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie89771700f0d460f9ee341c9f33ad463_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:DebtInstrumentByLeverageRatioTrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8b4a04615e76432ca77412a8ce8c97a7_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:DebtInstrumentByLeverageRatioTrancheOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:EurodollarMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i80a16d16af124d8e8088f9cd85a66aa7_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:DebtInstrumentByLeverageRatioTrancheOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i32469c69675f451a93e53e98fcb09d2b_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:DebtInstrumentByLeverageRatioTrancheTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i762c3eb26082484eb8eda66cf8da59d4_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:DebtInstrumentByLeverageRatioTrancheTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7ec9530f2497489684d4748db38f2068_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:DebtInstrumentByLeverageRatioTrancheTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9d2fd16e87294dce83ab4611dec95214_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:EurodollarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:DebtInstrumentByLeverageRatioTrancheTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i38341f6760194d9b94f32fad1615efeb_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:DebtInstrumentByLeverageRatioTrancheTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5a18c53bf827477aaee9ccc3df622571_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:DebtInstrumentByLeverageRatioTrancheThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib6f866620dc2459b8f67a5cfdadf6297_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:DebtInstrumentByLeverageRatioTrancheThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3c46dc14b6294ba49b9a3b6291f5935e_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:DebtInstrumentByLeverageRatioTrancheThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6981eb55a7b7401c865f1b05bd9c637f_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:DebtInstrumentByLeverageRatioTrancheThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:EurodollarMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib6892f04dce84842bc5c41b0589b3786_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:DebtInstrumentByLeverageRatioTrancheThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id9b0d221bc814a0cb3a2f624451a4f31_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:DebtInstrumentByLeverageRatioTrancheFourMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieb0d2d2742204b2695d46e6be0103cd6_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:DebtInstrumentByLeverageRatioTrancheFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i634fd9a568bf480e98d90ea8e22ee7fd_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:DebtInstrumentByLeverageRatioTrancheFourMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:EurodollarMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5ab7b8577acf41a4a08641839dff1c5f_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:DebtInstrumentByLeverageRatioTrancheFourMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9d61545dcadf4b1d94a320a38d0b1079_D20190204-20240204"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">amed:AmendedCreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-02-04</xbrli:startDate><xbrli:endDate>2024-02-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i100ffc02e1834ff6a0bbb7f8fc39dd3d_D20190204-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">amed:AmendedCreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:OneHundredSeventyFiveMillionTermLoanFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-02-04</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i641e495583ed40d7885721338515e386_D20200401-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">amed:AmendedCreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:OneHundredSeventyFiveMillionTermLoanFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9f2171b5c0f742c18a35279b1904e320_D20230401-20240204"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">amed:AmendedCreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:OneHundredSeventyFiveMillionTermLoanFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2024-02-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibc8d6081948b4e9190302d69d2b70231_D20190204-20190204"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">amed:AmendedCreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-02-04</xbrli:startDate><xbrli:endDate>2019-02-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i21fda464ca064b61a04aca5a4c5e6a99_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:FiveHundredFiftyMillionRevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idb01e853251e464c9326896aad4c2a8f_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:FiveHundredFiftyMillionRevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib304b65d4507498f9d3f7647d9dbaccd_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:FiveHundredFiftyMillionRevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib3b582f4212244b0884fcc031ea6c067_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:OneHundredSeventyFiveMillionTermLoanFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie080c42adb394ab1aac8bdf81d4f0952_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:OneHundredSeventyFiveMillionTermLoanFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2b242548637548e5845bd5ec7ebead8c_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:OneHundredSeventyFiveMillionTermLoanFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i123b2ec3b6424cd7858def47d8c592e4_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:FiveHundredFiftyMillionRevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia2de44b83d484d54a6dcb3b8f754c999_D20190204-20190204"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:AmendedCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-02-04</xbrli:startDate><xbrli:endDate>2019-02-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8f72f99e864d4c5192c1e32828587ac2_D20190204-20190204"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:EurodollarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:AmendedCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-02-04</xbrli:startDate><xbrli:endDate>2019-02-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i64a0980bb9334fcf8d6f808e3e3034e3_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amed:UsDepartmentOfJusticeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1743ef92c1a2465ea18877206de3e6eb_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amed:UsDepartmentOfJusticeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="patient"><xbrli:measure>amed:patient</xbrli:measure></xbrli:unit><xbrli:context id="icca6ffc5023e4d40ab2f30f7f1376996_D20150521-20150521"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amed:UsDepartmentOfJusticeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:MA</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-05-21</xbrli:startDate><xbrli:endDate>2015-05-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if9882b4fe5cf46d883f68e6c542f6671_D20151103-20151103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amed:UsDepartmentOfJusticeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">amed:MorgantownWestVirginiaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-11-03</xbrli:startDate><xbrli:endDate>2015-11-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i864f8ff014c445d3970f605bf1cf5633_D20160627-20160627"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amed:UsDepartmentOfJusticeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">amed:ParkersburgWestVirginiaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-06-27</xbrli:startDate><xbrli:endDate>2016-06-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="beneficiary"><xbrli:measure>amed:beneficiary</xbrli:measure></xbrli:unit><xbrli:context id="i56392e5d72914b00bf5ae116fa9bb7f9_D20080101-20100331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:SC</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2008-01-01</xbrli:startDate><xbrli:endDate>2010-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iad1c85c016834639b22c42870630702c_D20110606-20110606"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:SC</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">amed:ExtrapolatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2011-06-06</xbrli:startDate><xbrli:endDate>2011-06-06</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i417a271b7a39436d9ed178f9bb7bd0c6_I20160118"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">amed:UnfavorableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:SC</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-01-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="claim"><xbrli:measure>amed:claim</xbrli:measure></xbrli:unit><xbrli:context id="i937449c14ddf4057abd22b9d6ed3e210_D20160118-20160118"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">amed:UnfavorableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:SC</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-01-18</xbrli:startDate><xbrli:endDate>2016-01-18</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i562ae93979ca4fdb8e93e54fc08de2f4_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">amed:UnfavorableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:SC</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i45b052c3ab1d49c694a0154a1838b1a9_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:SC</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icf2b127cab17488d81818bf4e3d75ae0_I20190110"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:SC</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-01-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4850b525a25f4db491a946f4b9cd5379_I20170831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">amed:LakelandFloridaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amed:SafeguardZoneProgramIntegrityContractorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibe7994c4b86d4541b2d0ec37bace16d7_D20170801-20170831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">amed:LakelandFloridaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amed:SafeguardZoneProgramIntegrityContractorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-08-01</xbrli:startDate><xbrli:endDate>2017-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaab7945d135e446ab572c2d66f2fd19f_I20170831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">amed:ClearwaterFloridaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amed:SafeguardZoneProgramIntegrityContractorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i480a00d19d3d49a99637c18c9b072f05_D20170801-20170831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">amed:ClearwaterFloridaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amed:SafeguardZoneProgramIntegrityContractorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-08-01</xbrli:startDate><xbrli:endDate>2017-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1a6de48aaec6424c991ca149df38ebc4_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">amed:LakelandFloridaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amed:SafeguardZoneProgramIntegrityContractorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i257e928d56124ef98ae9d07b7f7d20e0_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">amed:ClearwaterFloridaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amed:SafeguardZoneProgramIntegrityContractorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i042d59baaf764eadb82a511fc4630d06_I20170831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:InfinityHomeCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:FL</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amed:SafeguardZoneProgramIntegrityContractorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i071a11675b024dfa92b8dd03678270ed_I20170831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:FL</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amed:SafeguardZoneProgramIntegrityContractorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8e89313551f44799b6300c11c9de29b3_I20170831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:FL</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amed:SafeguardZoneProgramIntegrityContractorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i33ec0cb49c7c45df918d10f6d8b12f6c_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:FL</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amed:SafeguardZoneProgramIntegrityContractorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icc9f4a15aebf47b28a9f5ea3e095ade5_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:FL</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amed:SafeguardZoneProgramIntegrityContractorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i035f004f00fb427aa308a668dff7bb13_I20170831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:FL</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amed:SafeguardZoneProgramIntegrityContractorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icd32a02105c3425089f7089841dde5b2_D20170101-20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:FL</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amed:SafeguardZoneProgramIntegrityContractorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if467e9fca3484710a3ac117350b56dd9_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:InfinityHomeCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:FL</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amed:SafeguardZoneProgramIntegrityContractorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="segments"><xbrli:measure>amed:Segments</xbrli:measure></xbrli:unit><xbrli:context id="i39e4f26632264baf9dbebb5fdcfb9311_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icf5dbb4a4428489fa4c64850e9a5a460_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i66723c555afc4c9ab4b0e69183d084cf_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:PersonalCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib10fab888a0d4becba7d4378b0313572_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1f0d04b97823461cabfaf4b2dbfbd657_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if43b4d7c93ab412a9c9070b831320d17_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i15797e02165b455389b33741463c1ecd_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:PersonalCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i06052fe21e8f47d88c0c73710f1feaa6_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia22ad972b1ec472b9114385ace42cd42_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:PersonalCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i91156243b7cb4900b72f0b116d3781c2_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i15c3520755c5444cb900d57537639c6c_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6ce911e452594105bd0677b242a6a2d3_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5e461372b93847a4b7c9e1e3e9206b30_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:PersonalCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2f63d6ecb3ef4b2f9a0e98f946e6f46e_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i479f4d0280434d3681861fd2e320cd99_I20201223"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">amed:A2021ShareRepurchaseProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-23</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0d540c3eb0984765b002cd7535b1f472_D20201223-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">amed:A2021ShareRepurchaseProgramMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-23</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7d058b3163364b51b7615e3e655ec631_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">amed:A2021ShareRepurchaseProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie99fb62084bb4f729ac77ff7dbaed893_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">amed:A2021ShareRepurchaseProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i55192f2892ba4410b4d8043c7bd3508f_I20210802"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">amed:ShareRepurchaseProgramMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-08-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ide446a75729e4d219d7267432d1f1fbc_D20210802-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">amed:ShareRepurchaseProgramMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-08-02</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iad1f6087d55542bd9518895ce038f77e_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">amed:MedalogixMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0e79ddec592d4a9286d6d4f8fbd7eebb_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">amed:MedalogixMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8fb7629dcb544e0686e55cbe211d9a9b_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">amed:MedalogixMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i10a4b9a4ae414719a5bbc87698268410_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">amed:MedalogixMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5bf5d306b1c14ff585373333170311d3_D20210701-20210701"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:VisitingNurseAssociationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-07-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1f8587237be448c2bf1c2bbffa581713_D20210712-20210712"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:NY</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-12</xbrli:startDate><xbrli:endDate>2021-07-12</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3fb42087c2d743cca8d759c85d31167b_D20210801-20210801"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:ContessaHealthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-08-01</xbrli:startDate><xbrli:endDate>2021-08-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i37b72216842c4630bdb672d9901858fe_I20210730"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">amed:SecondAmendmentToAmendedCreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-07-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5f0102c209874abb900b903e54aba58e_I20210730"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">amed:SecondAmendmentToAmendedCreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:FiveHundredFiftyMillionRevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-07-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i23747c712c2a44b5bf6a948f7a476aab_I20210730"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">amed:SecondAmendmentToAmendedCreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:FourHundredFiftyMillionTermLoanFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-07-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i013c83768a1e4e0b956e81903f1c8638_D20210730-20210730"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-30</xbrli:startDate><xbrli:endDate>2021-07-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i893fcad73cef4a18a7ab76f16e96f0ad_D20210730-20210730"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:AmendedDebtInstrumentByLeverageRatioTrancheOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-30</xbrli:startDate><xbrli:endDate>2021-07-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifa6c63e1eca547f89b708d6f34225a17_D20210730-20210730"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:AmendedDebtInstrumentByLeverageRatioTrancheOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-30</xbrli:startDate><xbrli:endDate>2021-07-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibd49c2b0ab464f6ab8d956a502559923_D20210730-20210730"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:AmendedDebtInstrumentByLeverageRatioTrancheOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:EurodollarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-30</xbrli:startDate><xbrli:endDate>2021-07-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i42d092eff4ad4200a0c01193347c59ba_D20210730-20210730"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:AmendedDebtInstrumentByLeverageRatioTrancheOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-30</xbrli:startDate><xbrli:endDate>2021-07-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i399c2067f87f4579a5bf6e8d11ed2b0e_D20210730-20210730"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:AmendedDebtInstrumentByLeverageRatioTrancheTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-30</xbrli:startDate><xbrli:endDate>2021-07-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i51a6e6e62aa24e08a1f42edef5dc3362_D20210730-20210730"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:AmendedDebtInstrumentByLeverageRatioTrancheTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-30</xbrli:startDate><xbrli:endDate>2021-07-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1806f555a63f4ad9be597bfa139ca430_D20210730-20210730"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:AmendedDebtInstrumentByLeverageRatioTrancheTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-30</xbrli:startDate><xbrli:endDate>2021-07-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idf8a0386bfef429dac8a61b128e23424_D20210730-20210730"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:AmendedDebtInstrumentByLeverageRatioTrancheTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:EurodollarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-30</xbrli:startDate><xbrli:endDate>2021-07-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibb50673cdce34a36abc32c81bca0b9c2_D20210730-20210730"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:AmendedDebtInstrumentByLeverageRatioTrancheTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-30</xbrli:startDate><xbrli:endDate>2021-07-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ica9a6dd6c4dd4b528399e24681759629_D20210730-20210730"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:AmendedDebtInstrumentByLeverageRatioTrancheThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-30</xbrli:startDate><xbrli:endDate>2021-07-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie135590e741545eaba8f6bb70561f7be_D20210730-20210730"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:AmendedDebtInstrumentByLeverageRatioTrancheThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-30</xbrli:startDate><xbrli:endDate>2021-07-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7ae8c5e5ea3f46338602af709a707586_D20210730-20210730"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:AmendedDebtInstrumentByLeverageRatioTrancheThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-30</xbrli:startDate><xbrli:endDate>2021-07-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0e146a61cc484c3085aa313c3aac07b6_D20210730-20210730"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:EurodollarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:AmendedDebtInstrumentByLeverageRatioTrancheThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-30</xbrli:startDate><xbrli:endDate>2021-07-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i379bc627f4a745e6937f7cc4a2357a7d_D20210730-20210730"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:AmendedDebtInstrumentByLeverageRatioTrancheThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-30</xbrli:startDate><xbrli:endDate>2021-07-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id407ccb903ff4b5dbcd97f48c071901c_D20210730-20210730"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:AmendedDebtInstrumentByLeverageRatioTrancheFourMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-30</xbrli:startDate><xbrli:endDate>2021-07-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i00349d2687c14dfba218b9ee86bf33b2_D20210730-20210730"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:AmendedDebtInstrumentByLeverageRatioTrancheFourMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-30</xbrli:startDate><xbrli:endDate>2021-07-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if952ebf0ec1f4f38950c654b7e9febb8_D20210730-20210730"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:EurodollarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:AmendedDebtInstrumentByLeverageRatioTrancheFourMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-30</xbrli:startDate><xbrli:endDate>2021-07-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia0a2cc02f30f44c481140c202f28cf4a_D20210730-20210730"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:AmendedDebtInstrumentByLeverageRatioTrancheFourMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-30</xbrli:startDate><xbrli:endDate>2021-07-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8f97846b33b54f368697ed0323cbb2b2_D20210730-20260730"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">amed:SecondAmendmentToAmendedCreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-30</xbrli:startDate><xbrli:endDate>2026-07-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id8e4663758bd4b8c908928b7178d6c4f_D20210730-20230930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">amed:SecondAmendmentToAmendedCreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:FourHundredFiftyMillionTermLoanFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-30</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i04246e2f9fa44955a7bdb76cd2520b0b_D20231001-20260730"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">amed:SecondAmendmentToAmendedCreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:FourHundredFiftyMillionTermLoanFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2026-07-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i704e6869254d4b25be00c91be5629417_D20210730-20210730"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">amed:SecondAmendmentToAmendedCreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-30</xbrli:startDate><xbrli:endDate>2021-07-30</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="iccd9c69ecd2c42e5897cfe9ab4e7e0b5_1"></div><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Washington D.C. 20549</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:19.444%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8xL2ZyYWc6YTliNzQzYzAwODU4NGYyNGFhYTM1N2E5ZjJjMWE0ZDYvdGV4dHJlZ2lvbjphOWI3NDNjMDA4NTg0ZjI0YWFhMzU3YTlmMmMxYTRkNl8yMjQ4_10c81f87-8cdb-4ac4-b4b0-6d0f8a830071">10-Q</ix:nonNumeric> </span></div><div style="margin-top:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:19.444%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Mark One)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:2.267%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:95.533%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630" format="ixt-sec:boolballotbox" name="dei:DocumentQuarterlyReport" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8xL2ZyYWc6YTliNzQzYzAwODU4NGYyNGFhYTM1N2E5ZjJjMWE0ZDYvdGFibGU6YTEwYTBiN2FjZmY3NGExNjk0OTdiMDY2MDNjMjVhNzAvdGFibGVyYW5nZTphMTBhMGI3YWNmZjc0YTE2OTQ5N2IwNjYwM2MyNWE3MF8wLTAtMS0xLTA_85ed1899-6b39-40d0-89a2-05631de2d542">&#9746;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the quarterly period ended <ix:nonNumeric contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8xL2ZyYWc6YTliNzQzYzAwODU4NGYyNGFhYTM1N2E5ZjJjMWE0ZDYvdGV4dHJlZ2lvbjphOWI3NDNjMDA4NTg0ZjI0YWFhMzU3YTlmMmMxYTRkNl8xNDA_0ddc3a2c-8289-4f8f-bd70-125cd4dac68c">June&#160;30, 2021</ix:nonNumeric> </span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">or</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:1.979%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:95.821%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630" format="ixt-sec:boolballotbox" name="dei:DocumentTransitionReport" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8xL2ZyYWc6YTliNzQzYzAwODU4NGYyNGFhYTM1N2E5ZjJjMWE0ZDYvdGFibGU6YWZlMDk5NmE3MTViNDNjMDkwMDQ5MjA4NzBlNmU3ZmUvdGFibGVyYW5nZTphZmUwOTk2YTcxNWI0M2MwOTAwNDkyMDg3MGU2ZTdmZV8wLTAtMS0xLTA_5d137cc0-5e53-4682-8c22-053c0bcf13af">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the transition period from </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commission File Number: <ix:nonNumeric contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8xL2ZyYWc6YTliNzQzYzAwODU4NGYyNGFhYTM1N2E5ZjJjMWE0ZDYvdGV4dHJlZ2lvbjphOWI3NDNjMDA4NTg0ZjI0YWFhMzU3YTlmMmMxYTRkNl8yMjQz_597ef27b-e2a6-4cf3-b9cf-7754c9d0db36">0-24260</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:19.444%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-top:3pt;text-align:center"><img src="amed-20210630_g1.jpg" alt="amed-20210630_g1.jpg" style="height:82px;margin-bottom:5pt;vertical-align:text-bottom;width:160px"/></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:24pt;font-weight:700;line-height:120%">AMEDISYS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Exact Name of Registrant as Specified in its Charter)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:19.444%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:48.533%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.581%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.486%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8xL2ZyYWc6YTliNzQzYzAwODU4NGYyNGFhYTM1N2E5ZjJjMWE0ZDYvdGFibGU6ODViZmI1Mzc5MjExNDM2YWE0M2VlOTliYzM2NDA2ODQvdGFibGVyYW5nZTo4NWJmYjUzNzkyMTE0MzZhYTQzZWU5OWJjMzY0MDY4NF8xLTAtMS0xLTA_126c6c3b-6f23-4b2c-8e52-e8363d88fc96">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8xL2ZyYWc6YTliNzQzYzAwODU4NGYyNGFhYTM1N2E5ZjJjMWE0ZDYvdGFibGU6ODViZmI1Mzc5MjExNDM2YWE0M2VlOTliYzM2NDA2ODQvdGFibGVyYW5nZTo4NWJmYjUzNzkyMTE0MzZhYTQzZWU5OWJjMzY0MDY4NF8xLTItMS0xLTA_54c6a5b6-793e-4e32-bdfa-050172a95352">11-3131700</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(State or other jurisdiction of<br/>incorporation or organization)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(I.R.S. Employer<br/>Identification No.)</span></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8xL2ZyYWc6YTliNzQzYzAwODU4NGYyNGFhYTM1N2E5ZjJjMWE0ZDYvdGV4dHJlZ2lvbjphOWI3NDNjMDA4NTg0ZjI0YWFhMzU3YTlmMmMxYTRkNl8yMjQ0_6ca5236f-7957-4dbb-ac93-c985f2b7d61f">3854 American Way</ix:nonNumeric>, <ix:nonNumeric contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630" name="dei:EntityAddressAddressLine2" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8xL2ZyYWc6YTliNzQzYzAwODU4NGYyNGFhYTM1N2E5ZjJjMWE0ZDYvdGV4dHJlZ2lvbjphOWI3NDNjMDA4NTg0ZjI0YWFhMzU3YTlmMmMxYTRkNl8yMjQ1_9eb8804c-8070-4707-85df-2856ac9227c8">Suite A</ix:nonNumeric>, <ix:nonNumeric contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8xL2ZyYWc6YTliNzQzYzAwODU4NGYyNGFhYTM1N2E5ZjJjMWE0ZDYvdGV4dHJlZ2lvbjphOWI3NDNjMDA4NTg0ZjI0YWFhMzU3YTlmMmMxYTRkNl8yMjQ5_8255e170-a829-4fbe-ad44-bef8e25b01e8">Baton Rouge</ix:nonNumeric>, <ix:nonNumeric contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8xL2ZyYWc6YTliNzQzYzAwODU4NGYyNGFhYTM1N2E5ZjJjMWE0ZDYvdGV4dHJlZ2lvbjphOWI3NDNjMDA4NTg0ZjI0YWFhMzU3YTlmMmMxYTRkNl8yMjQ2_767b021c-602c-48f0-95ba-a4c293ee6d02">LA</ix:nonNumeric> <ix:nonNumeric contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8xL2ZyYWc6YTliNzQzYzAwODU4NGYyNGFhYTM1N2E5ZjJjMWE0ZDYvdGV4dHJlZ2lvbjphOWI3NDNjMDA4NTg0ZjI0YWFhMzU3YTlmMmMxYTRkNl8yMjQ3_603f1218-e4f7-4f11-b0ce-103588cbb6cf">70816</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Address of principal executive offices, including zip code)</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8xL2ZyYWc6YTliNzQzYzAwODU4NGYyNGFhYTM1N2E5ZjJjMWE0ZDYvdGV4dHJlZ2lvbjphOWI3NDNjMDA4NTg0ZjI0YWFhMzU3YTlmMmMxYTRkNl8yMjUw_769a9d6b-fbe0-495b-bf74-c2025ffe69d3">225</ix:nonNumeric>) <ix:nonNumeric contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8xL2ZyYWc6YTliNzQzYzAwODU4NGYyNGFhYTM1N2E5ZjJjMWE0ZDYvdGV4dHJlZ2lvbjphOWI3NDNjMDA4NTg0ZjI0YWFhMzU3YTlmMmMxYTRkNl8yMjUx_3f9df67f-c206-40db-a7e6-44e0e3f51708">292-2031</ix:nonNumeric> or (800)&#160;467-2662</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Registrant&#8217;s telephone number, including area code)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:19.444%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:36.583%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.040%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.611%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Title of each class</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Trading Symbol(s)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8xL2ZyYWc6YTliNzQzYzAwODU4NGYyNGFhYTM1N2E5ZjJjMWE0ZDYvdGFibGU6OGY3NmQ3ODI5ZDU2NDA3OGEyMGZmNjc3NTAzZDg4ZjEvdGFibGVyYW5nZTo4Zjc2ZDc4MjlkNTY0MDc4YTIwZmY2Nzc1MDNkODhmMV8xLTAtMS0xLTA_fac809ae-2092-4e13-848a-87b905a5dc26">Common Stock, par value $0.001 per share</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8xL2ZyYWc6YTliNzQzYzAwODU4NGYyNGFhYTM1N2E5ZjJjMWE0ZDYvdGFibGU6OGY3NmQ3ODI5ZDU2NDA3OGEyMGZmNjc3NTAzZDg4ZjEvdGFibGVyYW5nZTo4Zjc2ZDc4MjlkNTY0MDc4YTIwZmY2Nzc1MDNkODhmMV8xLTItMS0xLTA_2a95462b-81b1-4082-bbea-f8c43cc65bf6">AMED</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8xL2ZyYWc6YTliNzQzYzAwODU4NGYyNGFhYTM1N2E5ZjJjMWE0ZDYvdGFibGU6OGY3NmQ3ODI5ZDU2NDA3OGEyMGZmNjc3NTAzZDg4ZjEvdGFibGVyYW5nZTo4Zjc2ZDc4MjlkNTY0MDc4YTIwZmY2Nzc1MDNkODhmMV8xLTQtMS0xLTA_c7866473-a2bb-4fa2-a0e5-c008cbfe8f05">The NASDAQ Global Select Market</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12&#160;months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90&#160;days.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8xL2ZyYWc6YTliNzQzYzAwODU4NGYyNGFhYTM1N2E5ZjJjMWE0ZDYvdGV4dHJlZ2lvbjphOWI3NDNjMDA4NTg0ZjI0YWFhMzU3YTlmMmMxYTRkNl8yMjUy_c55d3fc8-c3b0-419e-8262-2d5e9bf22462">Yes</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;No&#160;&#9744;</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8xL2ZyYWc6YTliNzQzYzAwODU4NGYyNGFhYTM1N2E5ZjJjMWE0ZDYvdGV4dHJlZ2lvbjphOWI3NDNjMDA4NTg0ZjI0YWFhMzU3YTlmMmMxYTRkNl8yMjQx_f237e278-3a93-404d-8aaa-ae51bc65586d">Yes</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;No&#160;&#160;&#9744;</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in&#160;Rule&#160;12b-2 of the Exchange Act. (Check one):</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:22.145%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.577%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.443%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.577%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.999%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.577%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.582%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630" format="ixt-sec:entityfilercategoryen" name="dei:EntityFilerCategory" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8xL2ZyYWc6YTliNzQzYzAwODU4NGYyNGFhYTM1N2E5ZjJjMWE0ZDYvdGFibGU6ZjQ2YjgwNjhjNzg2NGE4M2IzYjViMDVkNDk4MjYwOTIvdGFibGVyYW5nZTpmNDZiODA2OGM3ODY0YTgzYjNiNWIwNWQ0OTgyNjA5Ml8xLTAtMS0xLTA_d27427f9-9d69-4609-a689-d407f4f591c8">Large accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9746;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accelerated&#160;filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Smaller&#160;reporting&#160;company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;padding-right:2.25pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630" format="ixt-sec:boolballotbox" name="dei:EntitySmallBusiness" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8xL2ZyYWc6YTliNzQzYzAwODU4NGYyNGFhYTM1N2E5ZjJjMWE0ZDYvdGFibGU6ZjQ2YjgwNjhjNzg2NGE4M2IzYjViMDVkNDk4MjYwOTIvdGFibGVyYW5nZTpmNDZiODA2OGM3ODY0YTgzYjNiNWIwNWQ0OTgyNjA5Ml8zLTYtMS0xLTA_8c342535-58f0-4727-8dd5-ff9151c705ef">&#9744;</ix:nonNumeric></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Emerging&#160;growth&#160;company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;padding-right:2.25pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8xL2ZyYWc6YTliNzQzYzAwODU4NGYyNGFhYTM1N2E5ZjJjMWE0ZDYvdGFibGU6ZjQ2YjgwNjhjNzg2NGE4M2IzYjViMDVkNDk4MjYwOTIvdGFibGVyYW5nZTpmNDZiODA2OGM3ODY0YTgzYjNiNWIwNWQ0OTgyNjA5Ml81LTItMS0xLTA_1c1e18aa-a0d4-445b-86d3-b5edeb4c8ea7">&#9744;</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule&#160;12b-2 of the Exchange Act).&#160;&#160;&#160;&#160;Yes&#160;&#160;<ix:nonNumeric contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630" format="ixt-sec:boolballotbox" name="dei:EntityShellCompany" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8xL2ZyYWc6YTliNzQzYzAwODU4NGYyNGFhYTM1N2E5ZjJjMWE0ZDYvdGV4dHJlZ2lvbjphOWI3NDNjMDA4NTg0ZjI0YWFhMzU3YTlmMmMxYTRkNl8yMjQy_be9a7af3-0cd1-4ca5-b118-5a4720b77477">&#9744;</ix:nonNumeric>&#160;&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9746;</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The number of shares outstanding of each of the issuer&#8217;s classes of common stock, as of the latest practicable date, is as follows: Common stock, $0.001 par value, <ix:nonFraction unitRef="shares" contextRef="ifed7a9d7833f4709ab4d734d7c419fe7_I20210730" decimals="INF" format="ixt:numdotdecimal" name="dei:EntityCommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8xL2ZyYWc6YTliNzQzYzAwODU4NGYyNGFhYTM1N2E5ZjJjMWE0ZDYvdGV4dHJlZ2lvbjphOWI3NDNjMDA4NTg0ZjI0YWFhMzU3YTlmMmMxYTRkNl8yMjA4_e46d12ed-5fd6-4a3a-919d-34779402364c">32,631,959</ix:nonFraction> shares outstanding as of July&#160;30, 2021.</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div></div></div><div id="iccd9c69ecd2c42e5897cfe9ab4e7e0b5_7"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TABLE OF CONTENTS</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:8.270%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:85.576%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.854%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iccd9c69ecd2c42e5897cfe9ab4e7e0b5_10">SPECIAL CAUTION CONCERNING FORWARD-LOOKING STATEMENTS</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#iccd9c69ecd2c42e5897cfe9ab4e7e0b5_10">1</a></span></div></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">;;;</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PART I. </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iccd9c69ecd2c42e5897cfe9ab4e7e0b5_13">FINANCIAL INFORMATION</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ITEM 1.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iccd9c69ecd2c42e5897cfe9ab4e7e0b5_16">FINANCIAL STATEMENTS:</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iccd9c69ecd2c42e5897cfe9ab4e7e0b5_19">CONDENSED CONSOLIDATED BALANCE SHEETS AS OF JUNE 30, 2021 (UNAUDITED) AND DECEMBER&#160;31, 2020</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#iccd9c69ecd2c42e5897cfe9ab4e7e0b5_19">2</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iccd9c69ecd2c42e5897cfe9ab4e7e0b5_25">CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS FOR THE THREE AND SIX-MONTH PERIODS ENDED JUNE 30, 2021 AND 2020 (UNAUDITED)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#iccd9c69ecd2c42e5897cfe9ab4e7e0b5_25">3</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iccd9c69ecd2c42e5897cfe9ab4e7e0b5_28">CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY FOR THE THREE AND SIX-MONTH PERIODS ENDED JUNE 30, 2021 AND 2020 (UNAUDITED)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#iccd9c69ecd2c42e5897cfe9ab4e7e0b5_28">4</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iccd9c69ecd2c42e5897cfe9ab4e7e0b5_31">CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS FOR THE SIX-MONTH PERIODS ENDED JUNE 30, 2021 AND 2020 (UNAUDITED)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#iccd9c69ecd2c42e5897cfe9ab4e7e0b5_31">5</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ITEM 2.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iccd9c69ecd2c42e5897cfe9ab4e7e0b5_88">MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#iccd9c69ecd2c42e5897cfe9ab4e7e0b5_88">24</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ITEM 3</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iccd9c69ecd2c42e5897cfe9ab4e7e0b5_91">QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#iccd9c69ecd2c42e5897cfe9ab4e7e0b5_91">41</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ITEM&#160;4.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iccd9c69ecd2c42e5897cfe9ab4e7e0b5_94">CONTROLS AND PROCEDURES</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#iccd9c69ecd2c42e5897cfe9ab4e7e0b5_94">41</a></span></div></td></tr><tr style="height:12pt"><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iccd9c69ecd2c42e5897cfe9ab4e7e0b5_97">PART II. OTHER INFORMATION</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ITEM&#160;1.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iccd9c69ecd2c42e5897cfe9ab4e7e0b5_100">LEGAL PROCEEDINGS</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#iccd9c69ecd2c42e5897cfe9ab4e7e0b5_100">43</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ITEM&#160;1A.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iccd9c69ecd2c42e5897cfe9ab4e7e0b5_103">RISK FACTORS</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#iccd9c69ecd2c42e5897cfe9ab4e7e0b5_103">43</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ITEM 2.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iccd9c69ecd2c42e5897cfe9ab4e7e0b5_106">UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#iccd9c69ecd2c42e5897cfe9ab4e7e0b5_106">43</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ITEM&#160;3.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iccd9c69ecd2c42e5897cfe9ab4e7e0b5_109">DEFAULTS UPON SENIOR SECURITIES</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#iccd9c69ecd2c42e5897cfe9ab4e7e0b5_109">43</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ITEM&#160;4.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iccd9c69ecd2c42e5897cfe9ab4e7e0b5_112">MINE SAFETY DISCLOSURES</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#iccd9c69ecd2c42e5897cfe9ab4e7e0b5_112">43</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ITEM&#160;5.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iccd9c69ecd2c42e5897cfe9ab4e7e0b5_115">OTHER INFORMATION</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#iccd9c69ecd2c42e5897cfe9ab4e7e0b5_115">43</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ITEM&#160;6.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iccd9c69ecd2c42e5897cfe9ab4e7e0b5_118">EXHIBITS</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#iccd9c69ecd2c42e5897cfe9ab4e7e0b5_118">44</a></span></div></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iccd9c69ecd2c42e5897cfe9ab4e7e0b5_121">SIGNATURES</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#iccd9c69ecd2c42e5897cfe9ab4e7e0b5_121">45</a></span></div></td></tr></table></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div></div></div><div id="iccd9c69ecd2c42e5897cfe9ab4e7e0b5_10"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SPECIAL CAUTION CONCERNING FORWARD-LOOKING STATEMENTS</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">When included in this Quarterly Report on Form 10-Q, or in other documents that we file with the Securities and Exchange Commission (&#8220;SEC&#8221;) or in statements made by or on behalf of the Company, words like &#8220;believes,&#8221; &#8220;belief,&#8221; &#8220;expects,&#8221; &#8220;strategy,&#8221; &#8220;plans,&#8221; &#8220;anticipates,&#8221; &#8220;intends,&#8221; &#8220;projects,&#8221; &#8220;estimates,&#8221; &#8220;may,&#8221; &#8220;might,&#8221; &#8220;could,&#8221; &#8220;would,&#8221; &#8220;should&#8221; and similar expressions are intended to identify forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. These forward-looking statements involve a variety of risks and uncertainties that could cause actual results to differ materially from those described therein. These risks and uncertainties include, but are not limited to the following: the impact of the novel coronavirus pandemic ("COVID-19"), including the measures that have been and may be taken by governmental authorities to mitigate it, on our business, financial condition and results of operations, changes in or our failure to comply with existing federal and state laws or regulations or the inability to comply with new government regulations on a timely basis, changes in Medicare and other medical payment levels, our ability to open care centers, acquire additional care centers and integrate and operate these care centers effectively, competition in the healthcare industry, changes in the case mix of patients and payment methodologies, changes in estimates and judgments associated with critical accounting policies, our ability to maintain or establish new patient referral sources, our ability to consistently provide high-quality care, our ability to attract and retain qualified personnel, our ability to keep our patients and employees safe, changes in payments and covered services by federal and state governments, future cost containment initiatives undertaken by third-party payors, our access to financing, our ability to meet debt service requirements and comply with covenants in debt agreements, business disruptions due to natural disasters or acts of terrorism, widespread protests or civil unrest, our ability to integrate, manage and keep our information systems secure, our ability to realize the anticipated benefits of acquisitions, changes in law or developments with respect to any litigation relating to the Company, including various other matters, many of which are beyond our control.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified, you should not rely on any forward-looking statement as a prediction of future events.&#160;We expressly disclaim any obligation or undertaking and we do not intend to release publicly any updates or changes in our expectations concerning the forward-looking statements or any changes in events, conditions or circumstances upon which any forward-looking statement may be based, except as required by law.&#160;For a discussion of some of the factors discussed above as well as additional factors, see our Annual Report on Form 10-K for the year ended December&#160;31, 2020, filed with the SEC on February 25, 2021, particularly, Part I, Item&#160;1A - Risk Factors therein, which are incorporated herein by reference, and Part II, Item 1A. Risk Factors of this Quarterly Report on Form 10-Q. Additional risk factors may also be described in reports that we file from time to time with the SEC.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Available Information</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our company website address is www.amedisys.com. We use our website as a channel of distribution for important company information. Important information, including press releases, analyst presentations and financial information regarding our company, is routinely posted on and accessible on the Investor Relations subpage of our website, which is accessible by clicking on the tab labeled &#8220;Investors&#8221; on our website home page. Visitors to our website can also register to receive automatic e-mail and other notifications alerting them when new information is made available on the Investor Relations subpage of our website. In addition, we make available on the Investor Relations subpage of our website (under the link &#8220;SEC filings&#8221;), free of charge, our annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K, ownership reports on Forms 3, 4 and 5 and any amendments to those reports as soon as reasonably practicable after we electronically file or furnish such reports with the SEC. Further, copies of our Certificate of Incorporation and Bylaws, our Code of Ethical Business Conduct, our Corporate Governance Guidelines and the charters for the Audit, Compensation, Quality of Care, Compliance and Ethics and Nominating and Corporate Governance Committees of our Board are also available on the Investor Relations subpage of our website (under the link &#8220;Governance&#8221;). Reference to our website does not constitute incorporation by reference of the information contained on the website and should not be considered part of this document. Our electronically filed reports can also be obtained on the SEC&#8217;s internet site at http://www.sec.gov.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</span></div></div></div><div id="iccd9c69ecd2c42e5897cfe9ab4e7e0b5_13"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART I. FINANCIAL INFORMATION</span></div><div id="iccd9c69ecd2c42e5897cfe9ab4e7e0b5_16"></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1. FINANCIAL STATEMENTS</span></div><div id="iccd9c69ecd2c42e5897cfe9ab4e7e0b5_19"></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AMEDISYS, INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED BALANCE SHEETS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Amounts in thousands, except share data)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.684%"><tr><td style="width:1.0%"></td><td style="width:73.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.603%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.540%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.791%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2021 (Unaudited)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ASSETS</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e833203be6947b4968aba4d20064ec8_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8xOS9mcmFnOmY3ZTkzYjhjYTJiMDRhYmI4OTA2MDFkZWI3MGNmZTQ4L3RhYmxlOmRhYzI0NDM5OWU0NTRkZjJiYjI0MjUwMjA3OTFhOWY5L3RhYmxlcmFuZ2U6ZGFjMjQ0Mzk5ZTQ1NGRmMmJiMjQyNTAyMDc5MWE5ZjlfMy0xLTEtMS0w_cbf552c2-48c5-49a2-8f94-c1cfdc51127a">91,646</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87ceb60dc20d4df1b0a97d3514837910_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8xOS9mcmFnOmY3ZTkzYjhjYTJiMDRhYmI4OTA2MDFkZWI3MGNmZTQ4L3RhYmxlOmRhYzI0NDM5OWU0NTRkZjJiYjI0MjUwMjA3OTFhOWY5L3RhYmxlcmFuZ2U6ZGFjMjQ0Mzk5ZTQ1NGRmMmJiMjQyNTAyMDc5MWE5ZjlfMy0zLTEtMS0w_d927a305-5117-4c0b-b916-4e9402f8e0f8">81,808</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e833203be6947b4968aba4d20064ec8_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RestrictedCash" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8xOS9mcmFnOmY3ZTkzYjhjYTJiMDRhYmI4OTA2MDFkZWI3MGNmZTQ4L3RhYmxlOmRhYzI0NDM5OWU0NTRkZjJiYjI0MjUwMjA3OTFhOWY5L3RhYmxlcmFuZ2U6ZGFjMjQ0Mzk5ZTQ1NGRmMmJiMjQyNTAyMDc5MWE5ZjlfNC0xLTEtMS0w_e80b12ce-75cc-4ab2-92eb-2e17a76b3b5f">1,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87ceb60dc20d4df1b0a97d3514837910_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RestrictedCash" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8xOS9mcmFnOmY3ZTkzYjhjYTJiMDRhYmI4OTA2MDFkZWI3MGNmZTQ4L3RhYmxlOmRhYzI0NDM5OWU0NTRkZjJiYjI0MjUwMjA3OTFhOWY5L3RhYmxlcmFuZ2U6ZGFjMjQ0Mzk5ZTQ1NGRmMmJiMjQyNTAyMDc5MWE5ZjlfNC0zLTEtMS0w_bf76708c-a9c6-495e-ac21-2406d461c1da">1,549</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patient accounts receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e833203be6947b4968aba4d20064ec8_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8xOS9mcmFnOmY3ZTkzYjhjYTJiMDRhYmI4OTA2MDFkZWI3MGNmZTQ4L3RhYmxlOmRhYzI0NDM5OWU0NTRkZjJiYjI0MjUwMjA3OTFhOWY5L3RhYmxlcmFuZ2U6ZGFjMjQ0Mzk5ZTQ1NGRmMmJiMjQyNTAyMDc5MWE5ZjlfNS0xLTEtMS0w_d7b790b7-974f-4ec9-b796-92a9b4e8eadf">278,216</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87ceb60dc20d4df1b0a97d3514837910_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8xOS9mcmFnOmY3ZTkzYjhjYTJiMDRhYmI4OTA2MDFkZWI3MGNmZTQ4L3RhYmxlOmRhYzI0NDM5OWU0NTRkZjJiYjI0MjUwMjA3OTFhOWY5L3RhYmxlcmFuZ2U6ZGFjMjQ0Mzk5ZTQ1NGRmMmJiMjQyNTAyMDc5MWE5ZjlfNS0zLTEtMS0w_f79d45ac-2be8-4124-abd5-c79ed3e238e0">255,145</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e833203be6947b4968aba4d20064ec8_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8xOS9mcmFnOmY3ZTkzYjhjYTJiMDRhYmI4OTA2MDFkZWI3MGNmZTQ4L3RhYmxlOmRhYzI0NDM5OWU0NTRkZjJiYjI0MjUwMjA3OTFhOWY5L3RhYmxlcmFuZ2U6ZGFjMjQ0Mzk5ZTQ1NGRmMmJiMjQyNTAyMDc5MWE5ZjlfNi0xLTEtMS0w_05a2eaf7-6223-4b3a-bd0e-8cf86ef592e4">11,979</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87ceb60dc20d4df1b0a97d3514837910_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8xOS9mcmFnOmY3ZTkzYjhjYTJiMDRhYmI4OTA2MDFkZWI3MGNmZTQ4L3RhYmxlOmRhYzI0NDM5OWU0NTRkZjJiYjI0MjUwMjA3OTFhOWY5L3RhYmxlcmFuZ2U6ZGFjMjQ0Mzk5ZTQ1NGRmMmJiMjQyNTAyMDc5MWE5ZjlfNi0zLTEtMS0w_04f53a57-6c60-4c26-ac62-d339c272fecd">10,217</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e833203be6947b4968aba4d20064ec8_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8xOS9mcmFnOmY3ZTkzYjhjYTJiMDRhYmI4OTA2MDFkZWI3MGNmZTQ4L3RhYmxlOmRhYzI0NDM5OWU0NTRkZjJiYjI0MjUwMjA3OTFhOWY5L3RhYmxlcmFuZ2U6ZGFjMjQ0Mzk5ZTQ1NGRmMmJiMjQyNTAyMDc5MWE5ZjlfNy0xLTEtMS0w_36e6b65e-d695-4c38-9f08-2c224d433e94">8,124</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87ceb60dc20d4df1b0a97d3514837910_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8xOS9mcmFnOmY3ZTkzYjhjYTJiMDRhYmI4OTA2MDFkZWI3MGNmZTQ4L3RhYmxlOmRhYzI0NDM5OWU0NTRkZjJiYjI0MjUwMjA3OTFhOWY5L3RhYmxlcmFuZ2U6ZGFjMjQ0Mzk5ZTQ1NGRmMmJiMjQyNTAyMDc5MWE5ZjlfNy0zLTEtMS0w_7aad19b9-a07c-4548-9459-3d9e930a75ca">13,265</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e833203be6947b4968aba4d20064ec8_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8xOS9mcmFnOmY3ZTkzYjhjYTJiMDRhYmI4OTA2MDFkZWI3MGNmZTQ4L3RhYmxlOmRhYzI0NDM5OWU0NTRkZjJiYjI0MjUwMjA3OTFhOWY5L3RhYmxlcmFuZ2U6ZGFjMjQ0Mzk5ZTQ1NGRmMmJiMjQyNTAyMDc5MWE5ZjlfOC0xLTEtMS0w_ecf62d09-3574-42a9-9164-e87eb6bf03f1">390,965</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87ceb60dc20d4df1b0a97d3514837910_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8xOS9mcmFnOmY3ZTkzYjhjYTJiMDRhYmI4OTA2MDFkZWI3MGNmZTQ4L3RhYmxlOmRhYzI0NDM5OWU0NTRkZjJiYjI0MjUwMjA3OTFhOWY5L3RhYmxlcmFuZ2U6ZGFjMjQ0Mzk5ZTQ1NGRmMmJiMjQyNTAyMDc5MWE5ZjlfOC0zLTEtMS0w_3a9baf92-a84c-4c4f-8e84-df6594f66366">361,984</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net of accumulated depreciation of $<ix:nonFraction unitRef="usd" contextRef="i1e833203be6947b4968aba4d20064ec8_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8xOS9mcmFnOmY3ZTkzYjhjYTJiMDRhYmI4OTA2MDFkZWI3MGNmZTQ4L3RhYmxlOmRhYzI0NDM5OWU0NTRkZjJiYjI0MjUwMjA3OTFhOWY5L3RhYmxlcmFuZ2U6ZGFjMjQ0Mzk5ZTQ1NGRmMmJiMjQyNTAyMDc5MWE5ZjlfOS0wLTEtMS0wL3RleHRyZWdpb246YzczOTc4ZjE4Y2VmNDFlNGFiZWY5NjMwMzgxMGZlZTRfNjM_75e457ed-3ac3-4362-98e2-ab1b7d621f5a">98,552</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i87ceb60dc20d4df1b0a97d3514837910_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8xOS9mcmFnOmY3ZTkzYjhjYTJiMDRhYmI4OTA2MDFkZWI3MGNmZTQ4L3RhYmxlOmRhYzI0NDM5OWU0NTRkZjJiYjI0MjUwMjA3OTFhOWY5L3RhYmxlcmFuZ2U6ZGFjMjQ0Mzk5ZTQ1NGRmMmJiMjQyNTAyMDc5MWE5ZjlfOS0wLTEtMS0wL3RleHRyZWdpb246YzczOTc4ZjE4Y2VmNDFlNGFiZWY5NjMwMzgxMGZlZTRfNzA_ef02881a-0619-4228-81ce-5a9cda2e4195">95,024</ix:nonFraction></span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e833203be6947b4968aba4d20064ec8_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8xOS9mcmFnOmY3ZTkzYjhjYTJiMDRhYmI4OTA2MDFkZWI3MGNmZTQ4L3RhYmxlOmRhYzI0NDM5OWU0NTRkZjJiYjI0MjUwMjA3OTFhOWY5L3RhYmxlcmFuZ2U6ZGFjMjQ0Mzk5ZTQ1NGRmMmJiMjQyNTAyMDc5MWE5ZjlfOS0xLTEtMS0w_7de2952c-f6e0-498e-b36d-8b9489f30401">20,986</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87ceb60dc20d4df1b0a97d3514837910_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8xOS9mcmFnOmY3ZTkzYjhjYTJiMDRhYmI4OTA2MDFkZWI3MGNmZTQ4L3RhYmxlOmRhYzI0NDM5OWU0NTRkZjJiYjI0MjUwMjA3OTFhOWY5L3RhYmxlcmFuZ2U6ZGFjMjQ0Mzk5ZTQ1NGRmMmJiMjQyNTAyMDc5MWE5ZjlfOS0zLTEtMS0w_868644a2-9e07-41e1-bd24-f3cbe99b334e">23,719</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right of use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e833203be6947b4968aba4d20064ec8_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8xOS9mcmFnOmY3ZTkzYjhjYTJiMDRhYmI4OTA2MDFkZWI3MGNmZTQ4L3RhYmxlOmRhYzI0NDM5OWU0NTRkZjJiYjI0MjUwMjA3OTFhOWY5L3RhYmxlcmFuZ2U6ZGFjMjQ0Mzk5ZTQ1NGRmMmJiMjQyNTAyMDc5MWE5ZjlfMTAtMS0xLTEtMA_c21de4ec-6726-41e5-b59d-2bbd5f889634">95,034</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87ceb60dc20d4df1b0a97d3514837910_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8xOS9mcmFnOmY3ZTkzYjhjYTJiMDRhYmI4OTA2MDFkZWI3MGNmZTQ4L3RhYmxlOmRhYzI0NDM5OWU0NTRkZjJiYjI0MjUwMjA3OTFhOWY5L3RhYmxlcmFuZ2U6ZGFjMjQ0Mzk5ZTQ1NGRmMmJiMjQyNTAyMDc5MWE5ZjlfMTAtMy0xLTEtMA_3b4d5c48-9a23-4ae9-8f88-8d6591787223">93,440</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e833203be6947b4968aba4d20064ec8_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8xOS9mcmFnOmY3ZTkzYjhjYTJiMDRhYmI4OTA2MDFkZWI3MGNmZTQ4L3RhYmxlOmRhYzI0NDM5OWU0NTRkZjJiYjI0MjUwMjA3OTFhOWY5L3RhYmxlcmFuZ2U6ZGFjMjQ0Mzk5ZTQ1NGRmMmJiMjQyNTAyMDc5MWE5ZjlfMTEtMS0xLTEtMA_83abc54c-e97b-4a3e-85c3-cd75814e1bd3">936,772</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87ceb60dc20d4df1b0a97d3514837910_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8xOS9mcmFnOmY3ZTkzYjhjYTJiMDRhYmI4OTA2MDFkZWI3MGNmZTQ4L3RhYmxlOmRhYzI0NDM5OWU0NTRkZjJiYjI0MjUwMjA3OTFhOWY5L3RhYmxlcmFuZ2U6ZGFjMjQ0Mzk5ZTQ1NGRmMmJiMjQyNTAyMDc5MWE5ZjlfMTEtMy0xLTEtMA_d4331c60-8a79-4713-9e0b-87327b4c0568">932,685</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets, net of accumulated amortization of $<ix:nonFraction unitRef="usd" contextRef="i1e833203be6947b4968aba4d20064ec8_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8xOS9mcmFnOmY3ZTkzYjhjYTJiMDRhYmI4OTA2MDFkZWI3MGNmZTQ4L3RhYmxlOmRhYzI0NDM5OWU0NTRkZjJiYjI0MjUwMjA3OTFhOWY5L3RhYmxlcmFuZ2U6ZGFjMjQ0Mzk5ZTQ1NGRmMmJiMjQyNTAyMDc5MWE5ZjlfMTItMC0xLTEtMC90ZXh0cmVnaW9uOjhjNTIwYzUyNDJjNTRiMzBiNzY3MjVmMWVhYjE2MGExXzU4_40119560-aa2f-4eb1-b581-24bc71ac558a">15,842</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i87ceb60dc20d4df1b0a97d3514837910_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8xOS9mcmFnOmY3ZTkzYjhjYTJiMDRhYmI4OTA2MDFkZWI3MGNmZTQ4L3RhYmxlOmRhYzI0NDM5OWU0NTRkZjJiYjI0MjUwMjA3OTFhOWY5L3RhYmxlcmFuZ2U6ZGFjMjQ0Mzk5ZTQ1NGRmMmJiMjQyNTAyMDc5MWE5ZjlfMTItMC0xLTEtMC90ZXh0cmVnaW9uOjhjNTIwYzUyNDJjNTRiMzBiNzY3MjVmMWVhYjE2MGExXzY1_d9abca42-edcf-4f72-9936-bd8f474afd96">22,973</ix:nonFraction></span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e833203be6947b4968aba4d20064ec8_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8xOS9mcmFnOmY3ZTkzYjhjYTJiMDRhYmI4OTA2MDFkZWI3MGNmZTQ4L3RhYmxlOmRhYzI0NDM5OWU0NTRkZjJiYjI0MjUwMjA3OTFhOWY5L3RhYmxlcmFuZ2U6ZGFjMjQ0Mzk5ZTQ1NGRmMmJiMjQyNTAyMDc5MWE5ZjlfMTItMS0xLTEtMA_81919201-87bb-4363-8609-c69a63fb9d78">66,432</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87ceb60dc20d4df1b0a97d3514837910_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8xOS9mcmFnOmY3ZTkzYjhjYTJiMDRhYmI4OTA2MDFkZWI3MGNmZTQ4L3RhYmxlOmRhYzI0NDM5OWU0NTRkZjJiYjI0MjUwMjA3OTFhOWY5L3RhYmxlcmFuZ2U6ZGFjMjQ0Mzk5ZTQ1NGRmMmJiMjQyNTAyMDc5MWE5ZjlfMTItMy0xLTEtMA_6c91dc66-e463-4f6f-9453-c67bb445ece3">74,183</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e833203be6947b4968aba4d20064ec8_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxAssetsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8xOS9mcmFnOmY3ZTkzYjhjYTJiMDRhYmI4OTA2MDFkZWI3MGNmZTQ4L3RhYmxlOmRhYzI0NDM5OWU0NTRkZjJiYjI0MjUwMjA3OTFhOWY5L3RhYmxlcmFuZ2U6ZGFjMjQ0Mzk5ZTQ1NGRmMmJiMjQyNTAyMDc5MWE5ZjlfMTMtMS0xLTEtMA_59caf286-ec06-41ee-b7ca-8e2cc75e150b">25,271</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87ceb60dc20d4df1b0a97d3514837910_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxAssetsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8xOS9mcmFnOmY3ZTkzYjhjYTJiMDRhYmI4OTA2MDFkZWI3MGNmZTQ4L3RhYmxlOmRhYzI0NDM5OWU0NTRkZjJiYjI0MjUwMjA3OTFhOWY5L3RhYmxlcmFuZ2U6ZGFjMjQ0Mzk5ZTQ1NGRmMmJiMjQyNTAyMDc5MWE5ZjlfMTMtMy0xLTEtMA_8e586b49-13ff-4bd2-ab22-b76604d33a8c">47,987</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e833203be6947b4968aba4d20064ec8_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8xOS9mcmFnOmY3ZTkzYjhjYTJiMDRhYmI4OTA2MDFkZWI3MGNmZTQ4L3RhYmxlOmRhYzI0NDM5OWU0NTRkZjJiYjI0MjUwMjA3OTFhOWY5L3RhYmxlcmFuZ2U6ZGFjMjQ0Mzk5ZTQ1NGRmMmJiMjQyNTAyMDc5MWE5ZjlfMTQtMS0xLTEtMA_07d5d4e2-9067-4635-baae-7d0c32936de1">64,103</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87ceb60dc20d4df1b0a97d3514837910_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8xOS9mcmFnOmY3ZTkzYjhjYTJiMDRhYmI4OTA2MDFkZWI3MGNmZTQ4L3RhYmxlOmRhYzI0NDM5OWU0NTRkZjJiYjI0MjUwMjA3OTFhOWY5L3RhYmxlcmFuZ2U6ZGFjMjQ0Mzk5ZTQ1NGRmMmJiMjQyNTAyMDc5MWE5ZjlfMTQtMy0xLTEtMA_676d4762-7578-4d6b-ba67-4b2ff25b5798">33,200</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e833203be6947b4968aba4d20064ec8_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8xOS9mcmFnOmY3ZTkzYjhjYTJiMDRhYmI4OTA2MDFkZWI3MGNmZTQ4L3RhYmxlOmRhYzI0NDM5OWU0NTRkZjJiYjI0MjUwMjA3OTFhOWY5L3RhYmxlcmFuZ2U6ZGFjMjQ0Mzk5ZTQ1NGRmMmJiMjQyNTAyMDc5MWE5ZjlfMTUtMS0xLTEtMA_7b583694-8862-4f3c-a454-9ca8592b9f2e">1,599,563</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87ceb60dc20d4df1b0a97d3514837910_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8xOS9mcmFnOmY3ZTkzYjhjYTJiMDRhYmI4OTA2MDFkZWI3MGNmZTQ4L3RhYmxlOmRhYzI0NDM5OWU0NTRkZjJiYjI0MjUwMjA3OTFhOWY5L3RhYmxlcmFuZ2U6ZGFjMjQ0Mzk5ZTQ1NGRmMmJiMjQyNTAyMDc5MWE5ZjlfMTUtMy0xLTEtMA_a10fc46f-78b2-481a-80ae-c97ce7e5428d">1,567,198</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">LIABILITIES AND EQUITY</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e833203be6947b4968aba4d20064ec8_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8xOS9mcmFnOmY3ZTkzYjhjYTJiMDRhYmI4OTA2MDFkZWI3MGNmZTQ4L3RhYmxlOmRhYzI0NDM5OWU0NTRkZjJiYjI0MjUwMjA3OTFhOWY5L3RhYmxlcmFuZ2U6ZGFjMjQ0Mzk5ZTQ1NGRmMmJiMjQyNTAyMDc5MWE5ZjlfMTgtMS0xLTEtMA_1105c5ef-5fd1-4fc3-a349-c51cfa76caec">36,668</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87ceb60dc20d4df1b0a97d3514837910_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8xOS9mcmFnOmY3ZTkzYjhjYTJiMDRhYmI4OTA2MDFkZWI3MGNmZTQ4L3RhYmxlOmRhYzI0NDM5OWU0NTRkZjJiYjI0MjUwMjA3OTFhOWY5L3RhYmxlcmFuZ2U6ZGFjMjQ0Mzk5ZTQ1NGRmMmJiMjQyNTAyMDc5MWE5ZjlfMTgtMy0xLTEtMA_aa8500ba-7931-4bc7-b977-4307d18efacc">42,674</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payroll and employee benefits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e833203be6947b4968aba4d20064ec8_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8xOS9mcmFnOmY3ZTkzYjhjYTJiMDRhYmI4OTA2MDFkZWI3MGNmZTQ4L3RhYmxlOmRhYzI0NDM5OWU0NTRkZjJiYjI0MjUwMjA3OTFhOWY5L3RhYmxlcmFuZ2U6ZGFjMjQ0Mzk5ZTQ1NGRmMmJiMjQyNTAyMDc5MWE5ZjlfMTktMS0xLTEtMA_2575c62e-7a2a-4542-ba65-a5f16f7c8e54">147,017</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87ceb60dc20d4df1b0a97d3514837910_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8xOS9mcmFnOmY3ZTkzYjhjYTJiMDRhYmI4OTA2MDFkZWI3MGNmZTQ4L3RhYmxlOmRhYzI0NDM5OWU0NTRkZjJiYjI0MjUwMjA3OTFhOWY5L3RhYmxlcmFuZ2U6ZGFjMjQ0Mzk5ZTQ1NGRmMmJiMjQyNTAyMDc5MWE5ZjlfMTktMy0xLTEtMA_0202f74f-03c1-43cb-80ac-30720da539ea">146,929</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e833203be6947b4968aba4d20064ec8_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8xOS9mcmFnOmY3ZTkzYjhjYTJiMDRhYmI4OTA2MDFkZWI3MGNmZTQ4L3RhYmxlOmRhYzI0NDM5OWU0NTRkZjJiYjI0MjUwMjA3OTFhOWY5L3RhYmxlcmFuZ2U6ZGFjMjQ0Mzk5ZTQ1NGRmMmJiMjQyNTAyMDc5MWE5ZjlfMjAtMS0xLTEtMA_58584da9-686c-4fef-963d-b76dca657798">166,157</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87ceb60dc20d4df1b0a97d3514837910_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8xOS9mcmFnOmY3ZTkzYjhjYTJiMDRhYmI4OTA2MDFkZWI3MGNmZTQ4L3RhYmxlOmRhYzI0NDM5OWU0NTRkZjJiYjI0MjUwMjA3OTFhOWY5L3RhYmxlcmFuZ2U6ZGFjMjQ0Mzk5ZTQ1NGRmMmJiMjQyNTAyMDc5MWE5ZjlfMjAtMy0xLTEtMA_82025911-5707-4d6a-8e19-a35863ec7583">166,192</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provider relief fund advance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e833203be6947b4968aba4d20064ec8_I20210630" decimals="-3" format="ixt:numdotdecimal" name="amed:ProviderReliefFundAdvance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8xOS9mcmFnOmY3ZTkzYjhjYTJiMDRhYmI4OTA2MDFkZWI3MGNmZTQ4L3RhYmxlOmRhYzI0NDM5OWU0NTRkZjJiYjI0MjUwMjA3OTFhOWY5L3RhYmxlcmFuZ2U6ZGFjMjQ0Mzk5ZTQ1NGRmMmJiMjQyNTAyMDc5MWE5ZjlfMjEtMS0xLTEtMA_522c7a4b-271b-4e77-9e2c-34a0d5fbaf4d">58,328</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87ceb60dc20d4df1b0a97d3514837910_I20201231" decimals="-3" format="ixt:numdotdecimal" name="amed:ProviderReliefFundAdvance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8xOS9mcmFnOmY3ZTkzYjhjYTJiMDRhYmI4OTA2MDFkZWI3MGNmZTQ4L3RhYmxlOmRhYzI0NDM5OWU0NTRkZjJiYjI0MjUwMjA3OTFhOWY5L3RhYmxlcmFuZ2U6ZGFjMjQ0Mzk5ZTQ1NGRmMmJiMjQyNTAyMDc5MWE5ZjlfMjEtMy0xLTEtMA_c414b72e-07d7-436a-bd84-9b7c59f7b879">60,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of long-term obligations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e833203be6947b4968aba4d20064ec8_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8xOS9mcmFnOmY3ZTkzYjhjYTJiMDRhYmI4OTA2MDFkZWI3MGNmZTQ4L3RhYmxlOmRhYzI0NDM5OWU0NTRkZjJiYjI0MjUwMjA3OTFhOWY5L3RhYmxlcmFuZ2U6ZGFjMjQ0Mzk5ZTQ1NGRmMmJiMjQyNTAyMDc5MWE5ZjlfMjItMS0xLTEtMA_9ce39367-2531-43f9-b432-f1c80ca51c27">10,160</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87ceb60dc20d4df1b0a97d3514837910_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8xOS9mcmFnOmY3ZTkzYjhjYTJiMDRhYmI4OTA2MDFkZWI3MGNmZTQ4L3RhYmxlOmRhYzI0NDM5OWU0NTRkZjJiYjI0MjUwMjA3OTFhOWY5L3RhYmxlcmFuZ2U6ZGFjMjQ0Mzk5ZTQ1NGRmMmJiMjQyNTAyMDc5MWE5ZjlfMjItMy0xLTEtMA_ff11063f-c89f-4aa7-ae30-bcf060b88909">10,496</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e833203be6947b4968aba4d20064ec8_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8xOS9mcmFnOmY3ZTkzYjhjYTJiMDRhYmI4OTA2MDFkZWI3MGNmZTQ4L3RhYmxlOmRhYzI0NDM5OWU0NTRkZjJiYjI0MjUwMjA3OTFhOWY5L3RhYmxlcmFuZ2U6ZGFjMjQ0Mzk5ZTQ1NGRmMmJiMjQyNTAyMDc5MWE5ZjlfMjMtMS0xLTEtMA_d955a445-2acf-4ad6-a551-0a75729af84c">30,893</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87ceb60dc20d4df1b0a97d3514837910_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8xOS9mcmFnOmY3ZTkzYjhjYTJiMDRhYmI4OTA2MDFkZWI3MGNmZTQ4L3RhYmxlOmRhYzI0NDM5OWU0NTRkZjJiYjI0MjUwMjA3OTFhOWY5L3RhYmxlcmFuZ2U6ZGFjMjQ0Mzk5ZTQ1NGRmMmJiMjQyNTAyMDc5MWE5ZjlfMjMtMy0xLTEtMA_5138e54b-3a35-474b-9500-d517ab428039">30,046</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e833203be6947b4968aba4d20064ec8_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8xOS9mcmFnOmY3ZTkzYjhjYTJiMDRhYmI4OTA2MDFkZWI3MGNmZTQ4L3RhYmxlOmRhYzI0NDM5OWU0NTRkZjJiYjI0MjUwMjA3OTFhOWY5L3RhYmxlcmFuZ2U6ZGFjMjQ0Mzk5ZTQ1NGRmMmJiMjQyNTAyMDc5MWE5ZjlfMjQtMS0xLTEtMA_31900d65-852a-4c1a-aded-104a57f700a5">449,223</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87ceb60dc20d4df1b0a97d3514837910_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8xOS9mcmFnOmY3ZTkzYjhjYTJiMDRhYmI4OTA2MDFkZWI3MGNmZTQ4L3RhYmxlOmRhYzI0NDM5OWU0NTRkZjJiYjI0MjUwMjA3OTFhOWY5L3RhYmxlcmFuZ2U6ZGFjMjQ0Mzk5ZTQ1NGRmMmJiMjQyNTAyMDc5MWE5ZjlfMjQtMy0xLTEtMA_d0d4322f-7d52-4d68-a693-da60079262cc">456,337</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term obligations, less current portion</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e833203be6947b4968aba4d20064ec8_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtAndCapitalLeaseObligations" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8xOS9mcmFnOmY3ZTkzYjhjYTJiMDRhYmI4OTA2MDFkZWI3MGNmZTQ4L3RhYmxlOmRhYzI0NDM5OWU0NTRkZjJiYjI0MjUwMjA3OTFhOWY5L3RhYmxlcmFuZ2U6ZGFjMjQ0Mzk5ZTQ1NGRmMmJiMjQyNTAyMDc5MWE5ZjlfMjUtMS0xLTEtMA_fd8748b1-c54e-414f-a3c1-f81b1b7fba4d">179,415</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87ceb60dc20d4df1b0a97d3514837910_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtAndCapitalLeaseObligations" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8xOS9mcmFnOmY3ZTkzYjhjYTJiMDRhYmI4OTA2MDFkZWI3MGNmZTQ4L3RhYmxlOmRhYzI0NDM5OWU0NTRkZjJiYjI0MjUwMjA3OTFhOWY5L3RhYmxlcmFuZ2U6ZGFjMjQ0Mzk5ZTQ1NGRmMmJiMjQyNTAyMDc5MWE5ZjlfMjUtMy0xLTEtMA_4b7f0144-f92c-4e46-8862-216d0de3ccf8">204,511</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities, less current portion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e833203be6947b4968aba4d20064ec8_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8xOS9mcmFnOmY3ZTkzYjhjYTJiMDRhYmI4OTA2MDFkZWI3MGNmZTQ4L3RhYmxlOmRhYzI0NDM5OWU0NTRkZjJiYjI0MjUwMjA3OTFhOWY5L3RhYmxlcmFuZ2U6ZGFjMjQ0Mzk5ZTQ1NGRmMmJiMjQyNTAyMDc5MWE5ZjlfMjYtMS0xLTEtMA_c8183b0c-4e1e-440f-a726-6bc2de870f0b">63,152</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87ceb60dc20d4df1b0a97d3514837910_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8xOS9mcmFnOmY3ZTkzYjhjYTJiMDRhYmI4OTA2MDFkZWI3MGNmZTQ4L3RhYmxlOmRhYzI0NDM5OWU0NTRkZjJiYjI0MjUwMjA3OTFhOWY5L3RhYmxlcmFuZ2U6ZGFjMjQ0Mzk5ZTQ1NGRmMmJiMjQyNTAyMDc5MWE5ZjlfMjYtMy0xLTEtMA_8bfb45ed-4858-43be-a624-70cd6b9bf6d5">61,987</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term obligations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e833203be6947b4968aba4d20064ec8_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8xOS9mcmFnOmY3ZTkzYjhjYTJiMDRhYmI4OTA2MDFkZWI3MGNmZTQ4L3RhYmxlOmRhYzI0NDM5OWU0NTRkZjJiYjI0MjUwMjA3OTFhOWY5L3RhYmxlcmFuZ2U6ZGFjMjQ0Mzk5ZTQ1NGRmMmJiMjQyNTAyMDc5MWE5ZjlfMjctMS0xLTEtMA_605e7f74-4230-424e-b620-4a818a5d1b72">31,886</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87ceb60dc20d4df1b0a97d3514837910_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8xOS9mcmFnOmY3ZTkzYjhjYTJiMDRhYmI4OTA2MDFkZWI3MGNmZTQ4L3RhYmxlOmRhYzI0NDM5OWU0NTRkZjJiYjI0MjUwMjA3OTFhOWY5L3RhYmxlcmFuZ2U6ZGFjMjQ0Mzk5ZTQ1NGRmMmJiMjQyNTAyMDc5MWE5ZjlfMjctMy0xLTEtMA_ddb3f62d-b158-40d1-a0b0-465bcdfb9644">33,622</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e833203be6947b4968aba4d20064ec8_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8xOS9mcmFnOmY3ZTkzYjhjYTJiMDRhYmI4OTA2MDFkZWI3MGNmZTQ4L3RhYmxlOmRhYzI0NDM5OWU0NTRkZjJiYjI0MjUwMjA3OTFhOWY5L3RhYmxlcmFuZ2U6ZGFjMjQ0Mzk5ZTQ1NGRmMmJiMjQyNTAyMDc5MWE5ZjlfMjgtMS0xLTEtMA_8db11e2f-16ea-4731-bf33-5bdbd732cf51">723,676</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87ceb60dc20d4df1b0a97d3514837910_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8xOS9mcmFnOmY3ZTkzYjhjYTJiMDRhYmI4OTA2MDFkZWI3MGNmZTQ4L3RhYmxlOmRhYzI0NDM5OWU0NTRkZjJiYjI0MjUwMjA3OTFhOWY5L3RhYmxlcmFuZ2U6ZGFjMjQ0Mzk5ZTQ1NGRmMmJiMjQyNTAyMDc5MWE5ZjlfMjgtMy0xLTEtMA_6ee89b5b-3384-4717-8324-8ff9b8b65836">756,457</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commitments and Contingencies&#8212;Note 6</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i1e833203be6947b4968aba4d20064ec8_I20210630" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8xOS9mcmFnOmY3ZTkzYjhjYTJiMDRhYmI4OTA2MDFkZWI3MGNmZTQ4L3RhYmxlOmRhYzI0NDM5OWU0NTRkZjJiYjI0MjUwMjA3OTFhOWY5L3RhYmxlcmFuZ2U6ZGFjMjQ0Mzk5ZTQ1NGRmMmJiMjQyNTAyMDc5MWE5ZjlfMjktMS0xLTEtMA_a3ae8433-97f8-4399-84c1-d1f22146deb6"></ix:nonFraction></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preferred stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="i87ceb60dc20d4df1b0a97d3514837910_I20201231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8xOS9mcmFnOmY3ZTkzYjhjYTJiMDRhYmI4OTA2MDFkZWI3MGNmZTQ4L3RhYmxlOmRhYzI0NDM5OWU0NTRkZjJiYjI0MjUwMjA3OTFhOWY5L3RhYmxlcmFuZ2U6ZGFjMjQ0Mzk5ZTQ1NGRmMmJiMjQyNTAyMDc5MWE5ZjlfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOjdmNDI3OWQ5ODJhNDQxYzY5YzAyZjQ2NGYwMWE2ZDczXzIx_397a20d1-dfe9-4f49-bbc0-757090d05653"><ix:nonFraction unitRef="usdPerShare" contextRef="i1e833203be6947b4968aba4d20064ec8_I20210630" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8xOS9mcmFnOmY3ZTkzYjhjYTJiMDRhYmI4OTA2MDFkZWI3MGNmZTQ4L3RhYmxlOmRhYzI0NDM5OWU0NTRkZjJiYjI0MjUwMjA3OTFhOWY5L3RhYmxlcmFuZ2U6ZGFjMjQ0Mzk5ZTQ1NGRmMmJiMjQyNTAyMDc5MWE5ZjlfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOjdmNDI3OWQ5ODJhNDQxYzY5YzAyZjQ2NGYwMWE2ZDczXzIx_a26207d9-9ef2-4c56-bc4d-0b97461eae1b">0.001</ix:nonFraction></ix:nonFraction> par value, <ix:nonFraction unitRef="shares" contextRef="i1e833203be6947b4968aba4d20064ec8_I20210630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8xOS9mcmFnOmY3ZTkzYjhjYTJiMDRhYmI4OTA2MDFkZWI3MGNmZTQ4L3RhYmxlOmRhYzI0NDM5OWU0NTRkZjJiYjI0MjUwMjA3OTFhOWY5L3RhYmxlcmFuZ2U6ZGFjMjQ0Mzk5ZTQ1NGRmMmJiMjQyNTAyMDc5MWE5ZjlfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOjdmNDI3OWQ5ODJhNDQxYzY5YzAyZjQ2NGYwMWE2ZDczXzM1_84d985bc-9125-46aa-8b39-ded284ba340e"><ix:nonFraction unitRef="shares" contextRef="i87ceb60dc20d4df1b0a97d3514837910_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8xOS9mcmFnOmY3ZTkzYjhjYTJiMDRhYmI4OTA2MDFkZWI3MGNmZTQ4L3RhYmxlOmRhYzI0NDM5OWU0NTRkZjJiYjI0MjUwMjA3OTFhOWY5L3RhYmxlcmFuZ2U6ZGFjMjQ0Mzk5ZTQ1NGRmMmJiMjQyNTAyMDc5MWE5ZjlfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOjdmNDI3OWQ5ODJhNDQxYzY5YzAyZjQ2NGYwMWE2ZDczXzM1_bb6aec31-60f7-45a6-8f42-fcfdf54fa2b6">5,000,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction unitRef="shares" contextRef="i1e833203be6947b4968aba4d20064ec8_I20210630" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8xOS9mcmFnOmY3ZTkzYjhjYTJiMDRhYmI4OTA2MDFkZWI3MGNmZTQ4L3RhYmxlOmRhYzI0NDM5OWU0NTRkZjJiYjI0MjUwMjA3OTFhOWY5L3RhYmxlcmFuZ2U6ZGFjMjQ0Mzk5ZTQ1NGRmMmJiMjQyNTAyMDc5MWE5ZjlfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOjdmNDI3OWQ5ODJhNDQxYzY5YzAyZjQ2NGYwMWE2ZDczXzU3_14352eb5-4e04-4d6e-9b9c-633ec0e8894e"><ix:nonFraction unitRef="shares" contextRef="i87ceb60dc20d4df1b0a97d3514837910_I20201231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8xOS9mcmFnOmY3ZTkzYjhjYTJiMDRhYmI4OTA2MDFkZWI3MGNmZTQ4L3RhYmxlOmRhYzI0NDM5OWU0NTRkZjJiYjI0MjUwMjA3OTFhOWY5L3RhYmxlcmFuZ2U6ZGFjMjQ0Mzk5ZTQ1NGRmMmJiMjQyNTAyMDc5MWE5ZjlfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOjdmNDI3OWQ5ODJhNDQxYzY5YzAyZjQ2NGYwMWE2ZDczXzU3_24e2a6cf-a750-4629-9d4b-c427c655976b"><ix:nonFraction unitRef="shares" contextRef="i1e833203be6947b4968aba4d20064ec8_I20210630" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8xOS9mcmFnOmY3ZTkzYjhjYTJiMDRhYmI4OTA2MDFkZWI3MGNmZTQ4L3RhYmxlOmRhYzI0NDM5OWU0NTRkZjJiYjI0MjUwMjA3OTFhOWY5L3RhYmxlcmFuZ2U6ZGFjMjQ0Mzk5ZTQ1NGRmMmJiMjQyNTAyMDc5MWE5ZjlfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOjdmNDI3OWQ5ODJhNDQxYzY5YzAyZjQ2NGYwMWE2ZDczXzU3_2a1f8c2e-43f2-43c8-b679-8d8c0acf6b01"><ix:nonFraction unitRef="shares" contextRef="i87ceb60dc20d4df1b0a97d3514837910_I20201231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8xOS9mcmFnOmY3ZTkzYjhjYTJiMDRhYmI4OTA2MDFkZWI3MGNmZTQ4L3RhYmxlOmRhYzI0NDM5OWU0NTRkZjJiYjI0MjUwMjA3OTFhOWY5L3RhYmxlcmFuZ2U6ZGFjMjQ0Mzk5ZTQ1NGRmMmJiMjQyNTAyMDc5MWE5ZjlfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOjdmNDI3OWQ5ODJhNDQxYzY5YzAyZjQ2NGYwMWE2ZDczXzU3_ef70fdc8-ef76-4893-9150-7eca0d4a6670">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction>ne issued or outstanding</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e833203be6947b4968aba4d20064ec8_I20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:PreferredStockValueOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8xOS9mcmFnOmY3ZTkzYjhjYTJiMDRhYmI4OTA2MDFkZWI3MGNmZTQ4L3RhYmxlOmRhYzI0NDM5OWU0NTRkZjJiYjI0MjUwMjA3OTFhOWY5L3RhYmxlcmFuZ2U6ZGFjMjQ0Mzk5ZTQ1NGRmMmJiMjQyNTAyMDc5MWE5ZjlfMzEtMS0xLTEtMA_9dbfd81f-c86d-425d-8173-9c6d6118ac00">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87ceb60dc20d4df1b0a97d3514837910_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:PreferredStockValueOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8xOS9mcmFnOmY3ZTkzYjhjYTJiMDRhYmI4OTA2MDFkZWI3MGNmZTQ4L3RhYmxlOmRhYzI0NDM5OWU0NTRkZjJiYjI0MjUwMjA3OTFhOWY5L3RhYmxlcmFuZ2U6ZGFjMjQ0Mzk5ZTQ1NGRmMmJiMjQyNTAyMDc5MWE5ZjlfMzEtMy0xLTEtMA_a029e709-9036-41f1-b00a-5715669d48e1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="i87ceb60dc20d4df1b0a97d3514837910_I20201231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8xOS9mcmFnOmY3ZTkzYjhjYTJiMDRhYmI4OTA2MDFkZWI3MGNmZTQ4L3RhYmxlOmRhYzI0NDM5OWU0NTRkZjJiYjI0MjUwMjA3OTFhOWY5L3RhYmxlcmFuZ2U6ZGFjMjQ0Mzk5ZTQ1NGRmMmJiMjQyNTAyMDc5MWE5ZjlfMzItMC0xLTEtMC90ZXh0cmVnaW9uOjIyOTYxOGQzYzU4YzRkZTVhZjc1N2EzZThhMDI4YTVmXzE4_10cc7bd5-26ac-4c9d-982f-180104cafa10"><ix:nonFraction unitRef="usdPerShare" contextRef="i1e833203be6947b4968aba4d20064ec8_I20210630" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8xOS9mcmFnOmY3ZTkzYjhjYTJiMDRhYmI4OTA2MDFkZWI3MGNmZTQ4L3RhYmxlOmRhYzI0NDM5OWU0NTRkZjJiYjI0MjUwMjA3OTFhOWY5L3RhYmxlcmFuZ2U6ZGFjMjQ0Mzk5ZTQ1NGRmMmJiMjQyNTAyMDc5MWE5ZjlfMzItMC0xLTEtMC90ZXh0cmVnaW9uOjIyOTYxOGQzYzU4YzRkZTVhZjc1N2EzZThhMDI4YTVmXzE4_6a381d03-fcee-46fd-bb78-57f67d41625a">0.001</ix:nonFraction></ix:nonFraction> par value, <ix:nonFraction unitRef="shares" contextRef="i1e833203be6947b4968aba4d20064ec8_I20210630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8xOS9mcmFnOmY3ZTkzYjhjYTJiMDRhYmI4OTA2MDFkZWI3MGNmZTQ4L3RhYmxlOmRhYzI0NDM5OWU0NTRkZjJiYjI0MjUwMjA3OTFhOWY5L3RhYmxlcmFuZ2U6ZGFjMjQ0Mzk5ZTQ1NGRmMmJiMjQyNTAyMDc5MWE5ZjlfMzItMC0xLTEtMC90ZXh0cmVnaW9uOjIyOTYxOGQzYzU4YzRkZTVhZjc1N2EzZThhMDI4YTVmXzMy_0392f4e2-feb7-4ded-81e7-923430ea3a3c"><ix:nonFraction unitRef="shares" contextRef="i87ceb60dc20d4df1b0a97d3514837910_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8xOS9mcmFnOmY3ZTkzYjhjYTJiMDRhYmI4OTA2MDFkZWI3MGNmZTQ4L3RhYmxlOmRhYzI0NDM5OWU0NTRkZjJiYjI0MjUwMjA3OTFhOWY5L3RhYmxlcmFuZ2U6ZGFjMjQ0Mzk5ZTQ1NGRmMmJiMjQyNTAyMDc5MWE5ZjlfMzItMC0xLTEtMC90ZXh0cmVnaW9uOjIyOTYxOGQzYzU4YzRkZTVhZjc1N2EzZThhMDI4YTVmXzMy_17823c2e-8c2a-40b0-a997-4d92ae24153f">60,000,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction unitRef="shares" contextRef="i1e833203be6947b4968aba4d20064ec8_I20210630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8xOS9mcmFnOmY3ZTkzYjhjYTJiMDRhYmI4OTA2MDFkZWI3MGNmZTQ4L3RhYmxlOmRhYzI0NDM5OWU0NTRkZjJiYjI0MjUwMjA3OTFhOWY5L3RhYmxlcmFuZ2U6ZGFjMjQ0Mzk5ZTQ1NGRmMmJiMjQyNTAyMDc5MWE5ZjlfMzItMC0xLTEtMC90ZXh0cmVnaW9uOjIyOTYxOGQzYzU4YzRkZTVhZjc1N2EzZThhMDI4YTVmXzU0_0c8b8962-b18e-4601-a0f4-1edd7900f3a8">37,553,355</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i87ceb60dc20d4df1b0a97d3514837910_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8xOS9mcmFnOmY3ZTkzYjhjYTJiMDRhYmI4OTA2MDFkZWI3MGNmZTQ4L3RhYmxlOmRhYzI0NDM5OWU0NTRkZjJiYjI0MjUwMjA3OTFhOWY5L3RhYmxlcmFuZ2U6ZGFjMjQ0Mzk5ZTQ1NGRmMmJiMjQyNTAyMDc5MWE5ZjlfMzItMC0xLTEtMC90ZXh0cmVnaW9uOjIyOTYxOGQzYzU4YzRkZTVhZjc1N2EzZThhMDI4YTVmXzYx_41818329-fb61-4057-975d-fe45da69d381">37,470,212</ix:nonFraction> shares issued; and <ix:nonFraction unitRef="shares" contextRef="i1e833203be6947b4968aba4d20064ec8_I20210630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8xOS9mcmFnOmY3ZTkzYjhjYTJiMDRhYmI4OTA2MDFkZWI3MGNmZTQ4L3RhYmxlOmRhYzI0NDM5OWU0NTRkZjJiYjI0MjUwMjA3OTFhOWY5L3RhYmxlcmFuZ2U6ZGFjMjQ0Mzk5ZTQ1NGRmMmJiMjQyNTAyMDc5MWE5ZjlfMzItMC0xLTEtMC90ZXh0cmVnaW9uOjIyOTYxOGQzYzU4YzRkZTVhZjc1N2EzZThhMDI4YTVmXzgz_9928a97e-8118-4cd8-9377-1dcb74d0e6ad">32,576,829</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i87ceb60dc20d4df1b0a97d3514837910_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8xOS9mcmFnOmY3ZTkzYjhjYTJiMDRhYmI4OTA2MDFkZWI3MGNmZTQ4L3RhYmxlOmRhYzI0NDM5OWU0NTRkZjJiYjI0MjUwMjA3OTFhOWY5L3RhYmxlcmFuZ2U6ZGFjMjQ0Mzk5ZTQ1NGRmMmJiMjQyNTAyMDc5MWE5ZjlfMzItMC0xLTEtMC90ZXh0cmVnaW9uOjIyOTYxOGQzYzU4YzRkZTVhZjc1N2EzZThhMDI4YTVmXzkw_332c6b1e-976b-4de2-828c-b3af7ce898fb">32,814,278</ix:nonFraction> shares outstanding</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e833203be6947b4968aba4d20064ec8_I20210630" decimals="-3" name="us-gaap:CommonStockValueOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8xOS9mcmFnOmY3ZTkzYjhjYTJiMDRhYmI4OTA2MDFkZWI3MGNmZTQ4L3RhYmxlOmRhYzI0NDM5OWU0NTRkZjJiYjI0MjUwMjA3OTFhOWY5L3RhYmxlcmFuZ2U6ZGFjMjQ0Mzk5ZTQ1NGRmMmJiMjQyNTAyMDc5MWE5ZjlfMzItMS0xLTEtMA_32923153-9b47-4ddf-b46c-f3d7225b283c">38</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87ceb60dc20d4df1b0a97d3514837910_I20201231" decimals="-3" name="us-gaap:CommonStockValueOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8xOS9mcmFnOmY3ZTkzYjhjYTJiMDRhYmI4OTA2MDFkZWI3MGNmZTQ4L3RhYmxlOmRhYzI0NDM5OWU0NTRkZjJiYjI0MjUwMjA3OTFhOWY5L3RhYmxlcmFuZ2U6ZGFjMjQ0Mzk5ZTQ1NGRmMmJiMjQyNTAyMDc5MWE5ZjlfMzItMy0xLTEtMA_0460a3a6-7691-4e50-83c2-c0c4c5361148">38</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:20.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additional paid-in capital</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e833203be6947b4968aba4d20064ec8_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapitalCommonStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8xOS9mcmFnOmY3ZTkzYjhjYTJiMDRhYmI4OTA2MDFkZWI3MGNmZTQ4L3RhYmxlOmRhYzI0NDM5OWU0NTRkZjJiYjI0MjUwMjA3OTFhOWY5L3RhYmxlcmFuZ2U6ZGFjMjQ0Mzk5ZTQ1NGRmMmJiMjQyNTAyMDc5MWE5ZjlfMzMtMS0xLTEtMA_044a3480-bbd3-40c3-87a7-3646eac0b824">714,334</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87ceb60dc20d4df1b0a97d3514837910_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapitalCommonStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8xOS9mcmFnOmY3ZTkzYjhjYTJiMDRhYmI4OTA2MDFkZWI3MGNmZTQ4L3RhYmxlOmRhYzI0NDM5OWU0NTRkZjJiYjI0MjUwMjA3OTFhOWY5L3RhYmxlcmFuZ2U6ZGFjMjQ0Mzk5ZTQ1NGRmMmJiMjQyNTAyMDc5MWE5ZjlfMzMtMy0xLTEtMA_239e9860-95e7-40b7-86b2-d08d446368c1">698,287</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Treasury stock, at cost <ix:nonFraction unitRef="shares" contextRef="i1e833203be6947b4968aba4d20064ec8_I20210630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8xOS9mcmFnOmY3ZTkzYjhjYTJiMDRhYmI4OTA2MDFkZWI3MGNmZTQ4L3RhYmxlOmRhYzI0NDM5OWU0NTRkZjJiYjI0MjUwMjA3OTFhOWY5L3RhYmxlcmFuZ2U6ZGFjMjQ0Mzk5ZTQ1NGRmMmJiMjQyNTAyMDc5MWE5ZjlfMzQtMC0xLTEtMC90ZXh0cmVnaW9uOjU1MjQ0ZjE1Y2E1NTQ3OGFiNjg1NTEyODk5NGFiMWM4XzI4_308d5e6a-da6a-4970-9032-ed6b9a0396b0">4,976,526</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i87ceb60dc20d4df1b0a97d3514837910_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8xOS9mcmFnOmY3ZTkzYjhjYTJiMDRhYmI4OTA2MDFkZWI3MGNmZTQ4L3RhYmxlOmRhYzI0NDM5OWU0NTRkZjJiYjI0MjUwMjA3OTFhOWY5L3RhYmxlcmFuZ2U6ZGFjMjQ0Mzk5ZTQ1NGRmMmJiMjQyNTAyMDc5MWE5ZjlfMzQtMC0xLTEtMC90ZXh0cmVnaW9uOjU1MjQ0ZjE1Y2E1NTQ3OGFiNjg1NTEyODk5NGFiMWM4XzM1_64cbab90-dba0-4722-8ff9-094b81ceada2">4,655,934</ix:nonFraction> shares of common stock</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1e833203be6947b4968aba4d20064ec8_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8xOS9mcmFnOmY3ZTkzYjhjYTJiMDRhYmI4OTA2MDFkZWI3MGNmZTQ4L3RhYmxlOmRhYzI0NDM5OWU0NTRkZjJiYjI0MjUwMjA3OTFhOWY5L3RhYmxlcmFuZ2U6ZGFjMjQ0Mzk5ZTQ1NGRmMmJiMjQyNTAyMDc5MWE5ZjlfMzQtMS0xLTEtMA_0c14dad2-704b-44cd-aec0-802be88d637d">400,110</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i87ceb60dc20d4df1b0a97d3514837910_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8xOS9mcmFnOmY3ZTkzYjhjYTJiMDRhYmI4OTA2MDFkZWI3MGNmZTQ4L3RhYmxlOmRhYzI0NDM5OWU0NTRkZjJiYjI0MjUwMjA3OTFhOWY5L3RhYmxlcmFuZ2U6ZGFjMjQ0Mzk5ZTQ1NGRmMmJiMjQyNTAyMDc5MWE5ZjlfMzQtMy0xLTEtMA_c0ac4212-7a15-4b12-b2e0-fcec989e20bc">319,092</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Retained earnings</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e833203be6947b4968aba4d20064ec8_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8xOS9mcmFnOmY3ZTkzYjhjYTJiMDRhYmI4OTA2MDFkZWI3MGNmZTQ4L3RhYmxlOmRhYzI0NDM5OWU0NTRkZjJiYjI0MjUwMjA3OTFhOWY5L3RhYmxlcmFuZ2U6ZGFjMjQ0Mzk5ZTQ1NGRmMmJiMjQyNTAyMDc5MWE5ZjlfMzYtMS0xLTEtMA_eeebfd27-f07a-442d-a939-5504b01c3d74">560,010</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87ceb60dc20d4df1b0a97d3514837910_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8xOS9mcmFnOmY3ZTkzYjhjYTJiMDRhYmI4OTA2MDFkZWI3MGNmZTQ4L3RhYmxlOmRhYzI0NDM5OWU0NTRkZjJiYjI0MjUwMjA3OTFhOWY5L3RhYmxlcmFuZ2U6ZGFjMjQ0Mzk5ZTQ1NGRmMmJiMjQyNTAyMDc5MWE5ZjlfMzYtMy0xLTEtMA_ef70a8ae-c75a-450b-8b73-0e5db2efdb5f">429,991</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Amedisys, Inc. stockholders&#8217; equity</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e833203be6947b4968aba4d20064ec8_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8xOS9mcmFnOmY3ZTkzYjhjYTJiMDRhYmI4OTA2MDFkZWI3MGNmZTQ4L3RhYmxlOmRhYzI0NDM5OWU0NTRkZjJiYjI0MjUwMjA3OTFhOWY5L3RhYmxlcmFuZ2U6ZGFjMjQ0Mzk5ZTQ1NGRmMmJiMjQyNTAyMDc5MWE5ZjlfMzctMS0xLTEtMA_264757fc-4cc5-4c12-a4d1-485c2beea640">874,272</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87ceb60dc20d4df1b0a97d3514837910_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8xOS9mcmFnOmY3ZTkzYjhjYTJiMDRhYmI4OTA2MDFkZWI3MGNmZTQ4L3RhYmxlOmRhYzI0NDM5OWU0NTRkZjJiYjI0MjUwMjA3OTFhOWY5L3RhYmxlcmFuZ2U6ZGFjMjQ0Mzk5ZTQ1NGRmMmJiMjQyNTAyMDc5MWE5ZjlfMzctMy0xLTEtMA_0676a3ec-4521-4e78-b89f-70f844d4845c">809,224</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncontrolling interests</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e833203be6947b4968aba4d20064ec8_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:MinorityInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8xOS9mcmFnOmY3ZTkzYjhjYTJiMDRhYmI4OTA2MDFkZWI3MGNmZTQ4L3RhYmxlOmRhYzI0NDM5OWU0NTRkZjJiYjI0MjUwMjA3OTFhOWY5L3RhYmxlcmFuZ2U6ZGFjMjQ0Mzk5ZTQ1NGRmMmJiMjQyNTAyMDc5MWE5ZjlfMzgtMS0xLTEtMA_743031b4-e77f-4655-938f-dc0bd32d59e9">1,615</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87ceb60dc20d4df1b0a97d3514837910_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:MinorityInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8xOS9mcmFnOmY3ZTkzYjhjYTJiMDRhYmI4OTA2MDFkZWI3MGNmZTQ4L3RhYmxlOmRhYzI0NDM5OWU0NTRkZjJiYjI0MjUwMjA3OTFhOWY5L3RhYmxlcmFuZ2U6ZGFjMjQ0Mzk5ZTQ1NGRmMmJiMjQyNTAyMDc5MWE5ZjlfMzgtMy0xLTEtMA_eb1a5aba-129e-42e7-8b20-676eef7ffb9c">1,517</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total equity</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e833203be6947b4968aba4d20064ec8_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8xOS9mcmFnOmY3ZTkzYjhjYTJiMDRhYmI4OTA2MDFkZWI3MGNmZTQ4L3RhYmxlOmRhYzI0NDM5OWU0NTRkZjJiYjI0MjUwMjA3OTFhOWY5L3RhYmxlcmFuZ2U6ZGFjMjQ0Mzk5ZTQ1NGRmMmJiMjQyNTAyMDc5MWE5ZjlfMzktMS0xLTEtMA_1e6b9e7a-fe9c-440d-9c22-53edf9d80e1f">875,887</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87ceb60dc20d4df1b0a97d3514837910_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8xOS9mcmFnOmY3ZTkzYjhjYTJiMDRhYmI4OTA2MDFkZWI3MGNmZTQ4L3RhYmxlOmRhYzI0NDM5OWU0NTRkZjJiYjI0MjUwMjA3OTFhOWY5L3RhYmxlcmFuZ2U6ZGFjMjQ0Mzk5ZTQ1NGRmMmJiMjQyNTAyMDc5MWE5ZjlfMzktMy0xLTEtMA_abeacf05-b668-4925-8e7f-153a2e696118">810,741</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities and equity</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e833203be6947b4968aba4d20064ec8_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8xOS9mcmFnOmY3ZTkzYjhjYTJiMDRhYmI4OTA2MDFkZWI3MGNmZTQ4L3RhYmxlOmRhYzI0NDM5OWU0NTRkZjJiYjI0MjUwMjA3OTFhOWY5L3RhYmxlcmFuZ2U6ZGFjMjQ0Mzk5ZTQ1NGRmMmJiMjQyNTAyMDc5MWE5ZjlfNDAtMS0xLTEtMA_27795952-a71e-40b0-a8d7-c343652eeef7">1,599,563</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87ceb60dc20d4df1b0a97d3514837910_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8xOS9mcmFnOmY3ZTkzYjhjYTJiMDRhYmI4OTA2MDFkZWI3MGNmZTQ4L3RhYmxlOmRhYzI0NDM5OWU0NTRkZjJiYjI0MjUwMjA3OTFhOWY5L3RhYmxlcmFuZ2U6ZGFjMjQ0Mzk5ZTQ1NGRmMmJiMjQyNTAyMDc5MWE5ZjlfNDAtMy0xLTEtMA_761d18ad-ddee-4db6-a018-9f9c3d7262e6">1,567,198</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these condensed consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><div id="iccd9c69ecd2c42e5897cfe9ab4e7e0b5_25"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AMEDISYS, INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Amounts in thousands, except per share data)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.169%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.039%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For&#160;the&#160;Three-Month&#160;<br/>Periods&#160;Ended&#160;June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For&#160;the&#160;Six-Month&#160;<br/>Periods&#160;Ended&#160;June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net service revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib87cee58ccf2448a8d4422101bf61fa0_D20210401-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yNS9mcmFnOjEyZmVlZDI1M2Y4NjQ2MDk5OTcwNzk2Y2IxODEwNWJiL3RhYmxlOmVjYTIzOWJiNDgzMjQxMDViZDBiYTkwYWE0YjJkMjFlL3RhYmxlcmFuZ2U6ZWNhMjM5YmI0ODMyNDEwNWJkMGJhOTBhYTRiMmQyMWVfMi0xLTEtMS0w_6935b4da-8cea-4160-b52e-892ec31bf483">564,166</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c8351954d014a1c80a3d8cfc2327ab2_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yNS9mcmFnOjEyZmVlZDI1M2Y4NjQ2MDk5OTcwNzk2Y2IxODEwNWJiL3RhYmxlOmVjYTIzOWJiNDgzMjQxMDViZDBiYTkwYWE0YjJkMjFlL3RhYmxlcmFuZ2U6ZWNhMjM5YmI0ODMyNDEwNWJkMGJhOTBhYTRiMmQyMWVfMi0zLTEtMS0w_2468a13c-c874-4f35-b90a-f49d46658273">485,059</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yNS9mcmFnOjEyZmVlZDI1M2Y4NjQ2MDk5OTcwNzk2Y2IxODEwNWJiL3RhYmxlOmVjYTIzOWJiNDgzMjQxMDViZDBiYTkwYWE0YjJkMjFlL3RhYmxlcmFuZ2U6ZWNhMjM5YmI0ODMyNDEwNWJkMGJhOTBhYTRiMmQyMWVfMi01LTEtMS02NQ_ccce66b1-423d-47ac-8ee0-fe20ad615b7a">1,101,310</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i667fa0996400408f9cb2d7f4d3ee2087_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yNS9mcmFnOjEyZmVlZDI1M2Y4NjQ2MDk5OTcwNzk2Y2IxODEwNWJiL3RhYmxlOmVjYTIzOWJiNDgzMjQxMDViZDBiYTkwYWE0YjJkMjFlL3RhYmxlcmFuZ2U6ZWNhMjM5YmI0ODMyNDEwNWJkMGJhOTBhYTRiMmQyMWVfMi03LTEtMS02NQ_a63f62f0-6371-4cfc-a8d3-f1e6b288d1db">976,744</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other operating income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib87cee58ccf2448a8d4422101bf61fa0_D20210401-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherOperatingIncome" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yNS9mcmFnOjEyZmVlZDI1M2Y4NjQ2MDk5OTcwNzk2Y2IxODEwNWJiL3RhYmxlOmVjYTIzOWJiNDgzMjQxMDViZDBiYTkwYWE0YjJkMjFlL3RhYmxlcmFuZ2U6ZWNhMjM5YmI0ODMyNDEwNWJkMGJhOTBhYTRiMmQyMWVfMy0xLTEtMS0w_899628bc-a38e-4257-b568-30cbfaf38479">4,603</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c8351954d014a1c80a3d8cfc2327ab2_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherOperatingIncome" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yNS9mcmFnOjEyZmVlZDI1M2Y4NjQ2MDk5OTcwNzk2Y2IxODEwNWJiL3RhYmxlOmVjYTIzOWJiNDgzMjQxMDViZDBiYTkwYWE0YjJkMjFlL3RhYmxlcmFuZ2U6ZWNhMjM5YmI0ODMyNDEwNWJkMGJhOTBhYTRiMmQyMWVfMy0zLTEtMS0w_918dad3f-2303-4be0-b536-ab176b546149">22,780</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherOperatingIncome" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yNS9mcmFnOjEyZmVlZDI1M2Y4NjQ2MDk5OTcwNzk2Y2IxODEwNWJiL3RhYmxlOmVjYTIzOWJiNDgzMjQxMDViZDBiYTkwYWE0YjJkMjFlL3RhYmxlcmFuZ2U6ZWNhMjM5YmI0ODMyNDEwNWJkMGJhOTBhYTRiMmQyMWVfMy01LTEtMS02NQ_b7a6f14f-d0f7-4d8f-a0cf-52afa1409456">13,304</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i667fa0996400408f9cb2d7f4d3ee2087_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherOperatingIncome" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yNS9mcmFnOjEyZmVlZDI1M2Y4NjQ2MDk5OTcwNzk2Y2IxODEwNWJiL3RhYmxlOmVjYTIzOWJiNDgzMjQxMDViZDBiYTkwYWE0YjJkMjFlL3RhYmxlcmFuZ2U6ZWNhMjM5YmI0ODMyNDEwNWJkMGJhOTBhYTRiMmQyMWVfMy03LTEtMS02NQ_b74c78bb-5bea-4910-b1b8-b685c227aea6">22,780</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of service, excluding depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib87cee58ccf2448a8d4422101bf61fa0_D20210401-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yNS9mcmFnOjEyZmVlZDI1M2Y4NjQ2MDk5OTcwNzk2Y2IxODEwNWJiL3RhYmxlOmVjYTIzOWJiNDgzMjQxMDViZDBiYTkwYWE0YjJkMjFlL3RhYmxlcmFuZ2U6ZWNhMjM5YmI0ODMyNDEwNWJkMGJhOTBhYTRiMmQyMWVfNC0xLTEtMS0w_7ff42579-e33c-4711-b1a7-dc7647beee47">308,691</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c8351954d014a1c80a3d8cfc2327ab2_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yNS9mcmFnOjEyZmVlZDI1M2Y4NjQ2MDk5OTcwNzk2Y2IxODEwNWJiL3RhYmxlOmVjYTIzOWJiNDgzMjQxMDViZDBiYTkwYWE0YjJkMjFlL3RhYmxlcmFuZ2U6ZWNhMjM5YmI0ODMyNDEwNWJkMGJhOTBhYTRiMmQyMWVfNC0zLTEtMS0w_9998965b-865f-407d-a360-eb14e8c313c6">295,228</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yNS9mcmFnOjEyZmVlZDI1M2Y4NjQ2MDk5OTcwNzk2Y2IxODEwNWJiL3RhYmxlOmVjYTIzOWJiNDgzMjQxMDViZDBiYTkwYWE0YjJkMjFlL3RhYmxlcmFuZ2U6ZWNhMjM5YmI0ODMyNDEwNWJkMGJhOTBhYTRiMmQyMWVfNC01LTEtMS02NQ_ff45a2f7-ac3d-4cf9-be3f-6cffa57398c5">605,894</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i667fa0996400408f9cb2d7f4d3ee2087_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yNS9mcmFnOjEyZmVlZDI1M2Y4NjQ2MDk5OTcwNzk2Y2IxODEwNWJiL3RhYmxlOmVjYTIzOWJiNDgzMjQxMDViZDBiYTkwYWE0YjJkMjFlL3RhYmxlcmFuZ2U6ZWNhMjM5YmI0ODMyNDEwNWJkMGJhOTBhYTRiMmQyMWVfNC03LTEtMS02NQ_080d054a-bd58-40ee-a2be-587d54c4285a">580,965</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Salaries and benefits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib87cee58ccf2448a8d4422101bf61fa0_D20210401-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LaborAndRelatedExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yNS9mcmFnOjEyZmVlZDI1M2Y4NjQ2MDk5OTcwNzk2Y2IxODEwNWJiL3RhYmxlOmVjYTIzOWJiNDgzMjQxMDViZDBiYTkwYWE0YjJkMjFlL3RhYmxlcmFuZ2U6ZWNhMjM5YmI0ODMyNDEwNWJkMGJhOTBhYTRiMmQyMWVfNi0xLTEtMS0w_13ae2050-f256-402b-8564-103a796512e3">114,335</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c8351954d014a1c80a3d8cfc2327ab2_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LaborAndRelatedExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yNS9mcmFnOjEyZmVlZDI1M2Y4NjQ2MDk5OTcwNzk2Y2IxODEwNWJiL3RhYmxlOmVjYTIzOWJiNDgzMjQxMDViZDBiYTkwYWE0YjJkMjFlL3RhYmxlcmFuZ2U6ZWNhMjM5YmI0ODMyNDEwNWJkMGJhOTBhYTRiMmQyMWVfNi0zLTEtMS0w_b6c76ba6-3297-4e73-a8ce-4c7d344384ad">105,617</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LaborAndRelatedExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yNS9mcmFnOjEyZmVlZDI1M2Y4NjQ2MDk5OTcwNzk2Y2IxODEwNWJiL3RhYmxlOmVjYTIzOWJiNDgzMjQxMDViZDBiYTkwYWE0YjJkMjFlL3RhYmxlcmFuZ2U6ZWNhMjM5YmI0ODMyNDEwNWJkMGJhOTBhYTRiMmQyMWVfNi01LTEtMS02NQ_13e47f85-cdef-468c-9225-0c3b9bae4e22">230,160</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i667fa0996400408f9cb2d7f4d3ee2087_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LaborAndRelatedExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yNS9mcmFnOjEyZmVlZDI1M2Y4NjQ2MDk5OTcwNzk2Y2IxODEwNWJiL3RhYmxlOmVjYTIzOWJiNDgzMjQxMDViZDBiYTkwYWE0YjJkMjFlL3RhYmxlcmFuZ2U6ZWNhMjM5YmI0ODMyNDEwNWJkMGJhOTBhYTRiMmQyMWVfNi03LTEtMS02NQ_dc797399-e3b6-4630-801d-7485d57a706d">207,183</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib87cee58ccf2448a8d4422101bf61fa0_D20210401-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yNS9mcmFnOjEyZmVlZDI1M2Y4NjQ2MDk5OTcwNzk2Y2IxODEwNWJiL3RhYmxlOmVjYTIzOWJiNDgzMjQxMDViZDBiYTkwYWE0YjJkMjFlL3RhYmxlcmFuZ2U6ZWNhMjM5YmI0ODMyNDEwNWJkMGJhOTBhYTRiMmQyMWVfNy0xLTEtMS0w_a58d5cbc-7584-48d4-935e-d52d2e21efc4">6,156</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c8351954d014a1c80a3d8cfc2327ab2_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yNS9mcmFnOjEyZmVlZDI1M2Y4NjQ2MDk5OTcwNzk2Y2IxODEwNWJiL3RhYmxlOmVjYTIzOWJiNDgzMjQxMDViZDBiYTkwYWE0YjJkMjFlL3RhYmxlcmFuZ2U6ZWNhMjM5YmI0ODMyNDEwNWJkMGJhOTBhYTRiMmQyMWVfNy0zLTEtMS0w_6d8a0653-9d75-45b8-b16a-4ad6cccab712">6,725</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yNS9mcmFnOjEyZmVlZDI1M2Y4NjQ2MDk5OTcwNzk2Y2IxODEwNWJiL3RhYmxlOmVjYTIzOWJiNDgzMjQxMDViZDBiYTkwYWE0YjJkMjFlL3RhYmxlcmFuZ2U6ZWNhMjM5YmI0ODMyNDEwNWJkMGJhOTBhYTRiMmQyMWVfNy01LTEtMS02NQ_f7268d09-bc22-489f-84c1-72a7d8797741">13,463</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i667fa0996400408f9cb2d7f4d3ee2087_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yNS9mcmFnOjEyZmVlZDI1M2Y4NjQ2MDk5OTcwNzk2Y2IxODEwNWJiL3RhYmxlOmVjYTIzOWJiNDgzMjQxMDViZDBiYTkwYWE0YjJkMjFlL3RhYmxlcmFuZ2U6ZWNhMjM5YmI0ODMyNDEwNWJkMGJhOTBhYTRiMmQyMWVfNy03LTEtMS02NQ_eb30b06f-d138-41d8-a037-325e0ff4b6f6">12,634</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib87cee58ccf2448a8d4422101bf61fa0_D20210401-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherGeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yNS9mcmFnOjEyZmVlZDI1M2Y4NjQ2MDk5OTcwNzk2Y2IxODEwNWJiL3RhYmxlOmVjYTIzOWJiNDgzMjQxMDViZDBiYTkwYWE0YjJkMjFlL3RhYmxlcmFuZ2U6ZWNhMjM5YmI0ODMyNDEwNWJkMGJhOTBhYTRiMmQyMWVfOC0xLTEtMS0w_3862a77b-78e9-472f-9821-91bdb05d4184">54,731</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c8351954d014a1c80a3d8cfc2327ab2_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherGeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yNS9mcmFnOjEyZmVlZDI1M2Y4NjQ2MDk5OTcwNzk2Y2IxODEwNWJiL3RhYmxlOmVjYTIzOWJiNDgzMjQxMDViZDBiYTkwYWE0YjJkMjFlL3RhYmxlcmFuZ2U6ZWNhMjM5YmI0ODMyNDEwNWJkMGJhOTBhYTRiMmQyMWVfOC0zLTEtMS0w_50fca2a5-4476-46ed-b8b6-f5a77f0a8999">44,003</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherGeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yNS9mcmFnOjEyZmVlZDI1M2Y4NjQ2MDk5OTcwNzk2Y2IxODEwNWJiL3RhYmxlOmVjYTIzOWJiNDgzMjQxMDViZDBiYTkwYWE0YjJkMjFlL3RhYmxlcmFuZ2U6ZWNhMjM5YmI0ODMyNDEwNWJkMGJhOTBhYTRiMmQyMWVfOC01LTEtMS02NQ_ff3c6879-78a4-4e97-963a-9bc7bf1180af">103,837</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i667fa0996400408f9cb2d7f4d3ee2087_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherGeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yNS9mcmFnOjEyZmVlZDI1M2Y4NjQ2MDk5OTcwNzk2Y2IxODEwNWJiL3RhYmxlOmVjYTIzOWJiNDgzMjQxMDViZDBiYTkwYWE0YjJkMjFlL3RhYmxlcmFuZ2U6ZWNhMjM5YmI0ODMyNDEwNWJkMGJhOTBhYTRiMmQyMWVfOC03LTEtMS02NQ_ced02e47-7583-422e-be8a-5f977efd40b3">93,268</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib87cee58ccf2448a8d4422101bf61fa0_D20210401-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DepreciationAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yNS9mcmFnOjEyZmVlZDI1M2Y4NjQ2MDk5OTcwNzk2Y2IxODEwNWJiL3RhYmxlOmVjYTIzOWJiNDgzMjQxMDViZDBiYTkwYWE0YjJkMjFlL3RhYmxlcmFuZ2U6ZWNhMjM5YmI0ODMyNDEwNWJkMGJhOTBhYTRiMmQyMWVfOS0xLTEtMS0w_ca373865-b601-4105-961e-91e8892ccf07">6,721</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c8351954d014a1c80a3d8cfc2327ab2_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DepreciationAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yNS9mcmFnOjEyZmVlZDI1M2Y4NjQ2MDk5OTcwNzk2Y2IxODEwNWJiL3RhYmxlOmVjYTIzOWJiNDgzMjQxMDViZDBiYTkwYWE0YjJkMjFlL3RhYmxlcmFuZ2U6ZWNhMjM5YmI0ODMyNDEwNWJkMGJhOTBhYTRiMmQyMWVfOS0zLTEtMS0w_0384113a-74f4-4e3e-b784-34e2948405de">6,334</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DepreciationAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yNS9mcmFnOjEyZmVlZDI1M2Y4NjQ2MDk5OTcwNzk2Y2IxODEwNWJiL3RhYmxlOmVjYTIzOWJiNDgzMjQxMDViZDBiYTkwYWE0YjJkMjFlL3RhYmxlcmFuZ2U6ZWNhMjM5YmI0ODMyNDEwNWJkMGJhOTBhYTRiMmQyMWVfOS01LTEtMS02NQ_13efe110-5e16-4dd6-a958-799d09f5b9a9">14,276</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i667fa0996400408f9cb2d7f4d3ee2087_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DepreciationAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yNS9mcmFnOjEyZmVlZDI1M2Y4NjQ2MDk5OTcwNzk2Y2IxODEwNWJiL3RhYmxlOmVjYTIzOWJiNDgzMjQxMDViZDBiYTkwYWE0YjJkMjFlL3RhYmxlcmFuZ2U6ZWNhMjM5YmI0ODMyNDEwNWJkMGJhOTBhYTRiMmQyMWVfOS03LTEtMS02NQ_692727fe-d0a9-4b7c-8c5b-305f9993c898">11,672</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib87cee58ccf2448a8d4422101bf61fa0_D20210401-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostsAndExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yNS9mcmFnOjEyZmVlZDI1M2Y4NjQ2MDk5OTcwNzk2Y2IxODEwNWJiL3RhYmxlOmVjYTIzOWJiNDgzMjQxMDViZDBiYTkwYWE0YjJkMjFlL3RhYmxlcmFuZ2U6ZWNhMjM5YmI0ODMyNDEwNWJkMGJhOTBhYTRiMmQyMWVfMTAtMS0xLTEtMA_b3d7357d-92c5-44ef-a57c-195f8b83547a">490,634</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c8351954d014a1c80a3d8cfc2327ab2_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostsAndExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yNS9mcmFnOjEyZmVlZDI1M2Y4NjQ2MDk5OTcwNzk2Y2IxODEwNWJiL3RhYmxlOmVjYTIzOWJiNDgzMjQxMDViZDBiYTkwYWE0YjJkMjFlL3RhYmxlcmFuZ2U6ZWNhMjM5YmI0ODMyNDEwNWJkMGJhOTBhYTRiMmQyMWVfMTAtMy0xLTEtMA_642e2dd4-1302-4e32-9a74-ce4cf9d0b90c">457,907</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostsAndExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yNS9mcmFnOjEyZmVlZDI1M2Y4NjQ2MDk5OTcwNzk2Y2IxODEwNWJiL3RhYmxlOmVjYTIzOWJiNDgzMjQxMDViZDBiYTkwYWE0YjJkMjFlL3RhYmxlcmFuZ2U6ZWNhMjM5YmI0ODMyNDEwNWJkMGJhOTBhYTRiMmQyMWVfMTAtNS0xLTEtNjU_e1f4a49f-a173-4643-a673-72d77a1eec26">967,630</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i667fa0996400408f9cb2d7f4d3ee2087_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostsAndExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yNS9mcmFnOjEyZmVlZDI1M2Y4NjQ2MDk5OTcwNzk2Y2IxODEwNWJiL3RhYmxlOmVjYTIzOWJiNDgzMjQxMDViZDBiYTkwYWE0YjJkMjFlL3RhYmxlcmFuZ2U6ZWNhMjM5YmI0ODMyNDEwNWJkMGJhOTBhYTRiMmQyMWVfMTAtNy0xLTEtNjU_c8829abc-abbf-402a-8b66-747acf9e5c23">905,722</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating income</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib87cee58ccf2448a8d4422101bf61fa0_D20210401-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yNS9mcmFnOjEyZmVlZDI1M2Y4NjQ2MDk5OTcwNzk2Y2IxODEwNWJiL3RhYmxlOmVjYTIzOWJiNDgzMjQxMDViZDBiYTkwYWE0YjJkMjFlL3RhYmxlcmFuZ2U6ZWNhMjM5YmI0ODMyNDEwNWJkMGJhOTBhYTRiMmQyMWVfMTEtMS0xLTEtMA_9630bf77-3a72-43ea-a706-872c185c1401">78,135</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c8351954d014a1c80a3d8cfc2327ab2_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yNS9mcmFnOjEyZmVlZDI1M2Y4NjQ2MDk5OTcwNzk2Y2IxODEwNWJiL3RhYmxlOmVjYTIzOWJiNDgzMjQxMDViZDBiYTkwYWE0YjJkMjFlL3RhYmxlcmFuZ2U6ZWNhMjM5YmI0ODMyNDEwNWJkMGJhOTBhYTRiMmQyMWVfMTEtMy0xLTEtMA_be3beb16-7b02-4cdd-bda5-4f4c5bbe65c5">49,932</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yNS9mcmFnOjEyZmVlZDI1M2Y4NjQ2MDk5OTcwNzk2Y2IxODEwNWJiL3RhYmxlOmVjYTIzOWJiNDgzMjQxMDViZDBiYTkwYWE0YjJkMjFlL3RhYmxlcmFuZ2U6ZWNhMjM5YmI0ODMyNDEwNWJkMGJhOTBhYTRiMmQyMWVfMTEtNS0xLTEtNjU_ff16a029-34bf-49d1-b866-8191eee0adeb">146,984</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i667fa0996400408f9cb2d7f4d3ee2087_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yNS9mcmFnOjEyZmVlZDI1M2Y4NjQ2MDk5OTcwNzk2Y2IxODEwNWJiL3RhYmxlOmVjYTIzOWJiNDgzMjQxMDViZDBiYTkwYWE0YjJkMjFlL3RhYmxlcmFuZ2U6ZWNhMjM5YmI0ODMyNDEwNWJkMGJhOTBhYTRiMmQyMWVfMTEtNy0xLTEtNjU_f862f18f-00f8-4727-84af-0d2baef5e2f0">93,802</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense):</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib87cee58ccf2448a8d4422101bf61fa0_D20210401-20210630" decimals="-3" name="us-gaap:InvestmentIncomeInterestAndDividend" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yNS9mcmFnOjEyZmVlZDI1M2Y4NjQ2MDk5OTcwNzk2Y2IxODEwNWJiL3RhYmxlOmVjYTIzOWJiNDgzMjQxMDViZDBiYTkwYWE0YjJkMjFlL3RhYmxlcmFuZ2U6ZWNhMjM5YmI0ODMyNDEwNWJkMGJhOTBhYTRiMmQyMWVfMTMtMS0xLTEtMA_1dfe27f5-7d13-44c3-becc-58965f377c5d">25</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c8351954d014a1c80a3d8cfc2327ab2_D20200401-20200630" decimals="-3" name="us-gaap:InvestmentIncomeInterestAndDividend" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yNS9mcmFnOjEyZmVlZDI1M2Y4NjQ2MDk5OTcwNzk2Y2IxODEwNWJiL3RhYmxlOmVjYTIzOWJiNDgzMjQxMDViZDBiYTkwYWE0YjJkMjFlL3RhYmxlcmFuZ2U6ZWNhMjM5YmI0ODMyNDEwNWJkMGJhOTBhYTRiMmQyMWVfMTMtMy0xLTEtMA_44643f77-412f-428f-bdc1-b3d0431216af">214</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630" decimals="-3" name="us-gaap:InvestmentIncomeInterestAndDividend" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yNS9mcmFnOjEyZmVlZDI1M2Y4NjQ2MDk5OTcwNzk2Y2IxODEwNWJiL3RhYmxlOmVjYTIzOWJiNDgzMjQxMDViZDBiYTkwYWE0YjJkMjFlL3RhYmxlcmFuZ2U6ZWNhMjM5YmI0ODMyNDEwNWJkMGJhOTBhYTRiMmQyMWVfMTMtNS0xLTEtNjU_fff9bd41-3e5e-4bd9-9d97-2e16af5ee142">49</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i667fa0996400408f9cb2d7f4d3ee2087_D20200101-20200630" decimals="-3" name="us-gaap:InvestmentIncomeInterestAndDividend" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yNS9mcmFnOjEyZmVlZDI1M2Y4NjQ2MDk5OTcwNzk2Y2IxODEwNWJiL3RhYmxlOmVjYTIzOWJiNDgzMjQxMDViZDBiYTkwYWE0YjJkMjFlL3RhYmxlcmFuZ2U6ZWNhMjM5YmI0ODMyNDEwNWJkMGJhOTBhYTRiMmQyMWVfMTMtNy0xLTEtNjU_b87a4dff-8ed4-4bf2-9cf5-46e3137ab73b">227</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib87cee58ccf2448a8d4422101bf61fa0_D20210401-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yNS9mcmFnOjEyZmVlZDI1M2Y4NjQ2MDk5OTcwNzk2Y2IxODEwNWJiL3RhYmxlOmVjYTIzOWJiNDgzMjQxMDViZDBiYTkwYWE0YjJkMjFlL3RhYmxlcmFuZ2U6ZWNhMjM5YmI0ODMyNDEwNWJkMGJhOTBhYTRiMmQyMWVfMTQtMS0xLTEtMA_0b79f306-e3b9-4dbc-9cb6-bbe255e6c6d4">1,932</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2c8351954d014a1c80a3d8cfc2327ab2_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yNS9mcmFnOjEyZmVlZDI1M2Y4NjQ2MDk5OTcwNzk2Y2IxODEwNWJiL3RhYmxlOmVjYTIzOWJiNDgzMjQxMDViZDBiYTkwYWE0YjJkMjFlL3RhYmxlcmFuZ2U6ZWNhMjM5YmI0ODMyNDEwNWJkMGJhOTBhYTRiMmQyMWVfMTQtMy0xLTEtMA_29136c7f-5c95-4503-8947-179257adbc73">2,752</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yNS9mcmFnOjEyZmVlZDI1M2Y4NjQ2MDk5OTcwNzk2Y2IxODEwNWJiL3RhYmxlOmVjYTIzOWJiNDgzMjQxMDViZDBiYTkwYWE0YjJkMjFlL3RhYmxlcmFuZ2U6ZWNhMjM5YmI0ODMyNDEwNWJkMGJhOTBhYTRiMmQyMWVfMTQtNS0xLTEtNjU_24d35152-1529-4076-957b-110a63f71d14">4,004</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i667fa0996400408f9cb2d7f4d3ee2087_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yNS9mcmFnOjEyZmVlZDI1M2Y4NjQ2MDk5OTcwNzk2Y2IxODEwNWJiL3RhYmxlOmVjYTIzOWJiNDgzMjQxMDViZDBiYTkwYWE0YjJkMjFlL3RhYmxlcmFuZ2U6ZWNhMjM5YmI0ODMyNDEwNWJkMGJhOTBhYTRiMmQyMWVfMTQtNy0xLTEtNjU_b16554f6-8b0a-48cc-8d58-b2e8a5306039">5,983</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity in earnings from equity method investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib87cee58ccf2448a8d4422101bf61fa0_D20210401-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yNS9mcmFnOjEyZmVlZDI1M2Y4NjQ2MDk5OTcwNzk2Y2IxODEwNWJiL3RhYmxlOmVjYTIzOWJiNDgzMjQxMDViZDBiYTkwYWE0YjJkMjFlL3RhYmxlcmFuZ2U6ZWNhMjM5YmI0ODMyNDEwNWJkMGJhOTBhYTRiMmQyMWVfMTUtMS0xLTEtMA_0ba8f945-79f4-4474-abe7-a7922a7b1e5d">1,370</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c8351954d014a1c80a3d8cfc2327ab2_D20200401-20200630" decimals="-3" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yNS9mcmFnOjEyZmVlZDI1M2Y4NjQ2MDk5OTcwNzk2Y2IxODEwNWJiL3RhYmxlOmVjYTIzOWJiNDgzMjQxMDViZDBiYTkwYWE0YjJkMjFlL3RhYmxlcmFuZ2U6ZWNhMjM5YmI0ODMyNDEwNWJkMGJhOTBhYTRiMmQyMWVfMTUtMy0xLTEtMA_578dae4f-a37a-4b98-9d2f-851435a2184e">487</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yNS9mcmFnOjEyZmVlZDI1M2Y4NjQ2MDk5OTcwNzk2Y2IxODEwNWJiL3RhYmxlOmVjYTIzOWJiNDgzMjQxMDViZDBiYTkwYWE0YjJkMjFlL3RhYmxlcmFuZ2U6ZWNhMjM5YmI0ODMyNDEwNWJkMGJhOTBhYTRiMmQyMWVfMTUtNS0xLTEtNjU_39903f24-97ae-4eca-a71f-55e5023c07f2">2,488</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i667fa0996400408f9cb2d7f4d3ee2087_D20200101-20200630" decimals="-3" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yNS9mcmFnOjEyZmVlZDI1M2Y4NjQ2MDk5OTcwNzk2Y2IxODEwNWJiL3RhYmxlOmVjYTIzOWJiNDgzMjQxMDViZDBiYTkwYWE0YjJkMjFlL3RhYmxlcmFuZ2U6ZWNhMjM5YmI0ODMyNDEwNWJkMGJhOTBhYTRiMmQyMWVfMTUtNy0xLTEtNjU_0539b32c-42ce-471b-8fdd-d212980a188a">964</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain (loss) on equity method investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib87cee58ccf2448a8d4422101bf61fa0_D20210401-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GainLossOnInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yNS9mcmFnOjEyZmVlZDI1M2Y4NjQ2MDk5OTcwNzk2Y2IxODEwNWJiL3RhYmxlOmVjYTIzOWJiNDgzMjQxMDViZDBiYTkwYWE0YjJkMjFlL3RhYmxlcmFuZ2U6ZWNhMjM5YmI0ODMyNDEwNWJkMGJhOTBhYTRiMmQyMWVfMTYtMS0xLTEtMzA4MA_be6cf61f-aafc-44ed-84e1-2af518b46298">31,092</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2c8351954d014a1c80a3d8cfc2327ab2_D20200401-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:GainLossOnInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yNS9mcmFnOjEyZmVlZDI1M2Y4NjQ2MDk5OTcwNzk2Y2IxODEwNWJiL3RhYmxlOmVjYTIzOWJiNDgzMjQxMDViZDBiYTkwYWE0YjJkMjFlL3RhYmxlcmFuZ2U6ZWNhMjM5YmI0ODMyNDEwNWJkMGJhOTBhYTRiMmQyMWVfMTYtMy0xLTEtMzA4MA_321845da-b6e1-41a6-be9b-498b1cec4788">2,980</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GainLossOnInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yNS9mcmFnOjEyZmVlZDI1M2Y4NjQ2MDk5OTcwNzk2Y2IxODEwNWJiL3RhYmxlOmVjYTIzOWJiNDgzMjQxMDViZDBiYTkwYWE0YjJkMjFlL3RhYmxlcmFuZ2U6ZWNhMjM5YmI0ODMyNDEwNWJkMGJhOTBhYTRiMmQyMWVfMTYtNS0xLTEtMzA4MA_bd2e553c-03a7-4224-8e4e-7794cd20677d">31,092</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i667fa0996400408f9cb2d7f4d3ee2087_D20200101-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:GainLossOnInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yNS9mcmFnOjEyZmVlZDI1M2Y4NjQ2MDk5OTcwNzk2Y2IxODEwNWJiL3RhYmxlOmVjYTIzOWJiNDgzMjQxMDViZDBiYTkwYWE0YjJkMjFlL3RhYmxlcmFuZ2U6ZWNhMjM5YmI0ODMyNDEwNWJkMGJhOTBhYTRiMmQyMWVfMTYtNy0xLTEtMzA4MA_bc0ca2f9-76d7-437e-8c3c-a8a3f95986fa">2,980</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Miscellaneous, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib87cee58ccf2448a8d4422101bf61fa0_D20210401-20210630" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yNS9mcmFnOjEyZmVlZDI1M2Y4NjQ2MDk5OTcwNzk2Y2IxODEwNWJiL3RhYmxlOmVjYTIzOWJiNDgzMjQxMDViZDBiYTkwYWE0YjJkMjFlL3RhYmxlcmFuZ2U6ZWNhMjM5YmI0ODMyNDEwNWJkMGJhOTBhYTRiMmQyMWVfMTYtMS0xLTEtMA_6cfa9949-2f95-4632-a755-9bb18113f7dc">475</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c8351954d014a1c80a3d8cfc2327ab2_D20200401-20200630" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yNS9mcmFnOjEyZmVlZDI1M2Y4NjQ2MDk5OTcwNzk2Y2IxODEwNWJiL3RhYmxlOmVjYTIzOWJiNDgzMjQxMDViZDBiYTkwYWE0YjJkMjFlL3RhYmxlcmFuZ2U6ZWNhMjM5YmI0ODMyNDEwNWJkMGJhOTBhYTRiMmQyMWVfMTYtMy0xLTEtMA_17b79156-9da3-4969-92a3-50b9f74091f3">277</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yNS9mcmFnOjEyZmVlZDI1M2Y4NjQ2MDk5OTcwNzk2Y2IxODEwNWJiL3RhYmxlOmVjYTIzOWJiNDgzMjQxMDViZDBiYTkwYWE0YjJkMjFlL3RhYmxlcmFuZ2U6ZWNhMjM5YmI0ODMyNDEwNWJkMGJhOTBhYTRiMmQyMWVfMTYtNS0xLTEtNjU_a191f127-cdf2-47bd-905f-cebd4097f8c1">763</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i667fa0996400408f9cb2d7f4d3ee2087_D20200101-20200630" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yNS9mcmFnOjEyZmVlZDI1M2Y4NjQ2MDk5OTcwNzk2Y2IxODEwNWJiL3RhYmxlOmVjYTIzOWJiNDgzMjQxMDViZDBiYTkwYWE0YjJkMjFlL3RhYmxlcmFuZ2U6ZWNhMjM5YmI0ODMyNDEwNWJkMGJhOTBhYTRiMmQyMWVfMTYtNy0xLTEtNjU_8895a39d-d40d-4550-8fc9-43a6d6f6d492">540</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other income (expense), net</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib87cee58ccf2448a8d4422101bf61fa0_D20210401-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yNS9mcmFnOjEyZmVlZDI1M2Y4NjQ2MDk5OTcwNzk2Y2IxODEwNWJiL3RhYmxlOmVjYTIzOWJiNDgzMjQxMDViZDBiYTkwYWE0YjJkMjFlL3RhYmxlcmFuZ2U6ZWNhMjM5YmI0ODMyNDEwNWJkMGJhOTBhYTRiMmQyMWVfMTctMS0xLTEtMA_683bfbf2-e026-428f-ad31-b9bebb71e845">31,030</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2c8351954d014a1c80a3d8cfc2327ab2_D20200401-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yNS9mcmFnOjEyZmVlZDI1M2Y4NjQ2MDk5OTcwNzk2Y2IxODEwNWJiL3RhYmxlOmVjYTIzOWJiNDgzMjQxMDViZDBiYTkwYWE0YjJkMjFlL3RhYmxlcmFuZ2U6ZWNhMjM5YmI0ODMyNDEwNWJkMGJhOTBhYTRiMmQyMWVfMTctMy0xLTEtMA_94c303de-b3ae-4fb1-97cb-f91acd62419f">4,754</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yNS9mcmFnOjEyZmVlZDI1M2Y4NjQ2MDk5OTcwNzk2Y2IxODEwNWJiL3RhYmxlOmVjYTIzOWJiNDgzMjQxMDViZDBiYTkwYWE0YjJkMjFlL3RhYmxlcmFuZ2U6ZWNhMjM5YmI0ODMyNDEwNWJkMGJhOTBhYTRiMmQyMWVfMTctNS0xLTEtNjU_fc6416ac-82b8-4006-906c-01d8e7f18158">30,388</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i667fa0996400408f9cb2d7f4d3ee2087_D20200101-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yNS9mcmFnOjEyZmVlZDI1M2Y4NjQ2MDk5OTcwNzk2Y2IxODEwNWJiL3RhYmxlOmVjYTIzOWJiNDgzMjQxMDViZDBiYTkwYWE0YjJkMjFlL3RhYmxlcmFuZ2U6ZWNhMjM5YmI0ODMyNDEwNWJkMGJhOTBhYTRiMmQyMWVfMTctNy0xLTEtNjU_2958befd-a3e0-44f6-bb10-ba89ed326fd5">7,232</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income before income taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib87cee58ccf2448a8d4422101bf61fa0_D20210401-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yNS9mcmFnOjEyZmVlZDI1M2Y4NjQ2MDk5OTcwNzk2Y2IxODEwNWJiL3RhYmxlOmVjYTIzOWJiNDgzMjQxMDViZDBiYTkwYWE0YjJkMjFlL3RhYmxlcmFuZ2U6ZWNhMjM5YmI0ODMyNDEwNWJkMGJhOTBhYTRiMmQyMWVfMTgtMS0xLTEtMA_0b7b255b-8897-4271-91cb-5e607fdfd09d">109,165</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c8351954d014a1c80a3d8cfc2327ab2_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yNS9mcmFnOjEyZmVlZDI1M2Y4NjQ2MDk5OTcwNzk2Y2IxODEwNWJiL3RhYmxlOmVjYTIzOWJiNDgzMjQxMDViZDBiYTkwYWE0YjJkMjFlL3RhYmxlcmFuZ2U6ZWNhMjM5YmI0ODMyNDEwNWJkMGJhOTBhYTRiMmQyMWVfMTgtMy0xLTEtMA_20f1c5d1-dac9-4f4a-96fa-a2ab20791b6b">45,178</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yNS9mcmFnOjEyZmVlZDI1M2Y4NjQ2MDk5OTcwNzk2Y2IxODEwNWJiL3RhYmxlOmVjYTIzOWJiNDgzMjQxMDViZDBiYTkwYWE0YjJkMjFlL3RhYmxlcmFuZ2U6ZWNhMjM5YmI0ODMyNDEwNWJkMGJhOTBhYTRiMmQyMWVfMTgtNS0xLTEtNjU_031ccf50-0984-479b-acfb-81f4156e76f4">177,372</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i667fa0996400408f9cb2d7f4d3ee2087_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yNS9mcmFnOjEyZmVlZDI1M2Y4NjQ2MDk5OTcwNzk2Y2IxODEwNWJiL3RhYmxlOmVjYTIzOWJiNDgzMjQxMDViZDBiYTkwYWE0YjJkMjFlL3RhYmxlcmFuZ2U6ZWNhMjM5YmI0ODMyNDEwNWJkMGJhOTBhYTRiMmQyMWVfMTgtNy0xLTEtNjU_5ca78b14-0227-4854-9f2f-15379e42e9f4">86,570</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib87cee58ccf2448a8d4422101bf61fa0_D20210401-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yNS9mcmFnOjEyZmVlZDI1M2Y4NjQ2MDk5OTcwNzk2Y2IxODEwNWJiL3RhYmxlOmVjYTIzOWJiNDgzMjQxMDViZDBiYTkwYWE0YjJkMjFlL3RhYmxlcmFuZ2U6ZWNhMjM5YmI0ODMyNDEwNWJkMGJhOTBhYTRiMmQyMWVfMTktMS0xLTEtMA_3a0ae354-e158-4233-abba-ec6a33af0a2c">28,546</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2c8351954d014a1c80a3d8cfc2327ab2_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yNS9mcmFnOjEyZmVlZDI1M2Y4NjQ2MDk5OTcwNzk2Y2IxODEwNWJiL3RhYmxlOmVjYTIzOWJiNDgzMjQxMDViZDBiYTkwYWE0YjJkMjFlL3RhYmxlcmFuZ2U6ZWNhMjM5YmI0ODMyNDEwNWJkMGJhOTBhYTRiMmQyMWVfMTktMy0xLTEtMA_85fa932f-9b3f-4af3-9a1e-6dc296b5d549">10,031</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yNS9mcmFnOjEyZmVlZDI1M2Y4NjQ2MDk5OTcwNzk2Y2IxODEwNWJiL3RhYmxlOmVjYTIzOWJiNDgzMjQxMDViZDBiYTkwYWE0YjJkMjFlL3RhYmxlcmFuZ2U6ZWNhMjM5YmI0ODMyNDEwNWJkMGJhOTBhYTRiMmQyMWVfMTktNS0xLTEtNjU_e51bdae4-fcd0-48b9-b772-a62acacbaea6">46,461</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i667fa0996400408f9cb2d7f4d3ee2087_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yNS9mcmFnOjEyZmVlZDI1M2Y4NjQ2MDk5OTcwNzk2Y2IxODEwNWJiL3RhYmxlOmVjYTIzOWJiNDgzMjQxMDViZDBiYTkwYWE0YjJkMjFlL3RhYmxlcmFuZ2U6ZWNhMjM5YmI0ODMyNDEwNWJkMGJhOTBhYTRiMmQyMWVfMTktNy0xLTEtNjU_3eb27a6a-2251-45ab-aaee-a857653bb8c4">19,377</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib87cee58ccf2448a8d4422101bf61fa0_D20210401-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yNS9mcmFnOjEyZmVlZDI1M2Y4NjQ2MDk5OTcwNzk2Y2IxODEwNWJiL3RhYmxlOmVjYTIzOWJiNDgzMjQxMDViZDBiYTkwYWE0YjJkMjFlL3RhYmxlcmFuZ2U6ZWNhMjM5YmI0ODMyNDEwNWJkMGJhOTBhYTRiMmQyMWVfMjAtMS0xLTEtMA_a2a52bc8-f90d-44e0-8356-c0a768c13134">80,619</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c8351954d014a1c80a3d8cfc2327ab2_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yNS9mcmFnOjEyZmVlZDI1M2Y4NjQ2MDk5OTcwNzk2Y2IxODEwNWJiL3RhYmxlOmVjYTIzOWJiNDgzMjQxMDViZDBiYTkwYWE0YjJkMjFlL3RhYmxlcmFuZ2U6ZWNhMjM5YmI0ODMyNDEwNWJkMGJhOTBhYTRiMmQyMWVfMjAtMy0xLTEtMA_d143a4a3-679e-427d-af53-1ab5fc2c5670">35,147</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yNS9mcmFnOjEyZmVlZDI1M2Y4NjQ2MDk5OTcwNzk2Y2IxODEwNWJiL3RhYmxlOmVjYTIzOWJiNDgzMjQxMDViZDBiYTkwYWE0YjJkMjFlL3RhYmxlcmFuZ2U6ZWNhMjM5YmI0ODMyNDEwNWJkMGJhOTBhYTRiMmQyMWVfMjAtNS0xLTEtNjU_f9356941-bfeb-4b03-83b7-cc79a7a91e0a">130,911</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i667fa0996400408f9cb2d7f4d3ee2087_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yNS9mcmFnOjEyZmVlZDI1M2Y4NjQ2MDk5OTcwNzk2Y2IxODEwNWJiL3RhYmxlOmVjYTIzOWJiNDgzMjQxMDViZDBiYTkwYWE0YjJkMjFlL3RhYmxlcmFuZ2U6ZWNhMjM5YmI0ODMyNDEwNWJkMGJhOTBhYTRiMmQyMWVfMjAtNy0xLTEtNjU_61880bc8-623f-4995-af66-29fa6fc823c2">67,193</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to noncontrolling interests</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib87cee58ccf2448a8d4422101bf61fa0_D20210401-20210630" decimals="-3" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yNS9mcmFnOjEyZmVlZDI1M2Y4NjQ2MDk5OTcwNzk2Y2IxODEwNWJiL3RhYmxlOmVjYTIzOWJiNDgzMjQxMDViZDBiYTkwYWE0YjJkMjFlL3RhYmxlcmFuZ2U6ZWNhMjM5YmI0ODMyNDEwNWJkMGJhOTBhYTRiMmQyMWVfMjEtMS0xLTEtMA_f0a3d7df-aa35-4660-a6cf-1a63dd206386">470</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2c8351954d014a1c80a3d8cfc2327ab2_D20200401-20200630" decimals="-3" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yNS9mcmFnOjEyZmVlZDI1M2Y4NjQ2MDk5OTcwNzk2Y2IxODEwNWJiL3RhYmxlOmVjYTIzOWJiNDgzMjQxMDViZDBiYTkwYWE0YjJkMjFlL3RhYmxlcmFuZ2U6ZWNhMjM5YmI0ODMyNDEwNWJkMGJhOTBhYTRiMmQyMWVfMjEtMy0xLTEtMA_7edbf1b9-9c91-4593-bd84-33f8b1af990d">473</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630" decimals="-3" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yNS9mcmFnOjEyZmVlZDI1M2Y4NjQ2MDk5OTcwNzk2Y2IxODEwNWJiL3RhYmxlOmVjYTIzOWJiNDgzMjQxMDViZDBiYTkwYWE0YjJkMjFlL3RhYmxlcmFuZ2U6ZWNhMjM5YmI0ODMyNDEwNWJkMGJhOTBhYTRiMmQyMWVfMjEtNS0xLTEtNjU_a03cd9eb-0744-4e12-8cba-0fec103fed4d">892</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i667fa0996400408f9cb2d7f4d3ee2087_D20200101-20200630" decimals="-3" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yNS9mcmFnOjEyZmVlZDI1M2Y4NjQ2MDk5OTcwNzk2Y2IxODEwNWJiL3RhYmxlOmVjYTIzOWJiNDgzMjQxMDViZDBiYTkwYWE0YjJkMjFlL3RhYmxlcmFuZ2U6ZWNhMjM5YmI0ODMyNDEwNWJkMGJhOTBhYTRiMmQyMWVfMjEtNy0xLTEtNjU_44db5d00-cf3f-41cb-a14b-e46109e74cb0">717</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to Amedisys, Inc.</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib87cee58ccf2448a8d4422101bf61fa0_D20210401-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yNS9mcmFnOjEyZmVlZDI1M2Y4NjQ2MDk5OTcwNzk2Y2IxODEwNWJiL3RhYmxlOmVjYTIzOWJiNDgzMjQxMDViZDBiYTkwYWE0YjJkMjFlL3RhYmxlcmFuZ2U6ZWNhMjM5YmI0ODMyNDEwNWJkMGJhOTBhYTRiMmQyMWVfMjItMS0xLTEtMA_fc91ae5f-73a9-4104-af74-853504ad0e52">80,149</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c8351954d014a1c80a3d8cfc2327ab2_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yNS9mcmFnOjEyZmVlZDI1M2Y4NjQ2MDk5OTcwNzk2Y2IxODEwNWJiL3RhYmxlOmVjYTIzOWJiNDgzMjQxMDViZDBiYTkwYWE0YjJkMjFlL3RhYmxlcmFuZ2U6ZWNhMjM5YmI0ODMyNDEwNWJkMGJhOTBhYTRiMmQyMWVfMjItMy0xLTEtMA_6960c4ba-c74b-48d7-891c-462aebf75c19">34,674</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yNS9mcmFnOjEyZmVlZDI1M2Y4NjQ2MDk5OTcwNzk2Y2IxODEwNWJiL3RhYmxlOmVjYTIzOWJiNDgzMjQxMDViZDBiYTkwYWE0YjJkMjFlL3RhYmxlcmFuZ2U6ZWNhMjM5YmI0ODMyNDEwNWJkMGJhOTBhYTRiMmQyMWVfMjItNS0xLTEtNjU_7144d208-50dd-40e5-a7e2-cb98f8b04107">130,019</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i667fa0996400408f9cb2d7f4d3ee2087_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yNS9mcmFnOjEyZmVlZDI1M2Y4NjQ2MDk5OTcwNzk2Y2IxODEwNWJiL3RhYmxlOmVjYTIzOWJiNDgzMjQxMDViZDBiYTkwYWE0YjJkMjFlL3RhYmxlcmFuZ2U6ZWNhMjM5YmI0ODMyNDEwNWJkMGJhOTBhYTRiMmQyMWVfMjItNy0xLTEtNjU_8654048c-d400-4ae8-84a8-24b21abe9093">66,476</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic earnings per common share:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to Amedisys, Inc. common stockholders</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ib87cee58ccf2448a8d4422101bf61fa0_D20210401-20210630" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yNS9mcmFnOjEyZmVlZDI1M2Y4NjQ2MDk5OTcwNzk2Y2IxODEwNWJiL3RhYmxlOmVjYTIzOWJiNDgzMjQxMDViZDBiYTkwYWE0YjJkMjFlL3RhYmxlcmFuZ2U6ZWNhMjM5YmI0ODMyNDEwNWJkMGJhOTBhYTRiMmQyMWVfMjQtMS0xLTEtMA_7d40b4be-ad66-4698-a4b8-514f057820f0">2.46</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i2c8351954d014a1c80a3d8cfc2327ab2_D20200401-20200630" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yNS9mcmFnOjEyZmVlZDI1M2Y4NjQ2MDk5OTcwNzk2Y2IxODEwNWJiL3RhYmxlOmVjYTIzOWJiNDgzMjQxMDViZDBiYTkwYWE0YjJkMjFlL3RhYmxlcmFuZ2U6ZWNhMjM5YmI0ODMyNDEwNWJkMGJhOTBhYTRiMmQyMWVfMjQtMy0xLTEtMA_f3f01c35-efd4-4458-b4e1-6813ff63f3cb">1.07</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yNS9mcmFnOjEyZmVlZDI1M2Y4NjQ2MDk5OTcwNzk2Y2IxODEwNWJiL3RhYmxlOmVjYTIzOWJiNDgzMjQxMDViZDBiYTkwYWE0YjJkMjFlL3RhYmxlcmFuZ2U6ZWNhMjM5YmI0ODMyNDEwNWJkMGJhOTBhYTRiMmQyMWVfMjQtNS0xLTEtNjU_13505e1c-9009-494c-9473-96fb2afa8632">3.98</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i667fa0996400408f9cb2d7f4d3ee2087_D20200101-20200630" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yNS9mcmFnOjEyZmVlZDI1M2Y4NjQ2MDk5OTcwNzk2Y2IxODEwNWJiL3RhYmxlOmVjYTIzOWJiNDgzMjQxMDViZDBiYTkwYWE0YjJkMjFlL3RhYmxlcmFuZ2U6ZWNhMjM5YmI0ODMyNDEwNWJkMGJhOTBhYTRiMmQyMWVfMjQtNy0xLTEtNjU_9041603d-fcb2-4157-8a04-d06ed238f81a">2.05</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares outstanding</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib87cee58ccf2448a8d4422101bf61fa0_D20210401-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yNS9mcmFnOjEyZmVlZDI1M2Y4NjQ2MDk5OTcwNzk2Y2IxODEwNWJiL3RhYmxlOmVjYTIzOWJiNDgzMjQxMDViZDBiYTkwYWE0YjJkMjFlL3RhYmxlcmFuZ2U6ZWNhMjM5YmI0ODMyNDEwNWJkMGJhOTBhYTRiMmQyMWVfMjUtMS0xLTEtMA_9b251a30-efb9-42f7-b66b-c1109bca4361">32,588</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2c8351954d014a1c80a3d8cfc2327ab2_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yNS9mcmFnOjEyZmVlZDI1M2Y4NjQ2MDk5OTcwNzk2Y2IxODEwNWJiL3RhYmxlOmVjYTIzOWJiNDgzMjQxMDViZDBiYTkwYWE0YjJkMjFlL3RhYmxlcmFuZ2U6ZWNhMjM5YmI0ODMyNDEwNWJkMGJhOTBhYTRiMmQyMWVfMjUtMy0xLTEtMA_a6c9bc6d-bf74-4222-9346-6fabae5b5740">32,412</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yNS9mcmFnOjEyZmVlZDI1M2Y4NjQ2MDk5OTcwNzk2Y2IxODEwNWJiL3RhYmxlOmVjYTIzOWJiNDgzMjQxMDViZDBiYTkwYWE0YjJkMjFlL3RhYmxlcmFuZ2U6ZWNhMjM5YmI0ODMyNDEwNWJkMGJhOTBhYTRiMmQyMWVfMjUtNS0xLTEtNjU_4b2be42d-442f-46e3-a41c-2c8601a8a011">32,684</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i667fa0996400408f9cb2d7f4d3ee2087_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yNS9mcmFnOjEyZmVlZDI1M2Y4NjQ2MDk5OTcwNzk2Y2IxODEwNWJiL3RhYmxlOmVjYTIzOWJiNDgzMjQxMDViZDBiYTkwYWE0YjJkMjFlL3RhYmxlcmFuZ2U6ZWNhMjM5YmI0ODMyNDEwNWJkMGJhOTBhYTRiMmQyMWVfMjUtNy0xLTEtNjU_d5d7d785-5179-45b8-8ef6-5a26130e43f8">32,371</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted earnings per common share:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to Amedisys, Inc. common stockholders</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ib87cee58ccf2448a8d4422101bf61fa0_D20210401-20210630" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yNS9mcmFnOjEyZmVlZDI1M2Y4NjQ2MDk5OTcwNzk2Y2IxODEwNWJiL3RhYmxlOmVjYTIzOWJiNDgzMjQxMDViZDBiYTkwYWE0YjJkMjFlL3RhYmxlcmFuZ2U6ZWNhMjM5YmI0ODMyNDEwNWJkMGJhOTBhYTRiMmQyMWVfMjctMS0xLTEtMA_ba7814d4-11f1-4d19-ba15-e77763922b0c">2.43</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i2c8351954d014a1c80a3d8cfc2327ab2_D20200401-20200630" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yNS9mcmFnOjEyZmVlZDI1M2Y4NjQ2MDk5OTcwNzk2Y2IxODEwNWJiL3RhYmxlOmVjYTIzOWJiNDgzMjQxMDViZDBiYTkwYWE0YjJkMjFlL3RhYmxlcmFuZ2U6ZWNhMjM5YmI0ODMyNDEwNWJkMGJhOTBhYTRiMmQyMWVfMjctMy0xLTEtMA_bb88cb18-e271-484d-97ae-a8b4f3f95331">1.04</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yNS9mcmFnOjEyZmVlZDI1M2Y4NjQ2MDk5OTcwNzk2Y2IxODEwNWJiL3RhYmxlOmVjYTIzOWJiNDgzMjQxMDViZDBiYTkwYWE0YjJkMjFlL3RhYmxlcmFuZ2U6ZWNhMjM5YmI0ODMyNDEwNWJkMGJhOTBhYTRiMmQyMWVfMjctNS0xLTEtNjU_f1f18727-6e49-43cc-9e58-ffd8e4bec6b4">3.93</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i667fa0996400408f9cb2d7f4d3ee2087_D20200101-20200630" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yNS9mcmFnOjEyZmVlZDI1M2Y4NjQ2MDk5OTcwNzk2Y2IxODEwNWJiL3RhYmxlOmVjYTIzOWJiNDgzMjQxMDViZDBiYTkwYWE0YjJkMjFlL3RhYmxlcmFuZ2U6ZWNhMjM5YmI0ODMyNDEwNWJkMGJhOTBhYTRiMmQyMWVfMjctNy0xLTEtNjU_f09e4023-0913-4df3-8f5e-27717b1d85b6">2.00</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares outstanding</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib87cee58ccf2448a8d4422101bf61fa0_D20210401-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yNS9mcmFnOjEyZmVlZDI1M2Y4NjQ2MDk5OTcwNzk2Y2IxODEwNWJiL3RhYmxlOmVjYTIzOWJiNDgzMjQxMDViZDBiYTkwYWE0YjJkMjFlL3RhYmxlcmFuZ2U6ZWNhMjM5YmI0ODMyNDEwNWJkMGJhOTBhYTRiMmQyMWVfMjgtMS0xLTEtMA_646932e8-ff3c-43ea-b510-dfc9cbb4e814">32,981</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2c8351954d014a1c80a3d8cfc2327ab2_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yNS9mcmFnOjEyZmVlZDI1M2Y4NjQ2MDk5OTcwNzk2Y2IxODEwNWJiL3RhYmxlOmVjYTIzOWJiNDgzMjQxMDViZDBiYTkwYWE0YjJkMjFlL3RhYmxlcmFuZ2U6ZWNhMjM5YmI0ODMyNDEwNWJkMGJhOTBhYTRiMmQyMWVfMjgtMy0xLTEtMA_b0ca2f1f-fa88-46b8-b4bb-5da16d65defd">33,285</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yNS9mcmFnOjEyZmVlZDI1M2Y4NjQ2MDk5OTcwNzk2Y2IxODEwNWJiL3RhYmxlOmVjYTIzOWJiNDgzMjQxMDViZDBiYTkwYWE0YjJkMjFlL3RhYmxlcmFuZ2U6ZWNhMjM5YmI0ODMyNDEwNWJkMGJhOTBhYTRiMmQyMWVfMjgtNS0xLTEtNjU_52873162-7f19-4cb7-9060-f191be232d4e">33,085</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i667fa0996400408f9cb2d7f4d3ee2087_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yNS9mcmFnOjEyZmVlZDI1M2Y4NjQ2MDk5OTcwNzk2Y2IxODEwNWJiL3RhYmxlOmVjYTIzOWJiNDgzMjQxMDViZDBiYTkwYWE0YjJkMjFlL3RhYmxlcmFuZ2U6ZWNhMjM5YmI0ODMyNDEwNWJkMGJhOTBhYTRiMmQyMWVfMjgtNy0xLTEtNjU_2a1672d6-9c37-4d54-80ca-28003416aa5f">33,259</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these condensed consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><div id="iccd9c69ecd2c42e5897cfe9ab4e7e0b5_28"></div><hr style="page-break-after:always"/><div style="min-height:4.5pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> AMEDISYS, INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS&#8217; EQUITY</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Amounts in thousands, except common stock shares)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:29.455%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.538%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.150%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.816%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.122%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.983%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.601%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="45" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three-Months Ended June 30, 2021</span></td></tr><tr style="height:9pt"><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additional<br/>Paid-in<br/>Capital</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Treasury<br/>Stock</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Other<br/>Comprehensive Income</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Retained<br/>Earnings </span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Noncontrolling<br/>Interests</span></td></tr><tr style="height:23pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, March 31, 2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb79ce9f481b42d1ab430d3f3d11be5a_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yOC9mcmFnOjBlNDhiNzZhMTAxZjRjODJiMGUzNzJhYTlhOWNmNDhiL3RhYmxlOmRiMjI3MDg4YTQwODRmYWQ5NGEwMzFlNGMyODIyZTk3L3RhYmxlcmFuZ2U6ZGIyMjcwODhhNDA4NGZhZDk0YTAzMWU0YzI4MjJlOTdfMy0xLTEtMS0w_de78d0e3-c6a0-47c7-b65f-a3310eb1d93b">789,574</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6a51d0190d2c46638e83e1dd687ec01c_I20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yOC9mcmFnOjBlNDhiNzZhMTAxZjRjODJiMGUzNzJhYTlhOWNmNDhiL3RhYmxlOmRiMjI3MDg4YTQwODRmYWQ5NGEwMzFlNGMyODIyZTk3L3RhYmxlcmFuZ2U6ZGIyMjcwODhhNDA4NGZhZDk0YTAzMWU0YzI4MjJlOTdfMy0zLTEtMS0w_97df009e-fe1c-4252-875c-35ea35c5efe3">37,538,837</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a51d0190d2c46638e83e1dd687ec01c_I20210331" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yOC9mcmFnOjBlNDhiNzZhMTAxZjRjODJiMGUzNzJhYTlhOWNmNDhiL3RhYmxlOmRiMjI3MDg4YTQwODRmYWQ5NGEwMzFlNGMyODIyZTk3L3RhYmxlcmFuZ2U6ZGIyMjcwODhhNDA4NGZhZDk0YTAzMWU0YzI4MjJlOTdfMy01LTEtMS0w_a32bc23c-769d-4ec6-9886-574cadf639a8">38</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i505af52860ef4f88b5ff9bd288e4b861_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yOC9mcmFnOjBlNDhiNzZhMTAxZjRjODJiMGUzNzJhYTlhOWNmNDhiL3RhYmxlOmRiMjI3MDg4YTQwODRmYWQ5NGEwMzFlNGMyODIyZTk3L3RhYmxlcmFuZ2U6ZGIyMjcwODhhNDA4NGZhZDk0YTAzMWU0YzI4MjJlOTdfMy03LTEtMS0w_23f5d1dd-18be-41cf-a8b1-defb7461c2d5">707,006</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i74fd298667c64003ab51d64eb7694f4f_I20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yOC9mcmFnOjBlNDhiNzZhMTAxZjRjODJiMGUzNzJhYTlhOWNmNDhiL3RhYmxlOmRiMjI3MDg4YTQwODRmYWQ5NGEwMzFlNGMyODIyZTk3L3RhYmxlcmFuZ2U6ZGIyMjcwODhhNDA4NGZhZDk0YTAzMWU0YzI4MjJlOTdfMy05LTEtMS0w_55ea7060-d56c-4dd4-9408-0422d9c5ddfa">398,752</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idebaf491ed4a4eaa830b4edf82a260af_I20210331" decimals="-3" format="ixt:zerodash" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yOC9mcmFnOjBlNDhiNzZhMTAxZjRjODJiMGUzNzJhYTlhOWNmNDhiL3RhYmxlOmRiMjI3MDg4YTQwODRmYWQ5NGEwMzFlNGMyODIyZTk3L3RhYmxlcmFuZ2U6ZGIyMjcwODhhNDA4NGZhZDk0YTAzMWU0YzI4MjJlOTdfMy0xMS0xLTEtMA_8fa2300b-276e-40f9-b840-d62e1f984385">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2abc69b9d9f54af3a54fc8752ccb2ab0_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yOC9mcmFnOjBlNDhiNzZhMTAxZjRjODJiMGUzNzJhYTlhOWNmNDhiL3RhYmxlOmRiMjI3MDg4YTQwODRmYWQ5NGEwMzFlNGMyODIyZTk3L3RhYmxlcmFuZ2U6ZGIyMjcwODhhNDA4NGZhZDk0YTAzMWU0YzI4MjJlOTdfMy0xMy0xLTEtMA_1063b15d-d09a-4438-8efa-c9b37b3eaea4">479,861</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f49d2d5c447470d8ad1b0c00a898651_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yOC9mcmFnOjBlNDhiNzZhMTAxZjRjODJiMGUzNzJhYTlhOWNmNDhiL3RhYmxlOmRiMjI3MDg4YTQwODRmYWQ5NGEwMzFlNGMyODIyZTk3L3RhYmxlcmFuZ2U6ZGIyMjcwODhhNDA4NGZhZDk0YTAzMWU0YzI4MjJlOTdfMy0xNS0xLTEtMA_040d6aa0-fa98-4e4e-b569-b7b66717b530">1,421</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of stock &#8211; employee stock purchase plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib87cee58ccf2448a8d4422101bf61fa0_D20210401-20210630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yOC9mcmFnOjBlNDhiNzZhMTAxZjRjODJiMGUzNzJhYTlhOWNmNDhiL3RhYmxlOmRiMjI3MDg4YTQwODRmYWQ5NGEwMzFlNGMyODIyZTk3L3RhYmxlcmFuZ2U6ZGIyMjcwODhhNDA4NGZhZDk0YTAzMWU0YzI4MjJlOTdfNC0xLTEtMS0w_78019710-a6ec-49b7-8f32-fcc6473cd81f">913</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia839bd0c1e7440a2be8dd89d587ab038_D20210401-20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yOC9mcmFnOjBlNDhiNzZhMTAxZjRjODJiMGUzNzJhYTlhOWNmNDhiL3RhYmxlOmRiMjI3MDg4YTQwODRmYWQ5NGEwMzFlNGMyODIyZTk3L3RhYmxlcmFuZ2U6ZGIyMjcwODhhNDA4NGZhZDk0YTAzMWU0YzI4MjJlOTdfNC0zLTEtMS0w_f87c9bd4-2fed-402b-b1ab-5790f8b82cf0">4,060</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i873536f8b14a43938a68d5f9d661e909_D20210401-20210630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yOC9mcmFnOjBlNDhiNzZhMTAxZjRjODJiMGUzNzJhYTlhOWNmNDhiL3RhYmxlOmRiMjI3MDg4YTQwODRmYWQ5NGEwMzFlNGMyODIyZTk3L3RhYmxlcmFuZ2U6ZGIyMjcwODhhNDA4NGZhZDk0YTAzMWU0YzI4MjJlOTdfNC03LTEtMS0w_89938d7f-29a7-4c78-808d-153be7ab1128">913</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance/(cancellation) of non-vested stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib87cee58ccf2448a8d4422101bf61fa0_D20210401-20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yOC9mcmFnOjBlNDhiNzZhMTAxZjRjODJiMGUzNzJhYTlhOWNmNDhiL3RhYmxlOmRiMjI3MDg4YTQwODRmYWQ5NGEwMzFlNGMyODIyZTk3L3RhYmxlcmFuZ2U6ZGIyMjcwODhhNDA4NGZhZDk0YTAzMWU0YzI4MjJlOTdfNS0xLTEtMS0w_d36b6b4d-3945-46b3-a15b-775d5a873423">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia839bd0c1e7440a2be8dd89d587ab038_D20210401-20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yOC9mcmFnOjBlNDhiNzZhMTAxZjRjODJiMGUzNzJhYTlhOWNmNDhiL3RhYmxlOmRiMjI3MDg4YTQwODRmYWQ5NGEwMzFlNGMyODIyZTk3L3RhYmxlcmFuZ2U6ZGIyMjcwODhhNDA4NGZhZDk0YTAzMWU0YzI4MjJlOTdfNS0zLTEtMS0w_67749ce5-7d23-417c-8977-a4ae74973f79">4,068</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia839bd0c1e7440a2be8dd89d587ab038_D20210401-20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yOC9mcmFnOjBlNDhiNzZhMTAxZjRjODJiMGUzNzJhYTlhOWNmNDhiL3RhYmxlOmRiMjI3MDg4YTQwODRmYWQ5NGEwMzFlNGMyODIyZTk3L3RhYmxlcmFuZ2U6ZGIyMjcwODhhNDA4NGZhZDk0YTAzMWU0YzI4MjJlOTdfNS01LTEtMS0w_635fef53-af28-45da-b8d8-ce502bf5c21a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i873536f8b14a43938a68d5f9d661e909_D20210401-20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yOC9mcmFnOjBlNDhiNzZhMTAxZjRjODJiMGUzNzJhYTlhOWNmNDhiL3RhYmxlOmRiMjI3MDg4YTQwODRmYWQ5NGEwMzFlNGMyODIyZTk3L3RhYmxlcmFuZ2U6ZGIyMjcwODhhNDA4NGZhZDk0YTAzMWU0YzI4MjJlOTdfNS03LTEtMS0w_8a7ebd54-2b40-411c-8dfa-438a997dd8db">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exercise of stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib87cee58ccf2448a8d4422101bf61fa0_D20210401-20210630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yOC9mcmFnOjBlNDhiNzZhMTAxZjRjODJiMGUzNzJhYTlhOWNmNDhiL3RhYmxlOmRiMjI3MDg4YTQwODRmYWQ5NGEwMzFlNGMyODIyZTk3L3RhYmxlcmFuZ2U6ZGIyMjcwODhhNDA4NGZhZDk0YTAzMWU0YzI4MjJlOTdfNi0xLTEtMS0w_70569434-2b27-4051-a30d-56319a91743d">259</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia839bd0c1e7440a2be8dd89d587ab038_D20210401-20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yOC9mcmFnOjBlNDhiNzZhMTAxZjRjODJiMGUzNzJhYTlhOWNmNDhiL3RhYmxlOmRiMjI3MDg4YTQwODRmYWQ5NGEwMzFlNGMyODIyZTk3L3RhYmxlcmFuZ2U6ZGIyMjcwODhhNDA4NGZhZDk0YTAzMWU0YzI4MjJlOTdfNi0zLTEtMS0w_40813a25-cd27-436b-a27d-b2d743585a4a">6,390</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i873536f8b14a43938a68d5f9d661e909_D20210401-20210630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yOC9mcmFnOjBlNDhiNzZhMTAxZjRjODJiMGUzNzJhYTlhOWNmNDhiL3RhYmxlOmRiMjI3MDg4YTQwODRmYWQ5NGEwMzFlNGMyODIyZTk3L3RhYmxlcmFuZ2U6ZGIyMjcwODhhNDA4NGZhZDk0YTAzMWU0YzI4MjJlOTdfNi03LTEtMS0w_2bb5d200-1cd8-4000-80fc-9ca10b7ac021">259</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-cash compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib87cee58ccf2448a8d4422101bf61fa0_D20210401-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yOC9mcmFnOjBlNDhiNzZhMTAxZjRjODJiMGUzNzJhYTlhOWNmNDhiL3RhYmxlOmRiMjI3MDg4YTQwODRmYWQ5NGEwMzFlNGMyODIyZTk3L3RhYmxlcmFuZ2U6ZGIyMjcwODhhNDA4NGZhZDk0YTAzMWU0YzI4MjJlOTdfNy0xLTEtMS0w_5ae559f6-be98-46b0-a58c-ac146fd4a6db">6,156</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i873536f8b14a43938a68d5f9d661e909_D20210401-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yOC9mcmFnOjBlNDhiNzZhMTAxZjRjODJiMGUzNzJhYTlhOWNmNDhiL3RhYmxlOmRiMjI3MDg4YTQwODRmYWQ5NGEwMzFlNGMyODIyZTk3L3RhYmxlcmFuZ2U6ZGIyMjcwODhhNDA4NGZhZDk0YTAzMWU0YzI4MjJlOTdfNy03LTEtMS0w_cd36d17e-130a-4de3-9054-35ff24c86786">6,156</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Surrendered shares</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib87cee58ccf2448a8d4422101bf61fa0_D20210401-20210630" decimals="-3" name="amed:SurrenderedShares" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yOC9mcmFnOjBlNDhiNzZhMTAxZjRjODJiMGUzNzJhYTlhOWNmNDhiL3RhYmxlOmRiMjI3MDg4YTQwODRmYWQ5NGEwMzFlNGMyODIyZTk3L3RhYmxlcmFuZ2U6ZGIyMjcwODhhNDA4NGZhZDk0YTAzMWU0YzI4MjJlOTdfOC0xLTEtMS0w_aa8d4362-1e30-4cce-8b80-cbfa6925a52d">170</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iee63e04ff2174c9686bcc42c3eb46125_D20210401-20210630" decimals="-3" name="amed:SurrenderedShares" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yOC9mcmFnOjBlNDhiNzZhMTAxZjRjODJiMGUzNzJhYTlhOWNmNDhiL3RhYmxlOmRiMjI3MDg4YTQwODRmYWQ5NGEwMzFlNGMyODIyZTk3L3RhYmxlcmFuZ2U6ZGIyMjcwODhhNDA4NGZhZDk0YTAzMWU0YzI4MjJlOTdfOC05LTEtMS0w_4ec6cf40-385b-4ee2-8173-38a21289471d">170</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Shares repurchased</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib87cee58ccf2448a8d4422101bf61fa0_D20210401-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yOC9mcmFnOjBlNDhiNzZhMTAxZjRjODJiMGUzNzJhYTlhOWNmNDhiL3RhYmxlOmRiMjI3MDg4YTQwODRmYWQ5NGEwMzFlNGMyODIyZTk3L3RhYmxlcmFuZ2U6ZGIyMjcwODhhNDA4NGZhZDk0YTAzMWU0YzI4MjJlOTdfOS0xLTEtMS0w_c7bc2e22-7fdd-45f2-9be4-57a6f0d07bf8">1,188</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iee63e04ff2174c9686bcc42c3eb46125_D20210401-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yOC9mcmFnOjBlNDhiNzZhMTAxZjRjODJiMGUzNzJhYTlhOWNmNDhiL3RhYmxlOmRiMjI3MDg4YTQwODRmYWQ5NGEwMzFlNGMyODIyZTk3L3RhYmxlcmFuZ2U6ZGIyMjcwODhhNDA4NGZhZDk0YTAzMWU0YzI4MjJlOTdfOS05LTEtMS0w_6b3a70d5-ccf4-4583-a6b6-e31e27d626ec">1,188</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Noncontrolling interest distribution</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib87cee58ccf2448a8d4422101bf61fa0_D20210401-20210630" decimals="-3" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yOC9mcmFnOjBlNDhiNzZhMTAxZjRjODJiMGUzNzJhYTlhOWNmNDhiL3RhYmxlOmRiMjI3MDg4YTQwODRmYWQ5NGEwMzFlNGMyODIyZTk3L3RhYmxlcmFuZ2U6ZGIyMjcwODhhNDA4NGZhZDk0YTAzMWU0YzI4MjJlOTdfMTAtMS0xLTEtMA_d1c143f7-b57c-446e-8b41-25494a806112">276</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib467ac52451749bfb8cdba39aa1441a7_D20210401-20210630" decimals="-3" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yOC9mcmFnOjBlNDhiNzZhMTAxZjRjODJiMGUzNzJhYTlhOWNmNDhiL3RhYmxlOmRiMjI3MDg4YTQwODRmYWQ5NGEwMzFlNGMyODIyZTk3L3RhYmxlcmFuZ2U6ZGIyMjcwODhhNDA4NGZhZDk0YTAzMWU0YzI4MjJlOTdfMTAtMTUtMS0xLTA_1b69854a-031b-4bd6-a6c1-28d9f361d5bb">276</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib87cee58ccf2448a8d4422101bf61fa0_D20210401-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yOC9mcmFnOjBlNDhiNzZhMTAxZjRjODJiMGUzNzJhYTlhOWNmNDhiL3RhYmxlOmRiMjI3MDg4YTQwODRmYWQ5NGEwMzFlNGMyODIyZTk3L3RhYmxlcmFuZ2U6ZGIyMjcwODhhNDA4NGZhZDk0YTAzMWU0YzI4MjJlOTdfMTEtMS0xLTEtMA_180960ac-3525-4db2-9c5c-2173421fef8a">80,619</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d9970853b6d41799b9af78b866c694b_D20210401-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yOC9mcmFnOjBlNDhiNzZhMTAxZjRjODJiMGUzNzJhYTlhOWNmNDhiL3RhYmxlOmRiMjI3MDg4YTQwODRmYWQ5NGEwMzFlNGMyODIyZTk3L3RhYmxlcmFuZ2U6ZGIyMjcwODhhNDA4NGZhZDk0YTAzMWU0YzI4MjJlOTdfMTEtMTMtMS0xLTA_16c81076-08df-402b-94d4-4a9e018bdd23">80,149</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib467ac52451749bfb8cdba39aa1441a7_D20210401-20210630" decimals="-3" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yOC9mcmFnOjBlNDhiNzZhMTAxZjRjODJiMGUzNzJhYTlhOWNmNDhiL3RhYmxlOmRiMjI3MDg4YTQwODRmYWQ5NGEwMzFlNGMyODIyZTk3L3RhYmxlcmFuZ2U6ZGIyMjcwODhhNDA4NGZhZDk0YTAzMWU0YzI4MjJlOTdfMTEtMTUtMS0xLTA_2f60a942-728f-4386-9d92-a473d123cd9b">470</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, June 30, 2021</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e833203be6947b4968aba4d20064ec8_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yOC9mcmFnOjBlNDhiNzZhMTAxZjRjODJiMGUzNzJhYTlhOWNmNDhiL3RhYmxlOmRiMjI3MDg4YTQwODRmYWQ5NGEwMzFlNGMyODIyZTk3L3RhYmxlcmFuZ2U6ZGIyMjcwODhhNDA4NGZhZDk0YTAzMWU0YzI4MjJlOTdfMTItMS0xLTEtMA_3bb604cb-fa32-484d-93f4-0f565bfe28e6">875,887</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3e59fd3d3cfb4bb7ae9ea1d3af94e290_I20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yOC9mcmFnOjBlNDhiNzZhMTAxZjRjODJiMGUzNzJhYTlhOWNmNDhiL3RhYmxlOmRiMjI3MDg4YTQwODRmYWQ5NGEwMzFlNGMyODIyZTk3L3RhYmxlcmFuZ2U6ZGIyMjcwODhhNDA4NGZhZDk0YTAzMWU0YzI4MjJlOTdfMTItMy0xLTEtMA_addd2ccb-ac64-4be6-81c5-a42c6ca8dcae">37,553,355</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e59fd3d3cfb4bb7ae9ea1d3af94e290_I20210630" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yOC9mcmFnOjBlNDhiNzZhMTAxZjRjODJiMGUzNzJhYTlhOWNmNDhiL3RhYmxlOmRiMjI3MDg4YTQwODRmYWQ5NGEwMzFlNGMyODIyZTk3L3RhYmxlcmFuZ2U6ZGIyMjcwODhhNDA4NGZhZDk0YTAzMWU0YzI4MjJlOTdfMTItNS0xLTEtMA_00315127-9504-4aa8-a451-4b51c6c2e35d">38</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0e0b2cc08e747cba20ceed2b5382012_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yOC9mcmFnOjBlNDhiNzZhMTAxZjRjODJiMGUzNzJhYTlhOWNmNDhiL3RhYmxlOmRiMjI3MDg4YTQwODRmYWQ5NGEwMzFlNGMyODIyZTk3L3RhYmxlcmFuZ2U6ZGIyMjcwODhhNDA4NGZhZDk0YTAzMWU0YzI4MjJlOTdfMTItNy0xLTEtMA_64f56586-14f0-4fc7-a728-2051c4029e5b">714,334</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i01768f8d7ebc4cc18d5eb154976ba4d3_I20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yOC9mcmFnOjBlNDhiNzZhMTAxZjRjODJiMGUzNzJhYTlhOWNmNDhiL3RhYmxlOmRiMjI3MDg4YTQwODRmYWQ5NGEwMzFlNGMyODIyZTk3L3RhYmxlcmFuZ2U6ZGIyMjcwODhhNDA4NGZhZDk0YTAzMWU0YzI4MjJlOTdfMTItOS0xLTEtMA_e0ca2cb9-fa9d-4725-9643-d03dc897745d">400,110</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1302a68dd8ef42e6ab76db142d77aae4_I20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yOC9mcmFnOjBlNDhiNzZhMTAxZjRjODJiMGUzNzJhYTlhOWNmNDhiL3RhYmxlOmRiMjI3MDg4YTQwODRmYWQ5NGEwMzFlNGMyODIyZTk3L3RhYmxlcmFuZ2U6ZGIyMjcwODhhNDA4NGZhZDk0YTAzMWU0YzI4MjJlOTdfMTItMTEtMS0xLTA_2e2afe10-abb6-4051-95f5-eb3eaa3fa9ba">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i90abbd77ace44a6bac4330406a6d4810_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yOC9mcmFnOjBlNDhiNzZhMTAxZjRjODJiMGUzNzJhYTlhOWNmNDhiL3RhYmxlOmRiMjI3MDg4YTQwODRmYWQ5NGEwMzFlNGMyODIyZTk3L3RhYmxlcmFuZ2U6ZGIyMjcwODhhNDA4NGZhZDk0YTAzMWU0YzI4MjJlOTdfMTItMTMtMS0xLTA_04b8a332-b573-42cb-975e-3621076d3b7c">560,010</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie40ed45ce02a463b81cddfc774673775_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yOC9mcmFnOjBlNDhiNzZhMTAxZjRjODJiMGUzNzJhYTlhOWNmNDhiL3RhYmxlOmRiMjI3MDg4YTQwODRmYWQ5NGEwMzFlNGMyODIyZTk3L3RhYmxlcmFuZ2U6ZGIyMjcwODhhNDA4NGZhZDk0YTAzMWU0YzI4MjJlOTdfMTItMTUtMS0xLTA_196a7934-8710-4f0b-98c8-b22dfcda6d43">1,615</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="45" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three-Months Ended June 30, 2020</span></td></tr><tr style="height:9pt"><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additional<br/>Paid-in<br/>Capital</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Treasury<br/>Stock</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Other<br/>Comprehensive Income</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Retained<br/>Earnings </span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Noncontrolling<br/>Interests</span></td></tr><tr style="height:23pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, March 31, 2020</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e0bc5dd338e4f46a448f49e5796b04c_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yOC9mcmFnOjBlNDhiNzZhMTAxZjRjODJiMGUzNzJhYTlhOWNmNDhiL3RhYmxlOmRiMjI3MDg4YTQwODRmYWQ5NGEwMzFlNGMyODIyZTk3L3RhYmxlcmFuZ2U6ZGIyMjcwODhhNDA4NGZhZDk0YTAzMWU0YzI4MjJlOTdfMTctMS0xLTEtMA_868e30d7-b001-48e3-9d20-aed815e05b5d">680,144</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i50eeb2e1fb1c44a38c21b210240eb586_I20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yOC9mcmFnOjBlNDhiNzZhMTAxZjRjODJiMGUzNzJhYTlhOWNmNDhiL3RhYmxlOmRiMjI3MDg4YTQwODRmYWQ5NGEwMzFlNGMyODIyZTk3L3RhYmxlcmFuZ2U6ZGIyMjcwODhhNDA4NGZhZDk0YTAzMWU0YzI4MjJlOTdfMTctMy0xLTEtMA_d6ecd023-43d0-4c26-9478-ba9a68e1be24">36,746,554</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50eeb2e1fb1c44a38c21b210240eb586_I20200331" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yOC9mcmFnOjBlNDhiNzZhMTAxZjRjODJiMGUzNzJhYTlhOWNmNDhiL3RhYmxlOmRiMjI3MDg4YTQwODRmYWQ5NGEwMzFlNGMyODIyZTk3L3RhYmxlcmFuZ2U6ZGIyMjcwODhhNDA4NGZhZDk0YTAzMWU0YzI4MjJlOTdfMTctNS0xLTEtMA_bcee422d-0175-477e-8851-d2b30ed1db4b">37</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i293e823d67b246d381d9224a4d88ecb8_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yOC9mcmFnOjBlNDhiNzZhMTAxZjRjODJiMGUzNzJhYTlhOWNmNDhiL3RhYmxlOmRiMjI3MDg4YTQwODRmYWQ5NGEwMzFlNGMyODIyZTk3L3RhYmxlcmFuZ2U6ZGIyMjcwODhhNDA4NGZhZDk0YTAzMWU0YzI4MjJlOTdfMTctNy0xLTEtMA_f9b2abc8-b09e-43bb-94a7-34dc0de3233a">656,266</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie0f0ea8548294921ad4f0b1603762e12_I20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yOC9mcmFnOjBlNDhiNzZhMTAxZjRjODJiMGUzNzJhYTlhOWNmNDhiL3RhYmxlOmRiMjI3MDg4YTQwODRmYWQ5NGEwMzFlNGMyODIyZTk3L3RhYmxlcmFuZ2U6ZGIyMjcwODhhNDA4NGZhZDk0YTAzMWU0YzI4MjJlOTdfMTctOS0xLTEtMA_1d09173a-726e-4b0f-a362-97213405e6a8">255,291</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i259a6cf078e54dd1a1db53e0ddaaf3ee_I20200331" decimals="-3" format="ixt:zerodash" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yOC9mcmFnOjBlNDhiNzZhMTAxZjRjODJiMGUzNzJhYTlhOWNmNDhiL3RhYmxlOmRiMjI3MDg4YTQwODRmYWQ5NGEwMzFlNGMyODIyZTk3L3RhYmxlcmFuZ2U6ZGIyMjcwODhhNDA4NGZhZDk0YTAzMWU0YzI4MjJlOTdfMTctMTEtMS0xLTA_668b91a2-ed7c-4688-8f94-3b9ebcc0c5fd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8b5cc2263e34d7d829e9025bfd31619_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yOC9mcmFnOjBlNDhiNzZhMTAxZjRjODJiMGUzNzJhYTlhOWNmNDhiL3RhYmxlOmRiMjI3MDg4YTQwODRmYWQ5NGEwMzFlNGMyODIyZTk3L3RhYmxlcmFuZ2U6ZGIyMjcwODhhNDA4NGZhZDk0YTAzMWU0YzI4MjJlOTdfMTctMTMtMS0xLTA_213c9a6a-6fe7-43e4-bd0d-744cac670094">278,185</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74c16b1d1e794dca817c0cabfec5d055_I20200331" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yOC9mcmFnOjBlNDhiNzZhMTAxZjRjODJiMGUzNzJhYTlhOWNmNDhiL3RhYmxlOmRiMjI3MDg4YTQwODRmYWQ5NGEwMzFlNGMyODIyZTk3L3RhYmxlcmFuZ2U6ZGIyMjcwODhhNDA4NGZhZDk0YTAzMWU0YzI4MjJlOTdfMTctMTUtMS0xLTA_aedfd1c5-2f13-40b9-824e-8f640e867572">947</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of stock &#8211; employee stock purchase plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c8351954d014a1c80a3d8cfc2327ab2_D20200401-20200630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yOC9mcmFnOjBlNDhiNzZhMTAxZjRjODJiMGUzNzJhYTlhOWNmNDhiL3RhYmxlOmRiMjI3MDg4YTQwODRmYWQ5NGEwMzFlNGMyODIyZTk3L3RhYmxlcmFuZ2U6ZGIyMjcwODhhNDA4NGZhZDk0YTAzMWU0YzI4MjJlOTdfMTgtMS0xLTEtMA_d7cd8022-17ac-41f6-aa66-b14716162d82">826</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="idfe2bc4b48cf420480bdcedd1afce6c9_D20200401-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yOC9mcmFnOjBlNDhiNzZhMTAxZjRjODJiMGUzNzJhYTlhOWNmNDhiL3RhYmxlOmRiMjI3MDg4YTQwODRmYWQ5NGEwMzFlNGMyODIyZTk3L3RhYmxlcmFuZ2U6ZGIyMjcwODhhNDA4NGZhZDk0YTAzMWU0YzI4MjJlOTdfMTgtMy0xLTEtMA_4f15a109-4bb7-4af0-824e-c0b9f32a1697">5,295</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1667f8e90077426897db77b94e7b94d2_D20200401-20200630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yOC9mcmFnOjBlNDhiNzZhMTAxZjRjODJiMGUzNzJhYTlhOWNmNDhiL3RhYmxlOmRiMjI3MDg4YTQwODRmYWQ5NGEwMzFlNGMyODIyZTk3L3RhYmxlcmFuZ2U6ZGIyMjcwODhhNDA4NGZhZDk0YTAzMWU0YzI4MjJlOTdfMTgtNy0xLTEtMA_e8f5aebc-ecb9-4e06-84e2-60ad3594ce1d">826</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance/(cancellation) of non-vested stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c8351954d014a1c80a3d8cfc2327ab2_D20200401-20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yOC9mcmFnOjBlNDhiNzZhMTAxZjRjODJiMGUzNzJhYTlhOWNmNDhiL3RhYmxlOmRiMjI3MDg4YTQwODRmYWQ5NGEwMzFlNGMyODIyZTk3L3RhYmxlcmFuZ2U6ZGIyMjcwODhhNDA4NGZhZDk0YTAzMWU0YzI4MjJlOTdfMjAtMS0xLTEtMA_b212fa02-2315-475d-a500-95c46e88cd45">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="idfe2bc4b48cf420480bdcedd1afce6c9_D20200401-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yOC9mcmFnOjBlNDhiNzZhMTAxZjRjODJiMGUzNzJhYTlhOWNmNDhiL3RhYmxlOmRiMjI3MDg4YTQwODRmYWQ5NGEwMzFlNGMyODIyZTk3L3RhYmxlcmFuZ2U6ZGIyMjcwODhhNDA4NGZhZDk0YTAzMWU0YzI4MjJlOTdfMjAtMy0xLTEtMA_e308648a-97cf-4288-b475-dfe225360b27">29,461</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idfe2bc4b48cf420480bdcedd1afce6c9_D20200401-20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yOC9mcmFnOjBlNDhiNzZhMTAxZjRjODJiMGUzNzJhYTlhOWNmNDhiL3RhYmxlOmRiMjI3MDg4YTQwODRmYWQ5NGEwMzFlNGMyODIyZTk3L3RhYmxlcmFuZ2U6ZGIyMjcwODhhNDA4NGZhZDk0YTAzMWU0YzI4MjJlOTdfMjAtNS0xLTEtMA_317a00e6-7bc9-4ee5-af67-21c106a650f6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1667f8e90077426897db77b94e7b94d2_D20200401-20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yOC9mcmFnOjBlNDhiNzZhMTAxZjRjODJiMGUzNzJhYTlhOWNmNDhiL3RhYmxlOmRiMjI3MDg4YTQwODRmYWQ5NGEwMzFlNGMyODIyZTk3L3RhYmxlcmFuZ2U6ZGIyMjcwODhhNDA4NGZhZDk0YTAzMWU0YzI4MjJlOTdfMjAtNy0xLTEtMA_426a8698-d73c-42af-ae9e-7d6881952ab9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exercise of stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c8351954d014a1c80a3d8cfc2327ab2_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yOC9mcmFnOjBlNDhiNzZhMTAxZjRjODJiMGUzNzJhYTlhOWNmNDhiL3RhYmxlOmRiMjI3MDg4YTQwODRmYWQ5NGEwMzFlNGMyODIyZTk3L3RhYmxlcmFuZ2U6ZGIyMjcwODhhNDA4NGZhZDk0YTAzMWU0YzI4MjJlOTdfMjEtMS0xLTEtMA_ffc04aa2-23e9-49b3-b6ea-126f1a51314a">1,763</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="idfe2bc4b48cf420480bdcedd1afce6c9_D20200401-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yOC9mcmFnOjBlNDhiNzZhMTAxZjRjODJiMGUzNzJhYTlhOWNmNDhiL3RhYmxlOmRiMjI3MDg4YTQwODRmYWQ5NGEwMzFlNGMyODIyZTk3L3RhYmxlcmFuZ2U6ZGIyMjcwODhhNDA4NGZhZDk0YTAzMWU0YzI4MjJlOTdfMjEtMy0xLTEtMA_6deb098b-0925-4233-9caf-4187325c3806">49,988</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1667f8e90077426897db77b94e7b94d2_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yOC9mcmFnOjBlNDhiNzZhMTAxZjRjODJiMGUzNzJhYTlhOWNmNDhiL3RhYmxlOmRiMjI3MDg4YTQwODRmYWQ5NGEwMzFlNGMyODIyZTk3L3RhYmxlcmFuZ2U6ZGIyMjcwODhhNDA4NGZhZDk0YTAzMWU0YzI4MjJlOTdfMjEtNy0xLTEtMA_10d27b4e-6c50-4d26-844c-f2b673fea2a6">1,763</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-cash compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c8351954d014a1c80a3d8cfc2327ab2_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yOC9mcmFnOjBlNDhiNzZhMTAxZjRjODJiMGUzNzJhYTlhOWNmNDhiL3RhYmxlOmRiMjI3MDg4YTQwODRmYWQ5NGEwMzFlNGMyODIyZTk3L3RhYmxlcmFuZ2U6ZGIyMjcwODhhNDA4NGZhZDk0YTAzMWU0YzI4MjJlOTdfMjItMS0xLTEtMA_17897c74-a118-423b-b4be-8e936eba4b4b">6,725</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1667f8e90077426897db77b94e7b94d2_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yOC9mcmFnOjBlNDhiNzZhMTAxZjRjODJiMGUzNzJhYTlhOWNmNDhiL3RhYmxlOmRiMjI3MDg4YTQwODRmYWQ5NGEwMzFlNGMyODIyZTk3L3RhYmxlcmFuZ2U6ZGIyMjcwODhhNDA4NGZhZDk0YTAzMWU0YzI4MjJlOTdfMjItNy0xLTEtMA_37db7040-44c4-4c4a-be4b-21ddb27f7470">6,725</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Surrendered shares</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2c8351954d014a1c80a3d8cfc2327ab2_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="amed:SurrenderedShares" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yOC9mcmFnOjBlNDhiNzZhMTAxZjRjODJiMGUzNzJhYTlhOWNmNDhiL3RhYmxlOmRiMjI3MDg4YTQwODRmYWQ5NGEwMzFlNGMyODIyZTk3L3RhYmxlcmFuZ2U6ZGIyMjcwODhhNDA4NGZhZDk0YTAzMWU0YzI4MjJlOTdfMjMtMS0xLTEtMA_6807e8df-8164-4d23-a728-82ea1e8975d2">2,334</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7b84646fd5a5457ea3426c3891522efe_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="amed:SurrenderedShares" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yOC9mcmFnOjBlNDhiNzZhMTAxZjRjODJiMGUzNzJhYTlhOWNmNDhiL3RhYmxlOmRiMjI3MDg4YTQwODRmYWQ5NGEwMzFlNGMyODIyZTk3L3RhYmxlcmFuZ2U6ZGIyMjcwODhhNDA4NGZhZDk0YTAzMWU0YzI4MjJlOTdfMjMtOS0xLTEtMA_b5abe414-92fe-496b-9bfe-6cf003e5854c">2,334</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Noncontrolling interest distribution</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2c8351954d014a1c80a3d8cfc2327ab2_D20200401-20200630" decimals="-3" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yOC9mcmFnOjBlNDhiNzZhMTAxZjRjODJiMGUzNzJhYTlhOWNmNDhiL3RhYmxlOmRiMjI3MDg4YTQwODRmYWQ5NGEwMzFlNGMyODIyZTk3L3RhYmxlcmFuZ2U6ZGIyMjcwODhhNDA4NGZhZDk0YTAzMWU0YzI4MjJlOTdfMjQtMS0xLTEtMA_0bbda87b-e518-4096-a832-ae639e2df44c">12</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i513740b0a9e54ee1a6565acc0bdf79f2_D20200401-20200630" decimals="-3" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yOC9mcmFnOjBlNDhiNzZhMTAxZjRjODJiMGUzNzJhYTlhOWNmNDhiL3RhYmxlOmRiMjI3MDg4YTQwODRmYWQ5NGEwMzFlNGMyODIyZTk3L3RhYmxlcmFuZ2U6ZGIyMjcwODhhNDA4NGZhZDk0YTAzMWU0YzI4MjJlOTdfMjQtMTUtMS0xLTA_c97b5f1c-20b7-493c-959b-0a9cc4919635">12</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c8351954d014a1c80a3d8cfc2327ab2_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yOC9mcmFnOjBlNDhiNzZhMTAxZjRjODJiMGUzNzJhYTlhOWNmNDhiL3RhYmxlOmRiMjI3MDg4YTQwODRmYWQ5NGEwMzFlNGMyODIyZTk3L3RhYmxlcmFuZ2U6ZGIyMjcwODhhNDA4NGZhZDk0YTAzMWU0YzI4MjJlOTdfMjYtMS0xLTEtMA_46c0bd41-6a7a-46f7-9612-c5dd5e47bf98">35,147</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb32f2bfc5474a4199e7c84d1720275e_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yOC9mcmFnOjBlNDhiNzZhMTAxZjRjODJiMGUzNzJhYTlhOWNmNDhiL3RhYmxlOmRiMjI3MDg4YTQwODRmYWQ5NGEwMzFlNGMyODIyZTk3L3RhYmxlcmFuZ2U6ZGIyMjcwODhhNDA4NGZhZDk0YTAzMWU0YzI4MjJlOTdfMjYtMTMtMS0xLTA_a6309984-10a4-45a3-892c-bd1cc8fd21c2">34,674</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i513740b0a9e54ee1a6565acc0bdf79f2_D20200401-20200630" decimals="-3" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yOC9mcmFnOjBlNDhiNzZhMTAxZjRjODJiMGUzNzJhYTlhOWNmNDhiL3RhYmxlOmRiMjI3MDg4YTQwODRmYWQ5NGEwMzFlNGMyODIyZTk3L3RhYmxlcmFuZ2U6ZGIyMjcwODhhNDA4NGZhZDk0YTAzMWU0YzI4MjJlOTdfMjYtMTUtMS0xLTA_10f164bb-750c-4494-9298-0c61cc354b3a">473</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, June 30, 2020</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15586f038620443192b7c904beb4ad54_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yOC9mcmFnOjBlNDhiNzZhMTAxZjRjODJiMGUzNzJhYTlhOWNmNDhiL3RhYmxlOmRiMjI3MDg4YTQwODRmYWQ5NGEwMzFlNGMyODIyZTk3L3RhYmxlcmFuZ2U6ZGIyMjcwODhhNDA4NGZhZDk0YTAzMWU0YzI4MjJlOTdfMjctMS0xLTEtMA_ed7f7d5a-3f66-4e18-aac9-517543e14a0e">722,259</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6271c5457d114e698b9aa02424c6fba7_I20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yOC9mcmFnOjBlNDhiNzZhMTAxZjRjODJiMGUzNzJhYTlhOWNmNDhiL3RhYmxlOmRiMjI3MDg4YTQwODRmYWQ5NGEwMzFlNGMyODIyZTk3L3RhYmxlcmFuZ2U6ZGIyMjcwODhhNDA4NGZhZDk0YTAzMWU0YzI4MjJlOTdfMjctMy0xLTEtMA_aceaf9ac-b11d-4399-872a-889275cf59b9">36,831,298</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6271c5457d114e698b9aa02424c6fba7_I20200630" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yOC9mcmFnOjBlNDhiNzZhMTAxZjRjODJiMGUzNzJhYTlhOWNmNDhiL3RhYmxlOmRiMjI3MDg4YTQwODRmYWQ5NGEwMzFlNGMyODIyZTk3L3RhYmxlcmFuZ2U6ZGIyMjcwODhhNDA4NGZhZDk0YTAzMWU0YzI4MjJlOTdfMjctNS0xLTEtMA_3df3bfdb-3ee9-4c7a-8636-91ae64d4d527">37</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f5f7a1bdc904b23a1b3496bf1c343ed_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yOC9mcmFnOjBlNDhiNzZhMTAxZjRjODJiMGUzNzJhYTlhOWNmNDhiL3RhYmxlOmRiMjI3MDg4YTQwODRmYWQ5NGEwMzFlNGMyODIyZTk3L3RhYmxlcmFuZ2U6ZGIyMjcwODhhNDA4NGZhZDk0YTAzMWU0YzI4MjJlOTdfMjctNy0xLTEtMA_bc63077f-42b1-47d0-9801-9258d4e41ab4">665,580</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic2e9db201a8c41efacbe6c14b48f08c5_I20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yOC9mcmFnOjBlNDhiNzZhMTAxZjRjODJiMGUzNzJhYTlhOWNmNDhiL3RhYmxlOmRiMjI3MDg4YTQwODRmYWQ5NGEwMzFlNGMyODIyZTk3L3RhYmxlcmFuZ2U6ZGIyMjcwODhhNDA4NGZhZDk0YTAzMWU0YzI4MjJlOTdfMjctOS0xLTEtMA_6a2ed67b-cb31-4e06-b135-7a43d00d5c03">257,625</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie2958a3a3c7d4e89970b11fea75ea413_I20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yOC9mcmFnOjBlNDhiNzZhMTAxZjRjODJiMGUzNzJhYTlhOWNmNDhiL3RhYmxlOmRiMjI3MDg4YTQwODRmYWQ5NGEwMzFlNGMyODIyZTk3L3RhYmxlcmFuZ2U6ZGIyMjcwODhhNDA4NGZhZDk0YTAzMWU0YzI4MjJlOTdfMjctMTEtMS0xLTA_4752a40d-5c38-41f4-9bba-227dead912b1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f8cee8ab0a8499bb9039cd2b585f4be_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yOC9mcmFnOjBlNDhiNzZhMTAxZjRjODJiMGUzNzJhYTlhOWNmNDhiL3RhYmxlOmRiMjI3MDg4YTQwODRmYWQ5NGEwMzFlNGMyODIyZTk3L3RhYmxlcmFuZ2U6ZGIyMjcwODhhNDA4NGZhZDk0YTAzMWU0YzI4MjJlOTdfMjctMTMtMS0xLTA_0f573c7e-cd8e-46ab-a646-95d137868501">312,859</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0520e88179174d4c983746db6664ff87_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yOC9mcmFnOjBlNDhiNzZhMTAxZjRjODJiMGUzNzJhYTlhOWNmNDhiL3RhYmxlOmRiMjI3MDg4YTQwODRmYWQ5NGEwMzFlNGMyODIyZTk3L3RhYmxlcmFuZ2U6ZGIyMjcwODhhNDA4NGZhZDk0YTAzMWU0YzI4MjJlOTdfMjctMTUtMS0xLTA_2624dd5a-e7cd-4f8b-b001-92047ccc1998">1,408</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="45" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Six-Months Ended June 30, 2021</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additional<br/>Paid-in<br/>Capital</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Treasury<br/>Stock</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Other<br/>Comprehensive Income</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Retained<br/>Earnings</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Noncontrolling<br/>Interests</span></td></tr><tr style="height:23pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, December 31, 2020</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87ceb60dc20d4df1b0a97d3514837910_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yOC9mcmFnOjBlNDhiNzZhMTAxZjRjODJiMGUzNzJhYTlhOWNmNDhiL3RhYmxlOmRiMjI3MDg4YTQwODRmYWQ5NGEwMzFlNGMyODIyZTk3L3RhYmxlcmFuZ2U6ZGIyMjcwODhhNDA4NGZhZDk0YTAzMWU0YzI4MjJlOTdfMzAtMS0xLTEtNzk3_f04a187c-0741-4aae-b545-71bf63143371">810,741</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2f9b5ede983b458f9d589f077a9b9885_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yOC9mcmFnOjBlNDhiNzZhMTAxZjRjODJiMGUzNzJhYTlhOWNmNDhiL3RhYmxlOmRiMjI3MDg4YTQwODRmYWQ5NGEwMzFlNGMyODIyZTk3L3RhYmxlcmFuZ2U6ZGIyMjcwODhhNDA4NGZhZDk0YTAzMWU0YzI4MjJlOTdfMzAtMy0xLTEtNzk3_93479e56-4b42-4784-9bae-3dd82c317453">37,470,212</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f9b5ede983b458f9d589f077a9b9885_I20201231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yOC9mcmFnOjBlNDhiNzZhMTAxZjRjODJiMGUzNzJhYTlhOWNmNDhiL3RhYmxlOmRiMjI3MDg4YTQwODRmYWQ5NGEwMzFlNGMyODIyZTk3L3RhYmxlcmFuZ2U6ZGIyMjcwODhhNDA4NGZhZDk0YTAzMWU0YzI4MjJlOTdfMzAtNS0xLTEtNzk3_8a288cae-ff66-4fef-8e3c-0e78b91399b4">38</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00022a1a9b074ad09a7448259eb40d7b_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yOC9mcmFnOjBlNDhiNzZhMTAxZjRjODJiMGUzNzJhYTlhOWNmNDhiL3RhYmxlOmRiMjI3MDg4YTQwODRmYWQ5NGEwMzFlNGMyODIyZTk3L3RhYmxlcmFuZ2U6ZGIyMjcwODhhNDA4NGZhZDk0YTAzMWU0YzI4MjJlOTdfMzAtNy0xLTEtNzk3_922fc04f-654c-41aa-986b-6de46a11d9b0">698,287</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3904353da8ce4531bf4ac08cd4d11033_I20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yOC9mcmFnOjBlNDhiNzZhMTAxZjRjODJiMGUzNzJhYTlhOWNmNDhiL3RhYmxlOmRiMjI3MDg4YTQwODRmYWQ5NGEwMzFlNGMyODIyZTk3L3RhYmxlcmFuZ2U6ZGIyMjcwODhhNDA4NGZhZDk0YTAzMWU0YzI4MjJlOTdfMzAtOS0xLTEtNzk3_144be790-5873-4a12-9e49-e543cab8ce78">319,092</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ida4c2a7ffda04385afb5f441d707b3cc_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yOC9mcmFnOjBlNDhiNzZhMTAxZjRjODJiMGUzNzJhYTlhOWNmNDhiL3RhYmxlOmRiMjI3MDg4YTQwODRmYWQ5NGEwMzFlNGMyODIyZTk3L3RhYmxlcmFuZ2U6ZGIyMjcwODhhNDA4NGZhZDk0YTAzMWU0YzI4MjJlOTdfMzAtMTEtMS0xLTc5Nw_ec52d92b-5c2c-49a2-8cdf-93a3859a8a69">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i656ece5c7f7e4dff8816621dc7e0455f_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yOC9mcmFnOjBlNDhiNzZhMTAxZjRjODJiMGUzNzJhYTlhOWNmNDhiL3RhYmxlOmRiMjI3MDg4YTQwODRmYWQ5NGEwMzFlNGMyODIyZTk3L3RhYmxlcmFuZ2U6ZGIyMjcwODhhNDA4NGZhZDk0YTAzMWU0YzI4MjJlOTdfMzAtMTMtMS0xLTc5Nw_8fcb7a61-14d6-4ead-b4ee-c12bf17b7f7e">429,991</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic4cd949100864281ac1cb035f36fe501_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yOC9mcmFnOjBlNDhiNzZhMTAxZjRjODJiMGUzNzJhYTlhOWNmNDhiL3RhYmxlOmRiMjI3MDg4YTQwODRmYWQ5NGEwMzFlNGMyODIyZTk3L3RhYmxlcmFuZ2U6ZGIyMjcwODhhNDA4NGZhZDk0YTAzMWU0YzI4MjJlOTdfMzAtMTUtMS0xLTc5Nw_2b4bc0e4-eeb1-4b17-8a25-66f9d662216e">1,517</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of stock &#8211; employee stock purchase plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yOC9mcmFnOjBlNDhiNzZhMTAxZjRjODJiMGUzNzJhYTlhOWNmNDhiL3RhYmxlOmRiMjI3MDg4YTQwODRmYWQ5NGEwMzFlNGMyODIyZTk3L3RhYmxlcmFuZ2U6ZGIyMjcwODhhNDA4NGZhZDk0YTAzMWU0YzI4MjJlOTdfMzEtMS0xLTEtNzk3_e990cd60-d941-4a39-85f0-75fd24b78077">1,961</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4c81959cee2f417b9189bc4e6ad7f42d_D20210101-20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yOC9mcmFnOjBlNDhiNzZhMTAxZjRjODJiMGUzNzJhYTlhOWNmNDhiL3RhYmxlOmRiMjI3MDg4YTQwODRmYWQ5NGEwMzFlNGMyODIyZTk3L3RhYmxlcmFuZ2U6ZGIyMjcwODhhNDA4NGZhZDk0YTAzMWU0YzI4MjJlOTdfMzEtMy0xLTEtNzk3_bfcb3950-4bd9-4bdb-8acf-eb9d41d1a1f2">8,262</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a5e5c59232b4c58b6e84716db6d8973_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yOC9mcmFnOjBlNDhiNzZhMTAxZjRjODJiMGUzNzJhYTlhOWNmNDhiL3RhYmxlOmRiMjI3MDg4YTQwODRmYWQ5NGEwMzFlNGMyODIyZTk3L3RhYmxlcmFuZ2U6ZGIyMjcwODhhNDA4NGZhZDk0YTAzMWU0YzI4MjJlOTdfMzEtNy0xLTEtNzk3_3d14966d-5698-451e-b6e1-33d846fee719">1,961</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance/(cancellation) of non-vested stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yOC9mcmFnOjBlNDhiNzZhMTAxZjRjODJiMGUzNzJhYTlhOWNmNDhiL3RhYmxlOmRiMjI3MDg4YTQwODRmYWQ5NGEwMzFlNGMyODIyZTk3L3RhYmxlcmFuZ2U6ZGIyMjcwODhhNDA4NGZhZDk0YTAzMWU0YzI4MjJlOTdfMzItMS0xLTEtNzk3_a232803c-aaf7-49a8-93e0-c472752f9f2d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4c81959cee2f417b9189bc4e6ad7f42d_D20210101-20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yOC9mcmFnOjBlNDhiNzZhMTAxZjRjODJiMGUzNzJhYTlhOWNmNDhiL3RhYmxlOmRiMjI3MDg4YTQwODRmYWQ5NGEwMzFlNGMyODIyZTk3L3RhYmxlcmFuZ2U6ZGIyMjcwODhhNDA4NGZhZDk0YTAzMWU0YzI4MjJlOTdfMzItMy0xLTEtNzk3_8d64b85a-0b3e-4418-a783-42c80f62024a">61,069</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c81959cee2f417b9189bc4e6ad7f42d_D20210101-20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yOC9mcmFnOjBlNDhiNzZhMTAxZjRjODJiMGUzNzJhYTlhOWNmNDhiL3RhYmxlOmRiMjI3MDg4YTQwODRmYWQ5NGEwMzFlNGMyODIyZTk3L3RhYmxlcmFuZ2U6ZGIyMjcwODhhNDA4NGZhZDk0YTAzMWU0YzI4MjJlOTdfMzItNS0xLTEtNzk3_cdbe8a81-619b-4db5-9018-241cf3191d2a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a5e5c59232b4c58b6e84716db6d8973_D20210101-20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yOC9mcmFnOjBlNDhiNzZhMTAxZjRjODJiMGUzNzJhYTlhOWNmNDhiL3RhYmxlOmRiMjI3MDg4YTQwODRmYWQ5NGEwMzFlNGMyODIyZTk3L3RhYmxlcmFuZ2U6ZGIyMjcwODhhNDA4NGZhZDk0YTAzMWU0YzI4MjJlOTdfMzItNy0xLTEtNzk3_16b2a7d6-eb9d-4f94-841a-5ae5739634d6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exercise of stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yOC9mcmFnOjBlNDhiNzZhMTAxZjRjODJiMGUzNzJhYTlhOWNmNDhiL3RhYmxlOmRiMjI3MDg4YTQwODRmYWQ5NGEwMzFlNGMyODIyZTk3L3RhYmxlcmFuZ2U6ZGIyMjcwODhhNDA4NGZhZDk0YTAzMWU0YzI4MjJlOTdfMzMtMS0xLTEtNzk3_18a6c562-80c5-447b-98aa-49f95f145631">623</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4c81959cee2f417b9189bc4e6ad7f42d_D20210101-20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yOC9mcmFnOjBlNDhiNzZhMTAxZjRjODJiMGUzNzJhYTlhOWNmNDhiL3RhYmxlOmRiMjI3MDg4YTQwODRmYWQ5NGEwMzFlNGMyODIyZTk3L3RhYmxlcmFuZ2U6ZGIyMjcwODhhNDA4NGZhZDk0YTAzMWU0YzI4MjJlOTdfMzMtMy0xLTEtNzk3_889ffa99-1efe-4e39-889d-ee19494a6862">13,812</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a5e5c59232b4c58b6e84716db6d8973_D20210101-20210630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yOC9mcmFnOjBlNDhiNzZhMTAxZjRjODJiMGUzNzJhYTlhOWNmNDhiL3RhYmxlOmRiMjI3MDg4YTQwODRmYWQ5NGEwMzFlNGMyODIyZTk3L3RhYmxlcmFuZ2U6ZGIyMjcwODhhNDA4NGZhZDk0YTAzMWU0YzI4MjJlOTdfMzMtNy0xLTEtNzk3_4e3cdb13-2428-4113-b268-87a879623623">623</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-cash compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yOC9mcmFnOjBlNDhiNzZhMTAxZjRjODJiMGUzNzJhYTlhOWNmNDhiL3RhYmxlOmRiMjI3MDg4YTQwODRmYWQ5NGEwMzFlNGMyODIyZTk3L3RhYmxlcmFuZ2U6ZGIyMjcwODhhNDA4NGZhZDk0YTAzMWU0YzI4MjJlOTdfMzQtMS0xLTEtNzk3_1f02eee7-3770-4a14-be71-4ad316280ae6">13,463</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a5e5c59232b4c58b6e84716db6d8973_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yOC9mcmFnOjBlNDhiNzZhMTAxZjRjODJiMGUzNzJhYTlhOWNmNDhiL3RhYmxlOmRiMjI3MDg4YTQwODRmYWQ5NGEwMzFlNGMyODIyZTk3L3RhYmxlcmFuZ2U6ZGIyMjcwODhhNDA4NGZhZDk0YTAzMWU0YzI4MjJlOTdfMzQtNy0xLTEtNzk3_5d88faaa-14aa-4b08-a3c6-99a219fa5e54">13,463</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Surrendered shares</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="amed:SurrenderedShares" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yOC9mcmFnOjBlNDhiNzZhMTAxZjRjODJiMGUzNzJhYTlhOWNmNDhiL3RhYmxlOmRiMjI3MDg4YTQwODRmYWQ5NGEwMzFlNGMyODIyZTk3L3RhYmxlcmFuZ2U6ZGIyMjcwODhhNDA4NGZhZDk0YTAzMWU0YzI4MjJlOTdfMzUtMS0xLTEtNzk3_1a374073-d74e-48da-96b1-891d6a5b914c">6,944</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7299a7a0217a4939aebcf1747818528d_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="amed:SurrenderedShares" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yOC9mcmFnOjBlNDhiNzZhMTAxZjRjODJiMGUzNzJhYTlhOWNmNDhiL3RhYmxlOmRiMjI3MDg4YTQwODRmYWQ5NGEwMzFlNGMyODIyZTk3L3RhYmxlcmFuZ2U6ZGIyMjcwODhhNDA4NGZhZDk0YTAzMWU0YzI4MjJlOTdfMzUtOS0xLTEtNzk3_d4062570-4498-4138-952b-249f075ba676">6,944</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Shares repurchased</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yOC9mcmFnOjBlNDhiNzZhMTAxZjRjODJiMGUzNzJhYTlhOWNmNDhiL3RhYmxlOmRiMjI3MDg4YTQwODRmYWQ5NGEwMzFlNGMyODIyZTk3L3RhYmxlcmFuZ2U6ZGIyMjcwODhhNDA4NGZhZDk0YTAzMWU0YzI4MjJlOTdfMzYtMS0xLTEtNzk3_8d629d40-350a-4da8-b506-be30808c23cd">74,074</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7299a7a0217a4939aebcf1747818528d_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yOC9mcmFnOjBlNDhiNzZhMTAxZjRjODJiMGUzNzJhYTlhOWNmNDhiL3RhYmxlOmRiMjI3MDg4YTQwODRmYWQ5NGEwMzFlNGMyODIyZTk3L3RhYmxlcmFuZ2U6ZGIyMjcwODhhNDA4NGZhZDk0YTAzMWU0YzI4MjJlOTdfMzYtOS0xLTEtNzk3_50cbb854-69cc-4732-9fb1-6659932cb399">74,074</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Noncontrolling interest distribution</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630" decimals="-3" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yOC9mcmFnOjBlNDhiNzZhMTAxZjRjODJiMGUzNzJhYTlhOWNmNDhiL3RhYmxlOmRiMjI3MDg4YTQwODRmYWQ5NGEwMzFlNGMyODIyZTk3L3RhYmxlcmFuZ2U6ZGIyMjcwODhhNDA4NGZhZDk0YTAzMWU0YzI4MjJlOTdfMzctMS0xLTEtNzk3_fd726e83-aa0d-4daa-8037-e734ff46435c">794</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i87f87ab13a114dee919b9d2827a73fab_D20210101-20210630" decimals="-3" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yOC9mcmFnOjBlNDhiNzZhMTAxZjRjODJiMGUzNzJhYTlhOWNmNDhiL3RhYmxlOmRiMjI3MDg4YTQwODRmYWQ5NGEwMzFlNGMyODIyZTk3L3RhYmxlcmFuZ2U6ZGIyMjcwODhhNDA4NGZhZDk0YTAzMWU0YzI4MjJlOTdfMzctMTUtMS0xLTc5Nw_171d31b2-fe0d-49e2-ba27-d1204b860f9b">794</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yOC9mcmFnOjBlNDhiNzZhMTAxZjRjODJiMGUzNzJhYTlhOWNmNDhiL3RhYmxlOmRiMjI3MDg4YTQwODRmYWQ5NGEwMzFlNGMyODIyZTk3L3RhYmxlcmFuZ2U6ZGIyMjcwODhhNDA4NGZhZDk0YTAzMWU0YzI4MjJlOTdfMzgtMS0xLTEtNzk3_c5c3d183-1a14-4473-b066-0ce340eadeb2">130,911</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ac6fbdda808429998d8987cf9923712_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yOC9mcmFnOjBlNDhiNzZhMTAxZjRjODJiMGUzNzJhYTlhOWNmNDhiL3RhYmxlOmRiMjI3MDg4YTQwODRmYWQ5NGEwMzFlNGMyODIyZTk3L3RhYmxlcmFuZ2U6ZGIyMjcwODhhNDA4NGZhZDk0YTAzMWU0YzI4MjJlOTdfMzgtMTMtMS0xLTc5Nw_e972e9a1-4165-41a5-814a-9131426214d0">130,019</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87f87ab13a114dee919b9d2827a73fab_D20210101-20210630" decimals="-3" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yOC9mcmFnOjBlNDhiNzZhMTAxZjRjODJiMGUzNzJhYTlhOWNmNDhiL3RhYmxlOmRiMjI3MDg4YTQwODRmYWQ5NGEwMzFlNGMyODIyZTk3L3RhYmxlcmFuZ2U6ZGIyMjcwODhhNDA4NGZhZDk0YTAzMWU0YzI4MjJlOTdfMzgtMTUtMS0xLTc5Nw_12f79344-e10a-4121-bbe9-74492062ab15">892</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, June 30, 2021</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e833203be6947b4968aba4d20064ec8_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yOC9mcmFnOjBlNDhiNzZhMTAxZjRjODJiMGUzNzJhYTlhOWNmNDhiL3RhYmxlOmRiMjI3MDg4YTQwODRmYWQ5NGEwMzFlNGMyODIyZTk3L3RhYmxlcmFuZ2U6ZGIyMjcwODhhNDA4NGZhZDk0YTAzMWU0YzI4MjJlOTdfMzktMS0xLTEtNzk3_c7364d6c-31af-4179-acae-cc19283ed46c">875,887</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3e59fd3d3cfb4bb7ae9ea1d3af94e290_I20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yOC9mcmFnOjBlNDhiNzZhMTAxZjRjODJiMGUzNzJhYTlhOWNmNDhiL3RhYmxlOmRiMjI3MDg4YTQwODRmYWQ5NGEwMzFlNGMyODIyZTk3L3RhYmxlcmFuZ2U6ZGIyMjcwODhhNDA4NGZhZDk0YTAzMWU0YzI4MjJlOTdfMzktMy0xLTEtNzk3_fd06ab77-0e27-484e-a7eb-ba061c51d9d7">37,553,355</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e59fd3d3cfb4bb7ae9ea1d3af94e290_I20210630" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yOC9mcmFnOjBlNDhiNzZhMTAxZjRjODJiMGUzNzJhYTlhOWNmNDhiL3RhYmxlOmRiMjI3MDg4YTQwODRmYWQ5NGEwMzFlNGMyODIyZTk3L3RhYmxlcmFuZ2U6ZGIyMjcwODhhNDA4NGZhZDk0YTAzMWU0YzI4MjJlOTdfMzktNS0xLTEtNzk3_a2235016-8856-430a-bfd7-2c59746633e0">38</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0e0b2cc08e747cba20ceed2b5382012_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yOC9mcmFnOjBlNDhiNzZhMTAxZjRjODJiMGUzNzJhYTlhOWNmNDhiL3RhYmxlOmRiMjI3MDg4YTQwODRmYWQ5NGEwMzFlNGMyODIyZTk3L3RhYmxlcmFuZ2U6ZGIyMjcwODhhNDA4NGZhZDk0YTAzMWU0YzI4MjJlOTdfMzktNy0xLTEtNzk3_f8f7d23d-c3f1-4ceb-9545-8e535a771502">714,334</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i01768f8d7ebc4cc18d5eb154976ba4d3_I20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yOC9mcmFnOjBlNDhiNzZhMTAxZjRjODJiMGUzNzJhYTlhOWNmNDhiL3RhYmxlOmRiMjI3MDg4YTQwODRmYWQ5NGEwMzFlNGMyODIyZTk3L3RhYmxlcmFuZ2U6ZGIyMjcwODhhNDA4NGZhZDk0YTAzMWU0YzI4MjJlOTdfMzktOS0xLTEtNzk3_b42770c8-16b4-4819-b8e9-e53fed467193">400,110</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1302a68dd8ef42e6ab76db142d77aae4_I20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yOC9mcmFnOjBlNDhiNzZhMTAxZjRjODJiMGUzNzJhYTlhOWNmNDhiL3RhYmxlOmRiMjI3MDg4YTQwODRmYWQ5NGEwMzFlNGMyODIyZTk3L3RhYmxlcmFuZ2U6ZGIyMjcwODhhNDA4NGZhZDk0YTAzMWU0YzI4MjJlOTdfMzktMTEtMS0xLTc5Nw_0ae413b5-2701-47d7-a503-15fb17bea399">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i90abbd77ace44a6bac4330406a6d4810_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yOC9mcmFnOjBlNDhiNzZhMTAxZjRjODJiMGUzNzJhYTlhOWNmNDhiL3RhYmxlOmRiMjI3MDg4YTQwODRmYWQ5NGEwMzFlNGMyODIyZTk3L3RhYmxlcmFuZ2U6ZGIyMjcwODhhNDA4NGZhZDk0YTAzMWU0YzI4MjJlOTdfMzktMTMtMS0xLTc5Nw_31804f2c-ed15-448c-97b4-5b4a520107b5">560,010</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie40ed45ce02a463b81cddfc774673775_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yOC9mcmFnOjBlNDhiNzZhMTAxZjRjODJiMGUzNzJhYTlhOWNmNDhiL3RhYmxlOmRiMjI3MDg4YTQwODRmYWQ5NGEwMzFlNGMyODIyZTk3L3RhYmxlcmFuZ2U6ZGIyMjcwODhhNDA4NGZhZDk0YTAzMWU0YzI4MjJlOTdfMzktMTUtMS0xLTc5Nw_c20c8808-3ce5-4f90-be14-25f308c62cd1">1,615</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="45" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Six-Months Ended June 30, 2020</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additional<br/>Paid-in<br/>Capital</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Treasury<br/>Stock</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Other<br/>Comprehensive Income</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Retained<br/>Earnings</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Noncontrolling<br/>Interests</span></td></tr><tr style="height:23pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, December 31, 2019</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa673cc4c9af455b97f34a55548dfc84_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yOC9mcmFnOjBlNDhiNzZhMTAxZjRjODJiMGUzNzJhYTlhOWNmNDhiL3RhYmxlOmRiMjI3MDg4YTQwODRmYWQ5NGEwMzFlNGMyODIyZTk3L3RhYmxlcmFuZ2U6ZGIyMjcwODhhNDA4NGZhZDk0YTAzMWU0YzI4MjJlOTdfNDQtMS0xLTEtODAy_7e4707c2-2702-4672-ae84-b4da99f2a250">641,513</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i34b209949049477791ec23971ce9e445_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yOC9mcmFnOjBlNDhiNzZhMTAxZjRjODJiMGUzNzJhYTlhOWNmNDhiL3RhYmxlOmRiMjI3MDg4YTQwODRmYWQ5NGEwMzFlNGMyODIyZTk3L3RhYmxlcmFuZ2U6ZGIyMjcwODhhNDA4NGZhZDk0YTAzMWU0YzI4MjJlOTdfNDQtMy0xLTEtODAy_127f012e-bc07-486c-ad5d-cf2af3a98e67">36,638,021</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34b209949049477791ec23971ce9e445_I20191231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yOC9mcmFnOjBlNDhiNzZhMTAxZjRjODJiMGUzNzJhYTlhOWNmNDhiL3RhYmxlOmRiMjI3MDg4YTQwODRmYWQ5NGEwMzFlNGMyODIyZTk3L3RhYmxlcmFuZ2U6ZGIyMjcwODhhNDA4NGZhZDk0YTAzMWU0YzI4MjJlOTdfNDQtNS0xLTEtODAy_db3dc2b7-7426-44eb-a5ed-cf67e0ecc72c">37</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9b5755043594e6fac0445e663b73395_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yOC9mcmFnOjBlNDhiNzZhMTAxZjRjODJiMGUzNzJhYTlhOWNmNDhiL3RhYmxlOmRiMjI3MDg4YTQwODRmYWQ5NGEwMzFlNGMyODIyZTk3L3RhYmxlcmFuZ2U6ZGIyMjcwODhhNDA4NGZhZDk0YTAzMWU0YzI4MjJlOTdfNDQtNy0xLTEtODAy_8fd7b3cb-0f45-4562-8df1-b05646d7fe61">645,256</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i441145d29ff346a58266e6fa5735a383_I20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yOC9mcmFnOjBlNDhiNzZhMTAxZjRjODJiMGUzNzJhYTlhOWNmNDhiL3RhYmxlOmRiMjI3MDg4YTQwODRmYWQ5NGEwMzFlNGMyODIyZTk3L3RhYmxlcmFuZ2U6ZGIyMjcwODhhNDA4NGZhZDk0YTAzMWU0YzI4MjJlOTdfNDQtOS0xLTEtODAy_5c487b75-98db-4a41-ab28-7848cc7c95ef">251,241</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9c9163b115847718a0e04afa87d792f_I20191231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yOC9mcmFnOjBlNDhiNzZhMTAxZjRjODJiMGUzNzJhYTlhOWNmNDhiL3RhYmxlOmRiMjI3MDg4YTQwODRmYWQ5NGEwMzFlNGMyODIyZTk3L3RhYmxlcmFuZ2U6ZGIyMjcwODhhNDA4NGZhZDk0YTAzMWU0YzI4MjJlOTdfNDQtMTEtMS0xLTgwMg_71656276-6d77-4aa7-bd6d-c8ea5930e3cb">15</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f812fe62e9048c1b51562c9b05a841c_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yOC9mcmFnOjBlNDhiNzZhMTAxZjRjODJiMGUzNzJhYTlhOWNmNDhiL3RhYmxlOmRiMjI3MDg4YTQwODRmYWQ5NGEwMzFlNGMyODIyZTk3L3RhYmxlcmFuZ2U6ZGIyMjcwODhhNDA4NGZhZDk0YTAzMWU0YzI4MjJlOTdfNDQtMTMtMS0xLTgwMg_b95cea43-f132-434f-a10d-462b9adc6155">246,383</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2fef7471e4c74e2cac75b17f8e455e63_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yOC9mcmFnOjBlNDhiNzZhMTAxZjRjODJiMGUzNzJhYTlhOWNmNDhiL3RhYmxlOmRiMjI3MDg4YTQwODRmYWQ5NGEwMzFlNGMyODIyZTk3L3RhYmxlcmFuZ2U6ZGIyMjcwODhhNDA4NGZhZDk0YTAzMWU0YzI4MjJlOTdfNDQtMTUtMS0xLTgwMg_b53769c0-ef85-4321-9fb5-88ed145645b8">1,063</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of stock &#8211; employee stock purchase plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i667fa0996400408f9cb2d7f4d3ee2087_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yOC9mcmFnOjBlNDhiNzZhMTAxZjRjODJiMGUzNzJhYTlhOWNmNDhiL3RhYmxlOmRiMjI3MDg4YTQwODRmYWQ5NGEwMzFlNGMyODIyZTk3L3RhYmxlcmFuZ2U6ZGIyMjcwODhhNDA4NGZhZDk0YTAzMWU0YzI4MjJlOTdfNDUtMS0xLTEtODAy_3fbf4842-f4ff-4a53-ba51-6cc13575f89a">1,686</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia6768b0ddf76411381a296ae9d695ae6_D20200101-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yOC9mcmFnOjBlNDhiNzZhMTAxZjRjODJiMGUzNzJhYTlhOWNmNDhiL3RhYmxlOmRiMjI3MDg4YTQwODRmYWQ5NGEwMzFlNGMyODIyZTk3L3RhYmxlcmFuZ2U6ZGIyMjcwODhhNDA4NGZhZDk0YTAzMWU0YzI4MjJlOTdfNDUtMy0xLTEtODAy_fa38fe85-1ca8-4f0b-86d7-1366d82e2dad">11,358</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i846085ebf1cf4817ac0dd1e9245c242a_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yOC9mcmFnOjBlNDhiNzZhMTAxZjRjODJiMGUzNzJhYTlhOWNmNDhiL3RhYmxlOmRiMjI3MDg4YTQwODRmYWQ5NGEwMzFlNGMyODIyZTk3L3RhYmxlcmFuZ2U6ZGIyMjcwODhhNDA4NGZhZDk0YTAzMWU0YzI4MjJlOTdfNDUtNy0xLTEtODAy_459db252-6018-451f-a1f6-2a41027a9c09">1,686</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of stock &#8211; 401(k) plan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i667fa0996400408f9cb2d7f4d3ee2087_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="amed:StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yOC9mcmFnOjBlNDhiNzZhMTAxZjRjODJiMGUzNzJhYTlhOWNmNDhiL3RhYmxlOmRiMjI3MDg4YTQwODRmYWQ5NGEwMzFlNGMyODIyZTk3L3RhYmxlcmFuZ2U6ZGIyMjcwODhhNDA4NGZhZDk0YTAzMWU0YzI4MjJlOTdfNDYtMS0xLTEtODAy_2bc678c8-5157-4cb2-b9ad-eecd5f89c1c5">3,057</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia6768b0ddf76411381a296ae9d695ae6_D20200101-20200630" decimals="0" format="ixt:numdotdecimal" name="amed:StockIssuedDuringPeriodSharesFourZeroOneKEmployerMatch" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yOC9mcmFnOjBlNDhiNzZhMTAxZjRjODJiMGUzNzJhYTlhOWNmNDhiL3RhYmxlOmRiMjI3MDg4YTQwODRmYWQ5NGEwMzFlNGMyODIyZTk3L3RhYmxlcmFuZ2U6ZGIyMjcwODhhNDA4NGZhZDk0YTAzMWU0YzI4MjJlOTdfNDYtMy0xLTEtODAy_d5897e3e-48f2-45a3-8b11-b6ea0f302da6">18,312</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia6768b0ddf76411381a296ae9d695ae6_D20200101-20200630" decimals="-6" format="ixt:zerodash" name="amed:StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yOC9mcmFnOjBlNDhiNzZhMTAxZjRjODJiMGUzNzJhYTlhOWNmNDhiL3RhYmxlOmRiMjI3MDg4YTQwODRmYWQ5NGEwMzFlNGMyODIyZTk3L3RhYmxlcmFuZ2U6ZGIyMjcwODhhNDA4NGZhZDk0YTAzMWU0YzI4MjJlOTdfNDYtNS0xLTEtODAy_688dc348-2f67-4ba0-9a4a-a168c6b9295a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i846085ebf1cf4817ac0dd1e9245c242a_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="amed:StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yOC9mcmFnOjBlNDhiNzZhMTAxZjRjODJiMGUzNzJhYTlhOWNmNDhiL3RhYmxlOmRiMjI3MDg4YTQwODRmYWQ5NGEwMzFlNGMyODIyZTk3L3RhYmxlcmFuZ2U6ZGIyMjcwODhhNDA4NGZhZDk0YTAzMWU0YzI4MjJlOTdfNDYtNy0xLTEtODAy_231a6e4d-1e47-43ab-a001-37418edf6fc0">3,057</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance/(cancellation) of non-vested stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i667fa0996400408f9cb2d7f4d3ee2087_D20200101-20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yOC9mcmFnOjBlNDhiNzZhMTAxZjRjODJiMGUzNzJhYTlhOWNmNDhiL3RhYmxlOmRiMjI3MDg4YTQwODRmYWQ5NGEwMzFlNGMyODIyZTk3L3RhYmxlcmFuZ2U6ZGIyMjcwODhhNDA4NGZhZDk0YTAzMWU0YzI4MjJlOTdfNDctMS0xLTEtODAy_42a8fd24-8dec-49e0-87a0-319ade08a04f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia6768b0ddf76411381a296ae9d695ae6_D20200101-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yOC9mcmFnOjBlNDhiNzZhMTAxZjRjODJiMGUzNzJhYTlhOWNmNDhiL3RhYmxlOmRiMjI3MDg4YTQwODRmYWQ5NGEwMzFlNGMyODIyZTk3L3RhYmxlcmFuZ2U6ZGIyMjcwODhhNDA4NGZhZDk0YTAzMWU0YzI4MjJlOTdfNDctMy0xLTEtODAy_bbbed47a-bffa-49b5-862c-b3a0a8fe8780">84,884</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia6768b0ddf76411381a296ae9d695ae6_D20200101-20200630" decimals="-6" format="ixt:zerodash" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yOC9mcmFnOjBlNDhiNzZhMTAxZjRjODJiMGUzNzJhYTlhOWNmNDhiL3RhYmxlOmRiMjI3MDg4YTQwODRmYWQ5NGEwMzFlNGMyODIyZTk3L3RhYmxlcmFuZ2U6ZGIyMjcwODhhNDA4NGZhZDk0YTAzMWU0YzI4MjJlOTdfNDctNS0xLTEtODAy_3aa0ffd7-7db5-4589-858b-07658c0c9a96">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i846085ebf1cf4817ac0dd1e9245c242a_D20200101-20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yOC9mcmFnOjBlNDhiNzZhMTAxZjRjODJiMGUzNzJhYTlhOWNmNDhiL3RhYmxlOmRiMjI3MDg4YTQwODRmYWQ5NGEwMzFlNGMyODIyZTk3L3RhYmxlcmFuZ2U6ZGIyMjcwODhhNDA4NGZhZDk0YTAzMWU0YzI4MjJlOTdfNDctNy0xLTEtODAy_a3c51ae0-739e-4ab5-aa94-dc8cb3b0e378">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exercise of stock options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i667fa0996400408f9cb2d7f4d3ee2087_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yOC9mcmFnOjBlNDhiNzZhMTAxZjRjODJiMGUzNzJhYTlhOWNmNDhiL3RhYmxlOmRiMjI3MDg4YTQwODRmYWQ5NGEwMzFlNGMyODIyZTk3L3RhYmxlcmFuZ2U6ZGIyMjcwODhhNDA4NGZhZDk0YTAzMWU0YzI4MjJlOTdfNDgtMS0xLTEtODAy_fa1b5785-5e8c-473b-8504-d6a1218f1ba8">2,947</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia6768b0ddf76411381a296ae9d695ae6_D20200101-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yOC9mcmFnOjBlNDhiNzZhMTAxZjRjODJiMGUzNzJhYTlhOWNmNDhiL3RhYmxlOmRiMjI3MDg4YTQwODRmYWQ5NGEwMzFlNGMyODIyZTk3L3RhYmxlcmFuZ2U6ZGIyMjcwODhhNDA4NGZhZDk0YTAzMWU0YzI4MjJlOTdfNDgtMy0xLTEtODAy_d427cfe9-1ed6-4ec6-965c-664232c51f85">78,723</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i846085ebf1cf4817ac0dd1e9245c242a_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yOC9mcmFnOjBlNDhiNzZhMTAxZjRjODJiMGUzNzJhYTlhOWNmNDhiL3RhYmxlOmRiMjI3MDg4YTQwODRmYWQ5NGEwMzFlNGMyODIyZTk3L3RhYmxlcmFuZ2U6ZGIyMjcwODhhNDA4NGZhZDk0YTAzMWU0YzI4MjJlOTdfNDgtNy0xLTEtODAy_e77d7905-2fd9-499b-bf06-504e845cc824">2,947</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-cash compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i667fa0996400408f9cb2d7f4d3ee2087_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yOC9mcmFnOjBlNDhiNzZhMTAxZjRjODJiMGUzNzJhYTlhOWNmNDhiL3RhYmxlOmRiMjI3MDg4YTQwODRmYWQ5NGEwMzFlNGMyODIyZTk3L3RhYmxlcmFuZ2U6ZGIyMjcwODhhNDA4NGZhZDk0YTAzMWU0YzI4MjJlOTdfNDktMS0xLTEtODAy_6f5ee9b8-ade6-4176-85b4-257b1f609c90">12,634</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i846085ebf1cf4817ac0dd1e9245c242a_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yOC9mcmFnOjBlNDhiNzZhMTAxZjRjODJiMGUzNzJhYTlhOWNmNDhiL3RhYmxlOmRiMjI3MDg4YTQwODRmYWQ5NGEwMzFlNGMyODIyZTk3L3RhYmxlcmFuZ2U6ZGIyMjcwODhhNDA4NGZhZDk0YTAzMWU0YzI4MjJlOTdfNDktNy0xLTEtODAy_6b1659c7-6ff2-4147-a96e-e1c51b3d9d5d">12,634</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Surrendered shares</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i667fa0996400408f9cb2d7f4d3ee2087_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="amed:SurrenderedShares" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yOC9mcmFnOjBlNDhiNzZhMTAxZjRjODJiMGUzNzJhYTlhOWNmNDhiL3RhYmxlOmRiMjI3MDg4YTQwODRmYWQ5NGEwMzFlNGMyODIyZTk3L3RhYmxlcmFuZ2U6ZGIyMjcwODhhNDA4NGZhZDk0YTAzMWU0YzI4MjJlOTdfNTAtMS0xLTEtODAy_993782d3-07cb-41de-8f9e-5562f7d2e6b3">6,384</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib8af587d580b4f4e9cdf536e3b9b31e6_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="amed:SurrenderedShares" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yOC9mcmFnOjBlNDhiNzZhMTAxZjRjODJiMGUzNzJhYTlhOWNmNDhiL3RhYmxlOmRiMjI3MDg4YTQwODRmYWQ5NGEwMzFlNGMyODIyZTk3L3RhYmxlcmFuZ2U6ZGIyMjcwODhhNDA4NGZhZDk0YTAzMWU0YzI4MjJlOTdfNTAtOS0xLTEtODAy_320c5d3a-5899-440e-a678-7e1cc5d3b537">6,384</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Noncontrolling interest distribution</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i667fa0996400408f9cb2d7f4d3ee2087_D20200101-20200630" decimals="-3" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yOC9mcmFnOjBlNDhiNzZhMTAxZjRjODJiMGUzNzJhYTlhOWNmNDhiL3RhYmxlOmRiMjI3MDg4YTQwODRmYWQ5NGEwMzFlNGMyODIyZTk3L3RhYmxlcmFuZ2U6ZGIyMjcwODhhNDA4NGZhZDk0YTAzMWU0YzI4MjJlOTdfNTEtMS0xLTEtODAy_c33c5b48-c2af-4aec-a120-6e374e36a5b4">372</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i917af374eb6a409ebea5c8abe45a5a8e_D20200101-20200630" decimals="-3" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yOC9mcmFnOjBlNDhiNzZhMTAxZjRjODJiMGUzNzJhYTlhOWNmNDhiL3RhYmxlOmRiMjI3MDg4YTQwODRmYWQ5NGEwMzFlNGMyODIyZTk3L3RhYmxlcmFuZ2U6ZGIyMjcwODhhNDA4NGZhZDk0YTAzMWU0YzI4MjJlOTdfNTEtMTUtMS0xLTgwMg_5a6b7fae-18a4-44b0-8259-5b5c57a6033a">372</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Write-off of other comprehensive income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i667fa0996400408f9cb2d7f4d3ee2087_D20200101-20200630" decimals="-3" name="amed:EquityImpactOfWriteOffOfOtherComprehensiveIncome" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yOC9mcmFnOjBlNDhiNzZhMTAxZjRjODJiMGUzNzJhYTlhOWNmNDhiL3RhYmxlOmRiMjI3MDg4YTQwODRmYWQ5NGEwMzFlNGMyODIyZTk3L3RhYmxlcmFuZ2U6ZGIyMjcwODhhNDA4NGZhZDk0YTAzMWU0YzI4MjJlOTdfNTItMS0xLTEtODAy_9078be95-6a53-435c-bbfd-c84fe3db0841">15</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i105f613dfc9b4ea7afdeaf6f08277f25_D20200101-20200630" decimals="-3" name="amed:EquityImpactOfWriteOffOfOtherComprehensiveIncome" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yOC9mcmFnOjBlNDhiNzZhMTAxZjRjODJiMGUzNzJhYTlhOWNmNDhiL3RhYmxlOmRiMjI3MDg4YTQwODRmYWQ5NGEwMzFlNGMyODIyZTk3L3RhYmxlcmFuZ2U6ZGIyMjcwODhhNDA4NGZhZDk0YTAzMWU0YzI4MjJlOTdfNTItMTEtMS0xLTgwMg_b8dd2f89-da91-41f4-bd8e-34bb56ac56bb">15</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i667fa0996400408f9cb2d7f4d3ee2087_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yOC9mcmFnOjBlNDhiNzZhMTAxZjRjODJiMGUzNzJhYTlhOWNmNDhiL3RhYmxlOmRiMjI3MDg4YTQwODRmYWQ5NGEwMzFlNGMyODIyZTk3L3RhYmxlcmFuZ2U6ZGIyMjcwODhhNDA4NGZhZDk0YTAzMWU0YzI4MjJlOTdfNTMtMS0xLTEtODAy_cbdba268-62f3-4510-bfb5-944da4d2b0e3">67,193</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08ad12ef46cf4d2da58b68346a440ca1_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yOC9mcmFnOjBlNDhiNzZhMTAxZjRjODJiMGUzNzJhYTlhOWNmNDhiL3RhYmxlOmRiMjI3MDg4YTQwODRmYWQ5NGEwMzFlNGMyODIyZTk3L3RhYmxlcmFuZ2U6ZGIyMjcwODhhNDA4NGZhZDk0YTAzMWU0YzI4MjJlOTdfNTMtMTMtMS0xLTgwMg_aa801cbe-be18-4f76-b337-a7336b236f63">66,476</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i917af374eb6a409ebea5c8abe45a5a8e_D20200101-20200630" decimals="-3" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yOC9mcmFnOjBlNDhiNzZhMTAxZjRjODJiMGUzNzJhYTlhOWNmNDhiL3RhYmxlOmRiMjI3MDg4YTQwODRmYWQ5NGEwMzFlNGMyODIyZTk3L3RhYmxlcmFuZ2U6ZGIyMjcwODhhNDA4NGZhZDk0YTAzMWU0YzI4MjJlOTdfNTMtMTUtMS0xLTgwMg_e3d1c34f-1192-4eb3-b71d-b522699864c6">717</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, June 30, 2020</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15586f038620443192b7c904beb4ad54_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yOC9mcmFnOjBlNDhiNzZhMTAxZjRjODJiMGUzNzJhYTlhOWNmNDhiL3RhYmxlOmRiMjI3MDg4YTQwODRmYWQ5NGEwMzFlNGMyODIyZTk3L3RhYmxlcmFuZ2U6ZGIyMjcwODhhNDA4NGZhZDk0YTAzMWU0YzI4MjJlOTdfNTQtMS0xLTEtODAy_1c457ef3-83a2-4d3f-af7d-4453743ad35f">722,259</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6271c5457d114e698b9aa02424c6fba7_I20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yOC9mcmFnOjBlNDhiNzZhMTAxZjRjODJiMGUzNzJhYTlhOWNmNDhiL3RhYmxlOmRiMjI3MDg4YTQwODRmYWQ5NGEwMzFlNGMyODIyZTk3L3RhYmxlcmFuZ2U6ZGIyMjcwODhhNDA4NGZhZDk0YTAzMWU0YzI4MjJlOTdfNTQtMy0xLTEtODAy_6a4f6a27-54e8-45b0-a460-165f755f8a38">36,831,298</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6271c5457d114e698b9aa02424c6fba7_I20200630" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yOC9mcmFnOjBlNDhiNzZhMTAxZjRjODJiMGUzNzJhYTlhOWNmNDhiL3RhYmxlOmRiMjI3MDg4YTQwODRmYWQ5NGEwMzFlNGMyODIyZTk3L3RhYmxlcmFuZ2U6ZGIyMjcwODhhNDA4NGZhZDk0YTAzMWU0YzI4MjJlOTdfNTQtNS0xLTEtODAy_7a9160e4-1973-4154-975e-c0011ac3f613">37</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f5f7a1bdc904b23a1b3496bf1c343ed_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yOC9mcmFnOjBlNDhiNzZhMTAxZjRjODJiMGUzNzJhYTlhOWNmNDhiL3RhYmxlOmRiMjI3MDg4YTQwODRmYWQ5NGEwMzFlNGMyODIyZTk3L3RhYmxlcmFuZ2U6ZGIyMjcwODhhNDA4NGZhZDk0YTAzMWU0YzI4MjJlOTdfNTQtNy0xLTEtODAy_f3c71e79-7872-4e19-86aa-46212d64db05">665,580</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic2e9db201a8c41efacbe6c14b48f08c5_I20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yOC9mcmFnOjBlNDhiNzZhMTAxZjRjODJiMGUzNzJhYTlhOWNmNDhiL3RhYmxlOmRiMjI3MDg4YTQwODRmYWQ5NGEwMzFlNGMyODIyZTk3L3RhYmxlcmFuZ2U6ZGIyMjcwODhhNDA4NGZhZDk0YTAzMWU0YzI4MjJlOTdfNTQtOS0xLTEtODAy_8f224139-ee28-4063-9537-c4bdeb2d9d6b">257,625</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie2958a3a3c7d4e89970b11fea75ea413_I20200630" decimals="-6" format="ixt:zerodash" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yOC9mcmFnOjBlNDhiNzZhMTAxZjRjODJiMGUzNzJhYTlhOWNmNDhiL3RhYmxlOmRiMjI3MDg4YTQwODRmYWQ5NGEwMzFlNGMyODIyZTk3L3RhYmxlcmFuZ2U6ZGIyMjcwODhhNDA4NGZhZDk0YTAzMWU0YzI4MjJlOTdfNTQtMTEtMS0xLTgwMg_928ec62d-d5aa-4d7d-9fe4-368fbc1edd49">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f8cee8ab0a8499bb9039cd2b585f4be_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yOC9mcmFnOjBlNDhiNzZhMTAxZjRjODJiMGUzNzJhYTlhOWNmNDhiL3RhYmxlOmRiMjI3MDg4YTQwODRmYWQ5NGEwMzFlNGMyODIyZTk3L3RhYmxlcmFuZ2U6ZGIyMjcwODhhNDA4NGZhZDk0YTAzMWU0YzI4MjJlOTdfNTQtMTMtMS0xLTgwMg_fda3b04e-71b4-4b13-9f27-b5dfb16fcee6">312,859</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0520e88179174d4c983746db6664ff87_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yOC9mcmFnOjBlNDhiNzZhMTAxZjRjODJiMGUzNzJhYTlhOWNmNDhiL3RhYmxlOmRiMjI3MDg4YTQwODRmYWQ5NGEwMzFlNGMyODIyZTk3L3RhYmxlcmFuZ2U6ZGIyMjcwODhhNDA4NGZhZDk0YTAzMWU0YzI4MjJlOTdfNTQtMTUtMS0xLTgwMg_5b2d7ef2-fdb0-479f-8575-72e35c9df588">1,408</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these condensed consolidated financial statements.</span></div><div style="height:4.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><div id="iccd9c69ecd2c42e5897cfe9ab4e7e0b5_31"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AMEDISYS, INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Amounts in thousands)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:472.50pt"><tr><td style="width:1.0pt"></td><td style="width:357.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:52.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:52.75pt"></td><td style="width:1.0pt"></td></tr><tr style="height:21pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For&#160;the&#160;Six-Month&#160;<br/>Periods&#160;Ended June 30,</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash Flows from Operating Activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8zMS9mcmFnOjJjMWUxYzVmMTk4ZTQ1NDNiYzMwZTA3OWU1MjY2ODhhL3RhYmxlOmVlYjE5ZmUzODg2MTQ3NmE5MGJlZDMyODQ0NzUyMDYxL3RhYmxlcmFuZ2U6ZWViMTlmZTM4ODYxNDc2YTkwYmVkMzI4NDQ3NTIwNjFfMy0xLTEtMS0w_688a6ab3-9a38-4cb5-99b1-57a5a64fe66b">130,911</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i667fa0996400408f9cb2d7f4d3ee2087_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8zMS9mcmFnOjJjMWUxYzVmMTk4ZTQ1NDNiYzMwZTA3OWU1MjY2ODhhL3RhYmxlOmVlYjE5ZmUzODg2MTQ3NmE5MGJlZDMyODQ0NzUyMDYxL3RhYmxlcmFuZ2U6ZWViMTlmZTM4ODYxNDc2YTkwYmVkMzI4NDQ3NTIwNjFfMy0zLTEtMS0w_81167009-ba88-4383-ab35-7d7205cc0fe1">67,193</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments to reconcile net income to net cash provided by operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8zMS9mcmFnOjJjMWUxYzVmMTk4ZTQ1NDNiYzMwZTA3OWU1MjY2ODhhL3RhYmxlOmVlYjE5ZmUzODg2MTQ3NmE5MGJlZDMyODQ0NzUyMDYxL3RhYmxlcmFuZ2U6ZWViMTlmZTM4ODYxNDc2YTkwYmVkMzI4NDQ3NTIwNjFfNS0xLTEtMS0w_3290d2fb-8310-4d66-9337-57a7dfff084a">14,276</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i667fa0996400408f9cb2d7f4d3ee2087_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8zMS9mcmFnOjJjMWUxYzVmMTk4ZTQ1NDNiYzMwZTA3OWU1MjY2ODhhL3RhYmxlOmVlYjE5ZmUzODg2MTQ3NmE5MGJlZDMyODQ0NzUyMDYxL3RhYmxlcmFuZ2U6ZWViMTlmZTM4ODYxNDc2YTkwYmVkMzI4NDQ3NTIwNjFfNS0zLTEtMS0w_f76d7205-2caa-403c-b9cb-5eeffb2281e6">11,672</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8zMS9mcmFnOjJjMWUxYzVmMTk4ZTQ1NDNiYzMwZTA3OWU1MjY2ODhhL3RhYmxlOmVlYjE5ZmUzODg2MTQ3NmE5MGJlZDMyODQ0NzUyMDYxL3RhYmxlcmFuZ2U6ZWViMTlmZTM4ODYxNDc2YTkwYmVkMzI4NDQ3NTIwNjFfNi0xLTEtMS0w_1bc787e4-d589-44bb-85da-ac74bb597a2a">13,463</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i667fa0996400408f9cb2d7f4d3ee2087_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8zMS9mcmFnOjJjMWUxYzVmMTk4ZTQ1NDNiYzMwZTA3OWU1MjY2ODhhL3RhYmxlOmVlYjE5ZmUzODg2MTQ3NmE5MGJlZDMyODQ0NzUyMDYxL3RhYmxlcmFuZ2U6ZWViMTlmZTM4ODYxNDc2YTkwYmVkMzI4NDQ3NTIwNjFfNi0zLTEtMS0w_338b34fe-2cac-4704-9bad-143198ec19ac">12,634</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization and impairment of operating lease right of use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="amed:AmortizationandImpairmentofOperatingLeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8zMS9mcmFnOjJjMWUxYzVmMTk4ZTQ1NDNiYzMwZTA3OWU1MjY2ODhhL3RhYmxlOmVlYjE5ZmUzODg2MTQ3NmE5MGJlZDMyODQ0NzUyMDYxL3RhYmxlcmFuZ2U6ZWViMTlmZTM4ODYxNDc2YTkwYmVkMzI4NDQ3NTIwNjFfNy0xLTEtMS0w_1ff73ad8-84f7-42f9-9d98-1874657f1685">19,702</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i667fa0996400408f9cb2d7f4d3ee2087_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="amed:AmortizationandImpairmentofOperatingLeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8zMS9mcmFnOjJjMWUxYzVmMTk4ZTQ1NDNiYzMwZTA3OWU1MjY2ODhhL3RhYmxlOmVlYjE5ZmUzODg2MTQ3NmE5MGJlZDMyODQ0NzUyMDYxL3RhYmxlcmFuZ2U6ZWViMTlmZTM4ODYxNDc2YTkwYmVkMzI4NDQ3NTIwNjFfNy0zLTEtMS0w_f3459e07-64ec-4d2d-8d16-d289402000fa">18,558</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss (gain) on disposal of property and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8zMS9mcmFnOjJjMWUxYzVmMTk4ZTQ1NDNiYzMwZTA3OWU1MjY2ODhhL3RhYmxlOmVlYjE5ZmUzODg2MTQ3NmE5MGJlZDMyODQ0NzUyMDYxL3RhYmxlcmFuZ2U6ZWViMTlmZTM4ODYxNDc2YTkwYmVkMzI4NDQ3NTIwNjFfOC0xLTEtMS0w_925d3093-36bd-40bf-b751-a818b4e3c82a">8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i667fa0996400408f9cb2d7f4d3ee2087_D20200101-20200630" decimals="-3" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8zMS9mcmFnOjJjMWUxYzVmMTk4ZTQ1NDNiYzMwZTA3OWU1MjY2ODhhL3RhYmxlOmVlYjE5ZmUzODg2MTQ3NmE5MGJlZDMyODQ0NzUyMDYxL3RhYmxlcmFuZ2U6ZWViMTlmZTM4ODYxNDc2YTkwYmVkMzI4NDQ3NTIwNjFfOC0zLTEtMS0w_cbb516d6-df00-4cc2-b097-b89ad84f5a9f">94</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Gain) loss on equity method investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GainLossOnSaleOfInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8zMS9mcmFnOjJjMWUxYzVmMTk4ZTQ1NDNiYzMwZTA3OWU1MjY2ODhhL3RhYmxlOmVlYjE5ZmUzODg2MTQ3NmE5MGJlZDMyODQ0NzUyMDYxL3RhYmxlcmFuZ2U6ZWViMTlmZTM4ODYxNDc2YTkwYmVkMzI4NDQ3NTIwNjFfOS0xLTEtMS0xMzk_04a63eee-22d5-49cf-934a-8fd347534c65">31,092</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i667fa0996400408f9cb2d7f4d3ee2087_D20200101-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:GainLossOnSaleOfInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8zMS9mcmFnOjJjMWUxYzVmMTk4ZTQ1NDNiYzMwZTA3OWU1MjY2ODhhL3RhYmxlOmVlYjE5ZmUzODg2MTQ3NmE5MGJlZDMyODQ0NzUyMDYxL3RhYmxlcmFuZ2U6ZWViMTlmZTM4ODYxNDc2YTkwYmVkMzI4NDQ3NTIwNjFfOS0zLTEtMS0xMzk_4e5df52b-534a-44fd-995c-39fba42dac6d">2,980</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Write-off of other comprehensive income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630" decimals="-3" format="ixt:zerodash" name="amed:WriteOffOfOtherComprehensiveIncome" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8zMS9mcmFnOjJjMWUxYzVmMTk4ZTQ1NDNiYzMwZTA3OWU1MjY2ODhhL3RhYmxlOmVlYjE5ZmUzODg2MTQ3NmE5MGJlZDMyODQ0NzUyMDYxL3RhYmxlcmFuZ2U6ZWViMTlmZTM4ODYxNDc2YTkwYmVkMzI4NDQ3NTIwNjFfOS0xLTEtMS0w_8ad16adc-cbf8-4e77-83d6-8d7a4423cfc3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i667fa0996400408f9cb2d7f4d3ee2087_D20200101-20200630" decimals="-3" name="amed:WriteOffOfOtherComprehensiveIncome" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8zMS9mcmFnOjJjMWUxYzVmMTk4ZTQ1NDNiYzMwZTA3OWU1MjY2ODhhL3RhYmxlOmVlYjE5ZmUzODg2MTQ3NmE5MGJlZDMyODQ0NzUyMDYxL3RhYmxlcmFuZ2U6ZWViMTlmZTM4ODYxNDc2YTkwYmVkMzI4NDQ3NTIwNjFfOS0zLTEtMS0w_257e87db-5f95-49ee-b1e6-82379cf4b03e">15</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8zMS9mcmFnOjJjMWUxYzVmMTk4ZTQ1NDNiYzMwZTA3OWU1MjY2ODhhL3RhYmxlOmVlYjE5ZmUzODg2MTQ3NmE5MGJlZDMyODQ0NzUyMDYxL3RhYmxlcmFuZ2U6ZWViMTlmZTM4ODYxNDc2YTkwYmVkMzI4NDQ3NTIwNjFfMTAtMS0xLTEtMA_b8b53e7c-5a72-465e-9b2a-2ba2aaff2847">22,716</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i667fa0996400408f9cb2d7f4d3ee2087_D20200101-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8zMS9mcmFnOjJjMWUxYzVmMTk4ZTQ1NDNiYzMwZTA3OWU1MjY2ODhhL3RhYmxlOmVlYjE5ZmUzODg2MTQ3NmE5MGJlZDMyODQ0NzUyMDYxL3RhYmxlcmFuZ2U6ZWViMTlmZTM4ODYxNDc2YTkwYmVkMzI4NDQ3NTIwNjFfMTAtMy0xLTEtMA_90dab91b-b649-4988-92e0-4ed9ecf02cd3">4,036</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity in earnings from equity method investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8zMS9mcmFnOjJjMWUxYzVmMTk4ZTQ1NDNiYzMwZTA3OWU1MjY2ODhhL3RhYmxlOmVlYjE5ZmUzODg2MTQ3NmE5MGJlZDMyODQ0NzUyMDYxL3RhYmxlcmFuZ2U6ZWViMTlmZTM4ODYxNDc2YTkwYmVkMzI4NDQ3NTIwNjFfMTEtMS0xLTEtMA_f547771f-64fc-4a31-833b-8212782fa6c1">2,488</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i667fa0996400408f9cb2d7f4d3ee2087_D20200101-20200630" decimals="-3" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8zMS9mcmFnOjJjMWUxYzVmMTk4ZTQ1NDNiYzMwZTA3OWU1MjY2ODhhL3RhYmxlOmVlYjE5ZmUzODg2MTQ3NmE5MGJlZDMyODQ0NzUyMDYxL3RhYmxlcmFuZ2U6ZWViMTlmZTM4ODYxNDc2YTkwYmVkMzI4NDQ3NTIwNjFfMTEtMy0xLTEtMA_e5f1c13e-e0fb-45d4-ba0d-ce3c8f471594">964</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of deferred debt issuance costs/debt discount</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630" decimals="-3" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8zMS9mcmFnOjJjMWUxYzVmMTk4ZTQ1NDNiYzMwZTA3OWU1MjY2ODhhL3RhYmxlOmVlYjE5ZmUzODg2MTQ3NmE5MGJlZDMyODQ0NzUyMDYxL3RhYmxlcmFuZ2U6ZWViMTlmZTM4ODYxNDc2YTkwYmVkMzI4NDQ3NTIwNjFfMTItMS0xLTEtMA_d5c58e92-4495-4f1a-8874-9c084fbe4b9f">432</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i667fa0996400408f9cb2d7f4d3ee2087_D20200101-20200630" decimals="-3" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8zMS9mcmFnOjJjMWUxYzVmMTk4ZTQ1NDNiYzMwZTA3OWU1MjY2ODhhL3RhYmxlOmVlYjE5ZmUzODg2MTQ3NmE5MGJlZDMyODQ0NzUyMDYxL3RhYmxlcmFuZ2U6ZWViMTlmZTM4ODYxNDc2YTkwYmVkMzI4NDQ3NTIwNjFfMTItMy0xLTEtMA_073bb366-d8ff-4090-9d79-e3dba1b89b70">437</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Return on equity method investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EquityMethodInvestmentDividendsOrDistributions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8zMS9mcmFnOjJjMWUxYzVmMTk4ZTQ1NDNiYzMwZTA3OWU1MjY2ODhhL3RhYmxlOmVlYjE5ZmUzODg2MTQ3NmE5MGJlZDMyODQ0NzUyMDYxL3RhYmxlcmFuZ2U6ZWViMTlmZTM4ODYxNDc2YTkwYmVkMzI4NDQ3NTIwNjFfMTMtMS0xLTEtMA_724c681a-4270-4494-947a-6df12844616a">2,683</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i667fa0996400408f9cb2d7f4d3ee2087_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EquityMethodInvestmentDividendsOrDistributions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8zMS9mcmFnOjJjMWUxYzVmMTk4ZTQ1NDNiYzMwZTA3OWU1MjY2ODhhL3RhYmxlOmVlYjE5ZmUzODg2MTQ3NmE5MGJlZDMyODQ0NzUyMDYxL3RhYmxlcmFuZ2U6ZWViMTlmZTM4ODYxNDc2YTkwYmVkMzI4NDQ3NTIwNjFfMTMtMy0xLTEtMA_fec47cd5-7cd4-4db5-99b9-abfc793865e7">2,744</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities, net of impact of acquisitions:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patient accounts receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8zMS9mcmFnOjJjMWUxYzVmMTk4ZTQ1NDNiYzMwZTA3OWU1MjY2ODhhL3RhYmxlOmVlYjE5ZmUzODg2MTQ3NmE5MGJlZDMyODQ0NzUyMDYxL3RhYmxlcmFuZ2U6ZWViMTlmZTM4ODYxNDc2YTkwYmVkMzI4NDQ3NTIwNjFfMTUtMS0xLTEtMA_f5136d49-9b6c-4614-ada4-6edad9216593">22,787</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i667fa0996400408f9cb2d7f4d3ee2087_D20200101-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8zMS9mcmFnOjJjMWUxYzVmMTk4ZTQ1NDNiYzMwZTA3OWU1MjY2ODhhL3RhYmxlOmVlYjE5ZmUzODg2MTQ3NmE5MGJlZDMyODQ0NzUyMDYxL3RhYmxlcmFuZ2U6ZWViMTlmZTM4ODYxNDc2YTkwYmVkMzI4NDQ3NTIwNjFfMTUtMy0xLTEtMA_af052e5c-dcb7-4b1b-9fe9-8b60e4cf1bd0">8,997</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8zMS9mcmFnOjJjMWUxYzVmMTk4ZTQ1NDNiYzMwZTA3OWU1MjY2ODhhL3RhYmxlOmVlYjE5ZmUzODg2MTQ3NmE5MGJlZDMyODQ0NzUyMDYxL3RhYmxlcmFuZ2U6ZWViMTlmZTM4ODYxNDc2YTkwYmVkMzI4NDQ3NTIwNjFfMTYtMS0xLTEtMA_bd582818-5d3c-4cf0-b8c0-396048eca80c">3,560</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i667fa0996400408f9cb2d7f4d3ee2087_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8zMS9mcmFnOjJjMWUxYzVmMTk4ZTQ1NDNiYzMwZTA3OWU1MjY2ODhhL3RhYmxlOmVlYjE5ZmUzODg2MTQ3NmE5MGJlZDMyODQ0NzUyMDYxL3RhYmxlcmFuZ2U6ZWViMTlmZTM4ODYxNDc2YTkwYmVkMzI4NDQ3NTIwNjFfMTYtMy0xLTEtMA_4ee9d4c7-8e8e-4feb-9433-4cb80b3508ec">3,469</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8zMS9mcmFnOjJjMWUxYzVmMTk4ZTQ1NDNiYzMwZTA3OWU1MjY2ODhhL3RhYmxlOmVlYjE5ZmUzODg2MTQ3NmE5MGJlZDMyODQ0NzUyMDYxL3RhYmxlcmFuZ2U6ZWViMTlmZTM4ODYxNDc2YTkwYmVkMzI4NDQ3NTIwNjFfMTctMS0xLTEtMA_3b3bdad5-45b0-4f5e-aefe-4b8519b208e9">52</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i667fa0996400408f9cb2d7f4d3ee2087_D20200101-20200630" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8zMS9mcmFnOjJjMWUxYzVmMTk4ZTQ1NDNiYzMwZTA3OWU1MjY2ODhhL3RhYmxlOmVlYjE5ZmUzODg2MTQ3NmE5MGJlZDMyODQ0NzUyMDYxL3RhYmxlcmFuZ2U6ZWViMTlmZTM4ODYxNDc2YTkwYmVkMzI4NDQ3NTIwNjFfMTctMy0xLTEtMA_89c0f8fe-d323-49ac-9c4d-90f31b649fce">675</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8zMS9mcmFnOjJjMWUxYzVmMTk4ZTQ1NDNiYzMwZTA3OWU1MjY2ODhhL3RhYmxlOmVlYjE5ZmUzODg2MTQ3NmE5MGJlZDMyODQ0NzUyMDYxL3RhYmxlcmFuZ2U6ZWViMTlmZTM4ODYxNDc2YTkwYmVkMzI4NDQ3NTIwNjFfMTgtMS0xLTEtMA_2f9b4327-c56f-4f7a-8a98-2e35566fe876">6,530</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i667fa0996400408f9cb2d7f4d3ee2087_D20200101-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8zMS9mcmFnOjJjMWUxYzVmMTk4ZTQ1NDNiYzMwZTA3OWU1MjY2ODhhL3RhYmxlOmVlYjE5ZmUzODg2MTQ3NmE5MGJlZDMyODQ0NzUyMDYxL3RhYmxlcmFuZ2U6ZWViMTlmZTM4ODYxNDc2YTkwYmVkMzI4NDQ3NTIwNjFfMTgtMy0xLTEtMA_061fe00b-8cfb-425b-ba5c-ca931f6808d7">6,452</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8zMS9mcmFnOjJjMWUxYzVmMTk4ZTQ1NDNiYzMwZTA3OWU1MjY2ODhhL3RhYmxlOmVlYjE5ZmUzODg2MTQ3NmE5MGJlZDMyODQ0NzUyMDYxL3RhYmxlcmFuZ2U6ZWViMTlmZTM4ODYxNDc2YTkwYmVkMzI4NDQ3NTIwNjFfMTktMS0xLTEtMA_60825786-5c8d-489c-adce-059bd4e22505">1,627</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i667fa0996400408f9cb2d7f4d3ee2087_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8zMS9mcmFnOjJjMWUxYzVmMTk4ZTQ1NDNiYzMwZTA3OWU1MjY2ODhhL3RhYmxlOmVlYjE5ZmUzODg2MTQ3NmE5MGJlZDMyODQ0NzUyMDYxL3RhYmxlcmFuZ2U6ZWViMTlmZTM4ODYxNDc2YTkwYmVkMzI4NDQ3NTIwNjFfMTktMy0xLTEtMA_189ea338-5f3d-41fc-a0f3-1af9e0bf2f05">27,990</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term obligations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8zMS9mcmFnOjJjMWUxYzVmMTk4ZTQ1NDNiYzMwZTA3OWU1MjY2ODhhL3RhYmxlOmVlYjE5ZmUzODg2MTQ3NmE5MGJlZDMyODQ0NzUyMDYxL3RhYmxlcmFuZ2U6ZWViMTlmZTM4ODYxNDc2YTkwYmVkMzI4NDQ3NTIwNjFfMjAtMS0xLTEtMA_30a1aa32-27eb-4e6f-a050-9378158a76f7">1,736</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i667fa0996400408f9cb2d7f4d3ee2087_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8zMS9mcmFnOjJjMWUxYzVmMTk4ZTQ1NDNiYzMwZTA3OWU1MjY2ODhhL3RhYmxlOmVlYjE5ZmUzODg2MTQ3NmE5MGJlZDMyODQ0NzUyMDYxL3RhYmxlcmFuZ2U6ZWViMTlmZTM4ODYxNDc2YTkwYmVkMzI4NDQ3NTIwNjFfMjAtMy0xLTEtMA_1b0d7b76-5e10-4b16-a5b1-bac5d97ecbcc">20,746</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="amed:IncreaseDecreaseInOperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8zMS9mcmFnOjJjMWUxYzVmMTk4ZTQ1NDNiYzMwZTA3OWU1MjY2ODhhL3RhYmxlOmVlYjE5ZmUzODg2MTQ3NmE5MGJlZDMyODQ0NzUyMDYxL3RhYmxlcmFuZ2U6ZWViMTlmZTM4ODYxNDc2YTkwYmVkMzI4NDQ3NTIwNjFfMjEtMS0xLTEtMA_2e881ece-2ab3-496d-adf2-1273350cb762">17,955</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i667fa0996400408f9cb2d7f4d3ee2087_D20200101-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="amed:IncreaseDecreaseInOperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8zMS9mcmFnOjJjMWUxYzVmMTk4ZTQ1NDNiYzMwZTA3OWU1MjY2ODhhL3RhYmxlOmVlYjE5ZmUzODg2MTQ3NmE5MGJlZDMyODQ0NzUyMDYxL3RhYmxlcmFuZ2U6ZWViMTlmZTM4ODYxNDc2YTkwYmVkMzI4NDQ3NTIwNjFfMjEtMy0xLTEtMA_5c1e33da-c3b6-4a4c-af15-943d94494c32">16,365</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right of use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="amed:IncreaseDecreaseInOperatingLeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8zMS9mcmFnOjJjMWUxYzVmMTk4ZTQ1NDNiYzMwZTA3OWU1MjY2ODhhL3RhYmxlOmVlYjE5ZmUzODg2MTQ3NmE5MGJlZDMyODQ0NzUyMDYxL3RhYmxlcmFuZ2U6ZWViMTlmZTM4ODYxNDc2YTkwYmVkMzI4NDQ3NTIwNjFfMjItMS0xLTEtMA_5d382f5e-64e9-42c1-a8b0-a48c09c55711">1,524</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i667fa0996400408f9cb2d7f4d3ee2087_D20200101-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="amed:IncreaseDecreaseInOperatingLeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8zMS9mcmFnOjJjMWUxYzVmMTk4ZTQ1NDNiYzMwZTA3OWU1MjY2ODhhL3RhYmxlOmVlYjE5ZmUzODg2MTQ3NmE5MGJlZDMyODQ0NzUyMDYxL3RhYmxlcmFuZ2U6ZWViMTlmZTM4ODYxNDc2YTkwYmVkMzI4NDQ3NTIwNjFfMjItMy0xLTEtMA_53e62a8c-b1ae-4cce-a47b-782ebb37d80a">1,924</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by operating activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8zMS9mcmFnOjJjMWUxYzVmMTk4ZTQ1NDNiYzMwZTA3OWU1MjY2ODhhL3RhYmxlOmVlYjE5ZmUzODg2MTQ3NmE5MGJlZDMyODQ0NzUyMDYxL3RhYmxlcmFuZ2U6ZWViMTlmZTM4ODYxNDc2YTkwYmVkMzI4NDQ3NTIwNjFfMjMtMS0xLTEtMA_2b333b5e-63ba-4453-9cb3-fb9f0bf7bc4a">121,960</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i667fa0996400408f9cb2d7f4d3ee2087_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8zMS9mcmFnOjJjMWUxYzVmMTk4ZTQ1NDNiYzMwZTA3OWU1MjY2ODhhL3RhYmxlOmVlYjE5ZmUzODg2MTQ3NmE5MGJlZDMyODQ0NzUyMDYxL3RhYmxlcmFuZ2U6ZWViMTlmZTM4ODYxNDc2YTkwYmVkMzI4NDQ3NTIwNjFfMjMtMy0xLTEtMA_a9a2e18c-d909-43f1-915e-d633674092bd">139,957</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash Flows from Investing Activities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from sale of deferred compensation plan assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630" decimals="-3" name="us-gaap:ProceedsFromSaleOfRestrictedInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8zMS9mcmFnOjJjMWUxYzVmMTk4ZTQ1NDNiYzMwZTA3OWU1MjY2ODhhL3RhYmxlOmVlYjE5ZmUzODg2MTQ3NmE5MGJlZDMyODQ0NzUyMDYxL3RhYmxlcmFuZ2U6ZWViMTlmZTM4ODYxNDc2YTkwYmVkMzI4NDQ3NTIwNjFfMjUtMS0xLTEtMA_3af3620f-ba8f-4ec0-b6bc-892f6228a9d3">25</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i667fa0996400408f9cb2d7f4d3ee2087_D20200101-20200630" decimals="-3" name="us-gaap:ProceedsFromSaleOfRestrictedInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8zMS9mcmFnOjJjMWUxYzVmMTk4ZTQ1NDNiYzMwZTA3OWU1MjY2ODhhL3RhYmxlOmVlYjE5ZmUzODg2MTQ3NmE5MGJlZDMyODQ0NzUyMDYxL3RhYmxlcmFuZ2U6ZWViMTlmZTM4ODYxNDc2YTkwYmVkMzI4NDQ3NTIwNjFfMjUtMy0xLTEtMA_bbff9e35-3de8-4e0d-876f-d5113206b2df">21</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from sale of property and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630" decimals="-3" name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8zMS9mcmFnOjJjMWUxYzVmMTk4ZTQ1NDNiYzMwZTA3OWU1MjY2ODhhL3RhYmxlOmVlYjE5ZmUzODg2MTQ3NmE5MGJlZDMyODQ0NzUyMDYxL3RhYmxlcmFuZ2U6ZWViMTlmZTM4ODYxNDc2YTkwYmVkMzI4NDQ3NTIwNjFfMjYtMS0xLTEtMA_466779a1-99b0-4445-895c-cfb41a7ef5ae">42</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i667fa0996400408f9cb2d7f4d3ee2087_D20200101-20200630" decimals="-3" name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8zMS9mcmFnOjJjMWUxYzVmMTk4ZTQ1NDNiYzMwZTA3OWU1MjY2ODhhL3RhYmxlOmVlYjE5ZmUzODg2MTQ3NmE5MGJlZDMyODQ0NzUyMDYxL3RhYmxlcmFuZ2U6ZWViMTlmZTM4ODYxNDc2YTkwYmVkMzI4NDQ3NTIwNjFfMjYtMy0xLTEtMA_883b6537-be22-4096-95d5-4edd4eb02173">80</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of property and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8zMS9mcmFnOjJjMWUxYzVmMTk4ZTQ1NDNiYzMwZTA3OWU1MjY2ODhhL3RhYmxlOmVlYjE5ZmUzODg2MTQ3NmE5MGJlZDMyODQ0NzUyMDYxL3RhYmxlcmFuZ2U6ZWViMTlmZTM4ODYxNDc2YTkwYmVkMzI4NDQ3NTIwNjFfMjctMS0xLTEtMA_c96ba73e-8f64-47bd-b8bc-28367a05821d">2,943</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i667fa0996400408f9cb2d7f4d3ee2087_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8zMS9mcmFnOjJjMWUxYzVmMTk4ZTQ1NDNiYzMwZTA3OWU1MjY2ODhhL3RhYmxlOmVlYjE5ZmUzODg2MTQ3NmE5MGJlZDMyODQ0NzUyMDYxL3RhYmxlcmFuZ2U6ZWViMTlmZTM4ODYxNDc2YTkwYmVkMzI4NDQ3NTIwNjFfMjctMy0xLTEtMA_89c99a91-c021-45d1-a4d1-e7e3359415fb">1,701</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments in equity method investees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:PaymentsToAcquireInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8zMS9mcmFnOjJjMWUxYzVmMTk4ZTQ1NDNiYzMwZTA3OWU1MjY2ODhhL3RhYmxlOmVlYjE5ZmUzODg2MTQ3NmE5MGJlZDMyODQ0NzUyMDYxL3RhYmxlcmFuZ2U6ZWViMTlmZTM4ODYxNDc2YTkwYmVkMzI4NDQ3NTIwNjFfMjktMS0xLTEtMTQy_9956b72d-67e8-489f-bdd1-57ef85c7de62">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i667fa0996400408f9cb2d7f4d3ee2087_D20200101-20200630" decimals="-3" name="us-gaap:PaymentsToAcquireInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8zMS9mcmFnOjJjMWUxYzVmMTk4ZTQ1NDNiYzMwZTA3OWU1MjY2ODhhL3RhYmxlOmVlYjE5ZmUzODg2MTQ3NmE5MGJlZDMyODQ0NzUyMDYxL3RhYmxlcmFuZ2U6ZWViMTlmZTM4ODYxNDc2YTkwYmVkMzI4NDQ3NTIwNjFfMjktMy0xLTEtMTQy_c05309c8-d00e-41a1-94c3-f7af1c183502">875</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from sale of equity method investment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:ProceedsFromSaleOfEquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8zMS9mcmFnOjJjMWUxYzVmMTk4ZTQ1NDNiYzMwZTA3OWU1MjY2ODhhL3RhYmxlOmVlYjE5ZmUzODg2MTQ3NmE5MGJlZDMyODQ0NzUyMDYxL3RhYmxlcmFuZ2U6ZWViMTlmZTM4ODYxNDc2YTkwYmVkMzI4NDQ3NTIwNjFfMzAtMS0xLTEtMTQ1_e8d50e1a-6c3d-4a43-95e3-9b745c4fdbb6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i667fa0996400408f9cb2d7f4d3ee2087_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleOfEquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8zMS9mcmFnOjJjMWUxYzVmMTk4ZTQ1NDNiYzMwZTA3OWU1MjY2ODhhL3RhYmxlOmVlYjE5ZmUzODg2MTQ3NmE5MGJlZDMyODQ0NzUyMDYxL3RhYmxlcmFuZ2U6ZWViMTlmZTM4ODYxNDc2YTkwYmVkMzI4NDQ3NTIwNjFfMzAtMy0xLTEtMTQ1_31914120-4786-4e8b-a964-115b882a925b">17,876</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisitions of businesses, net of cash acquired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8zMS9mcmFnOjJjMWUxYzVmMTk4ZTQ1NDNiYzMwZTA3OWU1MjY2ODhhL3RhYmxlOmVlYjE5ZmUzODg2MTQ3NmE5MGJlZDMyODQ0NzUyMDYxL3RhYmxlcmFuZ2U6ZWViMTlmZTM4ODYxNDc2YTkwYmVkMzI4NDQ3NTIwNjFfMjgtMS0xLTEtMA_2c4cf163-7e87-45d9-b0a4-3f2721f924dd">2,503</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i667fa0996400408f9cb2d7f4d3ee2087_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8zMS9mcmFnOjJjMWUxYzVmMTk4ZTQ1NDNiYzMwZTA3OWU1MjY2ODhhL3RhYmxlOmVlYjE5ZmUzODg2MTQ3NmE5MGJlZDMyODQ0NzUyMDYxL3RhYmxlcmFuZ2U6ZWViMTlmZTM4ODYxNDc2YTkwYmVkMzI4NDQ3NTIwNjFfMjgtMy0xLTEtMA_249489e1-7bd0-498e-adac-1aff3ea8c618">299,723</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in investing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8zMS9mcmFnOjJjMWUxYzVmMTk4ZTQ1NDNiYzMwZTA3OWU1MjY2ODhhL3RhYmxlOmVlYjE5ZmUzODg2MTQ3NmE5MGJlZDMyODQ0NzUyMDYxL3RhYmxlcmFuZ2U6ZWViMTlmZTM4ODYxNDc2YTkwYmVkMzI4NDQ3NTIwNjFfMjktMS0xLTEtMA_5d0462a3-ef26-44a2-93b0-04a47ff213fc">5,379</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i667fa0996400408f9cb2d7f4d3ee2087_D20200101-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8zMS9mcmFnOjJjMWUxYzVmMTk4ZTQ1NDNiYzMwZTA3OWU1MjY2ODhhL3RhYmxlOmVlYjE5ZmUzODg2MTQ3NmE5MGJlZDMyODQ0NzUyMDYxL3RhYmxlcmFuZ2U6ZWViMTlmZTM4ODYxNDc2YTkwYmVkMzI4NDQ3NTIwNjFfMjktMy0xLTEtMA_9fbe7fb0-706c-4bb4-9c4e-1d3ac156182c">284,322</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash Flows from Financing Activities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from issuance of stock upon exercise of stock options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8zMS9mcmFnOjJjMWUxYzVmMTk4ZTQ1NDNiYzMwZTA3OWU1MjY2ODhhL3RhYmxlOmVlYjE5ZmUzODg2MTQ3NmE5MGJlZDMyODQ0NzUyMDYxL3RhYmxlcmFuZ2U6ZWViMTlmZTM4ODYxNDc2YTkwYmVkMzI4NDQ3NTIwNjFfMzEtMS0xLTEtMA_2ca97634-8fbc-4afe-abac-74bc130977df">623</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i667fa0996400408f9cb2d7f4d3ee2087_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8zMS9mcmFnOjJjMWUxYzVmMTk4ZTQ1NDNiYzMwZTA3OWU1MjY2ODhhL3RhYmxlOmVlYjE5ZmUzODg2MTQ3NmE5MGJlZDMyODQ0NzUyMDYxL3RhYmxlcmFuZ2U6ZWViMTlmZTM4ODYxNDc2YTkwYmVkMzI4NDQ3NTIwNjFfMzEtMy0xLTEtMA_98802280-a610-4260-9acf-8392dc21b206">2,947</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from issuance of stock to employee stock purchase plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromStockPlans" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8zMS9mcmFnOjJjMWUxYzVmMTk4ZTQ1NDNiYzMwZTA3OWU1MjY2ODhhL3RhYmxlOmVlYjE5ZmUzODg2MTQ3NmE5MGJlZDMyODQ0NzUyMDYxL3RhYmxlcmFuZ2U6ZWViMTlmZTM4ODYxNDc2YTkwYmVkMzI4NDQ3NTIwNjFfMzItMS0xLTEtMA_191cd716-6de7-416c-b566-c05861f3a8f5">1,961</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i667fa0996400408f9cb2d7f4d3ee2087_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromStockPlans" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8zMS9mcmFnOjJjMWUxYzVmMTk4ZTQ1NDNiYzMwZTA3OWU1MjY2ODhhL3RhYmxlOmVlYjE5ZmUzODg2MTQ3NmE5MGJlZDMyODQ0NzUyMDYxL3RhYmxlcmFuZ2U6ZWViMTlmZTM4ODYxNDc2YTkwYmVkMzI4NDQ3NTIwNjFfMzItMy0xLTEtMA_2133012a-4b68-495d-bb69-ae85d3382136">1,686</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares withheld to pay taxes on non-cash compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8zMS9mcmFnOjJjMWUxYzVmMTk4ZTQ1NDNiYzMwZTA3OWU1MjY2ODhhL3RhYmxlOmVlYjE5ZmUzODg2MTQ3NmE5MGJlZDMyODQ0NzUyMDYxL3RhYmxlcmFuZ2U6ZWViMTlmZTM4ODYxNDc2YTkwYmVkMzI4NDQ3NTIwNjFfMzMtMS0xLTEtMA_9c896b90-ffd9-4011-9efb-c08575027350">6,944</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i667fa0996400408f9cb2d7f4d3ee2087_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8zMS9mcmFnOjJjMWUxYzVmMTk4ZTQ1NDNiYzMwZTA3OWU1MjY2ODhhL3RhYmxlOmVlYjE5ZmUzODg2MTQ3NmE5MGJlZDMyODQ0NzUyMDYxL3RhYmxlcmFuZ2U6ZWViMTlmZTM4ODYxNDc2YTkwYmVkMzI4NDQ3NTIwNjFfMzMtMy0xLTEtMA_72044cf7-b38f-4b2c-a0ca-a8b1e092390a">6,384</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncontrolling interest distribution</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630" decimals="-3" name="amed:CashDistributionToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8zMS9mcmFnOjJjMWUxYzVmMTk4ZTQ1NDNiYzMwZTA3OWU1MjY2ODhhL3RhYmxlOmVlYjE5ZmUzODg2MTQ3NmE5MGJlZDMyODQ0NzUyMDYxL3RhYmxlcmFuZ2U6ZWViMTlmZTM4ODYxNDc2YTkwYmVkMzI4NDQ3NTIwNjFfMzQtMS0xLTEtMA_1c1e149c-830b-438f-b8f0-8871dfd1202a">794</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i667fa0996400408f9cb2d7f4d3ee2087_D20200101-20200630" decimals="-3" name="amed:CashDistributionToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8zMS9mcmFnOjJjMWUxYzVmMTk4ZTQ1NDNiYzMwZTA3OWU1MjY2ODhhL3RhYmxlOmVlYjE5ZmUzODg2MTQ3NmE5MGJlZDMyODQ0NzUyMDYxL3RhYmxlcmFuZ2U6ZWViMTlmZTM4ODYxNDc2YTkwYmVkMzI4NDQ3NTIwNjFfMzQtMy0xLTEtMA_cf52c8db-5041-45df-bd7a-b74f023e4319">372</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from borrowings under revolving line of credit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromShortTermDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8zMS9mcmFnOjJjMWUxYzVmMTk4ZTQ1NDNiYzMwZTA3OWU1MjY2ODhhL3RhYmxlOmVlYjE5ZmUzODg2MTQ3NmE5MGJlZDMyODQ0NzUyMDYxL3RhYmxlcmFuZ2U6ZWViMTlmZTM4ODYxNDc2YTkwYmVkMzI4NDQ3NTIwNjFfMzUtMS0xLTEtMA_859c4f47-0963-4757-a777-f85e880621fe">389,200</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i667fa0996400408f9cb2d7f4d3ee2087_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromShortTermDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8zMS9mcmFnOjJjMWUxYzVmMTk4ZTQ1NDNiYzMwZTA3OWU1MjY2ODhhL3RhYmxlOmVlYjE5ZmUzODg2MTQ3NmE5MGJlZDMyODQ0NzUyMDYxL3RhYmxlcmFuZ2U6ZWViMTlmZTM4ODYxNDc2YTkwYmVkMzI4NDQ3NTIwNjFfMzUtMy0xLTEtMA_fce18d2f-7a74-42f0-9e67-cb224a8dbc5d">424,500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repayments of borrowings under revolving line of credit </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfShortTermDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8zMS9mcmFnOjJjMWUxYzVmMTk4ZTQ1NDNiYzMwZTA3OWU1MjY2ODhhL3RhYmxlOmVlYjE5ZmUzODg2MTQ3NmE5MGJlZDMyODQ0NzUyMDYxL3RhYmxlcmFuZ2U6ZWViMTlmZTM4ODYxNDc2YTkwYmVkMzI4NDQ3NTIwNjFfMzYtMS0xLTEtMA_d40d0aa0-81f9-44c9-b273-6973fe7e1777">410,200</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i667fa0996400408f9cb2d7f4d3ee2087_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfShortTermDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8zMS9mcmFnOjJjMWUxYzVmMTk4ZTQ1NDNiYzMwZTA3OWU1MjY2ODhhL3RhYmxlOmVlYjE5ZmUzODg2MTQ3NmE5MGJlZDMyODQ0NzUyMDYxL3RhYmxlcmFuZ2U6ZWViMTlmZTM4ODYxNDc2YTkwYmVkMzI4NDQ3NTIwNjFfMzYtMy0xLTEtMA_f16873f5-abab-4cba-8461-646722d6e599">259,500</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Principal payments of long-term obligations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfLongTermDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8zMS9mcmFnOjJjMWUxYzVmMTk4ZTQ1NDNiYzMwZTA3OWU1MjY2ODhhL3RhYmxlOmVlYjE5ZmUzODg2MTQ3NmE5MGJlZDMyODQ0NzUyMDYxL3RhYmxlcmFuZ2U6ZWViMTlmZTM4ODYxNDc2YTkwYmVkMzI4NDQ3NTIwNjFfMzctMS0xLTEtMA_11445b5f-273a-4617-bc15-9084430c5efb">5,392</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i667fa0996400408f9cb2d7f4d3ee2087_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfLongTermDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8zMS9mcmFnOjJjMWUxYzVmMTk4ZTQ1NDNiYzMwZTA3OWU1MjY2ODhhL3RhYmxlOmVlYjE5ZmUzODg2MTQ3NmE5MGJlZDMyODQ0NzUyMDYxL3RhYmxlcmFuZ2U6ZWViMTlmZTM4ODYxNDc2YTkwYmVkMzI4NDQ3NTIwNjFfMzctMy0xLTEtMA_0e092680-3622-496c-a8f2-a95621605ec8">4,675</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchase of company stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsForRepurchaseOfCommonStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8zMS9mcmFnOjJjMWUxYzVmMTk4ZTQ1NDNiYzMwZTA3OWU1MjY2ODhhL3RhYmxlOmVlYjE5ZmUzODg2MTQ3NmE5MGJlZDMyODQ0NzUyMDYxL3RhYmxlcmFuZ2U6ZWViMTlmZTM4ODYxNDc2YTkwYmVkMzI4NDQ3NTIwNjFfMzgtMS0xLTEtMA_cb01f206-9232-4c86-bd0c-a6c2d374e67d">74,074</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i667fa0996400408f9cb2d7f4d3ee2087_D20200101-20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:PaymentsForRepurchaseOfCommonStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8zMS9mcmFnOjJjMWUxYzVmMTk4ZTQ1NDNiYzMwZTA3OWU1MjY2ODhhL3RhYmxlOmVlYjE5ZmUzODg2MTQ3NmE5MGJlZDMyODQ0NzUyMDYxL3RhYmxlcmFuZ2U6ZWViMTlmZTM4ODYxNDc2YTkwYmVkMzI4NDQ3NTIwNjFfMzgtMy0xLTEtMA_3601a2c2-ccc3-4131-89d8-93e05ee48abb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provider relief fund advance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="amed:FundsReceivedFromProviderReliefFundAdvance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8zMS9mcmFnOjJjMWUxYzVmMTk4ZTQ1NDNiYzMwZTA3OWU1MjY2ODhhL3RhYmxlOmVlYjE5ZmUzODg2MTQ3NmE5MGJlZDMyODQ0NzUyMDYxL3RhYmxlcmFuZ2U6ZWViMTlmZTM4ODYxNDc2YTkwYmVkMzI4NDQ3NTIwNjFfMzktMS0xLTEtMA_56ab97e1-863b-4a36-99eb-2a1462227d65">1,672</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i667fa0996400408f9cb2d7f4d3ee2087_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="amed:FundsReceivedFromProviderReliefFundAdvance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8zMS9mcmFnOjJjMWUxYzVmMTk4ZTQ1NDNiYzMwZTA3OWU1MjY2ODhhL3RhYmxlOmVlYjE5ZmUzODg2MTQ3NmE5MGJlZDMyODQ0NzUyMDYxL3RhYmxlcmFuZ2U6ZWViMTlmZTM4ODYxNDc2YTkwYmVkMzI4NDQ3NTIwNjFfMzktMy0xLTEtMA_8cf23786-03ba-481f-a4cb-5814533222b3">70,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash (used in) provided by financing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8zMS9mcmFnOjJjMWUxYzVmMTk4ZTQ1NDNiYzMwZTA3OWU1MjY2ODhhL3RhYmxlOmVlYjE5ZmUzODg2MTQ3NmE5MGJlZDMyODQ0NzUyMDYxL3RhYmxlcmFuZ2U6ZWViMTlmZTM4ODYxNDc2YTkwYmVkMzI4NDQ3NTIwNjFfNDAtMS0xLTEtMA_4f27d845-464b-4364-beed-c8c14623d1b6">107,292</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i667fa0996400408f9cb2d7f4d3ee2087_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8zMS9mcmFnOjJjMWUxYzVmMTk4ZTQ1NDNiYzMwZTA3OWU1MjY2ODhhL3RhYmxlOmVlYjE5ZmUzODg2MTQ3NmE5MGJlZDMyODQ0NzUyMDYxL3RhYmxlcmFuZ2U6ZWViMTlmZTM4ODYxNDc2YTkwYmVkMzI4NDQ3NTIwNjFfNDAtMy0xLTEtMA_12d23d49-b30f-4699-bfa0-4652c030dae3">228,202</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net increase in cash, cash equivalents and restricted cash</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8zMS9mcmFnOjJjMWUxYzVmMTk4ZTQ1NDNiYzMwZTA3OWU1MjY2ODhhL3RhYmxlOmVlYjE5ZmUzODg2MTQ3NmE5MGJlZDMyODQ0NzUyMDYxL3RhYmxlcmFuZ2U6ZWViMTlmZTM4ODYxNDc2YTkwYmVkMzI4NDQ3NTIwNjFfNDEtMS0xLTEtMA_33fea8d8-277d-41fe-b6d0-a5739b20826c">9,289</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i667fa0996400408f9cb2d7f4d3ee2087_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8zMS9mcmFnOjJjMWUxYzVmMTk4ZTQ1NDNiYzMwZTA3OWU1MjY2ODhhL3RhYmxlOmVlYjE5ZmUzODg2MTQ3NmE5MGJlZDMyODQ0NzUyMDYxL3RhYmxlcmFuZ2U6ZWViMTlmZTM4ODYxNDc2YTkwYmVkMzI4NDQ3NTIwNjFfNDEtMy0xLTEtMA_aba8481e-27eb-4314-9dd3-54a4ae3a620b">83,837</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash at beginning of period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87ceb60dc20d4df1b0a97d3514837910_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8zMS9mcmFnOjJjMWUxYzVmMTk4ZTQ1NDNiYzMwZTA3OWU1MjY2ODhhL3RhYmxlOmVlYjE5ZmUzODg2MTQ3NmE5MGJlZDMyODQ0NzUyMDYxL3RhYmxlcmFuZ2U6ZWViMTlmZTM4ODYxNDc2YTkwYmVkMzI4NDQ3NTIwNjFfNDItMS0xLTEtMA_c66eda09-86fb-46d1-a372-fa25f76e1bae">83,357</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa673cc4c9af455b97f34a55548dfc84_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8zMS9mcmFnOjJjMWUxYzVmMTk4ZTQ1NDNiYzMwZTA3OWU1MjY2ODhhL3RhYmxlOmVlYjE5ZmUzODg2MTQ3NmE5MGJlZDMyODQ0NzUyMDYxL3RhYmxlcmFuZ2U6ZWViMTlmZTM4ODYxNDc2YTkwYmVkMzI4NDQ3NTIwNjFfNDItMy0xLTEtMA_6909caad-f17a-4552-aba1-380471bb08a5">96,490</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash at end of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e833203be6947b4968aba4d20064ec8_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8zMS9mcmFnOjJjMWUxYzVmMTk4ZTQ1NDNiYzMwZTA3OWU1MjY2ODhhL3RhYmxlOmVlYjE5ZmUzODg2MTQ3NmE5MGJlZDMyODQ0NzUyMDYxL3RhYmxlcmFuZ2U6ZWViMTlmZTM4ODYxNDc2YTkwYmVkMzI4NDQ3NTIwNjFfNDMtMS0xLTEtMA_0e5a0f4f-b396-4fe9-9478-10439950952f">92,646</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15586f038620443192b7c904beb4ad54_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8zMS9mcmFnOjJjMWUxYzVmMTk4ZTQ1NDNiYzMwZTA3OWU1MjY2ODhhL3RhYmxlOmVlYjE5ZmUzODg2MTQ3NmE5MGJlZDMyODQ0NzUyMDYxL3RhYmxlcmFuZ2U6ZWViMTlmZTM4ODYxNDc2YTkwYmVkMzI4NDQ3NTIwNjFfNDMtMy0xLTEtMA_73877a1f-54d5-4eb7-b41d-fb0c425db7ce">180,327</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:472.50pt"><tr><td style="width:1.0pt"></td><td style="width:357.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:52.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:52.75pt"></td><td style="width:1.0pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Supplemental Disclosures of Cash Flow Information:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for interest</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestPaidNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8zMS9mcmFnOjJjMWUxYzVmMTk4ZTQ1NDNiYzMwZTA3OWU1MjY2ODhhL3RhYmxlOmVlYjE5ZmUzODg2MTQ3NmE5MGJlZDMyODQ0NzUyMDYxL3RhYmxlcmFuZ2U6ZWViMTlmZTM4ODYxNDc2YTkwYmVkMzI4NDQ3NTIwNjFfNDUtMS0xLTEtMA_f83f5951-2124-4392-9a68-457d1debaf1e">1,914</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i667fa0996400408f9cb2d7f4d3ee2087_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestPaidNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8zMS9mcmFnOjJjMWUxYzVmMTk4ZTQ1NDNiYzMwZTA3OWU1MjY2ODhhL3RhYmxlOmVlYjE5ZmUzODg2MTQ3NmE5MGJlZDMyODQ0NzUyMDYxL3RhYmxlcmFuZ2U6ZWViMTlmZTM4ODYxNDc2YTkwYmVkMzI4NDQ3NTIwNjFfNDUtMy0xLTEtMA_6763934d-bfd4-417b-96e9-c5d713c02566">3,292</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for income taxes, net of refunds received</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxesPaidNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8zMS9mcmFnOjJjMWUxYzVmMTk4ZTQ1NDNiYzMwZTA3OWU1MjY2ODhhL3RhYmxlOmVlYjE5ZmUzODg2MTQ3NmE5MGJlZDMyODQ0NzUyMDYxL3RhYmxlcmFuZ2U6ZWViMTlmZTM4ODYxNDc2YTkwYmVkMzI4NDQ3NTIwNjFfNDYtMS0xLTEtMA_32fe49ab-9f27-4423-8812-3f34753449b8">8,667</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i667fa0996400408f9cb2d7f4d3ee2087_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxesPaidNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8zMS9mcmFnOjJjMWUxYzVmMTk4ZTQ1NDNiYzMwZTA3OWU1MjY2ODhhL3RhYmxlOmVlYjE5ZmUzODg2MTQ3NmE5MGJlZDMyODQ0NzUyMDYxL3RhYmxlcmFuZ2U6ZWViMTlmZTM4ODYxNDc2YTkwYmVkMzI4NDQ3NTIwNjFfNDYtMy0xLTEtMA_d2908849-79d6-4203-9534-935710c7b5dd">8,153</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for operating lease liabilities</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="amed:CashPaidForOperatingLeaseLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8zMS9mcmFnOjJjMWUxYzVmMTk4ZTQ1NDNiYzMwZTA3OWU1MjY2ODhhL3RhYmxlOmVlYjE5ZmUzODg2MTQ3NmE5MGJlZDMyODQ0NzUyMDYxL3RhYmxlcmFuZ2U6ZWViMTlmZTM4ODYxNDc2YTkwYmVkMzI4NDQ3NTIwNjFfNDctMS0xLTEtMA_9cb5d110-eaea-4ec0-8840-2b1641e16533">19,479</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i667fa0996400408f9cb2d7f4d3ee2087_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="amed:CashPaidForOperatingLeaseLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8zMS9mcmFnOjJjMWUxYzVmMTk4ZTQ1NDNiYzMwZTA3OWU1MjY2ODhhL3RhYmxlOmVlYjE5ZmUzODg2MTQ3NmE5MGJlZDMyODQ0NzUyMDYxL3RhYmxlcmFuZ2U6ZWViMTlmZTM4ODYxNDc2YTkwYmVkMzI4NDQ3NTIwNjFfNDctMy0xLTEtMA_44a0e539-6cc3-4b70-a916-d53b5405362d">18,289</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for finance lease liabilities</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="amed:CashPaidForFinanceLeaseLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8zMS9mcmFnOjJjMWUxYzVmMTk4ZTQ1NDNiYzMwZTA3OWU1MjY2ODhhL3RhYmxlOmVlYjE5ZmUzODg2MTQ3NmE5MGJlZDMyODQ0NzUyMDYxL3RhYmxlcmFuZ2U6ZWViMTlmZTM4ODYxNDc2YTkwYmVkMzI4NDQ3NTIwNjFfNDgtMS0xLTEtMA_a4c3efaa-b762-4609-bb2c-3ad3c8cda9f1">1,017</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i667fa0996400408f9cb2d7f4d3ee2087_D20200101-20200630" decimals="-3" name="amed:CashPaidForFinanceLeaseLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8zMS9mcmFnOjJjMWUxYzVmMTk4ZTQ1NDNiYzMwZTA3OWU1MjY2ODhhL3RhYmxlOmVlYjE5ZmUzODg2MTQ3NmE5MGJlZDMyODQ0NzUyMDYxL3RhYmxlcmFuZ2U6ZWViMTlmZTM4ODYxNDc2YTkwYmVkMzI4NDQ3NTIwNjFfNDgtMy0xLTEtMA_f9bae11d-30bf-4362-929f-f16b23ddc370">986</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Supplemental Disclosures of Non-Cash Activity:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right of use assets obtained in exchange for operating lease liabilities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8zMS9mcmFnOjJjMWUxYzVmMTk4ZTQ1NDNiYzMwZTA3OWU1MjY2ODhhL3RhYmxlOmVlYjE5ZmUzODg2MTQ3NmE5MGJlZDMyODQ0NzUyMDYxL3RhYmxlcmFuZ2U6ZWViMTlmZTM4ODYxNDc2YTkwYmVkMzI4NDQ3NTIwNjFfNTAtMS0xLTEtMA_eb409e4b-4952-4695-892f-6105fa4052b2">20,689</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i667fa0996400408f9cb2d7f4d3ee2087_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8zMS9mcmFnOjJjMWUxYzVmMTk4ZTQ1NDNiYzMwZTA3OWU1MjY2ODhhL3RhYmxlOmVlYjE5ZmUzODg2MTQ3NmE5MGJlZDMyODQ0NzUyMDYxL3RhYmxlcmFuZ2U6ZWViMTlmZTM4ODYxNDc2YTkwYmVkMzI4NDQ3NTIwNjFfNTAtMy0xLTEtMA_b031ec59-4a30-4ec4-8992-e0e92556411b">18,891</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right of use assets obtained in exchange for finance lease liabilities</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8zMS9mcmFnOjJjMWUxYzVmMTk4ZTQ1NDNiYzMwZTA3OWU1MjY2ODhhL3RhYmxlOmVlYjE5ZmUzODg2MTQ3NmE5MGJlZDMyODQ0NzUyMDYxL3RhYmxlcmFuZ2U6ZWViMTlmZTM4ODYxNDc2YTkwYmVkMzI4NDQ3NTIwNjFfNTEtMS0xLTEtMA_3ec4acca-be15-4d6e-ad88-2b70c47c6b96">527</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i667fa0996400408f9cb2d7f4d3ee2087_D20200101-20200630" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8zMS9mcmFnOjJjMWUxYzVmMTk4ZTQ1NDNiYzMwZTA3OWU1MjY2ODhhL3RhYmxlOmVlYjE5ZmUzODg2MTQ3NmE5MGJlZDMyODQ0NzUyMDYxL3RhYmxlcmFuZ2U6ZWViMTlmZTM4ODYxNDc2YTkwYmVkMzI4NDQ3NTIwNjFfNTEtMy0xLTEtMA_637fd1a4-5561-499b-a55d-41b46f03ef1a">487</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reductions to right of use assets resulting from reductions to operating lease liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630" decimals="-3" name="amed:LesseeOperatingleaseReductionstoROUassetsresultingfromreductionstoleaseobligations" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8zMS9mcmFnOjJjMWUxYzVmMTk4ZTQ1NDNiYzMwZTA3OWU1MjY2ODhhL3RhYmxlOmVlYjE5ZmUzODg2MTQ3NmE5MGJlZDMyODQ0NzUyMDYxL3RhYmxlcmFuZ2U6ZWViMTlmZTM4ODYxNDc2YTkwYmVkMzI4NDQ3NTIwNjFfNTItMS0xLTEtMA_51dafcf7-bb4a-4d19-bd17-7175c2df33f0">904</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i667fa0996400408f9cb2d7f4d3ee2087_D20200101-20200630" decimals="-3" name="amed:LesseeOperatingleaseReductionstoROUassetsresultingfromreductionstoleaseobligations" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8zMS9mcmFnOjJjMWUxYzVmMTk4ZTQ1NDNiYzMwZTA3OWU1MjY2ODhhL3RhYmxlOmVlYjE5ZmUzODg2MTQ3NmE5MGJlZDMyODQ0NzUyMDYxL3RhYmxlcmFuZ2U6ZWViMTlmZTM4ODYxNDc2YTkwYmVkMzI4NDQ3NTIwNjFfNTItMy0xLTEtMA_23be7f66-28a1-4f62-bdcb-4188ac9347e1">407</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these condensed consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><div id="iccd9c69ecd2c42e5897cfe9ab4e7e0b5_34"></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AMEDISYS, INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></div><div style="text-align:center"><span><br/></span></div><div id="iccd9c69ecd2c42e5897cfe9ab4e7e0b5_37"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1. <ix:nonNumeric contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8zNy9mcmFnOmMxNzYyMDBlMGRjNjRjOGE4NzU4YTM5ZTUxODJhZDk1L3RleHRyZWdpb246YzE3NjIwMGUwZGM2NGM4YTg3NThhMzllNTE4MmFkOTVfNTEwMA_99cc7601-4027-483e-8ac5-01930bb3643f" continuedAt="ie487c3a0be1b41c983af33e2c819c1ad" escape="true">NATURE OF OPERATIONS, CONSOLIDATION AND PRESENTATION OF FINANCIAL STATEMENTS</ix:nonNumeric></span></div><ix:continuation id="ie487c3a0be1b41c983af33e2c819c1ad" continuedAt="ia58899ced6f242a39aa936dc7f965638"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amedisys, Inc., a Delaware corporation, (together with its consolidated subsidiaries, referred to herein as &#8220;Amedisys,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; or &#8220;our&#8221;) is a multi-state provider of home health, hospice and personal care services with approximately <ix:nonFraction unitRef="number" contextRef="i85ce6ba1e58b4b7c883aa1e71fb67e40_D20210101-20210630" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8zNy9mcmFnOmMxNzYyMDBlMGRjNjRjOGE4NzU4YTM5ZTUxODJhZDk1L3RleHRyZWdpb246YzE3NjIwMGUwZGM2NGM4YTg3NThhMzllNTE4MmFkOTVfMzIz_5f9826ef-670b-49f5-8377-3846749c2a0b"><ix:nonFraction unitRef="number" contextRef="ib0181bc176d24054b0b4382b5f3a2ef9_D20210401-20210630" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8zNy9mcmFnOmMxNzYyMDBlMGRjNjRjOGE4NzU4YTM5ZTUxODJhZDk1L3RleHRyZWdpb246YzE3NjIwMGUwZGM2NGM4YTg3NThhMzllNTE4MmFkOTVfMzIz_cbfdc1c8-4d59-4975-aee8-195726094432">75</ix:nonFraction></ix:nonFraction>% of our net service revenue derived from Medicare for the three and six-month periods ended June 30, 2021 and approximately <ix:nonFraction unitRef="number" contextRef="if78f143ce2814015b9ecc0469dc639f1_D20200101-20200630" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8zNy9mcmFnOmMxNzYyMDBlMGRjNjRjOGE4NzU4YTM5ZTUxODJhZDk1L3RleHRyZWdpb246YzE3NjIwMGUwZGM2NGM4YTg3NThhMzllNTE4MmFkOTVfMzMw_0cfb9d0a-e2ff-4b00-a391-a80d3b1c7bd4"><ix:nonFraction unitRef="number" contextRef="i9d0cb72c37b145799e408add964d0544_D20200401-20200630" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8zNy9mcmFnOmMxNzYyMDBlMGRjNjRjOGE4NzU4YTM5ZTUxODJhZDk1L3RleHRyZWdpb246YzE3NjIwMGUwZGM2NGM4YTg3NThhMzllNTE4MmFkOTVfMzMw_230c9191-8bd3-40e7-bea5-fc86b71ab8dc">74</ix:nonFraction></ix:nonFraction>% of our net service revenue derived from Medicare for the three and six-month periods ended June 30, 2020. As of June&#160;30, 2021, we owned and operated <ix:nonFraction unitRef="care_center" contextRef="i30a2e3b95ac74ea890c5478c6d00aa9d_I20210630" decimals="INF" name="amed:OperatingCareCenters" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8zNy9mcmFnOmMxNzYyMDBlMGRjNjRjOGE4NzU4YTM5ZTUxODJhZDk1L3RleHRyZWdpb246YzE3NjIwMGUwZGM2NGM4YTg3NThhMzllNTE4MmFkOTVfNDYx_0e766134-c7fd-4c2c-9b45-f1e189545175">320</ix:nonFraction> Medicare-certified home health care centers, <ix:nonFraction unitRef="care_center" contextRef="i3e0c07dff3444ff8bdeaaddc51231dfe_I20210630" decimals="INF" name="amed:OperatingCareCenters" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8zNy9mcmFnOmMxNzYyMDBlMGRjNjRjOGE4NzU4YTM5ZTUxODJhZDk1L3RleHRyZWdpb246YzE3NjIwMGUwZGM2NGM4YTg3NThhMzllNTE4MmFkOTVfNTA5_f64d70e3-f019-4c54-93ff-75ac788a4315">180</ix:nonFraction> Medicare-certified hospice care centers and <ix:nonFraction unitRef="care_center" contextRef="i7e884a08e6374bbb9ca4c0909fb43265_I20210630" decimals="INF" name="amed:OperatingCareCenters" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8zNy9mcmFnOmMxNzYyMDBlMGRjNjRjOGE4NzU4YTM5ZTUxODJhZDk1L3RleHRyZWdpb246YzE3NjIwMGUwZGM2NGM4YTg3NThhMzllNTE4MmFkOTVfNTU2_403b0d7d-863b-4280-a7cd-9fc1dab90417">14</ix:nonFraction> personal-care care centers in <ix:nonFraction unitRef="state" contextRef="i1e833203be6947b4968aba4d20064ec8_I20210630" decimals="INF" name="us-gaap:NumberOfStatesInWhichEntityOperates" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8zNy9mcmFnOmMxNzYyMDBlMGRjNjRjOGE4NzU4YTM5ZTUxODJhZDk1L3RleHRyZWdpb246YzE3NjIwMGUwZGM2NGM4YTg3NThhMzllNTE4MmFkOTVfNTg5_09861249-156c-48f3-92e9-e8672961209a">39</ix:nonFraction> states within the United States and the District of Columbia.</span></div><ix:nonNumeric contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8zNy9mcmFnOmMxNzYyMDBlMGRjNjRjOGE4NzU4YTM5ZTUxODJhZDk1L3RleHRyZWdpb246YzE3NjIwMGUwZGM2NGM4YTg3NThhMzllNTE4MmFkOTVfNTEwMQ_a73ffffe-1d54-4434-bba2-bde4fda970a5" continuedAt="i7fd9e3a06a7141a1b465def92ab554a1" escape="true"><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In our opinion, the accompanying unaudited condensed consolidated financial statements contain all adjustments (consisting solely of normal recurring adjustments) necessary to present fairly our financial position, our results of operations and our cash flows in accordance with U.S. generally accepted accounting principles (&#8220;U.S. GAAP&#8221;) for interim financial reporting. Our results of operations for the interim periods presented are not necessarily indicative of the results of our operations for the entire year and have not been audited by our independent auditors.</span></div></ix:nonNumeric><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i7fd9e3a06a7141a1b465def92ab554a1">This report should be read in conjunction with our consolidated financial statements and related notes included in our Annual Report on Form 10-K for the year ended December&#160;31, 2020, as filed with the Securities and Exchange Commission (&#8220;SEC&#8221;) on February 25, 2021 (the &#8220;Form 10-K&#8221;), which includes information and disclosures not included herein.</ix:continuation> Certain information and footnote disclosures normally included in annual financial statements prepared in accordance with U.S. GAAP have been condensed or omitted from the interim financial information presented, as allowed by SEC rules and regulations. </span></div><ix:nonNumeric contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8zNy9mcmFnOmMxNzYyMDBlMGRjNjRjOGE4NzU4YTM5ZTUxODJhZDk1L3RleHRyZWdpb246YzE3NjIwMGUwZGM2NGM4YTg3NThhMzllNTE4MmFkOTVfNTEwOA_958ed32c-110a-4d9c-8cbc-cb3435544819" continuedAt="i301be44f89724cdf985b3c0f8552fc2b" escape="true"><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Adopted Accounting Pronouncements</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 1, 2021, the Company adopted Accounting Standards Update ("ASU") 2020-10, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Codification Improvements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which included minor technical corrections and clarifications to improve consistency and clarify the application of various provisions of the codification by amending the codification to include all disclosure guidance in the appropriate disclosure sections and by amending and adding new headings, cross referencing to other guidance and refining or correcting terminology. Our adoption of this standard did not have a material effect on our condensed consolidated financial statements.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Issued Accounting Pronouncements</span></div></ix:nonNumeric><div style="margin-top:5pt;text-align:justify"><ix:continuation id="i301be44f89724cdf985b3c0f8552fc2b" continuedAt="iea27b6ab9c7b4a94b9cdfbfa47801e91"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, the Financial Accounting Standards Board ("FASB") issued ASU 2020-04, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which provides optional expedients and exceptions for applying U.S. GAAP to contract modifications and hedging relationships that reference the London Inter-Bank Offered Rate ("LIBOR") or another reference rate expected to be discontinued, subject to meeting certain criteria. In January 2021, the FASB issued ASU 2021-01, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reference Rate Reform (Topic 848)</span></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="iea27b6ab9c7b4a94b9cdfbfa47801e91">, which adds implementation guidance to ASU 2020-04 to clarify certain optional expedients in Topic 848. The guidance in ASU 2020-04 and ASU 2021-01 was effective upon issuance and may generally be applied prospectively through December 31, 2022. This standard will not have an effect on our condensed consolidated financial statements.</ix:continuation> </span></div><ix:nonNumeric contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630" name="us-gaap:UseOfEstimates" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8zNy9mcmFnOmMxNzYyMDBlMGRjNjRjOGE4NzU4YTM5ZTUxODJhZDk1L3RleHRyZWdpb246YzE3NjIwMGUwZGM2NGM4YTg3NThhMzllNTE4MmFkOTVfNTEwOQ_671e73a3-77d1-493e-9de1-a3e7d294317c" escape="true"><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our accounting and reporting policies conform with U.S. GAAP. In preparing the unaudited condensed consolidated financial statements, we are required to make estimates and assumptions that impact the amounts reported in the condensed consolidated financial statements and accompanying notes. Actual results could differ from those estimates.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630" name="us-gaap:ConsolidationPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8zNy9mcmFnOmMxNzYyMDBlMGRjNjRjOGE4NzU4YTM5ZTUxODJhZDk1L3RleHRyZWdpb246YzE3NjIwMGUwZGM2NGM4YTg3NThhMzllNTE4MmFkOTVfNTExNg_aa969598-394e-4698-886d-8c4627dd57af" escape="true"><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Principles of Consolidation</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These unaudited condensed consolidated financial statements include the accounts of Amedisys, Inc. and our wholly owned subsidiaries. All significant intercompany accounts and transactions have been eliminated and business combinations accounted for as purchases have been included from their respective dates of acquisition. In addition to our wholly owned subsidiaries, we also have certain equity investments that are accounted for as set forth below.</span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AMEDISYS, INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></div><ix:continuation id="ia58899ced6f242a39aa936dc7f965638" continuedAt="i19622a04a9d8432696267bab104ae911"><ix:nonNumeric contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630" name="us-gaap:EquityMethodInvestmentsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8zNy9mcmFnOmMxNzYyMDBlMGRjNjRjOGE4NzU4YTM5ZTUxODJhZDk1L3RleHRyZWdpb246YzE3NjIwMGUwZGM2NGM4YTg3NThhMzllNTE4MmFkOTVfNTExNw_98c88dca-639a-4183-8be7-175206df85d0" continuedAt="icba577704a7b4a199b3e6b4a85b2b8c1" escape="true"><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investments</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We consolidate investments when the entity is a variable interest entity and we are the primary beneficiary or if we have controlling interests in the entity, which is generally ownership in excess of <ix:nonFraction unitRef="number" contextRef="i1e833203be6947b4968aba4d20064ec8_I20210630" decimals="INF" name="amed:MinimumPercentOwnershipForControllingInterestPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8zNy9mcmFnOmMxNzYyMDBlMGRjNjRjOGE4NzU4YTM5ZTUxODJhZDk1L3RleHRyZWdpb246YzE3NjIwMGUwZGM2NGM4YTg3NThhMzllNTE4MmFkOTVfNDQ2MQ_c4a57ecf-e9c3-4f5e-9589-f20b148226c8">50</ix:nonFraction>%. Third-party equity interests in our consolidated joint ventures are reflected as noncontrolling interests in our condensed consolidated financial statements. We account for investments in entities in which we have the ability to exercise significant influence under the equity method if we hold <ix:nonFraction unitRef="number" contextRef="i1e833203be6947b4968aba4d20064ec8_I20210630" decimals="INF" name="amed:MaximumPercentOwnershipForEquityMethodPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8zNy9mcmFnOmMxNzYyMDBlMGRjNjRjOGE4NzU4YTM5ZTUxODJhZDk1L3RleHRyZWdpb246YzE3NjIwMGUwZGM2NGM4YTg3NThhMzllNTE4MmFkOTVfNDc2MA_dde61e0f-ce36-499e-8291-2472adfc6778">50</ix:nonFraction>% or less of the voting stock and the entity is not a variable interest entity in which we are the primary beneficiary. The book value of investments that we account for under the equity method of accounting was $<ix:nonFraction unitRef="usd" contextRef="i1e833203be6947b4968aba4d20064ec8_I20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EquityMethodInvestmentAggregateCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8zNy9mcmFnOmMxNzYyMDBlMGRjNjRjOGE4NzU4YTM5ZTUxODJhZDk1L3RleHRyZWdpb246YzE3NjIwMGUwZGM2NGM4YTg3NThhMzllNTE4MmFkOTVfMTA5OTUxMTYzNDc5Nw_6a7f2e11-b4c1-4737-beb1-1df65cc75647">45.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i87ceb60dc20d4df1b0a97d3514837910_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EquityMethodInvestmentAggregateCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8zNy9mcmFnOmMxNzYyMDBlMGRjNjRjOGE4NzU4YTM5ZTUxODJhZDk1L3RleHRyZWdpb246YzE3NjIwMGUwZGM2NGM4YTg3NThhMzllNTE4MmFkOTVfMTA5OTUxMTYzNDgwNQ_6577837f-8d7a-4ec0-9c1a-ad0cd0ca62d4">14.2</ix:nonFraction> million as of June&#160;30, 2021 and December&#160;31, 2020, respectively, and is reflected in other assets within our condensed consolidated balance sheets. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three-month period ended June 30, 2021, a third-party acquired a majority of the issued and outstanding membership interests of one of our equity method investments, Medalogix, for cash, with the remaining membership interests rolling over into a newly formed entity that includes Medalogix as well as another healthcare predictive data and analytics company. We rolled over 100% of our ownership interest in Medalogix to the newly formed entity, and in connection with this transaction, we recognized a $<ix:nonFraction unitRef="usd" contextRef="i56460531924447ac8bc770856f36964a_D20210401-20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:GainLossOnInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8zNy9mcmFnOmMxNzYyMDBlMGRjNjRjOGE4NzU4YTM5ZTUxODJhZDk1L3RleHRyZWdpb246YzE3NjIwMGUwZGM2NGM4YTg3NThhMzllNTE4MmFkOTVfMTA5OTUxMTYzNTE0Nw_2449c867-9d4c-434c-a2b3-6a6a177e8423">31.1</ix:nonFraction>&#160;million gain based on the purchase price of Medalogix which is reflected in gain (loss) on equity method investments within our condensed consolidated statements of operations. </span></div></ix:nonNumeric></ix:continuation><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i19622a04a9d8432696267bab104ae911"><ix:continuation id="icba577704a7b4a199b3e6b4a85b2b8c1">During the three-month period ended June 30, 2020, we sold our investment in the Heritage Healthcare Innovation Fund, LP via a secondary transaction for $<ix:nonFraction unitRef="usd" contextRef="i47cb3be3d5564293b84a6274e71f0a2c_D20200401-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleOfEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8zNy9mcmFnOmMxNzYyMDBlMGRjNjRjOGE4NzU4YTM5ZTUxODJhZDk1L3RleHRyZWdpb246YzE3NjIwMGUwZGM2NGM4YTg3NThhMzllNTE4MmFkOTVfMTA5OTUxMTYzMzcxNQ_b22ac94f-c4d8-4c5f-8d27-13d418bcb0ab">17.9</ix:nonFraction>&#160;million which resulted in a $3.0 million loss which is reflected in gain (loss) on equity method investments within our condensed consolidated statements of operations. The Company's original investment was made in 2010 and no longer fit within our strategic areas of focus. Proceeds from the sale were used to pay down debt and fund capital needs.</ix:continuation></ix:continuation> </span></div><div id="iccd9c69ecd2c42e5897cfe9ab4e7e0b5_43"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2. <ix:nonNumeric contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV80My9mcmFnOjFhYzcyMjM4MzVjYzRiMjFiMWMzNjkwMGJmZjQzMjM3L3RleHRyZWdpb246MWFjNzIyMzgzNWNjNGIyMWIxYzM2OTAwYmZmNDMyMzdfMjIyMTE_fb170d9b-cf20-4dc3-96b7-745fcb63a82d" continuedAt="i17b8d4698b61415da7d3b94515c2750a" escape="true">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</ix:nonNumeric></span></div><ix:continuation id="i17b8d4698b61415da7d3b94515c2750a" continuedAt="i4d337a5dad044eb3a953ffac4ac48b61"><ix:nonNumeric contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630" name="us-gaap:RevenueRecognitionPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV80My9mcmFnOjFhYzcyMjM4MzVjYzRiMjFiMWMzNjkwMGJmZjQzMjM3L3RleHRyZWdpb246MWFjNzIyMzgzNWNjNGIyMWIxYzM2OTAwYmZmNDMyMzdfMjIyMTQ_47f4d174-348c-422f-96c1-299542cfb2af" continuedAt="ic855e71e82e749f596f41bc07155df57" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We account for revenue from contracts with customers in accordance with Accounting Standards Codification ("ASC") 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and as such, we recognize revenue in the period in which we satisfy our performance obligations under our contracts by transferring our promised services to our customers in amounts that reflect the consideration to which we expect to be entitled in exchange for providing patient care, which are the transaction prices allocated to the distinct services. The Company's cost of obtaining contracts is not material.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues are recognized as performance obligations are satisfied, which varies based on the nature of the services provided. Our performance obligation is the delivery of patient care services in accordance with the nature and frequency of services outlined in physicians' orders, which are determined by a physician based on a patient's specific goals. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's performance obligations relate to contracts with a duration of less than one year; therefore, the Company has elected to apply the optional exemption provided by ASC 606 and is not required to disclose the aggregate amount of the transaction price allocated to performance obligations that are unsatisfied or partially unsatisfied as of the end of the reporting period. The unsatisfied or partially unsatisfied performance obligations are generally completed when the patients are discharged, which generally occurs within days or weeks of the end of the reporting period.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We determine the transaction price based on gross charges for services provided, reduced by estimates for contractual and non-contractual revenue adjustments. Contractual revenue adjustments are recorded for the difference between our standard rates and the contracted rates to be realized from patients, third-party payors and others for services provided. Non-contractual revenue adjustments include discounts provided to self-pay, uninsured patients or other payors, adjustments resulting from payment reviews and adjustments arising from our inability to obtain appropriate billing documentation, authorizations or face-to-face documentation. Subsequent changes to the estimate of the transaction price are recorded as adjustments to net service revenue in the period of change. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-contractual revenue adjustments are recorded for self-pay, uninsured patients and other payors by major payor class based on our historical collection experience, aged accounts receivable by payor and current economic conditions. The non-contractual revenue adjustments represent the difference between amounts billed and amounts we expect to collect based on our collection history with similar payors. The Company assesses its ability to collect for the healthcare services provided at the time of patient admission based on the Company's verification of the patient's insurance coverage under Medicare, Medicaid, and other commercial or managed care insurance programs. Medicare represents approximately <ix:nonFraction unitRef="number" contextRef="i85ce6ba1e58b4b7c883aa1e71fb67e40_D20210101-20210630" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV80My9mcmFnOjFhYzcyMjM4MzVjYzRiMjFiMWMzNjkwMGJmZjQzMjM3L3RleHRyZWdpb246MWFjNzIyMzgzNWNjNGIyMWIxYzM2OTAwYmZmNDMyMzdfMTA5OTUxMTY1MDEwNg_5f9826ef-670b-49f5-8377-3846749c2a0b"><ix:nonFraction unitRef="number" contextRef="ib0181bc176d24054b0b4382b5f3a2ef9_D20210401-20210630" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV80My9mcmFnOjFhYzcyMjM4MzVjYzRiMjFiMWMzNjkwMGJmZjQzMjM3L3RleHRyZWdpb246MWFjNzIyMzgzNWNjNGIyMWIxYzM2OTAwYmZmNDMyMzdfMTA5OTUxMTY1MDEwNg_cbfdc1c8-4d59-4975-aee8-195726094432">75</ix:nonFraction></ix:nonFraction>% of our net service revenue </span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AMEDISYS, INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></div><ix:continuation id="i4d337a5dad044eb3a953ffac4ac48b61" continuedAt="ia67a5c1dfa0441aeb51a4a149c1106fd"><ix:continuation id="ic855e71e82e749f596f41bc07155df57" continuedAt="i7e4521a30f2349f18334fa3a1e24f2ac"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for the three and six-month periods ended June 30, 2021 and approximately <ix:nonFraction unitRef="number" contextRef="if78f143ce2814015b9ecc0469dc639f1_D20200101-20200630" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV80My9mcmFnOjFhYzcyMjM4MzVjYzRiMjFiMWMzNjkwMGJmZjQzMjM3L3RleHRyZWdpb246MWFjNzIyMzgzNWNjNGIyMWIxYzM2OTAwYmZmNDMyMzdfMTA5OTUxMTY1MDIyMQ_0cfb9d0a-e2ff-4b00-a391-a80d3b1c7bd4"><ix:nonFraction unitRef="number" contextRef="i9d0cb72c37b145799e408add964d0544_D20200401-20200630" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV80My9mcmFnOjFhYzcyMjM4MzVjYzRiMjFiMWMzNjkwMGJmZjQzMjM3L3RleHRyZWdpb246MWFjNzIyMzgzNWNjNGIyMWIxYzM2OTAwYmZmNDMyMzdfMTA5OTUxMTY1MDIyMQ_230c9191-8bd3-40e7-bea5-fc86b71ab8dc">74</ix:nonFraction></ix:nonFraction>% of our net service revenue for the three and six-month periods ended June 30, 2020. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts due from third-party payors, primarily commercial health insurers and government programs (Medicare and Medicaid), include variable consideration for retroactive revenue adjustments due to settlements of audits and payment reviews. We determine our estimates for non-contractual revenue adjustments related to audits and payment reviews based on our historical experience and success rates in the claim appeals and adjudication process. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We determine our estimates for non-contractual revenue adjustments related to our inability to obtain appropriate billing documentation, authorizations, or face-to-face documentation based on our historical experience which primarily includes a historical collection rate of over <ix:nonFraction unitRef="number" contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630" decimals="2" name="amed:HistoricalCollectionRateFromMedicare" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV80My9mcmFnOjFhYzcyMjM4MzVjYzRiMjFiMWMzNjkwMGJmZjQzMjM3L3RleHRyZWdpb246MWFjNzIyMzgzNWNjNGIyMWIxYzM2OTAwYmZmNDMyMzdfMzg5Mw_f47cbdea-9157-4757-a5f2-e4f5e8f77820">99</ix:nonFraction>% on Medicare claims. Revenue is recorded at amounts we estimate to be realizable for services provided.</span></div><div style="text-align:justify"><span><br/></span></div><div><ix:nonNumeric contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630" name="us-gaap:ScheduleOfRevenueSourcesHealthCareOrganizationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV80My9mcmFnOjFhYzcyMjM4MzVjYzRiMjFiMWMzNjkwMGJmZjQzMjM3L3RleHRyZWdpb246MWFjNzIyMzgzNWNjNGIyMWIxYzM2OTAwYmZmNDMyMzdfMjIxOTk_8f7a3879-bcab-4b1a-af78-f90b51ba33e7" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue by payor class as a percentage of total net service revenue is as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.923%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.602%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three-Month Periods Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Six-Month Periods <br/>Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Home Health:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Medicare</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i819d1cc0f63448c9bae946092e2d9634_D20210401-20210630" decimals="2" name="amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV80My9mcmFnOjFhYzcyMjM4MzVjYzRiMjFiMWMzNjkwMGJmZjQzMjM3L3RhYmxlOjJkYTM1ZTFhMTg0YzQwYTc5NTZlMzYzMmYwZjU3YzQ3L3RhYmxlcmFuZ2U6MmRhMzVlMWExODRjNDBhNzk1NmUzNjMyZjBmNTdjNDdfMy0xLTEtMS0w_81556ff4-8f40-4452-97f8-d0d938341b26">42</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iab0c4aa1f54048f9bb07ee49f6bb395e_D20200401-20200630" decimals="2" name="amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV80My9mcmFnOjFhYzcyMjM4MzVjYzRiMjFiMWMzNjkwMGJmZjQzMjM3L3RhYmxlOjJkYTM1ZTFhMTg0YzQwYTc5NTZlMzYzMmYwZjU3YzQ3L3RhYmxlcmFuZ2U6MmRhMzVlMWExODRjNDBhNzk1NmUzNjMyZjBmNTdjNDdfMy0zLTEtMS0w_e62761d2-9c9d-456a-87ed-77d517ff6f2b">40</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i72044b2a44e74c5591b023a1c6e1f437_D20210101-20210630" decimals="2" name="amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV80My9mcmFnOjFhYzcyMjM4MzVjYzRiMjFiMWMzNjkwMGJmZjQzMjM3L3RhYmxlOjJkYTM1ZTFhMTg0YzQwYTc5NTZlMzYzMmYwZjU3YzQ3L3RhYmxlcmFuZ2U6MmRhMzVlMWExODRjNDBhNzk1NmUzNjMyZjBmNTdjNDdfMy01LTEtMS0yODA_07894343-56ab-4e70-972d-032b54dc1271">42</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iec44149de0804e90a0d618b5aab11df1_D20200101-20200630" decimals="2" name="amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV80My9mcmFnOjFhYzcyMjM4MzVjYzRiMjFiMWMzNjkwMGJmZjQzMjM3L3RhYmxlOjJkYTM1ZTFhMTg0YzQwYTc5NTZlMzYzMmYwZjU3YzQ3L3RhYmxlcmFuZ2U6MmRhMzVlMWExODRjNDBhNzk1NmUzNjMyZjBmNTdjNDdfMy03LTEtMS0yODA_b702c777-7c7a-4deb-88e1-6149ff6072fa">41</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Non-Medicare - Episodic-based</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iba4b4085e2a44ace9b534d8db3a5cb18_D20210401-20210630" decimals="2" name="amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV80My9mcmFnOjFhYzcyMjM4MzVjYzRiMjFiMWMzNjkwMGJmZjQzMjM3L3RhYmxlOjJkYTM1ZTFhMTg0YzQwYTc5NTZlMzYzMmYwZjU3YzQ3L3RhYmxlcmFuZ2U6MmRhMzVlMWExODRjNDBhNzk1NmUzNjMyZjBmNTdjNDdfNC0xLTEtMS0w_bd2aeda9-dafa-4a4a-970b-e8656d61a1b9">8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i62976d7f48f547f690d30bf5ecdc0c9d_D20200401-20200630" decimals="2" name="amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV80My9mcmFnOjFhYzcyMjM4MzVjYzRiMjFiMWMzNjkwMGJmZjQzMjM3L3RhYmxlOjJkYTM1ZTFhMTg0YzQwYTc5NTZlMzYzMmYwZjU3YzQ3L3RhYmxlcmFuZ2U6MmRhMzVlMWExODRjNDBhNzk1NmUzNjMyZjBmNTdjNDdfNC0zLTEtMS0w_7a857ccf-4828-4621-b217-ec436127f2f7">6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i2b90bd098db34908919842c129b2c275_D20210101-20210630" decimals="2" name="amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV80My9mcmFnOjFhYzcyMjM4MzVjYzRiMjFiMWMzNjkwMGJmZjQzMjM3L3RhYmxlOjJkYTM1ZTFhMTg0YzQwYTc5NTZlMzYzMmYwZjU3YzQ3L3RhYmxlcmFuZ2U6MmRhMzVlMWExODRjNDBhNzk1NmUzNjMyZjBmNTdjNDdfNC01LTEtMS0yODA_5aba69dc-c935-4c37-96b1-aa0fe3c08826">8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i986914649c744434996e298aed0a55de_D20200101-20200630" decimals="2" name="amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV80My9mcmFnOjFhYzcyMjM4MzVjYzRiMjFiMWMzNjkwMGJmZjQzMjM3L3RhYmxlOjJkYTM1ZTFhMTg0YzQwYTc5NTZlMzYzMmYwZjU3YzQ3L3RhYmxlcmFuZ2U6MmRhMzVlMWExODRjNDBhNzk1NmUzNjMyZjBmNTdjNDdfNC03LTEtMS0yODA_43aab793-7d7d-4c0d-b141-4e2d7b5dc947">6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Non-Medicare - Non-episodic based</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id3dfc4a215e346f2b62f7a0031e7a1c0_D20210401-20210630" decimals="2" name="amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV80My9mcmFnOjFhYzcyMjM4MzVjYzRiMjFiMWMzNjkwMGJmZjQzMjM3L3RhYmxlOjJkYTM1ZTFhMTg0YzQwYTc5NTZlMzYzMmYwZjU3YzQ3L3RhYmxlcmFuZ2U6MmRhMzVlMWExODRjNDBhNzk1NmUzNjMyZjBmNTdjNDdfNS0xLTEtMS0w_5483b0b4-d65f-433f-b57c-08d9ae42347c">12</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i1889f1856fd04eb9a83ad415f13bb6e1_D20200401-20200630" decimals="2" name="amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV80My9mcmFnOjFhYzcyMjM4MzVjYzRiMjFiMWMzNjkwMGJmZjQzMjM3L3RhYmxlOjJkYTM1ZTFhMTg0YzQwYTc5NTZlMzYzMmYwZjU3YzQ3L3RhYmxlcmFuZ2U6MmRhMzVlMWExODRjNDBhNzk1NmUzNjMyZjBmNTdjNDdfNS0zLTEtMS0w_c48ce460-0e87-4960-8cb9-4694082e126b">14</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i07bd2c944cf046a189fd4eb6529755d6_D20210101-20210630" decimals="2" name="amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV80My9mcmFnOjFhYzcyMjM4MzVjYzRiMjFiMWMzNjkwMGJmZjQzMjM3L3RhYmxlOjJkYTM1ZTFhMTg0YzQwYTc5NTZlMzYzMmYwZjU3YzQ3L3RhYmxlcmFuZ2U6MmRhMzVlMWExODRjNDBhNzk1NmUzNjMyZjBmNTdjNDdfNS01LTEtMS0yODA_1164f11b-41c4-4a74-b33b-23a77714a309">12</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i584d1976fa4740918795b29a298c07f8_D20200101-20200630" decimals="2" name="amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV80My9mcmFnOjFhYzcyMjM4MzVjYzRiMjFiMWMzNjkwMGJmZjQzMjM3L3RhYmxlOjJkYTM1ZTFhMTg0YzQwYTc5NTZlMzYzMmYwZjU3YzQ3L3RhYmxlcmFuZ2U6MmRhMzVlMWExODRjNDBhNzk1NmUzNjMyZjBmNTdjNDdfNS03LTEtMS0yODA_b117d2a8-d576-4677-ae8a-4262a8fa8748">14</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Hospice (1):</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Medicare</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i82e2454c5eed4b28ab058238918f809e_D20210401-20210630" decimals="2" name="amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV80My9mcmFnOjFhYzcyMjM4MzVjYzRiMjFiMWMzNjkwMGJmZjQzMjM3L3RhYmxlOjJkYTM1ZTFhMTg0YzQwYTc5NTZlMzYzMmYwZjU3YzQ3L3RhYmxlcmFuZ2U6MmRhMzVlMWExODRjNDBhNzk1NmUzNjMyZjBmNTdjNDdfNy0xLTEtMS0w_af747f1f-946b-43ac-9d10-07e63c0eeb6e">33</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i617f99e1213a4f2094c8432f4837db94_D20200401-20200630" decimals="2" name="amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV80My9mcmFnOjFhYzcyMjM4MzVjYzRiMjFiMWMzNjkwMGJmZjQzMjM3L3RhYmxlOjJkYTM1ZTFhMTg0YzQwYTc5NTZlMzYzMmYwZjU3YzQ3L3RhYmxlcmFuZ2U6MmRhMzVlMWExODRjNDBhNzk1NmUzNjMyZjBmNTdjNDdfNy0zLTEtMS0w_3bad2215-95da-44bc-9283-484352f61fda">34</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7a48258931a748a99b37e6058a5916e4_D20210101-20210630" decimals="2" name="amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV80My9mcmFnOjFhYzcyMjM4MzVjYzRiMjFiMWMzNjkwMGJmZjQzMjM3L3RhYmxlOjJkYTM1ZTFhMTg0YzQwYTc5NTZlMzYzMmYwZjU3YzQ3L3RhYmxlcmFuZ2U6MmRhMzVlMWExODRjNDBhNzk1NmUzNjMyZjBmNTdjNDdfNy01LTEtMS0yODM_1dc38bae-07c7-497b-b564-5b762d39ab35">33</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iff8b2cf9576146db8b00ff2d1d72091f_D20200101-20200630" decimals="2" name="amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV80My9mcmFnOjFhYzcyMjM4MzVjYzRiMjFiMWMzNjkwMGJmZjQzMjM3L3RhYmxlOjJkYTM1ZTFhMTg0YzQwYTc5NTZlMzYzMmYwZjU3YzQ3L3RhYmxlcmFuZ2U6MmRhMzVlMWExODRjNDBhNzk1NmUzNjMyZjBmNTdjNDdfNy03LTEtMS0yODM_99fd9cf3-aeea-45c2-bb00-00f3b5be7f2d">33</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Non-Medicare</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i575fb5ffd81f408fb483b5911db2264f_D20210401-20210630" decimals="2" name="amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV80My9mcmFnOjFhYzcyMjM4MzVjYzRiMjFiMWMzNjkwMGJmZjQzMjM3L3RhYmxlOjJkYTM1ZTFhMTg0YzQwYTc5NTZlMzYzMmYwZjU3YzQ3L3RhYmxlcmFuZ2U6MmRhMzVlMWExODRjNDBhNzk1NmUzNjMyZjBmNTdjNDdfOC0xLTEtMS0w_7a78ad7d-8a3a-41f6-8b11-439c1547d38a">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i79540dc5db374f3e8dad988e2d746e13_D20200401-20200630" decimals="2" name="amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV80My9mcmFnOjFhYzcyMjM4MzVjYzRiMjFiMWMzNjkwMGJmZjQzMjM3L3RhYmxlOjJkYTM1ZTFhMTg0YzQwYTc5NTZlMzYzMmYwZjU3YzQ3L3RhYmxlcmFuZ2U6MmRhMzVlMWExODRjNDBhNzk1NmUzNjMyZjBmNTdjNDdfOC0zLTEtMS0w_b20bc85e-e5f5-4d53-af74-c4b16461d56d">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i83c28c34df424dba99ce508660059376_D20210101-20210630" decimals="2" name="amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV80My9mcmFnOjFhYzcyMjM4MzVjYzRiMjFiMWMzNjkwMGJmZjQzMjM3L3RhYmxlOjJkYTM1ZTFhMTg0YzQwYTc5NTZlMzYzMmYwZjU3YzQ3L3RhYmxlcmFuZ2U6MmRhMzVlMWExODRjNDBhNzk1NmUzNjMyZjBmNTdjNDdfOC01LTEtMS0yODM_a95366a5-b590-431f-95af-4cbe6c143f4a">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib14de18b4a2d452c831ee77de19f382d_D20200101-20200630" decimals="2" name="amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV80My9mcmFnOjFhYzcyMjM4MzVjYzRiMjFiMWMzNjkwMGJmZjQzMjM3L3RhYmxlOjJkYTM1ZTFhMTg0YzQwYTc5NTZlMzYzMmYwZjU3YzQ3L3RhYmxlcmFuZ2U6MmRhMzVlMWExODRjNDBhNzk1NmUzNjMyZjBmNTdjNDdfOC03LTEtMS0yODM_0ea0533e-94fe-4a2e-a01b-a9e7a34e81b3">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Personal Care</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9459b4ff31494b3a8001d1ad78d69359_D20210401-20210630" decimals="2" name="amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV80My9mcmFnOjFhYzcyMjM4MzVjYzRiMjFiMWMzNjkwMGJmZjQzMjM3L3RhYmxlOjJkYTM1ZTFhMTg0YzQwYTc5NTZlMzYzMmYwZjU3YzQ3L3RhYmxlcmFuZ2U6MmRhMzVlMWExODRjNDBhNzk1NmUzNjMyZjBmNTdjNDdfOS0xLTEtMS0w_babecbd0-5bb1-4ced-b99c-4c01bac3021b">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i4720759f4b1249fc9f52ebf7d06b0d2c_D20200401-20200630" decimals="2" name="amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV80My9mcmFnOjFhYzcyMjM4MzVjYzRiMjFiMWMzNjkwMGJmZjQzMjM3L3RhYmxlOjJkYTM1ZTFhMTg0YzQwYTc5NTZlMzYzMmYwZjU3YzQ3L3RhYmxlcmFuZ2U6MmRhMzVlMWExODRjNDBhNzk1NmUzNjMyZjBmNTdjNDdfOS0zLTEtMS0w_00c878cb-a743-4a3d-80eb-5df4577ebdee">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i913d274664fd48a49b9a53ffbeeb81bd_D20210101-20210630" decimals="2" name="amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV80My9mcmFnOjFhYzcyMjM4MzVjYzRiMjFiMWMzNjkwMGJmZjQzMjM3L3RhYmxlOjJkYTM1ZTFhMTg0YzQwYTc5NTZlMzYzMmYwZjU3YzQ3L3RhYmxlcmFuZ2U6MmRhMzVlMWExODRjNDBhNzk1NmUzNjMyZjBmNTdjNDdfOS01LTEtMS0yODM_33f74912-6faf-4645-a655-ccc806de8091">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i2cd2a132976345f995477e91bea1b7a4_D20200101-20200630" decimals="2" name="amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV80My9mcmFnOjFhYzcyMjM4MzVjYzRiMjFiMWMzNjkwMGJmZjQzMjM3L3RhYmxlOjJkYTM1ZTFhMTg0YzQwYTc5NTZlMzYzMmYwZjU3YzQ3L3RhYmxlcmFuZ2U6MmRhMzVlMWExODRjNDBhNzk1NmUzNjMyZjBmNTdjNDdfOS03LTEtMS0yODM_0a02f81e-34e9-4ed4-996e-71445afa9ee7">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib87cee58ccf2448a8d4422101bf61fa0_D20210401-20210630" decimals="2" name="amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV80My9mcmFnOjFhYzcyMjM4MzVjYzRiMjFiMWMzNjkwMGJmZjQzMjM3L3RhYmxlOjJkYTM1ZTFhMTg0YzQwYTc5NTZlMzYzMmYwZjU3YzQ3L3RhYmxlcmFuZ2U6MmRhMzVlMWExODRjNDBhNzk1NmUzNjMyZjBmNTdjNDdfMTAtMS0xLTEtMA_c4009903-05d8-4232-84e7-9df1805a4198">100</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i2c8351954d014a1c80a3d8cfc2327ab2_D20200401-20200630" decimals="2" name="amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV80My9mcmFnOjFhYzcyMjM4MzVjYzRiMjFiMWMzNjkwMGJmZjQzMjM3L3RhYmxlOjJkYTM1ZTFhMTg0YzQwYTc5NTZlMzYzMmYwZjU3YzQ3L3RhYmxlcmFuZ2U6MmRhMzVlMWExODRjNDBhNzk1NmUzNjMyZjBmNTdjNDdfMTAtMy0xLTEtMA_fa32fdc9-e529-488f-a2e4-932e281d5d5d">100</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630" decimals="2" name="amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV80My9mcmFnOjFhYzcyMjM4MzVjYzRiMjFiMWMzNjkwMGJmZjQzMjM3L3RhYmxlOjJkYTM1ZTFhMTg0YzQwYTc5NTZlMzYzMmYwZjU3YzQ3L3RhYmxlcmFuZ2U6MmRhMzVlMWExODRjNDBhNzk1NmUzNjMyZjBmNTdjNDdfMTAtNS0xLTEtMjgz_e517b0ca-96c8-4fb1-9e58-12dc7c5a7f72">100</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i667fa0996400408f9cb2d7f4d3ee2087_D20200101-20200630" decimals="2" name="amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV80My9mcmFnOjFhYzcyMjM4MzVjYzRiMjFiMWMzNjkwMGJmZjQzMjM3L3RhYmxlOjJkYTM1ZTFhMTg0YzQwYTc5NTZlMzYzMmYwZjU3YzQ3L3RhYmxlcmFuZ2U6MmRhMzVlMWExODRjNDBhNzk1NmUzNjMyZjBmNTdjNDdfMTAtNy0xLTEtMjgz_2ab619cd-f4c7-4df7-ac08-a4a2f96f5f67">100</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="24" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1) Acquired AseraCare Hospice ("AseraCare") on June 1, 2020.</span></td></tr></table></ix:nonNumeric></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Home Health Revenue Recognition</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Medicare Revenue</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective January 1, 2020, the Centers for Medicare and Medicaid Services ("CMS") implemented a revised case-mix adjustment methodology, the Patient-Driven Groupings Model ("PDGM"), to better align payment with patient care needs and ensure that clinically complex and ill beneficiaries have adequate access to home health care. PDGM uses <ix:nonNumeric contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630" format="ixt-sec:durday" name="amed:NetServiceRevenuePeriodOfCarePaymentRateDuration" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV80My9mcmFnOjFhYzcyMjM4MzVjYzRiMjFiMWMzNjkwMGJmZjQzMjM3L3RleHRyZWdpb246MWFjNzIyMzgzNWNjNGIyMWIxYzM2OTAwYmZmNDMyMzdfNDQ3NA_cf808f76-53a7-400a-85f2-a0394a3e8dfd">30</ix:nonNumeric>-day periods of care rather than <ix:nonNumeric contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630" format="ixt-sec:durday" name="amed:NetServiceRevenueEpisodePaymentRateDuration" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV80My9mcmFnOjFhYzcyMjM4MzVjYzRiMjFiMWMzNjkwMGJmZjQzMjM3L3RleHRyZWdpb246MWFjNzIyMzgzNWNjNGIyMWIxYzM2OTAwYmZmNDMyMzdfNDUwOQ_85e895c0-953c-4f4d-a547-a5fdb385dd03">60</ix:nonNumeric>-day episodes of care as the unit of payment, eliminates the use of the number of therapy visits provided in determining payment and relies more heavily on clinical characteristics and other patient information.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net service revenue is recorded based on the established Federal Medicare home health payment rate for a <ix:nonNumeric contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630" format="ixt-sec:durday" name="amed:NetServiceRevenuePeriodOfCarePaymentRateDuration" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV80My9mcmFnOjFhYzcyMjM4MzVjYzRiMjFiMWMzNjkwMGJmZjQzMjM3L3RleHRyZWdpb246MWFjNzIyMzgzNWNjNGIyMWIxYzM2OTAwYmZmNDMyMzdfNDgyOA_bc2dc7c3-23a6-4159-b465-59e1ee9c83f5">30</ix:nonNumeric>-day period of care. ASC 606 notes that if an entity has a right to consideration from a customer in an amount that corresponds directly with the value of the entity&#8217;s performance completed to date, the entity may recognize revenue in the amount to which the entity has a right to invoice. We have elected to apply the "right to invoice" practical expedient and therefore, our revenue recognition is based on the reimbursement we are entitled to for each 30-day payment period. We utilize our historical average length of stay for each 30-day period of care as the measure of progress towards the satisfaction of our performance obligation.</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">PDGM uses timing, admission source, functional impairment levels and principal and other diagnoses to case-mix adjust payments. The case-mix adjusted payment for a 30-day period of care is subject to additional adjustments based on certain variables, including, but not limited to (a) an outlier payment if our patient's care was unusually costly (capped at <ix:nonFraction unitRef="number" contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630" decimals="INF" name="amed:PercentageOfTotalReimbursementOfOutlierPayment" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV80My9mcmFnOjFhYzcyMjM4MzVjYzRiMjFiMWMzNjkwMGJmZjQzMjM3L3RleHRyZWdpb246MWFjNzIyMzgzNWNjNGIyMWIxYzM2OTAwYmZmNDMyMzdfNjQ4NA_5c01dc8b-6269-46ad-bb85-5424aab66ec8">10</ix:nonFraction>% of total reimbursement per provider number); (b)&#160;a low utilization payment adjustment (&#8220;LUPA&#8221;) if the number of visits provided was less than the established threshold, which ranges from <ix:nonFraction unitRef="visit" contextRef="i90c63ef3c03b4a79b0e16bebccfb5aaa_D20210101-20210630" decimals="0" format="ixt-sec:numwordsen" name="amed:LowUtilizationPaymentAdjustmentNumberOfVisits" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV80My9mcmFnOjFhYzcyMjM4MzVjYzRiMjFiMWMzNjkwMGJmZjQzMjM3L3RleHRyZWdpb246MWFjNzIyMzgzNWNjNGIyMWIxYzM2OTAwYmZmNDMyMzdfNjY3NA_cac2c2aa-09fd-4c18-9bcb-a0104d0813fa">two</ix:nonFraction> to <ix:nonFraction unitRef="visit" contextRef="iea406e6210c24d67b95bd8bba7ed6315_D20210101-20210630" decimals="0" format="ixt-sec:numwordsen" name="amed:LowUtilizationPaymentAdjustmentNumberOfVisits" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV80My9mcmFnOjFhYzcyMjM4MzVjYzRiMjFiMWMzNjkwMGJmZjQzMjM3L3RleHRyZWdpb246MWFjNzIyMzgzNWNjNGIyMWIxYzM2OTAwYmZmNDMyMzdfNjY4MA_c5a9d304-aa8e-4f4b-98e7-189b6d9d9d52">six</ix:nonFraction> visits and varies for every case-mix group under PDGM; (c)&#160;a partial payment if a patient is transferred to another provider or from another provider before completing the 30-day period of care; and (d) the applicable geographic wage index. Payments for routine and non-routine supplies are included in the 30-day payment rate.</span></div></ix:continuation></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AMEDISYS, INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></div><ix:continuation id="ia67a5c1dfa0441aeb51a4a149c1106fd" continuedAt="i95f5d11e07814c73b096d7e812e37c3c"><ix:continuation id="i7e4521a30f2349f18334fa3a1e24f2ac" continuedAt="i7012eb6e222b484b800e10dc60c54701"><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medicare can also make various adjustments to payments received if we are unable to produce appropriate billing documentation or acceptable authorizations. We estimate the impact of such adjustments based on our historical experience, which primarily includes a historical collection rate of over <ix:nonFraction unitRef="number" contextRef="i1e89d4343fef486490e1fcdab10c1010_D20210101-20210630" decimals="2" name="amed:HistoricalCollectionRateFromMedicare" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV80My9mcmFnOjFhYzcyMjM4MzVjYzRiMjFiMWMzNjkwMGJmZjQzMjM3L3RleHRyZWdpb246MWFjNzIyMzgzNWNjNGIyMWIxYzM2OTAwYmZmNDMyMzdfNzMwOA_7f5abd3a-9c5a-4b80-b1da-282483e49cf3">99</ix:nonFraction>% on Medicare claims, and record this estimate during the period in which services are rendered to revenue with a corresponding reduction to patient accounts receivable.</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts due from Medicare include variable consideration for retroactive revenue adjustments due to settlements of audits and payment reviews. We determine our estimates for non-contractual revenue adjustments related to audits and payment reviews based on our historical experience and success rates in the claim appeals and adjudication process.</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All Medicare contracts are required to have a signed plan of care which represents a single performance obligation, comprised of the delivery of a series of distinct services that are substantially similar and have a similar pattern of transfer to the customer. Accordingly, the Company accounts for the series of services ("episode") as a single performance obligation satisfied over time, as the customer simultaneously receives and consumes the benefits of the goods and services provided. An episode starts the first day a billable visit is performed and ends 60 days later or upon discharge, if earlier, with multiple continuous episodes allowed. </span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Medicare home health benefit requires that beneficiaries be homebound (meaning that the beneficiary is unable to leave his/her home without a considerable and taxing effort), require intermittent skilled nursing, physical therapy or speech therapy services, and receive treatment under a plan of care established and periodically reviewed by a physician. In order to provide greater flexibility during the novel coronavirus pandemic ("COVID-19"), CMS relaxed the definition of homebound status through the duration of the public health emergency. During the pandemic, a beneficiary is considered homebound if they have been instructed by a physician not to leave their home because of a confirmed or suspected COVID-19 diagnosis or if the patient has a condition that makes them more susceptible to contracting COVID-19. Therefore, if a beneficiary is homebound due to COVID-19 and requires skilled services, the services will be covered under the Medicare home health benefit. </span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2020, <ix:nonFraction unitRef="number" contextRef="id4b15251aa8147bcb0b8c78424ea981c_D20200101-20201231" decimals="2" name="amed:RateOfRequestForAnticipatedPaymentSubmittedForInitialPeriodOfCare" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV80My9mcmFnOjFhYzcyMjM4MzVjYzRiMjFiMWMzNjkwMGJmZjQzMjM3L3RleHRyZWdpb246MWFjNzIyMzgzNWNjNGIyMWIxYzM2OTAwYmZmNDMyMzdfMTA5OTUxMTY1MTI2Mw_04295ca5-6927-4f2b-9a6d-26f441f79f97">20</ix:nonFraction>% of reimbursement from each Medicare episode, referred to as a request for anticipated payment ("RAP"), was billed near the start of each 30-day period of care, and cash was typically received before all services were rendered. Any cash received from Medicare for a RAP for a <ix:nonNumeric contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630" format="ixt-sec:durday" name="amed:NetServiceRevenuePeriodOfCarePaymentRateDuration" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV80My9mcmFnOjFhYzcyMjM4MzVjYzRiMjFiMWMzNjkwMGJmZjQzMjM3L3RleHRyZWdpb246MWFjNzIyMzgzNWNjNGIyMWIxYzM2OTAwYmZmNDMyMzdfOTExNA_b8b43c7e-1458-41d6-8f6c-debaebb42bc9">30</ix:nonNumeric>-day period of care that exceeded the associated revenue earned was recorded to accrued expenses within our condensed consolidated balance sheets. CMS fully eliminated all upfront payments associated with RAPs effective January 1, 2021.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Non-Medicare Revenue</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Episodic-based Revenue.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We recognize revenue in a similar manner as we recognize Medicare revenue for amounts that are paid by other insurance carriers, including Medicare Advantage programs; however, these amounts can vary based upon the negotiated terms, the majority of which range from <ix:nonFraction unitRef="number" contextRef="i90c63ef3c03b4a79b0e16bebccfb5aaa_D20210101-20210630" decimals="INF" name="amed:NonMedicareRevenueTermRates" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV80My9mcmFnOjFhYzcyMjM4MzVjYzRiMjFiMWMzNjkwMGJmZjQzMjM3L3RleHRyZWdpb246MWFjNzIyMzgzNWNjNGIyMWIxYzM2OTAwYmZmNDMyMzdfOTcwMg_d860e34d-b748-4c4e-ada9-2f3ccd49a1fa">95</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="iea406e6210c24d67b95bd8bba7ed6315_D20210101-20210630" decimals="INF" name="amed:NonMedicareRevenueTermRates" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV80My9mcmFnOjFhYzcyMjM4MzVjYzRiMjFiMWMzNjkwMGJmZjQzMjM3L3RleHRyZWdpb246MWFjNzIyMzgzNWNjNGIyMWIxYzM2OTAwYmZmNDMyMzdfOTcwOA_e411d502-1af9-45f9-a7b8-095eb39889a7">100</ix:nonFraction>% of Medicare rates.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Non-episodic based Revenue.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Gross revenue is recorded on an accrual basis based upon the date of service at amounts equal to our established or estimated per-visit rates. Contractual revenue adjustments are recorded for the difference between our standard rates and the contracted rates to be realized from patients, third parties and others for services provided and are deducted from gross revenue to determine net service revenue. We also make non-contractual revenue adjustments to non-episodic revenue based on our historical experience to reflect the estimated transaction price. We receive a minimal amount of our net service revenue from patients who are either self-insured or are obligated for an insurance co-payment.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Hospice Revenue Recognition</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Hospice Medicare Revenue</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gross revenue is recorded on an accrual basis based upon the date of service at amounts equal to the estimated payment rates. The estimated payment rates are predetermined daily or hourly rates for each of the four levels of care we deliver. The four levels of care are routine care, general inpatient care, continuous home care and respite care. Routine care accounted for <ix:nonFraction unitRef="number" contextRef="i667fa0996400408f9cb2d7f4d3ee2087_D20200101-20200630" decimals="2" name="amed:HospiceMedicareRevenueRateAccountedForRoutineCare" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV80My9mcmFnOjFhYzcyMjM4MzVjYzRiMjFiMWMzNjkwMGJmZjQzMjM3L3RleHRyZWdpb246MWFjNzIyMzgzNWNjNGIyMWIxYzM2OTAwYmZmNDMyMzdfMTA4ODY_17d0af9c-594d-4b61-9362-9d6608b174e9"><ix:nonFraction unitRef="number" contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630" decimals="2" name="amed:HospiceMedicareRevenueRateAccountedForRoutineCare" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV80My9mcmFnOjFhYzcyMjM4MzVjYzRiMjFiMWMzNjkwMGJmZjQzMjM3L3RleHRyZWdpb246MWFjNzIyMzgzNWNjNGIyMWIxYzM2OTAwYmZmNDMyMzdfMTA4ODY_ad0c75b8-1fa4-4bcc-bc8c-d06fe291405d"><ix:nonFraction unitRef="number" contextRef="i2c8351954d014a1c80a3d8cfc2327ab2_D20200401-20200630" decimals="2" name="amed:HospiceMedicareRevenueRateAccountedForRoutineCare" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV80My9mcmFnOjFhYzcyMjM4MzVjYzRiMjFiMWMzNjkwMGJmZjQzMjM3L3RleHRyZWdpb246MWFjNzIyMzgzNWNjNGIyMWIxYzM2OTAwYmZmNDMyMzdfMTA4ODY_c073d5cf-287c-469d-bc61-ddb23919deab"><ix:nonFraction unitRef="number" contextRef="ib87cee58ccf2448a8d4422101bf61fa0_D20210401-20210630" decimals="2" name="amed:HospiceMedicareRevenueRateAccountedForRoutineCare" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV80My9mcmFnOjFhYzcyMjM4MzVjYzRiMjFiMWMzNjkwMGJmZjQzMjM3L3RleHRyZWdpb246MWFjNzIyMzgzNWNjNGIyMWIxYzM2OTAwYmZmNDMyMzdfMTA4ODY_e41131a7-e5b5-4a61-97c9-49c6912769ef">97</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction>% of our total Medicare hospice service revenue for the three and six-month periods ended June&#160;30, 2021 and June 30, 2020. There are two separate payment rates for routine care: payments for the first 60 days of care and care beyond 60 days. In addition to the two routine rates, we may also receive a service intensity add-on (&#8220;SIA&#8221;). The SIA is based on visits made in the last seven days of life by a registered nurse or medical social worker for patients in a routine level of care.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The performance obligation is the delivery of hospice services to the patient, as determined by a physician, each day the patient is on hospice care.</span></div></ix:continuation></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AMEDISYS, INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></div><ix:continuation id="i95f5d11e07814c73b096d7e812e37c3c" continuedAt="i869572f11db74b7ea49f494f9b616078"><ix:continuation id="i7012eb6e222b484b800e10dc60c54701" continuedAt="id8d386c37c8c4af385aa5241372d65d0"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We make adjustments to Medicare revenue for non-contractual revenue adjustments, which include our inability to obtain appropriate billing documentation or acceptable authorizations and other reasons unrelated to credit risk. We estimate the impact of these non-contractual revenue adjustments based on our historical experience, which primarily includes a historical collection rate of over <ix:nonFraction unitRef="number" contextRef="i741b04b8cd704e398b27520bf8aea7fc_D20210101-20210630" decimals="2" name="amed:HistoricalCollectionRateFromMedicare" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV80My9mcmFnOjFhYzcyMjM4MzVjYzRiMjFiMWMzNjkwMGJmZjQzMjM3L3RleHRyZWdpb246MWFjNzIyMzgzNWNjNGIyMWIxYzM2OTAwYmZmNDMyMzdfMTE5MDM_a27c8f2d-17bd-4baa-8731-aeaa5c43ef54">99</ix:nonFraction>% on Medicare claims, and record it during the period services are rendered.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, our hospice service revenue is subject to certain limitations on payments from Medicare which are considered variable consideration. We are subject to an inpatient cap limit and an overall Medicare payment cap for each provider number. We monitor these caps on a provider-by-provider basis and estimate amounts due back to Medicare if we estimate a cap has been exceeded.&#160;We record these adjustments as a reduction to revenue and an increase in accrued expenses within our condensed consolidated balance sheets. Providers are required to self-report and pay their estimated cap liability by February 28</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">th</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of the following year. As of June&#160;30, 2021, we have recorded $<ix:nonFraction unitRef="usd" contextRef="i35e97441f2084fc28b554985218499ab_I20210630" decimals="-5" format="ixt:numdotdecimal" name="amed:EstimatedAmountDueBackToMedicareInOtherAccruedLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV80My9mcmFnOjFhYzcyMjM4MzVjYzRiMjFiMWMzNjkwMGJmZjQzMjM3L3RleHRyZWdpb246MWFjNzIyMzgzNWNjNGIyMWIxYzM2OTAwYmZmNDMyMzdfMTI2NTA_b65b673a-12fb-4978-b591-76b27dc27876">10.0</ix:nonFraction> million for estimated amounts due back to Medicare in accrued expenses for the Federal cap years ended October&#160;31, 2016 through September 30, 2021; $<ix:nonFraction unitRef="usd" contextRef="i7dc0b5d0b4c04b6ebdca7598a9e533de_I20210630" decimals="-5" format="ixt:numdotdecimal" name="amed:EstimatedAmountDueBackToMedicareInOtherAccruedLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV80My9mcmFnOjFhYzcyMjM4MzVjYzRiMjFiMWMzNjkwMGJmZjQzMjM3L3RleHRyZWdpb246MWFjNzIyMzgzNWNjNGIyMWIxYzM2OTAwYmZmNDMyMzdfMTI3OTM_039486c0-e40b-48ef-b240-09450f7badde">3.1</ix:nonFraction>&#160;million of this balance was acquired with the AseraCare acquisition. As of December&#160;31, 2020, we had recorded $<ix:nonFraction unitRef="usd" contextRef="i4f2f1eaba6994474b883c637fd8bdd09_I20201231" decimals="-5" format="ixt:numdotdecimal" name="amed:EstimatedAmountDueBackToMedicareInOtherAccruedLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV80My9mcmFnOjFhYzcyMjM4MzVjYzRiMjFiMWMzNjkwMGJmZjQzMjM3L3RleHRyZWdpb246MWFjNzIyMzgzNWNjNGIyMWIxYzM2OTAwYmZmNDMyMzdfMTI4ODM_66de6f6f-197a-4d24-8c6d-9425184b5ae0">9.3</ix:nonFraction> million for estimated amounts due back to Medicare in accrued expenses for the Federal cap years ended October&#160;31, 2014 through September 30, 2021.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Hospice Non-Medicare Revenue</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gross revenue is recorded on an accrual basis based upon the date of service at amounts equal to our established rates or estimated per day rates, as applicable. Contractual revenue adjustments are recorded for the difference between our standard rates and the contractual rates to be realized from patients, third-party payors and others for services provided and are deducted from gross revenue to determine our net service revenue. We also make non-contractual adjustments to non-Medicare revenue based on our historical experience to reflect the estimated transaction price.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Personal Care Revenue Recognition</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Personal Care Revenue</span></div></ix:continuation><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="id8d386c37c8c4af385aa5241372d65d0">We generate net service revenues by providing our services directly to patients based on authorized hours, visits or units determined by the relevant agency, at a rate that is either contractual or fixed by legislation. Net service revenue is recognized at the time services are rendered based on gross charges for the services provided, reduced by estimates for contractual and non-contractual revenue adjustments. We receive payment for providing such services from payors, including state and local governmental agencies, managed care organizations, commercial insurers and private consumers. Payors include the following elder service agencies: Aging Services Access Points ("ASAPs"), Senior Care Options ("SCOs"), Program of All-Inclusive Care for the Elderly ("PACE") and the Veterans Administration ("VA").</ix:continuation> </span></div><ix:nonNumeric contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630" name="amed:GovernmentGrantsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV80My9mcmFnOjFhYzcyMjM4MzVjYzRiMjFiMWMzNjkwMGJmZjQzMjM3L3RleHRyZWdpb246MWFjNzIyMzgzNWNjNGIyMWIxYzM2OTAwYmZmNDMyMzdfMjIyMTU_bdff7742-273f-436c-bc08-77b3cf11e81f" escape="true"><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Government Grants</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the absence of specific guidance to account for government grants under U.S. GAAP, we have decided to account for government grants in accordance with International Accounting Standard ("IAS") 20, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounting for Government Grants and Disclosure of Government Assistance</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and as such, we recognize grant income on a systematic basis in line with the recognition of expenses or the loss of revenues for which the grants are intended to compensate. We recognize grants once both of the following conditions are met: (1) we are able to comply with the relevant conditions of the grant and (2) the grant will be received. See Note 3 - Novel Coronavirus Pandemic ("COVID-19") for additional information on our accounting for government funds received under the Coronavirus Aid, Relief and Economic Security Act ("CARES Act") and the Mass Home Care ASAP COVID-19 Provider Sustainability Program.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630" name="us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV80My9mcmFnOjFhYzcyMjM4MzVjYzRiMjFiMWMzNjkwMGJmZjQzMjM3L3RleHRyZWdpb246MWFjNzIyMzgzNWNjNGIyMWIxYzM2OTAwYmZmNDMyMzdfMjIxOTU_df6efdee-7b6d-43e9-ad1b-481812c32b48" continuedAt="ib65827acdd1f478e8d48c95e7ce543f4" escape="true"><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash, Cash Equivalents and Restricted Cash </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents include certificates of deposit and all highly liquid debt instruments with maturities of three months or less when purchased. Our cash balance as of June 30, 2021 includes approximately $<ix:nonFraction unitRef="usd" contextRef="i1e833203be6947b4968aba4d20064ec8_I20210630" decimals="-6" format="ixt:numdotdecimal" name="amed:CashBalanceAssociatedWithProviderReliefFund" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV80My9mcmFnOjFhYzcyMjM4MzVjYzRiMjFiMWMzNjkwMGJmZjQzMjM3L3RleHRyZWdpb246MWFjNzIyMzgzNWNjNGIyMWIxYzM2OTAwYmZmNDMyMzdfMTU2MDQ_ba3a039b-eb4d-48de-b1ce-18dfcb8d74d5">62</ix:nonFraction>&#160;million associated with the CARES Act Provider Relief Fund ("PRF"). We separated the PRF funds into their own account and as of June 30, 2021, we have only transferred funds used through March 31, 2021 to our operating account. We will transfer funds used during the three-month period ended June 30, 2021, totaling approximately $<ix:nonFraction unitRef="usd" contextRef="ib87cee58ccf2448a8d4422101bf61fa0_D20210401-20210630" decimals="-6" format="ixt:numdotdecimal" name="amed:CARESActProviderReliefFundsUtilized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV80My9mcmFnOjFhYzcyMjM4MzVjYzRiMjFiMWMzNjkwMGJmZjQzMjM3L3RleHRyZWdpb246MWFjNzIyMzgzNWNjNGIyMWIxYzM2OTAwYmZmNDMyMzdfMTA5OTUxMTY1MTQ1Nw_e2a0598b-11fd-4c8b-8edf-dc11d9f20b6a">4</ix:nonFraction>&#160;million, to our operating account during the third quarter of 2021 and repay the remaining $<ix:nonFraction unitRef="usd" contextRef="i1e833203be6947b4968aba4d20064ec8_I20210630" decimals="-6" format="ixt:numdotdecimal" name="amed:ProviderReliefFundAdvance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV80My9mcmFnOjFhYzcyMjM4MzVjYzRiMjFiMWMzNjkwMGJmZjQzMjM3L3RleHRyZWdpb246MWFjNzIyMzgzNWNjNGIyMWIxYzM2OTAwYmZmNDMyMzdfMTA5OTUxMTY1MTQ2OQ_d170182c-e2dd-4192-9deb-809780456433">58</ix:nonFraction>&#160;million to the U.S. Department of Health and Human Services ("HHS") by October 30, 2021. Restricted cash includes cash that is not available for ordinary business use. As of June 30, 2021, we had $<ix:nonFraction unitRef="usd" contextRef="iab3b21e1071d46c3a8d7f08560252318_I20210630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RestrictedCash" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV80My9mcmFnOjFhYzcyMjM4MzVjYzRiMjFiMWMzNjkwMGJmZjQzMjM3L3RleHRyZWdpb246MWFjNzIyMzgzNWNjNGIyMWIxYzM2OTAwYmZmNDMyMzdfMTYwOTI_571a0580-31e6-4491-9277-e827b18052c8">1</ix:nonFraction>&#160;million of restricted cash that was placed into an escrow account related to the indemnity and closing payment adjustment provisions within the Asana Hospice purchase agreement.</span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AMEDISYS, INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></div><ix:continuation id="i869572f11db74b7ea49f494f9b616078" continuedAt="i9bc1d303daf64cbfa279643e9208b223"><div style="margin-top:9pt;text-align:justify"><ix:continuation id="ib65827acdd1f478e8d48c95e7ce543f4"><ix:nonNumeric contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630" name="amed:ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlockTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV80My9mcmFnOjFhYzcyMjM4MzVjYzRiMjFiMWMzNjkwMGJmZjQzMjM3L3RleHRyZWdpb246MWFjNzIyMzgzNWNjNGIyMWIxYzM2OTAwYmZmNDMyMzdfMjIyMjI_1f50dfb4-88bc-48fb-ac47-83b59076881d" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the balances related to our cash, cash equivalents and restricted cash (amounts in millions):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.250%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.981%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.739%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of June 30, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e833203be6947b4968aba4d20064ec8_I20210630" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV80My9mcmFnOjFhYzcyMjM4MzVjYzRiMjFiMWMzNjkwMGJmZjQzMjM3L3RhYmxlOjUyYTkwZWRjMDcxNDRjOGRhMDlhODU4ZTQ0MTgyNmMzL3RhYmxlcmFuZ2U6NTJhOTBlZGMwNzE0NGM4ZGEwOWE4NThlNDQxODI2YzNfMS0xLTEtMS0w_15453cf3-9f8c-4991-a680-f20efa99ab81">91.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87ceb60dc20d4df1b0a97d3514837910_I20201231" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV80My9mcmFnOjFhYzcyMjM4MzVjYzRiMjFiMWMzNjkwMGJmZjQzMjM3L3RhYmxlOjUyYTkwZWRjMDcxNDRjOGRhMDlhODU4ZTQ0MTgyNmMzL3RhYmxlcmFuZ2U6NTJhOTBlZGMwNzE0NGM4ZGEwOWE4NThlNDQxODI2YzNfMS0zLTEtMS0w_5b5796af-a2fc-4157-ad6e-4b1c4750b117">81.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e833203be6947b4968aba4d20064ec8_I20210630" decimals="-5" name="us-gaap:RestrictedCash" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV80My9mcmFnOjFhYzcyMjM4MzVjYzRiMjFiMWMzNjkwMGJmZjQzMjM3L3RhYmxlOjUyYTkwZWRjMDcxNDRjOGRhMDlhODU4ZTQ0MTgyNmMzL3RhYmxlcmFuZ2U6NTJhOTBlZGMwNzE0NGM4ZGEwOWE4NThlNDQxODI2YzNfMi0xLTEtMS0w_4915d956-f142-4862-8306-74db5932c829">1.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87ceb60dc20d4df1b0a97d3514837910_I20201231" decimals="-5" name="us-gaap:RestrictedCash" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV80My9mcmFnOjFhYzcyMjM4MzVjYzRiMjFiMWMzNjkwMGJmZjQzMjM3L3RhYmxlOjUyYTkwZWRjMDcxNDRjOGRhMDlhODU4ZTQ0MTgyNmMzL3RhYmxlcmFuZ2U6NTJhOTBlZGMwNzE0NGM4ZGEwOWE4NThlNDQxODI2YzNfMi0zLTEtMS0w_c4e0317f-29dc-40b0-8d8a-81149546fe6f">1.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e833203be6947b4968aba4d20064ec8_I20210630" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV80My9mcmFnOjFhYzcyMjM4MzVjYzRiMjFiMWMzNjkwMGJmZjQzMjM3L3RhYmxlOjUyYTkwZWRjMDcxNDRjOGRhMDlhODU4ZTQ0MTgyNmMzL3RhYmxlcmFuZ2U6NTJhOTBlZGMwNzE0NGM4ZGEwOWE4NThlNDQxODI2YzNfMy0xLTEtMS0w_f50a2b4e-3a00-40c2-9e22-6ddc4116dbb6">92.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83.3&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></ix:continuation></div><ix:nonNumeric contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630" name="us-gaap:TradeAndOtherAccountsReceivablePolicy" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV80My9mcmFnOjFhYzcyMjM4MzVjYzRiMjFiMWMzNjkwMGJmZjQzMjM3L3RleHRyZWdpb246MWFjNzIyMzgzNWNjNGIyMWIxYzM2OTAwYmZmNDMyMzdfMjIyMjM_45f99aff-36cc-4a95-b609-4ab4f52442da" continuedAt="i390f26efa74b4d2b94bbae1c2d38ccb7" escape="true"><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Patient Accounts Receivable </span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We report accounts receivable from services rendered at their estimated transaction price, which includes contractual and non-contractual revenue adjustments based on the amounts expected to be due from payors. Our patient accounts receivable are uncollateralized and consist of amounts due from Medicare, Medicaid, other third-party payors and patients. The Company's non-Medicare third-party payor base is comprised of a diverse group of payors that are geographically dispersed across the country. As of June&#160;30, 2021, there is one payor, other than Medicare, that accounts for <ix:nonFraction unitRef="number" contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630" decimals="INF" name="amed:PercentageOfPatientReceivablesOutstanding" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV80My9mcmFnOjFhYzcyMjM4MzVjYzRiMjFiMWMzNjkwMGJmZjQzMjM3L3RleHRyZWdpb246MWFjNzIyMzgzNWNjNGIyMWIxYzM2OTAwYmZmNDMyMzdfMTcwMDc_fa445008-a4a8-4c7d-a935-296fe4ae32c8">10</ix:nonFraction>% of our total outstanding patient receivables. Thus, we believe there are no other significant concentrations of receivables that would subject us to any significant credit risk in the collection of our patient accounts receivable. We write off accounts on a monthly basis once we have exhausted our collection efforts and deem an account to be uncollectible. We believe the collectability risk associated with our Medicare accounts, which represent <ix:nonFraction unitRef="number" contextRef="i1e833203be6947b4968aba4d20064ec8_I20210630" decimals="2" name="amed:AccountsReceivablePortionDerivedFromMedicare" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV80My9mcmFnOjFhYzcyMjM4MzVjYzRiMjFiMWMzNjkwMGJmZjQzMjM3L3RleHRyZWdpb246MWFjNzIyMzgzNWNjNGIyMWIxYzM2OTAwYmZmNDMyMzdfMTc0NTk_a0de9bb8-b012-4e2d-8c99-d42a99ea45ba">66</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i87ceb60dc20d4df1b0a97d3514837910_I20201231" decimals="2" name="amed:AccountsReceivablePortionDerivedFromMedicare" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV80My9mcmFnOjFhYzcyMjM4MzVjYzRiMjFiMWMzNjkwMGJmZjQzMjM3L3RleHRyZWdpb246MWFjNzIyMzgzNWNjNGIyMWIxYzM2OTAwYmZmNDMyMzdfMTc0NjY_bebdcb57-32b3-4f3d-9545-924c09b2d3f2">64</ix:nonFraction>% of our patient accounts receivable at June&#160;30, 2021 and December&#160;31, 2020, respectively, is limited due to our historical collection rate of over <ix:nonFraction unitRef="number" contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630" decimals="2" name="amed:HistoricalCollectionRateFromMedicare" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV80My9mcmFnOjFhYzcyMjM4MzVjYzRiMjFiMWMzNjkwMGJmZjQzMjM3L3RleHRyZWdpb246MWFjNzIyMzgzNWNjNGIyMWIxYzM2OTAwYmZmNDMyMzdfMTc1ODk_67147559-c19d-46a3-9e5b-32ef2058bc63">99</ix:nonFraction>% from Medicare and the fact that Medicare is a U.S. government payor. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not believe there are any significant concentrations of revenues from any payor that would subject us to any significant credit risk in the collection of our accounts receivable.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Medicare Home Health</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For our home health patients, our pre-billing process includes verifying that we are eligible for payment from Medicare for the services that we provide to our patients. Our Medicare billing begins with a process to ensure that our billings are accurate through the utilization of an electronic Medicare claim review. Prior to January 1, 2021, we submitted a RAP for <ix:nonFraction unitRef="number" contextRef="id4b15251aa8147bcb0b8c78424ea981c_D20200101-20201231" decimals="2" name="amed:RateOfRequestForAnticipatedPaymentSubmittedForInitialPeriodOfCare" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV80My9mcmFnOjFhYzcyMjM4MzVjYzRiMjFiMWMzNjkwMGJmZjQzMjM3L3RleHRyZWdpb246MWFjNzIyMzgzNWNjNGIyMWIxYzM2OTAwYmZmNDMyMzdfMTgyMzU_16c74f5f-66ef-44b8-8b79-7365f17d5cc8">20</ix:nonFraction>% of our estimated payment for each <ix:nonNumeric contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630" format="ixt-sec:durday" name="amed:NetServiceRevenuePeriodOfCarePaymentRateDuration" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV80My9mcmFnOjFhYzcyMjM4MzVjYzRiMjFiMWMzNjkwMGJmZjQzMjM3L3RleHRyZWdpb246MWFjNzIyMzgzNWNjNGIyMWIxYzM2OTAwYmZmNDMyMzdfMTgyNzI_c8ec9856-233e-4ffd-8c0e-6ba23a5eb52b">30</ix:nonNumeric>-day period of care. The RAP received was then deducted from our final payment. Effective January 1, 2021, CMS eliminated all upfront payments associated with RAPs.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Medicare Hospice</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For our hospice patients, our pre-billing process includes verifying that we are eligible for payment from Medicare for the services that we provide to our patients. Our Medicare billing begins with a process to ensure that our billings are accurate through the utilization of an electronic Medicare claim review. We bill Medicare on a monthly basis for the services provided to the patient.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Non-Medicare Home Health, Hospice and Personal Care</span></div></ix:nonNumeric><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i390f26efa74b4d2b94bbae1c2d38ccb7">For our non-Medicare patients, our pre-billing process primarily begins with verifying a patient&#8217;s eligibility for services with the applicable payor. Once the patient has been confirmed for eligibility, we will provide services to the patient and bill the applicable payor. Our review and evaluation of non-Medicare accounts receivable includes a detailed review of outstanding balances and special consideration to concentrations of receivables from particular payors or groups of payors with similar characteristics that would subject us to any significant credit risk.</ix:continuation> </span></div><ix:nonNumeric contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630" name="us-gaap:BusinessCombinationsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV80My9mcmFnOjFhYzcyMjM4MzVjYzRiMjFiMWMzNjkwMGJmZjQzMjM3L3RleHRyZWdpb246MWFjNzIyMzgzNWNjNGIyMWIxYzM2OTAwYmZmNDMyMzdfMjIyMTc_53883c45-c02b-40eb-9e85-28ea4b2de2c6" escape="true"><div style="margin-top:16pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Business Combinations</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We account for acquisitions using the acquisition method of accounting in accordance with ASC 805, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business Combinations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Acquisitions are accounted for as purchases and are included in our condensed consolidated financial statements from their respective acquisition dates. Assets acquired and liabilities assumed, if any, are measured at fair value on the acquisition date using the appropriate valuation method. Goodwill generated from acquisitions is recognized for the excess of the purchase price over tangible and identifiable intangible assets. In determining the fair value of identifiable intangible assets, we use various valuation techniques including discounted cash flow analysis, the income approach, the cost approach and the market approach. These valuation methods require us to make estimates and assumptions surrounding projected revenues and costs, growth rates and discount rates.</span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AMEDISYS, INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></div><ix:continuation id="i9bc1d303daf64cbfa279643e9208b223"><ix:nonNumeric contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630" name="us-gaap:FairValueOfFinancialInstrumentsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV80My9mcmFnOjFhYzcyMjM4MzVjYzRiMjFiMWMzNjkwMGJmZjQzMjM3L3RleHRyZWdpb246MWFjNzIyMzgzNWNjNGIyMWIxYzM2OTAwYmZmNDMyMzdfMjIyMDc_d0dd18bc-7d00-48dd-9797-e04fb47acffd" continuedAt="i34c826380e994b8fa7a6cb8e73db79e0" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value of Financial Instruments</span></div><ix:nonNumeric contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630" name="amed:FinancialInstrumentDetailsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV80My9mcmFnOjFhYzcyMjM4MzVjYzRiMjFiMWMzNjkwMGJmZjQzMjM3L3RleHRyZWdpb246MWFjNzIyMzgzNWNjNGIyMWIxYzM2OTAwYmZmNDMyMzdfMjIyMTg_80157f4e-fbeb-449f-8be1-03fccae02278" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following details our financial instruments where the carrying value and the fair value differ (amounts in millions):</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.076%"><tr><td style="width:1.0%"></td><td style="width:24.954%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.821%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.553%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.821%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.553%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.821%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.553%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.824%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value at Reporting Date Using</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Financial Instrument</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying Value as of June 30, 2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted&#160;Prices&#160;in&#160;Active<br/>Markets for Identical<br/>Items<br/>(Level 1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant&#160;Other<br/>Observable&#160;Inputs<br/>(Level 2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Unobservable&#160;Inputs<br/>(Level&#160;3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term obligations</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e833203be6947b4968aba4d20064ec8_I20210630" decimals="-5" name="amed:DebtInstrumentCarryingAmountExcludingFinanceLeases" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV80My9mcmFnOjFhYzcyMjM4MzVjYzRiMjFiMWMzNjkwMGJmZjQzMjM3L3RhYmxlOjQ4OGIwNmJjNTQ0ZjQ0OWY5YTk5YjMxY2NmNjJhMTg5L3RhYmxlcmFuZ2U6NDg4YjA2YmM1NDRmNDQ5ZjlhOTliMzFjY2Y2MmExODlfMi0xLTEtMS0w_e98fe29d-5127-414d-b6ac-93f8e547bd6f">189.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1dcbe4b6aa344ddad5971d791de6929_I20210630" decimals="1" format="ixt:zerodash" name="us-gaap:LongTermDebtFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV80My9mcmFnOjFhYzcyMjM4MzVjYzRiMjFiMWMzNjkwMGJmZjQzMjM3L3RhYmxlOjQ4OGIwNmJjNTQ0ZjQ0OWY5YTk5YjMxY2NmNjJhMTg5L3RhYmxlcmFuZ2U6NDg4YjA2YmM1NDRmNDQ5ZjlhOTliMzFjY2Y2MmExODlfMi0zLTEtMS0w_c79abc11-059e-4740-97ef-d1455e545e42">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd69fb45b72f455583eebe90df674886_I20210630" decimals="-5" name="us-gaap:LongTermDebtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV80My9mcmFnOjFhYzcyMjM4MzVjYzRiMjFiMWMzNjkwMGJmZjQzMjM3L3RhYmxlOjQ4OGIwNmJjNTQ0ZjQ0OWY5YTk5YjMxY2NmNjJhMTg5L3RhYmxlcmFuZ2U6NDg4YjA2YmM1NDRmNDQ5ZjlhOTliMzFjY2Y2MmExODlfMi01LTEtMS0w_7e252d74-ae19-4722-b021-b9629c9c91c7">191.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c7cadad474d42da9b01844212441bf3_I20210630" decimals="1" format="ixt:zerodash" name="us-gaap:LongTermDebtFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV80My9mcmFnOjFhYzcyMjM4MzVjYzRiMjFiMWMzNjkwMGJmZjQzMjM3L3RhYmxlOjQ4OGIwNmJjNTQ0ZjQ0OWY5YTk5YjMxY2NmNjJhMTg5L3RhYmxlcmFuZ2U6NDg4YjA2YmM1NDRmNDQ5ZjlhOTliMzFjY2Y2MmExODlfMi03LTEtMS0w_8fda96c5-7e3a-415a-b9e5-0dd330d3b947">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value hierarchy is based on three levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value. The three levels of inputs are as follows:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level&#160;1 &#8211; Quoted prices in active markets for identical assets and liabilities.</span></div><div style="padding-left:36pt;text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level&#160;2 &#8211; Inputs other than Level&#160;1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.</span></div><div style="padding-left:36pt;text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level&#160;3 &#8211; Unobservable inputs that are supported by little or no market activity and are significant to the fair value of the assets or liabilities.</span></div></ix:nonNumeric><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i34c826380e994b8fa7a6cb8e73db79e0">Our deferred compensation plan assets are recorded at fair value and are considered a level 2 measurement. For our other financial instruments, including our cash and cash equivalents, patient accounts receivable, accounts payable, payroll and employee benefits and accrued expenses, we estimate the carrying amounts approximate fair value.</ix:continuation> </span></div><div style="margin-top:16pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630" name="us-gaap:EarningsPerSharePolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV80My9mcmFnOjFhYzcyMjM4MzVjYzRiMjFiMWMzNjkwMGJmZjQzMjM3L3RleHRyZWdpb246MWFjNzIyMzgzNWNjNGIyMWIxYzM2OTAwYmZmNDMyMzdfMjIyMDQ_2b80b271-b442-4a5e-a632-8014223cb0c1" continuedAt="id4a0b59dc0854f8bab74a7745a517eda" escape="true">Weighted-Average Shares Outstanding</ix:nonNumeric></span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="id4a0b59dc0854f8bab74a7745a517eda">Net income per share attributable to Amedisys, Inc. common stockholders, calculated on the treasury stock method, is based on the weighted average number of shares outstanding during the period.</ix:continuation> <ix:nonNumeric contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630" name="us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV80My9mcmFnOjFhYzcyMjM4MzVjYzRiMjFiMWMzNjkwMGJmZjQzMjM3L3RleHRyZWdpb246MWFjNzIyMzgzNWNjNGIyMWIxYzM2OTAwYmZmNDMyMzdfMjIxOTc_56b6d27d-bb89-4a68-930e-41be7e1edeca" continuedAt="i4baae727a0be461c8bc0ba445d9d15fd" escape="true">The following table sets forth, for the periods indicated, shares used in our computation of the weighted-average shares outstanding, which are used to calculate our basic and diluted net income attributable to Amedisys, Inc. common stockholders (amounts in thousands):</ix:nonNumeric></span></div><div style="margin-top:6pt;text-align:justify"><ix:continuation id="i4baae727a0be461c8bc0ba445d9d15fd"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.829%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.624%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three-<br/>Month Periods<br/>Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Six-<br/>Month Periods<br/>Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average number of shares outstanding - basic</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib87cee58ccf2448a8d4422101bf61fa0_D20210401-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV80My9mcmFnOjFhYzcyMjM4MzVjYzRiMjFiMWMzNjkwMGJmZjQzMjM3L3RhYmxlOjY3MDk3MTFjMWQ5ZDRkMzFiM2M0Y2Q5ZWY5NTAwZjBmL3RhYmxlcmFuZ2U6NjcwOTcxMWMxZDlkNGQzMWIzYzRjZDllZjk1MDBmMGZfMi0xLTEtMS0w_489e8a24-51ff-410b-90ca-79fc713c60d4">32,588</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2c8351954d014a1c80a3d8cfc2327ab2_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV80My9mcmFnOjFhYzcyMjM4MzVjYzRiMjFiMWMzNjkwMGJmZjQzMjM3L3RhYmxlOjY3MDk3MTFjMWQ5ZDRkMzFiM2M0Y2Q5ZWY5NTAwZjBmL3RhYmxlcmFuZ2U6NjcwOTcxMWMxZDlkNGQzMWIzYzRjZDllZjk1MDBmMGZfMi0zLTEtMS0w_c70863ba-f9a5-4201-8d7e-f8f22280f88b">32,412</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV80My9mcmFnOjFhYzcyMjM4MzVjYzRiMjFiMWMzNjkwMGJmZjQzMjM3L3RhYmxlOjY3MDk3MTFjMWQ5ZDRkMzFiM2M0Y2Q5ZWY5NTAwZjBmL3RhYmxlcmFuZ2U6NjcwOTcxMWMxZDlkNGQzMWIzYzRjZDllZjk1MDBmMGZfMi01LTEtMS0zNDY_4382e839-aab0-42d7-8628-715602410fc5">32,684</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i667fa0996400408f9cb2d7f4d3ee2087_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV80My9mcmFnOjFhYzcyMjM4MzVjYzRiMjFiMWMzNjkwMGJmZjQzMjM3L3RhYmxlOjY3MDk3MTFjMWQ5ZDRkMzFiM2M0Y2Q5ZWY5NTAwZjBmL3RhYmxlcmFuZ2U6NjcwOTcxMWMxZDlkNGQzMWIzYzRjZDllZjk1MDBmMGZfMi03LTEtMS0zNDY_e31c9efc-ae8c-499d-b9e5-7fe424086c58">32,371</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of dilutive securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib87cee58ccf2448a8d4422101bf61fa0_D20210401-20210630" decimals="-3" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV80My9mcmFnOjFhYzcyMjM4MzVjYzRiMjFiMWMzNjkwMGJmZjQzMjM3L3RhYmxlOjY3MDk3MTFjMWQ5ZDRkMzFiM2M0Y2Q5ZWY5NTAwZjBmL3RhYmxlcmFuZ2U6NjcwOTcxMWMxZDlkNGQzMWIzYzRjZDllZjk1MDBmMGZfNC0xLTEtMS0w_4acac316-c23c-423f-a6d2-10ba16b51502">139</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2c8351954d014a1c80a3d8cfc2327ab2_D20200401-20200630" decimals="-3" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV80My9mcmFnOjFhYzcyMjM4MzVjYzRiMjFiMWMzNjkwMGJmZjQzMjM3L3RhYmxlOjY3MDk3MTFjMWQ5ZDRkMzFiM2M0Y2Q5ZWY5NTAwZjBmL3RhYmxlcmFuZ2U6NjcwOTcxMWMxZDlkNGQzMWIzYzRjZDllZjk1MDBmMGZfNC0zLTEtMS0w_eaf4df70-1946-4e62-a6c1-c31d93a913a0">570</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630" decimals="-3" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV80My9mcmFnOjFhYzcyMjM4MzVjYzRiMjFiMWMzNjkwMGJmZjQzMjM3L3RhYmxlOjY3MDk3MTFjMWQ5ZDRkMzFiM2M0Y2Q5ZWY5NTAwZjBmL3RhYmxlcmFuZ2U6NjcwOTcxMWMxZDlkNGQzMWIzYzRjZDllZjk1MDBmMGZfNC01LTEtMS0zNDY_732c454c-9eb0-4b8a-aa80-4dd2c368bb61">145</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i667fa0996400408f9cb2d7f4d3ee2087_D20200101-20200630" decimals="-3" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV80My9mcmFnOjFhYzcyMjM4MzVjYzRiMjFiMWMzNjkwMGJmZjQzMjM3L3RhYmxlOjY3MDk3MTFjMWQ5ZDRkMzFiM2M0Y2Q5ZWY5NTAwZjBmL3RhYmxlcmFuZ2U6NjcwOTcxMWMxZDlkNGQzMWIzYzRjZDllZjk1MDBmMGZfNC03LTEtMS0zNDY_ba4f0fbc-a501-4597-ada9-a50243b4e11e">582</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:20.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-vested stock and stock units</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib87cee58ccf2448a8d4422101bf61fa0_D20210401-20210630" decimals="-3" name="amed:NonVestedStockAndStockUnits" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV80My9mcmFnOjFhYzcyMjM4MzVjYzRiMjFiMWMzNjkwMGJmZjQzMjM3L3RhYmxlOjY3MDk3MTFjMWQ5ZDRkMzFiM2M0Y2Q5ZWY5NTAwZjBmL3RhYmxlcmFuZ2U6NjcwOTcxMWMxZDlkNGQzMWIzYzRjZDllZjk1MDBmMGZfNS0xLTEtMS0w_aebb5ddd-5d57-41fe-8728-139fa998de19">254</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2c8351954d014a1c80a3d8cfc2327ab2_D20200401-20200630" decimals="-3" name="amed:NonVestedStockAndStockUnits" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV80My9mcmFnOjFhYzcyMjM4MzVjYzRiMjFiMWMzNjkwMGJmZjQzMjM3L3RhYmxlOjY3MDk3MTFjMWQ5ZDRkMzFiM2M0Y2Q5ZWY5NTAwZjBmL3RhYmxlcmFuZ2U6NjcwOTcxMWMxZDlkNGQzMWIzYzRjZDllZjk1MDBmMGZfNS0zLTEtMS0w_bd672d2c-83d3-44a8-a6c6-fddf165075d6">303</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630" decimals="-3" name="amed:NonVestedStockAndStockUnits" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV80My9mcmFnOjFhYzcyMjM4MzVjYzRiMjFiMWMzNjkwMGJmZjQzMjM3L3RhYmxlOjY3MDk3MTFjMWQ5ZDRkMzFiM2M0Y2Q5ZWY5NTAwZjBmL3RhYmxlcmFuZ2U6NjcwOTcxMWMxZDlkNGQzMWIzYzRjZDllZjk1MDBmMGZfNS01LTEtMS0zNDY_2b86e38a-e494-44d1-a858-68209914f0b5">256</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i667fa0996400408f9cb2d7f4d3ee2087_D20200101-20200630" decimals="-3" name="amed:NonVestedStockAndStockUnits" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV80My9mcmFnOjFhYzcyMjM4MzVjYzRiMjFiMWMzNjkwMGJmZjQzMjM3L3RhYmxlOjY3MDk3MTFjMWQ5ZDRkMzFiM2M0Y2Q5ZWY5NTAwZjBmL3RhYmxlcmFuZ2U6NjcwOTcxMWMxZDlkNGQzMWIzYzRjZDllZjk1MDBmMGZfNS03LTEtMS0zNDY_7fb5bd72-9174-438a-8673-92de7d837cec">306</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average number of shares outstanding - diluted</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib87cee58ccf2448a8d4422101bf61fa0_D20210401-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV80My9mcmFnOjFhYzcyMjM4MzVjYzRiMjFiMWMzNjkwMGJmZjQzMjM3L3RhYmxlOjY3MDk3MTFjMWQ5ZDRkMzFiM2M0Y2Q5ZWY5NTAwZjBmL3RhYmxlcmFuZ2U6NjcwOTcxMWMxZDlkNGQzMWIzYzRjZDllZjk1MDBmMGZfNi0xLTEtMS0w_7e962dc4-7cfe-40c6-9df7-f551a603bf59">32,981</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2c8351954d014a1c80a3d8cfc2327ab2_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV80My9mcmFnOjFhYzcyMjM4MzVjYzRiMjFiMWMzNjkwMGJmZjQzMjM3L3RhYmxlOjY3MDk3MTFjMWQ5ZDRkMzFiM2M0Y2Q5ZWY5NTAwZjBmL3RhYmxlcmFuZ2U6NjcwOTcxMWMxZDlkNGQzMWIzYzRjZDllZjk1MDBmMGZfNi0zLTEtMS0w_5dd212d7-4181-463e-a794-a736b30a2fa7">33,285</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV80My9mcmFnOjFhYzcyMjM4MzVjYzRiMjFiMWMzNjkwMGJmZjQzMjM3L3RhYmxlOjY3MDk3MTFjMWQ5ZDRkMzFiM2M0Y2Q5ZWY5NTAwZjBmL3RhYmxlcmFuZ2U6NjcwOTcxMWMxZDlkNGQzMWIzYzRjZDllZjk1MDBmMGZfNi01LTEtMS0zNDY_41083f01-179c-4ebb-b9ef-52a7218cc7c2">33,085</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i667fa0996400408f9cb2d7f4d3ee2087_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV80My9mcmFnOjFhYzcyMjM4MzVjYzRiMjFiMWMzNjkwMGJmZjQzMjM3L3RhYmxlOjY3MDk3MTFjMWQ5ZDRkMzFiM2M0Y2Q5ZWY5NTAwZjBmL3RhYmxlcmFuZ2U6NjcwOTcxMWMxZDlkNGQzMWIzYzRjZDllZjk1MDBmMGZfNi03LTEtMS0zNDY_2110e176-c79e-47df-a0bb-e7d135536810">33,259</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Anti-dilutive securities</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib87cee58ccf2448a8d4422101bf61fa0_D20210401-20210630" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV80My9mcmFnOjFhYzcyMjM4MzVjYzRiMjFiMWMzNjkwMGJmZjQzMjM3L3RhYmxlOjY3MDk3MTFjMWQ5ZDRkMzFiM2M0Y2Q5ZWY5NTAwZjBmL3RhYmxlcmFuZ2U6NjcwOTcxMWMxZDlkNGQzMWIzYzRjZDllZjk1MDBmMGZfNy0xLTEtMS0w_f89d5313-5933-419f-9899-3d5bd4f6fdc3">71</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2c8351954d014a1c80a3d8cfc2327ab2_D20200401-20200630" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV80My9mcmFnOjFhYzcyMjM4MzVjYzRiMjFiMWMzNjkwMGJmZjQzMjM3L3RhYmxlOjY3MDk3MTFjMWQ5ZDRkMzFiM2M0Y2Q5ZWY5NTAwZjBmL3RhYmxlcmFuZ2U6NjcwOTcxMWMxZDlkNGQzMWIzYzRjZDllZjk1MDBmMGZfNy0zLTEtMS0w_6950040d-9361-4368-be33-7eb845a9177c">14</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV80My9mcmFnOjFhYzcyMjM4MzVjYzRiMjFiMWMzNjkwMGJmZjQzMjM3L3RhYmxlOjY3MDk3MTFjMWQ5ZDRkMzFiM2M0Y2Q5ZWY5NTAwZjBmL3RhYmxlcmFuZ2U6NjcwOTcxMWMxZDlkNGQzMWIzYzRjZDllZjk1MDBmMGZfNy01LTEtMS0zNDY_12fa0532-7880-4bd3-a457-35f765e6b46e">58</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i667fa0996400408f9cb2d7f4d3ee2087_D20200101-20200630" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV80My9mcmFnOjFhYzcyMjM4MzVjYzRiMjFiMWMzNjkwMGJmZjQzMjM3L3RhYmxlOjY3MDk3MTFjMWQ5ZDRkMzFiM2M0Y2Q5ZWY5NTAwZjBmL3RhYmxlcmFuZ2U6NjcwOTcxMWMxZDlkNGQzMWIzYzRjZDllZjk1MDBmMGZfNy03LTEtMS0zNDY_38a1f5d8-eabd-4e1a-b437-444d65521ec3">21</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div></ix:continuation><div style="margin-top:16pt;text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><div id="iccd9c69ecd2c42e5897cfe9ab4e7e0b5_49"></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AMEDISYS, INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3.&#160;<ix:nonNumeric contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630" name="amed:COVID19TextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV80OS9mcmFnOjA5MTE3NmEwOTJiMDQ0ODliYjQ5MDRhYTc5ODMyOTlhL3RleHRyZWdpb246MDkxMTc2YTA5MmIwNDQ4OWJiNDkwNGFhNzk4MzI5OWFfNTQzNw_ca6095cf-2e42-48a5-93ae-45b396985747" continuedAt="i9f6d5c110c88439ebf4e3b0ba6d46a6e" escape="true">NOVEL CORONAVIRUS PANDEMIC ("COVID-19")</ix:nonNumeric></span></div><ix:continuation id="i9f6d5c110c88439ebf4e3b0ba6d46a6e" continuedAt="if0457d4f2742417f99fe3629f7cd0823"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, the World Health Organization declared COVID-19 a pandemic. As a healthcare at home company, we have been and will continue to be impacted by the effects of COVID-19; however, we remain committed to carrying out our mission of caring for our patients. We will continue to closely monitor the impact of COVID-19 on all aspects of our business, including the impacts to our employees, patients and suppliers; however, at this time, we are unable to estimate the ultimate impact the pandemic will have on our consolidated financial condition, results of operations or cash flows.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 27, 2020, the CARES Act was signed into legislation. The CARES Act provided for $<ix:nonFraction unitRef="usd" contextRef="i0c4514a4ad16425f82d85ae99b3a59c1_I20200327" decimals="-9" format="ixt:numdotdecimal" name="amed:FundingForHealthcareProvidersIncludingHospitals" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV80OS9mcmFnOjA5MTE3NmEwOTJiMDQ0ODliYjQ5MDRhYTc5ODMyOTlhL3RleHRyZWdpb246MDkxMTc2YTA5MmIwNDQ4OWJiNDkwNGFhNzk4MzI5OWFfNzI5_f21de53c-0cbe-465c-b93a-2616006924a1">175</ix:nonFraction>&#160;billion to healthcare providers, including hospitals on the front lines of the COVID-19 pandemic. Of this total allocated amount, $<ix:nonFraction unitRef="usd" contextRef="i0c4514a4ad16425f82d85ae99b3a59c1_I20200327" decimals="-9" format="ixt:numdotdecimal" name="amed:FundingImmediatelyDistributedToHealthcareProvidersBasedOnTheir2019MedicareFeeForServiceReimbursements" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV80OS9mcmFnOjA5MTE3NmEwOTJiMDQ0ODliYjQ5MDRhYTc5ODMyOTlhL3RleHRyZWdpb246MDkxMTc2YTA5MmIwNDQ4OWJiNDkwNGFhNzk4MzI5OWFfODU0_4e79cad8-fd84-467b-bf04-f28d4c9b0813">30</ix:nonFraction>&#160;billion was distributed immediately to providers based on their proportionate share of Medicare fee-for-service reimbursements in 2019. Healthcare providers were required to sign an attestation confirming receipt of the Provider Relief Fund ("PRF") funds and agree to the terms and conditions of payment. Our home health and hospice segments received approximately $<ix:nonFraction unitRef="usd" contextRef="iac8bb77409a847a08a3de53000ce0e86_D20200401-20200430" decimals="-6" format="ixt:numdotdecimal" name="amed:FundingReceivedFromCARESAct" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV80OS9mcmFnOjA5MTE3NmEwOTJiMDQ0ODliYjQ5MDRhYTc5ODMyOTlhL3RleHRyZWdpb246MDkxMTc2YTA5MmIwNDQ4OWJiNDkwNGFhNzk4MzI5OWFfMTIxNA_6408e84e-7741-4dac-96d0-118679ec33c5">100</ix:nonFraction>&#160;million from the first $<ix:nonFraction unitRef="usd" contextRef="i0c4514a4ad16425f82d85ae99b3a59c1_I20200327" decimals="-9" format="ixt:numdotdecimal" name="amed:FundingImmediatelyDistributedToHealthcareProvidersBasedOnTheir2019MedicareFeeForServiceReimbursements" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV80OS9mcmFnOjA5MTE3NmEwOTJiMDQ0ODliYjQ5MDRhYTc5ODMyOTlhL3RleHRyZWdpb246MDkxMTc2YTA5MmIwNDQ4OWJiNDkwNGFhNzk4MzI5OWFfMTIzMg_09d5c8b8-591b-4b60-b051-9779497d69fb">30</ix:nonFraction>&#160;billion of funds distributed to healthcare providers in April 2020, which is inclusive of $<ix:nonFraction unitRef="usd" contextRef="i5e57d112c8b243c6ad6311b3c05c5d43_D20200401-20200430" decimals="-6" format="ixt:numdotdecimal" name="amed:FundingReceivedFromCARESAct" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV80OS9mcmFnOjA5MTE3NmEwOTJiMDQ0ODliYjQ5MDRhYTc5ODMyOTlhL3RleHRyZWdpb246MDkxMTc2YTA5MmIwNDQ4OWJiNDkwNGFhNzk4MzI5OWFfMTMxNw_37792bc1-2796-4378-a17e-2c0b4bed9de2">2</ix:nonFraction>&#160;million related to our joint venture care centers (equity method investments). We also acquired approximately $<ix:nonFraction unitRef="usd" contextRef="id175698a0fde4ea494dd3ebf050a22e3_D20200401-20200430" decimals="-6" format="ixt:numdotdecimal" name="amed:FundingReceivedFromCARESAct" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV80OS9mcmFnOjA5MTE3NmEwOTJiMDQ0ODliYjQ5MDRhYTc5ODMyOTlhL3RleHRyZWdpb246MDkxMTc2YTA5MmIwNDQ4OWJiNDkwNGFhNzk4MzI5OWFfMTQyMg_08f2b868-c8a0-4dac-aaad-a6ab70aab71d">6</ix:nonFraction>&#160;million of PRF funds in connection with the acquisition of AseraCare. Under the terms and conditions for receipt of the payment, we are allowed to use the funds to cover lost revenues and health care costs related to COVID-19, and we are required to properly and fully document the use of these funds in reports to the U.S. Department of Health and Human Services ("HHS"). </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For our wholly-owned subsidiaries, we have decided to only utilize PRF funds to the extent we have qualifying COVID-19 expenses, which totaled $<ix:nonFraction unitRef="usd" contextRef="ic7961b340f674cd8b10f0d54284e1eef_D20210401-20210630" decimals="-6" format="ixt:numdotdecimal" name="amed:COVID19ExpensesIncurred" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV80OS9mcmFnOjA5MTE3NmEwOTJiMDQ0ODliYjQ5MDRhYTc5ODMyOTlhL3RleHRyZWdpb246MDkxMTc2YTA5MmIwNDQ4OWJiNDkwNGFhNzk4MzI5OWFfMTkzNA_06871c5e-b179-4cd6-adc2-409389f015ea">5</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="ia821fd814fc04a678988e6c92ea2a385_D20210101-20210630" decimals="-6" format="ixt:numdotdecimal" name="amed:COVID19ExpensesIncurred" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV80OS9mcmFnOjA5MTE3NmEwOTJiMDQ0ODliYjQ5MDRhYTc5ODMyOTlhL3RleHRyZWdpb246MDkxMTc2YTA5MmIwNDQ4OWJiNDkwNGFhNzk4MzI5OWFfMTA5OTUxMTYzNjAwOQ_764df396-af0c-4ccd-8450-4b3b97f6d42c">13</ix:nonFraction>&#160;million for our home health and hospice segments during the three and six-month periods ended June 30, 2021, respectively, and $<ix:nonFraction unitRef="usd" contextRef="i1c8d3b2b4c064d6a90ebefef21edaeb5_D20200401-20200630" decimals="-6" format="ixt:numdotdecimal" name="amed:COVID19ExpensesIncurred" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV80OS9mcmFnOjA5MTE3NmEwOTJiMDQ0ODliYjQ5MDRhYTc5ODMyOTlhL3RleHRyZWdpb246MDkxMTc2YTA5MmIwNDQ4OWJiNDkwNGFhNzk4MzI5OWFfMTk0MQ_9f927c3b-7dc6-4596-a2fc-c6721b705d9b">21</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="ibb3ce40344c74f1581b747ba288ae945_D20200101-20200630" decimals="-6" format="ixt:numdotdecimal" name="amed:COVID19ExpensesIncurred" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV80OS9mcmFnOjA5MTE3NmEwOTJiMDQ0ODliYjQ5MDRhYTc5ODMyOTlhL3RleHRyZWdpb246MDkxMTc2YTA5MmIwNDQ4OWJiNDkwNGFhNzk4MzI5OWFfMTA5OTUxMTYzNDU1OQ_c2a64459-41a9-41a5-a605-3487b30e3eac">22</ix:nonFraction>&#160;million during the three and six-month periods ended June 30, 2020, respectively. Accordingly, for our wholly-owned subsidiaries, we have not used PRF funds to cover lost revenues resulting from COVID-19. The grant income associated with the COVID-19 expenses incurred during the three and six-month periods ended June 30, 2021 and 2020 is reflected in other operating income within our condensed consolidated statements of operations. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">PRF funds were available for use through June 30, 2021. We did not fully utilize the funds received; therefore, we have recorded a liability for the amount we expect to repay which totaled $<ix:nonFraction unitRef="usd" contextRef="i1e833203be6947b4968aba4d20064ec8_I20210630" decimals="-6" format="ixt:numdotdecimal" name="amed:ProviderReliefFundAdvance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV80OS9mcmFnOjA5MTE3NmEwOTJiMDQ0ODliYjQ5MDRhYTc5ODMyOTlhL3RleHRyZWdpb246MDkxMTc2YTA5MmIwNDQ4OWJiNDkwNGFhNzk4MzI5OWFfMjg4OQ_b23476fb-d9f4-4780-8b2f-f94dbb78fa59">58</ix:nonFraction>&#160;million at June 30, 2021 and $<ix:nonFraction unitRef="usd" contextRef="i87ceb60dc20d4df1b0a97d3514837910_I20201231" decimals="-6" format="ixt:numdotdecimal" name="amed:ProviderReliefFundAdvance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV80OS9mcmFnOjA5MTE3NmEwOTJiMDQ0ODliYjQ5MDRhYTc5ODMyOTlhL3RleHRyZWdpb246MDkxMTc2YTA5MmIwNDQ4OWJiNDkwNGFhNzk4MzI5OWFfMjkxNA_7cc28374-d43a-4222-82a1-763eebf9ef75">60</ix:nonFraction>&#160;million at December 31, 2020 (see the Provider Relief Fund Advance account in current liabilities within our condensed consolidated balance sheets). We intend to report on our use of the PRF funds to HHS during the three-month period ending September 30, 2021 and to return all unutilized funds by October 30, 2021. <ix:nonNumeric contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630" name="amed:ScheduleOfCaresActProviderReliefFundsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV80OS9mcmFnOjA5MTE3NmEwOTJiMDQ0ODliYjQ5MDRhYTc5ODMyOTlhL3RleHRyZWdpb246MDkxMTc2YTA5MmIwNDQ4OWJiNDkwNGFhNzk4MzI5OWFfNTQ0Mg_99650e62-89b9-4c0f-91f1-9c2f619a91e2" continuedAt="i4f45e625a1e0467cb44125ca62b34932" escape="true">In summary, the total funds that we have received from the CARES Act PRF have been accounted for as follows as of June 30, 2021 (amounts in millions):</ix:nonNumeric></span></div><div style="margin-top:6pt;text-align:center"><ix:continuation id="i4f45e625a1e0467cb44125ca62b34932"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:87.719%"><tr><td style="width:1.0%"></td><td style="width:76.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.567%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Funds utilized through June 30, 2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f67ab0074b94f94a94986aa649dde19_D20200327-20210630" decimals="-5" name="amed:CARESActProviderReliefFundsUtilized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV80OS9mcmFnOjA5MTE3NmEwOTJiMDQ0ODliYjQ5MDRhYTc5ODMyOTlhL3RhYmxlOjdhODIwOGY3M2I1MDRiYTNiYjY2NDYyMWUyODZlNGNiL3RhYmxlcmFuZ2U6N2E4MjA4ZjczYjUwNGJhM2JiNjY0NjIxZTI4NmU0Y2JfMS0xLTEtMS0w_d17446eb-284e-475e-8d08-b840da937314">46.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Estimated funds to be repaid to the government</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e833203be6947b4968aba4d20064ec8_I20210630" decimals="-5" name="amed:EstimatedCARESActProviderReliefFundAmountsToBeRepaid" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV80OS9mcmFnOjA5MTE3NmEwOTJiMDQ0ODliYjQ5MDRhYTc5ODMyOTlhL3RhYmxlOjdhODIwOGY3M2I1MDRiYTNiYjY2NDYyMWUyODZlNGNiL3RhYmxlcmFuZ2U6N2E4MjA4ZjczYjUwNGJhM2JiNjY0NjIxZTI4NmU0Y2JfMy0xLTEtMS0w_f334e61d-c5b9-4117-8115-9c290835e396">58.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Funds received by unconsolidated joint ventures</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e833203be6947b4968aba4d20064ec8_I20210630" decimals="-5" name="amed:CARESActProviderReliefFundsReceivedByUnconsolidatedJointVentures" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV80OS9mcmFnOjA5MTE3NmEwOTJiMDQ0ODliYjQ5MDRhYTc5ODMyOTlhL3RhYmxlOjdhODIwOGY3M2I1MDRiYTNiYjY2NDYyMWUyODZlNGNiL3RhYmxlcmFuZ2U6N2E4MjA4ZjczYjUwNGJhM2JiNjY0NjIxZTI4NmU0Y2JfNC0xLTEtMS0w_e03d9ff0-2d97-421b-aae0-5463d0a987e5">1.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e833203be6947b4968aba4d20064ec8_I20210630" decimals="-5" name="amed:TotalCARESActProviderReliefFundsReceived" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV80OS9mcmFnOjA5MTE3NmEwOTJiMDQ0ODliYjQ5MDRhYTc5ODMyOTlhL3RhYmxlOjdhODIwOGY3M2I1MDRiYTNiYjY2NDYyMWUyODZlNGNiL3RhYmxlcmFuZ2U6N2E4MjA4ZjczYjUwNGJhM2JiNjY0NjIxZTI4NmU0Y2JfNS0xLTEtMS0w_e4cdee57-a22d-4149-8e55-9dca55ed1096">106.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-top:6pt;text-align:justify"><span><br/></span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The CARES Act also provided for the temporary suspension of the automatic 2% reduction of Medicare claim reimbursements (sequestration) for the period May 1, 2020 through December 31, 2020. In December 2020, Congress passed additional COVID-19 relief legislation as part of the Consolidated Appropriations Act, 2021. This legislation extended the suspension of sequestration through March 31, 2021. In April 2021, Congress passed H.R. 1868, which among other items, provided for an additional extension of the temporary suspension of sequestration through December 31, 2021. We estimate that the suspension of sequestration will increase our 2021 net service revenue by approximately $<ix:nonFraction unitRef="usd" contextRef="ia6c66b5559184a299f6fd13a6091fd6c_D20210101-20211231" decimals="-5" format="ixt:numdotdecimal" name="amed:ExtensionOfTemporarySuspensionOfSequestrationRevenueImpact" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV80OS9mcmFnOjA5MTE3NmEwOTJiMDQ0ODliYjQ5MDRhYTc5ODMyOTlhL3RleHRyZWdpb246MDkxMTc2YTA5MmIwNDQ4OWJiNDkwNGFhNzk4MzI5OWFfNDY1OA_7df37985-88e4-4c49-949e-dafba4bb915d">36</ix:nonFraction>&#160;million.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, the CARES Act provided for the deferral of the employer share of social security tax (6.2%), effective for payments due after the enactment date through December 31, 2020. Fifty percent of the deferred payroll taxes are due on December 31, 2021 with the remaining amounts due on December 31, 2022. During 2020, we deferred approximately $<ix:nonFraction unitRef="usd" contextRef="i3800e4dbdd2b4b74be666a6efdf57781_I20201231" decimals="-5" format="ixt:numdotdecimal" name="amed:CARESActDeferralOfEmployerShareSocialSecurityTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV80OS9mcmFnOjA5MTE3NmEwOTJiMDQ0ODliYjQ5MDRhYTc5ODMyOTlhL3RleHRyZWdpb246MDkxMTc2YTA5MmIwNDQ4OWJiNDkwNGFhNzk4MzI5OWFfNDk4Nw_9eda53bc-13ce-4646-beae-bdb38268ceab">55.0</ix:nonFraction>&#160;million of social security tax; approximately $<ix:nonFraction unitRef="usd" contextRef="ifc0809f18c444433ac13693a115bb6bf_I20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV80OS9mcmFnOjA5MTE3NmEwOTJiMDQ0ODliYjQ5MDRhYTc5ODMyOTlhL3RleHRyZWdpb246MDkxMTc2YTA5MmIwNDQ4OWJiNDkwNGFhNzk4MzI5OWFfNTAzMA_56b5aa7c-9580-47c8-a77c-1d96a0f4bb69"><ix:nonFraction unitRef="usd" contextRef="ifc0809f18c444433ac13693a115bb6bf_I20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV80OS9mcmFnOjA5MTE3NmEwOTJiMDQ0ODliYjQ5MDRhYTc5ODMyOTlhL3RleHRyZWdpb246MDkxMTc2YTA5MmIwNDQ4OWJiNDkwNGFhNzk4MzI5OWFfNTAzMA_9a16c359-cf63-4963-ae68-9065c9c2243b">28</ix:nonFraction></ix:nonFraction>&#160;million is reflected in each of payroll and employee benefits and other long-term obligations within our condensed consolidated balance sheets.</span></div></ix:continuation><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="if0457d4f2742417f99fe3629f7cd0823">Our personal care segment did not receive funds under the CARES Act; however, it did receive funds totaling $<ix:nonFraction unitRef="usd" contextRef="ifd83ae148acd4a77824ab56405bb1c41_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="amed:FundingReceivedFromMassHomeCareASAPCOVID19ProviderSustainabilityProgram" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV80OS9mcmFnOjA5MTE3NmEwOTJiMDQ0ODliYjQ5MDRhYTc5ODMyOTlhL3RleHRyZWdpb246MDkxMTc2YTA5MmIwNDQ4OWJiNDkwNGFhNzk4MzI5OWFfNTI3OQ_8de58e25-de79-46cd-a430-f7edfe2ce467">1</ix:nonFraction>&#160;million from the Mass Home Care ASAP COVID-19 Provider Sustainability Program, which were used during 2020 to cover costs related to COVID-19.</ix:continuation>  </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AMEDISYS, INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify"><span><br/></span></div><div id="iccd9c69ecd2c42e5897cfe9ab4e7e0b5_52"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4. <ix:nonNumeric contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630" name="us-gaap:BusinessCombinationDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV81Mi9mcmFnOjE5NzlmNTFhOWI3NDQ1ZTA5ZTI4ODA2YjU2OTg0MzUwL3RleHRyZWdpb246MTk3OWY1MWE5Yjc0NDVlMDllMjg4MDZiNTY5ODQzNTBfMzI4MA_f54d7812-0206-467b-8ea3-30c8b58ea919" continuedAt="ic99ed216c318434ba3f92d8fc77cabe1" escape="true">ACQUISITIONS</ix:nonNumeric></span></div><ix:continuation id="ic99ed216c318434ba3f92d8fc77cabe1" continuedAt="i0b389b837f7a40d8a8131e98b39e420b"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We complete acquisitions from time to time in order to pursue our strategy of increasing our market presence by expanding our service base and enhancing our position in certain geographic areas as a leading provider of home health, hospice and personal care services. The purchase price paid for acquisitions is negotiated through arm&#8217;s length transactions, with consideration based on our analysis of, among other things, comparable acquisitions and expected cash flows. Acquisitions are accounted for as purchases and are included in our condensed consolidated financial statements from their respective acquisition dates. Goodwill generated from acquisitions is recognized for the excess of the purchase price over tangible and identifiable intangible assets because of the expected contributions of the acquisitions to our overall corporate strategy. We typically engage outside appraisal firms to assist in the fair value determination of identifiable intangible assets for significant acquisitions. The preliminary purchase price allocation is adjusted, as necessary, up to one year after the acquisition closing date if management obtains more information regarding asset valuations and liabilities assumed.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2021 Acquisitions</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 1, 2021, we acquired the regulatory assets of a home health provider in Randolph County, North Carolina for a purchase price of $<ix:nonFraction unitRef="usd" contextRef="i45e11b09cca8443d838df683d0210fd2_D20210501-20210501" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireBusinessesGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV81Mi9mcmFnOjE5NzlmNTFhOWI3NDQ1ZTA5ZTI4ODA2YjU2OTg0MzUwL3RleHRyZWdpb246MTk3OWY1MWE5Yjc0NDVlMDllMjg4MDZiNTY5ODQzNTBfMTA5OTUxMTYzMjQwNQ_9d6ad1ea-6557-48de-a04e-779e96e12da9">2.5</ix:nonFraction>&#160;million. The purchase price was paid with cash on hand on the date of the transaction. Based on the Company's preliminary valuation, we recorded goodwill of $<ix:nonFraction unitRef="usd" contextRef="i535b766678164627a4ddec7a5f2f5950_D20210401-20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:GoodwillAcquiredDuringPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV81Mi9mcmFnOjE5NzlmNTFhOWI3NDQ1ZTA5ZTI4ODA2YjU2OTg0MzUwL3RleHRyZWdpb246MTk3OWY1MWE5Yjc0NDVlMDllMjg4MDZiNTY5ODQzNTBfMTA5OTUxMTYzMjQzMw_467bf712-47ef-437c-9f9b-7d8912971759">2.4</ix:nonFraction>&#160;million and other intangibles (certificate of need) of $<ix:nonFraction unitRef="usd" contextRef="i8bbf534b5cc84c0e8690bc7618aac045_I20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV81Mi9mcmFnOjE5NzlmNTFhOWI3NDQ1ZTA5ZTI4ODA2YjU2OTg0MzUwL3RleHRyZWdpb246MTk3OWY1MWE5Yjc0NDVlMDllMjg4MDZiNTY5ODQzNTBfMTA5OTUxMTYzMjQxOQ_ca49fb05-a07c-4ad4-8e65-17c435b32dee">0.1</ix:nonFraction>&#160;million in connection with the acquisition.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2020 Acquisitions</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 1, 2020, we acquired Homecare Preferred Choice, Inc., doing business as AseraCare Hospice ("AseraCare"), a national hospice care provider with <ix:nonFraction unitRef="care_center" contextRef="i83f6f6c3fd9a43b9871634c7190f8d34_D20200601-20200601" decimals="INF" name="us-gaap:NumberOfBusinessesAcquired" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV81Mi9mcmFnOjE5NzlmNTFhOWI3NDQ1ZTA5ZTI4ODA2YjU2OTg0MzUwL3RleHRyZWdpb246MTk3OWY1MWE5Yjc0NDVlMDllMjg4MDZiNTY5ODQzNTBfMTQwNQ_78da4dd1-14d9-4871-97a8-981a6933a657">44</ix:nonFraction> locations, for an estimated purchase price of $<ix:nonFraction unitRef="usd" contextRef="i83f6f6c3fd9a43b9871634c7190f8d34_D20200601-20200601" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireBusinessesGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV81Mi9mcmFnOjE5NzlmNTFhOWI3NDQ1ZTA5ZTI4ODA2YjU2OTg0MzUwL3RleHRyZWdpb246MTk3OWY1MWE5Yjc0NDVlMDllMjg4MDZiNTY5ODQzNTBfMTQ1NA_9bbb06e1-8186-433b-9ae7-566312d72ad2">230.4</ix:nonFraction>&#160;million, net of cash acquired and inclusive of a $<ix:nonFraction unitRef="usd" contextRef="i83f6f6c3fd9a43b9871634c7190f8d34_D20200601-20200601" decimals="-5" format="ixt:numdotdecimal" name="amed:PaymentsRelatedToTaxAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV81Mi9mcmFnOjE5NzlmNTFhOWI3NDQ1ZTA5ZTI4ODA2YjU2OTg0MzUwL3RleHRyZWdpb246MTk3OWY1MWE5Yjc0NDVlMDllMjg4MDZiNTY5ODQzNTBfMTQ5OA_2b4e5ab5-786e-4889-beb0-e361290e81b3">32</ix:nonFraction>&#160;million tax asset. The closing payment for the purchase price included estimates for cash, working capital and various other items. Under the purchase agreement, the purchase price was subject to a closing payment adjustment for any differences between estimated amounts included in the closing payment and actual amounts at close, not to exceed $<ix:nonFraction unitRef="usd" contextRef="i867c8c481181405cacf65820555c0934_D20200601-20200601" decimals="-5" format="ixt:numdotdecimal" name="amed:BusinessAcquisitionClosingPaymentAdjustment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV81Mi9mcmFnOjE5NzlmNTFhOWI3NDQ1ZTA5ZTI4ODA2YjU2OTg0MzUwL3RleHRyZWdpb246MTk3OWY1MWE5Yjc0NDVlMDllMjg4MDZiNTY5ODQzNTBfMTgzOQ_1a18cddf-26dc-4c7f-929c-6e1b0d642f04">1.0</ix:nonFraction>&#160;million. The closing payment adjustment, which was finalized in October 2020, reduced the purchase price by $<ix:nonFraction unitRef="usd" contextRef="ifaa721259ce4436aa80fefef62ec970f_D20201001-20201001" decimals="-5" format="ixt:numdotdecimal" name="amed:BusinessAcquisitionClosingPaymentAdjustment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV81Mi9mcmFnOjE5NzlmNTFhOWI3NDQ1ZTA5ZTI4ODA2YjU2OTg0MzUwL3RleHRyZWdpb246MTk3OWY1MWE5Yjc0NDVlMDllMjg4MDZiNTY5ODQzNTBfMTk0Mg_0817bce7-4cd1-4e95-a0e2-6f4f2444480c">0.8</ix:nonFraction>&#160;million, from $<ix:nonFraction unitRef="usd" contextRef="i83f6f6c3fd9a43b9871634c7190f8d34_D20200601-20200601" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireBusinessesGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV81Mi9mcmFnOjE5NzlmNTFhOWI3NDQ1ZTA5ZTI4ODA2YjU2OTg0MzUwL3RleHRyZWdpb246MTk3OWY1MWE5Yjc0NDVlMDllMjg4MDZiNTY5ODQzNTBfMTk1MQ_53f4b0f8-6b18-46fb-9449-07c8b79cf415">230.4</ix:nonFraction>&#160;million&#160;to $<ix:nonFraction unitRef="usd" contextRef="i1af2ff078c3a4f71aa611b0e527d319e_I20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV81Mi9mcmFnOjE5NzlmNTFhOWI3NDQ1ZTA5ZTI4ODA2YjU2OTg0MzUwL3RleHRyZWdpb246MTk3OWY1MWE5Yjc0NDVlMDllMjg4MDZiNTY5ODQzNTBfMTk1Nw_f1655a29-fd3f-4e2e-b079-1dee116c3f9c">229.6</ix:nonFraction>&#160;million.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company finalized its valuation of the assets acquired and liabilities assumed during the three-month period ended June 30, 2021. <ix:nonNumeric contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630" name="us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV81Mi9mcmFnOjE5NzlmNTFhOWI3NDQ1ZTA5ZTI4ODA2YjU2OTg0MzUwL3RleHRyZWdpb246MTk3OWY1MWE5Yjc0NDVlMDllMjg4MDZiNTY5ODQzNTBfMzI5Mw_36722d1b-c689-4bea-8798-d23228105196" continuedAt="i07f442f8aa7e4940b69472d25a823a3f" escape="true">The total consideration of $<ix:nonFraction unitRef="usd" contextRef="i1af2ff078c3a4f71aa611b0e527d319e_I20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV81Mi9mcmFnOjE5NzlmNTFhOWI3NDQ1ZTA5ZTI4ODA2YjU2OTg0MzUwL3RleHRyZWdpb246MTk3OWY1MWE5Yjc0NDVlMDllMjg4MDZiNTY5ODQzNTBfMjQ4MA_e15460b1-8208-4cb4-b490-2f7a1d8dfc88">229.6</ix:nonFraction> million&#160;has been allocated to assets acquired and liabilities assumed as of the acquisition date as follows (amounts in millions):</ix:nonNumeric></span></div><div style="margin-top:6pt;text-align:center"><ix:continuation id="i07f442f8aa7e4940b69472d25a823a3f"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:79.970%"><tr><td style="width:1.0%"></td><td style="width:74.037%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.763%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patient accounts receivable</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1af2ff078c3a4f71aa611b0e527d319e_I20210630" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV81Mi9mcmFnOjE5NzlmNTFhOWI3NDQ1ZTA5ZTI4ODA2YjU2OTg0MzUwL3RhYmxlOmFkNDEzYjNmY2M1NTRlMjE4YzdlMzZjN2RjMmZiOTYzL3RhYmxlcmFuZ2U6YWQ0MTNiM2ZjYzU1NGUyMThjN2UzNmM3ZGMyZmI5NjNfMS0xLTEtMS0w_380c1ba8-dfb6-4950-b8c1-19e21edaebdc">15.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1af2ff078c3a4f71aa611b0e527d319e_I20210630" decimals="-5" name="amed:BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentAssetsPrepaidExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV81Mi9mcmFnOjE5NzlmNTFhOWI3NDQ1ZTA5ZTI4ODA2YjU2OTg0MzUwL3RhYmxlOmFkNDEzYjNmY2M1NTRlMjE4YzdlMzZjN2RjMmZiOTYzL3RhYmxlcmFuZ2U6YWQ0MTNiM2ZjYzU1NGUyMThjN2UzNmM3ZGMyZmI5NjNfMi0xLTEtMS0w_c9b2e68f-0fdd-422f-8db0-3d7bf9597fb5">0.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1af2ff078c3a4f71aa611b0e527d319e_I20210630" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV81Mi9mcmFnOjE5NzlmNTFhOWI3NDQ1ZTA5ZTI4ODA2YjU2OTg0MzUwL3RhYmxlOmFkNDEzYjNmY2M1NTRlMjE4YzdlMzZjN2RjMmZiOTYzL3RhYmxlcmFuZ2U6YWQ0MTNiM2ZjYzU1NGUyMThjN2UzNmM3ZGMyZmI5NjNfMy0xLTEtMS0w_7650dfc0-445c-448e-80e7-e60e028fd054">0.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right of use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1af2ff078c3a4f71aa611b0e527d319e_I20210630" decimals="-5" name="amed:BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingleaserightofuseassets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV81Mi9mcmFnOjE5NzlmNTFhOWI3NDQ1ZTA5ZTI4ODA2YjU2OTg0MzUwL3RhYmxlOmFkNDEzYjNmY2M1NTRlMjE4YzdlMzZjN2RjMmZiOTYzL3RhYmxlcmFuZ2U6YWQ0MTNiM2ZjYzU1NGUyMThjN2UzNmM3ZGMyZmI5NjNfNC0xLTEtMS0w_bde3ab3d-8ace-436b-9a2b-3ab5dc10c374">5.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1af2ff078c3a4f71aa611b0e527d319e_I20210630" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV81Mi9mcmFnOjE5NzlmNTFhOWI3NDQ1ZTA5ZTI4ODA2YjU2OTg0MzUwL3RhYmxlOmFkNDEzYjNmY2M1NTRlMjE4YzdlMzZjN2RjMmZiOTYzL3RhYmxlcmFuZ2U6YWQ0MTNiM2ZjYzU1NGUyMThjN2UzNmM3ZGMyZmI5NjNfNS0xLTEtMS0w_7c45089e-c60c-4e31-93c1-43df550f532e">24.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1af2ff078c3a4f71aa611b0e527d319e_I20210630" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV81Mi9mcmFnOjE5NzlmNTFhOWI3NDQ1ZTA5ZTI4ODA2YjU2OTg0MzUwL3RhYmxlOmFkNDEzYjNmY2M1NTRlMjE4YzdlMzZjN2RjMmZiOTYzL3RhYmxlcmFuZ2U6YWQ0MTNiM2ZjYzU1NGUyMThjN2UzNmM3ZGMyZmI5NjNfNi0xLTEtMS0w_af5d4966-914f-4894-b07c-18f8f4667300">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total assets acquired</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1af2ff078c3a4f71aa611b0e527d319e_I20210630" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV81Mi9mcmFnOjE5NzlmNTFhOWI3NDQ1ZTA5ZTI4ODA2YjU2OTg0MzUwL3RhYmxlOmFkNDEzYjNmY2M1NTRlMjE4YzdlMzZjN2RjMmZiOTYzL3RhYmxlcmFuZ2U6YWQ0MTNiM2ZjYzU1NGUyMThjN2UzNmM3ZGMyZmI5NjNfNy0xLTEtMS0w_02df40f5-97cd-464c-8e10-a0d6117c29c1">46.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1af2ff078c3a4f71aa611b0e527d319e_I20210630" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV81Mi9mcmFnOjE5NzlmNTFhOWI3NDQ1ZTA5ZTI4ODA2YjU2OTg0MzUwL3RhYmxlOmFkNDEzYjNmY2M1NTRlMjE4YzdlMzZjN2RjMmZiOTYzL3RhYmxlcmFuZ2U6YWQ0MTNiM2ZjYzU1NGUyMThjN2UzNmM3ZGMyZmI5NjNfOC0xLTEtMS0w_14562f68-1e51-452a-a46f-4244ca226fa7">6.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payroll and employee benefits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1af2ff078c3a4f71aa611b0e527d319e_I20210630" decimals="-5" name="amed:BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesPayrollandEmployeeBenefits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV81Mi9mcmFnOjE5NzlmNTFhOWI3NDQ1ZTA5ZTI4ODA2YjU2OTg0MzUwL3RhYmxlOmFkNDEzYjNmY2M1NTRlMjE4YzdlMzZjN2RjMmZiOTYzL3RhYmxlcmFuZ2U6YWQ0MTNiM2ZjYzU1NGUyMThjN2UzNmM3ZGMyZmI5NjNfOS0xLTEtMS0w_cf5e555c-7f87-4364-b4f0-bb8858727cf4">5.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1af2ff078c3a4f71aa611b0e527d319e_I20210630" decimals="-5" name="amed:BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV81Mi9mcmFnOjE5NzlmNTFhOWI3NDQ1ZTA5ZTI4ODA2YjU2OTg0MzUwL3RhYmxlOmFkNDEzYjNmY2M1NTRlMjE4YzdlMzZjN2RjMmZiOTYzL3RhYmxlcmFuZ2U6YWQ0MTNiM2ZjYzU1NGUyMThjN2UzNmM3ZGMyZmI5NjNfMTAtMS0xLTEtMA_0dd21235-5393-4e48-824b-2b84325c7594">11.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1af2ff078c3a4f71aa611b0e527d319e_I20210630" decimals="-5" name="amed:BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingLeaseLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV81Mi9mcmFnOjE5NzlmNTFhOWI3NDQ1ZTA5ZTI4ODA2YjU2OTg0MzUwL3RhYmxlOmFkNDEzYjNmY2M1NTRlMjE4YzdlMzZjN2RjMmZiOTYzL3RhYmxlcmFuZ2U6YWQ0MTNiM2ZjYzU1NGUyMThjN2UzNmM3ZGMyZmI5NjNfMTEtMS0xLTEtMA_53bd793f-782f-4395-bf64-58e6dba0057d">5.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total liabilities assumed</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1af2ff078c3a4f71aa611b0e527d319e_I20210630" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV81Mi9mcmFnOjE5NzlmNTFhOWI3NDQ1ZTA5ZTI4ODA2YjU2OTg0MzUwL3RhYmxlOmFkNDEzYjNmY2M1NTRlMjE4YzdlMzZjN2RjMmZiOTYzL3RhYmxlcmFuZ2U6YWQ0MTNiM2ZjYzU1NGUyMThjN2UzNmM3ZGMyZmI5NjNfMTItMS0xLTEtMA_e89b492b-8ad4-4173-b72c-21c6e005d895">29.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net identifiable assets acquired</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1af2ff078c3a4f71aa611b0e527d319e_I20210630" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV81Mi9mcmFnOjE5NzlmNTFhOWI3NDQ1ZTA5ZTI4ODA2YjU2OTg0MzUwL3RhYmxlOmFkNDEzYjNmY2M1NTRlMjE4YzdlMzZjN2RjMmZiOTYzL3RhYmxlcmFuZ2U6YWQ0MTNiM2ZjYzU1NGUyMThjN2UzNmM3ZGMyZmI5NjNfMTMtMS0xLTEtMA_e1153dd5-8fe3-4f2e-b15b-a25f247a7266">17.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie2776ede445a47be9f24c8e19df8e41a_D20210101-20210630" decimals="-5" name="us-gaap:GoodwillAcquiredDuringPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV81Mi9mcmFnOjE5NzlmNTFhOWI3NDQ1ZTA5ZTI4ODA2YjU2OTg0MzUwL3RhYmxlOmFkNDEzYjNmY2M1NTRlMjE4YzdlMzZjN2RjMmZiOTYzL3RhYmxlcmFuZ2U6YWQ0MTNiM2ZjYzU1NGUyMThjN2UzNmM3ZGMyZmI5NjNfMTQtMS0xLTEtMA_db6b62e3-e4bd-4cbe-9556-e24acf976be9">212.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total consideration</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1af2ff078c3a4f71aa611b0e527d319e_I20210630" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV81Mi9mcmFnOjE5NzlmNTFhOWI3NDQ1ZTA5ZTI4ODA2YjU2OTg0MzUwL3RhYmxlOmFkNDEzYjNmY2M1NTRlMjE4YzdlMzZjN2RjMmZiOTYzL3RhYmxlcmFuZ2U6YWQ0MTNiM2ZjYzU1NGUyMThjN2UzNmM3ZGMyZmI5NjNfMTUtMS0xLTEtMA_d35fe7fa-b452-42bd-86c2-bd07e8b8a9ab">229.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div></ix:continuation><div style="margin-top:6pt;text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AMEDISYS, INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></div><ix:continuation id="i0b389b837f7a40d8a8131e98b39e420b"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets acquired include licenses ($<ix:nonFraction unitRef="usd" contextRef="id89f6008c2694e98ab64e39c65f6ad94_I20200601" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV81Mi9mcmFnOjE5NzlmNTFhOWI3NDQ1ZTA5ZTI4ODA2YjU2OTg0MzUwL3RleHRyZWdpb246MTk3OWY1MWE5Yjc0NDVlMDllMjg4MDZiNTY5ODQzNTBfMjY1NQ_ad785999-9688-4890-a108-a7e482b7d1a0">8.7</ix:nonFraction>&#160;million), certificates of need ($<ix:nonFraction unitRef="usd" contextRef="i529e20e30522490fbfb5f6be349b8c2e_I20200601" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV81Mi9mcmFnOjE5NzlmNTFhOWI3NDQ1ZTA5ZTI4ODA2YjU2OTg0MzUwL3RleHRyZWdpb246MTk3OWY1MWE5Yjc0NDVlMDllMjg4MDZiNTY5ODQzNTBfMjY4Mg_a91b7b51-ba0a-4bb7-b86e-5f83f05e6eee">0.7</ix:nonFraction>&#160;million), acquired names ($<ix:nonFraction unitRef="usd" contextRef="i012cb8f0777f4308802fe58df675adca_I20200601" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV81Mi9mcmFnOjE5NzlmNTFhOWI3NDQ1ZTA5ZTI4ODA2YjU2OTg0MzUwL3RleHRyZWdpb246MTk3OWY1MWE5Yjc0NDVlMDllMjg4MDZiNTY5ODQzNTBfMjcwMw_bee3d697-43af-4701-a3e4-f154b02c8e54">5.7</ix:nonFraction>&#160;million) and non-compete agreements ($<ix:nonFraction unitRef="usd" contextRef="i3bd9e093562340059df041fec4f9ea9c_I20200601" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV81Mi9mcmFnOjE5NzlmNTFhOWI3NDQ1ZTA5ZTI4ODA2YjU2OTg0MzUwL3RleHRyZWdpb246MTk3OWY1MWE5Yjc0NDVlMDllMjg4MDZiNTY5ODQzNTBfMjczNQ_f7889589-8095-4cae-96b1-e6c042f2c2e8">9.2</ix:nonFraction>&#160;million). The acquired names will be amortized over a weighted-average period of <ix:nonNumeric contextRef="ib2a212363aa54dbc9ffb59f71147e64a_D20200601-20200601" format="ixt-sec:duryear" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV81Mi9mcmFnOjE5NzlmNTFhOWI3NDQ1ZTA5ZTI4ODA2YjU2OTg0MzUwL3RleHRyZWdpb246MTk3OWY1MWE5Yjc0NDVlMDllMjg4MDZiNTY5ODQzNTBfMjgxMQ_b7150421-e0f9-4dc8-a899-eb83830d4440">2.0</ix:nonNumeric> years, and the non-compete agreements will be amortized over a weighted-average period of <ix:nonNumeric contextRef="i203c1416080945b495a673816a335d4a_D20200601-20200601" format="ixt-sec:duryear" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV81Mi9mcmFnOjE5NzlmNTFhOWI3NDQ1ZTA5ZTI4ODA2YjU2OTg0MzUwL3RleHRyZWdpb246MTk3OWY1MWE5Yjc0NDVlMDllMjg4MDZiNTY5ODQzNTBfMjg5Nw_d83bd68c-797d-40bc-9ce6-5dd1b9d24c61">1.7</ix:nonNumeric> years. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AseraCare contributed $<ix:nonFraction unitRef="usd" contextRef="id2115fff96eb46a78868c96cf8b1c4a1_D20210401-20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV81Mi9mcmFnOjE5NzlmNTFhOWI3NDQ1ZTA5ZTI4ODA2YjU2OTg0MzUwL3RleHRyZWdpb246MTk3OWY1MWE5Yjc0NDVlMDllMjg4MDZiNTY5ODQzNTBfMjkzOA_d82fd711-0db9-478f-95d4-c621698d6a92">25.4</ix:nonFraction>&#160;million in net service revenue and operating income of $<ix:nonFraction unitRef="usd" contextRef="id2115fff96eb46a78868c96cf8b1c4a1_D20210401-20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV81Mi9mcmFnOjE5NzlmNTFhOWI3NDQ1ZTA5ZTI4ODA2YjU2OTg0MzUwL3RleHRyZWdpb246MTk3OWY1MWE5Yjc0NDVlMDllMjg4MDZiNTY5ODQzNTBfMjk4OQ_300d7286-7d76-4b72-a5b4-998f3f579884">0.5</ix:nonFraction>&#160;million (inclusive of acquisition and integration costs totaling $<ix:nonFraction unitRef="usd" contextRef="id2115fff96eb46a78868c96cf8b1c4a1_D20210401-20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationIntegrationRelatedCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV81Mi9mcmFnOjE5NzlmNTFhOWI3NDQ1ZTA5ZTI4ODA2YjU2OTg0MzUwL3RleHRyZWdpb246MTk3OWY1MWE5Yjc0NDVlMDllMjg4MDZiNTY5ODQzNTBfMzA0OQ_59601025-afd6-48bb-97da-39b466e8311d">0.6</ix:nonFraction>&#160;million and intangibles amortization totaling $<ix:nonFraction unitRef="usd" contextRef="id2115fff96eb46a78868c96cf8b1c4a1_D20210401-20210630" decimals="-5" format="ixt:numdotdecimal" name="amed:DepreciationAndAmortizationForContinuingOperations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV81Mi9mcmFnOjE5NzlmNTFhOWI3NDQ1ZTA5ZTI4ODA2YjU2OTg0MzUwL3RleHRyZWdpb246MTk3OWY1MWE5Yjc0NDVlMDllMjg4MDZiNTY5ODQzNTBfMzA5MA_cbe6eca6-db7e-4152-9a16-38c610bfa36b">2.0</ix:nonFraction>&#160;million) during the three-month period ended June 30, 2021 and $<ix:nonFraction unitRef="usd" contextRef="ie2776ede445a47be9f24c8e19df8e41a_D20210101-20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV81Mi9mcmFnOjE5NzlmNTFhOWI3NDQ1ZTA5ZTI4ODA2YjU2OTg0MzUwL3RleHRyZWdpb246MTk3OWY1MWE5Yjc0NDVlMDllMjg4MDZiNTY5ODQzNTBfMTA5OTUxMTYzMzE3MA_6cf66294-0dbf-44f8-b429-2952e1ad2b5a">50.0</ix:nonFraction>&#160;million in net service revenue and an operating loss of $0.1 million (inclusive of acquisition and integration costs totaling $<ix:nonFraction unitRef="usd" contextRef="ie2776ede445a47be9f24c8e19df8e41a_D20210101-20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationIntegrationRelatedCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV81Mi9mcmFnOjE5NzlmNTFhOWI3NDQ1ZTA5ZTI4ODA2YjU2OTg0MzUwL3RleHRyZWdpb246MTk3OWY1MWE5Yjc0NDVlMDllMjg4MDZiNTY5ODQzNTBfMTA5OTUxMTYzMzE4NQ_a2b1af69-b855-4c23-b365-111c45df33f7">1.2</ix:nonFraction>&#160;million and intangibles amortization totaling $<ix:nonFraction unitRef="usd" contextRef="ie2776ede445a47be9f24c8e19df8e41a_D20210101-20210630" decimals="-5" format="ixt:numdotdecimal" name="amed:DepreciationAndAmortizationForContinuingOperations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV81Mi9mcmFnOjE5NzlmNTFhOWI3NDQ1ZTA5ZTI4ODA2YjU2OTg0MzUwL3RleHRyZWdpb246MTk3OWY1MWE5Yjc0NDVlMDllMjg4MDZiNTY5ODQzNTBfMTA5OTUxMTYzMzE5OQ_e498917e-a7e6-4c09-b9eb-b2644d0fb880">4.4</ix:nonFraction>&#160;million) during the six-month period ended June 30, 2021. During the three and six-month periods ended June 30, 2020, AseraCare contributed $<ix:nonFraction unitRef="usd" contextRef="i93266b4b1d884fad8c5cb4456e2def79_D20200101-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV81Mi9mcmFnOjE5NzlmNTFhOWI3NDQ1ZTA5ZTI4ODA2YjU2OTg0MzUwL3RleHRyZWdpb246MTk3OWY1MWE5Yjc0NDVlMDllMjg4MDZiNTY5ODQzNTBfMTA5OTUxMTYzMzIxMw_0f60c6aa-0cfe-445e-a0a0-f4a6e9ac4d1b"><ix:nonFraction unitRef="usd" contextRef="id8f72c421ee54ba2a739418940dde57c_D20200401-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV81Mi9mcmFnOjE5NzlmNTFhOWI3NDQ1ZTA5ZTI4ODA2YjU2OTg0MzUwL3RleHRyZWdpb246MTk3OWY1MWE5Yjc0NDVlMDllMjg4MDZiNTY5ODQzNTBfMTA5OTUxMTYzMzIxMw_e0d6acd5-8835-4f62-899b-fb94ba757456">9.2</ix:nonFraction></ix:nonFraction>&#160;million in net service revenue and an operating loss of $3.0 million (inclusive of acquisition and integration costs totaling $<ix:nonFraction unitRef="usd" contextRef="i93266b4b1d884fad8c5cb4456e2def79_D20200101-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationIntegrationRelatedCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV81Mi9mcmFnOjE5NzlmNTFhOWI3NDQ1ZTA5ZTI4ODA2YjU2OTg0MzUwL3RleHRyZWdpb246MTk3OWY1MWE5Yjc0NDVlMDllMjg4MDZiNTY5ODQzNTBfMTA5OTUxMTYzMzIyNw_1f709e7f-23d9-41a5-81d0-6bbbc1c4175d"><ix:nonFraction unitRef="usd" contextRef="id8f72c421ee54ba2a739418940dde57c_D20200401-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationIntegrationRelatedCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV81Mi9mcmFnOjE5NzlmNTFhOWI3NDQ1ZTA5ZTI4ODA2YjU2OTg0MzUwL3RleHRyZWdpb246MTk3OWY1MWE5Yjc0NDVlMDllMjg4MDZiNTY5ODQzNTBfMTA5OTUxMTYzMzIyNw_bd505b34-86c4-45b4-994d-a243fa05ac83">3.3</ix:nonFraction></ix:nonFraction>&#160;million and intangibles amortization totaling $<ix:nonFraction unitRef="usd" contextRef="i93266b4b1d884fad8c5cb4456e2def79_D20200101-20200630" decimals="-5" format="ixt:numdotdecimal" name="amed:DepreciationAndAmortizationForContinuingOperations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV81Mi9mcmFnOjE5NzlmNTFhOWI3NDQ1ZTA5ZTI4ODA2YjU2OTg0MzUwL3RleHRyZWdpb246MTk3OWY1MWE5Yjc0NDVlMDllMjg4MDZiNTY5ODQzNTBfMTA5OTUxMTYzMzI0MQ_0fe821b1-d679-48f0-91ee-5e550d33326b"><ix:nonFraction unitRef="usd" contextRef="id8f72c421ee54ba2a739418940dde57c_D20200401-20200630" decimals="-5" format="ixt:numdotdecimal" name="amed:DepreciationAndAmortizationForContinuingOperations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV81Mi9mcmFnOjE5NzlmNTFhOWI3NDQ1ZTA5ZTI4ODA2YjU2OTg0MzUwL3RleHRyZWdpb246MTk3OWY1MWE5Yjc0NDVlMDllMjg4MDZiNTY5ODQzNTBfMTA5OTUxMTYzMzI0MQ_bb57a33f-9611-40f2-92a9-44c53d051842">0.2</ix:nonFraction></ix:nonFraction>&#160;million).</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect the entire amount of goodwill recorded for this acquisition to be deductible for income tax purposes over approximately <ix:nonNumeric contextRef="i83f6f6c3fd9a43b9871634c7190f8d34_D20200601-20200601" format="ixt-sec:duryear" name="amed:GoodwillDeductibleForIncomeTaxPurposesPeriod" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV81Mi9mcmFnOjE5NzlmNTFhOWI3NDQ1ZTA5ZTI4ODA2YjU2OTg0MzUwL3RleHRyZWdpb246MTk3OWY1MWE5Yjc0NDVlMDllMjg4MDZiNTY5ODQzNTBfMzI3Nw_003f4263-1ca5-4c31-a35f-304c1ed8db3f">15</ix:nonNumeric> years.</span></div></ix:continuation><div id="iccd9c69ecd2c42e5897cfe9ab4e7e0b5_58"></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5. <ix:nonNumeric contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630" name="us-gaap:DebtDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV81OC9mcmFnOjAyNjBhN2Y0MDYyNzQ1ZTRhZWNlNjk4NThjOTI1ZDkyL3RleHRyZWdpb246MDI2MGE3ZjQwNjI3NDVlNGFlY2U2OTg1OGM5MjVkOTJfNjg4Nw_c57ce018-5cac-49a7-89a7-66e60d702394" continuedAt="i9a558315c5ab4a36af6bf6043b8c54d5" escape="true">LONG-TERM OBLIGATIONS</ix:nonNumeric></span></div><ix:continuation id="i9a558315c5ab4a36af6bf6043b8c54d5" continuedAt="ia62edaa211e042f68fd700133ff2eb2d"><div style="margin-top:6pt"><ix:nonNumeric contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630" name="us-gaap:ScheduleOfDebtInstrumentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV81OC9mcmFnOjAyNjBhN2Y0MDYyNzQ1ZTRhZWNlNjk4NThjOTI1ZDkyL3RleHRyZWdpb246MDI2MGE3ZjQwNjI3NDVlNGFlY2U2OTg1OGM5MjVkOTJfNjg5Mg_a1c220d9-9f3c-4948-aa84-70aa54a9b8e2" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-term debt consists of the following for the periods indicated (amounts in millions):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.812%"><tr><td style="width:1.0%"></td><td style="width:66.256%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.823%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.596%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.825%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="i4f3b5acefd614cc18bfcd62fc3a07ded_I20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV81OC9mcmFnOjAyNjBhN2Y0MDYyNzQ1ZTRhZWNlNjk4NThjOTI1ZDkyL3RhYmxlOmNhODJmZmZkYTkwNDRkOWE4ZmJmMzM3ZGY1OGRmMDhjL3RhYmxlcmFuZ2U6Y2E4MmZmZmRhOTA0NGQ5YThmYmYzMzdkZjU4ZGYwOGNfMS0wLTEtMS0wL3RleHRyZWdpb246N2M5NjlhYmEwMTQwNGIyNmFlYTQxMjFkY2YxMWQ1M2VfNA_2f3942bc-501f-45c9-9ff0-f959fd079fe3">175.0</ix:nonFraction> million Term Loan; interest rate at Base Rate plus Applicable Rate or Eurodollar Rate plus Applicable Rate (<ix:nonFraction unitRef="number" contextRef="i47d7f0027dea435bbbef8d4d8e234b83_I20210630" decimals="3" name="amed:DebtInstrumentInterestRateatPeriodEnd" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV81OC9mcmFnOjAyNjBhN2Y0MDYyNzQ1ZTRhZWNlNjk4NThjOTI1ZDkyL3RhYmxlOmNhODJmZmZkYTkwNDRkOWE4ZmJmMzM3ZGY1OGRmMDhjL3RhYmxlcmFuZ2U6Y2E4MmZmZmRhOTA0NGQ5YThmYmYzMzdkZjU4ZGYwOGNfMS0wLTEtMS0wL3RleHRyZWdpb246N2M5NjlhYmEwMTQwNGIyNmFlYTQxMjFkY2YxMWQ1M2VfMTA3_d1d13bc5-2dbe-45da-a4bf-11b67aa3071f">1.4</ix:nonFraction>% at June 30, 2021); due <ix:nonNumeric contextRef="i282996a0cb644ac088b44f613c53cdcb_D20210101-20210630" format="ixt:datemonthdayyearen" name="us-gaap:DebtInstrumentMaturityDate" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV81OC9mcmFnOjAyNjBhN2Y0MDYyNzQ1ZTRhZWNlNjk4NThjOTI1ZDkyL3RhYmxlOmNhODJmZmZkYTkwNDRkOWE4ZmJmMzM3ZGY1OGRmMDhjL3RhYmxlcmFuZ2U6Y2E4MmZmZmRhOTA0NGQ5YThmYmYzMzdkZjU4ZGYwOGNfMS0wLTEtMS0wL3RleHRyZWdpb246N2M5NjlhYmEwMTQwNGIyNmFlYTQxMjFkY2YxMWQ1M2VfMTM0_4759afb2-022d-4377-8e28-1ebd7266b84d">February&#160;4, 2024</ix:nonNumeric></span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f3b5acefd614cc18bfcd62fc3a07ded_I20210630" decimals="-5" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV81OC9mcmFnOjAyNjBhN2Y0MDYyNzQ1ZTRhZWNlNjk4NThjOTI1ZDkyL3RhYmxlOmNhODJmZmZkYTkwNDRkOWE4ZmJmMzM3ZGY1OGRmMDhjL3RhYmxlcmFuZ2U6Y2E4MmZmZmRhOTA0NGQ5YThmYmYzMzdkZjU4ZGYwOGNfMS0xLTEtMS0w_a293fa68-50ac-4ba0-aca6-e1bd3a753702">159.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f0dd8df1d3345b4aa1558de68c7698c_I20201231" decimals="-5" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV81OC9mcmFnOjAyNjBhN2Y0MDYyNzQ1ZTRhZWNlNjk4NThjOTI1ZDkyL3RhYmxlOmNhODJmZmZkYTkwNDRkOWE4ZmJmMzM3ZGY1OGRmMDhjL3RhYmxlcmFuZ2U6Y2E4MmZmZmRhOTA0NGQ5YThmYmYzMzdkZjU4ZGYwOGNfMS0zLTEtMS0w_316c825b-fe01-4ad9-9aa9-9459301f79da">164.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="i9b034d16545343f69ba28f30d62f22c2_I20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV81OC9mcmFnOjAyNjBhN2Y0MDYyNzQ1ZTRhZWNlNjk4NThjOTI1ZDkyL3RhYmxlOmNhODJmZmZkYTkwNDRkOWE4ZmJmMzM3ZGY1OGRmMDhjL3RhYmxlcmFuZ2U6Y2E4MmZmZmRhOTA0NGQ5YThmYmYzMzdkZjU4ZGYwOGNfMi0wLTEtMS0wL3RleHRyZWdpb246ZmUxZWIwODY4MGVkNGI3Yjk4Y2U1OGIxNjA3NjkxMTBfNA_4663d741-1888-45e1-9952-0afec6dbcb73">550.0</ix:nonFraction> million Revolving Credit Facility; interest only payments; interest rate at Base Rate plus Applicable Rate or Eurodollar Rate plus Applicable Rate (<ix:nonFraction unitRef="number" contextRef="i805854b7963a41c7938b322adb3c1278_I20210630" decimals="3" name="amed:DebtInstrumentInterestRateatPeriodEnd" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV81OC9mcmFnOjAyNjBhN2Y0MDYyNzQ1ZTRhZWNlNjk4NThjOTI1ZDkyL3RhYmxlOmNhODJmZmZkYTkwNDRkOWE4ZmJmMzM3ZGY1OGRmMDhjL3RhYmxlcmFuZ2U6Y2E4MmZmZmRhOTA0NGQ5YThmYmYzMzdkZjU4ZGYwOGNfMi0wLTEtMS0wL3RleHRyZWdpb246ZmUxZWIwODY4MGVkNGI3Yjk4Y2U1OGIxNjA3NjkxMTBfMTQ3_f8bcea73-a1b6-4af2-8eaf-d0309f7f96a7">1.3</ix:nonFraction>% at June 30, 2021); due <ix:nonNumeric contextRef="if607f3cb243b4973902b1d41f80fb10c_D20210101-20210630" format="ixt:datemonthdayyearen" name="us-gaap:DebtInstrumentMaturityDate" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV81OC9mcmFnOjAyNjBhN2Y0MDYyNzQ1ZTRhZWNlNjk4NThjOTI1ZDkyL3RhYmxlOmNhODJmZmZkYTkwNDRkOWE4ZmJmMzM3ZGY1OGRmMDhjL3RhYmxlcmFuZ2U6Y2E4MmZmZmRhOTA0NGQ5YThmYmYzMzdkZjU4ZGYwOGNfMi0wLTEtMS0wL3RleHRyZWdpb246ZmUxZWIwODY4MGVkNGI3Yjk4Y2U1OGIxNjA3NjkxMTBfMTc0_df813017-1d04-487a-b395-5d9b4ee84a2b">February&#160;4, 2024</ix:nonNumeric></span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b034d16545343f69ba28f30d62f22c2_I20210630" decimals="-5" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV81OC9mcmFnOjAyNjBhN2Y0MDYyNzQ1ZTRhZWNlNjk4NThjOTI1ZDkyL3RhYmxlOmNhODJmZmZkYTkwNDRkOWE4ZmJmMzM3ZGY1OGRmMDhjL3RhYmxlcmFuZ2U6Y2E4MmZmZmRhOTA0NGQ5YThmYmYzMzdkZjU4ZGYwOGNfMi0xLTEtMS0w_b978315e-9d54-4f31-a14e-f9e90e241185">30.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0eccf63206474ddaa2ee2c286f646d71_I20201231" decimals="-5" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV81OC9mcmFnOjAyNjBhN2Y0MDYyNzQ1ZTRhZWNlNjk4NThjOTI1ZDkyL3RhYmxlOmNhODJmZmZkYTkwNDRkOWE4ZmJmMzM3ZGY1OGRmMDhjL3RhYmxlcmFuZ2U6Y2E4MmZmZmRhOTA0NGQ5YThmYmYzMzdkZjU4ZGYwOGNfMi0zLTEtMS0w_3b93297c-25c3-4c63-bdc5-f2d40da14949">51.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance leases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1083386f2394412b5f29ff8fd11b397_I20210630" decimals="-5" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV81OC9mcmFnOjAyNjBhN2Y0MDYyNzQ1ZTRhZWNlNjk4NThjOTI1ZDkyL3RhYmxlOmNhODJmZmZkYTkwNDRkOWE4ZmJmMzM3ZGY1OGRmMDhjL3RhYmxlcmFuZ2U6Y2E4MmZmZmRhOTA0NGQ5YThmYmYzMzdkZjU4ZGYwOGNfMy0xLTEtMS0w_e912be99-98cf-494e-a7c0-a4dcac10a84b">2.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibbcbe46ad8ac4ae8a7fd039b14ce5a80_I20201231" decimals="-5" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV81OC9mcmFnOjAyNjBhN2Y0MDYyNzQ1ZTRhZWNlNjk4NThjOTI1ZDkyL3RhYmxlOmNhODJmZmZkYTkwNDRkOWE4ZmJmMzM3ZGY1OGRmMDhjL3RhYmxlcmFuZ2U6Y2E4MmZmZmRhOTA0NGQ5YThmYmYzMzdkZjU4ZGYwOGNfMy0zLTEtMS0w_43dc8fa4-fa27-4ed3-a5c8-b5d591bd5b66">2.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Principal amount of long-term obligations</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e833203be6947b4968aba4d20064ec8_I20210630" decimals="-5" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV81OC9mcmFnOjAyNjBhN2Y0MDYyNzQ1ZTRhZWNlNjk4NThjOTI1ZDkyL3RhYmxlOmNhODJmZmZkYTkwNDRkOWE4ZmJmMzM3ZGY1OGRmMDhjL3RhYmxlcmFuZ2U6Y2E4MmZmZmRhOTA0NGQ5YThmYmYzMzdkZjU4ZGYwOGNfNC0xLTEtMS0w_a8ccd835-0d99-4aa6-8fca-9db4b7386a48">191.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87ceb60dc20d4df1b0a97d3514837910_I20201231" decimals="-5" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV81OC9mcmFnOjAyNjBhN2Y0MDYyNzQ1ZTRhZWNlNjk4NThjOTI1ZDkyL3RhYmxlOmNhODJmZmZkYTkwNDRkOWE4ZmJmMzM3ZGY1OGRmMDhjL3RhYmxlcmFuZ2U6Y2E4MmZmZmRhOTA0NGQ5YThmYmYzMzdkZjU4ZGYwOGNfNC0zLTEtMS0w_d5bd4c68-1238-4db6-9126-f2550e22d85b">217.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred debt issuance costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1e833203be6947b4968aba4d20064ec8_I20210630" decimals="-5" name="us-gaap:DeferredFinanceCostsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV81OC9mcmFnOjAyNjBhN2Y0MDYyNzQ1ZTRhZWNlNjk4NThjOTI1ZDkyL3RhYmxlOmNhODJmZmZkYTkwNDRkOWE4ZmJmMzM3ZGY1OGRmMDhjL3RhYmxlcmFuZ2U6Y2E4MmZmZmRhOTA0NGQ5YThmYmYzMzdkZjU4ZGYwOGNfNS0xLTEtMS0w_856edc94-4a25-406b-af9c-43da4c4c134e">2.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i87ceb60dc20d4df1b0a97d3514837910_I20201231" decimals="-5" name="us-gaap:DeferredFinanceCostsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV81OC9mcmFnOjAyNjBhN2Y0MDYyNzQ1ZTRhZWNlNjk4NThjOTI1ZDkyL3RhYmxlOmNhODJmZmZkYTkwNDRkOWE4ZmJmMzM3ZGY1OGRmMDhjL3RhYmxlcmFuZ2U6Y2E4MmZmZmRhOTA0NGQ5YThmYmYzMzdkZjU4ZGYwOGNfNS0zLTEtMS0w_66595d5e-3794-44de-8678-acc4437bb7c0">2.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e833203be6947b4968aba4d20064ec8_I20210630" decimals="-5" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV81OC9mcmFnOjAyNjBhN2Y0MDYyNzQ1ZTRhZWNlNjk4NThjOTI1ZDkyL3RhYmxlOmNhODJmZmZkYTkwNDRkOWE4ZmJmMzM3ZGY1OGRmMDhjL3RhYmxlcmFuZ2U6Y2E4MmZmZmRhOTA0NGQ5YThmYmYzMzdkZjU4ZGYwOGNfNi0xLTEtMS0w_c291234a-2607-404c-8266-3a71b2681a7a">189.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87ceb60dc20d4df1b0a97d3514837910_I20201231" decimals="-5" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV81OC9mcmFnOjAyNjBhN2Y0MDYyNzQ1ZTRhZWNlNjk4NThjOTI1ZDkyL3RhYmxlOmNhODJmZmZkYTkwNDRkOWE4ZmJmMzM3ZGY1OGRmMDhjL3RhYmxlcmFuZ2U6Y2E4MmZmZmRhOTA0NGQ5YThmYmYzMzdkZjU4ZGYwOGNfNi0zLTEtMS0w_5070f531-5498-40b3-9db6-ff361289a298">215.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of long-term obligations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1e833203be6947b4968aba4d20064ec8_I20210630" decimals="-5" name="us-gaap:LongTermDebtCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV81OC9mcmFnOjAyNjBhN2Y0MDYyNzQ1ZTRhZWNlNjk4NThjOTI1ZDkyL3RhYmxlOmNhODJmZmZkYTkwNDRkOWE4ZmJmMzM3ZGY1OGRmMDhjL3RhYmxlcmFuZ2U6Y2E4MmZmZmRhOTA0NGQ5YThmYmYzMzdkZjU4ZGYwOGNfNy0xLTEtMS0w_55a70a1e-1fd5-48c8-91fb-4dc557b4601b">10.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i87ceb60dc20d4df1b0a97d3514837910_I20201231" decimals="-5" name="us-gaap:LongTermDebtCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV81OC9mcmFnOjAyNjBhN2Y0MDYyNzQ1ZTRhZWNlNjk4NThjOTI1ZDkyL3RhYmxlOmNhODJmZmZkYTkwNDRkOWE4ZmJmMzM3ZGY1OGRmMDhjL3RhYmxlcmFuZ2U6Y2E4MmZmZmRhOTA0NGQ5YThmYmYzMzdkZjU4ZGYwOGNfNy0zLTEtMS0w_28293866-9533-4b31-97df-0833c2c0f142">10.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e833203be6947b4968aba4d20064ec8_I20210630" decimals="-5" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV81OC9mcmFnOjAyNjBhN2Y0MDYyNzQ1ZTRhZWNlNjk4NThjOTI1ZDkyL3RhYmxlOmNhODJmZmZkYTkwNDRkOWE4ZmJmMzM3ZGY1OGRmMDhjL3RhYmxlcmFuZ2U6Y2E4MmZmZmRhOTA0NGQ5YThmYmYzMzdkZjU4ZGYwOGNfOC0xLTEtMS0w_1b5fc7ec-c255-433b-ae14-b3b3a65af8f4">179.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87ceb60dc20d4df1b0a97d3514837910_I20201231" decimals="-5" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV81OC9mcmFnOjAyNjBhN2Y0MDYyNzQ1ZTRhZWNlNjk4NThjOTI1ZDkyL3RhYmxlOmNhODJmZmZkYTkwNDRkOWE4ZmJmMzM3ZGY1OGRmMDhjL3RhYmxlcmFuZ2U6Y2E4MmZmZmRhOTA0NGQ5YThmYmYzMzdkZjU4ZGYwOGNfOC0zLTEtMS0w_e79f21d9-758e-48e2-a4af-13ca83c5eabd">204.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div><div style="text-align:center"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">First Amendment to Amended and Restated Credit Agreement</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 4, 2019, we entered into the First Amendment to our Credit Agreement (as amended by the First Amendment, the "Amended Credit Agreement"). The Amended Credit Agreement provides for a senior secured credit facility in an initial aggregate principal amount of up to $<ix:nonFraction unitRef="usd" contextRef="i44c7af72d3a34639b4816895619e7f09_I20190204" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV81OC9mcmFnOjAyNjBhN2Y0MDYyNzQ1ZTRhZWNlNjk4NThjOTI1ZDkyL3RleHRyZWdpb246MDI2MGE3ZjQwNjI3NDVlNGFlY2U2OTg1OGM5MjVkOTJfNDU2_015d9e24-c6e7-40ae-814f-9f162b5eea01">725.0</ix:nonFraction> million, which includes a $<ix:nonFraction unitRef="usd" contextRef="i24530ac946f344808f972a08211612f0_I20190204" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV81OC9mcmFnOjAyNjBhN2Y0MDYyNzQ1ZTRhZWNlNjk4NThjOTI1ZDkyL3RleHRyZWdpb246MDI2MGE3ZjQwNjI3NDVlNGFlY2U2OTg1OGM5MjVkOTJfNDc3_a7420d25-fd12-433c-890d-4fab98d1dbc1">550.0</ix:nonFraction> million Revolving Credit Facility under the Credit Agreement, and a term loan facility with a principal amount of up to $<ix:nonFraction unitRef="usd" contextRef="i2d0c143d688b41d490b2ea06ad3046d0_I20190204" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV81OC9mcmFnOjAyNjBhN2Y0MDYyNzQ1ZTRhZWNlNjk4NThjOTI1ZDkyL3RleHRyZWdpb246MDI2MGE3ZjQwNjI3NDVlNGFlY2U2OTg1OGM5MjVkOTJfNTky_f3e44355-7950-4467-97b7-a046e0294cab">175.0</ix:nonFraction> million (the "Term Loan Facility" and collectively with the Revolving Credit Facility, the "Credit Facility"), which was added by the First Amendment.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The loans issued under the Credit Facility bear interest on a per annum basis, at our election, at either: (i) the Base Rate plus the Applicable Rate or (ii) the Eurodollar Rate plus the Applicable Rate. The &#8220;Base Rate&#8221; means a fluctuating rate per annum equal to the highest of (a) the federal funds rate plus <ix:nonFraction unitRef="number" contextRef="i9ae11ec3a41040829df9de1fe8e7b2bb_D20190204-20190204" decimals="INF" name="amed:DebtInstrumentInterestAdditionalInterestAboveFederalFundRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV81OC9mcmFnOjAyNjBhN2Y0MDYyNzQ1ZTRhZWNlNjk4NThjOTI1ZDkyL3RleHRyZWdpb246MDI2MGE3ZjQwNjI3NDVlNGFlY2U2OTg1OGM5MjVkOTJfMTA1MA_a0a2469e-5ad3-47f5-8b34-17ec1a93c170">0.50</ix:nonFraction>% per annum, (b) the prime rate of interest established by the Administrative Agent, and (c) the Eurodollar Rate plus <ix:nonFraction unitRef="number" contextRef="i9ae11ec3a41040829df9de1fe8e7b2bb_D20190204-20190204" decimals="INF" name="amed:DebtInstrumentInterestAdditionalInterestAboveEurodollarRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV81OC9mcmFnOjAyNjBhN2Y0MDYyNzQ1ZTRhZWNlNjk4NThjOTI1ZDkyL3RleHRyZWdpb246MDI2MGE3ZjQwNjI3NDVlNGFlY2U2OTg1OGM5MjVkOTJfMTE2OQ_1ff545c4-e545-47d8-9d16-7d17b67f8900">1</ix:nonFraction>% per annum. The &#8220;Eurodollar Rate&#8221; means the quoted rate per annum equal to the London Interbank Offered Rate (&#8220;LIBOR&#8221;) or a comparable successor rate approved by the Administrative Agent for an interest period of one, two, three or six months (as selected by us). The &#8220;Applicable Rate&#8221; is based on the consolidated leverage ratio and is presented in the table below. As of June&#160;30, 2021, the Applicable Rate is <ix:nonFraction unitRef="number" contextRef="iee6ede9b55994de38f9991f940db59e9_D20210101-20210630" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV81OC9mcmFnOjAyNjBhN2Y0MDYyNzQ1ZTRhZWNlNjk4NThjOTI1ZDkyL3RleHRyZWdpb246MDI2MGE3ZjQwNjI3NDVlNGFlY2U2OTg1OGM5MjVkOTJfMTU3MQ_569f6e58-51b4-4df9-b361-c69663912f83">0.25</ix:nonFraction>% per annum for Base Rate loans and <ix:nonFraction unitRef="number" contextRef="i572c716155d248eeb353108705827f98_D20210101-20210630" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV81OC9mcmFnOjAyNjBhN2Y0MDYyNzQ1ZTRhZWNlNjk4NThjOTI1ZDkyL3RleHRyZWdpb246MDI2MGE3ZjQwNjI3NDVlNGFlY2U2OTg1OGM5MjVkOTJfMTYwOA_d3f1a189-a208-4042-bd53-587fb192f534">1.25</ix:nonFraction>% per annum for Eurodollar Rate loans. <ix:nonNumeric contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630" name="us-gaap:ScheduleOfLineOfCreditFacilitiesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV81OC9mcmFnOjAyNjBhN2Y0MDYyNzQ1ZTRhZWNlNjk4NThjOTI1ZDkyL3RleHRyZWdpb246MDI2MGE3ZjQwNjI3NDVlNGFlY2U2OTg1OGM5MjVkOTJfNjg4NA_b2651087-2187-40af-8805-6c68fcca5d15" continuedAt="iae82d2c9e59443a794efda9a740df170" escape="true">We are also subject to a commitment fee and letter of credit fee under the terms of the Amended Credit Agreement, as presented in the table below.</ix:nonNumeric></span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AMEDISYS, INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></div><ix:continuation id="ia62edaa211e042f68fd700133ff2eb2d" continuedAt="i6e7d8357893e4ea9884853677b30cd69"><div style="text-align:center"><ix:continuation id="iae82d2c9e59443a794efda9a740df170"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.251%"><tr><td style="width:1.0%"></td><td style="width:10.151%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.158%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.808%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.736%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.808%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.739%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Pricing Tier</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Consolidated Leverage Ratio</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Commitment Fee</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Letter of Credit Fee</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Eurodollar Rate Loans</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Base Rate Loans</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">I</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8805; <ix:nonFraction unitRef="number" contextRef="ib51e6cda5b7f4d999f0a54be2194e8fd_D20210101-20210630" decimals="INF" name="amed:ConsolidatedLeverageRatio" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV81OC9mcmFnOjAyNjBhN2Y0MDYyNzQ1ZTRhZWNlNjk4NThjOTI1ZDkyL3RhYmxlOmE4ZTYyZDk1ZTQ1YjRjZmJhODhjZjg4Zjg0MThiOTU4L3RhYmxlcmFuZ2U6YThlNjJkOTVlNDViNGNmYmE4OGNmODhmODQxOGI5NThfMS0xLTEtMS0wL3RleHRyZWdpb246MGZkMDZhZGJkOTRlNGVjNWJiMWU1NmJhZGI3NzI4NTRfNg_3bfefe01-e537-4513-9624-9c66f71788a9">3.00</ix:nonFraction> to 1.0</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie89771700f0d460f9ee341c9f33ad463_D20210101-20210630" decimals="INF" name="us-gaap:LineOfCreditFacilityCommitmentFeePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV81OC9mcmFnOjAyNjBhN2Y0MDYyNzQ1ZTRhZWNlNjk4NThjOTI1ZDkyL3RhYmxlOmE4ZTYyZDk1ZTQ1YjRjZmJhODhjZjg4Zjg0MThiOTU4L3RhYmxlcmFuZ2U6YThlNjJkOTVlNDViNGNmYmE4OGNmODhmODQxOGI5NThfMS0yLTEtMS0w_9389ce9f-05e9-48dd-9652-e4064e4863f7">0.35</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie89771700f0d460f9ee341c9f33ad463_D20210101-20210630" decimals="INF" name="amed:LetterOfCreditFee" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV81OC9mcmFnOjAyNjBhN2Y0MDYyNzQ1ZTRhZWNlNjk4NThjOTI1ZDkyL3RhYmxlOmE4ZTYyZDk1ZTQ1YjRjZmJhODhjZjg4Zjg0MThiOTU4L3RhYmxlcmFuZ2U6YThlNjJkOTVlNDViNGNmYmE4OGNmODhmODQxOGI5NThfMS0zLTEtMS0w_899d59d4-9423-4f20-a6aa-a71ca01b67a6">1.75</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i8b4a04615e76432ca77412a8ce8c97a7_D20210101-20210630" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV81OC9mcmFnOjAyNjBhN2Y0MDYyNzQ1ZTRhZWNlNjk4NThjOTI1ZDkyL3RhYmxlOmE4ZTYyZDk1ZTQ1YjRjZmJhODhjZjg4Zjg0MThiOTU4L3RhYmxlcmFuZ2U6YThlNjJkOTVlNDViNGNmYmE4OGNmODhmODQxOGI5NThfMS00LTEtMS0w_b4e47269-729c-40f6-b3d1-7db843f5c949">2.00</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i80a16d16af124d8e8088f9cd85a66aa7_D20210101-20210630" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV81OC9mcmFnOjAyNjBhN2Y0MDYyNzQ1ZTRhZWNlNjk4NThjOTI1ZDkyL3RhYmxlOmE4ZTYyZDk1ZTQ1YjRjZmJhODhjZjg4Zjg0MThiOTU4L3RhYmxlcmFuZ2U6YThlNjJkOTVlNDViNGNmYmE4OGNmODhmODQxOGI5NThfMS01LTEtMS0w_8b93247c-6e9a-4635-95f8-222b1a84acdb">1.00</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">II</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&lt; <ix:nonFraction unitRef="number" contextRef="i32469c69675f451a93e53e98fcb09d2b_D20210101-20210630" decimals="INF" name="amed:ConsolidatedLeverageRatio" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV81OC9mcmFnOjAyNjBhN2Y0MDYyNzQ1ZTRhZWNlNjk4NThjOTI1ZDkyL3RhYmxlOmE4ZTYyZDk1ZTQ1YjRjZmJhODhjZjg4Zjg0MThiOTU4L3RhYmxlcmFuZ2U6YThlNjJkOTVlNDViNGNmYmE4OGNmODhmODQxOGI5NThfMi0xLTEtMS0wL3RleHRyZWdpb246NjAwN2ExYTJiZGFjNGU5ZDk4ZTkxMzA5MjliZmZlYjFfNg_c31b98f5-39a0-4d90-bf76-fd74532b6aa3">3.00</ix:nonFraction> to 1.0 but &#8805; <ix:nonFraction unitRef="number" contextRef="i762c3eb26082484eb8eda66cf8da59d4_D20210101-20210630" decimals="INF" name="amed:ConsolidatedLeverageRatio" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV81OC9mcmFnOjAyNjBhN2Y0MDYyNzQ1ZTRhZWNlNjk4NThjOTI1ZDkyL3RhYmxlOmE4ZTYyZDk1ZTQ1YjRjZmJhODhjZjg4Zjg0MThiOTU4L3RhYmxlcmFuZ2U6YThlNjJkOTVlNDViNGNmYmE4OGNmODhmODQxOGI5NThfMi0xLTEtMS0wL3RleHRyZWdpb246NjAwN2ExYTJiZGFjNGU5ZDk4ZTkxMzA5MjliZmZlYjFfMjI_21a21d5a-2608-4b23-bb94-cc8432a9ef3b">2.00</ix:nonFraction> to 1.0</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7ec9530f2497489684d4748db38f2068_D20210101-20210630" decimals="INF" name="us-gaap:LineOfCreditFacilityCommitmentFeePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV81OC9mcmFnOjAyNjBhN2Y0MDYyNzQ1ZTRhZWNlNjk4NThjOTI1ZDkyL3RhYmxlOmE4ZTYyZDk1ZTQ1YjRjZmJhODhjZjg4Zjg0MThiOTU4L3RhYmxlcmFuZ2U6YThlNjJkOTVlNDViNGNmYmE4OGNmODhmODQxOGI5NThfMi0yLTEtMS0w_263862a5-1f75-4b03-8790-5fc3000d0a5e">0.30</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7ec9530f2497489684d4748db38f2068_D20210101-20210630" decimals="INF" name="amed:LetterOfCreditFee" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV81OC9mcmFnOjAyNjBhN2Y0MDYyNzQ1ZTRhZWNlNjk4NThjOTI1ZDkyL3RhYmxlOmE4ZTYyZDk1ZTQ1YjRjZmJhODhjZjg4Zjg0MThiOTU4L3RhYmxlcmFuZ2U6YThlNjJkOTVlNDViNGNmYmE4OGNmODhmODQxOGI5NThfMi0zLTEtMS0w_f3cc9c9a-4ff7-4ee1-9566-0969b7201695">1.50</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9d2fd16e87294dce83ab4611dec95214_D20210101-20210630" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV81OC9mcmFnOjAyNjBhN2Y0MDYyNzQ1ZTRhZWNlNjk4NThjOTI1ZDkyL3RhYmxlOmE4ZTYyZDk1ZTQ1YjRjZmJhODhjZjg4Zjg0MThiOTU4L3RhYmxlcmFuZ2U6YThlNjJkOTVlNDViNGNmYmE4OGNmODhmODQxOGI5NThfMi00LTEtMS0w_1784646d-3978-445e-83ea-a778df376294">1.75</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i38341f6760194d9b94f32fad1615efeb_D20210101-20210630" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV81OC9mcmFnOjAyNjBhN2Y0MDYyNzQ1ZTRhZWNlNjk4NThjOTI1ZDkyL3RhYmxlOmE4ZTYyZDk1ZTQ1YjRjZmJhODhjZjg4Zjg0MThiOTU4L3RhYmxlcmFuZ2U6YThlNjJkOTVlNDViNGNmYmE4OGNmODhmODQxOGI5NThfMi01LTEtMS0w_87365ff1-b552-4d51-9670-4f1cb8ae81c0">0.75</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">III</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&lt; <ix:nonFraction unitRef="number" contextRef="i5a18c53bf827477aaee9ccc3df622571_D20210101-20210630" decimals="INF" name="amed:ConsolidatedLeverageRatio" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV81OC9mcmFnOjAyNjBhN2Y0MDYyNzQ1ZTRhZWNlNjk4NThjOTI1ZDkyL3RhYmxlOmE4ZTYyZDk1ZTQ1YjRjZmJhODhjZjg4Zjg0MThiOTU4L3RhYmxlcmFuZ2U6YThlNjJkOTVlNDViNGNmYmE4OGNmODhmODQxOGI5NThfMy0xLTEtMS0wL3RleHRyZWdpb246YWM0YjRiYzk3ODc5NGU5MWE0MjFkMjExY2I0OGEwYWVfNg_0db6fab0-f6aa-47d1-b97e-7206b584f061">2.00</ix:nonFraction> to 1.0 but &#8805; <ix:nonFraction unitRef="number" contextRef="ib6f866620dc2459b8f67a5cfdadf6297_D20210101-20210630" decimals="INF" name="amed:ConsolidatedLeverageRatio" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV81OC9mcmFnOjAyNjBhN2Y0MDYyNzQ1ZTRhZWNlNjk4NThjOTI1ZDkyL3RhYmxlOmE4ZTYyZDk1ZTQ1YjRjZmJhODhjZjg4Zjg0MThiOTU4L3RhYmxlcmFuZ2U6YThlNjJkOTVlNDViNGNmYmE4OGNmODhmODQxOGI5NThfMy0xLTEtMS0wL3RleHRyZWdpb246YWM0YjRiYzk3ODc5NGU5MWE0MjFkMjExY2I0OGEwYWVfMjI_cb13c6de-2785-4422-9eba-f70721ea165c">0.75</ix:nonFraction> to 1.0</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i3c46dc14b6294ba49b9a3b6291f5935e_D20210101-20210630" decimals="INF" name="us-gaap:LineOfCreditFacilityCommitmentFeePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV81OC9mcmFnOjAyNjBhN2Y0MDYyNzQ1ZTRhZWNlNjk4NThjOTI1ZDkyL3RhYmxlOmE4ZTYyZDk1ZTQ1YjRjZmJhODhjZjg4Zjg0MThiOTU4L3RhYmxlcmFuZ2U6YThlNjJkOTVlNDViNGNmYmE4OGNmODhmODQxOGI5NThfMy0yLTEtMS0w_178874de-e07a-4395-a7d4-ba4d9606d6b9">0.25</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i3c46dc14b6294ba49b9a3b6291f5935e_D20210101-20210630" decimals="INF" name="amed:LetterOfCreditFee" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV81OC9mcmFnOjAyNjBhN2Y0MDYyNzQ1ZTRhZWNlNjk4NThjOTI1ZDkyL3RhYmxlOmE4ZTYyZDk1ZTQ1YjRjZmJhODhjZjg4Zjg0MThiOTU4L3RhYmxlcmFuZ2U6YThlNjJkOTVlNDViNGNmYmE4OGNmODhmODQxOGI5NThfMy0zLTEtMS0w_90cc360b-c701-479a-819d-9b6c6eedb29f">1.25</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6981eb55a7b7401c865f1b05bd9c637f_D20210101-20210630" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV81OC9mcmFnOjAyNjBhN2Y0MDYyNzQ1ZTRhZWNlNjk4NThjOTI1ZDkyL3RhYmxlOmE4ZTYyZDk1ZTQ1YjRjZmJhODhjZjg4Zjg0MThiOTU4L3RhYmxlcmFuZ2U6YThlNjJkOTVlNDViNGNmYmE4OGNmODhmODQxOGI5NThfMy00LTEtMS0w_ef76fcfe-4c1b-4e37-80c8-0b1562915ce4">1.50</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib6892f04dce84842bc5c41b0589b3786_D20210101-20210630" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV81OC9mcmFnOjAyNjBhN2Y0MDYyNzQ1ZTRhZWNlNjk4NThjOTI1ZDkyL3RhYmxlOmE4ZTYyZDk1ZTQ1YjRjZmJhODhjZjg4Zjg0MThiOTU4L3RhYmxlcmFuZ2U6YThlNjJkOTVlNDViNGNmYmE4OGNmODhmODQxOGI5NThfMy01LTEtMS0w_d4138093-c180-4440-b9ae-3546dcc040ac">0.50</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IV</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&lt; <ix:nonFraction unitRef="number" contextRef="id9b0d221bc814a0cb3a2f624451a4f31_D20210101-20210630" decimals="INF" name="amed:ConsolidatedLeverageRatio" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV81OC9mcmFnOjAyNjBhN2Y0MDYyNzQ1ZTRhZWNlNjk4NThjOTI1ZDkyL3RhYmxlOmE4ZTYyZDk1ZTQ1YjRjZmJhODhjZjg4Zjg0MThiOTU4L3RhYmxlcmFuZ2U6YThlNjJkOTVlNDViNGNmYmE4OGNmODhmODQxOGI5NThfNC0xLTEtMS0wL3RleHRyZWdpb246ZGI2YTJjYWJiMGQ4NDZmZmE2OWFhMTU3MjBjNjkwNjlfNg_ddf21c19-b6a3-4635-a058-38dc9609d835">0.75</ix:nonFraction> to 1.0</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ieb0d2d2742204b2695d46e6be0103cd6_D20210101-20210630" decimals="INF" name="us-gaap:LineOfCreditFacilityCommitmentFeePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV81OC9mcmFnOjAyNjBhN2Y0MDYyNzQ1ZTRhZWNlNjk4NThjOTI1ZDkyL3RhYmxlOmE4ZTYyZDk1ZTQ1YjRjZmJhODhjZjg4Zjg0MThiOTU4L3RhYmxlcmFuZ2U6YThlNjJkOTVlNDViNGNmYmE4OGNmODhmODQxOGI5NThfNC0yLTEtMS0w_b0f6b86e-9ca6-4c78-92ff-701adb7eb283">0.20</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ieb0d2d2742204b2695d46e6be0103cd6_D20210101-20210630" decimals="INF" name="amed:LetterOfCreditFee" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV81OC9mcmFnOjAyNjBhN2Y0MDYyNzQ1ZTRhZWNlNjk4NThjOTI1ZDkyL3RhYmxlOmE4ZTYyZDk1ZTQ1YjRjZmJhODhjZjg4Zjg0MThiOTU4L3RhYmxlcmFuZ2U6YThlNjJkOTVlNDViNGNmYmE4OGNmODhmODQxOGI5NThfNC0zLTEtMS0w_ed3f0abf-9ea7-4963-9227-260e2d8df04e">1.00</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i634fd9a568bf480e98d90ea8e22ee7fd_D20210101-20210630" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV81OC9mcmFnOjAyNjBhN2Y0MDYyNzQ1ZTRhZWNlNjk4NThjOTI1ZDkyL3RhYmxlOmE4ZTYyZDk1ZTQ1YjRjZmJhODhjZjg4Zjg0MThiOTU4L3RhYmxlcmFuZ2U6YThlNjJkOTVlNDViNGNmYmE4OGNmODhmODQxOGI5NThfNC00LTEtMS0w_9547d916-a9f4-4d86-8e2d-05992068fa40">1.25</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i5ab7b8577acf41a4a08641839dff1c5f_D20210101-20210630" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV81OC9mcmFnOjAyNjBhN2Y0MDYyNzQ1ZTRhZWNlNjk4NThjOTI1ZDkyL3RhYmxlOmE4ZTYyZDk1ZTQ1YjRjZmJhODhjZjg4Zjg0MThiOTU4L3RhYmxlcmFuZ2U6YThlNjJkOTVlNDViNGNmYmE4OGNmODhmODQxOGI5NThfNC01LTEtMS0w_92ee7d4f-86bd-4d43-9e10-767abbdcf2dd">0.25</ix:nonFraction>%</span></td></tr></table></ix:continuation></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The final maturity date of the Credit Facility is <ix:nonNumeric contextRef="i9d61545dcadf4b1d94a320a38d0b1079_D20190204-20240204" format="ixt:datemonthdayyearen" name="us-gaap:DebtInstrumentMaturityDate" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV81OC9mcmFnOjAyNjBhN2Y0MDYyNzQ1ZTRhZWNlNjk4NThjOTI1ZDkyL3RleHRyZWdpb246MDI2MGE3ZjQwNjI3NDVlNGFlY2U2OTg1OGM5MjVkOTJfMTg0OQ_b8608e8c-38ed-4d5a-9081-ee7828c7d6e5">February 4, 2024</ix:nonNumeric>. The Revolving Credit Facility will terminate and be due and payable as of the final maturity date. The Term Loan Facility, however, is subject to quarterly amortization of principal in the amount of (i) <ix:nonFraction unitRef="number" contextRef="i100ffc02e1834ff6a0bbb7f8fc39dd3d_D20190204-20200331" decimals="INF" name="amed:DebtInstrumentPeriodicPaymentPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV81OC9mcmFnOjAyNjBhN2Y0MDYyNzQ1ZTRhZWNlNjk4NThjOTI1ZDkyL3RleHRyZWdpb246MDI2MGE3ZjQwNjI3NDVlNGFlY2U2OTg1OGM5MjVkOTJfMjA1Ng_00155a77-297a-4bde-8440-b7a99ca72e54">0.625</ix:nonFraction>% for the period commencing on February 4, 2019 and ending on March 31, 2020, (ii) <ix:nonFraction unitRef="number" contextRef="i641e495583ed40d7885721338515e386_D20200401-20230331" decimals="INF" name="amed:DebtInstrumentPeriodicPaymentPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV81OC9mcmFnOjAyNjBhN2Y0MDYyNzQ1ZTRhZWNlNjk4NThjOTI1ZDkyL3RleHRyZWdpb246MDI2MGE3ZjQwNjI3NDVlNGFlY2U2OTg1OGM5MjVkOTJfMjE0MA_9fb6d57c-3c60-4ff6-beed-ac6cfe936ab2">1.250</ix:nonFraction>% for the period commencing on April 1, 2020 and ending on March 31, 2023, and (iii) <ix:nonFraction unitRef="number" contextRef="i9f2171b5c0f742c18a35279b1904e320_D20230401-20240204" decimals="INF" name="amed:DebtInstrumentPeriodicPaymentPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV81OC9mcmFnOjAyNjBhN2Y0MDYyNzQ1ZTRhZWNlNjk4NThjOTI1ZDkyL3RleHRyZWdpb246MDI2MGE3ZjQwNjI3NDVlNGFlY2U2OTg1OGM5MjVkOTJfMjIyNg_ce146890-d315-4cbf-bd4a-d6f4b31d8ee0">1.875</ix:nonFraction>% for the period commencing on April 1, 2023 and ending on February 4, 2024. The remaining balance of the Term Loan Facility must be paid upon the final maturity date. In addition to the scheduled amortization of the Term Loan Facility, and subject to customary exceptions and reinvestment rights, we are required to prepay the Term Loan Facility first and the Revolving Credit Facility second with 100% of all net cash proceeds received by any loan party or any subsidiary thereof in connection with (a) any asset sale or disposition where such loan party receives net cash proceeds in excess of $<ix:nonFraction unitRef="usd" contextRef="ibc8d6081948b4e9190302d69d2b70231_D20190204-20190204" decimals="-5" format="ixt:numdotdecimal" name="amed:ProceedsReceivedFromLoanPartyOfSubsidiary" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV81OC9mcmFnOjAyNjBhN2Y0MDYyNzQ1ZTRhZWNlNjk4NThjOTI1ZDkyL3RleHRyZWdpb246MDI2MGE3ZjQwNjI3NDVlNGFlY2U2OTg1OGM5MjVkOTJfMjgyNA_4e896d6d-75ea-4c83-9a4d-25428cd796ce">5</ix:nonFraction> million or (b) any debt issuance that is not permitted under the Amended Credit Agreement.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Amended Credit Agreement requires maintenance of two financial covenants: (i) a consolidated leverage ratio of funded indebtedness to Earnings Before Interest, Taxes, Depreciation and Amortization ("EBITDA"), as defined in the Amended Credit Agreement, and (ii) a consolidated interest coverage ratio of EBITDA to cash interest charges, as defined in the Amended Credit Agreement. Each of these covenants is calculated over rolling four-quarter periods and also is subject to certain exceptions and baskets. The Amended Credit Agreement also contains customary covenants, including, but not limited to, restrictions on: incurrence of liens, incurrence of additional debt, sales of assets and other fundamental corporate changes, investments, and declarations of dividends. These covenants contain customary exclusions and baskets as detailed in the Amended Credit Agreement. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Revolving Credit Facility is guaranteed by substantially all of our wholly-owned direct and indirect subsidiaries. The Amended Credit Agreement requires at all times that we (i) provide guarantees from wholly-owned subsidiaries that in the aggregate represent not less than <ix:nonFraction unitRef="number" contextRef="i9ae11ec3a41040829df9de1fe8e7b2bb_D20190204-20190204" decimals="INF" name="amed:PercentageOfRevenueAndOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromWhollyOwnedSubsidiaries" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV81OC9mcmFnOjAyNjBhN2Y0MDYyNzQ1ZTRhZWNlNjk4NThjOTI1ZDkyL3RleHRyZWdpb246MDI2MGE3ZjQwNjI3NDVlNGFlY2U2OTg1OGM5MjVkOTJfNDA3MA_e6f007cd-e004-417c-bb36-1e8f30a89fd3">95</ix:nonFraction>% of our consolidated net revenues and adjusted EBITDA from all wholly-owned subsidiaries and (ii) provide guarantees from subsidiaries that in the aggregate represent not less than <ix:nonFraction unitRef="number" contextRef="i9ae11ec3a41040829df9de1fe8e7b2bb_D20190204-20190204" decimals="INF" name="amed:PercentageOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromSubsidiaries" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV81OC9mcmFnOjAyNjBhN2Y0MDYyNzQ1ZTRhZWNlNjk4NThjOTI1ZDkyL3RleHRyZWdpb246MDI2MGE3ZjQwNjI3NDVlNGFlY2U2OTg1OGM5MjVkOTJfNDI1Mw_053e783c-cde2-400c-8ae3-7795fac3488c">70</ix:nonFraction>% of consolidated adjusted EBITDA, subject to certain exceptions.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our weighted average interest rate for borrowings under our $<ix:nonFraction unitRef="usd" contextRef="i9b034d16545343f69ba28f30d62f22c2_I20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV81OC9mcmFnOjAyNjBhN2Y0MDYyNzQ1ZTRhZWNlNjk4NThjOTI1ZDkyL3RleHRyZWdpb246MDI2MGE3ZjQwNjI3NDVlNGFlY2U2OTg1OGM5MjVkOTJfNDM4MQ_391e7c82-8333-417d-844e-46ff4cf2c77c">550.0</ix:nonFraction> million Revolving Credit Facility was <ix:nonFraction unitRef="number" contextRef="i21fda464ca064b61a04aca5a4c5e6a99_D20210401-20210630" decimals="3" name="us-gaap:LongTermDebtWeightedAverageInterestRateOverTime" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV81OC9mcmFnOjAyNjBhN2Y0MDYyNzQ1ZTRhZWNlNjk4NThjOTI1ZDkyL3RleHRyZWdpb246MDI2MGE3ZjQwNjI3NDVlNGFlY2U2OTg1OGM5MjVkOTJfNDQxNA_b7cc9088-c55f-41f8-a502-59f3e50b38e9">1.7</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="if607f3cb243b4973902b1d41f80fb10c_D20210101-20210630" decimals="3" name="us-gaap:LongTermDebtWeightedAverageInterestRateOverTime" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV81OC9mcmFnOjAyNjBhN2Y0MDYyNzQ1ZTRhZWNlNjk4NThjOTI1ZDkyL3RleHRyZWdpb246MDI2MGE3ZjQwNjI3NDVlNGFlY2U2OTg1OGM5MjVkOTJfNDQyMQ_b74028cc-33c9-4308-b5af-94da3170453e">1.8</ix:nonFraction>% for the three and six-month periods ended June&#160;30, 2021, respectively, and <ix:nonFraction unitRef="number" contextRef="idb01e853251e464c9326896aad4c2a8f_D20200401-20200630" decimals="3" name="us-gaap:LongTermDebtWeightedAverageInterestRateOverTime" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV81OC9mcmFnOjAyNjBhN2Y0MDYyNzQ1ZTRhZWNlNjk4NThjOTI1ZDkyL3RleHRyZWdpb246MDI2MGE3ZjQwNjI3NDVlNGFlY2U2OTg1OGM5MjVkOTJfMTA5OTUxMTYzNDgwMg_1dbb8534-c0fb-4b9b-a1ae-52bcf1b1b48c">2.1</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="ib304b65d4507498f9d3f7647d9dbaccd_D20200101-20200630" decimals="3" name="us-gaap:LongTermDebtWeightedAverageInterestRateOverTime" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV81OC9mcmFnOjAyNjBhN2Y0MDYyNzQ1ZTRhZWNlNjk4NThjOTI1ZDkyL3RleHRyZWdpb246MDI2MGE3ZjQwNjI3NDVlNGFlY2U2OTg1OGM5MjVkOTJfMTA5OTUxMTYzNDgwOA_40bab50e-2c46-401d-b617-11aff353152a">2.5</ix:nonFraction>% for the three and six-month periods ended June 30, 2020, respectively. Our weighted average interest rate for borrowings under our $<ix:nonFraction unitRef="usd" contextRef="i4f3b5acefd614cc18bfcd62fc3a07ded_I20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV81OC9mcmFnOjAyNjBhN2Y0MDYyNzQ1ZTRhZWNlNjk4NThjOTI1ZDkyL3RleHRyZWdpb246MDI2MGE3ZjQwNjI3NDVlNGFlY2U2OTg1OGM5MjVkOTJfNDU0NQ_e5f08446-a11f-4211-ac33-b1971c59560b">175.0</ix:nonFraction> million Term Loan Facility was <ix:nonFraction unitRef="number" contextRef="ib3b582f4212244b0884fcc031ea6c067_D20210401-20210630" decimals="3" name="us-gaap:LongTermDebtWeightedAverageInterestRateOverTime" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV81OC9mcmFnOjAyNjBhN2Y0MDYyNzQ1ZTRhZWNlNjk4NThjOTI1ZDkyL3RleHRyZWdpb246MDI2MGE3ZjQwNjI3NDVlNGFlY2U2OTg1OGM5MjVkOTJfNDU3MQ_2420680c-4db7-4beb-b8be-3cca0b023f09">1.4</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i282996a0cb644ac088b44f613c53cdcb_D20210101-20210630" decimals="3" name="us-gaap:LongTermDebtWeightedAverageInterestRateOverTime" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV81OC9mcmFnOjAyNjBhN2Y0MDYyNzQ1ZTRhZWNlNjk4NThjOTI1ZDkyL3RleHRyZWdpb246MDI2MGE3ZjQwNjI3NDVlNGFlY2U2OTg1OGM5MjVkOTJfNDU3OA_152a097d-1bf2-4fa5-8e47-1b685160a897">1.5</ix:nonFraction>% for the three and six-month periods ended June&#160;30, 2021, respectively,  and <ix:nonFraction unitRef="number" contextRef="ie080c42adb394ab1aac8bdf81d4f0952_D20200401-20200630" decimals="3" name="us-gaap:LongTermDebtWeightedAverageInterestRateOverTime" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV81OC9mcmFnOjAyNjBhN2Y0MDYyNzQ1ZTRhZWNlNjk4NThjOTI1ZDkyL3RleHRyZWdpb246MDI2MGE3ZjQwNjI3NDVlNGFlY2U2OTg1OGM5MjVkOTJfMTA5OTUxMTYzNDkzMg_24ef27d3-a312-4319-9bba-193e33618b94">2.0</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i2b242548637548e5845bd5ec7ebead8c_D20200101-20200630" decimals="3" name="us-gaap:LongTermDebtWeightedAverageInterestRateOverTime" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV81OC9mcmFnOjAyNjBhN2Y0MDYyNzQ1ZTRhZWNlNjk4NThjOTI1ZDkyL3RleHRyZWdpb246MDI2MGE3ZjQwNjI3NDVlNGFlY2U2OTg1OGM5MjVkOTJfMTA5OTUxMTYzNDkzOA_9d7b568f-3dc2-430b-85b9-19c64337a2be">2.6</ix:nonFraction>% for the three and six-month periods ended June 30, 2020, respectively.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2021, our consolidated leverage ratio was <ix:nonFraction unitRef="number" contextRef="i1e833203be6947b4968aba4d20064ec8_I20210630" decimals="INF" name="amed:TotalLeverageRatio" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV81OC9mcmFnOjAyNjBhN2Y0MDYyNzQ1ZTRhZWNlNjk4NThjOTI1ZDkyL3RleHRyZWdpb246MDI2MGE3ZjQwNjI3NDVlNGFlY2U2OTg1OGM5MjVkOTJfNDY4OA_3dd63267-d30e-419a-93e4-47c54c80aa4c">0.5</ix:nonFraction>, our consolidated interest coverage ratio was <ix:nonFraction unitRef="number" contextRef="i1e833203be6947b4968aba4d20064ec8_I20210630" decimals="INF" name="amed:ConsolidatedInterestCoverageRatio" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV81OC9mcmFnOjAyNjBhN2Y0MDYyNzQ1ZTRhZWNlNjk4NThjOTI1ZDkyL3RleHRyZWdpb246MDI2MGE3ZjQwNjI3NDVlNGFlY2U2OTg1OGM5MjVkOTJfNDczNw_5e85bb12-b90b-4ae2-aabc-fffc164b7b20">41.9</ix:nonFraction> and we are in compliance with our covenants under the Amended Credit Agreement. In the event we are not in compliance with our debt covenants in the future, we would pursue various alternatives in an attempt to successfully resolve the non-compliance, which might include, among other things, seeking debt covenant waivers or amendments.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2021, our availability under our $<ix:nonFraction unitRef="usd" contextRef="i9b034d16545343f69ba28f30d62f22c2_I20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV81OC9mcmFnOjAyNjBhN2Y0MDYyNzQ1ZTRhZWNlNjk4NThjOTI1ZDkyL3RleHRyZWdpb246MDI2MGE3ZjQwNjI3NDVlNGFlY2U2OTg1OGM5MjVkOTJfNTExNQ_0becd939-4bf3-4611-9989-65b3ae6ee34d">550.0</ix:nonFraction> million Revolving Credit Facility was $<ix:nonFraction unitRef="usd" contextRef="i9b034d16545343f69ba28f30d62f22c2_I20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV81OC9mcmFnOjAyNjBhN2Y0MDYyNzQ1ZTRhZWNlNjk4NThjOTI1ZDkyL3RleHRyZWdpb246MDI2MGE3ZjQwNjI3NDVlNGFlY2U2OTg1OGM5MjVkOTJfNTE0OA_81eff7b6-65ef-4156-ab4e-cf3b50429316">490.3</ix:nonFraction> million as we have $<ix:nonFraction unitRef="usd" contextRef="i9b034d16545343f69ba28f30d62f22c2_I20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV81OC9mcmFnOjAyNjBhN2Y0MDYyNzQ1ZTRhZWNlNjk4NThjOTI1ZDkyL3RleHRyZWdpb246MDI2MGE3ZjQwNjI3NDVlNGFlY2U2OTg1OGM5MjVkOTJfNTE2Mg_acdf7974-173a-49e5-a1c1-df4c28c90b84">30.0</ix:nonFraction> million outstanding in borrowings and $<ix:nonFraction unitRef="usd" contextRef="i123b2ec3b6424cd7858def47d8c592e4_I20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LettersOfCreditOutstandingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV81OC9mcmFnOjAyNjBhN2Y0MDYyNzQ1ZTRhZWNlNjk4NThjOTI1ZDkyL3RleHRyZWdpb246MDI2MGE3ZjQwNjI3NDVlNGFlY2U2OTg1OGM5MjVkOTJfNTE5NQ_66413829-4361-4a7a-9ac5-71379762f5b9">29.7</ix:nonFraction> million outstanding in letters of credit.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 30, 2021, we entered into a Second Amendment to our Credit Agreement (the &#8220;Second Amended Credit Agreement&#8221;). See Note 10 - Subsequent Events for additional information on the Second Amended Credit Agreement.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AMEDISYS, INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></div><ix:continuation id="i6e7d8357893e4ea9884853677b30cd69"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Joinder Agreements</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Compassionate Care Hospice ("CCH") acquisition, we entered into a Joinder Agreement, dated as of February 4, 2019 (the &#8220;CCH Joinder&#8221;), pursuant to which CCH and its subsidiaries were made parties to, and became subject to the terms and conditions of, the Amended Credit Agreement, the Amended and Restated Security Agreement, dated as of June 29, 2018 (the &#8220;Amended and Restated Security Agreement&#8221;), and the Amended and Restated Pledge Agreement, dated as of June 29, 2018 (the &#8220;Amended and Restated Pledge Agreement&#8221;). In connection with the AseraCare acquisition, we entered into a Joinder Agreement, dated as of June 12, 2020, pursuant to which the AseraCare entities were made parties to, and became subject to the terms and conditions of, the Amended Credit Agreement, the Amended and Restated Security Agreement and the Amended and Restated Pledge Agreement (the &#8220;AseraCare Joinder,&#8221; and together with the CCH Joinder, the &#8220;Joinders&#8221;).  Pursuant to the Joinders, the Amended and Restated Security Agreement and the Amended and Restated Pledge Agreement, CCH and its subsidiaries and the AseraCare entities granted in favor of the Administrative Agent a first lien security interest in substantially all of their personal property assets and pledged to the Administrative Agent each of their respective subsidiaries' issued and outstanding equity interests. CCH and its subsidiaries and the AseraCare entities also guaranteed our obligations, whether now existing or arising after the respective effective dates of the Joinders, under the Amended Credit Agreement pursuant to the terms of the Joinders and the Amended Credit Agreement.</span></div></ix:continuation><div id="iccd9c69ecd2c42e5897cfe9ab4e7e0b5_64"></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6. <ix:nonNumeric contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV82NC9mcmFnOmI1OTRlNTY1YTdjYzQxMDRiMDFlMjQzN2RlNWRhNDMzL3RleHRyZWdpb246YjU5NGU1NjVhN2NjNDEwNGIwMWUyNDM3ZGU1ZGE0MzNfMTA0OTY_3ea6d213-d158-433e-a5a0-ce0abae6cb94" continuedAt="id9b8becae64f448c816740913774e47d" escape="true">COMMITMENTS AND CONTINGENCIES</ix:nonNumeric></span></div><ix:continuation id="id9b8becae64f448c816740913774e47d" continuedAt="ifbf62079de5e477c95e5b8eb0e47e2d4"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Legal Proceedings - Ongoing</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are involved in legal actions in the normal course of business, some of which seek monetary damages, including claims for punitive damages. Based on information available to us as of the date of this filing, we do not believe that these normal course actions, when finally concluded and determined, will have a material impact on our consolidated financial condition, results of operations or cash flows.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Legal fees related to all legal matters are expensed as incurred.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Legal Proceedings - Completed</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Subpoena Duces Tecum and Civil Investigative Demands Issued by the U.S. Department of Justice</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 7, 2021, the U.S. Department of Justice notified the Company that they were closing their investigation into the below-referenced Subpoena Duces Tecum ("Subpoena") and civil investigative demands ("CIDs"). As of March 31, 2021, we had recorded a total of $<ix:nonFraction unitRef="usd" contextRef="i64a0980bb9334fcf8d6f808e3e3034e3_I20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LossContingencyAccrualAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV82NC9mcmFnOmI1OTRlNTY1YTdjYzQxMDRiMDFlMjQzN2RlNWRhNDMzL3RleHRyZWdpb246YjU5NGU1NjVhN2NjNDEwNGIwMWUyNDM3ZGU1ZGE0MzNfMzg0ODI5MDcxMTgzOA_7f3304de-5dd5-486a-9fce-1b3c368a9caa"><ix:nonFraction unitRef="usd" contextRef="i1743ef92c1a2465ea18877206de3e6eb_I20210630" decimals="-5" format="ixt:numdotdecimal" name="amed:ReversalOfLossContingencyAccrual" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV82NC9mcmFnOmI1OTRlNTY1YTdjYzQxMDRiMDFlMjQzN2RlNWRhNDMzL3RleHRyZWdpb246YjU5NGU1NjVhN2NjNDEwNGIwMWUyNDM3ZGU1ZGE0MzNfMzg0ODI5MDcxMTgzOA_d6ef8e9c-9649-46b2-a7fe-e40ae0c32f2c">6.5</ix:nonFraction></ix:nonFraction> million to accrued expenses in our condensed consolidated balance sheets related to these matters. During the three-month period ended June 30, 2021, we reversed our accrual related to these matters.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May&#160;21, 2015, we received a Subpoena issued by the U.S. Department of Justice. The Subpoena requested the delivery of information regarding <ix:nonFraction unitRef="patient" contextRef="icca6ffc5023e4d40ab2f30f7f1376996_D20150521-20150521" decimals="INF" name="amed:Numberofpatients" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV82NC9mcmFnOmI1OTRlNTY1YTdjYzQxMDRiMDFlMjQzN2RlNWRhNDMzL3RleHRyZWdpb246YjU5NGU1NjVhN2NjNDEwNGIwMWUyNDM3ZGU1ZGE0MzNfMzc2_886cdd18-cebd-4b15-8f07-6a32c1fda5ce">53</ix:nonFraction> identified hospice patients to the United States Attorney&#8217;s Office for the District of Massachusetts. It also requested the delivery of documents relating to our hospice clinical and business operations and related compliance activities. The Subpoena generally covered the period from January&#160;1, 2011 through May&#160;21, 2015.  </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November&#160;3, 2015, we received a CID issued by the U.S. Department of Justice pursuant to the federal False Claims Act relating to claims submitted to Medicare and/or Medicaid for hospice services provided through designated facilities in the Morgantown, West Virginia area. The CID requested the delivery of information to the United States Attorney&#8217;s Office for the Northern District of West Virginia regarding <ix:nonFraction unitRef="patient" contextRef="if9882b4fe5cf46d883f68e6c542f6671_D20151103-20151103" decimals="INF" name="amed:Numberofpatients" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV82NC9mcmFnOmI1OTRlNTY1YTdjYzQxMDRiMDFlMjQzN2RlNWRhNDMzL3RleHRyZWdpb246YjU5NGU1NjVhN2NjNDEwNGIwMWUyNDM3ZGU1ZGE0MzNfMTI0Mw_48787ff5-19c6-4fe4-bdc9-36a0a19d8405">66</ix:nonFraction> identified hospice patients, as well as documents relating to our hospice clinical and business operations in the Morgantown area. The CID generally covered the period from January&#160;1, 2009 through August 31, 2015.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June&#160;27, 2016, we received a CID issued by the U.S. Department of Justice pursuant to the federal False Claims Act relating to claims submitted to Medicare and/or Medicaid for hospice services provided through designated facilities in the Parkersburg, West Virginia area. The CID requested the delivery of information to the United States Attorney&#8217;s Office for the Southern District of West Virginia regarding <ix:nonFraction unitRef="patient" contextRef="i864f8ff014c445d3970f605bf1cf5633_D20160627-20160627" decimals="INF" name="amed:Numberofpatients" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV82NC9mcmFnOmI1OTRlNTY1YTdjYzQxMDRiMDFlMjQzN2RlNWRhNDMzL3RleHRyZWdpb246YjU5NGU1NjVhN2NjNDEwNGIwMWUyNDM3ZGU1ZGE0MzNfMTk3MQ_daabb267-6d13-4eed-ba97-cfcd4d4a9d2e">68</ix:nonFraction> identified hospice patients, as well as documents relating to our hospice clinical and business operations in the Parkersburg area. The CID generally covered the period from January&#160;1, 2011 through June&#160;20, 2016. </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AMEDISYS, INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></div><ix:continuation id="ifbf62079de5e477c95e5b8eb0e47e2d4" continuedAt="ie748c5c8fa7345cb969c7bb98c8ced9a"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Third Party Audits - Ongoing</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, in the ordinary course of business, we are subject to audits under various governmental programs in which third party firms engaged by CMS, including Recovery Audit Contractors (&#8220;RACs&#8221;), Zone Program Integrity Contractors (&#8220;ZPICs&#8221;), Uniform Program Integrity Contractors (&#8220;UPICs&#8221;), Program Safeguard Contractors (&#8220;PSCs&#8221;), Medicaid Integrity Contractors (&#8220;MICs&#8221;), Supplemental Medical Review Contractors (&#8220;SMRCs&#8221;) and the Office of Inspector General (&#8220;OIG&#8221;), conduct extensive reviews of claims data to identify potential improper payments. We cannot predict the ultimate outcome of any regulatory reviews or other governmental audits and investigations.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2010, our subsidiary that provides hospice services in Florence, South Carolina received from a ZPIC a request for records regarding a sample of <ix:nonFraction unitRef="beneficiary" contextRef="i56392e5d72914b00bf5ae116fa9bb7f9_D20080101-20100331" decimals="INF" name="amed:NumberOfBeneficiaries" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV82NC9mcmFnOmI1OTRlNTY1YTdjYzQxMDRiMDFlMjQzN2RlNWRhNDMzL3RleHRyZWdpb246YjU5NGU1NjVhN2NjNDEwNGIwMWUyNDM3ZGU1ZGE0MzNfNDE0MQ_f00b8a84-52f5-4cc8-9722-71a9ef733899">30</ix:nonFraction> beneficiaries who received services from the subsidiary during the period of January&#160;1, 2008 through March&#160;31, 2010 (the &#8220;Review Period&#8221;) to determine whether the underlying services met pertinent Medicare payment requirements.&#160;We acquired the hospice operations subject to this review on August&#160;1, 2009; the Review Period covers time periods both before and after our ownership of these hospice operations.&#160;Based on the ZPIC&#8217;s findings for <ix:nonFraction unitRef="beneficiary" contextRef="iad1c85c016834639b22c42870630702c_D20110606-20110606" decimals="INF" name="amed:NumberOfBeneficiaries" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV82NC9mcmFnOmI1OTRlNTY1YTdjYzQxMDRiMDFlMjQzN2RlNWRhNDMzL3RleHRyZWdpb246YjU5NGU1NjVhN2NjNDEwNGIwMWUyNDM3ZGU1ZGE0MzNfNDU4NQ_f83c007a-2cdf-4f26-b367-d05cdf517a9c">16</ix:nonFraction> beneficiaries, which were extrapolated to all claims for hospice services provided by the Florence subsidiary billed during the Review Period, on June&#160;6, 2011, the Medicare Administrative Contractor (&#8220;MAC&#8221;) for the subsidiary issued a notice of overpayment seeking recovery from our subsidiary of an alleged overpayment. We dispute these findings, and our Florence subsidiary has filed appeals through the Original Medicare Standard Appeals Process, in which we are seeking to have those findings overturned. An administrative law judge ("ALJ") hearing was held in early January 2015. On January&#160;18, 2016, we received a letter dated January&#160;6, 2016 referencing the ALJ hearing decision for the overpayment issued on June&#160;6, 2011. The decision was partially favorable with a new overpayment amount of $<ix:nonFraction unitRef="usd" contextRef="i417a271b7a39436d9ed178f9bb7bd0c6_I20160118" decimals="-5" format="ixt:numdotdecimal" name="amed:RecoveryAmountOfOverpaymentMadeToSubsidiary" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV82NC9mcmFnOmI1OTRlNTY1YTdjYzQxMDRiMDFlMjQzN2RlNWRhNDMzL3RleHRyZWdpb246YjU5NGU1NjVhN2NjNDEwNGIwMWUyNDM3ZGU1ZGE0MzNfNTM4OA_e9deb788-ab45-427f-854f-f1a449c8129d">3.7</ix:nonFraction> million with a balance owed of $<ix:nonFraction unitRef="usd" contextRef="i417a271b7a39436d9ed178f9bb7bd0c6_I20160118" decimals="-5" format="ixt:numdotdecimal" name="amed:RecoveryAmountOfOverpaymentMadeToSubsidiaryIncludingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV82NC9mcmFnOmI1OTRlNTY1YTdjYzQxMDRiMDFlMjQzN2RlNWRhNDMzL3RleHRyZWdpb246YjU5NGU1NjVhN2NjNDEwNGIwMWUyNDM3ZGU1ZGE0MzNfNTQxNA_ff3b06fb-5dff-44e8-b12a-eca2747b3e59">5.6</ix:nonFraction> million, including interest, based on <ix:nonFraction unitRef="claim" contextRef="i937449c14ddf4057abd22b9d6ed3e210_D20160118-20160118" decimals="INF" name="amed:NumberOfClaimsSubmittedBySubsidiary" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV82NC9mcmFnOmI1OTRlNTY1YTdjYzQxMDRiMDFlMjQzN2RlNWRhNDMzL3RleHRyZWdpb246YjU5NGU1NjVhN2NjNDEwNGIwMWUyNDM3ZGU1ZGE0MzNfNTQ0Nw_b8c0dbbe-e4c1-430e-91b2-321d3cdbadbc">9</ix:nonFraction> disputed claims (originally <ix:nonFraction unitRef="beneficiary" contextRef="iad1c85c016834639b22c42870630702c_D20110606-20110606" decimals="INF" name="amed:NumberOfBeneficiaries" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV82NC9mcmFnOmI1OTRlNTY1YTdjYzQxMDRiMDFlMjQzN2RlNWRhNDMzL3RleHRyZWdpb246YjU5NGU1NjVhN2NjNDEwNGIwMWUyNDM3ZGU1ZGE0MzNfNTQ3OA_05797933-11c4-4293-a035-e31b02a1e7db">16</ix:nonFraction>). We filed an appeal to the Medicare Appeals Council on the remaining <ix:nonFraction unitRef="claim" contextRef="i937449c14ddf4057abd22b9d6ed3e210_D20160118-20160118" decimals="INF" name="amed:NumberOfClaimsSubmittedBySubsidiary" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV82NC9mcmFnOmI1OTRlNTY1YTdjYzQxMDRiMDFlMjQzN2RlNWRhNDMzL3RleHRyZWdpb246YjU5NGU1NjVhN2NjNDEwNGIwMWUyNDM3ZGU1ZGE0MzNfNTU1MQ_bdee4d40-09af-4b20-9db4-660c8f4b11e6">9</ix:nonFraction> disputed claims and also argued that the statistical method used to select the sample was not valid.&#160;No assurances can be given as to the timing or outcome of the Medicare Appeals Council decision. As of June&#160;30, 2021, Medicare has withheld payments of $<ix:nonFraction unitRef="usd" contextRef="i562ae93979ca4fdb8e93e54fc08de2f4_I20210630" decimals="-5" format="ixt:numdotdecimal" name="amed:Recoveryamountofoverpaymentmadetosubsidiaryincludinginterestwithheld" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV82NC9mcmFnOmI1OTRlNTY1YTdjYzQxMDRiMDFlMjQzN2RlNWRhNDMzL3RleHRyZWdpb246YjU5NGU1NjVhN2NjNDEwNGIwMWUyNDM3ZGU1ZGE0MzNfNTc5Ng_a76ac361-5b62-463f-8dc4-c928f7814944">5.7</ix:nonFraction> million (including additional interest) as part of their standard procedures once this level of the appeal process has been reached. In the event we are not able to recoup this alleged overpayment, we are entitled to be indemnified by the prior owners of the hospice operations for amounts relating to the period prior to August&#160;1, 2009. On January 10, 2019, an arbitration panel from the American Health Lawyers Association determined that the prior owners' liability for their indemnification obligation was $<ix:nonFraction unitRef="usd" contextRef="i45b052c3ab1d49c694a0154a1838b1a9_I20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LossContingencyReceivableNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV82NC9mcmFnOmI1OTRlNTY1YTdjYzQxMDRiMDFlMjQzN2RlNWRhNDMzL3RleHRyZWdpb246YjU5NGU1NjVhN2NjNDEwNGIwMWUyNDM3ZGU1ZGE0MzNfNjMwMQ_03c6b1fc-4c19-4519-baa8-dc91b329b194"><ix:nonFraction unitRef="usd" contextRef="icf2b127cab17488d81818bf4e3d75ae0_I20190110" decimals="-5" format="ixt:numdotdecimal" name="amed:IndemnificationAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV82NC9mcmFnOmI1OTRlNTY1YTdjYzQxMDRiMDFlMjQzN2RlNWRhNDMzL3RleHRyZWdpb246YjU5NGU1NjVhN2NjNDEwNGIwMWUyNDM3ZGU1ZGE0MzNfNjMwMQ_931e9f03-1cc1-4e1a-af22-a789ccda945e">2.8</ix:nonFraction></ix:nonFraction> million. This amount is recorded as an indemnity receivable within other assets in our condensed consolidated balance sheets.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2016, the Company received a request for medical records from SafeGuard Services, L.L.C (&#8220;SafeGuard&#8221;), a ZPIC, related to services provided by some of the care centers that the Company acquired from Infinity Home Care, L.L.C. The review period covers time periods both before and after our ownership of the care centers, which were acquired on December&#160;31, 2015. In August 2017, the Company received Requests for Repayment from Palmetto GBA, LLC ("Palmetto") regarding Infinity Home Care of Lakeland, LLC ("Lakeland Care Centers") and Infinity Home Care of Pinellas, LLC ("Clearwater Care Center"). The Palmetto letters are based on a statistical extrapolation performed by SafeGuard which alleged an overpayment of $<ix:nonFraction unitRef="usd" contextRef="i4850b525a25f4db491a946f4b9cd5379_I20170831" decimals="-5" format="ixt:numdotdecimal" name="amed:RecoveryAmountOfOverpaymentMadeToSubsidiary" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV82NC9mcmFnOmI1OTRlNTY1YTdjYzQxMDRiMDFlMjQzN2RlNWRhNDMzL3RleHRyZWdpb246YjU5NGU1NjVhN2NjNDEwNGIwMWUyNDM3ZGU1ZGE0MzNfNzE0Ng_29623db1-869b-411a-992e-a76f937ca570">34.0</ix:nonFraction> million for the Lakeland Care Centers on a universe of <ix:nonFraction unitRef="claim" contextRef="ibe7994c4b86d4541b2d0ec37bace16d7_D20170801-20170831" decimals="INF" name="amed:NumberOfClaimsSubmittedBySubsidiary" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV82NC9mcmFnOmI1OTRlNTY1YTdjYzQxMDRiMDFlMjQzN2RlNWRhNDMzL3RleHRyZWdpb246YjU5NGU1NjVhN2NjNDEwNGIwMWUyNDM3ZGU1ZGE0MzNfNzE5Ng_1b41b47b-3aab-4aab-8e3e-b4c21483a684">72</ix:nonFraction> Medicare claims totaling $<ix:nonFraction unitRef="usd" contextRef="i4850b525a25f4db491a946f4b9cd5379_I20170831" decimals="-5" format="ixt:numdotdecimal" name="amed:ActualClaimsPayment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV82NC9mcmFnOmI1OTRlNTY1YTdjYzQxMDRiMDFlMjQzN2RlNWRhNDMzL3RleHRyZWdpb246YjU5NGU1NjVhN2NjNDEwNGIwMWUyNDM3ZGU1ZGE0MzNfNzIyNA_a8bf2910-f77a-4d3c-8d57-3c3fe917372f">0.2</ix:nonFraction> million in actual claims payments using a <ix:nonFraction unitRef="number" contextRef="i4850b525a25f4db491a946f4b9cd5379_I20170831" decimals="INF" name="amed:ErrorRatePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV82NC9mcmFnOmI1OTRlNTY1YTdjYzQxMDRiMDFlMjQzN2RlNWRhNDMzL3RleHRyZWdpb246YjU5NGU1NjVhN2NjNDEwNGIwMWUyNDM3ZGU1ZGE0MzNfNzI2MQ_60fdc064-70ce-42f3-8c83-f2896de450bd">100</ix:nonFraction>% error rate and an overpayment of $<ix:nonFraction unitRef="usd" contextRef="iaab7945d135e446ab572c2d66f2fd19f_I20170831" decimals="-5" format="ixt:numdotdecimal" name="amed:RecoveryAmountOfOverpaymentMadeToSubsidiary" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV82NC9mcmFnOmI1OTRlNTY1YTdjYzQxMDRiMDFlMjQzN2RlNWRhNDMzL3RleHRyZWdpb246YjU5NGU1NjVhN2NjNDEwNGIwMWUyNDM3ZGU1ZGE0MzNfNzI5Nw_564ee170-8c47-4ab3-b359-3940758ab20d">4.8</ix:nonFraction> million for the Clearwater Care Center on a universe of <ix:nonFraction unitRef="claim" contextRef="i480a00d19d3d49a99637c18c9b072f05_D20170801-20170831" decimals="INF" name="amed:NumberOfClaimsSubmittedBySubsidiary" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV82NC9mcmFnOmI1OTRlNTY1YTdjYzQxMDRiMDFlMjQzN2RlNWRhNDMzL3RleHRyZWdpb246YjU5NGU1NjVhN2NjNDEwNGIwMWUyNDM3ZGU1ZGE0MzNfNzM0OA_4a770240-487c-48dd-91a2-96cebbaa3336">70</ix:nonFraction> Medicare claims totaling $<ix:nonFraction unitRef="usd" contextRef="iaab7945d135e446ab572c2d66f2fd19f_I20170831" decimals="-5" format="ixt:numdotdecimal" name="amed:ActualClaimsPayment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV82NC9mcmFnOmI1OTRlNTY1YTdjYzQxMDRiMDFlMjQzN2RlNWRhNDMzL3RleHRyZWdpb246YjU5NGU1NjVhN2NjNDEwNGIwMWUyNDM3ZGU1ZGE0MzNfNzM3Ng_ce4e6ade-3966-448b-a598-0f2a01fee56b">0.2</ix:nonFraction> million in actual claims payments using a <ix:nonFraction unitRef="number" contextRef="iaab7945d135e446ab572c2d66f2fd19f_I20170831" decimals="INF" name="amed:ErrorRatePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV82NC9mcmFnOmI1OTRlNTY1YTdjYzQxMDRiMDFlMjQzN2RlNWRhNDMzL3RleHRyZWdpb246YjU5NGU1NjVhN2NjNDEwNGIwMWUyNDM3ZGU1ZGE0MzNfNzQxMw_77413e64-0116-496e-b580-cdfffa8cf359">100</ix:nonFraction>% error rate.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Lakeland Request for Repayment covers claims between January 2, 2014 and September 13, 2016. The Clearwater Request for Repayment covers claims between January 2, 2015 and December 9, 2016. As a result of partially successful Level I and Level II Administrative Appeals, the alleged overpayment for the Lakeland Care Centers has been reduced to $<ix:nonFraction unitRef="usd" contextRef="i1a6de48aaec6424c991ca149df38ebc4_I20210630" decimals="-5" format="ixt:numdotdecimal" name="amed:RecoveryAmountOfOverpaymentMadeToSubsidiary" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV82NC9mcmFnOmI1OTRlNTY1YTdjYzQxMDRiMDFlMjQzN2RlNWRhNDMzL3RleHRyZWdpb246YjU5NGU1NjVhN2NjNDEwNGIwMWUyNDM3ZGU1ZGE0MzNfNzc3Nw_f0d34189-2f3e-44b7-8192-4415eda92c67">26.0</ix:nonFraction> million and the alleged overpayment for the Clearwater Care Center has been reduced to $<ix:nonFraction unitRef="usd" contextRef="i257e928d56124ef98ae9d07b7f7d20e0_I20210630" decimals="-5" format="ixt:numdotdecimal" name="amed:RecoveryAmountOfOverpaymentMadeToSubsidiary" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV82NC9mcmFnOmI1OTRlNTY1YTdjYzQxMDRiMDFlMjQzN2RlNWRhNDMzL3RleHRyZWdpb246YjU5NGU1NjVhN2NjNDEwNGIwMWUyNDM3ZGU1ZGE0MzNfNzg1OQ_c5a795e8-76c6-4844-8b7e-688240a775ec">3.3</ix:nonFraction> million. The Company has now filed Level III Administrative Appeals, and will continue to vigorously pursue its appeal rights, which include contesting the methodology used by the ZPIC contractor to perform statistical extrapolation. The Company is contractually entitled to indemnification by the prior owners for all claims prior to December 31, 2015, for up to $<ix:nonFraction unitRef="usd" contextRef="i042d59baaf764eadb82a511fc4630d06_I20170831" decimals="-5" format="ixt:numdotdecimal" name="amed:IndemnificationAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV82NC9mcmFnOmI1OTRlNTY1YTdjYzQxMDRiMDFlMjQzN2RlNWRhNDMzL3RleHRyZWdpb246YjU5NGU1NjVhN2NjNDEwNGIwMWUyNDM3ZGU1ZGE0MzNfODIxOA_86e7b815-4e3a-4599-a94d-642b3529e84d">12.6</ix:nonFraction> million.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At this stage of the review, based on the information currently available to the Company, the Company cannot predict the timing or outcome of this review. The Company estimates a low-end potential range of loss related to this review of $<ix:nonFraction unitRef="usd" contextRef="i071a11675b024dfa92b8dd03678270ed_I20170831" decimals="-5" format="ixt:numdotdecimal" name="amed:RecoveryAmountOfOverpaymentMadeToSubsidiary" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV82NC9mcmFnOmI1OTRlNTY1YTdjYzQxMDRiMDFlMjQzN2RlNWRhNDMzL3RleHRyZWdpb246YjU5NGU1NjVhN2NjNDEwNGIwMWUyNDM3ZGU1ZGE0MzNfODQ1OQ_df52e42a-77d4-4eea-9a19-578a9d5879eb">6.5</ix:nonFraction> million (assuming the Company is successful in seeking indemnity from the prior owners and unsuccessful in demonstrating that the extrapolation method used by SafeGuard was erroneous). The Company has reduced its high-end potential range of loss from $<ix:nonFraction unitRef="usd" contextRef="i8e89313551f44799b6300c11c9de29b3_I20170831" decimals="-5" format="ixt:numdotdecimal" name="amed:RecoveryAmountOfOverpaymentMadeToSubsidiary" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV82NC9mcmFnOmI1OTRlNTY1YTdjYzQxMDRiMDFlMjQzN2RlNWRhNDMzL3RleHRyZWdpb246YjU5NGU1NjVhN2NjNDEwNGIwMWUyNDM3ZGU1ZGE0MzNfODcwNQ_9a99d883-76ef-4f01-a928-59655ec9a3d7">38.8</ix:nonFraction> million (the maximum amount Palmetto claims has been overpaid for both the Lakeland Care Centers and the Clearwater Care Center, of which amount $<ix:nonFraction unitRef="usd" contextRef="i042d59baaf764eadb82a511fc4630d06_I20170831" decimals="-5" format="ixt:numdotdecimal" name="amed:IndemnificationAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV82NC9mcmFnOmI1OTRlNTY1YTdjYzQxMDRiMDFlMjQzN2RlNWRhNDMzL3RleHRyZWdpb246YjU5NGU1NjVhN2NjNDEwNGIwMWUyNDM3ZGU1ZGE0MzNfODg0NQ_9db27f91-37b9-4a99-931f-ddebda2b05e8">12.6</ix:nonFraction> million is subject to indemnification by the prior owners) to $<ix:nonFraction unitRef="usd" contextRef="i33ec0cb49c7c45df918d10f6d8b12f6c_I20210630" decimals="-5" format="ixt:numdotdecimal" name="amed:RecoveryAmountOfOverpaymentMadeToSubsidiary" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV82NC9mcmFnOmI1OTRlNTY1YTdjYzQxMDRiMDFlMjQzN2RlNWRhNDMzL3RleHRyZWdpb246YjU5NGU1NjVhN2NjNDEwNGIwMWUyNDM3ZGU1ZGE0MzNfODkwMg_242694cb-44de-46d5-9b1c-d019e5c7cc8a">29.3</ix:nonFraction> million based on the partial success achieved by the Company in prosecuting its Level I and II Administrative Appeals.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AMEDISYS, INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></div><ix:continuation id="ie748c5c8fa7345cb969c7bb98c8ced9a"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2021, we have an accrued liability of approximately $<ix:nonFraction unitRef="usd" contextRef="icc9f4a15aebf47b28a9f5ea3e095ade5_I20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LossContingencyAccrualAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV82NC9mcmFnOmI1OTRlNTY1YTdjYzQxMDRiMDFlMjQzN2RlNWRhNDMzL3RleHRyZWdpb246YjU5NGU1NjVhN2NjNDEwNGIwMWUyNDM3ZGU1ZGE0MzNfOTA3Mg_c35990f2-835c-4536-86af-767cc3bcb598">17.4</ix:nonFraction> million related to this matter. We expect to be indemnified by the prior owners for approximately $<ix:nonFraction unitRef="usd" contextRef="icc9f4a15aebf47b28a9f5ea3e095ade5_I20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LossContingencyReceivableNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV82NC9mcmFnOmI1OTRlNTY1YTdjYzQxMDRiMDFlMjQzN2RlNWRhNDMzL3RleHRyZWdpb246YjU5NGU1NjVhN2NjNDEwNGIwMWUyNDM3ZGU1ZGE0MzNfOTE2NQ_b3c02c85-88bc-40c2-9bf5-77cbbd793f42">10.9</ix:nonFraction> million of the total $<ix:nonFraction unitRef="usd" contextRef="i035f004f00fb427aa308a668dff7bb13_I20170831" decimals="-5" format="ixt:numdotdecimal" name="amed:IndemnificationAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV82NC9mcmFnOmI1OTRlNTY1YTdjYzQxMDRiMDFlMjQzN2RlNWRhNDMzL3RleHRyZWdpb246YjU5NGU1NjVhN2NjNDEwNGIwMWUyNDM3ZGU1ZGE0MzNfOTE4MQ_8833c8a5-04f4-4b46-a8ae-690b4018dcfb">12.6</ix:nonFraction> million available indemnification related to this matter and have recorded this amount within other assets in our condensed consolidated balance sheets. The net of these two amounts, $<ix:nonFraction unitRef="usd" contextRef="icd32a02105c3425089f7089841dde5b2_D20170101-20171231" decimals="-5" format="ixt:numdotdecimal" name="amed:FloridaZpicRevenueReduction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV82NC9mcmFnOmI1OTRlNTY1YTdjYzQxMDRiMDFlMjQzN2RlNWRhNDMzL3RleHRyZWdpb246YjU5NGU1NjVhN2NjNDEwNGIwMWUyNDM3ZGU1ZGE0MzNfOTM1OQ_ef07d295-4bee-45cc-b54b-24359e639dee">6.5</ix:nonFraction> million, was recorded as a reduction in net service revenue in our condensed consolidated statements of operations during 2017. As of June&#160;30, 2021, $<ix:nonFraction unitRef="usd" contextRef="if467e9fca3484710a3ac117350b56dd9_I20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV82NC9mcmFnOmI1OTRlNTY1YTdjYzQxMDRiMDFlMjQzN2RlNWRhNDMzL3RleHRyZWdpb246YjU5NGU1NjVhN2NjNDEwNGIwMWUyNDM3ZGU1ZGE0MzNfOTQ4MA_91b32b8e-1865-4af3-8326-6ca9a435a454">1.5</ix:nonFraction> million of receivables have been impacted by this payment suspension.</span></div><div style="margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Insurance</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are obligated for certain costs associated with our insurance programs, including employee health, workers&#8217; compensation and professional liability. While we maintain various insurance programs to cover these risks, we are self-insured for a substantial portion of our potential claims. We recognize our obligations associated with these costs, up to specified deductible limits in the period in which a claim is incurred, including with respect to both reported claims and claims incurred but not reported. These costs have generally been estimated based on historical data of our claims experience. Such estimates, and the resulting reserves, are reviewed and updated by us on a quarterly basis.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our health insurance has an exposure limit of $<ix:nonFraction unitRef="usd" contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630" decimals="-5" format="ixt:numdotdecimal" name="amed:HealthInsuranceRetentionLimit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV82NC9mcmFnOmI1OTRlNTY1YTdjYzQxMDRiMDFlMjQzN2RlNWRhNDMzL3RleHRyZWdpb246YjU5NGU1NjVhN2NjNDEwNGIwMWUyNDM3ZGU1ZGE0MzNfMTAzMDI_59f892d7-f426-4696-b2fa-8e9b148f7dc1">1.3</ix:nonFraction> million for any individual covered life. Our workers&#8217; compensation insurance has a retention limit of $<ix:nonFraction unitRef="usd" contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630" decimals="-5" format="ixt:numdotdecimal" name="amed:WorkersCompensationInsuranceRetentionLimit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV82NC9mcmFnOmI1OTRlNTY1YTdjYzQxMDRiMDFlMjQzN2RlNWRhNDMzL3RleHRyZWdpb246YjU5NGU1NjVhN2NjNDEwNGIwMWUyNDM3ZGU1ZGE0MzNfMTAzOTk_f00b5e89-2b72-4cef-b8da-5fc8d6b0e615">1.0</ix:nonFraction> million per incident and our professional liability insurance has a retention limit of $<ix:nonFraction unitRef="usd" contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630" decimals="-5" format="ixt:numdotdecimal" name="amed:ProfessionalLiabilityInsuranceRetentionLimit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV82NC9mcmFnOmI1OTRlNTY1YTdjYzQxMDRiMDFlMjQzN2RlNWRhNDMzL3RleHRyZWdpb246YjU5NGU1NjVhN2NjNDEwNGIwMWUyNDM3ZGU1ZGE0MzNfMTA0ODE_db5c03f2-01f0-4e9b-9d12-9a25c678f920">0.3</ix:nonFraction> million per incident.</span></div></ix:continuation><div id="iccd9c69ecd2c42e5897cfe9ab4e7e0b5_70"></div><div style="margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7. <ix:nonNumeric contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630" name="us-gaap:SegmentReportingDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV83MC9mcmFnOjVkNDg3NDY3NDZiZDQ1ZWVhZTczY2JkYjNjZTc2MDdhL3RleHRyZWdpb246NWQ0ODc0Njc0NmJkNDVlZWFlNzNjYmRiM2NlNzYwN2FfMTM4Mg_8b3c2175-684d-44d6-94f5-f50482aae4e3" continuedAt="if0f768da22394c2dbefe28ac9660eae9" escape="true">SEGMENT INFORMATION</ix:nonNumeric></span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="if0f768da22394c2dbefe28ac9660eae9" continuedAt="if86d61d1199a4382a45e6756bca59f48">Our operations involve servicing patients through our <ix:nonFraction unitRef="segments" contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:NumberOfReportableSegments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV83MC9mcmFnOjVkNDg3NDY3NDZiZDQ1ZWVhZTczY2JkYjNjZTc2MDdhL3RleHRyZWdpb246NWQ0ODc0Njc0NmJkNDVlZWFlNzNjYmRiM2NlNzYwN2FfODI_016700d1-ddca-4d8c-9f05-ff51cfbf0ba6">three</ix:nonFraction> reportable business segments: home health, hospice and personal care. Our home health segment delivers a wide range of services in the homes of individuals who may be recovering from surgery, have a chronic disability or terminal illness or need assistance with completing important personal tasks. Our hospice segment provides palliative care and comfort to terminally ill patients and their families. Our personal care segment provides patients with assistance with the essential activities of daily living. The &#8220;other&#8221; column in the following tables consists of costs relating to executive management and administrative support functions, primarily information services, accounting, finance, billing and collections, legal, compliance, risk management, procurement, marketing, clinical administration, training, human resources and administration.</ix:continuation></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AMEDISYS, INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></div><ix:continuation id="if86d61d1199a4382a45e6756bca59f48"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management evaluates performance and allocates resources based on the operating income of the reportable segments, which includes an allocation of corporate expenses directly attributable to the specific segment and includes revenues and all other costs directly attributable to the specific segment. Segment assets are not reviewed by the company&#8217;s chief operating decision maker and therefore are not disclosed below (amounts in millions).</span></div><div style="margin-top:10pt;text-align:justify"><ix:nonNumeric contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630" name="us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV83MC9mcmFnOjVkNDg3NDY3NDZiZDQ1ZWVhZTczY2JkYjNjZTc2MDdhL3RleHRyZWdpb246NWQ0ODc0Njc0NmJkNDVlZWFlNzNjYmRiM2NlNzYwN2FfMTM4Ng_689ed5df-5ea1-4e7d-aa50-42702a008203" escape="true"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:46.923%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.709%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.709%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.709%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.709%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.713%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three-Month Period Ended June 30, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Home<br/>Health</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Hospice</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Personal<br/>Care</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net service revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i39e4f26632264baf9dbebb5fdcfb9311_D20210401-20210630" decimals="-5" name="us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV83MC9mcmFnOjVkNDg3NDY3NDZiZDQ1ZWVhZTczY2JkYjNjZTc2MDdhL3RhYmxlOjQ2M2E4NDQ0NmMzOTQ0OWViMTI4Y2VkMzE5MjJmZjYxL3RhYmxlcmFuZ2U6NDYzYTg0NDQ2YzM5NDQ5ZWIxMjhjZWQzMTkyMmZmNjFfMi0xLTEtMS0w_6653b433-23d8-41a7-ac07-68280a3bd55e">349.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf5dbb4a4428489fa4c64850e9a5a460_D20210401-20210630" decimals="-5" name="us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV83MC9mcmFnOjVkNDg3NDY3NDZiZDQ1ZWVhZTczY2JkYjNjZTc2MDdhL3RhYmxlOjQ2M2E4NDQ0NmMzOTQ0OWViMTI4Y2VkMzE5MjJmZjYxL3RhYmxlcmFuZ2U6NDYzYTg0NDQ2YzM5NDQ5ZWIxMjhjZWQzMTkyMmZmNjFfMi0zLTEtMS0w_6b37ed91-3f26-447b-9ef2-db6ae333083d">197.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66723c555afc4c9ab4b0e69183d084cf_D20210401-20210630" decimals="-5" name="us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV83MC9mcmFnOjVkNDg3NDY3NDZiZDQ1ZWVhZTczY2JkYjNjZTc2MDdhL3RhYmxlOjQ2M2E4NDQ0NmMzOTQ0OWViMTI4Y2VkMzE5MjJmZjYxL3RhYmxlcmFuZ2U6NDYzYTg0NDQ2YzM5NDQ5ZWIxMjhjZWQzMTkyMmZmNjFfMi01LTEtMS0w_a99790e3-702e-4daf-b6a6-dcf4a0a989e2">17.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib10fab888a0d4becba7d4378b0313572_D20210401-20210630" decimals="-5" format="ixt:zerodash" name="us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV83MC9mcmFnOjVkNDg3NDY3NDZiZDQ1ZWVhZTczY2JkYjNjZTc2MDdhL3RhYmxlOjQ2M2E4NDQ0NmMzOTQ0OWViMTI4Y2VkMzE5MjJmZjYxL3RhYmxlcmFuZ2U6NDYzYTg0NDQ2YzM5NDQ5ZWIxMjhjZWQzMTkyMmZmNjFfMi03LTEtMS0w_d050b4ee-bf85-4bc7-9158-ae2aaf8d8104">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib87cee58ccf2448a8d4422101bf61fa0_D20210401-20210630" decimals="-5" name="us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV83MC9mcmFnOjVkNDg3NDY3NDZiZDQ1ZWVhZTczY2JkYjNjZTc2MDdhL3RhYmxlOjQ2M2E4NDQ0NmMzOTQ0OWViMTI4Y2VkMzE5MjJmZjYxL3RhYmxlcmFuZ2U6NDYzYTg0NDQ2YzM5NDQ5ZWIxMjhjZWQzMTkyMmZmNjFfMi05LTEtMS0w_40a6447f-ead9-44ab-92c1-ba55867c6c3a">564.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other operating income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i39e4f26632264baf9dbebb5fdcfb9311_D20210401-20210630" decimals="-5" name="us-gaap:OtherOperatingIncome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV83MC9mcmFnOjVkNDg3NDY3NDZiZDQ1ZWVhZTczY2JkYjNjZTc2MDdhL3RhYmxlOjQ2M2E4NDQ0NmMzOTQ0OWViMTI4Y2VkMzE5MjJmZjYxL3RhYmxlcmFuZ2U6NDYzYTg0NDQ2YzM5NDQ5ZWIxMjhjZWQzMTkyMmZmNjFfMy0xLTEtMS0w_14afbb48-ebe8-4423-a8d3-f0580aff910b">2.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf5dbb4a4428489fa4c64850e9a5a460_D20210401-20210630" decimals="-5" name="us-gaap:OtherOperatingIncome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV83MC9mcmFnOjVkNDg3NDY3NDZiZDQ1ZWVhZTczY2JkYjNjZTc2MDdhL3RhYmxlOjQ2M2E4NDQ0NmMzOTQ0OWViMTI4Y2VkMzE5MjJmZjYxL3RhYmxlcmFuZ2U6NDYzYTg0NDQ2YzM5NDQ5ZWIxMjhjZWQzMTkyMmZmNjFfMy0zLTEtMS0w_0416673c-af5e-44ff-ad87-5c6b9a427e2c">2.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66723c555afc4c9ab4b0e69183d084cf_D20210401-20210630" decimals="-5" format="ixt:zerodash" name="us-gaap:OtherOperatingIncome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV83MC9mcmFnOjVkNDg3NDY3NDZiZDQ1ZWVhZTczY2JkYjNjZTc2MDdhL3RhYmxlOjQ2M2E4NDQ0NmMzOTQ0OWViMTI4Y2VkMzE5MjJmZjYxL3RhYmxlcmFuZ2U6NDYzYTg0NDQ2YzM5NDQ5ZWIxMjhjZWQzMTkyMmZmNjFfMy01LTEtMS0w_3cb659ce-d9f8-4176-b29b-91e21a42c2bd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib10fab888a0d4becba7d4378b0313572_D20210401-20210630" decimals="-5" format="ixt:zerodash" name="us-gaap:OtherOperatingIncome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV83MC9mcmFnOjVkNDg3NDY3NDZiZDQ1ZWVhZTczY2JkYjNjZTc2MDdhL3RhYmxlOjQ2M2E4NDQ0NmMzOTQ0OWViMTI4Y2VkMzE5MjJmZjYxL3RhYmxlcmFuZ2U6NDYzYTg0NDQ2YzM5NDQ5ZWIxMjhjZWQzMTkyMmZmNjFfMy03LTEtMS0w_aaef2af8-9d71-4054-8dea-8829c68d1f72">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib87cee58ccf2448a8d4422101bf61fa0_D20210401-20210630" decimals="-5" name="us-gaap:OtherOperatingIncome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV83MC9mcmFnOjVkNDg3NDY3NDZiZDQ1ZWVhZTczY2JkYjNjZTc2MDdhL3RhYmxlOjQ2M2E4NDQ0NmMzOTQ0OWViMTI4Y2VkMzE5MjJmZjYxL3RhYmxlcmFuZ2U6NDYzYTg0NDQ2YzM5NDQ5ZWIxMjhjZWQzMTkyMmZmNjFfMy05LTEtMS0w_3f3e17bf-0629-4660-a9e4-7cec5e1f7d50">4.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of service, excluding depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i39e4f26632264baf9dbebb5fdcfb9311_D20210401-20210630" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV83MC9mcmFnOjVkNDg3NDY3NDZiZDQ1ZWVhZTczY2JkYjNjZTc2MDdhL3RhYmxlOjQ2M2E4NDQ0NmMzOTQ0OWViMTI4Y2VkMzE5MjJmZjYxL3RhYmxlcmFuZ2U6NDYzYTg0NDQ2YzM5NDQ5ZWIxMjhjZWQzMTkyMmZmNjFfNC0xLTEtMS0w_61060087-ddba-4346-8a7d-9576386604e3">190.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf5dbb4a4428489fa4c64850e9a5a460_D20210401-20210630" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV83MC9mcmFnOjVkNDg3NDY3NDZiZDQ1ZWVhZTczY2JkYjNjZTc2MDdhL3RhYmxlOjQ2M2E4NDQ0NmMzOTQ0OWViMTI4Y2VkMzE5MjJmZjYxL3RhYmxlcmFuZ2U6NDYzYTg0NDQ2YzM5NDQ5ZWIxMjhjZWQzMTkyMmZmNjFfNC0zLTEtMS0w_070ca58a-c521-4239-80d9-74df4420cbf8">105.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66723c555afc4c9ab4b0e69183d084cf_D20210401-20210630" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV83MC9mcmFnOjVkNDg3NDY3NDZiZDQ1ZWVhZTczY2JkYjNjZTc2MDdhL3RhYmxlOjQ2M2E4NDQ0NmMzOTQ0OWViMTI4Y2VkMzE5MjJmZjYxL3RhYmxlcmFuZ2U6NDYzYTg0NDQ2YzM5NDQ5ZWIxMjhjZWQzMTkyMmZmNjFfNC01LTEtMS0w_1f904e19-a8ae-4967-b924-050f2b151858">13.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib10fab888a0d4becba7d4378b0313572_D20210401-20210630" decimals="-5" format="ixt:zerodash" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV83MC9mcmFnOjVkNDg3NDY3NDZiZDQ1ZWVhZTczY2JkYjNjZTc2MDdhL3RhYmxlOjQ2M2E4NDQ0NmMzOTQ0OWViMTI4Y2VkMzE5MjJmZjYxL3RhYmxlcmFuZ2U6NDYzYTg0NDQ2YzM5NDQ5ZWIxMjhjZWQzMTkyMmZmNjFfNC03LTEtMS0w_5188845f-8465-42ef-81e8-88596b82a95b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib87cee58ccf2448a8d4422101bf61fa0_D20210401-20210630" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV83MC9mcmFnOjVkNDg3NDY3NDZiZDQ1ZWVhZTczY2JkYjNjZTc2MDdhL3RhYmxlOjQ2M2E4NDQ0NmMzOTQ0OWViMTI4Y2VkMzE5MjJmZjYxL3RhYmxlcmFuZ2U6NDYzYTg0NDQ2YzM5NDQ5ZWIxMjhjZWQzMTkyMmZmNjFfNC05LTEtMS0w_8a8b1b40-7b61-4667-82f5-3db96a87dad9">308.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i39e4f26632264baf9dbebb5fdcfb9311_D20210401-20210630" decimals="-5" name="us-gaap:GeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV83MC9mcmFnOjVkNDg3NDY3NDZiZDQ1ZWVhZTczY2JkYjNjZTc2MDdhL3RhYmxlOjQ2M2E4NDQ0NmMzOTQ0OWViMTI4Y2VkMzE5MjJmZjYxL3RhYmxlcmFuZ2U6NDYzYTg0NDQ2YzM5NDQ5ZWIxMjhjZWQzMTkyMmZmNjFfNS0xLTEtMS0w_7012dc8e-1b74-4ea7-9e82-65fb155a4b96">81.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf5dbb4a4428489fa4c64850e9a5a460_D20210401-20210630" decimals="-5" name="us-gaap:GeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV83MC9mcmFnOjVkNDg3NDY3NDZiZDQ1ZWVhZTczY2JkYjNjZTc2MDdhL3RhYmxlOjQ2M2E4NDQ0NmMzOTQ0OWViMTI4Y2VkMzE5MjJmZjYxL3RhYmxlcmFuZ2U6NDYzYTg0NDQ2YzM5NDQ5ZWIxMjhjZWQzMTkyMmZmNjFfNS0zLTEtMS0w_5109239f-955a-4ae4-9090-a2afcf994e17">48.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66723c555afc4c9ab4b0e69183d084cf_D20210401-20210630" decimals="-5" name="us-gaap:GeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV83MC9mcmFnOjVkNDg3NDY3NDZiZDQ1ZWVhZTczY2JkYjNjZTc2MDdhL3RhYmxlOjQ2M2E4NDQ0NmMzOTQ0OWViMTI4Y2VkMzE5MjJmZjYxL3RhYmxlcmFuZ2U6NDYzYTg0NDQ2YzM5NDQ5ZWIxMjhjZWQzMTkyMmZmNjFfNS01LTEtMS0w_fdf9733e-977f-4a17-a622-b1ba6b4657f2">3.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib10fab888a0d4becba7d4378b0313572_D20210401-20210630" decimals="-5" name="us-gaap:GeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV83MC9mcmFnOjVkNDg3NDY3NDZiZDQ1ZWVhZTczY2JkYjNjZTc2MDdhL3RhYmxlOjQ2M2E4NDQ0NmMzOTQ0OWViMTI4Y2VkMzE5MjJmZjYxL3RhYmxlcmFuZ2U6NDYzYTg0NDQ2YzM5NDQ5ZWIxMjhjZWQzMTkyMmZmNjFfNS03LTEtMS0w_8cdf236e-78e7-4c1d-ab4f-2f5d5a69e0a0">42.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib87cee58ccf2448a8d4422101bf61fa0_D20210401-20210630" decimals="-5" name="us-gaap:GeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV83MC9mcmFnOjVkNDg3NDY3NDZiZDQ1ZWVhZTczY2JkYjNjZTc2MDdhL3RhYmxlOjQ2M2E4NDQ0NmMzOTQ0OWViMTI4Y2VkMzE5MjJmZjYxL3RhYmxlcmFuZ2U6NDYzYTg0NDQ2YzM5NDQ5ZWIxMjhjZWQzMTkyMmZmNjFfNS05LTEtMS0w_0d7644ae-cf36-4944-accd-7e588359c288">175.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i39e4f26632264baf9dbebb5fdcfb9311_D20210401-20210630" decimals="-5" name="us-gaap:DepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV83MC9mcmFnOjVkNDg3NDY3NDZiZDQ1ZWVhZTczY2JkYjNjZTc2MDdhL3RhYmxlOjQ2M2E4NDQ0NmMzOTQ0OWViMTI4Y2VkMzE5MjJmZjYxL3RhYmxlcmFuZ2U6NDYzYTg0NDQ2YzM5NDQ5ZWIxMjhjZWQzMTkyMmZmNjFfNi0xLTEtMS0w_446f279f-46f6-4608-8532-0f164e431ec7">1.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf5dbb4a4428489fa4c64850e9a5a460_D20210401-20210630" decimals="-5" name="us-gaap:DepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV83MC9mcmFnOjVkNDg3NDY3NDZiZDQ1ZWVhZTczY2JkYjNjZTc2MDdhL3RhYmxlOjQ2M2E4NDQ0NmMzOTQ0OWViMTI4Y2VkMzE5MjJmZjYxL3RhYmxlcmFuZ2U6NDYzYTg0NDQ2YzM5NDQ5ZWIxMjhjZWQzMTkyMmZmNjFfNi0zLTEtMS0w_e6413569-0d52-46b5-a109-32392f42fe5a">0.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66723c555afc4c9ab4b0e69183d084cf_D20210401-20210630" decimals="-5" format="ixt:zerodash" name="us-gaap:DepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV83MC9mcmFnOjVkNDg3NDY3NDZiZDQ1ZWVhZTczY2JkYjNjZTc2MDdhL3RhYmxlOjQ2M2E4NDQ0NmMzOTQ0OWViMTI4Y2VkMzE5MjJmZjYxL3RhYmxlcmFuZ2U6NDYzYTg0NDQ2YzM5NDQ5ZWIxMjhjZWQzMTkyMmZmNjFfNi01LTEtMS0w_4866906d-af16-4455-9c91-6ed43f0a202f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib10fab888a0d4becba7d4378b0313572_D20210401-20210630" decimals="-5" name="us-gaap:DepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV83MC9mcmFnOjVkNDg3NDY3NDZiZDQ1ZWVhZTczY2JkYjNjZTc2MDdhL3RhYmxlOjQ2M2E4NDQ0NmMzOTQ0OWViMTI4Y2VkMzE5MjJmZjYxL3RhYmxlcmFuZ2U6NDYzYTg0NDQ2YzM5NDQ5ZWIxMjhjZWQzMTkyMmZmNjFfNi03LTEtMS0w_ce0296c4-18fe-44dc-8bc2-7e30a985c5ae">4.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib87cee58ccf2448a8d4422101bf61fa0_D20210401-20210630" decimals="-5" name="us-gaap:DepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV83MC9mcmFnOjVkNDg3NDY3NDZiZDQ1ZWVhZTczY2JkYjNjZTc2MDdhL3RhYmxlOjQ2M2E4NDQ0NmMzOTQ0OWViMTI4Y2VkMzE5MjJmZjYxL3RhYmxlcmFuZ2U6NDYzYTg0NDQ2YzM5NDQ5ZWIxMjhjZWQzMTkyMmZmNjFfNi05LTEtMS0w_d2cc2eaa-5f3b-4115-8ecf-a3e8827e5723">6.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i39e4f26632264baf9dbebb5fdcfb9311_D20210401-20210630" decimals="-5" name="us-gaap:CostsAndExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV83MC9mcmFnOjVkNDg3NDY3NDZiZDQ1ZWVhZTczY2JkYjNjZTc2MDdhL3RhYmxlOjQ2M2E4NDQ0NmMzOTQ0OWViMTI4Y2VkMzE5MjJmZjYxL3RhYmxlcmFuZ2U6NDYzYTg0NDQ2YzM5NDQ5ZWIxMjhjZWQzMTkyMmZmNjFfNy0xLTEtMS0w_b825ea59-307c-4ce8-a535-da30ba67947b">272.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf5dbb4a4428489fa4c64850e9a5a460_D20210401-20210630" decimals="-5" name="us-gaap:CostsAndExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV83MC9mcmFnOjVkNDg3NDY3NDZiZDQ1ZWVhZTczY2JkYjNjZTc2MDdhL3RhYmxlOjQ2M2E4NDQ0NmMzOTQ0OWViMTI4Y2VkMzE5MjJmZjYxL3RhYmxlcmFuZ2U6NDYzYTg0NDQ2YzM5NDQ5ZWIxMjhjZWQzMTkyMmZmNjFfNy0zLTEtMS0w_d51e99c7-8c16-40fc-8065-9c6e746dd8e1">154.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66723c555afc4c9ab4b0e69183d084cf_D20210401-20210630" decimals="-5" name="us-gaap:CostsAndExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV83MC9mcmFnOjVkNDg3NDY3NDZiZDQ1ZWVhZTczY2JkYjNjZTc2MDdhL3RhYmxlOjQ2M2E4NDQ0NmMzOTQ0OWViMTI4Y2VkMzE5MjJmZjYxL3RhYmxlcmFuZ2U6NDYzYTg0NDQ2YzM5NDQ5ZWIxMjhjZWQzMTkyMmZmNjFfNy01LTEtMS0w_33082975-d02b-426e-9c9b-5020bc801a5a">16.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib10fab888a0d4becba7d4378b0313572_D20210401-20210630" decimals="-5" name="us-gaap:CostsAndExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV83MC9mcmFnOjVkNDg3NDY3NDZiZDQ1ZWVhZTczY2JkYjNjZTc2MDdhL3RhYmxlOjQ2M2E4NDQ0NmMzOTQ0OWViMTI4Y2VkMzE5MjJmZjYxL3RhYmxlcmFuZ2U6NDYzYTg0NDQ2YzM5NDQ5ZWIxMjhjZWQzMTkyMmZmNjFfNy03LTEtMS0w_0afc32a3-b751-471c-b22f-97d24196ad06">47.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">490.7&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating income (loss)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i39e4f26632264baf9dbebb5fdcfb9311_D20210401-20210630" decimals="-5" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV83MC9mcmFnOjVkNDg3NDY3NDZiZDQ1ZWVhZTczY2JkYjNjZTc2MDdhL3RhYmxlOjQ2M2E4NDQ0NmMzOTQ0OWViMTI4Y2VkMzE5MjJmZjYxL3RhYmxlcmFuZ2U6NDYzYTg0NDQ2YzM5NDQ5ZWIxMjhjZWQzMTkyMmZmNjFfOC0xLTEtMS0w_73767906-fa1a-48fc-a969-dafd17907c76">78.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf5dbb4a4428489fa4c64850e9a5a460_D20210401-20210630" decimals="-5" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV83MC9mcmFnOjVkNDg3NDY3NDZiZDQ1ZWVhZTczY2JkYjNjZTc2MDdhL3RhYmxlOjQ2M2E4NDQ0NmMzOTQ0OWViMTI4Y2VkMzE5MjJmZjYxL3RhYmxlcmFuZ2U6NDYzYTg0NDQ2YzM5NDQ5ZWIxMjhjZWQzMTkyMmZmNjFfOC0zLTEtMS0w_c2ea30e0-8ff0-4804-8d45-50182c54e3b3">45.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66723c555afc4c9ab4b0e69183d084cf_D20210401-20210630" decimals="-5" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV83MC9mcmFnOjVkNDg3NDY3NDZiZDQ1ZWVhZTczY2JkYjNjZTc2MDdhL3RhYmxlOjQ2M2E4NDQ0NmMzOTQ0OWViMTI4Y2VkMzE5MjJmZjYxL3RhYmxlcmFuZ2U6NDYzYTg0NDQ2YzM5NDQ5ZWIxMjhjZWQzMTkyMmZmNjFfOC01LTEtMS0w_930d50de-d563-47f8-ac76-f02722b17130">0.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib10fab888a0d4becba7d4378b0313572_D20210401-20210630" decimals="-5" sign="-" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV83MC9mcmFnOjVkNDg3NDY3NDZiZDQ1ZWVhZTczY2JkYjNjZTc2MDdhL3RhYmxlOjQ2M2E4NDQ0NmMzOTQ0OWViMTI4Y2VkMzE5MjJmZjYxL3RhYmxlcmFuZ2U6NDYzYTg0NDQ2YzM5NDQ5ZWIxMjhjZWQzMTkyMmZmNjFfOC03LTEtMS0w_d77271ff-b507-44d0-90da-ab050726c4a0">47.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib87cee58ccf2448a8d4422101bf61fa0_D20210401-20210630" decimals="-5" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV83MC9mcmFnOjVkNDg3NDY3NDZiZDQ1ZWVhZTczY2JkYjNjZTc2MDdhL3RhYmxlOjQ2M2E4NDQ0NmMzOTQ0OWViMTI4Y2VkMzE5MjJmZjYxL3RhYmxlcmFuZ2U6NDYzYTg0NDQ2YzM5NDQ5ZWIxMjhjZWQzMTkyMmZmNjFfOC05LTEtMS0w_0a3fdeeb-3ead-45d0-b732-a0f3ee4d9c72">78.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three-Month Period Ended June 30, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Home<br/>Health</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Hospice</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Personal<br/>Care</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net service revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f0d04b97823461cabfaf4b2dbfbd657_D20200401-20200630" decimals="-5" name="us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV83MC9mcmFnOjVkNDg3NDY3NDZiZDQ1ZWVhZTczY2JkYjNjZTc2MDdhL3RhYmxlOjQ2M2E4NDQ0NmMzOTQ0OWViMTI4Y2VkMzE5MjJmZjYxL3RhYmxlcmFuZ2U6NDYzYTg0NDQ2YzM5NDQ5ZWIxMjhjZWQzMTkyMmZmNjFfMTItMS0xLTEtMA_cb67d292-d4f0-4708-a9b6-22a622cbaf47">290.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if43b4d7c93ab412a9c9070b831320d17_D20200401-20200630" decimals="-5" name="us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV83MC9mcmFnOjVkNDg3NDY3NDZiZDQ1ZWVhZTczY2JkYjNjZTc2MDdhL3RhYmxlOjQ2M2E4NDQ0NmMzOTQ0OWViMTI4Y2VkMzE5MjJmZjYxL3RhYmxlcmFuZ2U6NDYzYTg0NDQ2YzM5NDQ5ZWIxMjhjZWQzMTkyMmZmNjFfMTItMy0xLTEtMA_c5737adc-03a1-4122-b947-52bc156a0cc1">177.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15797e02165b455389b33741463c1ecd_D20200401-20200630" decimals="-5" name="us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV83MC9mcmFnOjVkNDg3NDY3NDZiZDQ1ZWVhZTczY2JkYjNjZTc2MDdhL3RhYmxlOjQ2M2E4NDQ0NmMzOTQ0OWViMTI4Y2VkMzE5MjJmZjYxL3RhYmxlcmFuZ2U6NDYzYTg0NDQ2YzM5NDQ5ZWIxMjhjZWQzMTkyMmZmNjFfMTItNS0xLTEtMA_8bce03a3-55c9-4e9c-8056-131ca009b19a">17.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06052fe21e8f47d88c0c73710f1feaa6_D20200401-20200630" decimals="-5" format="ixt:zerodash" name="us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV83MC9mcmFnOjVkNDg3NDY3NDZiZDQ1ZWVhZTczY2JkYjNjZTc2MDdhL3RhYmxlOjQ2M2E4NDQ0NmMzOTQ0OWViMTI4Y2VkMzE5MjJmZjYxL3RhYmxlcmFuZ2U6NDYzYTg0NDQ2YzM5NDQ5ZWIxMjhjZWQzMTkyMmZmNjFfMTItNy0xLTEtMA_3fd9da01-8a4f-4ba3-a635-017263d37065">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">485.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other operating income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f0d04b97823461cabfaf4b2dbfbd657_D20200401-20200630" decimals="-5" name="us-gaap:OtherOperatingIncome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV83MC9mcmFnOjVkNDg3NDY3NDZiZDQ1ZWVhZTczY2JkYjNjZTc2MDdhL3RhYmxlOjQ2M2E4NDQ0NmMzOTQ0OWViMTI4Y2VkMzE5MjJmZjYxL3RhYmxlcmFuZ2U6NDYzYTg0NDQ2YzM5NDQ5ZWIxMjhjZWQzMTkyMmZmNjFfMTMtMS0xLTEtNjkx_88cebb4d-8690-4073-a3a8-361d2af2e775">15.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if43b4d7c93ab412a9c9070b831320d17_D20200401-20200630" decimals="-5" name="us-gaap:OtherOperatingIncome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV83MC9mcmFnOjVkNDg3NDY3NDZiZDQ1ZWVhZTczY2JkYjNjZTc2MDdhL3RhYmxlOjQ2M2E4NDQ0NmMzOTQ0OWViMTI4Y2VkMzE5MjJmZjYxL3RhYmxlcmFuZ2U6NDYzYTg0NDQ2YzM5NDQ5ZWIxMjhjZWQzMTkyMmZmNjFfMTMtMy0xLTEtNjkx_b52e5645-1d58-4ca0-8cf4-467fecb089c1">7.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15797e02165b455389b33741463c1ecd_D20200401-20200630" decimals="-5" name="us-gaap:OtherOperatingIncome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV83MC9mcmFnOjVkNDg3NDY3NDZiZDQ1ZWVhZTczY2JkYjNjZTc2MDdhL3RhYmxlOjQ2M2E4NDQ0NmMzOTQ0OWViMTI4Y2VkMzE5MjJmZjYxL3RhYmxlcmFuZ2U6NDYzYTg0NDQ2YzM5NDQ5ZWIxMjhjZWQzMTkyMmZmNjFfMTMtNS0xLTEtNjkx_393a26fe-8242-493c-9988-6232d70847e3">0.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06052fe21e8f47d88c0c73710f1feaa6_D20200401-20200630" decimals="-5" format="ixt:zerodash" name="us-gaap:OtherOperatingIncome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV83MC9mcmFnOjVkNDg3NDY3NDZiZDQ1ZWVhZTczY2JkYjNjZTc2MDdhL3RhYmxlOjQ2M2E4NDQ0NmMzOTQ0OWViMTI4Y2VkMzE5MjJmZjYxL3RhYmxlcmFuZ2U6NDYzYTg0NDQ2YzM5NDQ5ZWIxMjhjZWQzMTkyMmZmNjFfMTMtNy0xLTEtNjkx_858ae600-5196-4182-8a71-1f09da959a8f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c8351954d014a1c80a3d8cfc2327ab2_D20200401-20200630" decimals="-5" name="us-gaap:OtherOperatingIncome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV83MC9mcmFnOjVkNDg3NDY3NDZiZDQ1ZWVhZTczY2JkYjNjZTc2MDdhL3RhYmxlOjQ2M2E4NDQ0NmMzOTQ0OWViMTI4Y2VkMzE5MjJmZjYxL3RhYmxlcmFuZ2U6NDYzYTg0NDQ2YzM5NDQ5ZWIxMjhjZWQzMTkyMmZmNjFfMTMtOS0xLTEtNjkx_5ccc1795-0eff-4aed-bf45-b84ebed5ff19">22.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of service, excluding depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f0d04b97823461cabfaf4b2dbfbd657_D20200401-20200630" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV83MC9mcmFnOjVkNDg3NDY3NDZiZDQ1ZWVhZTczY2JkYjNjZTc2MDdhL3RhYmxlOjQ2M2E4NDQ0NmMzOTQ0OWViMTI4Y2VkMzE5MjJmZjYxL3RhYmxlcmFuZ2U6NDYzYTg0NDQ2YzM5NDQ5ZWIxMjhjZWQzMTkyMmZmNjFfMTMtMS0xLTEtMA_ab56aef8-4137-4d98-ab20-3f539f6a25fb">184.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if43b4d7c93ab412a9c9070b831320d17_D20200401-20200630" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV83MC9mcmFnOjVkNDg3NDY3NDZiZDQ1ZWVhZTczY2JkYjNjZTc2MDdhL3RhYmxlOjQ2M2E4NDQ0NmMzOTQ0OWViMTI4Y2VkMzE5MjJmZjYxL3RhYmxlcmFuZ2U6NDYzYTg0NDQ2YzM5NDQ5ZWIxMjhjZWQzMTkyMmZmNjFfMTMtMy0xLTEtMA_95c4274e-87ac-47ee-8444-63a4ca8a7c20">97.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15797e02165b455389b33741463c1ecd_D20200401-20200630" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV83MC9mcmFnOjVkNDg3NDY3NDZiZDQ1ZWVhZTczY2JkYjNjZTc2MDdhL3RhYmxlOjQ2M2E4NDQ0NmMzOTQ0OWViMTI4Y2VkMzE5MjJmZjYxL3RhYmxlcmFuZ2U6NDYzYTg0NDQ2YzM5NDQ5ZWIxMjhjZWQzMTkyMmZmNjFfMTMtNS0xLTEtMA_ab8993de-c2fd-4fc8-9429-3a9f47729f36">14.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06052fe21e8f47d88c0c73710f1feaa6_D20200401-20200630" decimals="-5" format="ixt:zerodash" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV83MC9mcmFnOjVkNDg3NDY3NDZiZDQ1ZWVhZTczY2JkYjNjZTc2MDdhL3RhYmxlOjQ2M2E4NDQ0NmMzOTQ0OWViMTI4Y2VkMzE5MjJmZjYxL3RhYmxlcmFuZ2U6NDYzYTg0NDQ2YzM5NDQ5ZWIxMjhjZWQzMTkyMmZmNjFfMTMtNy0xLTEtMA_c021467c-8c34-47d0-b0c2-8c80f8b422ce">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">295.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f0d04b97823461cabfaf4b2dbfbd657_D20200401-20200630" decimals="-5" name="us-gaap:GeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV83MC9mcmFnOjVkNDg3NDY3NDZiZDQ1ZWVhZTczY2JkYjNjZTc2MDdhL3RhYmxlOjQ2M2E4NDQ0NmMzOTQ0OWViMTI4Y2VkMzE5MjJmZjYxL3RhYmxlcmFuZ2U6NDYzYTg0NDQ2YzM5NDQ5ZWIxMjhjZWQzMTkyMmZmNjFfMTQtMS0xLTEtMA_305a7939-b832-4fcc-99fa-20b7e7d56dd1">72.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if43b4d7c93ab412a9c9070b831320d17_D20200401-20200630" decimals="-5" name="us-gaap:GeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV83MC9mcmFnOjVkNDg3NDY3NDZiZDQ1ZWVhZTczY2JkYjNjZTc2MDdhL3RhYmxlOjQ2M2E4NDQ0NmMzOTQ0OWViMTI4Y2VkMzE5MjJmZjYxL3RhYmxlcmFuZ2U6NDYzYTg0NDQ2YzM5NDQ5ZWIxMjhjZWQzMTkyMmZmNjFfMTQtMy0xLTEtMA_bf5cbeda-48c9-4169-a335-df5aa06e6f29">40.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15797e02165b455389b33741463c1ecd_D20200401-20200630" decimals="-5" name="us-gaap:GeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV83MC9mcmFnOjVkNDg3NDY3NDZiZDQ1ZWVhZTczY2JkYjNjZTc2MDdhL3RhYmxlOjQ2M2E4NDQ0NmMzOTQ0OWViMTI4Y2VkMzE5MjJmZjYxL3RhYmxlcmFuZ2U6NDYzYTg0NDQ2YzM5NDQ5ZWIxMjhjZWQzMTkyMmZmNjFfMTQtNS0xLTEtMA_55cb00d2-457b-40f3-98c2-9b5b3e5fb84a">2.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06052fe21e8f47d88c0c73710f1feaa6_D20200401-20200630" decimals="-5" name="us-gaap:GeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV83MC9mcmFnOjVkNDg3NDY3NDZiZDQ1ZWVhZTczY2JkYjNjZTc2MDdhL3RhYmxlOjQ2M2E4NDQ0NmMzOTQ0OWViMTI4Y2VkMzE5MjJmZjYxL3RhYmxlcmFuZ2U6NDYzYTg0NDQ2YzM5NDQ5ZWIxMjhjZWQzMTkyMmZmNjFfMTQtNy0xLTEtMA_ecd7742e-8715-439b-98f1-a869aa649935">40.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c8351954d014a1c80a3d8cfc2327ab2_D20200401-20200630" decimals="-5" name="us-gaap:GeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV83MC9mcmFnOjVkNDg3NDY3NDZiZDQ1ZWVhZTczY2JkYjNjZTc2MDdhL3RhYmxlOjQ2M2E4NDQ0NmMzOTQ0OWViMTI4Y2VkMzE5MjJmZjYxL3RhYmxlcmFuZ2U6NDYzYTg0NDQ2YzM5NDQ5ZWIxMjhjZWQzMTkyMmZmNjFfMTQtOS0xLTEtMA_08fbf566-2fb9-43fe-a066-6c7e64f0d1f4">156.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f0d04b97823461cabfaf4b2dbfbd657_D20200401-20200630" decimals="-5" name="us-gaap:DepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV83MC9mcmFnOjVkNDg3NDY3NDZiZDQ1ZWVhZTczY2JkYjNjZTc2MDdhL3RhYmxlOjQ2M2E4NDQ0NmMzOTQ0OWViMTI4Y2VkMzE5MjJmZjYxL3RhYmxlcmFuZ2U6NDYzYTg0NDQ2YzM5NDQ5ZWIxMjhjZWQzMTkyMmZmNjFfMTUtMS0xLTEtMA_e9c42d7b-68f0-4109-8fb7-b74a6d708796">0.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if43b4d7c93ab412a9c9070b831320d17_D20200401-20200630" decimals="-5" name="us-gaap:DepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV83MC9mcmFnOjVkNDg3NDY3NDZiZDQ1ZWVhZTczY2JkYjNjZTc2MDdhL3RhYmxlOjQ2M2E4NDQ0NmMzOTQ0OWViMTI4Y2VkMzE5MjJmZjYxL3RhYmxlcmFuZ2U6NDYzYTg0NDQ2YzM5NDQ5ZWIxMjhjZWQzMTkyMmZmNjFfMTUtMy0xLTEtMA_045d5624-281d-492e-84d5-094ba634e11c">0.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15797e02165b455389b33741463c1ecd_D20200401-20200630" decimals="-5" name="us-gaap:DepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV83MC9mcmFnOjVkNDg3NDY3NDZiZDQ1ZWVhZTczY2JkYjNjZTc2MDdhL3RhYmxlOjQ2M2E4NDQ0NmMzOTQ0OWViMTI4Y2VkMzE5MjJmZjYxL3RhYmxlcmFuZ2U6NDYzYTg0NDQ2YzM5NDQ5ZWIxMjhjZWQzMTkyMmZmNjFfMTUtNS0xLTEtMA_ec9e862c-7904-4ca2-af42-b846c85f54fa">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06052fe21e8f47d88c0c73710f1feaa6_D20200401-20200630" decimals="-5" name="us-gaap:DepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV83MC9mcmFnOjVkNDg3NDY3NDZiZDQ1ZWVhZTczY2JkYjNjZTc2MDdhL3RhYmxlOjQ2M2E4NDQ0NmMzOTQ0OWViMTI4Y2VkMzE5MjJmZjYxL3RhYmxlcmFuZ2U6NDYzYTg0NDQ2YzM5NDQ5ZWIxMjhjZWQzMTkyMmZmNjFfMTUtNy0xLTEtMA_a9b3d18c-7670-4092-b5df-31ec40fa3401">4.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c8351954d014a1c80a3d8cfc2327ab2_D20200401-20200630" decimals="-5" name="us-gaap:DepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV83MC9mcmFnOjVkNDg3NDY3NDZiZDQ1ZWVhZTczY2JkYjNjZTc2MDdhL3RhYmxlOjQ2M2E4NDQ0NmMzOTQ0OWViMTI4Y2VkMzE5MjJmZjYxL3RhYmxlcmFuZ2U6NDYzYTg0NDQ2YzM5NDQ5ZWIxMjhjZWQzMTkyMmZmNjFfMTUtOS0xLTEtMA_b6c8550c-8c61-4373-8585-ec04e2423f02">6.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f0d04b97823461cabfaf4b2dbfbd657_D20200401-20200630" decimals="-5" name="us-gaap:CostsAndExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV83MC9mcmFnOjVkNDg3NDY3NDZiZDQ1ZWVhZTczY2JkYjNjZTc2MDdhL3RhYmxlOjQ2M2E4NDQ0NmMzOTQ0OWViMTI4Y2VkMzE5MjJmZjYxL3RhYmxlcmFuZ2U6NDYzYTg0NDQ2YzM5NDQ5ZWIxMjhjZWQzMTkyMmZmNjFfMTYtMS0xLTEtMA_705642ae-9253-43e4-8da6-9549525114da">257.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if43b4d7c93ab412a9c9070b831320d17_D20200401-20200630" decimals="-5" name="us-gaap:CostsAndExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV83MC9mcmFnOjVkNDg3NDY3NDZiZDQ1ZWVhZTczY2JkYjNjZTc2MDdhL3RhYmxlOjQ2M2E4NDQ0NmMzOTQ0OWViMTI4Y2VkMzE5MjJmZjYxL3RhYmxlcmFuZ2U6NDYzYTg0NDQ2YzM5NDQ5ZWIxMjhjZWQzMTkyMmZmNjFfMTYtMy0xLTEtMA_c12b4f63-caf4-4f96-9b85-675d3f33a335">138.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15797e02165b455389b33741463c1ecd_D20200401-20200630" decimals="-5" name="us-gaap:CostsAndExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV83MC9mcmFnOjVkNDg3NDY3NDZiZDQ1ZWVhZTczY2JkYjNjZTc2MDdhL3RhYmxlOjQ2M2E4NDQ0NmMzOTQ0OWViMTI4Y2VkMzE5MjJmZjYxL3RhYmxlcmFuZ2U6NDYzYTg0NDQ2YzM5NDQ5ZWIxMjhjZWQzMTkyMmZmNjFfMTYtNS0xLTEtMA_66d13002-da86-408f-8096-d038c21faa80">17.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06052fe21e8f47d88c0c73710f1feaa6_D20200401-20200630" decimals="-5" name="us-gaap:CostsAndExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV83MC9mcmFnOjVkNDg3NDY3NDZiZDQ1ZWVhZTczY2JkYjNjZTc2MDdhL3RhYmxlOjQ2M2E4NDQ0NmMzOTQ0OWViMTI4Y2VkMzE5MjJmZjYxL3RhYmxlcmFuZ2U6NDYzYTg0NDQ2YzM5NDQ5ZWIxMjhjZWQzMTkyMmZmNjFfMTYtNy0xLTEtMA_e0a761b0-870d-4f3e-a71a-5fef4e240bc0">45.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c8351954d014a1c80a3d8cfc2327ab2_D20200401-20200630" decimals="-5" name="us-gaap:CostsAndExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV83MC9mcmFnOjVkNDg3NDY3NDZiZDQ1ZWVhZTczY2JkYjNjZTc2MDdhL3RhYmxlOjQ2M2E4NDQ0NmMzOTQ0OWViMTI4Y2VkMzE5MjJmZjYxL3RhYmxlcmFuZ2U6NDYzYTg0NDQ2YzM5NDQ5ZWIxMjhjZWQzMTkyMmZmNjFfMTYtOS0xLTEtMA_9fcfbeef-b769-4196-8357-112f4ce72dbd">457.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating income (loss)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f0d04b97823461cabfaf4b2dbfbd657_D20200401-20200630" decimals="-5" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV83MC9mcmFnOjVkNDg3NDY3NDZiZDQ1ZWVhZTczY2JkYjNjZTc2MDdhL3RhYmxlOjQ2M2E4NDQ0NmMzOTQ0OWViMTI4Y2VkMzE5MjJmZjYxL3RhYmxlcmFuZ2U6NDYzYTg0NDQ2YzM5NDQ5ZWIxMjhjZWQzMTkyMmZmNjFfMTctMS0xLTEtMA_9c2e9303-472e-4d8c-8a01-f2921098a61e">48.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if43b4d7c93ab412a9c9070b831320d17_D20200401-20200630" decimals="-5" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV83MC9mcmFnOjVkNDg3NDY3NDZiZDQ1ZWVhZTczY2JkYjNjZTc2MDdhL3RhYmxlOjQ2M2E4NDQ0NmMzOTQ0OWViMTI4Y2VkMzE5MjJmZjYxL3RhYmxlcmFuZ2U6NDYzYTg0NDQ2YzM5NDQ5ZWIxMjhjZWQzMTkyMmZmNjFfMTctMy0xLTEtMA_87f412bf-a631-4f48-a0d0-93e49aec960d">45.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15797e02165b455389b33741463c1ecd_D20200401-20200630" decimals="-5" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV83MC9mcmFnOjVkNDg3NDY3NDZiZDQ1ZWVhZTczY2JkYjNjZTc2MDdhL3RhYmxlOjQ2M2E4NDQ0NmMzOTQ0OWViMTI4Y2VkMzE5MjJmZjYxL3RhYmxlcmFuZ2U6NDYzYTg0NDQ2YzM5NDQ5ZWIxMjhjZWQzMTkyMmZmNjFfMTctNS0xLTEtMA_31b49754-6317-48ee-b075-2aa030edc82f">1.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i06052fe21e8f47d88c0c73710f1feaa6_D20200401-20200630" decimals="-5" sign="-" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV83MC9mcmFnOjVkNDg3NDY3NDZiZDQ1ZWVhZTczY2JkYjNjZTc2MDdhL3RhYmxlOjQ2M2E4NDQ0NmMzOTQ0OWViMTI4Y2VkMzE5MjJmZjYxL3RhYmxlcmFuZ2U6NDYzYTg0NDQ2YzM5NDQ5ZWIxMjhjZWQzMTkyMmZmNjFfMTctNy0xLTEtMA_520f6c64-ba48-47e4-a3eb-6e61b585da94">45.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c8351954d014a1c80a3d8cfc2327ab2_D20200401-20200630" decimals="-5" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV83MC9mcmFnOjVkNDg3NDY3NDZiZDQ1ZWVhZTczY2JkYjNjZTc2MDdhL3RhYmxlOjQ2M2E4NDQ0NmMzOTQ0OWViMTI4Y2VkMzE5MjJmZjYxL3RhYmxlcmFuZ2U6NDYzYTg0NDQ2YzM5NDQ5ZWIxMjhjZWQzMTkyMmZmNjFfMTctOS0xLTEtMA_3b708fdf-3929-4fa3-a30e-5c53d81cd040">49.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Six-Month Period Ended June 30, 2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Home<br/>Health</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Hospice</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Personal<br/>Care</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net service revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e89d4343fef486490e1fcdab10c1010_D20210101-20210630" decimals="-5" name="us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV83MC9mcmFnOjVkNDg3NDY3NDZiZDQ1ZWVhZTczY2JkYjNjZTc2MDdhL3RhYmxlOjQ2M2E4NDQ0NmMzOTQ0OWViMTI4Y2VkMzE5MjJmZjYxL3RhYmxlcmFuZ2U6NDYzYTg0NDQ2YzM5NDQ5ZWIxMjhjZWQzMTkyMmZmNjFfMjItMS0xLTEtNjk2_4c117c0c-aa67-41bd-85b3-7e3c7558f6f3">677.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i741b04b8cd704e398b27520bf8aea7fc_D20210101-20210630" decimals="-5" name="us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV83MC9mcmFnOjVkNDg3NDY3NDZiZDQ1ZWVhZTczY2JkYjNjZTc2MDdhL3RhYmxlOjQ2M2E4NDQ0NmMzOTQ0OWViMTI4Y2VkMzE5MjJmZjYxL3RhYmxlcmFuZ2U6NDYzYTg0NDQ2YzM5NDQ5ZWIxMjhjZWQzMTkyMmZmNjFfMjItMy0xLTEtNjk2_5f3d0dad-08b8-4136-a2ae-89382cd51462">389.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia22ad972b1ec472b9114385ace42cd42_D20210101-20210630" decimals="-5" name="us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV83MC9mcmFnOjVkNDg3NDY3NDZiZDQ1ZWVhZTczY2JkYjNjZTc2MDdhL3RhYmxlOjQ2M2E4NDQ0NmMzOTQ0OWViMTI4Y2VkMzE5MjJmZjYxL3RhYmxlcmFuZ2U6NDYzYTg0NDQ2YzM5NDQ5ZWIxMjhjZWQzMTkyMmZmNjFfMjItNS0xLTEtNjk2_c783355a-c643-43a1-9302-40c9de116f37">34.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91156243b7cb4900b72f0b116d3781c2_D20210101-20210630" decimals="-5" format="ixt:zerodash" name="us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV83MC9mcmFnOjVkNDg3NDY3NDZiZDQ1ZWVhZTczY2JkYjNjZTc2MDdhL3RhYmxlOjQ2M2E4NDQ0NmMzOTQ0OWViMTI4Y2VkMzE5MjJmZjYxL3RhYmxlcmFuZ2U6NDYzYTg0NDQ2YzM5NDQ5ZWIxMjhjZWQzMTkyMmZmNjFfMjItNy0xLTEtNjk2_22d7ec9d-598d-436b-8150-60466355eacc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV83MC9mcmFnOjVkNDg3NDY3NDZiZDQ1ZWVhZTczY2JkYjNjZTc2MDdhL3RhYmxlOjQ2M2E4NDQ0NmMzOTQ0OWViMTI4Y2VkMzE5MjJmZjYxL3RhYmxlcmFuZ2U6NDYzYTg0NDQ2YzM5NDQ5ZWIxMjhjZWQzMTkyMmZmNjFfMjItOS0xLTEtNjk2_01fc91cd-7f1d-46fe-a72b-6a13ced29696">1,101.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other operating income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e89d4343fef486490e1fcdab10c1010_D20210101-20210630" decimals="-5" name="us-gaap:OtherOperatingIncome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV83MC9mcmFnOjVkNDg3NDY3NDZiZDQ1ZWVhZTczY2JkYjNjZTc2MDdhL3RhYmxlOjQ2M2E4NDQ0NmMzOTQ0OWViMTI4Y2VkMzE5MjJmZjYxL3RhYmxlcmFuZ2U6NDYzYTg0NDQ2YzM5NDQ5ZWIxMjhjZWQzMTkyMmZmNjFfMjMtMS0xLTEtNjk2_19608c4a-2954-4892-ab56-38b28492e9e0">7.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i741b04b8cd704e398b27520bf8aea7fc_D20210101-20210630" decimals="-5" name="us-gaap:OtherOperatingIncome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV83MC9mcmFnOjVkNDg3NDY3NDZiZDQ1ZWVhZTczY2JkYjNjZTc2MDdhL3RhYmxlOjQ2M2E4NDQ0NmMzOTQ0OWViMTI4Y2VkMzE5MjJmZjYxL3RhYmxlcmFuZ2U6NDYzYTg0NDQ2YzM5NDQ5ZWIxMjhjZWQzMTkyMmZmNjFfMjMtMy0xLTEtNjk2_12766b44-f755-4360-94cd-df89977ecac7">6.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia22ad972b1ec472b9114385ace42cd42_D20210101-20210630" decimals="-5" format="ixt:zerodash" name="us-gaap:OtherOperatingIncome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV83MC9mcmFnOjVkNDg3NDY3NDZiZDQ1ZWVhZTczY2JkYjNjZTc2MDdhL3RhYmxlOjQ2M2E4NDQ0NmMzOTQ0OWViMTI4Y2VkMzE5MjJmZjYxL3RhYmxlcmFuZ2U6NDYzYTg0NDQ2YzM5NDQ5ZWIxMjhjZWQzMTkyMmZmNjFfMjMtNS0xLTEtNjk2_90c2ad79-8dd3-480c-bd9a-116657303ad5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91156243b7cb4900b72f0b116d3781c2_D20210101-20210630" decimals="-5" format="ixt:zerodash" name="us-gaap:OtherOperatingIncome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV83MC9mcmFnOjVkNDg3NDY3NDZiZDQ1ZWVhZTczY2JkYjNjZTc2MDdhL3RhYmxlOjQ2M2E4NDQ0NmMzOTQ0OWViMTI4Y2VkMzE5MjJmZjYxL3RhYmxlcmFuZ2U6NDYzYTg0NDQ2YzM5NDQ5ZWIxMjhjZWQzMTkyMmZmNjFfMjMtNy0xLTEtNjk2_8f01025e-e4c6-42c0-bf46-7a709e26b9ac">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630" decimals="-5" name="us-gaap:OtherOperatingIncome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV83MC9mcmFnOjVkNDg3NDY3NDZiZDQ1ZWVhZTczY2JkYjNjZTc2MDdhL3RhYmxlOjQ2M2E4NDQ0NmMzOTQ0OWViMTI4Y2VkMzE5MjJmZjYxL3RhYmxlcmFuZ2U6NDYzYTg0NDQ2YzM5NDQ5ZWIxMjhjZWQzMTkyMmZmNjFfMjMtOS0xLTEtNjk2_5ff97499-745d-4cd0-a7a0-e03e2b0aed5f">13.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of service, excluding depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e89d4343fef486490e1fcdab10c1010_D20210101-20210630" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV83MC9mcmFnOjVkNDg3NDY3NDZiZDQ1ZWVhZTczY2JkYjNjZTc2MDdhL3RhYmxlOjQ2M2E4NDQ0NmMzOTQ0OWViMTI4Y2VkMzE5MjJmZjYxL3RhYmxlcmFuZ2U6NDYzYTg0NDQ2YzM5NDQ5ZWIxMjhjZWQzMTkyMmZmNjFfMjQtMS0xLTEtNjk2_149167fb-38ff-4ec0-a00a-04ad5200c317">373.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i741b04b8cd704e398b27520bf8aea7fc_D20210101-20210630" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV83MC9mcmFnOjVkNDg3NDY3NDZiZDQ1ZWVhZTczY2JkYjNjZTc2MDdhL3RhYmxlOjQ2M2E4NDQ0NmMzOTQ0OWViMTI4Y2VkMzE5MjJmZjYxL3RhYmxlcmFuZ2U6NDYzYTg0NDQ2YzM5NDQ5ZWIxMjhjZWQzMTkyMmZmNjFfMjQtMy0xLTEtNjk2_b448160f-904f-4891-884c-7610cb1f29c2">206.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia22ad972b1ec472b9114385ace42cd42_D20210101-20210630" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV83MC9mcmFnOjVkNDg3NDY3NDZiZDQ1ZWVhZTczY2JkYjNjZTc2MDdhL3RhYmxlOjQ2M2E4NDQ0NmMzOTQ0OWViMTI4Y2VkMzE5MjJmZjYxL3RhYmxlcmFuZ2U6NDYzYTg0NDQ2YzM5NDQ5ZWIxMjhjZWQzMTkyMmZmNjFfMjQtNS0xLTEtNjk2_e7f01e1e-e367-4da8-b4a9-d0c28d183f4f">25.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91156243b7cb4900b72f0b116d3781c2_D20210101-20210630" decimals="-5" format="ixt:zerodash" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV83MC9mcmFnOjVkNDg3NDY3NDZiZDQ1ZWVhZTczY2JkYjNjZTc2MDdhL3RhYmxlOjQ2M2E4NDQ0NmMzOTQ0OWViMTI4Y2VkMzE5MjJmZjYxL3RhYmxlcmFuZ2U6NDYzYTg0NDQ2YzM5NDQ5ZWIxMjhjZWQzMTkyMmZmNjFfMjQtNy0xLTEtNjk2_fd5c5ab9-b162-4cab-aaf9-4c172c8975ba">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV83MC9mcmFnOjVkNDg3NDY3NDZiZDQ1ZWVhZTczY2JkYjNjZTc2MDdhL3RhYmxlOjQ2M2E4NDQ0NmMzOTQ0OWViMTI4Y2VkMzE5MjJmZjYxL3RhYmxlcmFuZ2U6NDYzYTg0NDQ2YzM5NDQ5ZWIxMjhjZWQzMTkyMmZmNjFfMjQtOS0xLTEtNjk2_84e60f78-3b41-42e7-8dfb-1702388d3b13">605.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e89d4343fef486490e1fcdab10c1010_D20210101-20210630" decimals="-5" name="us-gaap:GeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV83MC9mcmFnOjVkNDg3NDY3NDZiZDQ1ZWVhZTczY2JkYjNjZTc2MDdhL3RhYmxlOjQ2M2E4NDQ0NmMzOTQ0OWViMTI4Y2VkMzE5MjJmZjYxL3RhYmxlcmFuZ2U6NDYzYTg0NDQ2YzM5NDQ5ZWIxMjhjZWQzMTkyMmZmNjFfMjUtMS0xLTEtNjk2_134e0990-4261-40ee-91b2-3082fb11e4ab">161.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i741b04b8cd704e398b27520bf8aea7fc_D20210101-20210630" decimals="-5" name="us-gaap:GeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV83MC9mcmFnOjVkNDg3NDY3NDZiZDQ1ZWVhZTczY2JkYjNjZTc2MDdhL3RhYmxlOjQ2M2E4NDQ0NmMzOTQ0OWViMTI4Y2VkMzE5MjJmZjYxL3RhYmxlcmFuZ2U6NDYzYTg0NDQ2YzM5NDQ5ZWIxMjhjZWQzMTkyMmZmNjFfMjUtMy0xLTEtNjk2_c1b6e703-0f33-4977-a58f-dd59ad65cba6">94.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia22ad972b1ec472b9114385ace42cd42_D20210101-20210630" decimals="-5" name="us-gaap:GeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV83MC9mcmFnOjVkNDg3NDY3NDZiZDQ1ZWVhZTczY2JkYjNjZTc2MDdhL3RhYmxlOjQ2M2E4NDQ0NmMzOTQ0OWViMTI4Y2VkMzE5MjJmZjYxL3RhYmxlcmFuZ2U6NDYzYTg0NDQ2YzM5NDQ5ZWIxMjhjZWQzMTkyMmZmNjFfMjUtNS0xLTEtNjk2_18e3adea-ca1e-4b36-94f1-8439d5e6909f">6.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91156243b7cb4900b72f0b116d3781c2_D20210101-20210630" decimals="-5" name="us-gaap:GeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV83MC9mcmFnOjVkNDg3NDY3NDZiZDQ1ZWVhZTczY2JkYjNjZTc2MDdhL3RhYmxlOjQ2M2E4NDQ0NmMzOTQ0OWViMTI4Y2VkMzE5MjJmZjYxL3RhYmxlcmFuZ2U6NDYzYTg0NDQ2YzM5NDQ5ZWIxMjhjZWQzMTkyMmZmNjFfMjUtNy0xLTEtNjk2_1c18ae92-b669-44f1-8456-6d84e8856bdf">84.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630" decimals="-5" name="us-gaap:GeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV83MC9mcmFnOjVkNDg3NDY3NDZiZDQ1ZWVhZTczY2JkYjNjZTc2MDdhL3RhYmxlOjQ2M2E4NDQ0NmMzOTQ0OWViMTI4Y2VkMzE5MjJmZjYxL3RhYmxlcmFuZ2U6NDYzYTg0NDQ2YzM5NDQ5ZWIxMjhjZWQzMTkyMmZmNjFfMjUtOS0xLTEtNjk2_b4b3dac7-dc34-4701-91db-d9551f89bc25">347.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e89d4343fef486490e1fcdab10c1010_D20210101-20210630" decimals="-5" name="us-gaap:DepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV83MC9mcmFnOjVkNDg3NDY3NDZiZDQ1ZWVhZTczY2JkYjNjZTc2MDdhL3RhYmxlOjQ2M2E4NDQ0NmMzOTQ0OWViMTI4Y2VkMzE5MjJmZjYxL3RhYmxlcmFuZ2U6NDYzYTg0NDQ2YzM5NDQ5ZWIxMjhjZWQzMTkyMmZmNjFfMjYtMS0xLTEtNjk2_0a72ea1f-71a4-4db0-a52c-b25afb0897bb">2.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i741b04b8cd704e398b27520bf8aea7fc_D20210101-20210630" decimals="-5" name="us-gaap:DepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV83MC9mcmFnOjVkNDg3NDY3NDZiZDQ1ZWVhZTczY2JkYjNjZTc2MDdhL3RhYmxlOjQ2M2E4NDQ0NmMzOTQ0OWViMTI4Y2VkMzE5MjJmZjYxL3RhYmxlcmFuZ2U6NDYzYTg0NDQ2YzM5NDQ5ZWIxMjhjZWQzMTkyMmZmNjFfMjYtMy0xLTEtNjk2_95f8e699-3425-4c2d-8cc5-9cd5645a09c6">1.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia22ad972b1ec472b9114385ace42cd42_D20210101-20210630" decimals="-5" name="us-gaap:DepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV83MC9mcmFnOjVkNDg3NDY3NDZiZDQ1ZWVhZTczY2JkYjNjZTc2MDdhL3RhYmxlOjQ2M2E4NDQ0NmMzOTQ0OWViMTI4Y2VkMzE5MjJmZjYxL3RhYmxlcmFuZ2U6NDYzYTg0NDQ2YzM5NDQ5ZWIxMjhjZWQzMTkyMmZmNjFfMjYtNS0xLTEtNjk2_4b31a23d-7b0a-433a-86ac-39c2e9450ec1">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91156243b7cb4900b72f0b116d3781c2_D20210101-20210630" decimals="-5" name="us-gaap:DepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV83MC9mcmFnOjVkNDg3NDY3NDZiZDQ1ZWVhZTczY2JkYjNjZTc2MDdhL3RhYmxlOjQ2M2E4NDQ0NmMzOTQ0OWViMTI4Y2VkMzE5MjJmZjYxL3RhYmxlcmFuZ2U6NDYzYTg0NDQ2YzM5NDQ5ZWIxMjhjZWQzMTkyMmZmNjFfMjYtNy0xLTEtNjk2_595d715a-e08c-4bbb-9c31-591c82e02e2e">10.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630" decimals="-5" name="us-gaap:DepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV83MC9mcmFnOjVkNDg3NDY3NDZiZDQ1ZWVhZTczY2JkYjNjZTc2MDdhL3RhYmxlOjQ2M2E4NDQ0NmMzOTQ0OWViMTI4Y2VkMzE5MjJmZjYxL3RhYmxlcmFuZ2U6NDYzYTg0NDQ2YzM5NDQ5ZWIxMjhjZWQzMTkyMmZmNjFfMjYtOS0xLTEtNjk2_4fc595f9-96ed-40c8-9254-41a20a6dbb22">14.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e89d4343fef486490e1fcdab10c1010_D20210101-20210630" decimals="-5" name="us-gaap:CostsAndExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV83MC9mcmFnOjVkNDg3NDY3NDZiZDQ1ZWVhZTczY2JkYjNjZTc2MDdhL3RhYmxlOjQ2M2E4NDQ0NmMzOTQ0OWViMTI4Y2VkMzE5MjJmZjYxL3RhYmxlcmFuZ2U6NDYzYTg0NDQ2YzM5NDQ5ZWIxMjhjZWQzMTkyMmZmNjFfMjctMS0xLTEtNjk2_3274a1e3-d34a-4952-87a4-0dd42126e416">537.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i741b04b8cd704e398b27520bf8aea7fc_D20210101-20210630" decimals="-5" name="us-gaap:CostsAndExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV83MC9mcmFnOjVkNDg3NDY3NDZiZDQ1ZWVhZTczY2JkYjNjZTc2MDdhL3RhYmxlOjQ2M2E4NDQ0NmMzOTQ0OWViMTI4Y2VkMzE5MjJmZjYxL3RhYmxlcmFuZ2U6NDYzYTg0NDQ2YzM5NDQ5ZWIxMjhjZWQzMTkyMmZmNjFfMjctMy0xLTEtNjk2_6c7d5255-1e10-4321-9064-ca54f24cdc24">303.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia22ad972b1ec472b9114385ace42cd42_D20210101-20210630" decimals="-5" name="us-gaap:CostsAndExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV83MC9mcmFnOjVkNDg3NDY3NDZiZDQ1ZWVhZTczY2JkYjNjZTc2MDdhL3RhYmxlOjQ2M2E4NDQ0NmMzOTQ0OWViMTI4Y2VkMzE5MjJmZjYxL3RhYmxlcmFuZ2U6NDYzYTg0NDQ2YzM5NDQ5ZWIxMjhjZWQzMTkyMmZmNjFfMjctNS0xLTEtNjk2_5139b8aa-9f43-4989-85d2-e85f289e6b72">32.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91156243b7cb4900b72f0b116d3781c2_D20210101-20210630" decimals="-5" name="us-gaap:CostsAndExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV83MC9mcmFnOjVkNDg3NDY3NDZiZDQ1ZWVhZTczY2JkYjNjZTc2MDdhL3RhYmxlOjQ2M2E4NDQ0NmMzOTQ0OWViMTI4Y2VkMzE5MjJmZjYxL3RhYmxlcmFuZ2U6NDYzYTg0NDQ2YzM5NDQ5ZWIxMjhjZWQzMTkyMmZmNjFfMjctNy0xLTEtNjk2_e0a3f566-60f5-4d35-a8a7-91a0111f0f89">95.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630" decimals="-5" name="us-gaap:CostsAndExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV83MC9mcmFnOjVkNDg3NDY3NDZiZDQ1ZWVhZTczY2JkYjNjZTc2MDdhL3RhYmxlOjQ2M2E4NDQ0NmMzOTQ0OWViMTI4Y2VkMzE5MjJmZjYxL3RhYmxlcmFuZ2U6NDYzYTg0NDQ2YzM5NDQ5ZWIxMjhjZWQzMTkyMmZmNjFfMjctOS0xLTEtNjk2_d8834325-8596-4874-a896-e79c024cbced">967.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating income (loss)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e89d4343fef486490e1fcdab10c1010_D20210101-20210630" decimals="-5" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV83MC9mcmFnOjVkNDg3NDY3NDZiZDQ1ZWVhZTczY2JkYjNjZTc2MDdhL3RhYmxlOjQ2M2E4NDQ0NmMzOTQ0OWViMTI4Y2VkMzE5MjJmZjYxL3RhYmxlcmFuZ2U6NDYzYTg0NDQ2YzM5NDQ5ZWIxMjhjZWQzMTkyMmZmNjFfMjgtMS0xLTEtNjk2_372cd4e6-eede-481d-a2f4-608bcfe256ee">148.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i741b04b8cd704e398b27520bf8aea7fc_D20210101-20210630" decimals="-5" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV83MC9mcmFnOjVkNDg3NDY3NDZiZDQ1ZWVhZTczY2JkYjNjZTc2MDdhL3RhYmxlOjQ2M2E4NDQ0NmMzOTQ0OWViMTI4Y2VkMzE5MjJmZjYxL3RhYmxlcmFuZ2U6NDYzYTg0NDQ2YzM5NDQ5ZWIxMjhjZWQzMTkyMmZmNjFfMjgtMy0xLTEtNjk2_8ca2877c-a071-432a-9e26-ee73fd195f0a">92.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia22ad972b1ec472b9114385ace42cd42_D20210101-20210630" decimals="-5" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV83MC9mcmFnOjVkNDg3NDY3NDZiZDQ1ZWVhZTczY2JkYjNjZTc2MDdhL3RhYmxlOjQ2M2E4NDQ0NmMzOTQ0OWViMTI4Y2VkMzE5MjJmZjYxL3RhYmxlcmFuZ2U6NDYzYTg0NDQ2YzM5NDQ5ZWIxMjhjZWQzMTkyMmZmNjFfMjgtNS0xLTEtNjk2_976d9ff1-f11a-41f9-98e7-3d75e3af132f">2.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i91156243b7cb4900b72f0b116d3781c2_D20210101-20210630" decimals="-5" sign="-" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV83MC9mcmFnOjVkNDg3NDY3NDZiZDQ1ZWVhZTczY2JkYjNjZTc2MDdhL3RhYmxlOjQ2M2E4NDQ0NmMzOTQ0OWViMTI4Y2VkMzE5MjJmZjYxL3RhYmxlcmFuZ2U6NDYzYTg0NDQ2YzM5NDQ5ZWIxMjhjZWQzMTkyMmZmNjFfMjgtNy0xLTEtNjk2_082e5bc3-0717-4eab-aaaa-d1bf212dae46">95.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630" decimals="-5" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV83MC9mcmFnOjVkNDg3NDY3NDZiZDQ1ZWVhZTczY2JkYjNjZTc2MDdhL3RhYmxlOjQ2M2E4NDQ0NmMzOTQ0OWViMTI4Y2VkMzE5MjJmZjYxL3RhYmxlcmFuZ2U6NDYzYTg0NDQ2YzM5NDQ5ZWIxMjhjZWQzMTkyMmZmNjFfMjgtOS0xLTEtNjk2_4f329f65-40eb-4fdf-8f9f-2ffda486cf35">147.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Six-Month Period Ended June 30, 2020</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Home<br/>Health</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Hospice</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Personal<br/>Care</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net service revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15c3520755c5444cb900d57537639c6c_D20200101-20200630" decimals="-5" name="us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV83MC9mcmFnOjVkNDg3NDY3NDZiZDQ1ZWVhZTczY2JkYjNjZTc2MDdhL3RhYmxlOjQ2M2E4NDQ0NmMzOTQ0OWViMTI4Y2VkMzE5MjJmZjYxL3RhYmxlcmFuZ2U6NDYzYTg0NDQ2YzM5NDQ5ZWIxMjhjZWQzMTkyMmZmNjFfMzItMS0xLTEtNzAw_cda28d3e-da5a-45ee-bbb9-25e4488baa5f">593.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ce911e452594105bd0677b242a6a2d3_D20200101-20200630" decimals="-5" name="us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV83MC9mcmFnOjVkNDg3NDY3NDZiZDQ1ZWVhZTczY2JkYjNjZTc2MDdhL3RhYmxlOjQ2M2E4NDQ0NmMzOTQ0OWViMTI4Y2VkMzE5MjJmZjYxL3RhYmxlcmFuZ2U6NDYzYTg0NDQ2YzM5NDQ5ZWIxMjhjZWQzMTkyMmZmNjFfMzItMy0xLTEtNzAw_b095b032-8c59-4d07-a824-9f0d6a8f4b77">346.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e461372b93847a4b7c9e1e3e9206b30_D20200101-20200630" decimals="-5" name="us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV83MC9mcmFnOjVkNDg3NDY3NDZiZDQ1ZWVhZTczY2JkYjNjZTc2MDdhL3RhYmxlOjQ2M2E4NDQ0NmMzOTQ0OWViMTI4Y2VkMzE5MjJmZjYxL3RhYmxlcmFuZ2U6NDYzYTg0NDQ2YzM5NDQ5ZWIxMjhjZWQzMTkyMmZmNjFfMzItNS0xLTEtNzAw_20fe4431-9fe4-4087-bc9d-f3699d2ddb9f">36.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f63d6ecb3ef4b2f9a0e98f946e6f46e_D20200101-20200630" decimals="-5" format="ixt:zerodash" name="us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV83MC9mcmFnOjVkNDg3NDY3NDZiZDQ1ZWVhZTczY2JkYjNjZTc2MDdhL3RhYmxlOjQ2M2E4NDQ0NmMzOTQ0OWViMTI4Y2VkMzE5MjJmZjYxL3RhYmxlcmFuZ2U6NDYzYTg0NDQ2YzM5NDQ5ZWIxMjhjZWQzMTkyMmZmNjFfMzItNy0xLTEtNzAw_442dc424-e748-4b80-9016-8dd9297b58be">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i667fa0996400408f9cb2d7f4d3ee2087_D20200101-20200630" decimals="-5" name="us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV83MC9mcmFnOjVkNDg3NDY3NDZiZDQ1ZWVhZTczY2JkYjNjZTc2MDdhL3RhYmxlOjQ2M2E4NDQ0NmMzOTQ0OWViMTI4Y2VkMzE5MjJmZjYxL3RhYmxlcmFuZ2U6NDYzYTg0NDQ2YzM5NDQ5ZWIxMjhjZWQzMTkyMmZmNjFfMzItOS0xLTEtNzAw_5b948767-efb6-4bc8-a17c-db5776d7f86d">976.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other operating income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15c3520755c5444cb900d57537639c6c_D20200101-20200630" decimals="-5" name="us-gaap:OtherOperatingIncome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV83MC9mcmFnOjVkNDg3NDY3NDZiZDQ1ZWVhZTczY2JkYjNjZTc2MDdhL3RhYmxlOjQ2M2E4NDQ0NmMzOTQ0OWViMTI4Y2VkMzE5MjJmZjYxL3RhYmxlcmFuZ2U6NDYzYTg0NDQ2YzM5NDQ5ZWIxMjhjZWQzMTkyMmZmNjFfMzMtMS0xLTEtNzAw_bc3dd621-c9b5-4e94-8ab0-332e9b8c600e">15.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ce911e452594105bd0677b242a6a2d3_D20200101-20200630" decimals="-5" name="us-gaap:OtherOperatingIncome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV83MC9mcmFnOjVkNDg3NDY3NDZiZDQ1ZWVhZTczY2JkYjNjZTc2MDdhL3RhYmxlOjQ2M2E4NDQ0NmMzOTQ0OWViMTI4Y2VkMzE5MjJmZjYxL3RhYmxlcmFuZ2U6NDYzYTg0NDQ2YzM5NDQ5ZWIxMjhjZWQzMTkyMmZmNjFfMzMtMy0xLTEtNzAw_75657600-e039-405c-8674-e6ef2270c5a8">7.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e461372b93847a4b7c9e1e3e9206b30_D20200101-20200630" decimals="-5" name="us-gaap:OtherOperatingIncome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV83MC9mcmFnOjVkNDg3NDY3NDZiZDQ1ZWVhZTczY2JkYjNjZTc2MDdhL3RhYmxlOjQ2M2E4NDQ0NmMzOTQ0OWViMTI4Y2VkMzE5MjJmZjYxL3RhYmxlcmFuZ2U6NDYzYTg0NDQ2YzM5NDQ5ZWIxMjhjZWQzMTkyMmZmNjFfMzMtNS0xLTEtNzAw_65803e74-4ab4-4e8d-b0d5-6ffa378c11d4">0.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f63d6ecb3ef4b2f9a0e98f946e6f46e_D20200101-20200630" decimals="-5" format="ixt:zerodash" name="us-gaap:OtherOperatingIncome" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV83MC9mcmFnOjVkNDg3NDY3NDZiZDQ1ZWVhZTczY2JkYjNjZTc2MDdhL3RhYmxlOjQ2M2E4NDQ0NmMzOTQ0OWViMTI4Y2VkMzE5MjJmZjYxL3RhYmxlcmFuZ2U6NDYzYTg0NDQ2YzM5NDQ5ZWIxMjhjZWQzMTkyMmZmNjFfMzMtNy0xLTEtMTI5Ng_fe5cbdee-117f-46a5-8d3e-594951211e77">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i667fa0996400408f9cb2d7f4d3ee2087_D20200101-20200630" decimals="-5" name="us-gaap:OtherOperatingIncome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV83MC9mcmFnOjVkNDg3NDY3NDZiZDQ1ZWVhZTczY2JkYjNjZTc2MDdhL3RhYmxlOjQ2M2E4NDQ0NmMzOTQ0OWViMTI4Y2VkMzE5MjJmZjYxL3RhYmxlcmFuZ2U6NDYzYTg0NDQ2YzM5NDQ5ZWIxMjhjZWQzMTkyMmZmNjFfMzMtOS0xLTEtNzAw_05023cbc-77c4-446c-ba9b-b8a84f425bb1">22.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of service, excluding depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15c3520755c5444cb900d57537639c6c_D20200101-20200630" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV83MC9mcmFnOjVkNDg3NDY3NDZiZDQ1ZWVhZTczY2JkYjNjZTc2MDdhL3RhYmxlOjQ2M2E4NDQ0NmMzOTQ0OWViMTI4Y2VkMzE5MjJmZjYxL3RhYmxlcmFuZ2U6NDYzYTg0NDQ2YzM5NDQ5ZWIxMjhjZWQzMTkyMmZmNjFfMzQtMS0xLTEtNzAw_8fb7b402-6e84-47c3-8cc5-c9f06bbbb33d">363.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ce911e452594105bd0677b242a6a2d3_D20200101-20200630" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV83MC9mcmFnOjVkNDg3NDY3NDZiZDQ1ZWVhZTczY2JkYjNjZTc2MDdhL3RhYmxlOjQ2M2E4NDQ0NmMzOTQ0OWViMTI4Y2VkMzE5MjJmZjYxL3RhYmxlcmFuZ2U6NDYzYTg0NDQ2YzM5NDQ5ZWIxMjhjZWQzMTkyMmZmNjFfMzQtMy0xLTEtNzAw_87208839-0c8e-4a5c-b69c-06a448ac29a4">189.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e461372b93847a4b7c9e1e3e9206b30_D20200101-20200630" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV83MC9mcmFnOjVkNDg3NDY3NDZiZDQ1ZWVhZTczY2JkYjNjZTc2MDdhL3RhYmxlOjQ2M2E4NDQ0NmMzOTQ0OWViMTI4Y2VkMzE5MjJmZjYxL3RhYmxlcmFuZ2U6NDYzYTg0NDQ2YzM5NDQ5ZWIxMjhjZWQzMTkyMmZmNjFfMzQtNS0xLTEtNzAw_6bcbce4a-0330-4a7e-931e-5eec6c8f7660">28.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f63d6ecb3ef4b2f9a0e98f946e6f46e_D20200101-20200630" decimals="-5" format="ixt:zerodash" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV83MC9mcmFnOjVkNDg3NDY3NDZiZDQ1ZWVhZTczY2JkYjNjZTc2MDdhL3RhYmxlOjQ2M2E4NDQ0NmMzOTQ0OWViMTI4Y2VkMzE5MjJmZjYxL3RhYmxlcmFuZ2U6NDYzYTg0NDQ2YzM5NDQ5ZWIxMjhjZWQzMTkyMmZmNjFfMzQtNy0xLTEtNzAw_ba2bfb2e-8365-4cac-9b2b-a44be2e61e7d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i667fa0996400408f9cb2d7f4d3ee2087_D20200101-20200630" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV83MC9mcmFnOjVkNDg3NDY3NDZiZDQ1ZWVhZTczY2JkYjNjZTc2MDdhL3RhYmxlOjQ2M2E4NDQ0NmMzOTQ0OWViMTI4Y2VkMzE5MjJmZjYxL3RhYmxlcmFuZ2U6NDYzYTg0NDQ2YzM5NDQ5ZWIxMjhjZWQzMTkyMmZmNjFfMzQtOS0xLTEtNzAw_4f2c7c41-822d-4b77-ba24-2bdf248e1e82">581.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15c3520755c5444cb900d57537639c6c_D20200101-20200630" decimals="-5" name="us-gaap:GeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV83MC9mcmFnOjVkNDg3NDY3NDZiZDQ1ZWVhZTczY2JkYjNjZTc2MDdhL3RhYmxlOjQ2M2E4NDQ0NmMzOTQ0OWViMTI4Y2VkMzE5MjJmZjYxL3RhYmxlcmFuZ2U6NDYzYTg0NDQ2YzM5NDQ5ZWIxMjhjZWQzMTkyMmZmNjFfMzUtMS0xLTEtNzAw_057792dc-0081-4434-a36d-ebbac69956c6">147.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ce911e452594105bd0677b242a6a2d3_D20200101-20200630" decimals="-5" name="us-gaap:GeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV83MC9mcmFnOjVkNDg3NDY3NDZiZDQ1ZWVhZTczY2JkYjNjZTc2MDdhL3RhYmxlOjQ2M2E4NDQ0NmMzOTQ0OWViMTI4Y2VkMzE5MjJmZjYxL3RhYmxlcmFuZ2U6NDYzYTg0NDQ2YzM5NDQ5ZWIxMjhjZWQzMTkyMmZmNjFfMzUtMy0xLTEtNzAw_8de68702-4ee1-40c6-aa03-73e6112240f8">79.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e461372b93847a4b7c9e1e3e9206b30_D20200101-20200630" decimals="-5" name="us-gaap:GeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV83MC9mcmFnOjVkNDg3NDY3NDZiZDQ1ZWVhZTczY2JkYjNjZTc2MDdhL3RhYmxlOjQ2M2E4NDQ0NmMzOTQ0OWViMTI4Y2VkMzE5MjJmZjYxL3RhYmxlcmFuZ2U6NDYzYTg0NDQ2YzM5NDQ5ZWIxMjhjZWQzMTkyMmZmNjFfMzUtNS0xLTEtNzAw_bf2187c4-6386-4ced-9316-0aa75f20a281">6.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f63d6ecb3ef4b2f9a0e98f946e6f46e_D20200101-20200630" decimals="-5" name="us-gaap:GeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV83MC9mcmFnOjVkNDg3NDY3NDZiZDQ1ZWVhZTczY2JkYjNjZTc2MDdhL3RhYmxlOjQ2M2E4NDQ0NmMzOTQ0OWViMTI4Y2VkMzE5MjJmZjYxL3RhYmxlcmFuZ2U6NDYzYTg0NDQ2YzM5NDQ5ZWIxMjhjZWQzMTkyMmZmNjFfMzUtNy0xLTEtNzAw_64bd9970-c1d6-4fe5-b52b-d83cea666187">79.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i667fa0996400408f9cb2d7f4d3ee2087_D20200101-20200630" decimals="-5" name="us-gaap:GeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV83MC9mcmFnOjVkNDg3NDY3NDZiZDQ1ZWVhZTczY2JkYjNjZTc2MDdhL3RhYmxlOjQ2M2E4NDQ0NmMzOTQ0OWViMTI4Y2VkMzE5MjJmZjYxL3RhYmxlcmFuZ2U6NDYzYTg0NDQ2YzM5NDQ5ZWIxMjhjZWQzMTkyMmZmNjFfMzUtOS0xLTEtNzAw_5eb9cdee-6b55-4a9b-93c3-581a79d07a1b">313.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15c3520755c5444cb900d57537639c6c_D20200101-20200630" decimals="-5" name="us-gaap:DepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV83MC9mcmFnOjVkNDg3NDY3NDZiZDQ1ZWVhZTczY2JkYjNjZTc2MDdhL3RhYmxlOjQ2M2E4NDQ0NmMzOTQ0OWViMTI4Y2VkMzE5MjJmZjYxL3RhYmxlcmFuZ2U6NDYzYTg0NDQ2YzM5NDQ5ZWIxMjhjZWQzMTkyMmZmNjFfMzYtMS0xLTEtNzAw_9616ad43-76ac-48ed-9253-4e8678e6f498">1.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ce911e452594105bd0677b242a6a2d3_D20200101-20200630" decimals="-5" name="us-gaap:DepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV83MC9mcmFnOjVkNDg3NDY3NDZiZDQ1ZWVhZTczY2JkYjNjZTc2MDdhL3RhYmxlOjQ2M2E4NDQ0NmMzOTQ0OWViMTI4Y2VkMzE5MjJmZjYxL3RhYmxlcmFuZ2U6NDYzYTg0NDQ2YzM5NDQ5ZWIxMjhjZWQzMTkyMmZmNjFfMzYtMy0xLTEtNzAw_b7e5cdce-303e-41e6-bca4-0a4a0f69b521">1.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e461372b93847a4b7c9e1e3e9206b30_D20200101-20200630" decimals="-5" name="us-gaap:DepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV83MC9mcmFnOjVkNDg3NDY3NDZiZDQ1ZWVhZTczY2JkYjNjZTc2MDdhL3RhYmxlOjQ2M2E4NDQ0NmMzOTQ0OWViMTI4Y2VkMzE5MjJmZjYxL3RhYmxlcmFuZ2U6NDYzYTg0NDQ2YzM5NDQ5ZWIxMjhjZWQzMTkyMmZmNjFfMzYtNS0xLTEtNzAw_09c8aa96-7e1b-47dc-bfda-621288e799ca">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f63d6ecb3ef4b2f9a0e98f946e6f46e_D20200101-20200630" decimals="-5" name="us-gaap:DepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV83MC9mcmFnOjVkNDg3NDY3NDZiZDQ1ZWVhZTczY2JkYjNjZTc2MDdhL3RhYmxlOjQ2M2E4NDQ0NmMzOTQ0OWViMTI4Y2VkMzE5MjJmZjYxL3RhYmxlcmFuZ2U6NDYzYTg0NDQ2YzM5NDQ5ZWIxMjhjZWQzMTkyMmZmNjFfMzYtNy0xLTEtNzAw_b0254f81-83c5-4b05-b85a-5c133b4c21a6">8.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i667fa0996400408f9cb2d7f4d3ee2087_D20200101-20200630" decimals="-5" name="us-gaap:DepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV83MC9mcmFnOjVkNDg3NDY3NDZiZDQ1ZWVhZTczY2JkYjNjZTc2MDdhL3RhYmxlOjQ2M2E4NDQ0NmMzOTQ0OWViMTI4Y2VkMzE5MjJmZjYxL3RhYmxlcmFuZ2U6NDYzYTg0NDQ2YzM5NDQ5ZWIxMjhjZWQzMTkyMmZmNjFfMzYtOS0xLTEtNzAw_9549a1d3-9018-4c90-87d6-51fd173db59c">11.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15c3520755c5444cb900d57537639c6c_D20200101-20200630" decimals="-5" name="us-gaap:CostsAndExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV83MC9mcmFnOjVkNDg3NDY3NDZiZDQ1ZWVhZTczY2JkYjNjZTc2MDdhL3RhYmxlOjQ2M2E4NDQ0NmMzOTQ0OWViMTI4Y2VkMzE5MjJmZjYxL3RhYmxlcmFuZ2U6NDYzYTg0NDQ2YzM5NDQ5ZWIxMjhjZWQzMTkyMmZmNjFfMzctMS0xLTEtNzAw_c5f048d0-74de-400e-affa-485612fe0b64">513.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ce911e452594105bd0677b242a6a2d3_D20200101-20200630" decimals="-5" name="us-gaap:CostsAndExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV83MC9mcmFnOjVkNDg3NDY3NDZiZDQ1ZWVhZTczY2JkYjNjZTc2MDdhL3RhYmxlOjQ2M2E4NDQ0NmMzOTQ0OWViMTI4Y2VkMzE5MjJmZjYxL3RhYmxlcmFuZ2U6NDYzYTg0NDQ2YzM5NDQ5ZWIxMjhjZWQzMTkyMmZmNjFfMzctMy0xLTEtNzAw_680ec770-d14b-4805-8d98-0e207a41ec1c">269.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e461372b93847a4b7c9e1e3e9206b30_D20200101-20200630" decimals="-5" name="us-gaap:CostsAndExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV83MC9mcmFnOjVkNDg3NDY3NDZiZDQ1ZWVhZTczY2JkYjNjZTc2MDdhL3RhYmxlOjQ2M2E4NDQ0NmMzOTQ0OWViMTI4Y2VkMzE5MjJmZjYxL3RhYmxlcmFuZ2U6NDYzYTg0NDQ2YzM5NDQ5ZWIxMjhjZWQzMTkyMmZmNjFfMzctNS0xLTEtNzAw_eadf4455-ace5-48e4-a93a-18c0e5383214">34.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f63d6ecb3ef4b2f9a0e98f946e6f46e_D20200101-20200630" decimals="-5" name="us-gaap:CostsAndExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV83MC9mcmFnOjVkNDg3NDY3NDZiZDQ1ZWVhZTczY2JkYjNjZTc2MDdhL3RhYmxlOjQ2M2E4NDQ0NmMzOTQ0OWViMTI4Y2VkMzE5MjJmZjYxL3RhYmxlcmFuZ2U6NDYzYTg0NDQ2YzM5NDQ5ZWIxMjhjZWQzMTkyMmZmNjFfMzctNy0xLTEtNzAw_4e1c1b37-e974-4df0-bb05-5efa20adf737">87.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i667fa0996400408f9cb2d7f4d3ee2087_D20200101-20200630" decimals="-5" name="us-gaap:CostsAndExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV83MC9mcmFnOjVkNDg3NDY3NDZiZDQ1ZWVhZTczY2JkYjNjZTc2MDdhL3RhYmxlOjQ2M2E4NDQ0NmMzOTQ0OWViMTI4Y2VkMzE5MjJmZjYxL3RhYmxlcmFuZ2U6NDYzYTg0NDQ2YzM5NDQ5ZWIxMjhjZWQzMTkyMmZmNjFfMzctOS0xLTEtNzAw_c3963dce-23a1-4019-8991-4527205dfb6d">905.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating income (loss)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15c3520755c5444cb900d57537639c6c_D20200101-20200630" decimals="-5" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV83MC9mcmFnOjVkNDg3NDY3NDZiZDQ1ZWVhZTczY2JkYjNjZTc2MDdhL3RhYmxlOjQ2M2E4NDQ0NmMzOTQ0OWViMTI4Y2VkMzE5MjJmZjYxL3RhYmxlcmFuZ2U6NDYzYTg0NDQ2YzM5NDQ5ZWIxMjhjZWQzMTkyMmZmNjFfMzgtMS0xLTEtNzAw_c4694c98-3186-4164-a089-2f200947fa94">95.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ce911e452594105bd0677b242a6a2d3_D20200101-20200630" decimals="-5" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV83MC9mcmFnOjVkNDg3NDY3NDZiZDQ1ZWVhZTczY2JkYjNjZTc2MDdhL3RhYmxlOjQ2M2E4NDQ0NmMzOTQ0OWViMTI4Y2VkMzE5MjJmZjYxL3RhYmxlcmFuZ2U6NDYzYTg0NDQ2YzM5NDQ5ZWIxMjhjZWQzMTkyMmZmNjFfMzgtMy0xLTEtNzAw_95cf4d2a-cc5d-4fca-8b60-bead17fb8773">84.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e461372b93847a4b7c9e1e3e9206b30_D20200101-20200630" decimals="-5" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV83MC9mcmFnOjVkNDg3NDY3NDZiZDQ1ZWVhZTczY2JkYjNjZTc2MDdhL3RhYmxlOjQ2M2E4NDQ0NmMzOTQ0OWViMTI4Y2VkMzE5MjJmZjYxL3RhYmxlcmFuZ2U6NDYzYTg0NDQ2YzM5NDQ5ZWIxMjhjZWQzMTkyMmZmNjFfMzgtNS0xLTEtNzAw_e79c00a8-71d2-477b-b828-9faa1f426620">2.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2f63d6ecb3ef4b2f9a0e98f946e6f46e_D20200101-20200630" decimals="-5" sign="-" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV83MC9mcmFnOjVkNDg3NDY3NDZiZDQ1ZWVhZTczY2JkYjNjZTc2MDdhL3RhYmxlOjQ2M2E4NDQ0NmMzOTQ0OWViMTI4Y2VkMzE5MjJmZjYxL3RhYmxlcmFuZ2U6NDYzYTg0NDQ2YzM5NDQ5ZWIxMjhjZWQzMTkyMmZmNjFfMzgtNy0xLTEtNzAw_9afcc6d3-06cb-465c-ba5a-87e5d13979ad">87.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i667fa0996400408f9cb2d7f4d3ee2087_D20200101-20200630" decimals="-5" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV83MC9mcmFnOjVkNDg3NDY3NDZiZDQ1ZWVhZTczY2JkYjNjZTc2MDdhL3RhYmxlOjQ2M2E4NDQ0NmMzOTQ0OWViMTI4Y2VkMzE5MjJmZjYxL3RhYmxlcmFuZ2U6NDYzYTg0NDQ2YzM5NDQ5ZWIxMjhjZWQzMTkyMmZmNjFfMzgtOS0xLTEtNzAw_a062857d-e3b2-4d8f-8681-85bc7f6647d7">93.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div></ix:continuation><div style="text-align:center"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><div id="iccd9c69ecd2c42e5897cfe9ab4e7e0b5_76"></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AMEDISYS, INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8. <ix:nonNumeric contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630" name="us-gaap:TreasuryStockTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV83Ni9mcmFnOjNlOTQ3NmZhYTBhNjRiN2RhZjZiNmM2NTQ0NGZlMTJjL3RleHRyZWdpb246M2U5NDc2ZmFhMGE2NGI3ZGFmNmI2YzY1NDQ0ZmUxMmNfMTA2NQ_84e27448-125a-46b9-9b54-127b6349d967" continuedAt="ibbecbebf609e4d89bb8eb5e61c6cfde4" escape="true">SHARE REPURCHASES </ix:nonNumeric></span></div><ix:continuation id="ibbecbebf609e4d89bb8eb5e61c6cfde4"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2021 Stock Repurchase Program</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 23, 2020, we announced that our Board of Directors authorized a stock repurchase program, under which we may repurchase up to $<ix:nonFraction unitRef="usd" contextRef="i479f4d0280434d3681861fd2e320cd99_I20201223" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockRepurchaseProgramAuthorizedAmount1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV83Ni9mcmFnOjNlOTQ3NmZhYTBhNjRiN2RhZjZiNmM2NTQ0NGZlMTJjL3RleHRyZWdpb246M2U5NDc2ZmFhMGE2NGI3ZGFmNmI2YzY1NDQ0ZmUxMmNfMTk1_bdad7083-0251-401d-b590-f1ff3203525d">100</ix:nonFraction>&#160;million of our outstanding common stock through <ix:nonNumeric contextRef="i0d540c3eb0984765b002cd7535b1f472_D20201223-20211231" format="ixt:datemonthdayyearen" name="us-gaap:StockRepurchaseProgramExpirationDate" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV83Ni9mcmFnOjNlOTQ3NmZhYTBhNjRiN2RhZjZiNmM2NTQ0NGZlMTJjL3RleHRyZWdpb246M2U5NDc2ZmFhMGE2NGI3ZGFmNmI2YzY1NDQ0ZmUxMmNfMjM4_9788ef35-c1b8-4ece-9b3a-d6c657679bd9">December 31, 2021</ix:nonNumeric>.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the program, we are allowed to repurchase shares from time to time through open market purchases, unsolicited or solicited privately negotiated transactions, an accelerated stock repurchase program, and/or a trading plan in compliance with Exchange Act Rule 10b5-1. The timing and the amount of the repurchases will be determined by management based on a number of factors, including but not limited to share price, trading volume and general market conditions, as well as on working capital requirements, general business conditions and other factors. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to this program, we repurchased <ix:nonFraction unitRef="shares" contextRef="i7d058b3163364b51b7615e3e655ec631_D20210401-20210630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockSharesAcquired" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV83Ni9mcmFnOjNlOTQ3NmZhYTBhNjRiN2RhZjZiNmM2NTQ0NGZlMTJjL3RleHRyZWdpb246M2U5NDc2ZmFhMGE2NGI3ZGFmNmI2YzY1NDQ0ZmUxMmNfODk2_f5fba492-f48f-4ce5-8ffa-13ae249b7867">4,757</ix:nonFraction> shares of our common stock at a weighted average price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i7d058b3163364b51b7615e3e655ec631_D20210401-20210630" decimals="2" name="us-gaap:TreasuryStockAcquiredAverageCostPerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV83Ni9mcmFnOjNlOTQ3NmZhYTBhNjRiN2RhZjZiNmM2NTQ0NGZlMTJjL3RleHRyZWdpb246M2U5NDc2ZmFhMGE2NGI3ZGFmNmI2YzY1NDQ0ZmUxMmNfOTU3_4fede443-2e5c-4c91-bd89-dd66d73f2988">249.72</ix:nonFraction> per share and a total cost of approximately $<ix:nonFraction unitRef="usd" contextRef="i7d058b3163364b51b7615e3e655ec631_D20210401-20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsForRepurchaseOfCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV83Ni9mcmFnOjNlOTQ3NmZhYTBhNjRiN2RhZjZiNmM2NTQ0NGZlMTJjL3RleHRyZWdpb246M2U5NDc2ZmFhMGE2NGI3ZGFmNmI2YzY1NDQ0ZmUxMmNfMTAwNA_ce7625bd-a712-4553-b1bf-55f0d4040269">1</ix:nonFraction>&#160;million during the three-month period ended June 30, 2021 and <ix:nonFraction unitRef="shares" contextRef="ie99fb62084bb4f729ac77ff7dbaed893_D20210101-20210630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockSharesAcquired" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV83Ni9mcmFnOjNlOTQ3NmZhYTBhNjRiN2RhZjZiNmM2NTQ0NGZlMTJjL3RleHRyZWdpb246M2U5NDc2ZmFhMGE2NGI3ZGFmNmI2YzY1NDQ0ZmUxMmNfMTA5OTUxMTYyOTcwMA_4dbfe67f-7dd3-40e7-81cb-cdabc7d87988">297,105</ix:nonFraction> shares of our common stock at a weighted average price of $<ix:nonFraction unitRef="usdPerShare" contextRef="ie99fb62084bb4f729ac77ff7dbaed893_D20210101-20210630" decimals="2" name="us-gaap:TreasuryStockAcquiredAverageCostPerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV83Ni9mcmFnOjNlOTQ3NmZhYTBhNjRiN2RhZjZiNmM2NTQ0NGZlMTJjL3RleHRyZWdpb246M2U5NDc2ZmFhMGE2NGI3ZGFmNmI2YzY1NDQ0ZmUxMmNfMTA5OTUxMTYyOTcyMg_4e58eec3-7c74-49a2-bc41-66bc97b62535">249.29</ix:nonFraction> per share and a total cost of approximately $<ix:nonFraction unitRef="usd" contextRef="ie99fb62084bb4f729ac77ff7dbaed893_D20210101-20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsForRepurchaseOfCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV83Ni9mcmFnOjNlOTQ3NmZhYTBhNjRiN2RhZjZiNmM2NTQ0NGZlMTJjL3RleHRyZWdpb246M2U5NDc2ZmFhMGE2NGI3ZGFmNmI2YzY1NDQ0ZmUxMmNfMTA5OTUxMTYyOTcwOQ_39067620-4e44-4689-9070-2a5040ad665c">74</ix:nonFraction>&#160;million during the six-month period ended June 30, 2021. The repurchased shares are classified as treasury shares. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 2, 2021, our Board of Directors authorized a share repurchase program, under which we may repurchase up to $<ix:nonFraction unitRef="usd" contextRef="i55192f2892ba4410b4d8043c7bd3508f_I20210802" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockRepurchaseProgramAuthorizedAmount1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV83Ni9mcmFnOjNlOTQ3NmZhYTBhNjRiN2RhZjZiNmM2NTQ0NGZlMTJjL3RleHRyZWdpb246M2U5NDc2ZmFhMGE2NGI3ZGFmNmI2YzY1NDQ0ZmUxMmNfMTA5OTUxMTYzMDU0OA_5da2c867-2059-4d11-ae1e-1acb858b3a03">100</ix:nonFraction>&#160;million of our outstanding common stock through <ix:nonNumeric contextRef="ide446a75729e4d219d7267432d1f1fbc_D20210802-20221231" format="ixt:datemonthdayyearen" name="us-gaap:StockRepurchaseProgramExpirationDate" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV83Ni9mcmFnOjNlOTQ3NmZhYTBhNjRiN2RhZjZiNmM2NTQ0NGZlMTJjL3RleHRyZWdpb246M2U5NDc2ZmFhMGE2NGI3ZGFmNmI2YzY1NDQ0ZmUxMmNfMTA5OTUxMTYzMDU3Ng_e4ef915b-3bfe-483c-98f7-cad8ea9a5114">December 31, 2022</ix:nonNumeric>, to commence upon the completion of the Company's existing $<ix:nonFraction unitRef="usd" contextRef="i479f4d0280434d3681861fd2e320cd99_I20201223" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockRepurchaseProgramAuthorizedAmount1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV83Ni9mcmFnOjNlOTQ3NmZhYTBhNjRiN2RhZjZiNmM2NTQ0NGZlMTJjL3RleHRyZWdpb246M2U5NDc2ZmFhMGE2NGI3ZGFmNmI2YzY1NDQ0ZmUxMmNfMTA5OTUxMTYzMDU2Mg_38098039-d3d8-469d-a53e-4cbb8b50bdca">100</ix:nonFraction>&#160;million share repurchase program. See Note 10 - Subsequent Events for additional information on the newly authorized share repurchase program.</span></div></ix:continuation><div id="iccd9c69ecd2c42e5897cfe9ab4e7e0b5_79"></div><div style="margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">9. <ix:nonNumeric contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV83OS9mcmFnOmQyNWIzMmE1OTBkNDQ2MWJhMDM0MzI3NjQ3Zjk3NmJlL3RleHRyZWdpb246ZDI1YjMyYTU5MGQ0NDYxYmEwMzQzMjc2NDdmOTc2YmVfNDY4_b57917c7-3c04-4907-9709-54484fa9f771" continuedAt="i512b6f2b194e4b7caad9f4b74556e85f" escape="true">RELATED PARTY TRANSACTIONS</ix:nonNumeric></span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i512b6f2b194e4b7caad9f4b74556e85f">We have an investment in Medalogix, a healthcare predictive data and analytics company, which is accounted for under the equity method. We incurred costs of approximately $<ix:nonFraction unitRef="usd" contextRef="iad1f6087d55542bd9518895ce038f77e_D20210401-20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV83OS9mcmFnOmQyNWIzMmE1OTBkNDQ2MWJhMDM0MzI3NjQ3Zjk3NmJlL3RleHRyZWdpb246ZDI1YjMyYTU5MGQ0NDYxYmEwMzQzMjc2NDdmOTc2YmVfMjMx_b59401bb-9e37-4a8c-9e41-ab345c15b98a">1.3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i0e79ddec592d4a9286d6d4f8fbd7eebb_D20210101-20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV83OS9mcmFnOmQyNWIzMmE1OTBkNDQ2MWJhMDM0MzI3NjQ3Zjk3NmJlL3RleHRyZWdpb246ZDI1YjMyYTU5MGQ0NDYxYmEwMzQzMjc2NDdmOTc2YmVfMjM4_7f418139-c3ab-49e4-ad8b-d2ab8a0847b8">2.6</ix:nonFraction>&#160;million during the three and six-month periods ended June&#160;30, 2021, respectively, and approximately $<ix:nonFraction unitRef="usd" contextRef="i8fb7629dcb544e0686e55cbe211d9a9b_D20200401-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV83OS9mcmFnOmQyNWIzMmE1OTBkNDQ2MWJhMDM0MzI3NjQ3Zjk3NmJlL3RleHRyZWdpb246ZDI1YjMyYTU5MGQ0NDYxYmEwMzQzMjc2NDdmOTc2YmVfMTA5OTUxMTYyODQxMw_42f6836e-f44a-42cf-bc33-331d49c972c3">0.7</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i10a4b9a4ae414719a5bbc87698268410_D20200101-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV83OS9mcmFnOmQyNWIzMmE1OTBkNDQ2MWJhMDM0MzI3NjQ3Zjk3NmJlL3RleHRyZWdpb246ZDI1YjMyYTU5MGQ0NDYxYmEwMzQzMjc2NDdmOTc2YmVfMTA5OTUxMTYyODQyNw_a2c7583b-d77e-4f68-a84d-ca29cb931cc5">1.1</ix:nonFraction>&#160;million during the three and six-month periods ended June 30, 2020, respectively, in connection with our usage of Medalogix's analytics platforms. We believe that the terms of these transactions are consistent with those negotiated at arm's length.</ix:continuation></span></div><div id="iccd9c69ecd2c42e5897cfe9ab4e7e0b5_1187"></div><div style="margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">10. <ix:nonNumeric contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630" name="us-gaap:SubsequentEventsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8xMTg3L2ZyYWc6ZDdkOTI4MzE0YWRmNGRkODkzOTQ1YzVhODBiMWRkMGYvdGV4dHJlZ2lvbjpkN2Q5MjgzMTRhZGY0ZGQ4OTM5NDVjNWE4MGIxZGQwZl8xMDk5NTExNjI4MTQx_1cac0880-8009-445e-8ea9-8336b53eb47a" continuedAt="i6e7778ebf5324e02bde61e88c53f4824" escape="true">SUBSEQUENT EVENTS</ix:nonNumeric></span></div><ix:continuation id="i6e7778ebf5324e02bde61e88c53f4824" continuedAt="i5ccdbe7249bf49d5ba77f8aea973ecd9"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Acquisitions</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 1, 2021, we acquired Visiting Nurse Association ("VNA"), a home health and hospice provider with locations in Nebraska and Iowa for a purchase price of $<ix:nonFraction unitRef="usd" contextRef="i5bf5d306b1c14ff585373333170311d3_D20210701-20210701" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireBusinessesGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8xMTg3L2ZyYWc6ZDdkOTI4MzE0YWRmNGRkODkzOTQ1YzVhODBiMWRkMGYvdGV4dHJlZ2lvbjpkN2Q5MjgzMTRhZGY0ZGQ4OTM5NDVjNWE4MGIxZGQwZl8xMDk5NTExNjI4OTEw_15d7962f-679f-48a7-a227-176c012a44c5">20.1</ix:nonFraction>&#160;million.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 12, 2021, we acquired the regulatory assets of a home health provider in New York for a purchase price of $<ix:nonFraction unitRef="usd" contextRef="i1f8587237be448c2bf1c2bbffa581713_D20210712-20210712" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireBusinessesGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8xMTg3L2ZyYWc6ZDdkOTI4MzE0YWRmNGRkODkzOTQ1YzVhODBiMWRkMGYvdGV4dHJlZ2lvbjpkN2Q5MjgzMTRhZGY0ZGQ4OTM5NDVjNWE4MGIxZGQwZl8xMDk5NTExNjI4OTI1_d727a606-904a-47ad-a381-3d21148969e1">1.5</ix:nonFraction>&#160;million. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 1, 2021, we acquired Contessa Health ("Contessa"), a leader in hospital-at-home and skilled nursing facility ("SNF") at-home services for a purchase price of $<ix:nonFraction unitRef="usd" contextRef="i3fb42087c2d743cca8d759c85d31167b_D20210801-20210801" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireBusinessesGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8xMTg3L2ZyYWc6ZDdkOTI4MzE0YWRmNGRkODkzOTQ1YzVhODBiMWRkMGYvdGV4dHJlZ2lvbjpkN2Q5MjgzMTRhZGY0ZGQ4OTM5NDVjNWE4MGIxZGQwZl8xMDk5NTExNjI4OTM5_73038d67-826f-4eb9-90ea-1ad2e10790db">250.0</ix:nonFraction>&#160;million. With the addition of Contessa&#8217;s risk-based model and claims analytics capabilities, we will be able to bring the essential elements of inpatient hospital and SNF care to patients&#8217; homes, allowing us to become a risk-bearing, home-based care delivery organization, expanding well beyond traditional Home Health and Hospice. Contessa will operate as a wholly owned division of Amedisys and will be reported as a separate operating segment in our future filings.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Second Amendment to Amended and Restated Credit Agreement</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On July 30, 2021, we entered into the Second Amendment to our Credit Agreement (as amended by the Second Amendment, the "Second Amended Credit Agreement"). The Second Amended Credit Agreement provides for a senior secured credit facility in an initial aggregate principal amount of up to $<ix:nonFraction unitRef="usd" contextRef="i37b72216842c4630bdb672d9901858fe_I20210730" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8xMTg3L2ZyYWc6ZDdkOTI4MzE0YWRmNGRkODkzOTQ1YzVhODBiMWRkMGYvdGV4dHJlZ2lvbjpkN2Q5MjgzMTRhZGY0ZGQ4OTM5NDVjNWE4MGIxZGQwZl8xMDk5NTExNjM1NTgy_80a01916-11b1-406b-8d1e-23b71e150f6d">1.0</ix:nonFraction>&#160;billion, which includes a $<ix:nonFraction unitRef="usd" contextRef="i5f0102c209874abb900b903e54aba58e_I20210730" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8xMTg3L2ZyYWc6ZDdkOTI4MzE0YWRmNGRkODkzOTQ1YzVhODBiMWRkMGYvdGV4dHJlZ2lvbjpkN2Q5MjgzMTRhZGY0ZGQ4OTM5NDVjNWE4MGIxZGQwZl8xMDk5NTExNjM1NTk2_f35a30ee-0428-406a-85b0-2fddd97f70f2">550.0</ix:nonFraction>&#160;million Revolving Credit Facility under the Second Amended Credit Agreement, and a term loan facility with a principal amount of up to $<ix:nonFraction unitRef="usd" contextRef="i23747c712c2a44b5bf6a948f7a476aab_I20210730" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8xMTg3L2ZyYWc6ZDdkOTI4MzE0YWRmNGRkODkzOTQ1YzVhODBiMWRkMGYvdGV4dHJlZ2lvbjpkN2Q5MjgzMTRhZGY0ZGQ4OTM5NDVjNWE4MGIxZGQwZl8xMDk5NTExNjM1NjEy_640b3141-5a92-44ad-a5fb-9c1b1282aedd">450.0</ix:nonFraction>&#160;million (the "Amended Term Loan Facility" and collectively with the Revolving Credit Facility, the "Amended Credit Facility").</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Proceeds from the $<ix:nonFraction unitRef="usd" contextRef="i23747c712c2a44b5bf6a948f7a476aab_I20210730" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8xMTg3L2ZyYWc6ZDdkOTI4MzE0YWRmNGRkODkzOTQ1YzVhODBiMWRkMGYvdGV4dHJlZ2lvbjpkN2Q5MjgzMTRhZGY0ZGQ4OTM5NDVjNWE4MGIxZGQwZl8xMDk5NTExNjM1NjMw_36206ad3-fa61-409f-870a-c9f6bc8e162a">450.0</ix:nonFraction>&#160;million Amended Term Loan Facility were used to pay off the outstanding Term Loan principal balance as of July 30, 2021, as well as to fund 100% of the Contessa acquisition. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The loans issued under the Amended Credit Facility bear interest on a per annum basis, at our election, at either: (i) the Base Rate plus the Applicable Rate or (ii) the Eurodollar Rate plus the Applicable Rate. <ix:nonNumeric contextRef="i013c83768a1e4e0b956e81903f1c8638_D20210730-20210730" name="us-gaap:ScheduleOfLineOfCreditFacilitiesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8xMTg3L2ZyYWc6ZDdkOTI4MzE0YWRmNGRkODkzOTQ1YzVhODBiMWRkMGYvdGV4dHJlZ2lvbjpkN2Q5MjgzMTRhZGY0ZGQ4OTM5NDVjNWE4MGIxZGQwZl8xMDk5NTExNjM2Mzk3_c6d58386-3066-4ac6-911e-9dffb24292a4" continuedAt="i039e84faf3134c238550aaf7b7317d2e" escape="true">We are also subject to a commitment fee and letter of credit fee under the terms of the Second Amended Credit Agreement, as presented in the table below.</ix:nonNumeric></span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AMEDISYS, INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="i5ccdbe7249bf49d5ba77f8aea973ecd9" continuedAt="ibee029b2c7024ad9a8083ff45827df9a"><div style="text-align:center"><ix:continuation id="i039e84faf3134c238550aaf7b7317d2e"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.251%"><tr><td style="width:1.0%"></td><td style="width:10.151%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.158%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.808%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.736%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.808%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.739%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Pricing Tier</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Consolidated Leverage Ratio</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Commitment Fee</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Letter of Credit Fee</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Eurodollar Rate Loans and Daily Floating LIBOR Rate Loans</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Base Rate Loans</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">I</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&gt; <ix:nonFraction unitRef="number" contextRef="i893fcad73cef4a18a7ab76f16e96f0ad_D20210730-20210730" decimals="INF" name="amed:ConsolidatedLeverageRatio" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8xMTg3L2ZyYWc6ZDdkOTI4MzE0YWRmNGRkODkzOTQ1YzVhODBiMWRkMGYvdGFibGU6MmI4MzdkYjk5NDhjNDg2Zjg0YzBlZjYyYjAzZTFiOWUvdGFibGVyYW5nZToyYjgzN2RiOTk0OGM0ODZmODRjMGVmNjJiMDNlMWI5ZV8xLTEtMS0xLTM2OTQvdGV4dHJlZ2lvbjo4MjM5NDZmNTZhYjU0YmRjYWY4NGU0MzUzMGE2YmRjOF8xMDk5NTExNjI3Nzk3_16014dd5-84f9-4613-9d44-fca011d7bb63">3.00</ix:nonFraction> to 1.0</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ifa6c63e1eca547f89b708d6f34225a17_D20210730-20210730" decimals="INF" name="us-gaap:LineOfCreditFacilityCommitmentFeePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8xMTg3L2ZyYWc6ZDdkOTI4MzE0YWRmNGRkODkzOTQ1YzVhODBiMWRkMGYvdGFibGU6MmI4MzdkYjk5NDhjNDg2Zjg0YzBlZjYyYjAzZTFiOWUvdGFibGVyYW5nZToyYjgzN2RiOTk0OGM0ODZmODRjMGVmNjJiMDNlMWI5ZV8xLTItMS0xLTM5OTE_d69fea0e-4005-4395-8cb9-99febf7594ac">0.30</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ifa6c63e1eca547f89b708d6f34225a17_D20210730-20210730" decimals="INF" name="amed:LetterOfCreditFee" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8xMTg3L2ZyYWc6ZDdkOTI4MzE0YWRmNGRkODkzOTQ1YzVhODBiMWRkMGYvdGFibGU6MmI4MzdkYjk5NDhjNDg2Zjg0YzBlZjYyYjAzZTFiOWUvdGFibGVyYW5nZToyYjgzN2RiOTk0OGM0ODZmODRjMGVmNjJiMDNlMWI5ZV8xLTMtMS0xLTM5OTE_d6ca73ff-cf82-4a0e-881d-0cf2a1e7b82c">1.75</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ibd49c2b0ab464f6ab8d956a502559923_D20210730-20210730" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8xMTg3L2ZyYWc6ZDdkOTI4MzE0YWRmNGRkODkzOTQ1YzVhODBiMWRkMGYvdGFibGU6MmI4MzdkYjk5NDhjNDg2Zjg0YzBlZjYyYjAzZTFiOWUvdGFibGVyYW5nZToyYjgzN2RiOTk0OGM0ODZmODRjMGVmNjJiMDNlMWI5ZV8xLTQtMS0xLTM5OTE_d441d4d8-ad49-4861-9781-629797981d29">2.00</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i42d092eff4ad4200a0c01193347c59ba_D20210730-20210730" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8xMTg3L2ZyYWc6ZDdkOTI4MzE0YWRmNGRkODkzOTQ1YzVhODBiMWRkMGYvdGFibGU6MmI4MzdkYjk5NDhjNDg2Zjg0YzBlZjYyYjAzZTFiOWUvdGFibGVyYW5nZToyYjgzN2RiOTk0OGM0ODZmODRjMGVmNjJiMDNlMWI5ZV8xLTUtMS0xLTM5OTE_fcaa93b2-7a52-4c26-a904-12312dbfc055">1.00</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">II</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">&lt;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> <ix:nonFraction unitRef="number" contextRef="i399c2067f87f4579a5bf6e8d11ed2b0e_D20210730-20210730" decimals="INF" name="amed:ConsolidatedLeverageRatio" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8xMTg3L2ZyYWc6ZDdkOTI4MzE0YWRmNGRkODkzOTQ1YzVhODBiMWRkMGYvdGFibGU6MmI4MzdkYjk5NDhjNDg2Zjg0YzBlZjYyYjAzZTFiOWUvdGFibGVyYW5nZToyYjgzN2RiOTk0OGM0ODZmODRjMGVmNjJiMDNlMWI5ZV8yLTEtMS0xLTM2OTQvdGV4dHJlZ2lvbjpjY2FkNDllMTc2Yjc0Mzk4YTVmZTBhZWUwZjU5Y2I5NV8xMDk5NTExNjI3ODM4_069886dd-3df8-4e4f-a637-572a3f7fc5ad">3.00</ix:nonFraction> to 1.0 but &gt; <ix:nonFraction unitRef="number" contextRef="i51a6e6e62aa24e08a1f42edef5dc3362_D20210730-20210730" decimals="INF" name="amed:ConsolidatedLeverageRatio" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8xMTg3L2ZyYWc6ZDdkOTI4MzE0YWRmNGRkODkzOTQ1YzVhODBiMWRkMGYvdGFibGU6MmI4MzdkYjk5NDhjNDg2Zjg0YzBlZjYyYjAzZTFiOWUvdGFibGVyYW5nZToyYjgzN2RiOTk0OGM0ODZmODRjMGVmNjJiMDNlMWI5ZV8yLTEtMS0xLTM2OTQvdGV4dHJlZ2lvbjpjY2FkNDllMTc2Yjc0Mzk4YTVmZTBhZWUwZjU5Y2I5NV8xMDk5NTExNjI3ODQ2_de2a3015-eb6d-4d54-85f3-41bb9eed46bb">2.00</ix:nonFraction> to 1.0</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i1806f555a63f4ad9be597bfa139ca430_D20210730-20210730" decimals="INF" name="us-gaap:LineOfCreditFacilityCommitmentFeePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8xMTg3L2ZyYWc6ZDdkOTI4MzE0YWRmNGRkODkzOTQ1YzVhODBiMWRkMGYvdGFibGU6MmI4MzdkYjk5NDhjNDg2Zjg0YzBlZjYyYjAzZTFiOWUvdGFibGVyYW5nZToyYjgzN2RiOTk0OGM0ODZmODRjMGVmNjJiMDNlMWI5ZV8yLTItMS0xLTM5OTE_4fb691d0-6f2b-4ae7-bbba-3c7c3351bdaa">0.25</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i1806f555a63f4ad9be597bfa139ca430_D20210730-20210730" decimals="INF" name="amed:LetterOfCreditFee" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8xMTg3L2ZyYWc6ZDdkOTI4MzE0YWRmNGRkODkzOTQ1YzVhODBiMWRkMGYvdGFibGU6MmI4MzdkYjk5NDhjNDg2Zjg0YzBlZjYyYjAzZTFiOWUvdGFibGVyYW5nZToyYjgzN2RiOTk0OGM0ODZmODRjMGVmNjJiMDNlMWI5ZV8yLTMtMS0xLTM5OTE_a1999e44-8659-4a68-8d9c-bf892cc75ae7">1.50</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="idf8a0386bfef429dac8a61b128e23424_D20210730-20210730" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8xMTg3L2ZyYWc6ZDdkOTI4MzE0YWRmNGRkODkzOTQ1YzVhODBiMWRkMGYvdGFibGU6MmI4MzdkYjk5NDhjNDg2Zjg0YzBlZjYyYjAzZTFiOWUvdGFibGVyYW5nZToyYjgzN2RiOTk0OGM0ODZmODRjMGVmNjJiMDNlMWI5ZV8yLTQtMS0xLTM5OTE_3f7a75dc-90ee-4fa1-af28-2236443121e0">1.75</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ibb50673cdce34a36abc32c81bca0b9c2_D20210730-20210730" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8xMTg3L2ZyYWc6ZDdkOTI4MzE0YWRmNGRkODkzOTQ1YzVhODBiMWRkMGYvdGFibGU6MmI4MzdkYjk5NDhjNDg2Zjg0YzBlZjYyYjAzZTFiOWUvdGFibGVyYW5nZToyYjgzN2RiOTk0OGM0ODZmODRjMGVmNjJiMDNlMWI5ZV8yLTUtMS0xLTM5OTE_75ed2715-c829-479a-b364-cbe5289706a1">0.75</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">III</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">&lt;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> <ix:nonFraction unitRef="number" contextRef="ica9a6dd6c4dd4b528399e24681759629_D20210730-20210730" decimals="INF" name="amed:ConsolidatedLeverageRatio" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8xMTg3L2ZyYWc6ZDdkOTI4MzE0YWRmNGRkODkzOTQ1YzVhODBiMWRkMGYvdGFibGU6MmI4MzdkYjk5NDhjNDg2Zjg0YzBlZjYyYjAzZTFiOWUvdGFibGVyYW5nZToyYjgzN2RiOTk0OGM0ODZmODRjMGVmNjJiMDNlMWI5ZV8zLTEtMS0xLTM2OTQvdGV4dHJlZ2lvbjpiZTkxYmRlOTA1YjQ0M2NiOWUxZTk2ZDE0NDdmNzllOV8xMDk5NTExNjI3ODE2_df6bc702-8209-4968-93d1-01044e3d63a8">2.00</ix:nonFraction> to 1.0 but &gt; <ix:nonFraction unitRef="number" contextRef="ie135590e741545eaba8f6bb70561f7be_D20210730-20210730" decimals="INF" name="amed:ConsolidatedLeverageRatio" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8xMTg3L2ZyYWc6ZDdkOTI4MzE0YWRmNGRkODkzOTQ1YzVhODBiMWRkMGYvdGFibGU6MmI4MzdkYjk5NDhjNDg2Zjg0YzBlZjYyYjAzZTFiOWUvdGFibGVyYW5nZToyYjgzN2RiOTk0OGM0ODZmODRjMGVmNjJiMDNlMWI5ZV8zLTEtMS0xLTM2OTQvdGV4dHJlZ2lvbjpiZTkxYmRlOTA1YjQ0M2NiOWUxZTk2ZDE0NDdmNzllOV8xMDk5NTExNjI3ODIz_d9e3fba6-626b-496f-8ec9-43c7cac41d17">0.75</ix:nonFraction> to 1.0</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7ae8c5e5ea3f46338602af709a707586_D20210730-20210730" decimals="INF" name="us-gaap:LineOfCreditFacilityCommitmentFeePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8xMTg3L2ZyYWc6ZDdkOTI4MzE0YWRmNGRkODkzOTQ1YzVhODBiMWRkMGYvdGFibGU6MmI4MzdkYjk5NDhjNDg2Zjg0YzBlZjYyYjAzZTFiOWUvdGFibGVyYW5nZToyYjgzN2RiOTk0OGM0ODZmODRjMGVmNjJiMDNlMWI5ZV8zLTItMS0xLTM5OTE_27267ac3-0a93-4166-9ff3-18ca2b03e99e">0.20</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7ae8c5e5ea3f46338602af709a707586_D20210730-20210730" decimals="INF" name="amed:LetterOfCreditFee" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8xMTg3L2ZyYWc6ZDdkOTI4MzE0YWRmNGRkODkzOTQ1YzVhODBiMWRkMGYvdGFibGU6MmI4MzdkYjk5NDhjNDg2Zjg0YzBlZjYyYjAzZTFiOWUvdGFibGVyYW5nZToyYjgzN2RiOTk0OGM0ODZmODRjMGVmNjJiMDNlMWI5ZV8zLTMtMS0xLTM5OTE_97d93d8c-4950-4ca8-948e-12992466965f">1.25</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0e146a61cc484c3085aa313c3aac07b6_D20210730-20210730" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8xMTg3L2ZyYWc6ZDdkOTI4MzE0YWRmNGRkODkzOTQ1YzVhODBiMWRkMGYvdGFibGU6MmI4MzdkYjk5NDhjNDg2Zjg0YzBlZjYyYjAzZTFiOWUvdGFibGVyYW5nZToyYjgzN2RiOTk0OGM0ODZmODRjMGVmNjJiMDNlMWI5ZV8zLTQtMS0xLTM5OTE_974e9195-a61e-4869-bc16-b12b8fba2e98">1.50</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i379bc627f4a745e6937f7cc4a2357a7d_D20210730-20210730" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8xMTg3L2ZyYWc6ZDdkOTI4MzE0YWRmNGRkODkzOTQ1YzVhODBiMWRkMGYvdGFibGU6MmI4MzdkYjk5NDhjNDg2Zjg0YzBlZjYyYjAzZTFiOWUvdGFibGVyYW5nZToyYjgzN2RiOTk0OGM0ODZmODRjMGVmNjJiMDNlMWI5ZV8zLTUtMS0xLTM5OTE_4daba372-8eec-422c-b910-aac23aaed5b1">0.50</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IV</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">&lt;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> <ix:nonFraction unitRef="number" contextRef="id407ccb903ff4b5dbcd97f48c071901c_D20210730-20210730" decimals="INF" name="amed:ConsolidatedLeverageRatio" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8xMTg3L2ZyYWc6ZDdkOTI4MzE0YWRmNGRkODkzOTQ1YzVhODBiMWRkMGYvdGFibGU6MmI4MzdkYjk5NDhjNDg2Zjg0YzBlZjYyYjAzZTFiOWUvdGFibGVyYW5nZToyYjgzN2RiOTk0OGM0ODZmODRjMGVmNjJiMDNlMWI5ZV80LTEtMS0xLTM2OTQvdGV4dHJlZ2lvbjoxNTc3NGI1YWYzYjM0MzIzYmM0ZDE0Nzg1NzkyMjNiMV8xMDk5NTExNjI3Nzk4_ed1f1649-5ed2-4e6a-b54f-a5ae6f6d5555">0.75</ix:nonFraction> to 1.0</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i00349d2687c14dfba218b9ee86bf33b2_D20210730-20210730" decimals="INF" name="us-gaap:LineOfCreditFacilityCommitmentFeePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8xMTg3L2ZyYWc6ZDdkOTI4MzE0YWRmNGRkODkzOTQ1YzVhODBiMWRkMGYvdGFibGU6MmI4MzdkYjk5NDhjNDg2Zjg0YzBlZjYyYjAzZTFiOWUvdGFibGVyYW5nZToyYjgzN2RiOTk0OGM0ODZmODRjMGVmNjJiMDNlMWI5ZV80LTItMS0xLTM5OTE_fd3dc4dd-722f-4196-953d-3837d49a6bae">0.15</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i00349d2687c14dfba218b9ee86bf33b2_D20210730-20210730" decimals="INF" name="amed:LetterOfCreditFee" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8xMTg3L2ZyYWc6ZDdkOTI4MzE0YWRmNGRkODkzOTQ1YzVhODBiMWRkMGYvdGFibGU6MmI4MzdkYjk5NDhjNDg2Zjg0YzBlZjYyYjAzZTFiOWUvdGFibGVyYW5nZToyYjgzN2RiOTk0OGM0ODZmODRjMGVmNjJiMDNlMWI5ZV80LTMtMS0xLTM5OTE_d6f8f23f-d84d-41a0-b9fa-f0ffa36f5e6c">1.00</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if952ebf0ec1f4f38950c654b7e9febb8_D20210730-20210730" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8xMTg3L2ZyYWc6ZDdkOTI4MzE0YWRmNGRkODkzOTQ1YzVhODBiMWRkMGYvdGFibGU6MmI4MzdkYjk5NDhjNDg2Zjg0YzBlZjYyYjAzZTFiOWUvdGFibGVyYW5nZToyYjgzN2RiOTk0OGM0ODZmODRjMGVmNjJiMDNlMWI5ZV80LTQtMS0xLTM5OTE_2d758b54-eb10-45da-9467-d130141b280c">1.25</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia0a2cc02f30f44c481140c202f28cf4a_D20210730-20210730" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8xMTg3L2ZyYWc6ZDdkOTI4MzE0YWRmNGRkODkzOTQ1YzVhODBiMWRkMGYvdGFibGU6MmI4MzdkYjk5NDhjNDg2Zjg0YzBlZjYyYjAzZTFiOWUvdGFibGVyYW5nZToyYjgzN2RiOTk0OGM0ODZmODRjMGVmNjJiMDNlMWI5ZV80LTUtMS0xLTM5OTE_73909bb7-2d4b-4475-80a3-191925c2a0ba">0.25</ix:nonFraction>%</span></td></tr></table></ix:continuation></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The final maturity date of the Amended Credit Facility is <ix:nonNumeric contextRef="i8f97846b33b54f368697ed0323cbb2b2_D20210730-20260730" format="ixt:datemonthdayyearen" name="us-gaap:DebtInstrumentMaturityDate" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8xMTg3L2ZyYWc6ZDdkOTI4MzE0YWRmNGRkODkzOTQ1YzVhODBiMWRkMGYvdGV4dHJlZ2lvbjpkN2Q5MjgzMTRhZGY0ZGQ4OTM5NDVjNWE4MGIxZGQwZl8xMDk5NTExNjM1Njcx_43011909-13da-4cb4-81a6-4cb30d1010b6">July 30, 2026</ix:nonNumeric>. The Revolving Credit Facility will terminate and be due and payable as of the final maturity date. The Amended Term Loan Facility, however, is subject to quarterly amortization of principal in the amount of (i) <ix:nonFraction unitRef="number" contextRef="id8e4663758bd4b8c908928b7178d6c4f_D20210730-20230930" decimals="INF" name="amed:DebtInstrumentPeriodicPaymentPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8xMTg3L2ZyYWc6ZDdkOTI4MzE0YWRmNGRkODkzOTQ1YzVhODBiMWRkMGYvdGV4dHJlZ2lvbjpkN2Q5MjgzMTRhZGY0ZGQ4OTM5NDVjNWE4MGIxZGQwZl8xMDk5NTExNjM1Njg2_39ebdb14-4503-4414-aef5-2d740b9abef7">0.625</ix:nonFraction>% for the period commencing on July 30, 2021 and ending on September 30, 2023, and (ii) <ix:nonFraction unitRef="number" contextRef="i04246e2f9fa44955a7bdb76cd2520b0b_D20231001-20260730" decimals="INF" name="amed:DebtInstrumentPeriodicPaymentPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8xMTg3L2ZyYWc6ZDdkOTI4MzE0YWRmNGRkODkzOTQ1YzVhODBiMWRkMGYvdGV4dHJlZ2lvbjpkN2Q5MjgzMTRhZGY0ZGQ4OTM5NDVjNWE4MGIxZGQwZl8xMDk5NTExNjM1Njk0_c09b5db1-1816-4996-8747-a61d5989df1d">1.250</ix:nonFraction>% for the period commencing on October 1, 2023 and ending on July 30, 2026. The remaining balance of the Amended Term Loan Facility must be paid upon the final maturity date. In addition to the scheduled amortization of the Amended Term Loan Facility, and subject to customary exceptions and reinvestment rights, we are required to prepay the Amended Term Loan Facility first and the Revolving Credit Facility second with 100% of all net cash proceeds received by any loan party or any subsidiary thereof in connection with (a) any asset sale or disposition where such loan party receives net cash proceeds in excess of $<ix:nonFraction unitRef="usd" contextRef="i704e6869254d4b25be00c91be5629417_D20210730-20210730" decimals="-5" format="ixt:numdotdecimal" name="amed:ProceedsReceivedFromLoanPartyOfSubsidiary" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8xMTg3L2ZyYWc6ZDdkOTI4MzE0YWRmNGRkODkzOTQ1YzVhODBiMWRkMGYvdGV4dHJlZ2lvbjpkN2Q5MjgzMTRhZGY0ZGQ4OTM5NDVjNWE4MGIxZGQwZl8xMDk5NTExNjM1NzAy_6dadafd4-b84b-4626-a95b-bdde904e5615">5</ix:nonFraction>&#160;million or (b) any debt issuance that is not permitted under the Second Amended Credit Agreement.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share Repurchase Program</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On August 2, 2021, our Board of Directors authorized a share repurchase program, under which we may repurchase up to $<ix:nonFraction unitRef="usd" contextRef="i55192f2892ba4410b4d8043c7bd3508f_I20210802" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockRepurchaseProgramAuthorizedAmount1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8xMTg3L2ZyYWc6ZDdkOTI4MzE0YWRmNGRkODkzOTQ1YzVhODBiMWRkMGYvdGV4dHJlZ2lvbjpkN2Q5MjgzMTRhZGY0ZGQ4OTM5NDVjNWE4MGIxZGQwZl8xMDk5NTExNjM2NDIy_61d82b8a-869f-4043-84ed-9ea1d14aea0b">100</ix:nonFraction>&#160;million of our outstanding common stock through <ix:nonNumeric contextRef="ide446a75729e4d219d7267432d1f1fbc_D20210802-20221231" format="ixt:datemonthdayyearen" name="us-gaap:StockRepurchaseProgramExpirationDate" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8xMTg3L2ZyYWc6ZDdkOTI4MzE0YWRmNGRkODkzOTQ1YzVhODBiMWRkMGYvdGV4dHJlZ2lvbjpkN2Q5MjgzMTRhZGY0ZGQ4OTM5NDVjNWE4MGIxZGQwZl8xMDk5NTExNjM2NDM2_74b38474-00c4-4f09-9462-51557a6bb1fe">December 31, 2022</ix:nonNumeric>, to commence upon the completion of the Company's existing $<ix:nonFraction unitRef="usd" contextRef="i479f4d0280434d3681861fd2e320cd99_I20201223" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockRepurchaseProgramAuthorizedAmount1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8xMTg3L2ZyYWc6ZDdkOTI4MzE0YWRmNGRkODkzOTQ1YzVhODBiMWRkMGYvdGV4dHJlZ2lvbjpkN2Q5MjgzMTRhZGY0ZGQ4OTM5NDVjNWE4MGIxZGQwZl8xMDk5NTExNjM2NDU1_e808e850-b815-448d-9449-e4e129977149">100</ix:nonFraction>&#160;million share repurchase program, approved by our Board of Directors on December 17, 2020 (the &#8220;Existing Share Repurchase Program&#8221;). Repurchases may be made under the Existing Share Repurchase Program through <ix:nonNumeric contextRef="i0d540c3eb0984765b002cd7535b1f472_D20201223-20211231" format="ixt:datemonthdayyearen" name="us-gaap:StockRepurchaseProgramExpirationDate" id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8xMTg3L2ZyYWc6ZDdkOTI4MzE0YWRmNGRkODkzOTQ1YzVhODBiMWRkMGYvdGV4dHJlZ2lvbjpkN2Q5MjgzMTRhZGY0ZGQ4OTM5NDVjNWE4MGIxZGQwZl8xMDk5NTExNjM2NDY5_31f9b8de-a3c4-430f-861c-c3121aafa6f4">December 31, 2021</ix:nonNumeric>. See Note 8 &#8211; Share Repurchases for additional information on the Existing Share Repurchase Program.</span></div></ix:continuation><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ibee029b2c7024ad9a8083ff45827df9a">Under the terms of the program, we are allowed to repurchase shares from time to time through open market purchases, unsolicited or solicited privately negotiated transactions, an accelerated stock repurchase program, and/or a trading plan in compliance with Exchange Act Rule 10b5-1. The timing and the amount of the repurchases will be determined by management based on a number of factors, including but not limited to share price, trading volume and general market conditions, as well as on working capital requirements, general business conditions and other factors.</ix:continuation> </span></div><div style="margin-top:14pt;text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><div id="iccd9c69ecd2c42e5897cfe9ab4e7e0b5_88"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;2. MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The following discussion and analysis provides information we believe is relevant to an assessment and understanding of our results of operations and financial condition for the three and six-month periods ended June&#160;30, 2021. This discussion should be read in conjunction with the condensed consolidated financial statements and notes thereto included herein, and the consolidated financial statements and notes and the related Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations in our Annual Report on Form 10-K for the year ended December&#160;31, 2020 filed with the Securities and Exchange Commission (&#8220;SEC&#8221;) on February 25, 2021 (the &#8220;Form 10-K&#8221;), which are incorporated herein by this reference. Historical results that appear in the condensed consolidated financial statements should not be interpreted as being indicative of future operations.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Unless otherwise provided, &#8220;Amedisys,&#8221; &#8220;we,&#8221; &#8220;our,&#8221; and the &#8220;Company&#8221; refer to Amedisys, Inc. and our consolidated subsidiaries.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a provider of high-quality in-home healthcare and related services to the chronic, co-morbid, aging American population, with approximately 75% of our net service revenue derived from Medicare for the three and six-month periods ended June 30, 2021 and approximately 74% of our net service revenue derived from Medicare for the three and six-month periods ended June 30, 2020.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operations involve servicing patients through our three reportable business segments: home health, hospice and personal care. Our home health segment delivers a wide range of services in the homes of individuals who may be recovering from an illness, injury or surgery. Our hospice segment provides care that is designed to provide comfort and support for those who are facing a terminal illness. Our personal care segment provides patients with assistance with the essential activities of daily living. As of June&#160;30, 2021, we owned and operated 320 Medicare-certified home health care centers, 180 Medicare-certified hospice care centers and 14 personal-care care centers in 39 states within the United States and the District of Columbia.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Care Centers Summary (Includes Unconsolidated Joint Ventures)</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.760%"><tr><td style="width:1.0%"></td><td style="width:60.732%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.113%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.113%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.116%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Home<br/>Health</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Hospice</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Personal<br/>Care</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As of December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">320&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">180&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisitions/Startups/Denovos</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Closed/Consolidated</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As of June 30, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">320&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">180&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Developments</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Governmental Inquiries and Investigations and Other Litigation</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 6 &#8211; Commitments and Contingencies to our condensed consolidated financial statements for a discussion of and updates regarding legal proceedings and investigations we are involved in. No assurances can be given as to the timing or outcome of these items. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Payment</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Hospice</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On July 31, 2020, the Centers for Medicare and Medicaid Services ("CMS") issued a final rule to update hospice payment rates and the wage index for fiscal year 2021, effective for services provided beginning October 1, 2020. CMS estimated hospices serving Medicare beneficiaries would see an e</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">stimated 2.4% increase in payments. This increase was the result of a 2.4% market basket adjustment as required under the Patient Protection and Affordable Health Care Act and the Health Care and Education Reconciliation Act (collectively, "PPACA"). The rule also changed the hospice wage index by adopting the most recent Office of Management and Budget statistical area delineations with a five percent cap on wage index decreases. Finally, CMS increased the aggregate cap amount by 2.4% to $30,684. Based on our analysis of the final rule, we estimated that our impact would be in line with the 2.4% increase.  </span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On July 29, 2021, CMS issued the final rule to update hospice payment rates and the wage index for fiscal year 2022, effective for services provided beginning October 1, 2021. CMS estimates </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">hospices serving Medicare beneficiaries will see an e</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">stimated 2.0% increase in payments. This increase is the result of a 2.7% market basket adjustment as required under PPACA less a 0.7% productivity adjustment. Additionally, CMS increased the aggregate cap amount by</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> 2.0% to $31,298. The final rule also </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">rebases the labor shares for all four levels of care, includes updates to the hospice conditions of participation ("COPs"), which would make permanent certain flexibilities allowed during the COVD-19 public health emergency and finalizes changes to the Hospice Quality Reporting Program. Based on our analysis of the final rule, we expect our impact to be in line with the 2.0% increase. </span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Home Health</span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On October 29, 2020, CMS issued the Home Health Final Rule for Medicare home health providers for calendar year 2021. CMS estimated that the final rule would result in a 1.9% increase in payments to home health providers. The increase was the result of a 2.0% market basket adjustment reduced by 0.1% for the rural add-on. Based on our analysis of the final rule, we estimated that our impact would be in line with th</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">e 1.9% increase. Ad</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">ditionally, CMS made permanent the telehealth flexibilities that were announced in the Interim Final Rule (Emergency Rule) for COVID-19 in March 2020. These flexibilities allow home health agencies to provide certain care via telehealth if it is clinically appropriate and included in the plan of care; however, these visits still do not count as visits for purposes of patient eligibility or payment.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On June 28, 2021, CMS issued a proposed payment change for Medicare home health providers for calendar year 2022. CMS estimates that the proposed rule will result in a 1.7% increase in payments to home health providers. This increase is the result of a 2.4% market basket adjustment less a 0.6% productivity adjustment, reduced by 0.1% for the rural add-on. Based on our preliminary analysis of the proposed rule, we expect our impact to be slightly higher than the industry average. The proposed rule also provides for the expansion of the Home Health Value-Based Purchasing ("HHVBP") model to all 50 states beginning January 1, 2022 with calendar year 2022 being the first performance year and calendar year 2024 being the first payment year with a proposed maximum payment adjustment, up or down, of 5%.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Novel Coronavirus Pandemic ("COVID-19")</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operations and financial performance continue to be impacted by COVID-19. The financial impacts of COVID-19 are discussed in further detail under "Results of Operations" below. While we currently believe that we have a reasonable view of operations, the uncertainty created by COVID-19 could alter our outlook of the pandemic's impact on our consolidated financial condition, results of operations or cash flows. The following factors could potentially impact our performance: the continued increase or decrease in the number of COVID-19 cases nationwide, the severity and impacts of new variants of the virus, uncertainty regarding vaccine utilization rates and efficacy, the utilization of elective procedures, the return of patient confidence to enter a hospital or a doctor's office, the ability to have access to our patients in their homes and in facilities, cost normalization around personal protective equipment ("PPE") and any future or prolonged shelter-in-place orders and other federal, state and local requirements. Potential impacts of COVID-19 on our results include lower revenue; higher salary and wage expense related to quarantine pay, contract clinicians and training; and increased supply costs related to PPE and COVID-19 testing. The impacts to net service revenue may consist of the following:</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">lower volumes due to interruption of the operations of our referral sources, patients' unwillingness to accept services and restrictions on access to facilities for hospice services;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">lower reimbursement due to missed visits resulting in an increase in low utilization payment adjustments ("LUPAs") and lost billing periods; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">lower hospice average daily census due to a decline in our average length of stay.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 27, 2020, the bipartisan Coronavirus Aid, Relief, and Economic Security Act ("CARES Act") was signed into legislation. The CARES Act provided for the following:</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">$175 billion to healthcare providers, including hospitals on the front lines of the COVID-19 pandemic. Of this total allocated amount, $30&#160;billion was distributed immediately to providers based on their proportionate share of Medicare fee-for-service reimbursements in 2019. Healthcare providers were required to sign an attestation confirming receipt of the Provider Relief Fund ("PRF") funds and agree to the terms and conditions of payment. Our home health and hospice segments received approximately $100&#160;million from the first $30&#160;billion of funds distributed to healthcare providers in April 2020, which is inclusive of $2&#160;million related to our joint venture care centers (equity method investments). We also acquired approximately $6&#160;million of PRF funds in connection with the acquisition of AseraCare. Consistent with the terms and conditions for receipt of the payment, we are allowed to use the funds to cover lost revenues and health care costs related to COVID-19 through June 30, 2021, and we are required to properly and fully document the use of these funds in reports to the U.S. Department of Health and Human Services ("HHS"). </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For our wholly-owned subsidiaries, we have decided to only utilize PRF funds to the extent we have qualifying COVID-19 expenses, which totaled $5&#160;million and $13 million for our home health and hospice segments during the three and six-month periods ended June 30, 2021, respectively, and $21&#160;million and $22 million during the three and six-month periods ended June 30, 2020, respectively.  We did not fully utilize the PRF funds received by the June 30, 2021 deadline; therefore, we have recorded a liability for the amount that we plan to repay, which totaled $58&#160;million at June 30, 2021, to the Provider Relief Fund Advance account in current liabilities within our condensed consolidated </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">balance sheet. We intend to report on our use of the PRF funds to HHS during the three-month period ending September 30, 2021 and to return all unutilized funds by October 30, 2021. </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The temporary suspension of the automatic 2% reduction of Medicare claim reimbursements ("sequestration") for the period May 1, 2020 through December 31, 2020. In December 2020, Congress passed additional COVID-19 relief legislation as part of the Consolidated Appropriations Act, 2021. This legislation extended the suspension of sequestration through March 31, 2021. In April 2021, Congress passed H.R. 1868, which among other items, provided for an additional extension of the temporary suspension of sequestration through December 31, 2021. We estimate that the suspension of sequestration will increase our 2021 net service revenue by approximately $36 million.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The deferral of the employer share of social security tax (6.2%), effective for payments due after the enactment date through December 31, 2020. Fifty percent of the deferred payments is due on December 31, 2021 with the remaining amounts due on December 31, 2022. During 2020, we deferred approximately $55 million of social security tax; approximately $28 million is reflected in each of payroll and employee benefits and other long-term obligations within our condensed consolidated balance sheets.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The temporary suspension of Medicare patient coverage criteria and documentation and care requirements and the expansion of providing home health and hospice care to patients via telehealth.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The ability for non-physician practitioners to certify for home health, order home health services, establish and review plans of care and certify and recertify eligibility.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The well-being of our employees has been one of our top priorities during the pandemic. We have taken the following steps to support our employees: implemented up to 14 days of paid leave during any required quarantine periods; awarded bonuses to our clinicians and caregivers who have seen patients during the pandemic; completed an early cash pay-out of employee paid-time-off; instituted work-from-home arrangements for our corporate and administrative support employees; allowed employees to temporarily suspend any 401(k) plan loan deductions and offered employees the option of making a withdrawal from their 401(k) plan for coronavirus-related distributions without incurring the additional 10% early withdrawal penalty; expanded access to telehealth services to all employees; provided access to COVID-19 self-test kits to all employees and created a COVID-19 Resource Center, available 24 hours a day, seven days a week for employees to access educational materials, safety documents, policies, clinical protocols and operational metrics. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The safety of our clinicians and patients has also been a focus, and as a result, we have made the following business changes: developed clinical protocols for COVID-19 testing, proper usage of PPE, caring for COVID-positive patients and maintaining safety measures in our care centers; researched each state's vaccination plan to develop a state by state protocol to work with local health departments and other health systems to obtain vaccine appointments for our clinical staff; implemented software enabling us to track staff that have been vaccinated; procured millions in PPE and created a centralized distribution center for all critical PPE, allowing us to flex our inventory on a care center by care center basis, based on need and demand.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Three-Month Period Ended June&#160;30, 2021 Compared to the Three-Month Period Ended June&#160;30, 2020 </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Consolidated</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our consolidated results of operations (amounts in millions):</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:85.672%"><tr><td style="width:1.0%"></td><td style="width:70.743%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.551%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.653%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.553%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three-Month Periods<br/>Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net service revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">564.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">485.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other operating income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of service, excluding depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">308.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">295.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross margin, excluding depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">260.1&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">212.5&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">% of revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">46.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">43.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other operating expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">175.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">156.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">% of revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">31.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">32.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating income</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other income (expense)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.8)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Effective income tax rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">26.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">22.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to noncontrolling interests</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to Amedisys, Inc.</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80.1&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34.7&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On a consolidated basis, our operating income increased $28 million on a revenue increase of $79 million. The year-over-year increases are primarily related to the impact of COVID-19 on prior year&#8217;s results, severance incurred in prior year related to reductions in staffing primarily within our home health segment and the acquisition of AseraCare on June 1, 2020. Additionally, rate increases, a full quarter of the suspension of sequestration, a reduction in revenue adjustments and improvements in clinician utilization and discipline mix helped drive the increase in net service revenue and operating income. Partially offsetting these items, we experienced a decline in our hospice average daily census, which is the main driver of hospice revenue, and an increase in our cost of service resulting from the use of contract clinicians to supplement our staffing levels, an increase in visits performed by our hourly hospice employees due to greater access to patients in both facilities and their homes and higher health insurance costs. Additionally, our other operating expenses, which are described in more detail below, increased year over year.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our results include a full quarter of the acquired operations of AseraCare in the current year compared to one month in the prior year which resulted in an increase in net service revenue totaling $16 million and an increase in operating income totaling $3 million (which is inclusive of a decrease in acquisition and integration costs totaling $3 million and an increase in intangibles amortization totaling $2 million).</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our home health and hospice rate increases resulted in an increase in net service revenue and operating income of approximately $9 million (excluding the AseraCare acquisition). We also benefited from a full quarter of the suspension of sequestration effective May 1, 2020, which resulted in an increase in net service revenue and operating income of approximately $4 million (excluding the AseraCare acquisition).</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As noted above, for our wholly-owned subsidiaries, we have elected to use the CARES Act PRF funds to cover COVID-19 expenses incurred by our home health and hospice segments which totaled $5 million and $21 million during the three-month periods ended June 30, 2021 and 2020, respectively. Our personal care segment received funds from the Mass Home Care ASAP COVID-19 Provider Sustainability Program totaling less than $1 million during the three-month period ended June 30, 2020. We elected to use these funds to cover COVID-19 expenses as well. We recorded income related to both of these programs totaling $5 million and $23 million in other operating income within our condensed consolidated statements of operations during the three-month periods ended June 30, 2021 and 2020, respectively. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operating results reflect a 12.2% increase in our other operating expenses compared to prior year. Our 2021 other operating expenses include a full quarter of the acquired operations of AseraCare compared to one month in the prior year which resulted </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in a year over year increase totaling $3 million. Excluding the AseraCare acquisition, our other operating expenses increased 10.7% due to a slowdown in prior year spend related to COVID-19, the addition of resources to support growth (primarily business development employees and care center administrative staff), planned wage increases, higher health insurance costs, investments related to PDGM, increased information technology fees, higher acquisition costs and increased costs associated with a pre-acquisition legal settlement related to our Compassionate Care Hospice ("CCH") acquisition partially offset by lower incentive compensation accruals, lower costs directly attributable to COVID-19 and higher gains on the sale of fleet vehicles.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total other income for the three-month period ended June 30, 2021 includes a $31 million gain related to our investment in Medalogix (see Note 1 - Nature of Operations, Consolidation and Presentation of Financial Statements to our condensed consolidated financial statements for additional information).</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Home Health Segment</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our home health segment results of operations:</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:85.672%"><tr><td style="width:1.0%"></td><td style="width:70.743%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.551%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.653%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.553%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three-Month Periods<br/>Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financial Information</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">:</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">234.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">192.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-Medicare</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net service revenue</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">349.3&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">290.2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other operating income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of service</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">190.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">184.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross margin</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">161.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other operating expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating income</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Same Store Growth (1):</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-Medicare revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total admissions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total volume (2) (6)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%)</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Key Statistical Data - Total (3):</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Admissions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89,371&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74,327&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Recertifications (6)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,014&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,758&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total volume (6)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135,385&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121,085&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare completed episodes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79,188&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,660&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Average Medicare revenue per completed episode (4)</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,986&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,818&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare visits per completed episode (5)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Visiting Clinician Cost per Visit</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91.24&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93.17&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinical Manager Cost per Visit</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.31&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.42&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Cost per Visit</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.55&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102.59&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Visits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,894,006&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,793,652&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) Same store information represents the percent change in our Medicare, Non-Medicare and Total revenue, admissions or volume for the period as a percent of the Medicare, Non-Medicare and Total revenue, admissions or volume of the prior period. Same store is defined as care centers that we have operated for at least the last twelve months and startups that are an expansion of a same store care center.</span></div><div style="padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2) Total volume includes all admissions and recertifications.</span></div><div style="padding-left:49.5pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3) Total includes acquisitions, start-ups and denovos.</span></div><div style="padding-left:40.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4) Average Medicare revenue per completed episode is the average Medicare revenue earned for each Medicare completed episode of care. Average Medicare revenue per completed episode reflects the transition to PDGM effective January 1, 2020 and the suspension of sequestration effective May 1, 2020. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="padding-left:40.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(5) Medicare visits per completed episode are the home health Medicare visits on completed episodes divided by the home health Medicare episodes completed during the period.</span></div><div style="padding-left:40.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(6) Prior year amounts have been recast to conform to the current year calculation.</span></div><div style="margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Operating Results</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Overall, our operating income increased $31 million on a $59 million increase in net service revenue. The year over year increases are primarily related to the impact of COVID-19 on prior year's results, an increase in our Medicare revenue per episode, which is described in more detail below, severance incurred in prior year related to reductions in staffing and  significant improvement in our operating performance driven by improvements in our clinician utilization and discipline mix, both of which have contributed to year over year gross margin expansion. These items were partially offset by an increase in the usage of contract clinicians to supplement our staffing levels and an increase in our other operating expenses.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operating results were also impacted by costs related to COVID-19 totaling $2 million and $14 million for the three-month periods ended June 30, 2021 and 2020, respectively, which were offset by the recognition of income associated with the CARES Act PRF. </span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Net Service Revenue</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our net service revenue increased $59 million (20%) on a 12% increase in total volume and a 6% increase in Medicare revenue per episode. The volume growth was driven by a 20% increase in admissions, which were significantly impacted by COVID-19 in prior year. The increase in Medicare revenue per episode is the result of a 1.9% increase in reimbursement, a full quarter of the suspension of sequestration effective May 1, 2020, a decline in LUPAs resulting from missed visits related to COVID-19 in prior year, an increase in the functional impairment of our patients and a change in the source/timing and geographic dispersion of our patients. </span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Other Operating Income</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other operating income consists of the recognition of funds received from the CARES Act PRF. In accordance with the terms and conditions, these funds can be used to cover lost revenues as well as costs directly attributable to COVID-19. For our wholly-owned subsidiaries, we have elected to utilize the funds to cover COVID-19 related costs only, and therefore, have recognized income related to these costs totaling $2 million and $15 million during the three-month periods ended June 30, 2021 and 2020, respectively. The COVID-19 costs are associated with the purchase of PPE, bonuses paid to our clinicians, premiums paid to contract clinicians in COVID-19 high demand areas, clinician training, quarantine pay and COVID-19 testing. The COVID-19 costs incurred during the three-month period ended June 30, 2021 totaling $2 million have been recorded to cost of service within our condensed consolidated statements of operations. Of the $15 million of COVID-19 costs incurred in the prior year, $14 million was recorded to cost of service ($13 milling during the three-month period ended June 30, 2020 and $1 million during the three-month period ended March 31, 2020) and $1 million was recorded to other operating expenses within our condensed consolidated statements of operations.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Cost of Service, Excluding Depreciation and Amortization</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our cost of service consists of costs associated with direct clinician care in the homes of our patients as well as the cost of clinical managers who monitor the overall delivery of care. Overall, our total cost of service increased 3% primarily due to a 6% increase in total visits partially offset by a 2% decrease in our total cost per visit. The 6% increase in total visits is due to a 12% increase in total volume partially offset by improvements in clinician utilization, as evidenced by a decline of 1.2 visits per completed episode year over year, and optimization of discipline mix. The 2% decrease in our total cost per visit is due to a  decrease in costs directly attributable to COVID-19 as well as severance incurred in prior year in connection with a reduction in staffing partially offset by planned wage increases, higher costs associated with the utilization of contractors to supplement our staffing levels, increases in new hire pay and higher health insurance costs. </span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Other Operating Expenses</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other operating expenses increased $9 million primarily due to a slowdown in prior year spend related to COVID-19, planned wage increases, higher health insurance costs, the addition of resources to support volume growth (business development employees and care center administrative staff) and investments related to PDGM partially offset by lower costs directly attributable to COVID-19. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Hospice Segment</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our hospice segment results of operations:</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:85.672%"><tr><td style="width:1.0%"></td><td style="width:70.743%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.551%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.653%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.553%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three-Month Periods <br/>Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financial Information</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">(in millions):</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">186.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">167.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-Medicare</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net service revenue</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">197.9&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">177.1&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other operating income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of service</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross margin</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other operating expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating income</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Same Store Growth (1):</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hospice admissions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Average daily census</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Key Statistical Data - Total (2):</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hospice admissions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,675&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,411&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Average daily census</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,254&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,513&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue per day, net</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">164.10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">155.51&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of service per day</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87.17&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85.34&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Average discharge length of stay</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:36pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) Same store information represents the percent change in our Medicare revenue, Hospice admissions or average daily  census for the period as a percent of the Medicare revenue, Hospice admissions or average daily census of the prior period. Same store is defined as care centers that we have operated for at least the last twelve months and startups that are an expansion of a same store care center.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2) Total includes acquisitions, start-ups and denovos.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Operating Results</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operating results for the three-month period ended June 30, 2021 include the results of the acquisition of AseraCare on June 1, 2020 (44 hospice care centers). Acquisitions are included in our condensed consolidated financial statements from their respective acquisition dates. As a result, our hospice segment operating results for 2021 and 2020 are not fully comparable.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Overall, our operating income remained flat on a $21&#160;million increase in net service revenue. These results include the reversal of a $7 million accrual previously recorded in connection with settlement discussions with the U.S. Department of Justice; we received notice during the second quarter of 2021 that the U.S. Department of Justice has closed its investigation (see Note 6 - Commitments and Contingencies to our condensed consolidated financial statements for additional information). Our results also include a full quarter of the acquired operations of AseraCare compared to one month in the prior year, which resulted in increases to net service revenue and operating income totaling $16 million and $3 million, respectively. Additionally, our operating results were favorably impacted by changes in reimbursement and a full quarter of the suspension of sequestration effective May 1, 2020. These items were offset by a decline in our average daily census, an increase in our cost of service due to access restrictions being eased, higher health insurance costs and an increase in our other operating expenses.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Net Service Revenue</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our net service revenue increased $21&#160;million. Our results include a full quarter of the acquired operations of AseraCare in the current year compared to one month in the prior year which resulted in an increase to net service revenue of $16 million. Additionally, our revenue for the quarter was positively impacted by the increase in reimbursement effective October 1, 2020 ($4 million excluding the AseraCare acquisition) and a full quarter of the suspension of sequestration effective May 1, 2020 ($1 million excluding the AseraCare acquisition). Our revenue adjustments also decreased year over year due to the reversal of a $7 million accrual as mentioned above. These items were partially offset by a decline in our average daily census, which is the </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">main driver of hospice revenue. Our same store average daily census was down 3% year over year primarily due to a decline in our length of stay during the fourth quarter of 2020 resulting from an increase in the discharge rate of our patients and a delay in the timing of patients coming onto service due to COVID-19. This lower length of stay resulted in a declining census as we exited 2020 and has continued to impact our 2021 results. We expect to see growth in our average daily census as our admissions continue to increase and as our length of stay continues to normalize. </span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Other Operating Income</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other operating income consists of the recognition of funds received from the CARES Act PRF. In accordance with the terms and conditions, these funds can be used to cover lost revenues as well as costs directly attributable to COVID-19. For our wholly-owned subsidiaries, we have elected to utilize the funds to cover COVID-19 related costs only, and therefore, have recognized income related to these costs totaling $2 million and $7 million during the three-month periods ended June 30, 2021 and 2020, respectively. The COVID-19 costs are associated with the purchase of PPE, bonuses paid to our clinicians, clinician training, quarantine pay and COVID-19 testing and have been recorded to cost of service within our condensed consolidated statements of operations.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Cost of Service, Excluding Depreciation and Amortization</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our hospice cost of service increased $8&#160;million. The AseraCare acquisition includes a full quarter of acquired operations in the current year compared to one month in the prior year which resulted in an increase in costs totaling $8 million. Excluding our AseraCare acquisition, our cost of service remained flat as planned wage increases, higher health insurance costs, higher transportation costs and an increase in visits performed by our hourly hospice aides and licensed practical nurses due to access restrictions being eased were partially offset by a 3% decline in our average daily census and lower COVID-19 costs. We expect our cost of service to continue to increase as access restrictions are lifted and as the visits performed by our hourly hospice aides and licensed practical nurses return to pre-COVID-19 levels.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Other Operating Expenses</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other operating expenses increased $8&#160;million, approximately $5 million of which is related to our AseraCare acquisition. The remaining increase is due to a slowdown in prior year spend related to COVID-19, planned wage increases and higher health insurance costs partially offset by lower incentive compensation costs.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Personal Care Segment</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our personal care segment results of operations:</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:85.672%"><tr><td style="width:1.0%"></td><td style="width:70.743%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.551%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.653%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.553%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three-Month Periods <br/>Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financial Information</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">(in millions):</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-Medicare</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net service revenue</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.7&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other operating income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of service</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross margin</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other operating expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating income</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Key Statistical Data - Total (1):</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Billable hours</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">609,301&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">642,720&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clients served</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,371&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,956&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shifts</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">260,897&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">282,207&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue per hour</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.95&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.58&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue per shift</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65.29&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62.80&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hours per shift</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:49.5pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)    Total includes acquisitions, start-ups and denovos.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;padding-left:4.5pt;padding-right:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Operating Results</span></div><div style="margin-top:5pt;padding-left:4.5pt;padding-right:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating income related to our personal care segment remained flat on a $1 million decrease in net service revenue. The decrease in net service revenue is due to the impact of COVID-19, staffing shortages and the expiration of temporary rate increases implemented in prior year. The impact of COVID-19 has been partially mitigated by a reduction in costs as most of our personal care employees are paid on an hourly basis. </span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Corporate</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our corporate results of operations:</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:85.672%"><tr><td style="width:1.0%"></td><td style="width:70.743%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.551%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.653%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.553%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three-Month Periods<br/>Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financial Information</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">(in millions):</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other operating expenses</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47.2&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45.1&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Corporate expenses consist of costs related to our executive management and corporate and administrative support functions, primarily information services, accounting, finance, billing and collections, legal, compliance, risk management, procurement, marketing, clinical administration, training, human resources and administration. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Corporate other operating expenses increased approximately $2 million during the three-month period ended June 30, 2021. Other operating expenses associated with our AseraCare acquisition, which closed on June 1, 2020, declined $2 million year over year primarily due to higher acquisition and integration costs incurred in prior year. Excluding the AseraCare acquisition, corporate other operating expenses increased $4 million year over year due to planned wage increases, additional functional support, higher health insurance costs, increased information technology fees, higher acquisition costs and increased costs associated with a pre-acquisition legal settlement related to our CCH acquisition partially offset by lower incentive compensation costs and higher gains on the sale of fleet vehicles.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Six-Month Period Ended June&#160;30, 2021 Compared to the Six-Month Period Ended June&#160;30, 2020 </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Consolidated</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our consolidated results of operations (amounts in millions):</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:85.672%"><tr><td style="width:1.0%"></td><td style="width:70.743%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.551%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.653%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.553%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Six-Month Periods<br/>Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net service revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,101.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">976.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other operating income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of service, excluding depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">605.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">581.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross margin, excluding depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">508.7&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">418.5&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">% of revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">46.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">42.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other operating expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">347.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">313.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">% of revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">31.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">32.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating income</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">147.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other income (expense)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.4&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.2)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(46.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Effective income tax rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">26.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">22.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to noncontrolling interests</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.9)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to Amedisys, Inc.</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66.5&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On a consolidated basis, our operating income increased approximately $53 million on a revenue increase of $125 million. The year-over-year increases are primarily related to the impact of COVID-19 on prior year&#8217;s results, the acquisition of AseraCare on June 1, 2020, rate increases, the suspension of sequestration effective May 1, 2020, severance incurred in prior year related to reductions in staffing primarily within our home health segment, a reduction in revenue adjustments and improvements in clinician utilization and discipline mix. Partially offsetting these items, we experienced a decline in our hospice average daily census, which is the main driver of hospice revenue, and an increase in our cost of service resulting from the use of contract clinicians to supplement our staffing levels, an increase in visits performed by our hourly hospice employees due to greater access to patients in both facilities and their homes and higher health insurance costs. Additionally, our other operating expenses, which are described in more detail below, increased year over year.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our AseraCare acquisition, which closed on June 1, 2020, includes six months of acquired operations in the current year compared to one month in the prior year which resulted in an increase in net service revenue totaling $41 million and an increase in operating income totaling $3 million (which is inclusive of a decrease in acquisition and integration costs totaling $2 million and an increase in intangibles amortization totaling $4 million).</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Rate increases in all three of our operating segments resulted in an increase in net service revenue and operating income totaling approximately $19 million (excluding the AseraCare acquisition). We also benefited from the suspension of sequestration effective May 1, 2020, which resulted in an increase in net service revenue and operating income totaling approximately $12 million (excluding the AseraCare acquisition).</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As noted above, for our wholly-owned subsidiaries, we have elected to use the CARES Act PRF funds to cover COVID-19 expenses incurred by our home health and hospice segments which totaled $13 million and $22 million during the six-month periods ended June 30, 2021 and 2020, respectively. Our personal care segment received funds from the Mass Home Care ASAP COVID-19 Provider Sustainability Program totaling less than $1 million. We elected to use these funds to cover COVID-19 expenses as well. We recorded income related to both of these programs totaling $13 million and $23 million in other operating income within our condensed consolidated statements of operations during the six-month periods ended June 30, 2021 and 2020, respectively. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operating results reflect an 11.0% increase in our other operating expenses compared to prior year. Our 2021 other operating expenses include six months of the acquired operations of AseraCare compared to one month in the prior year which resulted in a year over year increase totaling $12 million. Excluding the AseraCare acquisition, our other operating expenses increased 7.3% due to a slowdown in prior year spend related to COVID-19, the addition of resources to support growth </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(primarily business development employees and care center administrative staff), planned wage increases, higher health insurance costs, investments related to PDGM, increased costs associated with a pre-acquisition legal settlement related to our CCH acquisition and increased information technology fees partially offset by lower costs directly attributable to COVID-19 and higher gains on the sale of fleet vehicles.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total other income for the six-month period ended June 30, 2021 includes a $31 million gain related to our investment in Medalogix (see Note 1 - Nature of Operations, Consolidation and Presentation of Financial Statements to our condensed consolidated financial statements for additional information).</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Home Health Segment</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our home health segment results of operations:</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:85.672%"><tr><td style="width:1.0%"></td><td style="width:70.743%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.551%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.653%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.553%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Six-Month Periods<br/>Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financial Information</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">:</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">456.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">396.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-Medicare</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">221.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">197.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net service revenue</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">677.9&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">593.8&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other operating income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of service</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">373.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">363.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross margin</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">311.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">245.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other operating expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">163.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">149.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating income</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Same Store Growth (1):</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-Medicare revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total admissions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total volume (2)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%)</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Key Statistical Data - Total (3):</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Admissions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">179,201&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">160,302&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Recertifications (6)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89,825&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86,625&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total volume (6)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">269,026&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">246,927&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare completed episodes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">154,520&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">144,296&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Average Medicare revenue per completed episode (4)</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,959&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,774&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare visits per completed episode (5)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Visiting Clinician Cost per Visit</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90.79&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88.41&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinical Manager Cost per Visit</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.40&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.19&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Cost per Visit</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.19&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97.60&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Visits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,726,918&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,727,097&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) Same store information represents the percent change in our Medicare, Non-Medicare and Total revenue, admissions or volume for the period as a percent of the Medicare, Non-Medicare and Total revenue, admissions or volume of the prior period. Same store is defined as care centers that we have operated for at least the last twelve months and startups that are an expansion of a same store care center.</span></div><div style="padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2) Total volume includes all admissions and recertifications.</span></div><div style="padding-left:49.5pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3) Total includes acquisitions, start-ups and denovos.</span></div><div style="padding-left:40.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4) Average Medicare revenue per completed episode is the average Medicare revenue earned for each Medicare completed episode of care. Average Medicare revenue per completed episode reflects the transition to PDGM effective January 1, 2020 and the suspension of sequestration effective May 1, 2020. </span></div><div style="padding-left:40.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(5) Medicare visits per completed episode are the home health Medicare visits on completed episodes divided by the home health Medicare episodes completed during the period.</span></div><div style="padding-left:40.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(6) Prior year amounts have been recast to conform to the current year calculation.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Operating Results</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Overall, our operating income increased $53 million on an $84 million increase in net service revenue. The year over year increases are primarily related to the impact of COVID-19 on prior year's results, an increase in our Medicare revenue per episode, which is described in more detail below, severance incurred in prior year related to reductions in staffing and significant improvement in our operating performance driven by improvements in our clinician utilization and discipline mix, both of which have contributed to year over year gross margin expansion. These items were partially offset by an increase in the usage of contract clinicians to supplement our staffing levels and an increase in our other operating expenses.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operating results were also impacted by costs related to COVID-19 totaling $7 million and $15 million for the six-month periods ended June 30, 2021 and 2020, respectively, which were offset by the recognition of income associated with the CARES Act PRF.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Net Service Revenue</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our net service revenue increased $84 million (14%) on a 9% increase in total volume and a 7% increase in Medicare revenue per episode. The volume growth was driven by a 12% increase in admissions and a 4% increase in recertification volume. Our admissions were significantly impacted by COVID-19 in prior year. The increase in Medicare revenue per episode is the result of a 1.9% increase in reimbursement, a full year of the 2.0% benefit related to the suspension of sequestration effective May 1, 2020, an increase in the functional impairment of our patients and a change in the source/timing and geographic dispersion of our patients. </span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Other Operating Income</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other operating income consists of the recognition of funds received from the CARES Act PRF. In accordance with the terms and conditions, these funds can be used to cover lost revenues as well as costs directly attributable to COVID-19. For our wholly-owned subsidiaries, we have elected to utilize the funds to cover COVID-19 related costs only, and therefore, have recognized income related to these costs totaling $7 million and $15 million during the six-month periods ended June 30, 2021 and 2020, respectively. The COVID-19 costs are associated with the purchase of PPE, bonuses paid to our clinicians, premiums paid to contract clinicians in COVID-19 high demand areas, clinician training, quarantine pay and COVID-19 testing. The COVID-19 costs incurred during the six-month period ended June 30, 2021 totaling $7 million have been recorded to cost of service within our condensed consolidated statements of operations. Of the $15 million of COVID-19 costs incurred in the prior year, $14 million was recorded to cost of service and $1 million was recorded to other operating expenses within our condensed consolidated statements of operations.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Cost of Service, Excluding Depreciation and Amortization</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our total cost of service increased 3% primarily due to a 3% increase in our total cost per visit. Our total visits were relatively flat year over year despite a 9% increase in total volume primarily due to improvements in clinician utilization, as evidenced by a decline of 1.5 visits per completed episode year over year. The 3% increase in our total cost per visit is due to planned wage increases, higher costs associated with the utilization of contractors to supplement our staffing levels, increases in new hire pay, inclement weather pay and higher health insurance costs partially offset by a decrease in costs directly attributable to COVID-19 and severance incurred in prior year in connection with a reduction in staffing.  </span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Other Operating Expenses</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other operating expenses increased approximately $14 million primarily due to a slowdown in prior year spend related to COVID-19, planned wage increases, higher health insurance costs, the addition of resources to support volume growth (business development employees and care center administrative staff) and investments related to PDGM. These increases were partially offset by lower costs directly attributable to COVID-19 in the current year.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Hospice Segment</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our hospice segment results of operations:</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:85.672%"><tr><td style="width:1.0%"></td><td style="width:70.743%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.551%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.653%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.553%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Six-Month Periods <br/>Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financial Information</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">(in millions):</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">368.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">327.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-Medicare</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net service revenue</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">389.4&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">346.5&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other operating income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of service</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">206.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">189.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross margin</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">188.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">164.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other operating expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating income</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Same Store Growth (1):</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hospice admissions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Average daily census</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Key Statistical Data - Total (2):</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hospice admissions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,358&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,729&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Average daily census</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,287&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,279&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue per day, net</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">161.93&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">155.04&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of service per day</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85.99&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84.58&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Average discharge length of stay</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)  Same store information represents the percent change in our Medicare revenue, Hospice admissions or average daily census for the period as a percent of the Medicare revenue, Hospice admissions or average daily census of the prior period. Same store is defined as care centers that we have operated for at least the last twelve months and startups that are an expansion of a same store care center.</span></div><div style="padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)  Total includes acquisitions, start-ups and denovos.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Operating Results</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operating results for the six-month period ended June 30, 2021 include the results of the acquisition of AseraCare on June 1, 2020 (44 hospice care centers). Acquisitions are included in our condensed consolidated financial statements from their respective acquisition dates. As a result, our hospice segment operating results for 2021 and 2020 are not fully comparable.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Overall, our operating income increased $8 million on a $43&#160;million increase in net service revenue. These results include the reversal of a $7 million accrual previously recorded in connection with settlement discussions with the U.S. Department of Justice; we received notice during the second quarter of 2021 that the U.S. Department of Justice has closed its investigation (see Note 6 - Commitments and Contingencies to our condensed consolidated financial statements for additional information). Our results also include six months of the acquired operations of AseraCare compared to one month in the prior year, which resulted in increases to net service revenue and operating income totaling $41 million and $6 million, respectively. Additionally, our operating results were favorably impacted by changes in reimbursement and the suspension of sequestration effective May 1, 2020. These items were offset by a decline in our average daily census, an increase in our cost of service due to access restrictions being eased, higher health insurance costs and an increase in our other operating expenses.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Net Service Revenue</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our net service revenue increased $43&#160;million. Our results include six months of the acquired operations of AseraCare in the current year compared to one month in the prior year which resulted in an increase to net service revenue of $41 million. Additionally, our year over year revenue was positively impacted by the increase in reimbursement effective October 1, 2020 ($8 million excluding the AseraCare acquisition) and the suspension of sequestration effective May 1, 2020 ($4 million, excluding the AseraCare acquisition). Our revenue adjustments also decreased year over year due to the reversal of a $7 million accrual as mentioned above. These items were partially offset by a decline in our average daily census, which is the main driver </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of hospice revenue. Our same store average daily census was down 3% year over year primarily due to a decline in our length of stay during the fourth quarter of 2020 resulting from an increase in the discharge rate of our patients and a delay in the timing of patients coming onto service due to COVID-19. This lower length of stay resulted in a declining census as we exited 2020 and has continued to impact our 2021 results. We expect to see growth in our average daily census as our admissions continue to increase and as our length of stay continues to normalize. </span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Other Operating Income</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other operating income consists of the recognition of funds received from the CARES Act PRF. In accordance with the terms and conditions, these funds can be used to cover lost revenues as well as costs directly attributable to COVID-19. For our wholly-owned subsidiaries, we have elected to utilize the funds to cover COVID-19 related costs only, and therefore, have recognized income related to these costs totaling $6 million and $7 million during the six-month periods ended June 30, 2021 and 2020, respectively. The COVID-19 costs are associated with the purchase of PPE, bonuses paid to our clinicians, clinician training, quarantine pay and COVID-19 testing and have been recorded to cost of service within our condensed consolidated statements of operations.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Cost of Service, Excluding Depreciation and Amortization</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our hospice cost of service increased $18&#160;million. The AseraCare acquisition includes six months of acquired operations in the current year compared to one month in the prior year which resulted in an increase in costs totaling $22 million. Excluding our AseraCare acquisition, our cost of service decreased $4 million due to a 3% decline in average daily census and lower COVID-19 costs partially offset by planned wage increases, higher health insurance costs, higher transportation costs and an increase in visits performed by our hourly hospice aides and licensed practical nurses due to access restrictions being eased. Toward the end of the first quarter and throughout the second quarter, we started to see an increase in access to patients in both facilities and their homes. We expect our cost of service to continue to increase as access restrictions are lifted and as the visits performed by our hourly hospice aides and licensed practical nurses return to pre-COVID-19 levels.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Other Operating Expenses</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other operating expenses increased $16&#160;million, approximately $13 million of which is related to our AseraCare acquisition. The remaining increase is due to a slowdown in prior year spend related to COVID-19, planned wage increases and higher health insurance costs.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Personal Care Segment</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our personal care segment results of operations:</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:85.672%"><tr><td style="width:1.0%"></td><td style="width:70.743%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.551%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.653%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.553%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Six-Month Periods <br/>Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financial Information</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">(in millions):</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-Medicare</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net service revenue</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36.4&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other operating income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of service</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross margin</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other operating expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating income</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Key Statistical Data - Total (1):</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Billable hours</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,216,738&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,394,797&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clients served</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,908&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,936&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shifts</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">518,506&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">615,671&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue per hour</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.96&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue per shift</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65.60&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59.17&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hours per shift</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:49.5pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)    Total includes acquisitions, start-ups and denovos.</span></div><div style="margin-top:12pt;padding-left:4.5pt;padding-right:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Operating Results</span></div><div style="margin-top:5pt;padding-left:4.5pt;padding-right:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating income related to our personal care segment remained flat on a $2 million decrease in net service revenue. The decrease in net service revenue is due to the impact of COVID-19 and staffing shortages partially offset by rate increases totaling approximately $1 million year over year. The impact of COVID-19 has been partially mitigated by a reduction in costs as most of our personal care employees are paid on an hourly basis. </span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Corporate</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our corporate results of operations:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:85.672%"><tr><td style="width:1.0%"></td><td style="width:70.743%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.551%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.653%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.553%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Six-Month Periods<br/>Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financial Information</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">(in millions):</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other operating expenses</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95.6&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87.8&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Corporate other operating expenses increased approximately $6 million during the six-month period ended June 30, 2021. Other operating expenses associated with our AseraCare acquisition declined $1 million year over year primarily due to higher acquisition and integration costs incurred in prior year. Excluding the AseraCare acquisition, corporate other operating expenses increased $7 million year over year due to planned wage increases, additional functional support, higher health insurance costs, increased information technology fees and increased costs associated with a pre-acquisition legal settlement related to our CCH acquisition; these items were partially offset by higher gains on the sale of fleet vehicles.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Resources</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Flows</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our cash flows for the periods indicated (amounts in millions):</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:85.672%"><tr><td style="width:1.0%"></td><td style="width:70.743%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.551%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.653%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.553%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Six-Month Periods<br/>Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash provided by operating activities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">139.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash used in investing activities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(284.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash (used in) provided by financing activities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(107.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">228.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net increase in cash, cash equivalents and restricted cash</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.3&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83.8&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash at beginning of period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash at end of period</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92.6&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">180.3&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash provided by operating activities decreased $17.9&#160;million during the six-month period ended June&#160;30, 2021 compared to the six-month period ended June&#160;30, 2020 primarily due to the deferral of payroll taxes and the receipt of CARES Act PRF funds in prior year as well as an increase in days revenue outstanding in the current year partially offset by an increase in operating income.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our cash used in investing activities primarily consists of the purchase of property and equipment and acquisition activity. Cash used in investing activities decreased $278.9&#160;million during the six-month period ended June&#160;30, 2021 compared to the six-month period ended June&#160;30, 2020 as a result of a reduction in acquisition spend.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our financing activities primarily consist of borrowings under our term loan and/or revolving credit facility, repayments of borrowings, the remittance of taxes associated with shares withheld on non-cash compensation, proceeds related to the exercise of stock options and the purchase of stock under either our employee stock purchase plan or our 2021 stock repurchase program. Cash used in financing activities totaled $107.3 million during the six-month period ended June&#160;30, 2021 primarily due to the repurchase of company stock and the repayments of borrowings. Cash provided by financing activities totaled $228.2 million during the six-month period ended June&#160;30, 2020 due to borrowings under our Amended Credit Agreement to minimize potential cash disruption related to COVID-19.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidity</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Typically, our principal source of liquidity is the collection of our patient accounts receivable, primarily through the Medicare program. In addition to our collection of patient accounts receivable, from time to time, we can and do obtain additional sources of liquidity by the incurrence of additional indebtedness.  </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the six-month period ended June&#160;30, 2021, we spent $2.9 million in capital expenditures as compared to $1.7 million during the six-month period ended June&#160;30, 2020. Our capital expenditures for 2021 are expected to be approximately $6.0 million to $8.0&#160;million, excluding the impact of any future acquisitions.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, during the six-month period ended June 30, 2021, pursuant to our authorized stock repurchase program, we repurchased 297,105 shares of our common stock at a weighted average price of $249.29 per share and a total cost of approximately $74 million. The repurchased shares are classified as treasury shares.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2021, we had $91.6 million in cash and cash equivalents and $490.3 million in availability under our $550.0&#160;million Revolving Credit Facility. Our cash and cash equivalents include approximately $62 million associated with the CARES Act PRF, $58 million of which we do not expect to utilize and which is recorded as a liability within our condensed consolidated balance sheet as of June 30, 2021.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on our operating forecasts and our debt service requirements, we believe we will have sufficient liquidity to fund our operations, capital requirements and debt service requirements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Outstanding Patient Accounts Receivable</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our patient accounts receivable increased $23.1&#160;million from December&#160;31, 2020 primarily due to the elimination of requests for anticipated payment ("RAPs") effective January 1, 2021. Our cash collection as a percentage of revenue was 103% and 106% for the six-month periods ended June&#160;30, 2021 and 2020, respectively. Our days revenue outstanding at June&#160;30, 2021 was 42.7 days, which is an increase of 2.5 days from December&#160;31, 2020 and a decrease of 1.2 days from March 31, 2021. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our patient accounts receivable includes unbilled receivables and are aged based upon our initial service date. We monitor unbilled receivables on a care center by care center basis to ensure that all efforts are made to bill claims within timely filing deadlines. Our unbilled patient accounts receivable can be impacted by acquisition activity, probe edits or regulatory changes which result in additional information or procedures needed prior to billing. The timely filing deadline for Medicare is one year from the last day of the billing period and varies by state for Medicaid-reimbursable services and among insurance companies and other private payors.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following schedules detail our patient accounts receivable, by payor class, aged based upon initial date of service (amounts in millions, except days revenue outstanding):</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:42.282%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.635%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.635%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.635%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.635%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.638%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">0-90</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">91-180</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">181-365</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Over&#160;365</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">At June 30, 2021:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare patient accounts receivable</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">169.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">182.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other patient accounts receivable:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicaid</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86.4&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.8&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total patient accounts receivable</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">278.2&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Days revenue outstanding (1)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42.7&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">0-90</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">91-180</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">181-365</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Over 365</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">At December 31, 2020:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare patient accounts receivable</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">156.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">164.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other patient accounts receivable:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicaid</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total patient accounts receivable</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">255.1&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Days revenue outstanding (1)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40.2&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Our calculation of days revenue outstanding is derived by dividing our ending patient accounts receivable at June&#160;30, 2021 and December&#160;31, 2020 by our average daily net patient service revenue for the three-month periods ended June&#160;30, 2021 and December&#160;31, 2020, respectively.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Indebtedness</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">First Amendment to Amended and Restated Credit Agreement</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 4, 2019, we entered into the First Amendment to our Credit Agreement (as amended by the First Amendment, the "Amended Credit Agreement"). The Amended Credit Agreement provides for a senior secured credit facility in an initial aggregate principal amount of up to $725.0 million, which includes a $550.0 million Revolving Credit Facility under the Credit Agreement and a term loan facility with a principal amount of up to $175.0 million (the "Term Loan Facility" and collectively with the Revolving Credit Facility, the "Credit Facility"), which was added by the First Amendment.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our weighted average interest rate for borrowings under our $550.0 million Revolving Credit Facility was 1.7% and 1.8% for the three and six-month periods ended June&#160;30, 2021, respectively, and 2.1% and 2.5% for the three and six-month periods </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ended June 30, 2020, respectively. Our weighted average interest rate for borrowings under our $175.0 million Term Loan Facility was 1.4% and 1.5% for the three and six-month periods ended June&#160;30, 2021, respectively, and 2.0% and 2.6% for the three and six-month periods ended June 30, 2020, respectively.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2021, our consolidated leverage ratio was 0.5, our consolidated interest coverage ratio was 41.9 and we are in compliance with our covenants under the Amended Credit Agreement.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2021, our availability under our $550.0&#160;million Revolving Credit Facility was $490.3 million as we have $30.0 million outstanding in borrowings and $29.7 million outstanding in letters of credit.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 5 - Long Term Obligations and Note 10 - Subsequent Events to our condensed consolidated financial statements for additional details on our outstanding long-term obligations.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share Repurchases</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2021 Stock Repurchase Program</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 23, 2020, we announced that our Board of Directors authorized a stock repurchase program, under which we may repurchase up to $100&#160;million of our outstanding common stock through December&#160;31, 2021.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the program, we are allowed to repurchase shares from time to time through open market purchases, unsolicited or solicited privately negotiated transactions, an accelerated stock repurchase program, and/or a trading plan in compliance with Exchange Act Rule 10b5-1. The timing and the amount of the repurchases will be determined by management based on a number of factors, including but not limited to share price, trading volume and general market conditions, as well as on working capital requirements, general business conditions and other factors. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to this program, we repurchased 4,757 shares of our common stock at a weighted average price of $249.72 per share and a total cost of approximately $1&#160;million during the three-month period ended June 30, 2021 and 297,105 shares of our common stock at a weighted average price of $249.29 per share and a total cost of approximately $74 million during the six-month period ended June 30, 2021. The repurchased shares are classified as treasury shares. </span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Inflation</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not believe inflation has significantly impacted our results of operations.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Estimates</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Part II, Item 7 &#8211; Critical Accounting Estimates and our consolidated financial statements and related notes in Part II, Item 8 of our 2020 Annual Report on Form 10-K, for accounting policies and related estimates we believe are the most critical to understanding our condensed consolidated financial statements, financial condition and results of operations and which require complex management judgment and assumptions, or involve uncertainties. These critical accounting estimates include revenue recognition and goodwill and other intangible assets. There have not been any changes to our significant accounting policies or their application since we filed our 2020 Annual Report on Form 10-K.</span></div><div id="iccd9c69ecd2c42e5897cfe9ab4e7e0b5_91"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;3.&#160;QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to market risk from fluctuations in interest rates. Our Revolving Credit Facility carries a floating interest rate which is tied to the Eurodollar rate (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">i.e.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> LIBOR) and the Prime Rate and therefore, our condensed consolidated statements of operations and our condensed consolidated statements of cash flows are exposed to changes in interest rates. As of June&#160;30, 2021, the total amount of outstanding debt subject to interest rate fluctuations was $189.7 million. A 1.0% interest rate change would cause interest expense to change by approximately $1.9 million annually, assuming the Company makes no principal repayments.</span></div><div id="iccd9c69ecd2c42e5897cfe9ab4e7e0b5_94"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;4.&#160;CONTROLS AND PROCEDURES</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Evaluation of Disclosure Controls and Procedures</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have established disclosure controls and procedures which are designed to provide reasonable assurance of achieving their objectives and to ensure that information required to be disclosed in our reports filed under the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), is recorded, processed, summarized, disclosed and reported within the time periods </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">specified in the Securities and Exchange Commission's rules and forms. This information is also accumulated and communicated to our management and Board of Directors to allow timely decisions regarding required disclosure.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the preparation of this Quarterly Report on Form 10-Q, as of June&#160;30, 2021, under the supervision and with the participation of our management, including our principal executive officer and principal financial officer, we conducted an evaluation of the effectiveness of our disclosure controls and procedures, as such term is defined under Rules 13a-15(e) and 15d-15(e) promulgated under the Exchange Act.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on this evaluation, our principal executive officer and principal financial officer concluded that our disclosure controls and procedures were effective at a reasonable assurance level as of June&#160;30, 2021, the end of the period covered by this Quarterly Report.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Changes in Internal Controls</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no changes in our internal control over financial reporting (as defined in Exchange Act Rule 13a-15(f)) that have occurred during the quarter ended June&#160;30, 2021, that have materially impacted, or are reasonably likely to materially impact, our internal control over financial reporting.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inherent Limitations on Effectiveness of Controls</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management, including our principal executive officer and principal financial officer, does not expect that our disclosure controls or our internal controls over financial reporting will prevent or detect all errors and all fraud. A control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the control system&#8217;s objectives will be met. The design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Further, because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that misstatements due to error or fraud will not occur or that all control issues and instances of fraud, if any, have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty and that breakdowns can occur because of simple error or mistake. Controls can also be circumvented by the individual acts of some persons, by collusion of two or more people, or by management override of the controls. The design of any system of controls is based in part on certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions. Projections of any evaluation of controls&#8217; effectiveness to future periods are subject to risks. Over time, controls may become inadequate because of changes in conditions or deterioration in the degree of compliance with policies and procedures. Our disclosure controls and procedures are designed to provide reasonable assurance of achieving their objectives and, based on an evaluation of our controls and procedures, our principal executive officer and our principal financial officer concluded our disclosure controls and procedures were effective at a reasonable assurance level as of June&#160;30, 2021, the end of the period covered by this Quarterly Report.</span></div><div style="margin-top:6pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div></div></div><div id="iccd9c69ecd2c42e5897cfe9ab4e7e0b5_97"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II. OTHER INFORMATION</span></div><div id="iccd9c69ecd2c42e5897cfe9ab4e7e0b5_100"></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;1. LEGAL PROCEEDINGS</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 6 - Commitments and Contingencies to the condensed consolidated financial statements for information concerning our legal proceedings.</span></div><div id="iccd9c69ecd2c42e5897cfe9ab4e7e0b5_103"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;1A. RISK FACTORS</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no material changes in the risk factors described in our Annual Report on Form 10-K for the year ended December 31, 2020.</span></div><div id="iccd9c69ecd2c42e5897cfe9ab4e7e0b5_106"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides the information with respect to purchases made by us of shares of our common stock during each of the months during the three-month period ended June&#160;30, 2021:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:33.599%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.052%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.853%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.568%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Period</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">(a)&#160;Total&#160;Number<br/>of&#160;Shares&#160;(or&#160;Units)<br/>Purchased</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">(b)&#160;Average&#160;Price<br/>Paid&#160;per&#160;Share&#160;(or<br/>Unit)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">(c)&#160;Total&#160;Number&#160;of<br/>Shares (or Units)<br/>Purchased&#160;as&#160;Part&#160;of<br/>Publicly Announced<br/>Plans or Programs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">(d)&#160;Maximum&#160;Number&#160;(or<br/>Approximate Dollar<br/>Value) of Shares (or<br/>Units) That May Yet Be<br/>Purchased Under the<br/>Plans or Programs</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 1, 2021&#160;to&#160;April 30,&#160;2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">177&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">284.57&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,113,795&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 1,&#160;2021&#160;to May 31,&#160;2021</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,757&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,925,725&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 1, 2021 to June 30, 2021</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">467&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">255.60&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,925,725&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">644&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">263.56&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,757&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,925,725&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span></div><div style="padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Includes shares of common stock surrendered to us by certain employees to satisfy tax withholding and/or strike price obligations in connection with the vesting of non-vested stock and exercise of stock options previously awarded to such employees under our 2008 and 2018 Omnibus Incentive Compensation Plans.</span></div><div id="iccd9c69ecd2c42e5897cfe9ab4e7e0b5_109"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;3. DEFAULTS UPON SENIOR SECURITIES</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="iccd9c69ecd2c42e5897cfe9ab4e7e0b5_112"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;4. MINE SAFETY DISCLOSURES</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div id="iccd9c69ecd2c42e5897cfe9ab4e7e0b5_115"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;5. OTHER INFORMATION</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div></div></div><div id="iccd9c69ecd2c42e5897cfe9ab4e7e0b5_118"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="-sec-extract:summary;margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;6. EXHIBITS</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The exhibits marked with the cross symbol (&#8224;) are filed and the exhibits marked with a double cross (&#8224;&#8224;) are furnished with this Form 10-Q. Any exhibits marked with the asterisk symbol (*) are management contracts or compensatory plans or arrangements filed pursuant to Item 601(b)(10)(iii) of Regulation S-K. </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:9.249%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.383%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.360%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.528%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.244%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.528%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.375%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.528%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.505%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit<br/>Number</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Document Description</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Report or Registration Statement</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">SEC File or<br/>Registration<br/>Number</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit<br/>or Other<br/>Reference</span></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/896262/000119312507166703/dex31.htm">Composite of Certificate of Incorporation of the Company inclusive of all amendments through June&#160;14, 2007</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Company&#8217;s Quarterly Report on Form 10-Q for the quarter ended June&#160;30, 2007</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0-24260</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/896262/000089626219000014/amed-20193009xexx32.htm">Composite of By-Laws of the Company inclusive of all amendments through October 17, 2019</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Company&#8217;s Quarterly Report on Form 10-Q for the quarter ended September 30, 2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0-24260</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/896262/000119312521236286/d196437dex21.htm">Agreement and Plan of Merger, dated as of June 27, 2021, by and among Amedisys Holding, L.L.C., Amedisys Commodore, L.L.C., Contessa Health, Inc., Shareholder Representative Services LLC, and, solely for purposes of Section 10.17, Amedisys, Inc. (Immaterial schedules and exhibits have been omitted pursuant to Item 601(a)(5) of Regulation S-K. The registrant agrees to furnish supplementally a copy of any omitted schedule or exhibit to the U.S. Securities and Exchange Commission upon request)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Company's Current Report on Form 8-K filed on August 4, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0-24260</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.1</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8224;31.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="amed-20213006xexx311.htm">Certification of Paul B. Kusserow, Chief Executive Officer (principal executive officer), pursuant to Section&#160;302 of the Sarbanes-Oxley Act of 2002</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8224;31.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="amed-20213006xexx312.htm">Certification of Scott G. Ginn, Executive Vice President and Chief Financial Officer (principal financial officer), pursuant to Section&#160;302 of the Sarbanes-Oxley Act of 2002</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8224;&#8224;32.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="amed-20213006xexx321.htm">Certification of Paul B. Kusserow, Chief Executive Officer (principal executive officer), pursuant to 18 U.S.C. Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8224;&#8224;32.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="amed-20213006xexx322.htm">Certification of Scott G. Ginn, Executive Vice President and Chief Financial Officer (principal financial officer), pursuant to 18&#160;U.S.C. Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8224;101.INS</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Instance - The instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8224;101.SCH</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Schema Document</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8224;101.CAL</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Calculation Linkbase Document</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8224;101.DEF</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Definition Linkbase</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8224;101.LAB</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Labels Linkbase Document</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8224;101.PRE</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Presentation Linkbase Document</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</span></div></div></div><div id="iccd9c69ecd2c42e5897cfe9ab4e7e0b5_121"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of Section&#160;13 or 15(d) of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:39.912%"><tr><td style="width:1.0%"></td><td style="width:19.412%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.226%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:71.062%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">A</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">MEDISYS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, I</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">NC</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Registrant)</span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ SCOTT G. GINN</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Scott G. Ginn,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Principal Financial Officer and</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Duly Authorized Officer</span></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date: August&#160;5, 2021</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>amed-20213006xexx311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i7fd1b9ec7f3c4509b6c6083c23c9fa3e_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="-sec-extract:summary;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.1</font></div><div style="margin-top:24pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Paul B. Kusserow, certify that&#58;</font></div><div style="margin-top:6pt;padding-left:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1. I have reviewed this Quarterly Report on Form 10-Q for the quarter ended June&#160;30, 2021, of Amedisys, Inc.&#59;</font></div><div style="margin-top:6pt;padding-left:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:6pt;padding-left:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:6pt;padding-left:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4. The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:6pt;padding-left:49.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:6pt;padding-left:49.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:6pt;padding-left:49.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c. Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:6pt;padding-left:49.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d. Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:6pt;padding-left:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5. The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:6pt;padding-left:49.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:6pt;padding-left:49.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; August&#160;5, 2021 </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:32.748%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47; Paul B. Kusserow</font></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Paul B. Kusserow</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Chief Executive Officer<br>(Principal Executive Officer)</font></td></tr></table></div><div style="text-align:right"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>amed-20213006xexx312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i7340aab86ed3455b963f4ab6c7efd123_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.2</font></div><div style="margin-top:24pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Scott G. Ginn, certify that&#58;</font></div><div style="margin-top:6pt;padding-left:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1. I have reviewed this Quarterly Report on Form 10-Q for the quarter ended June&#160;30, 2021, of Amedisys, Inc.&#59;</font></div><div style="margin-top:6pt;padding-left:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:6pt;padding-left:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:6pt;padding-left:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4. The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:6pt;padding-left:49.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:6pt;padding-left:49.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:6pt;padding-left:49.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c. Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:6pt;padding-left:49.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d. Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:6pt;padding-left:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5. The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:6pt;padding-left:49.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:6pt;padding-left:49.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; August&#160;5, 2021 </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:25.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47; Scott G. Ginn</font></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Scott G. Ginn<br>Executive Vice President and Chief Financial Officer</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Principal Financial Officer)</font></td></tr></table></div><div style="text-align:right"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>amed-20213006xexx321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="if4ec7135727c4734ae4e9e412132419c_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.1</font></div><div style="margin-top:24pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER PURSUANT TO 18 U.S.C. SECTION 1350,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Quarterly Report of Amedisys, Inc. (the &#8220;Company&#8221;) on Form 10-Q for the quarter ended June&#160;30, 2021 (the &#8220;Report&#8221;), I, Paul B. Kusserow, Chief Executive Officer of the Company, hereby certify to my knowledge, pursuant to 18 U.S.C. Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002, that&#58;</font></div><div style="margin-top:6pt;padding-left:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) The Report fully complies with the requirements of Section&#160;13(a) or 15(d) of the Securities Exchange Act of 1934&#59; and</font></div><div style="margin-top:6pt;padding-left:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company as of and for the periods presented in the Report.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; August&#160;5, 2021 </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:32.748%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47; Paul B. Kusserow</font></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Paul B. Kusserow<br>Chief Executive Officer</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Principal Executive Officer)</font></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>5
<FILENAME>amed-20213006xexx322.htm
<DESCRIPTION>EX-32.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i226acf721c1544788f770ff7d3a34e4a_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.2</font></div><div style="margin-top:24pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER PURSUANT TO 18 U.S.C. SECTION 1350,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Quarterly Report of Amedisys, Inc. (the &#8220;Company&#8221;) on Form 10-Q for the quarter ended June&#160;30, 2021 (the &#8220;Report&#8221;), I, Scott G. Ginn, Executive Vice President and Chief Financial Officer of the Company, hereby certify to my knowledge, pursuant to 18 U.S.C. Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002, that&#58;</font></div><div style="margin-top:6pt;padding-left:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) The Report fully complies with the requirements of Section&#160;13(a) or 15(d) of the Securities Exchange Act of 1934&#59; and</font></div><div style="margin-top:6pt;padding-left:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company as of and for the periods presented in the Report.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; August&#160;5, 2021 </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:25.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47; Scott G. Ginn</font></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Scott G. Ginn<br>Executive Vice President and Chief Financial Officer</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Principal Financial Officer)</font></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>6
<FILENAME>amed-20210630.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:9b598574-bbed-4d17-bc5e-2b8ec86d1c16,g:311e4854-6196-49e6-97c5-f444b0264a32-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:amed="http://www.amedisys.com/20210630" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.amedisys.com/20210630">
  <xs:import namespace="http://fasb.org/srt/2020-01-31" schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2020-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2020-01-31" schemaLocation="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/stpr/2018-01-31" schemaLocation="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="amed-20210630_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="amed-20210630_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="amed-20210630_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="amed-20210630_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://www.amedisys.com/role/Cover">
        <link:definition>0001001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDBALANCESHEETS" roleURI="http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS">
        <link:definition>1001002 - Statement - CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDBALANCESHEETSParenthetical" roleURI="http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETSParenthetical">
        <link:definition>1002003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFOPERATIONS" roleURI="http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS">
        <link:definition>1003004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYStatement" roleURI="http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYStatement">
        <link:definition>1004005 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY Statement</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFCASHFLOWS" roleURI="http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS">
        <link:definition>1005006 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTS" roleURI="http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTS">
        <link:definition>2101101 - Disclosure - NATURE OF OPERATIONS, CONSOLIDATION AND PRESENTATION OF FINANCIAL STATEMENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails" roleURI="http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails">
        <link:definition>2402401 - Disclosure - NATURE OF OPERATIONS, CONSOLIDATION AND PRESENTATION OF FINANCIAL STATEMENTS - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES" roleURI="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES">
        <link:definition>2103102 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" roleURI="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies">
        <link:definition>2204201 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables" roleURI="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables">
        <link:definition>2305301 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails" roleURI="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails">
        <link:definition>2406402 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Revenue Recognition Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenuebyPayorClassDetails" roleURI="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenuebyPayorClassDetails">
        <link:definition>2407403 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Revenue by Payor Class (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESCashandCashEquivalentsDetails" roleURI="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESCashandCashEquivalentsDetails">
        <link:definition>2408404 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Cash and Cash Equivalents (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPatientAccountsReceivableNarrativeDetails" roleURI="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPatientAccountsReceivableNarrativeDetails">
        <link:definition>2409405 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Patient Accounts Receivable Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESFairValueofFinancialInstrumentsDetails" roleURI="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESFairValueofFinancialInstrumentsDetails">
        <link:definition>2410406 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Fair Value of Financial Instruments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESWeightedAverageSharesOutstandingDetails" roleURI="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESWeightedAverageSharesOutstandingDetails">
        <link:definition>2411407 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Weighted-Average Shares Outstanding (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NOVELCORONAVIRUSPANDEMICCOVID19" roleURI="http://www.amedisys.com/role/NOVELCORONAVIRUSPANDEMICCOVID19">
        <link:definition>2112103 - Disclosure - NOVEL CORONAVIRUS PANDEMIC "COVID-19"</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NOVELCORONAVIRUSPANDEMICCOVID19Tables" roleURI="http://www.amedisys.com/role/NOVELCORONAVIRUSPANDEMICCOVID19Tables">
        <link:definition>2313302 - Disclosure - NOVEL CORONAVIRUS PANDEMIC "COVID-19" (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NOVELCORONAVIRUSPANDEMICCOVID19Details" roleURI="http://www.amedisys.com/role/NOVELCORONAVIRUSPANDEMICCOVID19Details">
        <link:definition>2414408 - Disclosure - NOVEL CORONAVIRUS PANDEMIC "COVID-19" (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ACQUISITIONS" roleURI="http://www.amedisys.com/role/ACQUISITIONS">
        <link:definition>2115104 - Disclosure - ACQUISITIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ACQUISITIONSTables" roleURI="http://www.amedisys.com/role/ACQUISITIONSTables">
        <link:definition>2316303 - Disclosure - ACQUISITIONS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ACQUISITIONSNarrativeDetails" roleURI="http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails">
        <link:definition>2417409 - Disclosure - ACQUISITIONS - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ACQUISITIONSProFormaDetails" roleURI="http://www.amedisys.com/role/ACQUISITIONSProFormaDetails">
        <link:definition>2418410 - Disclosure - ACQUISITIONS - Pro Forma (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LONGTERMOBLIGATIONS" roleURI="http://www.amedisys.com/role/LONGTERMOBLIGATIONS">
        <link:definition>2119105 - Disclosure - LONG-TERM OBLIGATIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LONGTERMOBLIGATIONSLONGTERMOBLIGATIONSTables" roleURI="http://www.amedisys.com/role/LONGTERMOBLIGATIONSLONGTERMOBLIGATIONSTables">
        <link:definition>2320304 - Disclosure - LONG-TERM OBLIGATIONS LONG-TERM OBLIGATIONS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LONGTERMOBLIGATIONSScheduleofLongTermDebtDetails" roleURI="http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtDetails">
        <link:definition>2421411 - Disclosure - LONG-TERM OBLIGATIONS - Schedule of Long-Term Debt (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LONGTERMOBLIGATIONSScheduleofLongTermDebtDetails_1" roleURI="http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtDetails_1">
        <link:definition>2421411 - Disclosure - LONG-TERM OBLIGATIONS - Schedule of Long-Term Debt (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LONGTERMOBLIGATIONSScheduleofLongTermDebtAdditionalInformationDetails" roleURI="http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtAdditionalInformationDetails">
        <link:definition>2422412 - Disclosure - LONG-TERM OBLIGATIONS - Schedule of Long-Term Debt Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LONGTERMOBLIGATIONSFeesandRatesUnderCreditFacilitiesDetails" roleURI="http://www.amedisys.com/role/LONGTERMOBLIGATIONSFeesandRatesUnderCreditFacilitiesDetails">
        <link:definition>2423413 - Disclosure - LONG-TERM OBLIGATIONS - Fees and Rates Under Credit Facilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LONGTERMOBLIGATIONSNarrativeDetails" roleURI="http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails">
        <link:definition>2424414 - Disclosure - LONG-TERM OBLIGATIONS - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="COMMITMENTSANDCONTINGENCIES" roleURI="http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIES">
        <link:definition>2125106 - Disclosure - COMMITMENTS AND CONTINGENCIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="COMMITMENTSANDCONTINGENCIESNarrativeDetails" roleURI="http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails">
        <link:definition>2426415 - Disclosure - COMMITMENTS AND CONTINGENCIES - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SEGMENTINFORMATION" roleURI="http://www.amedisys.com/role/SEGMENTINFORMATION">
        <link:definition>2127107 - Disclosure - SEGMENT INFORMATION</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SEGMENTINFORMATIONTables" roleURI="http://www.amedisys.com/role/SEGMENTINFORMATIONTables">
        <link:definition>2328305 - Disclosure - SEGMENT INFORMATION (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SEGMENTINFORMATIONNarrativeDetails" roleURI="http://www.amedisys.com/role/SEGMENTINFORMATIONNarrativeDetails">
        <link:definition>2429416 - Disclosure - SEGMENT INFORMATION - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SEGMENTINFORMATIONOperatingIncomeofReportableSegmentsDetails" roleURI="http://www.amedisys.com/role/SEGMENTINFORMATIONOperatingIncomeofReportableSegmentsDetails">
        <link:definition>2430417 - Disclosure - SEGMENT INFORMATION - Operating Income of Reportable Segments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SHAREREPURCHASESHAREREPURCHASE" roleURI="http://www.amedisys.com/role/SHAREREPURCHASESHAREREPURCHASE">
        <link:definition>2131108 - Disclosure - SHARE REPURCHASE SHARE REPURCHASE</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SHAREREPURCHASENarrativeDetails" roleURI="http://www.amedisys.com/role/SHAREREPURCHASENarrativeDetails">
        <link:definition>2432418 - Disclosure - SHARE REPURCHASE Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RELATEDPARTYTRANSACTIONSRELATEDPARTYTRANSACTIONS" roleURI="http://www.amedisys.com/role/RELATEDPARTYTRANSACTIONSRELATEDPARTYTRANSACTIONS">
        <link:definition>2133109 - Disclosure - RELATED PARTY TRANSACTIONS RELATED PARTY TRANSACTIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RELATEDPARTYTRANSACTIONSNarrativeDetails" roleURI="http://www.amedisys.com/role/RELATEDPARTYTRANSACTIONSNarrativeDetails">
        <link:definition>2434419 - Disclosure - RELATED PARTY TRANSACTIONS Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUBSEQUENTEVENT" roleURI="http://www.amedisys.com/role/SUBSEQUENTEVENT">
        <link:definition>2135110 - Disclosure - SUBSEQUENT EVENT</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUBSEQUENTEVENTTables" roleURI="http://www.amedisys.com/role/SUBSEQUENTEVENTTables">
        <link:definition>2336306 - Disclosure - SUBSEQUENT EVENT (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUBSEQUENTEVENTNarrativeDetails" roleURI="http://www.amedisys.com/role/SUBSEQUENTEVENTNarrativeDetails">
        <link:definition>2437420 - Disclosure - SUBSEQUENT EVENT - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUBSEQUENTEVENTFeesandRatesUnderCreditFacilitiesDetails" roleURI="http://www.amedisys.com/role/SUBSEQUENTEVENTFeesandRatesUnderCreditFacilitiesDetails">
        <link:definition>2438421 - Disclosure - SUBSEQUENT EVENT- Fees and Rates Under Credit Facilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="amed_ExtensionOfTemporarySuspensionOfSequestrationRevenueImpact" abstract="false" name="ExtensionOfTemporarySuspensionOfSequestrationRevenueImpact" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_FundingReceivedFromMassHomeCareASAPCOVID19ProviderSustainabilityProgram" abstract="false" name="FundingReceivedFromMassHomeCareASAPCOVID19ProviderSustainabilityProgram" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_ShareRepurchaseProgramMember" abstract="true" name="ShareRepurchaseProgramMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amed_ThirdThresholdOfTherapyServicesRequired" abstract="false" name="ThirdThresholdOfTherapyServicesRequired" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="amed_LineOfCreditFacilityAdditionalBorrowingCapacity" abstract="false" name="LineOfCreditFacilityAdditionalBorrowingCapacity" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_MajorSinglePayorCustomerMember" abstract="true" name="MajorSinglePayorCustomerMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amed_CompassionateCareHospiceMember" abstract="true" name="CompassionateCareHospiceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amed_HomeHealthMedicareMember" abstract="true" name="HomeHealthMedicareMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amed_Revenuebypayorclassasapercentageoftotalnetservicerevenue" abstract="false" name="Revenuebypayorclassasapercentageoftotalnetservicerevenue" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="amed_HomeHealthNonMedicareNonEpisodicBasedMember" abstract="true" name="HomeHealthNonMedicareNonEpisodicBasedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amed_UnfavorableMember" abstract="true" name="UnfavorableMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amed_HospiceMedicareMember" abstract="true" name="HospiceMedicareMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amed_PaymentsRelatedToTaxAsset" abstract="false" name="PaymentsRelatedToTaxAsset" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_EquityImpactofRepurchaseofNoncontrollingInterest" abstract="false" name="EquityImpactofRepurchaseofNoncontrollingInterest" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_OneHundredMillionTermLoanMember" abstract="true" name="OneHundredMillionTermLoanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amed_HospiceNonMedicareMember" abstract="true" name="HospiceNonMedicareMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amed_CashPaidForFinanceLeaseLiabilities" abstract="false" name="CashPaidForFinanceLeaseLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_COVID19DeferralOfSocialSecurityMember" abstract="true" name="COVID19DeferralOfSocialSecurityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amed_Recoveryamountofoverpaymentmadetosubsidiaryincludinginterestwithheld" abstract="false" name="Recoveryamountofoverpaymentmadetosubsidiaryincludinginterestwithheld" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_RateOfRequestForAnticipatedPaymentSubmittedForInitialPeriodOfCare" abstract="false" name="RateOfRequestForAnticipatedPaymentSubmittedForInitialPeriodOfCare" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="amed_WriteOffOfOtherComprehensiveIncome" abstract="false" name="WriteOffOfOtherComprehensiveIncome" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_AsanaHospiceAquisitionMember" abstract="true" name="AsanaHospiceAquisitionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amed_FundsReceivedFromProviderReliefFundAdvance" abstract="false" name="FundsReceivedFromProviderReliefFundAdvance" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_TotalLeverageRatio" abstract="false" name="TotalLeverageRatio" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="amed_MaximumPercentOwnershipForCostMethodPercent" abstract="false" name="MaximumPercentOwnershipForCostMethodPercent" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="amed_DebtInstrumentCarryingAmountExcludingFinanceLeases" abstract="false" name="DebtInstrumentCarryingAmountExcludingFinanceLeases" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_TwoHundredMillionRevolvingCreditFacilityMember" abstract="true" name="TwoHundredMillionRevolvingCreditFacilityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amed_ConsolidatedInterestCoverageRatio" abstract="false" name="ConsolidatedInterestCoverageRatio" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="amed_SafeguardZoneProgramIntegrityContractorMember" abstract="true" name="SafeguardZoneProgramIntegrityContractorMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amed_HealthInsuranceRetentionLimit" abstract="false" name="HealthInsuranceRetentionLimit" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_PriorCreditAgreementMember" abstract="true" name="PriorCreditAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amed_CapYearAxis" abstract="true" name="CapYearAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="amed_ScheduleOfCaresActProviderReliefFundsTableTextBlock" abstract="false" name="ScheduleOfCaresActProviderReliefFundsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="amed_LowUtilizationPaymentAdjustmentNumberOfVisits" abstract="false" name="LowUtilizationPaymentAdjustmentNumberOfVisits" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="amed_HospiceMedicareRevenueRateAccountedForRoutineCare" abstract="false" name="HospiceMedicareRevenueRateAccountedForRoutineCare" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="amed_AdditionalFundingDistributedToHealthcareProviders" abstract="false" name="AdditionalFundingDistributedToHealthcareProviders" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_MedicareLicenseMember" abstract="true" name="MedicareLicenseMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amed_AmedisysCIAMember" abstract="true" name="AmedisysCIAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amed_SwingLineLoanMember" abstract="true" name="SwingLineLoanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amed_MaximumDaysToSubmitFinalBillFromStartOfPeriodOfCare" abstract="false" name="MaximumDaysToSubmitFinalBillFromStartOfPeriodOfCare" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="amed_MedicareRevenueMember" abstract="true" name="MedicareRevenueMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amed_DebtInstrumentPeriodicPaymentPercentage" abstract="false" name="DebtInstrumentPeriodicPaymentPercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="amed_TypeOfEquityMethodInvestmentDomain" abstract="true" name="TypeOfEquityMethodInvestmentDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amed_NumberOfBeneficiaries" abstract="false" name="NumberOfBeneficiaries" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="amed_SecondAmendmentToAmendedCreditAgreementMember" abstract="true" name="SecondAmendmentToAmendedCreditAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amed_LetterOfCreditFee" abstract="false" name="LetterOfCreditFee" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="amed_AmendedDebtInstrumentByLeverageRatioTrancheFourMember" abstract="true" name="AmendedDebtInstrumentByLeverageRatioTrancheFourMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amed_AmendedDebtInstrumentByLeverageRatioTrancheThreeMember" abstract="true" name="AmendedDebtInstrumentByLeverageRatioTrancheThreeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses" abstract="false" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_CashBalanceAssociatedWithProviderReliefFund" abstract="false" name="CashBalanceAssociatedWithProviderReliefFund" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_MaximumDaysToSubmitFinalBillFromDateRequestForAnticipatedPaymentWasPaid" abstract="false" name="MaximumDaysToSubmitFinalBillFromDateRequestForAnticipatedPaymentWasPaid" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="amed_PayorClassDomain" abstract="true" name="PayorClassDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amed_SecondThresholdOfServicesRequired" abstract="false" name="SecondThresholdOfServicesRequired" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="amed_NonVestedStockAndStockUnits" abstract="false" name="NonVestedStockAndStockUnits" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="amed_NumberOfClaimsSubmittedBySubsidiary" abstract="false" name="NumberOfClaimsSubmittedBySubsidiary" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="amed_AmortizationandImpairmentofOperatingLeaseRightOfUseAsset" abstract="false" name="AmortizationandImpairmentofOperatingLeaseRightOfUseAsset" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_TypeofEquityMethodInvestmentAxis" abstract="true" name="TypeofEquityMethodInvestmentAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="amed_AmendedDebtInstrumentByLeverageRatioTrancheTwoMember" abstract="true" name="AmendedDebtInstrumentByLeverageRatioTrancheTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amed_IncreaseDecreaseInOperatingLeaseLiability" abstract="false" name="IncreaseDecreaseInOperatingLeaseLiability" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_MinimumPercentOwnershipForControllingInterestPercent" abstract="false" name="MinimumPercentOwnershipForControllingInterestPercent" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="amed_HomeHealthAndHospiceMember" abstract="true" name="HomeHealthAndHospiceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amed_ParkersburgWestVirginiaMember" abstract="true" name="ParkersburgWestVirginiaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amed_RateOfRequestForAnticipatedPaymentSubmittedForSubsequentEpisodesOfCare" abstract="false" name="RateOfRequestForAnticipatedPaymentSubmittedForSubsequentEpisodesOfCare" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="amed_DebtInstrumentByLeverageRatioTrancheOneMember" abstract="true" name="DebtInstrumentByLeverageRatioTrancheOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amed_DebtInstrumentByLeverageRatioTrancheFourMember" abstract="true" name="DebtInstrumentByLeverageRatioTrancheFourMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amed_A2019ShareRepurchaseProgramMember" abstract="true" name="A2019ShareRepurchaseProgramMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amed_Discountedclosingstockprice" abstract="false" name="Discountedclosingstockprice" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:perShareItemType"/>
  <xs:element id="amed_GoodwillDeductibleForIncomeTaxPurposesPeriod" abstract="false" name="GoodwillDeductibleForIncomeTaxPurposesPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="amed_COVID19ExpensesIncurred" abstract="false" name="COVID19ExpensesIncurred" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_ExtrapolatedMember" abstract="true" name="ExtrapolatedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amed_NetServiceRevenueEpisodePaymentRateDuration" abstract="false" name="NetServiceRevenueEpisodePaymentRateDuration" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="amed_PromissoryNotesMember" abstract="true" name="PromissoryNotesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amed_ShareRepurchaseTable" abstract="true" name="ShareRepurchaseTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="amed_A2021ShareRepurchaseProgramMember" abstract="true" name="A2021ShareRepurchaseProgramMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amed_CertificateOfNeedMember" abstract="true" name="CertificateOfNeedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amed_EstimatedCARESActProviderReliefFundAmountsToBeRepaid" abstract="false" name="EstimatedCARESActProviderReliefFundAmountsToBeRepaid" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_PayorsAxis" abstract="true" name="PayorsAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="amed_HeritageHealthcareInnovationFundLPMember" abstract="true" name="HeritageHealthcareInnovationFundLPMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amed_CompassionateCareHospiceCIAMember" abstract="true" name="CompassionateCareHospiceCIAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amed_WorkersCompensationInsuranceRetentionLimit" abstract="false" name="WorkersCompensationInsuranceRetentionLimit" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_CapYearDomain" abstract="true" name="CapYearDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amed_FloridaZpicRevenueReduction" abstract="false" name="FloridaZpicRevenueReduction" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_Percentageofclosingstockprice" abstract="false" name="Percentageofclosingstockprice" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="amed_VisitingNurseAssociationMember" abstract="true" name="VisitingNurseAssociationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amed_GovernmentGrantsPolicyTextBlock" abstract="false" name="GovernmentGrantsPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="amed_OperatingCareCenters" abstract="false" name="OperatingCareCenters" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="amed_COVID19PPEMember" abstract="true" name="COVID19PPEMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amed_DebtInstrumentByLeverageRatioTrancheTwoMember" abstract="true" name="DebtInstrumentByLeverageRatioTrancheTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amed_InfinityHomeCareMember" abstract="true" name="InfinityHomeCareMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amed_AcquiredNamesMember" abstract="true" name="AcquiredNamesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amed_DepreciationAndAmortizationForContinuingOperations" abstract="false" name="DepreciationAndAmortizationForContinuingOperations" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_FinancialInstrumentDetailsTableTextBlock" abstract="false" name="FinancialInstrumentDetailsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="amed_DebtInstrumentInterestAdditionalInterestAboveFederalFundRate" abstract="false" name="DebtInstrumentInterestAdditionalInterestAboveFederalFundRate" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="amed_FundingReceivedFromCARESAct" abstract="false" name="FundingReceivedFromCARESAct" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_DebtInstrumentInterestRateatPeriodEnd" abstract="false" name="DebtInstrumentInterestRateatPeriodEnd" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="amed_HospiceMember" abstract="true" name="HospiceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amed_HistoricalCollectionRateFromMedicare" abstract="false" name="HistoricalCollectionRateFromMedicare" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="amed_StockIssuedDuringPeriodSharesFourZeroOneKEmployerMatch" abstract="false" name="StockIssuedDuringPeriodSharesFourZeroOneKEmployerMatch" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="amed_IndemnificationAmount" abstract="false" name="IndemnificationAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch" abstract="false" name="StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_PercentageOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromSubsidiaries" abstract="false" name="PercentageOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromSubsidiaries" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="amed_ProviderReliefFundAdvance" abstract="false" name="ProviderReliefFundAdvance" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_ActualClaimsPayment" abstract="false" name="ActualClaimsPayment" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlockTableTextBlock" abstract="false" name="ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlockTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="amed_PersonalCareMember" abstract="true" name="PersonalCareMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amed_SecuritiesClassActionLawsuitMember" abstract="true" name="SecuritiesClassActionLawsuitMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amed_PayorsDomain" abstract="true" name="PayorsDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amed_HomeHealthMember" abstract="true" name="HomeHealthMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amed_SecuritiesClassActionLawsuitsettlement" abstract="false" name="SecuritiesClassActionLawsuitsettlement" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_RevolvingCreditFacilityTotal" abstract="false" name="RevolvingCreditFacilityTotal" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_CorporateIntegrityAgreementTerm" abstract="false" name="CorporateIntegrityAgreementTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="amed_DebtInstrumentInterestAdditionalInterestAboveEurodollarRate" abstract="false" name="DebtInstrumentInterestAdditionalInterestAboveEurodollarRate" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="amed_ErrorRatePercentage" abstract="false" name="ErrorRatePercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="amed_TotalCARESActProviderReliefFundsReceived" abstract="false" name="TotalCARESActProviderReliefFundsReceived" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_Creditfacilitymaximumallowableconsolidatedleverageratio" abstract="false" name="Creditfacilitymaximumallowableconsolidatedleverageratio" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="amed_HomeHealthNonMedicareEpisodicBasedMember" abstract="true" name="HomeHealthNonMedicareEpisodicBasedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amed_PercentageOfRevenueAndOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromWhollyOwnedSubsidiaries" abstract="false" name="PercentageOfRevenueAndOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromWhollyOwnedSubsidiaries" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="amed_PercentageOfTotalReimbursementOfOutlierPayment" abstract="false" name="PercentageOfTotalReimbursementOfOutlierPayment" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="amed_FundingImmediatelyDistributedToHealthcareProvidersBasedOnTheir2019MedicareFeeForServiceReimbursements" abstract="false" name="FundingImmediatelyDistributedToHealthcareProvidersBasedOnTheir2019MedicareFeeForServiceReimbursements" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_ProfessionalLiabilityInsuranceRetentionLimit" abstract="false" name="ProfessionalLiabilityInsuranceRetentionLimit" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_EstimatedCARESActProviderReliefFundsExpectedToBeUtilized" abstract="false" name="EstimatedCARESActProviderReliefFundsExpectedToBeUtilized" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_PercentageofSharesOutstanding" abstract="false" name="PercentageofSharesOutstanding" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="amed_AmendedDebtInstrumentByLeverageRatioTrancheOneMember" abstract="true" name="AmendedDebtInstrumentByLeverageRatioTrancheOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amed_ContessaHealthMember" abstract="true" name="ContessaHealthMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amed_FirstThresholdOfTherapyServicesRequired" abstract="false" name="FirstThresholdOfTherapyServicesRequired" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="amed_Numberofpatients" abstract="false" name="Numberofpatients" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="amed_OneHundredSeventyFiveMillionTermLoanFacilityMember" abstract="true" name="OneHundredSeventyFiveMillionTermLoanFacilityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amed_FourHundredFiftyMillionTermLoanFacilityMember" abstract="true" name="FourHundredFiftyMillionTermLoanFacilityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amed_PercentageOfPatientReceivablesOutstanding" abstract="false" name="PercentageOfPatientReceivablesOutstanding" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="amed_DebtInstrumentByLeverageRatioTrancheThreeMember" abstract="true" name="DebtInstrumentByLeverageRatioTrancheThreeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amed_LossContingencyReceivableNoncurrentRelatedToAmountsWithheldPriorToAugust2009" abstract="false" name="LossContingencyReceivableNoncurrentRelatedToAmountsWithheldPriorToAugust2009" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_AseraCareHospiceMember" abstract="true" name="AseraCareHospiceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amed_ReversalOfLossContingencyAccrual" abstract="false" name="ReversalOfLossContingencyAccrual" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentAssetsPrepaidExpense" abstract="false" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentAssetsPrepaidExpense" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" abstract="false" name="IncreaseDecreaseInOperatingLeaseRightOfUseAsset" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_AmendedCreditAgreementMember" abstract="true" name="AmendedCreditAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amed_EstimatedAmountDueBackToMedicareInOtherAccruedLiabilities" abstract="false" name="EstimatedAmountDueBackToMedicareInOtherAccruedLiabilities" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherCurrentAsset" abstract="false" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherCurrentAsset" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_PayorClassAxis" abstract="true" name="PayorClassAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="amed_RecoveryAmountOfOverpaymentMadeToSubsidiary" abstract="false" name="RecoveryAmountOfOverpaymentMadeToSubsidiary" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_EstimatedFutureCOVID19RelatedExpenses" abstract="false" name="EstimatedFutureCOVID19RelatedExpenses" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_SurrenderedShares" abstract="false" name="SurrenderedShares" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_FundingForHealthcareProvidersIncludingHospitals" abstract="false" name="FundingForHealthcareProvidersIncludingHospitals" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_COVID19TextBlock" abstract="false" name="COVID19TextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="amed_UsDepartmentOfJusticeMember" abstract="true" name="UsDepartmentOfJusticeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amed_EquityImpactOfWriteOffOfOtherComprehensiveIncome" abstract="false" name="EquityImpactOfWriteOffOfOtherComprehensiveIncome" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember" abstract="true" name="FiveHundredFiftyMillionRevolvingCreditFacilityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amed_CertificatesOfNeedMember" abstract="true" name="CertificatesOfNeedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amed_NetServiceRevenuePeriodOfCarePaymentRateDuration" abstract="false" name="NetServiceRevenuePeriodOfCarePaymentRateDuration" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="amed_MaximumPercentOwnershipForEquityMethodPercent" abstract="false" name="MaximumPercentOwnershipForEquityMethodPercent" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="amed_CARESActDeferralOfEmployerShareSocialSecurityTax" abstract="false" name="CARESActDeferralOfEmployerShareSocialSecurityTax" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_CompanysinsurancecarriersMember" abstract="true" name="CompanysinsurancecarriersMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amed_CARESActProviderReliefFundsUtilized" abstract="false" name="CARESActProviderReliefFundsUtilized" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingleaserightofuseassets" abstract="false" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingleaserightofuseassets" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_AsanaHospiceMember" abstract="true" name="AsanaHospiceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amed_ProceedsReceivedFromLoanPartyOfSubsidiary" abstract="false" name="ProceedsReceivedFromLoanPartyOfSubsidiary" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_CapYearTwoThousandSixteenThroughTwoThousandTwentyOneMember" abstract="true" name="CapYearTwoThousandSixteenThroughTwoThousandTwentyOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amed_Businessacquisitionproformaoperatingincomeloss" abstract="false" name="Businessacquisitionproformaoperatingincomeloss" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_LesseeOperatingleaseReductionstoROUassetsresultingfromreductionstoleaseobligations" abstract="false" name="LesseeOperatingleaseReductionstoROUassetsresultingfromreductionstoleaseobligations" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_ShareRepurchaseLineItems" abstract="true" name="ShareRepurchaseLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="amed_BusinessAcquisitionWorkingCapitalAdjustment" abstract="false" name="BusinessAcquisitionWorkingCapitalAdjustment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_CashPaidForOperatingLeaseLiabilities" abstract="false" name="CashPaidForOperatingLeaseLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_BusinessAcquisitionClosingPaymentAdjustment" abstract="false" name="BusinessAcquisitionClosingPaymentAdjustment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_RevenueAdjustmentToMedicareRevenue" abstract="false" name="RevenueAdjustmentToMedicareRevenue" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_ClearwaterFloridaMember" abstract="true" name="ClearwaterFloridaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amed_InternalAuditComplianceReviewMember" abstract="true" name="InternalAuditComplianceReviewMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amed_IncreaseInEstimatedFutureCOVID19RelatedExpenses" abstract="false" name="IncreaseInEstimatedFutureCOVID19RelatedExpenses" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_EpisodeOfCareAsEpisodicBasedRevenueDuration" abstract="false" name="EpisodeOfCareAsEpisodicBasedRevenueDuration" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="amed_MorgantownWestVirginiaMember" abstract="true" name="MorgantownWestVirginiaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingLeaseLiabilities" abstract="false" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingLeaseLiabilities" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_CashDistributionToNoncontrollingInterest" abstract="false" name="CashDistributionToNoncontrollingInterest" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_CreditFacilityMaximumAllowableConsolidatedLeverageRatioMultiple" abstract="false" name="CreditFacilityMaximumAllowableConsolidatedLeverageRatioMultiple" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="amed_MedalogixMember" abstract="true" name="MedalogixMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amed_ConsolidatedLeverageRatio" abstract="false" name="ConsolidatedLeverageRatio" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="amed_PeriodOfCareAsEpisodicBasedRevenueDuration" abstract="false" name="PeriodOfCareAsEpisodicBasedRevenueDuration" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="amed_LakelandFloridaMember" abstract="true" name="LakelandFloridaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amed_CARESActProviderReliefFundsReceivedByUnconsolidatedJointVentures" abstract="false" name="CARESActProviderReliefFundsReceivedByUnconsolidatedJointVentures" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_NonMedicareRevenueTermRates" abstract="false" name="NonMedicareRevenueTermRates" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="amed_RecoveryAmountOfOverpaymentMadeToSubsidiaryIncludingInterest" abstract="false" name="RecoveryAmountOfOverpaymentMadeToSubsidiaryIncludingInterest" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_CapYearTwoThousandFourteenThroughTwoThousandTwentyOneMember" abstract="true" name="CapYearTwoThousandFourteenThroughTwoThousandTwentyOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amed_AccountsReceivablePortionDerivedFromMedicare" abstract="false" name="AccountsReceivablePortionDerivedFromMedicare" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesPayrollandEmployeeBenefits" abstract="false" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesPayrollandEmployeeBenefits" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>7
<FILENAME>amed-20210630_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:9b598574-bbed-4d17-bc5e-2b8ec86d1c16,g:311e4854-6196-49e6-97c5-f444b0264a32-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="amed-20210630.xsd#CONSOLIDATEDBALANCESHEETS"/>
  <link:calculationLink xlink:role="http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_c7541dd9-f316-4f41-8c94-677223fe2fe3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_be0caea0-4c6f-43d3-9e1f-ed1fe3f419d0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_c7541dd9-f316-4f41-8c94-677223fe2fe3" xlink:to="loc_us-gaap_AccountsPayableCurrent_be0caea0-4c6f-43d3-9e1f-ed1fe3f419d0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_f1f93746-b07d-4c86-8e1d-f3706fb4e1e1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_c7541dd9-f316-4f41-8c94-677223fe2fe3" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_f1f93746-b07d-4c86-8e1d-f3706fb4e1e1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_7aa72bfe-9e25-41ec-a656-f88679410304" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_c7541dd9-f316-4f41-8c94-677223fe2fe3" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_7aa72bfe-9e25-41ec-a656-f88679410304" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ProviderReliefFundAdvance_b0fc1ae8-25a6-4336-9e1f-2f1b11e42785" xlink:href="amed-20210630.xsd#amed_ProviderReliefFundAdvance"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_c7541dd9-f316-4f41-8c94-677223fe2fe3" xlink:to="loc_amed_ProviderReliefFundAdvance_b0fc1ae8-25a6-4336-9e1f-2f1b11e42785" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_e9791b40-005c-4f4f-ad52-6ce6c9ecbea1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_c7541dd9-f316-4f41-8c94-677223fe2fe3" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_e9791b40-005c-4f4f-ad52-6ce6c9ecbea1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_6f516837-d35a-40a7-865d-31aa7efd0ba2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_c7541dd9-f316-4f41-8c94-677223fe2fe3" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_6f516837-d35a-40a7-865d-31aa7efd0ba2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_8a27f2cd-b249-4c1a-9acb-0f4305a9490f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_8d238d06-9b20-4854-bd3c-c77eb695d53f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_8a27f2cd-b249-4c1a-9acb-0f4305a9490f" xlink:to="loc_us-gaap_Liabilities_8d238d06-9b20-4854-bd3c-c77eb695d53f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_0821f95a-5018-4a6e-952e-d5d7a0a164df" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_8a27f2cd-b249-4c1a-9acb-0f4305a9490f" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_0821f95a-5018-4a6e-952e-d5d7a0a164df" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_924b3cf2-e50e-4770-9e64-2b2b46c59ef3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_11a7f9aa-7e27-43d1-a20d-91857c66bd04" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_924b3cf2-e50e-4770-9e64-2b2b46c59ef3" xlink:to="loc_us-gaap_AssetsCurrent_11a7f9aa-7e27-43d1-a20d-91857c66bd04" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_5fab812b-9da6-44be-a9db-d58351bc782e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_924b3cf2-e50e-4770-9e64-2b2b46c59ef3" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_5fab812b-9da6-44be-a9db-d58351bc782e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_854fafed-4e51-4b0e-90bf-2c58727ff3b8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_924b3cf2-e50e-4770-9e64-2b2b46c59ef3" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_854fafed-4e51-4b0e-90bf-2c58727ff3b8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_60e8a6eb-1c9c-49f5-80a7-458751d68221" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_924b3cf2-e50e-4770-9e64-2b2b46c59ef3" xlink:to="loc_us-gaap_Goodwill_60e8a6eb-1c9c-49f5-80a7-458751d68221" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_473761d9-14aa-4088-b7dc-471699cad35f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_924b3cf2-e50e-4770-9e64-2b2b46c59ef3" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_473761d9-14aa-4088-b7dc-471699cad35f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_50d8c7de-95b4-4d50-b96f-2afea8797f59" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_924b3cf2-e50e-4770-9e64-2b2b46c59ef3" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet_50d8c7de-95b4-4d50-b96f-2afea8797f59" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_6f04fd49-540a-4c57-bfdb-1ef2d3d71ece" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_924b3cf2-e50e-4770-9e64-2b2b46c59ef3" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_6f04fd49-540a-4c57-bfdb-1ef2d3d71ece" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_499e93a2-6a00-4376-b404-43b1b4487663" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_41d3ea0b-2fd3-402f-99ed-6028104a04f9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_499e93a2-6a00-4376-b404-43b1b4487663" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_41d3ea0b-2fd3-402f-99ed-6028104a04f9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCash_b8c82c3e-2299-4828-897d-63ccbf7d1ddb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCash"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_499e93a2-6a00-4376-b404-43b1b4487663" xlink:to="loc_us-gaap_RestrictedCash_b8c82c3e-2299-4828-897d-63ccbf7d1ddb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_d629d583-6f33-4bec-819b-50f3abb20abe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_499e93a2-6a00-4376-b404-43b1b4487663" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_d629d583-6f33-4bec-819b-50f3abb20abe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_ae1728fe-1368-4afe-805a-f3422ba1545c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_499e93a2-6a00-4376-b404-43b1b4487663" xlink:to="loc_us-gaap_PrepaidExpenseCurrent_ae1728fe-1368-4afe-805a-f3422ba1545c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_ff2dd075-46ee-481c-9a13-34ee1a12aa5d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_499e93a2-6a00-4376-b404-43b1b4487663" xlink:to="loc_us-gaap_OtherAssetsCurrent_ff2dd075-46ee-481c-9a13-34ee1a12aa5d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_cdbd223c-a743-476d-8144-e7565e561938" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_6181240e-718f-4d72-92e7-6c842564c5a8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_cdbd223c-a743-476d-8144-e7565e561938" xlink:to="loc_us-gaap_LiabilitiesCurrent_6181240e-718f-4d72-92e7-6c842564c5a8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_0518badd-dba3-4954-92fe-aeb2085d9d13" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligations"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_cdbd223c-a743-476d-8144-e7565e561938" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_0518badd-dba3-4954-92fe-aeb2085d9d13" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_51a56e22-1286-42ca-838d-235718e04066" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_cdbd223c-a743-476d-8144-e7565e561938" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_51a56e22-1286-42ca-838d-235718e04066" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_e3655a78-7cf6-4e8c-900f-1837ddc07a92" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_cdbd223c-a743-476d-8144-e7565e561938" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_e3655a78-7cf6-4e8c-900f-1837ddc07a92" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_149cefe0-d438-4106-8678-592f7c343f25" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValueOutstanding_2f3cfcb7-822c-4d69-972d-94e1985cd204" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValueOutstanding"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_149cefe0-d438-4106-8678-592f7c343f25" xlink:to="loc_us-gaap_PreferredStockValueOutstanding_2f3cfcb7-822c-4d69-972d-94e1985cd204" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValueOutstanding_0c5cb0b9-2cd1-4c95-acf6-d6e22ad985b4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValueOutstanding"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_149cefe0-d438-4106-8678-592f7c343f25" xlink:to="loc_us-gaap_CommonStockValueOutstanding_0c5cb0b9-2cd1-4c95-acf6-d6e22ad985b4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_fd0320db-3ed6-4cae-8495-cbd3795d4804" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_149cefe0-d438-4106-8678-592f7c343f25" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_fd0320db-3ed6-4cae-8495-cbd3795d4804" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue_1ad648fe-0fed-4c37-97cd-0107151d02a5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockValue"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_149cefe0-d438-4106-8678-592f7c343f25" xlink:to="loc_us-gaap_TreasuryStockValue_1ad648fe-0fed-4c37-97cd-0107151d02a5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_94bca789-bb0d-4d4c-ab7a-c02be9221f0b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_149cefe0-d438-4106-8678-592f7c343f25" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_94bca789-bb0d-4d4c-ab7a-c02be9221f0b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_1495c9ee-6e2b-499e-ac46-0e65645fe199" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_9afbd7ef-7c43-4c93-85cc-cd71d298c7dc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_1495c9ee-6e2b-499e-ac46-0e65645fe199" xlink:to="loc_us-gaap_StockholdersEquity_9afbd7ef-7c43-4c93-85cc-cd71d298c7dc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_5b8390e0-f8f0-43ea-84fb-08ab11201b5b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_1495c9ee-6e2b-499e-ac46-0e65645fe199" xlink:to="loc_us-gaap_MinorityInterest_5b8390e0-f8f0-43ea-84fb-08ab11201b5b" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="simple" xlink:href="amed-20210630.xsd#CONSOLIDATEDSTATEMENTSOFOPERATIONS"/>
  <link:calculationLink xlink:role="http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_d4b226d0-b60a-4e86-9191-799e131a29f0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions_8a860f2a-fbec-48f4-8045-5efd6ae510b0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_d4b226d0-b60a-4e86-9191-799e131a29f0" xlink:to="loc_us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions_8a860f2a-fbec-48f4-8045-5efd6ae510b0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncome_9db2e1ab-40c6-4663-bfb9-fd78816f36e9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherOperatingIncome"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_d4b226d0-b60a-4e86-9191-799e131a29f0" xlink:to="loc_us-gaap_OtherOperatingIncome_9db2e1ab-40c6-4663-bfb9-fd78816f36e9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_01570297-ad87-4eba-9d34-1c85a3fd0fdb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_d4b226d0-b60a-4e86-9191-799e131a29f0" xlink:to="loc_us-gaap_CostsAndExpenses_01570297-ad87-4eba-9d34-1c85a3fd0fdb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_02cbff5d-3b89-47d6-b281-cfc89dea0408" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_fdd86bda-fd5a-447f-8666-5c126e0a56c7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_02cbff5d-3b89-47d6-b281-cfc89dea0408" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_fdd86bda-fd5a-447f-8666-5c126e0a56c7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LaborAndRelatedExpense_514bd871-e2ad-477e-a7ea-3b34dc4ebdf2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LaborAndRelatedExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_02cbff5d-3b89-47d6-b281-cfc89dea0408" xlink:to="loc_us-gaap_LaborAndRelatedExpense_514bd871-e2ad-477e-a7ea-3b34dc4ebdf2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_80260c26-5f57-49c1-baf3-30acf226e50b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_02cbff5d-3b89-47d6-b281-cfc89dea0408" xlink:to="loc_us-gaap_ShareBasedCompensation_80260c26-5f57-49c1-baf3-30acf226e50b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherGeneralAndAdministrativeExpense_3980b715-2337-485b-94a3-54d2c5f332e7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherGeneralAndAdministrativeExpense"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_02cbff5d-3b89-47d6-b281-cfc89dea0408" xlink:to="loc_us-gaap_OtherGeneralAndAdministrativeExpense_3980b715-2337-485b-94a3-54d2c5f332e7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization_172ad608-d12e-4d21-8274-55c9de0d2be6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_02cbff5d-3b89-47d6-b281-cfc89dea0408" xlink:to="loc_us-gaap_DepreciationAndAmortization_172ad608-d12e-4d21-8274-55c9de0d2be6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_42acba39-11be-47ce-8817-d97ca880474d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_2cd2fb80-3b80-419b-a6f3-3b5acf4233e4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_42acba39-11be-47ce-8817-d97ca880474d" xlink:to="loc_us-gaap_OperatingIncomeLoss_2cd2fb80-3b80-419b-a6f3-3b5acf4233e4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_7b5cac83-7623-4d5b-8d3c-ec433a9521fb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_42acba39-11be-47ce-8817-d97ca880474d" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_7b5cac83-7623-4d5b-8d3c-ec433a9521fb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_82f804c6-45c7-4068-aff3-4206eb80a210" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_6ee5ac9b-6060-4569-94f0-21e84d167628" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_82f804c6-45c7-4068-aff3-4206eb80a210" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_6ee5ac9b-6060-4569-94f0-21e84d167628" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_d38b46dd-3ae2-4a16-a927-3c00978c0df3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_82f804c6-45c7-4068-aff3-4206eb80a210" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_d38b46dd-3ae2-4a16-a927-3c00978c0df3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_455e3ef5-3108-4809-b1c6-07757074e873" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterestAndDividend_d4d4dd63-41f1-4040-bd82-91412c1abec3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeInterestAndDividend"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_455e3ef5-3108-4809-b1c6-07757074e873" xlink:to="loc_us-gaap_InvestmentIncomeInterestAndDividend_d4d4dd63-41f1-4040-bd82-91412c1abec3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_a2e19f30-5bcb-4718-8dee-7eceaf16d33c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_455e3ef5-3108-4809-b1c6-07757074e873" xlink:to="loc_us-gaap_InterestExpense_a2e19f30-5bcb-4718-8dee-7eceaf16d33c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_8393bdce-d734-4e57-82ee-a8b89f5cda10" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_455e3ef5-3108-4809-b1c6-07757074e873" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_8393bdce-d734-4e57-82ee-a8b89f5cda10" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnInvestments_2c4245be-eae1-4812-b3be-b6bb427344ac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnInvestments"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_455e3ef5-3108-4809-b1c6-07757074e873" xlink:to="loc_us-gaap_GainLossOnInvestments_2c4245be-eae1-4812-b3be-b6bb427344ac" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_5cd4e4f4-c86c-4e81-a3eb-efeca85f74b8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_455e3ef5-3108-4809-b1c6-07757074e873" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_5cd4e4f4-c86c-4e81-a3eb-efeca85f74b8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_7347d870-ef2e-4c8d-8898-ff04dacf3372" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_082e789a-b2e6-4301-902e-312c5d66fad5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_7347d870-ef2e-4c8d-8898-ff04dacf3372" xlink:to="loc_us-gaap_ProfitLoss_082e789a-b2e6-4301-902e-312c5d66fad5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_1ff9f54d-719c-4abd-866c-25c5b5444fc4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_7347d870-ef2e-4c8d-8898-ff04dacf3372" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_1ff9f54d-719c-4abd-866c-25c5b5444fc4" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="amed-20210630.xsd#CONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:calculationLink xlink:role="http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_b831ead5-2274-4171-936d-55405d43d839" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_fc055980-d326-4d90-ba69-ac78354ceaf5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_b831ead5-2274-4171-936d-55405d43d839" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_fc055980-d326-4d90-ba69-ac78354ceaf5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockPlans_00bda992-fef3-427a-be50-5b8093041692" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockPlans"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_b831ead5-2274-4171-936d-55405d43d839" xlink:to="loc_us-gaap_ProceedsFromStockPlans_00bda992-fef3-427a-be50-5b8093041692" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_1e29b32d-2dcf-4d54-82b9-107cdba0f3e5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_b831ead5-2274-4171-936d-55405d43d839" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_1e29b32d-2dcf-4d54-82b9-107cdba0f3e5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CashDistributionToNoncontrollingInterest_eabcf74e-b398-44af-85e5-50054b85bb6b" xlink:href="amed-20210630.xsd#amed_CashDistributionToNoncontrollingInterest"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_b831ead5-2274-4171-936d-55405d43d839" xlink:to="loc_amed_CashDistributionToNoncontrollingInterest_eabcf74e-b398-44af-85e5-50054b85bb6b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromShortTermDebt_97be8102-0a60-40ba-b328-5d3a2af61357" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromShortTermDebt"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_b831ead5-2274-4171-936d-55405d43d839" xlink:to="loc_us-gaap_ProceedsFromShortTermDebt_97be8102-0a60-40ba-b328-5d3a2af61357" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfShortTermDebt_46007718-dafb-491a-87bf-c26cf47572d1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfShortTermDebt"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_b831ead5-2274-4171-936d-55405d43d839" xlink:to="loc_us-gaap_RepaymentsOfShortTermDebt_46007718-dafb-491a-87bf-c26cf47572d1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_45833916-7ba0-40b1-b4aa-a4f801a426a5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_b831ead5-2274-4171-936d-55405d43d839" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_45833916-7ba0-40b1-b4aa-a4f801a426a5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_FundsReceivedFromProviderReliefFundAdvance_61475abe-981f-4c35-b0a9-eebcad35c5f8" xlink:href="amed-20210630.xsd#amed_FundsReceivedFromProviderReliefFundAdvance"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_b831ead5-2274-4171-936d-55405d43d839" xlink:to="loc_amed_FundsReceivedFromProviderReliefFundAdvance_61475abe-981f-4c35-b0a9-eebcad35c5f8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_c26f7da2-c21d-4408-893e-b2a521df6edc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_b831ead5-2274-4171-936d-55405d43d839" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_c26f7da2-c21d-4408-893e-b2a521df6edc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_64b0031b-ccd1-4836-ad4b-ec2378e648e8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_640d790f-ea9e-4aab-834d-5734ae504910" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_64b0031b-ccd1-4836-ad4b-ec2378e648e8" xlink:to="loc_us-gaap_ProfitLoss_640d790f-ea9e-4aab-834d-5734ae504910" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_9f7876a1-dabd-4bdb-b0ed-33aa88a19a8e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_64b0031b-ccd1-4836-ad4b-ec2378e648e8" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_9f7876a1-dabd-4bdb-b0ed-33aa88a19a8e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_a473ce4d-cf17-42c1-b939-297f56279d84" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_64b0031b-ccd1-4836-ad4b-ec2378e648e8" xlink:to="loc_us-gaap_ShareBasedCompensation_a473ce4d-cf17-42c1-b939-297f56279d84" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AmortizationandImpairmentofOperatingLeaseRightOfUseAsset_76f16678-d617-4215-acdb-751d658ea1cd" xlink:href="amed-20210630.xsd#amed_AmortizationandImpairmentofOperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_64b0031b-ccd1-4836-ad4b-ec2378e648e8" xlink:to="loc_amed_AmortizationandImpairmentofOperatingLeaseRightOfUseAsset_76f16678-d617-4215-acdb-751d658ea1cd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_ebd0b1a9-025d-4a17-a590-89bdb449eb23" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_64b0031b-ccd1-4836-ad4b-ec2378e648e8" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_ebd0b1a9-025d-4a17-a590-89bdb449eb23" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfInvestments_31c90fec-3e0e-41c4-be4b-b19258998108" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnSaleOfInvestments"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_64b0031b-ccd1-4836-ad4b-ec2378e648e8" xlink:to="loc_us-gaap_GainLossOnSaleOfInvestments_31c90fec-3e0e-41c4-be4b-b19258998108" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_WriteOffOfOtherComprehensiveIncome_0052b50b-2669-4c71-80fd-88291227ac11" xlink:href="amed-20210630.xsd#amed_WriteOffOfOtherComprehensiveIncome"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_64b0031b-ccd1-4836-ad4b-ec2378e648e8" xlink:to="loc_amed_WriteOffOfOtherComprehensiveIncome_0052b50b-2669-4c71-80fd-88291227ac11" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_85d2a4bd-f6c5-4748-ae30-0b1e155d6e16" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_64b0031b-ccd1-4836-ad4b-ec2378e648e8" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_85d2a4bd-f6c5-4748-ae30-0b1e155d6e16" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_d61297bd-b420-46a5-b98d-845c30a454f2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_64b0031b-ccd1-4836-ad4b-ec2378e648e8" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_d61297bd-b420-46a5-b98d-845c30a454f2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_cb259305-2c51-4ccb-aaa4-7af1e8ef542b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_64b0031b-ccd1-4836-ad4b-ec2378e648e8" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_cb259305-2c51-4ccb-aaa4-7af1e8ef542b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentDividendsOrDistributions_911a4639-395e-4973-8678-5b90650ee022" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentDividendsOrDistributions"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_64b0031b-ccd1-4836-ad4b-ec2378e648e8" xlink:to="loc_us-gaap_EquityMethodInvestmentDividendsOrDistributions_911a4639-395e-4973-8678-5b90650ee022" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_834b46b2-9e0f-4993-9955-3d8205fe2b7a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="12" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_64b0031b-ccd1-4836-ad4b-ec2378e648e8" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_834b46b2-9e0f-4993-9955-3d8205fe2b7a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_af1eb45a-dfa6-45ef-9cd3-62598739a1f4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="13" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_64b0031b-ccd1-4836-ad4b-ec2378e648e8" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_af1eb45a-dfa6-45ef-9cd3-62598739a1f4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_20587ec2-6986-4c4e-8146-1c419d2b3baf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:calculationArc order="14" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_64b0031b-ccd1-4836-ad4b-ec2378e648e8" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_20587ec2-6986-4c4e-8146-1c419d2b3baf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_c6b07b0d-2699-4c0e-ab9e-4c970ab61a2c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:calculationArc order="15" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_64b0031b-ccd1-4836-ad4b-ec2378e648e8" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_c6b07b0d-2699-4c0e-ab9e-4c970ab61a2c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_90da70f4-7449-4669-bea7-9cedc7d3e0a9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:calculationArc order="16" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_64b0031b-ccd1-4836-ad4b-ec2378e648e8" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_90da70f4-7449-4669-bea7-9cedc7d3e0a9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_d551ef73-8222-4b0b-a9f0-ed14f568d41d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities"/>
    <link:calculationArc order="17" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_64b0031b-ccd1-4836-ad4b-ec2378e648e8" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_d551ef73-8222-4b0b-a9f0-ed14f568d41d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_IncreaseDecreaseInOperatingLeaseLiability_155a38a2-18b7-42f5-bef6-fe843f359dcc" xlink:href="amed-20210630.xsd#amed_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:calculationArc order="18" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_64b0031b-ccd1-4836-ad4b-ec2378e648e8" xlink:to="loc_amed_IncreaseDecreaseInOperatingLeaseLiability_155a38a2-18b7-42f5-bef6-fe843f359dcc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_e48c7df8-bf6a-4958-9c1f-644b545fa996" xlink:href="amed-20210630.xsd#amed_IncreaseDecreaseInOperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="19" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_64b0031b-ccd1-4836-ad4b-ec2378e648e8" xlink:to="loc_amed_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_e48c7df8-bf6a-4958-9c1f-644b545fa996" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_43c485f9-2dc6-4dbc-a02a-a505e3446b18" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfRestrictedInvestments_33bbb5d6-321c-4c2e-be9e-f7d36160153a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleOfRestrictedInvestments"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_43c485f9-2dc6-4dbc-a02a-a505e3446b18" xlink:to="loc_us-gaap_ProceedsFromSaleOfRestrictedInvestments_33bbb5d6-321c-4c2e-be9e-f7d36160153a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_01fc46cc-77e6-41ab-a936-c9a2049651ec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_43c485f9-2dc6-4dbc-a02a-a505e3446b18" xlink:to="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_01fc46cc-77e6-41ab-a936-c9a2049651ec" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_1c9854aa-2d3b-4508-8a7f-7a8e54469357" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_43c485f9-2dc6-4dbc-a02a-a505e3446b18" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_1c9854aa-2d3b-4508-8a7f-7a8e54469357" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments_845f225e-d205-4c5c-b370-074aeec162e4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireInvestments"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_43c485f9-2dc6-4dbc-a02a-a505e3446b18" xlink:to="loc_us-gaap_PaymentsToAcquireInvestments_845f225e-d205-4c5c-b370-074aeec162e4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfEquityMethodInvestments_28f9d16b-2821-41a8-93d9-5444ab4e41fc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleOfEquityMethodInvestments"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_43c485f9-2dc6-4dbc-a02a-a505e3446b18" xlink:to="loc_us-gaap_ProceedsFromSaleOfEquityMethodInvestments_28f9d16b-2821-41a8-93d9-5444ab4e41fc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_16a8fa38-d7fc-4416-a3bc-6a2ce2a6c652" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_43c485f9-2dc6-4dbc-a02a-a505e3446b18" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_16a8fa38-d7fc-4416-a3bc-6a2ce2a6c652" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_748956a9-ec6b-4da3-bf75-df24bcdbdb0a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6ceaee74-2265-4d83-9104-ebac8f6ff35b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_748956a9-ec6b-4da3-bf75-df24bcdbdb0a" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6ceaee74-2265-4d83-9104-ebac8f6ff35b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_c0cf57f1-a222-4734-a2bc-676d594f84bd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_748956a9-ec6b-4da3-bf75-df24bcdbdb0a" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_c0cf57f1-a222-4734-a2bc-676d594f84bd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_35767135-5cd5-4c7d-ad5e-0eebb706a167" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_748956a9-ec6b-4da3-bf75-df24bcdbdb0a" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_35767135-5cd5-4c7d-ad5e-0eebb706a167" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESWeightedAverageSharesOutstandingDetails" xlink:type="simple" xlink:href="amed-20210630.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESWeightedAverageSharesOutstandingDetails"/>
  <link:calculationLink xlink:role="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESWeightedAverageSharesOutstandingDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_02c337fe-798f-4bfe-8b24-51c3990eafd3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_4761de13-bef1-46d1-a329-2f55f2827ac2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_02c337fe-798f-4bfe-8b24-51c3990eafd3" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_4761de13-bef1-46d1-a329-2f55f2827ac2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_0c12325d-cdbb-44b3-af0e-136ad745fa37" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_02c337fe-798f-4bfe-8b24-51c3990eafd3" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_0c12325d-cdbb-44b3-af0e-136ad745fa37" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_NonVestedStockAndStockUnits_c2ddacc2-ac14-4b4c-a67b-b6cdc969c059" xlink:href="amed-20210630.xsd#amed_NonVestedStockAndStockUnits"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_02c337fe-798f-4bfe-8b24-51c3990eafd3" xlink:to="loc_amed_NonVestedStockAndStockUnits_c2ddacc2-ac14-4b4c-a67b-b6cdc969c059" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtDetails" xlink:type="simple" xlink:href="amed-20210630.xsd#LONGTERMOBLIGATIONSScheduleofLongTermDebtDetails"/>
  <link:calculationLink xlink:role="http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_d629b496-7afb-4cfd-9c0e-61206372dd97" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_94fca875-96b5-4f7f-b162-60a030502775" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_d629b496-7afb-4cfd-9c0e-61206372dd97" xlink:to="loc_us-gaap_LongTermDebtCurrent_94fca875-96b5-4f7f-b162-60a030502775" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_1cf155c9-f745-410e-9b4e-2a9b2fe96ef4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_d629b496-7afb-4cfd-9c0e-61206372dd97" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_1cf155c9-f745-410e-9b4e-2a9b2fe96ef4" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtDetails_1" xlink:type="simple" xlink:href="amed-20210630.xsd#LONGTERMOBLIGATIONSScheduleofLongTermDebtDetails_1"/>
  <link:calculationLink xlink:role="http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_b87ebcfa-789a-4c2c-9aab-176f0ea733d1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_58b513ba-1565-40a1-b9ec-6602b5fa3977" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_b87ebcfa-789a-4c2c-9aab-176f0ea733d1" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_58b513ba-1565-40a1-b9ec-6602b5fa3977" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_c5df8c0f-dc77-4843-a247-66165a75fc74" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_b87ebcfa-789a-4c2c-9aab-176f0ea733d1" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_c5df8c0f-dc77-4843-a247-66165a75fc74" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>8
<FILENAME>amed-20210630_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:9b598574-bbed-4d17-bc5e-2b8ec86d1c16,g:311e4854-6196-49e6-97c5-f444b0264a32-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYStatement" xlink:type="simple" xlink:href="amed-20210630.xsd#CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYStatement"/>
  <link:definitionLink xlink:role="http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYStatement" xlink:type="extended" id="i1421806ad84044ca9b121b9fc4eb928f_CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYStatement">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_e2440b55-eae7-49dc-a6e8-bb7a76d888df" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_3ac29b36-75e2-40dd-a339-6f54aa7edbf3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_e2440b55-eae7-49dc-a6e8-bb7a76d888df" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_3ac29b36-75e2-40dd-a339-6f54aa7edbf3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_b5324eba-8647-4e83-a883-ba67f09b1c05" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_e2440b55-eae7-49dc-a6e8-bb7a76d888df" xlink:to="loc_us-gaap_SharesOutstanding_b5324eba-8647-4e83-a883-ba67f09b1c05" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_de2da58c-8fa7-4d64-b9f3-27b4e576f43e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_e2440b55-eae7-49dc-a6e8-bb7a76d888df" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_de2da58c-8fa7-4d64-b9f3-27b4e576f43e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_d6b6a2c1-6f0a-4828-8e50-002a66ddd69b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_e2440b55-eae7-49dc-a6e8-bb7a76d888df" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_d6b6a2c1-6f0a-4828-8e50-002a66ddd69b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch_f5508ace-0463-4eca-9511-7ab5908c84df" xlink:href="amed-20210630.xsd#amed_StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_e2440b55-eae7-49dc-a6e8-bb7a76d888df" xlink:to="loc_amed_StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch_f5508ace-0463-4eca-9511-7ab5908c84df" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_StockIssuedDuringPeriodSharesFourZeroOneKEmployerMatch_daf0920d-955c-42f3-9209-29b8e4aff374" xlink:href="amed-20210630.xsd#amed_StockIssuedDuringPeriodSharesFourZeroOneKEmployerMatch"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_e2440b55-eae7-49dc-a6e8-bb7a76d888df" xlink:to="loc_amed_StockIssuedDuringPeriodSharesFourZeroOneKEmployerMatch_daf0920d-955c-42f3-9209-29b8e4aff374" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_126ac6e2-4742-4a46-a23d-fa1cc88a6e54" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_e2440b55-eae7-49dc-a6e8-bb7a76d888df" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_126ac6e2-4742-4a46-a23d-fa1cc88a6e54" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_5ac1f792-f22b-4728-ae4c-bfdbbbf0299d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_e2440b55-eae7-49dc-a6e8-bb7a76d888df" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_5ac1f792-f22b-4728-ae4c-bfdbbbf0299d" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_2cb2289a-791b-4105-ab62-57f4fd8088a5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_e2440b55-eae7-49dc-a6e8-bb7a76d888df" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_2cb2289a-791b-4105-ab62-57f4fd8088a5" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_4142c8c2-d775-4b7f-9d7a-462c5f7dd06b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_e2440b55-eae7-49dc-a6e8-bb7a76d888df" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_4142c8c2-d775-4b7f-9d7a-462c5f7dd06b" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_b3dd11d2-7ae9-4e02-9019-7e2aab7b8c36" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_e2440b55-eae7-49dc-a6e8-bb7a76d888df" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_b3dd11d2-7ae9-4e02-9019-7e2aab7b8c36" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_SurrenderedShares_7f5966d6-c065-4675-897c-b611ffc6f658" xlink:href="amed-20210630.xsd#amed_SurrenderedShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_e2440b55-eae7-49dc-a6e8-bb7a76d888df" xlink:to="loc_amed_SurrenderedShares_7f5966d6-c065-4675-897c-b611ffc6f658" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_7f0005b9-bb0d-4a5f-bc1f-207698d61208" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_e2440b55-eae7-49dc-a6e8-bb7a76d888df" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_7f0005b9-bb0d-4a5f-bc1f-207698d61208" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_0c27d923-c937-44e7-91f3-bc1d3e633242" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_e2440b55-eae7-49dc-a6e8-bb7a76d888df" xlink:to="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_0c27d923-c937-44e7-91f3-bc1d3e633242" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_EquityImpactofRepurchaseofNoncontrollingInterest_04120da8-0c07-4217-aa91-4b7c05bffdab" xlink:href="amed-20210630.xsd#amed_EquityImpactofRepurchaseofNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_e2440b55-eae7-49dc-a6e8-bb7a76d888df" xlink:to="loc_amed_EquityImpactofRepurchaseofNoncontrollingInterest_04120da8-0c07-4217-aa91-4b7c05bffdab" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_EquityImpactOfWriteOffOfOtherComprehensiveIncome_4fe69a45-c684-4438-8c74-9bf7a899dc1e" xlink:href="amed-20210630.xsd#amed_EquityImpactOfWriteOffOfOtherComprehensiveIncome"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_e2440b55-eae7-49dc-a6e8-bb7a76d888df" xlink:to="loc_amed_EquityImpactOfWriteOffOfOtherComprehensiveIncome_4fe69a45-c684-4438-8c74-9bf7a899dc1e" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_d9ed6111-f800-4a5d-9e74-2e11be2d2cca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_e2440b55-eae7-49dc-a6e8-bb7a76d888df" xlink:to="loc_us-gaap_ProfitLoss_d9ed6111-f800-4a5d-9e74-2e11be2d2cca" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_a60d1fa5-63d6-4dc7-9679-fbf9729114d0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_c6952e66-fe3f-45e1-b386-85a470e29a19" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_31fa1865-946a-4494-ac59-c042aa72169c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_e2440b55-eae7-49dc-a6e8-bb7a76d888df" xlink:to="loc_us-gaap_StatementTable_31fa1865-946a-4494-ac59-c042aa72169c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_308a2f73-d2b3-4223-8bbf-112bb2875d7f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_31fa1865-946a-4494-ac59-c042aa72169c" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_308a2f73-d2b3-4223-8bbf-112bb2875d7f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_308a2f73-d2b3-4223-8bbf-112bb2875d7f_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_308a2f73-d2b3-4223-8bbf-112bb2875d7f" xlink:to="loc_us-gaap_EquityComponentDomain_308a2f73-d2b3-4223-8bbf-112bb2875d7f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_8f83fde8-8980-4879-a26b-00e9ea31e6bd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_308a2f73-d2b3-4223-8bbf-112bb2875d7f" xlink:to="loc_us-gaap_EquityComponentDomain_8f83fde8-8980-4879-a26b-00e9ea31e6bd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_c1221614-43f6-42cc-93f9-f944d145028e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_8f83fde8-8980-4879-a26b-00e9ea31e6bd" xlink:to="loc_us-gaap_CommonStockMember_c1221614-43f6-42cc-93f9-f944d145028e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_bd5507a9-8567-4ce0-9dc7-b235730a1b2c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_8f83fde8-8980-4879-a26b-00e9ea31e6bd" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_bd5507a9-8567-4ce0-9dc7-b235730a1b2c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember_94deeb95-b6bb-4828-b680-be5ff8b28583" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_8f83fde8-8980-4879-a26b-00e9ea31e6bd" xlink:to="loc_us-gaap_TreasuryStockMember_94deeb95-b6bb-4828-b680-be5ff8b28583" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_02ec7b21-7a82-4bde-a1fb-c54b53edfb30" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_8f83fde8-8980-4879-a26b-00e9ea31e6bd" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_02ec7b21-7a82-4bde-a1fb-c54b53edfb30" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_981989e9-99af-4651-85a7-0f3c301f70be" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_8f83fde8-8980-4879-a26b-00e9ea31e6bd" xlink:to="loc_us-gaap_RetainedEarningsMember_981989e9-99af-4651-85a7-0f3c301f70be" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_a5f6343f-e6e3-43e1-8537-cdd68deacf68" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_8f83fde8-8980-4879-a26b-00e9ea31e6bd" xlink:to="loc_us-gaap_NoncontrollingInterestMember_a5f6343f-e6e3-43e1-8537-cdd68deacf68" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AociAttributableToNoncontrollingInterestMember_1fd955d7-2393-41d1-847d-cb841330a187" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AociAttributableToNoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_8f83fde8-8980-4879-a26b-00e9ea31e6bd" xlink:to="loc_us-gaap_AociAttributableToNoncontrollingInterestMember_1fd955d7-2393-41d1-847d-cb841330a187" xlink:type="arc" order="6"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails" xlink:type="simple" xlink:href="amed-20210630.xsd#NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails" xlink:type="extended" id="i0c98b4fd349a4c37bc68c4cd26c8f080_NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_8bfbbd74-cc2b-4f58-9b14-07eef305c05b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_33721f69-9544-4f2b-adce-8da98f8144b0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_8bfbbd74-cc2b-4f58-9b14-07eef305c05b" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_33721f69-9544-4f2b-adce-8da98f8144b0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_OperatingCareCenters_64810bf1-21da-4cc2-a43f-2c1ef946c917" xlink:href="amed-20210630.xsd#amed_OperatingCareCenters"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_8bfbbd74-cc2b-4f58-9b14-07eef305c05b" xlink:to="loc_amed_OperatingCareCenters_64810bf1-21da-4cc2-a43f-2c1ef946c917" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfStatesInWhichEntityOperates_91f24672-c8b3-46fd-bff9-40cf86ee5d66" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfStatesInWhichEntityOperates"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_8bfbbd74-cc2b-4f58-9b14-07eef305c05b" xlink:to="loc_us-gaap_NumberOfStatesInWhichEntityOperates_91f24672-c8b3-46fd-bff9-40cf86ee5d66" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_MinimumPercentOwnershipForControllingInterestPercent_6873b927-0779-4ded-91fc-79c43ea7a744" xlink:href="amed-20210630.xsd#amed_MinimumPercentOwnershipForControllingInterestPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_8bfbbd74-cc2b-4f58-9b14-07eef305c05b" xlink:to="loc_amed_MinimumPercentOwnershipForControllingInterestPercent_6873b927-0779-4ded-91fc-79c43ea7a744" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_MaximumPercentOwnershipForEquityMethodPercent_85eeb59f-a73f-441e-a803-851a349c34fd" xlink:href="amed-20210630.xsd#amed_MaximumPercentOwnershipForEquityMethodPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_8bfbbd74-cc2b-4f58-9b14-07eef305c05b" xlink:to="loc_amed_MaximumPercentOwnershipForEquityMethodPercent_85eeb59f-a73f-441e-a803-851a349c34fd" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentAggregateCost_3b1d4a73-a127-48d3-a81b-778f6e0606be" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentAggregateCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_8bfbbd74-cc2b-4f58-9b14-07eef305c05b" xlink:to="loc_us-gaap_EquityMethodInvestmentAggregateCost_3b1d4a73-a127-48d3-a81b-778f6e0606be" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_MaximumPercentOwnershipForCostMethodPercent_09f7c56d-11d3-4f20-ad7e-8955854b9e36" xlink:href="amed-20210630.xsd#amed_MaximumPercentOwnershipForCostMethodPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_8bfbbd74-cc2b-4f58-9b14-07eef305c05b" xlink:to="loc_amed_MaximumPercentOwnershipForCostMethodPercent_09f7c56d-11d3-4f20-ad7e-8955854b9e36" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_cfcc7c40-bfb6-4948-867a-c5c578cb438d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_8bfbbd74-cc2b-4f58-9b14-07eef305c05b" xlink:to="loc_us-gaap_EquityMethodInvestments_cfcc7c40-bfb6-4948-867a-c5c578cb438d" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfEquityMethodInvestments_f153ae02-48ff-49eb-b8c1-776735ab5e1e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleOfEquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_8bfbbd74-cc2b-4f58-9b14-07eef305c05b" xlink:to="loc_us-gaap_ProceedsFromSaleOfEquityMethodInvestments_f153ae02-48ff-49eb-b8c1-776735ab5e1e" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainOnSaleOfInvestments_73e6a426-d433-4f0d-988e-28c67caf59da" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainOnSaleOfInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_8bfbbd74-cc2b-4f58-9b14-07eef305c05b" xlink:to="loc_us-gaap_GainOnSaleOfInvestments_73e6a426-d433-4f0d-988e-28c67caf59da" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnInvestments_79de014f-3f88-4c97-a840-ce53bd313c6f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_8bfbbd74-cc2b-4f58-9b14-07eef305c05b" xlink:to="loc_us-gaap_GainLossOnInvestments_79de014f-3f88-4c97-a840-ce53bd313c6f" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable_8de95f06-4875-4ed3-9773-33485effd152" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_8bfbbd74-cc2b-4f58-9b14-07eef305c05b" xlink:to="loc_us-gaap_ConcentrationRiskTable_8de95f06-4875-4ed3-9773-33485effd152" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_85090172-84bb-4631-b2d8-f7dd772a04a6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_8de95f06-4875-4ed3-9773-33485effd152" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_85090172-84bb-4631-b2d8-f7dd772a04a6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember_85090172-84bb-4631-b2d8-f7dd772a04a6_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_85090172-84bb-4631-b2d8-f7dd772a04a6" xlink:to="loc_us-gaap_TypeOfAdoptionMember_85090172-84bb-4631-b2d8-f7dd772a04a6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember_04d0669d-24e0-4450-8ec2-ea5f36955a19" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_85090172-84bb-4631-b2d8-f7dd772a04a6" xlink:to="loc_us-gaap_TypeOfAdoptionMember_04d0669d-24e0-4450-8ec2-ea5f36955a19" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate201602Member_13c6a1e0-9c8f-429f-a6d3-dabeba095cee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfAdoptionMember_04d0669d-24e0-4450-8ec2-ea5f36955a19" xlink:to="loc_us-gaap_AccountingStandardsUpdate201602Member_13c6a1e0-9c8f-429f-a6d3-dabeba095cee" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_ff88661c-b248-4f11-a8bf-bf61a4391633" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_8de95f06-4875-4ed3-9773-33485effd152" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_ff88661c-b248-4f11-a8bf-bf61a4391633" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_ff88661c-b248-4f11-a8bf-bf61a4391633_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_ff88661c-b248-4f11-a8bf-bf61a4391633" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_ff88661c-b248-4f11-a8bf-bf61a4391633_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_735ea19f-06f8-43e2-88ea-b48f7a45f777" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_ff88661c-b248-4f11-a8bf-bf61a4391633" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_735ea19f-06f8-43e2-88ea-b48f7a45f777" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerMember_e2733642-c188-49c9-811d-3dd86fc93e3d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_735ea19f-06f8-43e2-88ea-b48f7a45f777" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerMember_e2733642-c188-49c9-811d-3dd86fc93e3d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_8925792f-b0ff-4da3-b942-b3b1dd73a68c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_8de95f06-4875-4ed3-9773-33485effd152" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_8925792f-b0ff-4da3-b942-b3b1dd73a68c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_8925792f-b0ff-4da3-b942-b3b1dd73a68c_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_8925792f-b0ff-4da3-b942-b3b1dd73a68c" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_8925792f-b0ff-4da3-b942-b3b1dd73a68c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_79abe9ee-3d11-48ed-936d-8850bb3304ce" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_8925792f-b0ff-4da3-b942-b3b1dd73a68c" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_79abe9ee-3d11-48ed-936d-8850bb3304ce" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_MedicareRevenueMember_bd40566d-37e7-4fa9-84e0-3a43ed0ec9f5" xlink:href="amed-20210630.xsd#amed_MedicareRevenueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_79abe9ee-3d11-48ed-936d-8850bb3304ce" xlink:to="loc_amed_MedicareRevenueMember_bd40566d-37e7-4fa9-84e0-3a43ed0ec9f5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductConcentrationRiskMember_b68e79b0-0017-4394-885e-9bb2abd4795f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_79abe9ee-3d11-48ed-936d-8850bb3304ce" xlink:to="loc_us-gaap_ProductConcentrationRiskMember_b68e79b0-0017-4394-885e-9bb2abd4795f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_141d05fc-1d14-4728-bf4c-6ada2fb379d2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_8de95f06-4875-4ed3-9773-33485effd152" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_141d05fc-1d14-4728-bf4c-6ada2fb379d2" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_141d05fc-1d14-4728-bf4c-6ada2fb379d2_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_141d05fc-1d14-4728-bf4c-6ada2fb379d2" xlink:to="loc_us-gaap_SegmentDomain_141d05fc-1d14-4728-bf4c-6ada2fb379d2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_e5e2c66d-5e0c-4486-9aa2-01c51c89ebe5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_141d05fc-1d14-4728-bf4c-6ada2fb379d2" xlink:to="loc_us-gaap_SegmentDomain_e5e2c66d-5e0c-4486-9aa2-01c51c89ebe5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HomeHealthMember_cfe3a234-8d5c-4eca-8d33-9e9f1e569632" xlink:href="amed-20210630.xsd#amed_HomeHealthMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_e5e2c66d-5e0c-4486-9aa2-01c51c89ebe5" xlink:to="loc_amed_HomeHealthMember_cfe3a234-8d5c-4eca-8d33-9e9f1e569632" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HospiceMember_fc3eda3c-0e62-467b-aebc-e79c1d4ea664" xlink:href="amed-20210630.xsd#amed_HospiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_e5e2c66d-5e0c-4486-9aa2-01c51c89ebe5" xlink:to="loc_amed_HospiceMember_fc3eda3c-0e62-467b-aebc-e79c1d4ea664" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PersonalCareMember_bdc88075-c749-4bdf-8671-f5ff77a6ed90" xlink:href="amed-20210630.xsd#amed_PersonalCareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_e5e2c66d-5e0c-4486-9aa2-01c51c89ebe5" xlink:to="loc_amed_PersonalCareMember_bdc88075-c749-4bdf-8671-f5ff77a6ed90" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_TypeofEquityMethodInvestmentAxis_167ce630-011e-427e-a259-2bcfab9ec008" xlink:href="amed-20210630.xsd#amed_TypeofEquityMethodInvestmentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_8de95f06-4875-4ed3-9773-33485effd152" xlink:to="loc_amed_TypeofEquityMethodInvestmentAxis_167ce630-011e-427e-a259-2bcfab9ec008" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_TypeOfEquityMethodInvestmentDomain_167ce630-011e-427e-a259-2bcfab9ec008_default" xlink:href="amed-20210630.xsd#amed_TypeOfEquityMethodInvestmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_amed_TypeofEquityMethodInvestmentAxis_167ce630-011e-427e-a259-2bcfab9ec008" xlink:to="loc_amed_TypeOfEquityMethodInvestmentDomain_167ce630-011e-427e-a259-2bcfab9ec008_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_TypeOfEquityMethodInvestmentDomain_9da4bbef-1331-44cf-82c3-5a5009fee0c9" xlink:href="amed-20210630.xsd#amed_TypeOfEquityMethodInvestmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_amed_TypeofEquityMethodInvestmentAxis_167ce630-011e-427e-a259-2bcfab9ec008" xlink:to="loc_amed_TypeOfEquityMethodInvestmentDomain_9da4bbef-1331-44cf-82c3-5a5009fee0c9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HeritageHealthcareInnovationFundLPMember_2c873266-28f8-4ffc-bf7e-2e766f87738f" xlink:href="amed-20210630.xsd#amed_HeritageHealthcareInnovationFundLPMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_amed_TypeOfEquityMethodInvestmentDomain_9da4bbef-1331-44cf-82c3-5a5009fee0c9" xlink:to="loc_amed_HeritageHealthcareInnovationFundLPMember_2c873266-28f8-4ffc-bf7e-2e766f87738f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_MedalogixMember_d6ec0714-d0d4-4d20-bd1a-ddcdfa652ffb" xlink:href="amed-20210630.xsd#amed_MedalogixMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_amed_TypeOfEquityMethodInvestmentDomain_9da4bbef-1331-44cf-82c3-5a5009fee0c9" xlink:to="loc_amed_MedalogixMember_d6ec0714-d0d4-4d20-bd1a-ddcdfa652ffb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_28cc4a17-c459-4a04-aab1-8bdf91fefad0" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_8de95f06-4875-4ed3-9773-33485effd152" xlink:to="loc_srt_ProductOrServiceAxis_28cc4a17-c459-4a04-aab1-8bdf91fefad0" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_28cc4a17-c459-4a04-aab1-8bdf91fefad0_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_28cc4a17-c459-4a04-aab1-8bdf91fefad0" xlink:to="loc_srt_ProductsAndServicesDomain_28cc4a17-c459-4a04-aab1-8bdf91fefad0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_31a86e59-23d9-4cc8-b1c8-1a0938f04171" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_28cc4a17-c459-4a04-aab1-8bdf91fefad0" xlink:to="loc_srt_ProductsAndServicesDomain_31a86e59-23d9-4cc8-b1c8-1a0938f04171" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_MedicareRevenueMember_0051a9e8-b6b2-46f1-9fcc-6ec45f7a6924" xlink:href="amed-20210630.xsd#amed_MedicareRevenueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_31a86e59-23d9-4cc8-b1c8-1a0938f04171" xlink:to="loc_amed_MedicareRevenueMember_0051a9e8-b6b2-46f1-9fcc-6ec45f7a6924" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails" xlink:type="simple" xlink:href="amed-20210630.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails" xlink:type="extended" id="i2d3689267c4c40baadeb0026bab38711_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_62da7a9b-73e3-48a8-a76f-566e30ae558e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_baa615ce-2b95-4e34-9baa-45509b4208d8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_62da7a9b-73e3-48a8-a76f-566e30ae558e" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_baa615ce-2b95-4e34-9baa-45509b4208d8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_EpisodeOfCareAsEpisodicBasedRevenueDuration_1b0b4e33-5c1a-4532-955f-52030c1c9ec7" xlink:href="amed-20210630.xsd#amed_EpisodeOfCareAsEpisodicBasedRevenueDuration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_62da7a9b-73e3-48a8-a76f-566e30ae558e" xlink:to="loc_amed_EpisodeOfCareAsEpisodicBasedRevenueDuration_1b0b4e33-5c1a-4532-955f-52030c1c9ec7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_NetServiceRevenuePeriodOfCarePaymentRateDuration_6ffac860-d686-4d75-8b27-1b1a4da1e6db" xlink:href="amed-20210630.xsd#amed_NetServiceRevenuePeriodOfCarePaymentRateDuration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_62da7a9b-73e3-48a8-a76f-566e30ae558e" xlink:to="loc_amed_NetServiceRevenuePeriodOfCarePaymentRateDuration_6ffac860-d686-4d75-8b27-1b1a4da1e6db" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PeriodOfCareAsEpisodicBasedRevenueDuration_c8cae07c-b133-4235-bef8-179b2c5b9322" xlink:href="amed-20210630.xsd#amed_PeriodOfCareAsEpisodicBasedRevenueDuration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_62da7a9b-73e3-48a8-a76f-566e30ae558e" xlink:to="loc_amed_PeriodOfCareAsEpisodicBasedRevenueDuration_c8cae07c-b133-4235-bef8-179b2c5b9322" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PercentageOfTotalReimbursementOfOutlierPayment_454c206f-6213-4d6e-9a04-35d6c6d5ad0c" xlink:href="amed-20210630.xsd#amed_PercentageOfTotalReimbursementOfOutlierPayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_62da7a9b-73e3-48a8-a76f-566e30ae558e" xlink:to="loc_amed_PercentageOfTotalReimbursementOfOutlierPayment_454c206f-6213-4d6e-9a04-35d6c6d5ad0c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_LowUtilizationPaymentAdjustmentNumberOfVisits_4db1bcc0-3895-46ef-be3a-0e4826d737d9" xlink:href="amed-20210630.xsd#amed_LowUtilizationPaymentAdjustmentNumberOfVisits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_62da7a9b-73e3-48a8-a76f-566e30ae558e" xlink:to="loc_amed_LowUtilizationPaymentAdjustmentNumberOfVisits_4db1bcc0-3895-46ef-be3a-0e4826d737d9" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_FirstThresholdOfTherapyServicesRequired_6f35d95b-9b21-4bde-a05b-bc9ef0cb3145" xlink:href="amed-20210630.xsd#amed_FirstThresholdOfTherapyServicesRequired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_62da7a9b-73e3-48a8-a76f-566e30ae558e" xlink:to="loc_amed_FirstThresholdOfTherapyServicesRequired_6f35d95b-9b21-4bde-a05b-bc9ef0cb3145" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_SecondThresholdOfServicesRequired_022c3dc6-c6a4-4ece-a498-814fcff69226" xlink:href="amed-20210630.xsd#amed_SecondThresholdOfServicesRequired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_62da7a9b-73e3-48a8-a76f-566e30ae558e" xlink:to="loc_amed_SecondThresholdOfServicesRequired_022c3dc6-c6a4-4ece-a498-814fcff69226" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ThirdThresholdOfTherapyServicesRequired_0e515be9-b497-4cea-bb2c-f186cabc269d" xlink:href="amed-20210630.xsd#amed_ThirdThresholdOfTherapyServicesRequired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_62da7a9b-73e3-48a8-a76f-566e30ae558e" xlink:to="loc_amed_ThirdThresholdOfTherapyServicesRequired_0e515be9-b497-4cea-bb2c-f186cabc269d" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HistoricalCollectionRateFromMedicare_d82de9c9-cb49-4855-8b34-f274c275c1db" xlink:href="amed-20210630.xsd#amed_HistoricalCollectionRateFromMedicare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_62da7a9b-73e3-48a8-a76f-566e30ae558e" xlink:to="loc_amed_HistoricalCollectionRateFromMedicare_d82de9c9-cb49-4855-8b34-f274c275c1db" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_NonMedicareRevenueTermRates_a6c35d4f-53f2-43ee-a3d4-5e172fdf694b" xlink:href="amed-20210630.xsd#amed_NonMedicareRevenueTermRates"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_62da7a9b-73e3-48a8-a76f-566e30ae558e" xlink:to="loc_amed_NonMedicareRevenueTermRates_a6c35d4f-53f2-43ee-a3d4-5e172fdf694b" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HospiceMedicareRevenueRateAccountedForRoutineCare_dbf7587a-d05c-4e81-a463-237136a1457e" xlink:href="amed-20210630.xsd#amed_HospiceMedicareRevenueRateAccountedForRoutineCare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_62da7a9b-73e3-48a8-a76f-566e30ae558e" xlink:to="loc_amed_HospiceMedicareRevenueRateAccountedForRoutineCare_dbf7587a-d05c-4e81-a463-237136a1457e" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_EstimatedAmountDueBackToMedicareInOtherAccruedLiabilities_6e4a1209-9f34-4a7a-ad29-34bf1edaf062" xlink:href="amed-20210630.xsd#amed_EstimatedAmountDueBackToMedicareInOtherAccruedLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_62da7a9b-73e3-48a8-a76f-566e30ae558e" xlink:to="loc_amed_EstimatedAmountDueBackToMedicareInOtherAccruedLiabilities_6e4a1209-9f34-4a7a-ad29-34bf1edaf062" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_NetServiceRevenueEpisodePaymentRateDuration_6b8bd8c6-275e-451e-82a6-fc2c4ac7eb89" xlink:href="amed-20210630.xsd#amed_NetServiceRevenueEpisodePaymentRateDuration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_62da7a9b-73e3-48a8-a76f-566e30ae558e" xlink:to="loc_amed_NetServiceRevenueEpisodePaymentRateDuration_6b8bd8c6-275e-451e-82a6-fc2c4ac7eb89" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_RateOfRequestForAnticipatedPaymentSubmittedForInitialPeriodOfCare_12f4d8e7-3ef1-4f71-88b8-7e61714002cb" xlink:href="amed-20210630.xsd#amed_RateOfRequestForAnticipatedPaymentSubmittedForInitialPeriodOfCare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_62da7a9b-73e3-48a8-a76f-566e30ae558e" xlink:to="loc_amed_RateOfRequestForAnticipatedPaymentSubmittedForInitialPeriodOfCare_12f4d8e7-3ef1-4f71-88b8-7e61714002cb" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable_f8b4b9be-3dcb-4dff-8b38-c5212e417585" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_62da7a9b-73e3-48a8-a76f-566e30ae558e" xlink:to="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable_f8b4b9be-3dcb-4dff-8b38-c5212e417585" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_26cda65c-c9e6-42c7-941e-4aaf618f85f1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable_f8b4b9be-3dcb-4dff-8b38-c5212e417585" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_26cda65c-c9e6-42c7-941e-4aaf618f85f1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_26cda65c-c9e6-42c7-941e-4aaf618f85f1_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_26cda65c-c9e6-42c7-941e-4aaf618f85f1" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_26cda65c-c9e6-42c7-941e-4aaf618f85f1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6464a6a2-4634-437a-a44e-c8ff416f4484" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_26cda65c-c9e6-42c7-941e-4aaf618f85f1" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6464a6a2-4634-437a-a44e-c8ff416f4484" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CompassionateCareHospiceMember_8a8f1d4a-da0b-497b-9bdb-6277597f0c69" xlink:href="amed-20210630.xsd#amed_CompassionateCareHospiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6464a6a2-4634-437a-a44e-c8ff416f4484" xlink:to="loc_amed_CompassionateCareHospiceMember_8a8f1d4a-da0b-497b-9bdb-6277597f0c69" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AseraCareHospiceMember_1e341682-acbd-4826-bfc6-3c7ef7ddd01f" xlink:href="amed-20210630.xsd#amed_AseraCareHospiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6464a6a2-4634-437a-a44e-c8ff416f4484" xlink:to="loc_amed_AseraCareHospiceMember_1e341682-acbd-4826-bfc6-3c7ef7ddd01f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_5051c602-f475-4355-b616-da03da7953c5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable_f8b4b9be-3dcb-4dff-8b38-c5212e417585" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_5051c602-f475-4355-b616-da03da7953c5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_5051c602-f475-4355-b616-da03da7953c5_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_5051c602-f475-4355-b616-da03da7953c5" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_5051c602-f475-4355-b616-da03da7953c5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_2b6734ea-606e-4521-9bd5-770526441f0e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_5051c602-f475-4355-b616-da03da7953c5" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_2b6734ea-606e-4521-9bd5-770526441f0e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_MedicareRevenueMember_3bc08e2e-ff78-4c4a-b112-ea84f97bd24f" xlink:href="amed-20210630.xsd#amed_MedicareRevenueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_2b6734ea-606e-4521-9bd5-770526441f0e" xlink:to="loc_amed_MedicareRevenueMember_3bc08e2e-ff78-4c4a-b112-ea84f97bd24f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductConcentrationRiskMember_0dd68d90-9e28-43e0-aeef-c622b0806954" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_2b6734ea-606e-4521-9bd5-770526441f0e" xlink:to="loc_us-gaap_ProductConcentrationRiskMember_0dd68d90-9e28-43e0-aeef-c622b0806954" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_c1772299-8866-4f23-ae54-9e2fb0c065e7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable_f8b4b9be-3dcb-4dff-8b38-c5212e417585" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_c1772299-8866-4f23-ae54-9e2fb0c065e7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_c1772299-8866-4f23-ae54-9e2fb0c065e7_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_c1772299-8866-4f23-ae54-9e2fb0c065e7" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_c1772299-8866-4f23-ae54-9e2fb0c065e7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_3fe9ed77-0072-4833-b531-c8accf3d874d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_c1772299-8866-4f23-ae54-9e2fb0c065e7" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_3fe9ed77-0072-4833-b531-c8accf3d874d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerMember_fa24986c-3f96-4d1e-822d-9dad4d0793b5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_3fe9ed77-0072-4833-b531-c8accf3d874d" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerMember_fa24986c-3f96-4d1e-822d-9dad4d0793b5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CapYearAxis_2a76db6c-d0b0-4cbd-8911-3a976d8fd890" xlink:href="amed-20210630.xsd#amed_CapYearAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable_f8b4b9be-3dcb-4dff-8b38-c5212e417585" xlink:to="loc_amed_CapYearAxis_2a76db6c-d0b0-4cbd-8911-3a976d8fd890" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CapYearDomain_2a76db6c-d0b0-4cbd-8911-3a976d8fd890_default" xlink:href="amed-20210630.xsd#amed_CapYearDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_amed_CapYearAxis_2a76db6c-d0b0-4cbd-8911-3a976d8fd890" xlink:to="loc_amed_CapYearDomain_2a76db6c-d0b0-4cbd-8911-3a976d8fd890_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CapYearDomain_a95d489a-cc6e-44f6-abeb-5724f7270b78" xlink:href="amed-20210630.xsd#amed_CapYearDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_amed_CapYearAxis_2a76db6c-d0b0-4cbd-8911-3a976d8fd890" xlink:to="loc_amed_CapYearDomain_a95d489a-cc6e-44f6-abeb-5724f7270b78" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CapYearTwoThousandFourteenThroughTwoThousandTwentyOneMember_989a0d8b-44b0-4131-bf91-a63d5f76976d" xlink:href="amed-20210630.xsd#amed_CapYearTwoThousandFourteenThroughTwoThousandTwentyOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_amed_CapYearDomain_a95d489a-cc6e-44f6-abeb-5724f7270b78" xlink:to="loc_amed_CapYearTwoThousandFourteenThroughTwoThousandTwentyOneMember_989a0d8b-44b0-4131-bf91-a63d5f76976d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CapYearTwoThousandSixteenThroughTwoThousandTwentyOneMember_21a8c690-39f0-4148-9622-c9d3c617bb40" xlink:href="amed-20210630.xsd#amed_CapYearTwoThousandSixteenThroughTwoThousandTwentyOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_amed_CapYearDomain_a95d489a-cc6e-44f6-abeb-5724f7270b78" xlink:to="loc_amed_CapYearTwoThousandSixteenThroughTwoThousandTwentyOneMember_21a8c690-39f0-4148-9622-c9d3c617bb40" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_41c17b8b-cc5f-4481-a432-4ed5f81c4e65" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable_f8b4b9be-3dcb-4dff-8b38-c5212e417585" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_41c17b8b-cc5f-4481-a432-4ed5f81c4e65" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_41c17b8b-cc5f-4481-a432-4ed5f81c4e65_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_41c17b8b-cc5f-4481-a432-4ed5f81c4e65" xlink:to="loc_us-gaap_SegmentDomain_41c17b8b-cc5f-4481-a432-4ed5f81c4e65_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_3f052d62-26d4-434b-99c1-555806cadc71" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_41c17b8b-cc5f-4481-a432-4ed5f81c4e65" xlink:to="loc_us-gaap_SegmentDomain_3f052d62-26d4-434b-99c1-555806cadc71" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HomeHealthMember_ac789f68-ed95-41b4-9235-01f0123f34c5" xlink:href="amed-20210630.xsd#amed_HomeHealthMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_3f052d62-26d4-434b-99c1-555806cadc71" xlink:to="loc_amed_HomeHealthMember_ac789f68-ed95-41b4-9235-01f0123f34c5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HospiceMember_fadcbc98-9a59-480e-a5cb-2c75147a9d92" xlink:href="amed-20210630.xsd#amed_HospiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_3f052d62-26d4-434b-99c1-555806cadc71" xlink:to="loc_amed_HospiceMember_fadcbc98-9a59-480e-a5cb-2c75147a9d92" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_8be2e444-306b-4ced-97a0-96d26b65cba6" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable_f8b4b9be-3dcb-4dff-8b38-c5212e417585" xlink:to="loc_srt_RangeAxis_8be2e444-306b-4ced-97a0-96d26b65cba6" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_8be2e444-306b-4ced-97a0-96d26b65cba6_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_8be2e444-306b-4ced-97a0-96d26b65cba6" xlink:to="loc_srt_RangeMember_8be2e444-306b-4ced-97a0-96d26b65cba6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_124b4c52-f25e-4579-aab6-576a6950b503" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_8be2e444-306b-4ced-97a0-96d26b65cba6" xlink:to="loc_srt_RangeMember_124b4c52-f25e-4579-aab6-576a6950b503" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_bd6f2a32-0cb2-4b27-8a8a-1c4c03c2e14e" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_124b4c52-f25e-4579-aab6-576a6950b503" xlink:to="loc_srt_MinimumMember_bd6f2a32-0cb2-4b27-8a8a-1c4c03c2e14e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_5591da3a-727e-4601-8c28-c4915d91b1c2" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_124b4c52-f25e-4579-aab6-576a6950b503" xlink:to="loc_srt_MaximumMember_5591da3a-727e-4601-8c28-c4915d91b1c2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_0d9741e6-8494-407a-a174-5db662caae37" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable_f8b4b9be-3dcb-4dff-8b38-c5212e417585" xlink:to="loc_srt_ProductOrServiceAxis_0d9741e6-8494-407a-a174-5db662caae37" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_0d9741e6-8494-407a-a174-5db662caae37_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_0d9741e6-8494-407a-a174-5db662caae37" xlink:to="loc_srt_ProductsAndServicesDomain_0d9741e6-8494-407a-a174-5db662caae37_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_ef8c007c-2913-4b7d-9e88-7f5694d6f415" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_0d9741e6-8494-407a-a174-5db662caae37" xlink:to="loc_srt_ProductsAndServicesDomain_ef8c007c-2913-4b7d-9e88-7f5694d6f415" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_MedicareRevenueMember_aeeb7f9f-b843-45f8-bec8-c02abc2efb49" xlink:href="amed-20210630.xsd#amed_MedicareRevenueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_ef8c007c-2913-4b7d-9e88-7f5694d6f415" xlink:to="loc_amed_MedicareRevenueMember_aeeb7f9f-b843-45f8-bec8-c02abc2efb49" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenuebyPayorClassDetails" xlink:type="simple" xlink:href="amed-20210630.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenuebyPayorClassDetails"/>
  <link:definitionLink xlink:role="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenuebyPayorClassDetails" xlink:type="extended" id="i3f226cf5209c4cce82128d88ae5d3bff_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenuebyPayorClassDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_46fbb1c3-e7ca-489e-8639-470078e61858" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_Revenuebypayorclassasapercentageoftotalnetservicerevenue_3ac576e3-b475-4edc-8d2a-2ca4cd15c24e" xlink:href="amed-20210630.xsd#amed_Revenuebypayorclassasapercentageoftotalnetservicerevenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_46fbb1c3-e7ca-489e-8639-470078e61858" xlink:to="loc_amed_Revenuebypayorclassasapercentageoftotalnetservicerevenue_3ac576e3-b475-4edc-8d2a-2ca4cd15c24e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTable_9ef30923-90c3-425b-90c3-f805b79104d3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_46fbb1c3-e7ca-489e-8639-470078e61858" xlink:to="loc_us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTable_9ef30923-90c3-425b-90c3-f805b79104d3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PayorClassAxis_f2b3570b-8230-4a35-801a-962b759e3c2b" xlink:href="amed-20210630.xsd#amed_PayorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTable_9ef30923-90c3-425b-90c3-f805b79104d3" xlink:to="loc_amed_PayorClassAxis_f2b3570b-8230-4a35-801a-962b759e3c2b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PayorClassDomain_f2b3570b-8230-4a35-801a-962b759e3c2b_default" xlink:href="amed-20210630.xsd#amed_PayorClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_amed_PayorClassAxis_f2b3570b-8230-4a35-801a-962b759e3c2b" xlink:to="loc_amed_PayorClassDomain_f2b3570b-8230-4a35-801a-962b759e3c2b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PayorClassDomain_50c3659c-4d91-49e5-9e71-b3f55214c361" xlink:href="amed-20210630.xsd#amed_PayorClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_amed_PayorClassAxis_f2b3570b-8230-4a35-801a-962b759e3c2b" xlink:to="loc_amed_PayorClassDomain_50c3659c-4d91-49e5-9e71-b3f55214c361" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HomeHealthMedicareMember_75393f37-a755-494a-95a7-2ed89e06e2a9" xlink:href="amed-20210630.xsd#amed_HomeHealthMedicareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_amed_PayorClassDomain_50c3659c-4d91-49e5-9e71-b3f55214c361" xlink:to="loc_amed_HomeHealthMedicareMember_75393f37-a755-494a-95a7-2ed89e06e2a9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HomeHealthNonMedicareEpisodicBasedMember_57c325f0-64d0-4951-bb1f-0a3145f7f7cf" xlink:href="amed-20210630.xsd#amed_HomeHealthNonMedicareEpisodicBasedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_amed_PayorClassDomain_50c3659c-4d91-49e5-9e71-b3f55214c361" xlink:to="loc_amed_HomeHealthNonMedicareEpisodicBasedMember_57c325f0-64d0-4951-bb1f-0a3145f7f7cf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HomeHealthNonMedicareNonEpisodicBasedMember_3ae77c7d-d73d-4b62-bf46-f62cdc5d09eb" xlink:href="amed-20210630.xsd#amed_HomeHealthNonMedicareNonEpisodicBasedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_amed_PayorClassDomain_50c3659c-4d91-49e5-9e71-b3f55214c361" xlink:to="loc_amed_HomeHealthNonMedicareNonEpisodicBasedMember_3ae77c7d-d73d-4b62-bf46-f62cdc5d09eb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HospiceMedicareMember_f3b33be9-f6c7-4acb-9a78-052801580cd1" xlink:href="amed-20210630.xsd#amed_HospiceMedicareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_amed_PayorClassDomain_50c3659c-4d91-49e5-9e71-b3f55214c361" xlink:to="loc_amed_HospiceMedicareMember_f3b33be9-f6c7-4acb-9a78-052801580cd1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HospiceNonMedicareMember_bd725d15-e4a6-454c-9df8-3e89c2b9d392" xlink:href="amed-20210630.xsd#amed_HospiceNonMedicareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_amed_PayorClassDomain_50c3659c-4d91-49e5-9e71-b3f55214c361" xlink:to="loc_amed_HospiceNonMedicareMember_bd725d15-e4a6-454c-9df8-3e89c2b9d392" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PersonalCareMember_7c9583f4-5c6b-4ac9-8247-eb8f920d9554" xlink:href="amed-20210630.xsd#amed_PersonalCareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_amed_PayorClassDomain_50c3659c-4d91-49e5-9e71-b3f55214c361" xlink:to="loc_amed_PersonalCareMember_7c9583f4-5c6b-4ac9-8247-eb8f920d9554" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESCashandCashEquivalentsDetails" xlink:type="simple" xlink:href="amed-20210630.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESCashandCashEquivalentsDetails"/>
  <link:definitionLink xlink:role="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESCashandCashEquivalentsDetails" xlink:type="extended" id="if9ad8535ebe640688adbe25245f7d739_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESCashandCashEquivalentsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_a129a490-f1c1-4e15-b628-a4b823fab7d2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_11783576-189b-4b00-8066-88d6c4891f1d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_a129a490-f1c1-4e15-b628-a4b823fab7d2" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_11783576-189b-4b00-8066-88d6c4891f1d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCash_e5b1f57a-08f6-439f-850a-5ae9d6c81a01" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCash"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_a129a490-f1c1-4e15-b628-a4b823fab7d2" xlink:to="loc_us-gaap_RestrictedCash_e5b1f57a-08f6-439f-850a-5ae9d6c81a01" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_27e86cb0-5118-404e-bca5-cf396abfceca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_a129a490-f1c1-4e15-b628-a4b823fab7d2" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_27e86cb0-5118-404e-bca5-cf396abfceca" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CashBalanceAssociatedWithProviderReliefFund_fca9b678-c825-4ad9-a47c-1114d5fc3d6e" xlink:href="amed-20210630.xsd#amed_CashBalanceAssociatedWithProviderReliefFund"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_a129a490-f1c1-4e15-b628-a4b823fab7d2" xlink:to="loc_amed_CashBalanceAssociatedWithProviderReliefFund_fca9b678-c825-4ad9-a47c-1114d5fc3d6e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ProviderReliefFundAdvance_d395e00a-6036-4515-801e-4d54ac5a0941" xlink:href="amed-20210630.xsd#amed_ProviderReliefFundAdvance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_a129a490-f1c1-4e15-b628-a4b823fab7d2" xlink:to="loc_amed_ProviderReliefFundAdvance_d395e00a-6036-4515-801e-4d54ac5a0941" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CARESActProviderReliefFundsUtilized_062fb50a-1ec7-4ed4-bce8-dbcc0f9833d2" xlink:href="amed-20210630.xsd#amed_CARESActProviderReliefFundsUtilized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_a129a490-f1c1-4e15-b628-a4b823fab7d2" xlink:to="loc_amed_CARESActProviderReliefFundsUtilized_062fb50a-1ec7-4ed4-bce8-dbcc0f9833d2" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_b9a6a4b0-0e56-4859-822e-f6b634fdadaf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_a129a490-f1c1-4e15-b628-a4b823fab7d2" xlink:to="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_b9a6a4b0-0e56-4859-822e-f6b634fdadaf" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_44fbed39-5d32-45ea-a9f3-6e1a9399bf2f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_b9a6a4b0-0e56-4859-822e-f6b634fdadaf" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_44fbed39-5d32-45ea-a9f3-6e1a9399bf2f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_44fbed39-5d32-45ea-a9f3-6e1a9399bf2f_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_44fbed39-5d32-45ea-a9f3-6e1a9399bf2f" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_44fbed39-5d32-45ea-a9f3-6e1a9399bf2f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_05847505-04cb-4b6c-902c-1d07847013bb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_44fbed39-5d32-45ea-a9f3-6e1a9399bf2f" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_05847505-04cb-4b6c-902c-1d07847013bb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AsanaHospiceAquisitionMember_e720790b-f38a-4ae1-8c66-77dbfd0fb320" xlink:href="amed-20210630.xsd#amed_AsanaHospiceAquisitionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_05847505-04cb-4b6c-902c-1d07847013bb" xlink:to="loc_amed_AsanaHospiceAquisitionMember_e720790b-f38a-4ae1-8c66-77dbfd0fb320" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_COVID19PPEMember_6c7e90d3-8e3b-4578-a51f-1e76ff944228" xlink:href="amed-20210630.xsd#amed_COVID19PPEMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_05847505-04cb-4b6c-902c-1d07847013bb" xlink:to="loc_amed_COVID19PPEMember_6c7e90d3-8e3b-4578-a51f-1e76ff944228" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AseraCareHospiceMember_f9245c3a-0cb8-4ad3-a3dc-928b90686028" xlink:href="amed-20210630.xsd#amed_AseraCareHospiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_05847505-04cb-4b6c-902c-1d07847013bb" xlink:to="loc_amed_AseraCareHospiceMember_f9245c3a-0cb8-4ad3-a3dc-928b90686028" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_3e05fc45-1d56-4184-8839-674c44a95639" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_b9a6a4b0-0e56-4859-822e-f6b634fdadaf" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_3e05fc45-1d56-4184-8839-674c44a95639" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3e05fc45-1d56-4184-8839-674c44a95639_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_3e05fc45-1d56-4184-8839-674c44a95639" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3e05fc45-1d56-4184-8839-674c44a95639_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_f0a8a76d-5060-41ac-ba18-c32aec8cc575" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_3e05fc45-1d56-4184-8839-674c44a95639" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_f0a8a76d-5060-41ac-ba18-c32aec8cc575" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AsanaHospiceMember_0aaa720c-b721-44fc-bec5-68432c8964b4" xlink:href="amed-20210630.xsd#amed_AsanaHospiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_f0a8a76d-5060-41ac-ba18-c32aec8cc575" xlink:to="loc_amed_AsanaHospiceMember_0aaa720c-b721-44fc-bec5-68432c8964b4" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPatientAccountsReceivableNarrativeDetails" xlink:type="simple" xlink:href="amed-20210630.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPatientAccountsReceivableNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPatientAccountsReceivableNarrativeDetails" xlink:type="extended" id="i55a1b4cdaf3649cb8a8818a89c03239d_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPatientAccountsReceivableNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_31c89fe0-e688-4602-b9c9-3fa0c2e32a57" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AccountsReceivablePortionDerivedFromMedicare_6bb42fbb-46f8-4ec0-b6f5-ae390f39deae" xlink:href="amed-20210630.xsd#amed_AccountsReceivablePortionDerivedFromMedicare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_31c89fe0-e688-4602-b9c9-3fa0c2e32a57" xlink:to="loc_amed_AccountsReceivablePortionDerivedFromMedicare_6bb42fbb-46f8-4ec0-b6f5-ae390f39deae" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_580d8876-5ab6-4248-9430-cffefe7ee8a7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_31c89fe0-e688-4602-b9c9-3fa0c2e32a57" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_580d8876-5ab6-4248-9430-cffefe7ee8a7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_NetServiceRevenuePeriodOfCarePaymentRateDuration_e33ede93-c84c-473c-9b0f-7589ceebd82e" xlink:href="amed-20210630.xsd#amed_NetServiceRevenuePeriodOfCarePaymentRateDuration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_31c89fe0-e688-4602-b9c9-3fa0c2e32a57" xlink:to="loc_amed_NetServiceRevenuePeriodOfCarePaymentRateDuration_e33ede93-c84c-473c-9b0f-7589ceebd82e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable_865b08e3-31c9-4bc4-9452-9b6ffb155666" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_31c89fe0-e688-4602-b9c9-3fa0c2e32a57" xlink:to="loc_us-gaap_ConcentrationRiskTable_865b08e3-31c9-4bc4-9452-9b6ffb155666" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_6c265c7b-a309-4b07-8f63-b1985bbc34e5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_865b08e3-31c9-4bc4-9452-9b6ffb155666" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_6c265c7b-a309-4b07-8f63-b1985bbc34e5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_6c265c7b-a309-4b07-8f63-b1985bbc34e5_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_6c265c7b-a309-4b07-8f63-b1985bbc34e5" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_6c265c7b-a309-4b07-8f63-b1985bbc34e5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_b3cb0f21-ac59-4873-8983-4f9389aab324" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_6c265c7b-a309-4b07-8f63-b1985bbc34e5" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_b3cb0f21-ac59-4873-8983-4f9389aab324" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_5dcb0c96-9f46-4f72-9f8e-2b70e9e3efb3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_b3cb0f21-ac59-4873-8983-4f9389aab324" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_5dcb0c96-9f46-4f72-9f8e-2b70e9e3efb3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_2e2482be-4cf3-4ab3-bb12-7ab40f7d75b9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_865b08e3-31c9-4bc4-9452-9b6ffb155666" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_2e2482be-4cf3-4ab3-bb12-7ab40f7d75b9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_2e2482be-4cf3-4ab3-bb12-7ab40f7d75b9_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_2e2482be-4cf3-4ab3-bb12-7ab40f7d75b9" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_2e2482be-4cf3-4ab3-bb12-7ab40f7d75b9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_33cb8c01-afb3-4ace-ac81-9718a75e7a44" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_2e2482be-4cf3-4ab3-bb12-7ab40f7d75b9" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_33cb8c01-afb3-4ace-ac81-9718a75e7a44" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember_de04dc62-16b4-4d61-a005-ee626ae58aff" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_33cb8c01-afb3-4ace-ac81-9718a75e7a44" xlink:to="loc_us-gaap_AccountsReceivableMember_de04dc62-16b4-4d61-a005-ee626ae58aff" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_32bbeacd-f2ce-4192-afc8-3d6b3fc93fca" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_865b08e3-31c9-4bc4-9452-9b6ffb155666" xlink:to="loc_srt_MajorCustomersAxis_32bbeacd-f2ce-4192-afc8-3d6b3fc93fca" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_32bbeacd-f2ce-4192-afc8-3d6b3fc93fca_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_32bbeacd-f2ce-4192-afc8-3d6b3fc93fca" xlink:to="loc_srt_NameOfMajorCustomerDomain_32bbeacd-f2ce-4192-afc8-3d6b3fc93fca_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_4c263879-2e3d-46d9-8389-41c1ee456171" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_32bbeacd-f2ce-4192-afc8-3d6b3fc93fca" xlink:to="loc_srt_NameOfMajorCustomerDomain_4c263879-2e3d-46d9-8389-41c1ee456171" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_MajorSinglePayorCustomerMember_cebbf06f-3eda-4650-83f9-57e6faea3b0b" xlink:href="amed-20210630.xsd#amed_MajorSinglePayorCustomerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_4c263879-2e3d-46d9-8389-41c1ee456171" xlink:to="loc_amed_MajorSinglePayorCustomerMember_cebbf06f-3eda-4650-83f9-57e6faea3b0b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_834c2794-7c77-4cfb-9af3-c6e102eea56b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_865b08e3-31c9-4bc4-9452-9b6ffb155666" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_834c2794-7c77-4cfb-9af3-c6e102eea56b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_834c2794-7c77-4cfb-9af3-c6e102eea56b_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_834c2794-7c77-4cfb-9af3-c6e102eea56b" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_834c2794-7c77-4cfb-9af3-c6e102eea56b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_cb33fc11-c980-4cac-bf12-35ad8d722c88" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_834c2794-7c77-4cfb-9af3-c6e102eea56b" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_cb33fc11-c980-4cac-bf12-35ad8d722c88" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CompassionateCareHospiceMember_4ef7d8a7-2a6e-494e-9ba3-6e342aa9a678" xlink:href="amed-20210630.xsd#amed_CompassionateCareHospiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_cb33fc11-c980-4cac-bf12-35ad8d722c88" xlink:to="loc_amed_CompassionateCareHospiceMember_4ef7d8a7-2a6e-494e-9ba3-6e342aa9a678" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESFairValueofFinancialInstrumentsDetails" xlink:type="simple" xlink:href="amed-20210630.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESFairValueofFinancialInstrumentsDetails"/>
  <link:definitionLink xlink:role="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESFairValueofFinancialInstrumentsDetails" xlink:type="extended" id="ib07769eb01f74a7488dc9dbc7c2664bb_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESFairValueofFinancialInstrumentsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_8a964cb7-3e8b-4ace-8e77-cfe0bec3dadc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_DebtInstrumentCarryingAmountExcludingFinanceLeases_a02a95e6-5163-42d9-b272-ced5454eff2b" xlink:href="amed-20210630.xsd#amed_DebtInstrumentCarryingAmountExcludingFinanceLeases"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_8a964cb7-3e8b-4ace-8e77-cfe0bec3dadc" xlink:to="loc_amed_DebtInstrumentCarryingAmountExcludingFinanceLeases_a02a95e6-5163-42d9-b272-ced5454eff2b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtFairValue_8fe33b4f-e992-44db-a166-55a1d540ed59" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_8a964cb7-3e8b-4ace-8e77-cfe0bec3dadc" xlink:to="loc_us-gaap_LongTermDebtFairValue_8fe33b4f-e992-44db-a166-55a1d540ed59" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4884c906-dfb6-4224-9c44-c280417de72e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_8a964cb7-3e8b-4ace-8e77-cfe0bec3dadc" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4884c906-dfb6-4224-9c44-c280417de72e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_af1644d2-7886-4ae2-8f98-463b52f7d6e3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4884c906-dfb6-4224-9c44-c280417de72e" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_af1644d2-7886-4ae2-8f98-463b52f7d6e3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_af1644d2-7886-4ae2-8f98-463b52f7d6e3_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_af1644d2-7886-4ae2-8f98-463b52f7d6e3" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_af1644d2-7886-4ae2-8f98-463b52f7d6e3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4e755a08-dacb-40c5-804a-e656fff1451b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_af1644d2-7886-4ae2-8f98-463b52f7d6e3" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4e755a08-dacb-40c5-804a-e656fff1451b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_4cc1284a-967c-4823-afd0-4f3745daa929" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4e755a08-dacb-40c5-804a-e656fff1451b" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_4cc1284a-967c-4823-afd0-4f3745daa929" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_5cbef58f-5d4b-49ab-9754-35437c494a72" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4e755a08-dacb-40c5-804a-e656fff1451b" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_5cbef58f-5d4b-49ab-9754-35437c494a72" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_25216e51-276f-4145-b822-403fb3e65a51" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4e755a08-dacb-40c5-804a-e656fff1451b" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_25216e51-276f-4145-b822-403fb3e65a51" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/NOVELCORONAVIRUSPANDEMICCOVID19Details" xlink:type="simple" xlink:href="amed-20210630.xsd#NOVELCORONAVIRUSPANDEMICCOVID19Details"/>
  <link:definitionLink xlink:role="http://www.amedisys.com/role/NOVELCORONAVIRUSPANDEMICCOVID19Details" xlink:type="extended" id="ie874f0b5fe5047a492258499cd522c19_NOVELCORONAVIRUSPANDEMICCOVID19Details">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnusualOrInfrequentItemLineItems_1634119b-b79f-4d8b-a9cf-64d614aa4ab8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnusualOrInfrequentItemLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_FundingForHealthcareProvidersIncludingHospitals_7ffaaae4-83ba-4ebc-9f79-d013b17d9092" xlink:href="amed-20210630.xsd#amed_FundingForHealthcareProvidersIncludingHospitals"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_UnusualOrInfrequentItemLineItems_1634119b-b79f-4d8b-a9cf-64d614aa4ab8" xlink:to="loc_amed_FundingForHealthcareProvidersIncludingHospitals_7ffaaae4-83ba-4ebc-9f79-d013b17d9092" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_FundingImmediatelyDistributedToHealthcareProvidersBasedOnTheir2019MedicareFeeForServiceReimbursements_3bc9c256-6fbc-436c-a9f7-0ac0b5b59a90" xlink:href="amed-20210630.xsd#amed_FundingImmediatelyDistributedToHealthcareProvidersBasedOnTheir2019MedicareFeeForServiceReimbursements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_UnusualOrInfrequentItemLineItems_1634119b-b79f-4d8b-a9cf-64d614aa4ab8" xlink:to="loc_amed_FundingImmediatelyDistributedToHealthcareProvidersBasedOnTheir2019MedicareFeeForServiceReimbursements_3bc9c256-6fbc-436c-a9f7-0ac0b5b59a90" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_FundingReceivedFromCARESAct_b941c466-551f-4cda-ab23-5a9db8c6a75e" xlink:href="amed-20210630.xsd#amed_FundingReceivedFromCARESAct"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_UnusualOrInfrequentItemLineItems_1634119b-b79f-4d8b-a9cf-64d614aa4ab8" xlink:to="loc_amed_FundingReceivedFromCARESAct_b941c466-551f-4cda-ab23-5a9db8c6a75e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ProviderReliefFundAdvance_6d360b91-82a4-4c3d-b2aa-9255e9f318e5" xlink:href="amed-20210630.xsd#amed_ProviderReliefFundAdvance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_UnusualOrInfrequentItemLineItems_1634119b-b79f-4d8b-a9cf-64d614aa4ab8" xlink:to="loc_amed_ProviderReliefFundAdvance_6d360b91-82a4-4c3d-b2aa-9255e9f318e5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AdditionalFundingDistributedToHealthcareProviders_d44c12e2-f9a1-47e5-a4e8-5b037f421272" xlink:href="amed-20210630.xsd#amed_AdditionalFundingDistributedToHealthcareProviders"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_UnusualOrInfrequentItemLineItems_1634119b-b79f-4d8b-a9cf-64d614aa4ab8" xlink:to="loc_amed_AdditionalFundingDistributedToHealthcareProviders_d44c12e2-f9a1-47e5-a4e8-5b037f421272" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CARESActDeferralOfEmployerShareSocialSecurityTax_3204541c-5c8d-441f-ba31-c48a0304b6b7" xlink:href="amed-20210630.xsd#amed_CARESActDeferralOfEmployerShareSocialSecurityTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_UnusualOrInfrequentItemLineItems_1634119b-b79f-4d8b-a9cf-64d614aa4ab8" xlink:to="loc_amed_CARESActDeferralOfEmployerShareSocialSecurityTax_3204541c-5c8d-441f-ba31-c48a0304b6b7" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_EstimatedFutureCOVID19RelatedExpenses_59502be1-4cdf-4307-88dc-0de5053dd397" xlink:href="amed-20210630.xsd#amed_EstimatedFutureCOVID19RelatedExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_UnusualOrInfrequentItemLineItems_1634119b-b79f-4d8b-a9cf-64d614aa4ab8" xlink:to="loc_amed_EstimatedFutureCOVID19RelatedExpenses_59502be1-4cdf-4307-88dc-0de5053dd397" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_COVID19ExpensesIncurred_18940f7f-dccb-4e2e-a557-bc45a88c1feb" xlink:href="amed-20210630.xsd#amed_COVID19ExpensesIncurred"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_UnusualOrInfrequentItemLineItems_1634119b-b79f-4d8b-a9cf-64d614aa4ab8" xlink:to="loc_amed_COVID19ExpensesIncurred_18940f7f-dccb-4e2e-a557-bc45a88c1feb" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CARESActProviderReliefFundsUtilized_909637a6-e1be-4099-96f8-c27a4e43d97b" xlink:href="amed-20210630.xsd#amed_CARESActProviderReliefFundsUtilized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_UnusualOrInfrequentItemLineItems_1634119b-b79f-4d8b-a9cf-64d614aa4ab8" xlink:to="loc_amed_CARESActProviderReliefFundsUtilized_909637a6-e1be-4099-96f8-c27a4e43d97b" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_EstimatedCARESActProviderReliefFundsExpectedToBeUtilized_af008406-d967-4d97-b3b2-53c87ab661ab" xlink:href="amed-20210630.xsd#amed_EstimatedCARESActProviderReliefFundsExpectedToBeUtilized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_UnusualOrInfrequentItemLineItems_1634119b-b79f-4d8b-a9cf-64d614aa4ab8" xlink:to="loc_amed_EstimatedCARESActProviderReliefFundsExpectedToBeUtilized_af008406-d967-4d97-b3b2-53c87ab661ab" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_EstimatedCARESActProviderReliefFundAmountsToBeRepaid_201da753-7761-4d8f-8bea-7a5419935083" xlink:href="amed-20210630.xsd#amed_EstimatedCARESActProviderReliefFundAmountsToBeRepaid"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_UnusualOrInfrequentItemLineItems_1634119b-b79f-4d8b-a9cf-64d614aa4ab8" xlink:to="loc_amed_EstimatedCARESActProviderReliefFundAmountsToBeRepaid_201da753-7761-4d8f-8bea-7a5419935083" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CARESActProviderReliefFundsReceivedByUnconsolidatedJointVentures_5c759cac-0ab8-491a-984b-b0e1bf2f4100" xlink:href="amed-20210630.xsd#amed_CARESActProviderReliefFundsReceivedByUnconsolidatedJointVentures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_UnusualOrInfrequentItemLineItems_1634119b-b79f-4d8b-a9cf-64d614aa4ab8" xlink:to="loc_amed_CARESActProviderReliefFundsReceivedByUnconsolidatedJointVentures_5c759cac-0ab8-491a-984b-b0e1bf2f4100" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_TotalCARESActProviderReliefFundsReceived_d2fa180a-c373-4b91-b7d1-1d69a7147d7a" xlink:href="amed-20210630.xsd#amed_TotalCARESActProviderReliefFundsReceived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_UnusualOrInfrequentItemLineItems_1634119b-b79f-4d8b-a9cf-64d614aa4ab8" xlink:to="loc_amed_TotalCARESActProviderReliefFundsReceived_d2fa180a-c373-4b91-b7d1-1d69a7147d7a" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_FundingReceivedFromMassHomeCareASAPCOVID19ProviderSustainabilityProgram_00374328-c4a2-41d2-bfa4-cc6aa4317b05" xlink:href="amed-20210630.xsd#amed_FundingReceivedFromMassHomeCareASAPCOVID19ProviderSustainabilityProgram"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_UnusualOrInfrequentItemLineItems_1634119b-b79f-4d8b-a9cf-64d614aa4ab8" xlink:to="loc_amed_FundingReceivedFromMassHomeCareASAPCOVID19ProviderSustainabilityProgram_00374328-c4a2-41d2-bfa4-cc6aa4317b05" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_IncreaseInEstimatedFutureCOVID19RelatedExpenses_a72ef124-999f-4028-8c80-a44b614d523c" xlink:href="amed-20210630.xsd#amed_IncreaseInEstimatedFutureCOVID19RelatedExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_UnusualOrInfrequentItemLineItems_1634119b-b79f-4d8b-a9cf-64d614aa4ab8" xlink:to="loc_amed_IncreaseInEstimatedFutureCOVID19RelatedExpenses_a72ef124-999f-4028-8c80-a44b614d523c" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_d21312f8-f999-4f46-babf-717b0f0d79c7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_UnusualOrInfrequentItemLineItems_1634119b-b79f-4d8b-a9cf-64d614aa4ab8" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_d21312f8-f999-4f46-babf-717b0f0d79c7" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_01bdff81-ec80-4b97-881c-869aa494df51" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_UnusualOrInfrequentItemLineItems_1634119b-b79f-4d8b-a9cf-64d614aa4ab8" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_01bdff81-ec80-4b97-881c-869aa494df51" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ExtensionOfTemporarySuspensionOfSequestrationRevenueImpact_245bade5-caf3-4102-88b4-67d10a0e8ba2" xlink:href="amed-20210630.xsd#amed_ExtensionOfTemporarySuspensionOfSequestrationRevenueImpact"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_UnusualOrInfrequentItemLineItems_1634119b-b79f-4d8b-a9cf-64d614aa4ab8" xlink:to="loc_amed_ExtensionOfTemporarySuspensionOfSequestrationRevenueImpact_245bade5-caf3-4102-88b4-67d10a0e8ba2" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnusualOrInfrequentItemTable_f849c7ca-6381-4a07-b166-3a3c3ad988fa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnusualOrInfrequentItemTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_UnusualOrInfrequentItemLineItems_1634119b-b79f-4d8b-a9cf-64d614aa4ab8" xlink:to="loc_us-gaap_UnusualOrInfrequentItemTable_f849c7ca-6381-4a07-b166-3a3c3ad988fa" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_b6ca7871-e5b8-489e-b190-373e2cddeef4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_UnusualOrInfrequentItemTable_f849c7ca-6381-4a07-b166-3a3c3ad988fa" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_b6ca7871-e5b8-489e-b190-373e2cddeef4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_b6ca7871-e5b8-489e-b190-373e2cddeef4_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_b6ca7871-e5b8-489e-b190-373e2cddeef4" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_b6ca7871-e5b8-489e-b190-373e2cddeef4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_1b10e92b-0066-4dcb-9a61-d31ecb66d65f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_b6ca7871-e5b8-489e-b190-373e2cddeef4" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_1b10e92b-0066-4dcb-9a61-d31ecb66d65f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsMember_d325309c-0409-47e5-ad16-5f1b7dd08c90" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_1b10e92b-0066-4dcb-9a61-d31ecb66d65f" xlink:to="loc_us-gaap_EquityMethodInvestmentsMember_d325309c-0409-47e5-ad16-5f1b7dd08c90" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_452dade3-1888-498f-a0ff-2d048afa9c08" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_UnusualOrInfrequentItemTable_f849c7ca-6381-4a07-b166-3a3c3ad988fa" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_452dade3-1888-498f-a0ff-2d048afa9c08" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_452dade3-1888-498f-a0ff-2d048afa9c08_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_452dade3-1888-498f-a0ff-2d048afa9c08" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_452dade3-1888-498f-a0ff-2d048afa9c08_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_c312c7f8-4f08-4f38-95e4-5f6926400589" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_452dade3-1888-498f-a0ff-2d048afa9c08" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_c312c7f8-4f08-4f38-95e4-5f6926400589" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AseraCareHospiceMember_5ad1bdea-ff67-4107-b720-6d6a772b5e2d" xlink:href="amed-20210630.xsd#amed_AseraCareHospiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_c312c7f8-4f08-4f38-95e4-5f6926400589" xlink:to="loc_amed_AseraCareHospiceMember_5ad1bdea-ff67-4107-b720-6d6a772b5e2d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_99271689-ff37-475b-8caa-85f5553650cb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_UnusualOrInfrequentItemTable_f849c7ca-6381-4a07-b166-3a3c3ad988fa" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_99271689-ff37-475b-8caa-85f5553650cb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_99271689-ff37-475b-8caa-85f5553650cb_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_99271689-ff37-475b-8caa-85f5553650cb" xlink:to="loc_us-gaap_SegmentDomain_99271689-ff37-475b-8caa-85f5553650cb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_ffb289a4-1a19-4d98-a472-4377d07fd832" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_99271689-ff37-475b-8caa-85f5553650cb" xlink:to="loc_us-gaap_SegmentDomain_ffb289a4-1a19-4d98-a472-4377d07fd832" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HomeHealthAndHospiceMember_69e0618c-93f7-4ea2-be8a-798bf49c5e68" xlink:href="amed-20210630.xsd#amed_HomeHealthAndHospiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_ffb289a4-1a19-4d98-a472-4377d07fd832" xlink:to="loc_amed_HomeHealthAndHospiceMember_69e0618c-93f7-4ea2-be8a-798bf49c5e68" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PersonalCareMember_077eab8b-993a-4164-9e60-3a6f619914cd" xlink:href="amed-20210630.xsd#amed_PersonalCareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_ffb289a4-1a19-4d98-a472-4377d07fd832" xlink:to="loc_amed_PersonalCareMember_077eab8b-993a-4164-9e60-3a6f619914cd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HomeHealthMember_c2751aec-4b18-42c8-921a-0a27ecf437b2" xlink:href="amed-20210630.xsd#amed_HomeHealthMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_ffb289a4-1a19-4d98-a472-4377d07fd832" xlink:to="loc_amed_HomeHealthMember_c2751aec-4b18-42c8-921a-0a27ecf437b2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnusualOrInfrequentItemAxis_9de6a979-cdac-4c23-b226-38edca87cf1c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnusualOrInfrequentItemAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_UnusualOrInfrequentItemTable_f849c7ca-6381-4a07-b166-3a3c3ad988fa" xlink:to="loc_us-gaap_UnusualOrInfrequentItemAxis_9de6a979-cdac-4c23-b226-38edca87cf1c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnusualOrInfrequentItemDomain_9de6a979-cdac-4c23-b226-38edca87cf1c_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnusualOrInfrequentItemDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_UnusualOrInfrequentItemAxis_9de6a979-cdac-4c23-b226-38edca87cf1c" xlink:to="loc_us-gaap_UnusualOrInfrequentItemDomain_9de6a979-cdac-4c23-b226-38edca87cf1c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnusualOrInfrequentItemDomain_21094e02-7c8e-476e-9a0f-94d203ab6fdd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnusualOrInfrequentItemDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_UnusualOrInfrequentItemAxis_9de6a979-cdac-4c23-b226-38edca87cf1c" xlink:to="loc_us-gaap_UnusualOrInfrequentItemDomain_21094e02-7c8e-476e-9a0f-94d203ab6fdd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_COVID19DeferralOfSocialSecurityMember_fca06073-b9e4-476a-8237-635ca0f3b1e5" xlink:href="amed-20210630.xsd#amed_COVID19DeferralOfSocialSecurityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_UnusualOrInfrequentItemDomain_21094e02-7c8e-476e-9a0f-94d203ab6fdd" xlink:to="loc_amed_COVID19DeferralOfSocialSecurityMember_fca06073-b9e4-476a-8237-635ca0f3b1e5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_4addfa38-154b-4d07-b206-cc1f3b9ed9db" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_UnusualOrInfrequentItemTable_f849c7ca-6381-4a07-b166-3a3c3ad988fa" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_4addfa38-154b-4d07-b206-cc1f3b9ed9db" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_4addfa38-154b-4d07-b206-cc1f3b9ed9db_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_4addfa38-154b-4d07-b206-cc1f3b9ed9db" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_4addfa38-154b-4d07-b206-cc1f3b9ed9db_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_7c35f5da-feaf-4dc9-bc1b-5337c430577f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_4addfa38-154b-4d07-b206-cc1f3b9ed9db" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_7c35f5da-feaf-4dc9-bc1b-5337c430577f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_32f76c3b-a25f-4182-9a93-8676e51b1105" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_7c35f5da-feaf-4dc9-bc1b-5337c430577f" xlink:to="loc_us-gaap_SubsequentEventMember_32f76c3b-a25f-4182-9a93-8676e51b1105" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails" xlink:type="simple" xlink:href="amed-20210630.xsd#ACQUISITIONSNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails" xlink:type="extended" id="iceea0bfb9f2b40a5b1f268fbb9be7a99_ACQUISITIONSNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_30ef7a82-1e52-4709-bbf1-8b98e1db894c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PercentageofSharesOutstanding_7bc933a2-66a0-4e3a-b9df-a6e832d83479" xlink:href="amed-20210630.xsd#amed_PercentageofSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_30ef7a82-1e52-4709-bbf1-8b98e1db894c" xlink:to="loc_amed_PercentageofSharesOutstanding_7bc933a2-66a0-4e3a-b9df-a6e832d83479" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_72f3ae01-26d0-41c3-9802-e1e1914d48a8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_30ef7a82-1e52-4709-bbf1-8b98e1db894c" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_72f3ae01-26d0-41c3-9802-e1e1914d48a8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAcquiredFromAcquisition_65bf833a-00dc-4a4f-8ab0-577ea733cb9a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAcquiredFromAcquisition"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_30ef7a82-1e52-4709-bbf1-8b98e1db894c" xlink:to="loc_us-gaap_CashAcquiredFromAcquisition_65bf833a-00dc-4a4f-8ab0-577ea733cb9a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfBusinessesAcquired_bd4cebbb-9484-4451-a86d-088335f7d829" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfBusinessesAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_30ef7a82-1e52-4709-bbf1-8b98e1db894c" xlink:to="loc_us-gaap_NumberOfBusinessesAcquired_bd4cebbb-9484-4451-a86d-088335f7d829" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_5b2342d0-161a-4d5a-8d96-0c1c160c5e2f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_30ef7a82-1e52-4709-bbf1-8b98e1db894c" xlink:to="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_5b2342d0-161a-4d5a-8d96-0c1c160c5e2f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PaymentsRelatedToTaxAsset_ccdceb51-ab58-487d-8d07-2e6c6235643d" xlink:href="amed-20210630.xsd#amed_PaymentsRelatedToTaxAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_30ef7a82-1e52-4709-bbf1-8b98e1db894c" xlink:to="loc_amed_PaymentsRelatedToTaxAsset_ccdceb51-ab58-487d-8d07-2e6c6235643d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_b37da83b-8ed1-462b-91a7-0f6df5ffe84a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_30ef7a82-1e52-4709-bbf1-8b98e1db894c" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_b37da83b-8ed1-462b-91a7-0f6df5ffe84a" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentAssetsPrepaidExpense_73d9a225-d92d-40d0-93dc-7f06ec7c29a4" xlink:href="amed-20210630.xsd#amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentAssetsPrepaidExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_30ef7a82-1e52-4709-bbf1-8b98e1db894c" xlink:to="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentAssetsPrepaidExpense_73d9a225-d92d-40d0-93dc-7f06ec7c29a4" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherCurrentAsset_c782af7d-29a0-4cec-a664-4e01cd352ff8" xlink:href="amed-20210630.xsd#amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherCurrentAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_30ef7a82-1e52-4709-bbf1-8b98e1db894c" xlink:to="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherCurrentAsset_c782af7d-29a0-4cec-a664-4e01cd352ff8" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_7ea99d3d-a8d6-4972-8244-d3b96352efe1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_30ef7a82-1e52-4709-bbf1-8b98e1db894c" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_7ea99d3d-a8d6-4972-8244-d3b96352efe1" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingleaserightofuseassets_bb93097d-592e-4a6d-99ba-0e49bdcb9725" xlink:href="amed-20210630.xsd#amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingleaserightofuseassets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_30ef7a82-1e52-4709-bbf1-8b98e1db894c" xlink:to="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingleaserightofuseassets_bb93097d-592e-4a6d-99ba-0e49bdcb9725" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_0c0049ff-9d2f-4535-b096-aa6098727c67" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_30ef7a82-1e52-4709-bbf1-8b98e1db894c" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_0c0049ff-9d2f-4535-b096-aa6098727c67" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_306c83cc-cf1a-4cff-9a91-3887bdf60661" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_30ef7a82-1e52-4709-bbf1-8b98e1db894c" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_306c83cc-cf1a-4cff-9a91-3887bdf60661" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_5efd38e5-8ff1-4f39-ac90-9f43b61d1f55" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_30ef7a82-1e52-4709-bbf1-8b98e1db894c" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_5efd38e5-8ff1-4f39-ac90-9f43b61d1f55" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_b2ff7a43-513f-49e3-a2ac-f3138dbac312" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_30ef7a82-1e52-4709-bbf1-8b98e1db894c" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_b2ff7a43-513f-49e3-a2ac-f3138dbac312" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesPayrollandEmployeeBenefits_f2f1eb92-d4f6-4cae-b36b-65f5d19b9af5" xlink:href="amed-20210630.xsd#amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesPayrollandEmployeeBenefits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_30ef7a82-1e52-4709-bbf1-8b98e1db894c" xlink:to="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesPayrollandEmployeeBenefits_f2f1eb92-d4f6-4cae-b36b-65f5d19b9af5" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses_186c7b36-7b4e-4239-aaab-be1de3eb4628" xlink:href="amed-20210630.xsd#amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_30ef7a82-1e52-4709-bbf1-8b98e1db894c" xlink:to="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses_186c7b36-7b4e-4239-aaab-be1de3eb4628" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_d1463d71-2cde-4ccf-9ed0-bffcad2eb123" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_30ef7a82-1e52-4709-bbf1-8b98e1db894c" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_d1463d71-2cde-4ccf-9ed0-bffcad2eb123" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingLeaseLiabilities_6cfeab10-f8a1-44dd-8caf-1da67945ac1d" xlink:href="amed-20210630.xsd#amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingLeaseLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_30ef7a82-1e52-4709-bbf1-8b98e1db894c" xlink:to="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingLeaseLiabilities_6cfeab10-f8a1-44dd-8caf-1da67945ac1d" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt_7c5f978a-b0b3-4852-9148-d219723b9afe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_30ef7a82-1e52-4709-bbf1-8b98e1db894c" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt_7c5f978a-b0b3-4852-9148-d219723b9afe" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther_ae25c6b4-eae6-45f8-b44b-725c84efac68" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_30ef7a82-1e52-4709-bbf1-8b98e1db894c" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther_ae25c6b4-eae6-45f8-b44b-725c84efac68" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_7cc7b6c7-23e2-46a1-8295-dc6146dbb216" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_30ef7a82-1e52-4709-bbf1-8b98e1db894c" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_7cc7b6c7-23e2-46a1-8295-dc6146dbb216" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_f2b753d3-60b6-4b13-a9fd-19abb45a73c4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_30ef7a82-1e52-4709-bbf1-8b98e1db894c" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_f2b753d3-60b6-4b13-a9fd-19abb45a73c4" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod_618c40f3-5a3e-469c-9f50-71bb1505b3f8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAcquiredDuringPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_30ef7a82-1e52-4709-bbf1-8b98e1db894c" xlink:to="loc_us-gaap_GoodwillAcquiredDuringPeriod_618c40f3-5a3e-469c-9f50-71bb1505b3f8" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_a79df637-1247-47a6-bb50-2cb4ed30d37c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_30ef7a82-1e52-4709-bbf1-8b98e1db894c" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_a79df637-1247-47a6-bb50-2cb4ed30d37c" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions_264fcb2e-f470-4a9e-9783-f28e83437441" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_30ef7a82-1e52-4709-bbf1-8b98e1db894c" xlink:to="loc_us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions_264fcb2e-f470-4a9e-9783-f28e83437441" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_aec8b045-de55-45e7-b08f-6775ccc50140" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_30ef7a82-1e52-4709-bbf1-8b98e1db894c" xlink:to="loc_us-gaap_OperatingIncomeLoss_aec8b045-de55-45e7-b08f-6775ccc50140" xlink:type="arc" order="26"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationIntegrationRelatedCosts_6adc414c-dfb6-42ca-8866-84ded9f3fd8d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationIntegrationRelatedCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_30ef7a82-1e52-4709-bbf1-8b98e1db894c" xlink:to="loc_us-gaap_BusinessCombinationIntegrationRelatedCosts_6adc414c-dfb6-42ca-8866-84ded9f3fd8d" xlink:type="arc" order="27"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_BusinessAcquisitionWorkingCapitalAdjustment_8d2e0993-e175-43c6-82f2-01dfdb351dc0" xlink:href="amed-20210630.xsd#amed_BusinessAcquisitionWorkingCapitalAdjustment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_30ef7a82-1e52-4709-bbf1-8b98e1db894c" xlink:to="loc_amed_BusinessAcquisitionWorkingCapitalAdjustment_8d2e0993-e175-43c6-82f2-01dfdb351dc0" xlink:type="arc" order="28"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OffMarketLeaseUnfavorable_24efb970-468f-4304-b372-101a4c02cab5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OffMarketLeaseUnfavorable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_30ef7a82-1e52-4709-bbf1-8b98e1db894c" xlink:to="loc_us-gaap_OffMarketLeaseUnfavorable_24efb970-468f-4304-b372-101a4c02cab5" xlink:type="arc" order="29"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_BusinessAcquisitionClosingPaymentAdjustment_71428ddb-83b7-47eb-80cd-69cd31f8bd90" xlink:href="amed-20210630.xsd#amed_BusinessAcquisitionClosingPaymentAdjustment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_30ef7a82-1e52-4709-bbf1-8b98e1db894c" xlink:to="loc_amed_BusinessAcquisitionClosingPaymentAdjustment_71428ddb-83b7-47eb-80cd-69cd31f8bd90" xlink:type="arc" order="30"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_DepreciationAndAmortizationForContinuingOperations_6f861c66-3a57-4d68-a718-e9824cf68213" xlink:href="amed-20210630.xsd#amed_DepreciationAndAmortizationForContinuingOperations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_30ef7a82-1e52-4709-bbf1-8b98e1db894c" xlink:to="loc_amed_DepreciationAndAmortizationForContinuingOperations_6f861c66-3a57-4d68-a718-e9824cf68213" xlink:type="arc" order="31"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_GoodwillDeductibleForIncomeTaxPurposesPeriod_13fb1432-aa4f-44e3-b50e-5209f5e10d50" xlink:href="amed-20210630.xsd#amed_GoodwillDeductibleForIncomeTaxPurposesPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_30ef7a82-1e52-4709-bbf1-8b98e1db894c" xlink:to="loc_amed_GoodwillDeductibleForIncomeTaxPurposesPeriod_13fb1432-aa4f-44e3-b50e-5209f5e10d50" xlink:type="arc" order="32"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_41f760f7-5345-4750-b4a2-4fa1e643e968" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_30ef7a82-1e52-4709-bbf1-8b98e1db894c" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_41f760f7-5345-4750-b4a2-4fa1e643e968" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_6975c313-2857-43a3-a130-e515d006ba02" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_41f760f7-5345-4750-b4a2-4fa1e643e968" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_6975c313-2857-43a3-a130-e515d006ba02" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_6975c313-2857-43a3-a130-e515d006ba02_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_6975c313-2857-43a3-a130-e515d006ba02" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_6975c313-2857-43a3-a130-e515d006ba02_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_5459ace9-552e-45e1-aaf8-6b31be0b3495" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_6975c313-2857-43a3-a130-e515d006ba02" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_5459ace9-552e-45e1-aaf8-6b31be0b3495" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeNamesMember_c125034d-52de-4b22-a0c7-0867b8e48a94" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TradeNamesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_5459ace9-552e-45e1-aaf8-6b31be0b3495" xlink:to="loc_us-gaap_TradeNamesMember_c125034d-52de-4b22-a0c7-0867b8e48a94" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncompeteAgreementsMember_eb2636b1-a9a4-435e-ad3b-984eeced0926" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncompeteAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_5459ace9-552e-45e1-aaf8-6b31be0b3495" xlink:to="loc_us-gaap_NoncompeteAgreementsMember_eb2636b1-a9a4-435e-ad3b-984eeced0926" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AcquiredNamesMember_89edf89c-78c9-454e-a009-535d3971c8de" xlink:href="amed-20210630.xsd#amed_AcquiredNamesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_5459ace9-552e-45e1-aaf8-6b31be0b3495" xlink:to="loc_amed_AcquiredNamesMember_89edf89c-78c9-454e-a009-535d3971c8de" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OffMarketFavorableLeaseMember_ab9cf85a-97c5-43b9-8608-34a0adaeeb6a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OffMarketFavorableLeaseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_5459ace9-552e-45e1-aaf8-6b31be0b3495" xlink:to="loc_us-gaap_OffMarketFavorableLeaseMember_ab9cf85a-97c5-43b9-8608-34a0adaeeb6a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_MedicareLicenseMember_e07fbba9-c181-456e-b3f9-c0cf347ba862" xlink:href="amed-20210630.xsd#amed_MedicareLicenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_5459ace9-552e-45e1-aaf8-6b31be0b3495" xlink:to="loc_amed_MedicareLicenseMember_e07fbba9-c181-456e-b3f9-c0cf347ba862" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionNameOfAcquiredEntity_e16ac943-757e-4de9-8715-ed9a065afc74" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionNameOfAcquiredEntity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_5459ace9-552e-45e1-aaf8-6b31be0b3495" xlink:to="loc_us-gaap_BusinessAcquisitionNameOfAcquiredEntity_e16ac943-757e-4de9-8715-ed9a065afc74" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CertificatesOfNeedMember_8c30a6a3-0d08-4f79-b2af-c611ee2fb8fd" xlink:href="amed-20210630.xsd#amed_CertificatesOfNeedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_5459ace9-552e-45e1-aaf8-6b31be0b3495" xlink:to="loc_amed_CertificatesOfNeedMember_8c30a6a3-0d08-4f79-b2af-c611ee2fb8fd" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CertificateOfNeedMember_05ab8a48-753f-4dba-85c9-3d8459116005" xlink:href="amed-20210630.xsd#amed_CertificateOfNeedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_5459ace9-552e-45e1-aaf8-6b31be0b3495" xlink:to="loc_amed_CertificateOfNeedMember_05ab8a48-753f-4dba-85c9-3d8459116005" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_711798cf-c9a7-4642-8c97-032677dae5f7" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_41f760f7-5345-4750-b4a2-4fa1e643e968" xlink:to="loc_srt_StatementGeographicalAxis_711798cf-c9a7-4642-8c97-032677dae5f7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_711798cf-c9a7-4642-8c97-032677dae5f7_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_711798cf-c9a7-4642-8c97-032677dae5f7" xlink:to="loc_srt_SegmentGeographicalDomain_711798cf-c9a7-4642-8c97-032677dae5f7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_43ba4b37-b5a8-432e-aeb7-f147eafd6618" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_711798cf-c9a7-4642-8c97-032677dae5f7" xlink:to="loc_srt_SegmentGeographicalDomain_43ba4b37-b5a8-432e-aeb7-f147eafd6618" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_TN_362fe980-46ff-4701-baab-e9215d01e7c8" xlink:href="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd#stpr_TN"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_43ba4b37-b5a8-432e-aeb7-f147eafd6618" xlink:to="loc_stpr_TN_362fe980-46ff-4701-baab-e9215d01e7c8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_WA_5d0238b9-936e-454f-81d2-639068650f83" xlink:href="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd#stpr_WA"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_43ba4b37-b5a8-432e-aeb7-f147eafd6618" xlink:to="loc_stpr_WA_5d0238b9-936e-454f-81d2-639068650f83" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_KY_c7929fd3-4e89-4915-9b24-e71fab6c87c4" xlink:href="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd#stpr_KY"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_43ba4b37-b5a8-432e-aeb7-f147eafd6618" xlink:to="loc_stpr_KY_c7929fd3-4e89-4915-9b24-e71fab6c87c4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_NC_fd7768da-9cae-4628-9d63-b9b2a23ea1b3" xlink:href="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd#stpr_NC"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_43ba4b37-b5a8-432e-aeb7-f147eafd6618" xlink:to="loc_stpr_NC_fd7768da-9cae-4628-9d63-b9b2a23ea1b3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_c026528a-89ba-4a38-a6fe-76336b0def76" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_41f760f7-5345-4750-b4a2-4fa1e643e968" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_c026528a-89ba-4a38-a6fe-76336b0def76" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_c026528a-89ba-4a38-a6fe-76336b0def76_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_c026528a-89ba-4a38-a6fe-76336b0def76" xlink:to="loc_us-gaap_SegmentDomain_c026528a-89ba-4a38-a6fe-76336b0def76_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_852113e3-0d77-4127-9664-0db7a860da8a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_c026528a-89ba-4a38-a6fe-76336b0def76" xlink:to="loc_us-gaap_SegmentDomain_852113e3-0d77-4127-9664-0db7a860da8a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HospiceMember_d2c27245-bc53-4c01-8c76-ef3f0dba8a04" xlink:href="amed-20210630.xsd#amed_HospiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_852113e3-0d77-4127-9664-0db7a860da8a" xlink:to="loc_amed_HospiceMember_d2c27245-bc53-4c01-8c76-ef3f0dba8a04" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HomeHealthMember_878e5dae-0e52-4d4d-ada8-f4dbe9d1eee6" xlink:href="amed-20210630.xsd#amed_HomeHealthMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_852113e3-0d77-4127-9664-0db7a860da8a" xlink:to="loc_amed_HomeHealthMember_878e5dae-0e52-4d4d-ada8-f4dbe9d1eee6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_064a94bc-f8da-40f1-b1ee-b98b356b2554" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_41f760f7-5345-4750-b4a2-4fa1e643e968" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_064a94bc-f8da-40f1-b1ee-b98b356b2554" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_064a94bc-f8da-40f1-b1ee-b98b356b2554_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_064a94bc-f8da-40f1-b1ee-b98b356b2554" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_064a94bc-f8da-40f1-b1ee-b98b356b2554_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e7ea5ef3-e1cc-4618-a1f2-4765d6cbc54a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_064a94bc-f8da-40f1-b1ee-b98b356b2554" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e7ea5ef3-e1cc-4618-a1f2-4765d6cbc54a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AseraCareHospiceMember_d2426b9a-6f7c-4407-8983-280c0292422d" xlink:href="amed-20210630.xsd#amed_AseraCareHospiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e7ea5ef3-e1cc-4618-a1f2-4765d6cbc54a" xlink:to="loc_amed_AseraCareHospiceMember_d2426b9a-6f7c-4407-8983-280c0292422d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_4be53bf5-efe1-42a6-aae4-1fb6cde02393" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_41f760f7-5345-4750-b4a2-4fa1e643e968" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_4be53bf5-efe1-42a6-aae4-1fb6cde02393" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_4be53bf5-efe1-42a6-aae4-1fb6cde02393_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_4be53bf5-efe1-42a6-aae4-1fb6cde02393" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_4be53bf5-efe1-42a6-aae4-1fb6cde02393_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_8fbc5e16-f557-4323-a261-8302ae6c4031" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_4be53bf5-efe1-42a6-aae4-1fb6cde02393" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_8fbc5e16-f557-4323-a261-8302ae6c4031" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CertificateOfNeedMember_d16511b2-becf-4d56-987a-f94553d1a5ec" xlink:href="amed-20210630.xsd#amed_CertificateOfNeedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_8fbc5e16-f557-4323-a261-8302ae6c4031" xlink:to="loc_amed_CertificateOfNeedMember_d16511b2-becf-4d56-987a-f94553d1a5ec" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_MedicareLicenseMember_95023f5c-50c0-412e-b413-1458fd784241" xlink:href="amed-20210630.xsd#amed_MedicareLicenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_8fbc5e16-f557-4323-a261-8302ae6c4031" xlink:to="loc_amed_MedicareLicenseMember_95023f5c-50c0-412e-b413-1458fd784241" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_1f4de1fe-fc22-4307-ae8e-55496cb234bd" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_41f760f7-5345-4750-b4a2-4fa1e643e968" xlink:to="loc_srt_RangeAxis_1f4de1fe-fc22-4307-ae8e-55496cb234bd" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_1f4de1fe-fc22-4307-ae8e-55496cb234bd_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_1f4de1fe-fc22-4307-ae8e-55496cb234bd" xlink:to="loc_srt_RangeMember_1f4de1fe-fc22-4307-ae8e-55496cb234bd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_351efb08-5a7a-44f5-8104-b41e818e12ab" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_1f4de1fe-fc22-4307-ae8e-55496cb234bd" xlink:to="loc_srt_RangeMember_351efb08-5a7a-44f5-8104-b41e818e12ab" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_b31cf005-4f27-42ea-a74b-beb9bde038b6" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_351efb08-5a7a-44f5-8104-b41e818e12ab" xlink:to="loc_srt_MaximumMember_b31cf005-4f27-42ea-a74b-beb9bde038b6" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/ACQUISITIONSProFormaDetails" xlink:type="simple" xlink:href="amed-20210630.xsd#ACQUISITIONSProFormaDetails"/>
  <link:definitionLink xlink:role="http://www.amedisys.com/role/ACQUISITIONSProFormaDetails" xlink:type="extended" id="i4da84f35281f4d1ab4243864efe378e5_ACQUISITIONSProFormaDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_cde53dbc-444c-4055-a17d-fab828132ff7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionsProFormaRevenue_213a4df8-23e0-4344-a9e4-06a7d9ab9092" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionsProFormaRevenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_cde53dbc-444c-4055-a17d-fab828132ff7" xlink:to="loc_us-gaap_BusinessAcquisitionsProFormaRevenue_213a4df8-23e0-4344-a9e4-06a7d9ab9092" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_Businessacquisitionproformaoperatingincomeloss_f4859274-0ede-4a34-8499-a7bebe3394f8" xlink:href="amed-20210630.xsd#amed_Businessacquisitionproformaoperatingincomeloss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_cde53dbc-444c-4055-a17d-fab828132ff7" xlink:to="loc_amed_Businessacquisitionproformaoperatingincomeloss_f4859274-0ede-4a34-8499-a7bebe3394f8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_f8eac593-4f63-41a8-8484-a57dbb08c546" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_cde53dbc-444c-4055-a17d-fab828132ff7" xlink:to="loc_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_f8eac593-4f63-41a8-8484-a57dbb08c546" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic_51169f9d-c976-44c1-8456-803cf304ee73" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_cde53dbc-444c-4055-a17d-fab828132ff7" xlink:to="loc_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic_51169f9d-c976-44c1-8456-803cf304ee73" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted_8f93947b-9520-49a6-85eb-1abe337e2a14" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_cde53dbc-444c-4055-a17d-fab828132ff7" xlink:to="loc_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted_8f93947b-9520-49a6-85eb-1abe337e2a14" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_008b2285-d0a2-49b5-b356-46045f367aa5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_cde53dbc-444c-4055-a17d-fab828132ff7" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_008b2285-d0a2-49b5-b356-46045f367aa5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_e495e239-1bdb-42a0-8878-a75fb83ace9d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_008b2285-d0a2-49b5-b356-46045f367aa5" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_e495e239-1bdb-42a0-8878-a75fb83ace9d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_e495e239-1bdb-42a0-8878-a75fb83ace9d_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_e495e239-1bdb-42a0-8878-a75fb83ace9d" xlink:to="loc_us-gaap_SegmentDomain_e495e239-1bdb-42a0-8878-a75fb83ace9d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_52eb8381-bfe9-4c53-a08f-b8c79d5f2f92" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_e495e239-1bdb-42a0-8878-a75fb83ace9d" xlink:to="loc_us-gaap_SegmentDomain_52eb8381-bfe9-4c53-a08f-b8c79d5f2f92" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HospiceMember_4a1321e5-3c28-4575-9bd1-48cabf56ab27" xlink:href="amed-20210630.xsd#amed_HospiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_52eb8381-bfe9-4c53-a08f-b8c79d5f2f92" xlink:to="loc_amed_HospiceMember_4a1321e5-3c28-4575-9bd1-48cabf56ab27" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_4c6addad-af62-4b4a-b083-4d8d5150bb49" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_008b2285-d0a2-49b5-b356-46045f367aa5" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_4c6addad-af62-4b4a-b083-4d8d5150bb49" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4c6addad-af62-4b4a-b083-4d8d5150bb49_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_4c6addad-af62-4b4a-b083-4d8d5150bb49" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4c6addad-af62-4b4a-b083-4d8d5150bb49_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b68c42c5-d022-4e6b-bc66-3596aeab76fb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_4c6addad-af62-4b4a-b083-4d8d5150bb49" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b68c42c5-d022-4e6b-bc66-3596aeab76fb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CompassionateCareHospiceMember_8692595d-3fb8-48ac-907c-1fd3090ad26c" xlink:href="amed-20210630.xsd#amed_CompassionateCareHospiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b68c42c5-d022-4e6b-bc66-3596aeab76fb" xlink:to="loc_amed_CompassionateCareHospiceMember_8692595d-3fb8-48ac-907c-1fd3090ad26c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AseraCareHospiceMember_aa266cd2-697d-4bdd-a20f-263a8d1ea620" xlink:href="amed-20210630.xsd#amed_AseraCareHospiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b68c42c5-d022-4e6b-bc66-3596aeab76fb" xlink:to="loc_amed_AseraCareHospiceMember_aa266cd2-697d-4bdd-a20f-263a8d1ea620" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_22a98fad-1cbc-4d55-ad1c-efb4335f4c2c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_008b2285-d0a2-49b5-b356-46045f367aa5" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_22a98fad-1cbc-4d55-ad1c-efb4335f4c2c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_22a98fad-1cbc-4d55-ad1c-efb4335f4c2c_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_22a98fad-1cbc-4d55-ad1c-efb4335f4c2c" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_22a98fad-1cbc-4d55-ad1c-efb4335f4c2c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_47db813e-6a83-47a5-ab70-89b874b2d100" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_22a98fad-1cbc-4d55-ad1c-efb4335f4c2c" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_47db813e-6a83-47a5-ab70-89b874b2d100" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_c7116357-b9ce-47a0-877b-2561de9eabc0" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_OwnershipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_008b2285-d0a2-49b5-b356-46045f367aa5" xlink:to="loc_srt_OwnershipAxis_c7116357-b9ce-47a0-877b-2561de9eabc0" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_c7116357-b9ce-47a0-877b-2561de9eabc0_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_OwnershipAxis_c7116357-b9ce-47a0-877b-2561de9eabc0" xlink:to="loc_srt_OwnershipDomain_c7116357-b9ce-47a0-877b-2561de9eabc0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_d5e11e97-7e2b-46b9-bebe-77ddf2bb1090" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_OwnershipAxis_c7116357-b9ce-47a0-877b-2561de9eabc0" xlink:to="loc_srt_OwnershipDomain_d5e11e97-7e2b-46b9-bebe-77ddf2bb1090" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_0f5f844c-cb19-4c36-853a-10642148e5e9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_008b2285-d0a2-49b5-b356-46045f367aa5" xlink:to="loc_us-gaap_StatementClassOfStockAxis_0f5f844c-cb19-4c36-853a-10642148e5e9" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_0f5f844c-cb19-4c36-853a-10642148e5e9_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_0f5f844c-cb19-4c36-853a-10642148e5e9" xlink:to="loc_us-gaap_ClassOfStockDomain_0f5f844c-cb19-4c36-853a-10642148e5e9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_04ad9f9d-8887-478b-ae34-5fb00a2b996f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_0f5f844c-cb19-4c36-853a-10642148e5e9" xlink:to="loc_us-gaap_ClassOfStockDomain_04ad9f9d-8887-478b-ae34-5fb00a2b996f" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtDetails" xlink:type="simple" xlink:href="amed-20210630.xsd#LONGTERMOBLIGATIONSScheduleofLongTermDebtDetails"/>
  <link:definitionLink xlink:role="http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtDetails" xlink:type="extended" id="i032a7740af8845adafa869140a24b053_LONGTERMOBLIGATIONSScheduleofLongTermDebtDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_e23119e0-07f1-4302-adb4-b899e3c41abc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_5e239b8a-6cac-4920-a2f6-937ca3dd5eed" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e23119e0-07f1-4302-adb4-b899e3c41abc" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_5e239b8a-6cac-4920-a2f6-937ca3dd5eed" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_7996e3ba-6510-404e-a7fe-7af08e7ad69d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e23119e0-07f1-4302-adb4-b899e3c41abc" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_7996e3ba-6510-404e-a7fe-7af08e7ad69d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_845abb79-be5e-40c6-9b2c-ca60ce2fda70" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e23119e0-07f1-4302-adb4-b899e3c41abc" xlink:to="loc_us-gaap_LongTermDebt_845abb79-be5e-40c6-9b2c-ca60ce2fda70" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_315cb369-6192-40b5-8ea8-99b238e66b11" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e23119e0-07f1-4302-adb4-b899e3c41abc" xlink:to="loc_us-gaap_LongTermDebtCurrent_315cb369-6192-40b5-8ea8-99b238e66b11" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_d31a41fd-0c49-4773-99e1-c0e01cf80478" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e23119e0-07f1-4302-adb4-b899e3c41abc" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_d31a41fd-0c49-4773-99e1-c0e01cf80478" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_38f628d8-c620-42ce-be51-8f181da36a0d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e23119e0-07f1-4302-adb4-b899e3c41abc" xlink:to="loc_us-gaap_DebtInstrumentTable_38f628d8-c620-42ce-be51-8f181da36a0d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_c11dc671-ccd4-4772-9f7e-0db91650805b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_38f628d8-c620-42ce-be51-8f181da36a0d" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_c11dc671-ccd4-4772-9f7e-0db91650805b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_c11dc671-ccd4-4772-9f7e-0db91650805b_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_c11dc671-ccd4-4772-9f7e-0db91650805b" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_c11dc671-ccd4-4772-9f7e-0db91650805b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_e358238d-7859-43aa-b26b-4b768d9e38b6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_c11dc671-ccd4-4772-9f7e-0db91650805b" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_e358238d-7859-43aa-b26b-4b768d9e38b6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LoansPayableMember_57bfcb32-5553-40d2-93db-af62b7db6614" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LoansPayableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_e358238d-7859-43aa-b26b-4b768d9e38b6" xlink:to="loc_us-gaap_LoansPayableMember_57bfcb32-5553-40d2-93db-af62b7db6614" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_55d6c14a-9da8-4443-9c61-98d5423cd83f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_e358238d-7859-43aa-b26b-4b768d9e38b6" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_55d6c14a-9da8-4443-9c61-98d5423cd83f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PromissoryNotesMember_fe285832-1619-41d1-8806-0ea65a2f9b91" xlink:href="amed-20210630.xsd#amed_PromissoryNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_e358238d-7859-43aa-b26b-4b768d9e38b6" xlink:to="loc_amed_PromissoryNotesMember_fe285832-1619-41d1-8806-0ea65a2f9b91" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalLeaseObligationsMember_44293227-452d-4d15-9083-6941bbf0bf43" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalLeaseObligationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_e358238d-7859-43aa-b26b-4b768d9e38b6" xlink:to="loc_us-gaap_CapitalLeaseObligationsMember_44293227-452d-4d15-9083-6941bbf0bf43" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_42203d7d-5a21-4896-bf04-15f43f674045" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_38f628d8-c620-42ce-be51-8f181da36a0d" xlink:to="loc_us-gaap_DebtInstrumentAxis_42203d7d-5a21-4896-bf04-15f43f674045" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_42203d7d-5a21-4896-bf04-15f43f674045_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_42203d7d-5a21-4896-bf04-15f43f674045" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_42203d7d-5a21-4896-bf04-15f43f674045_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_d6af7ab1-b1c6-40e1-b4cf-0372e03db405" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_42203d7d-5a21-4896-bf04-15f43f674045" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_d6af7ab1-b1c6-40e1-b4cf-0372e03db405" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_OneHundredSeventyFiveMillionTermLoanFacilityMember_c8161ab1-0f93-453d-84b3-cf8822bdecfa" xlink:href="amed-20210630.xsd#amed_OneHundredSeventyFiveMillionTermLoanFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d6af7ab1-b1c6-40e1-b4cf-0372e03db405" xlink:to="loc_amed_OneHundredSeventyFiveMillionTermLoanFacilityMember_c8161ab1-0f93-453d-84b3-cf8822bdecfa" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember_3a948ae4-3117-49cc-a928-af0f7ed2333e" xlink:href="amed-20210630.xsd#amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d6af7ab1-b1c6-40e1-b4cf-0372e03db405" xlink:to="loc_amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember_3a948ae4-3117-49cc-a928-af0f7ed2333e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_57c00439-c425-4d7b-a387-e650d61801b4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_38f628d8-c620-42ce-be51-8f181da36a0d" xlink:to="loc_us-gaap_VariableRateAxis_57c00439-c425-4d7b-a387-e650d61801b4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_57c00439-c425-4d7b-a387-e650d61801b4_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VariableRateAxis_57c00439-c425-4d7b-a387-e650d61801b4" xlink:to="loc_us-gaap_VariableRateDomain_57c00439-c425-4d7b-a387-e650d61801b4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_f7153214-0ddb-4aff-841c-73efd0be2668" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VariableRateAxis_57c00439-c425-4d7b-a387-e650d61801b4" xlink:to="loc_us-gaap_VariableRateDomain_f7153214-0ddb-4aff-841c-73efd0be2668" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EurodollarMember_71856533-b2ca-4578-8e1a-876efc1fe0e4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EurodollarMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_f7153214-0ddb-4aff-841c-73efd0be2668" xlink:to="loc_us-gaap_EurodollarMember_71856533-b2ca-4578-8e1a-876efc1fe0e4" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtAdditionalInformationDetails" xlink:type="simple" xlink:href="amed-20210630.xsd#LONGTERMOBLIGATIONSScheduleofLongTermDebtAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtAdditionalInformationDetails" xlink:type="extended" id="i7ec3d8ce9cbb475da36dc15a68739655_LONGTERMOBLIGATIONSScheduleofLongTermDebtAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_7be65452-f80b-47df-9e38-3916f3c2a33f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_e4e27c69-5176-4a3b-8ad0-1342377338af" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7be65452-f80b-47df-9e38-3916f3c2a33f" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_e4e27c69-5176-4a3b-8ad0-1342377338af" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_DebtInstrumentInterestRateatPeriodEnd_026f6a43-d445-454f-8e6d-fd9a5b2f481f" xlink:href="amed-20210630.xsd#amed_DebtInstrumentInterestRateatPeriodEnd"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7be65452-f80b-47df-9e38-3916f3c2a33f" xlink:to="loc_amed_DebtInstrumentInterestRateatPeriodEnd_026f6a43-d445-454f-8e6d-fd9a5b2f481f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentMaturityDate_58b489d0-23cc-4730-a3a2-fe0240ef8fb0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentMaturityDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7be65452-f80b-47df-9e38-3916f3c2a33f" xlink:to="loc_us-gaap_DebtInstrumentMaturityDate_58b489d0-23cc-4730-a3a2-fe0240ef8fb0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_24f94f44-1865-477c-b806-9a8ca1111346" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7be65452-f80b-47df-9e38-3916f3c2a33f" xlink:to="loc_us-gaap_DebtInstrumentTable_24f94f44-1865-477c-b806-9a8ca1111346" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_3768ee4b-0508-4439-9c7c-e40237fe35c3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_24f94f44-1865-477c-b806-9a8ca1111346" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_3768ee4b-0508-4439-9c7c-e40237fe35c3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_3768ee4b-0508-4439-9c7c-e40237fe35c3_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_3768ee4b-0508-4439-9c7c-e40237fe35c3" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_3768ee4b-0508-4439-9c7c-e40237fe35c3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_ab5bb1c2-0a21-447f-bd88-d90dfe3fdfad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_3768ee4b-0508-4439-9c7c-e40237fe35c3" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_ab5bb1c2-0a21-447f-bd88-d90dfe3fdfad" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LoansPayableMember_469265a1-b6a6-4285-97bf-646b77e735fb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LoansPayableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_ab5bb1c2-0a21-447f-bd88-d90dfe3fdfad" xlink:to="loc_us-gaap_LoansPayableMember_469265a1-b6a6-4285-97bf-646b77e735fb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_770c6df4-b85a-456c-b03d-62d9597ab703" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_ab5bb1c2-0a21-447f-bd88-d90dfe3fdfad" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_770c6df4-b85a-456c-b03d-62d9597ab703" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_11f10544-a9ae-4bef-a89f-e46da521ebb3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_24f94f44-1865-477c-b806-9a8ca1111346" xlink:to="loc_us-gaap_DebtInstrumentAxis_11f10544-a9ae-4bef-a89f-e46da521ebb3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_11f10544-a9ae-4bef-a89f-e46da521ebb3_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_11f10544-a9ae-4bef-a89f-e46da521ebb3" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_11f10544-a9ae-4bef-a89f-e46da521ebb3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_820cabe2-6147-44e3-81d8-8c63fe085eb0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_11f10544-a9ae-4bef-a89f-e46da521ebb3" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_820cabe2-6147-44e3-81d8-8c63fe085eb0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_OneHundredSeventyFiveMillionTermLoanFacilityMember_bf12059a-1370-47b1-8982-13b84bbbbba1" xlink:href="amed-20210630.xsd#amed_OneHundredSeventyFiveMillionTermLoanFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_820cabe2-6147-44e3-81d8-8c63fe085eb0" xlink:to="loc_amed_OneHundredSeventyFiveMillionTermLoanFacilityMember_bf12059a-1370-47b1-8982-13b84bbbbba1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_TwoHundredMillionRevolvingCreditFacilityMember_d0913654-46b8-4455-8c8a-50b1ca3ce0b7" xlink:href="amed-20210630.xsd#amed_TwoHundredMillionRevolvingCreditFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_820cabe2-6147-44e3-81d8-8c63fe085eb0" xlink:to="loc_amed_TwoHundredMillionRevolvingCreditFacilityMember_d0913654-46b8-4455-8c8a-50b1ca3ce0b7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember_fad58f0a-8d62-428a-864f-77c41d14d175" xlink:href="amed-20210630.xsd#amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_820cabe2-6147-44e3-81d8-8c63fe085eb0" xlink:to="loc_amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember_fad58f0a-8d62-428a-864f-77c41d14d175" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_12011010-de14-499a-96ae-1841d05d09f2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_24f94f44-1865-477c-b806-9a8ca1111346" xlink:to="loc_us-gaap_VariableRateAxis_12011010-de14-499a-96ae-1841d05d09f2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_12011010-de14-499a-96ae-1841d05d09f2_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VariableRateAxis_12011010-de14-499a-96ae-1841d05d09f2" xlink:to="loc_us-gaap_VariableRateDomain_12011010-de14-499a-96ae-1841d05d09f2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_43a4ff75-a41d-493f-b7d6-d63a2f8abc2d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VariableRateAxis_12011010-de14-499a-96ae-1841d05d09f2" xlink:to="loc_us-gaap_VariableRateDomain_43a4ff75-a41d-493f-b7d6-d63a2f8abc2d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EurodollarMember_40bcea47-d50c-45a9-8b0b-18e2f3425dd6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EurodollarMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_43a4ff75-a41d-493f-b7d6-d63a2f8abc2d" xlink:to="loc_us-gaap_EurodollarMember_40bcea47-d50c-45a9-8b0b-18e2f3425dd6" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/LONGTERMOBLIGATIONSFeesandRatesUnderCreditFacilitiesDetails" xlink:type="simple" xlink:href="amed-20210630.xsd#LONGTERMOBLIGATIONSFeesandRatesUnderCreditFacilitiesDetails"/>
  <link:definitionLink xlink:role="http://www.amedisys.com/role/LONGTERMOBLIGATIONSFeesandRatesUnderCreditFacilitiesDetails" xlink:type="extended" id="if07ac2eb55ec43b591c92cd6fa514025_LONGTERMOBLIGATIONSFeesandRatesUnderCreditFacilitiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLineItems_001f8989-8ce7-4d63-ba81-a2b5de76af0d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ConsolidatedLeverageRatio_eee0f5fa-0192-4204-ba90-2a4418bfb731" xlink:href="amed-20210630.xsd#amed_ConsolidatedLeverageRatio"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_001f8989-8ce7-4d63-ba81-a2b5de76af0d" xlink:to="loc_amed_ConsolidatedLeverageRatio_eee0f5fa-0192-4204-ba90-2a4418bfb731" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_cb24e696-dc37-4408-90e6-02232d90087a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityCommitmentFeePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_001f8989-8ce7-4d63-ba81-a2b5de76af0d" xlink:to="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_cb24e696-dc37-4408-90e6-02232d90087a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_LetterOfCreditFee_c6d98c16-e627-4536-9f4d-8c773ebe5127" xlink:href="amed-20210630.xsd#amed_LetterOfCreditFee"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_001f8989-8ce7-4d63-ba81-a2b5de76af0d" xlink:to="loc_amed_LetterOfCreditFee_c6d98c16-e627-4536-9f4d-8c773ebe5127" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_9d7569df-e84a-480d-8969-932f24b7e488" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_001f8989-8ce7-4d63-ba81-a2b5de76af0d" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_9d7569df-e84a-480d-8969-932f24b7e488" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityTable_6237af1e-77da-4400-b0ac-a94e8740042d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_001f8989-8ce7-4d63-ba81-a2b5de76af0d" xlink:to="loc_us-gaap_LineOfCreditFacilityTable_6237af1e-77da-4400-b0ac-a94e8740042d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_0b098753-d70a-4d48-9d4d-ae65c1c8472c" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_6237af1e-77da-4400-b0ac-a94e8740042d" xlink:to="loc_srt_RangeAxis_0b098753-d70a-4d48-9d4d-ae65c1c8472c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_0b098753-d70a-4d48-9d4d-ae65c1c8472c_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_0b098753-d70a-4d48-9d4d-ae65c1c8472c" xlink:to="loc_srt_RangeMember_0b098753-d70a-4d48-9d4d-ae65c1c8472c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_baa1a85f-6507-4e92-b983-836a75e2fcbc" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_0b098753-d70a-4d48-9d4d-ae65c1c8472c" xlink:to="loc_srt_RangeMember_baa1a85f-6507-4e92-b983-836a75e2fcbc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_5f848ec4-a782-40ea-867f-822429e38d27" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_baa1a85f-6507-4e92-b983-836a75e2fcbc" xlink:to="loc_srt_MinimumMember_5f848ec4-a782-40ea-867f-822429e38d27" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_935a6527-6a2c-4bc5-9fc5-93d1d74b9ef1" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_baa1a85f-6507-4e92-b983-836a75e2fcbc" xlink:to="loc_srt_MaximumMember_935a6527-6a2c-4bc5-9fc5-93d1d74b9ef1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_8eb35d64-2fe3-4e98-8644-3fbc3db6a592" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_6237af1e-77da-4400-b0ac-a94e8740042d" xlink:to="loc_us-gaap_DebtInstrumentAxis_8eb35d64-2fe3-4e98-8644-3fbc3db6a592" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_8eb35d64-2fe3-4e98-8644-3fbc3db6a592_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_8eb35d64-2fe3-4e98-8644-3fbc3db6a592" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_8eb35d64-2fe3-4e98-8644-3fbc3db6a592_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_9a69bf86-4b1c-426f-806c-f2d786f5347e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_8eb35d64-2fe3-4e98-8644-3fbc3db6a592" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_9a69bf86-4b1c-426f-806c-f2d786f5347e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_DebtInstrumentByLeverageRatioTrancheOneMember_cbd108ba-d7c4-41f6-93df-59d459e6692e" xlink:href="amed-20210630.xsd#amed_DebtInstrumentByLeverageRatioTrancheOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_9a69bf86-4b1c-426f-806c-f2d786f5347e" xlink:to="loc_amed_DebtInstrumentByLeverageRatioTrancheOneMember_cbd108ba-d7c4-41f6-93df-59d459e6692e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_DebtInstrumentByLeverageRatioTrancheTwoMember_cdc48ae2-eb1a-4314-baa3-ccd9afe29be4" xlink:href="amed-20210630.xsd#amed_DebtInstrumentByLeverageRatioTrancheTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_9a69bf86-4b1c-426f-806c-f2d786f5347e" xlink:to="loc_amed_DebtInstrumentByLeverageRatioTrancheTwoMember_cdc48ae2-eb1a-4314-baa3-ccd9afe29be4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_DebtInstrumentByLeverageRatioTrancheThreeMember_276901b1-8542-40c4-bc63-caea929a941e" xlink:href="amed-20210630.xsd#amed_DebtInstrumentByLeverageRatioTrancheThreeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_9a69bf86-4b1c-426f-806c-f2d786f5347e" xlink:to="loc_amed_DebtInstrumentByLeverageRatioTrancheThreeMember_276901b1-8542-40c4-bc63-caea929a941e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_DebtInstrumentByLeverageRatioTrancheFourMember_399f0d02-5904-46e3-bbb3-b1ce76053377" xlink:href="amed-20210630.xsd#amed_DebtInstrumentByLeverageRatioTrancheFourMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_9a69bf86-4b1c-426f-806c-f2d786f5347e" xlink:to="loc_amed_DebtInstrumentByLeverageRatioTrancheFourMember_399f0d02-5904-46e3-bbb3-b1ce76053377" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_202d0791-6fbb-4b51-bd24-6a8520b492df" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_6237af1e-77da-4400-b0ac-a94e8740042d" xlink:to="loc_us-gaap_VariableRateAxis_202d0791-6fbb-4b51-bd24-6a8520b492df" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_202d0791-6fbb-4b51-bd24-6a8520b492df_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VariableRateAxis_202d0791-6fbb-4b51-bd24-6a8520b492df" xlink:to="loc_us-gaap_VariableRateDomain_202d0791-6fbb-4b51-bd24-6a8520b492df_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_f79fd4e5-b2d9-4a5f-8030-5930f5f97bb0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VariableRateAxis_202d0791-6fbb-4b51-bd24-6a8520b492df" xlink:to="loc_us-gaap_VariableRateDomain_f79fd4e5-b2d9-4a5f-8030-5930f5f97bb0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EurodollarMember_beb1ef1d-878d-459d-853a-6e989afad812" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EurodollarMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_f79fd4e5-b2d9-4a5f-8030-5930f5f97bb0" xlink:to="loc_us-gaap_EurodollarMember_beb1ef1d-878d-459d-853a-6e989afad812" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BaseRateMember_a3943c8b-73c8-4ace-a063-31253b385871" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BaseRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_f79fd4e5-b2d9-4a5f-8030-5930f5f97bb0" xlink:to="loc_us-gaap_BaseRateMember_a3943c8b-73c8-4ace-a063-31253b385871" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityAxis_27de86a1-fb63-442a-87eb-85f27f6cf57f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_6237af1e-77da-4400-b0ac-a94e8740042d" xlink:to="loc_us-gaap_LineOfCreditFacilityAxis_27de86a1-fb63-442a-87eb-85f27f6cf57f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain_27de86a1-fb63-442a-87eb-85f27f6cf57f_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis_27de86a1-fb63-442a-87eb-85f27f6cf57f" xlink:to="loc_us-gaap_LineOfCreditFacilityLenderDomain_27de86a1-fb63-442a-87eb-85f27f6cf57f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain_591b258e-c99d-4fd3-8c18-e4e2438a4c7e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis_27de86a1-fb63-442a-87eb-85f27f6cf57f" xlink:to="loc_us-gaap_LineOfCreditFacilityLenderDomain_591b258e-c99d-4fd3-8c18-e4e2438a4c7e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_ebe56f2d-dd6b-44d3-b849-29a22abde7ab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_6237af1e-77da-4400-b0ac-a94e8740042d" xlink:to="loc_us-gaap_CreditFacilityAxis_ebe56f2d-dd6b-44d3-b849-29a22abde7ab" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_ebe56f2d-dd6b-44d3-b849-29a22abde7ab_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_ebe56f2d-dd6b-44d3-b849-29a22abde7ab" xlink:to="loc_us-gaap_CreditFacilityDomain_ebe56f2d-dd6b-44d3-b849-29a22abde7ab_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_6b94efe3-31bd-49fd-ae56-0875838426d4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_ebe56f2d-dd6b-44d3-b849-29a22abde7ab" xlink:to="loc_us-gaap_CreditFacilityDomain_6b94efe3-31bd-49fd-ae56-0875838426d4" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails" xlink:type="simple" xlink:href="amed-20210630.xsd#LONGTERMOBLIGATIONSNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails" xlink:type="extended" id="i92586a05b3ff4f498f29e1927734a5e5_LONGTERMOBLIGATIONSNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_2e363d22-fd6b-415b-a987-738568fb5201" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_DebtInstrumentPeriodicPaymentPercentage_2ccf8a9a-602c-423e-8d23-565bbfb50c2f" xlink:href="amed-20210630.xsd#amed_DebtInstrumentPeriodicPaymentPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2e363d22-fd6b-415b-a987-738568fb5201" xlink:to="loc_amed_DebtInstrumentPeriodicPaymentPercentage_2ccf8a9a-602c-423e-8d23-565bbfb50c2f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ProceedsReceivedFromLoanPartyOfSubsidiary_2ea19808-6a2f-4709-a525-72065f7bf70f" xlink:href="amed-20210630.xsd#amed_ProceedsReceivedFromLoanPartyOfSubsidiary"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2e363d22-fd6b-415b-a987-738568fb5201" xlink:to="loc_amed_ProceedsReceivedFromLoanPartyOfSubsidiary_2ea19808-6a2f-4709-a525-72065f7bf70f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfFinancingCosts_d0754063-993b-4fea-abc5-a9798117b724" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfFinancingCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2e363d22-fd6b-415b-a987-738568fb5201" xlink:to="loc_us-gaap_PaymentsOfFinancingCosts_d0754063-993b-4fea-abc5-a9798117b724" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_453327cf-b42b-4feb-9b25-a97e06720b5a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2e363d22-fd6b-415b-a987-738568fb5201" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_453327cf-b42b-4feb-9b25-a97e06720b5a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtWeightedAverageInterestRateOverTime_8fdc4213-1ca3-415c-b4de-a3f70d8e1df6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtWeightedAverageInterestRateOverTime"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2e363d22-fd6b-415b-a987-738568fb5201" xlink:to="loc_us-gaap_LongTermDebtWeightedAverageInterestRateOverTime_8fdc4213-1ca3-415c-b4de-a3f70d8e1df6" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_TotalLeverageRatio_86835c5a-f7ea-4c3e-8dd2-23e24073cc89" xlink:href="amed-20210630.xsd#amed_TotalLeverageRatio"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2e363d22-fd6b-415b-a987-738568fb5201" xlink:to="loc_amed_TotalLeverageRatio_86835c5a-f7ea-4c3e-8dd2-23e24073cc89" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ConsolidatedInterestCoverageRatio_882b348e-c1a7-4d96-a30d-9117622c2090" xlink:href="amed-20210630.xsd#amed_ConsolidatedInterestCoverageRatio"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2e363d22-fd6b-415b-a987-738568fb5201" xlink:to="loc_amed_ConsolidatedInterestCoverageRatio_882b348e-c1a7-4d96-a30d-9117622c2090" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_58876773-5bd6-4d2e-913f-09133acdd305" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2e363d22-fd6b-415b-a987-738568fb5201" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_58876773-5bd6-4d2e-913f-09133acdd305" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_RevolvingCreditFacilityTotal_11e80a6f-0650-48d5-b1df-c09049757e94" xlink:href="amed-20210630.xsd#amed_RevolvingCreditFacilityTotal"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2e363d22-fd6b-415b-a987-738568fb5201" xlink:to="loc_amed_RevolvingCreditFacilityTotal_11e80a6f-0650-48d5-b1df-c09049757e94" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_LineOfCreditFacilityAdditionalBorrowingCapacity_64ac3877-6e12-41ba-964d-592cdf89f72a" xlink:href="amed-20210630.xsd#amed_LineOfCreditFacilityAdditionalBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2e363d22-fd6b-415b-a987-738568fb5201" xlink:to="loc_amed_LineOfCreditFacilityAdditionalBorrowingCapacity_64ac3877-6e12-41ba-964d-592cdf89f72a" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CreditFacilityMaximumAllowableConsolidatedLeverageRatioMultiple_7282bb60-b0b6-47fa-aa3d-306055e0d4db" xlink:href="amed-20210630.xsd#amed_CreditFacilityMaximumAllowableConsolidatedLeverageRatioMultiple"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2e363d22-fd6b-415b-a987-738568fb5201" xlink:to="loc_amed_CreditFacilityMaximumAllowableConsolidatedLeverageRatioMultiple_7282bb60-b0b6-47fa-aa3d-306055e0d4db" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_Creditfacilitymaximumallowableconsolidatedleverageratio_268ac76d-919f-44b4-9578-fb1004fb3e06" xlink:href="amed-20210630.xsd#amed_Creditfacilitymaximumallowableconsolidatedleverageratio"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2e363d22-fd6b-415b-a987-738568fb5201" xlink:to="loc_amed_Creditfacilitymaximumallowableconsolidatedleverageratio_268ac76d-919f-44b4-9578-fb1004fb3e06" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentMaturityDate_9318bfbf-111a-4fa4-8583-ba1e7df54e2d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentMaturityDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2e363d22-fd6b-415b-a987-738568fb5201" xlink:to="loc_us-gaap_DebtInstrumentMaturityDate_9318bfbf-111a-4fa4-8583-ba1e7df54e2d" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_DebtInstrumentInterestAdditionalInterestAboveFederalFundRate_e9881beb-e110-4354-be15-9d29c51014d8" xlink:href="amed-20210630.xsd#amed_DebtInstrumentInterestAdditionalInterestAboveFederalFundRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2e363d22-fd6b-415b-a987-738568fb5201" xlink:to="loc_amed_DebtInstrumentInterestAdditionalInterestAboveFederalFundRate_e9881beb-e110-4354-be15-9d29c51014d8" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_DebtInstrumentInterestAdditionalInterestAboveEurodollarRate_13e74a7c-2d7e-4cd7-9333-e9a149f38e65" xlink:href="amed-20210630.xsd#amed_DebtInstrumentInterestAdditionalInterestAboveEurodollarRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2e363d22-fd6b-415b-a987-738568fb5201" xlink:to="loc_amed_DebtInstrumentInterestAdditionalInterestAboveEurodollarRate_13e74a7c-2d7e-4cd7-9333-e9a149f38e65" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_b30806ae-7144-4958-b981-530af281d25a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2e363d22-fd6b-415b-a987-738568fb5201" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_b30806ae-7144-4958-b981-530af281d25a" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PercentageOfRevenueAndOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromWhollyOwnedSubsidiaries_520bc3f7-02b2-40e4-b20f-ee32914dbde0" xlink:href="amed-20210630.xsd#amed_PercentageOfRevenueAndOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromWhollyOwnedSubsidiaries"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2e363d22-fd6b-415b-a987-738568fb5201" xlink:to="loc_amed_PercentageOfRevenueAndOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromWhollyOwnedSubsidiaries_520bc3f7-02b2-40e4-b20f-ee32914dbde0" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PercentageOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromSubsidiaries_751f48b9-e9cf-4ca0-80d6-437624ec45db" xlink:href="amed-20210630.xsd#amed_PercentageOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromSubsidiaries"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2e363d22-fd6b-415b-a987-738568fb5201" xlink:to="loc_amed_PercentageOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromSubsidiaries_751f48b9-e9cf-4ca0-80d6-437624ec45db" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtIssuanceCostsLineOfCreditArrangementsGross_78133d4c-f7c6-4e93-9f24-7b574a601832" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtIssuanceCostsLineOfCreditArrangementsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2e363d22-fd6b-415b-a987-738568fb5201" xlink:to="loc_us-gaap_DebtIssuanceCostsLineOfCreditArrangementsGross_78133d4c-f7c6-4e93-9f24-7b574a601832" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_c0e2bfbe-91aa-4a9a-a472-4e40e2a16b79" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2e363d22-fd6b-415b-a987-738568fb5201" xlink:to="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_c0e2bfbe-91aa-4a9a-a472-4e40e2a16b79" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_74a1fd6a-6957-45b4-ae99-e11127200b88" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2e363d22-fd6b-415b-a987-738568fb5201" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_74a1fd6a-6957-45b4-ae99-e11127200b88" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LettersOfCreditOutstandingAmount_c6ea4717-64c1-4283-8ef1-86717421721d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LettersOfCreditOutstandingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2e363d22-fd6b-415b-a987-738568fb5201" xlink:to="loc_us-gaap_LettersOfCreditOutstandingAmount_c6ea4717-64c1-4283-8ef1-86717421721d" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis_42a9c005-3823-4a50-b9fb-ef9ecb00e144" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentDescriptionOfVariableRateBasis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2e363d22-fd6b-415b-a987-738568fb5201" xlink:to="loc_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis_42a9c005-3823-4a50-b9fb-ef9ecb00e144" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_DebtInstrumentInterestRateatPeriodEnd_13a5f991-29cc-44c4-ac21-647a4afae90c" xlink:href="amed-20210630.xsd#amed_DebtInstrumentInterestRateatPeriodEnd"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2e363d22-fd6b-415b-a987-738568fb5201" xlink:to="loc_amed_DebtInstrumentInterestRateatPeriodEnd_13a5f991-29cc-44c4-ac21-647a4afae90c" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_ab471c14-6165-4955-9b44-232093e97de6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2e363d22-fd6b-415b-a987-738568fb5201" xlink:to="loc_us-gaap_DebtInstrumentTable_ab471c14-6165-4955-9b44-232093e97de6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_3b46bd41-809e-43b1-a112-5d999bd3c2fb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_ab471c14-6165-4955-9b44-232093e97de6" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_3b46bd41-809e-43b1-a112-5d999bd3c2fb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_3b46bd41-809e-43b1-a112-5d999bd3c2fb_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_3b46bd41-809e-43b1-a112-5d999bd3c2fb" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_3b46bd41-809e-43b1-a112-5d999bd3c2fb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_6a2ff9ea-7588-4cfa-8a4c-d0006c5b19b3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_3b46bd41-809e-43b1-a112-5d999bd3c2fb" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_6a2ff9ea-7588-4cfa-8a4c-d0006c5b19b3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_5b0161b6-a7e4-444a-a1aa-d1cad6d90c8b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_6a2ff9ea-7588-4cfa-8a4c-d0006c5b19b3" xlink:to="loc_us-gaap_SubsequentEventMember_5b0161b6-a7e4-444a-a1aa-d1cad6d90c8b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_8c475aa8-5922-4390-9d12-5bd5afc5f31c" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_ab471c14-6165-4955-9b44-232093e97de6" xlink:to="loc_srt_RangeAxis_8c475aa8-5922-4390-9d12-5bd5afc5f31c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_8c475aa8-5922-4390-9d12-5bd5afc5f31c_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_8c475aa8-5922-4390-9d12-5bd5afc5f31c" xlink:to="loc_srt_RangeMember_8c475aa8-5922-4390-9d12-5bd5afc5f31c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_f4eec402-8b07-45f6-82ad-6cf96901d8ef" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_8c475aa8-5922-4390-9d12-5bd5afc5f31c" xlink:to="loc_srt_RangeMember_f4eec402-8b07-45f6-82ad-6cf96901d8ef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_f31e60f6-6840-47d7-9790-fdc99e161bf0" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_f4eec402-8b07-45f6-82ad-6cf96901d8ef" xlink:to="loc_srt_MinimumMember_f31e60f6-6840-47d7-9790-fdc99e161bf0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_eeaa32f0-955e-4189-bb89-2a48400e9804" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_ab471c14-6165-4955-9b44-232093e97de6" xlink:to="loc_us-gaap_VariableRateAxis_eeaa32f0-955e-4189-bb89-2a48400e9804" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_eeaa32f0-955e-4189-bb89-2a48400e9804_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VariableRateAxis_eeaa32f0-955e-4189-bb89-2a48400e9804" xlink:to="loc_us-gaap_VariableRateDomain_eeaa32f0-955e-4189-bb89-2a48400e9804_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_0214567e-4427-46b0-9548-9781757000fd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VariableRateAxis_eeaa32f0-955e-4189-bb89-2a48400e9804" xlink:to="loc_us-gaap_VariableRateDomain_0214567e-4427-46b0-9548-9781757000fd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BaseRateMember_92f5299a-5143-4943-989d-6cff5f15d11e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BaseRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_0214567e-4427-46b0-9548-9781757000fd" xlink:to="loc_us-gaap_BaseRateMember_92f5299a-5143-4943-989d-6cff5f15d11e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EurodollarMember_15c45fea-ebc5-4f5c-865c-da1e2a18d24b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EurodollarMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_0214567e-4427-46b0-9548-9781757000fd" xlink:to="loc_us-gaap_EurodollarMember_15c45fea-ebc5-4f5c-865c-da1e2a18d24b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_108edf43-9a86-463c-a0d6-a3fad9d4054a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_ab471c14-6165-4955-9b44-232093e97de6" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_108edf43-9a86-463c-a0d6-a3fad9d4054a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_108edf43-9a86-463c-a0d6-a3fad9d4054a_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_108edf43-9a86-463c-a0d6-a3fad9d4054a" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_108edf43-9a86-463c-a0d6-a3fad9d4054a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_dc16825b-b6c2-4091-a7d3-1cd4d5152566" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_108edf43-9a86-463c-a0d6-a3fad9d4054a" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_dc16825b-b6c2-4091-a7d3-1cd4d5152566" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_SwingLineLoanMember_34a97785-b509-4477-8450-0040dafa8cd1" xlink:href="amed-20210630.xsd#amed_SwingLineLoanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_dc16825b-b6c2-4091-a7d3-1cd4d5152566" xlink:to="loc_amed_SwingLineLoanMember_34a97785-b509-4477-8450-0040dafa8cd1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LetterOfCreditMember_0dfaacdf-ca12-4b89-a51c-3f429d4f2bda" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LetterOfCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_dc16825b-b6c2-4091-a7d3-1cd4d5152566" xlink:to="loc_us-gaap_LetterOfCreditMember_0dfaacdf-ca12-4b89-a51c-3f429d4f2bda" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LoansPayableMember_9b729fd2-a763-4d80-a534-0bb3a3460fe3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LoansPayableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_dc16825b-b6c2-4091-a7d3-1cd4d5152566" xlink:to="loc_us-gaap_LoansPayableMember_9b729fd2-a763-4d80-a534-0bb3a3460fe3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_a415a899-c391-4abf-96fa-374bd4337df8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_dc16825b-b6c2-4091-a7d3-1cd4d5152566" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_a415a899-c391-4abf-96fa-374bd4337df8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PriorCreditAgreementMember_68aa34e0-0a4b-4035-b457-daa021b8fb6e" xlink:href="amed-20210630.xsd#amed_PriorCreditAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_dc16825b-b6c2-4091-a7d3-1cd4d5152566" xlink:to="loc_amed_PriorCreditAgreementMember_68aa34e0-0a4b-4035-b457-daa021b8fb6e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_7f8f22b7-00ac-467b-9e72-093a47dc4233" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_dc16825b-b6c2-4091-a7d3-1cd4d5152566" xlink:to="loc_us-gaap_LineOfCreditMember_7f8f22b7-00ac-467b-9e72-093a47dc4233" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AmendedCreditAgreementMember_2bbe379d-4bb5-4cb5-931d-f50d374921fe" xlink:href="amed-20210630.xsd#amed_AmendedCreditAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_dc16825b-b6c2-4091-a7d3-1cd4d5152566" xlink:to="loc_amed_AmendedCreditAgreementMember_2bbe379d-4bb5-4cb5-931d-f50d374921fe" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_2b341679-bce5-426e-a92d-09f30b74f295" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_ab471c14-6165-4955-9b44-232093e97de6" xlink:to="loc_us-gaap_DebtInstrumentAxis_2b341679-bce5-426e-a92d-09f30b74f295" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_2b341679-bce5-426e-a92d-09f30b74f295_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_2b341679-bce5-426e-a92d-09f30b74f295" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_2b341679-bce5-426e-a92d-09f30b74f295_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_4985727c-9b49-405e-9810-c0bc4977b644" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_2b341679-bce5-426e-a92d-09f30b74f295" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_4985727c-9b49-405e-9810-c0bc4977b644" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AmendedCreditAgreementMember_2ff6583e-8d3a-4ebd-8264-4176639ea55c" xlink:href="amed-20210630.xsd#amed_AmendedCreditAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_4985727c-9b49-405e-9810-c0bc4977b644" xlink:to="loc_amed_AmendedCreditAgreementMember_2ff6583e-8d3a-4ebd-8264-4176639ea55c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_OneHundredMillionTermLoanMember_c6e49abf-c3a0-46ff-8ca9-f8300e21362d" xlink:href="amed-20210630.xsd#amed_OneHundredMillionTermLoanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_4985727c-9b49-405e-9810-c0bc4977b644" xlink:to="loc_amed_OneHundredMillionTermLoanMember_c6e49abf-c3a0-46ff-8ca9-f8300e21362d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_TwoHundredMillionRevolvingCreditFacilityMember_c97eec58-22d8-4bba-844f-92f01292b982" xlink:href="amed-20210630.xsd#amed_TwoHundredMillionRevolvingCreditFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_4985727c-9b49-405e-9810-c0bc4977b644" xlink:to="loc_amed_TwoHundredMillionRevolvingCreditFacilityMember_c97eec58-22d8-4bba-844f-92f01292b982" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember_60744874-b562-41f8-8517-5409cacdc3b4" xlink:href="amed-20210630.xsd#amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_4985727c-9b49-405e-9810-c0bc4977b644" xlink:to="loc_amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember_60744874-b562-41f8-8517-5409cacdc3b4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_OneHundredSeventyFiveMillionTermLoanFacilityMember_37bc7cf7-64ca-4dec-b72c-8b9194ead653" xlink:href="amed-20210630.xsd#amed_OneHundredSeventyFiveMillionTermLoanFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_4985727c-9b49-405e-9810-c0bc4977b644" xlink:to="loc_amed_OneHundredSeventyFiveMillionTermLoanFacilityMember_37bc7cf7-64ca-4dec-b72c-8b9194ead653" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails" xlink:type="simple" xlink:href="amed-20210630.xsd#COMMITMENTSANDCONTINGENCIESNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails" xlink:type="extended" id="i6282752bf0ed48de97f3ee33b520d75a_COMMITMENTSANDCONTINGENCIESNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_65b85ce6-f4bf-43be-b8b5-cef836158316" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForLegalSettlements_c578f9cb-425d-48aa-ae3b-f3a4f25c93a5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForLegalSettlements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_65b85ce6-f4bf-43be-b8b5-cef836158316" xlink:to="loc_us-gaap_PaymentsForLegalSettlements_c578f9cb-425d-48aa-ae3b-f3a4f25c93a5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_Numberofpatients_45c270ad-4312-43df-a34e-8e4a3b37ada1" xlink:href="amed-20210630.xsd#amed_Numberofpatients"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_65b85ce6-f4bf-43be-b8b5-cef836158316" xlink:to="loc_amed_Numberofpatients_45c270ad-4312-43df-a34e-8e4a3b37ada1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CorporateIntegrityAgreementTerm_c0339ee8-adc3-4eb0-889f-593610dc9386" xlink:href="amed-20210630.xsd#amed_CorporateIntegrityAgreementTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_65b85ce6-f4bf-43be-b8b5-cef836158316" xlink:to="loc_amed_CorporateIntegrityAgreementTerm_c0339ee8-adc3-4eb0-889f-593610dc9386" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualAtCarryingValue_176ccbe8-c6bf-4591-aad7-6cfbab0f658a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyAccrualAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_65b85ce6-f4bf-43be-b8b5-cef836158316" xlink:to="loc_us-gaap_LossContingencyAccrualAtCarryingValue_176ccbe8-c6bf-4591-aad7-6cfbab0f658a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualCarryingValuePeriodIncreaseDecrease_20891b11-eff2-4685-ae2c-297b4ef9ab6f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyAccrualCarryingValuePeriodIncreaseDecrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_65b85ce6-f4bf-43be-b8b5-cef836158316" xlink:to="loc_us-gaap_LossContingencyAccrualCarryingValuePeriodIncreaseDecrease_20891b11-eff2-4685-ae2c-297b4ef9ab6f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyReceivableCurrent_da981f41-480c-4b34-89a0-064bd38a1e83" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyReceivableCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_65b85ce6-f4bf-43be-b8b5-cef836158316" xlink:to="loc_us-gaap_LossContingencyReceivableCurrent_da981f41-480c-4b34-89a0-064bd38a1e83" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_SecuritiesClassActionLawsuitsettlement_552c6e6d-a9c9-45c0-825a-ea890ebcd976" xlink:href="amed-20210630.xsd#amed_SecuritiesClassActionLawsuitsettlement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_65b85ce6-f4bf-43be-b8b5-cef836158316" xlink:to="loc_amed_SecuritiesClassActionLawsuitsettlement_552c6e6d-a9c9-45c0-825a-ea890ebcd976" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_NumberOfBeneficiaries_0e964be2-9004-4481-b4ae-4a16b05c1c05" xlink:href="amed-20210630.xsd#amed_NumberOfBeneficiaries"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_65b85ce6-f4bf-43be-b8b5-cef836158316" xlink:to="loc_amed_NumberOfBeneficiaries_0e964be2-9004-4481-b4ae-4a16b05c1c05" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_RecoveryAmountOfOverpaymentMadeToSubsidiary_7a50c80f-ed4f-44dc-b9ea-73dd9cff146f" xlink:href="amed-20210630.xsd#amed_RecoveryAmountOfOverpaymentMadeToSubsidiary"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_65b85ce6-f4bf-43be-b8b5-cef836158316" xlink:to="loc_amed_RecoveryAmountOfOverpaymentMadeToSubsidiary_7a50c80f-ed4f-44dc-b9ea-73dd9cff146f" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_RecoveryAmountOfOverpaymentMadeToSubsidiaryIncludingInterest_d701fde3-e130-4727-be65-194e97a3f98e" xlink:href="amed-20210630.xsd#amed_RecoveryAmountOfOverpaymentMadeToSubsidiaryIncludingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_65b85ce6-f4bf-43be-b8b5-cef836158316" xlink:to="loc_amed_RecoveryAmountOfOverpaymentMadeToSubsidiaryIncludingInterest_d701fde3-e130-4727-be65-194e97a3f98e" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_NumberOfClaimsSubmittedBySubsidiary_cdd420a9-c2e1-4323-bd4b-9132ae5b99d4" xlink:href="amed-20210630.xsd#amed_NumberOfClaimsSubmittedBySubsidiary"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_65b85ce6-f4bf-43be-b8b5-cef836158316" xlink:to="loc_amed_NumberOfClaimsSubmittedBySubsidiary_cdd420a9-c2e1-4323-bd4b-9132ae5b99d4" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_Recoveryamountofoverpaymentmadetosubsidiaryincludinginterestwithheld_ab5b1309-0566-471c-b962-d97234740275" xlink:href="amed-20210630.xsd#amed_Recoveryamountofoverpaymentmadetosubsidiaryincludinginterestwithheld"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_65b85ce6-f4bf-43be-b8b5-cef836158316" xlink:to="loc_amed_Recoveryamountofoverpaymentmadetosubsidiaryincludinginterestwithheld_ab5b1309-0566-471c-b962-d97234740275" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_LossContingencyReceivableNoncurrentRelatedToAmountsWithheldPriorToAugust2009_4b62ff2a-58f0-4ea1-9902-b43425ddb9a0" xlink:href="amed-20210630.xsd#amed_LossContingencyReceivableNoncurrentRelatedToAmountsWithheldPriorToAugust2009"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_65b85ce6-f4bf-43be-b8b5-cef836158316" xlink:to="loc_amed_LossContingencyReceivableNoncurrentRelatedToAmountsWithheldPriorToAugust2009_4b62ff2a-58f0-4ea1-9902-b43425ddb9a0" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyReceivableNoncurrent_8b4edbeb-1194-4fc5-b4a8-0d63bc45212d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyReceivableNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_65b85ce6-f4bf-43be-b8b5-cef836158316" xlink:to="loc_us-gaap_LossContingencyReceivableNoncurrent_8b4edbeb-1194-4fc5-b4a8-0d63bc45212d" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ActualClaimsPayment_79845ff8-bfd1-4276-ab7f-c0b280c5e63b" xlink:href="amed-20210630.xsd#amed_ActualClaimsPayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_65b85ce6-f4bf-43be-b8b5-cef836158316" xlink:to="loc_amed_ActualClaimsPayment_79845ff8-bfd1-4276-ab7f-c0b280c5e63b" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ErrorRatePercentage_99f31685-72aa-4b78-bbb7-84aa6637f25c" xlink:href="amed-20210630.xsd#amed_ErrorRatePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_65b85ce6-f4bf-43be-b8b5-cef836158316" xlink:to="loc_amed_ErrorRatePercentage_99f31685-72aa-4b78-bbb7-84aa6637f25c" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_IndemnificationAmount_ea241854-b2ac-488b-8977-da5837261e8a" xlink:href="amed-20210630.xsd#amed_IndemnificationAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_65b85ce6-f4bf-43be-b8b5-cef836158316" xlink:to="loc_amed_IndemnificationAmount_ea241854-b2ac-488b-8977-da5837261e8a" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_FloridaZpicRevenueReduction_c21ebc35-8ab9-4a89-9ad8-87bf7b2ed62c" xlink:href="amed-20210630.xsd#amed_FloridaZpicRevenueReduction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_65b85ce6-f4bf-43be-b8b5-cef836158316" xlink:to="loc_amed_FloridaZpicRevenueReduction_c21ebc35-8ab9-4a89-9ad8-87bf7b2ed62c" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_552407ff-2a7d-4d2a-aa82-8887c9d87f23" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_65b85ce6-f4bf-43be-b8b5-cef836158316" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_552407ff-2a7d-4d2a-aa82-8887c9d87f23" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HealthInsuranceRetentionLimit_f2e2bc1d-2de5-46ee-b579-7b45c9f3bc47" xlink:href="amed-20210630.xsd#amed_HealthInsuranceRetentionLimit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_65b85ce6-f4bf-43be-b8b5-cef836158316" xlink:to="loc_amed_HealthInsuranceRetentionLimit_f2e2bc1d-2de5-46ee-b579-7b45c9f3bc47" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_WorkersCompensationInsuranceRetentionLimit_71f9e502-bea6-4421-9acb-434388c8c0b6" xlink:href="amed-20210630.xsd#amed_WorkersCompensationInsuranceRetentionLimit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_65b85ce6-f4bf-43be-b8b5-cef836158316" xlink:to="loc_amed_WorkersCompensationInsuranceRetentionLimit_71f9e502-bea6-4421-9acb-434388c8c0b6" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ProfessionalLiabilityInsuranceRetentionLimit_6b9a2002-c815-40fc-9af6-042fabe88fde" xlink:href="amed-20210630.xsd#amed_ProfessionalLiabilityInsuranceRetentionLimit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_65b85ce6-f4bf-43be-b8b5-cef836158316" xlink:to="loc_amed_ProfessionalLiabilityInsuranceRetentionLimit_6b9a2002-c815-40fc-9af6-042fabe88fde" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ReversalOfLossContingencyAccrual_52ba98e3-fd16-4e02-adb7-a13a8d83dafd" xlink:href="amed-20210630.xsd#amed_ReversalOfLossContingencyAccrual"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_65b85ce6-f4bf-43be-b8b5-cef836158316" xlink:to="loc_amed_ReversalOfLossContingencyAccrual_52ba98e3-fd16-4e02-adb7-a13a8d83dafd" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_4fdd2d3e-4e62-4513-bd64-94cb288c7a6a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LossContingenciesLineItems_65b85ce6-f4bf-43be-b8b5-cef836158316" xlink:to="loc_us-gaap_LossContingenciesTable_4fdd2d3e-4e62-4513-bd64-94cb288c7a6a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PayorsAxis_373787c8-885c-4c80-acd2-5459f302f0a9" xlink:href="amed-20210630.xsd#amed_PayorsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_4fdd2d3e-4e62-4513-bd64-94cb288c7a6a" xlink:to="loc_amed_PayorsAxis_373787c8-885c-4c80-acd2-5459f302f0a9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PayorsDomain_373787c8-885c-4c80-acd2-5459f302f0a9_default" xlink:href="amed-20210630.xsd#amed_PayorsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_amed_PayorsAxis_373787c8-885c-4c80-acd2-5459f302f0a9" xlink:to="loc_amed_PayorsDomain_373787c8-885c-4c80-acd2-5459f302f0a9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PayorsDomain_fc8401ad-0846-4b33-b7bf-bb4f7f80ce82" xlink:href="amed-20210630.xsd#amed_PayorsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_amed_PayorsAxis_373787c8-885c-4c80-acd2-5459f302f0a9" xlink:to="loc_amed_PayorsDomain_fc8401ad-0846-4b33-b7bf-bb4f7f80ce82" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CompanysinsurancecarriersMember_18137023-81dc-45c3-add3-82b6e05c01bf" xlink:href="amed-20210630.xsd#amed_CompanysinsurancecarriersMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_amed_PayorsDomain_fc8401ad-0846-4b33-b7bf-bb4f7f80ce82" xlink:to="loc_amed_CompanysinsurancecarriersMember_18137023-81dc-45c3-add3-82b6e05c01bf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_97b942ca-5e91-4e3c-ae0a-f2c07ef2c93f" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_LitigationCaseAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_4fdd2d3e-4e62-4513-bd64-94cb288c7a6a" xlink:to="loc_srt_LitigationCaseAxis_97b942ca-5e91-4e3c-ae0a-f2c07ef2c93f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_97b942ca-5e91-4e3c-ae0a-f2c07ef2c93f_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_LitigationCaseAxis_97b942ca-5e91-4e3c-ae0a-f2c07ef2c93f" xlink:to="loc_srt_LitigationCaseTypeDomain_97b942ca-5e91-4e3c-ae0a-f2c07ef2c93f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_70e4becc-f971-4726-824c-65865aea4560" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_LitigationCaseAxis_97b942ca-5e91-4e3c-ae0a-f2c07ef2c93f" xlink:to="loc_srt_LitigationCaseTypeDomain_70e4becc-f971-4726-824c-65865aea4560" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_UsDepartmentOfJusticeMember_c9cfcf19-c2e4-48a1-900e-f78ded437db7" xlink:href="amed-20210630.xsd#amed_UsDepartmentOfJusticeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_70e4becc-f971-4726-824c-65865aea4560" xlink:to="loc_amed_UsDepartmentOfJusticeMember_c9cfcf19-c2e4-48a1-900e-f78ded437db7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AmedisysCIAMember_9b2fd535-f0bd-4b51-b21c-025f6f42e522" xlink:href="amed-20210630.xsd#amed_AmedisysCIAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_70e4becc-f971-4726-824c-65865aea4560" xlink:to="loc_amed_AmedisysCIAMember_9b2fd535-f0bd-4b51-b21c-025f6f42e522" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CompassionateCareHospiceCIAMember_dd0d642e-b929-4140-8eb1-387951e89e87" xlink:href="amed-20210630.xsd#amed_CompassionateCareHospiceCIAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_70e4becc-f971-4726-824c-65865aea4560" xlink:to="loc_amed_CompassionateCareHospiceCIAMember_dd0d642e-b929-4140-8eb1-387951e89e87" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_SecuritiesClassActionLawsuitMember_8a3a8875-ab65-4a7f-bab3-62fcf4ada7f1" xlink:href="amed-20210630.xsd#amed_SecuritiesClassActionLawsuitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_70e4becc-f971-4726-824c-65865aea4560" xlink:to="loc_amed_SecuritiesClassActionLawsuitMember_8a3a8875-ab65-4a7f-bab3-62fcf4ada7f1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_SafeguardZoneProgramIntegrityContractorMember_10d059c1-7c41-4bd9-8119-cb61e00ad582" xlink:href="amed-20210630.xsd#amed_SafeguardZoneProgramIntegrityContractorMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_70e4becc-f971-4726-824c-65865aea4560" xlink:to="loc_amed_SafeguardZoneProgramIntegrityContractorMember_10d059c1-7c41-4bd9-8119-cb61e00ad582" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_InternalAuditComplianceReviewMember_7e596457-f5a1-443e-88d1-4d205828d276" xlink:href="amed-20210630.xsd#amed_InternalAuditComplianceReviewMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_70e4becc-f971-4726-824c-65865aea4560" xlink:to="loc_amed_InternalAuditComplianceReviewMember_7e596457-f5a1-443e-88d1-4d205828d276" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_ed81fe35-c41d-4ebb-9d0b-18bee0426699" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_4fdd2d3e-4e62-4513-bd64-94cb288c7a6a" xlink:to="loc_srt_StatementGeographicalAxis_ed81fe35-c41d-4ebb-9d0b-18bee0426699" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_ed81fe35-c41d-4ebb-9d0b-18bee0426699_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_ed81fe35-c41d-4ebb-9d0b-18bee0426699" xlink:to="loc_srt_SegmentGeographicalDomain_ed81fe35-c41d-4ebb-9d0b-18bee0426699_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_2c7e05d0-cfd8-4251-bd3f-6c4f164f25a1" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_ed81fe35-c41d-4ebb-9d0b-18bee0426699" xlink:to="loc_srt_SegmentGeographicalDomain_2c7e05d0-cfd8-4251-bd3f-6c4f164f25a1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_MA_5d24d4ba-00cd-4291-ae06-794b564aeb44" xlink:href="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd#stpr_MA"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_2c7e05d0-cfd8-4251-bd3f-6c4f164f25a1" xlink:to="loc_stpr_MA_5d24d4ba-00cd-4291-ae06-794b564aeb44" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_MorgantownWestVirginiaMember_41beaac6-6560-4495-966b-e21b6903c517" xlink:href="amed-20210630.xsd#amed_MorgantownWestVirginiaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_2c7e05d0-cfd8-4251-bd3f-6c4f164f25a1" xlink:to="loc_amed_MorgantownWestVirginiaMember_41beaac6-6560-4495-966b-e21b6903c517" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ParkersburgWestVirginiaMember_03cbb9fe-9ff2-425c-8cc0-0623b24f0b58" xlink:href="amed-20210630.xsd#amed_ParkersburgWestVirginiaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_2c7e05d0-cfd8-4251-bd3f-6c4f164f25a1" xlink:to="loc_amed_ParkersburgWestVirginiaMember_03cbb9fe-9ff2-425c-8cc0-0623b24f0b58" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_SC_f71cdd35-a858-4732-83ca-3e4d98247bb7" xlink:href="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd#stpr_SC"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_2c7e05d0-cfd8-4251-bd3f-6c4f164f25a1" xlink:to="loc_stpr_SC_f71cdd35-a858-4732-83ca-3e4d98247bb7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_FL_15b6606d-0885-4e58-9a8c-e3b98bed1dd1" xlink:href="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd#stpr_FL"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_2c7e05d0-cfd8-4251-bd3f-6c4f164f25a1" xlink:to="loc_stpr_FL_15b6606d-0885-4e58-9a8c-e3b98bed1dd1" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_LakelandFloridaMember_d687f79f-24ae-493f-84ff-cd9b0778ceaf" xlink:href="amed-20210630.xsd#amed_LakelandFloridaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_stpr_FL_15b6606d-0885-4e58-9a8c-e3b98bed1dd1" xlink:to="loc_amed_LakelandFloridaMember_d687f79f-24ae-493f-84ff-cd9b0778ceaf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ClearwaterFloridaMember_dcb444dd-ea1b-4163-be2f-095bf72f197a" xlink:href="amed-20210630.xsd#amed_ClearwaterFloridaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_stpr_FL_15b6606d-0885-4e58-9a8c-e3b98bed1dd1" xlink:to="loc_amed_ClearwaterFloridaMember_dcb444dd-ea1b-4163-be2f-095bf72f197a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_8b8ed0b8-e80d-40a5-b35e-7a95940840a1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_4fdd2d3e-4e62-4513-bd64-94cb288c7a6a" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_8b8ed0b8-e80d-40a5-b35e-7a95940840a1" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_8b8ed0b8-e80d-40a5-b35e-7a95940840a1_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_8b8ed0b8-e80d-40a5-b35e-7a95940840a1" xlink:to="loc_us-gaap_SegmentDomain_8b8ed0b8-e80d-40a5-b35e-7a95940840a1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_79d7073e-6163-4010-a50d-e12639fa6759" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_8b8ed0b8-e80d-40a5-b35e-7a95940840a1" xlink:to="loc_us-gaap_SegmentDomain_79d7073e-6163-4010-a50d-e12639fa6759" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HospiceMember_ae839710-4323-4794-8d10-3683fe53d0ac" xlink:href="amed-20210630.xsd#amed_HospiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_79d7073e-6163-4010-a50d-e12639fa6759" xlink:to="loc_amed_HospiceMember_ae839710-4323-4794-8d10-3683fe53d0ac" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HomeHealthMember_bcc8da72-e73f-4d57-bfd7-91444e57b4ce" xlink:href="amed-20210630.xsd#amed_HomeHealthMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_79d7073e-6163-4010-a50d-e12639fa6759" xlink:to="loc_amed_HomeHealthMember_bcc8da72-e73f-4d57-bfd7-91444e57b4ce" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_eedb13ba-1ee4-438f-9ebd-bdf0e1a7ca27" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_4fdd2d3e-4e62-4513-bd64-94cb288c7a6a" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_eedb13ba-1ee4-438f-9ebd-bdf0e1a7ca27" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_eedb13ba-1ee4-438f-9ebd-bdf0e1a7ca27_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_eedb13ba-1ee4-438f-9ebd-bdf0e1a7ca27" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_eedb13ba-1ee4-438f-9ebd-bdf0e1a7ca27_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_337d885b-d3b5-42d7-a903-c12b248e535a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_eedb13ba-1ee4-438f-9ebd-bdf0e1a7ca27" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_337d885b-d3b5-42d7-a903-c12b248e535a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_InfinityHomeCareMember_ca6ebccc-593d-45b5-8808-9fd9d756ae71" xlink:href="amed-20210630.xsd#amed_InfinityHomeCareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_337d885b-d3b5-42d7-a903-c12b248e535a" xlink:to="loc_amed_InfinityHomeCareMember_ca6ebccc-593d-45b5-8808-9fd9d756ae71" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_dad1f315-3be4-476d-a472-9fd131f44f9d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_4fdd2d3e-4e62-4513-bd64-94cb288c7a6a" xlink:to="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_dad1f315-3be4-476d-a472-9fd131f44f9d" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain_dad1f315-3be4-476d-a472-9fd131f44f9d_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_dad1f315-3be4-476d-a472-9fd131f44f9d" xlink:to="loc_us-gaap_LossContingencyNatureDomain_dad1f315-3be4-476d-a472-9fd131f44f9d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain_0817624a-4e4a-4339-9459-ee36cbd2f3cd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_dad1f315-3be4-476d-a472-9fd131f44f9d" xlink:to="loc_us-gaap_LossContingencyNatureDomain_0817624a-4e4a-4339-9459-ee36cbd2f3cd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ExtrapolatedMember_3c46b155-3583-4139-8f0a-f3ec824b8f8d" xlink:href="amed-20210630.xsd#amed_ExtrapolatedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingencyNatureDomain_0817624a-4e4a-4339-9459-ee36cbd2f3cd" xlink:to="loc_amed_ExtrapolatedMember_3c46b155-3583-4139-8f0a-f3ec824b8f8d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_UnfavorableMember_80dfc35f-57fa-49c1-9f52-5c469e1f1700" xlink:href="amed-20210630.xsd#amed_UnfavorableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingencyNatureDomain_0817624a-4e4a-4339-9459-ee36cbd2f3cd" xlink:to="loc_amed_UnfavorableMember_80dfc35f-57fa-49c1-9f52-5c469e1f1700" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_36e513a7-58c8-446e-9213-1bbb7a12d62e" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_4fdd2d3e-4e62-4513-bd64-94cb288c7a6a" xlink:to="loc_srt_RangeAxis_36e513a7-58c8-446e-9213-1bbb7a12d62e" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_36e513a7-58c8-446e-9213-1bbb7a12d62e_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_36e513a7-58c8-446e-9213-1bbb7a12d62e" xlink:to="loc_srt_RangeMember_36e513a7-58c8-446e-9213-1bbb7a12d62e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_90b40128-fe34-4627-a0fc-d2b63da2818f" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_36e513a7-58c8-446e-9213-1bbb7a12d62e" xlink:to="loc_srt_RangeMember_90b40128-fe34-4627-a0fc-d2b63da2818f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_70da8572-651b-46d5-9cc0-a9eba2fd2973" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_90b40128-fe34-4627-a0fc-d2b63da2818f" xlink:to="loc_srt_MinimumMember_70da8572-651b-46d5-9cc0-a9eba2fd2973" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_d4e21855-3fbd-4425-afac-0fbc8a746ab3" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_90b40128-fe34-4627-a0fc-d2b63da2818f" xlink:to="loc_srt_MaximumMember_d4e21855-3fbd-4425-afac-0fbc8a746ab3" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/SEGMENTINFORMATIONOperatingIncomeofReportableSegmentsDetails" xlink:type="simple" xlink:href="amed-20210630.xsd#SEGMENTINFORMATIONOperatingIncomeofReportableSegmentsDetails"/>
  <link:definitionLink xlink:role="http://www.amedisys.com/role/SEGMENTINFORMATIONOperatingIncomeofReportableSegmentsDetails" xlink:type="extended" id="i2070e1baea4a40ecb69c5dd4c95735a8_SEGMENTINFORMATIONOperatingIncomeofReportableSegmentsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_c6d35024-8c37-4907-99b2-7fed2b545eea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions_4aa86ed3-b88a-4add-a03b-2e927c789324" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_c6d35024-8c37-4907-99b2-7fed2b545eea" xlink:to="loc_us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions_4aa86ed3-b88a-4add-a03b-2e927c789324" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncome_76a2220b-f43a-4073-8189-1d66f79a5b7b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherOperatingIncome"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_c6d35024-8c37-4907-99b2-7fed2b545eea" xlink:to="loc_us-gaap_OtherOperatingIncome_76a2220b-f43a-4073-8189-1d66f79a5b7b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_43912e84-8443-48a5-9be3-02d4f07cb5b7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_c6d35024-8c37-4907-99b2-7fed2b545eea" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_43912e84-8443-48a5-9be3-02d4f07cb5b7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_f5c21531-80ea-4a74-b0aa-01acb7134eba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_c6d35024-8c37-4907-99b2-7fed2b545eea" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_f5c21531-80ea-4a74-b0aa-01acb7134eba" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization_1cd8e71f-0e59-4be9-b0ec-f6bd3abd49ad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_c6d35024-8c37-4907-99b2-7fed2b545eea" xlink:to="loc_us-gaap_DepreciationAndAmortization_1cd8e71f-0e59-4be9-b0ec-f6bd3abd49ad" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_f2d7e413-844d-4342-bbbc-53cba8929692" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_c6d35024-8c37-4907-99b2-7fed2b545eea" xlink:to="loc_us-gaap_CostsAndExpenses_f2d7e413-844d-4342-bbbc-53cba8929692" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_4391fae0-5625-41c4-a581-e1df4a672b56" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_c6d35024-8c37-4907-99b2-7fed2b545eea" xlink:to="loc_us-gaap_OperatingIncomeLoss_4391fae0-5625-41c4-a581-e1df4a672b56" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_2d68b5b0-c733-4b5f-9d27-757fb8d341c5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_c6d35024-8c37-4907-99b2-7fed2b545eea" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_2d68b5b0-c733-4b5f-9d27-757fb8d341c5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_0fb1be3a-bebb-4a34-b406-3bd6deac0e40" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_2d68b5b0-c733-4b5f-9d27-757fb8d341c5" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_0fb1be3a-bebb-4a34-b406-3bd6deac0e40" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_0fb1be3a-bebb-4a34-b406-3bd6deac0e40_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_0fb1be3a-bebb-4a34-b406-3bd6deac0e40" xlink:to="loc_us-gaap_SegmentDomain_0fb1be3a-bebb-4a34-b406-3bd6deac0e40_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_4b5ddf80-2553-475a-a941-cc6aee12cda6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_0fb1be3a-bebb-4a34-b406-3bd6deac0e40" xlink:to="loc_us-gaap_SegmentDomain_4b5ddf80-2553-475a-a941-cc6aee12cda6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HomeHealthMember_f1e25057-7e44-49f4-a0b9-f7a3cceb0213" xlink:href="amed-20210630.xsd#amed_HomeHealthMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_4b5ddf80-2553-475a-a941-cc6aee12cda6" xlink:to="loc_amed_HomeHealthMember_f1e25057-7e44-49f4-a0b9-f7a3cceb0213" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HospiceMember_070da007-5921-437f-8fa8-ce763bfc75ff" xlink:href="amed-20210630.xsd#amed_HospiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_4b5ddf80-2553-475a-a941-cc6aee12cda6" xlink:to="loc_amed_HospiceMember_070da007-5921-437f-8fa8-ce763bfc75ff" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PersonalCareMember_a2f825a4-81f1-4d8d-8c64-523cad14317c" xlink:href="amed-20210630.xsd#amed_PersonalCareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_4b5ddf80-2553-475a-a941-cc6aee12cda6" xlink:to="loc_amed_PersonalCareMember_a2f825a4-81f1-4d8d-8c64-523cad14317c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllOtherSegmentsMember_c26ae767-67c6-4b3f-9773-0ec01e2a2ae3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllOtherSegmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_4b5ddf80-2553-475a-a941-cc6aee12cda6" xlink:to="loc_us-gaap_AllOtherSegmentsMember_c26ae767-67c6-4b3f-9773-0ec01e2a2ae3" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/SHAREREPURCHASENarrativeDetails" xlink:type="simple" xlink:href="amed-20210630.xsd#SHAREREPURCHASENarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.amedisys.com/role/SHAREREPURCHASENarrativeDetails" xlink:type="extended" id="i24643654d8f142d497f666fe9f655b92_SHAREREPURCHASENarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_amed_ShareRepurchaseLineItems_c7095863-fd07-471b-b278-ee838c7ea2fc" xlink:href="amed-20210630.xsd#amed_ShareRepurchaseLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_0bcf51c4-fa4c-4add-9a5d-07d0e7a30044" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_amed_ShareRepurchaseLineItems_c7095863-fd07-471b-b278-ee838c7ea2fc" xlink:to="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_0bcf51c4-fa4c-4add-9a5d-07d0e7a30044" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramExpirationDate_ea6dc325-535a-4fa2-a2e4-9ce5d66c8274" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchaseProgramExpirationDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_amed_ShareRepurchaseLineItems_c7095863-fd07-471b-b278-ee838c7ea2fc" xlink:to="loc_us-gaap_StockRepurchaseProgramExpirationDate_ea6dc325-535a-4fa2-a2e4-9ce5d66c8274" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_54dcf5c0-ec0c-43c4-a619-ec70c0cdc166" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_amed_ShareRepurchaseLineItems_c7095863-fd07-471b-b278-ee838c7ea2fc" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_54dcf5c0-ec0c-43c4-a619-ec70c0cdc166" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PercentageofSharesOutstanding_4760093b-9d67-4e21-98a1-d0ed1b33b1d4" xlink:href="amed-20210630.xsd#amed_PercentageofSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_amed_ShareRepurchaseLineItems_c7095863-fd07-471b-b278-ee838c7ea2fc" xlink:to="loc_amed_PercentageofSharesOutstanding_4760093b-9d67-4e21-98a1-d0ed1b33b1d4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_07d0c623-3a9e-49ab-9270-5719e376921d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_amed_ShareRepurchaseLineItems_c7095863-fd07-471b-b278-ee838c7ea2fc" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_07d0c623-3a9e-49ab-9270-5719e376921d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_Discountedclosingstockprice_4bed1747-8188-4096-829b-1a2ff8a59d2b" xlink:href="amed-20210630.xsd#amed_Discountedclosingstockprice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_amed_ShareRepurchaseLineItems_c7095863-fd07-471b-b278-ee838c7ea2fc" xlink:to="loc_amed_Discountedclosingstockprice_4bed1747-8188-4096-829b-1a2ff8a59d2b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_Percentageofclosingstockprice_21ddae05-ce9e-495f-a69a-12810713e130" xlink:href="amed-20210630.xsd#amed_Percentageofclosingstockprice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_amed_ShareRepurchaseLineItems_c7095863-fd07-471b-b278-ee838c7ea2fc" xlink:to="loc_amed_Percentageofclosingstockprice_21ddae05-ce9e-495f-a69a-12810713e130" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare_7125d5da-5436-46cc-b7f3-6da2bc84bb19" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockAcquiredAverageCostPerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_amed_ShareRepurchaseLineItems_c7095863-fd07-471b-b278-ee838c7ea2fc" xlink:to="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare_7125d5da-5436-46cc-b7f3-6da2bc84bb19" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ShareRepurchaseTable_113ac65b-f630-4855-acd7-bf509a512901" xlink:href="amed-20210630.xsd#amed_ShareRepurchaseTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_amed_ShareRepurchaseLineItems_c7095863-fd07-471b-b278-ee838c7ea2fc" xlink:to="loc_amed_ShareRepurchaseTable_113ac65b-f630-4855-acd7-bf509a512901" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramAxis_38afa32a-9d23-4b81-a4ac-5f795a454a07" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareRepurchaseProgramAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_amed_ShareRepurchaseTable_113ac65b-f630-4855-acd7-bf509a512901" xlink:to="loc_us-gaap_ShareRepurchaseProgramAxis_38afa32a-9d23-4b81-a4ac-5f795a454a07" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_38afa32a-9d23-4b81-a4ac-5f795a454a07_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareRepurchaseProgramDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_38afa32a-9d23-4b81-a4ac-5f795a454a07" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_38afa32a-9d23-4b81-a4ac-5f795a454a07_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_93deb2c7-e713-4864-b8c6-e432c4a4accf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareRepurchaseProgramDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_38afa32a-9d23-4b81-a4ac-5f795a454a07" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_93deb2c7-e713-4864-b8c6-e432c4a4accf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_A2019ShareRepurchaseProgramMember_cc0882be-2b4d-47e9-a462-56eeb263a27a" xlink:href="amed-20210630.xsd#amed_A2019ShareRepurchaseProgramMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_93deb2c7-e713-4864-b8c6-e432c4a4accf" xlink:to="loc_amed_A2019ShareRepurchaseProgramMember_cc0882be-2b4d-47e9-a462-56eeb263a27a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_A2021ShareRepurchaseProgramMember_f0c1999f-2b48-4e2b-8073-050c89b1ece6" xlink:href="amed-20210630.xsd#amed_A2021ShareRepurchaseProgramMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_93deb2c7-e713-4864-b8c6-e432c4a4accf" xlink:to="loc_amed_A2021ShareRepurchaseProgramMember_f0c1999f-2b48-4e2b-8073-050c89b1ece6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ShareRepurchaseProgramMember_9d08f830-eddf-4b14-bcd9-492d5d42f906" xlink:href="amed-20210630.xsd#amed_ShareRepurchaseProgramMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_93deb2c7-e713-4864-b8c6-e432c4a4accf" xlink:to="loc_amed_ShareRepurchaseProgramMember_9d08f830-eddf-4b14-bcd9-492d5d42f906" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_03cdb074-eca8-492d-acfa-ea8f077f3933" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_amed_ShareRepurchaseTable_113ac65b-f630-4855-acd7-bf509a512901" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_03cdb074-eca8-492d-acfa-ea8f077f3933" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_03cdb074-eca8-492d-acfa-ea8f077f3933_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_03cdb074-eca8-492d-acfa-ea8f077f3933" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_03cdb074-eca8-492d-acfa-ea8f077f3933_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_38806b3c-b1d6-4d70-b566-46c6f8fef5ff" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_03cdb074-eca8-492d-acfa-ea8f077f3933" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_38806b3c-b1d6-4d70-b566-46c6f8fef5ff" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_35cb97df-e7f3-4a27-8778-43f571be4afe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_38806b3c-b1d6-4d70-b566-46c6f8fef5ff" xlink:to="loc_us-gaap_SubsequentEventMember_35cb97df-e7f3-4a27-8778-43f571be4afe" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/RELATEDPARTYTRANSACTIONSNarrativeDetails" xlink:type="simple" xlink:href="amed-20210630.xsd#RELATEDPARTYTRANSACTIONSNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.amedisys.com/role/RELATEDPARTYTRANSACTIONSNarrativeDetails" xlink:type="extended" id="i0de6fc43e388482d88e1698fc1b06ff9_RELATEDPARTYTRANSACTIONSNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_681e0177-057e-4b3b-9ddf-50f1824a4d35" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction_ffab5353-51fb-422c-b9b8-48acee706036" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_681e0177-057e-4b3b-9ddf-50f1824a4d35" xlink:to="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction_ffab5353-51fb-422c-b9b8-48acee706036" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_7435d094-7bef-4e87-a2ac-6cbbe6bffb82" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_681e0177-057e-4b3b-9ddf-50f1824a4d35" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_7435d094-7bef-4e87-a2ac-6cbbe6bffb82" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_0ea251f7-9147-4090-a73d-d6a365c3d3cf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_7435d094-7bef-4e87-a2ac-6cbbe6bffb82" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_0ea251f7-9147-4090-a73d-d6a365c3d3cf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_0ea251f7-9147-4090-a73d-d6a365c3d3cf_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_0ea251f7-9147-4090-a73d-d6a365c3d3cf" xlink:to="loc_us-gaap_RelatedPartyDomain_0ea251f7-9147-4090-a73d-d6a365c3d3cf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_1a275804-f2ab-495e-a842-408e4516d1e3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_0ea251f7-9147-4090-a73d-d6a365c3d3cf" xlink:to="loc_us-gaap_RelatedPartyDomain_1a275804-f2ab-495e-a842-408e4516d1e3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_MedalogixMember_6b21cf6c-0c99-4216-8b34-66105c9efa73" xlink:href="amed-20210630.xsd#amed_MedalogixMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_1a275804-f2ab-495e-a842-408e4516d1e3" xlink:to="loc_amed_MedalogixMember_6b21cf6c-0c99-4216-8b34-66105c9efa73" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_2f962f9c-9cda-436f-9128-55618cddeb2c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_7435d094-7bef-4e87-a2ac-6cbbe6bffb82" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_2f962f9c-9cda-436f-9128-55618cddeb2c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_2f962f9c-9cda-436f-9128-55618cddeb2c_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_2f962f9c-9cda-436f-9128-55618cddeb2c" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_2f962f9c-9cda-436f-9128-55618cddeb2c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_5efbc66a-909a-472c-bfb2-a8aaa41b2abb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_2f962f9c-9cda-436f-9128-55618cddeb2c" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_5efbc66a-909a-472c-bfb2-a8aaa41b2abb" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/SUBSEQUENTEVENTTables" xlink:type="simple" xlink:href="amed-20210630.xsd#SUBSEQUENTEVENTTables"/>
  <link:definitionLink xlink:role="http://www.amedisys.com/role/SUBSEQUENTEVENTTables" xlink:type="extended" id="i7a326b00551a4313b76848ca0fbe99a2_SUBSEQUENTEVENTTables">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_b608438c-b597-485b-bd02-587557fc2019" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock_f51c2639-dfc1-4949-af70-eb894848c47b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_b608438c-b597-485b-bd02-587557fc2019" xlink:to="loc_us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock_f51c2639-dfc1-4949-af70-eb894848c47b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_5f72abc8-eb93-498d-96bc-e15bbc817e68" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsequentEventLineItems_b608438c-b597-485b-bd02-587557fc2019" xlink:to="loc_us-gaap_SubsequentEventTable_5f72abc8-eb93-498d-96bc-e15bbc817e68" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_64918b1d-4c0b-4538-837c-128f1c03095b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_5f72abc8-eb93-498d-96bc-e15bbc817e68" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_64918b1d-4c0b-4538-837c-128f1c03095b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_64918b1d-4c0b-4538-837c-128f1c03095b_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_64918b1d-4c0b-4538-837c-128f1c03095b" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_64918b1d-4c0b-4538-837c-128f1c03095b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_a0e0c07a-e12b-4e1e-b5c0-5d56dd64cc74" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_64918b1d-4c0b-4538-837c-128f1c03095b" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_a0e0c07a-e12b-4e1e-b5c0-5d56dd64cc74" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_57f05e8d-3f0b-4675-b96a-377e41a487be" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_a0e0c07a-e12b-4e1e-b5c0-5d56dd64cc74" xlink:to="loc_us-gaap_SubsequentEventMember_57f05e8d-3f0b-4675-b96a-377e41a487be" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/SUBSEQUENTEVENTNarrativeDetails" xlink:type="simple" xlink:href="amed-20210630.xsd#SUBSEQUENTEVENTNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.amedisys.com/role/SUBSEQUENTEVENTNarrativeDetails" xlink:type="extended" id="i584dfa0d416e4c469f155515cbef0100_SUBSEQUENTEVENTNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_456c99cd-ddc9-48de-a5e9-a04f7b144b74" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_1532bd4f-6721-4a41-af64-e3e59d9c50bb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_456c99cd-ddc9-48de-a5e9-a04f7b144b74" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_1532bd4f-6721-4a41-af64-e3e59d9c50bb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PaymentsRelatedToTaxAsset_73f6f36f-c99b-40fd-9e84-cae27f04e90b" xlink:href="amed-20210630.xsd#amed_PaymentsRelatedToTaxAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_456c99cd-ddc9-48de-a5e9-a04f7b144b74" xlink:to="loc_amed_PaymentsRelatedToTaxAsset_73f6f36f-c99b-40fd-9e84-cae27f04e90b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfBusinessesAcquired_a40cf2c0-9dc2-422f-974e-8e19239a8fd3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfBusinessesAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_456c99cd-ddc9-48de-a5e9-a04f7b144b74" xlink:to="loc_us-gaap_NumberOfBusinessesAcquired_a40cf2c0-9dc2-422f-974e-8e19239a8fd3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_1e7ccc86-a1e2-49a1-a551-02fad1c990e9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_456c99cd-ddc9-48de-a5e9-a04f7b144b74" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_1e7ccc86-a1e2-49a1-a551-02fad1c990e9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_dadec47b-88b5-478c-a931-bb754f130d8c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_456c99cd-ddc9-48de-a5e9-a04f7b144b74" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_dadec47b-88b5-478c-a931-bb754f130d8c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_9ccc6576-21f8-457c-8306-d548ca669e9f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_456c99cd-ddc9-48de-a5e9-a04f7b144b74" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_9ccc6576-21f8-457c-8306-d548ca669e9f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_DebtInstrumentInterestAdditionalInterestAboveFederalFundRate_ea82bb64-cb96-4e03-89e3-5d2c130a7dde" xlink:href="amed-20210630.xsd#amed_DebtInstrumentInterestAdditionalInterestAboveFederalFundRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_456c99cd-ddc9-48de-a5e9-a04f7b144b74" xlink:to="loc_amed_DebtInstrumentInterestAdditionalInterestAboveFederalFundRate_ea82bb64-cb96-4e03-89e3-5d2c130a7dde" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_DebtInstrumentInterestAdditionalInterestAboveEurodollarRate_fb7fcbdd-aed5-45f7-94bf-71a9f5842bd4" xlink:href="amed-20210630.xsd#amed_DebtInstrumentInterestAdditionalInterestAboveEurodollarRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_456c99cd-ddc9-48de-a5e9-a04f7b144b74" xlink:to="loc_amed_DebtInstrumentInterestAdditionalInterestAboveEurodollarRate_fb7fcbdd-aed5-45f7-94bf-71a9f5842bd4" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentMaturityDate_831b807d-8cf3-4f19-9f7d-03747581c0bd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentMaturityDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_456c99cd-ddc9-48de-a5e9-a04f7b144b74" xlink:to="loc_us-gaap_DebtInstrumentMaturityDate_831b807d-8cf3-4f19-9f7d-03747581c0bd" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_DebtInstrumentPeriodicPaymentPercentage_7f06df29-44d6-415a-a001-225d352ff81a" xlink:href="amed-20210630.xsd#amed_DebtInstrumentPeriodicPaymentPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_456c99cd-ddc9-48de-a5e9-a04f7b144b74" xlink:to="loc_amed_DebtInstrumentPeriodicPaymentPercentage_7f06df29-44d6-415a-a001-225d352ff81a" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ProceedsReceivedFromLoanPartyOfSubsidiary_62526136-94cb-4b65-b312-fbb2c5e26856" xlink:href="amed-20210630.xsd#amed_ProceedsReceivedFromLoanPartyOfSubsidiary"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_456c99cd-ddc9-48de-a5e9-a04f7b144b74" xlink:to="loc_amed_ProceedsReceivedFromLoanPartyOfSubsidiary_62526136-94cb-4b65-b312-fbb2c5e26856" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PercentageOfRevenueAndOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromWhollyOwnedSubsidiaries_13802f42-bc14-474f-a72c-c911d2dc9dc7" xlink:href="amed-20210630.xsd#amed_PercentageOfRevenueAndOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromWhollyOwnedSubsidiaries"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_456c99cd-ddc9-48de-a5e9-a04f7b144b74" xlink:to="loc_amed_PercentageOfRevenueAndOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromWhollyOwnedSubsidiaries_13802f42-bc14-474f-a72c-c911d2dc9dc7" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PercentageOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromSubsidiaries_13c658ca-4b95-4896-b300-ece2094aa68c" xlink:href="amed-20210630.xsd#amed_PercentageOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromSubsidiaries"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_456c99cd-ddc9-48de-a5e9-a04f7b144b74" xlink:to="loc_amed_PercentageOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromSubsidiaries_13c658ca-4b95-4896-b300-ece2094aa68c" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_3feba0bb-a0d4-471c-9cfb-f03b90947e17" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_456c99cd-ddc9-48de-a5e9-a04f7b144b74" xlink:to="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_3feba0bb-a0d4-471c-9cfb-f03b90947e17" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramExpirationDate_252ddad4-e914-4bc1-b04f-0f9dac3c241f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchaseProgramExpirationDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_456c99cd-ddc9-48de-a5e9-a04f7b144b74" xlink:to="loc_us-gaap_StockRepurchaseProgramExpirationDate_252ddad4-e914-4bc1-b04f-0f9dac3c241f" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_a9065f39-6c45-4d32-aaf3-63882db67be6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsequentEventLineItems_456c99cd-ddc9-48de-a5e9-a04f7b144b74" xlink:to="loc_us-gaap_SubsequentEventTable_a9065f39-6c45-4d32-aaf3-63882db67be6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_d60f4921-6ca1-4ca4-94ba-11cd92b0978b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_a9065f39-6c45-4d32-aaf3-63882db67be6" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_d60f4921-6ca1-4ca4-94ba-11cd92b0978b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_d60f4921-6ca1-4ca4-94ba-11cd92b0978b_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_d60f4921-6ca1-4ca4-94ba-11cd92b0978b" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_d60f4921-6ca1-4ca4-94ba-11cd92b0978b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_2375981a-4940-4b3d-8882-3c88b93b3062" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_d60f4921-6ca1-4ca4-94ba-11cd92b0978b" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_2375981a-4940-4b3d-8882-3c88b93b3062" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_ca3553b5-21bf-4e80-8e8b-93a7920348d0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_2375981a-4940-4b3d-8882-3c88b93b3062" xlink:to="loc_us-gaap_SubsequentEventMember_ca3553b5-21bf-4e80-8e8b-93a7920348d0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_b262cce0-dd2c-4b32-9fce-64da9317eb0b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_a9065f39-6c45-4d32-aaf3-63882db67be6" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_b262cce0-dd2c-4b32-9fce-64da9317eb0b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_b262cce0-dd2c-4b32-9fce-64da9317eb0b_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_b262cce0-dd2c-4b32-9fce-64da9317eb0b" xlink:to="loc_us-gaap_SegmentDomain_b262cce0-dd2c-4b32-9fce-64da9317eb0b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_e0f3ac60-23fb-4f09-beae-ca5d57d76323" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_b262cce0-dd2c-4b32-9fce-64da9317eb0b" xlink:to="loc_us-gaap_SegmentDomain_e0f3ac60-23fb-4f09-beae-ca5d57d76323" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HospiceMember_27a32142-bb7c-4bf5-ac8d-91c46bb08263" xlink:href="amed-20210630.xsd#amed_HospiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_e0f3ac60-23fb-4f09-beae-ca5d57d76323" xlink:to="loc_amed_HospiceMember_27a32142-bb7c-4bf5-ac8d-91c46bb08263" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HomeHealthMember_59757134-e071-4d02-9f30-2b9444bfe349" xlink:href="amed-20210630.xsd#amed_HomeHealthMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_e0f3ac60-23fb-4f09-beae-ca5d57d76323" xlink:to="loc_amed_HomeHealthMember_59757134-e071-4d02-9f30-2b9444bfe349" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_f05095b9-5907-4737-b7e0-28c685b45afc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_a9065f39-6c45-4d32-aaf3-63882db67be6" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_f05095b9-5907-4737-b7e0-28c685b45afc" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_f05095b9-5907-4737-b7e0-28c685b45afc_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_f05095b9-5907-4737-b7e0-28c685b45afc" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_f05095b9-5907-4737-b7e0-28c685b45afc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_523ffe81-4b38-4265-9761-15be52af5ee8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_f05095b9-5907-4737-b7e0-28c685b45afc" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_523ffe81-4b38-4265-9761-15be52af5ee8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_VisitingNurseAssociationMember_551b2644-8a38-42c7-9f90-82f7c78deeb5" xlink:href="amed-20210630.xsd#amed_VisitingNurseAssociationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_523ffe81-4b38-4265-9761-15be52af5ee8" xlink:to="loc_amed_VisitingNurseAssociationMember_551b2644-8a38-42c7-9f90-82f7c78deeb5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ContessaHealthMember_cc039d49-d0db-4365-bf35-dcd0423dec0a" xlink:href="amed-20210630.xsd#amed_ContessaHealthMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_523ffe81-4b38-4265-9761-15be52af5ee8" xlink:to="loc_amed_ContessaHealthMember_cc039d49-d0db-4365-bf35-dcd0423dec0a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_472b0174-2675-4205-893f-a1fb9eacef04" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_a9065f39-6c45-4d32-aaf3-63882db67be6" xlink:to="loc_srt_StatementGeographicalAxis_472b0174-2675-4205-893f-a1fb9eacef04" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_472b0174-2675-4205-893f-a1fb9eacef04_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_472b0174-2675-4205-893f-a1fb9eacef04" xlink:to="loc_srt_SegmentGeographicalDomain_472b0174-2675-4205-893f-a1fb9eacef04_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_a5ca289e-1041-4494-b5df-33d1660854b3" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_472b0174-2675-4205-893f-a1fb9eacef04" xlink:to="loc_srt_SegmentGeographicalDomain_a5ca289e-1041-4494-b5df-33d1660854b3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_NY_857c2a7e-73c1-4600-be18-9342451df821" xlink:href="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd#stpr_NY"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_a5ca289e-1041-4494-b5df-33d1660854b3" xlink:to="loc_stpr_NY_857c2a7e-73c1-4600-be18-9342451df821" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_fb8070d7-8623-4e16-9580-4b3c369ee37c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_a9065f39-6c45-4d32-aaf3-63882db67be6" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_fb8070d7-8623-4e16-9580-4b3c369ee37c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_fb8070d7-8623-4e16-9580-4b3c369ee37c_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_fb8070d7-8623-4e16-9580-4b3c369ee37c" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_fb8070d7-8623-4e16-9580-4b3c369ee37c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_7d292264-8847-4415-9ac8-8a28b0dc1c35" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_fb8070d7-8623-4e16-9580-4b3c369ee37c" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_7d292264-8847-4415-9ac8-8a28b0dc1c35" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_SecondAmendmentToAmendedCreditAgreementMember_78048a68-63e9-4e87-8686-daff804acea4" xlink:href="amed-20210630.xsd#amed_SecondAmendmentToAmendedCreditAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_7d292264-8847-4415-9ac8-8a28b0dc1c35" xlink:to="loc_amed_SecondAmendmentToAmendedCreditAgreementMember_78048a68-63e9-4e87-8686-daff804acea4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_e894aa10-ee35-4ddd-8367-e593cd6d680c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_a9065f39-6c45-4d32-aaf3-63882db67be6" xlink:to="loc_us-gaap_DebtInstrumentAxis_e894aa10-ee35-4ddd-8367-e593cd6d680c" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_e894aa10-ee35-4ddd-8367-e593cd6d680c_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_e894aa10-ee35-4ddd-8367-e593cd6d680c" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_e894aa10-ee35-4ddd-8367-e593cd6d680c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_c0a47480-b84b-4d54-9ebe-eadc4f0eb4d7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_e894aa10-ee35-4ddd-8367-e593cd6d680c" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_c0a47480-b84b-4d54-9ebe-eadc4f0eb4d7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember_054bd3dd-d9b9-4612-b768-183b5364c26f" xlink:href="amed-20210630.xsd#amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_c0a47480-b84b-4d54-9ebe-eadc4f0eb4d7" xlink:to="loc_amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember_054bd3dd-d9b9-4612-b768-183b5364c26f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_FourHundredFiftyMillionTermLoanFacilityMember_c3495a0e-b289-479e-809c-1e31e1874349" xlink:href="amed-20210630.xsd#amed_FourHundredFiftyMillionTermLoanFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_c0a47480-b84b-4d54-9ebe-eadc4f0eb4d7" xlink:to="loc_amed_FourHundredFiftyMillionTermLoanFacilityMember_c3495a0e-b289-479e-809c-1e31e1874349" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramAxis_f1e67983-b92c-4f39-b1d7-4e24fd5bc517" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareRepurchaseProgramAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_a9065f39-6c45-4d32-aaf3-63882db67be6" xlink:to="loc_us-gaap_ShareRepurchaseProgramAxis_f1e67983-b92c-4f39-b1d7-4e24fd5bc517" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_f1e67983-b92c-4f39-b1d7-4e24fd5bc517_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareRepurchaseProgramDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_f1e67983-b92c-4f39-b1d7-4e24fd5bc517" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_f1e67983-b92c-4f39-b1d7-4e24fd5bc517_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_0aabb9c8-4b7e-4e01-b181-8c56a3078a96" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareRepurchaseProgramDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_f1e67983-b92c-4f39-b1d7-4e24fd5bc517" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_0aabb9c8-4b7e-4e01-b181-8c56a3078a96" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_A2021ShareRepurchaseProgramMember_493f3d7a-3bd3-4f10-a766-f735a2f09d5b" xlink:href="amed-20210630.xsd#amed_A2021ShareRepurchaseProgramMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_0aabb9c8-4b7e-4e01-b181-8c56a3078a96" xlink:to="loc_amed_A2021ShareRepurchaseProgramMember_493f3d7a-3bd3-4f10-a766-f735a2f09d5b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ShareRepurchaseProgramMember_cbafb690-dcd4-469a-ba3c-1879fbdce1a5" xlink:href="amed-20210630.xsd#amed_ShareRepurchaseProgramMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_0aabb9c8-4b7e-4e01-b181-8c56a3078a96" xlink:to="loc_amed_ShareRepurchaseProgramMember_cbafb690-dcd4-469a-ba3c-1879fbdce1a5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_4d22942f-6770-4f75-943f-1cf8c88e7cbe" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_a9065f39-6c45-4d32-aaf3-63882db67be6" xlink:to="loc_srt_RangeAxis_4d22942f-6770-4f75-943f-1cf8c88e7cbe" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_4d22942f-6770-4f75-943f-1cf8c88e7cbe_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_4d22942f-6770-4f75-943f-1cf8c88e7cbe" xlink:to="loc_srt_RangeMember_4d22942f-6770-4f75-943f-1cf8c88e7cbe_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_b79a209e-9de3-4141-af37-20792e39d5fc" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_4d22942f-6770-4f75-943f-1cf8c88e7cbe" xlink:to="loc_srt_RangeMember_b79a209e-9de3-4141-af37-20792e39d5fc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_5b5cd523-6ebc-4591-bc99-e6b4d23b36a7" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_b79a209e-9de3-4141-af37-20792e39d5fc" xlink:to="loc_srt_MinimumMember_5b5cd523-6ebc-4591-bc99-e6b4d23b36a7" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/SUBSEQUENTEVENTFeesandRatesUnderCreditFacilitiesDetails" xlink:type="simple" xlink:href="amed-20210630.xsd#SUBSEQUENTEVENTFeesandRatesUnderCreditFacilitiesDetails"/>
  <link:definitionLink xlink:role="http://www.amedisys.com/role/SUBSEQUENTEVENTFeesandRatesUnderCreditFacilitiesDetails" xlink:type="extended" id="if2f178fa4af94c75b59e119a460363af_SUBSEQUENTEVENTFeesandRatesUnderCreditFacilitiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_de729053-bc5c-43e2-8c23-e0369a9483cc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ConsolidatedLeverageRatio_6c199151-f7d5-4fba-88a9-9a5d31e479cc" xlink:href="amed-20210630.xsd#amed_ConsolidatedLeverageRatio"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_de729053-bc5c-43e2-8c23-e0369a9483cc" xlink:to="loc_amed_ConsolidatedLeverageRatio_6c199151-f7d5-4fba-88a9-9a5d31e479cc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_5fbd5989-4a3b-4fc7-ba2a-b184177c796e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityCommitmentFeePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_de729053-bc5c-43e2-8c23-e0369a9483cc" xlink:to="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_5fbd5989-4a3b-4fc7-ba2a-b184177c796e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_LetterOfCreditFee_5e783a01-1df5-4472-ad3a-281df553a620" xlink:href="amed-20210630.xsd#amed_LetterOfCreditFee"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_de729053-bc5c-43e2-8c23-e0369a9483cc" xlink:to="loc_amed_LetterOfCreditFee_5e783a01-1df5-4472-ad3a-281df553a620" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_9d732bc4-ca5d-4493-bf91-cfbbab1d16ce" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_de729053-bc5c-43e2-8c23-e0369a9483cc" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_9d732bc4-ca5d-4493-bf91-cfbbab1d16ce" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_b4520142-e52d-4b35-947f-ed5a18d77a63" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsequentEventLineItems_de729053-bc5c-43e2-8c23-e0369a9483cc" xlink:to="loc_us-gaap_SubsequentEventTable_b4520142-e52d-4b35-947f-ed5a18d77a63" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_e0d9e10e-1437-40c4-aa3c-ed9df9538ecf" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_b4520142-e52d-4b35-947f-ed5a18d77a63" xlink:to="loc_srt_RangeAxis_e0d9e10e-1437-40c4-aa3c-ed9df9538ecf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_e0d9e10e-1437-40c4-aa3c-ed9df9538ecf_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_e0d9e10e-1437-40c4-aa3c-ed9df9538ecf" xlink:to="loc_srt_RangeMember_e0d9e10e-1437-40c4-aa3c-ed9df9538ecf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_4408df20-fdb2-4351-bb98-4b86ad864f13" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_e0d9e10e-1437-40c4-aa3c-ed9df9538ecf" xlink:to="loc_srt_RangeMember_4408df20-fdb2-4351-bb98-4b86ad864f13" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_0219dadd-8e10-42e9-b624-2dad2f5a13e4" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_4408df20-fdb2-4351-bb98-4b86ad864f13" xlink:to="loc_srt_MinimumMember_0219dadd-8e10-42e9-b624-2dad2f5a13e4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_c04255c3-599f-46ba-962e-7ecba56943e1" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_4408df20-fdb2-4351-bb98-4b86ad864f13" xlink:to="loc_srt_MaximumMember_c04255c3-599f-46ba-962e-7ecba56943e1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_8fcb4fa8-9aa2-4f7d-b8c1-b9f171395ad4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_b4520142-e52d-4b35-947f-ed5a18d77a63" xlink:to="loc_us-gaap_DebtInstrumentAxis_8fcb4fa8-9aa2-4f7d-b8c1-b9f171395ad4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_8fcb4fa8-9aa2-4f7d-b8c1-b9f171395ad4_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_8fcb4fa8-9aa2-4f7d-b8c1-b9f171395ad4" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_8fcb4fa8-9aa2-4f7d-b8c1-b9f171395ad4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_9e168815-8641-4572-9311-bc5c302f0f09" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_8fcb4fa8-9aa2-4f7d-b8c1-b9f171395ad4" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_9e168815-8641-4572-9311-bc5c302f0f09" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AmendedDebtInstrumentByLeverageRatioTrancheOneMember_c4db6266-ae21-4898-b2b6-7798dc753a6d" xlink:href="amed-20210630.xsd#amed_AmendedDebtInstrumentByLeverageRatioTrancheOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_9e168815-8641-4572-9311-bc5c302f0f09" xlink:to="loc_amed_AmendedDebtInstrumentByLeverageRatioTrancheOneMember_c4db6266-ae21-4898-b2b6-7798dc753a6d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AmendedDebtInstrumentByLeverageRatioTrancheTwoMember_a49976a1-eddc-426c-842d-71ef65190d1c" xlink:href="amed-20210630.xsd#amed_AmendedDebtInstrumentByLeverageRatioTrancheTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_9e168815-8641-4572-9311-bc5c302f0f09" xlink:to="loc_amed_AmendedDebtInstrumentByLeverageRatioTrancheTwoMember_a49976a1-eddc-426c-842d-71ef65190d1c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AmendedDebtInstrumentByLeverageRatioTrancheThreeMember_cc3f67d7-5622-4a87-b047-3cbff3da2fcd" xlink:href="amed-20210630.xsd#amed_AmendedDebtInstrumentByLeverageRatioTrancheThreeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_9e168815-8641-4572-9311-bc5c302f0f09" xlink:to="loc_amed_AmendedDebtInstrumentByLeverageRatioTrancheThreeMember_cc3f67d7-5622-4a87-b047-3cbff3da2fcd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AmendedDebtInstrumentByLeverageRatioTrancheFourMember_26a6ae14-2f14-4723-8a93-ab2516830426" xlink:href="amed-20210630.xsd#amed_AmendedDebtInstrumentByLeverageRatioTrancheFourMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_9e168815-8641-4572-9311-bc5c302f0f09" xlink:to="loc_amed_AmendedDebtInstrumentByLeverageRatioTrancheFourMember_26a6ae14-2f14-4723-8a93-ab2516830426" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_047417e6-2b65-4ec2-9a45-ded6f8900352" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_b4520142-e52d-4b35-947f-ed5a18d77a63" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_047417e6-2b65-4ec2-9a45-ded6f8900352" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_047417e6-2b65-4ec2-9a45-ded6f8900352_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_047417e6-2b65-4ec2-9a45-ded6f8900352" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_047417e6-2b65-4ec2-9a45-ded6f8900352_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_c4dfb6a3-43e9-429a-a446-e6c8cf77a642" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_047417e6-2b65-4ec2-9a45-ded6f8900352" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_c4dfb6a3-43e9-429a-a446-e6c8cf77a642" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_968c5853-5235-4b9a-a2b7-a1dbe5385284" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_c4dfb6a3-43e9-429a-a446-e6c8cf77a642" xlink:to="loc_us-gaap_SubsequentEventMember_968c5853-5235-4b9a-a2b7-a1dbe5385284" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_faf63477-3eb8-4ae3-879e-88291e80dc4f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_b4520142-e52d-4b35-947f-ed5a18d77a63" xlink:to="loc_us-gaap_VariableRateAxis_faf63477-3eb8-4ae3-879e-88291e80dc4f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_faf63477-3eb8-4ae3-879e-88291e80dc4f_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VariableRateAxis_faf63477-3eb8-4ae3-879e-88291e80dc4f" xlink:to="loc_us-gaap_VariableRateDomain_faf63477-3eb8-4ae3-879e-88291e80dc4f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_15b55896-48ee-4442-9d91-874500f8b0e5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VariableRateAxis_faf63477-3eb8-4ae3-879e-88291e80dc4f" xlink:to="loc_us-gaap_VariableRateDomain_15b55896-48ee-4442-9d91-874500f8b0e5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EurodollarMember_5a145737-bdc9-45a0-9df2-c4b92978bc6c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EurodollarMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_15b55896-48ee-4442-9d91-874500f8b0e5" xlink:to="loc_us-gaap_EurodollarMember_5a145737-bdc9-45a0-9df2-c4b92978bc6c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BaseRateMember_22ef9699-1cb5-49c9-a931-0a544f1112bf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BaseRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_15b55896-48ee-4442-9d91-874500f8b0e5" xlink:to="loc_us-gaap_BaseRateMember_22ef9699-1cb5-49c9-a931-0a544f1112bf" xlink:type="arc" order="1"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>9
<FILENAME>amed-20210630_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:9b598574-bbed-4d17-bc5e-2b8ec86d1c16,g:311e4854-6196-49e6-97c5-f444b0264a32-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_LossContingencyReceivableNoncurrent_7527e7e4-d3cf-4b0b-86e6-093c3e36f95c_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyReceivableNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indemnity receivable</link:label>
    <link:label id="lab_us-gaap_LossContingencyReceivableNoncurrent_label_en-US" xlink:label="lab_us-gaap_LossContingencyReceivableNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Receivable, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyReceivableNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyReceivableNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyReceivableNoncurrent" xlink:to="lab_us-gaap_LossContingencyReceivableNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_NetServiceRevenuePeriodOfCarePaymentRateDuration_53db73b2-aa7e-4a00-8c24-15531f327066_terseLabel_en-US" xlink:label="lab_amed_NetServiceRevenuePeriodOfCarePaymentRateDuration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net service revenue period of care payment rate (days)</link:label>
    <link:label id="lab_amed_NetServiceRevenuePeriodOfCarePaymentRateDuration_label_en-US" xlink:label="lab_amed_NetServiceRevenuePeriodOfCarePaymentRateDuration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Service Revenue, Period of Care Payment Rate Duration</link:label>
    <link:label id="lab_amed_NetServiceRevenuePeriodOfCarePaymentRateDuration_documentation_en-US" xlink:label="lab_amed_NetServiceRevenuePeriodOfCarePaymentRateDuration" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description containing the number of days from the date the request for anticipated payment was received in which the final bill must be submitted to Medicare.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_NetServiceRevenuePeriodOfCarePaymentRateDuration" xlink:href="amed-20210630.xsd#amed_NetServiceRevenuePeriodOfCarePaymentRateDuration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_NetServiceRevenuePeriodOfCarePaymentRateDuration" xlink:to="lab_amed_NetServiceRevenuePeriodOfCarePaymentRateDuration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationsPolicy_bc7d9a8d-bdb0-44b6-8c17-d85875e99b2e_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationsPolicy_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsPolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationsPolicy" xlink:to="lab_us-gaap_BusinessCombinationsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_0d36bae4-cd8e-4bc3-a3c1-51b24d429896_terseLabel_en-US" xlink:label="lab_amed_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease right of use assets</link:label>
    <link:label id="lab_amed_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_amed_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Operating Lease Right Of Use Asset</link:label>
    <link:label id="lab_amed_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_documentation_en-US" xlink:label="lab_amed_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The amount of increase (decrease) In Operating Lease Right Of Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" xlink:href="amed-20210630.xsd#amed_IncreaseDecreaseInOperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" xlink:to="lab_amed_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_4b7c7c8d-8209-442e-a977-07d7a8ab71e0_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_ClearwaterFloridaMember_13baef53-2a41-4d4f-a70a-880d789ac94f_terseLabel_en-US" xlink:label="lab_amed_ClearwaterFloridaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clearwater, Florida</link:label>
    <link:label id="lab_amed_ClearwaterFloridaMember_label_en-US" xlink:label="lab_amed_ClearwaterFloridaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clearwater, Florida [Member]</link:label>
    <link:label id="lab_amed_ClearwaterFloridaMember_documentation_en-US" xlink:label="lab_amed_ClearwaterFloridaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clearwater, Florida [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ClearwaterFloridaMember" xlink:href="amed-20210630.xsd#amed_ClearwaterFloridaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_ClearwaterFloridaMember" xlink:to="lab_amed_ClearwaterFloridaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_stpr_SC_5f3e1443-a4d2-4a7c-b2eb-3e21882cd587_terseLabel_en-US" xlink:label="lab_stpr_SC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">South Carolina</link:label>
    <link:label id="lab_stpr_SC_label_en-US" xlink:label="lab_stpr_SC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SOUTH CAROLINA</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_SC" xlink:href="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd#stpr_SC"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_stpr_SC" xlink:to="lab_stpr_SC" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_ec466af7-64f5-4cc1-9366-5e08cda0828b_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Miscellaneous, net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_VisitingNurseAssociationMember_4e862289-d508-43bc-a03b-0b1987bc0de9_terseLabel_en-US" xlink:label="lab_amed_VisitingNurseAssociationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Visiting Nurse Association</link:label>
    <link:label id="lab_amed_VisitingNurseAssociationMember_label_en-US" xlink:label="lab_amed_VisitingNurseAssociationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Visiting Nurse Association [Member]</link:label>
    <link:label id="lab_amed_VisitingNurseAssociationMember_documentation_en-US" xlink:label="lab_amed_VisitingNurseAssociationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Visiting Nurse Association</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_VisitingNurseAssociationMember" xlink:href="amed-20210630.xsd#amed_VisitingNurseAssociationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_VisitingNurseAssociationMember" xlink:to="lab_amed_VisitingNurseAssociationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_876e7768-58c5-4654-95f4-2d805315b355_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COMMITMENTS AND CONTINGENCIES</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_022611ea-a7f8-4304-85d6-967e7f2f0b7b_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockMember_44de182c-e147-4e89-b9fd-efb95a452382_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock</link:label>
    <link:label id="lab_us-gaap_TreasuryStockMember_label_en-US" xlink:label="lab_us-gaap_TreasuryStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockMember" xlink:to="lab_us-gaap_TreasuryStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_8a09540d-e5fe-43bd-a00a-c995d1a1cacd_negatedLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_PeriodOfCareAsEpisodicBasedRevenueDuration_f718aa7d-fb85-41b2-904f-9b2f39f459b3_terseLabel_en-US" xlink:label="lab_amed_PeriodOfCareAsEpisodicBasedRevenueDuration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Period of care as episodic-based revenue (days)</link:label>
    <link:label id="lab_amed_PeriodOfCareAsEpisodicBasedRevenueDuration_label_en-US" xlink:label="lab_amed_PeriodOfCareAsEpisodicBasedRevenueDuration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Period of Care As Episodic Based Revenue Duration</link:label>
    <link:label id="lab_amed_PeriodOfCareAsEpisodicBasedRevenueDuration_documentation_en-US" xlink:label="lab_amed_PeriodOfCareAsEpisodicBasedRevenueDuration" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description containing the number of days in a home health period of care using PDGM</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PeriodOfCareAsEpisodicBasedRevenueDuration" xlink:href="amed-20210630.xsd#amed_PeriodOfCareAsEpisodicBasedRevenueDuration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_PeriodOfCareAsEpisodicBasedRevenueDuration" xlink:to="lab_amed_PeriodOfCareAsEpisodicBasedRevenueDuration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_945b2c54-4fcb-483e-a6b9-9a50da32661e_terseLabel_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis" xlink:to="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_1d193dc3-8fe5-46a3-981d-e49ad7857aad_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_MorgantownWestVirginiaMember_3108a810-26a0-4ce8-8cc5-603f903f03f0_terseLabel_en-US" xlink:label="lab_amed_MorgantownWestVirginiaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Morgantown, West Virginia</link:label>
    <link:label id="lab_amed_MorgantownWestVirginiaMember_label_en-US" xlink:label="lab_amed_MorgantownWestVirginiaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Morgantown, West Virginia [Member]</link:label>
    <link:label id="lab_amed_MorgantownWestVirginiaMember_documentation_en-US" xlink:label="lab_amed_MorgantownWestVirginiaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Morgantown, West Virginia [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_MorgantownWestVirginiaMember" xlink:href="amed-20210630.xsd#amed_MorgantownWestVirginiaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_MorgantownWestVirginiaMember" xlink:to="lab_amed_MorgantownWestVirginiaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_6c56b036-297c-4e19-a1bd-d0a658d41f94_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_d108e08b-ce21-4291-80b5-f8d14a455f4c_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LIABILITIES AND EQUITY</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditMember_8ffaaf82-1922-4802-9712-e7d5ad458743_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit [Member]</link:label>
    <link:label id="lab_us-gaap_LineOfCreditMember_label_en-US" xlink:label="lab_us-gaap_LineOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditMember" xlink:to="lab_us-gaap_LineOfCreditMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_24a5c0d6-8660-4ec8-88bb-838ef87745ba_negatedLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling interest distribution</link:label>
    <link:label id="lab_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_label_en-US" xlink:label="lab_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Decrease from Distributions to Noncontrolling Interest Holders</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" xlink:to="lab_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_7f72028a-2a4c-40ea-a747-de6e2af1c891_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term obligations</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Noncurrent Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LaborAndRelatedExpense_30d0d9ad-3d4f-46cd-8d29-ba2594d6591a_terseLabel_en-US" xlink:label="lab_us-gaap_LaborAndRelatedExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Salaries and benefits</link:label>
    <link:label id="lab_us-gaap_LaborAndRelatedExpense_label_en-US" xlink:label="lab_us-gaap_LaborAndRelatedExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Labor and Related Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LaborAndRelatedExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LaborAndRelatedExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LaborAndRelatedExpense" xlink:to="lab_us-gaap_LaborAndRelatedExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_999c7bcb-b6e7-4250-b859-637c6b6e3f2d_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Name of each exchange on which registered</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_c1f4e4d0-b86b-408e-8fff-63f376fb963a_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets, net of accumulated amortization of $15,842 and $22,973</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_FundingImmediatelyDistributedToHealthcareProvidersBasedOnTheir2019MedicareFeeForServiceReimbursements_9dac9a75-9fee-4939-aeb5-245b807e2f41_terseLabel_en-US" xlink:label="lab_amed_FundingImmediatelyDistributedToHealthcareProvidersBasedOnTheir2019MedicareFeeForServiceReimbursements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Funding Immediately Distributed to Healthcare Providers Based on Their 2019 Medicare Fee-For-Service Reimbursements</link:label>
    <link:label id="lab_amed_FundingImmediatelyDistributedToHealthcareProvidersBasedOnTheir2019MedicareFeeForServiceReimbursements_label_en-US" xlink:label="lab_amed_FundingImmediatelyDistributedToHealthcareProvidersBasedOnTheir2019MedicareFeeForServiceReimbursements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Funding Immediately Distributed to Healthcare Providers Based on Their 2019 Medicare Fee-For-Service Reimbursements</link:label>
    <link:label id="lab_amed_FundingImmediatelyDistributedToHealthcareProvidersBasedOnTheir2019MedicareFeeForServiceReimbursements_documentation_en-US" xlink:label="lab_amed_FundingImmediatelyDistributedToHealthcareProvidersBasedOnTheir2019MedicareFeeForServiceReimbursements" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Funding immediately distributed to healthcare providers based on their 2019 Medicare Fee-For-Service reimbursements provided by the Coronavirus Aid, Relief and Economic Security (CARES) Act</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_FundingImmediatelyDistributedToHealthcareProvidersBasedOnTheir2019MedicareFeeForServiceReimbursements" xlink:href="amed-20210630.xsd#amed_FundingImmediatelyDistributedToHealthcareProvidersBasedOnTheir2019MedicareFeeForServiceReimbursements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_FundingImmediatelyDistributedToHealthcareProvidersBasedOnTheir2019MedicareFeeForServiceReimbursements" xlink:to="lab_amed_FundingImmediatelyDistributedToHealthcareProvidersBasedOnTheir2019MedicareFeeForServiceReimbursements" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_ConsolidatedLeverageRatio_74074d2f-7ca1-43f5-8dc3-0545f3c56ae4_terseLabel_en-US" xlink:label="lab_amed_ConsolidatedLeverageRatio" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Leverage Ratio</link:label>
    <link:label id="lab_amed_ConsolidatedLeverageRatio_label_en-US" xlink:label="lab_amed_ConsolidatedLeverageRatio" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Leverage Ratio</link:label>
    <link:label id="lab_amed_ConsolidatedLeverageRatio_documentation_en-US" xlink:label="lab_amed_ConsolidatedLeverageRatio" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Leverage Ratio</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ConsolidatedLeverageRatio" xlink:href="amed-20210630.xsd#amed_ConsolidatedLeverageRatio"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_ConsolidatedLeverageRatio" xlink:to="lab_amed_ConsolidatedLeverageRatio" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_5acdd6e2-8488-4b4f-96af-b74a7b987d8c_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating income</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_655b8ff2-40cb-4e22-af5f-18e19809ba9f_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_2ae067a8-5b6f-4c4c-9887-c95c3ca3c7dc_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating income (loss)</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_0aeb2e48-4893-4cc5-bf87-b6f81b4c0e9c_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy_e72b03b0-3122-467f-a1b8-d659b917a750_terseLabel_en-US" xlink:label="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patient Accounts Receivable</link:label>
    <link:label id="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy_label_en-US" xlink:label="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:to="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_MajorSinglePayorCustomerMember_5f016d92-f40e-404d-8466-eceeb91abc8f_terseLabel_en-US" xlink:label="lab_amed_MajorSinglePayorCustomerMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Single Payor</link:label>
    <link:label id="lab_amed_MajorSinglePayorCustomerMember_label_en-US" xlink:label="lab_amed_MajorSinglePayorCustomerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Major Single Payor Customer [Member]</link:label>
    <link:label id="lab_amed_MajorSinglePayorCustomerMember_documentation_en-US" xlink:label="lab_amed_MajorSinglePayorCustomerMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Major Single Payor Customer [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_MajorSinglePayorCustomerMember" xlink:href="amed-20210630.xsd#amed_MajorSinglePayorCustomerMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_MajorSinglePayorCustomerMember" xlink:to="lab_amed_MajorSinglePayorCustomerMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted_0025b88c-c0b0-446f-94e9-c912d7f1362e_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted earnings per share</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Pro Forma Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted" xlink:to="lab_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_MinimumPercentOwnershipForControllingInterestPercent_94449702-7593-4d23-b94b-ce0ef5a7446f_terseLabel_en-US" xlink:label="lab_amed_MinimumPercentOwnershipForControllingInterestPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum ownership percentage for controlling interest (percent)</link:label>
    <link:label id="lab_amed_MinimumPercentOwnershipForControllingInterestPercent_label_en-US" xlink:label="lab_amed_MinimumPercentOwnershipForControllingInterestPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum Percent Ownership For Controlling Interest Percent</link:label>
    <link:label id="lab_amed_MinimumPercentOwnershipForControllingInterestPercent_documentation_en-US" xlink:label="lab_amed_MinimumPercentOwnershipForControllingInterestPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description containing the percentage ownership required in order for a variable interest entity (VIE) to be consolidated in the entity's financial statements.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_MinimumPercentOwnershipForControllingInterestPercent" xlink:href="amed-20210630.xsd#amed_MinimumPercentOwnershipForControllingInterestPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_MinimumPercentOwnershipForControllingInterestPercent" xlink:to="lab_amed_MinimumPercentOwnershipForControllingInterestPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_9fd33e52-9e92-4efa-9fe1-c9c34966d162_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash and Cash Equivalents Items [Line Items]</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash and Cash Equivalents Items [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableRateDomain_bfc2c683-bb08-4ff5-9bcf-eb2959006a2c_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:label id="lab_us-gaap_VariableRateDomain_label_en-US" xlink:label="lab_us-gaap_VariableRateDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateDomain" xlink:to="lab_us-gaap_VariableRateDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableRateAxis_5851f3fb-3b05-4b82-a09d-45ce1644d845_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:label id="lab_us-gaap_VariableRateAxis_label_en-US" xlink:label="lab_us-gaap_VariableRateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateAxis" xlink:to="lab_us-gaap_VariableRateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_4b51e773-f798-488a-bd0e-d50f67aca094_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_24d19fb6-1ae3-4b5b-8550-0fc0bc1ea697_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies&#8212;Note 6</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_7cd63a24-8326-40f8-921a-e501d0919b28_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance/(cancellation) of non-vested stock</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_345f547e-5e54-4c0d-b1dc-39fa2a535c63_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of company stock</link:label>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_c5ad1957-6a4f-4133-9979-f3dd23039e2e_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of company stock</link:label>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_label_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Repurchase of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:to="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_EquityImpactofRepurchaseofNoncontrollingInterest_7015b78a-35ed-4229-874c-5dcabe3348c7_negatedLabel_en-US" xlink:label="lab_amed_EquityImpactofRepurchaseofNoncontrollingInterest" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase of noncontrolling interest</link:label>
    <link:label id="lab_amed_EquityImpactofRepurchaseofNoncontrollingInterest_label_en-US" xlink:label="lab_amed_EquityImpactofRepurchaseofNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Impact of Repurchase of Noncontrolling Interest</link:label>
    <link:label id="lab_amed_EquityImpactofRepurchaseofNoncontrollingInterest_documentation_en-US" xlink:label="lab_amed_EquityImpactofRepurchaseofNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Impact of Repurchase of Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_EquityImpactofRepurchaseofNoncontrollingInterest" xlink:href="amed-20210630.xsd#amed_EquityImpactofRepurchaseofNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_EquityImpactofRepurchaseofNoncontrollingInterest" xlink:to="lab_amed_EquityImpactofRepurchaseofNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_ab875812-7e97-4549-8b2f-25bba508c634_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ASSETS</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_PercentageOfPatientReceivablesOutstanding_8bfd5577-3b91-4ed8-981b-c9347c9e6c23_terseLabel_en-US" xlink:label="lab_amed_PercentageOfPatientReceivablesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of patient receivables outstanding</link:label>
    <link:label id="lab_amed_PercentageOfPatientReceivablesOutstanding_label_en-US" xlink:label="lab_amed_PercentageOfPatientReceivablesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Of Patient Receivables Outstanding</link:label>
    <link:label id="lab_amed_PercentageOfPatientReceivablesOutstanding_documentation_en-US" xlink:label="lab_amed_PercentageOfPatientReceivablesOutstanding" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of patient receivables outstanding.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PercentageOfPatientReceivablesOutstanding" xlink:href="amed-20210630.xsd#amed_PercentageOfPatientReceivablesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_PercentageOfPatientReceivablesOutstanding" xlink:to="lab_amed_PercentageOfPatientReceivablesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAcquiredFromAcquisition_e4118446-f149-4657-958d-e538b553ee2a_terseLabel_en-US" xlink:label="lab_us-gaap_CashAcquiredFromAcquisition" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Acquired from Acquisition</link:label>
    <link:label id="lab_us-gaap_CashAcquiredFromAcquisition_label_en-US" xlink:label="lab_us-gaap_CashAcquiredFromAcquisition" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Acquired from Acquisition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAcquiredFromAcquisition" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAcquiredFromAcquisition"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAcquiredFromAcquisition" xlink:to="lab_us-gaap_CashAcquiredFromAcquisition" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_88e2ea5f-db95-4885-98b0-f2d37f4a75ee_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_938f15b6-7b19-4522-9b5c-3898c8203265_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents and Restricted Cash</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:to="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_4859e12f-ec8f-46cc-bb3b-2563dd885cf5_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromStockPlans_d12dc6e6-6519-47f9-a188-e576dde53b98_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockPlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of stock to employee stock purchase plan</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockPlans_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockPlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Stock Plans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockPlans" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockPlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockPlans" xlink:to="lab_us-gaap_ProceedsFromStockPlans" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_18017b70-342d-4e38-8f00-23e3d4471bdc_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_HistoricalCollectionRateFromMedicare_bb0d603c-512f-47f3-bb0e-e0d04cf62077_terseLabel_en-US" xlink:label="lab_amed_HistoricalCollectionRateFromMedicare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Historical collection rate from Medicare</link:label>
    <link:label id="lab_amed_HistoricalCollectionRateFromMedicare_label_en-US" xlink:label="lab_amed_HistoricalCollectionRateFromMedicare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Historical Collection Rate From Medicare</link:label>
    <link:label id="lab_amed_HistoricalCollectionRateFromMedicare_documentation_en-US" xlink:label="lab_amed_HistoricalCollectionRateFromMedicare" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Historical collection rate from Medicare.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HistoricalCollectionRateFromMedicare" xlink:href="amed-20210630.xsd#amed_HistoricalCollectionRateFromMedicare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_HistoricalCollectionRateFromMedicare" xlink:to="lab_amed_HistoricalCollectionRateFromMedicare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis_1bce4276-4dc6-41d9-8ee6-0ff170e4618e_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description of variable rate basis</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Description of Variable Rate Basis</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentDescriptionOfVariableRateBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis" xlink:to="lab_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnusualOrInfrequentItemLineItems_a2aa30e4-e58e-46b4-84ba-d12b5f28ba1c_terseLabel_en-US" xlink:label="lab_us-gaap_UnusualOrInfrequentItemLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NOVEL CORONAVIRUS PANDEMIC "COVID-19" [Line Items]</link:label>
    <link:label id="lab_us-gaap_UnusualOrInfrequentItemLineItems_label_en-US" xlink:label="lab_us-gaap_UnusualOrInfrequentItemLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unusual or Infrequent Item, or Both [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnusualOrInfrequentItemLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnusualOrInfrequentItemLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnusualOrInfrequentItemLineItems" xlink:to="lab_us-gaap_UnusualOrInfrequentItemLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_EpisodeOfCareAsEpisodicBasedRevenueDuration_b17fc869-a0f8-4345-9841-74661132233c_terseLabel_en-US" xlink:label="lab_amed_EpisodeOfCareAsEpisodicBasedRevenueDuration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Episode of care as episodic-based revenue (days)</link:label>
    <link:label id="lab_amed_EpisodeOfCareAsEpisodicBasedRevenueDuration_label_en-US" xlink:label="lab_amed_EpisodeOfCareAsEpisodicBasedRevenueDuration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Episode Of Care As Episodic Based Revenue Duration</link:label>
    <link:label id="lab_amed_EpisodeOfCareAsEpisodicBasedRevenueDuration_documentation_en-US" xlink:label="lab_amed_EpisodeOfCareAsEpisodicBasedRevenueDuration" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description containing the number of days in a home health episode of care.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_EpisodeOfCareAsEpisodicBasedRevenueDuration" xlink:href="amed-20210630.xsd#amed_EpisodeOfCareAsEpisodicBasedRevenueDuration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_EpisodeOfCareAsEpisodicBasedRevenueDuration" xlink:to="lab_amed_EpisodeOfCareAsEpisodicBasedRevenueDuration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_4973ebe9-db33-4c57-95e6-fd78bf7aba86_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained earnings</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_f858a0dc-4cf2-432a-8ad8-df78e94a1594_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease right of use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_CashDistributionToNoncontrollingInterest_23f506a5-75b3-4f87-9409-73d534523151_negatedLabel_en-US" xlink:label="lab_amed_CashDistributionToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling interest distribution</link:label>
    <link:label id="lab_amed_CashDistributionToNoncontrollingInterest_label_en-US" xlink:label="lab_amed_CashDistributionToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Distribution To Noncontrolling Interest</link:label>
    <link:label id="lab_amed_CashDistributionToNoncontrollingInterest_documentation_en-US" xlink:label="lab_amed_CashDistributionToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment of dividends or other distributions to noncontrolling interest holders.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CashDistributionToNoncontrollingInterest" xlink:href="amed-20210630.xsd#amed_CashDistributionToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_CashDistributionToNoncontrollingInterest" xlink:to="lab_amed_CashDistributionToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_HomeHealthNonMedicareNonEpisodicBasedMember_78e3024b-1f64-4e0d-912d-2ec0ea5e449f_terseLabel_en-US" xlink:label="lab_amed_HomeHealthNonMedicareNonEpisodicBasedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Home Health Non-Medicare - Non-Episodic Based [Member]</link:label>
    <link:label id="lab_amed_HomeHealthNonMedicareNonEpisodicBasedMember_label_en-US" xlink:label="lab_amed_HomeHealthNonMedicareNonEpisodicBasedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Home Health Non-Medicare - Non-Episodic Based [Member]</link:label>
    <link:label id="lab_amed_HomeHealthNonMedicareNonEpisodicBasedMember_documentation_en-US" xlink:label="lab_amed_HomeHealthNonMedicareNonEpisodicBasedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Home Health Non-Medicare - Non-Episodic Based [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HomeHealthNonMedicareNonEpisodicBasedMember" xlink:href="amed-20210630.xsd#amed_HomeHealthNonMedicareNonEpisodicBasedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_HomeHealthNonMedicareNonEpisodicBasedMember" xlink:to="lab_amed_HomeHealthNonMedicareNonEpisodicBasedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_bbf745d5-81c3-486c-876b-c2d6273ea6f3_terseLabel_en-US" xlink:label="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average amortization period</link:label>
    <link:label id="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_label_en-US" xlink:label="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired Finite-lived Intangible Assets, Weighted Average Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:to="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForLegalSettlements_d4d75ff3-950d-4f09-b534-21c9bfaf22d5_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForLegalSettlements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for legal settlements</link:label>
    <link:label id="lab_us-gaap_PaymentsForLegalSettlements_label_en-US" xlink:label="lab_us-gaap_PaymentsForLegalSettlements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Legal Settlements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForLegalSettlements" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForLegalSettlements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForLegalSettlements" xlink:to="lab_us-gaap_PaymentsForLegalSettlements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductConcentrationRiskMember_90388ce1-ab98-42dc-a957-209fc8afabde_terseLabel_en-US" xlink:label="lab_us-gaap_ProductConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Concentration Risk</link:label>
    <link:label id="lab_us-gaap_ProductConcentrationRiskMember_label_en-US" xlink:label="lab_us-gaap_ProductConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Concentration Risk [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductConcentrationRiskMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductConcentrationRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductConcentrationRiskMember" xlink:to="lab_us-gaap_ProductConcentrationRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockSharesAcquired_bf28cf44-0f8d-448b-9e74-a84869b4e54d_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesAcquired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares repurchased (shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockSharesAcquired_label_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Shares, Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockSharesAcquired" xlink:to="lab_us-gaap_TreasuryStockSharesAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_CapYearDomain_37f6d6dd-0567-4e16-a5e5-4989bc28ecbf_terseLabel_en-US" xlink:label="lab_amed_CapYearDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cap Year [Domain]</link:label>
    <link:label id="lab_amed_CapYearDomain_label_en-US" xlink:label="lab_amed_CapYearDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cap Year [Domain]</link:label>
    <link:label id="lab_amed_CapYearDomain_documentation_en-US" xlink:label="lab_amed_CapYearDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cap Year [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CapYearDomain" xlink:href="amed-20210630.xsd#amed_CapYearDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_CapYearDomain" xlink:to="lab_amed_CapYearDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_fca441a4-a1c9-4bfb-8e71-dd0edd637768_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_0322b97b-0117-43b7-a231-cd4a42cf5e40_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtAndCapitalLeaseObligations_cc254c9c-bbfd-411e-a116-11bd72543354_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term obligations, less current portion</link:label>
    <link:label id="lab_us-gaap_LongTermDebtAndCapitalLeaseObligations_label_en-US" xlink:label="lab_us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt and Lease Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:to="lab_us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MajorCustomersAxis_bb74bb7b-74dd-42f9-ac3f-f082ccdd4ca4_terseLabel_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:label id="lab_srt_MajorCustomersAxis_label_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MajorCustomersAxis" xlink:to="lab_srt_MajorCustomersAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesOutstanding_39988b8c-5e4f-432d-83cd-5f7fdf981b12_periodStartLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_c7990344-59a7-48fb-ba9e-f8260bcfa27d_periodEndLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_label_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesOutstanding" xlink:to="lab_us-gaap_SharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_HospiceMedicareRevenueRateAccountedForRoutineCare_27ef8bf3-c96a-4ff5-8d6e-537eb44c3436_terseLabel_en-US" xlink:label="lab_amed_HospiceMedicareRevenueRateAccountedForRoutineCare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hospice Medicare revenue rate accounted for routine care</link:label>
    <link:label id="lab_amed_HospiceMedicareRevenueRateAccountedForRoutineCare_label_en-US" xlink:label="lab_amed_HospiceMedicareRevenueRateAccountedForRoutineCare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hospice Medicare Revenue Rate Accounted For Routine Care</link:label>
    <link:label id="lab_amed_HospiceMedicareRevenueRateAccountedForRoutineCare_documentation_en-US" xlink:label="lab_amed_HospiceMedicareRevenueRateAccountedForRoutineCare" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description containing the percentage of the entity's Hospice net Medicare service revenue that is derived from routine care.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HospiceMedicareRevenueRateAccountedForRoutineCare" xlink:href="amed-20210630.xsd#amed_HospiceMedicareRevenueRateAccountedForRoutineCare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_HospiceMedicareRevenueRateAccountedForRoutineCare" xlink:to="lab_amed_HospiceMedicareRevenueRateAccountedForRoutineCare" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_LesseeOperatingleaseReductionstoROUassetsresultingfromreductionstoleaseobligations_891b0c14-7db5-4c97-92ee-9641f0f75d85_terseLabel_en-US" xlink:label="lab_amed_LesseeOperatingleaseReductionstoROUassetsresultingfromreductionstoleaseobligations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reductions to right of use assets resulting from reductions to operating lease liabilities</link:label>
    <link:label id="lab_amed_LesseeOperatingleaseReductionstoROUassetsresultingfromreductionstoleaseobligations_label_en-US" xlink:label="lab_amed_LesseeOperatingleaseReductionstoROUassetsresultingfromreductionstoleaseobligations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating lease, Reductions to ROU assets resulting from reductions to lease obligations</link:label>
    <link:label id="lab_amed_LesseeOperatingleaseReductionstoROUassetsresultingfromreductionstoleaseobligations_documentation_en-US" xlink:label="lab_amed_LesseeOperatingleaseReductionstoROUassetsresultingfromreductionstoleaseobligations" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating lease, Reductions to ROU assets resulting from reductions to lease obligations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_LesseeOperatingleaseReductionstoROUassetsresultingfromreductionstoleaseobligations" xlink:href="amed-20210630.xsd#amed_LesseeOperatingleaseReductionstoROUassetsresultingfromreductionstoleaseobligations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_LesseeOperatingleaseReductionstoROUassetsresultingfromreductionstoleaseobligations" xlink:to="lab_amed_LesseeOperatingleaseReductionstoROUassetsresultingfromreductionstoleaseobligations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_6e8773fe-2701-44aa-91bb-22a28eacdd37_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (usd per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfFinancingCosts_f1ce0ae3-b3a5-4d3a-a17f-3aabf4748147_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt issuance costs</link:label>
    <link:label id="lab_us-gaap_PaymentsOfFinancingCosts_label_en-US" xlink:label="lab_us-gaap_PaymentsOfFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Financing Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfFinancingCosts" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfFinancingCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfFinancingCosts" xlink:to="lab_us-gaap_PaymentsOfFinancingCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_5ab6b4c4-002d-4911-b523-f54e59afea17_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term obligations</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxAssetsNet_d1c21059-8833-4537-b434-e3febadeb850_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred income taxes</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxAssetsNet_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxAssetsNet" xlink:to="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember_e0791445-56f5-4766-b4f5-d6c853b200e2_terseLabel_en-US" xlink:label="lab_amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Five Hundred Fifty Million Revolving Credit Facility [Member]</link:label>
    <link:label id="lab_amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember_label_en-US" xlink:label="lab_amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Five Hundred Fifty Million Revolving Credit Facility [Member]</link:label>
    <link:label id="lab_amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember_documentation_en-US" xlink:label="lab_amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Five Hundred Fifty Million Revolving Credit Facility [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember" xlink:href="amed-20210630.xsd#amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember" xlink:to="lab_amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_ProviderReliefFundAdvance_77759a98-3680-4bc9-ad50-d1f22d97cae9_terseLabel_en-US" xlink:label="lab_amed_ProviderReliefFundAdvance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provider relief fund advance</link:label>
    <link:label id="lab_amed_ProviderReliefFundAdvance_label_en-US" xlink:label="lab_amed_ProviderReliefFundAdvance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provider relief fund advance</link:label>
    <link:label id="lab_amed_ProviderReliefFundAdvance_documentation_en-US" xlink:label="lab_amed_ProviderReliefFundAdvance" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payable related to funds received from the government related to COVID-19</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ProviderReliefFundAdvance" xlink:href="amed-20210630.xsd#amed_ProviderReliefFundAdvance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_ProviderReliefFundAdvance" xlink:to="lab_amed_ProviderReliefFundAdvance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_6569917c-bbd2-4b03-a82a-f15f98c81ab9_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash compensation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_HomeHealthMember_96b57e7f-8838-4ef7-be70-7912af221b50_terseLabel_en-US" xlink:label="lab_amed_HomeHealthMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Home Health [Member]</link:label>
    <link:label id="lab_amed_HomeHealthMember_label_en-US" xlink:label="lab_amed_HomeHealthMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Home Health [Member]</link:label>
    <link:label id="lab_amed_HomeHealthMember_documentation_en-US" xlink:label="lab_amed_HomeHealthMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Home Health [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HomeHealthMember" xlink:href="amed-20210630.xsd#amed_HomeHealthMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_HomeHealthMember" xlink:to="lab_amed_HomeHealthMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionAmountsOfTransaction_cc4abeef-c186-4129-8e52-50cc269a7f23_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction, Amounts of Transaction</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionAmountsOfTransaction_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction, Amounts of Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:to="lab_us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_RateOfRequestForAnticipatedPaymentSubmittedForSubsequentEpisodesOfCare_e86b48e2-4fc0-4765-8280-53640b5f1d17_terseLabel_en-US" xlink:label="lab_amed_RateOfRequestForAnticipatedPaymentSubmittedForSubsequentEpisodesOfCare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rate of request for anticipated payment submitted for subsequent episodes of care</link:label>
    <link:label id="lab_amed_RateOfRequestForAnticipatedPaymentSubmittedForSubsequentEpisodesOfCare_label_en-US" xlink:label="lab_amed_RateOfRequestForAnticipatedPaymentSubmittedForSubsequentEpisodesOfCare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rate Of Request For Anticipated Payment Submitted For Subsequent Episodes Of Care</link:label>
    <link:label id="lab_amed_RateOfRequestForAnticipatedPaymentSubmittedForSubsequentEpisodesOfCare_documentation_en-US" xlink:label="lab_amed_RateOfRequestForAnticipatedPaymentSubmittedForSubsequentEpisodesOfCare" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description containing the percentage of estimated payment that is requested at the start of care for any subsequent episodes of care.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_RateOfRequestForAnticipatedPaymentSubmittedForSubsequentEpisodesOfCare" xlink:href="amed-20210630.xsd#amed_RateOfRequestForAnticipatedPaymentSubmittedForSubsequentEpisodesOfCare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_RateOfRequestForAnticipatedPaymentSubmittedForSubsequentEpisodesOfCare" xlink:to="lab_amed_RateOfRequestForAnticipatedPaymentSubmittedForSubsequentEpisodesOfCare" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_LowUtilizationPaymentAdjustmentNumberOfVisits_0ab9bac5-a637-41a0-a70f-f2acbaa82858_terseLabel_en-US" xlink:label="lab_amed_LowUtilizationPaymentAdjustmentNumberOfVisits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Low utilization payment adjustment, maximum number of visits</link:label>
    <link:label id="lab_amed_LowUtilizationPaymentAdjustmentNumberOfVisits_label_en-US" xlink:label="lab_amed_LowUtilizationPaymentAdjustmentNumberOfVisits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Low Utilization Payment Adjustment Number Of Visits</link:label>
    <link:label id="lab_amed_LowUtilizationPaymentAdjustmentNumberOfVisits_documentation_en-US" xlink:label="lab_amed_LowUtilizationPaymentAdjustmentNumberOfVisits" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description containing the visit threshold for a low utilization payment adjustment.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_LowUtilizationPaymentAdjustmentNumberOfVisits" xlink:href="amed-20210630.xsd#amed_LowUtilizationPaymentAdjustmentNumberOfVisits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_LowUtilizationPaymentAdjustmentNumberOfVisits" xlink:to="lab_amed_LowUtilizationPaymentAdjustmentNumberOfVisits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityAxis_4710c9c8-56eb-44c1-b601-0c28cab342bd_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lender Name [Axis]</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityAxis_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lender Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis" xlink:to="lab_us-gaap_LineOfCreditFacilityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_c5484e5c-4bde-46b5-84d8-486397eae77b_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percent of net services revenue</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_19bb5bea-6c31-4716-8cb1-a6cde0f7ed96_verboseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration risk (percent)</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskPercentage1" xlink:to="lab_us-gaap_ConcentrationRiskPercentage1" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_EstimatedCARESActProviderReliefFundsExpectedToBeUtilized_4c63d397-78cf-474f-beef-197a010f8ddb_terseLabel_en-US" xlink:label="lab_amed_EstimatedCARESActProviderReliefFundsExpectedToBeUtilized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated CARES Act Provider Relief Funds Expected to be Utilized</link:label>
    <link:label id="lab_amed_EstimatedCARESActProviderReliefFundsExpectedToBeUtilized_label_en-US" xlink:label="lab_amed_EstimatedCARESActProviderReliefFundsExpectedToBeUtilized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated CARES Act Provider Relief Funds Expected to be Utilized</link:label>
    <link:label id="lab_amed_EstimatedCARESActProviderReliefFundsExpectedToBeUtilized_documentation_en-US" xlink:label="lab_amed_EstimatedCARESActProviderReliefFundsExpectedToBeUtilized" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated CARES Act Provider Relief Funds Expected to be Utilized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_EstimatedCARESActProviderReliefFundsExpectedToBeUtilized" xlink:href="amed-20210630.xsd#amed_EstimatedCARESActProviderReliefFundsExpectedToBeUtilized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_EstimatedCARESActProviderReliefFundsExpectedToBeUtilized" xlink:to="lab_amed_EstimatedCARESActProviderReliefFundsExpectedToBeUtilized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_412550c0-fe74-4994-a0f4-144eb35f01ef_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAxis" xlink:to="lab_us-gaap_BusinessAcquisitionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_SegmentGeographicalDomain_62fb2477-3d0f-40b9-a565-ee02ea14b3c3_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_GovernmentGrantsPolicyTextBlock_49be8fbb-0ad7-4f57-a1f9-26dee8dec23c_terseLabel_en-US" xlink:label="lab_amed_GovernmentGrantsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government Grants</link:label>
    <link:label id="lab_amed_GovernmentGrantsPolicyTextBlock_label_en-US" xlink:label="lab_amed_GovernmentGrantsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government Grants [Policy Text Block]</link:label>
    <link:label id="lab_amed_GovernmentGrantsPolicyTextBlock_documentation_en-US" xlink:label="lab_amed_GovernmentGrantsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting policy disclosure text block for government grants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_GovernmentGrantsPolicyTextBlock" xlink:href="amed-20210630.xsd#amed_GovernmentGrantsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_GovernmentGrantsPolicyTextBlock" xlink:to="lab_amed_GovernmentGrantsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_95c883a5-f976-49e3-ac20-95385d8eaf05_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockDomain_c61e3a4d-1b3c-450a-a2e2-6be812f6e313_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_stpr_WA_caadcc96-72c5-4087-9fd9-5cb89d5e9ecd_terseLabel_en-US" xlink:label="lab_stpr_WA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">WASHINGTON</link:label>
    <link:label id="lab_stpr_WA_label_en-US" xlink:label="lab_stpr_WA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">WASHINGTON</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_WA" xlink:href="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd#stpr_WA"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_stpr_WA" xlink:to="lab_stpr_WA" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_InfinityHomeCareMember_289e8433-afe8-42a5-9447-ddcf1a09d752_terseLabel_en-US" xlink:label="lab_amed_InfinityHomeCareMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Infinity HomeCare</link:label>
    <link:label id="lab_amed_InfinityHomeCareMember_label_en-US" xlink:label="lab_amed_InfinityHomeCareMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Infinity HomeCare [Member]</link:label>
    <link:label id="lab_amed_InfinityHomeCareMember_documentation_en-US" xlink:label="lab_amed_InfinityHomeCareMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Infinity HomeCare [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_InfinityHomeCareMember" xlink:href="amed-20210630.xsd#amed_InfinityHomeCareMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_InfinityHomeCareMember" xlink:to="lab_amed_InfinityHomeCareMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityVoluntaryFilers_a1e948a9-17ae-4d28-811c-56e1061eca4e_terseLabel_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:label id="lab_dei_EntityVoluntaryFilers_label_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityVoluntaryFilers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityVoluntaryFilers" xlink:to="lab_dei_EntityVoluntaryFilers" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_941f45ad-38f0-4a9c-8e3e-b6bc1f564f75_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_7e129c09-ffb5-4890-9874-9dc2d1b4b79d_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityAxis_ae7f6d6f-e6d4-4c69-8a59-38c9ecda796c_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityAxis_label_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityAxis" xlink:to="lab_us-gaap_CreditFacilityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_OneHundredSeventyFiveMillionTermLoanFacilityMember_e0723128-441e-4289-8a7d-65137aede390_terseLabel_en-US" xlink:label="lab_amed_OneHundredSeventyFiveMillionTermLoanFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">One Hundred Seventy Five Million Term Loan Facility [Member]</link:label>
    <link:label id="lab_amed_OneHundredSeventyFiveMillionTermLoanFacilityMember_label_en-US" xlink:label="lab_amed_OneHundredSeventyFiveMillionTermLoanFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">One Hundred Seventy Five Million Term Loan Facility [Member]</link:label>
    <link:label id="lab_amed_OneHundredSeventyFiveMillionTermLoanFacilityMember_documentation_en-US" xlink:label="lab_amed_OneHundredSeventyFiveMillionTermLoanFacilityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">One Hundred Seventy Five Million Term Loan Facility [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_OneHundredSeventyFiveMillionTermLoanFacilityMember" xlink:href="amed-20210630.xsd#amed_OneHundredSeventyFiveMillionTermLoanFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_OneHundredSeventyFiveMillionTermLoanFacilityMember" xlink:to="lab_amed_OneHundredSeventyFiveMillionTermLoanFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_5c4cac22-6e91-4b05-b00e-09b7a37d3006_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, issued (shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_FundingReceivedFromMassHomeCareASAPCOVID19ProviderSustainabilityProgram_1ec1cbf7-b570-4ffb-bc71-7a6f0883e7be_terseLabel_en-US" xlink:label="lab_amed_FundingReceivedFromMassHomeCareASAPCOVID19ProviderSustainabilityProgram" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Funding Received From Mass Home Care ASAP COVID-19 Provider Sustainability Program</link:label>
    <link:label id="lab_amed_FundingReceivedFromMassHomeCareASAPCOVID19ProviderSustainabilityProgram_label_en-US" xlink:label="lab_amed_FundingReceivedFromMassHomeCareASAPCOVID19ProviderSustainabilityProgram" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Funding Received From Mass Home Care ASAP COVID-19 Provider Sustainability Program</link:label>
    <link:label id="lab_amed_FundingReceivedFromMassHomeCareASAPCOVID19ProviderSustainabilityProgram_documentation_en-US" xlink:label="lab_amed_FundingReceivedFromMassHomeCareASAPCOVID19ProviderSustainabilityProgram" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Funding Received From Mass Home Care ASAP COVID-19 Provider Sustainability Program</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_FundingReceivedFromMassHomeCareASAPCOVID19ProviderSustainabilityProgram" xlink:href="amed-20210630.xsd#amed_FundingReceivedFromMassHomeCareASAPCOVID19ProviderSustainabilityProgram"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_FundingReceivedFromMassHomeCareASAPCOVID19ProviderSustainabilityProgram" xlink:to="lab_amed_FundingReceivedFromMassHomeCareASAPCOVID19ProviderSustainabilityProgram" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_EstimatedCARESActProviderReliefFundAmountsToBeRepaid_4dadb94a-c42f-4687-b637-dfdd389e95df_terseLabel_en-US" xlink:label="lab_amed_EstimatedCARESActProviderReliefFundAmountsToBeRepaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated CARES Act Provider Relief Fund Amounts to be Repaid</link:label>
    <link:label id="lab_amed_EstimatedCARESActProviderReliefFundAmountsToBeRepaid_label_en-US" xlink:label="lab_amed_EstimatedCARESActProviderReliefFundAmountsToBeRepaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated CARES Act Provider Relief Fund Amounts to be Repaid</link:label>
    <link:label id="lab_amed_EstimatedCARESActProviderReliefFundAmountsToBeRepaid_documentation_en-US" xlink:label="lab_amed_EstimatedCARESActProviderReliefFundAmountsToBeRepaid" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated CARES Act Provider Relief Fund Amounts to be Repaid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_EstimatedCARESActProviderReliefFundAmountsToBeRepaid" xlink:href="amed-20210630.xsd#amed_EstimatedCARESActProviderReliefFundAmountsToBeRepaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_EstimatedCARESActProviderReliefFundAmountsToBeRepaid" xlink:to="lab_amed_EstimatedCARESActProviderReliefFundAmountsToBeRepaid" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_DebtInstrumentByLeverageRatioTrancheFourMember_0c751ded-84ff-464c-a195-18fbea6eb685_terseLabel_en-US" xlink:label="lab_amed_DebtInstrumentByLeverageRatioTrancheFourMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Leverage Ratio: Less Than 0.75 to 1.0</link:label>
    <link:label id="lab_amed_DebtInstrumentByLeverageRatioTrancheFourMember_label_en-US" xlink:label="lab_amed_DebtInstrumentByLeverageRatioTrancheFourMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, By Leverage Ratio, Tranche Four [Member]</link:label>
    <link:label id="lab_amed_DebtInstrumentByLeverageRatioTrancheFourMember_documentation_en-US" xlink:label="lab_amed_DebtInstrumentByLeverageRatioTrancheFourMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, By Leverage Ratio, Tranche Four [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_DebtInstrumentByLeverageRatioTrancheFourMember" xlink:href="amed-20210630.xsd#amed_DebtInstrumentByLeverageRatioTrancheFourMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_DebtInstrumentByLeverageRatioTrancheFourMember" xlink:to="lab_amed_DebtInstrumentByLeverageRatioTrancheFourMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ExtraordinaryAndUnusualItemsAbstract_label_en-US" xlink:label="lab_us-gaap_ExtraordinaryAndUnusualItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unusual or Infrequent Items, or Both [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ExtraordinaryAndUnusualItemsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ExtraordinaryAndUnusualItemsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ExtraordinaryAndUnusualItemsAbstract" xlink:to="lab_us-gaap_ExtraordinaryAndUnusualItemsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_c62f6745-585c-4a34-9afc-53d39fad7a10_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Weighted-Average Shares Outstanding</link:label>
    <link:label id="lab_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Weighted Average Number of Shares [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationsAbstract_1b14226f-6436-49b4-bbc3-ed8ac128039a_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations [Abstract]</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationsAbstract_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationsAbstract" xlink:to="lab_us-gaap_BusinessCombinationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_c1fbc15d-6a90-4bee-bc62-0e6f204ab25a_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_827d9cb9-1b1e-490a-9d42-39b8eb8bc8c4_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principles of Consolidation</link:label>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_Numberofpatients_a6408f98-70da-49e9-8ffb-fb995b7dadb5_terseLabel_en-US" xlink:label="lab_amed_Numberofpatients" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of patients</link:label>
    <link:label id="lab_amed_Numberofpatients_label_en-US" xlink:label="lab_amed_Numberofpatients" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of patients</link:label>
    <link:label id="lab_amed_Numberofpatients_documentation_en-US" xlink:label="lab_amed_Numberofpatients" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of patients</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_Numberofpatients" xlink:href="amed-20210630.xsd#amed_Numberofpatients"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_Numberofpatients" xlink:to="lab_amed_Numberofpatients" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_HomeHealthAndHospiceMember_b9fbff22-46d9-49ac-9945-924a854f8a4b_terseLabel_en-US" xlink:label="lab_amed_HomeHealthAndHospiceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Home Health and Hospice [Member]</link:label>
    <link:label id="lab_amed_HomeHealthAndHospiceMember_label_en-US" xlink:label="lab_amed_HomeHealthAndHospiceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Home Health and Hospice [Member]</link:label>
    <link:label id="lab_amed_HomeHealthAndHospiceMember_documentation_en-US" xlink:label="lab_amed_HomeHealthAndHospiceMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Home Health and Hospice</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HomeHealthAndHospiceMember" xlink:href="amed-20210630.xsd#amed_HomeHealthAndHospiceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_HomeHealthAndHospiceMember" xlink:to="lab_amed_HomeHealthAndHospiceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsMember_5d647c1f-6302-4d29-a112-d17e58168f8f_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments [Member]</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsMember_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentsMember" xlink:to="lab_us-gaap_EquityMethodInvestmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_58f97a3c-bbf2-4e01-9cb6-c9148a0fc1b2_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LONG-TERM OBLIGATIONS</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_us-gaap_DebtDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6cfda6d5-554b-4af6-8c86-2be317a74440_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseCurrent_ea087e95-83df-46de-a3cc-38ce9c133e58_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseCurrent" xlink:to="lab_us-gaap_PrepaidExpenseCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareRepurchaseProgramDomain_0bffde1f-4ef5-4068-ad91-3db75a18b55f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareRepurchaseProgramDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase Program [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareRepurchaseProgramDomain_label_en-US" xlink:label="lab_us-gaap_ShareRepurchaseProgramDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase Program [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareRepurchaseProgramDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain" xlink:to="lab_us-gaap_ShareRepurchaseProgramDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_7a91dd41-9d97-4814-8b8e-806fae968615_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restrictions on Cash and Cash Equivalents [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restrictions on Cash and Cash Equivalents [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable" xlink:to="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_f0971c3d-5f4c-42bb-bedb-d98d61b02438_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_dc724191-0892-4fd0-8950-b3c250205eed_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition, Multiple-deliverable Arrangements [Line Items]</link:label>
    <link:label id="lab_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_label_en-US" xlink:label="lab_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition, Multiple-deliverable Arrangements [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" xlink:to="lab_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_72012a9c-a55e-4403-8d6a-4e0e29e18755_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtIssuanceCostsLineOfCreditArrangementsGross_fdd93d63-9070-4582-bb72-38022b0cdb1e_terseLabel_en-US" xlink:label="lab_us-gaap_DebtIssuanceCostsLineOfCreditArrangementsGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred debt issuance cost</link:label>
    <link:label id="lab_us-gaap_DebtIssuanceCostsLineOfCreditArrangementsGross_label_en-US" xlink:label="lab_us-gaap_DebtIssuanceCostsLineOfCreditArrangementsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Issuance Costs, Line of Credit Arrangements, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtIssuanceCostsLineOfCreditArrangementsGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtIssuanceCostsLineOfCreditArrangementsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtIssuanceCostsLineOfCreditArrangementsGross" xlink:to="lab_us-gaap_DebtIssuanceCostsLineOfCreditArrangementsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_MedicareRevenueMember_aacdab75-eae0-4adf-a6bf-50c4ea6050a4_terseLabel_en-US" xlink:label="lab_amed_MedicareRevenueMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicare Revenue [Member]</link:label>
    <link:label id="lab_amed_MedicareRevenueMember_label_en-US" xlink:label="lab_amed_MedicareRevenueMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicare Revenue [Member]</link:label>
    <link:label id="lab_amed_MedicareRevenueMember_documentation_en-US" xlink:label="lab_amed_MedicareRevenueMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicare Revenue [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_MedicareRevenueMember" xlink:href="amed-20210630.xsd#amed_MedicareRevenueMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_MedicareRevenueMember" xlink:to="lab_amed_MedicareRevenueMember" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_LineOfCreditFacilityAdditionalBorrowingCapacity_129fcdc1-1efd-41e8-b092-596e22b4b1cc_terseLabel_en-US" xlink:label="lab_amed_LineOfCreditFacilityAdditionalBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit facility, maximum additional borrowing capacity</link:label>
    <link:label id="lab_amed_LineOfCreditFacilityAdditionalBorrowingCapacity_label_en-US" xlink:label="lab_amed_LineOfCreditFacilityAdditionalBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line Of Credit Facility Additional Borrowing Capacity</link:label>
    <link:label id="lab_amed_LineOfCreditFacilityAdditionalBorrowingCapacity_documentation_en-US" xlink:label="lab_amed_LineOfCreditFacilityAdditionalBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line Of Credit Facility Additional Borrowing Capacity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_LineOfCreditFacilityAdditionalBorrowingCapacity" xlink:href="amed-20210630.xsd#amed_LineOfCreditFacilityAdditionalBorrowingCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_LineOfCreditFacilityAdditionalBorrowingCapacity" xlink:to="lab_amed_LineOfCreditFacilityAdditionalBorrowingCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalLeaseObligationsMember_eef39c84-28cd-467e-903d-f1c6bd5e770d_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalLeaseObligationsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance leases [Member]</link:label>
    <link:label id="lab_us-gaap_CapitalLeaseObligationsMember_label_en-US" xlink:label="lab_us-gaap_CapitalLeaseObligationsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital Lease Obligations [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalLeaseObligationsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalLeaseObligationsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalLeaseObligationsMember" xlink:to="lab_us-gaap_CapitalLeaseObligationsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_d32810e8-f9ab-4e1b-9177-d4b2230ee97d_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_5ffb0db4-134f-4d02-bdf0-c830f56ffea9_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyDomain_fbd20fc0-07ad-4e6e-bdd6-5521261ea4a9_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyDomain_label_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyDomain" xlink:to="lab_us-gaap_RelatedPartyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_SecuritiesClassActionLawsuitsettlement_17ce1e8d-e2bb-46ef-8216-892e9e5fd69d_terseLabel_en-US" xlink:label="lab_amed_SecuritiesClassActionLawsuitsettlement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Securities Class Action Lawsuit settlement, net</link:label>
    <link:label id="lab_amed_SecuritiesClassActionLawsuitsettlement_label_en-US" xlink:label="lab_amed_SecuritiesClassActionLawsuitsettlement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Securities Class Action Lawsuit settlement</link:label>
    <link:label id="lab_amed_SecuritiesClassActionLawsuitsettlement_documentation_en-US" xlink:label="lab_amed_SecuritiesClassActionLawsuitsettlement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Charge related to Securities Class Action Lawsuit settlement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_SecuritiesClassActionLawsuitsettlement" xlink:href="amed-20210630.xsd#amed_SecuritiesClassActionLawsuitsettlement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_SecuritiesClassActionLawsuitsettlement" xlink:to="lab_amed_SecuritiesClassActionLawsuitsettlement" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_Businessacquisitionproformaoperatingincomeloss_ae57c261-59f5-47d0-ab12-83013664787d_terseLabel_en-US" xlink:label="lab_amed_Businessacquisitionproformaoperatingincomeloss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating income</link:label>
    <link:label id="lab_amed_Businessacquisitionproformaoperatingincomeloss_label_en-US" xlink:label="lab_amed_Businessacquisitionproformaoperatingincomeloss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business acquisition pro forma operating income loss</link:label>
    <link:label id="lab_amed_Businessacquisitionproformaoperatingincomeloss_documentation_en-US" xlink:label="lab_amed_Businessacquisitionproformaoperatingincomeloss" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The pro forma operating income (loss) for the period as if the business combination or combinations had been completed at the beginning of a period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_Businessacquisitionproformaoperatingincomeloss" xlink:href="amed-20210630.xsd#amed_Businessacquisitionproformaoperatingincomeloss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_Businessacquisitionproformaoperatingincomeloss" xlink:to="lab_amed_Businessacquisitionproformaoperatingincomeloss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_9eb822be-22e9-4389-a6af-c27a8e322245_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:to="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_90015550-28a0-4cb5-99d5-7c73c2e9babe_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_SecondAmendmentToAmendedCreditAgreementMember_a391d3fc-46bb-4e57-b04f-27f56f31d493_terseLabel_en-US" xlink:label="lab_amed_SecondAmendmentToAmendedCreditAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Second Amended Credit Agreement</link:label>
    <link:label id="lab_amed_SecondAmendmentToAmendedCreditAgreementMember_label_en-US" xlink:label="lab_amed_SecondAmendmentToAmendedCreditAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Second Amendment to Amended Credit Agreement [Member]</link:label>
    <link:label id="lab_amed_SecondAmendmentToAmendedCreditAgreementMember_documentation_en-US" xlink:label="lab_amed_SecondAmendmentToAmendedCreditAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Second Amendment to Amended Credit Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_SecondAmendmentToAmendedCreditAgreementMember" xlink:href="amed-20210630.xsd#amed_SecondAmendmentToAmendedCreditAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_SecondAmendmentToAmendedCreditAgreementMember" xlink:to="lab_amed_SecondAmendmentToAmendedCreditAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsPolicy_cfafabcf-cf80-4cc6-8d80-a05960afa7fe_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsPolicy_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsPolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentsPolicy" xlink:to="lab_us-gaap_EquityMethodInvestmentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_PayorsDomain_aa5a4c38-9fdc-451e-87b4-115af09b20c2_terseLabel_en-US" xlink:label="lab_amed_PayorsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payors [Domain]</link:label>
    <link:label id="lab_amed_PayorsDomain_label_en-US" xlink:label="lab_amed_PayorsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payors [Domain]</link:label>
    <link:label id="lab_amed_PayorsDomain_documentation_en-US" xlink:label="lab_amed_PayorsDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">[Domain] for Payors [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PayorsDomain" xlink:href="amed-20210630.xsd#amed_PayorsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_PayorsDomain" xlink:to="lab_amed_PayorsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_stpr_TN_a912b50c-ab3e-4ea2-b53d-826bd34d9614_terseLabel_en-US" xlink:label="lab_stpr_TN" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tennessee [Member]</link:label>
    <link:label id="lab_stpr_TN_label_en-US" xlink:label="lab_stpr_TN" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TENNESSEE</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_TN" xlink:href="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd#stpr_TN"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_stpr_TN" xlink:to="lab_stpr_TN" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_DebtInstrumentByLeverageRatioTrancheThreeMember_afa90fae-10fc-41ed-8ed5-b2c333a2ec2d_terseLabel_en-US" xlink:label="lab_amed_DebtInstrumentByLeverageRatioTrancheThreeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Leverage Ratio: Less Than 2.00 to 1.0 but Greater Than Equal To 0.75 to 1.0</link:label>
    <link:label id="lab_amed_DebtInstrumentByLeverageRatioTrancheThreeMember_label_en-US" xlink:label="lab_amed_DebtInstrumentByLeverageRatioTrancheThreeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, By Leverage Ratio, Tranche Three [Member]</link:label>
    <link:label id="lab_amed_DebtInstrumentByLeverageRatioTrancheThreeMember_documentation_en-US" xlink:label="lab_amed_DebtInstrumentByLeverageRatioTrancheThreeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, By Leverage Ratio, Tranche Three [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_DebtInstrumentByLeverageRatioTrancheThreeMember" xlink:href="amed-20210630.xsd#amed_DebtInstrumentByLeverageRatioTrancheThreeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_DebtInstrumentByLeverageRatioTrancheThreeMember" xlink:to="lab_amed_DebtInstrumentByLeverageRatioTrancheThreeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromShortTermDebt_b7c8697f-643c-4cfe-97f4-65c6fccadc4c_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromShortTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from borrowings under revolving line of credit</link:label>
    <link:label id="lab_us-gaap_ProceedsFromShortTermDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromShortTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Short-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromShortTermDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromShortTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromShortTermDebt" xlink:to="lab_us-gaap_ProceedsFromShortTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementGeographicalAxis_e55f3ef8-efb3-4f9b-81e9-c773a6548f56_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_82edb03f-3839-4f15-b6d9-70369db73595_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SUBSEQUENT EVENT</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock" xlink:to="lab_us-gaap_SubsequentEventsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_ScheduleOfCaresActProviderReliefFundsTableTextBlock_64c06480-960a-4872-bf40-de85b4f2810c_terseLabel_en-US" xlink:label="lab_amed_ScheduleOfCaresActProviderReliefFundsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cares Act Provider Relief Funds</link:label>
    <link:label id="lab_amed_ScheduleOfCaresActProviderReliefFundsTableTextBlock_label_en-US" xlink:label="lab_amed_ScheduleOfCaresActProviderReliefFundsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cares Act Provider Relief Funds [Table Text Block]</link:label>
    <link:label id="lab_amed_ScheduleOfCaresActProviderReliefFundsTableTextBlock_documentation_en-US" xlink:label="lab_amed_ScheduleOfCaresActProviderReliefFundsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cares Act Provider Relief Funds</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ScheduleOfCaresActProviderReliefFundsTableTextBlock" xlink:href="amed-20210630.xsd#amed_ScheduleOfCaresActProviderReliefFundsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_ScheduleOfCaresActProviderReliefFundsTableTextBlock" xlink:to="lab_amed_ScheduleOfCaresActProviderReliefFundsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentDomain_62154b5c-9a5c-47b0-bc8c-a0d79a3f3394_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Domain]</link:label>
    <link:label id="lab_us-gaap_SegmentDomain_label_en-US" xlink:label="lab_us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentDomain" xlink:to="lab_us-gaap_SegmentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_DebtInstrumentInterestRateatPeriodEnd_00c96260-6a4d-4732-9962-06ec1385d623_terseLabel_en-US" xlink:label="lab_amed_DebtInstrumentInterestRateatPeriodEnd" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument Interest Rate at Period End</link:label>
    <link:label id="lab_amed_DebtInstrumentInterestRateatPeriodEnd_label_en-US" xlink:label="lab_amed_DebtInstrumentInterestRateatPeriodEnd" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument Interest Rate at Period End</link:label>
    <link:label id="lab_amed_DebtInstrumentInterestRateatPeriodEnd_documentation_en-US" xlink:label="lab_amed_DebtInstrumentInterestRateatPeriodEnd" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument Interest Rate at Period End</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_DebtInstrumentInterestRateatPeriodEnd" xlink:href="amed-20210630.xsd#amed_DebtInstrumentInterestRateatPeriodEnd"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_DebtInstrumentInterestRateatPeriodEnd" xlink:to="lab_amed_DebtInstrumentInterestRateatPeriodEnd" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_MaximumDaysToSubmitFinalBillFromStartOfPeriodOfCare_2202c919-01dd-4ae9-860d-59cc1517e640_terseLabel_en-US" xlink:label="lab_amed_MaximumDaysToSubmitFinalBillFromStartOfPeriodOfCare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum days to submit final bill from the start of episode</link:label>
    <link:label id="lab_amed_MaximumDaysToSubmitFinalBillFromStartOfPeriodOfCare_label_en-US" xlink:label="lab_amed_MaximumDaysToSubmitFinalBillFromStartOfPeriodOfCare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum Days To Submit Final Bill From Start Of Period of Care</link:label>
    <link:label id="lab_amed_MaximumDaysToSubmitFinalBillFromStartOfPeriodOfCare_documentation_en-US" xlink:label="lab_amed_MaximumDaysToSubmitFinalBillFromStartOfPeriodOfCare" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description containing the number of days from the start of the period of care in which the final bill must be submitted to Medicare.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_MaximumDaysToSubmitFinalBillFromStartOfPeriodOfCare" xlink:href="amed-20210630.xsd#amed_MaximumDaysToSubmitFinalBillFromStartOfPeriodOfCare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_MaximumDaysToSubmitFinalBillFromStartOfPeriodOfCare" xlink:to="lab_amed_MaximumDaysToSubmitFinalBillFromStartOfPeriodOfCare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_727f336f-7697-4c3b-b0ce-ae0f01d64f04_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_9a231462-5349-4e7b-b39a-2cbba10bedd3_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Pro Forma Net Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:to="lab_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_DebtInstrumentByLeverageRatioTrancheOneMember_da17fe22-7e89-49b4-b424-57246a5e3ab5_terseLabel_en-US" xlink:label="lab_amed_DebtInstrumentByLeverageRatioTrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Leverage Ratio: Greater Than Equal To 3.00 to 1.0</link:label>
    <link:label id="lab_amed_DebtInstrumentByLeverageRatioTrancheOneMember_label_en-US" xlink:label="lab_amed_DebtInstrumentByLeverageRatioTrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, By Leverage Ratio, Tranche One [Member]</link:label>
    <link:label id="lab_amed_DebtInstrumentByLeverageRatioTrancheOneMember_documentation_en-US" xlink:label="lab_amed_DebtInstrumentByLeverageRatioTrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, By Leverage Ratio, Tranche One [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_DebtInstrumentByLeverageRatioTrancheOneMember" xlink:href="amed-20210630.xsd#amed_DebtInstrumentByLeverageRatioTrancheOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_DebtInstrumentByLeverageRatioTrancheOneMember" xlink:to="lab_amed_DebtInstrumentByLeverageRatioTrancheOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock_d846c733-0055-4a53-829a-48d875bfcdfd_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Commitment Fee Under Credit Facilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Line of Credit Facilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock" xlink:to="lab_us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_9e95a0b2-3423-4705-807c-f0f55482f7ca_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_736bf078-2053-4e4e-8c2c-cf356c6b981f_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_AmendedCreditAgreementMember_260c94ac-fc18-42f5-9968-cf266d027a3c_terseLabel_en-US" xlink:label="lab_amed_AmendedCreditAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amended Credit Agreement [Member]</link:label>
    <link:label id="lab_amed_AmendedCreditAgreementMember_label_en-US" xlink:label="lab_amed_AmendedCreditAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amended Credit Agreement [Member]</link:label>
    <link:label id="lab_amed_AmendedCreditAgreementMember_documentation_en-US" xlink:label="lab_amed_AmendedCreditAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amended Credit Agreement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AmendedCreditAgreementMember" xlink:href="amed-20210630.xsd#amed_AmendedCreditAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_AmendedCreditAgreementMember" xlink:to="lab_amed_AmendedCreditAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_GoodwillDeductibleForIncomeTaxPurposesPeriod_4dcce077-deb8-407a-ac01-aa2036dd64af_terseLabel_en-US" xlink:label="lab_amed_GoodwillDeductibleForIncomeTaxPurposesPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">GoodwillDeductibleForIncomeTaxPurposesPeriod</link:label>
    <link:label id="lab_amed_GoodwillDeductibleForIncomeTaxPurposesPeriod_label_en-US" xlink:label="lab_amed_GoodwillDeductibleForIncomeTaxPurposesPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">GoodwillDeductibleForIncomeTaxPurposesPeriod</link:label>
    <link:label id="lab_amed_GoodwillDeductibleForIncomeTaxPurposesPeriod_documentation_en-US" xlink:label="lab_amed_GoodwillDeductibleForIncomeTaxPurposesPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The period of time that goodwill is deductible for income tax purposes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_GoodwillDeductibleForIncomeTaxPurposesPeriod" xlink:href="amed-20210630.xsd#amed_GoodwillDeductibleForIncomeTaxPurposesPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_GoodwillDeductibleForIncomeTaxPurposesPeriod" xlink:to="lab_amed_GoodwillDeductibleForIncomeTaxPurposesPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_a93ad7fd-cf47-4dfc-9f11-c1c4222e21df_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockAcquiredAverageCostPerShare_72ed6824-3e0a-4441-93a8-8a44763c0cdf_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockAcquiredAverageCostPerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock Acquired, Average Cost Per Share</link:label>
    <link:label id="lab_us-gaap_TreasuryStockAcquiredAverageCostPerShare_label_en-US" xlink:label="lab_us-gaap_TreasuryStockAcquiredAverageCostPerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock Acquired, Average Cost Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockAcquiredAverageCostPerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare" xlink:to="lab_us-gaap_TreasuryStockAcquiredAverageCostPerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_EquityImpactOfWriteOffOfOtherComprehensiveIncome_d762629b-25dd-43e3-8fa4-db11cac8d8cc_negatedLabel_en-US" xlink:label="lab_amed_EquityImpactOfWriteOffOfOtherComprehensiveIncome" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Write-off of other comprehensive income</link:label>
    <link:label id="lab_amed_EquityImpactOfWriteOffOfOtherComprehensiveIncome_label_en-US" xlink:label="lab_amed_EquityImpactOfWriteOffOfOtherComprehensiveIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Impact of Write Off of Other Comprehensive Income</link:label>
    <link:label id="lab_amed_EquityImpactOfWriteOffOfOtherComprehensiveIncome_documentation_en-US" xlink:label="lab_amed_EquityImpactOfWriteOffOfOtherComprehensiveIncome" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Impact of Write Off of Other Comprehensive Income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_EquityImpactOfWriteOffOfOtherComprehensiveIncome" xlink:href="amed-20210630.xsd#amed_EquityImpactOfWriteOffOfOtherComprehensiveIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_EquityImpactOfWriteOffOfOtherComprehensiveIncome" xlink:to="lab_amed_EquityImpactOfWriteOffOfOtherComprehensiveIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_ReversalOfLossContingencyAccrual_8cf6659b-6aa2-4ed2-9dbe-6da55562bc75_terseLabel_en-US" xlink:label="lab_amed_ReversalOfLossContingencyAccrual" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reversal of Loss Contingency Accrual</link:label>
    <link:label id="lab_amed_ReversalOfLossContingencyAccrual_label_en-US" xlink:label="lab_amed_ReversalOfLossContingencyAccrual" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reversal of Loss Contingency Accrual</link:label>
    <link:label id="lab_amed_ReversalOfLossContingencyAccrual_documentation_en-US" xlink:label="lab_amed_ReversalOfLossContingencyAccrual" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reversal of Loss Contingency Accrual</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ReversalOfLossContingencyAccrual" xlink:href="amed-20210630.xsd#amed_ReversalOfLossContingencyAccrual"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_ReversalOfLossContingencyAccrual" xlink:to="lab_amed_ReversalOfLossContingencyAccrual" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_c38e3942-42fe-4c96-9996-a24942fae931_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flows from Financing Activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_IncreaseInEstimatedFutureCOVID19RelatedExpenses_014aa5b8-4a21-4b94-899b-cb662ecc332d_terseLabel_en-US" xlink:label="lab_amed_IncreaseInEstimatedFutureCOVID19RelatedExpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase in Estimated Future COVID-19 Related Expenses</link:label>
    <link:label id="lab_amed_IncreaseInEstimatedFutureCOVID19RelatedExpenses_label_en-US" xlink:label="lab_amed_IncreaseInEstimatedFutureCOVID19RelatedExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase in Estimated Future COVID-19 Related Expenses</link:label>
    <link:label id="lab_amed_IncreaseInEstimatedFutureCOVID19RelatedExpenses_documentation_en-US" xlink:label="lab_amed_IncreaseInEstimatedFutureCOVID19RelatedExpenses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase in Estimated Future COVID-19 Related Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_IncreaseInEstimatedFutureCOVID19RelatedExpenses" xlink:href="amed-20210630.xsd#amed_IncreaseInEstimatedFutureCOVID19RelatedExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_IncreaseInEstimatedFutureCOVID19RelatedExpenses" xlink:to="lab_amed_IncreaseInEstimatedFutureCOVID19RelatedExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityTable_5ac78d3f-2207-4ae7-9b91-e347f44055ea_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility [Table]</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityTable_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityTable" xlink:to="lab_us-gaap_LineOfCreditFacilityTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_6c0b3e74-cc15-4ab2-8c66-5f9f2f490982_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentAssetsPrepaidExpense_f5e9b6d9-57f8-4152-b833-4fcbebf2cbc1_terseLabel_en-US" xlink:label="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentAssetsPrepaidExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense</link:label>
    <link:label id="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentAssetsPrepaidExpense_label_en-US" xlink:label="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentAssetsPrepaidExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense</link:label>
    <link:label id="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentAssetsPrepaidExpense_documentation_en-US" xlink:label="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentAssetsPrepaidExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, acquired at the acquisition date.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentAssetsPrepaidExpense" xlink:href="amed-20210630.xsd#amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentAssetsPrepaidExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentAssetsPrepaidExpense" xlink:to="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentAssetsPrepaidExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_35996f19-e802-4cf4-9a3f-f13aeae59b18_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEGMENT INFORMATION</link:label>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_f977e63c-a55c-4fde-84bb-c5fe4056fd8f_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance/(cancellation) of non-vested stock (shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTable_b1acffdd-7acc-4f4b-9e07-e5d308106fa3_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk [Table]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTable_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTable" xlink:to="lab_us-gaap_ConcentrationRiskTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnSaleOfInvestments_369125da-17fc-40e3-b0b4-8ae7f92508ee_negatedLabel_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">(Gain) loss on equity method investments</link:label>
    <link:label id="lab_us-gaap_GainLossOnSaleOfInvestments_label_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Sale of Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnSaleOfInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnSaleOfInvestments" xlink:to="lab_us-gaap_GainLossOnSaleOfInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_737a09de-6abb-429a-b749-a9957b328b9e_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_9dc3046c-502d-4b48-9869-09a9cfb1c183_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RELATED PARTY TRANSACTIONS</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_AmendedDebtInstrumentByLeverageRatioTrancheThreeMember_c580af0c-e655-4d84-aef6-724782d3c5a2_terseLabel_en-US" xlink:label="lab_amed_AmendedDebtInstrumentByLeverageRatioTrancheThreeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Leverage Ratio: Less Than Equal To 2.00 to 1.0 but Greater Than 0.75 to 1.0</link:label>
    <link:label id="lab_amed_AmendedDebtInstrumentByLeverageRatioTrancheThreeMember_label_en-US" xlink:label="lab_amed_AmendedDebtInstrumentByLeverageRatioTrancheThreeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amended Debt Instrument, By Leverage Ratio, Tranche Three [Member]</link:label>
    <link:label id="lab_amed_AmendedDebtInstrumentByLeverageRatioTrancheThreeMember_documentation_en-US" xlink:label="lab_amed_AmendedDebtInstrumentByLeverageRatioTrancheThreeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amended Debt Instrument, By Leverage Ratio, Tranche Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AmendedDebtInstrumentByLeverageRatioTrancheThreeMember" xlink:href="amed-20210630.xsd#amed_AmendedDebtInstrumentByLeverageRatioTrancheThreeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_AmendedDebtInstrumentByLeverageRatioTrancheThreeMember" xlink:to="lab_amed_AmendedDebtInstrumentByLeverageRatioTrancheThreeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyAccrualCarryingValuePeriodIncreaseDecrease_f7534171-3ef2-4fd7-888f-27fba88ea25f_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyAccrualCarryingValuePeriodIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss contingency accrual, period increase (decrease)</link:label>
    <link:label id="lab_us-gaap_LossContingencyAccrualCarryingValuePeriodIncreaseDecrease_label_en-US" xlink:label="lab_us-gaap_LossContingencyAccrualCarryingValuePeriodIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency Accrual, Period Increase (Decrease)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualCarryingValuePeriodIncreaseDecrease" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyAccrualCarryingValuePeriodIncreaseDecrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyAccrualCarryingValuePeriodIncreaseDecrease" xlink:to="lab_us-gaap_LossContingencyAccrualCarryingValuePeriodIncreaseDecrease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerMember_e12c34a5-ecb9-4925-92a2-2357107c5662_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Member]</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerMember_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer Benchmark [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerMember" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerMember" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_DebtInstrumentByLeverageRatioTrancheTwoMember_f5d760d7-8b84-423c-8a44-43f0a2d67d89_terseLabel_en-US" xlink:label="lab_amed_DebtInstrumentByLeverageRatioTrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Leverage Ratio: Less Than 3.00 to 1.0 but Greater Than Equal To 2.00 to 1.0</link:label>
    <link:label id="lab_amed_DebtInstrumentByLeverageRatioTrancheTwoMember_label_en-US" xlink:label="lab_amed_DebtInstrumentByLeverageRatioTrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, By Leverage Ratio, Tranche Two [Member]</link:label>
    <link:label id="lab_amed_DebtInstrumentByLeverageRatioTrancheTwoMember_documentation_en-US" xlink:label="lab_amed_DebtInstrumentByLeverageRatioTrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, By Leverage Ratio, Tranche Two [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_DebtInstrumentByLeverageRatioTrancheTwoMember" xlink:href="amed-20210630.xsd#amed_DebtInstrumentByLeverageRatioTrancheTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_DebtInstrumentByLeverageRatioTrancheTwoMember" xlink:to="lab_amed_DebtInstrumentByLeverageRatioTrancheTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_0a286ed6-b25e-4d61-9e77-0ef777db6193_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of each class</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_LossContingencyReceivableNoncurrentRelatedToAmountsWithheldPriorToAugust2009_c5b3bb75-45a4-410b-8871-e6ea45ed9b54_terseLabel_en-US" xlink:label="lab_amed_LossContingencyReceivableNoncurrentRelatedToAmountsWithheldPriorToAugust2009" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indemnity receivable related to amounts withheld prior to August 2009</link:label>
    <link:label id="lab_amed_LossContingencyReceivableNoncurrentRelatedToAmountsWithheldPriorToAugust2009_label_en-US" xlink:label="lab_amed_LossContingencyReceivableNoncurrentRelatedToAmountsWithheldPriorToAugust2009" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Receivable, Noncurrent, Related To Amounts Withheld Prior To August 2009</link:label>
    <link:label id="lab_amed_LossContingencyReceivableNoncurrentRelatedToAmountsWithheldPriorToAugust2009_documentation_en-US" xlink:label="lab_amed_LossContingencyReceivableNoncurrentRelatedToAmountsWithheldPriorToAugust2009" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Receivable, Noncurrent, Related To Amounts Withheld Prior To August 2009</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_LossContingencyReceivableNoncurrentRelatedToAmountsWithheldPriorToAugust2009" xlink:href="amed-20210630.xsd#amed_LossContingencyReceivableNoncurrentRelatedToAmountsWithheldPriorToAugust2009"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_LossContingencyReceivableNoncurrentRelatedToAmountsWithheldPriorToAugust2009" xlink:to="lab_amed_LossContingencyReceivableNoncurrentRelatedToAmountsWithheldPriorToAugust2009" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_FinancialInstrumentDetailsTableTextBlock_88bb686b-f920-47fc-94eb-3031f8e3e7dc_terseLabel_en-US" xlink:label="lab_amed_FinancialInstrumentDetailsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value of Financial Instruments</link:label>
    <link:label id="lab_amed_FinancialInstrumentDetailsTableTextBlock_label_en-US" xlink:label="lab_amed_FinancialInstrumentDetailsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument Details [Table Text Block]</link:label>
    <link:label id="lab_amed_FinancialInstrumentDetailsTableTextBlock_documentation_en-US" xlink:label="lab_amed_FinancialInstrumentDetailsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial instrument details, table.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_FinancialInstrumentDetailsTableTextBlock" xlink:href="amed-20210630.xsd#amed_FinancialInstrumentDetailsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_FinancialInstrumentDetailsTableTextBlock" xlink:to="lab_amed_FinancialInstrumentDetailsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_3d40fec0-382d-4883-a4e2-224f4766f4f4_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_RevolvingCreditFacilityTotal_bc5c2ab9-06f7-4729-a847-261020a249f5_terseLabel_en-US" xlink:label="lab_amed_RevolvingCreditFacilityTotal" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving Credit Facility Total</link:label>
    <link:label id="lab_amed_RevolvingCreditFacilityTotal_label_en-US" xlink:label="lab_amed_RevolvingCreditFacilityTotal" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving Credit Facility Total</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_RevolvingCreditFacilityTotal" xlink:href="amed-20210630.xsd#amed_RevolvingCreditFacilityTotal"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_RevolvingCreditFacilityTotal" xlink:to="lab_amed_RevolvingCreditFacilityTotal" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_OneHundredMillionTermLoanMember_1abcaa3c-8caf-4a03-a901-5be2aecf4641_terseLabel_en-US" xlink:label="lab_amed_OneHundredMillionTermLoanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">100 Million Term Loan</link:label>
    <link:label id="lab_amed_OneHundredMillionTermLoanMember_label_en-US" xlink:label="lab_amed_OneHundredMillionTermLoanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">One Hundred Million Term Loan [Member]</link:label>
    <link:label id="lab_amed_OneHundredMillionTermLoanMember_documentation_en-US" xlink:label="lab_amed_OneHundredMillionTermLoanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">100 Million Term Loan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_OneHundredMillionTermLoanMember" xlink:href="amed-20210630.xsd#amed_OneHundredMillionTermLoanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_OneHundredMillionTermLoanMember" xlink:to="lab_amed_OneHundredMillionTermLoanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_CertificateOfNeedMember_a6c22417-0130-40c3-97e7-5ddaa22543fe_terseLabel_en-US" xlink:label="lab_amed_CertificateOfNeedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certificate of Need [Member]</link:label>
    <link:label id="lab_amed_CertificateOfNeedMember_label_en-US" xlink:label="lab_amed_CertificateOfNeedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certificate of Need [Member]</link:label>
    <link:label id="lab_amed_CertificateOfNeedMember_documentation_en-US" xlink:label="lab_amed_CertificateOfNeedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certificate of Need</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CertificateOfNeedMember" xlink:href="amed-20210630.xsd#amed_CertificateOfNeedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_CertificateOfNeedMember" xlink:to="lab_amed_CertificateOfNeedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_TotalCARESActProviderReliefFundsReceived_0b37e6b0-6a66-4d81-9b73-fa078f65775b_terseLabel_en-US" xlink:label="lab_amed_TotalCARESActProviderReliefFundsReceived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total CARES Act Provider Relief Funds Received</link:label>
    <link:label id="lab_amed_TotalCARESActProviderReliefFundsReceived_label_en-US" xlink:label="lab_amed_TotalCARESActProviderReliefFundsReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total CARES Act Provider Relief Funds Received</link:label>
    <link:label id="lab_amed_TotalCARESActProviderReliefFundsReceived_documentation_en-US" xlink:label="lab_amed_TotalCARESActProviderReliefFundsReceived" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total CARES Act Provider Relief Funds Received</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_TotalCARESActProviderReliefFundsReceived" xlink:href="amed-20210630.xsd#amed_TotalCARESActProviderReliefFundsReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_TotalCARESActProviderReliefFundsReceived" xlink:to="lab_amed_TotalCARESActProviderReliefFundsReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpense_3ac7f38c-7a68-4b49-adb8-936003628900_negatedLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_label_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_MedalogixMember_3058c4f8-4ddb-4ee5-b6f0-613329d66d8d_terseLabel_en-US" xlink:label="lab_amed_MedalogixMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medalogix [Member]</link:label>
    <link:label id="lab_amed_MedalogixMember_label_en-US" xlink:label="lab_amed_MedalogixMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medalogix [Member]</link:label>
    <link:label id="lab_amed_MedalogixMember_documentation_en-US" xlink:label="lab_amed_MedalogixMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medalogix [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_MedalogixMember" xlink:href="amed-20210630.xsd#amed_MedalogixMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_MedalogixMember" xlink:to="lab_amed_MedalogixMember" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_InternalAuditComplianceReviewMember_13558f1c-82d4-45fc-bb9d-3e277f9bb335_terseLabel_en-US" xlink:label="lab_amed_InternalAuditComplianceReviewMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Internal Audit Compliance Review [Member]</link:label>
    <link:label id="lab_amed_InternalAuditComplianceReviewMember_label_en-US" xlink:label="lab_amed_InternalAuditComplianceReviewMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Internal Audit Compliance Review [Member]</link:label>
    <link:label id="lab_amed_InternalAuditComplianceReviewMember_documentation_en-US" xlink:label="lab_amed_InternalAuditComplianceReviewMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Internal Audit Compliance Review [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_InternalAuditComplianceReviewMember" xlink:href="amed-20210630.xsd#amed_InternalAuditComplianceReviewMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_InternalAuditComplianceReviewMember" xlink:to="lab_amed_InternalAuditComplianceReviewMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_1dda679b-a747-4280-b9a1-ed5465d9d9b1_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_AccountsReceivablePortionDerivedFromMedicare_4dc98d28-a152-4fba-95bc-2c35f462a1fe_terseLabel_en-US" xlink:label="lab_amed_AccountsReceivablePortionDerivedFromMedicare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable derived from Medicare</link:label>
    <link:label id="lab_amed_AccountsReceivablePortionDerivedFromMedicare_label_en-US" xlink:label="lab_amed_AccountsReceivablePortionDerivedFromMedicare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Portion Derived From Medicare</link:label>
    <link:label id="lab_amed_AccountsReceivablePortionDerivedFromMedicare_documentation_en-US" xlink:label="lab_amed_AccountsReceivablePortionDerivedFromMedicare" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Portion Derived From Medicare</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AccountsReceivablePortionDerivedFromMedicare" xlink:href="amed-20210630.xsd#amed_AccountsReceivablePortionDerivedFromMedicare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_AccountsReceivablePortionDerivedFromMedicare" xlink:to="lab_amed_AccountsReceivablePortionDerivedFromMedicare" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_23c07315-3839-4be3-9f48-bee2f0dd2570_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_136a4ef5-d9a6-49e7-9eea-41f5ea948da4_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_NumberOfClaimsSubmittedBySubsidiary_6345b6ba-f1bf-4133-8705-2eb9ce8d6eca_terseLabel_en-US" xlink:label="lab_amed_NumberOfClaimsSubmittedBySubsidiary" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of claims submitted by subsidiary</link:label>
    <link:label id="lab_amed_NumberOfClaimsSubmittedBySubsidiary_label_en-US" xlink:label="lab_amed_NumberOfClaimsSubmittedBySubsidiary" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Claims Submitted By Subsidiary</link:label>
    <link:label id="lab_amed_NumberOfClaimsSubmittedBySubsidiary_documentation_en-US" xlink:label="lab_amed_NumberOfClaimsSubmittedBySubsidiary" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of claims submitted by subsidiary.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_NumberOfClaimsSubmittedBySubsidiary" xlink:href="amed-20210630.xsd#amed_NumberOfClaimsSubmittedBySubsidiary"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_NumberOfClaimsSubmittedBySubsidiary" xlink:to="lab_amed_NumberOfClaimsSubmittedBySubsidiary" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllOtherSegmentsMember_44d6e097-210b-4d77-a403-b7d8c718dcab_terseLabel_en-US" xlink:label="lab_us-gaap_AllOtherSegmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_AllOtherSegmentsMember_label_en-US" xlink:label="lab_us-gaap_AllOtherSegmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Segments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllOtherSegmentsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllOtherSegmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllOtherSegmentsMember" xlink:to="lab_us-gaap_AllOtherSegmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_CapYearTwoThousandSixteenThroughTwoThousandTwentyOneMember_a4dadc1a-5a6c-4270-9690-de5ac7dc29e0_terseLabel_en-US" xlink:label="lab_amed_CapYearTwoThousandSixteenThroughTwoThousandTwentyOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cap Year 2016 Through 2021</link:label>
    <link:label id="lab_amed_CapYearTwoThousandSixteenThroughTwoThousandTwentyOneMember_label_en-US" xlink:label="lab_amed_CapYearTwoThousandSixteenThroughTwoThousandTwentyOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cap Year Two Thousand Sixteen Through Two Thousand Twenty One [Member]</link:label>
    <link:label id="lab_amed_CapYearTwoThousandSixteenThroughTwoThousandTwentyOneMember_documentation_en-US" xlink:label="lab_amed_CapYearTwoThousandSixteenThroughTwoThousandTwentyOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cap Year Two Thousand Sixteen Through Two Thousand Twenty One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CapYearTwoThousandSixteenThroughTwoThousandTwentyOneMember" xlink:href="amed-20210630.xsd#amed_CapYearTwoThousandSixteenThroughTwoThousandTwentyOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_CapYearTwoThousandSixteenThroughTwoThousandTwentyOneMember" xlink:to="lab_amed_CapYearTwoThousandSixteenThroughTwoThousandTwentyOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_3c4db141-2f32-4e77-b011-1953eb054ac7_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_LakelandFloridaMember_b69f6a6b-42b4-4044-8a8d-f3b0fdcd6dd2_terseLabel_en-US" xlink:label="lab_amed_LakelandFloridaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lakeland, Florida</link:label>
    <link:label id="lab_amed_LakelandFloridaMember_label_en-US" xlink:label="lab_amed_LakelandFloridaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lakeland, Florida [Member]</link:label>
    <link:label id="lab_amed_LakelandFloridaMember_documentation_en-US" xlink:label="lab_amed_LakelandFloridaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lakeland, Florida [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_LakelandFloridaMember" xlink:href="amed-20210630.xsd#amed_LakelandFloridaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_LakelandFloridaMember" xlink:to="lab_amed_LakelandFloridaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_b4752405-63c7-4506-89f3-fc183dd93b9a_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_e1da4967-97c5-4a66-92f7-4d86dfed27e4_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7a758d76-534d-4985-9cd5-c5e9129ff65e_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfStatesInWhichEntityOperates_7c208536-e1c6-49c0-8200-c23de64faba8_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfStatesInWhichEntityOperates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of states with facilities</link:label>
    <link:label id="lab_us-gaap_NumberOfStatesInWhichEntityOperates_label_en-US" xlink:label="lab_us-gaap_NumberOfStatesInWhichEntityOperates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of States in which Entity Operates</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfStatesInWhichEntityOperates" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfStatesInWhichEntityOperates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfStatesInWhichEntityOperates" xlink:to="lab_us-gaap_NumberOfStatesInWhichEntityOperates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_0eb906b4-8ce5-4ffe-8460-4f4f7ba06a83_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_99b87656-628a-42b9-b308-83b8b186f1bb_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_69988096-af72-4e6a-b279-3f88ffc90eaa_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_1b8bd666-d4ab-41db-a531-1a27c9b5eff8_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_69e4363c-b677-4a9c-942c-06a8eaef0997_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByAssetClassAxis_3d4fe948-4fc6-47e5-837d-c188aee4ab06_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByAssetClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByAssetClassAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByAssetClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByAssetClassAxis" xlink:to="lab_us-gaap_FairValueByAssetClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_cd4cde5e-447a-437f-b462-1b2a089daaf7_negatedLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares repurchased</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_label_en-US" xlink:label="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Value, Acquired, Cost Method</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:to="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_AmortizationandImpairmentofOperatingLeaseRightOfUseAsset_dab901b3-8ae5-4d93-8052-33f3f031d1b8_terseLabel_en-US" xlink:label="lab_amed_AmortizationandImpairmentofOperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization and impairment of operating lease right of use assets</link:label>
    <link:label id="lab_amed_AmortizationandImpairmentofOperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_amed_AmortizationandImpairmentofOperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization and Impairment of Operating Lease Right Of Use Asset</link:label>
    <link:label id="lab_amed_AmortizationandImpairmentofOperatingLeaseRightOfUseAsset_documentation_en-US" xlink:label="lab_amed_AmortizationandImpairmentofOperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization and Impairment of Operating Lease Right Of Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AmortizationandImpairmentofOperatingLeaseRightOfUseAsset" xlink:href="amed-20210630.xsd#amed_AmortizationandImpairmentofOperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_AmortizationandImpairmentofOperatingLeaseRightOfUseAsset" xlink:to="lab_amed_AmortizationandImpairmentofOperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_92debee8-7daa-497b-8483-2b2a9ef4a845_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net income to net cash provided by operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_LitigationCaseAxis_57ececef-d3de-47ea-829a-9347b21c4963_terseLabel_en-US" xlink:label="lab_srt_LitigationCaseAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Axis]</link:label>
    <link:label id="lab_srt_LitigationCaseAxis_label_en-US" xlink:label="lab_srt_LitigationCaseAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_LitigationCaseAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LitigationCaseAxis" xlink:to="lab_srt_LitigationCaseAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_EstimatedFutureCOVID19RelatedExpenses_0a0b5783-f8ac-4bbf-973f-0db91d6e1bbc_terseLabel_en-US" xlink:label="lab_amed_EstimatedFutureCOVID19RelatedExpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Future COVID-19 related expenses</link:label>
    <link:label id="lab_amed_EstimatedFutureCOVID19RelatedExpenses_label_en-US" xlink:label="lab_amed_EstimatedFutureCOVID19RelatedExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Future COVID-19 related expenses</link:label>
    <link:label id="lab_amed_EstimatedFutureCOVID19RelatedExpenses_documentation_en-US" xlink:label="lab_amed_EstimatedFutureCOVID19RelatedExpenses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated expenses as a result of the Novel Coronavirus Pandemic "COVID-19"</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_EstimatedFutureCOVID19RelatedExpenses" xlink:href="amed-20210630.xsd#amed_EstimatedFutureCOVID19RelatedExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_EstimatedFutureCOVID19RelatedExpenses" xlink:to="lab_amed_EstimatedFutureCOVID19RelatedExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_a062a374-4a65-41a8-938a-a352ff21e462_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value of Financial Instruments</link:label>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_label_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value of Financial Instruments, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_TypeOfEquityMethodInvestmentDomain_10d15337-6d2e-474a-91ba-570d857f6f9d_terseLabel_en-US" xlink:label="lab_amed_TypeOfEquityMethodInvestmentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Equity Method Investment [Domain]</link:label>
    <link:label id="lab_amed_TypeOfEquityMethodInvestmentDomain_label_en-US" xlink:label="lab_amed_TypeOfEquityMethodInvestmentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Equity Method Investment [Domain]</link:label>
    <link:label id="lab_amed_TypeOfEquityMethodInvestmentDomain_documentation_en-US" xlink:label="lab_amed_TypeOfEquityMethodInvestmentDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Equity Method Investment [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_TypeOfEquityMethodInvestmentDomain" xlink:href="amed-20210630.xsd#amed_TypeOfEquityMethodInvestmentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_TypeOfEquityMethodInvestmentDomain" xlink:to="lab_amed_TypeOfEquityMethodInvestmentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestments_2b6f3d31-d8dc-489f-8531-2aeb0086ee2b_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestments" xlink:to="lab_us-gaap_EquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_72eb334a-6686-4df0-8d2f-5a9266e02caa_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, outstanding (shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherOperatingIncome_5096001b-8c5e-44a5-98a5-3507a77f1bf7_terseLabel_en-US" xlink:label="lab_us-gaap_OtherOperatingIncome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other operating income</link:label>
    <link:label id="lab_us-gaap_OtherOperatingIncome_label_en-US" xlink:label="lab_us-gaap_OtherOperatingIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Operating Income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncome" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherOperatingIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherOperatingIncome" xlink:to="lab_us-gaap_OtherOperatingIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevolvingCreditFacilityMember_ff13091d-42ff-419d-a45b-f3cf3d45b285_terseLabel_en-US" xlink:label="lab_us-gaap_RevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving Credit Facility [Member]</link:label>
    <link:label id="lab_us-gaap_RevolvingCreditFacilityMember_label_en-US" xlink:label="lab_us-gaap_RevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving Credit Facility [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevolvingCreditFacilityMember" xlink:to="lab_us-gaap_RevolvingCreditFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_HospiceMedicareMember_1b977b5f-d396-424c-9242-af7b2cb44d75_terseLabel_en-US" xlink:label="lab_amed_HospiceMedicareMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hospice Medicare [Member]</link:label>
    <link:label id="lab_amed_HospiceMedicareMember_label_en-US" xlink:label="lab_amed_HospiceMedicareMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hospice Medicare [Member]</link:label>
    <link:label id="lab_amed_HospiceMedicareMember_documentation_en-US" xlink:label="lab_amed_HospiceMedicareMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hospice Medicare [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HospiceMedicareMember" xlink:href="amed-20210630.xsd#amed_HospiceMedicareMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_HospiceMedicareMember" xlink:to="lab_amed_HospiceMedicareMember" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_BusinessAcquisitionWorkingCapitalAdjustment_5f466024-b3de-475d-a1e8-c29517e18833_terseLabel_en-US" xlink:label="lab_amed_BusinessAcquisitionWorkingCapitalAdjustment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition Working Capital Adjustment</link:label>
    <link:label id="lab_amed_BusinessAcquisitionWorkingCapitalAdjustment_label_en-US" xlink:label="lab_amed_BusinessAcquisitionWorkingCapitalAdjustment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition Working Capital Adjustment</link:label>
    <link:label id="lab_amed_BusinessAcquisitionWorkingCapitalAdjustment_documentation_en-US" xlink:label="lab_amed_BusinessAcquisitionWorkingCapitalAdjustment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Working Capital Adjustment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_BusinessAcquisitionWorkingCapitalAdjustment" xlink:href="amed-20210630.xsd#amed_BusinessAcquisitionWorkingCapitalAdjustment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_BusinessAcquisitionWorkingCapitalAdjustment" xlink:to="lab_amed_BusinessAcquisitionWorkingCapitalAdjustment" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_NonVestedStockAndStockUnits_f7291790-0c22-421a-86b2-8700e22c017c_terseLabel_en-US" xlink:label="lab_amed_NonVestedStockAndStockUnits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-vested stock and stock units (shares)</link:label>
    <link:label id="lab_amed_NonVestedStockAndStockUnits_label_en-US" xlink:label="lab_amed_NonVestedStockAndStockUnits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non Vested Stock And Stock Units</link:label>
    <link:label id="lab_amed_NonVestedStockAndStockUnits_documentation_en-US" xlink:label="lab_amed_NonVestedStockAndStockUnits" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non vested stock and stock units.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_NonVestedStockAndStockUnits" xlink:href="amed-20210630.xsd#amed_NonVestedStockAndStockUnits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_NonVestedStockAndStockUnits" xlink:to="lab_amed_NonVestedStockAndStockUnits" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_PercentageofSharesOutstanding_d46e0867-d299-4dde-a754-22dab2b226d0_terseLabel_en-US" xlink:label="lab_amed_PercentageofSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of shares outstanding</link:label>
    <link:label id="lab_amed_PercentageofSharesOutstanding_label_en-US" xlink:label="lab_amed_PercentageofSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of Shares Outstanding</link:label>
    <link:label id="lab_amed_PercentageofSharesOutstanding_documentation_en-US" xlink:label="lab_amed_PercentageofSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PercentageofSharesOutstanding" xlink:href="amed-20210630.xsd#amed_PercentageofSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_PercentageofSharesOutstanding" xlink:to="lab_amed_PercentageofSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_d9d270fd-627b-4770-9670-d47a5adf8ea8_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income before income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis_b352ce3c-2ba3-43c0-925c-bb66733c7a6e_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency Nature [Axis]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis_label_en-US" xlink:label="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency Nature [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:to="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationIntegrationRelatedCosts_2ff86763-a510-4615-a14e-f9394566e33e_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationIntegrationRelatedCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Integration Related Costs</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationIntegrationRelatedCosts_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationIntegrationRelatedCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Integration Related Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationIntegrationRelatedCosts" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationIntegrationRelatedCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationIntegrationRelatedCosts" xlink:to="lab_us-gaap_BusinessCombinationIntegrationRelatedCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable_23868c4d-b565-426b-89a0-da519aa42581_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition, Multiple-deliverable Arrangements [Table]</link:label>
    <link:label id="lab_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable_label_en-US" xlink:label="lab_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition, Multiple-deliverable Arrangements [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable" xlink:to="lab_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventMember_e4e6308b-0891-4c31-bf5d-4ce3c1881a71_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_ShareRepurchaseProgramMember_d9d0f3a3-20ae-4575-b5c5-e9dbe705f011_terseLabel_en-US" xlink:label="lab_amed_ShareRepurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase Program</link:label>
    <link:label id="lab_amed_ShareRepurchaseProgramMember_label_en-US" xlink:label="lab_amed_ShareRepurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase Program [Member]</link:label>
    <link:label id="lab_amed_ShareRepurchaseProgramMember_documentation_en-US" xlink:label="lab_amed_ShareRepurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase Program</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ShareRepurchaseProgramMember" xlink:href="amed-20210630.xsd#amed_ShareRepurchaseProgramMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_ShareRepurchaseProgramMember" xlink:to="lab_amed_ShareRepurchaseProgramMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LettersOfCreditOutstandingAmount_a5c6a668-aaa1-4485-8507-c1760b34177b_terseLabel_en-US" xlink:label="lab_us-gaap_LettersOfCreditOutstandingAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding letters of credit</link:label>
    <link:label id="lab_us-gaap_LettersOfCreditOutstandingAmount_label_en-US" xlink:label="lab_us-gaap_LettersOfCreditOutstandingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Letters of Credit Outstanding, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LettersOfCreditOutstandingAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LettersOfCreditOutstandingAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LettersOfCreditOutstandingAmount" xlink:to="lab_us-gaap_LettersOfCreditOutstandingAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_c5c5c16b-a733-4e88-b5ab-08a57352f087_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisitions of businesses, net of cash acquired</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Businesses, Net of Cash Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_IncreaseDecreaseInOperatingLeaseLiability_5cfa3280-8ce1-43b1-a077-2927fc60a266_terseLabel_en-US" xlink:label="lab_amed_IncreaseDecreaseInOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_amed_IncreaseDecreaseInOperatingLeaseLiability_label_en-US" xlink:label="lab_amed_IncreaseDecreaseInOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Operating Lease Liability</link:label>
    <link:label id="lab_amed_IncreaseDecreaseInOperatingLeaseLiability_documentation_en-US" xlink:label="lab_amed_IncreaseDecreaseInOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of increase (decrease) in operating lease liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_IncreaseDecreaseInOperatingLeaseLiability" xlink:href="amed-20210630.xsd#amed_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="lab_amed_IncreaseDecreaseInOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_8b219cea-cbbe-44f8-ad51-834e2d3d04d1_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, authorized (shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_f565db61-b05b-48ad-b06b-28b418301638_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:to="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_a68ea686-9494-42d6-832f-4156567906ee_terseLabel_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options (shares)</link:label>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_label_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:to="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_799b6f32-07d7-48f5-b13f-4f56893a5f32_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of stock upon exercise of stock options</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_62e23b82-cf55-4f71-8db5-8fd0669717fd_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion of long-term obligations</link:label>
    <link:label id="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt and Lease Obligation, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:to="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRecognitionPolicyTextBlock_54d2b21f-73ee-4f7c-9bae-662e9632d2cc_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition</link:label>
    <link:label id="lab_us-gaap_RevenueRecognitionPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_ea03912d-e593-4ac3-b133-f4d166a6de1d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Operating Income of Reportable Segments</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:to="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_EstimatedAmountDueBackToMedicareInOtherAccruedLiabilities_7411216e-803f-4ebb-b828-5356f3ce3e8c_terseLabel_en-US" xlink:label="lab_amed_EstimatedAmountDueBackToMedicareInOtherAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated amounts due back to Medicare</link:label>
    <link:label id="lab_amed_EstimatedAmountDueBackToMedicareInOtherAccruedLiabilities_label_en-US" xlink:label="lab_amed_EstimatedAmountDueBackToMedicareInOtherAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Amount Due Back To Medicare In Other Accrued Liabilities</link:label>
    <link:label id="lab_amed_EstimatedAmountDueBackToMedicareInOtherAccruedLiabilities_documentation_en-US" xlink:label="lab_amed_EstimatedAmountDueBackToMedicareInOtherAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimate of obligations due Medicare upon demand due to overages for the inpatient cap and/or overall payment cap.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_EstimatedAmountDueBackToMedicareInOtherAccruedLiabilities" xlink:href="amed-20210630.xsd#amed_EstimatedAmountDueBackToMedicareInOtherAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_EstimatedAmountDueBackToMedicareInOtherAccruedLiabilities" xlink:to="lab_amed_EstimatedAmountDueBackToMedicareInOtherAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_stpr_NY_ab9b37f1-0299-46a6-ba2a-db726ea996f0_terseLabel_en-US" xlink:label="lab_stpr_NY" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NEW YORK</link:label>
    <link:label id="lab_stpr_NY_label_en-US" xlink:label="lab_stpr_NY" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NEW YORK</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_NY" xlink:href="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd#stpr_NY"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_stpr_NY" xlink:to="lab_stpr_NY" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_PersonalCareMember_1bb0e300-8b85-426f-91ea-684a6f955e64_terseLabel_en-US" xlink:label="lab_amed_PersonalCareMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Personal Care [Member]</link:label>
    <link:label id="lab_amed_PersonalCareMember_label_en-US" xlink:label="lab_amed_PersonalCareMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Personal Care [Member]</link:label>
    <link:label id="lab_amed_PersonalCareMember_documentation_en-US" xlink:label="lab_amed_PersonalCareMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Personal Care [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PersonalCareMember" xlink:href="amed-20210630.xsd#amed_PersonalCareMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_PersonalCareMember" xlink:to="lab_amed_PersonalCareMember" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_COVID19DeferralOfSocialSecurityMember_f27e9769-aca0-426a-8892-7f05a403b722_terseLabel_en-US" xlink:label="lab_amed_COVID19DeferralOfSocialSecurityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COVID-19 Deferral of Social Security</link:label>
    <link:label id="lab_amed_COVID19DeferralOfSocialSecurityMember_label_en-US" xlink:label="lab_amed_COVID19DeferralOfSocialSecurityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COVID-19 Deferral of Social Security [Member]</link:label>
    <link:label id="lab_amed_COVID19DeferralOfSocialSecurityMember_documentation_en-US" xlink:label="lab_amed_COVID19DeferralOfSocialSecurityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COVID-19 Deferral of Social Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_COVID19DeferralOfSocialSecurityMember" xlink:href="amed-20210630.xsd#amed_COVID19DeferralOfSocialSecurityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_COVID19DeferralOfSocialSecurityMember" xlink:to="lab_amed_COVID19DeferralOfSocialSecurityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_5f3f30ab-5aef-4743-b6db-ca17ac96df1b_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_e551c810-d5f2-4ad2-a371-87dcd03aafe1_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_RateOfRequestForAnticipatedPaymentSubmittedForInitialPeriodOfCare_135be350-e91f-4146-91fe-52f059f5b2cb_terseLabel_en-US" xlink:label="lab_amed_RateOfRequestForAnticipatedPaymentSubmittedForInitialPeriodOfCare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rate of request for anticipated payment submitted for the initial episode of care</link:label>
    <link:label id="lab_amed_RateOfRequestForAnticipatedPaymentSubmittedForInitialPeriodOfCare_label_en-US" xlink:label="lab_amed_RateOfRequestForAnticipatedPaymentSubmittedForInitialPeriodOfCare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rate Of Request For Anticipated Payment Submitted For Initial Period Of Care</link:label>
    <link:label id="lab_amed_RateOfRequestForAnticipatedPaymentSubmittedForInitialPeriodOfCare_documentation_en-US" xlink:label="lab_amed_RateOfRequestForAnticipatedPaymentSubmittedForInitialPeriodOfCare" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description containing the percentage of estimated payment that is requested at the start of care for an initial period of care.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_RateOfRequestForAnticipatedPaymentSubmittedForInitialPeriodOfCare" xlink:href="amed-20210630.xsd#amed_RateOfRequestForAnticipatedPaymentSubmittedForInitialPeriodOfCare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_RateOfRequestForAnticipatedPaymentSubmittedForInitialPeriodOfCare" xlink:to="lab_amed_RateOfRequestForAnticipatedPaymentSubmittedForInitialPeriodOfCare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_ca085104-e819-42d4-b843-7b92348ed6c4_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities, less current portion</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_d0383735-acbd-4204-8076-28a96825d816_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_ParkersburgWestVirginiaMember_1403ab58-1adf-486e-916d-9053cad31340_terseLabel_en-US" xlink:label="lab_amed_ParkersburgWestVirginiaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Parkersburg, West Virginia</link:label>
    <link:label id="lab_amed_ParkersburgWestVirginiaMember_label_en-US" xlink:label="lab_amed_ParkersburgWestVirginiaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Parkersburg, West Virginia [Member]</link:label>
    <link:label id="lab_amed_ParkersburgWestVirginiaMember_documentation_en-US" xlink:label="lab_amed_ParkersburgWestVirginiaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Parkersburg, West Virginia [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ParkersburgWestVirginiaMember" xlink:href="amed-20210630.xsd#amed_ParkersburgWestVirginiaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_ParkersburgWestVirginiaMember" xlink:to="lab_amed_ParkersburgWestVirginiaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_stpr_NC_179b6329-20ab-46ad-bb3d-6ade835e254d_terseLabel_en-US" xlink:label="lab_stpr_NC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NORTH CAROLINA</link:label>
    <link:label id="lab_stpr_NC_label_en-US" xlink:label="lab_stpr_NC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NORTH CAROLINA</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_NC" xlink:href="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd#stpr_NC"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_stpr_NC" xlink:to="lab_stpr_NC" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_FundingReceivedFromCARESAct_63b1740c-700b-480c-8ef9-8424beedc8c0_terseLabel_en-US" xlink:label="lab_amed_FundingReceivedFromCARESAct" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Funding Received From CARES Act</link:label>
    <link:label id="lab_amed_FundingReceivedFromCARESAct_label_en-US" xlink:label="lab_amed_FundingReceivedFromCARESAct" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Funding Received From CARES Act</link:label>
    <link:label id="lab_amed_FundingReceivedFromCARESAct_documentation_en-US" xlink:label="lab_amed_FundingReceivedFromCARESAct" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Funding received by the Company from the Coronavirus Aid Relief and Economic Security (CARES) Act</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_FundingReceivedFromCARESAct" xlink:href="amed-20210630.xsd#amed_FundingReceivedFromCARESAct"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_FundingReceivedFromCARESAct" xlink:to="lab_amed_FundingReceivedFromCARESAct" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_848693b4-f7c5-4559-8df3-6e4bff42f63b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_5ff52083-49c6-4bca-ba44-d8a4b2406d38_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_RecoveryAmountOfOverpaymentMadeToSubsidiaryIncludingInterest_1ffef0f0-1b5e-43e1-a891-34b59ee4ac76_terseLabel_en-US" xlink:label="lab_amed_RecoveryAmountOfOverpaymentMadeToSubsidiaryIncludingInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recovery amount of overpayment made to subsidiary including interest</link:label>
    <link:label id="lab_amed_RecoveryAmountOfOverpaymentMadeToSubsidiaryIncludingInterest_label_en-US" xlink:label="lab_amed_RecoveryAmountOfOverpaymentMadeToSubsidiaryIncludingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recovery Amount of Overpayment Made To Subsidiary Including Interest</link:label>
    <link:label id="lab_amed_RecoveryAmountOfOverpaymentMadeToSubsidiaryIncludingInterest_documentation_en-US" xlink:label="lab_amed_RecoveryAmountOfOverpaymentMadeToSubsidiaryIncludingInterest" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recovery amount of overpayment made to subsidiary including interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_RecoveryAmountOfOverpaymentMadeToSubsidiaryIncludingInterest" xlink:href="amed-20210630.xsd#amed_RecoveryAmountOfOverpaymentMadeToSubsidiaryIncludingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_RecoveryAmountOfOverpaymentMadeToSubsidiaryIncludingInterest" xlink:to="lab_amed_RecoveryAmountOfOverpaymentMadeToSubsidiaryIncludingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_75669751-cbc5-441b-9618-3ab52d5785ea_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesPayrollandEmployeeBenefits_689336e0-9ef9-4c11-8f5e-be22b21a8b7c_negatedLabel_en-US" xlink:label="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesPayrollandEmployeeBenefits" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Payroll and Employee Benefits</link:label>
    <link:label id="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesPayrollandEmployeeBenefits_label_en-US" xlink:label="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesPayrollandEmployeeBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Payroll and Employee Benefits</link:label>
    <link:label id="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesPayrollandEmployeeBenefits_documentation_en-US" xlink:label="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesPayrollandEmployeeBenefits" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Payroll and Employee Benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesPayrollandEmployeeBenefits" xlink:href="amed-20210630.xsd#amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesPayrollandEmployeeBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesPayrollandEmployeeBenefits" xlink:to="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesPayrollandEmployeeBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingleaserightofuseassets_e6961f02-f221-4b68-ace5-36bc6f858acb_terseLabel_en-US" xlink:label="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingleaserightofuseassets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Operating lease right of use assets</link:label>
    <link:label id="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingleaserightofuseassets_label_en-US" xlink:label="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingleaserightofuseassets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Operating lease right of use assets</link:label>
    <link:label id="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingleaserightofuseassets_documentation_en-US" xlink:label="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingleaserightofuseassets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Operating lease right of use assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingleaserightofuseassets" xlink:href="amed-20210630.xsd#amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingleaserightofuseassets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingleaserightofuseassets" xlink:to="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingleaserightofuseassets" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_PayorClassDomain_78bb13af-ea32-4a9f-81b3-44350a5327cc_terseLabel_en-US" xlink:label="lab_amed_PayorClassDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payor Class [Domain]</link:label>
    <link:label id="lab_amed_PayorClassDomain_label_en-US" xlink:label="lab_amed_PayorClassDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payor Class [Domain]</link:label>
    <link:label id="lab_amed_PayorClassDomain_documentation_en-US" xlink:label="lab_amed_PayorClassDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">[Domain] for Payor Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PayorClassDomain" xlink:href="amed-20210630.xsd#amed_PayorClassDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_PayorClassDomain" xlink:to="lab_amed_PayorClassDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_CashPaidForOperatingLeaseLiabilities_32eb87e4-739c-4023-8229-9c8ddbb7d49c_terseLabel_en-US" xlink:label="lab_amed_CashPaidForOperatingLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for operating lease liabilities</link:label>
    <link:label id="lab_amed_CashPaidForOperatingLeaseLiabilities_label_en-US" xlink:label="lab_amed_CashPaidForOperatingLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for operating lease liabilities</link:label>
    <link:label id="lab_amed_CashPaidForOperatingLeaseLiabilities_documentation_en-US" xlink:label="lab_amed_CashPaidForOperatingLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The amount of cash paid for operating lease liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CashPaidForOperatingLeaseLiabilities" xlink:href="amed-20210630.xsd#amed_CashPaidForOperatingLeaseLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_CashPaidForOperatingLeaseLiabilities" xlink:to="lab_amed_CashPaidForOperatingLeaseLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseAbstract_1f2d35c9-3b88-49ad-aac6-8d76f45df167_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative expenses:</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseAbstract_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseAbstract" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_168b1075-ff9d-4348-9e02-e7a5ba12c939_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, par value (usd per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_stpr_MA_719e3ad7-ebc0-4aa1-bcf4-b99be6e662a6_terseLabel_en-US" xlink:label="lab_stpr_MA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Massachusetts</link:label>
    <link:label id="lab_stpr_MA_label_en-US" xlink:label="lab_stpr_MA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MASSACHUSETTS</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_MA" xlink:href="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd#stpr_MA"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_stpr_MA" xlink:to="lab_stpr_MA" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_0cbd8e77-6f12-4dc6-8b7a-fea095a31d36_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_3a6545a0-ff2c-497b-91b7-74d4133a53cb_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_f9ff2ee7-71b1-41f8-abf5-dcf2985eccbe_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_HospiceMember_f54aef3e-8699-45c7-8da0-c2e41cd60e2d_terseLabel_en-US" xlink:label="lab_amed_HospiceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hospice [Member]</link:label>
    <link:label id="lab_amed_HospiceMember_label_en-US" xlink:label="lab_amed_HospiceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hospice [Member]</link:label>
    <link:label id="lab_amed_HospiceMember_documentation_en-US" xlink:label="lab_amed_HospiceMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hospice [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HospiceMember" xlink:href="amed-20210630.xsd#amed_HospiceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_HospiceMember" xlink:to="lab_amed_HospiceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyAccrualAtCarryingValue_4a9cb035-f00a-468e-9f44-63ba74a25f91_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss contingency accrual</link:label>
    <link:label id="lab_us-gaap_LossContingencyAccrualAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency Accrual</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyAccrualAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:to="lab_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_AcquiredNamesMember_192a6d9e-5db1-4d81-a7f6-aaf2d72aed0d_terseLabel_en-US" xlink:label="lab_amed_AcquiredNamesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired Names [Member]</link:label>
    <link:label id="lab_amed_AcquiredNamesMember_label_en-US" xlink:label="lab_amed_AcquiredNamesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired Names [Member]</link:label>
    <link:label id="lab_amed_AcquiredNamesMember_documentation_en-US" xlink:label="lab_amed_AcquiredNamesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired Names</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AcquiredNamesMember" xlink:href="amed-20210630.xsd#amed_AcquiredNamesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_AcquiredNamesMember" xlink:to="lab_amed_AcquiredNamesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_81e84e42-bbba-480c-9d3b-06e73bb64d9d_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity in earnings from equity method investments</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_a58361e8-b244-45c9-a5ae-49727eb7c384_negatedLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity in earnings from equity method investments</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Equity Method Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:to="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1_085dcb7b-013e-46a9-95f6-6ec42788d98d_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchase Program, Authorized Amount</link:label>
    <link:label id="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1_label_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchase Program, Authorized Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:to="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProfitLoss_bd848628-6467-4064-9bbd-245017262e0e_totalLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_c696cfe1-da83-4ed9-84f3-8dca5d6dda93_terseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_label_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss" xlink:to="lab_us-gaap_ProfitLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_0e7abc71-01db-4bb5-96dd-f56abc10c279_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net increase in cash, cash equivalents and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_ContessaHealthMember_2812ef51-102e-4788-b65a-2d54ae55f4b5_terseLabel_en-US" xlink:label="lab_amed_ContessaHealthMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contessa Health</link:label>
    <link:label id="lab_amed_ContessaHealthMember_label_en-US" xlink:label="lab_amed_ContessaHealthMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contessa Health [Member]</link:label>
    <link:label id="lab_amed_ContessaHealthMember_documentation_en-US" xlink:label="lab_amed_ContessaHealthMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contessa Health</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ContessaHealthMember" xlink:href="amed-20210630.xsd#amed_ContessaHealthMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_ContessaHealthMember" xlink:to="lab_amed_ContessaHealthMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_badd27ea-e09c-4d6e-aeb0-5aeb1a3fab56_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain" xlink:to="lab_us-gaap_LongtermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_560e3354-4b4d-4ec8-98cf-9fc98784e583_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_ActualClaimsPayment_80334315-18db-4b97-89d8-dbb3076784a0_terseLabel_en-US" xlink:label="lab_amed_ActualClaimsPayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Actual claims payment</link:label>
    <link:label id="lab_amed_ActualClaimsPayment_label_en-US" xlink:label="lab_amed_ActualClaimsPayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Actual Claims Payment</link:label>
    <link:label id="lab_amed_ActualClaimsPayment_documentation_en-US" xlink:label="lab_amed_ActualClaimsPayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Actual Claims Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ActualClaimsPayment" xlink:href="amed-20210630.xsd#amed_ActualClaimsPayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_ActualClaimsPayment" xlink:to="lab_amed_ActualClaimsPayment" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_CapYearTwoThousandFourteenThroughTwoThousandTwentyOneMember_a030294c-8ab3-4478-92cb-5c9e45f9aceb_terseLabel_en-US" xlink:label="lab_amed_CapYearTwoThousandFourteenThroughTwoThousandTwentyOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cap Year 2014 Through 2021</link:label>
    <link:label id="lab_amed_CapYearTwoThousandFourteenThroughTwoThousandTwentyOneMember_label_en-US" xlink:label="lab_amed_CapYearTwoThousandFourteenThroughTwoThousandTwentyOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cap Year Two Thousand Fourteen Through Two Thousand Twenty One [Member]</link:label>
    <link:label id="lab_amed_CapYearTwoThousandFourteenThroughTwoThousandTwentyOneMember_documentation_en-US" xlink:label="lab_amed_CapYearTwoThousandFourteenThroughTwoThousandTwentyOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cap Year Two Thousand Fourteen Through Two Thousand Twenty One[Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CapYearTwoThousandFourteenThroughTwoThousandTwentyOneMember" xlink:href="amed-20210630.xsd#amed_CapYearTwoThousandFourteenThroughTwoThousandTwentyOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_CapYearTwoThousandFourteenThroughTwoThousandTwentyOneMember" xlink:to="lab_amed_CapYearTwoThousandFourteenThroughTwoThousandTwentyOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_83819270-859d-4b07-9514-eac0731ceaef_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares withheld to pay taxes on non-cash compensation</link:label>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment, Tax Withholding, Share-based Payment Arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_ProceedsReceivedFromLoanPartyOfSubsidiary_e606b2fc-ff5d-4f97-958b-53c6c7dbe13c_terseLabel_en-US" xlink:label="lab_amed_ProceedsReceivedFromLoanPartyOfSubsidiary" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds Received From Loan Party Of Subsidiary</link:label>
    <link:label id="lab_amed_ProceedsReceivedFromLoanPartyOfSubsidiary_label_en-US" xlink:label="lab_amed_ProceedsReceivedFromLoanPartyOfSubsidiary" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds Received From Loan Party Of Subsidiary</link:label>
    <link:label id="lab_amed_ProceedsReceivedFromLoanPartyOfSubsidiary_documentation_en-US" xlink:label="lab_amed_ProceedsReceivedFromLoanPartyOfSubsidiary" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds Received From Loan Party Of Subsidiary</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ProceedsReceivedFromLoanPartyOfSubsidiary" xlink:href="amed-20210630.xsd#amed_ProceedsReceivedFromLoanPartyOfSubsidiary"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_ProceedsReceivedFromLoanPartyOfSubsidiary" xlink:to="lab_amed_ProceedsReceivedFromLoanPartyOfSubsidiary" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_de8f90b5-bc66-4c02-81d4-aafd8a1beb7b_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover page.</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BaseRateMember_c56606c2-8381-41eb-9863-6b8f4c0953b0_terseLabel_en-US" xlink:label="lab_us-gaap_BaseRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Base Rate [Member]</link:label>
    <link:label id="lab_us-gaap_BaseRateMember_label_en-US" xlink:label="lab_us-gaap_BaseRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Base Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BaseRateMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BaseRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BaseRateMember" xlink:to="lab_us-gaap_BaseRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAcquiredDuringPeriod_195ff440-e904-4ffd-b9a8-f1d65e3dec9b_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAcquiredDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill recorded during period</link:label>
    <link:label id="lab_us-gaap_GoodwillAcquiredDuringPeriod_label_en-US" xlink:label="lab_us-gaap_GoodwillAcquiredDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Acquired During Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAcquiredDuringPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAcquiredDuringPeriod" xlink:to="lab_us-gaap_GoodwillAcquiredDuringPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_AmendedDebtInstrumentByLeverageRatioTrancheFourMember_ad54cf6a-0313-4d7d-84d2-e3109e3377ff_terseLabel_en-US" xlink:label="lab_amed_AmendedDebtInstrumentByLeverageRatioTrancheFourMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Leverage Ratio: Less Than Equal To 0.75 to 1.0</link:label>
    <link:label id="lab_amed_AmendedDebtInstrumentByLeverageRatioTrancheFourMember_label_en-US" xlink:label="lab_amed_AmendedDebtInstrumentByLeverageRatioTrancheFourMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amended Debt Instrument, By Leverage Ratio, Tranche Four [Member]</link:label>
    <link:label id="lab_amed_AmendedDebtInstrumentByLeverageRatioTrancheFourMember_documentation_en-US" xlink:label="lab_amed_AmendedDebtInstrumentByLeverageRatioTrancheFourMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amended Debt Instrument, By Leverage Ratio, Tranche Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AmendedDebtInstrumentByLeverageRatioTrancheFourMember" xlink:href="amed-20210630.xsd#amed_AmendedDebtInstrumentByLeverageRatioTrancheFourMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_AmendedDebtInstrumentByLeverageRatioTrancheFourMember" xlink:to="lab_amed_AmendedDebtInstrumentByLeverageRatioTrancheFourMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_a441ce09-4677-4d05-8900-1130d065d1cd_negatedLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentDividendsOrDistributions_71ae4b12-e35d-46f8-9287-2d73d494b2bf_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentDividendsOrDistributions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Return on equity method investments</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentDividendsOrDistributions_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentDividendsOrDistributions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Equity Method Investment, Distribution</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentDividendsOrDistributions" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentDividendsOrDistributions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentDividendsOrDistributions" xlink:to="lab_us-gaap_EquityMethodInvestmentDividendsOrDistributions" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_AdditionalFundingDistributedToHealthcareProviders_414b6bb5-60ea-4369-81b2-9bef353a3151_terseLabel_en-US" xlink:label="lab_amed_AdditionalFundingDistributedToHealthcareProviders" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Funding Distributed to Healthcare Providers</link:label>
    <link:label id="lab_amed_AdditionalFundingDistributedToHealthcareProviders_label_en-US" xlink:label="lab_amed_AdditionalFundingDistributedToHealthcareProviders" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Funding Distributed to Healthcare Providers</link:label>
    <link:label id="lab_amed_AdditionalFundingDistributedToHealthcareProviders_documentation_en-US" xlink:label="lab_amed_AdditionalFundingDistributedToHealthcareProviders" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional funding distributed to healthcare providers provided by the Coronavirus Aid, Relief and Economic Security (CARES) Act</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AdditionalFundingDistributedToHealthcareProviders" xlink:href="amed-20210630.xsd#amed_AdditionalFundingDistributedToHealthcareProviders"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_AdditionalFundingDistributedToHealthcareProviders" xlink:to="lab_amed_AdditionalFundingDistributedToHealthcareProviders" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_NonMedicareRevenueTermRates_5da20e4a-f833-4109-8a27-99eb906d0e1d_terseLabel_en-US" xlink:label="lab_amed_NonMedicareRevenueTermRates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Medicare revenue term rates</link:label>
    <link:label id="lab_amed_NonMedicareRevenueTermRates_label_en-US" xlink:label="lab_amed_NonMedicareRevenueTermRates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Medicare Revenue Term Rates</link:label>
    <link:label id="lab_amed_NonMedicareRevenueTermRates_documentation_en-US" xlink:label="lab_amed_NonMedicareRevenueTermRates" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Medicare Revenue Term Rates as a percentage of Medicare Term Rates</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_NonMedicareRevenueTermRates" xlink:href="amed-20210630.xsd#amed_NonMedicareRevenueTermRates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_NonMedicareRevenueTermRates" xlink:to="lab_amed_NonMedicareRevenueTermRates" xlink:type="arc" order="1"/>
    <link:label id="lab_stpr_KY_a35dc89b-a67b-4bf5-b683-b696ee81a27c_terseLabel_en-US" xlink:label="lab_stpr_KY" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">KENTUCKY</link:label>
    <link:label id="lab_stpr_KY_label_en-US" xlink:label="lab_stpr_KY" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">KENTUCKY</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_KY" xlink:href="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd#stpr_KY"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_stpr_KY" xlink:to="lab_stpr_KY" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_4d792901-304c-47f9-b7be-e0a08bb2a4ce_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Domain]</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LoansPayableMember_7e31425b-9948-4786-a53b-c43425f6d027_terseLabel_en-US" xlink:label="lab_us-gaap_LoansPayableMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan [Member]</link:label>
    <link:label id="lab_us-gaap_LoansPayableMember_label_en-US" xlink:label="lab_us-gaap_LoansPayableMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loans Payable [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LoansPayableMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LoansPayableMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LoansPayableMember" xlink:to="lab_us-gaap_LoansPayableMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebt_fad3672a-9811-4113-b84b-1f3b02aa88d0_totalLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term obligations, including current portion</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_label_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebt" xlink:to="lab_us-gaap_LongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_PayorsAxis_bf879ef4-f42c-4877-9e8b-71dd82f3770b_terseLabel_en-US" xlink:label="lab_amed_PayorsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payors [Axis]</link:label>
    <link:label id="lab_amed_PayorsAxis_label_en-US" xlink:label="lab_amed_PayorsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payors [Axis]</link:label>
    <link:label id="lab_amed_PayorsAxis_documentation_en-US" xlink:label="lab_amed_PayorsAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payors [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PayorsAxis" xlink:href="amed-20210630.xsd#amed_PayorsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_PayorsAxis" xlink:to="lab_amed_PayorsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_Creditfacilitymaximumallowableconsolidatedleverageratio_39fd81ac-07db-4342-84f8-1b61756dcd7f_terseLabel_en-US" xlink:label="lab_amed_Creditfacilitymaximumallowableconsolidatedleverageratio" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit facility, maximum allowable consolidated leverage ratio</link:label>
    <link:label id="lab_amed_Creditfacilitymaximumallowableconsolidatedleverageratio_label_en-US" xlink:label="lab_amed_Creditfacilitymaximumallowableconsolidatedleverageratio" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit facility maximum allowable consolidated leverage ratio</link:label>
    <link:label id="lab_amed_Creditfacilitymaximumallowableconsolidatedleverageratio_documentation_en-US" xlink:label="lab_amed_Creditfacilitymaximumallowableconsolidatedleverageratio" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit facility maximum allowable consolidated leverage ratio as defined in the Company's Credit Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_Creditfacilitymaximumallowableconsolidatedleverageratio" xlink:href="amed-20210630.xsd#amed_Creditfacilitymaximumallowableconsolidatedleverageratio"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_Creditfacilitymaximumallowableconsolidatedleverageratio" xlink:to="lab_amed_Creditfacilitymaximumallowableconsolidatedleverageratio" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_PromissoryNotesMember_55caac71-58d4-44c8-83c7-6194a34f7426_terseLabel_en-US" xlink:label="lab_amed_PromissoryNotesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Promissory Notes [Member]</link:label>
    <link:label id="lab_amed_PromissoryNotesMember_label_en-US" xlink:label="lab_amed_PromissoryNotesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Promissory Notes [Member]</link:label>
    <link:label id="lab_amed_PromissoryNotesMember_documentation_en-US" xlink:label="lab_amed_PromissoryNotesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Promissory Notes [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PromissoryNotesMember" xlink:href="amed-20210630.xsd#amed_PromissoryNotesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_PromissoryNotesMember" xlink:to="lab_amed_PromissoryNotesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_178b121c-b44d-424e-9b89-eba1e0a236ad_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_c8e3e719-7469-4c74-b0b9-0cb817eea3a3_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of service, excluding depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods and Services Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTable_b6d6d2a3-4906-4c4e-b221-515c51e26b2d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Revenue Sources, Health Care Organization [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Revenue Sources, Health Care Organization [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTable" xlink:to="lab_us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpenses_4bc26617-d946-4d96-a6fb-97c19775084d_totalLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses</link:label>
    <link:label id="lab_us-gaap_CostsAndExpenses_54d2da79-9e34-42b6-a663-9d52e1678ac9_terseLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses</link:label>
    <link:label id="lab_us-gaap_CostsAndExpenses_label_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpenses" xlink:to="lab_us-gaap_CostsAndExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_HealthInsuranceRetentionLimit_71357e9f-6a8c-42e1-8a91-0eccea97cf4f_terseLabel_en-US" xlink:label="lab_amed_HealthInsuranceRetentionLimit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health insurance retention limit</link:label>
    <link:label id="lab_amed_HealthInsuranceRetentionLimit_label_en-US" xlink:label="lab_amed_HealthInsuranceRetentionLimit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health Insurance Retention Limit</link:label>
    <link:label id="lab_amed_HealthInsuranceRetentionLimit_documentation_en-US" xlink:label="lab_amed_HealthInsuranceRetentionLimit" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum potential amount of future payments the entity could be required to make related to a specific Health Insurance Claim.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HealthInsuranceRetentionLimit" xlink:href="amed-20210630.xsd#amed_HealthInsuranceRetentionLimit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_HealthInsuranceRetentionLimit" xlink:to="lab_amed_HealthInsuranceRetentionLimit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_c03069a0-fa32-49f7-b098-fc0ada14a51b_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_18299dff-32e0-456e-a228-69fb07bd400a_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_83aa5335-3053-4a41-8523-1e0cc625f4e3_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_ac8b186c-f622-4ef1-bedd-ed31ee8c76b6_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_ProfessionalLiabilityInsuranceRetentionLimit_11656031-9393-4f01-ad1e-77f36781389a_terseLabel_en-US" xlink:label="lab_amed_ProfessionalLiabilityInsuranceRetentionLimit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Professional liability insurance retention limit</link:label>
    <link:label id="lab_amed_ProfessionalLiabilityInsuranceRetentionLimit_label_en-US" xlink:label="lab_amed_ProfessionalLiabilityInsuranceRetentionLimit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Professional Liability Insurance Retention Limit</link:label>
    <link:label id="lab_amed_ProfessionalLiabilityInsuranceRetentionLimit_documentation_en-US" xlink:label="lab_amed_ProfessionalLiabilityInsuranceRetentionLimit" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum potential amount of future payments the entity could be required to make related to a specific Professional Liability Claim.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ProfessionalLiabilityInsuranceRetentionLimit" xlink:href="amed-20210630.xsd#amed_ProfessionalLiabilityInsuranceRetentionLimit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_ProfessionalLiabilityInsuranceRetentionLimit" xlink:to="lab_amed_ProfessionalLiabilityInsuranceRetentionLimit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_25d8eb6f-02af-441e-b6ea-979790cfbb50_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_70f4fafb-0af1-4e15-be8f-b884e5e50493_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash and Cash Equivalents [Axis]</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash and Cash Equivalents [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_DepreciationAndAmortizationForContinuingOperations_a9845f9c-0851-4817-adbe-cb51f59aa62f_terseLabel_en-US" xlink:label="lab_amed_DepreciationAndAmortizationForContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_amed_DepreciationAndAmortizationForContinuingOperations_label_en-US" xlink:label="lab_amed_DepreciationAndAmortizationForContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation And Amortization For Continuing Operations</link:label>
    <link:label id="lab_amed_DepreciationAndAmortizationForContinuingOperations_documentation_en-US" xlink:label="lab_amed_DepreciationAndAmortizationForContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation And Amortization For Continuing Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_DepreciationAndAmortizationForContinuingOperations" xlink:href="amed-20210630.xsd#amed_DepreciationAndAmortizationForContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_DepreciationAndAmortizationForContinuingOperations" xlink:to="lab_amed_DepreciationAndAmortizationForContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_70cf17af-c2ac-46cf-8312-0801b2cf304a_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion of operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt_df308794-b867-463e-8cc3-9474c6e5980f_negatedLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Long-term Debt</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Long-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_ExtrapolatedMember_5ba21e1a-6a0f-4fde-a369-d2f2b55d4e45_terseLabel_en-US" xlink:label="lab_amed_ExtrapolatedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Extrapolated [Member]</link:label>
    <link:label id="lab_amed_ExtrapolatedMember_label_en-US" xlink:label="lab_amed_ExtrapolatedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Extrapolated [Member]</link:label>
    <link:label id="lab_amed_ExtrapolatedMember_documentation_en-US" xlink:label="lab_amed_ExtrapolatedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Extrapolated [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ExtrapolatedMember" xlink:href="amed-20210630.xsd#amed_ExtrapolatedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_ExtrapolatedMember" xlink:to="lab_amed_ExtrapolatedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_ThirdThresholdOfTherapyServicesRequired_f6a7bab3-ae17-4c8e-bbed-bf9397f04f7c_terseLabel_en-US" xlink:label="lab_amed_ThirdThresholdOfTherapyServicesRequired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Third threshold of therapy services required (visits)</link:label>
    <link:label id="lab_amed_ThirdThresholdOfTherapyServicesRequired_label_en-US" xlink:label="lab_amed_ThirdThresholdOfTherapyServicesRequired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Third Threshold Of Therapy Services Required</link:label>
    <link:label id="lab_amed_ThirdThresholdOfTherapyServicesRequired_documentation_en-US" xlink:label="lab_amed_ThirdThresholdOfTherapyServicesRequired" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description containing the number of visits related to the third threshold of therapy services required.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ThirdThresholdOfTherapyServicesRequired" xlink:href="amed-20210630.xsd#amed_ThirdThresholdOfTherapyServicesRequired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_ThirdThresholdOfTherapyServicesRequired" xlink:to="lab_amed_ThirdThresholdOfTherapyServicesRequired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_26cad8b5-1cbd-402a-9356-45cd5e7c9ff7_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right of use assets obtained in exchange for finance lease liabilities</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Finance Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_IndemnificationAmount_58245377-24ca-48dd-b7bb-49ab078ba4d4_terseLabel_en-US" xlink:label="lab_amed_IndemnificationAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indemnification amount</link:label>
    <link:label id="lab_amed_IndemnificationAmount_label_en-US" xlink:label="lab_amed_IndemnificationAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indemnification Amount</link:label>
    <link:label id="lab_amed_IndemnificationAmount_documentation_en-US" xlink:label="lab_amed_IndemnificationAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The amount to be reimbursed if and when certain assumed liabilities are paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_IndemnificationAmount" xlink:href="amed-20210630.xsd#amed_IndemnificationAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_IndemnificationAmount" xlink:to="lab_amed_IndemnificationAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_78ffe5ca-31d3-4714-adc5-0f1580913fe3_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income attributable to noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_HomeHealthMedicareMember_806b6b9f-9a9f-423f-ab75-9daf79509279_terseLabel_en-US" xlink:label="lab_amed_HomeHealthMedicareMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Home Health Medicare [Member]</link:label>
    <link:label id="lab_amed_HomeHealthMedicareMember_label_en-US" xlink:label="lab_amed_HomeHealthMedicareMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Home Health Medicare [Member]</link:label>
    <link:label id="lab_amed_HomeHealthMedicareMember_documentation_en-US" xlink:label="lab_amed_HomeHealthMedicareMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Home Health Medicare [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HomeHealthMedicareMember" xlink:href="amed-20210630.xsd#amed_HomeHealthMedicareMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_HomeHealthMedicareMember" xlink:to="lab_amed_HomeHealthMedicareMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_2f75c1fc-8677-46d3-b53c-60f4b4631f03_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_2cdd4f28-9bcf-4cb5-b484-603c8e554c2c_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flows from Operating Activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableMember_afce5b39-cfbb-49ba-bfec-7b519ac1b363_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableMember_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableMember" xlink:to="lab_us-gaap_AccountsReceivableMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_e38e6a21-ba99-4cbb-bdeb-a059fc9989b9_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitment fee percentage</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Commitment Fee Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityCommitmentFeePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:to="lab_us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_15fc6687-208d-4923-8587-50f152cefde2_terseLabel_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_label_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_NameOfMajorCustomerDomain" xlink:to="lab_srt_NameOfMajorCustomerDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_DebtInstrumentInterestAdditionalInterestAboveFederalFundRate_eec73225-79c6-4e9a-87ed-8246e3b09835_terseLabel_en-US" xlink:label="lab_amed_DebtInstrumentInterestAdditionalInterestAboveFederalFundRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional interest rate above Federal Fund rate</link:label>
    <link:label id="lab_amed_DebtInstrumentInterestAdditionalInterestAboveFederalFundRate_label_en-US" xlink:label="lab_amed_DebtInstrumentInterestAdditionalInterestAboveFederalFundRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument Interest Additional Interest Above Federal Fund Rate</link:label>
    <link:label id="lab_amed_DebtInstrumentInterestAdditionalInterestAboveFederalFundRate_documentation_en-US" xlink:label="lab_amed_DebtInstrumentInterestAdditionalInterestAboveFederalFundRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument Interest Additional Interest Above Federal Fund Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_DebtInstrumentInterestAdditionalInterestAboveFederalFundRate" xlink:href="amed-20210630.xsd#amed_DebtInstrumentInterestAdditionalInterestAboveFederalFundRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_DebtInstrumentInterestAdditionalInterestAboveFederalFundRate" xlink:to="lab_amed_DebtInstrumentInterestAdditionalInterestAboveFederalFundRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnusualOrInfrequentItemAxis_04278ef9-13bd-4d70-9dc1-01b0ea79fccc_terseLabel_en-US" xlink:label="lab_us-gaap_UnusualOrInfrequentItemAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unusual or Infrequent Item, or Both [Axis]</link:label>
    <link:label id="lab_us-gaap_UnusualOrInfrequentItemAxis_label_en-US" xlink:label="lab_us-gaap_UnusualOrInfrequentItemAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unusual or Infrequent Item, or Both [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnusualOrInfrequentItemAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnusualOrInfrequentItemAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnusualOrInfrequentItemAxis" xlink:to="lab_us-gaap_UnusualOrInfrequentItemAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_ad0fb5ec-5e5e-4ec4-9406-01431d5870c9_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital, Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_187a4036-a40e-4e7f-812d-1fe8dcefd88c_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_16f28054-93b5-49e6-9af8-8e52ce8d4607_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_PayorClassAxis_d1a47159-4ba2-4c83-9065-1201ffee8786_terseLabel_en-US" xlink:label="lab_amed_PayorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payor Class [Axis]</link:label>
    <link:label id="lab_amed_PayorClassAxis_label_en-US" xlink:label="lab_amed_PayorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payor Class [Axis]</link:label>
    <link:label id="lab_amed_PayorClassAxis_documentation_en-US" xlink:label="lab_amed_PayorClassAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payor Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PayorClassAxis" xlink:href="amed-20210630.xsd#amed_PayorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_PayorClassAxis" xlink:to="lab_amed_PayorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_MaximumPercentOwnershipForEquityMethodPercent_90c9ad9e-0272-4f74-a94e-85fd224ad000_terseLabel_en-US" xlink:label="lab_amed_MaximumPercentOwnershipForEquityMethodPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum ownership percentage for equity method investment (percent)</link:label>
    <link:label id="lab_amed_MaximumPercentOwnershipForEquityMethodPercent_label_en-US" xlink:label="lab_amed_MaximumPercentOwnershipForEquityMethodPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum Percent Ownership For Equity Method Percent</link:label>
    <link:label id="lab_amed_MaximumPercentOwnershipForEquityMethodPercent_documentation_en-US" xlink:label="lab_amed_MaximumPercentOwnershipForEquityMethodPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description containing the percentage ownership required in order for an investment to be treated under the equity method of accounting in the entity's financial statements.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_MaximumPercentOwnershipForEquityMethodPercent" xlink:href="amed-20210630.xsd#amed_MaximumPercentOwnershipForEquityMethodPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_MaximumPercentOwnershipForEquityMethodPercent" xlink:to="lab_amed_MaximumPercentOwnershipForEquityMethodPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_6271d735-0fc2-4f7a-a537-5169db199995_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems" xlink:to="lab_us-gaap_BusinessAcquisitionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_a3609d9d-ea43-4865-b6b7-53d867f690c4_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskLineItems_5aa2d2bc-a23e-4dc3-b151-0de133a1d1da_verboseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskLineItems" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Line Items]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskLineItems_79f682f9-20ea-4b81-ad6c-4c453e2d3cbe_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk [Line Items]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskLineItems_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskLineItems" xlink:to="lab_us-gaap_ConcentrationRiskLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_HospiceNonMedicareMember_738b1171-370f-4720-bb52-97d7a8345d9d_terseLabel_en-US" xlink:label="lab_amed_HospiceNonMedicareMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hospice Non-Medicare [Member]</link:label>
    <link:label id="lab_amed_HospiceNonMedicareMember_label_en-US" xlink:label="lab_amed_HospiceNonMedicareMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hospice Non-Medicare [Member]</link:label>
    <link:label id="lab_amed_HospiceNonMedicareMember_documentation_en-US" xlink:label="lab_amed_HospiceNonMedicareMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hospice Non-Medicare [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HospiceNonMedicareMember" xlink:href="amed-20210630.xsd#amed_HospiceNonMedicareMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_HospiceNonMedicareMember" xlink:to="lab_amed_HospiceNonMedicareMember" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_MedicareLicenseMember_76226d80-b053-4634-9274-c3e49d918e7d_terseLabel_en-US" xlink:label="lab_amed_MedicareLicenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicare licenses [Member]</link:label>
    <link:label id="lab_amed_MedicareLicenseMember_label_en-US" xlink:label="lab_amed_MedicareLicenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicare license [Member]</link:label>
    <link:label id="lab_amed_MedicareLicenseMember_documentation_en-US" xlink:label="lab_amed_MedicareLicenseMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicare license</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_MedicareLicenseMember" xlink:href="amed-20210630.xsd#amed_MedicareLicenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_MedicareLicenseMember" xlink:to="lab_amed_MedicareLicenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_cbdda71b-9506-4f08-b88d-671d14349744_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sale of property and equipment</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale of Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:to="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFinanceCostsNet_fa0f7405-c8f3-4eeb-b15c-a5980d9af5e2_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsNet" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred debt issuance costs</link:label>
    <link:label id="lab_us-gaap_DeferredFinanceCostsNet_label_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Issuance Costs, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFinanceCostsNet" xlink:to="lab_us-gaap_DeferredFinanceCostsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_08937170-5551-4895-a99f-3ec54cbf50d7_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of reportable business segments</link:label>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Reportable Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfReportableSegments" xlink:to="lab_us-gaap_NumberOfReportableSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_AsanaHospiceMember_dd4d4af6-f39c-4ca8-ae42-acf97dc07f6d_terseLabel_en-US" xlink:label="lab_amed_AsanaHospiceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asana Hospice [Member]</link:label>
    <link:label id="lab_amed_AsanaHospiceMember_label_en-US" xlink:label="lab_amed_AsanaHospiceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asana Hospice [Member]</link:label>
    <link:label id="lab_amed_AsanaHospiceMember_documentation_en-US" xlink:label="lab_amed_AsanaHospiceMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asana Hospice</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AsanaHospiceMember" xlink:href="amed-20210630.xsd#amed_AsanaHospiceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_AsanaHospiceMember" xlink:to="lab_amed_AsanaHospiceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_BusinessAcquisitionClosingPaymentAdjustment_93f9a905-9d4e-4014-9f2d-80df44f90641_terseLabel_en-US" xlink:label="lab_amed_BusinessAcquisitionClosingPaymentAdjustment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition Closing Payment Adjustment</link:label>
    <link:label id="lab_amed_BusinessAcquisitionClosingPaymentAdjustment_label_en-US" xlink:label="lab_amed_BusinessAcquisitionClosingPaymentAdjustment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition Closing Payment Adjustment</link:label>
    <link:label id="lab_amed_BusinessAcquisitionClosingPaymentAdjustment_documentation_en-US" xlink:label="lab_amed_BusinessAcquisitionClosingPaymentAdjustment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition Closing Payment Adjustment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_BusinessAcquisitionClosingPaymentAdjustment" xlink:href="amed-20210630.xsd#amed_BusinessAcquisitionClosingPaymentAdjustment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_BusinessAcquisitionClosingPaymentAdjustment" xlink:to="lab_amed_BusinessAcquisitionClosingPaymentAdjustment" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_PercentageOfTotalReimbursementOfOutlierPayment_afd8ca63-ce20-45b3-92df-21b4a3ec735a_terseLabel_en-US" xlink:label="lab_amed_PercentageOfTotalReimbursementOfOutlierPayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of total reimbursement of outlier payment</link:label>
    <link:label id="lab_amed_PercentageOfTotalReimbursementOfOutlierPayment_label_en-US" xlink:label="lab_amed_PercentageOfTotalReimbursementOfOutlierPayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Of Total Reimbursement Of Outlier Payment</link:label>
    <link:label id="lab_amed_PercentageOfTotalReimbursementOfOutlierPayment_documentation_en-US" xlink:label="lab_amed_PercentageOfTotalReimbursementOfOutlierPayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage at which total reimbursement is capped if cost of care is unusually costly.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PercentageOfTotalReimbursementOfOutlierPayment" xlink:href="amed-20210630.xsd#amed_PercentageOfTotalReimbursementOfOutlierPayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_PercentageOfTotalReimbursementOfOutlierPayment" xlink:to="lab_amed_PercentageOfTotalReimbursementOfOutlierPayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainOnSaleOfInvestments_947d6dd9-6ba5-4773-bf8c-2bac0a11f5c7_terseLabel_en-US" xlink:label="lab_us-gaap_GainOnSaleOfInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain on Sale of Investments</link:label>
    <link:label id="lab_us-gaap_GainOnSaleOfInvestments_label_en-US" xlink:label="lab_us-gaap_GainOnSaleOfInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain on Sale of Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainOnSaleOfInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainOnSaleOfInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainOnSaleOfInvestments" xlink:to="lab_us-gaap_GainOnSaleOfInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_18fcbe23-f2ad-4d62-b83d-304b5b660297_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of dilutive securities:</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incremental Weighted Average Shares Attributable to Dilutive Effect [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherCurrentAsset_d9e6db63-36a1-4990-845f-2345f93af92b_terseLabel_en-US" xlink:label="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherCurrentAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Other Current Asset</link:label>
    <link:label id="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherCurrentAsset_label_en-US" xlink:label="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherCurrentAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Other Current Asset</link:label>
    <link:label id="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherCurrentAsset_documentation_en-US" xlink:label="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherCurrentAsset" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of asset related to consideration amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, acquired at the acquisition date.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherCurrentAsset" xlink:href="amed-20210630.xsd#amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherCurrentAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherCurrentAsset" xlink:to="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherCurrentAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_ab831b86-ef6f-4c79-b824-9de45b649ac4_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_e65de84d-b2ff-43be-8a14-ee619869891a_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patient accounts receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockTextBlock_1a012ffc-869d-450e-bc84-ae1256c7bc66_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SHARE REPURCHASE</link:label>
    <link:label id="lab_us-gaap_TreasuryStockTextBlock_label_en-US" xlink:label="lab_us-gaap_TreasuryStockTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockTextBlock" xlink:to="lab_us-gaap_TreasuryStockTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationAndAmortization_80ab5a8a-f1d1-4697-ad65-d3fb6b50c5b0_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization, Nonproduction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationAndAmortization" xlink:to="lab_us-gaap_DepreciationAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_FundingForHealthcareProvidersIncludingHospitals_cc90a0e0-03ba-4d2c-9807-9e53d15aa456_terseLabel_en-US" xlink:label="lab_amed_FundingForHealthcareProvidersIncludingHospitals" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Funding for Healthcare Providers, Including Hospitals</link:label>
    <link:label id="lab_amed_FundingForHealthcareProvidersIncludingHospitals_label_en-US" xlink:label="lab_amed_FundingForHealthcareProvidersIncludingHospitals" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Funding for Healthcare Providers, Including Hospitals</link:label>
    <link:label id="lab_amed_FundingForHealthcareProvidersIncludingHospitals_documentation_en-US" xlink:label="lab_amed_FundingForHealthcareProvidersIncludingHospitals" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Funding for healthcare providers, including hospitals provided by the Coronavirus Aid, Relief and Economic Security (CARES) Act</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_FundingForHealthcareProvidersIncludingHospitals" xlink:href="amed-20210630.xsd#amed_FundingForHealthcareProvidersIncludingHospitals"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_FundingForHealthcareProvidersIncludingHospitals" xlink:to="lab_amed_FundingForHealthcareProvidersIncludingHospitals" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_PercentageOfRevenueAndOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromWhollyOwnedSubsidiaries_f3b70e3a-413c-4262-a614-60603f15c8ab_terseLabel_en-US" xlink:label="lab_amed_PercentageOfRevenueAndOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromWhollyOwnedSubsidiaries" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of consolidated revenue and adjusted EBITDA that guarantor wholly-owned subsidiaries represent</link:label>
    <link:label id="lab_amed_PercentageOfRevenueAndOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromWhollyOwnedSubsidiaries_label_en-US" xlink:label="lab_amed_PercentageOfRevenueAndOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromWhollyOwnedSubsidiaries" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Of Revenue And Of Earnings Before Interest Taxes Depreciation And Amortization From Wholly Owned Subsidiaries</link:label>
    <link:label id="lab_amed_PercentageOfRevenueAndOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromWhollyOwnedSubsidiaries_documentation_en-US" xlink:label="lab_amed_PercentageOfRevenueAndOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromWhollyOwnedSubsidiaries" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of consolidated net revenues and adjusted EBITDA that guarantor wholly-owned subsidiaries represent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PercentageOfRevenueAndOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromWhollyOwnedSubsidiaries" xlink:href="amed-20210630.xsd#amed_PercentageOfRevenueAndOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromWhollyOwnedSubsidiaries"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_PercentageOfRevenueAndOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromWhollyOwnedSubsidiaries" xlink:to="lab_amed_PercentageOfRevenueAndOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromWhollyOwnedSubsidiaries" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_de6984c7-5919-47df-8201-6c760e0e2ff6_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments for New Accounting Pronouncements [Axis]</link:label>
    <link:label id="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_label_en-US" xlink:label="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_CashPaidForFinanceLeaseLiabilities_cca4c7bc-48ac-4ba2-916c-9a8e69086b7c_terseLabel_en-US" xlink:label="lab_amed_CashPaidForFinanceLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for finance lease liabilities</link:label>
    <link:label id="lab_amed_CashPaidForFinanceLeaseLiabilities_label_en-US" xlink:label="lab_amed_CashPaidForFinanceLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for finance lease liabilities</link:label>
    <link:label id="lab_amed_CashPaidForFinanceLeaseLiabilities_documentation_en-US" xlink:label="lab_amed_CashPaidForFinanceLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The amount of cash paid for finance lease liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CashPaidForFinanceLeaseLiabilities" xlink:href="amed-20210630.xsd#amed_CashPaidForFinanceLeaseLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_CashPaidForFinanceLeaseLiabilities" xlink:to="lab_amed_CashPaidForFinanceLeaseLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchaseProgramExpirationDate_6c6d8ae5-402b-4c3a-bf31-89f4efed513a_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramExpirationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchase Program Expiration Date</link:label>
    <link:label id="lab_us-gaap_StockRepurchaseProgramExpirationDate_label_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramExpirationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchase Program Expiration Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramExpirationDate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchaseProgramExpirationDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchaseProgramExpirationDate" xlink:to="lab_us-gaap_StockRepurchaseProgramExpirationDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingStandardsUpdate201602Member_cbc840ef-cde1-4fbb-ad26-1a7b21319e33_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdate201602Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update 2016-02 [Member]</link:label>
    <link:label id="lab_us-gaap_AccountingStandardsUpdate201602Member_label_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdate201602Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update 2016-02 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate201602Member" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingStandardsUpdate201602Member" xlink:to="lab_us-gaap_AccountingStandardsUpdate201602Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_46679647-cca2-4d08-bba2-4a6047e887dc_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_ErrorRatePercentage_e6baf230-7313-49e6-9762-ae0a8c254882_terseLabel_en-US" xlink:label="lab_amed_ErrorRatePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Error rate (percent)</link:label>
    <link:label id="lab_amed_ErrorRatePercentage_label_en-US" xlink:label="lab_amed_ErrorRatePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Error Rate Percentage</link:label>
    <link:label id="lab_amed_ErrorRatePercentage_documentation_en-US" xlink:label="lab_amed_ErrorRatePercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Error Rate Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ErrorRatePercentage" xlink:href="amed-20210630.xsd#amed_ErrorRatePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_ErrorRatePercentage" xlink:to="lab_amed_ErrorRatePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_MaximumDaysToSubmitFinalBillFromDateRequestForAnticipatedPaymentWasPaid_6438fbff-808c-4e6f-8dfb-0c277fa2dc17_terseLabel_en-US" xlink:label="lab_amed_MaximumDaysToSubmitFinalBillFromDateRequestForAnticipatedPaymentWasPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum days to submit final bill from the date the request for anticipated payment was paid</link:label>
    <link:label id="lab_amed_MaximumDaysToSubmitFinalBillFromDateRequestForAnticipatedPaymentWasPaid_label_en-US" xlink:label="lab_amed_MaximumDaysToSubmitFinalBillFromDateRequestForAnticipatedPaymentWasPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum Days To Submit Final Bill From Date Request For Anticipated Payment Was Paid</link:label>
    <link:label id="lab_amed_MaximumDaysToSubmitFinalBillFromDateRequestForAnticipatedPaymentWasPaid_documentation_en-US" xlink:label="lab_amed_MaximumDaysToSubmitFinalBillFromDateRequestForAnticipatedPaymentWasPaid" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description containing the number of days from the date the request for anticipated payment was received in which the final bill must be submitted to Medicare.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_MaximumDaysToSubmitFinalBillFromDateRequestForAnticipatedPaymentWasPaid" xlink:href="amed-20210630.xsd#amed_MaximumDaysToSubmitFinalBillFromDateRequestForAnticipatedPaymentWasPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_MaximumDaysToSubmitFinalBillFromDateRequestForAnticipatedPaymentWasPaid" xlink:to="lab_amed_MaximumDaysToSubmitFinalBillFromDateRequestForAnticipatedPaymentWasPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_NetServiceRevenueEpisodePaymentRateDuration_f607a38e-93dd-49e4-bc66-abb896494eec_terseLabel_en-US" xlink:label="lab_amed_NetServiceRevenueEpisodePaymentRateDuration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net service revenue episode payment rate</link:label>
    <link:label id="lab_amed_NetServiceRevenueEpisodePaymentRateDuration_label_en-US" xlink:label="lab_amed_NetServiceRevenueEpisodePaymentRateDuration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Service Revenue, Episode Payment Rate Duration</link:label>
    <link:label id="lab_amed_NetServiceRevenueEpisodePaymentRateDuration_documentation_en-US" xlink:label="lab_amed_NetServiceRevenueEpisodePaymentRateDuration" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description containing the number of days from the date the request for anticipated payment was received in which the final bill must be submitted to Medicare.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_NetServiceRevenueEpisodePaymentRateDuration" xlink:href="amed-20210630.xsd#amed_NetServiceRevenueEpisodePaymentRateDuration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_NetServiceRevenueEpisodePaymentRateDuration" xlink:to="lab_amed_NetServiceRevenueEpisodePaymentRateDuration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic_59c54ca9-d470-4577-a359-4a9d5cf480fc_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic earnings per share</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Pro Forma Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic" xlink:to="lab_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Goodwill_6e30a71d-b969-47c5-8a08-3db4fabdda36_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_label_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_SecuritiesClassActionLawsuitMember_c3837d68-9d42-48b6-b338-f241f7af9062_terseLabel_en-US" xlink:label="lab_amed_SecuritiesClassActionLawsuitMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Securities Class Action Lawsuit [Member]</link:label>
    <link:label id="lab_amed_SecuritiesClassActionLawsuitMember_label_en-US" xlink:label="lab_amed_SecuritiesClassActionLawsuitMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Securities Class Action Lawsuit [Member]</link:label>
    <link:label id="lab_amed_SecuritiesClassActionLawsuitMember_documentation_en-US" xlink:label="lab_amed_SecuritiesClassActionLawsuitMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Securities Class Action Lawsuit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_SecuritiesClassActionLawsuitMember" xlink:href="amed-20210630.xsd#amed_SecuritiesClassActionLawsuitMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_SecuritiesClassActionLawsuitMember" xlink:to="lab_amed_SecuritiesClassActionLawsuitMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_dd8b44c6-a844-426b-95fe-83e910d81d61_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_Recoveryamountofoverpaymentmadetosubsidiaryincludinginterestwithheld_ef1a7490-686d-4c55-83d4-9721646f565c_terseLabel_en-US" xlink:label="lab_amed_Recoveryamountofoverpaymentmadetosubsidiaryincludinginterestwithheld" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recovery amount of over payment made to subsidiary including interest withheld</link:label>
    <link:label id="lab_amed_Recoveryamountofoverpaymentmadetosubsidiaryincludinginterestwithheld_label_en-US" xlink:label="lab_amed_Recoveryamountofoverpaymentmadetosubsidiaryincludinginterestwithheld" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recovery Amount Of Over Payment Made To Subsidiary Including Interest Withheld</link:label>
    <link:label id="lab_amed_Recoveryamountofoverpaymentmadetosubsidiaryincludinginterestwithheld_documentation_en-US" xlink:label="lab_amed_Recoveryamountofoverpaymentmadetosubsidiaryincludinginterestwithheld" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recovery amount of over payment made to subsidiary including interest withheld</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_Recoveryamountofoverpaymentmadetosubsidiaryincludinginterestwithheld" xlink:href="amed-20210630.xsd#amed_Recoveryamountofoverpaymentmadetosubsidiaryincludinginterestwithheld"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_Recoveryamountofoverpaymentmadetosubsidiaryincludinginterestwithheld" xlink:to="lab_amed_Recoveryamountofoverpaymentmadetosubsidiaryincludinginterestwithheld" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther_cb0d06a3-f8ec-435c-9826-6875180bb9ea_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Other</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_0c240a30-102a-43e3-9955-ec3e51d0bba0_terseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income (expense):</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_PriorCreditAgreementMember_f1de1668-7405-4ef1-bd01-1ea53f72b32a_terseLabel_en-US" xlink:label="lab_amed_PriorCreditAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prior Credit Agreement [Member]</link:label>
    <link:label id="lab_amed_PriorCreditAgreementMember_label_en-US" xlink:label="lab_amed_PriorCreditAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prior Credit Agreement [Member]</link:label>
    <link:label id="lab_amed_PriorCreditAgreementMember_documentation_en-US" xlink:label="lab_amed_PriorCreditAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prior Credit Agreement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PriorCreditAgreementMember" xlink:href="amed-20210630.xsd#amed_PriorCreditAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_PriorCreditAgreementMember" xlink:to="lab_amed_PriorCreditAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_8e5ed1d3-ddb4-4b10-8a00-32b5f07be872_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, face amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_7232eb12-6857-41a5-90fe-9c4e9b37a5e8_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_ebd73437-344d-4483-b845-3f65ab2a9b6c_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsCurrent" xlink:to="lab_us-gaap_OtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_3c31a99d-ec24-4401-a2bf-c675c1e73c40_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_ec3cb010-247b-4080-bf43-0e0451053253_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_93624eda-c69f-4d01-b482-d8d4adfb2f23_terseLabel_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_COVID19ExpensesIncurred_418575d8-3861-4daf-9a9d-4751bae4905d_terseLabel_en-US" xlink:label="lab_amed_COVID19ExpensesIncurred" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COVID-19 Expenses Incurred</link:label>
    <link:label id="lab_amed_COVID19ExpensesIncurred_label_en-US" xlink:label="lab_amed_COVID19ExpensesIncurred" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COVID-19 Expenses Incurred</link:label>
    <link:label id="lab_amed_COVID19ExpensesIncurred_documentation_en-US" xlink:label="lab_amed_COVID19ExpensesIncurred" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expenses incurred as a result of the Novel Coronavirus Pandemic "COVID-19"</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_COVID19ExpensesIncurred" xlink:href="amed-20210630.xsd#amed_COVID19ExpensesIncurred"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_COVID19ExpensesIncurred" xlink:to="lab_amed_COVID19ExpensesIncurred" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_FourHundredFiftyMillionTermLoanFacilityMember_d9f611e3-b49c-44ce-95d6-4e46285919fe_terseLabel_en-US" xlink:label="lab_amed_FourHundredFiftyMillionTermLoanFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Four Hundred Fifty Million Term Loan Facility</link:label>
    <link:label id="lab_amed_FourHundredFiftyMillionTermLoanFacilityMember_label_en-US" xlink:label="lab_amed_FourHundredFiftyMillionTermLoanFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Four Hundred Fifty Million Term Loan Facility [Member]</link:label>
    <link:label id="lab_amed_FourHundredFiftyMillionTermLoanFacilityMember_documentation_en-US" xlink:label="lab_amed_FourHundredFiftyMillionTermLoanFacilityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Four Hundred Fifty Million Term Loan Facility</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_FourHundredFiftyMillionTermLoanFacilityMember" xlink:href="amed-20210630.xsd#amed_FourHundredFiftyMillionTermLoanFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_FourHundredFiftyMillionTermLoanFacilityMember" xlink:to="lab_amed_FourHundredFiftyMillionTermLoanFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_a1e3eea7-a621-4bd6-97f4-72bfc7dccc69_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_label_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventLineItems" xlink:to="lab_us-gaap_SubsequentEventLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_A2019ShareRepurchaseProgramMember_c088cac2-7879-4c7d-a6c2-55dadaea972c_terseLabel_en-US" xlink:label="lab_amed_A2019ShareRepurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2019 Share Repurchase Program</link:label>
    <link:label id="lab_amed_A2019ShareRepurchaseProgramMember_label_en-US" xlink:label="lab_amed_A2019ShareRepurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2019 Share Repurchase Program [Member]</link:label>
    <link:label id="lab_amed_A2019ShareRepurchaseProgramMember_documentation_en-US" xlink:label="lab_amed_A2019ShareRepurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2019 Share Repurchase Program</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_A2019ShareRepurchaseProgramMember" xlink:href="amed-20210630.xsd#amed_A2019ShareRepurchaseProgramMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_A2019ShareRepurchaseProgramMember" xlink:to="lab_amed_A2019ShareRepurchaseProgramMember" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_SafeguardZoneProgramIntegrityContractorMember_50d7939d-ec68-4eb9-829b-7ce55ee5f91d_terseLabel_en-US" xlink:label="lab_amed_SafeguardZoneProgramIntegrityContractorMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Safeguard Zone Program Integrity Contractor</link:label>
    <link:label id="lab_amed_SafeguardZoneProgramIntegrityContractorMember_label_en-US" xlink:label="lab_amed_SafeguardZoneProgramIntegrityContractorMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Safeguard Zone Program Integrity Contractor [Member]</link:label>
    <link:label id="lab_amed_SafeguardZoneProgramIntegrityContractorMember_documentation_en-US" xlink:label="lab_amed_SafeguardZoneProgramIntegrityContractorMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Safeguard Zone Program Integrity Contractor [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_SafeguardZoneProgramIntegrityContractorMember" xlink:href="amed-20210630.xsd#amed_SafeguardZoneProgramIntegrityContractorMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_SafeguardZoneProgramIntegrityContractorMember" xlink:to="lab_amed_SafeguardZoneProgramIntegrityContractorMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_3f3dce2a-d173-44f5-b0fb-1daf951cf2c9_terseLabel_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Concentration Risk</link:label>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_label_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Concentration Risk [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerConcentrationRiskMember" xlink:to="lab_us-gaap_CustomerConcentrationRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfShortTermDebt_d933160f-cc40-490c-9922-92f8aacb507e_negatedLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfShortTermDebt" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of borrowings under revolving line of credit</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfShortTermDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfShortTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Short-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfShortTermDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfShortTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfShortTermDebt" xlink:to="lab_us-gaap_RepaymentsOfShortTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityDomain_a1a5b824-8806-4ef2-8a97-36958e466f79_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityDomain_label_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityDomain" xlink:to="lab_us-gaap_CreditFacilityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_stpr_FL_12d77598-ad6b-44db-8838-c5fd45d17956_terseLabel_en-US" xlink:label="lab_stpr_FL" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Florida</link:label>
    <link:label id="lab_stpr_FL_label_en-US" xlink:label="lab_stpr_FL" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">FLORIDA</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_FL" xlink:href="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd#stpr_FL"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_stpr_FL" xlink:to="lab_stpr_FL" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_5ca78071-5583-41b7-b5b1-559071d2f5cf_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average shares outstanding, diluted (shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_a08052fa-07d9-41e0-a443-b748da42ecb8_totalLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average number of shares outstanding - diluted (shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_LitigationCaseTypeDomain_5930b81d-b5a6-41d0-a25a-357eca0f9c41_terseLabel_en-US" xlink:label="lab_srt_LitigationCaseTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Domain]</link:label>
    <link:label id="lab_srt_LitigationCaseTypeDomain_label_en-US" xlink:label="lab_srt_LitigationCaseTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LitigationCaseTypeDomain" xlink:to="lab_srt_LitigationCaseTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LetterOfCreditMember_a83905c5-6e7a-42df-a2af-e8fde80e3aa1_terseLabel_en-US" xlink:label="lab_us-gaap_LetterOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Letter of Credit [Member]</link:label>
    <link:label id="lab_us-gaap_LetterOfCreditMember_label_en-US" xlink:label="lab_us-gaap_LetterOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Letter of Credit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LetterOfCreditMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LetterOfCreditMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LetterOfCreditMember" xlink:to="lab_us-gaap_LetterOfCreditMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_a0d24b1a-a8d1-4934-af0f-0b2616ed59e4_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income attributable to Amedisys, Inc. common stockholders, basic (usd per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_CompassionateCareHospiceMember_dea166df-0a7d-48a5-99e2-5c75e74665f5_terseLabel_en-US" xlink:label="lab_amed_CompassionateCareHospiceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compassionate Care Hospice [Member]</link:label>
    <link:label id="lab_amed_CompassionateCareHospiceMember_label_en-US" xlink:label="lab_amed_CompassionateCareHospiceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compassionate Care Hospice [Member]</link:label>
    <link:label id="lab_amed_CompassionateCareHospiceMember_documentation_en-US" xlink:label="lab_amed_CompassionateCareHospiceMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compassionate Care Hospice [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CompassionateCareHospiceMember" xlink:href="amed-20210630.xsd#amed_CompassionateCareHospiceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_CompassionateCareHospiceMember" xlink:to="lab_amed_CompassionateCareHospiceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_1db7a326-533b-44b9-982f-a927a6d324f3_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_bbff31b4-ad2c-449f-8f91-f969d68cbd3d_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_AsanaHospiceAquisitionMember_c340eb0a-e901-43e7-ac3c-6efa4f204837_terseLabel_en-US" xlink:label="lab_amed_AsanaHospiceAquisitionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asana Hospice Aquisition [Member]</link:label>
    <link:label id="lab_amed_AsanaHospiceAquisitionMember_label_en-US" xlink:label="lab_amed_AsanaHospiceAquisitionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asana Hospice Aquisition [Member]</link:label>
    <link:label id="lab_amed_AsanaHospiceAquisitionMember_documentation_en-US" xlink:label="lab_amed_AsanaHospiceAquisitionMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asana Hospice Aquisition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AsanaHospiceAquisitionMember" xlink:href="amed-20210630.xsd#amed_AsanaHospiceAquisitionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_AsanaHospiceAquisitionMember" xlink:to="lab_amed_AsanaHospiceAquisitionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_CashBalanceAssociatedWithProviderReliefFund_079d5738-2bf5-4750-b1e6-e17e08fdf8e1_terseLabel_en-US" xlink:label="lab_amed_CashBalanceAssociatedWithProviderReliefFund" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Balance Associated with Provider Relief Fund</link:label>
    <link:label id="lab_amed_CashBalanceAssociatedWithProviderReliefFund_label_en-US" xlink:label="lab_amed_CashBalanceAssociatedWithProviderReliefFund" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Balance Associated with Provider Relief Fund</link:label>
    <link:label id="lab_amed_CashBalanceAssociatedWithProviderReliefFund_documentation_en-US" xlink:label="lab_amed_CashBalanceAssociatedWithProviderReliefFund" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Balance Associated with the CARES Act Provider Relief Fund</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CashBalanceAssociatedWithProviderReliefFund" xlink:href="amed-20210630.xsd#amed_CashBalanceAssociatedWithProviderReliefFund"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_CashBalanceAssociatedWithProviderReliefFund" xlink:to="lab_amed_CashBalanceAssociatedWithProviderReliefFund" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts_7c40be38-19d2-46a9-b28e-cdeb3628ec43_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of deferred debt issuance costs/debt discount</link:label>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts_label_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Debt Issuance Costs and Discounts</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:to="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValueOutstanding_18840573-d2b5-454a-9d83-098993a0eafa_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValueOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, $0.001 par value, 60,000,000 shares authorized; 37,553,355 and 37,470,212 shares issued; and 32,576,829 and 32,814,278 shares outstanding</link:label>
    <link:label id="lab_us-gaap_CommonStockValueOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockValueOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValueOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValueOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValueOutstanding" xlink:to="lab_us-gaap_CommonStockValueOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_ba4f3051-f7a3-4845-892c-873fe93e4f94_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash (used in) provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_e43bb954-6be1-426f-acf2-e70ead6f7cce_negatedLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principal payments of long-term obligations</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Long-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfLongTermDebt" xlink:to="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_COVID19TextBlock_90e944fe-66b2-4677-9b02-99b79d966781_terseLabel_en-US" xlink:label="lab_amed_COVID19TextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COVID-19</link:label>
    <link:label id="lab_amed_COVID19TextBlock_label_en-US" xlink:label="lab_amed_COVID19TextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COVID-19 [Text Block]</link:label>
    <link:label id="lab_amed_COVID19TextBlock_documentation_en-US" xlink:label="lab_amed_COVID19TextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The entire disclosure for Novel Coronavirus Pandemic "COVID-19"</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_COVID19TextBlock" xlink:href="amed-20210630.xsd#amed_COVID19TextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_COVID19TextBlock" xlink:to="lab_amed_COVID19TextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_b7d392e7-e65a-4d20-be03-289e1d574e85_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of stock - employee stock purchase plan</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Employee Stock Purchase Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OffMarketFavorableLeaseMember_283dece4-5ded-41d3-9ae6-d646fc30c631_terseLabel_en-US" xlink:label="lab_us-gaap_OffMarketFavorableLeaseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Favorable Lease Contract [Member]</link:label>
    <link:label id="lab_us-gaap_OffMarketFavorableLeaseMember_label_en-US" xlink:label="lab_us-gaap_OffMarketFavorableLeaseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Off-Market Favorable Lease [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OffMarketFavorableLeaseMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OffMarketFavorableLeaseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OffMarketFavorableLeaseMember" xlink:to="lab_us-gaap_OffMarketFavorableLeaseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_d82179ce-a5a6-4f74-a085-572498e0fa44_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_11485537-0303-4aea-b75b-5ac8ece3ad81_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion of long-term obligations</link:label>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtCurrent" xlink:to="lab_us-gaap_LongTermDebtCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_1615055f-4c8c-4704-9f79-98017d56849a_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentIncomeInterestAndDividend_4c9e9667-5fa9-4bdf-8e87-e298de6f8dd7_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterestAndDividend" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeInterestAndDividend_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterestAndDividend" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Income, Interest and Dividend</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterestAndDividend" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeInterestAndDividend"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeInterestAndDividend" xlink:to="lab_us-gaap_InvestmentIncomeInterestAndDividend" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_TotalLeverageRatio_029f7f10-c0cf-4075-8c8e-6cee5aad981b_terseLabel_en-US" xlink:label="lab_amed_TotalLeverageRatio" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated leverage ratio</link:label>
    <link:label id="lab_amed_TotalLeverageRatio_label_en-US" xlink:label="lab_amed_TotalLeverageRatio" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Leverage Ratio</link:label>
    <link:label id="lab_amed_TotalLeverageRatio_documentation_en-US" xlink:label="lab_amed_TotalLeverageRatio" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ratio of debt to earnings before interest, taxes, depreciation and amortization.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_TotalLeverageRatio" xlink:href="amed-20210630.xsd#amed_TotalLeverageRatio"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_TotalLeverageRatio" xlink:to="lab_amed_TotalLeverageRatio" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_SwingLineLoanMember_35b881c2-95fa-4ba9-a03d-f8db73a886e2_terseLabel_en-US" xlink:label="lab_amed_SwingLineLoanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Swing Line Loan [Member]</link:label>
    <link:label id="lab_amed_SwingLineLoanMember_label_en-US" xlink:label="lab_amed_SwingLineLoanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Swing Line Loan [Member]</link:label>
    <link:label id="lab_amed_SwingLineLoanMember_documentation_en-US" xlink:label="lab_amed_SwingLineLoanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Swing Line Loan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_SwingLineLoanMember" xlink:href="amed-20210630.xsd#amed_SwingLineLoanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_SwingLineLoanMember" xlink:to="lab_amed_SwingLineLoanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionAxis_c2f96289-3db5-4305-96c8-047f46a1a0a0_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Axis]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionAxis_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfEquityMethodInvestments_4262deba-e957-4d15-a13d-130eddc1136c_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sale of equity method investment</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfEquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale of Equity Method Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfEquityMethodInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleOfEquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfEquityMethodInvestments" xlink:to="lab_us-gaap_ProceedsFromSaleOfEquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTable_d021775a-e552-4f9c-9129-fe5b6e724169_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTable_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTable" xlink:to="lab_us-gaap_SubsequentEventTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_e09124df-746f-462f-9962-efffd3ca59f4_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-Average Shares Outstanding</link:label>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTable_b44a75f9-a243-498b-809a-46b5cfbd85e9_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="lab_us-gaap_DebtInstrumentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityLenderDomain_0945f3c0-fc38-4fcb-b578-30fce5053aee_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityLenderDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Lender [Domain]</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityLenderDomain_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityLenderDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Lender [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain" xlink:to="lab_us-gaap_LineOfCreditFacilityLenderDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_f0c4cd88-f278-448e-a25e-42a6853d095d_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterest_78dd82f6-87a5-4a31-b6fb-1002741a443d_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_MinorityInterest_label_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterest" xlink:to="lab_us-gaap_MinorityInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_f291ff1b-2049-44c7-9096-4e5279b6d5d8_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flows from Investing Activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_702f3365-9e5f-46a0-9edc-46398db70b9a_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, issued (shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_c7734a0f-27d1-4e85-b2a9-0df83ea3d88d_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EurodollarMember_a47340cd-a97c-4043-957f-6a6e96b0ceee_terseLabel_en-US" xlink:label="lab_us-gaap_EurodollarMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Eurodollar [Member]</link:label>
    <link:label id="lab_us-gaap_EurodollarMember_label_en-US" xlink:label="lab_us-gaap_EurodollarMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Eurodollar [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EurodollarMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EurodollarMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EurodollarMember" xlink:to="lab_us-gaap_EurodollarMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions_fc532992-99a2-4d6d-96b4-25babc12a326_terseLabel_en-US" xlink:label="lab_us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net service revenue</link:label>
    <link:label id="lab_us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions_label_en-US" xlink:label="lab_us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health Care Organization, Revenue Net of Patient Service Revenue Provisions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions" xlink:to="lab_us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_AmedisysCIAMember_29c2ca99-2882-44b6-8788-68d09bfc65ee_terseLabel_en-US" xlink:label="lab_amed_AmedisysCIAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amedisys CIA</link:label>
    <link:label id="lab_amed_AmedisysCIAMember_label_en-US" xlink:label="lab_amed_AmedisysCIAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amedisys CIA [Member]</link:label>
    <link:label id="lab_amed_AmedisysCIAMember_documentation_en-US" xlink:label="lab_amed_AmedisysCIAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amedisys CIA [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AmedisysCIAMember" xlink:href="amed-20210630.xsd#amed_AmedisysCIAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_AmedisysCIAMember" xlink:to="lab_amed_AmedisysCIAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_CompanysinsurancecarriersMember_114c8f3e-0d69-4b1d-8d48-0fa11c6e141b_terseLabel_en-US" xlink:label="lab_amed_CompanysinsurancecarriersMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Company's insurance carriers [Member]</link:label>
    <link:label id="lab_amed_CompanysinsurancecarriersMember_label_en-US" xlink:label="lab_amed_CompanysinsurancecarriersMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Company's insurance carriers [Member]</link:label>
    <link:label id="lab_amed_CompanysinsurancecarriersMember_documentation_en-US" xlink:label="lab_amed_CompanysinsurancecarriersMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Company's insurance carriers [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CompanysinsurancecarriersMember" xlink:href="amed-20210630.xsd#amed_CompanysinsurancecarriersMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_CompanysinsurancecarriersMember" xlink:to="lab_amed_CompanysinsurancecarriersMember" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_A2021ShareRepurchaseProgramMember_88e2465f-be12-4102-bfbb-fefeee04ec53_terseLabel_en-US" xlink:label="lab_amed_A2021ShareRepurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021 Share Repurchase Program</link:label>
    <link:label id="lab_amed_A2021ShareRepurchaseProgramMember_label_en-US" xlink:label="lab_amed_A2021ShareRepurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021 Share Repurchase Program [Member]</link:label>
    <link:label id="lab_amed_A2021ShareRepurchaseProgramMember_documentation_en-US" xlink:label="lab_amed_A2021ShareRepurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021 Share Repurchase Program</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_A2021ShareRepurchaseProgramMember" xlink:href="amed-20210630.xsd#amed_A2021ShareRepurchaseProgramMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_A2021ShareRepurchaseProgramMember" xlink:to="lab_amed_A2021ShareRepurchaseProgramMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_600e4d09-35d8-452e-86f1-723e30784b55_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term obligations, less current portion</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Excluding Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtNoncurrent" xlink:to="lab_us-gaap_LongTermDebtNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingAbstract_0da92e95-1087-40bc-99b9-1c6dd93bc2c6_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:label id="lab_us-gaap_SegmentReportingAbstract_label_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingAbstract" xlink:to="lab_us-gaap_SegmentReportingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareRepurchaseProgramAxis_b59ee02a-4c8f-4ded-bce1-8fd76af3e41b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareRepurchaseProgramAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase Program [Axis]</link:label>
    <link:label id="lab_us-gaap_ShareRepurchaseProgramAxis_label_en-US" xlink:label="lab_us-gaap_ShareRepurchaseProgramAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase Program [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareRepurchaseProgramAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis" xlink:to="lab_us-gaap_ShareRepurchaseProgramAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_DebtInstrumentPeriodicPaymentPercentage_3c6d9e72-34e5-4120-bdc0-491580a3e2ac_terseLabel_en-US" xlink:label="lab_amed_DebtInstrumentPeriodicPaymentPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument Periodic Payment Percentage</link:label>
    <link:label id="lab_amed_DebtInstrumentPeriodicPaymentPercentage_label_en-US" xlink:label="lab_amed_DebtInstrumentPeriodicPaymentPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument Periodic Payment Percentage</link:label>
    <link:label id="lab_amed_DebtInstrumentPeriodicPaymentPercentage_documentation_en-US" xlink:label="lab_amed_DebtInstrumentPeriodicPaymentPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The percentage of the Term Loan that is required as periodic payments including both interest and principal payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_DebtInstrumentPeriodicPaymentPercentage" xlink:href="amed-20210630.xsd#amed_DebtInstrumentPeriodicPaymentPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_DebtInstrumentPeriodicPaymentPercentage" xlink:to="lab_amed_DebtInstrumentPeriodicPaymentPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_726b989b-bcf0-490e-bb21-7719b12f5360_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patient accounts receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_bb8a608a-0f25-4bb4-bf7d-ddca0fdd67d7_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_WriteOffOfOtherComprehensiveIncome_cdacb1bd-0a25-4c2c-adba-6cba0d1de38f_negatedLabel_en-US" xlink:label="lab_amed_WriteOffOfOtherComprehensiveIncome" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Write-off of other comprehensive income</link:label>
    <link:label id="lab_amed_WriteOffOfOtherComprehensiveIncome_label_en-US" xlink:label="lab_amed_WriteOffOfOtherComprehensiveIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Write off of Other Comprehensive Income</link:label>
    <link:label id="lab_amed_WriteOffOfOtherComprehensiveIncome_documentation_en-US" xlink:label="lab_amed_WriteOffOfOtherComprehensiveIncome" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Write off of Other Comprehensive Income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_WriteOffOfOtherComprehensiveIncome" xlink:href="amed-20210630.xsd#amed_WriteOffOfOtherComprehensiveIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_WriteOffOfOtherComprehensiveIncome" xlink:to="lab_amed_WriteOffOfOtherComprehensiveIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_b82d5563-a4df-4aef-96d8-6c90ea4cd3c3_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Amedisys, Inc. stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferred1_17304c62-da02-4141-b193-cf25e4b15d64_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total purchase price for acquisition</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferred1_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration Transferred</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:to="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_99af3649-203e-442d-ac0b-ae9442e7195a_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:to="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_b2011ee4-b19f-403b-bfc4-62e097cd9916_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_fb4eb16f-4d88-4fa6-aa67-453262a38783_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_label_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesLineItems" xlink:to="lab_us-gaap_LossContingenciesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfBusinessesAcquired_460e219a-8282-4140-aafe-c9369c898e1d_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfBusinessesAcquired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition, number of care centers acquired</link:label>
    <link:label id="lab_us-gaap_NumberOfBusinessesAcquired_label_en-US" xlink:label="lab_us-gaap_NumberOfBusinessesAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Businesses Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfBusinessesAcquired" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfBusinessesAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfBusinessesAcquired" xlink:to="lab_us-gaap_NumberOfBusinessesAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_06a26b14-3da7-4946-97bd-c1216f72438b_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_a2fc5dd5-ab8d-4224-ab3a-d3fbcd3654ad_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payroll and employee benefits</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_38d44774-f292-49f9-a546-9e97f6663f62_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlockTableTextBlock_2ec99884-24ff-4c3b-bff3-3972014f4d96_terseLabel_en-US" xlink:label="lab_amed_ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlockTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cash Cash Equivalents and Restricted Cash</link:label>
    <link:label id="lab_amed_ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlockTableTextBlock_label_en-US" xlink:label="lab_amed_ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlockTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlock [Table Text Block]</link:label>
    <link:label id="lab_amed_ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlockTableTextBlock_documentation_en-US" xlink:label="lab_amed_ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlockTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cash, Cash Equivalents and Restricted Cash Table Text Block</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlockTableTextBlock" xlink:href="amed-20210630.xsd#amed_ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlockTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlockTableTextBlock" xlink:to="lab_amed_ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlockTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_46f89361-4fdb-40b9-ae1f-44af96c4331b_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_98782663-4eb7-49ba-bc12-f95659aa69c3_negatedLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_a9a6ff3c-1f61-42b1-81b7-a15b44d68f9e_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative expenses</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OffMarketLeaseUnfavorable_e1cd52fa-04e3-47dc-a754-4f33674051d8_terseLabel_en-US" xlink:label="lab_us-gaap_OffMarketLeaseUnfavorable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Off-market Lease, Unfavorable</link:label>
    <link:label id="lab_us-gaap_OffMarketLeaseUnfavorable_label_en-US" xlink:label="lab_us-gaap_OffMarketLeaseUnfavorable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Off-market Lease, Unfavorable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OffMarketLeaseUnfavorable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OffMarketLeaseUnfavorable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OffMarketLeaseUnfavorable" xlink:to="lab_us-gaap_OffMarketLeaseUnfavorable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfAdoptionMember_e10c5bf5-9824-4901-a2c8-5ab77cabd684_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfAdoptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Adoption [Domain]</link:label>
    <link:label id="lab_us-gaap_TypeOfAdoptionMember_label_en-US" xlink:label="lab_us-gaap_TypeOfAdoptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfAdoptionMember" xlink:to="lab_us-gaap_TypeOfAdoptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_125476ea-1256-4290-83c9-3afdde9694e4_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Anti-dilutive securities (shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityLineItems_67efe332-9c9d-48cd-8028-b63a4da9bfcc_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility [Line Items]</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityLineItems_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems" xlink:to="lab_us-gaap_LineOfCreditFacilityLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_DebtInstrumentCarryingAmountExcludingFinanceLeases_7b154d22-28a9-4aa4-917b-84bda62285ec_terseLabel_en-US" xlink:label="lab_amed_DebtInstrumentCarryingAmountExcludingFinanceLeases" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument Carrying Amount Excluding Finance Leases</link:label>
    <link:label id="lab_amed_DebtInstrumentCarryingAmountExcludingFinanceLeases_label_en-US" xlink:label="lab_amed_DebtInstrumentCarryingAmountExcludingFinanceLeases" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument Carrying Amount Excluding Finance Leases</link:label>
    <link:label id="lab_amed_DebtInstrumentCarryingAmountExcludingFinanceLeases_documentation_en-US" xlink:label="lab_amed_DebtInstrumentCarryingAmountExcludingFinanceLeases" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument Carrying Amount Excluding Finance Leases</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_DebtInstrumentCarryingAmountExcludingFinanceLeases" xlink:href="amed-20210630.xsd#amed_DebtInstrumentCarryingAmountExcludingFinanceLeases"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_DebtInstrumentCarryingAmountExcludingFinanceLeases" xlink:to="lab_amed_DebtInstrumentCarryingAmountExcludingFinanceLeases" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_a02a21b8-14e1-459b-aa9c-f345113e3b87_negatedLabel_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss (gain) on disposal of property and equipment</link:label>
    <link:label id="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_label_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Disposition of Property Plant Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:to="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_dfb5c804-de21-418a-9e2f-8ccf56a1333e_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets [Axis]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_94a713fb-feaa-4bf3-827c-0e6c1ad15308_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_PercentageOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromSubsidiaries_26c8fda8-e491-4f69-a453-af536da7fd09_terseLabel_en-US" xlink:label="lab_amed_PercentageOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromSubsidiaries" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of adjusted EBITDA that guarantor subsidiaries represent</link:label>
    <link:label id="lab_amed_PercentageOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromSubsidiaries_label_en-US" xlink:label="lab_amed_PercentageOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromSubsidiaries" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Of Earnings Before Interest Taxes Depreciation And Amortization From Subsidiaries</link:label>
    <link:label id="lab_amed_PercentageOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromSubsidiaries_documentation_en-US" xlink:label="lab_amed_PercentageOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromSubsidiaries" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of adjusted EBITDA that guarantor subsidiaries represent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PercentageOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromSubsidiaries" xlink:href="amed-20210630.xsd#amed_PercentageOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromSubsidiaries"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_PercentageOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromSubsidiaries" xlink:to="lab_amed_PercentageOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromSubsidiaries" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_eb9f06b0-a870-4ce9-afbd-08b99b419657_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net of accumulated depreciation of $98,552 and $95,024</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_8d6513da-0b51-4650-a121-58f73b150bb8_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_7463d790-540f-467d-9bc1-9e15da3502d5_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income attributable to Amedisys, Inc.</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_HeritageHealthcareInnovationFundLPMember_a4fb74b6-2040-4583-9f00-f414fb7fa386_terseLabel_en-US" xlink:label="lab_amed_HeritageHealthcareInnovationFundLPMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Heritage Healthcare Innovation Fund, LP [Member]</link:label>
    <link:label id="lab_amed_HeritageHealthcareInnovationFundLPMember_label_en-US" xlink:label="lab_amed_HeritageHealthcareInnovationFundLPMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Heritage Healthcare Innovation Fund, LP [Member]</link:label>
    <link:label id="lab_amed_HeritageHealthcareInnovationFundLPMember_documentation_en-US" xlink:label="lab_amed_HeritageHealthcareInnovationFundLPMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Heritage Healthcare Innovation Fund, LP</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HeritageHealthcareInnovationFundLPMember" xlink:href="amed-20210630.xsd#amed_HeritageHealthcareInnovationFundLPMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_HeritageHealthcareInnovationFundLPMember" xlink:to="lab_amed_HeritageHealthcareInnovationFundLPMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_5f6d798d-81c6-4604-acd5-f8378d845633_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in operating assets and liabilities, net of impact of acquisitions:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TradeNamesMember_a0d809a4-5585-444a-aace-f9e8f9be022b_terseLabel_en-US" xlink:label="lab_us-gaap_TradeNamesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade Names [Member]</link:label>
    <link:label id="lab_us-gaap_TradeNamesMember_label_en-US" xlink:label="lab_us-gaap_TradeNamesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade Names [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeNamesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TradeNamesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TradeNamesMember" xlink:to="lab_us-gaap_TradeNamesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_UnfavorableMember_e32fab68-f30d-4ccf-93c4-75bfc311cb57_terseLabel_en-US" xlink:label="lab_amed_UnfavorableMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unfavorable [Member]</link:label>
    <link:label id="lab_amed_UnfavorableMember_label_en-US" xlink:label="lab_amed_UnfavorableMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unfavorable [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_UnfavorableMember" xlink:href="amed-20210630.xsd#amed_UnfavorableMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_UnfavorableMember" xlink:to="lab_amed_UnfavorableMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyReceivableCurrent_03d87bab-2402-477d-b1fd-1eea4b815a0d_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settlement amount to be paid by company's insurance carriers</link:label>
    <link:label id="lab_us-gaap_LossContingencyReceivableCurrent_label_en-US" xlink:label="lab_us-gaap_LossContingencyReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Receivable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyReceivableCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyReceivableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyReceivableCurrent" xlink:to="lab_us-gaap_LossContingencyReceivableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_8e352765-d42c-4c1d-ae9b-d129da2a980e_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis" xlink:to="lab_us-gaap_LongtermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_316907ac-567e-4c69-829a-f21a1ed70b3d_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_e4c5f04f-5146-4b96-9773-4d59931ba9d6_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_CapYearAxis_9a492b3b-2a74-46f4-a5de-23b9c10edf1a_terseLabel_en-US" xlink:label="lab_amed_CapYearAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cap Year [Axis]</link:label>
    <link:label id="lab_amed_CapYearAxis_label_en-US" xlink:label="lab_amed_CapYearAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cap Year [Axis]</link:label>
    <link:label id="lab_amed_CapYearAxis_documentation_en-US" xlink:label="lab_amed_CapYearAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cap Year [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CapYearAxis" xlink:href="amed-20210630.xsd#amed_CapYearAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_CapYearAxis" xlink:to="lab_amed_CapYearAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_UsDepartmentOfJusticeMember_204f4b89-e889-45fa-8ed7-75ad82d3a574_terseLabel_en-US" xlink:label="lab_amed_UsDepartmentOfJusticeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Department of Justice</link:label>
    <link:label id="lab_amed_UsDepartmentOfJusticeMember_label_en-US" xlink:label="lab_amed_UsDepartmentOfJusticeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Department of Justice [Member]</link:label>
    <link:label id="lab_amed_UsDepartmentOfJusticeMember_documentation_en-US" xlink:label="lab_amed_UsDepartmentOfJusticeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Department of Justice</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_UsDepartmentOfJusticeMember" xlink:href="amed-20210630.xsd#amed_UsDepartmentOfJusticeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_UsDepartmentOfJusticeMember" xlink:to="lab_amed_UsDepartmentOfJusticeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_ShareRepurchaseTable_d0826d63-888a-4cc7-8476-e16f34d6eea0_terseLabel_en-US" xlink:label="lab_amed_ShareRepurchaseTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase [Table]</link:label>
    <link:label id="lab_amed_ShareRepurchaseTable_label_en-US" xlink:label="lab_amed_ShareRepurchaseTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase [Table]</link:label>
    <link:label id="lab_amed_ShareRepurchaseTable_documentation_en-US" xlink:label="lab_amed_ShareRepurchaseTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ShareRepurchaseTable" xlink:href="amed-20210630.xsd#amed_ShareRepurchaseTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_ShareRepurchaseTable" xlink:to="lab_amed_ShareRepurchaseTable" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_RevenueAdjustmentToMedicareRevenue_6ce0fe2f-7309-47d7-82a5-7483718f32e3_terseLabel_en-US" xlink:label="lab_amed_RevenueAdjustmentToMedicareRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue adjustment to Medicare revenue</link:label>
    <link:label id="lab_amed_RevenueAdjustmentToMedicareRevenue_label_en-US" xlink:label="lab_amed_RevenueAdjustmentToMedicareRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Adjustment To Medicare Revenue</link:label>
    <link:label id="lab_amed_RevenueAdjustmentToMedicareRevenue_documentation_en-US" xlink:label="lab_amed_RevenueAdjustmentToMedicareRevenue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description of the provisions that reduce the amount of Medicare revenue recognized by the entity.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_RevenueAdjustmentToMedicareRevenue" xlink:href="amed-20210630.xsd#amed_RevenueAdjustmentToMedicareRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_RevenueAdjustmentToMedicareRevenue" xlink:to="lab_amed_RevenueAdjustmentToMedicareRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_2067910a-1eeb-499f-858d-32e4df7eecae_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition, other intangibles recorded</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_3ab9734b-fd3f-4b6a-a986-c92c8c253ed5_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_ConsolidatedInterestCoverageRatio_90167a68-48cc-4099-adae-fd3ab2ce933a_terseLabel_en-US" xlink:label="lab_amed_ConsolidatedInterestCoverageRatio" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated interest coverage ratio</link:label>
    <link:label id="lab_amed_ConsolidatedInterestCoverageRatio_label_en-US" xlink:label="lab_amed_ConsolidatedInterestCoverageRatio" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Interest Coverage Ratio</link:label>
    <link:label id="lab_amed_ConsolidatedInterestCoverageRatio_documentation_en-US" xlink:label="lab_amed_ConsolidatedInterestCoverageRatio" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ratio of adjusted earnings before interest, taxes, depreciation and amortization to cash interest charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ConsolidatedInterestCoverageRatio" xlink:href="amed-20210630.xsd#amed_ConsolidatedInterestCoverageRatio"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_ConsolidatedInterestCoverageRatio" xlink:to="lab_amed_ConsolidatedInterestCoverageRatio" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_HomeHealthNonMedicareEpisodicBasedMember_75dc0537-a261-4d60-8b6e-d0f65b9d87e7_terseLabel_en-US" xlink:label="lab_amed_HomeHealthNonMedicareEpisodicBasedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Home Health Non-Medicare - Episodic Based [Member]</link:label>
    <link:label id="lab_amed_HomeHealthNonMedicareEpisodicBasedMember_label_en-US" xlink:label="lab_amed_HomeHealthNonMedicareEpisodicBasedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Home Health Non-Medicare - Episodic Based [Member]</link:label>
    <link:label id="lab_amed_HomeHealthNonMedicareEpisodicBasedMember_documentation_en-US" xlink:label="lab_amed_HomeHealthNonMedicareEpisodicBasedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Home Health Non-Medicare - Episodic Based [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HomeHealthNonMedicareEpisodicBasedMember" xlink:href="amed-20210630.xsd#amed_HomeHealthNonMedicareEpisodicBasedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_HomeHealthNonMedicareEpisodicBasedMember" xlink:to="lab_amed_HomeHealthNonMedicareEpisodicBasedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_FloridaZpicRevenueReduction_4f8bc3fd-bdb3-4bc8-8ef5-e80fdba95f19_terseLabel_en-US" xlink:label="lab_amed_FloridaZpicRevenueReduction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Florida ZPIC revenue reduction</link:label>
    <link:label id="lab_amed_FloridaZpicRevenueReduction_label_en-US" xlink:label="lab_amed_FloridaZpicRevenueReduction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Florida Zpic Revenue Reduction</link:label>
    <link:label id="lab_amed_FloridaZpicRevenueReduction_documentation_en-US" xlink:label="lab_amed_FloridaZpicRevenueReduction" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reduction in revenue as a result of the Florida ZPIC audit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_FloridaZpicRevenueReduction" xlink:href="amed-20210630.xsd#amed_FloridaZpicRevenueReduction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_FloridaZpicRevenueReduction" xlink:to="lab_amed_FloridaZpicRevenueReduction" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_TwoHundredMillionRevolvingCreditFacilityMember_b2ad2842-c191-47e6-affc-8c308d24231f_terseLabel_en-US" xlink:label="lab_amed_TwoHundredMillionRevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">200 Million Revolving Credit Facility</link:label>
    <link:label id="lab_amed_TwoHundredMillionRevolvingCreditFacilityMember_label_en-US" xlink:label="lab_amed_TwoHundredMillionRevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Hundred Million Revolving Credit Facility [Member]</link:label>
    <link:label id="lab_amed_TwoHundredMillionRevolvingCreditFacilityMember_documentation_en-US" xlink:label="lab_amed_TwoHundredMillionRevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Hundred Million Revolving Credit Facility [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_TwoHundredMillionRevolvingCreditFacilityMember" xlink:href="amed-20210630.xsd#amed_TwoHundredMillionRevolvingCreditFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_TwoHundredMillionRevolvingCreditFacilityMember" xlink:to="lab_amed_TwoHundredMillionRevolvingCreditFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_AseraCareHospiceMember_f47af169-d42d-4f5d-884e-ec1d89e9307a_terseLabel_en-US" xlink:label="lab_amed_AseraCareHospiceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AseraCare Hospice [Member]</link:label>
    <link:label id="lab_amed_AseraCareHospiceMember_label_en-US" xlink:label="lab_amed_AseraCareHospiceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AseraCare Hospice [Member]</link:label>
    <link:label id="lab_amed_AseraCareHospiceMember_documentation_en-US" xlink:label="lab_amed_AseraCareHospiceMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AseraCare Hospice</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AseraCareHospiceMember" xlink:href="amed-20210630.xsd#amed_AseraCareHospiceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_AseraCareHospiceMember" xlink:to="lab_amed_AseraCareHospiceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRecognitionAndDeferredRevenueAbstract_39395d31-b414-4204-ae76-d6f19a7ae0ea_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRecognitionAndDeferredRevenueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition and Deferred Revenue [Abstract]</link:label>
    <link:label id="lab_us-gaap_RevenueRecognitionAndDeferredRevenueAbstract_label_en-US" xlink:label="lab_us-gaap_RevenueRecognitionAndDeferredRevenueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition and Deferred Revenue [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionAndDeferredRevenueAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRecognitionAndDeferredRevenueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRecognitionAndDeferredRevenueAbstract" xlink:to="lab_us-gaap_RevenueRecognitionAndDeferredRevenueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_ae03604d-a9c7-48ff-b839-22c41c84ebc0_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Disclosures of Cash Flow Information:</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_StockIssuedDuringPeriodSharesFourZeroOneKEmployerMatch_b65d94fa-24d4-4090-8912-91d8a7f84292_terseLabel_en-US" xlink:label="lab_amed_StockIssuedDuringPeriodSharesFourZeroOneKEmployerMatch" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of stock - 401(k) plan (shares)</link:label>
    <link:label id="lab_amed_StockIssuedDuringPeriodSharesFourZeroOneKEmployerMatch_label_en-US" xlink:label="lab_amed_StockIssuedDuringPeriodSharesFourZeroOneKEmployerMatch" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period Shares Four Zero One K Employer Match</link:label>
    <link:label id="lab_amed_StockIssuedDuringPeriodSharesFourZeroOneKEmployerMatch_documentation_en-US" xlink:label="lab_amed_StockIssuedDuringPeriodSharesFourZeroOneKEmployerMatch" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares issued during the period to employees as employer's matching contribution to the company's 401(K) plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_StockIssuedDuringPeriodSharesFourZeroOneKEmployerMatch" xlink:href="amed-20210630.xsd#amed_StockIssuedDuringPeriodSharesFourZeroOneKEmployerMatch"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_StockIssuedDuringPeriodSharesFourZeroOneKEmployerMatch" xlink:to="lab_amed_StockIssuedDuringPeriodSharesFourZeroOneKEmployerMatch" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_ShareRepurchaseLineItems_4266fa9a-9c21-4f1d-9dde-0c897eeba998_terseLabel_en-US" xlink:label="lab_amed_ShareRepurchaseLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase [Line Items]</link:label>
    <link:label id="lab_amed_ShareRepurchaseLineItems_label_en-US" xlink:label="lab_amed_ShareRepurchaseLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase [Line Items]</link:label>
    <link:label id="lab_amed_ShareRepurchaseLineItems_documentation_en-US" xlink:label="lab_amed_ShareRepurchaseLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">[Line Items] for Share Repurchase [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ShareRepurchaseLineItems" xlink:href="amed-20210630.xsd#amed_ShareRepurchaseLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_ShareRepurchaseLineItems" xlink:to="lab_amed_ShareRepurchaseLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_OperatingCareCenters_b8c342d0-ae27-407b-8d83-8d8ab808f501_terseLabel_en-US" xlink:label="lab_amed_OperatingCareCenters" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of owned and operated care centers</link:label>
    <link:label id="lab_amed_OperatingCareCenters_label_en-US" xlink:label="lab_amed_OperatingCareCenters" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Care Centers</link:label>
    <link:label id="lab_amed_OperatingCareCenters_documentation_en-US" xlink:label="lab_amed_OperatingCareCenters" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description containing the number of care centers owned by the entity as of the balance sheet date.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_OperatingCareCenters" xlink:href="amed-20210630.xsd#amed_OperatingCareCenters"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_OperatingCareCenters" xlink:to="lab_amed_OperatingCareCenters" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_780c4ebe-bbb9-4289-83af-21d3cb774502_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentAggregateCost_6ceb9b52-3c00-47b5-8f1d-fca5945b0ee8_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentAggregateCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity method investment, aggregate cost</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentAggregateCost_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentAggregateCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Aggregate Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentAggregateCost" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentAggregateCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentAggregateCost" xlink:to="lab_us-gaap_EquityMethodInvestmentAggregateCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_c8bb97fa-d68c-4d4e-ba30-11d0342a2701_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of stock - employee stock purchase plan (shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Employee Stock Purchase Plans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_Discountedclosingstockprice_4846939d-6dda-464b-9288-0e48fa3f952a_terseLabel_en-US" xlink:label="lab_amed_Discountedclosingstockprice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discounted closing stock price</link:label>
    <link:label id="lab_amed_Discountedclosingstockprice_label_en-US" xlink:label="lab_amed_Discountedclosingstockprice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discounted closing stock price</link:label>
    <link:label id="lab_amed_Discountedclosingstockprice_documentation_en-US" xlink:label="lab_amed_Discountedclosingstockprice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discounted closing stock price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_Discountedclosingstockprice" xlink:href="amed-20210630.xsd#amed_Discountedclosingstockprice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_Discountedclosingstockprice" xlink:to="lab_amed_Discountedclosingstockprice" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_34895120-595e-4ab5-904a-15506915e647_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_080c5297-6bb1-4688-8874-82896acdbd3c_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_d06d30b9-4fc7-4a54-93e1-7d629d5b36b1_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_LetterOfCreditFee_ad8d694b-cee0-42bf-b10c-fde15b0b0cbf_terseLabel_en-US" xlink:label="lab_amed_LetterOfCreditFee" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Letter Of Credit Fee</link:label>
    <link:label id="lab_amed_LetterOfCreditFee_label_en-US" xlink:label="lab_amed_LetterOfCreditFee" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Letter Of Credit Fee</link:label>
    <link:label id="lab_amed_LetterOfCreditFee_documentation_en-US" xlink:label="lab_amed_LetterOfCreditFee" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The fee, expressed as a percentage of the letters of credit, for the letters of credit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_LetterOfCreditFee" xlink:href="amed-20210630.xsd#amed_LetterOfCreditFee"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_LetterOfCreditFee" xlink:to="lab_amed_LetterOfCreditFee" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_ee6e5d47-e5f6-4ee2-8e20-3ceae091aa92_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_RecoveryAmountOfOverpaymentMadeToSubsidiary_87fe1ce7-d750-42e6-a448-656b5c58e116_terseLabel_en-US" xlink:label="lab_amed_RecoveryAmountOfOverpaymentMadeToSubsidiary" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recovery amount of overpayment made to subsidiary</link:label>
    <link:label id="lab_amed_RecoveryAmountOfOverpaymentMadeToSubsidiary_label_en-US" xlink:label="lab_amed_RecoveryAmountOfOverpaymentMadeToSubsidiary" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recovery Amount Of Overpayment Made To Subsidiary</link:label>
    <link:label id="lab_amed_RecoveryAmountOfOverpaymentMadeToSubsidiary_documentation_en-US" xlink:label="lab_amed_RecoveryAmountOfOverpaymentMadeToSubsidiary" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recovery amount of the overpayment made to the subsidiary.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_RecoveryAmountOfOverpaymentMadeToSubsidiary" xlink:href="amed-20210630.xsd#amed_RecoveryAmountOfOverpaymentMadeToSubsidiary"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_RecoveryAmountOfOverpaymentMadeToSubsidiary" xlink:to="lab_amed_RecoveryAmountOfOverpaymentMadeToSubsidiary" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_SurrenderedShares_395e6559-52db-4083-96db-9f13a06d0e39_negatedLabel_en-US" xlink:label="lab_amed_SurrenderedShares" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Surrendered Shares</link:label>
    <link:label id="lab_amed_SurrenderedShares_label_en-US" xlink:label="lab_amed_SurrenderedShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Surrendered Shares</link:label>
    <link:label id="lab_amed_SurrenderedShares_documentation_en-US" xlink:label="lab_amed_SurrenderedShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares of common stock surrendered by certain employees to satisfy obligations in connection with the vesting of stock. Shares held in Treasury Stock at cost.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_SurrenderedShares" xlink:href="amed-20210630.xsd#amed_SurrenderedShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_SurrenderedShares" xlink:to="lab_amed_SurrenderedShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionNameOfAcquiredEntity_5375e337-c712-44fd-8fab-863074a31d3f_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionNameOfAcquiredEntity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Name of Acquired Entity</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionNameOfAcquiredEntity_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionNameOfAcquiredEntity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Name of Acquired Entity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionNameOfAcquiredEntity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionNameOfAcquiredEntity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionNameOfAcquiredEntity" xlink:to="lab_us-gaap_BusinessAcquisitionNameOfAcquiredEntity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_c8c97cb9-f5b1-4e64-b0e2-a27764a6cf92_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining availability under revolving credit facility</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Remaining Borrowing Capacity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:to="lab_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_NumberOfBeneficiaries_267d7044-0d35-43ea-8216-2965a515a588_terseLabel_en-US" xlink:label="lab_amed_NumberOfBeneficiaries" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of beneficiaries</link:label>
    <link:label id="lab_amed_NumberOfBeneficiaries_label_en-US" xlink:label="lab_amed_NumberOfBeneficiaries" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of beneficiaries</link:label>
    <link:label id="lab_amed_NumberOfBeneficiaries_documentation_en-US" xlink:label="lab_amed_NumberOfBeneficiaries" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of beneficiaries who received services</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_NumberOfBeneficiaries" xlink:href="amed-20210630.xsd#amed_NumberOfBeneficiaries"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_NumberOfBeneficiaries" xlink:to="lab_amed_NumberOfBeneficiaries" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnusualOrInfrequentItemDomain_1133a318-73a6-46dc-93d4-5db55d5003d6_terseLabel_en-US" xlink:label="lab_us-gaap_UnusualOrInfrequentItemDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unusual or Infrequent Item, or Both [Domain]</link:label>
    <link:label id="lab_us-gaap_UnusualOrInfrequentItemDomain_label_en-US" xlink:label="lab_us-gaap_UnusualOrInfrequentItemDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unusual or Infrequent Item, or Both [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnusualOrInfrequentItemDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnusualOrInfrequentItemDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnusualOrInfrequentItemDomain" xlink:to="lab_us-gaap_UnusualOrInfrequentItemDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_Revenuebypayorclassasapercentageoftotalnetservicerevenue_2ed65644-86c7-4a5c-bb01-7c70e5029b49_terseLabel_en-US" xlink:label="lab_amed_Revenuebypayorclassasapercentageoftotalnetservicerevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue by payor class as a percentage of total net service revenue</link:label>
    <link:label id="lab_amed_Revenuebypayorclassasapercentageoftotalnetservicerevenue_label_en-US" xlink:label="lab_amed_Revenuebypayorclassasapercentageoftotalnetservicerevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue by payor class as a percentage of total net service revenue</link:label>
    <link:label id="lab_amed_Revenuebypayorclassasapercentageoftotalnetservicerevenue_documentation_en-US" xlink:label="lab_amed_Revenuebypayorclassasapercentageoftotalnetservicerevenue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue by payor class as a percentage of total net service revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_Revenuebypayorclassasapercentageoftotalnetservicerevenue" xlink:href="amed-20210630.xsd#amed_Revenuebypayorclassasapercentageoftotalnetservicerevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_Revenuebypayorclassasapercentageoftotalnetservicerevenue" xlink:to="lab_amed_Revenuebypayorclassasapercentageoftotalnetservicerevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_b205ddc1-e882-4c21-a796-8426022a3d87_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, accumulated depreciation</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValueOutstanding_1a4e7e08-5223-457f-b1a9-99fd3520c611_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValueOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, $0.001 par value, 5,000,000 shares authorized; none issued or outstanding</link:label>
    <link:label id="lab_us-gaap_PreferredStockValueOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockValueOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Value, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValueOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValueOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValueOutstanding" xlink:to="lab_us-gaap_PreferredStockValueOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDilutedAbstract_61632db8-4886-4f41-b231-b47db669e405_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDilutedAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted earnings per common share:</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDilutedAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDilutedAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDilutedAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareDilutedAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDilutedAbstract" xlink:to="lab_us-gaap_EarningsPerShareDilutedAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtWeightedAverageInterestRateOverTime_fae96118-fa45-472b-962f-97f3c2943155_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtWeightedAverageInterestRateOverTime" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average interest rate (percent)</link:label>
    <link:label id="lab_us-gaap_LongTermDebtWeightedAverageInterestRateOverTime_label_en-US" xlink:label="lab_us-gaap_LongTermDebtWeightedAverageInterestRateOverTime" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Weighted Average Interest Rate, over Time</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtWeightedAverageInterestRateOverTime" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtWeightedAverageInterestRateOverTime"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtWeightedAverageInterestRateOverTime" xlink:to="lab_us-gaap_LongTermDebtWeightedAverageInterestRateOverTime" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract_1b95f518-a8d5-43a0-9ec9-3b5ce7052327_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Disclosures of Non-Cash Activity:</link:label>
    <link:label id="lab_us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Cash Flow Elements and Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_TypeofEquityMethodInvestmentAxis_1e18a2e9-2f16-4855-8e25-a7c861673808_terseLabel_en-US" xlink:label="lab_amed_TypeofEquityMethodInvestmentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Equity Method Investment [Axis]</link:label>
    <link:label id="lab_amed_TypeofEquityMethodInvestmentAxis_label_en-US" xlink:label="lab_amed_TypeofEquityMethodInvestmentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Equity Method Investment [Axis]</link:label>
    <link:label id="lab_amed_TypeofEquityMethodInvestmentAxis_documentation_en-US" xlink:label="lab_amed_TypeofEquityMethodInvestmentAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Equity Method Investment [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_TypeofEquityMethodInvestmentAxis" xlink:href="amed-20210630.xsd#amed_TypeofEquityMethodInvestmentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_TypeofEquityMethodInvestmentAxis" xlink:to="lab_amed_TypeofEquityMethodInvestmentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_7817b20e-e196-4215-bc17-9f707fc14064_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise of stock options (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsAbstract_26fc5acb-47b2-4ad4-a24e-efdb2528837c_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsAbstract_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:to="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_889f5b3d-e86d-4dd9-91be-7b12a76369da_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ACQUISITIONS</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:to="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_c2d1960e-d8e4-4a5d-9e3e-91b8758d6954_totalLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total other income (expense), net</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="lab_us-gaap_NonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTableTextBlock_c7fd1714-4876-448a-8bc3-28799ab9395f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Revenue by Payor Class</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Revenue Sources, Health Care Organization [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyNatureDomain_21f0099e-6182-4965-9c2a-7cdb5047f3f5_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyNatureDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Nature [Domain]</link:label>
    <link:label id="lab_us-gaap_LossContingencyNatureDomain_label_en-US" xlink:label="lab_us-gaap_LossContingencyNatureDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Nature [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyNatureDomain" xlink:to="lab_us-gaap_LossContingencyNatureDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_CompassionateCareHospiceCIAMember_b391277e-c98f-4d6e-bc29-a0c0917cd8f0_terseLabel_en-US" xlink:label="lab_amed_CompassionateCareHospiceCIAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compassionate Care Hospice CIA</link:label>
    <link:label id="lab_amed_CompassionateCareHospiceCIAMember_label_en-US" xlink:label="lab_amed_CompassionateCareHospiceCIAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compassionate Care Hospice CIA [Member]</link:label>
    <link:label id="lab_amed_CompassionateCareHospiceCIAMember_documentation_en-US" xlink:label="lab_amed_CompassionateCareHospiceCIAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compassionate Care Hospice CIA [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CompassionateCareHospiceCIAMember" xlink:href="amed-20210630.xsd#amed_CompassionateCareHospiceCIAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_CompassionateCareHospiceCIAMember" xlink:to="lab_amed_CompassionateCareHospiceCIAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_PaymentsRelatedToTaxAsset_6afdbf38-0f1a-45c6-90db-79f4912d052f_terseLabel_en-US" xlink:label="lab_amed_PaymentsRelatedToTaxAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments related to tax asset</link:label>
    <link:label id="lab_amed_PaymentsRelatedToTaxAsset_label_en-US" xlink:label="lab_amed_PaymentsRelatedToTaxAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments related to tax asset</link:label>
    <link:label id="lab_amed_PaymentsRelatedToTaxAsset_documentation_en-US" xlink:label="lab_amed_PaymentsRelatedToTaxAsset" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments related to tax asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PaymentsRelatedToTaxAsset" xlink:href="amed-20210630.xsd#amed_PaymentsRelatedToTaxAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_PaymentsRelatedToTaxAsset" xlink:to="lab_amed_PaymentsRelatedToTaxAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_0f445311-6d57-4d7a-9c41-42c4c2769cc8_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_07635b23-3116-466e-8e5e-b34cadece251_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average shares outstanding, basic (shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_9888af89-9e40-40b2-a7f2-5839c29d06fa_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average number of shares outstanding - basic (shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_821d854e-e828-42ea-a75e-868b52f51fce_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis spread on variable rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Basis Spread on Variable Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:to="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_f550438f-7d98-4cd5-a6fb-4355fce8fea5_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract" xlink:to="lab_us-gaap_SubsequentEventsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_OwnershipAxis_965f469b-b59a-45ff-95da-85c56b837de0_terseLabel_en-US" xlink:label="lab_srt_OwnershipAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Axis]</link:label>
    <link:label id="lab_srt_OwnershipAxis_label_en-US" xlink:label="lab_srt_OwnershipAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_OwnershipAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_OwnershipAxis" xlink:to="lab_srt_OwnershipAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingLeaseLiabilities_26c64081-4582-49ef-b0c9-455335f23aff_negatedLabel_en-US" xlink:label="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingLeaseLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Operating Lease Liabilities</link:label>
    <link:label id="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingLeaseLiabilities_label_en-US" xlink:label="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Operating Lease Liabilities</link:label>
    <link:label id="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingLeaseLiabilities_documentation_en-US" xlink:label="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Operating Lease Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingLeaseLiabilities" xlink:href="amed-20210630.xsd#amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingLeaseLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingLeaseLiabilities" xlink:to="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingLeaseLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockShares_4c1ad0cb-f267-4c96-9844-be868287f586_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury stock at cost (shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockShares_label_en-US" xlink:label="lab_us-gaap_TreasuryStockShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockShares" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockShares" xlink:to="lab_us-gaap_TreasuryStockShares" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_CorporateIntegrityAgreementTerm_7eb5df98-8705-4547-8435-b1f8924c9e28_terseLabel_en-US" xlink:label="lab_amed_CorporateIntegrityAgreementTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate integrity agreement term (years)</link:label>
    <link:label id="lab_amed_CorporateIntegrityAgreementTerm_label_en-US" xlink:label="lab_amed_CorporateIntegrityAgreementTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Integrity Agreement Term</link:label>
    <link:label id="lab_amed_CorporateIntegrityAgreementTerm_documentation_en-US" xlink:label="lab_amed_CorporateIntegrityAgreementTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Integrity Agreement Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CorporateIntegrityAgreementTerm" xlink:href="amed-20210630.xsd#amed_CorporateIntegrityAgreementTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_CorporateIntegrityAgreementTerm" xlink:to="lab_amed_CorporateIntegrityAgreementTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesTable_0fd25eb9-9775-48ab-bf1c-b00231221252_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesTable_label_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesTable" xlink:to="lab_us-gaap_LossContingenciesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_OwnershipDomain_c3dc98af-d095-4de1-b63d-2ba41a74f169_terseLabel_en-US" xlink:label="lab_srt_OwnershipDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Domain]</link:label>
    <link:label id="lab_srt_OwnershipDomain_label_en-US" xlink:label="lab_srt_OwnershipDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_OwnershipDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_OwnershipDomain" xlink:to="lab_srt_OwnershipDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_DebtInstrumentInterestAdditionalInterestAboveEurodollarRate_0f2969aa-a6f6-48c7-80e8-05713485e61a_terseLabel_en-US" xlink:label="lab_amed_DebtInstrumentInterestAdditionalInterestAboveEurodollarRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional interest rate above Eurodollar rate</link:label>
    <link:label id="lab_amed_DebtInstrumentInterestAdditionalInterestAboveEurodollarRate_label_en-US" xlink:label="lab_amed_DebtInstrumentInterestAdditionalInterestAboveEurodollarRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument Interest Additional Interest Above Eurodollar Rate</link:label>
    <link:label id="lab_amed_DebtInstrumentInterestAdditionalInterestAboveEurodollarRate_documentation_en-US" xlink:label="lab_amed_DebtInstrumentInterestAdditionalInterestAboveEurodollarRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument Interest Additional Interest Above Eurodollar Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_DebtInstrumentInterestAdditionalInterestAboveEurodollarRate" xlink:href="amed-20210630.xsd#amed_DebtInstrumentInterestAdditionalInterestAboveEurodollarRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_DebtInstrumentInterestAdditionalInterestAboveEurodollarRate" xlink:to="lab_amed_DebtInstrumentInterestAdditionalInterestAboveEurodollarRate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_bd45e849-9922-404f-8979-24783304b5be_terseLabel_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_label_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityWellKnownSeasonedIssuer" xlink:to="lab_dei_EntityWellKnownSeasonedIssuer" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPaidNet_fc80865b-b5b2-4a4d-b1c5-b62aca8b0f3b_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for interest</link:label>
    <link:label id="lab_us-gaap_InterestPaidNet_label_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet" xlink:to="lab_us-gaap_InterestPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch_734e3b97-97ea-4951-92a3-dfa3a1dd8bad_terseLabel_en-US" xlink:label="lab_amed_StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of stock - 401(k) plan</link:label>
    <link:label id="lab_amed_StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch_label_en-US" xlink:label="lab_amed_StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period Value Four Zero One K Employer Match</link:label>
    <link:label id="lab_amed_StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch_documentation_en-US" xlink:label="lab_amed_StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Value of stock issued during the period to employees as employer's matching contribution to the company's 401(K) plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch" xlink:href="amed-20210630.xsd#amed_StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch" xlink:to="lab_amed_StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_4c73e190-3207-4d9c-94e8-2911253050f1_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_a0370973-b9f5-4cd5-964c-35da169d2185_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance, Stockholders Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_0fa4787b-c8ad-4ca0-b65f-87e437b81ec2_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance, Stockholders Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_eef1abb1-b577-4fd4-a33e-bed30a0095da_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NATURE OF OPERATIONS, CONSOLIDATION AND PRESENTATION OF FINANCIAL STATEMENTS</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_d917806b-4bfc-42ed-a05c-576dda09b24c_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right of use assets obtained in exchange for operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_MaximumPercentOwnershipForCostMethodPercent_0724b7b2-12c0-49a3-b29a-d28b183ffbbd_terseLabel_en-US" xlink:label="lab_amed_MaximumPercentOwnershipForCostMethodPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum ownership percentage for cost method investment (percent)</link:label>
    <link:label id="lab_amed_MaximumPercentOwnershipForCostMethodPercent_label_en-US" xlink:label="lab_amed_MaximumPercentOwnershipForCostMethodPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum Percent Ownership For Cost Method Percent</link:label>
    <link:label id="lab_amed_MaximumPercentOwnershipForCostMethodPercent_documentation_en-US" xlink:label="lab_amed_MaximumPercentOwnershipForCostMethodPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description containing the percentage ownership required in order for an investment to be treated under the cost method of accounting in the entity's financial statements.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_MaximumPercentOwnershipForCostMethodPercent" xlink:href="amed-20210630.xsd#amed_MaximumPercentOwnershipForCostMethodPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_MaximumPercentOwnershipForCostMethodPercent" xlink:to="lab_amed_MaximumPercentOwnershipForCostMethodPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtFairValue_9e9d82c7-6fd4-46ef-b679-f7fafc10e00a_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Fair Value</link:label>
    <link:label id="lab_us-gaap_LongTermDebtFairValue_label_en-US" xlink:label="lab_us-gaap_LongTermDebtFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtFairValue" xlink:to="lab_us-gaap_LongTermDebtFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_5ef6bf04-ca5c-4115-83d3-3468fb281197_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_COVID19PPEMember_72fe6b9d-9f8f-48bb-8fa4-d294c87b832c_terseLabel_en-US" xlink:label="lab_amed_COVID19PPEMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COVID-19 PPE [Member]</link:label>
    <link:label id="lab_amed_COVID19PPEMember_label_en-US" xlink:label="lab_amed_COVID19PPEMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COVID-19 PPE [Member]</link:label>
    <link:label id="lab_amed_COVID19PPEMember_documentation_en-US" xlink:label="lab_amed_COVID19PPEMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COVID-19 PPE</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_COVID19PPEMember" xlink:href="amed-20210630.xsd#amed_COVID19PPEMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_COVID19PPEMember" xlink:to="lab_amed_COVID19PPEMember" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_CertificatesOfNeedMember_629f9127-ce8b-481c-9176-35eecfe641c5_terseLabel_en-US" xlink:label="lab_amed_CertificatesOfNeedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certificates Of Need</link:label>
    <link:label id="lab_amed_CertificatesOfNeedMember_label_en-US" xlink:label="lab_amed_CertificatesOfNeedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certificates Of Need [Member]</link:label>
    <link:label id="lab_amed_CertificatesOfNeedMember_documentation_en-US" xlink:label="lab_amed_CertificatesOfNeedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certificates Of Need</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CertificatesOfNeedMember" xlink:href="amed-20210630.xsd#amed_CertificatesOfNeedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_CertificatesOfNeedMember" xlink:to="lab_amed_CertificatesOfNeedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_c9739f4a-5c1f-4e90-8981-0afc0f72b2d9_negatedLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax expense</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses_a849d7f3-788e-4841-8991-9315796adf67_negatedLabel_en-US" xlink:label="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accrued Expenses</link:label>
    <link:label id="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses_label_en-US" xlink:label="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accrued Expenses</link:label>
    <link:label id="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses_documentation_en-US" xlink:label="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accrued Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses" xlink:href="amed-20210630.xsd#amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses" xlink:to="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxesPaidNet_95147006-45b7-4194-8c8b-2506b535f902_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for income taxes, net of refunds received</link:label>
    <link:label id="lab_us-gaap_IncomeTaxesPaidNet_label_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes Paid, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaidNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxesPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesPaidNet" xlink:to="lab_us-gaap_IncomeTaxesPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_f6b68291-8580-4058-b46b-5f39543dcf55_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and restricted cash at beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_8a3081e9-723e-41ca-a582-377fcce9c22b_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and restricted cash at end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_49502503-8727-4317-9b39-0913c5ebfc9a_terseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents and Restricted Cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AociAttributableToNoncontrollingInterestMember_e853336e-2084-44d4-8024-16a0320d5d03_terseLabel_en-US" xlink:label="lab_us-gaap_AociAttributableToNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Noncontrolling Interest</link:label>
    <link:label id="lab_us-gaap_AociAttributableToNoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_AociAttributableToNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AociAttributableToNoncontrollingInterestMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AociAttributableToNoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AociAttributableToNoncontrollingInterestMember" xlink:to="lab_us-gaap_AociAttributableToNoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentMaturityDate_857b1e76-d700-4149-89d6-310b28277915_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentMaturityDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maturity Date</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentMaturityDate_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentMaturityDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Maturity Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentMaturityDate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentMaturityDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentMaturityDate" xlink:to="lab_us-gaap_DebtInstrumentMaturityDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_eb3cee7e-b417-45a3-b2ff-8abfb9ec8252_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_a280c05d-5305-4cbf-8148-79514c359a6c_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_31aa2d19-14cb-4593-8f33-2d42cb7f4277_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income attributable to Amedisys, Inc. common stockholders, diluted (usd per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_15dd1d54-e426-4dbe-a85f-9038bded3c8a_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_d47b0292-a98d-4093-8e3a-1734715a13a7_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to acquire business</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Businesses, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesGross" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionProFormaInformationTextBlock_8598d674-0e66-40b4-a2f8-5653a4fc669a_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Pro Forma Information</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionProFormaInformationTextBlock_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Pro Forma Information [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionProFormaInformationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:to="lab_us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_AmendedDebtInstrumentByLeverageRatioTrancheTwoMember_3c1bbea5-6b1b-41a4-9c66-73030c45dad1_terseLabel_en-US" xlink:label="lab_amed_AmendedDebtInstrumentByLeverageRatioTrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Leverage Ratio: Less Than Equal 3.00 to 1.0 but Greater Than 2.00 to 1.0</link:label>
    <link:label id="lab_amed_AmendedDebtInstrumentByLeverageRatioTrancheTwoMember_label_en-US" xlink:label="lab_amed_AmendedDebtInstrumentByLeverageRatioTrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amended Debt Instrument, By Leverage Ratio, Tranche Two [Member]</link:label>
    <link:label id="lab_amed_AmendedDebtInstrumentByLeverageRatioTrancheTwoMember_documentation_en-US" xlink:label="lab_amed_AmendedDebtInstrumentByLeverageRatioTrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amended Debt Instrument, By Leverage Ratio, Tranche Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AmendedDebtInstrumentByLeverageRatioTrancheTwoMember" xlink:href="amed-20210630.xsd#amed_AmendedDebtInstrumentByLeverageRatioTrancheTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_AmendedDebtInstrumentByLeverageRatioTrancheTwoMember" xlink:to="lab_amed_AmendedDebtInstrumentByLeverageRatioTrancheTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_AmendedDebtInstrumentByLeverageRatioTrancheOneMember_b0892640-4fbb-4fc2-ac6e-a08b6a70ca90_terseLabel_en-US" xlink:label="lab_amed_AmendedDebtInstrumentByLeverageRatioTrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Leverage Ratio: Greater Than 3.00 to 1.0</link:label>
    <link:label id="lab_amed_AmendedDebtInstrumentByLeverageRatioTrancheOneMember_label_en-US" xlink:label="lab_amed_AmendedDebtInstrumentByLeverageRatioTrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amended Debt Instrument, By Leverage Ratio, Tranche One [Member]</link:label>
    <link:label id="lab_amed_AmendedDebtInstrumentByLeverageRatioTrancheOneMember_documentation_en-US" xlink:label="lab_amed_AmendedDebtInstrumentByLeverageRatioTrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amended Debt Instrument, By Leverage Ratio, Tranche One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AmendedDebtInstrumentByLeverageRatioTrancheOneMember" xlink:href="amed-20210630.xsd#amed_AmendedDebtInstrumentByLeverageRatioTrancheOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_AmendedDebtInstrumentByLeverageRatioTrancheOneMember" xlink:to="lab_amed_AmendedDebtInstrumentByLeverageRatioTrancheOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfRestrictedInvestments_b2e77595-e437-4d10-9df7-7a2cf5c6ab4d_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfRestrictedInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sale of deferred compensation plan assets</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfRestrictedInvestments_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfRestrictedInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale of Restricted Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfRestrictedInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleOfRestrictedInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfRestrictedInvestments" xlink:to="lab_us-gaap_ProceedsFromSaleOfRestrictedInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_CARESActProviderReliefFundsReceivedByUnconsolidatedJointVentures_0eef3969-1281-469f-9542-3d767262ec8b_terseLabel_en-US" xlink:label="lab_amed_CARESActProviderReliefFundsReceivedByUnconsolidatedJointVentures" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CARES Act Provider Relief Funds Received by Unconsolidated Joint Ventures</link:label>
    <link:label id="lab_amed_CARESActProviderReliefFundsReceivedByUnconsolidatedJointVentures_label_en-US" xlink:label="lab_amed_CARESActProviderReliefFundsReceivedByUnconsolidatedJointVentures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CARES Act Provider Relief Funds Received by Unconsolidated Joint Ventures</link:label>
    <link:label id="lab_amed_CARESActProviderReliefFundsReceivedByUnconsolidatedJointVentures_documentation_en-US" xlink:label="lab_amed_CARESActProviderReliefFundsReceivedByUnconsolidatedJointVentures" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CARES Act Provider Relief Funds Received by Unconsolidated Joint Ventures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CARESActProviderReliefFundsReceivedByUnconsolidatedJointVentures" xlink:href="amed-20210630.xsd#amed_CARESActProviderReliefFundsReceivedByUnconsolidatedJointVentures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_CARESActProviderReliefFundsReceivedByUnconsolidatedJointVentures" xlink:to="lab_amed_CARESActProviderReliefFundsReceivedByUnconsolidatedJointVentures" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_7afd1659-9f5c-47f8-b7c7-3c91cdecc057_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principal amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:to="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock_9e769ac8-9076-4507-9a8d-578a7a70f07f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-Term Debt</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:to="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_a8546f03-c907-4f69-ba50-f09990f5e233_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Street Name</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncompeteAgreementsMember_bbd6a089-2be8-4827-9cc7-935678cd1776_terseLabel_en-US" xlink:label="lab_us-gaap_NoncompeteAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncompete Agreements [Member]</link:label>
    <link:label id="lab_us-gaap_NoncompeteAgreementsMember_label_en-US" xlink:label="lab_us-gaap_NoncompeteAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncompete Agreements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncompeteAgreementsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncompeteAgreementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncompeteAgreementsMember" xlink:to="lab_us-gaap_NoncompeteAgreementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine2_1e22f37d-394c-4c54-a559-7e3bf0f938a9_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Suite</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine2_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine2" xlink:to="lab_dei_EntityAddressAddressLine2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionDomain_0564159f-7b1e-4b5c-8b11-1dc9d065b132_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Domain]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionDomain_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain" xlink:to="lab_us-gaap_RelatedPartyTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_babb2b4d-86d3-4d91-9f07-a93b52371c6f_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Operating Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_4094e9d4-fed8-413b-add2-5fddcd189042_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_f140ad49-14f1-47a4-9c23-2d152f328c27_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise of stock options</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionsProFormaRevenue_10aefae7-3330-4403-9f45-d33a74c148d1_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net service revenue</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionsProFormaRevenue_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Pro Forma Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionsProFormaRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:to="lab_us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnusualOrInfrequentItemTable_c8f30f67-9aee-4141-aec0-82777826cf2f_terseLabel_en-US" xlink:label="lab_us-gaap_UnusualOrInfrequentItemTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NOVEL CORONAVIRUS PANDEMIC "COVID-19" [Table]</link:label>
    <link:label id="lab_us-gaap_UnusualOrInfrequentItemTable_label_en-US" xlink:label="lab_us-gaap_UnusualOrInfrequentItemTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unusual or Infrequent Item, or Both [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnusualOrInfrequentItemTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnusualOrInfrequentItemTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnusualOrInfrequentItemTable" xlink:to="lab_us-gaap_UnusualOrInfrequentItemTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_fc2fc623-a05d-4f8f-9b5d-f305d1cc1b84_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred income taxes</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_b11e7559-df00-480a-8b7e-f55c87672f03_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit facility, maximum borrowing capacity</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Maximum Borrowing Capacity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_WorkersCompensationInsuranceRetentionLimit_577128d6-fa1b-486b-bf30-e36e55245c20_terseLabel_en-US" xlink:label="lab_amed_WorkersCompensationInsuranceRetentionLimit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Workers compensation insurance retention limit</link:label>
    <link:label id="lab_amed_WorkersCompensationInsuranceRetentionLimit_label_en-US" xlink:label="lab_amed_WorkersCompensationInsuranceRetentionLimit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Workers Compensation Insurance Retention Limit</link:label>
    <link:label id="lab_amed_WorkersCompensationInsuranceRetentionLimit_documentation_en-US" xlink:label="lab_amed_WorkersCompensationInsuranceRetentionLimit" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum potential amount of future payments the entity could be required to make related to a specific Workers' Compensation Insurance Claim.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_WorkersCompensationInsuranceRetentionLimit" xlink:href="amed-20210630.xsd#amed_WorkersCompensationInsuranceRetentionLimit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_WorkersCompensationInsuranceRetentionLimit" xlink:to="lab_amed_WorkersCompensationInsuranceRetentionLimit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_d87674e5-34b9-4264-9b22-27a61780c70f_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets, accumulated amortization</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_SecondThresholdOfServicesRequired_64357593-f273-4d7e-9f32-b3d774d5900e_terseLabel_en-US" xlink:label="lab_amed_SecondThresholdOfServicesRequired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Second threshold of therapy services required (visits)</link:label>
    <link:label id="lab_amed_SecondThresholdOfServicesRequired_label_en-US" xlink:label="lab_amed_SecondThresholdOfServicesRequired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Second Threshold Of Services Required</link:label>
    <link:label id="lab_amed_SecondThresholdOfServicesRequired_documentation_en-US" xlink:label="lab_amed_SecondThresholdOfServicesRequired" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description containing the number of visits related to the second threshold of therapy services required.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_SecondThresholdOfServicesRequired" xlink:href="amed-20210630.xsd#amed_SecondThresholdOfServicesRequired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_SecondThresholdOfServicesRequired" xlink:to="lab_amed_SecondThresholdOfServicesRequired" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_caa2983e-ea72-43d4-995d-4aed015c082a_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_b1722406-30d8-44e6-a400-34b53f6c43c3_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_59043f21-8fc8-42f5-b538-fdec46e4729d_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, authorized (shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_b89503b8-73ec-487a-b26b-2a8ae46ffa9c_terseLabel_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interests</link:label>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestMember" xlink:to="lab_us-gaap_NoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnInvestments_4e1dc5a7-0a53-46ee-bb15-0e15a6702c65_terseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (loss) on equity method investments</link:label>
    <link:label id="lab_us-gaap_GainLossOnInvestments_label_en-US" xlink:label="lab_us-gaap_GainLossOnInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnInvestments" xlink:to="lab_us-gaap_GainLossOnInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCash_cc226f89-4795-4e30-a3c3-b17ffc675fa3_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCash" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCash_label_en-US" xlink:label="lab_us-gaap_RestrictedCash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCash" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCash" xlink:to="lab_us-gaap_RestrictedCash" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_99bc94dd-e363-4fe8-90ee-692e09638828_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_7df6e8a6-7b31-4f97-af75-149a42ce69f1_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, outstanding (shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_FirstThresholdOfTherapyServicesRequired_46682864-5496-41ab-a666-926c1005bcdc_terseLabel_en-US" xlink:label="lab_amed_FirstThresholdOfTherapyServicesRequired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">First threshold of therapy services required (visits)</link:label>
    <link:label id="lab_amed_FirstThresholdOfTherapyServicesRequired_label_en-US" xlink:label="lab_amed_FirstThresholdOfTherapyServicesRequired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">First Threshold Of Therapy Services Required</link:label>
    <link:label id="lab_amed_FirstThresholdOfTherapyServicesRequired_documentation_en-US" xlink:label="lab_amed_FirstThresholdOfTherapyServicesRequired" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description containing the number of visits related to the first threshold of therapy services required.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_FirstThresholdOfTherapyServicesRequired" xlink:href="amed-20210630.xsd#amed_FirstThresholdOfTherapyServicesRequired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_FirstThresholdOfTherapyServicesRequired" xlink:to="lab_amed_FirstThresholdOfTherapyServicesRequired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_78dcf8de-8ec3-4fc8-99bf-4d7fa4ef7c92_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_390a5d49-18e1-4b22-8440-ef650bb77c28_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_53f117ba-9a52-4cc6-84c1-2bbc6abcdd7c_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireInvestments_7b5bb06f-0688-401d-a2b5-2cd28d9c9fb2_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in equity method investees</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireInvestments_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireInvestments" xlink:to="lab_us-gaap_PaymentsToAcquireInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherGeneralAndAdministrativeExpense_04f0f4b6-61f2-4a31-840c-7944be028c60_terseLabel_en-US" xlink:label="lab_us-gaap_OtherGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherGeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_OtherGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherGeneralAndAdministrativeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherGeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherGeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_OtherGeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_FundsReceivedFromProviderReliefFundAdvance_93273bf5-e8ea-4074-808d-83297b266692_terseLabel_en-US" xlink:label="lab_amed_FundsReceivedFromProviderReliefFundAdvance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provider relief fund advance</link:label>
    <link:label id="lab_amed_FundsReceivedFromProviderReliefFundAdvance_label_en-US" xlink:label="lab_amed_FundsReceivedFromProviderReliefFundAdvance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Funds received from Provider relief fund advance</link:label>
    <link:label id="lab_amed_FundsReceivedFromProviderReliefFundAdvance_documentation_en-US" xlink:label="lab_amed_FundsReceivedFromProviderReliefFundAdvance" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The cash inflow from funds received by the government related to the Novel Coronavirus Pandemic "COVID-19"</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_FundsReceivedFromProviderReliefFundAdvance" xlink:href="amed-20210630.xsd#amed_FundsReceivedFromProviderReliefFundAdvance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_FundsReceivedFromProviderReliefFundAdvance" xlink:to="lab_amed_FundsReceivedFromProviderReliefFundAdvance" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_0f9bb03c-0179-40be-af9c-4d3a79d53e1b_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_CARESActProviderReliefFundsUtilized_ea744660-8d1d-4e97-99f8-6c47dcdafdc0_terseLabel_en-US" xlink:label="lab_amed_CARESActProviderReliefFundsUtilized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CARES Act Provider Relief Funds Utilized</link:label>
    <link:label id="lab_amed_CARESActProviderReliefFundsUtilized_label_en-US" xlink:label="lab_amed_CARESActProviderReliefFundsUtilized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CARES Act Provider Relief Funds Utilized</link:label>
    <link:label id="lab_amed_CARESActProviderReliefFundsUtilized_documentation_en-US" xlink:label="lab_amed_CARESActProviderReliefFundsUtilized" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CARES Act Provider Relief Funds Utilized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CARESActProviderReliefFundsUtilized" xlink:href="amed-20210630.xsd#amed_CARESActProviderReliefFundsUtilized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_CARESActProviderReliefFundsUtilized" xlink:to="lab_amed_CARESActProviderReliefFundsUtilized" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_ExtensionOfTemporarySuspensionOfSequestrationRevenueImpact_3f05077d-fb0f-42cf-b0d2-9601e8887f32_terseLabel_en-US" xlink:label="lab_amed_ExtensionOfTemporarySuspensionOfSequestrationRevenueImpact" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Extension of Temporary Suspension of Sequestration, Revenue Impact</link:label>
    <link:label id="lab_amed_ExtensionOfTemporarySuspensionOfSequestrationRevenueImpact_label_en-US" xlink:label="lab_amed_ExtensionOfTemporarySuspensionOfSequestrationRevenueImpact" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Extension of Temporary Suspension of Sequestration, Revenue Impact</link:label>
    <link:label id="lab_amed_ExtensionOfTemporarySuspensionOfSequestrationRevenueImpact_documentation_en-US" xlink:label="lab_amed_ExtensionOfTemporarySuspensionOfSequestrationRevenueImpact" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The impact on revenue due to the extension of the temporary suspension of sequestration as a result of the novel coronavrius pandemic ("COVID-19").</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ExtensionOfTemporarySuspensionOfSequestrationRevenueImpact" xlink:href="amed-20210630.xsd#amed_ExtensionOfTemporarySuspensionOfSequestrationRevenueImpact"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_ExtensionOfTemporarySuspensionOfSequestrationRevenueImpact" xlink:to="lab_amed_ExtensionOfTemporarySuspensionOfSequestrationRevenueImpact" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_CreditFacilityMaximumAllowableConsolidatedLeverageRatioMultiple_96b576bb-867e-4a4f-90c4-07de9c15f794_terseLabel_en-US" xlink:label="lab_amed_CreditFacilityMaximumAllowableConsolidatedLeverageRatioMultiple" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility Maximum Allowable Consolidated Leverage Ratio Multiple</link:label>
    <link:label id="lab_amed_CreditFacilityMaximumAllowableConsolidatedLeverageRatioMultiple_label_en-US" xlink:label="lab_amed_CreditFacilityMaximumAllowableConsolidatedLeverageRatioMultiple" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility Maximum Allowable Consolidated Leverage Ratio Multiple</link:label>
    <link:label id="lab_amed_CreditFacilityMaximumAllowableConsolidatedLeverageRatioMultiple_documentation_en-US" xlink:label="lab_amed_CreditFacilityMaximumAllowableConsolidatedLeverageRatioMultiple" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility, Maximum Allowable Consolidated Leverage Ratio Multiple</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CreditFacilityMaximumAllowableConsolidatedLeverageRatioMultiple" xlink:href="amed-20210630.xsd#amed_CreditFacilityMaximumAllowableConsolidatedLeverageRatioMultiple"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_CreditFacilityMaximumAllowableConsolidatedLeverageRatioMultiple" xlink:to="lab_amed_CreditFacilityMaximumAllowableConsolidatedLeverageRatioMultiple" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockValue_6c60a569-58f9-4d75-9b27-75f5eff57b20_negatedLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValue" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury stock, at cost 4,976,526 and 4,655,934 shares of common stock</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValue_label_en-US" xlink:label="lab_us-gaap_TreasuryStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockValue" xlink:to="lab_us-gaap_TreasuryStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_Percentageofclosingstockprice_73db66b6-7e62-44b6-b51f-16f860a4f75d_terseLabel_en-US" xlink:label="lab_amed_Percentageofclosingstockprice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of closing stock price</link:label>
    <link:label id="lab_amed_Percentageofclosingstockprice_label_en-US" xlink:label="lab_amed_Percentageofclosingstockprice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of closing stock price</link:label>
    <link:label id="lab_amed_Percentageofclosingstockprice_documentation_en-US" xlink:label="lab_amed_Percentageofclosingstockprice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of closing stock price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_Percentageofclosingstockprice" xlink:href="amed-20210630.xsd#amed_Percentageofclosingstockprice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_Percentageofclosingstockprice" xlink:to="lab_amed_Percentageofclosingstockprice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_190b456d-fd38-4fa2-b097-e2ebfde59c7d_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_1b58b92e-0d6c-476e-b637-5be2a4d97900_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_140e998b-1027-4eb6-a118-86a5c1daf229_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingInformationLineItems_7786296a-e948-4f21-936b-4e779a1dce88_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Information [Line Items]</link:label>
    <link:label id="lab_us-gaap_SegmentReportingInformationLineItems_label_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Information [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems" xlink:to="lab_us-gaap_SegmentReportingInformationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_CARESActDeferralOfEmployerShareSocialSecurityTax_a857394c-ebaf-4ef1-b7c4-864429a4a938_terseLabel_en-US" xlink:label="lab_amed_CARESActDeferralOfEmployerShareSocialSecurityTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CARES Act Deferral of Employer Share Social Security Tax</link:label>
    <link:label id="lab_amed_CARESActDeferralOfEmployerShareSocialSecurityTax_label_en-US" xlink:label="lab_amed_CARESActDeferralOfEmployerShareSocialSecurityTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CARES Act Deferral of Employer Share Social Security Tax</link:label>
    <link:label id="lab_amed_CARESActDeferralOfEmployerShareSocialSecurityTax_documentation_en-US" xlink:label="lab_amed_CARESActDeferralOfEmployerShareSocialSecurityTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The deferral of the employer's share social security tax provided by the CARES Act</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CARESActDeferralOfEmployerShareSocialSecurityTax" xlink:href="amed-20210630.xsd#amed_CARESActDeferralOfEmployerShareSocialSecurityTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_CARESActDeferralOfEmployerShareSocialSecurityTax" xlink:to="lab_amed_CARESActDeferralOfEmployerShareSocialSecurityTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_842c2ba6-c8fc-43d7-99e8-42a3528368fa_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recent Accounting Pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_7a81a8ca-b09b-4570-b1be-5d3160660d0a_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAbstract_27a19cd1-7fc1-4762-8f9e-bb01be79de3d_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic earnings per common share:</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract" xlink:to="lab_us-gaap_EarningsPerShareBasicAbstract" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>10
<FILENAME>amed-20210630_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:9b598574-bbed-4d17-bc5e-2b8ec86d1c16,g:311e4854-6196-49e6-97c5-f444b0264a32-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.amedisys.com/role/Cover" xlink:type="simple" xlink:href="amed-20210630.xsd#Cover"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_24b79f99-b284-49c1-bee7-e2594be61589" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_65be133d-ae9d-41cc-a7b3-b76bf4b703ae" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_24b79f99-b284-49c1-bee7-e2594be61589" xlink:to="loc_dei_DocumentType_65be133d-ae9d-41cc-a7b3-b76bf4b703ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_2a1ae48a-6478-468a-8768-fb5c16543c86" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_24b79f99-b284-49c1-bee7-e2594be61589" xlink:to="loc_dei_DocumentQuarterlyReport_2a1ae48a-6478-468a-8768-fb5c16543c86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_4e92bee5-63d0-4a61-991b-dc1840e4e90c" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_24b79f99-b284-49c1-bee7-e2594be61589" xlink:to="loc_dei_DocumentPeriodEndDate_4e92bee5-63d0-4a61-991b-dc1840e4e90c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_8dd9246a-0cfa-4088-a777-f7893716c703" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_24b79f99-b284-49c1-bee7-e2594be61589" xlink:to="loc_dei_DocumentTransitionReport_8dd9246a-0cfa-4088-a777-f7893716c703" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_0fd16ef4-a87c-4b32-b136-1c82dc2fdaf2" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_24b79f99-b284-49c1-bee7-e2594be61589" xlink:to="loc_dei_EntityFileNumber_0fd16ef4-a87c-4b32-b136-1c82dc2fdaf2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_bceea2e2-aeeb-403f-9783-13b1a92361c8" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_24b79f99-b284-49c1-bee7-e2594be61589" xlink:to="loc_dei_EntityRegistrantName_bceea2e2-aeeb-403f-9783-13b1a92361c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_0e24cd4c-65ad-4321-840c-22d0c5889238" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_24b79f99-b284-49c1-bee7-e2594be61589" xlink:to="loc_dei_EntityIncorporationStateCountryCode_0e24cd4c-65ad-4321-840c-22d0c5889238" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_0faf688d-1a60-4e0c-aa85-258bd27d78be" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_24b79f99-b284-49c1-bee7-e2594be61589" xlink:to="loc_dei_EntityTaxIdentificationNumber_0faf688d-1a60-4e0c-aa85-258bd27d78be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_b4500786-d855-4d49-9923-8bd48c91e473" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_24b79f99-b284-49c1-bee7-e2594be61589" xlink:to="loc_dei_EntityAddressAddressLine1_b4500786-d855-4d49-9923-8bd48c91e473" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2_d2dcfe6c-ca5d-4b25-b81b-c9df15090fe6" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine2"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_24b79f99-b284-49c1-bee7-e2594be61589" xlink:to="loc_dei_EntityAddressAddressLine2_d2dcfe6c-ca5d-4b25-b81b-c9df15090fe6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_975f1a2d-9b69-4736-97d4-9fafb7a117ba" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_24b79f99-b284-49c1-bee7-e2594be61589" xlink:to="loc_dei_EntityAddressCityOrTown_975f1a2d-9b69-4736-97d4-9fafb7a117ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_ca1d0a19-56c7-4109-ac04-c9c6b4fff6a4" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_24b79f99-b284-49c1-bee7-e2594be61589" xlink:to="loc_dei_EntityAddressStateOrProvince_ca1d0a19-56c7-4109-ac04-c9c6b4fff6a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_5b470473-1bcf-4388-bef5-ec482c4c8b76" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_24b79f99-b284-49c1-bee7-e2594be61589" xlink:to="loc_dei_EntityAddressPostalZipCode_5b470473-1bcf-4388-bef5-ec482c4c8b76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_3b21602a-5c05-490f-b68b-5ca44b59adc3" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_24b79f99-b284-49c1-bee7-e2594be61589" xlink:to="loc_dei_CityAreaCode_3b21602a-5c05-490f-b68b-5ca44b59adc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_4a37c461-cc55-4255-8e19-92a527f33f50" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_24b79f99-b284-49c1-bee7-e2594be61589" xlink:to="loc_dei_LocalPhoneNumber_4a37c461-cc55-4255-8e19-92a527f33f50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_ac5e2745-ad57-4f2e-b39f-1ff28ad32b05" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_24b79f99-b284-49c1-bee7-e2594be61589" xlink:to="loc_dei_Security12bTitle_ac5e2745-ad57-4f2e-b39f-1ff28ad32b05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_7176ef47-1c1d-4ba5-9ab9-16516929b57b" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_24b79f99-b284-49c1-bee7-e2594be61589" xlink:to="loc_dei_TradingSymbol_7176ef47-1c1d-4ba5-9ab9-16516929b57b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_b819d3a4-d943-4648-bf1a-c32f41d7a9eb" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_24b79f99-b284-49c1-bee7-e2594be61589" xlink:to="loc_dei_SecurityExchangeName_b819d3a4-d943-4648-bf1a-c32f41d7a9eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_5691827a-e7be-404a-b3dd-1e2efa600ca5" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_24b79f99-b284-49c1-bee7-e2594be61589" xlink:to="loc_dei_EntityCurrentReportingStatus_5691827a-e7be-404a-b3dd-1e2efa600ca5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_e531cb51-b61a-4ae5-b3a2-d3781e8d7da5" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_24b79f99-b284-49c1-bee7-e2594be61589" xlink:to="loc_dei_EntityInteractiveDataCurrent_e531cb51-b61a-4ae5-b3a2-d3781e8d7da5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_30b8a9db-4d93-4a8b-96e7-0a21c522140f" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_24b79f99-b284-49c1-bee7-e2594be61589" xlink:to="loc_dei_EntityFilerCategory_30b8a9db-4d93-4a8b-96e7-0a21c522140f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_8fc48944-28bf-411e-9b9a-c6547ae0a8f4" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_24b79f99-b284-49c1-bee7-e2594be61589" xlink:to="loc_dei_EntityEmergingGrowthCompany_8fc48944-28bf-411e-9b9a-c6547ae0a8f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_9d1bfecd-0bbd-4f60-887f-0f02e975d99a" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_24b79f99-b284-49c1-bee7-e2594be61589" xlink:to="loc_dei_EntitySmallBusiness_9d1bfecd-0bbd-4f60-887f-0f02e975d99a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_e5a39ae6-4849-4cae-b314-c6658bff1c9c" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_24b79f99-b284-49c1-bee7-e2594be61589" xlink:to="loc_dei_EntityShellCompany_e5a39ae6-4849-4cae-b314-c6658bff1c9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_3ce993e6-b458-4031-94ce-0a1f8a32c33c" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_24b79f99-b284-49c1-bee7-e2594be61589" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_3ce993e6-b458-4031-94ce-0a1f8a32c33c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_9646e551-f83f-4888-ba28-00e2026b3e5e" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_24b79f99-b284-49c1-bee7-e2594be61589" xlink:to="loc_dei_AmendmentFlag_9646e551-f83f-4888-ba28-00e2026b3e5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_1fd30ee4-2cd0-4d71-a4aa-9208b1ea6bbd" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_24b79f99-b284-49c1-bee7-e2594be61589" xlink:to="loc_dei_DocumentFiscalYearFocus_1fd30ee4-2cd0-4d71-a4aa-9208b1ea6bbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_2377067a-872b-42f4-b53f-7747fd7a278a" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_24b79f99-b284-49c1-bee7-e2594be61589" xlink:to="loc_dei_DocumentFiscalPeriodFocus_2377067a-872b-42f4-b53f-7747fd7a278a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_aee4606d-0c81-44dc-ab2b-580a69e5fac1" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_24b79f99-b284-49c1-bee7-e2594be61589" xlink:to="loc_dei_EntityCentralIndexKey_aee4606d-0c81-44dc-ab2b-580a69e5fac1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_06e7d368-0d78-4ea1-a276-4847f6ad1304" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_24b79f99-b284-49c1-bee7-e2594be61589" xlink:to="loc_dei_CurrentFiscalYearEndDate_06e7d368-0d78-4ea1-a276-4847f6ad1304" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers_45f04d37-f531-46a5-8d78-eefdf82b6737" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityVoluntaryFilers"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_24b79f99-b284-49c1-bee7-e2594be61589" xlink:to="loc_dei_EntityVoluntaryFilers_45f04d37-f531-46a5-8d78-eefdf82b6737" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_5db7ad9d-6054-4152-a848-56e38361ed7e" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_24b79f99-b284-49c1-bee7-e2594be61589" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_5db7ad9d-6054-4152-a848-56e38361ed7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="amed-20210630.xsd#CONSOLIDATEDBALANCESHEETS"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_4f4e2649-a6eb-42d3-8749-0945e6bc0e82" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_9d298ae5-0aa1-4c81-ab82-144203a40a0f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_4f4e2649-a6eb-42d3-8749-0945e6bc0e82" xlink:to="loc_us-gaap_AssetsAbstract_9d298ae5-0aa1-4c81-ab82-144203a40a0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_ffa2953a-2e59-479c-8a88-151721003b76" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_9d298ae5-0aa1-4c81-ab82-144203a40a0f" xlink:to="loc_us-gaap_AssetsCurrentAbstract_ffa2953a-2e59-479c-8a88-151721003b76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_4f01f90b-4810-4893-a205-54a9d45c98f4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_ffa2953a-2e59-479c-8a88-151721003b76" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_4f01f90b-4810-4893-a205-54a9d45c98f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCash_0e2858fd-e2d6-415b-bf13-48e432cff18e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCash"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_ffa2953a-2e59-479c-8a88-151721003b76" xlink:to="loc_us-gaap_RestrictedCash_0e2858fd-e2d6-415b-bf13-48e432cff18e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_5d804c63-2703-4089-b54e-aa36de98c12d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_ffa2953a-2e59-479c-8a88-151721003b76" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_5d804c63-2703-4089-b54e-aa36de98c12d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_d003e5b2-c1bb-425e-b2e1-3d11376be47e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_ffa2953a-2e59-479c-8a88-151721003b76" xlink:to="loc_us-gaap_PrepaidExpenseCurrent_d003e5b2-c1bb-425e-b2e1-3d11376be47e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_a75682b6-f6ed-4728-8e5c-69427fbe9527" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_ffa2953a-2e59-479c-8a88-151721003b76" xlink:to="loc_us-gaap_OtherAssetsCurrent_a75682b6-f6ed-4728-8e5c-69427fbe9527" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_2bf76acc-ef89-41af-bbd2-ec9143039832" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_ffa2953a-2e59-479c-8a88-151721003b76" xlink:to="loc_us-gaap_AssetsCurrent_2bf76acc-ef89-41af-bbd2-ec9143039832" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_5a08f7a1-0628-461a-ad9b-d6e31b29c875" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_9d298ae5-0aa1-4c81-ab82-144203a40a0f" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_5a08f7a1-0628-461a-ad9b-d6e31b29c875" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_c269edda-62be-4c5c-8d0e-8dbf330f3026" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_9d298ae5-0aa1-4c81-ab82-144203a40a0f" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_c269edda-62be-4c5c-8d0e-8dbf330f3026" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_f4a440a1-0a73-458d-94ec-844bf3f1c274" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_9d298ae5-0aa1-4c81-ab82-144203a40a0f" xlink:to="loc_us-gaap_Goodwill_f4a440a1-0a73-458d-94ec-844bf3f1c274" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_0c65ffb9-232b-4a1d-b520-85eb2064a7cd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_9d298ae5-0aa1-4c81-ab82-144203a40a0f" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_0c65ffb9-232b-4a1d-b520-85eb2064a7cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_8b44071e-57b3-477a-84cd-aa0072bd136e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_9d298ae5-0aa1-4c81-ab82-144203a40a0f" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet_8b44071e-57b3-477a-84cd-aa0072bd136e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_a19eb674-5b3d-4e4a-980c-a20301d47712" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_9d298ae5-0aa1-4c81-ab82-144203a40a0f" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_a19eb674-5b3d-4e4a-980c-a20301d47712" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_1833386f-c2f9-4a30-b052-e3cde9a1cd0b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_9d298ae5-0aa1-4c81-ab82-144203a40a0f" xlink:to="loc_us-gaap_Assets_1833386f-c2f9-4a30-b052-e3cde9a1cd0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_12d673d7-804f-41fd-ad0b-b1fbe494a65a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_4f4e2649-a6eb-42d3-8749-0945e6bc0e82" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_12d673d7-804f-41fd-ad0b-b1fbe494a65a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_a695b404-ddf2-4e0f-83bb-4804660dc1e8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_12d673d7-804f-41fd-ad0b-b1fbe494a65a" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_a695b404-ddf2-4e0f-83bb-4804660dc1e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_64e0f677-7429-40de-87d8-90d6d4e70906" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_a695b404-ddf2-4e0f-83bb-4804660dc1e8" xlink:to="loc_us-gaap_AccountsPayableCurrent_64e0f677-7429-40de-87d8-90d6d4e70906" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_b53f59c9-3170-4f45-93a5-b645fd977c39" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_a695b404-ddf2-4e0f-83bb-4804660dc1e8" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_b53f59c9-3170-4f45-93a5-b645fd977c39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_0a71c8c3-5bb7-42c5-8ba7-78b0a8d5bcf7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_a695b404-ddf2-4e0f-83bb-4804660dc1e8" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_0a71c8c3-5bb7-42c5-8ba7-78b0a8d5bcf7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ProviderReliefFundAdvance_94e6661a-1969-474d-bb49-3c0c901751a2" xlink:href="amed-20210630.xsd#amed_ProviderReliefFundAdvance"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_a695b404-ddf2-4e0f-83bb-4804660dc1e8" xlink:to="loc_amed_ProviderReliefFundAdvance_94e6661a-1969-474d-bb49-3c0c901751a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_1addcb46-38b6-4246-afb4-b5941eba2d6e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_a695b404-ddf2-4e0f-83bb-4804660dc1e8" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_1addcb46-38b6-4246-afb4-b5941eba2d6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_73c639fa-f9c9-451e-93ac-a85894a8fafe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_a695b404-ddf2-4e0f-83bb-4804660dc1e8" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_73c639fa-f9c9-451e-93ac-a85894a8fafe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_f698a491-4f5b-46cd-9409-065ef998c66c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_a695b404-ddf2-4e0f-83bb-4804660dc1e8" xlink:to="loc_us-gaap_LiabilitiesCurrent_f698a491-4f5b-46cd-9409-065ef998c66c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_18f252c3-513f-42ed-9a14-43a7fe3e1131" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligations"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_12d673d7-804f-41fd-ad0b-b1fbe494a65a" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_18f252c3-513f-42ed-9a14-43a7fe3e1131" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_f3f8d17b-38eb-4f97-a4be-143312d90848" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_12d673d7-804f-41fd-ad0b-b1fbe494a65a" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_f3f8d17b-38eb-4f97-a4be-143312d90848" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_f10c929a-314e-4fcb-9c1d-7e9de846855d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_12d673d7-804f-41fd-ad0b-b1fbe494a65a" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_f10c929a-314e-4fcb-9c1d-7e9de846855d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_8d45db6c-b53a-40cd-9c8e-3af39ee9500f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_12d673d7-804f-41fd-ad0b-b1fbe494a65a" xlink:to="loc_us-gaap_Liabilities_8d45db6c-b53a-40cd-9c8e-3af39ee9500f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_97f18cd4-6e75-4591-8278-3b467338d64b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_12d673d7-804f-41fd-ad0b-b1fbe494a65a" xlink:to="loc_us-gaap_CommitmentsAndContingencies_97f18cd4-6e75-4591-8278-3b467338d64b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_61ff15fe-1e76-45cb-9a16-b7b81dd3027f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_12d673d7-804f-41fd-ad0b-b1fbe494a65a" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_61ff15fe-1e76-45cb-9a16-b7b81dd3027f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValueOutstanding_964bd080-f323-4a85-9f0a-96ca7c8ff38e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValueOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_61ff15fe-1e76-45cb-9a16-b7b81dd3027f" xlink:to="loc_us-gaap_PreferredStockValueOutstanding_964bd080-f323-4a85-9f0a-96ca7c8ff38e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValueOutstanding_40995939-a8a7-4001-80bd-4f3a7b92fe50" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValueOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_61ff15fe-1e76-45cb-9a16-b7b81dd3027f" xlink:to="loc_us-gaap_CommonStockValueOutstanding_40995939-a8a7-4001-80bd-4f3a7b92fe50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_badd70c7-b850-42a4-ad35-053e70712eec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_61ff15fe-1e76-45cb-9a16-b7b81dd3027f" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_badd70c7-b850-42a4-ad35-053e70712eec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue_d0e09a5c-6374-417b-986e-88087c97b143" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_61ff15fe-1e76-45cb-9a16-b7b81dd3027f" xlink:to="loc_us-gaap_TreasuryStockValue_d0e09a5c-6374-417b-986e-88087c97b143" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_baaf5892-869b-44cf-aec2-9cd08b333c45" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_61ff15fe-1e76-45cb-9a16-b7b81dd3027f" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_baaf5892-869b-44cf-aec2-9cd08b333c45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_f9275a75-e73f-437c-a632-b7fe1c577546" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_61ff15fe-1e76-45cb-9a16-b7b81dd3027f" xlink:to="loc_us-gaap_StockholdersEquity_f9275a75-e73f-437c-a632-b7fe1c577546" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_45ac3cd1-ae9b-497a-82f0-3e0ef0e35fd9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterest"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_61ff15fe-1e76-45cb-9a16-b7b81dd3027f" xlink:to="loc_us-gaap_MinorityInterest_45ac3cd1-ae9b-497a-82f0-3e0ef0e35fd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_f46ba29b-9eb4-4f16-815c-4456c9f47293" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_61ff15fe-1e76-45cb-9a16-b7b81dd3027f" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_f46ba29b-9eb4-4f16-815c-4456c9f47293" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_fd455a18-299c-4943-a8a3-c7cddc31ddfc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_12d673d7-804f-41fd-ad0b-b1fbe494a65a" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_fd455a18-299c-4943-a8a3-c7cddc31ddfc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="simple" xlink:href="amed-20210630.xsd#CONSOLIDATEDBALANCESHEETSParenthetical"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_f600b96a-fa38-46ea-bc08-e4033159251b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_266469f3-bee2-431c-8c07-a5700cb48031" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_f600b96a-fa38-46ea-bc08-e4033159251b" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_266469f3-bee2-431c-8c07-a5700cb48031" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_b610c48c-7f23-4400-a7da-fc1d3a5564f9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_f600b96a-fa38-46ea-bc08-e4033159251b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_b610c48c-7f23-4400-a7da-fc1d3a5564f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_26692a6a-5512-4e69-a515-8e233da7f063" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_f600b96a-fa38-46ea-bc08-e4033159251b" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_26692a6a-5512-4e69-a515-8e233da7f063" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_3ad73b32-6f17-48c7-994a-58cd85f17fc1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_f600b96a-fa38-46ea-bc08-e4033159251b" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_3ad73b32-6f17-48c7-994a-58cd85f17fc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_1ed86248-124b-4d37-beda-b77d23fbec83" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_f600b96a-fa38-46ea-bc08-e4033159251b" xlink:to="loc_us-gaap_PreferredStockSharesIssued_1ed86248-124b-4d37-beda-b77d23fbec83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_4ea15e8f-71a8-4b2f-b8c7-695241843e80" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_f600b96a-fa38-46ea-bc08-e4033159251b" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_4ea15e8f-71a8-4b2f-b8c7-695241843e80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_7f9b7c6c-a902-4f17-a160-07df7501a8f5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_f600b96a-fa38-46ea-bc08-e4033159251b" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_7f9b7c6c-a902-4f17-a160-07df7501a8f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_0efd290f-45df-4b58-ad24-95414fb68021" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_f600b96a-fa38-46ea-bc08-e4033159251b" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_0efd290f-45df-4b58-ad24-95414fb68021" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_af9051da-fed9-4410-a401-527d6c921c98" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_f600b96a-fa38-46ea-bc08-e4033159251b" xlink:to="loc_us-gaap_CommonStockSharesIssued_af9051da-fed9-4410-a401-527d6c921c98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_91638e6b-cba5-4b77-b92c-3b8e299047b6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_f600b96a-fa38-46ea-bc08-e4033159251b" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_91638e6b-cba5-4b77-b92c-3b8e299047b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockShares_d0666f6f-a890-44ea-9a9c-a0250400acd2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockShares"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_f600b96a-fa38-46ea-bc08-e4033159251b" xlink:to="loc_us-gaap_TreasuryStockShares_d0666f6f-a890-44ea-9a9c-a0250400acd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="simple" xlink:href="amed-20210630.xsd#CONSOLIDATEDSTATEMENTSOFOPERATIONS"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_8a187285-ef76-4a53-8a04-da1bb5e2d7e1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions_11fd3fa7-fb86-4d74-9149-5531251d1d1a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_8a187285-ef76-4a53-8a04-da1bb5e2d7e1" xlink:to="loc_us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions_11fd3fa7-fb86-4d74-9149-5531251d1d1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncome_bce170c1-cab8-4f4c-9d93-64f00e821578" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherOperatingIncome"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_8a187285-ef76-4a53-8a04-da1bb5e2d7e1" xlink:to="loc_us-gaap_OtherOperatingIncome_bce170c1-cab8-4f4c-9d93-64f00e821578" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_fca9c7a3-dde3-4bcc-ae42-a47cec1c5dfc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_8a187285-ef76-4a53-8a04-da1bb5e2d7e1" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_fca9c7a3-dde3-4bcc-ae42-a47cec1c5dfc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseAbstract_d26a372e-3dbb-4c06-a948-896d9dfa5ea0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_8a187285-ef76-4a53-8a04-da1bb5e2d7e1" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseAbstract_d26a372e-3dbb-4c06-a948-896d9dfa5ea0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LaborAndRelatedExpense_612d0fb2-fca7-4b0b-894a-9d248238e8a5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LaborAndRelatedExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseAbstract_d26a372e-3dbb-4c06-a948-896d9dfa5ea0" xlink:to="loc_us-gaap_LaborAndRelatedExpense_612d0fb2-fca7-4b0b-894a-9d248238e8a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_23d84ce5-0673-4514-89c8-7ebe43dfee33" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseAbstract_d26a372e-3dbb-4c06-a948-896d9dfa5ea0" xlink:to="loc_us-gaap_ShareBasedCompensation_23d84ce5-0673-4514-89c8-7ebe43dfee33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherGeneralAndAdministrativeExpense_d2f1abdf-cb92-4b88-8b8d-bb8b68cefd5c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseAbstract_d26a372e-3dbb-4c06-a948-896d9dfa5ea0" xlink:to="loc_us-gaap_OtherGeneralAndAdministrativeExpense_d2f1abdf-cb92-4b88-8b8d-bb8b68cefd5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization_1dc6e9b3-94f3-4ff4-9614-f06d363621cf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_8a187285-ef76-4a53-8a04-da1bb5e2d7e1" xlink:to="loc_us-gaap_DepreciationAndAmortization_1dc6e9b3-94f3-4ff4-9614-f06d363621cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_97f14170-b986-4862-8b46-06b32e653644" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_8a187285-ef76-4a53-8a04-da1bb5e2d7e1" xlink:to="loc_us-gaap_CostsAndExpenses_97f14170-b986-4862-8b46-06b32e653644" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_d046861f-adfc-4a27-a9c9-576ba857b0e8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_8a187285-ef76-4a53-8a04-da1bb5e2d7e1" xlink:to="loc_us-gaap_OperatingIncomeLoss_d046861f-adfc-4a27-a9c9-576ba857b0e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_2dffd7da-2717-499d-9cb5-3dd2ade27a39" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_8a187285-ef76-4a53-8a04-da1bb5e2d7e1" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_2dffd7da-2717-499d-9cb5-3dd2ade27a39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterestAndDividend_f0bdc621-4e86-4a8c-b1b2-a8107aee07b1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeInterestAndDividend"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_2dffd7da-2717-499d-9cb5-3dd2ade27a39" xlink:to="loc_us-gaap_InvestmentIncomeInterestAndDividend_f0bdc621-4e86-4a8c-b1b2-a8107aee07b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_fdeb8ee0-c89c-49ff-b73d-d1eeb89af4d1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_2dffd7da-2717-499d-9cb5-3dd2ade27a39" xlink:to="loc_us-gaap_InterestExpense_fdeb8ee0-c89c-49ff-b73d-d1eeb89af4d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_9f01ccae-dbec-47bb-8464-07b5b5bf667e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_2dffd7da-2717-499d-9cb5-3dd2ade27a39" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_9f01ccae-dbec-47bb-8464-07b5b5bf667e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnInvestments_3c0cca39-4047-4da3-be2c-8083bbca68e4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnInvestments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_2dffd7da-2717-499d-9cb5-3dd2ade27a39" xlink:to="loc_us-gaap_GainLossOnInvestments_3c0cca39-4047-4da3-be2c-8083bbca68e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_c260d64c-ae08-4552-b843-7a6a3f737550" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_2dffd7da-2717-499d-9cb5-3dd2ade27a39" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_c260d64c-ae08-4552-b843-7a6a3f737550" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_ed5409f7-d591-40c1-9b6e-289a168abf58" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_2dffd7da-2717-499d-9cb5-3dd2ade27a39" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_ed5409f7-d591-40c1-9b6e-289a168abf58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_ff25938e-230d-4253-81ee-78ca7dacd164" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_8a187285-ef76-4a53-8a04-da1bb5e2d7e1" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_ff25938e-230d-4253-81ee-78ca7dacd164" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_283dbfd4-a963-4f73-b41d-4670817b98eb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_8a187285-ef76-4a53-8a04-da1bb5e2d7e1" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_283dbfd4-a963-4f73-b41d-4670817b98eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_dd61700f-9e01-449e-ab43-8a4e82aed8b3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_8a187285-ef76-4a53-8a04-da1bb5e2d7e1" xlink:to="loc_us-gaap_ProfitLoss_dd61700f-9e01-449e-ab43-8a4e82aed8b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_eaf85326-adc3-4e48-bd4c-f4af16fa767f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_8a187285-ef76-4a53-8a04-da1bb5e2d7e1" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_eaf85326-adc3-4e48-bd4c-f4af16fa767f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_9c3ec265-4531-457b-abeb-83057fb61ef5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_8a187285-ef76-4a53-8a04-da1bb5e2d7e1" xlink:to="loc_us-gaap_NetIncomeLoss_9c3ec265-4531-457b-abeb-83057fb61ef5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAbstract_563d060f-07ec-4836-a88b-411cadd59075" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAbstract"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_8a187285-ef76-4a53-8a04-da1bb5e2d7e1" xlink:to="loc_us-gaap_EarningsPerShareBasicAbstract_563d060f-07ec-4836-a88b-411cadd59075" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_6d175acf-3718-473b-ac63-ab28fc04b052" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_563d060f-07ec-4836-a88b-411cadd59075" xlink:to="loc_us-gaap_EarningsPerShareBasic_6d175acf-3718-473b-ac63-ab28fc04b052" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_b30bac95-eb10-4544-b326-dc824cbb9714" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_563d060f-07ec-4836-a88b-411cadd59075" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_b30bac95-eb10-4544-b326-dc824cbb9714" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDilutedAbstract_e903cba9-4014-48c4-b6e0-300e3600bd7d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareDilutedAbstract"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_8a187285-ef76-4a53-8a04-da1bb5e2d7e1" xlink:to="loc_us-gaap_EarningsPerShareDilutedAbstract_e903cba9-4014-48c4-b6e0-300e3600bd7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_2819b1e6-f95f-4aa6-ac66-4368bd3b56d7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareDilutedAbstract_e903cba9-4014-48c4-b6e0-300e3600bd7d" xlink:to="loc_us-gaap_EarningsPerShareDiluted_2819b1e6-f95f-4aa6-ac66-4368bd3b56d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_aebc878d-8d42-49b1-9a61-be9eb07e74f6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareDilutedAbstract_e903cba9-4014-48c4-b6e0-300e3600bd7d" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_aebc878d-8d42-49b1-9a61-be9eb07e74f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYStatement" xlink:type="simple" xlink:href="amed-20210630.xsd#CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYStatement"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYStatement" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_e9f4dbe9-c3a1-457f-8ef9-ef691d3230d9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_31fa1865-946a-4494-ac59-c042aa72169c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_e9f4dbe9-c3a1-457f-8ef9-ef691d3230d9" xlink:to="loc_us-gaap_StatementTable_31fa1865-946a-4494-ac59-c042aa72169c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_308a2f73-d2b3-4223-8bbf-112bb2875d7f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_31fa1865-946a-4494-ac59-c042aa72169c" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_308a2f73-d2b3-4223-8bbf-112bb2875d7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_8f83fde8-8980-4879-a26b-00e9ea31e6bd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_308a2f73-d2b3-4223-8bbf-112bb2875d7f" xlink:to="loc_us-gaap_EquityComponentDomain_8f83fde8-8980-4879-a26b-00e9ea31e6bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_c1221614-43f6-42cc-93f9-f944d145028e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_8f83fde8-8980-4879-a26b-00e9ea31e6bd" xlink:to="loc_us-gaap_CommonStockMember_c1221614-43f6-42cc-93f9-f944d145028e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_bd5507a9-8567-4ce0-9dc7-b235730a1b2c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_8f83fde8-8980-4879-a26b-00e9ea31e6bd" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_bd5507a9-8567-4ce0-9dc7-b235730a1b2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember_94deeb95-b6bb-4828-b680-be5ff8b28583" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_8f83fde8-8980-4879-a26b-00e9ea31e6bd" xlink:to="loc_us-gaap_TreasuryStockMember_94deeb95-b6bb-4828-b680-be5ff8b28583" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_02ec7b21-7a82-4bde-a1fb-c54b53edfb30" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_8f83fde8-8980-4879-a26b-00e9ea31e6bd" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_02ec7b21-7a82-4bde-a1fb-c54b53edfb30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_981989e9-99af-4651-85a7-0f3c301f70be" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_8f83fde8-8980-4879-a26b-00e9ea31e6bd" xlink:to="loc_us-gaap_RetainedEarningsMember_981989e9-99af-4651-85a7-0f3c301f70be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_a5f6343f-e6e3-43e1-8537-cdd68deacf68" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_8f83fde8-8980-4879-a26b-00e9ea31e6bd" xlink:to="loc_us-gaap_NoncontrollingInterestMember_a5f6343f-e6e3-43e1-8537-cdd68deacf68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AociAttributableToNoncontrollingInterestMember_1fd955d7-2393-41d1-847d-cb841330a187" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AociAttributableToNoncontrollingInterestMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_8f83fde8-8980-4879-a26b-00e9ea31e6bd" xlink:to="loc_us-gaap_AociAttributableToNoncontrollingInterestMember_1fd955d7-2393-41d1-847d-cb841330a187" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_e2440b55-eae7-49dc-a6e8-bb7a76d888df" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_31fa1865-946a-4494-ac59-c042aa72169c" xlink:to="loc_us-gaap_StatementLineItems_e2440b55-eae7-49dc-a6e8-bb7a76d888df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_3ac29b36-75e2-40dd-a339-6f54aa7edbf3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_e2440b55-eae7-49dc-a6e8-bb7a76d888df" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_3ac29b36-75e2-40dd-a339-6f54aa7edbf3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_b5324eba-8647-4e83-a883-ba67f09b1c05" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_e2440b55-eae7-49dc-a6e8-bb7a76d888df" xlink:to="loc_us-gaap_SharesOutstanding_b5324eba-8647-4e83-a883-ba67f09b1c05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_de2da58c-8fa7-4d64-b9f3-27b4e576f43e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_e2440b55-eae7-49dc-a6e8-bb7a76d888df" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_de2da58c-8fa7-4d64-b9f3-27b4e576f43e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_d6b6a2c1-6f0a-4828-8e50-002a66ddd69b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_e2440b55-eae7-49dc-a6e8-bb7a76d888df" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_d6b6a2c1-6f0a-4828-8e50-002a66ddd69b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch_f5508ace-0463-4eca-9511-7ab5908c84df" xlink:href="amed-20210630.xsd#amed_StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_e2440b55-eae7-49dc-a6e8-bb7a76d888df" xlink:to="loc_amed_StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch_f5508ace-0463-4eca-9511-7ab5908c84df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_StockIssuedDuringPeriodSharesFourZeroOneKEmployerMatch_daf0920d-955c-42f3-9209-29b8e4aff374" xlink:href="amed-20210630.xsd#amed_StockIssuedDuringPeriodSharesFourZeroOneKEmployerMatch"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_e2440b55-eae7-49dc-a6e8-bb7a76d888df" xlink:to="loc_amed_StockIssuedDuringPeriodSharesFourZeroOneKEmployerMatch_daf0920d-955c-42f3-9209-29b8e4aff374" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_126ac6e2-4742-4a46-a23d-fa1cc88a6e54" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_e2440b55-eae7-49dc-a6e8-bb7a76d888df" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_126ac6e2-4742-4a46-a23d-fa1cc88a6e54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_5ac1f792-f22b-4728-ae4c-bfdbbbf0299d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_e2440b55-eae7-49dc-a6e8-bb7a76d888df" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_5ac1f792-f22b-4728-ae4c-bfdbbbf0299d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_2cb2289a-791b-4105-ab62-57f4fd8088a5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_e2440b55-eae7-49dc-a6e8-bb7a76d888df" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_2cb2289a-791b-4105-ab62-57f4fd8088a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_4142c8c2-d775-4b7f-9d7a-462c5f7dd06b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_e2440b55-eae7-49dc-a6e8-bb7a76d888df" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_4142c8c2-d775-4b7f-9d7a-462c5f7dd06b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_b3dd11d2-7ae9-4e02-9019-7e2aab7b8c36" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_e2440b55-eae7-49dc-a6e8-bb7a76d888df" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_b3dd11d2-7ae9-4e02-9019-7e2aab7b8c36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_SurrenderedShares_7f5966d6-c065-4675-897c-b611ffc6f658" xlink:href="amed-20210630.xsd#amed_SurrenderedShares"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_e2440b55-eae7-49dc-a6e8-bb7a76d888df" xlink:to="loc_amed_SurrenderedShares_7f5966d6-c065-4675-897c-b611ffc6f658" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_7f0005b9-bb0d-4a5f-bc1f-207698d61208" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_e2440b55-eae7-49dc-a6e8-bb7a76d888df" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_7f0005b9-bb0d-4a5f-bc1f-207698d61208" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_0c27d923-c937-44e7-91f3-bc1d3e633242" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_e2440b55-eae7-49dc-a6e8-bb7a76d888df" xlink:to="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_0c27d923-c937-44e7-91f3-bc1d3e633242" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_EquityImpactofRepurchaseofNoncontrollingInterest_04120da8-0c07-4217-aa91-4b7c05bffdab" xlink:href="amed-20210630.xsd#amed_EquityImpactofRepurchaseofNoncontrollingInterest"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_e2440b55-eae7-49dc-a6e8-bb7a76d888df" xlink:to="loc_amed_EquityImpactofRepurchaseofNoncontrollingInterest_04120da8-0c07-4217-aa91-4b7c05bffdab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_EquityImpactOfWriteOffOfOtherComprehensiveIncome_4fe69a45-c684-4438-8c74-9bf7a899dc1e" xlink:href="amed-20210630.xsd#amed_EquityImpactOfWriteOffOfOtherComprehensiveIncome"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_e2440b55-eae7-49dc-a6e8-bb7a76d888df" xlink:to="loc_amed_EquityImpactOfWriteOffOfOtherComprehensiveIncome_4fe69a45-c684-4438-8c74-9bf7a899dc1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_d9ed6111-f800-4a5d-9e74-2e11be2d2cca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_e2440b55-eae7-49dc-a6e8-bb7a76d888df" xlink:to="loc_us-gaap_ProfitLoss_d9ed6111-f800-4a5d-9e74-2e11be2d2cca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_a60d1fa5-63d6-4dc7-9679-fbf9729114d0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_e2440b55-eae7-49dc-a6e8-bb7a76d888df" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_a60d1fa5-63d6-4dc7-9679-fbf9729114d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_c6952e66-fe3f-45e1-b386-85a470e29a19" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_e2440b55-eae7-49dc-a6e8-bb7a76d888df" xlink:to="loc_us-gaap_SharesOutstanding_c6952e66-fe3f-45e1-b386-85a470e29a19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="amed-20210630.xsd#CONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_7dc41590-2ca7-4306-9bae-86af211619b0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_0488218b-ace6-47bc-badc-f8cdbe1c904d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_7dc41590-2ca7-4306-9bae-86af211619b0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_0488218b-ace6-47bc-badc-f8cdbe1c904d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_d53baeb5-c4f8-45aa-b97a-40583f8c2069" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_0488218b-ace6-47bc-badc-f8cdbe1c904d" xlink:to="loc_us-gaap_ProfitLoss_d53baeb5-c4f8-45aa-b97a-40583f8c2069" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_fb86127d-1036-4aad-9b06-563539509f41" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_0488218b-ace6-47bc-badc-f8cdbe1c904d" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_fb86127d-1036-4aad-9b06-563539509f41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_2fc59988-935e-4b9c-8374-5f585aa05a46" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_fb86127d-1036-4aad-9b06-563539509f41" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_2fc59988-935e-4b9c-8374-5f585aa05a46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_60a8dbe0-c6c3-4a6d-bee1-9ad74c78a211" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_fb86127d-1036-4aad-9b06-563539509f41" xlink:to="loc_us-gaap_ShareBasedCompensation_60a8dbe0-c6c3-4a6d-bee1-9ad74c78a211" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AmortizationandImpairmentofOperatingLeaseRightOfUseAsset_27200307-97d0-41aa-a879-d4a8b508397c" xlink:href="amed-20210630.xsd#amed_AmortizationandImpairmentofOperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_fb86127d-1036-4aad-9b06-563539509f41" xlink:to="loc_amed_AmortizationandImpairmentofOperatingLeaseRightOfUseAsset_27200307-97d0-41aa-a879-d4a8b508397c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_9443e2ea-4f1a-4118-987a-5c4cc1819c8a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_fb86127d-1036-4aad-9b06-563539509f41" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_9443e2ea-4f1a-4118-987a-5c4cc1819c8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfInvestments_c9b32778-1e60-4076-a456-965a5e09dfd1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnSaleOfInvestments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_fb86127d-1036-4aad-9b06-563539509f41" xlink:to="loc_us-gaap_GainLossOnSaleOfInvestments_c9b32778-1e60-4076-a456-965a5e09dfd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_WriteOffOfOtherComprehensiveIncome_2167dc1c-2ce3-4a74-9b79-598047ac9a68" xlink:href="amed-20210630.xsd#amed_WriteOffOfOtherComprehensiveIncome"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_fb86127d-1036-4aad-9b06-563539509f41" xlink:to="loc_amed_WriteOffOfOtherComprehensiveIncome_2167dc1c-2ce3-4a74-9b79-598047ac9a68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_91f0322e-1504-46a9-bc3b-9ab98f40ec5a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_fb86127d-1036-4aad-9b06-563539509f41" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_91f0322e-1504-46a9-bc3b-9ab98f40ec5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_80ee865c-3f30-428e-b00e-9d7fe4f333ad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_fb86127d-1036-4aad-9b06-563539509f41" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_80ee865c-3f30-428e-b00e-9d7fe4f333ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_b2f30ee4-807d-48d8-98a8-8cfe983f8b6d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_fb86127d-1036-4aad-9b06-563539509f41" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_b2f30ee4-807d-48d8-98a8-8cfe983f8b6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentDividendsOrDistributions_a03ede98-86bc-437c-b214-993b2a929e92" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentDividendsOrDistributions"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_fb86127d-1036-4aad-9b06-563539509f41" xlink:to="loc_us-gaap_EquityMethodInvestmentDividendsOrDistributions_a03ede98-86bc-437c-b214-993b2a929e92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_9509f97d-9bc9-451b-96cd-795e5133aaf2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_fb86127d-1036-4aad-9b06-563539509f41" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_9509f97d-9bc9-451b-96cd-795e5133aaf2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_58e4e98c-2023-4f91-bd06-c1eb9e634c8b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_9509f97d-9bc9-451b-96cd-795e5133aaf2" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_58e4e98c-2023-4f91-bd06-c1eb9e634c8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_9df3e46c-2211-4de9-836f-f93f7848bb30" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_9509f97d-9bc9-451b-96cd-795e5133aaf2" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_9df3e46c-2211-4de9-836f-f93f7848bb30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_94ce602b-8b28-4ede-9452-29686a7e6221" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_9509f97d-9bc9-451b-96cd-795e5133aaf2" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_94ce602b-8b28-4ede-9452-29686a7e6221" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_8366f2b2-ec77-432d-aa87-11248d097190" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_9509f97d-9bc9-451b-96cd-795e5133aaf2" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_8366f2b2-ec77-432d-aa87-11248d097190" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_027fe3fc-6849-42de-99b3-183d35a6f5d9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_9509f97d-9bc9-451b-96cd-795e5133aaf2" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_027fe3fc-6849-42de-99b3-183d35a6f5d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_0a3739a8-9b72-4c53-b6e8-8a9b9cc0a0b6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_9509f97d-9bc9-451b-96cd-795e5133aaf2" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_0a3739a8-9b72-4c53-b6e8-8a9b9cc0a0b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_IncreaseDecreaseInOperatingLeaseLiability_4628010c-8e05-48d4-84e1-6a4654ad6e19" xlink:href="amed-20210630.xsd#amed_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_9509f97d-9bc9-451b-96cd-795e5133aaf2" xlink:to="loc_amed_IncreaseDecreaseInOperatingLeaseLiability_4628010c-8e05-48d4-84e1-6a4654ad6e19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_405b0774-f02d-44d9-89d9-70bf766bc1b2" xlink:href="amed-20210630.xsd#amed_IncreaseDecreaseInOperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_9509f97d-9bc9-451b-96cd-795e5133aaf2" xlink:to="loc_amed_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_405b0774-f02d-44d9-89d9-70bf766bc1b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_62282d0f-cc12-441f-a4f3-c9d528754704" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_0488218b-ace6-47bc-badc-f8cdbe1c904d" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_62282d0f-cc12-441f-a4f3-c9d528754704" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_123d5786-7be3-4276-8e56-74d4d95a61a2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_7dc41590-2ca7-4306-9bae-86af211619b0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_123d5786-7be3-4276-8e56-74d4d95a61a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfRestrictedInvestments_03d63e2c-83fc-412e-a3d4-d7bf900e3d88" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleOfRestrictedInvestments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_123d5786-7be3-4276-8e56-74d4d95a61a2" xlink:to="loc_us-gaap_ProceedsFromSaleOfRestrictedInvestments_03d63e2c-83fc-412e-a3d4-d7bf900e3d88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_69881520-a513-42a5-b658-506ca82a783a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_123d5786-7be3-4276-8e56-74d4d95a61a2" xlink:to="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_69881520-a513-42a5-b658-506ca82a783a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_5aa689cc-7824-455a-a9f9-7c0f36c4d80f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_123d5786-7be3-4276-8e56-74d4d95a61a2" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_5aa689cc-7824-455a-a9f9-7c0f36c4d80f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments_ea919797-72e8-4f61-8fcd-32467f6a0835" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireInvestments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_123d5786-7be3-4276-8e56-74d4d95a61a2" xlink:to="loc_us-gaap_PaymentsToAcquireInvestments_ea919797-72e8-4f61-8fcd-32467f6a0835" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfEquityMethodInvestments_2def401a-af9b-4b92-9d65-4dd10d4f6b8b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleOfEquityMethodInvestments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_123d5786-7be3-4276-8e56-74d4d95a61a2" xlink:to="loc_us-gaap_ProceedsFromSaleOfEquityMethodInvestments_2def401a-af9b-4b92-9d65-4dd10d4f6b8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_a6484add-51b1-47ac-a760-8f22cabc9007" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_123d5786-7be3-4276-8e56-74d4d95a61a2" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_a6484add-51b1-47ac-a760-8f22cabc9007" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_d2041421-a4c2-4b1d-98c7-7aaf857a90ff" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_123d5786-7be3-4276-8e56-74d4d95a61a2" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_d2041421-a4c2-4b1d-98c7-7aaf857a90ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_e16bd2dc-6d19-422e-b7df-eee073087570" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_7dc41590-2ca7-4306-9bae-86af211619b0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_e16bd2dc-6d19-422e-b7df-eee073087570" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_76365386-100c-41a0-9ab0-e2d739d2b84a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_e16bd2dc-6d19-422e-b7df-eee073087570" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_76365386-100c-41a0-9ab0-e2d739d2b84a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockPlans_8251eac2-a195-4388-9828-9e88682cf526" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockPlans"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_e16bd2dc-6d19-422e-b7df-eee073087570" xlink:to="loc_us-gaap_ProceedsFromStockPlans_8251eac2-a195-4388-9828-9e88682cf526" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_4e386cb1-e57e-4792-959f-0d679c003e05" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_e16bd2dc-6d19-422e-b7df-eee073087570" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_4e386cb1-e57e-4792-959f-0d679c003e05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CashDistributionToNoncontrollingInterest_6975a64e-ec8a-4edd-a66e-2f058841f6dc" xlink:href="amed-20210630.xsd#amed_CashDistributionToNoncontrollingInterest"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_e16bd2dc-6d19-422e-b7df-eee073087570" xlink:to="loc_amed_CashDistributionToNoncontrollingInterest_6975a64e-ec8a-4edd-a66e-2f058841f6dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromShortTermDebt_1cae6245-f265-41b3-af49-6e8b3730fb03" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromShortTermDebt"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_e16bd2dc-6d19-422e-b7df-eee073087570" xlink:to="loc_us-gaap_ProceedsFromShortTermDebt_1cae6245-f265-41b3-af49-6e8b3730fb03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfShortTermDebt_d6c8a948-1705-4305-95b7-17c235d1e942" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfShortTermDebt"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_e16bd2dc-6d19-422e-b7df-eee073087570" xlink:to="loc_us-gaap_RepaymentsOfShortTermDebt_d6c8a948-1705-4305-95b7-17c235d1e942" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_9120364b-74c2-434c-9269-58972938449e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_e16bd2dc-6d19-422e-b7df-eee073087570" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_9120364b-74c2-434c-9269-58972938449e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_a9f703e9-3b0b-435c-8d4d-8e331aa33a84" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_e16bd2dc-6d19-422e-b7df-eee073087570" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_a9f703e9-3b0b-435c-8d4d-8e331aa33a84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_FundsReceivedFromProviderReliefFundAdvance_8cd27094-dbbb-47f8-813c-cdb7c75e17ae" xlink:href="amed-20210630.xsd#amed_FundsReceivedFromProviderReliefFundAdvance"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_e16bd2dc-6d19-422e-b7df-eee073087570" xlink:to="loc_amed_FundsReceivedFromProviderReliefFundAdvance_8cd27094-dbbb-47f8-813c-cdb7c75e17ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_93f2e6df-7719-406d-9b84-fe60f5722ec0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_e16bd2dc-6d19-422e-b7df-eee073087570" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_93f2e6df-7719-406d-9b84-fe60f5722ec0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_bfb016b7-7001-4dba-a057-49a19bcf1bcc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_7dc41590-2ca7-4306-9bae-86af211619b0" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_bfb016b7-7001-4dba-a057-49a19bcf1bcc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_f4405f3e-54ed-41e6-9da9-ee36c5df5355" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_7dc41590-2ca7-4306-9bae-86af211619b0" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_f4405f3e-54ed-41e6-9da9-ee36c5df5355" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_e3ccf358-3562-4cf2-9d74-479a83db4268" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_7dc41590-2ca7-4306-9bae-86af211619b0" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_e3ccf358-3562-4cf2-9d74-479a83db4268" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_4e3e56ca-1d09-4c74-a121-a629e1933ac4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_7dc41590-2ca7-4306-9bae-86af211619b0" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_4e3e56ca-1d09-4c74-a121-a629e1933ac4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_0061b371-d7a7-4519-a851-5ba3858141ca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestPaidNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_4e3e56ca-1d09-4c74-a121-a629e1933ac4" xlink:to="loc_us-gaap_InterestPaidNet_0061b371-d7a7-4519-a851-5ba3858141ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaidNet_40e6f301-a6c0-4950-a482-af2ec2d19273" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxesPaidNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_4e3e56ca-1d09-4c74-a121-a629e1933ac4" xlink:to="loc_us-gaap_IncomeTaxesPaidNet_40e6f301-a6c0-4950-a482-af2ec2d19273" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CashPaidForOperatingLeaseLiabilities_361d6ce9-c0c9-49ec-9612-ea2ece15bcfa" xlink:href="amed-20210630.xsd#amed_CashPaidForOperatingLeaseLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_4e3e56ca-1d09-4c74-a121-a629e1933ac4" xlink:to="loc_amed_CashPaidForOperatingLeaseLiabilities_361d6ce9-c0c9-49ec-9612-ea2ece15bcfa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CashPaidForFinanceLeaseLiabilities_54fa6404-2add-46bc-b041-d9f16ed169b3" xlink:href="amed-20210630.xsd#amed_CashPaidForFinanceLeaseLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_4e3e56ca-1d09-4c74-a121-a629e1933ac4" xlink:to="loc_amed_CashPaidForFinanceLeaseLiabilities_54fa6404-2add-46bc-b041-d9f16ed169b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract_681ab082-b7b5-4bdf-b1d3-68f973f82a29" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_7dc41590-2ca7-4306-9bae-86af211619b0" xlink:to="loc_us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract_681ab082-b7b5-4bdf-b1d3-68f973f82a29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_40190393-9678-49de-81df-ddacb1869747" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract_681ab082-b7b5-4bdf-b1d3-68f973f82a29" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_40190393-9678-49de-81df-ddacb1869747" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_23f7f900-8ee0-45dd-80a3-e0c13e3dcac0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract_681ab082-b7b5-4bdf-b1d3-68f973f82a29" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_23f7f900-8ee0-45dd-80a3-e0c13e3dcac0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_LesseeOperatingleaseReductionstoROUassetsresultingfromreductionstoleaseobligations_7375f91d-8e68-4499-9c08-a0260906cffb" xlink:href="amed-20210630.xsd#amed_LesseeOperatingleaseReductionstoROUassetsresultingfromreductionstoleaseobligations"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract_681ab082-b7b5-4bdf-b1d3-68f973f82a29" xlink:to="loc_amed_LesseeOperatingleaseReductionstoROUassetsresultingfromreductionstoleaseobligations_7375f91d-8e68-4499-9c08-a0260906cffb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTS" xlink:type="simple" xlink:href="amed-20210630.xsd#NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTS"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_3563ab20-c8c6-45f7-a36c-0066de1bcd4e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_cad6a49d-da8f-4b80-8ebd-ccfec5d32dbc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_3563ab20-c8c6-45f7-a36c-0066de1bcd4e" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_cad6a49d-da8f-4b80-8ebd-ccfec5d32dbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails" xlink:type="simple" xlink:href="amed-20210630.xsd#NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_cd7715e5-b595-420b-a4c7-09161b3bb0a1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable_8de95f06-4875-4ed3-9773-33485effd152" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_cd7715e5-b595-420b-a4c7-09161b3bb0a1" xlink:to="loc_us-gaap_ConcentrationRiskTable_8de95f06-4875-4ed3-9773-33485effd152" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_85090172-84bb-4631-b2d8-f7dd772a04a6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_8de95f06-4875-4ed3-9773-33485effd152" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_85090172-84bb-4631-b2d8-f7dd772a04a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember_04d0669d-24e0-4450-8ec2-ea5f36955a19" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_85090172-84bb-4631-b2d8-f7dd772a04a6" xlink:to="loc_us-gaap_TypeOfAdoptionMember_04d0669d-24e0-4450-8ec2-ea5f36955a19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate201602Member_13c6a1e0-9c8f-429f-a6d3-dabeba095cee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfAdoptionMember_04d0669d-24e0-4450-8ec2-ea5f36955a19" xlink:to="loc_us-gaap_AccountingStandardsUpdate201602Member_13c6a1e0-9c8f-429f-a6d3-dabeba095cee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_ff88661c-b248-4f11-a8bf-bf61a4391633" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_8de95f06-4875-4ed3-9773-33485effd152" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_ff88661c-b248-4f11-a8bf-bf61a4391633" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_735ea19f-06f8-43e2-88ea-b48f7a45f777" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_ff88661c-b248-4f11-a8bf-bf61a4391633" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_735ea19f-06f8-43e2-88ea-b48f7a45f777" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerMember_e2733642-c188-49c9-811d-3dd86fc93e3d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_735ea19f-06f8-43e2-88ea-b48f7a45f777" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerMember_e2733642-c188-49c9-811d-3dd86fc93e3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_8925792f-b0ff-4da3-b942-b3b1dd73a68c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_8de95f06-4875-4ed3-9773-33485effd152" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_8925792f-b0ff-4da3-b942-b3b1dd73a68c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_79abe9ee-3d11-48ed-936d-8850bb3304ce" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_8925792f-b0ff-4da3-b942-b3b1dd73a68c" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_79abe9ee-3d11-48ed-936d-8850bb3304ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_MedicareRevenueMember_bd40566d-37e7-4fa9-84e0-3a43ed0ec9f5" xlink:href="amed-20210630.xsd#amed_MedicareRevenueMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_79abe9ee-3d11-48ed-936d-8850bb3304ce" xlink:to="loc_amed_MedicareRevenueMember_bd40566d-37e7-4fa9-84e0-3a43ed0ec9f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductConcentrationRiskMember_b68e79b0-0017-4394-885e-9bb2abd4795f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductConcentrationRiskMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_79abe9ee-3d11-48ed-936d-8850bb3304ce" xlink:to="loc_us-gaap_ProductConcentrationRiskMember_b68e79b0-0017-4394-885e-9bb2abd4795f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_141d05fc-1d14-4728-bf4c-6ada2fb379d2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_8de95f06-4875-4ed3-9773-33485effd152" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_141d05fc-1d14-4728-bf4c-6ada2fb379d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_e5e2c66d-5e0c-4486-9aa2-01c51c89ebe5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_141d05fc-1d14-4728-bf4c-6ada2fb379d2" xlink:to="loc_us-gaap_SegmentDomain_e5e2c66d-5e0c-4486-9aa2-01c51c89ebe5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HomeHealthMember_cfe3a234-8d5c-4eca-8d33-9e9f1e569632" xlink:href="amed-20210630.xsd#amed_HomeHealthMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_e5e2c66d-5e0c-4486-9aa2-01c51c89ebe5" xlink:to="loc_amed_HomeHealthMember_cfe3a234-8d5c-4eca-8d33-9e9f1e569632" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HospiceMember_fc3eda3c-0e62-467b-aebc-e79c1d4ea664" xlink:href="amed-20210630.xsd#amed_HospiceMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_e5e2c66d-5e0c-4486-9aa2-01c51c89ebe5" xlink:to="loc_amed_HospiceMember_fc3eda3c-0e62-467b-aebc-e79c1d4ea664" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PersonalCareMember_bdc88075-c749-4bdf-8671-f5ff77a6ed90" xlink:href="amed-20210630.xsd#amed_PersonalCareMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_e5e2c66d-5e0c-4486-9aa2-01c51c89ebe5" xlink:to="loc_amed_PersonalCareMember_bdc88075-c749-4bdf-8671-f5ff77a6ed90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_TypeofEquityMethodInvestmentAxis_167ce630-011e-427e-a259-2bcfab9ec008" xlink:href="amed-20210630.xsd#amed_TypeofEquityMethodInvestmentAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_8de95f06-4875-4ed3-9773-33485effd152" xlink:to="loc_amed_TypeofEquityMethodInvestmentAxis_167ce630-011e-427e-a259-2bcfab9ec008" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_TypeOfEquityMethodInvestmentDomain_9da4bbef-1331-44cf-82c3-5a5009fee0c9" xlink:href="amed-20210630.xsd#amed_TypeOfEquityMethodInvestmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_TypeofEquityMethodInvestmentAxis_167ce630-011e-427e-a259-2bcfab9ec008" xlink:to="loc_amed_TypeOfEquityMethodInvestmentDomain_9da4bbef-1331-44cf-82c3-5a5009fee0c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HeritageHealthcareInnovationFundLPMember_2c873266-28f8-4ffc-bf7e-2e766f87738f" xlink:href="amed-20210630.xsd#amed_HeritageHealthcareInnovationFundLPMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_TypeOfEquityMethodInvestmentDomain_9da4bbef-1331-44cf-82c3-5a5009fee0c9" xlink:to="loc_amed_HeritageHealthcareInnovationFundLPMember_2c873266-28f8-4ffc-bf7e-2e766f87738f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_MedalogixMember_d6ec0714-d0d4-4d20-bd1a-ddcdfa652ffb" xlink:href="amed-20210630.xsd#amed_MedalogixMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_TypeOfEquityMethodInvestmentDomain_9da4bbef-1331-44cf-82c3-5a5009fee0c9" xlink:to="loc_amed_MedalogixMember_d6ec0714-d0d4-4d20-bd1a-ddcdfa652ffb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_28cc4a17-c459-4a04-aab1-8bdf91fefad0" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_8de95f06-4875-4ed3-9773-33485effd152" xlink:to="loc_srt_ProductOrServiceAxis_28cc4a17-c459-4a04-aab1-8bdf91fefad0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_31a86e59-23d9-4cc8-b1c8-1a0938f04171" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_28cc4a17-c459-4a04-aab1-8bdf91fefad0" xlink:to="loc_srt_ProductsAndServicesDomain_31a86e59-23d9-4cc8-b1c8-1a0938f04171" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_MedicareRevenueMember_0051a9e8-b6b2-46f1-9fcc-6ec45f7a6924" xlink:href="amed-20210630.xsd#amed_MedicareRevenueMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_31a86e59-23d9-4cc8-b1c8-1a0938f04171" xlink:to="loc_amed_MedicareRevenueMember_0051a9e8-b6b2-46f1-9fcc-6ec45f7a6924" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_8bfbbd74-cc2b-4f58-9b14-07eef305c05b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_8de95f06-4875-4ed3-9773-33485effd152" xlink:to="loc_us-gaap_ConcentrationRiskLineItems_8bfbbd74-cc2b-4f58-9b14-07eef305c05b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_33721f69-9544-4f2b-adce-8da98f8144b0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_8bfbbd74-cc2b-4f58-9b14-07eef305c05b" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_33721f69-9544-4f2b-adce-8da98f8144b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_OperatingCareCenters_64810bf1-21da-4cc2-a43f-2c1ef946c917" xlink:href="amed-20210630.xsd#amed_OperatingCareCenters"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_8bfbbd74-cc2b-4f58-9b14-07eef305c05b" xlink:to="loc_amed_OperatingCareCenters_64810bf1-21da-4cc2-a43f-2c1ef946c917" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfStatesInWhichEntityOperates_91f24672-c8b3-46fd-bff9-40cf86ee5d66" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfStatesInWhichEntityOperates"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_8bfbbd74-cc2b-4f58-9b14-07eef305c05b" xlink:to="loc_us-gaap_NumberOfStatesInWhichEntityOperates_91f24672-c8b3-46fd-bff9-40cf86ee5d66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_MinimumPercentOwnershipForControllingInterestPercent_6873b927-0779-4ded-91fc-79c43ea7a744" xlink:href="amed-20210630.xsd#amed_MinimumPercentOwnershipForControllingInterestPercent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_8bfbbd74-cc2b-4f58-9b14-07eef305c05b" xlink:to="loc_amed_MinimumPercentOwnershipForControllingInterestPercent_6873b927-0779-4ded-91fc-79c43ea7a744" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_MaximumPercentOwnershipForEquityMethodPercent_85eeb59f-a73f-441e-a803-851a349c34fd" xlink:href="amed-20210630.xsd#amed_MaximumPercentOwnershipForEquityMethodPercent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_8bfbbd74-cc2b-4f58-9b14-07eef305c05b" xlink:to="loc_amed_MaximumPercentOwnershipForEquityMethodPercent_85eeb59f-a73f-441e-a803-851a349c34fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentAggregateCost_3b1d4a73-a127-48d3-a81b-778f6e0606be" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentAggregateCost"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_8bfbbd74-cc2b-4f58-9b14-07eef305c05b" xlink:to="loc_us-gaap_EquityMethodInvestmentAggregateCost_3b1d4a73-a127-48d3-a81b-778f6e0606be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_MaximumPercentOwnershipForCostMethodPercent_09f7c56d-11d3-4f20-ad7e-8955854b9e36" xlink:href="amed-20210630.xsd#amed_MaximumPercentOwnershipForCostMethodPercent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_8bfbbd74-cc2b-4f58-9b14-07eef305c05b" xlink:to="loc_amed_MaximumPercentOwnershipForCostMethodPercent_09f7c56d-11d3-4f20-ad7e-8955854b9e36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_cfcc7c40-bfb6-4948-867a-c5c578cb438d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestments"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_8bfbbd74-cc2b-4f58-9b14-07eef305c05b" xlink:to="loc_us-gaap_EquityMethodInvestments_cfcc7c40-bfb6-4948-867a-c5c578cb438d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfEquityMethodInvestments_f153ae02-48ff-49eb-b8c1-776735ab5e1e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleOfEquityMethodInvestments"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_8bfbbd74-cc2b-4f58-9b14-07eef305c05b" xlink:to="loc_us-gaap_ProceedsFromSaleOfEquityMethodInvestments_f153ae02-48ff-49eb-b8c1-776735ab5e1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainOnSaleOfInvestments_73e6a426-d433-4f0d-988e-28c67caf59da" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainOnSaleOfInvestments"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_8bfbbd74-cc2b-4f58-9b14-07eef305c05b" xlink:to="loc_us-gaap_GainOnSaleOfInvestments_73e6a426-d433-4f0d-988e-28c67caf59da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnInvestments_79de014f-3f88-4c97-a840-ce53bd313c6f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnInvestments"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_8bfbbd74-cc2b-4f58-9b14-07eef305c05b" xlink:to="loc_us-gaap_GainLossOnInvestments_79de014f-3f88-4c97-a840-ce53bd313c6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES" xlink:type="simple" xlink:href="amed-20210630.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_7e7db28e-e772-4bf1-b5fc-521326368c77" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_93fe84ca-4909-4c36-b86d-b9b2cd0ce182" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7e7db28e-e772-4bf1-b5fc-521326368c77" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_93fe84ca-4909-4c36-b86d-b9b2cd0ce182" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" xlink:type="simple" xlink:href="amed-20210630.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_11568c4a-de76-496c-9960-b2fb3f0c84b4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_2b9bd5b8-c7d0-4406-bced-b1bb717c0500" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_11568c4a-de76-496c-9960-b2fb3f0c84b4" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_2b9bd5b8-c7d0-4406-bced-b1bb717c0500" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_7782933e-a975-4df1-bc28-5f98401df95b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_11568c4a-de76-496c-9960-b2fb3f0c84b4" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_7782933e-a975-4df1-bc28-5f98401df95b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_980ae089-684c-4b53-9c32-1fa83a6b85d2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_11568c4a-de76-496c-9960-b2fb3f0c84b4" xlink:to="loc_us-gaap_UseOfEstimates_980ae089-684c-4b53-9c32-1fa83a6b85d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_9af85dbb-d338-4ed0-81e4-93f8044cb849" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_11568c4a-de76-496c-9960-b2fb3f0c84b4" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_9af85dbb-d338-4ed0-81e4-93f8044cb849" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsPolicy_91491bc6-3de9-4f8e-90b5-10c77fff9e21" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentsPolicy"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_11568c4a-de76-496c-9960-b2fb3f0c84b4" xlink:to="loc_us-gaap_EquityMethodInvestmentsPolicy_91491bc6-3de9-4f8e-90b5-10c77fff9e21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock_6870e14d-de8e-4184-918e-0389ee65b1b2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_11568c4a-de76-496c-9960-b2fb3f0c84b4" xlink:to="loc_us-gaap_RevenueRecognitionPolicyTextBlock_6870e14d-de8e-4184-918e-0389ee65b1b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_GovernmentGrantsPolicyTextBlock_a9bc72cb-f026-4645-95c8-020202165aea" xlink:href="amed-20210630.xsd#amed_GovernmentGrantsPolicyTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_11568c4a-de76-496c-9960-b2fb3f0c84b4" xlink:to="loc_amed_GovernmentGrantsPolicyTextBlock_a9bc72cb-f026-4645-95c8-020202165aea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_39e05ee9-32cb-44d4-944b-643c511a8a21" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_11568c4a-de76-496c-9960-b2fb3f0c84b4" xlink:to="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_39e05ee9-32cb-44d4-944b-643c511a8a21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy_2e4fa252-a3a5-4743-9181-05aaaab4c628" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_11568c4a-de76-496c-9960-b2fb3f0c84b4" xlink:to="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy_2e4fa252-a3a5-4743-9181-05aaaab4c628" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsPolicy_6b005c4a-1b1f-490c-b3c8-c39daad8b62b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationsPolicy"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_11568c4a-de76-496c-9960-b2fb3f0c84b4" xlink:to="loc_us-gaap_BusinessCombinationsPolicy_6b005c4a-1b1f-490c-b3c8-c39daad8b62b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_864b2931-8036-4441-bcb7-c5b894d31c69" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_11568c4a-de76-496c-9960-b2fb3f0c84b4" xlink:to="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_864b2931-8036-4441-bcb7-c5b894d31c69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_a4863db8-09b6-48c7-8e81-c3ada43d0c5d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_11568c4a-de76-496c-9960-b2fb3f0c84b4" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_a4863db8-09b6-48c7-8e81-c3ada43d0c5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables" xlink:type="simple" xlink:href="amed-20210630.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_4f7bec7a-9b8f-4c56-8f3c-50d37e2d5046" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTableTextBlock_c60d3334-e980-4054-927b-8ea1773aa26a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4f7bec7a-9b8f-4c56-8f3c-50d37e2d5046" xlink:to="loc_us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTableTextBlock_c60d3334-e980-4054-927b-8ea1773aa26a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlockTableTextBlock_0f64be28-8369-41dc-9b2b-6b3949773772" xlink:href="amed-20210630.xsd#amed_ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlockTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4f7bec7a-9b8f-4c56-8f3c-50d37e2d5046" xlink:to="loc_amed_ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlockTableTextBlock_0f64be28-8369-41dc-9b2b-6b3949773772" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_FinancialInstrumentDetailsTableTextBlock_cdfda2f2-fba7-4dd2-9195-beb7a2174af5" xlink:href="amed-20210630.xsd#amed_FinancialInstrumentDetailsTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4f7bec7a-9b8f-4c56-8f3c-50d37e2d5046" xlink:to="loc_amed_FinancialInstrumentDetailsTableTextBlock_cdfda2f2-fba7-4dd2-9195-beb7a2174af5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_38a00047-9c53-4330-abe4-f236c6769921" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4f7bec7a-9b8f-4c56-8f3c-50d37e2d5046" xlink:to="loc_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_38a00047-9c53-4330-abe4-f236c6769921" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails" xlink:type="simple" xlink:href="amed-20210630.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_398e5f0d-433c-4ec8-8de3-dd92b1558a6e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable_f8b4b9be-3dcb-4dff-8b38-c5212e417585" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_398e5f0d-433c-4ec8-8de3-dd92b1558a6e" xlink:to="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable_f8b4b9be-3dcb-4dff-8b38-c5212e417585" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_26cda65c-c9e6-42c7-941e-4aaf618f85f1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable_f8b4b9be-3dcb-4dff-8b38-c5212e417585" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_26cda65c-c9e6-42c7-941e-4aaf618f85f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6464a6a2-4634-437a-a44e-c8ff416f4484" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_26cda65c-c9e6-42c7-941e-4aaf618f85f1" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6464a6a2-4634-437a-a44e-c8ff416f4484" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CompassionateCareHospiceMember_8a8f1d4a-da0b-497b-9bdb-6277597f0c69" xlink:href="amed-20210630.xsd#amed_CompassionateCareHospiceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6464a6a2-4634-437a-a44e-c8ff416f4484" xlink:to="loc_amed_CompassionateCareHospiceMember_8a8f1d4a-da0b-497b-9bdb-6277597f0c69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AseraCareHospiceMember_1e341682-acbd-4826-bfc6-3c7ef7ddd01f" xlink:href="amed-20210630.xsd#amed_AseraCareHospiceMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6464a6a2-4634-437a-a44e-c8ff416f4484" xlink:to="loc_amed_AseraCareHospiceMember_1e341682-acbd-4826-bfc6-3c7ef7ddd01f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_5051c602-f475-4355-b616-da03da7953c5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable_f8b4b9be-3dcb-4dff-8b38-c5212e417585" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_5051c602-f475-4355-b616-da03da7953c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_2b6734ea-606e-4521-9bd5-770526441f0e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_5051c602-f475-4355-b616-da03da7953c5" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_2b6734ea-606e-4521-9bd5-770526441f0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_MedicareRevenueMember_3bc08e2e-ff78-4c4a-b112-ea84f97bd24f" xlink:href="amed-20210630.xsd#amed_MedicareRevenueMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_2b6734ea-606e-4521-9bd5-770526441f0e" xlink:to="loc_amed_MedicareRevenueMember_3bc08e2e-ff78-4c4a-b112-ea84f97bd24f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductConcentrationRiskMember_0dd68d90-9e28-43e0-aeef-c622b0806954" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductConcentrationRiskMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_2b6734ea-606e-4521-9bd5-770526441f0e" xlink:to="loc_us-gaap_ProductConcentrationRiskMember_0dd68d90-9e28-43e0-aeef-c622b0806954" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_c1772299-8866-4f23-ae54-9e2fb0c065e7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable_f8b4b9be-3dcb-4dff-8b38-c5212e417585" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_c1772299-8866-4f23-ae54-9e2fb0c065e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_3fe9ed77-0072-4833-b531-c8accf3d874d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_c1772299-8866-4f23-ae54-9e2fb0c065e7" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_3fe9ed77-0072-4833-b531-c8accf3d874d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerMember_fa24986c-3f96-4d1e-822d-9dad4d0793b5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_3fe9ed77-0072-4833-b531-c8accf3d874d" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerMember_fa24986c-3f96-4d1e-822d-9dad4d0793b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CapYearAxis_2a76db6c-d0b0-4cbd-8911-3a976d8fd890" xlink:href="amed-20210630.xsd#amed_CapYearAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable_f8b4b9be-3dcb-4dff-8b38-c5212e417585" xlink:to="loc_amed_CapYearAxis_2a76db6c-d0b0-4cbd-8911-3a976d8fd890" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CapYearDomain_a95d489a-cc6e-44f6-abeb-5724f7270b78" xlink:href="amed-20210630.xsd#amed_CapYearDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_CapYearAxis_2a76db6c-d0b0-4cbd-8911-3a976d8fd890" xlink:to="loc_amed_CapYearDomain_a95d489a-cc6e-44f6-abeb-5724f7270b78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CapYearTwoThousandFourteenThroughTwoThousandTwentyOneMember_989a0d8b-44b0-4131-bf91-a63d5f76976d" xlink:href="amed-20210630.xsd#amed_CapYearTwoThousandFourteenThroughTwoThousandTwentyOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_CapYearDomain_a95d489a-cc6e-44f6-abeb-5724f7270b78" xlink:to="loc_amed_CapYearTwoThousandFourteenThroughTwoThousandTwentyOneMember_989a0d8b-44b0-4131-bf91-a63d5f76976d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CapYearTwoThousandSixteenThroughTwoThousandTwentyOneMember_21a8c690-39f0-4148-9622-c9d3c617bb40" xlink:href="amed-20210630.xsd#amed_CapYearTwoThousandSixteenThroughTwoThousandTwentyOneMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_CapYearDomain_a95d489a-cc6e-44f6-abeb-5724f7270b78" xlink:to="loc_amed_CapYearTwoThousandSixteenThroughTwoThousandTwentyOneMember_21a8c690-39f0-4148-9622-c9d3c617bb40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_41c17b8b-cc5f-4481-a432-4ed5f81c4e65" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable_f8b4b9be-3dcb-4dff-8b38-c5212e417585" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_41c17b8b-cc5f-4481-a432-4ed5f81c4e65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_3f052d62-26d4-434b-99c1-555806cadc71" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_41c17b8b-cc5f-4481-a432-4ed5f81c4e65" xlink:to="loc_us-gaap_SegmentDomain_3f052d62-26d4-434b-99c1-555806cadc71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HomeHealthMember_ac789f68-ed95-41b4-9235-01f0123f34c5" xlink:href="amed-20210630.xsd#amed_HomeHealthMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_3f052d62-26d4-434b-99c1-555806cadc71" xlink:to="loc_amed_HomeHealthMember_ac789f68-ed95-41b4-9235-01f0123f34c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HospiceMember_fadcbc98-9a59-480e-a5cb-2c75147a9d92" xlink:href="amed-20210630.xsd#amed_HospiceMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_3f052d62-26d4-434b-99c1-555806cadc71" xlink:to="loc_amed_HospiceMember_fadcbc98-9a59-480e-a5cb-2c75147a9d92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_8be2e444-306b-4ced-97a0-96d26b65cba6" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable_f8b4b9be-3dcb-4dff-8b38-c5212e417585" xlink:to="loc_srt_RangeAxis_8be2e444-306b-4ced-97a0-96d26b65cba6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_124b4c52-f25e-4579-aab6-576a6950b503" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_8be2e444-306b-4ced-97a0-96d26b65cba6" xlink:to="loc_srt_RangeMember_124b4c52-f25e-4579-aab6-576a6950b503" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_bd6f2a32-0cb2-4b27-8a8a-1c4c03c2e14e" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_124b4c52-f25e-4579-aab6-576a6950b503" xlink:to="loc_srt_MinimumMember_bd6f2a32-0cb2-4b27-8a8a-1c4c03c2e14e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_5591da3a-727e-4601-8c28-c4915d91b1c2" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_124b4c52-f25e-4579-aab6-576a6950b503" xlink:to="loc_srt_MaximumMember_5591da3a-727e-4601-8c28-c4915d91b1c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_0d9741e6-8494-407a-a174-5db662caae37" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable_f8b4b9be-3dcb-4dff-8b38-c5212e417585" xlink:to="loc_srt_ProductOrServiceAxis_0d9741e6-8494-407a-a174-5db662caae37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_ef8c007c-2913-4b7d-9e88-7f5694d6f415" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_0d9741e6-8494-407a-a174-5db662caae37" xlink:to="loc_srt_ProductsAndServicesDomain_ef8c007c-2913-4b7d-9e88-7f5694d6f415" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_MedicareRevenueMember_aeeb7f9f-b843-45f8-bec8-c02abc2efb49" xlink:href="amed-20210630.xsd#amed_MedicareRevenueMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_ef8c007c-2913-4b7d-9e88-7f5694d6f415" xlink:to="loc_amed_MedicareRevenueMember_aeeb7f9f-b843-45f8-bec8-c02abc2efb49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_62da7a9b-73e3-48a8-a76f-566e30ae558e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable_f8b4b9be-3dcb-4dff-8b38-c5212e417585" xlink:to="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_62da7a9b-73e3-48a8-a76f-566e30ae558e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_baa615ce-2b95-4e34-9baa-45509b4208d8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_62da7a9b-73e3-48a8-a76f-566e30ae558e" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_baa615ce-2b95-4e34-9baa-45509b4208d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_EpisodeOfCareAsEpisodicBasedRevenueDuration_1b0b4e33-5c1a-4532-955f-52030c1c9ec7" xlink:href="amed-20210630.xsd#amed_EpisodeOfCareAsEpisodicBasedRevenueDuration"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_62da7a9b-73e3-48a8-a76f-566e30ae558e" xlink:to="loc_amed_EpisodeOfCareAsEpisodicBasedRevenueDuration_1b0b4e33-5c1a-4532-955f-52030c1c9ec7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_NetServiceRevenuePeriodOfCarePaymentRateDuration_6ffac860-d686-4d75-8b27-1b1a4da1e6db" xlink:href="amed-20210630.xsd#amed_NetServiceRevenuePeriodOfCarePaymentRateDuration"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_62da7a9b-73e3-48a8-a76f-566e30ae558e" xlink:to="loc_amed_NetServiceRevenuePeriodOfCarePaymentRateDuration_6ffac860-d686-4d75-8b27-1b1a4da1e6db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PeriodOfCareAsEpisodicBasedRevenueDuration_c8cae07c-b133-4235-bef8-179b2c5b9322" xlink:href="amed-20210630.xsd#amed_PeriodOfCareAsEpisodicBasedRevenueDuration"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_62da7a9b-73e3-48a8-a76f-566e30ae558e" xlink:to="loc_amed_PeriodOfCareAsEpisodicBasedRevenueDuration_c8cae07c-b133-4235-bef8-179b2c5b9322" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PercentageOfTotalReimbursementOfOutlierPayment_454c206f-6213-4d6e-9a04-35d6c6d5ad0c" xlink:href="amed-20210630.xsd#amed_PercentageOfTotalReimbursementOfOutlierPayment"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_62da7a9b-73e3-48a8-a76f-566e30ae558e" xlink:to="loc_amed_PercentageOfTotalReimbursementOfOutlierPayment_454c206f-6213-4d6e-9a04-35d6c6d5ad0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_LowUtilizationPaymentAdjustmentNumberOfVisits_4db1bcc0-3895-46ef-be3a-0e4826d737d9" xlink:href="amed-20210630.xsd#amed_LowUtilizationPaymentAdjustmentNumberOfVisits"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_62da7a9b-73e3-48a8-a76f-566e30ae558e" xlink:to="loc_amed_LowUtilizationPaymentAdjustmentNumberOfVisits_4db1bcc0-3895-46ef-be3a-0e4826d737d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_FirstThresholdOfTherapyServicesRequired_6f35d95b-9b21-4bde-a05b-bc9ef0cb3145" xlink:href="amed-20210630.xsd#amed_FirstThresholdOfTherapyServicesRequired"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_62da7a9b-73e3-48a8-a76f-566e30ae558e" xlink:to="loc_amed_FirstThresholdOfTherapyServicesRequired_6f35d95b-9b21-4bde-a05b-bc9ef0cb3145" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_SecondThresholdOfServicesRequired_022c3dc6-c6a4-4ece-a498-814fcff69226" xlink:href="amed-20210630.xsd#amed_SecondThresholdOfServicesRequired"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_62da7a9b-73e3-48a8-a76f-566e30ae558e" xlink:to="loc_amed_SecondThresholdOfServicesRequired_022c3dc6-c6a4-4ece-a498-814fcff69226" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ThirdThresholdOfTherapyServicesRequired_0e515be9-b497-4cea-bb2c-f186cabc269d" xlink:href="amed-20210630.xsd#amed_ThirdThresholdOfTherapyServicesRequired"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_62da7a9b-73e3-48a8-a76f-566e30ae558e" xlink:to="loc_amed_ThirdThresholdOfTherapyServicesRequired_0e515be9-b497-4cea-bb2c-f186cabc269d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HistoricalCollectionRateFromMedicare_d82de9c9-cb49-4855-8b34-f274c275c1db" xlink:href="amed-20210630.xsd#amed_HistoricalCollectionRateFromMedicare"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_62da7a9b-73e3-48a8-a76f-566e30ae558e" xlink:to="loc_amed_HistoricalCollectionRateFromMedicare_d82de9c9-cb49-4855-8b34-f274c275c1db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_NonMedicareRevenueTermRates_a6c35d4f-53f2-43ee-a3d4-5e172fdf694b" xlink:href="amed-20210630.xsd#amed_NonMedicareRevenueTermRates"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_62da7a9b-73e3-48a8-a76f-566e30ae558e" xlink:to="loc_amed_NonMedicareRevenueTermRates_a6c35d4f-53f2-43ee-a3d4-5e172fdf694b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HospiceMedicareRevenueRateAccountedForRoutineCare_dbf7587a-d05c-4e81-a463-237136a1457e" xlink:href="amed-20210630.xsd#amed_HospiceMedicareRevenueRateAccountedForRoutineCare"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_62da7a9b-73e3-48a8-a76f-566e30ae558e" xlink:to="loc_amed_HospiceMedicareRevenueRateAccountedForRoutineCare_dbf7587a-d05c-4e81-a463-237136a1457e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_EstimatedAmountDueBackToMedicareInOtherAccruedLiabilities_6e4a1209-9f34-4a7a-ad29-34bf1edaf062" xlink:href="amed-20210630.xsd#amed_EstimatedAmountDueBackToMedicareInOtherAccruedLiabilities"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_62da7a9b-73e3-48a8-a76f-566e30ae558e" xlink:to="loc_amed_EstimatedAmountDueBackToMedicareInOtherAccruedLiabilities_6e4a1209-9f34-4a7a-ad29-34bf1edaf062" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_NetServiceRevenueEpisodePaymentRateDuration_6b8bd8c6-275e-451e-82a6-fc2c4ac7eb89" xlink:href="amed-20210630.xsd#amed_NetServiceRevenueEpisodePaymentRateDuration"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_62da7a9b-73e3-48a8-a76f-566e30ae558e" xlink:to="loc_amed_NetServiceRevenueEpisodePaymentRateDuration_6b8bd8c6-275e-451e-82a6-fc2c4ac7eb89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_RateOfRequestForAnticipatedPaymentSubmittedForInitialPeriodOfCare_12f4d8e7-3ef1-4f71-88b8-7e61714002cb" xlink:href="amed-20210630.xsd#amed_RateOfRequestForAnticipatedPaymentSubmittedForInitialPeriodOfCare"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_62da7a9b-73e3-48a8-a76f-566e30ae558e" xlink:to="loc_amed_RateOfRequestForAnticipatedPaymentSubmittedForInitialPeriodOfCare_12f4d8e7-3ef1-4f71-88b8-7e61714002cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenuebyPayorClassDetails" xlink:type="simple" xlink:href="amed-20210630.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenuebyPayorClassDetails"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenuebyPayorClassDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionAndDeferredRevenueAbstract_b17c114c-ea4c-49f4-a213-e351a7502eae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRecognitionAndDeferredRevenueAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTable_9ef30923-90c3-425b-90c3-f805b79104d3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionAndDeferredRevenueAbstract_b17c114c-ea4c-49f4-a213-e351a7502eae" xlink:to="loc_us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTable_9ef30923-90c3-425b-90c3-f805b79104d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PayorClassAxis_f2b3570b-8230-4a35-801a-962b759e3c2b" xlink:href="amed-20210630.xsd#amed_PayorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTable_9ef30923-90c3-425b-90c3-f805b79104d3" xlink:to="loc_amed_PayorClassAxis_f2b3570b-8230-4a35-801a-962b759e3c2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PayorClassDomain_50c3659c-4d91-49e5-9e71-b3f55214c361" xlink:href="amed-20210630.xsd#amed_PayorClassDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_PayorClassAxis_f2b3570b-8230-4a35-801a-962b759e3c2b" xlink:to="loc_amed_PayorClassDomain_50c3659c-4d91-49e5-9e71-b3f55214c361" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HomeHealthMedicareMember_75393f37-a755-494a-95a7-2ed89e06e2a9" xlink:href="amed-20210630.xsd#amed_HomeHealthMedicareMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_PayorClassDomain_50c3659c-4d91-49e5-9e71-b3f55214c361" xlink:to="loc_amed_HomeHealthMedicareMember_75393f37-a755-494a-95a7-2ed89e06e2a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HomeHealthNonMedicareEpisodicBasedMember_57c325f0-64d0-4951-bb1f-0a3145f7f7cf" xlink:href="amed-20210630.xsd#amed_HomeHealthNonMedicareEpisodicBasedMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_PayorClassDomain_50c3659c-4d91-49e5-9e71-b3f55214c361" xlink:to="loc_amed_HomeHealthNonMedicareEpisodicBasedMember_57c325f0-64d0-4951-bb1f-0a3145f7f7cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HomeHealthNonMedicareNonEpisodicBasedMember_3ae77c7d-d73d-4b62-bf46-f62cdc5d09eb" xlink:href="amed-20210630.xsd#amed_HomeHealthNonMedicareNonEpisodicBasedMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_PayorClassDomain_50c3659c-4d91-49e5-9e71-b3f55214c361" xlink:to="loc_amed_HomeHealthNonMedicareNonEpisodicBasedMember_3ae77c7d-d73d-4b62-bf46-f62cdc5d09eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HospiceMedicareMember_f3b33be9-f6c7-4acb-9a78-052801580cd1" xlink:href="amed-20210630.xsd#amed_HospiceMedicareMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_PayorClassDomain_50c3659c-4d91-49e5-9e71-b3f55214c361" xlink:to="loc_amed_HospiceMedicareMember_f3b33be9-f6c7-4acb-9a78-052801580cd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HospiceNonMedicareMember_bd725d15-e4a6-454c-9df8-3e89c2b9d392" xlink:href="amed-20210630.xsd#amed_HospiceNonMedicareMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_PayorClassDomain_50c3659c-4d91-49e5-9e71-b3f55214c361" xlink:to="loc_amed_HospiceNonMedicareMember_bd725d15-e4a6-454c-9df8-3e89c2b9d392" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PersonalCareMember_7c9583f4-5c6b-4ac9-8247-eb8f920d9554" xlink:href="amed-20210630.xsd#amed_PersonalCareMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_PayorClassDomain_50c3659c-4d91-49e5-9e71-b3f55214c361" xlink:to="loc_amed_PersonalCareMember_7c9583f4-5c6b-4ac9-8247-eb8f920d9554" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_46fbb1c3-e7ca-489e-8639-470078e61858" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTable_9ef30923-90c3-425b-90c3-f805b79104d3" xlink:to="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_46fbb1c3-e7ca-489e-8639-470078e61858" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_Revenuebypayorclassasapercentageoftotalnetservicerevenue_3ac576e3-b475-4edc-8d2a-2ca4cd15c24e" xlink:href="amed-20210630.xsd#amed_Revenuebypayorclassasapercentageoftotalnetservicerevenue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_46fbb1c3-e7ca-489e-8639-470078e61858" xlink:to="loc_amed_Revenuebypayorclassasapercentageoftotalnetservicerevenue_3ac576e3-b475-4edc-8d2a-2ca4cd15c24e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESCashandCashEquivalentsDetails" xlink:type="simple" xlink:href="amed-20210630.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESCashandCashEquivalentsDetails"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESCashandCashEquivalentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_c34fdbb6-5c2f-4633-a333-7af65270f7e4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_b9a6a4b0-0e56-4859-822e-f6b634fdadaf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c34fdbb6-5c2f-4633-a333-7af65270f7e4" xlink:to="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_b9a6a4b0-0e56-4859-822e-f6b634fdadaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_44fbed39-5d32-45ea-a9f3-6e1a9399bf2f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_b9a6a4b0-0e56-4859-822e-f6b634fdadaf" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_44fbed39-5d32-45ea-a9f3-6e1a9399bf2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_05847505-04cb-4b6c-902c-1d07847013bb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_44fbed39-5d32-45ea-a9f3-6e1a9399bf2f" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_05847505-04cb-4b6c-902c-1d07847013bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AsanaHospiceAquisitionMember_e720790b-f38a-4ae1-8c66-77dbfd0fb320" xlink:href="amed-20210630.xsd#amed_AsanaHospiceAquisitionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_05847505-04cb-4b6c-902c-1d07847013bb" xlink:to="loc_amed_AsanaHospiceAquisitionMember_e720790b-f38a-4ae1-8c66-77dbfd0fb320" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_COVID19PPEMember_6c7e90d3-8e3b-4578-a51f-1e76ff944228" xlink:href="amed-20210630.xsd#amed_COVID19PPEMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_05847505-04cb-4b6c-902c-1d07847013bb" xlink:to="loc_amed_COVID19PPEMember_6c7e90d3-8e3b-4578-a51f-1e76ff944228" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AseraCareHospiceMember_f9245c3a-0cb8-4ad3-a3dc-928b90686028" xlink:href="amed-20210630.xsd#amed_AseraCareHospiceMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_05847505-04cb-4b6c-902c-1d07847013bb" xlink:to="loc_amed_AseraCareHospiceMember_f9245c3a-0cb8-4ad3-a3dc-928b90686028" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_3e05fc45-1d56-4184-8839-674c44a95639" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_b9a6a4b0-0e56-4859-822e-f6b634fdadaf" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_3e05fc45-1d56-4184-8839-674c44a95639" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_f0a8a76d-5060-41ac-ba18-c32aec8cc575" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_3e05fc45-1d56-4184-8839-674c44a95639" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_f0a8a76d-5060-41ac-ba18-c32aec8cc575" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AsanaHospiceMember_0aaa720c-b721-44fc-bec5-68432c8964b4" xlink:href="amed-20210630.xsd#amed_AsanaHospiceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_f0a8a76d-5060-41ac-ba18-c32aec8cc575" xlink:to="loc_amed_AsanaHospiceMember_0aaa720c-b721-44fc-bec5-68432c8964b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_a129a490-f1c1-4e15-b628-a4b823fab7d2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_b9a6a4b0-0e56-4859-822e-f6b634fdadaf" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_a129a490-f1c1-4e15-b628-a4b823fab7d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_11783576-189b-4b00-8066-88d6c4891f1d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_a129a490-f1c1-4e15-b628-a4b823fab7d2" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_11783576-189b-4b00-8066-88d6c4891f1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCash_e5b1f57a-08f6-439f-850a-5ae9d6c81a01" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCash"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_a129a490-f1c1-4e15-b628-a4b823fab7d2" xlink:to="loc_us-gaap_RestrictedCash_e5b1f57a-08f6-439f-850a-5ae9d6c81a01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_27e86cb0-5118-404e-bca5-cf396abfceca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_a129a490-f1c1-4e15-b628-a4b823fab7d2" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_27e86cb0-5118-404e-bca5-cf396abfceca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CashBalanceAssociatedWithProviderReliefFund_fca9b678-c825-4ad9-a47c-1114d5fc3d6e" xlink:href="amed-20210630.xsd#amed_CashBalanceAssociatedWithProviderReliefFund"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_a129a490-f1c1-4e15-b628-a4b823fab7d2" xlink:to="loc_amed_CashBalanceAssociatedWithProviderReliefFund_fca9b678-c825-4ad9-a47c-1114d5fc3d6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ProviderReliefFundAdvance_d395e00a-6036-4515-801e-4d54ac5a0941" xlink:href="amed-20210630.xsd#amed_ProviderReliefFundAdvance"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_a129a490-f1c1-4e15-b628-a4b823fab7d2" xlink:to="loc_amed_ProviderReliefFundAdvance_d395e00a-6036-4515-801e-4d54ac5a0941" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CARESActProviderReliefFundsUtilized_062fb50a-1ec7-4ed4-bce8-dbcc0f9833d2" xlink:href="amed-20210630.xsd#amed_CARESActProviderReliefFundsUtilized"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_a129a490-f1c1-4e15-b628-a4b823fab7d2" xlink:to="loc_amed_CARESActProviderReliefFundsUtilized_062fb50a-1ec7-4ed4-bce8-dbcc0f9833d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPatientAccountsReceivableNarrativeDetails" xlink:type="simple" xlink:href="amed-20210630.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPatientAccountsReceivableNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPatientAccountsReceivableNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_0415ed7e-3d61-422e-b6e4-9d1e6370a1dc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable_865b08e3-31c9-4bc4-9452-9b6ffb155666" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0415ed7e-3d61-422e-b6e4-9d1e6370a1dc" xlink:to="loc_us-gaap_ConcentrationRiskTable_865b08e3-31c9-4bc4-9452-9b6ffb155666" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_6c265c7b-a309-4b07-8f63-b1985bbc34e5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_865b08e3-31c9-4bc4-9452-9b6ffb155666" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_6c265c7b-a309-4b07-8f63-b1985bbc34e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_b3cb0f21-ac59-4873-8983-4f9389aab324" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_6c265c7b-a309-4b07-8f63-b1985bbc34e5" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_b3cb0f21-ac59-4873-8983-4f9389aab324" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_5dcb0c96-9f46-4f72-9f8e-2b70e9e3efb3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_b3cb0f21-ac59-4873-8983-4f9389aab324" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_5dcb0c96-9f46-4f72-9f8e-2b70e9e3efb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_2e2482be-4cf3-4ab3-bb12-7ab40f7d75b9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_865b08e3-31c9-4bc4-9452-9b6ffb155666" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_2e2482be-4cf3-4ab3-bb12-7ab40f7d75b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_33cb8c01-afb3-4ace-ac81-9718a75e7a44" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_2e2482be-4cf3-4ab3-bb12-7ab40f7d75b9" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_33cb8c01-afb3-4ace-ac81-9718a75e7a44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember_de04dc62-16b4-4d61-a005-ee626ae58aff" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_33cb8c01-afb3-4ace-ac81-9718a75e7a44" xlink:to="loc_us-gaap_AccountsReceivableMember_de04dc62-16b4-4d61-a005-ee626ae58aff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_32bbeacd-f2ce-4192-afc8-3d6b3fc93fca" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_865b08e3-31c9-4bc4-9452-9b6ffb155666" xlink:to="loc_srt_MajorCustomersAxis_32bbeacd-f2ce-4192-afc8-3d6b3fc93fca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_4c263879-2e3d-46d9-8389-41c1ee456171" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_32bbeacd-f2ce-4192-afc8-3d6b3fc93fca" xlink:to="loc_srt_NameOfMajorCustomerDomain_4c263879-2e3d-46d9-8389-41c1ee456171" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_MajorSinglePayorCustomerMember_cebbf06f-3eda-4650-83f9-57e6faea3b0b" xlink:href="amed-20210630.xsd#amed_MajorSinglePayorCustomerMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_4c263879-2e3d-46d9-8389-41c1ee456171" xlink:to="loc_amed_MajorSinglePayorCustomerMember_cebbf06f-3eda-4650-83f9-57e6faea3b0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_834c2794-7c77-4cfb-9af3-c6e102eea56b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_865b08e3-31c9-4bc4-9452-9b6ffb155666" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_834c2794-7c77-4cfb-9af3-c6e102eea56b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_cb33fc11-c980-4cac-bf12-35ad8d722c88" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_834c2794-7c77-4cfb-9af3-c6e102eea56b" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_cb33fc11-c980-4cac-bf12-35ad8d722c88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CompassionateCareHospiceMember_4ef7d8a7-2a6e-494e-9ba3-6e342aa9a678" xlink:href="amed-20210630.xsd#amed_CompassionateCareHospiceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_cb33fc11-c980-4cac-bf12-35ad8d722c88" xlink:to="loc_amed_CompassionateCareHospiceMember_4ef7d8a7-2a6e-494e-9ba3-6e342aa9a678" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_31c89fe0-e688-4602-b9c9-3fa0c2e32a57" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_865b08e3-31c9-4bc4-9452-9b6ffb155666" xlink:to="loc_us-gaap_ConcentrationRiskLineItems_31c89fe0-e688-4602-b9c9-3fa0c2e32a57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AccountsReceivablePortionDerivedFromMedicare_6bb42fbb-46f8-4ec0-b6f5-ae390f39deae" xlink:href="amed-20210630.xsd#amed_AccountsReceivablePortionDerivedFromMedicare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_31c89fe0-e688-4602-b9c9-3fa0c2e32a57" xlink:to="loc_amed_AccountsReceivablePortionDerivedFromMedicare_6bb42fbb-46f8-4ec0-b6f5-ae390f39deae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_580d8876-5ab6-4248-9430-cffefe7ee8a7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_31c89fe0-e688-4602-b9c9-3fa0c2e32a57" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_580d8876-5ab6-4248-9430-cffefe7ee8a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_NetServiceRevenuePeriodOfCarePaymentRateDuration_e33ede93-c84c-473c-9b0f-7589ceebd82e" xlink:href="amed-20210630.xsd#amed_NetServiceRevenuePeriodOfCarePaymentRateDuration"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_31c89fe0-e688-4602-b9c9-3fa0c2e32a57" xlink:to="loc_amed_NetServiceRevenuePeriodOfCarePaymentRateDuration_e33ede93-c84c-473c-9b0f-7589ceebd82e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PercentageOfPatientReceivablesOutstanding_95c39e9d-ad60-444b-b4d0-0f6ba3413c40" xlink:href="amed-20210630.xsd#amed_PercentageOfPatientReceivablesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0415ed7e-3d61-422e-b6e4-9d1e6370a1dc" xlink:to="loc_amed_PercentageOfPatientReceivablesOutstanding_95c39e9d-ad60-444b-b4d0-0f6ba3413c40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HistoricalCollectionRateFromMedicare_267cfbe9-b437-4c69-8cf4-dd863d2ecdbd" xlink:href="amed-20210630.xsd#amed_HistoricalCollectionRateFromMedicare"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0415ed7e-3d61-422e-b6e4-9d1e6370a1dc" xlink:to="loc_amed_HistoricalCollectionRateFromMedicare_267cfbe9-b437-4c69-8cf4-dd863d2ecdbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_RevenueAdjustmentToMedicareRevenue_317eba75-1b05-449a-ba35-012e3a5b5ce4" xlink:href="amed-20210630.xsd#amed_RevenueAdjustmentToMedicareRevenue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0415ed7e-3d61-422e-b6e4-9d1e6370a1dc" xlink:to="loc_amed_RevenueAdjustmentToMedicareRevenue_317eba75-1b05-449a-ba35-012e3a5b5ce4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_RateOfRequestForAnticipatedPaymentSubmittedForInitialPeriodOfCare_77ac4710-c2fe-4bd6-99ae-9bb9ff191045" xlink:href="amed-20210630.xsd#amed_RateOfRequestForAnticipatedPaymentSubmittedForInitialPeriodOfCare"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0415ed7e-3d61-422e-b6e4-9d1e6370a1dc" xlink:to="loc_amed_RateOfRequestForAnticipatedPaymentSubmittedForInitialPeriodOfCare_77ac4710-c2fe-4bd6-99ae-9bb9ff191045" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_RateOfRequestForAnticipatedPaymentSubmittedForSubsequentEpisodesOfCare_a79c7118-1d4d-42d3-a33b-b62f9a075ab5" xlink:href="amed-20210630.xsd#amed_RateOfRequestForAnticipatedPaymentSubmittedForSubsequentEpisodesOfCare"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0415ed7e-3d61-422e-b6e4-9d1e6370a1dc" xlink:to="loc_amed_RateOfRequestForAnticipatedPaymentSubmittedForSubsequentEpisodesOfCare_a79c7118-1d4d-42d3-a33b-b62f9a075ab5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_MaximumDaysToSubmitFinalBillFromStartOfPeriodOfCare_d2602146-da21-4a8b-8d0a-4f91f8ff10a4" xlink:href="amed-20210630.xsd#amed_MaximumDaysToSubmitFinalBillFromStartOfPeriodOfCare"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0415ed7e-3d61-422e-b6e4-9d1e6370a1dc" xlink:to="loc_amed_MaximumDaysToSubmitFinalBillFromStartOfPeriodOfCare_d2602146-da21-4a8b-8d0a-4f91f8ff10a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_MaximumDaysToSubmitFinalBillFromDateRequestForAnticipatedPaymentWasPaid_652fdb74-1ddc-4e11-b06b-ae1974f5049c" xlink:href="amed-20210630.xsd#amed_MaximumDaysToSubmitFinalBillFromDateRequestForAnticipatedPaymentWasPaid"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0415ed7e-3d61-422e-b6e4-9d1e6370a1dc" xlink:to="loc_amed_MaximumDaysToSubmitFinalBillFromDateRequestForAnticipatedPaymentWasPaid_652fdb74-1ddc-4e11-b06b-ae1974f5049c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESFairValueofFinancialInstrumentsDetails" xlink:type="simple" xlink:href="amed-20210630.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESFairValueofFinancialInstrumentsDetails"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESFairValueofFinancialInstrumentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_1e42d4b2-5900-451f-a435-5cb42b566468" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4884c906-dfb6-4224-9c44-c280417de72e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1e42d4b2-5900-451f-a435-5cb42b566468" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4884c906-dfb6-4224-9c44-c280417de72e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_af1644d2-7886-4ae2-8f98-463b52f7d6e3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4884c906-dfb6-4224-9c44-c280417de72e" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_af1644d2-7886-4ae2-8f98-463b52f7d6e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4e755a08-dacb-40c5-804a-e656fff1451b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_af1644d2-7886-4ae2-8f98-463b52f7d6e3" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4e755a08-dacb-40c5-804a-e656fff1451b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_4cc1284a-967c-4823-afd0-4f3745daa929" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4e755a08-dacb-40c5-804a-e656fff1451b" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_4cc1284a-967c-4823-afd0-4f3745daa929" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_5cbef58f-5d4b-49ab-9754-35437c494a72" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4e755a08-dacb-40c5-804a-e656fff1451b" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_5cbef58f-5d4b-49ab-9754-35437c494a72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_25216e51-276f-4145-b822-403fb3e65a51" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4e755a08-dacb-40c5-804a-e656fff1451b" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_25216e51-276f-4145-b822-403fb3e65a51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_8a964cb7-3e8b-4ace-8e77-cfe0bec3dadc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4884c906-dfb6-4224-9c44-c280417de72e" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_8a964cb7-3e8b-4ace-8e77-cfe0bec3dadc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_DebtInstrumentCarryingAmountExcludingFinanceLeases_a02a95e6-5163-42d9-b272-ced5454eff2b" xlink:href="amed-20210630.xsd#amed_DebtInstrumentCarryingAmountExcludingFinanceLeases"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_8a964cb7-3e8b-4ace-8e77-cfe0bec3dadc" xlink:to="loc_amed_DebtInstrumentCarryingAmountExcludingFinanceLeases_a02a95e6-5163-42d9-b272-ced5454eff2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtFairValue_8fe33b4f-e992-44db-a166-55a1d540ed59" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_8a964cb7-3e8b-4ace-8e77-cfe0bec3dadc" xlink:to="loc_us-gaap_LongTermDebtFairValue_8fe33b4f-e992-44db-a166-55a1d540ed59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESWeightedAverageSharesOutstandingDetails" xlink:type="simple" xlink:href="amed-20210630.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESWeightedAverageSharesOutstandingDetails"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESWeightedAverageSharesOutstandingDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_ca14522c-c1dc-4494-bffd-ef59f8acb912" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_92979027-8f49-46a3-a103-ecf5cdedc2ba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_ca14522c-c1dc-4494-bffd-ef59f8acb912" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_92979027-8f49-46a3-a103-ecf5cdedc2ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_a0f7d40b-45e1-41bd-8e39-4ed6951318af" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_ca14522c-c1dc-4494-bffd-ef59f8acb912" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_a0f7d40b-45e1-41bd-8e39-4ed6951318af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_3fb32f20-aaee-4668-a693-a85acec97d9f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_a0f7d40b-45e1-41bd-8e39-4ed6951318af" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_3fb32f20-aaee-4668-a693-a85acec97d9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_NonVestedStockAndStockUnits_7e730c8e-f0a0-42be-b48c-1717867f6cde" xlink:href="amed-20210630.xsd#amed_NonVestedStockAndStockUnits"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_a0f7d40b-45e1-41bd-8e39-4ed6951318af" xlink:to="loc_amed_NonVestedStockAndStockUnits_7e730c8e-f0a0-42be-b48c-1717867f6cde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_0a3156c8-3d87-4d10-b222-bcf79d8f338a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_ca14522c-c1dc-4494-bffd-ef59f8acb912" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_0a3156c8-3d87-4d10-b222-bcf79d8f338a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_256b0cfa-92d0-4059-b8fc-1949e122dc11" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_ca14522c-c1dc-4494-bffd-ef59f8acb912" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_256b0cfa-92d0-4059-b8fc-1949e122dc11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/NOVELCORONAVIRUSPANDEMICCOVID19" xlink:type="simple" xlink:href="amed-20210630.xsd#NOVELCORONAVIRUSPANDEMICCOVID19"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/NOVELCORONAVIRUSPANDEMICCOVID19" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ExtraordinaryAndUnusualItemsAbstract_d9f2e126-07d2-4d1d-964c-89c110d7992e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ExtraordinaryAndUnusualItemsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_COVID19TextBlock_e74c7baa-691a-4e1b-95d9-804ddb7883fd" xlink:href="amed-20210630.xsd#amed_COVID19TextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ExtraordinaryAndUnusualItemsAbstract_d9f2e126-07d2-4d1d-964c-89c110d7992e" xlink:to="loc_amed_COVID19TextBlock_e74c7baa-691a-4e1b-95d9-804ddb7883fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/NOVELCORONAVIRUSPANDEMICCOVID19Tables" xlink:type="simple" xlink:href="amed-20210630.xsd#NOVELCORONAVIRUSPANDEMICCOVID19Tables"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/NOVELCORONAVIRUSPANDEMICCOVID19Tables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ExtraordinaryAndUnusualItemsAbstract_a84029e1-ef87-4896-9bad-2e1d4841c249" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ExtraordinaryAndUnusualItemsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ScheduleOfCaresActProviderReliefFundsTableTextBlock_2f404835-fea9-44e4-ad40-2b7563f74c6b" xlink:href="amed-20210630.xsd#amed_ScheduleOfCaresActProviderReliefFundsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ExtraordinaryAndUnusualItemsAbstract_a84029e1-ef87-4896-9bad-2e1d4841c249" xlink:to="loc_amed_ScheduleOfCaresActProviderReliefFundsTableTextBlock_2f404835-fea9-44e4-ad40-2b7563f74c6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/NOVELCORONAVIRUSPANDEMICCOVID19Details" xlink:type="simple" xlink:href="amed-20210630.xsd#NOVELCORONAVIRUSPANDEMICCOVID19Details"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/NOVELCORONAVIRUSPANDEMICCOVID19Details" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ExtraordinaryAndUnusualItemsAbstract_4abd2436-1c37-498c-98be-aef04e32bbe9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ExtraordinaryAndUnusualItemsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnusualOrInfrequentItemTable_f849c7ca-6381-4a07-b166-3a3c3ad988fa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnusualOrInfrequentItemTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ExtraordinaryAndUnusualItemsAbstract_4abd2436-1c37-498c-98be-aef04e32bbe9" xlink:to="loc_us-gaap_UnusualOrInfrequentItemTable_f849c7ca-6381-4a07-b166-3a3c3ad988fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_b6ca7871-e5b8-489e-b190-373e2cddeef4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnusualOrInfrequentItemTable_f849c7ca-6381-4a07-b166-3a3c3ad988fa" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_b6ca7871-e5b8-489e-b190-373e2cddeef4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_1b10e92b-0066-4dcb-9a61-d31ecb66d65f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_b6ca7871-e5b8-489e-b190-373e2cddeef4" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_1b10e92b-0066-4dcb-9a61-d31ecb66d65f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsMember_d325309c-0409-47e5-ad16-5f1b7dd08c90" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_1b10e92b-0066-4dcb-9a61-d31ecb66d65f" xlink:to="loc_us-gaap_EquityMethodInvestmentsMember_d325309c-0409-47e5-ad16-5f1b7dd08c90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_452dade3-1888-498f-a0ff-2d048afa9c08" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnusualOrInfrequentItemTable_f849c7ca-6381-4a07-b166-3a3c3ad988fa" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_452dade3-1888-498f-a0ff-2d048afa9c08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_c312c7f8-4f08-4f38-95e4-5f6926400589" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_452dade3-1888-498f-a0ff-2d048afa9c08" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_c312c7f8-4f08-4f38-95e4-5f6926400589" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AseraCareHospiceMember_5ad1bdea-ff67-4107-b720-6d6a772b5e2d" xlink:href="amed-20210630.xsd#amed_AseraCareHospiceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_c312c7f8-4f08-4f38-95e4-5f6926400589" xlink:to="loc_amed_AseraCareHospiceMember_5ad1bdea-ff67-4107-b720-6d6a772b5e2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_99271689-ff37-475b-8caa-85f5553650cb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnusualOrInfrequentItemTable_f849c7ca-6381-4a07-b166-3a3c3ad988fa" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_99271689-ff37-475b-8caa-85f5553650cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_ffb289a4-1a19-4d98-a472-4377d07fd832" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_99271689-ff37-475b-8caa-85f5553650cb" xlink:to="loc_us-gaap_SegmentDomain_ffb289a4-1a19-4d98-a472-4377d07fd832" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HomeHealthAndHospiceMember_69e0618c-93f7-4ea2-be8a-798bf49c5e68" xlink:href="amed-20210630.xsd#amed_HomeHealthAndHospiceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_ffb289a4-1a19-4d98-a472-4377d07fd832" xlink:to="loc_amed_HomeHealthAndHospiceMember_69e0618c-93f7-4ea2-be8a-798bf49c5e68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PersonalCareMember_077eab8b-993a-4164-9e60-3a6f619914cd" xlink:href="amed-20210630.xsd#amed_PersonalCareMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_ffb289a4-1a19-4d98-a472-4377d07fd832" xlink:to="loc_amed_PersonalCareMember_077eab8b-993a-4164-9e60-3a6f619914cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HomeHealthMember_c2751aec-4b18-42c8-921a-0a27ecf437b2" xlink:href="amed-20210630.xsd#amed_HomeHealthMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_ffb289a4-1a19-4d98-a472-4377d07fd832" xlink:to="loc_amed_HomeHealthMember_c2751aec-4b18-42c8-921a-0a27ecf437b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnusualOrInfrequentItemAxis_9de6a979-cdac-4c23-b226-38edca87cf1c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnusualOrInfrequentItemAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnusualOrInfrequentItemTable_f849c7ca-6381-4a07-b166-3a3c3ad988fa" xlink:to="loc_us-gaap_UnusualOrInfrequentItemAxis_9de6a979-cdac-4c23-b226-38edca87cf1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnusualOrInfrequentItemDomain_21094e02-7c8e-476e-9a0f-94d203ab6fdd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnusualOrInfrequentItemDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnusualOrInfrequentItemAxis_9de6a979-cdac-4c23-b226-38edca87cf1c" xlink:to="loc_us-gaap_UnusualOrInfrequentItemDomain_21094e02-7c8e-476e-9a0f-94d203ab6fdd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_COVID19DeferralOfSocialSecurityMember_fca06073-b9e4-476a-8237-635ca0f3b1e5" xlink:href="amed-20210630.xsd#amed_COVID19DeferralOfSocialSecurityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnusualOrInfrequentItemDomain_21094e02-7c8e-476e-9a0f-94d203ab6fdd" xlink:to="loc_amed_COVID19DeferralOfSocialSecurityMember_fca06073-b9e4-476a-8237-635ca0f3b1e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_4addfa38-154b-4d07-b206-cc1f3b9ed9db" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnusualOrInfrequentItemTable_f849c7ca-6381-4a07-b166-3a3c3ad988fa" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_4addfa38-154b-4d07-b206-cc1f3b9ed9db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_7c35f5da-feaf-4dc9-bc1b-5337c430577f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_4addfa38-154b-4d07-b206-cc1f3b9ed9db" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_7c35f5da-feaf-4dc9-bc1b-5337c430577f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_32f76c3b-a25f-4182-9a93-8676e51b1105" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_7c35f5da-feaf-4dc9-bc1b-5337c430577f" xlink:to="loc_us-gaap_SubsequentEventMember_32f76c3b-a25f-4182-9a93-8676e51b1105" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnusualOrInfrequentItemLineItems_1634119b-b79f-4d8b-a9cf-64d614aa4ab8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnusualOrInfrequentItemLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnusualOrInfrequentItemTable_f849c7ca-6381-4a07-b166-3a3c3ad988fa" xlink:to="loc_us-gaap_UnusualOrInfrequentItemLineItems_1634119b-b79f-4d8b-a9cf-64d614aa4ab8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_FundingForHealthcareProvidersIncludingHospitals_7ffaaae4-83ba-4ebc-9f79-d013b17d9092" xlink:href="amed-20210630.xsd#amed_FundingForHealthcareProvidersIncludingHospitals"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnusualOrInfrequentItemLineItems_1634119b-b79f-4d8b-a9cf-64d614aa4ab8" xlink:to="loc_amed_FundingForHealthcareProvidersIncludingHospitals_7ffaaae4-83ba-4ebc-9f79-d013b17d9092" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_FundingImmediatelyDistributedToHealthcareProvidersBasedOnTheir2019MedicareFeeForServiceReimbursements_3bc9c256-6fbc-436c-a9f7-0ac0b5b59a90" xlink:href="amed-20210630.xsd#amed_FundingImmediatelyDistributedToHealthcareProvidersBasedOnTheir2019MedicareFeeForServiceReimbursements"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnusualOrInfrequentItemLineItems_1634119b-b79f-4d8b-a9cf-64d614aa4ab8" xlink:to="loc_amed_FundingImmediatelyDistributedToHealthcareProvidersBasedOnTheir2019MedicareFeeForServiceReimbursements_3bc9c256-6fbc-436c-a9f7-0ac0b5b59a90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_FundingReceivedFromCARESAct_b941c466-551f-4cda-ab23-5a9db8c6a75e" xlink:href="amed-20210630.xsd#amed_FundingReceivedFromCARESAct"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnusualOrInfrequentItemLineItems_1634119b-b79f-4d8b-a9cf-64d614aa4ab8" xlink:to="loc_amed_FundingReceivedFromCARESAct_b941c466-551f-4cda-ab23-5a9db8c6a75e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ProviderReliefFundAdvance_6d360b91-82a4-4c3d-b2aa-9255e9f318e5" xlink:href="amed-20210630.xsd#amed_ProviderReliefFundAdvance"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnusualOrInfrequentItemLineItems_1634119b-b79f-4d8b-a9cf-64d614aa4ab8" xlink:to="loc_amed_ProviderReliefFundAdvance_6d360b91-82a4-4c3d-b2aa-9255e9f318e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AdditionalFundingDistributedToHealthcareProviders_d44c12e2-f9a1-47e5-a4e8-5b037f421272" xlink:href="amed-20210630.xsd#amed_AdditionalFundingDistributedToHealthcareProviders"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnusualOrInfrequentItemLineItems_1634119b-b79f-4d8b-a9cf-64d614aa4ab8" xlink:to="loc_amed_AdditionalFundingDistributedToHealthcareProviders_d44c12e2-f9a1-47e5-a4e8-5b037f421272" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CARESActDeferralOfEmployerShareSocialSecurityTax_3204541c-5c8d-441f-ba31-c48a0304b6b7" xlink:href="amed-20210630.xsd#amed_CARESActDeferralOfEmployerShareSocialSecurityTax"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnusualOrInfrequentItemLineItems_1634119b-b79f-4d8b-a9cf-64d614aa4ab8" xlink:to="loc_amed_CARESActDeferralOfEmployerShareSocialSecurityTax_3204541c-5c8d-441f-ba31-c48a0304b6b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_EstimatedFutureCOVID19RelatedExpenses_59502be1-4cdf-4307-88dc-0de5053dd397" xlink:href="amed-20210630.xsd#amed_EstimatedFutureCOVID19RelatedExpenses"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnusualOrInfrequentItemLineItems_1634119b-b79f-4d8b-a9cf-64d614aa4ab8" xlink:to="loc_amed_EstimatedFutureCOVID19RelatedExpenses_59502be1-4cdf-4307-88dc-0de5053dd397" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_COVID19ExpensesIncurred_18940f7f-dccb-4e2e-a557-bc45a88c1feb" xlink:href="amed-20210630.xsd#amed_COVID19ExpensesIncurred"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnusualOrInfrequentItemLineItems_1634119b-b79f-4d8b-a9cf-64d614aa4ab8" xlink:to="loc_amed_COVID19ExpensesIncurred_18940f7f-dccb-4e2e-a557-bc45a88c1feb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CARESActProviderReliefFundsUtilized_909637a6-e1be-4099-96f8-c27a4e43d97b" xlink:href="amed-20210630.xsd#amed_CARESActProviderReliefFundsUtilized"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnusualOrInfrequentItemLineItems_1634119b-b79f-4d8b-a9cf-64d614aa4ab8" xlink:to="loc_amed_CARESActProviderReliefFundsUtilized_909637a6-e1be-4099-96f8-c27a4e43d97b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_EstimatedCARESActProviderReliefFundsExpectedToBeUtilized_af008406-d967-4d97-b3b2-53c87ab661ab" xlink:href="amed-20210630.xsd#amed_EstimatedCARESActProviderReliefFundsExpectedToBeUtilized"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnusualOrInfrequentItemLineItems_1634119b-b79f-4d8b-a9cf-64d614aa4ab8" xlink:to="loc_amed_EstimatedCARESActProviderReliefFundsExpectedToBeUtilized_af008406-d967-4d97-b3b2-53c87ab661ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_EstimatedCARESActProviderReliefFundAmountsToBeRepaid_201da753-7761-4d8f-8bea-7a5419935083" xlink:href="amed-20210630.xsd#amed_EstimatedCARESActProviderReliefFundAmountsToBeRepaid"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnusualOrInfrequentItemLineItems_1634119b-b79f-4d8b-a9cf-64d614aa4ab8" xlink:to="loc_amed_EstimatedCARESActProviderReliefFundAmountsToBeRepaid_201da753-7761-4d8f-8bea-7a5419935083" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CARESActProviderReliefFundsReceivedByUnconsolidatedJointVentures_5c759cac-0ab8-491a-984b-b0e1bf2f4100" xlink:href="amed-20210630.xsd#amed_CARESActProviderReliefFundsReceivedByUnconsolidatedJointVentures"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnusualOrInfrequentItemLineItems_1634119b-b79f-4d8b-a9cf-64d614aa4ab8" xlink:to="loc_amed_CARESActProviderReliefFundsReceivedByUnconsolidatedJointVentures_5c759cac-0ab8-491a-984b-b0e1bf2f4100" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_TotalCARESActProviderReliefFundsReceived_d2fa180a-c373-4b91-b7d1-1d69a7147d7a" xlink:href="amed-20210630.xsd#amed_TotalCARESActProviderReliefFundsReceived"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnusualOrInfrequentItemLineItems_1634119b-b79f-4d8b-a9cf-64d614aa4ab8" xlink:to="loc_amed_TotalCARESActProviderReliefFundsReceived_d2fa180a-c373-4b91-b7d1-1d69a7147d7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_FundingReceivedFromMassHomeCareASAPCOVID19ProviderSustainabilityProgram_00374328-c4a2-41d2-bfa4-cc6aa4317b05" xlink:href="amed-20210630.xsd#amed_FundingReceivedFromMassHomeCareASAPCOVID19ProviderSustainabilityProgram"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnusualOrInfrequentItemLineItems_1634119b-b79f-4d8b-a9cf-64d614aa4ab8" xlink:to="loc_amed_FundingReceivedFromMassHomeCareASAPCOVID19ProviderSustainabilityProgram_00374328-c4a2-41d2-bfa4-cc6aa4317b05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_IncreaseInEstimatedFutureCOVID19RelatedExpenses_a72ef124-999f-4028-8c80-a44b614d523c" xlink:href="amed-20210630.xsd#amed_IncreaseInEstimatedFutureCOVID19RelatedExpenses"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnusualOrInfrequentItemLineItems_1634119b-b79f-4d8b-a9cf-64d614aa4ab8" xlink:to="loc_amed_IncreaseInEstimatedFutureCOVID19RelatedExpenses_a72ef124-999f-4028-8c80-a44b614d523c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_d21312f8-f999-4f46-babf-717b0f0d79c7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnusualOrInfrequentItemLineItems_1634119b-b79f-4d8b-a9cf-64d614aa4ab8" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_d21312f8-f999-4f46-babf-717b0f0d79c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_01bdff81-ec80-4b97-881c-869aa494df51" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnusualOrInfrequentItemLineItems_1634119b-b79f-4d8b-a9cf-64d614aa4ab8" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_01bdff81-ec80-4b97-881c-869aa494df51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ExtensionOfTemporarySuspensionOfSequestrationRevenueImpact_245bade5-caf3-4102-88b4-67d10a0e8ba2" xlink:href="amed-20210630.xsd#amed_ExtensionOfTemporarySuspensionOfSequestrationRevenueImpact"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnusualOrInfrequentItemLineItems_1634119b-b79f-4d8b-a9cf-64d614aa4ab8" xlink:to="loc_amed_ExtensionOfTemporarySuspensionOfSequestrationRevenueImpact_245bade5-caf3-4102-88b4-67d10a0e8ba2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/ACQUISITIONS" xlink:type="simple" xlink:href="amed-20210630.xsd#ACQUISITIONS"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/ACQUISITIONS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_99d402ca-a09e-447a-bd41-2950f2e74a8c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock_1a0f44eb-b972-471a-a3ae-b89f5a77259d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_99d402ca-a09e-447a-bd41-2950f2e74a8c" xlink:to="loc_us-gaap_BusinessCombinationDisclosureTextBlock_1a0f44eb-b972-471a-a3ae-b89f5a77259d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/ACQUISITIONSTables" xlink:type="simple" xlink:href="amed-20210630.xsd#ACQUISITIONSTables"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/ACQUISITIONSTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_94d256fe-b02a-48c6-b5af-8d249ee6b3b4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_7534484c-03f6-489e-a6b3-ea8be989db2b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_94d256fe-b02a-48c6-b5af-8d249ee6b3b4" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_7534484c-03f6-489e-a6b3-ea8be989db2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionProFormaInformationTextBlock_f42c6bc7-592b-47ae-9b8e-7ea03035b84d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionProFormaInformationTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_94d256fe-b02a-48c6-b5af-8d249ee6b3b4" xlink:to="loc_us-gaap_BusinessAcquisitionProFormaInformationTextBlock_f42c6bc7-592b-47ae-9b8e-7ea03035b84d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails" xlink:type="simple" xlink:href="amed-20210630.xsd#ACQUISITIONSNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_6c16ec3f-69ca-4244-ac72-1510b11c2be4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_41f760f7-5345-4750-b4a2-4fa1e643e968" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_6c16ec3f-69ca-4244-ac72-1510b11c2be4" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_41f760f7-5345-4750-b4a2-4fa1e643e968" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_6975c313-2857-43a3-a130-e515d006ba02" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_41f760f7-5345-4750-b4a2-4fa1e643e968" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_6975c313-2857-43a3-a130-e515d006ba02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_5459ace9-552e-45e1-aaf8-6b31be0b3495" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_6975c313-2857-43a3-a130-e515d006ba02" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_5459ace9-552e-45e1-aaf8-6b31be0b3495" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeNamesMember_c125034d-52de-4b22-a0c7-0867b8e48a94" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TradeNamesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_5459ace9-552e-45e1-aaf8-6b31be0b3495" xlink:to="loc_us-gaap_TradeNamesMember_c125034d-52de-4b22-a0c7-0867b8e48a94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncompeteAgreementsMember_eb2636b1-a9a4-435e-ad3b-984eeced0926" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncompeteAgreementsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_5459ace9-552e-45e1-aaf8-6b31be0b3495" xlink:to="loc_us-gaap_NoncompeteAgreementsMember_eb2636b1-a9a4-435e-ad3b-984eeced0926" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AcquiredNamesMember_89edf89c-78c9-454e-a009-535d3971c8de" xlink:href="amed-20210630.xsd#amed_AcquiredNamesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_5459ace9-552e-45e1-aaf8-6b31be0b3495" xlink:to="loc_amed_AcquiredNamesMember_89edf89c-78c9-454e-a009-535d3971c8de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OffMarketFavorableLeaseMember_ab9cf85a-97c5-43b9-8608-34a0adaeeb6a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OffMarketFavorableLeaseMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_5459ace9-552e-45e1-aaf8-6b31be0b3495" xlink:to="loc_us-gaap_OffMarketFavorableLeaseMember_ab9cf85a-97c5-43b9-8608-34a0adaeeb6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_MedicareLicenseMember_e07fbba9-c181-456e-b3f9-c0cf347ba862" xlink:href="amed-20210630.xsd#amed_MedicareLicenseMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_5459ace9-552e-45e1-aaf8-6b31be0b3495" xlink:to="loc_amed_MedicareLicenseMember_e07fbba9-c181-456e-b3f9-c0cf347ba862" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionNameOfAcquiredEntity_e16ac943-757e-4de9-8715-ed9a065afc74" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionNameOfAcquiredEntity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_5459ace9-552e-45e1-aaf8-6b31be0b3495" xlink:to="loc_us-gaap_BusinessAcquisitionNameOfAcquiredEntity_e16ac943-757e-4de9-8715-ed9a065afc74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CertificatesOfNeedMember_8c30a6a3-0d08-4f79-b2af-c611ee2fb8fd" xlink:href="amed-20210630.xsd#amed_CertificatesOfNeedMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_5459ace9-552e-45e1-aaf8-6b31be0b3495" xlink:to="loc_amed_CertificatesOfNeedMember_8c30a6a3-0d08-4f79-b2af-c611ee2fb8fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CertificateOfNeedMember_05ab8a48-753f-4dba-85c9-3d8459116005" xlink:href="amed-20210630.xsd#amed_CertificateOfNeedMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_5459ace9-552e-45e1-aaf8-6b31be0b3495" xlink:to="loc_amed_CertificateOfNeedMember_05ab8a48-753f-4dba-85c9-3d8459116005" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_711798cf-c9a7-4642-8c97-032677dae5f7" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_41f760f7-5345-4750-b4a2-4fa1e643e968" xlink:to="loc_srt_StatementGeographicalAxis_711798cf-c9a7-4642-8c97-032677dae5f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_43ba4b37-b5a8-432e-aeb7-f147eafd6618" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_711798cf-c9a7-4642-8c97-032677dae5f7" xlink:to="loc_srt_SegmentGeographicalDomain_43ba4b37-b5a8-432e-aeb7-f147eafd6618" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_TN_362fe980-46ff-4701-baab-e9215d01e7c8" xlink:href="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd#stpr_TN"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_43ba4b37-b5a8-432e-aeb7-f147eafd6618" xlink:to="loc_stpr_TN_362fe980-46ff-4701-baab-e9215d01e7c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_WA_5d0238b9-936e-454f-81d2-639068650f83" xlink:href="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd#stpr_WA"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_43ba4b37-b5a8-432e-aeb7-f147eafd6618" xlink:to="loc_stpr_WA_5d0238b9-936e-454f-81d2-639068650f83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_KY_c7929fd3-4e89-4915-9b24-e71fab6c87c4" xlink:href="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd#stpr_KY"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_43ba4b37-b5a8-432e-aeb7-f147eafd6618" xlink:to="loc_stpr_KY_c7929fd3-4e89-4915-9b24-e71fab6c87c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_NC_fd7768da-9cae-4628-9d63-b9b2a23ea1b3" xlink:href="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd#stpr_NC"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_43ba4b37-b5a8-432e-aeb7-f147eafd6618" xlink:to="loc_stpr_NC_fd7768da-9cae-4628-9d63-b9b2a23ea1b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_c026528a-89ba-4a38-a6fe-76336b0def76" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_41f760f7-5345-4750-b4a2-4fa1e643e968" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_c026528a-89ba-4a38-a6fe-76336b0def76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_852113e3-0d77-4127-9664-0db7a860da8a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_c026528a-89ba-4a38-a6fe-76336b0def76" xlink:to="loc_us-gaap_SegmentDomain_852113e3-0d77-4127-9664-0db7a860da8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HospiceMember_d2c27245-bc53-4c01-8c76-ef3f0dba8a04" xlink:href="amed-20210630.xsd#amed_HospiceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_852113e3-0d77-4127-9664-0db7a860da8a" xlink:to="loc_amed_HospiceMember_d2c27245-bc53-4c01-8c76-ef3f0dba8a04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HomeHealthMember_878e5dae-0e52-4d4d-ada8-f4dbe9d1eee6" xlink:href="amed-20210630.xsd#amed_HomeHealthMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_852113e3-0d77-4127-9664-0db7a860da8a" xlink:to="loc_amed_HomeHealthMember_878e5dae-0e52-4d4d-ada8-f4dbe9d1eee6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_064a94bc-f8da-40f1-b1ee-b98b356b2554" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_41f760f7-5345-4750-b4a2-4fa1e643e968" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_064a94bc-f8da-40f1-b1ee-b98b356b2554" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e7ea5ef3-e1cc-4618-a1f2-4765d6cbc54a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_064a94bc-f8da-40f1-b1ee-b98b356b2554" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e7ea5ef3-e1cc-4618-a1f2-4765d6cbc54a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AseraCareHospiceMember_d2426b9a-6f7c-4407-8983-280c0292422d" xlink:href="amed-20210630.xsd#amed_AseraCareHospiceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e7ea5ef3-e1cc-4618-a1f2-4765d6cbc54a" xlink:to="loc_amed_AseraCareHospiceMember_d2426b9a-6f7c-4407-8983-280c0292422d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_4be53bf5-efe1-42a6-aae4-1fb6cde02393" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_41f760f7-5345-4750-b4a2-4fa1e643e968" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_4be53bf5-efe1-42a6-aae4-1fb6cde02393" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_8fbc5e16-f557-4323-a261-8302ae6c4031" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_4be53bf5-efe1-42a6-aae4-1fb6cde02393" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_8fbc5e16-f557-4323-a261-8302ae6c4031" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CertificateOfNeedMember_d16511b2-becf-4d56-987a-f94553d1a5ec" xlink:href="amed-20210630.xsd#amed_CertificateOfNeedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_8fbc5e16-f557-4323-a261-8302ae6c4031" xlink:to="loc_amed_CertificateOfNeedMember_d16511b2-becf-4d56-987a-f94553d1a5ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_MedicareLicenseMember_95023f5c-50c0-412e-b413-1458fd784241" xlink:href="amed-20210630.xsd#amed_MedicareLicenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_8fbc5e16-f557-4323-a261-8302ae6c4031" xlink:to="loc_amed_MedicareLicenseMember_95023f5c-50c0-412e-b413-1458fd784241" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_1f4de1fe-fc22-4307-ae8e-55496cb234bd" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_41f760f7-5345-4750-b4a2-4fa1e643e968" xlink:to="loc_srt_RangeAxis_1f4de1fe-fc22-4307-ae8e-55496cb234bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_351efb08-5a7a-44f5-8104-b41e818e12ab" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_1f4de1fe-fc22-4307-ae8e-55496cb234bd" xlink:to="loc_srt_RangeMember_351efb08-5a7a-44f5-8104-b41e818e12ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_b31cf005-4f27-42ea-a74b-beb9bde038b6" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_351efb08-5a7a-44f5-8104-b41e818e12ab" xlink:to="loc_srt_MaximumMember_b31cf005-4f27-42ea-a74b-beb9bde038b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_30ef7a82-1e52-4709-bbf1-8b98e1db894c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_41f760f7-5345-4750-b4a2-4fa1e643e968" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_30ef7a82-1e52-4709-bbf1-8b98e1db894c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PercentageofSharesOutstanding_7bc933a2-66a0-4e3a-b9df-a6e832d83479" xlink:href="amed-20210630.xsd#amed_PercentageofSharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_30ef7a82-1e52-4709-bbf1-8b98e1db894c" xlink:to="loc_amed_PercentageofSharesOutstanding_7bc933a2-66a0-4e3a-b9df-a6e832d83479" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_72f3ae01-26d0-41c3-9802-e1e1914d48a8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_30ef7a82-1e52-4709-bbf1-8b98e1db894c" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_72f3ae01-26d0-41c3-9802-e1e1914d48a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAcquiredFromAcquisition_65bf833a-00dc-4a4f-8ab0-577ea733cb9a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAcquiredFromAcquisition"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_30ef7a82-1e52-4709-bbf1-8b98e1db894c" xlink:to="loc_us-gaap_CashAcquiredFromAcquisition_65bf833a-00dc-4a4f-8ab0-577ea733cb9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfBusinessesAcquired_bd4cebbb-9484-4451-a86d-088335f7d829" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfBusinessesAcquired"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_30ef7a82-1e52-4709-bbf1-8b98e1db894c" xlink:to="loc_us-gaap_NumberOfBusinessesAcquired_bd4cebbb-9484-4451-a86d-088335f7d829" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_5b2342d0-161a-4d5a-8d96-0c1c160c5e2f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_30ef7a82-1e52-4709-bbf1-8b98e1db894c" xlink:to="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_5b2342d0-161a-4d5a-8d96-0c1c160c5e2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PaymentsRelatedToTaxAsset_ccdceb51-ab58-487d-8d07-2e6c6235643d" xlink:href="amed-20210630.xsd#amed_PaymentsRelatedToTaxAsset"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_30ef7a82-1e52-4709-bbf1-8b98e1db894c" xlink:to="loc_amed_PaymentsRelatedToTaxAsset_ccdceb51-ab58-487d-8d07-2e6c6235643d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_b37da83b-8ed1-462b-91a7-0f6df5ffe84a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_30ef7a82-1e52-4709-bbf1-8b98e1db894c" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_b37da83b-8ed1-462b-91a7-0f6df5ffe84a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentAssetsPrepaidExpense_73d9a225-d92d-40d0-93dc-7f06ec7c29a4" xlink:href="amed-20210630.xsd#amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentAssetsPrepaidExpense"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_30ef7a82-1e52-4709-bbf1-8b98e1db894c" xlink:to="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentAssetsPrepaidExpense_73d9a225-d92d-40d0-93dc-7f06ec7c29a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherCurrentAsset_c782af7d-29a0-4cec-a664-4e01cd352ff8" xlink:href="amed-20210630.xsd#amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherCurrentAsset"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_30ef7a82-1e52-4709-bbf1-8b98e1db894c" xlink:to="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherCurrentAsset_c782af7d-29a0-4cec-a664-4e01cd352ff8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_7ea99d3d-a8d6-4972-8244-d3b96352efe1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_30ef7a82-1e52-4709-bbf1-8b98e1db894c" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_7ea99d3d-a8d6-4972-8244-d3b96352efe1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingleaserightofuseassets_bb93097d-592e-4a6d-99ba-0e49bdcb9725" xlink:href="amed-20210630.xsd#amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingleaserightofuseassets"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_30ef7a82-1e52-4709-bbf1-8b98e1db894c" xlink:to="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingleaserightofuseassets_bb93097d-592e-4a6d-99ba-0e49bdcb9725" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_0c0049ff-9d2f-4535-b096-aa6098727c67" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_30ef7a82-1e52-4709-bbf1-8b98e1db894c" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_0c0049ff-9d2f-4535-b096-aa6098727c67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_306c83cc-cf1a-4cff-9a91-3887bdf60661" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_30ef7a82-1e52-4709-bbf1-8b98e1db894c" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_306c83cc-cf1a-4cff-9a91-3887bdf60661" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_5efd38e5-8ff1-4f39-ac90-9f43b61d1f55" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_30ef7a82-1e52-4709-bbf1-8b98e1db894c" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_5efd38e5-8ff1-4f39-ac90-9f43b61d1f55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_b2ff7a43-513f-49e3-a2ac-f3138dbac312" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_30ef7a82-1e52-4709-bbf1-8b98e1db894c" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_b2ff7a43-513f-49e3-a2ac-f3138dbac312" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesPayrollandEmployeeBenefits_f2f1eb92-d4f6-4cae-b36b-65f5d19b9af5" xlink:href="amed-20210630.xsd#amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesPayrollandEmployeeBenefits"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_30ef7a82-1e52-4709-bbf1-8b98e1db894c" xlink:to="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesPayrollandEmployeeBenefits_f2f1eb92-d4f6-4cae-b36b-65f5d19b9af5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses_186c7b36-7b4e-4239-aaab-be1de3eb4628" xlink:href="amed-20210630.xsd#amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_30ef7a82-1e52-4709-bbf1-8b98e1db894c" xlink:to="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses_186c7b36-7b4e-4239-aaab-be1de3eb4628" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_d1463d71-2cde-4ccf-9ed0-bffcad2eb123" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_30ef7a82-1e52-4709-bbf1-8b98e1db894c" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_d1463d71-2cde-4ccf-9ed0-bffcad2eb123" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingLeaseLiabilities_6cfeab10-f8a1-44dd-8caf-1da67945ac1d" xlink:href="amed-20210630.xsd#amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingLeaseLiabilities"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_30ef7a82-1e52-4709-bbf1-8b98e1db894c" xlink:to="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingLeaseLiabilities_6cfeab10-f8a1-44dd-8caf-1da67945ac1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt_7c5f978a-b0b3-4852-9148-d219723b9afe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_30ef7a82-1e52-4709-bbf1-8b98e1db894c" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt_7c5f978a-b0b3-4852-9148-d219723b9afe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther_ae25c6b4-eae6-45f8-b44b-725c84efac68" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_30ef7a82-1e52-4709-bbf1-8b98e1db894c" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther_ae25c6b4-eae6-45f8-b44b-725c84efac68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_7cc7b6c7-23e2-46a1-8295-dc6146dbb216" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_30ef7a82-1e52-4709-bbf1-8b98e1db894c" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_7cc7b6c7-23e2-46a1-8295-dc6146dbb216" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_f2b753d3-60b6-4b13-a9fd-19abb45a73c4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_30ef7a82-1e52-4709-bbf1-8b98e1db894c" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_f2b753d3-60b6-4b13-a9fd-19abb45a73c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod_618c40f3-5a3e-469c-9f50-71bb1505b3f8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAcquiredDuringPeriod"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_30ef7a82-1e52-4709-bbf1-8b98e1db894c" xlink:to="loc_us-gaap_GoodwillAcquiredDuringPeriod_618c40f3-5a3e-469c-9f50-71bb1505b3f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_a79df637-1247-47a6-bb50-2cb4ed30d37c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_30ef7a82-1e52-4709-bbf1-8b98e1db894c" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_a79df637-1247-47a6-bb50-2cb4ed30d37c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions_264fcb2e-f470-4a9e-9783-f28e83437441" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_30ef7a82-1e52-4709-bbf1-8b98e1db894c" xlink:to="loc_us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions_264fcb2e-f470-4a9e-9783-f28e83437441" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_aec8b045-de55-45e7-b08f-6775ccc50140" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_30ef7a82-1e52-4709-bbf1-8b98e1db894c" xlink:to="loc_us-gaap_OperatingIncomeLoss_aec8b045-de55-45e7-b08f-6775ccc50140" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationIntegrationRelatedCosts_6adc414c-dfb6-42ca-8866-84ded9f3fd8d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationIntegrationRelatedCosts"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_30ef7a82-1e52-4709-bbf1-8b98e1db894c" xlink:to="loc_us-gaap_BusinessCombinationIntegrationRelatedCosts_6adc414c-dfb6-42ca-8866-84ded9f3fd8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_BusinessAcquisitionWorkingCapitalAdjustment_8d2e0993-e175-43c6-82f2-01dfdb351dc0" xlink:href="amed-20210630.xsd#amed_BusinessAcquisitionWorkingCapitalAdjustment"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_30ef7a82-1e52-4709-bbf1-8b98e1db894c" xlink:to="loc_amed_BusinessAcquisitionWorkingCapitalAdjustment_8d2e0993-e175-43c6-82f2-01dfdb351dc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OffMarketLeaseUnfavorable_24efb970-468f-4304-b372-101a4c02cab5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OffMarketLeaseUnfavorable"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_30ef7a82-1e52-4709-bbf1-8b98e1db894c" xlink:to="loc_us-gaap_OffMarketLeaseUnfavorable_24efb970-468f-4304-b372-101a4c02cab5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_BusinessAcquisitionClosingPaymentAdjustment_71428ddb-83b7-47eb-80cd-69cd31f8bd90" xlink:href="amed-20210630.xsd#amed_BusinessAcquisitionClosingPaymentAdjustment"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_30ef7a82-1e52-4709-bbf1-8b98e1db894c" xlink:to="loc_amed_BusinessAcquisitionClosingPaymentAdjustment_71428ddb-83b7-47eb-80cd-69cd31f8bd90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_DepreciationAndAmortizationForContinuingOperations_6f861c66-3a57-4d68-a718-e9824cf68213" xlink:href="amed-20210630.xsd#amed_DepreciationAndAmortizationForContinuingOperations"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_30ef7a82-1e52-4709-bbf1-8b98e1db894c" xlink:to="loc_amed_DepreciationAndAmortizationForContinuingOperations_6f861c66-3a57-4d68-a718-e9824cf68213" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_GoodwillDeductibleForIncomeTaxPurposesPeriod_13fb1432-aa4f-44e3-b50e-5209f5e10d50" xlink:href="amed-20210630.xsd#amed_GoodwillDeductibleForIncomeTaxPurposesPeriod"/>
    <link:presentationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_30ef7a82-1e52-4709-bbf1-8b98e1db894c" xlink:to="loc_amed_GoodwillDeductibleForIncomeTaxPurposesPeriod_13fb1432-aa4f-44e3-b50e-5209f5e10d50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/ACQUISITIONSProFormaDetails" xlink:type="simple" xlink:href="amed-20210630.xsd#ACQUISITIONSProFormaDetails"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/ACQUISITIONSProFormaDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_d682e041-8c89-404a-850a-b17906d32f21" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_008b2285-d0a2-49b5-b356-46045f367aa5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_d682e041-8c89-404a-850a-b17906d32f21" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_008b2285-d0a2-49b5-b356-46045f367aa5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_e495e239-1bdb-42a0-8878-a75fb83ace9d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_008b2285-d0a2-49b5-b356-46045f367aa5" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_e495e239-1bdb-42a0-8878-a75fb83ace9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_52eb8381-bfe9-4c53-a08f-b8c79d5f2f92" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_e495e239-1bdb-42a0-8878-a75fb83ace9d" xlink:to="loc_us-gaap_SegmentDomain_52eb8381-bfe9-4c53-a08f-b8c79d5f2f92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HospiceMember_4a1321e5-3c28-4575-9bd1-48cabf56ab27" xlink:href="amed-20210630.xsd#amed_HospiceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_52eb8381-bfe9-4c53-a08f-b8c79d5f2f92" xlink:to="loc_amed_HospiceMember_4a1321e5-3c28-4575-9bd1-48cabf56ab27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_4c6addad-af62-4b4a-b083-4d8d5150bb49" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_008b2285-d0a2-49b5-b356-46045f367aa5" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_4c6addad-af62-4b4a-b083-4d8d5150bb49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b68c42c5-d022-4e6b-bc66-3596aeab76fb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_4c6addad-af62-4b4a-b083-4d8d5150bb49" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b68c42c5-d022-4e6b-bc66-3596aeab76fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CompassionateCareHospiceMember_8692595d-3fb8-48ac-907c-1fd3090ad26c" xlink:href="amed-20210630.xsd#amed_CompassionateCareHospiceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b68c42c5-d022-4e6b-bc66-3596aeab76fb" xlink:to="loc_amed_CompassionateCareHospiceMember_8692595d-3fb8-48ac-907c-1fd3090ad26c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AseraCareHospiceMember_aa266cd2-697d-4bdd-a20f-263a8d1ea620" xlink:href="amed-20210630.xsd#amed_AseraCareHospiceMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b68c42c5-d022-4e6b-bc66-3596aeab76fb" xlink:to="loc_amed_AseraCareHospiceMember_aa266cd2-697d-4bdd-a20f-263a8d1ea620" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_22a98fad-1cbc-4d55-ad1c-efb4335f4c2c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_008b2285-d0a2-49b5-b356-46045f367aa5" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_22a98fad-1cbc-4d55-ad1c-efb4335f4c2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_47db813e-6a83-47a5-ab70-89b874b2d100" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_22a98fad-1cbc-4d55-ad1c-efb4335f4c2c" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_47db813e-6a83-47a5-ab70-89b874b2d100" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_c7116357-b9ce-47a0-877b-2561de9eabc0" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_OwnershipAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_008b2285-d0a2-49b5-b356-46045f367aa5" xlink:to="loc_srt_OwnershipAxis_c7116357-b9ce-47a0-877b-2561de9eabc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_d5e11e97-7e2b-46b9-bebe-77ddf2bb1090" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_OwnershipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipAxis_c7116357-b9ce-47a0-877b-2561de9eabc0" xlink:to="loc_srt_OwnershipDomain_d5e11e97-7e2b-46b9-bebe-77ddf2bb1090" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_0f5f844c-cb19-4c36-853a-10642148e5e9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_008b2285-d0a2-49b5-b356-46045f367aa5" xlink:to="loc_us-gaap_StatementClassOfStockAxis_0f5f844c-cb19-4c36-853a-10642148e5e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_04ad9f9d-8887-478b-ae34-5fb00a2b996f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_0f5f844c-cb19-4c36-853a-10642148e5e9" xlink:to="loc_us-gaap_ClassOfStockDomain_04ad9f9d-8887-478b-ae34-5fb00a2b996f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_cde53dbc-444c-4055-a17d-fab828132ff7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_008b2285-d0a2-49b5-b356-46045f367aa5" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_cde53dbc-444c-4055-a17d-fab828132ff7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionsProFormaRevenue_213a4df8-23e0-4344-a9e4-06a7d9ab9092" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionsProFormaRevenue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_cde53dbc-444c-4055-a17d-fab828132ff7" xlink:to="loc_us-gaap_BusinessAcquisitionsProFormaRevenue_213a4df8-23e0-4344-a9e4-06a7d9ab9092" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_Businessacquisitionproformaoperatingincomeloss_f4859274-0ede-4a34-8499-a7bebe3394f8" xlink:href="amed-20210630.xsd#amed_Businessacquisitionproformaoperatingincomeloss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_cde53dbc-444c-4055-a17d-fab828132ff7" xlink:to="loc_amed_Businessacquisitionproformaoperatingincomeloss_f4859274-0ede-4a34-8499-a7bebe3394f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_f8eac593-4f63-41a8-8484-a57dbb08c546" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_cde53dbc-444c-4055-a17d-fab828132ff7" xlink:to="loc_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_f8eac593-4f63-41a8-8484-a57dbb08c546" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic_51169f9d-c976-44c1-8456-803cf304ee73" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_cde53dbc-444c-4055-a17d-fab828132ff7" xlink:to="loc_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic_51169f9d-c976-44c1-8456-803cf304ee73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted_8f93947b-9520-49a6-85eb-1abe337e2a14" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_cde53dbc-444c-4055-a17d-fab828132ff7" xlink:to="loc_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted_8f93947b-9520-49a6-85eb-1abe337e2a14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/LONGTERMOBLIGATIONS" xlink:type="simple" xlink:href="amed-20210630.xsd#LONGTERMOBLIGATIONS"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/LONGTERMOBLIGATIONS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_52ad1bb8-76ac-4e02-a788-8b643fb3234c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_39e26152-9636-4ed7-b88f-ea2a24f810f0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_52ad1bb8-76ac-4e02-a788-8b643fb3234c" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_39e26152-9636-4ed7-b88f-ea2a24f810f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/LONGTERMOBLIGATIONSLONGTERMOBLIGATIONSTables" xlink:type="simple" xlink:href="amed-20210630.xsd#LONGTERMOBLIGATIONSLONGTERMOBLIGATIONSTables"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/LONGTERMOBLIGATIONSLONGTERMOBLIGATIONSTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_74226e6c-4564-4434-b4d3-ef151affd76e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock_9b4234da-7f3f-4d15-9cba-bd444fbe2833" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_74226e6c-4564-4434-b4d3-ef151affd76e" xlink:to="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock_9b4234da-7f3f-4d15-9cba-bd444fbe2833" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock_8ee0f635-3399-4ec8-a8a4-0f6d54ebae81" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_74226e6c-4564-4434-b4d3-ef151affd76e" xlink:to="loc_us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock_8ee0f635-3399-4ec8-a8a4-0f6d54ebae81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtDetails" xlink:type="simple" xlink:href="amed-20210630.xsd#LONGTERMOBLIGATIONSScheduleofLongTermDebtDetails"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_7213bba9-7252-4b32-858b-43f5173f46a3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_38f628d8-c620-42ce-be51-8f181da36a0d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_7213bba9-7252-4b32-858b-43f5173f46a3" xlink:to="loc_us-gaap_DebtInstrumentTable_38f628d8-c620-42ce-be51-8f181da36a0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_c11dc671-ccd4-4772-9f7e-0db91650805b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_38f628d8-c620-42ce-be51-8f181da36a0d" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_c11dc671-ccd4-4772-9f7e-0db91650805b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_e358238d-7859-43aa-b26b-4b768d9e38b6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_c11dc671-ccd4-4772-9f7e-0db91650805b" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_e358238d-7859-43aa-b26b-4b768d9e38b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LoansPayableMember_57bfcb32-5553-40d2-93db-af62b7db6614" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LoansPayableMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_e358238d-7859-43aa-b26b-4b768d9e38b6" xlink:to="loc_us-gaap_LoansPayableMember_57bfcb32-5553-40d2-93db-af62b7db6614" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_55d6c14a-9da8-4443-9c61-98d5423cd83f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_e358238d-7859-43aa-b26b-4b768d9e38b6" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_55d6c14a-9da8-4443-9c61-98d5423cd83f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PromissoryNotesMember_fe285832-1619-41d1-8806-0ea65a2f9b91" xlink:href="amed-20210630.xsd#amed_PromissoryNotesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_e358238d-7859-43aa-b26b-4b768d9e38b6" xlink:to="loc_amed_PromissoryNotesMember_fe285832-1619-41d1-8806-0ea65a2f9b91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalLeaseObligationsMember_44293227-452d-4d15-9083-6941bbf0bf43" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalLeaseObligationsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_e358238d-7859-43aa-b26b-4b768d9e38b6" xlink:to="loc_us-gaap_CapitalLeaseObligationsMember_44293227-452d-4d15-9083-6941bbf0bf43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_42203d7d-5a21-4896-bf04-15f43f674045" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_38f628d8-c620-42ce-be51-8f181da36a0d" xlink:to="loc_us-gaap_DebtInstrumentAxis_42203d7d-5a21-4896-bf04-15f43f674045" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_d6af7ab1-b1c6-40e1-b4cf-0372e03db405" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_42203d7d-5a21-4896-bf04-15f43f674045" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_d6af7ab1-b1c6-40e1-b4cf-0372e03db405" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_OneHundredSeventyFiveMillionTermLoanFacilityMember_c8161ab1-0f93-453d-84b3-cf8822bdecfa" xlink:href="amed-20210630.xsd#amed_OneHundredSeventyFiveMillionTermLoanFacilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d6af7ab1-b1c6-40e1-b4cf-0372e03db405" xlink:to="loc_amed_OneHundredSeventyFiveMillionTermLoanFacilityMember_c8161ab1-0f93-453d-84b3-cf8822bdecfa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember_3a948ae4-3117-49cc-a928-af0f7ed2333e" xlink:href="amed-20210630.xsd#amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d6af7ab1-b1c6-40e1-b4cf-0372e03db405" xlink:to="loc_amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember_3a948ae4-3117-49cc-a928-af0f7ed2333e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_57c00439-c425-4d7b-a387-e650d61801b4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_38f628d8-c620-42ce-be51-8f181da36a0d" xlink:to="loc_us-gaap_VariableRateAxis_57c00439-c425-4d7b-a387-e650d61801b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_f7153214-0ddb-4aff-841c-73efd0be2668" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateAxis_57c00439-c425-4d7b-a387-e650d61801b4" xlink:to="loc_us-gaap_VariableRateDomain_f7153214-0ddb-4aff-841c-73efd0be2668" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EurodollarMember_71856533-b2ca-4578-8e1a-876efc1fe0e4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EurodollarMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_f7153214-0ddb-4aff-841c-73efd0be2668" xlink:to="loc_us-gaap_EurodollarMember_71856533-b2ca-4578-8e1a-876efc1fe0e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_e23119e0-07f1-4302-adb4-b899e3c41abc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_38f628d8-c620-42ce-be51-8f181da36a0d" xlink:to="loc_us-gaap_DebtInstrumentLineItems_e23119e0-07f1-4302-adb4-b899e3c41abc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_5e239b8a-6cac-4920-a2f6-937ca3dd5eed" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e23119e0-07f1-4302-adb4-b899e3c41abc" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_5e239b8a-6cac-4920-a2f6-937ca3dd5eed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_7996e3ba-6510-404e-a7fe-7af08e7ad69d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e23119e0-07f1-4302-adb4-b899e3c41abc" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_7996e3ba-6510-404e-a7fe-7af08e7ad69d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_845abb79-be5e-40c6-9b2c-ca60ce2fda70" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e23119e0-07f1-4302-adb4-b899e3c41abc" xlink:to="loc_us-gaap_LongTermDebt_845abb79-be5e-40c6-9b2c-ca60ce2fda70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_315cb369-6192-40b5-8ea8-99b238e66b11" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e23119e0-07f1-4302-adb4-b899e3c41abc" xlink:to="loc_us-gaap_LongTermDebtCurrent_315cb369-6192-40b5-8ea8-99b238e66b11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_d31a41fd-0c49-4773-99e1-c0e01cf80478" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e23119e0-07f1-4302-adb4-b899e3c41abc" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_d31a41fd-0c49-4773-99e1-c0e01cf80478" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtDetails_1" xlink:type="simple" xlink:href="amed-20210630.xsd#LONGTERMOBLIGATIONSScheduleofLongTermDebtDetails_1"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtAdditionalInformationDetails" xlink:type="simple" xlink:href="amed-20210630.xsd#LONGTERMOBLIGATIONSScheduleofLongTermDebtAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_547ea048-df70-4221-a07a-7d8aa06d92f3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_24f94f44-1865-477c-b806-9a8ca1111346" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_547ea048-df70-4221-a07a-7d8aa06d92f3" xlink:to="loc_us-gaap_DebtInstrumentTable_24f94f44-1865-477c-b806-9a8ca1111346" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_3768ee4b-0508-4439-9c7c-e40237fe35c3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_24f94f44-1865-477c-b806-9a8ca1111346" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_3768ee4b-0508-4439-9c7c-e40237fe35c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_ab5bb1c2-0a21-447f-bd88-d90dfe3fdfad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_3768ee4b-0508-4439-9c7c-e40237fe35c3" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_ab5bb1c2-0a21-447f-bd88-d90dfe3fdfad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LoansPayableMember_469265a1-b6a6-4285-97bf-646b77e735fb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LoansPayableMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_ab5bb1c2-0a21-447f-bd88-d90dfe3fdfad" xlink:to="loc_us-gaap_LoansPayableMember_469265a1-b6a6-4285-97bf-646b77e735fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_770c6df4-b85a-456c-b03d-62d9597ab703" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_ab5bb1c2-0a21-447f-bd88-d90dfe3fdfad" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_770c6df4-b85a-456c-b03d-62d9597ab703" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_11f10544-a9ae-4bef-a89f-e46da521ebb3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_24f94f44-1865-477c-b806-9a8ca1111346" xlink:to="loc_us-gaap_DebtInstrumentAxis_11f10544-a9ae-4bef-a89f-e46da521ebb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_820cabe2-6147-44e3-81d8-8c63fe085eb0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_11f10544-a9ae-4bef-a89f-e46da521ebb3" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_820cabe2-6147-44e3-81d8-8c63fe085eb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_OneHundredSeventyFiveMillionTermLoanFacilityMember_bf12059a-1370-47b1-8982-13b84bbbbba1" xlink:href="amed-20210630.xsd#amed_OneHundredSeventyFiveMillionTermLoanFacilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_820cabe2-6147-44e3-81d8-8c63fe085eb0" xlink:to="loc_amed_OneHundredSeventyFiveMillionTermLoanFacilityMember_bf12059a-1370-47b1-8982-13b84bbbbba1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_TwoHundredMillionRevolvingCreditFacilityMember_d0913654-46b8-4455-8c8a-50b1ca3ce0b7" xlink:href="amed-20210630.xsd#amed_TwoHundredMillionRevolvingCreditFacilityMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_820cabe2-6147-44e3-81d8-8c63fe085eb0" xlink:to="loc_amed_TwoHundredMillionRevolvingCreditFacilityMember_d0913654-46b8-4455-8c8a-50b1ca3ce0b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember_fad58f0a-8d62-428a-864f-77c41d14d175" xlink:href="amed-20210630.xsd#amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_820cabe2-6147-44e3-81d8-8c63fe085eb0" xlink:to="loc_amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember_fad58f0a-8d62-428a-864f-77c41d14d175" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_12011010-de14-499a-96ae-1841d05d09f2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_24f94f44-1865-477c-b806-9a8ca1111346" xlink:to="loc_us-gaap_VariableRateAxis_12011010-de14-499a-96ae-1841d05d09f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_43a4ff75-a41d-493f-b7d6-d63a2f8abc2d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateAxis_12011010-de14-499a-96ae-1841d05d09f2" xlink:to="loc_us-gaap_VariableRateDomain_43a4ff75-a41d-493f-b7d6-d63a2f8abc2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EurodollarMember_40bcea47-d50c-45a9-8b0b-18e2f3425dd6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EurodollarMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_43a4ff75-a41d-493f-b7d6-d63a2f8abc2d" xlink:to="loc_us-gaap_EurodollarMember_40bcea47-d50c-45a9-8b0b-18e2f3425dd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_7be65452-f80b-47df-9e38-3916f3c2a33f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_24f94f44-1865-477c-b806-9a8ca1111346" xlink:to="loc_us-gaap_DebtInstrumentLineItems_7be65452-f80b-47df-9e38-3916f3c2a33f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_e4e27c69-5176-4a3b-8ad0-1342377338af" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7be65452-f80b-47df-9e38-3916f3c2a33f" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_e4e27c69-5176-4a3b-8ad0-1342377338af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_DebtInstrumentInterestRateatPeriodEnd_026f6a43-d445-454f-8e6d-fd9a5b2f481f" xlink:href="amed-20210630.xsd#amed_DebtInstrumentInterestRateatPeriodEnd"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7be65452-f80b-47df-9e38-3916f3c2a33f" xlink:to="loc_amed_DebtInstrumentInterestRateatPeriodEnd_026f6a43-d445-454f-8e6d-fd9a5b2f481f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentMaturityDate_58b489d0-23cc-4730-a3a2-fe0240ef8fb0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentMaturityDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7be65452-f80b-47df-9e38-3916f3c2a33f" xlink:to="loc_us-gaap_DebtInstrumentMaturityDate_58b489d0-23cc-4730-a3a2-fe0240ef8fb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/LONGTERMOBLIGATIONSFeesandRatesUnderCreditFacilitiesDetails" xlink:type="simple" xlink:href="amed-20210630.xsd#LONGTERMOBLIGATIONSFeesandRatesUnderCreditFacilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/LONGTERMOBLIGATIONSFeesandRatesUnderCreditFacilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_0bfd712b-cb7e-4d52-9d8d-50bc8a21a39a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityTable_6237af1e-77da-4400-b0ac-a94e8740042d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_0bfd712b-cb7e-4d52-9d8d-50bc8a21a39a" xlink:to="loc_us-gaap_LineOfCreditFacilityTable_6237af1e-77da-4400-b0ac-a94e8740042d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_0b098753-d70a-4d48-9d4d-ae65c1c8472c" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_6237af1e-77da-4400-b0ac-a94e8740042d" xlink:to="loc_srt_RangeAxis_0b098753-d70a-4d48-9d4d-ae65c1c8472c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_baa1a85f-6507-4e92-b983-836a75e2fcbc" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_0b098753-d70a-4d48-9d4d-ae65c1c8472c" xlink:to="loc_srt_RangeMember_baa1a85f-6507-4e92-b983-836a75e2fcbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_5f848ec4-a782-40ea-867f-822429e38d27" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_baa1a85f-6507-4e92-b983-836a75e2fcbc" xlink:to="loc_srt_MinimumMember_5f848ec4-a782-40ea-867f-822429e38d27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_935a6527-6a2c-4bc5-9fc5-93d1d74b9ef1" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_baa1a85f-6507-4e92-b983-836a75e2fcbc" xlink:to="loc_srt_MaximumMember_935a6527-6a2c-4bc5-9fc5-93d1d74b9ef1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_8eb35d64-2fe3-4e98-8644-3fbc3db6a592" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_6237af1e-77da-4400-b0ac-a94e8740042d" xlink:to="loc_us-gaap_DebtInstrumentAxis_8eb35d64-2fe3-4e98-8644-3fbc3db6a592" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_9a69bf86-4b1c-426f-806c-f2d786f5347e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_8eb35d64-2fe3-4e98-8644-3fbc3db6a592" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_9a69bf86-4b1c-426f-806c-f2d786f5347e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_DebtInstrumentByLeverageRatioTrancheOneMember_cbd108ba-d7c4-41f6-93df-59d459e6692e" xlink:href="amed-20210630.xsd#amed_DebtInstrumentByLeverageRatioTrancheOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_9a69bf86-4b1c-426f-806c-f2d786f5347e" xlink:to="loc_amed_DebtInstrumentByLeverageRatioTrancheOneMember_cbd108ba-d7c4-41f6-93df-59d459e6692e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_DebtInstrumentByLeverageRatioTrancheTwoMember_cdc48ae2-eb1a-4314-baa3-ccd9afe29be4" xlink:href="amed-20210630.xsd#amed_DebtInstrumentByLeverageRatioTrancheTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_9a69bf86-4b1c-426f-806c-f2d786f5347e" xlink:to="loc_amed_DebtInstrumentByLeverageRatioTrancheTwoMember_cdc48ae2-eb1a-4314-baa3-ccd9afe29be4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_DebtInstrumentByLeverageRatioTrancheThreeMember_276901b1-8542-40c4-bc63-caea929a941e" xlink:href="amed-20210630.xsd#amed_DebtInstrumentByLeverageRatioTrancheThreeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_9a69bf86-4b1c-426f-806c-f2d786f5347e" xlink:to="loc_amed_DebtInstrumentByLeverageRatioTrancheThreeMember_276901b1-8542-40c4-bc63-caea929a941e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_DebtInstrumentByLeverageRatioTrancheFourMember_399f0d02-5904-46e3-bbb3-b1ce76053377" xlink:href="amed-20210630.xsd#amed_DebtInstrumentByLeverageRatioTrancheFourMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_9a69bf86-4b1c-426f-806c-f2d786f5347e" xlink:to="loc_amed_DebtInstrumentByLeverageRatioTrancheFourMember_399f0d02-5904-46e3-bbb3-b1ce76053377" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_202d0791-6fbb-4b51-bd24-6a8520b492df" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_6237af1e-77da-4400-b0ac-a94e8740042d" xlink:to="loc_us-gaap_VariableRateAxis_202d0791-6fbb-4b51-bd24-6a8520b492df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_f79fd4e5-b2d9-4a5f-8030-5930f5f97bb0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateAxis_202d0791-6fbb-4b51-bd24-6a8520b492df" xlink:to="loc_us-gaap_VariableRateDomain_f79fd4e5-b2d9-4a5f-8030-5930f5f97bb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EurodollarMember_beb1ef1d-878d-459d-853a-6e989afad812" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EurodollarMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_f79fd4e5-b2d9-4a5f-8030-5930f5f97bb0" xlink:to="loc_us-gaap_EurodollarMember_beb1ef1d-878d-459d-853a-6e989afad812" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BaseRateMember_a3943c8b-73c8-4ace-a063-31253b385871" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BaseRateMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_f79fd4e5-b2d9-4a5f-8030-5930f5f97bb0" xlink:to="loc_us-gaap_BaseRateMember_a3943c8b-73c8-4ace-a063-31253b385871" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityAxis_27de86a1-fb63-442a-87eb-85f27f6cf57f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_6237af1e-77da-4400-b0ac-a94e8740042d" xlink:to="loc_us-gaap_LineOfCreditFacilityAxis_27de86a1-fb63-442a-87eb-85f27f6cf57f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain_591b258e-c99d-4fd3-8c18-e4e2438a4c7e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis_27de86a1-fb63-442a-87eb-85f27f6cf57f" xlink:to="loc_us-gaap_LineOfCreditFacilityLenderDomain_591b258e-c99d-4fd3-8c18-e4e2438a4c7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_ebe56f2d-dd6b-44d3-b849-29a22abde7ab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_6237af1e-77da-4400-b0ac-a94e8740042d" xlink:to="loc_us-gaap_CreditFacilityAxis_ebe56f2d-dd6b-44d3-b849-29a22abde7ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_6b94efe3-31bd-49fd-ae56-0875838426d4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_ebe56f2d-dd6b-44d3-b849-29a22abde7ab" xlink:to="loc_us-gaap_CreditFacilityDomain_6b94efe3-31bd-49fd-ae56-0875838426d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLineItems_001f8989-8ce7-4d63-ba81-a2b5de76af0d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_6237af1e-77da-4400-b0ac-a94e8740042d" xlink:to="loc_us-gaap_LineOfCreditFacilityLineItems_001f8989-8ce7-4d63-ba81-a2b5de76af0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ConsolidatedLeverageRatio_eee0f5fa-0192-4204-ba90-2a4418bfb731" xlink:href="amed-20210630.xsd#amed_ConsolidatedLeverageRatio"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_001f8989-8ce7-4d63-ba81-a2b5de76af0d" xlink:to="loc_amed_ConsolidatedLeverageRatio_eee0f5fa-0192-4204-ba90-2a4418bfb731" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_cb24e696-dc37-4408-90e6-02232d90087a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityCommitmentFeePercentage"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_001f8989-8ce7-4d63-ba81-a2b5de76af0d" xlink:to="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_cb24e696-dc37-4408-90e6-02232d90087a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_LetterOfCreditFee_c6d98c16-e627-4536-9f4d-8c773ebe5127" xlink:href="amed-20210630.xsd#amed_LetterOfCreditFee"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_001f8989-8ce7-4d63-ba81-a2b5de76af0d" xlink:to="loc_amed_LetterOfCreditFee_c6d98c16-e627-4536-9f4d-8c773ebe5127" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_9d7569df-e84a-480d-8969-932f24b7e488" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_001f8989-8ce7-4d63-ba81-a2b5de76af0d" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_9d7569df-e84a-480d-8969-932f24b7e488" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails" xlink:type="simple" xlink:href="amed-20210630.xsd#LONGTERMOBLIGATIONSNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_7d6528bb-7073-4dbc-bfea-5f16e3a3637d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_ab471c14-6165-4955-9b44-232093e97de6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_7d6528bb-7073-4dbc-bfea-5f16e3a3637d" xlink:to="loc_us-gaap_DebtInstrumentTable_ab471c14-6165-4955-9b44-232093e97de6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_3b46bd41-809e-43b1-a112-5d999bd3c2fb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_ab471c14-6165-4955-9b44-232093e97de6" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_3b46bd41-809e-43b1-a112-5d999bd3c2fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_6a2ff9ea-7588-4cfa-8a4c-d0006c5b19b3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_3b46bd41-809e-43b1-a112-5d999bd3c2fb" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_6a2ff9ea-7588-4cfa-8a4c-d0006c5b19b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_5b0161b6-a7e4-444a-a1aa-d1cad6d90c8b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_6a2ff9ea-7588-4cfa-8a4c-d0006c5b19b3" xlink:to="loc_us-gaap_SubsequentEventMember_5b0161b6-a7e4-444a-a1aa-d1cad6d90c8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_8c475aa8-5922-4390-9d12-5bd5afc5f31c" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_ab471c14-6165-4955-9b44-232093e97de6" xlink:to="loc_srt_RangeAxis_8c475aa8-5922-4390-9d12-5bd5afc5f31c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_f4eec402-8b07-45f6-82ad-6cf96901d8ef" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_8c475aa8-5922-4390-9d12-5bd5afc5f31c" xlink:to="loc_srt_RangeMember_f4eec402-8b07-45f6-82ad-6cf96901d8ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_f31e60f6-6840-47d7-9790-fdc99e161bf0" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_f4eec402-8b07-45f6-82ad-6cf96901d8ef" xlink:to="loc_srt_MinimumMember_f31e60f6-6840-47d7-9790-fdc99e161bf0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_eeaa32f0-955e-4189-bb89-2a48400e9804" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_ab471c14-6165-4955-9b44-232093e97de6" xlink:to="loc_us-gaap_VariableRateAxis_eeaa32f0-955e-4189-bb89-2a48400e9804" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_0214567e-4427-46b0-9548-9781757000fd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateAxis_eeaa32f0-955e-4189-bb89-2a48400e9804" xlink:to="loc_us-gaap_VariableRateDomain_0214567e-4427-46b0-9548-9781757000fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BaseRateMember_92f5299a-5143-4943-989d-6cff5f15d11e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BaseRateMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_0214567e-4427-46b0-9548-9781757000fd" xlink:to="loc_us-gaap_BaseRateMember_92f5299a-5143-4943-989d-6cff5f15d11e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EurodollarMember_15c45fea-ebc5-4f5c-865c-da1e2a18d24b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EurodollarMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_0214567e-4427-46b0-9548-9781757000fd" xlink:to="loc_us-gaap_EurodollarMember_15c45fea-ebc5-4f5c-865c-da1e2a18d24b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_108edf43-9a86-463c-a0d6-a3fad9d4054a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_ab471c14-6165-4955-9b44-232093e97de6" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_108edf43-9a86-463c-a0d6-a3fad9d4054a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_dc16825b-b6c2-4091-a7d3-1cd4d5152566" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_108edf43-9a86-463c-a0d6-a3fad9d4054a" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_dc16825b-b6c2-4091-a7d3-1cd4d5152566" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_SwingLineLoanMember_34a97785-b509-4477-8450-0040dafa8cd1" xlink:href="amed-20210630.xsd#amed_SwingLineLoanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_dc16825b-b6c2-4091-a7d3-1cd4d5152566" xlink:to="loc_amed_SwingLineLoanMember_34a97785-b509-4477-8450-0040dafa8cd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LetterOfCreditMember_0dfaacdf-ca12-4b89-a51c-3f429d4f2bda" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LetterOfCreditMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_dc16825b-b6c2-4091-a7d3-1cd4d5152566" xlink:to="loc_us-gaap_LetterOfCreditMember_0dfaacdf-ca12-4b89-a51c-3f429d4f2bda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LoansPayableMember_9b729fd2-a763-4d80-a534-0bb3a3460fe3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LoansPayableMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_dc16825b-b6c2-4091-a7d3-1cd4d5152566" xlink:to="loc_us-gaap_LoansPayableMember_9b729fd2-a763-4d80-a534-0bb3a3460fe3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_a415a899-c391-4abf-96fa-374bd4337df8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_dc16825b-b6c2-4091-a7d3-1cd4d5152566" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_a415a899-c391-4abf-96fa-374bd4337df8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PriorCreditAgreementMember_68aa34e0-0a4b-4035-b457-daa021b8fb6e" xlink:href="amed-20210630.xsd#amed_PriorCreditAgreementMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_dc16825b-b6c2-4091-a7d3-1cd4d5152566" xlink:to="loc_amed_PriorCreditAgreementMember_68aa34e0-0a4b-4035-b457-daa021b8fb6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_7f8f22b7-00ac-467b-9e72-093a47dc4233" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_dc16825b-b6c2-4091-a7d3-1cd4d5152566" xlink:to="loc_us-gaap_LineOfCreditMember_7f8f22b7-00ac-467b-9e72-093a47dc4233" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AmendedCreditAgreementMember_2bbe379d-4bb5-4cb5-931d-f50d374921fe" xlink:href="amed-20210630.xsd#amed_AmendedCreditAgreementMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_dc16825b-b6c2-4091-a7d3-1cd4d5152566" xlink:to="loc_amed_AmendedCreditAgreementMember_2bbe379d-4bb5-4cb5-931d-f50d374921fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_2b341679-bce5-426e-a92d-09f30b74f295" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_ab471c14-6165-4955-9b44-232093e97de6" xlink:to="loc_us-gaap_DebtInstrumentAxis_2b341679-bce5-426e-a92d-09f30b74f295" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_4985727c-9b49-405e-9810-c0bc4977b644" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_2b341679-bce5-426e-a92d-09f30b74f295" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_4985727c-9b49-405e-9810-c0bc4977b644" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AmendedCreditAgreementMember_2ff6583e-8d3a-4ebd-8264-4176639ea55c" xlink:href="amed-20210630.xsd#amed_AmendedCreditAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_4985727c-9b49-405e-9810-c0bc4977b644" xlink:to="loc_amed_AmendedCreditAgreementMember_2ff6583e-8d3a-4ebd-8264-4176639ea55c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_OneHundredMillionTermLoanMember_c6e49abf-c3a0-46ff-8ca9-f8300e21362d" xlink:href="amed-20210630.xsd#amed_OneHundredMillionTermLoanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_4985727c-9b49-405e-9810-c0bc4977b644" xlink:to="loc_amed_OneHundredMillionTermLoanMember_c6e49abf-c3a0-46ff-8ca9-f8300e21362d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_TwoHundredMillionRevolvingCreditFacilityMember_c97eec58-22d8-4bba-844f-92f01292b982" xlink:href="amed-20210630.xsd#amed_TwoHundredMillionRevolvingCreditFacilityMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_4985727c-9b49-405e-9810-c0bc4977b644" xlink:to="loc_amed_TwoHundredMillionRevolvingCreditFacilityMember_c97eec58-22d8-4bba-844f-92f01292b982" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember_60744874-b562-41f8-8517-5409cacdc3b4" xlink:href="amed-20210630.xsd#amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_4985727c-9b49-405e-9810-c0bc4977b644" xlink:to="loc_amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember_60744874-b562-41f8-8517-5409cacdc3b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_OneHundredSeventyFiveMillionTermLoanFacilityMember_37bc7cf7-64ca-4dec-b72c-8b9194ead653" xlink:href="amed-20210630.xsd#amed_OneHundredSeventyFiveMillionTermLoanFacilityMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_4985727c-9b49-405e-9810-c0bc4977b644" xlink:to="loc_amed_OneHundredSeventyFiveMillionTermLoanFacilityMember_37bc7cf7-64ca-4dec-b72c-8b9194ead653" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_2e363d22-fd6b-415b-a987-738568fb5201" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_ab471c14-6165-4955-9b44-232093e97de6" xlink:to="loc_us-gaap_DebtInstrumentLineItems_2e363d22-fd6b-415b-a987-738568fb5201" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_DebtInstrumentPeriodicPaymentPercentage_2ccf8a9a-602c-423e-8d23-565bbfb50c2f" xlink:href="amed-20210630.xsd#amed_DebtInstrumentPeriodicPaymentPercentage"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2e363d22-fd6b-415b-a987-738568fb5201" xlink:to="loc_amed_DebtInstrumentPeriodicPaymentPercentage_2ccf8a9a-602c-423e-8d23-565bbfb50c2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ProceedsReceivedFromLoanPartyOfSubsidiary_2ea19808-6a2f-4709-a525-72065f7bf70f" xlink:href="amed-20210630.xsd#amed_ProceedsReceivedFromLoanPartyOfSubsidiary"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2e363d22-fd6b-415b-a987-738568fb5201" xlink:to="loc_amed_ProceedsReceivedFromLoanPartyOfSubsidiary_2ea19808-6a2f-4709-a525-72065f7bf70f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfFinancingCosts_d0754063-993b-4fea-abc5-a9798117b724" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfFinancingCosts"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2e363d22-fd6b-415b-a987-738568fb5201" xlink:to="loc_us-gaap_PaymentsOfFinancingCosts_d0754063-993b-4fea-abc5-a9798117b724" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_453327cf-b42b-4feb-9b25-a97e06720b5a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2e363d22-fd6b-415b-a987-738568fb5201" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_453327cf-b42b-4feb-9b25-a97e06720b5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtWeightedAverageInterestRateOverTime_8fdc4213-1ca3-415c-b4de-a3f70d8e1df6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtWeightedAverageInterestRateOverTime"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2e363d22-fd6b-415b-a987-738568fb5201" xlink:to="loc_us-gaap_LongTermDebtWeightedAverageInterestRateOverTime_8fdc4213-1ca3-415c-b4de-a3f70d8e1df6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_TotalLeverageRatio_86835c5a-f7ea-4c3e-8dd2-23e24073cc89" xlink:href="amed-20210630.xsd#amed_TotalLeverageRatio"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2e363d22-fd6b-415b-a987-738568fb5201" xlink:to="loc_amed_TotalLeverageRatio_86835c5a-f7ea-4c3e-8dd2-23e24073cc89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ConsolidatedInterestCoverageRatio_882b348e-c1a7-4d96-a30d-9117622c2090" xlink:href="amed-20210630.xsd#amed_ConsolidatedInterestCoverageRatio"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2e363d22-fd6b-415b-a987-738568fb5201" xlink:to="loc_amed_ConsolidatedInterestCoverageRatio_882b348e-c1a7-4d96-a30d-9117622c2090" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_58876773-5bd6-4d2e-913f-09133acdd305" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2e363d22-fd6b-415b-a987-738568fb5201" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_58876773-5bd6-4d2e-913f-09133acdd305" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_RevolvingCreditFacilityTotal_11e80a6f-0650-48d5-b1df-c09049757e94" xlink:href="amed-20210630.xsd#amed_RevolvingCreditFacilityTotal"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2e363d22-fd6b-415b-a987-738568fb5201" xlink:to="loc_amed_RevolvingCreditFacilityTotal_11e80a6f-0650-48d5-b1df-c09049757e94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_LineOfCreditFacilityAdditionalBorrowingCapacity_64ac3877-6e12-41ba-964d-592cdf89f72a" xlink:href="amed-20210630.xsd#amed_LineOfCreditFacilityAdditionalBorrowingCapacity"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2e363d22-fd6b-415b-a987-738568fb5201" xlink:to="loc_amed_LineOfCreditFacilityAdditionalBorrowingCapacity_64ac3877-6e12-41ba-964d-592cdf89f72a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CreditFacilityMaximumAllowableConsolidatedLeverageRatioMultiple_7282bb60-b0b6-47fa-aa3d-306055e0d4db" xlink:href="amed-20210630.xsd#amed_CreditFacilityMaximumAllowableConsolidatedLeverageRatioMultiple"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2e363d22-fd6b-415b-a987-738568fb5201" xlink:to="loc_amed_CreditFacilityMaximumAllowableConsolidatedLeverageRatioMultiple_7282bb60-b0b6-47fa-aa3d-306055e0d4db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_Creditfacilitymaximumallowableconsolidatedleverageratio_268ac76d-919f-44b4-9578-fb1004fb3e06" xlink:href="amed-20210630.xsd#amed_Creditfacilitymaximumallowableconsolidatedleverageratio"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2e363d22-fd6b-415b-a987-738568fb5201" xlink:to="loc_amed_Creditfacilitymaximumallowableconsolidatedleverageratio_268ac76d-919f-44b4-9578-fb1004fb3e06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentMaturityDate_9318bfbf-111a-4fa4-8583-ba1e7df54e2d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentMaturityDate"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2e363d22-fd6b-415b-a987-738568fb5201" xlink:to="loc_us-gaap_DebtInstrumentMaturityDate_9318bfbf-111a-4fa4-8583-ba1e7df54e2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_DebtInstrumentInterestAdditionalInterestAboveFederalFundRate_e9881beb-e110-4354-be15-9d29c51014d8" xlink:href="amed-20210630.xsd#amed_DebtInstrumentInterestAdditionalInterestAboveFederalFundRate"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2e363d22-fd6b-415b-a987-738568fb5201" xlink:to="loc_amed_DebtInstrumentInterestAdditionalInterestAboveFederalFundRate_e9881beb-e110-4354-be15-9d29c51014d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_DebtInstrumentInterestAdditionalInterestAboveEurodollarRate_13e74a7c-2d7e-4cd7-9333-e9a149f38e65" xlink:href="amed-20210630.xsd#amed_DebtInstrumentInterestAdditionalInterestAboveEurodollarRate"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2e363d22-fd6b-415b-a987-738568fb5201" xlink:to="loc_amed_DebtInstrumentInterestAdditionalInterestAboveEurodollarRate_13e74a7c-2d7e-4cd7-9333-e9a149f38e65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_b30806ae-7144-4958-b981-530af281d25a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2e363d22-fd6b-415b-a987-738568fb5201" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_b30806ae-7144-4958-b981-530af281d25a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PercentageOfRevenueAndOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromWhollyOwnedSubsidiaries_520bc3f7-02b2-40e4-b20f-ee32914dbde0" xlink:href="amed-20210630.xsd#amed_PercentageOfRevenueAndOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromWhollyOwnedSubsidiaries"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2e363d22-fd6b-415b-a987-738568fb5201" xlink:to="loc_amed_PercentageOfRevenueAndOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromWhollyOwnedSubsidiaries_520bc3f7-02b2-40e4-b20f-ee32914dbde0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PercentageOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromSubsidiaries_751f48b9-e9cf-4ca0-80d6-437624ec45db" xlink:href="amed-20210630.xsd#amed_PercentageOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromSubsidiaries"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2e363d22-fd6b-415b-a987-738568fb5201" xlink:to="loc_amed_PercentageOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromSubsidiaries_751f48b9-e9cf-4ca0-80d6-437624ec45db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtIssuanceCostsLineOfCreditArrangementsGross_78133d4c-f7c6-4e93-9f24-7b574a601832" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtIssuanceCostsLineOfCreditArrangementsGross"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2e363d22-fd6b-415b-a987-738568fb5201" xlink:to="loc_us-gaap_DebtIssuanceCostsLineOfCreditArrangementsGross_78133d4c-f7c6-4e93-9f24-7b574a601832" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_c0e2bfbe-91aa-4a9a-a472-4e40e2a16b79" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2e363d22-fd6b-415b-a987-738568fb5201" xlink:to="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_c0e2bfbe-91aa-4a9a-a472-4e40e2a16b79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_74a1fd6a-6957-45b4-ae99-e11127200b88" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2e363d22-fd6b-415b-a987-738568fb5201" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_74a1fd6a-6957-45b4-ae99-e11127200b88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LettersOfCreditOutstandingAmount_c6ea4717-64c1-4283-8ef1-86717421721d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LettersOfCreditOutstandingAmount"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2e363d22-fd6b-415b-a987-738568fb5201" xlink:to="loc_us-gaap_LettersOfCreditOutstandingAmount_c6ea4717-64c1-4283-8ef1-86717421721d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis_42a9c005-3823-4a50-b9fb-ef9ecb00e144" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentDescriptionOfVariableRateBasis"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2e363d22-fd6b-415b-a987-738568fb5201" xlink:to="loc_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis_42a9c005-3823-4a50-b9fb-ef9ecb00e144" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_DebtInstrumentInterestRateatPeriodEnd_13a5f991-29cc-44c4-ac21-647a4afae90c" xlink:href="amed-20210630.xsd#amed_DebtInstrumentInterestRateatPeriodEnd"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2e363d22-fd6b-415b-a987-738568fb5201" xlink:to="loc_amed_DebtInstrumentInterestRateatPeriodEnd_13a5f991-29cc-44c4-ac21-647a4afae90c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIES" xlink:type="simple" xlink:href="amed-20210630.xsd#COMMITMENTSANDCONTINGENCIES"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_5b6ca8f0-549b-47ac-abd4-f16ec42d3bf4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_d620e91e-e590-471b-a0d9-01376944189b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_5b6ca8f0-549b-47ac-abd4-f16ec42d3bf4" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_d620e91e-e590-471b-a0d9-01376944189b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails" xlink:type="simple" xlink:href="amed-20210630.xsd#COMMITMENTSANDCONTINGENCIESNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_eafaf913-d299-43ce-9f04-d582f90bb5fe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_4fdd2d3e-4e62-4513-bd64-94cb288c7a6a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_eafaf913-d299-43ce-9f04-d582f90bb5fe" xlink:to="loc_us-gaap_LossContingenciesTable_4fdd2d3e-4e62-4513-bd64-94cb288c7a6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PayorsAxis_373787c8-885c-4c80-acd2-5459f302f0a9" xlink:href="amed-20210630.xsd#amed_PayorsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_4fdd2d3e-4e62-4513-bd64-94cb288c7a6a" xlink:to="loc_amed_PayorsAxis_373787c8-885c-4c80-acd2-5459f302f0a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PayorsDomain_fc8401ad-0846-4b33-b7bf-bb4f7f80ce82" xlink:href="amed-20210630.xsd#amed_PayorsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_PayorsAxis_373787c8-885c-4c80-acd2-5459f302f0a9" xlink:to="loc_amed_PayorsDomain_fc8401ad-0846-4b33-b7bf-bb4f7f80ce82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CompanysinsurancecarriersMember_18137023-81dc-45c3-add3-82b6e05c01bf" xlink:href="amed-20210630.xsd#amed_CompanysinsurancecarriersMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_PayorsDomain_fc8401ad-0846-4b33-b7bf-bb4f7f80ce82" xlink:to="loc_amed_CompanysinsurancecarriersMember_18137023-81dc-45c3-add3-82b6e05c01bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_97b942ca-5e91-4e3c-ae0a-f2c07ef2c93f" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_LitigationCaseAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_4fdd2d3e-4e62-4513-bd64-94cb288c7a6a" xlink:to="loc_srt_LitigationCaseAxis_97b942ca-5e91-4e3c-ae0a-f2c07ef2c93f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_70e4becc-f971-4726-824c-65865aea4560" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseAxis_97b942ca-5e91-4e3c-ae0a-f2c07ef2c93f" xlink:to="loc_srt_LitigationCaseTypeDomain_70e4becc-f971-4726-824c-65865aea4560" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_UsDepartmentOfJusticeMember_c9cfcf19-c2e4-48a1-900e-f78ded437db7" xlink:href="amed-20210630.xsd#amed_UsDepartmentOfJusticeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_70e4becc-f971-4726-824c-65865aea4560" xlink:to="loc_amed_UsDepartmentOfJusticeMember_c9cfcf19-c2e4-48a1-900e-f78ded437db7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AmedisysCIAMember_9b2fd535-f0bd-4b51-b21c-025f6f42e522" xlink:href="amed-20210630.xsd#amed_AmedisysCIAMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_70e4becc-f971-4726-824c-65865aea4560" xlink:to="loc_amed_AmedisysCIAMember_9b2fd535-f0bd-4b51-b21c-025f6f42e522" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CompassionateCareHospiceCIAMember_dd0d642e-b929-4140-8eb1-387951e89e87" xlink:href="amed-20210630.xsd#amed_CompassionateCareHospiceCIAMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_70e4becc-f971-4726-824c-65865aea4560" xlink:to="loc_amed_CompassionateCareHospiceCIAMember_dd0d642e-b929-4140-8eb1-387951e89e87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_SecuritiesClassActionLawsuitMember_8a3a8875-ab65-4a7f-bab3-62fcf4ada7f1" xlink:href="amed-20210630.xsd#amed_SecuritiesClassActionLawsuitMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_70e4becc-f971-4726-824c-65865aea4560" xlink:to="loc_amed_SecuritiesClassActionLawsuitMember_8a3a8875-ab65-4a7f-bab3-62fcf4ada7f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_SafeguardZoneProgramIntegrityContractorMember_10d059c1-7c41-4bd9-8119-cb61e00ad582" xlink:href="amed-20210630.xsd#amed_SafeguardZoneProgramIntegrityContractorMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_70e4becc-f971-4726-824c-65865aea4560" xlink:to="loc_amed_SafeguardZoneProgramIntegrityContractorMember_10d059c1-7c41-4bd9-8119-cb61e00ad582" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_InternalAuditComplianceReviewMember_7e596457-f5a1-443e-88d1-4d205828d276" xlink:href="amed-20210630.xsd#amed_InternalAuditComplianceReviewMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_70e4becc-f971-4726-824c-65865aea4560" xlink:to="loc_amed_InternalAuditComplianceReviewMember_7e596457-f5a1-443e-88d1-4d205828d276" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_ed81fe35-c41d-4ebb-9d0b-18bee0426699" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_4fdd2d3e-4e62-4513-bd64-94cb288c7a6a" xlink:to="loc_srt_StatementGeographicalAxis_ed81fe35-c41d-4ebb-9d0b-18bee0426699" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_2c7e05d0-cfd8-4251-bd3f-6c4f164f25a1" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_ed81fe35-c41d-4ebb-9d0b-18bee0426699" xlink:to="loc_srt_SegmentGeographicalDomain_2c7e05d0-cfd8-4251-bd3f-6c4f164f25a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_MA_5d24d4ba-00cd-4291-ae06-794b564aeb44" xlink:href="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd#stpr_MA"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_2c7e05d0-cfd8-4251-bd3f-6c4f164f25a1" xlink:to="loc_stpr_MA_5d24d4ba-00cd-4291-ae06-794b564aeb44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_MorgantownWestVirginiaMember_41beaac6-6560-4495-966b-e21b6903c517" xlink:href="amed-20210630.xsd#amed_MorgantownWestVirginiaMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_2c7e05d0-cfd8-4251-bd3f-6c4f164f25a1" xlink:to="loc_amed_MorgantownWestVirginiaMember_41beaac6-6560-4495-966b-e21b6903c517" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ParkersburgWestVirginiaMember_03cbb9fe-9ff2-425c-8cc0-0623b24f0b58" xlink:href="amed-20210630.xsd#amed_ParkersburgWestVirginiaMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_2c7e05d0-cfd8-4251-bd3f-6c4f164f25a1" xlink:to="loc_amed_ParkersburgWestVirginiaMember_03cbb9fe-9ff2-425c-8cc0-0623b24f0b58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_SC_f71cdd35-a858-4732-83ca-3e4d98247bb7" xlink:href="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd#stpr_SC"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_2c7e05d0-cfd8-4251-bd3f-6c4f164f25a1" xlink:to="loc_stpr_SC_f71cdd35-a858-4732-83ca-3e4d98247bb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_FL_15b6606d-0885-4e58-9a8c-e3b98bed1dd1" xlink:href="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd#stpr_FL"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_2c7e05d0-cfd8-4251-bd3f-6c4f164f25a1" xlink:to="loc_stpr_FL_15b6606d-0885-4e58-9a8c-e3b98bed1dd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_LakelandFloridaMember_d687f79f-24ae-493f-84ff-cd9b0778ceaf" xlink:href="amed-20210630.xsd#amed_LakelandFloridaMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_stpr_FL_15b6606d-0885-4e58-9a8c-e3b98bed1dd1" xlink:to="loc_amed_LakelandFloridaMember_d687f79f-24ae-493f-84ff-cd9b0778ceaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ClearwaterFloridaMember_dcb444dd-ea1b-4163-be2f-095bf72f197a" xlink:href="amed-20210630.xsd#amed_ClearwaterFloridaMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_stpr_FL_15b6606d-0885-4e58-9a8c-e3b98bed1dd1" xlink:to="loc_amed_ClearwaterFloridaMember_dcb444dd-ea1b-4163-be2f-095bf72f197a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_8b8ed0b8-e80d-40a5-b35e-7a95940840a1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_4fdd2d3e-4e62-4513-bd64-94cb288c7a6a" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_8b8ed0b8-e80d-40a5-b35e-7a95940840a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_79d7073e-6163-4010-a50d-e12639fa6759" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_8b8ed0b8-e80d-40a5-b35e-7a95940840a1" xlink:to="loc_us-gaap_SegmentDomain_79d7073e-6163-4010-a50d-e12639fa6759" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HospiceMember_ae839710-4323-4794-8d10-3683fe53d0ac" xlink:href="amed-20210630.xsd#amed_HospiceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_79d7073e-6163-4010-a50d-e12639fa6759" xlink:to="loc_amed_HospiceMember_ae839710-4323-4794-8d10-3683fe53d0ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HomeHealthMember_bcc8da72-e73f-4d57-bfd7-91444e57b4ce" xlink:href="amed-20210630.xsd#amed_HomeHealthMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_79d7073e-6163-4010-a50d-e12639fa6759" xlink:to="loc_amed_HomeHealthMember_bcc8da72-e73f-4d57-bfd7-91444e57b4ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_eedb13ba-1ee4-438f-9ebd-bdf0e1a7ca27" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_4fdd2d3e-4e62-4513-bd64-94cb288c7a6a" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_eedb13ba-1ee4-438f-9ebd-bdf0e1a7ca27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_337d885b-d3b5-42d7-a903-c12b248e535a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_eedb13ba-1ee4-438f-9ebd-bdf0e1a7ca27" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_337d885b-d3b5-42d7-a903-c12b248e535a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_InfinityHomeCareMember_ca6ebccc-593d-45b5-8808-9fd9d756ae71" xlink:href="amed-20210630.xsd#amed_InfinityHomeCareMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_337d885b-d3b5-42d7-a903-c12b248e535a" xlink:to="loc_amed_InfinityHomeCareMember_ca6ebccc-593d-45b5-8808-9fd9d756ae71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_dad1f315-3be4-476d-a472-9fd131f44f9d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_4fdd2d3e-4e62-4513-bd64-94cb288c7a6a" xlink:to="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_dad1f315-3be4-476d-a472-9fd131f44f9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain_0817624a-4e4a-4339-9459-ee36cbd2f3cd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_dad1f315-3be4-476d-a472-9fd131f44f9d" xlink:to="loc_us-gaap_LossContingencyNatureDomain_0817624a-4e4a-4339-9459-ee36cbd2f3cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ExtrapolatedMember_3c46b155-3583-4139-8f0a-f3ec824b8f8d" xlink:href="amed-20210630.xsd#amed_ExtrapolatedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingencyNatureDomain_0817624a-4e4a-4339-9459-ee36cbd2f3cd" xlink:to="loc_amed_ExtrapolatedMember_3c46b155-3583-4139-8f0a-f3ec824b8f8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_UnfavorableMember_80dfc35f-57fa-49c1-9f52-5c469e1f1700" xlink:href="amed-20210630.xsd#amed_UnfavorableMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingencyNatureDomain_0817624a-4e4a-4339-9459-ee36cbd2f3cd" xlink:to="loc_amed_UnfavorableMember_80dfc35f-57fa-49c1-9f52-5c469e1f1700" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_36e513a7-58c8-446e-9213-1bbb7a12d62e" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_4fdd2d3e-4e62-4513-bd64-94cb288c7a6a" xlink:to="loc_srt_RangeAxis_36e513a7-58c8-446e-9213-1bbb7a12d62e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_90b40128-fe34-4627-a0fc-d2b63da2818f" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_36e513a7-58c8-446e-9213-1bbb7a12d62e" xlink:to="loc_srt_RangeMember_90b40128-fe34-4627-a0fc-d2b63da2818f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_70da8572-651b-46d5-9cc0-a9eba2fd2973" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_90b40128-fe34-4627-a0fc-d2b63da2818f" xlink:to="loc_srt_MinimumMember_70da8572-651b-46d5-9cc0-a9eba2fd2973" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_d4e21855-3fbd-4425-afac-0fbc8a746ab3" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_90b40128-fe34-4627-a0fc-d2b63da2818f" xlink:to="loc_srt_MaximumMember_d4e21855-3fbd-4425-afac-0fbc8a746ab3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_65b85ce6-f4bf-43be-b8b5-cef836158316" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_4fdd2d3e-4e62-4513-bd64-94cb288c7a6a" xlink:to="loc_us-gaap_LossContingenciesLineItems_65b85ce6-f4bf-43be-b8b5-cef836158316" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForLegalSettlements_c578f9cb-425d-48aa-ae3b-f3a4f25c93a5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForLegalSettlements"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_65b85ce6-f4bf-43be-b8b5-cef836158316" xlink:to="loc_us-gaap_PaymentsForLegalSettlements_c578f9cb-425d-48aa-ae3b-f3a4f25c93a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_Numberofpatients_45c270ad-4312-43df-a34e-8e4a3b37ada1" xlink:href="amed-20210630.xsd#amed_Numberofpatients"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_65b85ce6-f4bf-43be-b8b5-cef836158316" xlink:to="loc_amed_Numberofpatients_45c270ad-4312-43df-a34e-8e4a3b37ada1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CorporateIntegrityAgreementTerm_c0339ee8-adc3-4eb0-889f-593610dc9386" xlink:href="amed-20210630.xsd#amed_CorporateIntegrityAgreementTerm"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_65b85ce6-f4bf-43be-b8b5-cef836158316" xlink:to="loc_amed_CorporateIntegrityAgreementTerm_c0339ee8-adc3-4eb0-889f-593610dc9386" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualAtCarryingValue_176ccbe8-c6bf-4591-aad7-6cfbab0f658a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyAccrualAtCarryingValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_65b85ce6-f4bf-43be-b8b5-cef836158316" xlink:to="loc_us-gaap_LossContingencyAccrualAtCarryingValue_176ccbe8-c6bf-4591-aad7-6cfbab0f658a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualCarryingValuePeriodIncreaseDecrease_20891b11-eff2-4685-ae2c-297b4ef9ab6f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyAccrualCarryingValuePeriodIncreaseDecrease"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_65b85ce6-f4bf-43be-b8b5-cef836158316" xlink:to="loc_us-gaap_LossContingencyAccrualCarryingValuePeriodIncreaseDecrease_20891b11-eff2-4685-ae2c-297b4ef9ab6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyReceivableCurrent_da981f41-480c-4b34-89a0-064bd38a1e83" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyReceivableCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_65b85ce6-f4bf-43be-b8b5-cef836158316" xlink:to="loc_us-gaap_LossContingencyReceivableCurrent_da981f41-480c-4b34-89a0-064bd38a1e83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_SecuritiesClassActionLawsuitsettlement_552c6e6d-a9c9-45c0-825a-ea890ebcd976" xlink:href="amed-20210630.xsd#amed_SecuritiesClassActionLawsuitsettlement"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_65b85ce6-f4bf-43be-b8b5-cef836158316" xlink:to="loc_amed_SecuritiesClassActionLawsuitsettlement_552c6e6d-a9c9-45c0-825a-ea890ebcd976" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_NumberOfBeneficiaries_0e964be2-9004-4481-b4ae-4a16b05c1c05" xlink:href="amed-20210630.xsd#amed_NumberOfBeneficiaries"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_65b85ce6-f4bf-43be-b8b5-cef836158316" xlink:to="loc_amed_NumberOfBeneficiaries_0e964be2-9004-4481-b4ae-4a16b05c1c05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_RecoveryAmountOfOverpaymentMadeToSubsidiary_7a50c80f-ed4f-44dc-b9ea-73dd9cff146f" xlink:href="amed-20210630.xsd#amed_RecoveryAmountOfOverpaymentMadeToSubsidiary"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_65b85ce6-f4bf-43be-b8b5-cef836158316" xlink:to="loc_amed_RecoveryAmountOfOverpaymentMadeToSubsidiary_7a50c80f-ed4f-44dc-b9ea-73dd9cff146f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_RecoveryAmountOfOverpaymentMadeToSubsidiaryIncludingInterest_d701fde3-e130-4727-be65-194e97a3f98e" xlink:href="amed-20210630.xsd#amed_RecoveryAmountOfOverpaymentMadeToSubsidiaryIncludingInterest"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_65b85ce6-f4bf-43be-b8b5-cef836158316" xlink:to="loc_amed_RecoveryAmountOfOverpaymentMadeToSubsidiaryIncludingInterest_d701fde3-e130-4727-be65-194e97a3f98e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_NumberOfClaimsSubmittedBySubsidiary_cdd420a9-c2e1-4323-bd4b-9132ae5b99d4" xlink:href="amed-20210630.xsd#amed_NumberOfClaimsSubmittedBySubsidiary"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_65b85ce6-f4bf-43be-b8b5-cef836158316" xlink:to="loc_amed_NumberOfClaimsSubmittedBySubsidiary_cdd420a9-c2e1-4323-bd4b-9132ae5b99d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_Recoveryamountofoverpaymentmadetosubsidiaryincludinginterestwithheld_ab5b1309-0566-471c-b962-d97234740275" xlink:href="amed-20210630.xsd#amed_Recoveryamountofoverpaymentmadetosubsidiaryincludinginterestwithheld"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_65b85ce6-f4bf-43be-b8b5-cef836158316" xlink:to="loc_amed_Recoveryamountofoverpaymentmadetosubsidiaryincludinginterestwithheld_ab5b1309-0566-471c-b962-d97234740275" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_LossContingencyReceivableNoncurrentRelatedToAmountsWithheldPriorToAugust2009_4b62ff2a-58f0-4ea1-9902-b43425ddb9a0" xlink:href="amed-20210630.xsd#amed_LossContingencyReceivableNoncurrentRelatedToAmountsWithheldPriorToAugust2009"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_65b85ce6-f4bf-43be-b8b5-cef836158316" xlink:to="loc_amed_LossContingencyReceivableNoncurrentRelatedToAmountsWithheldPriorToAugust2009_4b62ff2a-58f0-4ea1-9902-b43425ddb9a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyReceivableNoncurrent_8b4edbeb-1194-4fc5-b4a8-0d63bc45212d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyReceivableNoncurrent"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_65b85ce6-f4bf-43be-b8b5-cef836158316" xlink:to="loc_us-gaap_LossContingencyReceivableNoncurrent_8b4edbeb-1194-4fc5-b4a8-0d63bc45212d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ActualClaimsPayment_79845ff8-bfd1-4276-ab7f-c0b280c5e63b" xlink:href="amed-20210630.xsd#amed_ActualClaimsPayment"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_65b85ce6-f4bf-43be-b8b5-cef836158316" xlink:to="loc_amed_ActualClaimsPayment_79845ff8-bfd1-4276-ab7f-c0b280c5e63b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ErrorRatePercentage_99f31685-72aa-4b78-bbb7-84aa6637f25c" xlink:href="amed-20210630.xsd#amed_ErrorRatePercentage"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_65b85ce6-f4bf-43be-b8b5-cef836158316" xlink:to="loc_amed_ErrorRatePercentage_99f31685-72aa-4b78-bbb7-84aa6637f25c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_IndemnificationAmount_ea241854-b2ac-488b-8977-da5837261e8a" xlink:href="amed-20210630.xsd#amed_IndemnificationAmount"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_65b85ce6-f4bf-43be-b8b5-cef836158316" xlink:to="loc_amed_IndemnificationAmount_ea241854-b2ac-488b-8977-da5837261e8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_FloridaZpicRevenueReduction_c21ebc35-8ab9-4a89-9ad8-87bf7b2ed62c" xlink:href="amed-20210630.xsd#amed_FloridaZpicRevenueReduction"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_65b85ce6-f4bf-43be-b8b5-cef836158316" xlink:to="loc_amed_FloridaZpicRevenueReduction_c21ebc35-8ab9-4a89-9ad8-87bf7b2ed62c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_552407ff-2a7d-4d2a-aa82-8887c9d87f23" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_65b85ce6-f4bf-43be-b8b5-cef836158316" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_552407ff-2a7d-4d2a-aa82-8887c9d87f23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HealthInsuranceRetentionLimit_f2e2bc1d-2de5-46ee-b579-7b45c9f3bc47" xlink:href="amed-20210630.xsd#amed_HealthInsuranceRetentionLimit"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_65b85ce6-f4bf-43be-b8b5-cef836158316" xlink:to="loc_amed_HealthInsuranceRetentionLimit_f2e2bc1d-2de5-46ee-b579-7b45c9f3bc47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_WorkersCompensationInsuranceRetentionLimit_71f9e502-bea6-4421-9acb-434388c8c0b6" xlink:href="amed-20210630.xsd#amed_WorkersCompensationInsuranceRetentionLimit"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_65b85ce6-f4bf-43be-b8b5-cef836158316" xlink:to="loc_amed_WorkersCompensationInsuranceRetentionLimit_71f9e502-bea6-4421-9acb-434388c8c0b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ProfessionalLiabilityInsuranceRetentionLimit_6b9a2002-c815-40fc-9af6-042fabe88fde" xlink:href="amed-20210630.xsd#amed_ProfessionalLiabilityInsuranceRetentionLimit"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_65b85ce6-f4bf-43be-b8b5-cef836158316" xlink:to="loc_amed_ProfessionalLiabilityInsuranceRetentionLimit_6b9a2002-c815-40fc-9af6-042fabe88fde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ReversalOfLossContingencyAccrual_52ba98e3-fd16-4e02-adb7-a13a8d83dafd" xlink:href="amed-20210630.xsd#amed_ReversalOfLossContingencyAccrual"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_65b85ce6-f4bf-43be-b8b5-cef836158316" xlink:to="loc_amed_ReversalOfLossContingencyAccrual_52ba98e3-fd16-4e02-adb7-a13a8d83dafd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/SEGMENTINFORMATION" xlink:type="simple" xlink:href="amed-20210630.xsd#SEGMENTINFORMATION"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/SEGMENTINFORMATION" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_8e0e02b5-2b30-4a3f-b250-ee7a93faad5f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock_9c15a2aa-884b-4275-a3e8-0ba308e8670c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_8e0e02b5-2b30-4a3f-b250-ee7a93faad5f" xlink:to="loc_us-gaap_SegmentReportingDisclosureTextBlock_9c15a2aa-884b-4275-a3e8-0ba308e8670c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/SEGMENTINFORMATIONTables" xlink:type="simple" xlink:href="amed-20210630.xsd#SEGMENTINFORMATIONTables"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/SEGMENTINFORMATIONTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_4b2d0e7b-8f0e-43d2-94b1-79785bd85a1d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_9bd0d625-66cb-4357-90a6-4bf037846d99" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_4b2d0e7b-8f0e-43d2-94b1-79785bd85a1d" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_9bd0d625-66cb-4357-90a6-4bf037846d99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/SEGMENTINFORMATIONNarrativeDetails" xlink:type="simple" xlink:href="amed-20210630.xsd#SEGMENTINFORMATIONNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/SEGMENTINFORMATIONNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_1e98d649-be5e-49dc-8c0d-9371ca90c5a1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments_f92dae9f-187c-4c25-bf0c-617c2cac1822" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_1e98d649-be5e-49dc-8c0d-9371ca90c5a1" xlink:to="loc_us-gaap_NumberOfReportableSegments_f92dae9f-187c-4c25-bf0c-617c2cac1822" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/SEGMENTINFORMATIONOperatingIncomeofReportableSegmentsDetails" xlink:type="simple" xlink:href="amed-20210630.xsd#SEGMENTINFORMATIONOperatingIncomeofReportableSegmentsDetails"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/SEGMENTINFORMATIONOperatingIncomeofReportableSegmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_4866b5f0-d724-4555-bb1c-4104efaf9d9d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_2d68b5b0-c733-4b5f-9d27-757fb8d341c5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_4866b5f0-d724-4555-bb1c-4104efaf9d9d" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_2d68b5b0-c733-4b5f-9d27-757fb8d341c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_0fb1be3a-bebb-4a34-b406-3bd6deac0e40" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_2d68b5b0-c733-4b5f-9d27-757fb8d341c5" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_0fb1be3a-bebb-4a34-b406-3bd6deac0e40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_4b5ddf80-2553-475a-a941-cc6aee12cda6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_0fb1be3a-bebb-4a34-b406-3bd6deac0e40" xlink:to="loc_us-gaap_SegmentDomain_4b5ddf80-2553-475a-a941-cc6aee12cda6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HomeHealthMember_f1e25057-7e44-49f4-a0b9-f7a3cceb0213" xlink:href="amed-20210630.xsd#amed_HomeHealthMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_4b5ddf80-2553-475a-a941-cc6aee12cda6" xlink:to="loc_amed_HomeHealthMember_f1e25057-7e44-49f4-a0b9-f7a3cceb0213" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HospiceMember_070da007-5921-437f-8fa8-ce763bfc75ff" xlink:href="amed-20210630.xsd#amed_HospiceMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_4b5ddf80-2553-475a-a941-cc6aee12cda6" xlink:to="loc_amed_HospiceMember_070da007-5921-437f-8fa8-ce763bfc75ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PersonalCareMember_a2f825a4-81f1-4d8d-8c64-523cad14317c" xlink:href="amed-20210630.xsd#amed_PersonalCareMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_4b5ddf80-2553-475a-a941-cc6aee12cda6" xlink:to="loc_amed_PersonalCareMember_a2f825a4-81f1-4d8d-8c64-523cad14317c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllOtherSegmentsMember_c26ae767-67c6-4b3f-9773-0ec01e2a2ae3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllOtherSegmentsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_4b5ddf80-2553-475a-a941-cc6aee12cda6" xlink:to="loc_us-gaap_AllOtherSegmentsMember_c26ae767-67c6-4b3f-9773-0ec01e2a2ae3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_c6d35024-8c37-4907-99b2-7fed2b545eea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_2d68b5b0-c733-4b5f-9d27-757fb8d341c5" xlink:to="loc_us-gaap_SegmentReportingInformationLineItems_c6d35024-8c37-4907-99b2-7fed2b545eea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions_4aa86ed3-b88a-4add-a03b-2e927c789324" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_c6d35024-8c37-4907-99b2-7fed2b545eea" xlink:to="loc_us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions_4aa86ed3-b88a-4add-a03b-2e927c789324" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncome_76a2220b-f43a-4073-8189-1d66f79a5b7b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherOperatingIncome"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_c6d35024-8c37-4907-99b2-7fed2b545eea" xlink:to="loc_us-gaap_OtherOperatingIncome_76a2220b-f43a-4073-8189-1d66f79a5b7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_43912e84-8443-48a5-9be3-02d4f07cb5b7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_c6d35024-8c37-4907-99b2-7fed2b545eea" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_43912e84-8443-48a5-9be3-02d4f07cb5b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_f5c21531-80ea-4a74-b0aa-01acb7134eba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_c6d35024-8c37-4907-99b2-7fed2b545eea" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_f5c21531-80ea-4a74-b0aa-01acb7134eba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization_1cd8e71f-0e59-4be9-b0ec-f6bd3abd49ad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_c6d35024-8c37-4907-99b2-7fed2b545eea" xlink:to="loc_us-gaap_DepreciationAndAmortization_1cd8e71f-0e59-4be9-b0ec-f6bd3abd49ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_f2d7e413-844d-4342-bbbc-53cba8929692" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_c6d35024-8c37-4907-99b2-7fed2b545eea" xlink:to="loc_us-gaap_CostsAndExpenses_f2d7e413-844d-4342-bbbc-53cba8929692" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_4391fae0-5625-41c4-a581-e1df4a672b56" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_c6d35024-8c37-4907-99b2-7fed2b545eea" xlink:to="loc_us-gaap_OperatingIncomeLoss_4391fae0-5625-41c4-a581-e1df4a672b56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/SHAREREPURCHASESHAREREPURCHASE" xlink:type="simple" xlink:href="amed-20210630.xsd#SHAREREPURCHASESHAREREPURCHASE"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/SHAREREPURCHASESHAREREPURCHASE" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_8de92642-0386-4e81-ab8f-f3f61df1a42b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockTextBlock_b4619fcc-6520-447f-9a36-a5ee19b7b92e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_8de92642-0386-4e81-ab8f-f3f61df1a42b" xlink:to="loc_us-gaap_TreasuryStockTextBlock_b4619fcc-6520-447f-9a36-a5ee19b7b92e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/SHAREREPURCHASENarrativeDetails" xlink:type="simple" xlink:href="amed-20210630.xsd#SHAREREPURCHASENarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/SHAREREPURCHASENarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_489ee42d-3f46-481d-938f-00f0e30c366f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ShareRepurchaseTable_113ac65b-f630-4855-acd7-bf509a512901" xlink:href="amed-20210630.xsd#amed_ShareRepurchaseTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_489ee42d-3f46-481d-938f-00f0e30c366f" xlink:to="loc_amed_ShareRepurchaseTable_113ac65b-f630-4855-acd7-bf509a512901" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramAxis_38afa32a-9d23-4b81-a4ac-5f795a454a07" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareRepurchaseProgramAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_ShareRepurchaseTable_113ac65b-f630-4855-acd7-bf509a512901" xlink:to="loc_us-gaap_ShareRepurchaseProgramAxis_38afa32a-9d23-4b81-a4ac-5f795a454a07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_93deb2c7-e713-4864-b8c6-e432c4a4accf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareRepurchaseProgramDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_38afa32a-9d23-4b81-a4ac-5f795a454a07" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_93deb2c7-e713-4864-b8c6-e432c4a4accf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_A2019ShareRepurchaseProgramMember_cc0882be-2b4d-47e9-a462-56eeb263a27a" xlink:href="amed-20210630.xsd#amed_A2019ShareRepurchaseProgramMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_93deb2c7-e713-4864-b8c6-e432c4a4accf" xlink:to="loc_amed_A2019ShareRepurchaseProgramMember_cc0882be-2b4d-47e9-a462-56eeb263a27a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_A2021ShareRepurchaseProgramMember_f0c1999f-2b48-4e2b-8073-050c89b1ece6" xlink:href="amed-20210630.xsd#amed_A2021ShareRepurchaseProgramMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_93deb2c7-e713-4864-b8c6-e432c4a4accf" xlink:to="loc_amed_A2021ShareRepurchaseProgramMember_f0c1999f-2b48-4e2b-8073-050c89b1ece6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ShareRepurchaseProgramMember_9d08f830-eddf-4b14-bcd9-492d5d42f906" xlink:href="amed-20210630.xsd#amed_ShareRepurchaseProgramMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_93deb2c7-e713-4864-b8c6-e432c4a4accf" xlink:to="loc_amed_ShareRepurchaseProgramMember_9d08f830-eddf-4b14-bcd9-492d5d42f906" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_03cdb074-eca8-492d-acfa-ea8f077f3933" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_ShareRepurchaseTable_113ac65b-f630-4855-acd7-bf509a512901" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_03cdb074-eca8-492d-acfa-ea8f077f3933" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_38806b3c-b1d6-4d70-b566-46c6f8fef5ff" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_03cdb074-eca8-492d-acfa-ea8f077f3933" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_38806b3c-b1d6-4d70-b566-46c6f8fef5ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_35cb97df-e7f3-4a27-8778-43f571be4afe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_38806b3c-b1d6-4d70-b566-46c6f8fef5ff" xlink:to="loc_us-gaap_SubsequentEventMember_35cb97df-e7f3-4a27-8778-43f571be4afe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ShareRepurchaseLineItems_c7095863-fd07-471b-b278-ee838c7ea2fc" xlink:href="amed-20210630.xsd#amed_ShareRepurchaseLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_ShareRepurchaseTable_113ac65b-f630-4855-acd7-bf509a512901" xlink:to="loc_amed_ShareRepurchaseLineItems_c7095863-fd07-471b-b278-ee838c7ea2fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_0bcf51c4-fa4c-4add-9a5d-07d0e7a30044" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_ShareRepurchaseLineItems_c7095863-fd07-471b-b278-ee838c7ea2fc" xlink:to="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_0bcf51c4-fa4c-4add-9a5d-07d0e7a30044" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramExpirationDate_ea6dc325-535a-4fa2-a2e4-9ce5d66c8274" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchaseProgramExpirationDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_ShareRepurchaseLineItems_c7095863-fd07-471b-b278-ee838c7ea2fc" xlink:to="loc_us-gaap_StockRepurchaseProgramExpirationDate_ea6dc325-535a-4fa2-a2e4-9ce5d66c8274" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_54dcf5c0-ec0c-43c4-a619-ec70c0cdc166" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_ShareRepurchaseLineItems_c7095863-fd07-471b-b278-ee838c7ea2fc" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_54dcf5c0-ec0c-43c4-a619-ec70c0cdc166" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PercentageofSharesOutstanding_4760093b-9d67-4e21-98a1-d0ed1b33b1d4" xlink:href="amed-20210630.xsd#amed_PercentageofSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_ShareRepurchaseLineItems_c7095863-fd07-471b-b278-ee838c7ea2fc" xlink:to="loc_amed_PercentageofSharesOutstanding_4760093b-9d67-4e21-98a1-d0ed1b33b1d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_07d0c623-3a9e-49ab-9270-5719e376921d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_ShareRepurchaseLineItems_c7095863-fd07-471b-b278-ee838c7ea2fc" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_07d0c623-3a9e-49ab-9270-5719e376921d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_Discountedclosingstockprice_4bed1747-8188-4096-829b-1a2ff8a59d2b" xlink:href="amed-20210630.xsd#amed_Discountedclosingstockprice"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_ShareRepurchaseLineItems_c7095863-fd07-471b-b278-ee838c7ea2fc" xlink:to="loc_amed_Discountedclosingstockprice_4bed1747-8188-4096-829b-1a2ff8a59d2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_Percentageofclosingstockprice_21ddae05-ce9e-495f-a69a-12810713e130" xlink:href="amed-20210630.xsd#amed_Percentageofclosingstockprice"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_ShareRepurchaseLineItems_c7095863-fd07-471b-b278-ee838c7ea2fc" xlink:to="loc_amed_Percentageofclosingstockprice_21ddae05-ce9e-495f-a69a-12810713e130" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare_7125d5da-5436-46cc-b7f3-6da2bc84bb19" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockAcquiredAverageCostPerShare"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_ShareRepurchaseLineItems_c7095863-fd07-471b-b278-ee838c7ea2fc" xlink:to="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare_7125d5da-5436-46cc-b7f3-6da2bc84bb19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/RELATEDPARTYTRANSACTIONSRELATEDPARTYTRANSACTIONS" xlink:type="simple" xlink:href="amed-20210630.xsd#RELATEDPARTYTRANSACTIONSRELATEDPARTYTRANSACTIONS"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/RELATEDPARTYTRANSACTIONSRELATEDPARTYTRANSACTIONS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_62977b47-92e6-45b3-bec2-032d6ce795a1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_d3f8ce6a-12f8-4a3c-9305-e02109751bc6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_62977b47-92e6-45b3-bec2-032d6ce795a1" xlink:to="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_d3f8ce6a-12f8-4a3c-9305-e02109751bc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/RELATEDPARTYTRANSACTIONSNarrativeDetails" xlink:type="simple" xlink:href="amed-20210630.xsd#RELATEDPARTYTRANSACTIONSNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/RELATEDPARTYTRANSACTIONSNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_e05eeb7c-464d-4ca1-9895-c1aa1dba67ee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_7435d094-7bef-4e87-a2ac-6cbbe6bffb82" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_e05eeb7c-464d-4ca1-9895-c1aa1dba67ee" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_7435d094-7bef-4e87-a2ac-6cbbe6bffb82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_0ea251f7-9147-4090-a73d-d6a365c3d3cf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_7435d094-7bef-4e87-a2ac-6cbbe6bffb82" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_0ea251f7-9147-4090-a73d-d6a365c3d3cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_1a275804-f2ab-495e-a842-408e4516d1e3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_0ea251f7-9147-4090-a73d-d6a365c3d3cf" xlink:to="loc_us-gaap_RelatedPartyDomain_1a275804-f2ab-495e-a842-408e4516d1e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_MedalogixMember_6b21cf6c-0c99-4216-8b34-66105c9efa73" xlink:href="amed-20210630.xsd#amed_MedalogixMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_1a275804-f2ab-495e-a842-408e4516d1e3" xlink:to="loc_amed_MedalogixMember_6b21cf6c-0c99-4216-8b34-66105c9efa73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_2f962f9c-9cda-436f-9128-55618cddeb2c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_7435d094-7bef-4e87-a2ac-6cbbe6bffb82" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_2f962f9c-9cda-436f-9128-55618cddeb2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_5efbc66a-909a-472c-bfb2-a8aaa41b2abb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_2f962f9c-9cda-436f-9128-55618cddeb2c" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_5efbc66a-909a-472c-bfb2-a8aaa41b2abb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_681e0177-057e-4b3b-9ddf-50f1824a4d35" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_7435d094-7bef-4e87-a2ac-6cbbe6bffb82" xlink:to="loc_us-gaap_RelatedPartyTransactionLineItems_681e0177-057e-4b3b-9ddf-50f1824a4d35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction_ffab5353-51fb-422c-b9b8-48acee706036" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_681e0177-057e-4b3b-9ddf-50f1824a4d35" xlink:to="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction_ffab5353-51fb-422c-b9b8-48acee706036" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/SUBSEQUENTEVENT" xlink:type="simple" xlink:href="amed-20210630.xsd#SUBSEQUENTEVENT"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/SUBSEQUENTEVENT" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_d25408c9-c3d1-4138-89dd-489154a23cc3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_bf98c13d-70b4-40a2-b786-e19867f4c573" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_d25408c9-c3d1-4138-89dd-489154a23cc3" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_bf98c13d-70b4-40a2-b786-e19867f4c573" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/SUBSEQUENTEVENTTables" xlink:type="simple" xlink:href="amed-20210630.xsd#SUBSEQUENTEVENTTables"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/SUBSEQUENTEVENTTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_aa58faaa-8b9a-4215-8451-32a983acd60f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_5f72abc8-eb93-498d-96bc-e15bbc817e68" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_aa58faaa-8b9a-4215-8451-32a983acd60f" xlink:to="loc_us-gaap_SubsequentEventTable_5f72abc8-eb93-498d-96bc-e15bbc817e68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_64918b1d-4c0b-4538-837c-128f1c03095b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_5f72abc8-eb93-498d-96bc-e15bbc817e68" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_64918b1d-4c0b-4538-837c-128f1c03095b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_a0e0c07a-e12b-4e1e-b5c0-5d56dd64cc74" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_64918b1d-4c0b-4538-837c-128f1c03095b" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_a0e0c07a-e12b-4e1e-b5c0-5d56dd64cc74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_57f05e8d-3f0b-4675-b96a-377e41a487be" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_a0e0c07a-e12b-4e1e-b5c0-5d56dd64cc74" xlink:to="loc_us-gaap_SubsequentEventMember_57f05e8d-3f0b-4675-b96a-377e41a487be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_b608438c-b597-485b-bd02-587557fc2019" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_5f72abc8-eb93-498d-96bc-e15bbc817e68" xlink:to="loc_us-gaap_SubsequentEventLineItems_b608438c-b597-485b-bd02-587557fc2019" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock_f51c2639-dfc1-4949-af70-eb894848c47b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_b608438c-b597-485b-bd02-587557fc2019" xlink:to="loc_us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock_f51c2639-dfc1-4949-af70-eb894848c47b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/SUBSEQUENTEVENTNarrativeDetails" xlink:type="simple" xlink:href="amed-20210630.xsd#SUBSEQUENTEVENTNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/SUBSEQUENTEVENTNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_385b699a-a37c-450e-9c2a-f7297c952a3b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_a9065f39-6c45-4d32-aaf3-63882db67be6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_385b699a-a37c-450e-9c2a-f7297c952a3b" xlink:to="loc_us-gaap_SubsequentEventTable_a9065f39-6c45-4d32-aaf3-63882db67be6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_d60f4921-6ca1-4ca4-94ba-11cd92b0978b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_a9065f39-6c45-4d32-aaf3-63882db67be6" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_d60f4921-6ca1-4ca4-94ba-11cd92b0978b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_2375981a-4940-4b3d-8882-3c88b93b3062" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_d60f4921-6ca1-4ca4-94ba-11cd92b0978b" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_2375981a-4940-4b3d-8882-3c88b93b3062" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_ca3553b5-21bf-4e80-8e8b-93a7920348d0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_2375981a-4940-4b3d-8882-3c88b93b3062" xlink:to="loc_us-gaap_SubsequentEventMember_ca3553b5-21bf-4e80-8e8b-93a7920348d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_b262cce0-dd2c-4b32-9fce-64da9317eb0b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_a9065f39-6c45-4d32-aaf3-63882db67be6" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_b262cce0-dd2c-4b32-9fce-64da9317eb0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_e0f3ac60-23fb-4f09-beae-ca5d57d76323" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_b262cce0-dd2c-4b32-9fce-64da9317eb0b" xlink:to="loc_us-gaap_SegmentDomain_e0f3ac60-23fb-4f09-beae-ca5d57d76323" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HospiceMember_27a32142-bb7c-4bf5-ac8d-91c46bb08263" xlink:href="amed-20210630.xsd#amed_HospiceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_e0f3ac60-23fb-4f09-beae-ca5d57d76323" xlink:to="loc_amed_HospiceMember_27a32142-bb7c-4bf5-ac8d-91c46bb08263" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HomeHealthMember_59757134-e071-4d02-9f30-2b9444bfe349" xlink:href="amed-20210630.xsd#amed_HomeHealthMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_e0f3ac60-23fb-4f09-beae-ca5d57d76323" xlink:to="loc_amed_HomeHealthMember_59757134-e071-4d02-9f30-2b9444bfe349" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_f05095b9-5907-4737-b7e0-28c685b45afc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_a9065f39-6c45-4d32-aaf3-63882db67be6" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_f05095b9-5907-4737-b7e0-28c685b45afc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_523ffe81-4b38-4265-9761-15be52af5ee8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_f05095b9-5907-4737-b7e0-28c685b45afc" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_523ffe81-4b38-4265-9761-15be52af5ee8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_VisitingNurseAssociationMember_551b2644-8a38-42c7-9f90-82f7c78deeb5" xlink:href="amed-20210630.xsd#amed_VisitingNurseAssociationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_523ffe81-4b38-4265-9761-15be52af5ee8" xlink:to="loc_amed_VisitingNurseAssociationMember_551b2644-8a38-42c7-9f90-82f7c78deeb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ContessaHealthMember_cc039d49-d0db-4365-bf35-dcd0423dec0a" xlink:href="amed-20210630.xsd#amed_ContessaHealthMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_523ffe81-4b38-4265-9761-15be52af5ee8" xlink:to="loc_amed_ContessaHealthMember_cc039d49-d0db-4365-bf35-dcd0423dec0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_472b0174-2675-4205-893f-a1fb9eacef04" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_a9065f39-6c45-4d32-aaf3-63882db67be6" xlink:to="loc_srt_StatementGeographicalAxis_472b0174-2675-4205-893f-a1fb9eacef04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_a5ca289e-1041-4494-b5df-33d1660854b3" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_472b0174-2675-4205-893f-a1fb9eacef04" xlink:to="loc_srt_SegmentGeographicalDomain_a5ca289e-1041-4494-b5df-33d1660854b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_NY_857c2a7e-73c1-4600-be18-9342451df821" xlink:href="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd#stpr_NY"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_a5ca289e-1041-4494-b5df-33d1660854b3" xlink:to="loc_stpr_NY_857c2a7e-73c1-4600-be18-9342451df821" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_fb8070d7-8623-4e16-9580-4b3c369ee37c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_a9065f39-6c45-4d32-aaf3-63882db67be6" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_fb8070d7-8623-4e16-9580-4b3c369ee37c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_7d292264-8847-4415-9ac8-8a28b0dc1c35" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_fb8070d7-8623-4e16-9580-4b3c369ee37c" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_7d292264-8847-4415-9ac8-8a28b0dc1c35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_SecondAmendmentToAmendedCreditAgreementMember_78048a68-63e9-4e87-8686-daff804acea4" xlink:href="amed-20210630.xsd#amed_SecondAmendmentToAmendedCreditAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_7d292264-8847-4415-9ac8-8a28b0dc1c35" xlink:to="loc_amed_SecondAmendmentToAmendedCreditAgreementMember_78048a68-63e9-4e87-8686-daff804acea4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_e894aa10-ee35-4ddd-8367-e593cd6d680c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_a9065f39-6c45-4d32-aaf3-63882db67be6" xlink:to="loc_us-gaap_DebtInstrumentAxis_e894aa10-ee35-4ddd-8367-e593cd6d680c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_c0a47480-b84b-4d54-9ebe-eadc4f0eb4d7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_e894aa10-ee35-4ddd-8367-e593cd6d680c" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_c0a47480-b84b-4d54-9ebe-eadc4f0eb4d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember_054bd3dd-d9b9-4612-b768-183b5364c26f" xlink:href="amed-20210630.xsd#amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_c0a47480-b84b-4d54-9ebe-eadc4f0eb4d7" xlink:to="loc_amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember_054bd3dd-d9b9-4612-b768-183b5364c26f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_FourHundredFiftyMillionTermLoanFacilityMember_c3495a0e-b289-479e-809c-1e31e1874349" xlink:href="amed-20210630.xsd#amed_FourHundredFiftyMillionTermLoanFacilityMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_c0a47480-b84b-4d54-9ebe-eadc4f0eb4d7" xlink:to="loc_amed_FourHundredFiftyMillionTermLoanFacilityMember_c3495a0e-b289-479e-809c-1e31e1874349" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramAxis_f1e67983-b92c-4f39-b1d7-4e24fd5bc517" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareRepurchaseProgramAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_a9065f39-6c45-4d32-aaf3-63882db67be6" xlink:to="loc_us-gaap_ShareRepurchaseProgramAxis_f1e67983-b92c-4f39-b1d7-4e24fd5bc517" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_0aabb9c8-4b7e-4e01-b181-8c56a3078a96" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareRepurchaseProgramDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_f1e67983-b92c-4f39-b1d7-4e24fd5bc517" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_0aabb9c8-4b7e-4e01-b181-8c56a3078a96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_A2021ShareRepurchaseProgramMember_493f3d7a-3bd3-4f10-a766-f735a2f09d5b" xlink:href="amed-20210630.xsd#amed_A2021ShareRepurchaseProgramMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_0aabb9c8-4b7e-4e01-b181-8c56a3078a96" xlink:to="loc_amed_A2021ShareRepurchaseProgramMember_493f3d7a-3bd3-4f10-a766-f735a2f09d5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ShareRepurchaseProgramMember_cbafb690-dcd4-469a-ba3c-1879fbdce1a5" xlink:href="amed-20210630.xsd#amed_ShareRepurchaseProgramMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_0aabb9c8-4b7e-4e01-b181-8c56a3078a96" xlink:to="loc_amed_ShareRepurchaseProgramMember_cbafb690-dcd4-469a-ba3c-1879fbdce1a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_4d22942f-6770-4f75-943f-1cf8c88e7cbe" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_a9065f39-6c45-4d32-aaf3-63882db67be6" xlink:to="loc_srt_RangeAxis_4d22942f-6770-4f75-943f-1cf8c88e7cbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_b79a209e-9de3-4141-af37-20792e39d5fc" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_4d22942f-6770-4f75-943f-1cf8c88e7cbe" xlink:to="loc_srt_RangeMember_b79a209e-9de3-4141-af37-20792e39d5fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_5b5cd523-6ebc-4591-bc99-e6b4d23b36a7" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_b79a209e-9de3-4141-af37-20792e39d5fc" xlink:to="loc_srt_MinimumMember_5b5cd523-6ebc-4591-bc99-e6b4d23b36a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_456c99cd-ddc9-48de-a5e9-a04f7b144b74" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_a9065f39-6c45-4d32-aaf3-63882db67be6" xlink:to="loc_us-gaap_SubsequentEventLineItems_456c99cd-ddc9-48de-a5e9-a04f7b144b74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_1532bd4f-6721-4a41-af64-e3e59d9c50bb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_456c99cd-ddc9-48de-a5e9-a04f7b144b74" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_1532bd4f-6721-4a41-af64-e3e59d9c50bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PaymentsRelatedToTaxAsset_73f6f36f-c99b-40fd-9e84-cae27f04e90b" xlink:href="amed-20210630.xsd#amed_PaymentsRelatedToTaxAsset"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_456c99cd-ddc9-48de-a5e9-a04f7b144b74" xlink:to="loc_amed_PaymentsRelatedToTaxAsset_73f6f36f-c99b-40fd-9e84-cae27f04e90b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfBusinessesAcquired_a40cf2c0-9dc2-422f-974e-8e19239a8fd3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfBusinessesAcquired"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_456c99cd-ddc9-48de-a5e9-a04f7b144b74" xlink:to="loc_us-gaap_NumberOfBusinessesAcquired_a40cf2c0-9dc2-422f-974e-8e19239a8fd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_1e7ccc86-a1e2-49a1-a551-02fad1c990e9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_456c99cd-ddc9-48de-a5e9-a04f7b144b74" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_1e7ccc86-a1e2-49a1-a551-02fad1c990e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_dadec47b-88b5-478c-a931-bb754f130d8c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_456c99cd-ddc9-48de-a5e9-a04f7b144b74" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_dadec47b-88b5-478c-a931-bb754f130d8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_9ccc6576-21f8-457c-8306-d548ca669e9f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_456c99cd-ddc9-48de-a5e9-a04f7b144b74" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_9ccc6576-21f8-457c-8306-d548ca669e9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_DebtInstrumentInterestAdditionalInterestAboveFederalFundRate_ea82bb64-cb96-4e03-89e3-5d2c130a7dde" xlink:href="amed-20210630.xsd#amed_DebtInstrumentInterestAdditionalInterestAboveFederalFundRate"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_456c99cd-ddc9-48de-a5e9-a04f7b144b74" xlink:to="loc_amed_DebtInstrumentInterestAdditionalInterestAboveFederalFundRate_ea82bb64-cb96-4e03-89e3-5d2c130a7dde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_DebtInstrumentInterestAdditionalInterestAboveEurodollarRate_fb7fcbdd-aed5-45f7-94bf-71a9f5842bd4" xlink:href="amed-20210630.xsd#amed_DebtInstrumentInterestAdditionalInterestAboveEurodollarRate"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_456c99cd-ddc9-48de-a5e9-a04f7b144b74" xlink:to="loc_amed_DebtInstrumentInterestAdditionalInterestAboveEurodollarRate_fb7fcbdd-aed5-45f7-94bf-71a9f5842bd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentMaturityDate_831b807d-8cf3-4f19-9f7d-03747581c0bd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentMaturityDate"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_456c99cd-ddc9-48de-a5e9-a04f7b144b74" xlink:to="loc_us-gaap_DebtInstrumentMaturityDate_831b807d-8cf3-4f19-9f7d-03747581c0bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_DebtInstrumentPeriodicPaymentPercentage_7f06df29-44d6-415a-a001-225d352ff81a" xlink:href="amed-20210630.xsd#amed_DebtInstrumentPeriodicPaymentPercentage"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_456c99cd-ddc9-48de-a5e9-a04f7b144b74" xlink:to="loc_amed_DebtInstrumentPeriodicPaymentPercentage_7f06df29-44d6-415a-a001-225d352ff81a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ProceedsReceivedFromLoanPartyOfSubsidiary_62526136-94cb-4b65-b312-fbb2c5e26856" xlink:href="amed-20210630.xsd#amed_ProceedsReceivedFromLoanPartyOfSubsidiary"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_456c99cd-ddc9-48de-a5e9-a04f7b144b74" xlink:to="loc_amed_ProceedsReceivedFromLoanPartyOfSubsidiary_62526136-94cb-4b65-b312-fbb2c5e26856" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PercentageOfRevenueAndOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromWhollyOwnedSubsidiaries_13802f42-bc14-474f-a72c-c911d2dc9dc7" xlink:href="amed-20210630.xsd#amed_PercentageOfRevenueAndOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromWhollyOwnedSubsidiaries"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_456c99cd-ddc9-48de-a5e9-a04f7b144b74" xlink:to="loc_amed_PercentageOfRevenueAndOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromWhollyOwnedSubsidiaries_13802f42-bc14-474f-a72c-c911d2dc9dc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PercentageOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromSubsidiaries_13c658ca-4b95-4896-b300-ece2094aa68c" xlink:href="amed-20210630.xsd#amed_PercentageOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromSubsidiaries"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_456c99cd-ddc9-48de-a5e9-a04f7b144b74" xlink:to="loc_amed_PercentageOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromSubsidiaries_13c658ca-4b95-4896-b300-ece2094aa68c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_3feba0bb-a0d4-471c-9cfb-f03b90947e17" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_456c99cd-ddc9-48de-a5e9-a04f7b144b74" xlink:to="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_3feba0bb-a0d4-471c-9cfb-f03b90947e17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramExpirationDate_252ddad4-e914-4bc1-b04f-0f9dac3c241f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchaseProgramExpirationDate"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_456c99cd-ddc9-48de-a5e9-a04f7b144b74" xlink:to="loc_us-gaap_StockRepurchaseProgramExpirationDate_252ddad4-e914-4bc1-b04f-0f9dac3c241f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/SUBSEQUENTEVENTFeesandRatesUnderCreditFacilitiesDetails" xlink:type="simple" xlink:href="amed-20210630.xsd#SUBSEQUENTEVENTFeesandRatesUnderCreditFacilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/SUBSEQUENTEVENTFeesandRatesUnderCreditFacilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_4b618826-196d-4132-b621-d00ea37e584a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_b4520142-e52d-4b35-947f-ed5a18d77a63" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_4b618826-196d-4132-b621-d00ea37e584a" xlink:to="loc_us-gaap_SubsequentEventTable_b4520142-e52d-4b35-947f-ed5a18d77a63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_e0d9e10e-1437-40c4-aa3c-ed9df9538ecf" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_b4520142-e52d-4b35-947f-ed5a18d77a63" xlink:to="loc_srt_RangeAxis_e0d9e10e-1437-40c4-aa3c-ed9df9538ecf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_4408df20-fdb2-4351-bb98-4b86ad864f13" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_e0d9e10e-1437-40c4-aa3c-ed9df9538ecf" xlink:to="loc_srt_RangeMember_4408df20-fdb2-4351-bb98-4b86ad864f13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_0219dadd-8e10-42e9-b624-2dad2f5a13e4" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_4408df20-fdb2-4351-bb98-4b86ad864f13" xlink:to="loc_srt_MinimumMember_0219dadd-8e10-42e9-b624-2dad2f5a13e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_c04255c3-599f-46ba-962e-7ecba56943e1" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_4408df20-fdb2-4351-bb98-4b86ad864f13" xlink:to="loc_srt_MaximumMember_c04255c3-599f-46ba-962e-7ecba56943e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_8fcb4fa8-9aa2-4f7d-b8c1-b9f171395ad4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_b4520142-e52d-4b35-947f-ed5a18d77a63" xlink:to="loc_us-gaap_DebtInstrumentAxis_8fcb4fa8-9aa2-4f7d-b8c1-b9f171395ad4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_9e168815-8641-4572-9311-bc5c302f0f09" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_8fcb4fa8-9aa2-4f7d-b8c1-b9f171395ad4" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_9e168815-8641-4572-9311-bc5c302f0f09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AmendedDebtInstrumentByLeverageRatioTrancheOneMember_c4db6266-ae21-4898-b2b6-7798dc753a6d" xlink:href="amed-20210630.xsd#amed_AmendedDebtInstrumentByLeverageRatioTrancheOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_9e168815-8641-4572-9311-bc5c302f0f09" xlink:to="loc_amed_AmendedDebtInstrumentByLeverageRatioTrancheOneMember_c4db6266-ae21-4898-b2b6-7798dc753a6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AmendedDebtInstrumentByLeverageRatioTrancheTwoMember_a49976a1-eddc-426c-842d-71ef65190d1c" xlink:href="amed-20210630.xsd#amed_AmendedDebtInstrumentByLeverageRatioTrancheTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_9e168815-8641-4572-9311-bc5c302f0f09" xlink:to="loc_amed_AmendedDebtInstrumentByLeverageRatioTrancheTwoMember_a49976a1-eddc-426c-842d-71ef65190d1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AmendedDebtInstrumentByLeverageRatioTrancheThreeMember_cc3f67d7-5622-4a87-b047-3cbff3da2fcd" xlink:href="amed-20210630.xsd#amed_AmendedDebtInstrumentByLeverageRatioTrancheThreeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_9e168815-8641-4572-9311-bc5c302f0f09" xlink:to="loc_amed_AmendedDebtInstrumentByLeverageRatioTrancheThreeMember_cc3f67d7-5622-4a87-b047-3cbff3da2fcd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AmendedDebtInstrumentByLeverageRatioTrancheFourMember_26a6ae14-2f14-4723-8a93-ab2516830426" xlink:href="amed-20210630.xsd#amed_AmendedDebtInstrumentByLeverageRatioTrancheFourMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_9e168815-8641-4572-9311-bc5c302f0f09" xlink:to="loc_amed_AmendedDebtInstrumentByLeverageRatioTrancheFourMember_26a6ae14-2f14-4723-8a93-ab2516830426" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_047417e6-2b65-4ec2-9a45-ded6f8900352" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_b4520142-e52d-4b35-947f-ed5a18d77a63" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_047417e6-2b65-4ec2-9a45-ded6f8900352" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_c4dfb6a3-43e9-429a-a446-e6c8cf77a642" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_047417e6-2b65-4ec2-9a45-ded6f8900352" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_c4dfb6a3-43e9-429a-a446-e6c8cf77a642" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_968c5853-5235-4b9a-a2b7-a1dbe5385284" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_c4dfb6a3-43e9-429a-a446-e6c8cf77a642" xlink:to="loc_us-gaap_SubsequentEventMember_968c5853-5235-4b9a-a2b7-a1dbe5385284" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_faf63477-3eb8-4ae3-879e-88291e80dc4f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_b4520142-e52d-4b35-947f-ed5a18d77a63" xlink:to="loc_us-gaap_VariableRateAxis_faf63477-3eb8-4ae3-879e-88291e80dc4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_15b55896-48ee-4442-9d91-874500f8b0e5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateAxis_faf63477-3eb8-4ae3-879e-88291e80dc4f" xlink:to="loc_us-gaap_VariableRateDomain_15b55896-48ee-4442-9d91-874500f8b0e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EurodollarMember_5a145737-bdc9-45a0-9df2-c4b92978bc6c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EurodollarMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_15b55896-48ee-4442-9d91-874500f8b0e5" xlink:to="loc_us-gaap_EurodollarMember_5a145737-bdc9-45a0-9df2-c4b92978bc6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BaseRateMember_22ef9699-1cb5-49c9-a931-0a544f1112bf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BaseRateMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_15b55896-48ee-4442-9d91-874500f8b0e5" xlink:to="loc_us-gaap_BaseRateMember_22ef9699-1cb5-49c9-a931-0a544f1112bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_de729053-bc5c-43e2-8c23-e0369a9483cc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_b4520142-e52d-4b35-947f-ed5a18d77a63" xlink:to="loc_us-gaap_SubsequentEventLineItems_de729053-bc5c-43e2-8c23-e0369a9483cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ConsolidatedLeverageRatio_6c199151-f7d5-4fba-88a9-9a5d31e479cc" xlink:href="amed-20210630.xsd#amed_ConsolidatedLeverageRatio"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_de729053-bc5c-43e2-8c23-e0369a9483cc" xlink:to="loc_amed_ConsolidatedLeverageRatio_6c199151-f7d5-4fba-88a9-9a5d31e479cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_5fbd5989-4a3b-4fc7-ba2a-b184177c796e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityCommitmentFeePercentage"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_de729053-bc5c-43e2-8c23-e0369a9483cc" xlink:to="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_5fbd5989-4a3b-4fc7-ba2a-b184177c796e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_LetterOfCreditFee_5e783a01-1df5-4472-ad3a-281df553a620" xlink:href="amed-20210630.xsd#amed_LetterOfCreditFee"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_de729053-bc5c-43e2-8c23-e0369a9483cc" xlink:to="loc_amed_LetterOfCreditFee_5e783a01-1df5-4472-ad3a-281df553a620" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_9d732bc4-ca5d-4493-bf91-cfbbab1d16ce" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_de729053-bc5c-43e2-8c23-e0369a9483cc" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_9d732bc4-ca5d-4493-bf91-cfbbab1d16ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>amed-20210630_g1.jpg
<TEXT>
begin 644 amed-20210630_g1.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X1"@17AI9@  34T *@    @ ! $[  (
M   /   (2H=I  0    !   (6IR=  $    >   0>NH<  <   @,    /@
M   <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 $ME96=A;BY+
M=VER86YT     >H<  <   @,   (;      <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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MU=;7V-G:X>+CY.7FY^CIZO'R\_3U]O?X^?K_Q  ? 0 # 0$! 0$! 0$!
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH ***;+*D$32S.J1H-S,QP /6@!7=
M8T9Y&"JHRS,< #UKS[Q-XZ>??9Z(Y2/H]R.&;_=]![]:S_%7BV76)&M;)FCL
M5/T,I]3[>@_R.8K@K5[^[$XZM:^D0)).3R:***Y#E"BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH M:=J5WI5VMQ8S-'(.N.C#T([BO4/#GBNVUV,
M1/B"\4?-$3PWNOK].H_6O):?%+)!,LL+M'(ARK*<$&M:=65-^1K3J.#/=J*Y
M?PGXM36(Q:7Q5+Y1P>@E'J/?U'^1U%>G&2DKH[XR4E=!1115%!1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 !(4$DX Y)/:O,/&'BHZM.;*Q<BRC/+#_ );$=_IZ
M?G6OX[\2>4C:19/\[#_2'!Z#^[^/?V^M>?5PXBK]A''6J?904445QG*%%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% #HY'AE62)F1T
M.593@@^M>J^$_$Z:Y:^3<D+?1+\XZ>8/[P_K7E%3V5Y/I]Y%=6KE)8FRI_I]
M*UI5'3?D:TZC@SW*BL[0]8AUO2X[N'Y6^[(F?N-W%:->HFFKH]!--704444Q
MA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** ,3Q;JO]D^'IG1L33?NHO4$]3^ R:\AKK?B%J7V
MK6TLT.4M4Y_WVY/Z8_6N2KS,1/FG;L<%:7-+T"BBBL# **** "BBB@ HHHH
M**** "O0/!_@[RPFI:O'\_WH8&'W?]IAZ^@[?R/!_@_RO+U+5H_G^]# P^[_
M +3#U]!V_EW-=M&A]J1UTJ7VI!13)IH[>%YIW6.-!N9F. !6/HOBJPUNZFM[
M<M'(A.Q7X\Q?[P_PKK<DG9G4Y).S+6M:+:ZY8FWNEPPYCE ^:,^H_P *\EU;
M2;K1K]K6\3!'*N/NN/45[76?K6BVNN6!MKH8(YCD ^:,^H_PK&M14U=;F56D
MIJZW/%J*O:MI-UHU^UK>)@CE7'W7'J*HUYK33LS@::=F%%6M,LCJ6IV]FKB,
MS.%W$9Q77_\ "M)O^@FG_?D_XU<:<IJ\45&$I;(X:BNLUCP+)I&DSWS7ZRB$
M [!$1G) ZY]ZY.E*$H.TA2BXNS"BBBI)"BBB@ K5\-ZH=(UZWN2<1$[)?]P]
M?RZ_A65133:=T--IW1[R#D9'(HK#\'ZC_:7AJW9CF2$>2_U7I^F*W*]>+YE=
M'J1=U<****H84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M(4444 %%=KX9\&Z?K.AQWEU-<I(S,"(V4#@X[J:U_P#A7&D?\_-[_P!]I_\
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MH^I.*]S1!'&J+PJ@ ?2NS"K5LZ\.M6QU%%%=QUA1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5D^*+3[;X9OH
M@,L(BZ_5?F_I6M2,H92K#((P0>]*2NK":NK'@]%6]5LCIVK7-HW_ "QD*C/<
M=C^6*J5XS5G8\MZ!7H/@_P '^3Y>I:M'^\^]# P^Y_M,/7T';Z]#P?X/\GR]
M2U:/]Y]Z&!A]S_:8>OH.WUZ=Q7;1H_:D==*E]J04R::.V@>:=UCC0;F9C@ 4
M331VT#S3NL<:#<S,< "O+/%7BJ37)S!;%H[%#\J]#(?[Q_H*Z*E14T;5*B@@
M\5>*I-<F-O;%H[%#\J]#(?[Q_H*YRBBO,E)R=V>?*3D[L****DD**** "BBB
M@#U;P'_R*</_ %T?_P!"KHZYSP'_ ,BG#_UT?_T*NCKUJ7P(].G\"/*/'7_(
MW7/^XG_H(KG:Z+QU_P C=<_[B?\ H(KG:\RI\;//J?&PHHHJ" HHHH *?#-)
M;S)- [1R(=RLIP0:910!ZKX5\5QZW"+>Z*QWR#D=!*/4>_J*Z2O"89I+>9)H
M':.1#N5E."#7J7A7Q7'K<(M[HK'?(.1T$H]1[^HKT*-;F]V6YW4JO-[LMS4U
MG1K77+!K:Z7!ZQR ?-&?4?X5Y)J^D76BW[6MXN".4<?=<>HKVNL_6=&M=<L&
MMKI<'K'(!\T9]1_A55J*FKK<JK24U=;GBU%7M7TBZT6_:UO%P1RCC[KCU%4:
M\UIIV9P--.S-KPC9_;/%-DA&5C?S6]MO(_4"O7ZX#X;6&9KO4&'"@0H?<\M_
M)?SKOZ]'#QM"_<[J$;0N%%%%=)N%%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M3\/?^1F;_KW;^8KEJZ?P#+'#XD9I76-?(898X'45I2^-&E/XT>I457^WV?\
MS]0?]_!1]OL_^?J#_OX*]6Z/1NBQ138Y$E3?$ZNOJIR*=3&%%127=O$Y26>)
M&'56< TS[?9_\_4'_?P4KH5T-U3_ ) ]Y_UP?_T$UXA7M&IWUHVDW86ZA),#
M@ 2#GY37B]<.*W1R8C=!1117(<H4444 %/BED@F66%VCD0Y5E."#3** -/\
MX236?^@I=?\ ?TT?\))K/_04NO\ OZ:S**KFEW*YI=RW>:I?:@BK>W<LZJ<J
M)&SBJE%;GA'2?[6\00JZY@@_>R^X'0?B<?K0DYRL"3D['H_AC3/[*\/6UNPQ
M*R^9)_O-SC\.GX5K445ZZ22LCTTK*R"BBBF,**** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KRWQSHO\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M5%%>FE961Z.P4444P"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M)8L&%KY[C^*<[_TZ?I6]16D:4([(T5."V0B(L:!(U"J. JC %+116IH%%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M\2/^0':_]?(_]!:O-J\W$?Q#@K_&%>R>&/\ D5]/_P"N(KQNO9/#'_(KZ?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M4?E^-;QQ$)>1K&M"1UM%-CD2:-9(G61&&593D$?6G5N;!1110 4444 %%%%
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M/T7_ !_*HG4C#<B4XPW.[JO+J%E <37<$?\ ORJ/ZUX[?ZYJ>I,3>7LL@/\
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M ,L;W3XY,K<?D*TE\.:,GW=,M?QC!KH6%GU9NL/+J>,45[0WA_2'^]IMJ?\
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MSB-_G'JIX/Z5C2GR33,J<N629[5134=9(U>,AE8 J1W%.KUCT@HHHH ****
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MU*/,MT85H<T;]3S.I+>XDM;J.>%MLD;!E([$5'17G' >X:=>IJ.FV]W%]V9
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M\,?\BOI__7$5XW7LGAC_ )%?3_\ KB*Z\+\3.C#_ !,U:***[SM"BBB@#/\
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MFHEQMC*QA4W<GJ?RS^=<44G))G)%)NS/4[*SBT^QAM;==L<*A5_Q^M3US/\
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MTUU._P#'&K6&I^'+<V%W'/BY4E5/S ;6ZCJ*X"BBHJ3<W=D3DYN["O6_!/\
MR)UC_P!M/_1C5Y)7K?@C_D3K+_MI_P"C&K?"_&_0UP_QF]1117H'<%%%% 'B
MFM_\A_4/^OF3_P!"-4:O:W_R']0_Z^9/_0C5&O&ENSRGN;G@V$3^+;($9"EG
M_)2?YUZ[7E?@)<^*XCZ1N?TKU2N_#? =N'^ ****ZCH"BBB@ HHHH **** /
M%_$ QXCU#'_/PY_6LZM+Q#_R,FH?]?#_ ,ZS:\>7Q,\N6[-GPC +CQ98HW(#
ME_\ OE2?Z5[!7D_@89\76I]%<_\ CAKUBN["_ SLP_PA11174= 4444 %%%%
M !1110!X[XK39XJOP.\N?S%9%;/B[_D:[[_?_H*QJ\>?Q,\R?Q,W_!!QXPL_
M^!_^@-7K5>2>"?\ D<++_@?_ * U>MUW87X/F=>'^ ****ZCH,CQ7/\ 9_"N
MH/ZQ;/\ OHA?ZUX[7K/C@X\(7?N8_P#T-:\FKS\5\:.+$?$%%%=!IO@S4]5T
M^*]MFMQ%+G;O<@\$CT]JYHQ<G9&"BY;'/T5U7_"O-9_OVO\ W\/^%'_"O-9_
MOVO_ '\/^%7[*IV*]G/L<K175?\ "O-9_OVO_?P_X4?\*\UG^_:_]_#_ (4>
MRJ=@]G/L<K175?\ "O-9_OVO_?P_X4?\*\UG^_:_]_#_ (4>RJ=@]G/L<K17
M5?\ "O-9_OVO_?P_X4?\*\UG^_:_]_#_ (4>RJ=@]G/L<K175?\ "O-9_OVO
M_?P_X4?\*\UG^_:_]_#_ (4>RJ=@]G/L<K175?\ "O-9_OVO_?P_X4?\*\UG
M^_:_]_#_ (4>RJ=@]G/L<K175?\ "O-9_OVO_?P_X4?\*\UG^_:_]_#_ (4>
MRJ=@]G/L=OX3E,WA2P8]HMO_ 'R2/Z5L5E^&].GTK0+>RNRAEB+9V'(Y8G^M
M:E>I"_*KGH1ORJX5P?Q+D_Y!\0_Z:,?_ !W_ .O7>5Y[\2O^/RQ_ZYM_.LL1
M_#9G6^!G$4#DT4Y/]8OU%>8>>>W:=!]ETNU@QCRH43\@!5FD'W1CTI:]E:(]
M9!1113 **** "BBB@ HHHH **** .&^)5N#;V-SW5FC/XC/]*\_KTOXCC.@6
MY]+D?^@M7FE>9B%^\9P5_C"O9/#'_(KZ?_UQ%>-U[)X8_P"17T__ *XBM,+\
M3*P_Q,U:***[SM"BBB@#/\0?\BYJ/_7M)_Z":\6KVGQ!_P BYJ/_ %[2?^@F
MO%JX,5\2./$;H*]%^&W_ ""[S_KL/_0:\ZKT7X;?\@N\_P"NP_\ 0:SP_P#$
M1%#XSM****],[PHHHH *R?$6A1:]II@<A)D^:&3'W3_@>]:U%)I25F)I-69X
M=?6%SIMX]M>Q&*5.H/<>H]15>O:-8T.RUNU\F]C^9?N2+PR'V/\ 2O.=9\%Z
MGI;,\*&[MQTDB'('NO4?J*\ZI0E#5:HX:E%QU6QSM6;+4;S3I-]C<RP'OL;
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ML9T'5HV'Z4GL!X:S%F+,<DG)/K2445XQY)V_PUM5>]O;IAS&BQK_ ,"))_\
M017H5<!\-)E$VH0D_,RQN![#<#_,5W]>GA_X:/0H_ @HHHK<V"BBB@ HHHH
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MV=%X%_Y&VV_W'_\ 037J]>4>!?\ D;;;_<?_ -!->KUWX;X#LP_P!11172=
M4444 %%%% !1110!X_XN_P"1KOO]_P#H*QJV?%W_ "-=]_O_ -!6-7D5/C9Y
MD_B9O>"?^1PLO^!_^@-7K=>2>"?^1PLO^!_^@-7K==N%^#YG7A_@"BBBNHZ
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M10^,[2BBBO3.\**** "BBD9U12SL%4=23@"@!:*BM[JWNT9[6>.95;:6C<,
M?3CZU+0 4444 %%%% !7G?Q!T2.UGCU2V0(L[;)@!QOZAOQP?R]Z]$KG?':J
M?"5P6ZJZ%?KN'],UC6BI09E5BG!GE% ..E%%>6><>VZ/=F^T6SNF.6EA5F_W
ML<_KFKE8?@QBWA"Q+=<./PWM6Y7L0=XIGJ1=XIA1115%!1110!6U"RCU'3I[
M2;[DR%<^GH?PKQ2YMY+2ZEMYUVR1.48>A!KW2O-_B%I/V;4H]0B7"7(VOCLX
M_P 1_*N3$PO'F['-B(W7,<=76?#_ %3[)K+64C8CNAA<]G'(_,9'Y5R=203O
M;7$<\)VR1L'4^A!R*XH2Y9)G)&7+*Y[K7+^/=3^Q:#]FC;$EVVS_ ("/O?T'
MXUOZ=>IJ.FP7<7W9D#8]#W'YUYAXUU/^T?$<JHV8K8>2F/4?>/YY_*O1K3M3
MTZG=5G:&G4YZBBK^B::VK:S;V:YP[?.1V4<D_E7FI-NR.!*[L>B>!-+^P: M
MQ(N);L^8<]E_A']?QKIJ1$6.-40!54 *!V%+7KQCRQ2/3C'E5@HHHJB@HHHH
M **** "BH7O;6.X6![F)9G.%C+@,?H*FH **** "BBB@ K.UW1X=;TN2UE W
MXS$Y_@;L:T:*32:LQ-)JS/"'1HY&1QM920P/8TVM+Q$JKXEU$)T^T.?UK-KQ
MVK.QY;5G8[GX:WA%S>V9/#()5'I@X/\ ,?E7H%>7_#UB/$Y Z&!P?ID5ZA7H
MX=WIG=0=X!11170;A1110!XIK-D=.UJ[M2,".4A?]WJ/T(JC7??$/16;R]6@
M7(4".?';^ZW]/RK@:\FI#DDT>;4CRRL:GAW5SHNM0W9R8ON2@=T/7\N#^%>Q
M0S1W$*30.'CD4,K*>"#7A-=#X<\6W6A?N)%^T69.3&3@I[J?Z5K0K<FCV-*-
M7ET>QZQ167IOB/2]55?LMV@D;_EE(=KC\#U_"M2O0335T=J:>P4444QA12.Z
MQH6=@JCDDG %<]JOC;2=.5EAE^V3#HD)R/Q;I^6:F4HQ5VR7)1W.A9E1"SL%
M51DDG  KS[Q;XT%S&^GZ.Y\H_++./XQZ+[>_>L+7/%6H:YE)F$-OGB"/@'ZG
MO6+7%5Q'-I$Y*E:^D0HK6MM$DD\-WNKS K%%M2'_ &V+@$_0 D?7Z5DURM-;
MG.TUN%>M^"?^1.L?^VG_ *,:O)*];\$_\B=8_P#;3_T8U=.%^-^AOA_C-ZBB
MBO0.X**** /%-;_Y#^H?]?,G_H1JC5[6_P#D/ZA_U\R?^A&J->-+=GE/<Z;P
M!_R-2?\ 7%Z]3KRSP!_R-2?]<7KU.O0PWP'=A_@"BBBNDW"BBB@ HHHH ***
M* /&/$/_ ",FH?\ 7P_\ZS:TO$/_ ",FH?\ 7P_\ZS:\>7Q,\N6[.B\"_P#(
MVVW^X_\ Z":]7KRCP+_R-MM_N/\ ^@FO5Z[\-\!V8?X HHHKI.@**** "BBB
M@ HHHH \?\7?\C7??[_]!6-6SXN_Y&N^_P!_^@K&KR*GQL\R?Q,WO!/_ ".%
ME_P/_P! :O6Z\D\$_P#(X67_  /_ - :O6Z[<+\'S.O#_ %%%%=1T!4=Q!'=
M6\D$Z!XY%*LI[@U)10!XQKVCRZ)JLEK+DI]Z)_[Z]C6;7L?B+08=?T[R7(29
M/FADQ]T^A]C7D=[93Z?>26MW&8Y8SAE/\_I7EUJ3@]-CSZM/D?D%G>3Z?>1W
M-I(8Y8SE6'^>E>J^'/%-KKL(0E8;Q1\\)/7W7U'\J\CIR.\<BO&S(ZG*LIP0
M:5.JZ;\A4ZC@SW>BO.-&^(-S;*L.KQFYC' E3 <?7L?TKM-.\1Z5J@ M+R/>
M?^6;G:WY'K^%>A"K">S.V-2,MC3HHHK4T"BBB@ HJ"ZOK6QCWWES% OK(X7-
M<QJGQ!T^U!334:\D_O'Y4'Y\G\OQJ)3C'=DRG&.[.KFFCMX6EGD6.-!EG8X
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M#Q_Q=_R-=]_O_P!!6-6SXN_Y&N^_ZZ?T%8U>14^-GF3^)F]X)_Y'"R_X'_Z
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M@**T=;G6&6XE'*PKRBGW_O?R^M=F!@8%=M'#N_-,ZJ5%WO(****[3K"BBB@
MHHHH **** "F2Q1SQF.:-9$/577(/X4^B@# O/!6AW9+?9/(8]X6*_IT_2LN
M7X;6+?ZB^N$_WPK?X5V=%9NE![HS=.#Z'"'X9KNXU4X]/L__ -E4T7PUM P\
M[4)G'<(@7_&NUHJ?84^PO8P[&!9^"M#L\'[*;AA_%.V[].GZ5N10Q01B."-(
MT'144 #\!3Z*TC&,=D6HI;(****HHCGMX;J%HKF))HVZI(H93^!JI_86D?\
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MB7>3+IT2D]X\I_Z#BM>BDXI[B:3W.2N/AUI4F3!-<PGTW!A^HS^M4F^&<?\
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M6D8QCLC112V044450PHHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ KSKXBZIYU]#IT;96 ;Y!_M'I^0_G7H
M%U<QV=I+<S'$<2%V/L!7B5[=R7]]-=3??F<N?;/:N7$SM'E[G/7E:-B"GP0O
M<7$<,*[I)&"*/4DX%,KK/A_I7VO66O9%S':C*Y'5ST_+D_E7#"/-)(XXQYI6
M/0],L4TS3(+.+I$@4GU/<_G5JBBO72LK'J+30****8!1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% ''_$/5/L^F1Z?&V)+D[GQV0?XG^5>;5W'B7PUKNLZ[/<I;H81A(LRK
M]T?CZY/XUE?\()KW_/M'_P!_E_QKSJL9SFW8X:BG*5['.5[!X4TO^RO#T$3+
MB60>;+]3V_ 8'X5Q^C^!=275[=]2A1;9&W/^\#9QVP/6O2:UP]-Q;E)&E"FU
MJPHHHKL.H**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /_
!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>amed-20210630_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:amed="http://www.amedisys.com/20210630"
  xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2020-01-31"
  xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="amed-20210630.xsd" xlink:type="simple"/>
    <context id="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ifed7a9d7833f4709ab4d734d7c419fe7_I20210730">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
        </entity>
        <period>
            <instant>2021-07-30</instant>
        </period>
    </context>
    <context id="i1e833203be6947b4968aba4d20064ec8_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i87ceb60dc20d4df1b0a97d3514837910_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib87cee58ccf2448a8d4422101bf61fa0_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i2c8351954d014a1c80a3d8cfc2327ab2_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i667fa0996400408f9cb2d7f4d3ee2087_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ieb79ce9f481b42d1ab430d3f3d11be5a_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i6a51d0190d2c46638e83e1dd687ec01c_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i505af52860ef4f88b5ff9bd288e4b861_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i74fd298667c64003ab51d64eb7694f4f_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="idebaf491ed4a4eaa830b4edf82a260af_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i2abc69b9d9f54af3a54fc8752ccb2ab0_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i1f49d2d5c447470d8ad1b0c00a898651_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ia839bd0c1e7440a2be8dd89d587ab038_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i873536f8b14a43938a68d5f9d661e909_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="iee63e04ff2174c9686bcc42c3eb46125_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ib467ac52451749bfb8cdba39aa1441a7_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i6d9970853b6d41799b9af78b866c694b_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i3e59fd3d3cfb4bb7ae9ea1d3af94e290_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="id0e0b2cc08e747cba20ceed2b5382012_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i01768f8d7ebc4cc18d5eb154976ba4d3_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i1302a68dd8ef42e6ab76db142d77aae4_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i90abbd77ace44a6bac4330406a6d4810_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ie40ed45ce02a463b81cddfc774673775_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i7e0bc5dd338e4f46a448f49e5796b04c_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i50eeb2e1fb1c44a38c21b210240eb586_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i293e823d67b246d381d9224a4d88ecb8_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="ie0f0ea8548294921ad4f0b1603762e12_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i259a6cf078e54dd1a1db53e0ddaaf3ee_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="if8b5cc2263e34d7d829e9025bfd31619_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i74c16b1d1e794dca817c0cabfec5d055_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="idfe2bc4b48cf420480bdcedd1afce6c9_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i1667f8e90077426897db77b94e7b94d2_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i7b84646fd5a5457ea3426c3891522efe_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i513740b0a9e54ee1a6565acc0bdf79f2_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="idb32f2bfc5474a4199e7c84d1720275e_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i15586f038620443192b7c904beb4ad54_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i6271c5457d114e698b9aa02424c6fba7_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i7f5f7a1bdc904b23a1b3496bf1c343ed_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="ic2e9db201a8c41efacbe6c14b48f08c5_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="ie2958a3a3c7d4e89970b11fea75ea413_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i1f8cee8ab0a8499bb9039cd2b585f4be_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i0520e88179174d4c983746db6664ff87_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i2f9b5ede983b458f9d589f077a9b9885_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i00022a1a9b074ad09a7448259eb40d7b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i3904353da8ce4531bf4ac08cd4d11033_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ida4c2a7ffda04385afb5f441d707b3cc_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i656ece5c7f7e4dff8816621dc7e0455f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic4cd949100864281ac1cb035f36fe501_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i4c81959cee2f417b9189bc4e6ad7f42d_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i3a5e5c59232b4c58b6e84716db6d8973_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i7299a7a0217a4939aebcf1747818528d_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i87f87ab13a114dee919b9d2827a73fab_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i5ac6fbdda808429998d8987cf9923712_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ifa673cc4c9af455b97f34a55548dfc84_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i34b209949049477791ec23971ce9e445_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ia9b5755043594e6fac0445e663b73395_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i441145d29ff346a58266e6fa5735a383_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ie9c9163b115847718a0e04afa87d792f_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i2f812fe62e9048c1b51562c9b05a841c_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i2fef7471e4c74e2cac75b17f8e455e63_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ia6768b0ddf76411381a296ae9d695ae6_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i846085ebf1cf4817ac0dd1e9245c242a_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ib8af587d580b4f4e9cdf536e3b9b31e6_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i917af374eb6a409ebea5c8abe45a5a8e_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i105f613dfc9b4ea7afdeaf6f08277f25_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i08ad12ef46cf4d2da58b68346a440ca1_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i85ce6ba1e58b4b7c883aa1e71fb67e40_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amed:MedicareRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ib0181bc176d24054b0b4382b5f3a2ef9_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amed:MedicareRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="if78f143ce2814015b9ecc0469dc639f1_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amed:MedicareRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i9d0cb72c37b145799e408add964d0544_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amed:MedicareRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i30a2e3b95ac74ea890c5478c6d00aa9d_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i3e0c07dff3444ff8bdeaaddc51231dfe_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i7e884a08e6374bbb9ca4c0909fb43265_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:PersonalCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i56460531924447ac8bc770856f36964a_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="amed:TypeofEquityMethodInvestmentAxis">amed:MedalogixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i47cb3be3d5564293b84a6274e71f0a2c_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="amed:TypeofEquityMethodInvestmentAxis">amed:HeritageHealthcareInnovationFundLPMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i819d1cc0f63448c9bae946092e2d9634_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:HomeHealthMedicareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="iab0c4aa1f54048f9bb07ee49f6bb395e_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:HomeHealthMedicareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i72044b2a44e74c5591b023a1c6e1f437_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:HomeHealthMedicareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="iec44149de0804e90a0d618b5aab11df1_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:HomeHealthMedicareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="iba4b4085e2a44ace9b534d8db3a5cb18_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:HomeHealthNonMedicareEpisodicBasedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i62976d7f48f547f690d30bf5ecdc0c9d_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:HomeHealthNonMedicareEpisodicBasedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i2b90bd098db34908919842c129b2c275_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:HomeHealthNonMedicareEpisodicBasedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i986914649c744434996e298aed0a55de_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:HomeHealthNonMedicareEpisodicBasedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="id3dfc4a215e346f2b62f7a0031e7a1c0_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:HomeHealthNonMedicareNonEpisodicBasedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i1889f1856fd04eb9a83ad415f13bb6e1_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:HomeHealthNonMedicareNonEpisodicBasedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i07bd2c944cf046a189fd4eb6529755d6_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:HomeHealthNonMedicareNonEpisodicBasedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i584d1976fa4740918795b29a298c07f8_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:HomeHealthNonMedicareNonEpisodicBasedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i82e2454c5eed4b28ab058238918f809e_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:HospiceMedicareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i617f99e1213a4f2094c8432f4837db94_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:HospiceMedicareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i7a48258931a748a99b37e6058a5916e4_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:HospiceMedicareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="iff8b2cf9576146db8b00ff2d1d72091f_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:HospiceMedicareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i575fb5ffd81f408fb483b5911db2264f_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:HospiceNonMedicareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i79540dc5db374f3e8dad988e2d746e13_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:HospiceNonMedicareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i83c28c34df424dba99ce508660059376_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:HospiceNonMedicareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ib14de18b4a2d452c831ee77de19f382d_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:HospiceNonMedicareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i9459b4ff31494b3a8001d1ad78d69359_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:PersonalCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i4720759f4b1249fc9f52ebf7d06b0d2c_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:PersonalCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i913d274664fd48a49b9a53ffbeeb81bd_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:PersonalCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i2cd2a132976345f995477e91bea1b7a4_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:PersonalCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i90c63ef3c03b4a79b0e16bebccfb5aaa_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="iea406e6210c24d67b95bd8bba7ed6315_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i1e89d4343fef486490e1fcdab10c1010_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="id4b15251aa8147bcb0b8c78424ea981c_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i741b04b8cd704e398b27520bf8aea7fc_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i35e97441f2084fc28b554985218499ab_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="amed:CapYearAxis">amed:CapYearTwoThousandSixteenThroughTwoThousandTwentyOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i7dc0b5d0b4c04b6ebdca7598a9e533de_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:AseraCareHospiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="amed:CapYearAxis">amed:CapYearTwoThousandSixteenThroughTwoThousandTwentyOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i4f2f1eaba6994474b883c637fd8bdd09_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="amed:CapYearAxis">amed:CapYearTwoThousandFourteenThroughTwoThousandTwentyOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iab3b21e1071d46c3a8d7f08560252318_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:AsanaHospiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ia1dcbe4b6aa344ddad5971d791de6929_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="idd69fb45b72f455583eebe90df674886_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i9c7cadad474d42da9b01844212441bf3_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i0c4514a4ad16425f82d85ae99b3a59c1_I20200327">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
        </entity>
        <period>
            <instant>2020-03-27</instant>
        </period>
    </context>
    <context id="iac8bb77409a847a08a3de53000ce0e86_D20200401-20200430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-04-30</endDate>
        </period>
    </context>
    <context id="i5e57d112c8b243c6ad6311b3c05c5d43_D20200401-20200430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquityMethodInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-04-30</endDate>
        </period>
    </context>
    <context id="id175698a0fde4ea494dd3ebf050a22e3_D20200401-20200430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:AseraCareHospiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-04-30</endDate>
        </period>
    </context>
    <context id="ic7961b340f674cd8b10f0d54284e1eef_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthAndHospiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ia821fd814fc04a678988e6c92ea2a385_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthAndHospiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i1c8d3b2b4c064d6a90ebefef21edaeb5_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthAndHospiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ibb3ce40344c74f1581b747ba288ae945_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthAndHospiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i8f67ab0074b94f94a94986aa649dde19_D20200327-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
        </entity>
        <period>
            <startDate>2020-03-27</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ia6c66b5559184a299f6fd13a6091fd6c_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i3800e4dbdd2b4b74be666a6efdf57781_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:UnusualOrInfrequentItemAxis">amed:COVID19DeferralOfSocialSecurityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ifc0809f18c444433ac13693a115bb6bf_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:UnusualOrInfrequentItemAxis">amed:COVID19DeferralOfSocialSecurityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ifd83ae148acd4a77824ab56405bb1c41_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:PersonalCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i45e11b09cca8443d838df683d0210fd2_D20210501-20210501">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:NC</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-01</startDate>
            <endDate>2021-05-01</endDate>
        </period>
    </context>
    <context id="i535b766678164627a4ddec7a5f2f5950_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:NC</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i8bbf534b5cc84c0e8690bc7618aac045_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:NC</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">amed:CertificateOfNeedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i83f6f6c3fd9a43b9871634c7190f8d34_D20200601-20200601">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:AseraCareHospiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-01</startDate>
            <endDate>2020-06-01</endDate>
        </period>
    </context>
    <context id="i867c8c481181405cacf65820555c0934_D20200601-20200601">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:AseraCareHospiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-01</startDate>
            <endDate>2020-06-01</endDate>
        </period>
    </context>
    <context id="ifaa721259ce4436aa80fefef62ec970f_D20201001-20201001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:AseraCareHospiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-10-01</endDate>
        </period>
    </context>
    <context id="i1af2ff078c3a4f71aa611b0e527d319e_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:AseraCareHospiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ie2776ede445a47be9f24c8e19df8e41a_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:AseraCareHospiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="id89f6008c2694e98ab64e39c65f6ad94_I20200601">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:AseraCareHospiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">amed:MedicareLicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-01</instant>
        </period>
    </context>
    <context id="i529e20e30522490fbfb5f6be349b8c2e_I20200601">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:AseraCareHospiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">amed:CertificatesOfNeedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-01</instant>
        </period>
    </context>
    <context id="i012cb8f0777f4308802fe58df675adca_I20200601">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:AseraCareHospiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">amed:AcquiredNamesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-01</instant>
        </period>
    </context>
    <context id="i3bd9e093562340059df041fec4f9ea9c_I20200601">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:AseraCareHospiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:NoncompeteAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-01</instant>
        </period>
    </context>
    <context id="ib2a212363aa54dbc9ffb59f71147e64a_D20200601-20200601">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:AseraCareHospiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">amed:AcquiredNamesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-01</startDate>
            <endDate>2020-06-01</endDate>
        </period>
    </context>
    <context id="i203c1416080945b495a673816a335d4a_D20200601-20200601">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:AseraCareHospiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:NoncompeteAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-01</startDate>
            <endDate>2020-06-01</endDate>
        </period>
    </context>
    <context id="id2115fff96eb46a78868c96cf8b1c4a1_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:AseraCareHospiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i93266b4b1d884fad8c5cb4456e2def79_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:AseraCareHospiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="id8f72c421ee54ba2a739418940dde57c_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:AseraCareHospiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i4f3b5acefd614cc18bfcd62fc3a07ded_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:OneHundredSeventyFiveMillionTermLoanFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i47d7f0027dea435bbbef8d4d8e234b83_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:OneHundredSeventyFiveMillionTermLoanFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:EurodollarMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i282996a0cb644ac088b44f613c53cdcb_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:OneHundredSeventyFiveMillionTermLoanFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i6f0dd8df1d3345b4aa1558de68c7698c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:OneHundredSeventyFiveMillionTermLoanFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i9b034d16545343f69ba28f30d62f22c2_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:FiveHundredFiftyMillionRevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i805854b7963a41c7938b322adb3c1278_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:FiveHundredFiftyMillionRevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:EurodollarMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="if607f3cb243b4973902b1d41f80fb10c_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:FiveHundredFiftyMillionRevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i0eccf63206474ddaa2ee2c286f646d71_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:FiveHundredFiftyMillionRevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id1083386f2394412b5f29ff8fd11b397_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:CapitalLeaseObligationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ibbcbe46ad8ac4ae8a7fd039b14ce5a80_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:CapitalLeaseObligationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i44c7af72d3a34639b4816895619e7f09_I20190204">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">amed:AmendedCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-02-04</instant>
        </period>
    </context>
    <context id="i24530ac946f344808f972a08211612f0_I20190204">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:FiveHundredFiftyMillionRevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">amed:AmendedCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-02-04</instant>
        </period>
    </context>
    <context id="i2d0c143d688b41d490b2ea06ad3046d0_I20190204">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:OneHundredSeventyFiveMillionTermLoanFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">amed:AmendedCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-02-04</instant>
        </period>
    </context>
    <context id="i9ae11ec3a41040829df9de1fe8e7b2bb_D20190204-20190204">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">amed:AmendedCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-02-04</startDate>
            <endDate>2019-02-04</endDate>
        </period>
    </context>
    <context id="iee6ede9b55994de38f9991f940db59e9_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">amed:AmendedCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i572c716155d248eeb353108705827f98_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">amed:AmendedCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:EurodollarMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ib51e6cda5b7f4d999f0a54be2194e8fd_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:DebtInstrumentByLeverageRatioTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ie89771700f0d460f9ee341c9f33ad463_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:DebtInstrumentByLeverageRatioTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i8b4a04615e76432ca77412a8ce8c97a7_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:DebtInstrumentByLeverageRatioTrancheOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:EurodollarMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i80a16d16af124d8e8088f9cd85a66aa7_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:DebtInstrumentByLeverageRatioTrancheOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i32469c69675f451a93e53e98fcb09d2b_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:DebtInstrumentByLeverageRatioTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i762c3eb26082484eb8eda66cf8da59d4_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:DebtInstrumentByLeverageRatioTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i7ec9530f2497489684d4748db38f2068_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:DebtInstrumentByLeverageRatioTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i9d2fd16e87294dce83ab4611dec95214_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:DebtInstrumentByLeverageRatioTrancheTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:EurodollarMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i38341f6760194d9b94f32fad1615efeb_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:DebtInstrumentByLeverageRatioTrancheTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i5a18c53bf827477aaee9ccc3df622571_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:DebtInstrumentByLeverageRatioTrancheThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ib6f866620dc2459b8f67a5cfdadf6297_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:DebtInstrumentByLeverageRatioTrancheThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i3c46dc14b6294ba49b9a3b6291f5935e_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:DebtInstrumentByLeverageRatioTrancheThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i6981eb55a7b7401c865f1b05bd9c637f_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:DebtInstrumentByLeverageRatioTrancheThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:EurodollarMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ib6892f04dce84842bc5c41b0589b3786_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:DebtInstrumentByLeverageRatioTrancheThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="id9b0d221bc814a0cb3a2f624451a4f31_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:DebtInstrumentByLeverageRatioTrancheFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ieb0d2d2742204b2695d46e6be0103cd6_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:DebtInstrumentByLeverageRatioTrancheFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i634fd9a568bf480e98d90ea8e22ee7fd_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:DebtInstrumentByLeverageRatioTrancheFourMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:EurodollarMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i5ab7b8577acf41a4a08641839dff1c5f_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:DebtInstrumentByLeverageRatioTrancheFourMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i9d61545dcadf4b1d94a320a38d0b1079_D20190204-20240204">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">amed:AmendedCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-02-04</startDate>
            <endDate>2024-02-04</endDate>
        </period>
    </context>
    <context id="i100ffc02e1834ff6a0bbb7f8fc39dd3d_D20190204-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:OneHundredSeventyFiveMillionTermLoanFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">amed:AmendedCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-02-04</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i641e495583ed40d7885721338515e386_D20200401-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:OneHundredSeventyFiveMillionTermLoanFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">amed:AmendedCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i9f2171b5c0f742c18a35279b1904e320_D20230401-20240204">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:OneHundredSeventyFiveMillionTermLoanFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">amed:AmendedCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-02-04</endDate>
        </period>
    </context>
    <context id="ibc8d6081948b4e9190302d69d2b70231_D20190204-20190204">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">amed:AmendedCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-02-04</startDate>
            <endDate>2019-02-04</endDate>
        </period>
    </context>
    <context id="i21fda464ca064b61a04aca5a4c5e6a99_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:FiveHundredFiftyMillionRevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="idb01e853251e464c9326896aad4c2a8f_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:FiveHundredFiftyMillionRevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ib304b65d4507498f9d3f7647d9dbaccd_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:FiveHundredFiftyMillionRevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ib3b582f4212244b0884fcc031ea6c067_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:OneHundredSeventyFiveMillionTermLoanFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ie080c42adb394ab1aac8bdf81d4f0952_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:OneHundredSeventyFiveMillionTermLoanFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i2b242548637548e5845bd5ec7ebead8c_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:OneHundredSeventyFiveMillionTermLoanFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i123b2ec3b6424cd7858def47d8c592e4_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:FiveHundredFiftyMillionRevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ia2de44b83d484d54a6dcb3b8f754c999_D20190204-20190204">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:AmendedCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-02-04</startDate>
            <endDate>2019-02-04</endDate>
        </period>
    </context>
    <context id="i8f72f99e864d4c5192c1e32828587ac2_D20190204-20190204">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:AmendedCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:EurodollarMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-02-04</startDate>
            <endDate>2019-02-04</endDate>
        </period>
    </context>
    <context id="i64a0980bb9334fcf8d6f808e3e3034e3_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amed:UsDepartmentOfJusticeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i1743ef92c1a2465ea18877206de3e6eb_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amed:UsDepartmentOfJusticeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="icca6ffc5023e4d40ab2f30f7f1376996_D20150521-20150521">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amed:UsDepartmentOfJusticeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:MA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-05-21</startDate>
            <endDate>2015-05-21</endDate>
        </period>
    </context>
    <context id="if9882b4fe5cf46d883f68e6c542f6671_D20151103-20151103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amed:UsDepartmentOfJusticeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">amed:MorgantownWestVirginiaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-11-03</startDate>
            <endDate>2015-11-03</endDate>
        </period>
    </context>
    <context id="i864f8ff014c445d3970f605bf1cf5633_D20160627-20160627">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amed:UsDepartmentOfJusticeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">amed:ParkersburgWestVirginiaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-06-27</startDate>
            <endDate>2016-06-27</endDate>
        </period>
    </context>
    <context id="i56392e5d72914b00bf5ae116fa9bb7f9_D20080101-20100331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:SC</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2008-01-01</startDate>
            <endDate>2010-03-31</endDate>
        </period>
    </context>
    <context id="iad1c85c016834639b22c42870630702c_D20110606-20110606">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:SC</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">amed:ExtrapolatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2011-06-06</startDate>
            <endDate>2011-06-06</endDate>
        </period>
    </context>
    <context id="i417a271b7a39436d9ed178f9bb7bd0c6_I20160118">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:SC</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">amed:UnfavorableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-01-18</instant>
        </period>
    </context>
    <context id="i937449c14ddf4057abd22b9d6ed3e210_D20160118-20160118">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:SC</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">amed:UnfavorableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-01-18</startDate>
            <endDate>2016-01-18</endDate>
        </period>
    </context>
    <context id="i562ae93979ca4fdb8e93e54fc08de2f4_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:SC</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">amed:UnfavorableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i45b052c3ab1d49c694a0154a1838b1a9_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:SC</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="icf2b127cab17488d81818bf4e3d75ae0_I20190110">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:SC</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-01-10</instant>
        </period>
    </context>
    <context id="i4850b525a25f4db491a946f4b9cd5379_I20170831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amed:SafeguardZoneProgramIntegrityContractorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">amed:LakelandFloridaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-08-31</instant>
        </period>
    </context>
    <context id="ibe7994c4b86d4541b2d0ec37bace16d7_D20170801-20170831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amed:SafeguardZoneProgramIntegrityContractorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">amed:LakelandFloridaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-08-01</startDate>
            <endDate>2017-08-31</endDate>
        </period>
    </context>
    <context id="iaab7945d135e446ab572c2d66f2fd19f_I20170831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amed:SafeguardZoneProgramIntegrityContractorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">amed:ClearwaterFloridaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-08-31</instant>
        </period>
    </context>
    <context id="i480a00d19d3d49a99637c18c9b072f05_D20170801-20170831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amed:SafeguardZoneProgramIntegrityContractorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">amed:ClearwaterFloridaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-08-01</startDate>
            <endDate>2017-08-31</endDate>
        </period>
    </context>
    <context id="i1a6de48aaec6424c991ca149df38ebc4_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amed:SafeguardZoneProgramIntegrityContractorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">amed:LakelandFloridaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i257e928d56124ef98ae9d07b7f7d20e0_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amed:SafeguardZoneProgramIntegrityContractorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">amed:ClearwaterFloridaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i042d59baaf764eadb82a511fc4630d06_I20170831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amed:SafeguardZoneProgramIntegrityContractorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:FL</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:InfinityHomeCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-08-31</instant>
        </period>
    </context>
    <context id="i071a11675b024dfa92b8dd03678270ed_I20170831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amed:SafeguardZoneProgramIntegrityContractorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:FL</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-08-31</instant>
        </period>
    </context>
    <context id="i8e89313551f44799b6300c11c9de29b3_I20170831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amed:SafeguardZoneProgramIntegrityContractorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:FL</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-08-31</instant>
        </period>
    </context>
    <context id="i33ec0cb49c7c45df918d10f6d8b12f6c_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amed:SafeguardZoneProgramIntegrityContractorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:FL</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="icc9f4a15aebf47b28a9f5ea3e095ade5_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amed:SafeguardZoneProgramIntegrityContractorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:FL</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i035f004f00fb427aa308a668dff7bb13_I20170831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amed:SafeguardZoneProgramIntegrityContractorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:FL</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-08-31</instant>
        </period>
    </context>
    <context id="icd32a02105c3425089f7089841dde5b2_D20170101-20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amed:SafeguardZoneProgramIntegrityContractorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:FL</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="if467e9fca3484710a3ac117350b56dd9_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amed:SafeguardZoneProgramIntegrityContractorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:FL</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:InfinityHomeCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i39e4f26632264baf9dbebb5fdcfb9311_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="icf5dbb4a4428489fa4c64850e9a5a460_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i66723c555afc4c9ab4b0e69183d084cf_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:PersonalCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ib10fab888a0d4becba7d4378b0313572_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i1f0d04b97823461cabfaf4b2dbfbd657_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="if43b4d7c93ab412a9c9070b831320d17_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i15797e02165b455389b33741463c1ecd_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:PersonalCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i06052fe21e8f47d88c0c73710f1feaa6_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ia22ad972b1ec472b9114385ace42cd42_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:PersonalCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i91156243b7cb4900b72f0b116d3781c2_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i15c3520755c5444cb900d57537639c6c_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i6ce911e452594105bd0677b242a6a2d3_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i5e461372b93847a4b7c9e1e3e9206b30_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:PersonalCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i2f63d6ecb3ef4b2f9a0e98f946e6f46e_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i479f4d0280434d3681861fd2e320cd99_I20201223">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">amed:A2021ShareRepurchaseProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-23</instant>
        </period>
    </context>
    <context id="i0d540c3eb0984765b002cd7535b1f472_D20201223-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">amed:A2021ShareRepurchaseProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-23</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i7d058b3163364b51b7615e3e655ec631_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">amed:A2021ShareRepurchaseProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ie99fb62084bb4f729ac77ff7dbaed893_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">amed:A2021ShareRepurchaseProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i55192f2892ba4410b4d8043c7bd3508f_I20210802">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">amed:ShareRepurchaseProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-08-02</instant>
        </period>
    </context>
    <context id="ide446a75729e4d219d7267432d1f1fbc_D20210802-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">amed:ShareRepurchaseProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-08-02</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="iad1f6087d55542bd9518895ce038f77e_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">amed:MedalogixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i0e79ddec592d4a9286d6d4f8fbd7eebb_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">amed:MedalogixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i8fb7629dcb544e0686e55cbe211d9a9b_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">amed:MedalogixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i10a4b9a4ae414719a5bbc87698268410_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">amed:MedalogixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i5bf5d306b1c14ff585373333170311d3_D20210701-20210701">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:VisitingNurseAssociationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-07-01</endDate>
        </period>
    </context>
    <context id="i1f8587237be448c2bf1c2bbffa581713_D20210712-20210712">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:NY</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-12</startDate>
            <endDate>2021-07-12</endDate>
        </period>
    </context>
    <context id="i3fb42087c2d743cca8d759c85d31167b_D20210801-20210801">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:ContessaHealthMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-08-01</startDate>
            <endDate>2021-08-01</endDate>
        </period>
    </context>
    <context id="i37b72216842c4630bdb672d9901858fe_I20210730">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">amed:SecondAmendmentToAmendedCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-30</instant>
        </period>
    </context>
    <context id="i5f0102c209874abb900b903e54aba58e_I20210730">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:FiveHundredFiftyMillionRevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">amed:SecondAmendmentToAmendedCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-30</instant>
        </period>
    </context>
    <context id="i23747c712c2a44b5bf6a948f7a476aab_I20210730">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:FourHundredFiftyMillionTermLoanFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">amed:SecondAmendmentToAmendedCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-30</instant>
        </period>
    </context>
    <context id="i013c83768a1e4e0b956e81903f1c8638_D20210730-20210730">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-30</startDate>
            <endDate>2021-07-30</endDate>
        </period>
    </context>
    <context id="i893fcad73cef4a18a7ab76f16e96f0ad_D20210730-20210730">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:AmendedDebtInstrumentByLeverageRatioTrancheOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-30</startDate>
            <endDate>2021-07-30</endDate>
        </period>
    </context>
    <context id="ifa6c63e1eca547f89b708d6f34225a17_D20210730-20210730">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:AmendedDebtInstrumentByLeverageRatioTrancheOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-30</startDate>
            <endDate>2021-07-30</endDate>
        </period>
    </context>
    <context id="ibd49c2b0ab464f6ab8d956a502559923_D20210730-20210730">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:AmendedDebtInstrumentByLeverageRatioTrancheOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:EurodollarMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-30</startDate>
            <endDate>2021-07-30</endDate>
        </period>
    </context>
    <context id="i42d092eff4ad4200a0c01193347c59ba_D20210730-20210730">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:AmendedDebtInstrumentByLeverageRatioTrancheOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-30</startDate>
            <endDate>2021-07-30</endDate>
        </period>
    </context>
    <context id="i399c2067f87f4579a5bf6e8d11ed2b0e_D20210730-20210730">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:AmendedDebtInstrumentByLeverageRatioTrancheTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-30</startDate>
            <endDate>2021-07-30</endDate>
        </period>
    </context>
    <context id="i51a6e6e62aa24e08a1f42edef5dc3362_D20210730-20210730">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:AmendedDebtInstrumentByLeverageRatioTrancheTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-30</startDate>
            <endDate>2021-07-30</endDate>
        </period>
    </context>
    <context id="i1806f555a63f4ad9be597bfa139ca430_D20210730-20210730">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:AmendedDebtInstrumentByLeverageRatioTrancheTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-30</startDate>
            <endDate>2021-07-30</endDate>
        </period>
    </context>
    <context id="idf8a0386bfef429dac8a61b128e23424_D20210730-20210730">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:AmendedDebtInstrumentByLeverageRatioTrancheTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:EurodollarMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-30</startDate>
            <endDate>2021-07-30</endDate>
        </period>
    </context>
    <context id="ibb50673cdce34a36abc32c81bca0b9c2_D20210730-20210730">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:AmendedDebtInstrumentByLeverageRatioTrancheTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-30</startDate>
            <endDate>2021-07-30</endDate>
        </period>
    </context>
    <context id="ica9a6dd6c4dd4b528399e24681759629_D20210730-20210730">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:AmendedDebtInstrumentByLeverageRatioTrancheThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-30</startDate>
            <endDate>2021-07-30</endDate>
        </period>
    </context>
    <context id="ie135590e741545eaba8f6bb70561f7be_D20210730-20210730">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:AmendedDebtInstrumentByLeverageRatioTrancheThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-30</startDate>
            <endDate>2021-07-30</endDate>
        </period>
    </context>
    <context id="i7ae8c5e5ea3f46338602af709a707586_D20210730-20210730">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:AmendedDebtInstrumentByLeverageRatioTrancheThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-30</startDate>
            <endDate>2021-07-30</endDate>
        </period>
    </context>
    <context id="i0e146a61cc484c3085aa313c3aac07b6_D20210730-20210730">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:AmendedDebtInstrumentByLeverageRatioTrancheThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:EurodollarMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-30</startDate>
            <endDate>2021-07-30</endDate>
        </period>
    </context>
    <context id="i379bc627f4a745e6937f7cc4a2357a7d_D20210730-20210730">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:AmendedDebtInstrumentByLeverageRatioTrancheThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-30</startDate>
            <endDate>2021-07-30</endDate>
        </period>
    </context>
    <context id="id407ccb903ff4b5dbcd97f48c071901c_D20210730-20210730">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:AmendedDebtInstrumentByLeverageRatioTrancheFourMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-30</startDate>
            <endDate>2021-07-30</endDate>
        </period>
    </context>
    <context id="i00349d2687c14dfba218b9ee86bf33b2_D20210730-20210730">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:AmendedDebtInstrumentByLeverageRatioTrancheFourMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-30</startDate>
            <endDate>2021-07-30</endDate>
        </period>
    </context>
    <context id="if952ebf0ec1f4f38950c654b7e9febb8_D20210730-20210730">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:AmendedDebtInstrumentByLeverageRatioTrancheFourMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:EurodollarMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-30</startDate>
            <endDate>2021-07-30</endDate>
        </period>
    </context>
    <context id="ia0a2cc02f30f44c481140c202f28cf4a_D20210730-20210730">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:AmendedDebtInstrumentByLeverageRatioTrancheFourMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-30</startDate>
            <endDate>2021-07-30</endDate>
        </period>
    </context>
    <context id="i8f97846b33b54f368697ed0323cbb2b2_D20210730-20260730">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">amed:SecondAmendmentToAmendedCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-30</startDate>
            <endDate>2026-07-30</endDate>
        </period>
    </context>
    <context id="id8e4663758bd4b8c908928b7178d6c4f_D20210730-20230930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:FourHundredFiftyMillionTermLoanFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">amed:SecondAmendmentToAmendedCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-30</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="i04246e2f9fa44955a7bdb76cd2520b0b_D20231001-20260730">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:FourHundredFiftyMillionTermLoanFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">amed:SecondAmendmentToAmendedCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2026-07-30</endDate>
        </period>
    </context>
    <context id="i704e6869254d4b25be00c91be5629417_D20210730-20210730">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">amed:SecondAmendmentToAmendedCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-30</startDate>
            <endDate>2021-07-30</endDate>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="care_center">
        <measure>amed:care_center</measure>
    </unit>
    <unit id="state">
        <measure>amed:state</measure>
    </unit>
    <unit id="visit">
        <measure>amed:visit</measure>
    </unit>
    <unit id="patient">
        <measure>amed:patient</measure>
    </unit>
    <unit id="beneficiary">
        <measure>amed:beneficiary</measure>
    </unit>
    <unit id="claim">
        <measure>amed:claim</measure>
    </unit>
    <unit id="segments">
        <measure>amed:Segments</measure>
    </unit>
    <dei:AmendmentFlag
      contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV80L2ZyYWc6N2M4Y2M4NWJmM2E3NDA3ODljNWMzYzQ3ZjcxZTE1OWYvdGFibGU6NmYzMjVhNmU3YTg5NGRkNDk2ZjZkOThkNDYwYjRiYzgvdGFibGVyYW5nZTo2ZjMyNWE2ZTdhODk0ZGQ0OTZmNmQ5OGQ0NjBiNGJjOF80LTEtMS0xLTA_5f442d1e-eb01-44eb-ae22-3d97454ba6d0">false</dei:AmendmentFlag>
    <dei:DocumentFiscalYearFocus
      contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV80L2ZyYWc6N2M4Y2M4NWJmM2E3NDA3ODljNWMzYzQ3ZjcxZTE1OWYvdGFibGU6NmYzMjVhNmU3YTg5NGRkNDk2ZjZkOThkNDYwYjRiYzgvdGFibGVyYW5nZTo2ZjMyNWE2ZTdhODk0ZGQ0OTZmNmQ5OGQ0NjBiNGJjOF82LTEtMS0xLTA_52646e75-5b4e-421f-a8ab-0be4ce6597b8">2021</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV80L2ZyYWc6N2M4Y2M4NWJmM2E3NDA3ODljNWMzYzQ3ZjcxZTE1OWYvdGFibGU6NmYzMjVhNmU3YTg5NGRkNDk2ZjZkOThkNDYwYjRiYzgvdGFibGVyYW5nZTo2ZjMyNWE2ZTdhODk0ZGQ0OTZmNmQ5OGQ0NjBiNGJjOF83LTEtMS0xLTA_6068327d-1b75-4a83-8ba1-5a1d722d75a6">Q2</dei:DocumentFiscalPeriodFocus>
    <dei:EntityRegistrantName
      contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV80L2ZyYWc6N2M4Y2M4NWJmM2E3NDA3ODljNWMzYzQ3ZjcxZTE1OWYvdGFibGU6NmYzMjVhNmU3YTg5NGRkNDk2ZjZkOThkNDYwYjRiYzgvdGFibGVyYW5nZTo2ZjMyNWE2ZTdhODk0ZGQ0OTZmNmQ5OGQ0NjBiNGJjOF85LTEtMS0xLTA_573e8149-a4fa-4b56-8183-20421bf77cd8">AMEDISYS INC</dei:EntityRegistrantName>
    <dei:EntityCentralIndexKey
      contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV80L2ZyYWc6N2M4Y2M4NWJmM2E3NDA3ODljNWMzYzQ3ZjcxZTE1OWYvdGFibGU6NmYzMjVhNmU3YTg5NGRkNDk2ZjZkOThkNDYwYjRiYzgvdGFibGVyYW5nZTo2ZjMyNWE2ZTdhODk0ZGQ0OTZmNmQ5OGQ0NjBiNGJjOF8xMC0xLTEtMS0w_c75f1c75-a0a2-414a-bf13-736fe8ace4f6">0000896262</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV80L2ZyYWc6N2M4Y2M4NWJmM2E3NDA3ODljNWMzYzQ3ZjcxZTE1OWYvdGFibGU6NmYzMjVhNmU3YTg5NGRkNDk2ZjZkOThkNDYwYjRiYzgvdGFibGVyYW5nZTo2ZjMyNWE2ZTdhODk0ZGQ0OTZmNmQ5OGQ0NjBiNGJjOF8xMS0xLTEtMS0w_54c21015-e543-4528-a91e-4b05c0f0beb6">--12-31</dei:CurrentFiscalYearEndDate>
    <us-gaap:GainLossOnInvestments
      contextRef="i47cb3be3d5564293b84a6274e71f0a2c_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV80MC9mcmFnOjFjYzZhMTg2ZGVmMjQzZDg4ZTU2OTg1YzViMzM3OWEwL3RhYmxlOmJiNTZhMTZhNjJiNzQ5NWU4NTg5NjFmYjc1MGUyMGE3L3RhYmxlcmFuZ2U6YmI1NmExNmE2MmI3NDk1ZTg1ODk2MWZiNzUwZTIwYTdfNC0xLTEtMS0xNDE0_1cc13b15-7692-494a-821d-24dd547dcfdf"
      unitRef="usd">3000000.0</us-gaap:GainLossOnInvestments>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i87ceb60dc20d4df1b0a97d3514837910_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV80Ni9mcmFnOjdjZDcwOWVjYjkzOTQ3ZWI5YzA1ZTUyMjU5OGJmMzgxL3RhYmxlOmEwZGFhMjU1NjY4MDRmZThiZDcxYWMwNjE0NWFlZjg3L3RhYmxlcmFuZ2U6YTBkYWEyNTU2NjgwNGZlOGJkNzFhYzA2MTQ1YWVmODdfMy0xLTEtMS0w_19144da3-41aa-45d6-8598-e3e92ce10d52"
      unitRef="usd">83357000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:OperatingIncomeLoss
      contextRef="ie2776ede445a47be9f24c8e19df8e41a_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV81NS9mcmFnOjkzMzc2ZDZkZTZhZTQ0OTM5Y2I4ZDg0ZWUzM2YxNGQwL3RhYmxlOmFlMGY1OTFhZGVkZDRlZmFiNjMyNGU2ODMxNzg0OGY5L3RhYmxlcmFuZ2U6YWUwZjU5MWFkZWRkNGVmYWI2MzI0ZTY4MzE3ODQ4ZjlfMi0xLTEtMS0w_763eaa52-c8b2-4ac8-ae0f-689ca371dd9f"
      unitRef="usd">-100000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="id8f72c421ee54ba2a739418940dde57c_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV81NS9mcmFnOjkzMzc2ZDZkZTZhZTQ0OTM5Y2I4ZDg0ZWUzM2YxNGQwL3RhYmxlOmFlMGY1OTFhZGVkZDRlZmFiNjMyNGU2ODMxNzg0OGY5L3RhYmxlcmFuZ2U6YWUwZjU5MWFkZWRkNGVmYWI2MzI0ZTY4MzE3ODQ4ZjlfMi0yLTEtMS0yOTQ4_5e7b9738-69d7-4dcd-aac8-97aff95ff328"
      unitRef="usd">-3000000.0</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i93266b4b1d884fad8c5cb4456e2def79_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV81NS9mcmFnOjkzMzc2ZDZkZTZhZTQ0OTM5Y2I4ZDg0ZWUzM2YxNGQwL3RhYmxlOmFlMGY1OTFhZGVkZDRlZmFiNjMyNGU2ODMxNzg0OGY5L3RhYmxlcmFuZ2U6YWUwZjU5MWFkZWRkNGVmYWI2MzI0ZTY4MzE3ODQ4ZjlfMi0zLTEtMS0yOTQ4_05062f13-6686-42db-9847-b914ebeabea2"
      unitRef="usd">-3000000.0</us-gaap:OperatingIncomeLoss>
    <us-gaap:DebtInstrumentDescriptionOfVariableRateBasis
      contextRef="ia2de44b83d484d54a6dcb3b8f754c999_D20190204-20190204"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV82MS9mcmFnOjRlOTFjMTdjOGQxYjQxNTg5ZGQzZjdmNTg2ZTQ2MjkzL3RleHRyZWdpb246NGU5MWMxN2M4ZDFiNDE1ODlkZDNmN2Y1ODZlNDYyOTNfODEx_eb308438-7b3e-41e0-9cee-a71bd28e9d3b">Fluctuating rate per annum equal to the highest of (a)&#160;the federal funds rate plus 0.50% per annum, (b)&#160;the prime rate of interest established by the Administrative Agent, and (c)&#160;the Eurodollar Rate for an interest period of one month plus 1% per annum.</us-gaap:DebtInstrumentDescriptionOfVariableRateBasis>
    <us-gaap:DebtInstrumentDescriptionOfVariableRateBasis
      contextRef="i8f72f99e864d4c5192c1e32828587ac2_D20190204-20190204"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV82MS9mcmFnOjRlOTFjMTdjOGQxYjQxNTg5ZGQzZjdmNTg2ZTQ2MjkzL3RleHRyZWdpb246NGU5MWMxN2M4ZDFiNDE1ODlkZDNmN2Y1ODZlNDYyOTNfODEy_9d889f6e-a855-45f1-8b1e-b33db838a91f">Rate at which Eurodollar deposits in the London interbank market for an interest period of one, two, three or six months</us-gaap:DebtInstrumentDescriptionOfVariableRateBasis>
    <us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions
      contextRef="i2c8351954d014a1c80a3d8cfc2327ab2_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV83My9mcmFnOmFlZTE3NzNjM2Y4OTQ3NWI4ZDk4ZmIwM2FhOWY4ZDNmL3RhYmxlOjcxZmJkYWZmMDlmZTRmOGJhMzQ5MGIwNmVjNDM4MDQyL3RhYmxlcmFuZ2U6NzFmYmRhZmYwOWZlNGY4YmEzNDkwYjA2ZWM0MzgwNDJfMi0yLTEtMS0yOTky_135700a7-2230-48bb-9fc2-f2e9bfe47cd6"
      unitRef="usd">485059000</us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i2c8351954d014a1c80a3d8cfc2327ab2_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV83My9mcmFnOmFlZTE3NzNjM2Y4OTQ3NWI4ZDk4ZmIwM2FhOWY4ZDNmL3RhYmxlOjcxZmJkYWZmMDlmZTRmOGJhMzQ5MGIwNmVjNDM4MDQyL3RhYmxlcmFuZ2U6NzFmYmRhZmYwOWZlNGY4YmEzNDkwYjA2ZWM0MzgwNDJfMy0yLTEtMS0yOTk2_325745d9-68dd-4f85-b88f-156515892796"
      unitRef="usd">295228000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostsAndExpenses
      contextRef="ib87cee58ccf2448a8d4422101bf61fa0_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV83My9mcmFnOmFlZTE3NzNjM2Y4OTQ3NWI4ZDk4ZmIwM2FhOWY4ZDNmL3RhYmxlOjcxZmJkYWZmMDlmZTRmOGJhMzQ5MGIwNmVjNDM4MDQyL3RhYmxlcmFuZ2U6NzFmYmRhZmYwOWZlNGY4YmEzNDkwYjA2ZWM0MzgwNDJfNC0xLTEtMS0zMDAz_fe690f40-00ed-4c6e-bc4f-ac7941d65040"
      unitRef="usd">490634000</us-gaap:CostsAndExpenses>
    <dei:DocumentType
      contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8xL2ZyYWc6YTliNzQzYzAwODU4NGYyNGFhYTM1N2E5ZjJjMWE0ZDYvdGV4dHJlZ2lvbjphOWI3NDNjMDA4NTg0ZjI0YWFhMzU3YTlmMmMxYTRkNl8yMjQ4_10c81f87-8cdb-4ac4-b4b0-6d0f8a830071">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8xL2ZyYWc6YTliNzQzYzAwODU4NGYyNGFhYTM1N2E5ZjJjMWE0ZDYvdGFibGU6YTEwYTBiN2FjZmY3NGExNjk0OTdiMDY2MDNjMjVhNzAvdGFibGVyYW5nZTphMTBhMGI3YWNmZjc0YTE2OTQ5N2IwNjYwM2MyNWE3MF8wLTAtMS0xLTA_85ed1899-6b39-40d0-89a2-05631de2d542">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8xL2ZyYWc6YTliNzQzYzAwODU4NGYyNGFhYTM1N2E5ZjJjMWE0ZDYvdGV4dHJlZ2lvbjphOWI3NDNjMDA4NTg0ZjI0YWFhMzU3YTlmMmMxYTRkNl8xNDA_0ddc3a2c-8289-4f8f-bd70-125cd4dac68c">2021-06-30</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8xL2ZyYWc6YTliNzQzYzAwODU4NGYyNGFhYTM1N2E5ZjJjMWE0ZDYvdGFibGU6YWZlMDk5NmE3MTViNDNjMDkwMDQ5MjA4NzBlNmU3ZmUvdGFibGVyYW5nZTphZmUwOTk2YTcxNWI0M2MwOTAwNDkyMDg3MGU2ZTdmZV8wLTAtMS0xLTA_5d137cc0-5e53-4682-8c22-053c0bcf13af">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8xL2ZyYWc6YTliNzQzYzAwODU4NGYyNGFhYTM1N2E5ZjJjMWE0ZDYvdGV4dHJlZ2lvbjphOWI3NDNjMDA4NTg0ZjI0YWFhMzU3YTlmMmMxYTRkNl8yMjQz_597ef27b-e2a6-4cf3-b9cf-7754c9d0db36">0-24260</dei:EntityFileNumber>
    <dei:EntityIncorporationStateCountryCode
      contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8xL2ZyYWc6YTliNzQzYzAwODU4NGYyNGFhYTM1N2E5ZjJjMWE0ZDYvdGFibGU6ODViZmI1Mzc5MjExNDM2YWE0M2VlOTliYzM2NDA2ODQvdGFibGVyYW5nZTo4NWJmYjUzNzkyMTE0MzZhYTQzZWU5OWJjMzY0MDY4NF8xLTAtMS0xLTA_126c6c3b-6f23-4b2c-8e52-e8363d88fc96">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8xL2ZyYWc6YTliNzQzYzAwODU4NGYyNGFhYTM1N2E5ZjJjMWE0ZDYvdGFibGU6ODViZmI1Mzc5MjExNDM2YWE0M2VlOTliYzM2NDA2ODQvdGFibGVyYW5nZTo4NWJmYjUzNzkyMTE0MzZhYTQzZWU5OWJjMzY0MDY4NF8xLTItMS0xLTA_54c6a5b6-793e-4e32-bdfa-050172a95352">11-3131700</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8xL2ZyYWc6YTliNzQzYzAwODU4NGYyNGFhYTM1N2E5ZjJjMWE0ZDYvdGV4dHJlZ2lvbjphOWI3NDNjMDA4NTg0ZjI0YWFhMzU3YTlmMmMxYTRkNl8yMjQ0_6ca5236f-7957-4dbb-ac93-c985f2b7d61f">3854 American Way</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8xL2ZyYWc6YTliNzQzYzAwODU4NGYyNGFhYTM1N2E5ZjJjMWE0ZDYvdGV4dHJlZ2lvbjphOWI3NDNjMDA4NTg0ZjI0YWFhMzU3YTlmMmMxYTRkNl8yMjQ1_9eb8804c-8070-4707-85df-2856ac9227c8">Suite A</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8xL2ZyYWc6YTliNzQzYzAwODU4NGYyNGFhYTM1N2E5ZjJjMWE0ZDYvdGV4dHJlZ2lvbjphOWI3NDNjMDA4NTg0ZjI0YWFhMzU3YTlmMmMxYTRkNl8yMjQ5_8255e170-a829-4fbe-ad44-bef8e25b01e8">Baton Rouge</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8xL2ZyYWc6YTliNzQzYzAwODU4NGYyNGFhYTM1N2E5ZjJjMWE0ZDYvdGV4dHJlZ2lvbjphOWI3NDNjMDA4NTg0ZjI0YWFhMzU3YTlmMmMxYTRkNl8yMjQ2_767b021c-602c-48f0-95ba-a4c293ee6d02">LA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8xL2ZyYWc6YTliNzQzYzAwODU4NGYyNGFhYTM1N2E5ZjJjMWE0ZDYvdGV4dHJlZ2lvbjphOWI3NDNjMDA4NTg0ZjI0YWFhMzU3YTlmMmMxYTRkNl8yMjQ3_603f1218-e4f7-4f11-b0ce-103588cbb6cf">70816</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8xL2ZyYWc6YTliNzQzYzAwODU4NGYyNGFhYTM1N2E5ZjJjMWE0ZDYvdGV4dHJlZ2lvbjphOWI3NDNjMDA4NTg0ZjI0YWFhMzU3YTlmMmMxYTRkNl8yMjUw_769a9d6b-fbe0-495b-bf74-c2025ffe69d3">225</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8xL2ZyYWc6YTliNzQzYzAwODU4NGYyNGFhYTM1N2E5ZjJjMWE0ZDYvdGV4dHJlZ2lvbjphOWI3NDNjMDA4NTg0ZjI0YWFhMzU3YTlmMmMxYTRkNl8yMjUx_3f9df67f-c206-40db-a7e6-44e0e3f51708">292-2031</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8xL2ZyYWc6YTliNzQzYzAwODU4NGYyNGFhYTM1N2E5ZjJjMWE0ZDYvdGFibGU6OGY3NmQ3ODI5ZDU2NDA3OGEyMGZmNjc3NTAzZDg4ZjEvdGFibGVyYW5nZTo4Zjc2ZDc4MjlkNTY0MDc4YTIwZmY2Nzc1MDNkODhmMV8xLTAtMS0xLTA_fac809ae-2092-4e13-848a-87b905a5dc26">Common Stock, par value $0.001 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8xL2ZyYWc6YTliNzQzYzAwODU4NGYyNGFhYTM1N2E5ZjJjMWE0ZDYvdGFibGU6OGY3NmQ3ODI5ZDU2NDA3OGEyMGZmNjc3NTAzZDg4ZjEvdGFibGVyYW5nZTo4Zjc2ZDc4MjlkNTY0MDc4YTIwZmY2Nzc1MDNkODhmMV8xLTItMS0xLTA_2a95462b-81b1-4082-bbea-f8c43cc65bf6">AMED</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8xL2ZyYWc6YTliNzQzYzAwODU4NGYyNGFhYTM1N2E5ZjJjMWE0ZDYvdGFibGU6OGY3NmQ3ODI5ZDU2NDA3OGEyMGZmNjc3NTAzZDg4ZjEvdGFibGVyYW5nZTo4Zjc2ZDc4MjlkNTY0MDc4YTIwZmY2Nzc1MDNkODhmMV8xLTQtMS0xLTA_c7866473-a2bb-4fa2-a0e5-c008cbfe8f05">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8xL2ZyYWc6YTliNzQzYzAwODU4NGYyNGFhYTM1N2E5ZjJjMWE0ZDYvdGV4dHJlZ2lvbjphOWI3NDNjMDA4NTg0ZjI0YWFhMzU3YTlmMmMxYTRkNl8yMjUy_c55d3fc8-c3b0-419e-8262-2d5e9bf22462">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8xL2ZyYWc6YTliNzQzYzAwODU4NGYyNGFhYTM1N2E5ZjJjMWE0ZDYvdGV4dHJlZ2lvbjphOWI3NDNjMDA4NTg0ZjI0YWFhMzU3YTlmMmMxYTRkNl8yMjQx_f237e278-3a93-404d-8aaa-ae51bc65586d">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8xL2ZyYWc6YTliNzQzYzAwODU4NGYyNGFhYTM1N2E5ZjJjMWE0ZDYvdGFibGU6ZjQ2YjgwNjhjNzg2NGE4M2IzYjViMDVkNDk4MjYwOTIvdGFibGVyYW5nZTpmNDZiODA2OGM3ODY0YTgzYjNiNWIwNWQ0OTgyNjA5Ml8xLTAtMS0xLTA_d27427f9-9d69-4609-a689-d407f4f591c8">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8xL2ZyYWc6YTliNzQzYzAwODU4NGYyNGFhYTM1N2E5ZjJjMWE0ZDYvdGFibGU6ZjQ2YjgwNjhjNzg2NGE4M2IzYjViMDVkNDk4MjYwOTIvdGFibGVyYW5nZTpmNDZiODA2OGM3ODY0YTgzYjNiNWIwNWQ0OTgyNjA5Ml8zLTYtMS0xLTA_8c342535-58f0-4727-8dd5-ff9151c705ef">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8xL2ZyYWc6YTliNzQzYzAwODU4NGYyNGFhYTM1N2E5ZjJjMWE0ZDYvdGFibGU6ZjQ2YjgwNjhjNzg2NGE4M2IzYjViMDVkNDk4MjYwOTIvdGFibGVyYW5nZTpmNDZiODA2OGM3ODY0YTgzYjNiNWIwNWQ0OTgyNjA5Ml81LTItMS0xLTA_1c1e18aa-a0d4-445b-86d3-b5edeb4c8ea7">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8xL2ZyYWc6YTliNzQzYzAwODU4NGYyNGFhYTM1N2E5ZjJjMWE0ZDYvdGV4dHJlZ2lvbjphOWI3NDNjMDA4NTg0ZjI0YWFhMzU3YTlmMmMxYTRkNl8yMjQy_be9a7af3-0cd1-4ca5-b118-5a4720b77477">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="ifed7a9d7833f4709ab4d734d7c419fe7_I20210730"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8xL2ZyYWc6YTliNzQzYzAwODU4NGYyNGFhYTM1N2E5ZjJjMWE0ZDYvdGV4dHJlZ2lvbjphOWI3NDNjMDA4NTg0ZjI0YWFhMzU3YTlmMmMxYTRkNl8yMjA4_e46d12ed-5fd6-4a3a-919d-34779402364c"
      unitRef="shares">32631959</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i1e833203be6947b4968aba4d20064ec8_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8xOS9mcmFnOmY3ZTkzYjhjYTJiMDRhYmI4OTA2MDFkZWI3MGNmZTQ4L3RhYmxlOmRhYzI0NDM5OWU0NTRkZjJiYjI0MjUwMjA3OTFhOWY5L3RhYmxlcmFuZ2U6ZGFjMjQ0Mzk5ZTQ1NGRmMmJiMjQyNTAyMDc5MWE5ZjlfMy0xLTEtMS0w_cbf552c2-48c5-49a2-8f94-c1cfdc51127a"
      unitRef="usd">91646000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i87ceb60dc20d4df1b0a97d3514837910_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8xOS9mcmFnOmY3ZTkzYjhjYTJiMDRhYmI4OTA2MDFkZWI3MGNmZTQ4L3RhYmxlOmRhYzI0NDM5OWU0NTRkZjJiYjI0MjUwMjA3OTFhOWY5L3RhYmxlcmFuZ2U6ZGFjMjQ0Mzk5ZTQ1NGRmMmJiMjQyNTAyMDc5MWE5ZjlfMy0zLTEtMS0w_d927a305-5117-4c0b-b916-4e9402f8e0f8"
      unitRef="usd">81808000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCash
      contextRef="i1e833203be6947b4968aba4d20064ec8_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8xOS9mcmFnOmY3ZTkzYjhjYTJiMDRhYmI4OTA2MDFkZWI3MGNmZTQ4L3RhYmxlOmRhYzI0NDM5OWU0NTRkZjJiYjI0MjUwMjA3OTFhOWY5L3RhYmxlcmFuZ2U6ZGFjMjQ0Mzk5ZTQ1NGRmMmJiMjQyNTAyMDc5MWE5ZjlfNC0xLTEtMS0w_e80b12ce-75cc-4ab2-92eb-2e17a76b3b5f"
      unitRef="usd">1000000</us-gaap:RestrictedCash>
    <us-gaap:RestrictedCash
      contextRef="i87ceb60dc20d4df1b0a97d3514837910_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8xOS9mcmFnOmY3ZTkzYjhjYTJiMDRhYmI4OTA2MDFkZWI3MGNmZTQ4L3RhYmxlOmRhYzI0NDM5OWU0NTRkZjJiYjI0MjUwMjA3OTFhOWY5L3RhYmxlcmFuZ2U6ZGFjMjQ0Mzk5ZTQ1NGRmMmJiMjQyNTAyMDc5MWE5ZjlfNC0zLTEtMS0w_bf76708c-a9c6-495e-ac21-2406d461c1da"
      unitRef="usd">1549000</us-gaap:RestrictedCash>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i1e833203be6947b4968aba4d20064ec8_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8xOS9mcmFnOmY3ZTkzYjhjYTJiMDRhYmI4OTA2MDFkZWI3MGNmZTQ4L3RhYmxlOmRhYzI0NDM5OWU0NTRkZjJiYjI0MjUwMjA3OTFhOWY5L3RhYmxlcmFuZ2U6ZGFjMjQ0Mzk5ZTQ1NGRmMmJiMjQyNTAyMDc5MWE5ZjlfNS0xLTEtMS0w_d7b790b7-974f-4ec9-b796-92a9b4e8eadf"
      unitRef="usd">278216000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i87ceb60dc20d4df1b0a97d3514837910_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8xOS9mcmFnOmY3ZTkzYjhjYTJiMDRhYmI4OTA2MDFkZWI3MGNmZTQ4L3RhYmxlOmRhYzI0NDM5OWU0NTRkZjJiYjI0MjUwMjA3OTFhOWY5L3RhYmxlcmFuZ2U6ZGFjMjQ0Mzk5ZTQ1NGRmMmJiMjQyNTAyMDc5MWE5ZjlfNS0zLTEtMS0w_f79d45ac-2be8-4124-abd5-c79ed3e238e0"
      unitRef="usd">255145000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="i1e833203be6947b4968aba4d20064ec8_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8xOS9mcmFnOmY3ZTkzYjhjYTJiMDRhYmI4OTA2MDFkZWI3MGNmZTQ4L3RhYmxlOmRhYzI0NDM5OWU0NTRkZjJiYjI0MjUwMjA3OTFhOWY5L3RhYmxlcmFuZ2U6ZGFjMjQ0Mzk5ZTQ1NGRmMmJiMjQyNTAyMDc5MWE5ZjlfNi0xLTEtMS0w_05a2eaf7-6223-4b3a-bd0e-8cf86ef592e4"
      unitRef="usd">11979000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="i87ceb60dc20d4df1b0a97d3514837910_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8xOS9mcmFnOmY3ZTkzYjhjYTJiMDRhYmI4OTA2MDFkZWI3MGNmZTQ4L3RhYmxlOmRhYzI0NDM5OWU0NTRkZjJiYjI0MjUwMjA3OTFhOWY5L3RhYmxlcmFuZ2U6ZGFjMjQ0Mzk5ZTQ1NGRmMmJiMjQyNTAyMDc5MWE5ZjlfNi0zLTEtMS0w_04f53a57-6c60-4c26-ac62-d339c272fecd"
      unitRef="usd">10217000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="i1e833203be6947b4968aba4d20064ec8_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8xOS9mcmFnOmY3ZTkzYjhjYTJiMDRhYmI4OTA2MDFkZWI3MGNmZTQ4L3RhYmxlOmRhYzI0NDM5OWU0NTRkZjJiYjI0MjUwMjA3OTFhOWY5L3RhYmxlcmFuZ2U6ZGFjMjQ0Mzk5ZTQ1NGRmMmJiMjQyNTAyMDc5MWE5ZjlfNy0xLTEtMS0w_36e6b65e-d695-4c38-9f08-2c224d433e94"
      unitRef="usd">8124000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="i87ceb60dc20d4df1b0a97d3514837910_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8xOS9mcmFnOmY3ZTkzYjhjYTJiMDRhYmI4OTA2MDFkZWI3MGNmZTQ4L3RhYmxlOmRhYzI0NDM5OWU0NTRkZjJiYjI0MjUwMjA3OTFhOWY5L3RhYmxlcmFuZ2U6ZGFjMjQ0Mzk5ZTQ1NGRmMmJiMjQyNTAyMDc5MWE5ZjlfNy0zLTEtMS0w_7aad19b9-a07c-4548-9459-3d9e930a75ca"
      unitRef="usd">13265000</us-gaap:OtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i1e833203be6947b4968aba4d20064ec8_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8xOS9mcmFnOmY3ZTkzYjhjYTJiMDRhYmI4OTA2MDFkZWI3MGNmZTQ4L3RhYmxlOmRhYzI0NDM5OWU0NTRkZjJiYjI0MjUwMjA3OTFhOWY5L3RhYmxlcmFuZ2U6ZGFjMjQ0Mzk5ZTQ1NGRmMmJiMjQyNTAyMDc5MWE5ZjlfOC0xLTEtMS0w_ecf62d09-3574-42a9-9164-e87eb6bf03f1"
      unitRef="usd">390965000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i87ceb60dc20d4df1b0a97d3514837910_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8xOS9mcmFnOmY3ZTkzYjhjYTJiMDRhYmI4OTA2MDFkZWI3MGNmZTQ4L3RhYmxlOmRhYzI0NDM5OWU0NTRkZjJiYjI0MjUwMjA3OTFhOWY5L3RhYmxlcmFuZ2U6ZGFjMjQ0Mzk5ZTQ1NGRmMmJiMjQyNTAyMDc5MWE5ZjlfOC0zLTEtMS0w_3a9baf92-a84c-4c4f-8e84-df6594f66366"
      unitRef="usd">361984000</us-gaap:AssetsCurrent>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i1e833203be6947b4968aba4d20064ec8_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8xOS9mcmFnOmY3ZTkzYjhjYTJiMDRhYmI4OTA2MDFkZWI3MGNmZTQ4L3RhYmxlOmRhYzI0NDM5OWU0NTRkZjJiYjI0MjUwMjA3OTFhOWY5L3RhYmxlcmFuZ2U6ZGFjMjQ0Mzk5ZTQ1NGRmMmJiMjQyNTAyMDc5MWE5ZjlfOS0wLTEtMS0wL3RleHRyZWdpb246YzczOTc4ZjE4Y2VmNDFlNGFiZWY5NjMwMzgxMGZlZTRfNjM_75e457ed-3ac3-4362-98e2-ab1b7d621f5a"
      unitRef="usd">98552000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i87ceb60dc20d4df1b0a97d3514837910_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8xOS9mcmFnOmY3ZTkzYjhjYTJiMDRhYmI4OTA2MDFkZWI3MGNmZTQ4L3RhYmxlOmRhYzI0NDM5OWU0NTRkZjJiYjI0MjUwMjA3OTFhOWY5L3RhYmxlcmFuZ2U6ZGFjMjQ0Mzk5ZTQ1NGRmMmJiMjQyNTAyMDc5MWE5ZjlfOS0wLTEtMS0wL3RleHRyZWdpb246YzczOTc4ZjE4Y2VmNDFlNGFiZWY5NjMwMzgxMGZlZTRfNzA_ef02881a-0619-4228-81ce-5a9cda2e4195"
      unitRef="usd">95024000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i1e833203be6947b4968aba4d20064ec8_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8xOS9mcmFnOmY3ZTkzYjhjYTJiMDRhYmI4OTA2MDFkZWI3MGNmZTQ4L3RhYmxlOmRhYzI0NDM5OWU0NTRkZjJiYjI0MjUwMjA3OTFhOWY5L3RhYmxlcmFuZ2U6ZGFjMjQ0Mzk5ZTQ1NGRmMmJiMjQyNTAyMDc5MWE5ZjlfOS0xLTEtMS0w_7de2952c-f6e0-498e-b36d-8b9489f30401"
      unitRef="usd">20986000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i87ceb60dc20d4df1b0a97d3514837910_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8xOS9mcmFnOmY3ZTkzYjhjYTJiMDRhYmI4OTA2MDFkZWI3MGNmZTQ4L3RhYmxlOmRhYzI0NDM5OWU0NTRkZjJiYjI0MjUwMjA3OTFhOWY5L3RhYmxlcmFuZ2U6ZGFjMjQ0Mzk5ZTQ1NGRmMmJiMjQyNTAyMDc5MWE5ZjlfOS0zLTEtMS0w_868644a2-9e07-41e1-bd24-f3cbe99b334e"
      unitRef="usd">23719000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i1e833203be6947b4968aba4d20064ec8_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8xOS9mcmFnOmY3ZTkzYjhjYTJiMDRhYmI4OTA2MDFkZWI3MGNmZTQ4L3RhYmxlOmRhYzI0NDM5OWU0NTRkZjJiYjI0MjUwMjA3OTFhOWY5L3RhYmxlcmFuZ2U6ZGFjMjQ0Mzk5ZTQ1NGRmMmJiMjQyNTAyMDc5MWE5ZjlfMTAtMS0xLTEtMA_c21de4ec-6726-41e5-b59d-2bbd5f889634"
      unitRef="usd">95034000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i87ceb60dc20d4df1b0a97d3514837910_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8xOS9mcmFnOmY3ZTkzYjhjYTJiMDRhYmI4OTA2MDFkZWI3MGNmZTQ4L3RhYmxlOmRhYzI0NDM5OWU0NTRkZjJiYjI0MjUwMjA3OTFhOWY5L3RhYmxlcmFuZ2U6ZGFjMjQ0Mzk5ZTQ1NGRmMmJiMjQyNTAyMDc5MWE5ZjlfMTAtMy0xLTEtMA_3b4d5c48-9a23-4ae9-8f88-8d6591787223"
      unitRef="usd">93440000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:Goodwill
      contextRef="i1e833203be6947b4968aba4d20064ec8_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8xOS9mcmFnOmY3ZTkzYjhjYTJiMDRhYmI4OTA2MDFkZWI3MGNmZTQ4L3RhYmxlOmRhYzI0NDM5OWU0NTRkZjJiYjI0MjUwMjA3OTFhOWY5L3RhYmxlcmFuZ2U6ZGFjMjQ0Mzk5ZTQ1NGRmMmJiMjQyNTAyMDc5MWE5ZjlfMTEtMS0xLTEtMA_83abc54c-e97b-4a3e-85c3-cd75814e1bd3"
      unitRef="usd">936772000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i87ceb60dc20d4df1b0a97d3514837910_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8xOS9mcmFnOmY3ZTkzYjhjYTJiMDRhYmI4OTA2MDFkZWI3MGNmZTQ4L3RhYmxlOmRhYzI0NDM5OWU0NTRkZjJiYjI0MjUwMjA3OTFhOWY5L3RhYmxlcmFuZ2U6ZGFjMjQ0Mzk5ZTQ1NGRmMmJiMjQyNTAyMDc5MWE5ZjlfMTEtMy0xLTEtMA_d4331c60-8a79-4713-9e0b-87327b4c0568"
      unitRef="usd">932685000</us-gaap:Goodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i1e833203be6947b4968aba4d20064ec8_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8xOS9mcmFnOmY3ZTkzYjhjYTJiMDRhYmI4OTA2MDFkZWI3MGNmZTQ4L3RhYmxlOmRhYzI0NDM5OWU0NTRkZjJiYjI0MjUwMjA3OTFhOWY5L3RhYmxlcmFuZ2U6ZGFjMjQ0Mzk5ZTQ1NGRmMmJiMjQyNTAyMDc5MWE5ZjlfMTItMC0xLTEtMC90ZXh0cmVnaW9uOjhjNTIwYzUyNDJjNTRiMzBiNzY3MjVmMWVhYjE2MGExXzU4_40119560-aa2f-4eb1-b581-24bc71ac558a"
      unitRef="usd">15842000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i87ceb60dc20d4df1b0a97d3514837910_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8xOS9mcmFnOmY3ZTkzYjhjYTJiMDRhYmI4OTA2MDFkZWI3MGNmZTQ4L3RhYmxlOmRhYzI0NDM5OWU0NTRkZjJiYjI0MjUwMjA3OTFhOWY5L3RhYmxlcmFuZ2U6ZGFjMjQ0Mzk5ZTQ1NGRmMmJiMjQyNTAyMDc5MWE5ZjlfMTItMC0xLTEtMC90ZXh0cmVnaW9uOjhjNTIwYzUyNDJjNTRiMzBiNzY3MjVmMWVhYjE2MGExXzY1_d9abca42-edcf-4f72-9936-bd8f474afd96"
      unitRef="usd">22973000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i1e833203be6947b4968aba4d20064ec8_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8xOS9mcmFnOmY3ZTkzYjhjYTJiMDRhYmI4OTA2MDFkZWI3MGNmZTQ4L3RhYmxlOmRhYzI0NDM5OWU0NTRkZjJiYjI0MjUwMjA3OTFhOWY5L3RhYmxlcmFuZ2U6ZGFjMjQ0Mzk5ZTQ1NGRmMmJiMjQyNTAyMDc5MWE5ZjlfMTItMS0xLTEtMA_81919201-87bb-4363-8609-c69a63fb9d78"
      unitRef="usd">66432000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i87ceb60dc20d4df1b0a97d3514837910_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8xOS9mcmFnOmY3ZTkzYjhjYTJiMDRhYmI4OTA2MDFkZWI3MGNmZTQ4L3RhYmxlOmRhYzI0NDM5OWU0NTRkZjJiYjI0MjUwMjA3OTFhOWY5L3RhYmxlcmFuZ2U6ZGFjMjQ0Mzk5ZTQ1NGRmMmJiMjQyNTAyMDc5MWE5ZjlfMTItMy0xLTEtMA_6c91dc66-e463-4f6f-9453-c67bb445ece3"
      unitRef="usd">74183000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:DeferredIncomeTaxAssetsNet
      contextRef="i1e833203be6947b4968aba4d20064ec8_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8xOS9mcmFnOmY3ZTkzYjhjYTJiMDRhYmI4OTA2MDFkZWI3MGNmZTQ4L3RhYmxlOmRhYzI0NDM5OWU0NTRkZjJiYjI0MjUwMjA3OTFhOWY5L3RhYmxlcmFuZ2U6ZGFjMjQ0Mzk5ZTQ1NGRmMmJiMjQyNTAyMDc5MWE5ZjlfMTMtMS0xLTEtMA_59caf286-ec06-41ee-b7ca-8e2cc75e150b"
      unitRef="usd">25271000</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:DeferredIncomeTaxAssetsNet
      contextRef="i87ceb60dc20d4df1b0a97d3514837910_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8xOS9mcmFnOmY3ZTkzYjhjYTJiMDRhYmI4OTA2MDFkZWI3MGNmZTQ4L3RhYmxlOmRhYzI0NDM5OWU0NTRkZjJiYjI0MjUwMjA3OTFhOWY5L3RhYmxlcmFuZ2U6ZGFjMjQ0Mzk5ZTQ1NGRmMmJiMjQyNTAyMDc5MWE5ZjlfMTMtMy0xLTEtMA_8e586b49-13ff-4bd2-ab22-b76604d33a8c"
      unitRef="usd">47987000</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i1e833203be6947b4968aba4d20064ec8_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8xOS9mcmFnOmY3ZTkzYjhjYTJiMDRhYmI4OTA2MDFkZWI3MGNmZTQ4L3RhYmxlOmRhYzI0NDM5OWU0NTRkZjJiYjI0MjUwMjA3OTFhOWY5L3RhYmxlcmFuZ2U6ZGFjMjQ0Mzk5ZTQ1NGRmMmJiMjQyNTAyMDc5MWE5ZjlfMTQtMS0xLTEtMA_07d5d4e2-9067-4635-baae-7d0c32936de1"
      unitRef="usd">64103000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i87ceb60dc20d4df1b0a97d3514837910_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8xOS9mcmFnOmY3ZTkzYjhjYTJiMDRhYmI4OTA2MDFkZWI3MGNmZTQ4L3RhYmxlOmRhYzI0NDM5OWU0NTRkZjJiYjI0MjUwMjA3OTFhOWY5L3RhYmxlcmFuZ2U6ZGFjMjQ0Mzk5ZTQ1NGRmMmJiMjQyNTAyMDc5MWE5ZjlfMTQtMy0xLTEtMA_676d4762-7578-4d6b-ba67-4b2ff25b5798"
      unitRef="usd">33200000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="i1e833203be6947b4968aba4d20064ec8_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8xOS9mcmFnOmY3ZTkzYjhjYTJiMDRhYmI4OTA2MDFkZWI3MGNmZTQ4L3RhYmxlOmRhYzI0NDM5OWU0NTRkZjJiYjI0MjUwMjA3OTFhOWY5L3RhYmxlcmFuZ2U6ZGFjMjQ0Mzk5ZTQ1NGRmMmJiMjQyNTAyMDc5MWE5ZjlfMTUtMS0xLTEtMA_7b583694-8862-4f3c-a454-9ca8592b9f2e"
      unitRef="usd">1599563000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i87ceb60dc20d4df1b0a97d3514837910_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8xOS9mcmFnOmY3ZTkzYjhjYTJiMDRhYmI4OTA2MDFkZWI3MGNmZTQ4L3RhYmxlOmRhYzI0NDM5OWU0NTRkZjJiYjI0MjUwMjA3OTFhOWY5L3RhYmxlcmFuZ2U6ZGFjMjQ0Mzk5ZTQ1NGRmMmJiMjQyNTAyMDc5MWE5ZjlfMTUtMy0xLTEtMA_a10fc46f-78b2-481a-80ae-c97ce7e5428d"
      unitRef="usd">1567198000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="i1e833203be6947b4968aba4d20064ec8_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8xOS9mcmFnOmY3ZTkzYjhjYTJiMDRhYmI4OTA2MDFkZWI3MGNmZTQ4L3RhYmxlOmRhYzI0NDM5OWU0NTRkZjJiYjI0MjUwMjA3OTFhOWY5L3RhYmxlcmFuZ2U6ZGFjMjQ0Mzk5ZTQ1NGRmMmJiMjQyNTAyMDc5MWE5ZjlfMTgtMS0xLTEtMA_1105c5ef-5fd1-4fc3-a349-c51cfa76caec"
      unitRef="usd">36668000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="i87ceb60dc20d4df1b0a97d3514837910_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8xOS9mcmFnOmY3ZTkzYjhjYTJiMDRhYmI4OTA2MDFkZWI3MGNmZTQ4L3RhYmxlOmRhYzI0NDM5OWU0NTRkZjJiYjI0MjUwMjA3OTFhOWY5L3RhYmxlcmFuZ2U6ZGFjMjQ0Mzk5ZTQ1NGRmMmJiMjQyNTAyMDc5MWE5ZjlfMTgtMy0xLTEtMA_aa8500ba-7931-4bc7-b977-4307d18efacc"
      unitRef="usd">42674000</us-gaap:AccountsPayableCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i1e833203be6947b4968aba4d20064ec8_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8xOS9mcmFnOmY3ZTkzYjhjYTJiMDRhYmI4OTA2MDFkZWI3MGNmZTQ4L3RhYmxlOmRhYzI0NDM5OWU0NTRkZjJiYjI0MjUwMjA3OTFhOWY5L3RhYmxlcmFuZ2U6ZGFjMjQ0Mzk5ZTQ1NGRmMmJiMjQyNTAyMDc5MWE5ZjlfMTktMS0xLTEtMA_2575c62e-7a2a-4542-ba65-a5f16f7c8e54"
      unitRef="usd">147017000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i87ceb60dc20d4df1b0a97d3514837910_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8xOS9mcmFnOmY3ZTkzYjhjYTJiMDRhYmI4OTA2MDFkZWI3MGNmZTQ4L3RhYmxlOmRhYzI0NDM5OWU0NTRkZjJiYjI0MjUwMjA3OTFhOWY5L3RhYmxlcmFuZ2U6ZGFjMjQ0Mzk5ZTQ1NGRmMmJiMjQyNTAyMDc5MWE5ZjlfMTktMy0xLTEtMA_0202f74f-03c1-43cb-80ac-30720da539ea"
      unitRef="usd">146929000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i1e833203be6947b4968aba4d20064ec8_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8xOS9mcmFnOmY3ZTkzYjhjYTJiMDRhYmI4OTA2MDFkZWI3MGNmZTQ4L3RhYmxlOmRhYzI0NDM5OWU0NTRkZjJiYjI0MjUwMjA3OTFhOWY5L3RhYmxlcmFuZ2U6ZGFjMjQ0Mzk5ZTQ1NGRmMmJiMjQyNTAyMDc5MWE5ZjlfMjAtMS0xLTEtMA_58584da9-686c-4fef-963d-b76dca657798"
      unitRef="usd">166157000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i87ceb60dc20d4df1b0a97d3514837910_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8xOS9mcmFnOmY3ZTkzYjhjYTJiMDRhYmI4OTA2MDFkZWI3MGNmZTQ4L3RhYmxlOmRhYzI0NDM5OWU0NTRkZjJiYjI0MjUwMjA3OTFhOWY5L3RhYmxlcmFuZ2U6ZGFjMjQ0Mzk5ZTQ1NGRmMmJiMjQyNTAyMDc5MWE5ZjlfMjAtMy0xLTEtMA_82025911-5707-4d6a-8e19-a35863ec7583"
      unitRef="usd">166192000</us-gaap:AccruedLiabilitiesCurrent>
    <amed:ProviderReliefFundAdvance
      contextRef="i1e833203be6947b4968aba4d20064ec8_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8xOS9mcmFnOmY3ZTkzYjhjYTJiMDRhYmI4OTA2MDFkZWI3MGNmZTQ4L3RhYmxlOmRhYzI0NDM5OWU0NTRkZjJiYjI0MjUwMjA3OTFhOWY5L3RhYmxlcmFuZ2U6ZGFjMjQ0Mzk5ZTQ1NGRmMmJiMjQyNTAyMDc5MWE5ZjlfMjEtMS0xLTEtMA_522c7a4b-271b-4e77-9e2c-34a0d5fbaf4d"
      unitRef="usd">58328000</amed:ProviderReliefFundAdvance>
    <amed:ProviderReliefFundAdvance
      contextRef="i87ceb60dc20d4df1b0a97d3514837910_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8xOS9mcmFnOmY3ZTkzYjhjYTJiMDRhYmI4OTA2MDFkZWI3MGNmZTQ4L3RhYmxlOmRhYzI0NDM5OWU0NTRkZjJiYjI0MjUwMjA3OTFhOWY5L3RhYmxlcmFuZ2U6ZGFjMjQ0Mzk5ZTQ1NGRmMmJiMjQyNTAyMDc5MWE5ZjlfMjEtMy0xLTEtMA_c414b72e-07d7-436a-bd84-9b7c59f7b879"
      unitRef="usd">60000000</amed:ProviderReliefFundAdvance>
    <us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent
      contextRef="i1e833203be6947b4968aba4d20064ec8_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8xOS9mcmFnOmY3ZTkzYjhjYTJiMDRhYmI4OTA2MDFkZWI3MGNmZTQ4L3RhYmxlOmRhYzI0NDM5OWU0NTRkZjJiYjI0MjUwMjA3OTFhOWY5L3RhYmxlcmFuZ2U6ZGFjMjQ0Mzk5ZTQ1NGRmMmJiMjQyNTAyMDc5MWE5ZjlfMjItMS0xLTEtMA_9ce39367-2531-43f9-b432-f1c80ca51c27"
      unitRef="usd">10160000</us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent>
    <us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent
      contextRef="i87ceb60dc20d4df1b0a97d3514837910_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8xOS9mcmFnOmY3ZTkzYjhjYTJiMDRhYmI4OTA2MDFkZWI3MGNmZTQ4L3RhYmxlOmRhYzI0NDM5OWU0NTRkZjJiYjI0MjUwMjA3OTFhOWY5L3RhYmxlcmFuZ2U6ZGFjMjQ0Mzk5ZTQ1NGRmMmJiMjQyNTAyMDc5MWE5ZjlfMjItMy0xLTEtMA_ff11063f-c89f-4aa7-ae30-bcf060b88909"
      unitRef="usd">10496000</us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i1e833203be6947b4968aba4d20064ec8_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8xOS9mcmFnOmY3ZTkzYjhjYTJiMDRhYmI4OTA2MDFkZWI3MGNmZTQ4L3RhYmxlOmRhYzI0NDM5OWU0NTRkZjJiYjI0MjUwMjA3OTFhOWY5L3RhYmxlcmFuZ2U6ZGFjMjQ0Mzk5ZTQ1NGRmMmJiMjQyNTAyMDc5MWE5ZjlfMjMtMS0xLTEtMA_d955a445-2acf-4ad6-a551-0a75729af84c"
      unitRef="usd">30893000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i87ceb60dc20d4df1b0a97d3514837910_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8xOS9mcmFnOmY3ZTkzYjhjYTJiMDRhYmI4OTA2MDFkZWI3MGNmZTQ4L3RhYmxlOmRhYzI0NDM5OWU0NTRkZjJiYjI0MjUwMjA3OTFhOWY5L3RhYmxlcmFuZ2U6ZGFjMjQ0Mzk5ZTQ1NGRmMmJiMjQyNTAyMDc5MWE5ZjlfMjMtMy0xLTEtMA_5138e54b-3a35-474b-9500-d517ab428039"
      unitRef="usd">30046000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i1e833203be6947b4968aba4d20064ec8_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8xOS9mcmFnOmY3ZTkzYjhjYTJiMDRhYmI4OTA2MDFkZWI3MGNmZTQ4L3RhYmxlOmRhYzI0NDM5OWU0NTRkZjJiYjI0MjUwMjA3OTFhOWY5L3RhYmxlcmFuZ2U6ZGFjMjQ0Mzk5ZTQ1NGRmMmJiMjQyNTAyMDc5MWE5ZjlfMjQtMS0xLTEtMA_31900d65-852a-4c1a-aded-104a57f700a5"
      unitRef="usd">449223000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i87ceb60dc20d4df1b0a97d3514837910_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8xOS9mcmFnOmY3ZTkzYjhjYTJiMDRhYmI4OTA2MDFkZWI3MGNmZTQ4L3RhYmxlOmRhYzI0NDM5OWU0NTRkZjJiYjI0MjUwMjA3OTFhOWY5L3RhYmxlcmFuZ2U6ZGFjMjQ0Mzk5ZTQ1NGRmMmJiMjQyNTAyMDc5MWE5ZjlfMjQtMy0xLTEtMA_d0d4322f-7d52-4d68-a693-da60079262cc"
      unitRef="usd">456337000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LongTermDebtAndCapitalLeaseObligations
      contextRef="i1e833203be6947b4968aba4d20064ec8_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8xOS9mcmFnOmY3ZTkzYjhjYTJiMDRhYmI4OTA2MDFkZWI3MGNmZTQ4L3RhYmxlOmRhYzI0NDM5OWU0NTRkZjJiYjI0MjUwMjA3OTFhOWY5L3RhYmxlcmFuZ2U6ZGFjMjQ0Mzk5ZTQ1NGRmMmJiMjQyNTAyMDc5MWE5ZjlfMjUtMS0xLTEtMA_fd8748b1-c54e-414f-a3c1-f81b1b7fba4d"
      unitRef="usd">179415000</us-gaap:LongTermDebtAndCapitalLeaseObligations>
    <us-gaap:LongTermDebtAndCapitalLeaseObligations
      contextRef="i87ceb60dc20d4df1b0a97d3514837910_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8xOS9mcmFnOmY3ZTkzYjhjYTJiMDRhYmI4OTA2MDFkZWI3MGNmZTQ4L3RhYmxlOmRhYzI0NDM5OWU0NTRkZjJiYjI0MjUwMjA3OTFhOWY5L3RhYmxlcmFuZ2U6ZGFjMjQ0Mzk5ZTQ1NGRmMmJiMjQyNTAyMDc5MWE5ZjlfMjUtMy0xLTEtMA_4b7f0144-f92c-4e46-8862-216d0de3ccf8"
      unitRef="usd">204511000</us-gaap:LongTermDebtAndCapitalLeaseObligations>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i1e833203be6947b4968aba4d20064ec8_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8xOS9mcmFnOmY3ZTkzYjhjYTJiMDRhYmI4OTA2MDFkZWI3MGNmZTQ4L3RhYmxlOmRhYzI0NDM5OWU0NTRkZjJiYjI0MjUwMjA3OTFhOWY5L3RhYmxlcmFuZ2U6ZGFjMjQ0Mzk5ZTQ1NGRmMmJiMjQyNTAyMDc5MWE5ZjlfMjYtMS0xLTEtMA_c8183b0c-4e1e-440f-a726-6bc2de870f0b"
      unitRef="usd">63152000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i87ceb60dc20d4df1b0a97d3514837910_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8xOS9mcmFnOmY3ZTkzYjhjYTJiMDRhYmI4OTA2MDFkZWI3MGNmZTQ4L3RhYmxlOmRhYzI0NDM5OWU0NTRkZjJiYjI0MjUwMjA3OTFhOWY5L3RhYmxlcmFuZ2U6ZGFjMjQ0Mzk5ZTQ1NGRmMmJiMjQyNTAyMDc5MWE5ZjlfMjYtMy0xLTEtMA_8bfb45ed-4858-43be-a624-70cd6b9bf6d5"
      unitRef="usd">61987000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i1e833203be6947b4968aba4d20064ec8_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8xOS9mcmFnOmY3ZTkzYjhjYTJiMDRhYmI4OTA2MDFkZWI3MGNmZTQ4L3RhYmxlOmRhYzI0NDM5OWU0NTRkZjJiYjI0MjUwMjA3OTFhOWY5L3RhYmxlcmFuZ2U6ZGFjMjQ0Mzk5ZTQ1NGRmMmJiMjQyNTAyMDc5MWE5ZjlfMjctMS0xLTEtMA_605e7f74-4230-424e-b620-4a818a5d1b72"
      unitRef="usd">31886000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i87ceb60dc20d4df1b0a97d3514837910_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8xOS9mcmFnOmY3ZTkzYjhjYTJiMDRhYmI4OTA2MDFkZWI3MGNmZTQ4L3RhYmxlOmRhYzI0NDM5OWU0NTRkZjJiYjI0MjUwMjA3OTFhOWY5L3RhYmxlcmFuZ2U6ZGFjMjQ0Mzk5ZTQ1NGRmMmJiMjQyNTAyMDc5MWE5ZjlfMjctMy0xLTEtMA_ddb3f62d-b158-40d1-a0b0-465bcdfb9644"
      unitRef="usd">33622000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="i1e833203be6947b4968aba4d20064ec8_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8xOS9mcmFnOmY3ZTkzYjhjYTJiMDRhYmI4OTA2MDFkZWI3MGNmZTQ4L3RhYmxlOmRhYzI0NDM5OWU0NTRkZjJiYjI0MjUwMjA3OTFhOWY5L3RhYmxlcmFuZ2U6ZGFjMjQ0Mzk5ZTQ1NGRmMmJiMjQyNTAyMDc5MWE5ZjlfMjgtMS0xLTEtMA_8db11e2f-16ea-4731-bf33-5bdbd732cf51"
      unitRef="usd">723676000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="i87ceb60dc20d4df1b0a97d3514837910_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8xOS9mcmFnOmY3ZTkzYjhjYTJiMDRhYmI4OTA2MDFkZWI3MGNmZTQ4L3RhYmxlOmRhYzI0NDM5OWU0NTRkZjJiYjI0MjUwMjA3OTFhOWY5L3RhYmxlcmFuZ2U6ZGFjMjQ0Mzk5ZTQ1NGRmMmJiMjQyNTAyMDc5MWE5ZjlfMjgtMy0xLTEtMA_6ee89b5b-3384-4717-8324-8ff9b8b65836"
      unitRef="usd">756457000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i1e833203be6947b4968aba4d20064ec8_I20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8xOS9mcmFnOmY3ZTkzYjhjYTJiMDRhYmI4OTA2MDFkZWI3MGNmZTQ4L3RhYmxlOmRhYzI0NDM5OWU0NTRkZjJiYjI0MjUwMjA3OTFhOWY5L3RhYmxlcmFuZ2U6ZGFjMjQ0Mzk5ZTQ1NGRmMmJiMjQyNTAyMDc5MWE5ZjlfMjktMS0xLTEtMA_a3ae8433-97f8-4399-84c1-d1f22146deb6"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i87ceb60dc20d4df1b0a97d3514837910_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8xOS9mcmFnOmY3ZTkzYjhjYTJiMDRhYmI4OTA2MDFkZWI3MGNmZTQ4L3RhYmxlOmRhYzI0NDM5OWU0NTRkZjJiYjI0MjUwMjA3OTFhOWY5L3RhYmxlcmFuZ2U6ZGFjMjQ0Mzk5ZTQ1NGRmMmJiMjQyNTAyMDc5MWE5ZjlfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOjdmNDI3OWQ5ODJhNDQxYzY5YzAyZjQ2NGYwMWE2ZDczXzIx_397a20d1-dfe9-4f49-bbc0-757090d05653"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i1e833203be6947b4968aba4d20064ec8_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8xOS9mcmFnOmY3ZTkzYjhjYTJiMDRhYmI4OTA2MDFkZWI3MGNmZTQ4L3RhYmxlOmRhYzI0NDM5OWU0NTRkZjJiYjI0MjUwMjA3OTFhOWY5L3RhYmxlcmFuZ2U6ZGFjMjQ0Mzk5ZTQ1NGRmMmJiMjQyNTAyMDc5MWE5ZjlfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOjdmNDI3OWQ5ODJhNDQxYzY5YzAyZjQ2NGYwMWE2ZDczXzIx_a26207d9-9ef2-4c56-bc4d-0b97461eae1b"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i1e833203be6947b4968aba4d20064ec8_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8xOS9mcmFnOmY3ZTkzYjhjYTJiMDRhYmI4OTA2MDFkZWI3MGNmZTQ4L3RhYmxlOmRhYzI0NDM5OWU0NTRkZjJiYjI0MjUwMjA3OTFhOWY5L3RhYmxlcmFuZ2U6ZGFjMjQ0Mzk5ZTQ1NGRmMmJiMjQyNTAyMDc5MWE5ZjlfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOjdmNDI3OWQ5ODJhNDQxYzY5YzAyZjQ2NGYwMWE2ZDczXzM1_84d985bc-9125-46aa-8b39-ded284ba340e"
      unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i87ceb60dc20d4df1b0a97d3514837910_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8xOS9mcmFnOmY3ZTkzYjhjYTJiMDRhYmI4OTA2MDFkZWI3MGNmZTQ4L3RhYmxlOmRhYzI0NDM5OWU0NTRkZjJiYjI0MjUwMjA3OTFhOWY5L3RhYmxlcmFuZ2U6ZGFjMjQ0Mzk5ZTQ1NGRmMmJiMjQyNTAyMDc5MWE5ZjlfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOjdmNDI3OWQ5ODJhNDQxYzY5YzAyZjQ2NGYwMWE2ZDczXzM1_bb6aec31-60f7-45a6-8f42-fcfdf54fa2b6"
      unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i1e833203be6947b4968aba4d20064ec8_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8xOS9mcmFnOmY3ZTkzYjhjYTJiMDRhYmI4OTA2MDFkZWI3MGNmZTQ4L3RhYmxlOmRhYzI0NDM5OWU0NTRkZjJiYjI0MjUwMjA3OTFhOWY5L3RhYmxlcmFuZ2U6ZGFjMjQ0Mzk5ZTQ1NGRmMmJiMjQyNTAyMDc5MWE5ZjlfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOjdmNDI3OWQ5ODJhNDQxYzY5YzAyZjQ2NGYwMWE2ZDczXzU3_14352eb5-4e04-4d6e-9b9c-633ec0e8894e"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i87ceb60dc20d4df1b0a97d3514837910_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8xOS9mcmFnOmY3ZTkzYjhjYTJiMDRhYmI4OTA2MDFkZWI3MGNmZTQ4L3RhYmxlOmRhYzI0NDM5OWU0NTRkZjJiYjI0MjUwMjA3OTFhOWY5L3RhYmxlcmFuZ2U6ZGFjMjQ0Mzk5ZTQ1NGRmMmJiMjQyNTAyMDc5MWE5ZjlfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOjdmNDI3OWQ5ODJhNDQxYzY5YzAyZjQ2NGYwMWE2ZDczXzU3_24e2a6cf-a750-4629-9d4b-c427c655976b"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i1e833203be6947b4968aba4d20064ec8_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8xOS9mcmFnOmY3ZTkzYjhjYTJiMDRhYmI4OTA2MDFkZWI3MGNmZTQ4L3RhYmxlOmRhYzI0NDM5OWU0NTRkZjJiYjI0MjUwMjA3OTFhOWY5L3RhYmxlcmFuZ2U6ZGFjMjQ0Mzk5ZTQ1NGRmMmJiMjQyNTAyMDc5MWE5ZjlfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOjdmNDI3OWQ5ODJhNDQxYzY5YzAyZjQ2NGYwMWE2ZDczXzU3_2a1f8c2e-43f2-43c8-b679-8d8c0acf6b01"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i87ceb60dc20d4df1b0a97d3514837910_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8xOS9mcmFnOmY3ZTkzYjhjYTJiMDRhYmI4OTA2MDFkZWI3MGNmZTQ4L3RhYmxlOmRhYzI0NDM5OWU0NTRkZjJiYjI0MjUwMjA3OTFhOWY5L3RhYmxlcmFuZ2U6ZGFjMjQ0Mzk5ZTQ1NGRmMmJiMjQyNTAyMDc5MWE5ZjlfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOjdmNDI3OWQ5ODJhNDQxYzY5YzAyZjQ2NGYwMWE2ZDczXzU3_ef70fdc8-ef76-4893-9150-7eca0d4a6670"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockValueOutstanding
      contextRef="i1e833203be6947b4968aba4d20064ec8_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8xOS9mcmFnOmY3ZTkzYjhjYTJiMDRhYmI4OTA2MDFkZWI3MGNmZTQ4L3RhYmxlOmRhYzI0NDM5OWU0NTRkZjJiYjI0MjUwMjA3OTFhOWY5L3RhYmxlcmFuZ2U6ZGFjMjQ0Mzk5ZTQ1NGRmMmJiMjQyNTAyMDc5MWE5ZjlfMzEtMS0xLTEtMA_9dbfd81f-c86d-425d-8173-9c6d6118ac00"
      unitRef="usd">0</us-gaap:PreferredStockValueOutstanding>
    <us-gaap:PreferredStockValueOutstanding
      contextRef="i87ceb60dc20d4df1b0a97d3514837910_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8xOS9mcmFnOmY3ZTkzYjhjYTJiMDRhYmI4OTA2MDFkZWI3MGNmZTQ4L3RhYmxlOmRhYzI0NDM5OWU0NTRkZjJiYjI0MjUwMjA3OTFhOWY5L3RhYmxlcmFuZ2U6ZGFjMjQ0Mzk5ZTQ1NGRmMmJiMjQyNTAyMDc5MWE5ZjlfMzEtMy0xLTEtMA_a029e709-9036-41f1-b00a-5715669d48e1"
      unitRef="usd">0</us-gaap:PreferredStockValueOutstanding>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i87ceb60dc20d4df1b0a97d3514837910_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8xOS9mcmFnOmY3ZTkzYjhjYTJiMDRhYmI4OTA2MDFkZWI3MGNmZTQ4L3RhYmxlOmRhYzI0NDM5OWU0NTRkZjJiYjI0MjUwMjA3OTFhOWY5L3RhYmxlcmFuZ2U6ZGFjMjQ0Mzk5ZTQ1NGRmMmJiMjQyNTAyMDc5MWE5ZjlfMzItMC0xLTEtMC90ZXh0cmVnaW9uOjIyOTYxOGQzYzU4YzRkZTVhZjc1N2EzZThhMDI4YTVmXzE4_10cc7bd5-26ac-4c9d-982f-180104cafa10"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i1e833203be6947b4968aba4d20064ec8_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8xOS9mcmFnOmY3ZTkzYjhjYTJiMDRhYmI4OTA2MDFkZWI3MGNmZTQ4L3RhYmxlOmRhYzI0NDM5OWU0NTRkZjJiYjI0MjUwMjA3OTFhOWY5L3RhYmxlcmFuZ2U6ZGFjMjQ0Mzk5ZTQ1NGRmMmJiMjQyNTAyMDc5MWE5ZjlfMzItMC0xLTEtMC90ZXh0cmVnaW9uOjIyOTYxOGQzYzU4YzRkZTVhZjc1N2EzZThhMDI4YTVmXzE4_6a381d03-fcee-46fd-bb78-57f67d41625a"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i1e833203be6947b4968aba4d20064ec8_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8xOS9mcmFnOmY3ZTkzYjhjYTJiMDRhYmI4OTA2MDFkZWI3MGNmZTQ4L3RhYmxlOmRhYzI0NDM5OWU0NTRkZjJiYjI0MjUwMjA3OTFhOWY5L3RhYmxlcmFuZ2U6ZGFjMjQ0Mzk5ZTQ1NGRmMmJiMjQyNTAyMDc5MWE5ZjlfMzItMC0xLTEtMC90ZXh0cmVnaW9uOjIyOTYxOGQzYzU4YzRkZTVhZjc1N2EzZThhMDI4YTVmXzMy_0392f4e2-feb7-4ded-81e7-923430ea3a3c"
      unitRef="shares">60000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i87ceb60dc20d4df1b0a97d3514837910_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8xOS9mcmFnOmY3ZTkzYjhjYTJiMDRhYmI4OTA2MDFkZWI3MGNmZTQ4L3RhYmxlOmRhYzI0NDM5OWU0NTRkZjJiYjI0MjUwMjA3OTFhOWY5L3RhYmxlcmFuZ2U6ZGFjMjQ0Mzk5ZTQ1NGRmMmJiMjQyNTAyMDc5MWE5ZjlfMzItMC0xLTEtMC90ZXh0cmVnaW9uOjIyOTYxOGQzYzU4YzRkZTVhZjc1N2EzZThhMDI4YTVmXzMy_17823c2e-8c2a-40b0-a997-4d92ae24153f"
      unitRef="shares">60000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="i1e833203be6947b4968aba4d20064ec8_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8xOS9mcmFnOmY3ZTkzYjhjYTJiMDRhYmI4OTA2MDFkZWI3MGNmZTQ4L3RhYmxlOmRhYzI0NDM5OWU0NTRkZjJiYjI0MjUwMjA3OTFhOWY5L3RhYmxlcmFuZ2U6ZGFjMjQ0Mzk5ZTQ1NGRmMmJiMjQyNTAyMDc5MWE5ZjlfMzItMC0xLTEtMC90ZXh0cmVnaW9uOjIyOTYxOGQzYzU4YzRkZTVhZjc1N2EzZThhMDI4YTVmXzU0_0c8b8962-b18e-4601-a0f4-1edd7900f3a8"
      unitRef="shares">37553355</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="i87ceb60dc20d4df1b0a97d3514837910_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8xOS9mcmFnOmY3ZTkzYjhjYTJiMDRhYmI4OTA2MDFkZWI3MGNmZTQ4L3RhYmxlOmRhYzI0NDM5OWU0NTRkZjJiYjI0MjUwMjA3OTFhOWY5L3RhYmxlcmFuZ2U6ZGFjMjQ0Mzk5ZTQ1NGRmMmJiMjQyNTAyMDc5MWE5ZjlfMzItMC0xLTEtMC90ZXh0cmVnaW9uOjIyOTYxOGQzYzU4YzRkZTVhZjc1N2EzZThhMDI4YTVmXzYx_41818329-fb61-4057-975d-fe45da69d381"
      unitRef="shares">37470212</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i1e833203be6947b4968aba4d20064ec8_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8xOS9mcmFnOmY3ZTkzYjhjYTJiMDRhYmI4OTA2MDFkZWI3MGNmZTQ4L3RhYmxlOmRhYzI0NDM5OWU0NTRkZjJiYjI0MjUwMjA3OTFhOWY5L3RhYmxlcmFuZ2U6ZGFjMjQ0Mzk5ZTQ1NGRmMmJiMjQyNTAyMDc5MWE5ZjlfMzItMC0xLTEtMC90ZXh0cmVnaW9uOjIyOTYxOGQzYzU4YzRkZTVhZjc1N2EzZThhMDI4YTVmXzgz_9928a97e-8118-4cd8-9377-1dcb74d0e6ad"
      unitRef="shares">32576829</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i87ceb60dc20d4df1b0a97d3514837910_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8xOS9mcmFnOmY3ZTkzYjhjYTJiMDRhYmI4OTA2MDFkZWI3MGNmZTQ4L3RhYmxlOmRhYzI0NDM5OWU0NTRkZjJiYjI0MjUwMjA3OTFhOWY5L3RhYmxlcmFuZ2U6ZGFjMjQ0Mzk5ZTQ1NGRmMmJiMjQyNTAyMDc5MWE5ZjlfMzItMC0xLTEtMC90ZXh0cmVnaW9uOjIyOTYxOGQzYzU4YzRkZTVhZjc1N2EzZThhMDI4YTVmXzkw_332c6b1e-976b-4de2-828c-b3af7ce898fb"
      unitRef="shares">32814278</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValueOutstanding
      contextRef="i1e833203be6947b4968aba4d20064ec8_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8xOS9mcmFnOmY3ZTkzYjhjYTJiMDRhYmI4OTA2MDFkZWI3MGNmZTQ4L3RhYmxlOmRhYzI0NDM5OWU0NTRkZjJiYjI0MjUwMjA3OTFhOWY5L3RhYmxlcmFuZ2U6ZGFjMjQ0Mzk5ZTQ1NGRmMmJiMjQyNTAyMDc5MWE5ZjlfMzItMS0xLTEtMA_32923153-9b47-4ddf-b46c-f3d7225b283c"
      unitRef="usd">38000</us-gaap:CommonStockValueOutstanding>
    <us-gaap:CommonStockValueOutstanding
      contextRef="i87ceb60dc20d4df1b0a97d3514837910_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8xOS9mcmFnOmY3ZTkzYjhjYTJiMDRhYmI4OTA2MDFkZWI3MGNmZTQ4L3RhYmxlOmRhYzI0NDM5OWU0NTRkZjJiYjI0MjUwMjA3OTFhOWY5L3RhYmxlcmFuZ2U6ZGFjMjQ0Mzk5ZTQ1NGRmMmJiMjQyNTAyMDc5MWE5ZjlfMzItMy0xLTEtMA_0460a3a6-7691-4e50-83c2-c0c4c5361148"
      unitRef="usd">38000</us-gaap:CommonStockValueOutstanding>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="i1e833203be6947b4968aba4d20064ec8_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8xOS9mcmFnOmY3ZTkzYjhjYTJiMDRhYmI4OTA2MDFkZWI3MGNmZTQ4L3RhYmxlOmRhYzI0NDM5OWU0NTRkZjJiYjI0MjUwMjA3OTFhOWY5L3RhYmxlcmFuZ2U6ZGFjMjQ0Mzk5ZTQ1NGRmMmJiMjQyNTAyMDc5MWE5ZjlfMzMtMS0xLTEtMA_044a3480-bbd3-40c3-87a7-3646eac0b824"
      unitRef="usd">714334000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="i87ceb60dc20d4df1b0a97d3514837910_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8xOS9mcmFnOmY3ZTkzYjhjYTJiMDRhYmI4OTA2MDFkZWI3MGNmZTQ4L3RhYmxlOmRhYzI0NDM5OWU0NTRkZjJiYjI0MjUwMjA3OTFhOWY5L3RhYmxlcmFuZ2U6ZGFjMjQ0Mzk5ZTQ1NGRmMmJiMjQyNTAyMDc5MWE5ZjlfMzMtMy0xLTEtMA_239e9860-95e7-40b7-86b2-d08d446368c1"
      unitRef="usd">698287000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:TreasuryStockShares
      contextRef="i1e833203be6947b4968aba4d20064ec8_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8xOS9mcmFnOmY3ZTkzYjhjYTJiMDRhYmI4OTA2MDFkZWI3MGNmZTQ4L3RhYmxlOmRhYzI0NDM5OWU0NTRkZjJiYjI0MjUwMjA3OTFhOWY5L3RhYmxlcmFuZ2U6ZGFjMjQ0Mzk5ZTQ1NGRmMmJiMjQyNTAyMDc5MWE5ZjlfMzQtMC0xLTEtMC90ZXh0cmVnaW9uOjU1MjQ0ZjE1Y2E1NTQ3OGFiNjg1NTEyODk5NGFiMWM4XzI4_308d5e6a-da6a-4970-9032-ed6b9a0396b0"
      unitRef="shares">4976526</us-gaap:TreasuryStockShares>
    <us-gaap:TreasuryStockShares
      contextRef="i87ceb60dc20d4df1b0a97d3514837910_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8xOS9mcmFnOmY3ZTkzYjhjYTJiMDRhYmI4OTA2MDFkZWI3MGNmZTQ4L3RhYmxlOmRhYzI0NDM5OWU0NTRkZjJiYjI0MjUwMjA3OTFhOWY5L3RhYmxlcmFuZ2U6ZGFjMjQ0Mzk5ZTQ1NGRmMmJiMjQyNTAyMDc5MWE5ZjlfMzQtMC0xLTEtMC90ZXh0cmVnaW9uOjU1MjQ0ZjE1Y2E1NTQ3OGFiNjg1NTEyODk5NGFiMWM4XzM1_64cbab90-dba0-4722-8ff9-094b81ceada2"
      unitRef="shares">4655934</us-gaap:TreasuryStockShares>
    <us-gaap:TreasuryStockValue
      contextRef="i1e833203be6947b4968aba4d20064ec8_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8xOS9mcmFnOmY3ZTkzYjhjYTJiMDRhYmI4OTA2MDFkZWI3MGNmZTQ4L3RhYmxlOmRhYzI0NDM5OWU0NTRkZjJiYjI0MjUwMjA3OTFhOWY5L3RhYmxlcmFuZ2U6ZGFjMjQ0Mzk5ZTQ1NGRmMmJiMjQyNTAyMDc5MWE5ZjlfMzQtMS0xLTEtMA_0c14dad2-704b-44cd-aec0-802be88d637d"
      unitRef="usd">400110000</us-gaap:TreasuryStockValue>
    <us-gaap:TreasuryStockValue
      contextRef="i87ceb60dc20d4df1b0a97d3514837910_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8xOS9mcmFnOmY3ZTkzYjhjYTJiMDRhYmI4OTA2MDFkZWI3MGNmZTQ4L3RhYmxlOmRhYzI0NDM5OWU0NTRkZjJiYjI0MjUwMjA3OTFhOWY5L3RhYmxlcmFuZ2U6ZGFjMjQ0Mzk5ZTQ1NGRmMmJiMjQyNTAyMDc5MWE5ZjlfMzQtMy0xLTEtMA_c0ac4212-7a15-4b12-b2e0-fcec989e20bc"
      unitRef="usd">319092000</us-gaap:TreasuryStockValue>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i1e833203be6947b4968aba4d20064ec8_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8xOS9mcmFnOmY3ZTkzYjhjYTJiMDRhYmI4OTA2MDFkZWI3MGNmZTQ4L3RhYmxlOmRhYzI0NDM5OWU0NTRkZjJiYjI0MjUwMjA3OTFhOWY5L3RhYmxlcmFuZ2U6ZGFjMjQ0Mzk5ZTQ1NGRmMmJiMjQyNTAyMDc5MWE5ZjlfMzYtMS0xLTEtMA_eeebfd27-f07a-442d-a939-5504b01c3d74"
      unitRef="usd">560010000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i87ceb60dc20d4df1b0a97d3514837910_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8xOS9mcmFnOmY3ZTkzYjhjYTJiMDRhYmI4OTA2MDFkZWI3MGNmZTQ4L3RhYmxlOmRhYzI0NDM5OWU0NTRkZjJiYjI0MjUwMjA3OTFhOWY5L3RhYmxlcmFuZ2U6ZGFjMjQ0Mzk5ZTQ1NGRmMmJiMjQyNTAyMDc5MWE5ZjlfMzYtMy0xLTEtMA_ef70a8ae-c75a-450b-8b73-0e5db2efdb5f"
      unitRef="usd">429991000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="i1e833203be6947b4968aba4d20064ec8_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8xOS9mcmFnOmY3ZTkzYjhjYTJiMDRhYmI4OTA2MDFkZWI3MGNmZTQ4L3RhYmxlOmRhYzI0NDM5OWU0NTRkZjJiYjI0MjUwMjA3OTFhOWY5L3RhYmxlcmFuZ2U6ZGFjMjQ0Mzk5ZTQ1NGRmMmJiMjQyNTAyMDc5MWE5ZjlfMzctMS0xLTEtMA_264757fc-4cc5-4c12-a4d1-485c2beea640"
      unitRef="usd">874272000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i87ceb60dc20d4df1b0a97d3514837910_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8xOS9mcmFnOmY3ZTkzYjhjYTJiMDRhYmI4OTA2MDFkZWI3MGNmZTQ4L3RhYmxlOmRhYzI0NDM5OWU0NTRkZjJiYjI0MjUwMjA3OTFhOWY5L3RhYmxlcmFuZ2U6ZGFjMjQ0Mzk5ZTQ1NGRmMmJiMjQyNTAyMDc5MWE5ZjlfMzctMy0xLTEtMA_0676a3ec-4521-4e78-b89f-70f844d4845c"
      unitRef="usd">809224000</us-gaap:StockholdersEquity>
    <us-gaap:MinorityInterest
      contextRef="i1e833203be6947b4968aba4d20064ec8_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8xOS9mcmFnOmY3ZTkzYjhjYTJiMDRhYmI4OTA2MDFkZWI3MGNmZTQ4L3RhYmxlOmRhYzI0NDM5OWU0NTRkZjJiYjI0MjUwMjA3OTFhOWY5L3RhYmxlcmFuZ2U6ZGFjMjQ0Mzk5ZTQ1NGRmMmJiMjQyNTAyMDc5MWE5ZjlfMzgtMS0xLTEtMA_743031b4-e77f-4655-938f-dc0bd32d59e9"
      unitRef="usd">1615000</us-gaap:MinorityInterest>
    <us-gaap:MinorityInterest
      contextRef="i87ceb60dc20d4df1b0a97d3514837910_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8xOS9mcmFnOmY3ZTkzYjhjYTJiMDRhYmI4OTA2MDFkZWI3MGNmZTQ4L3RhYmxlOmRhYzI0NDM5OWU0NTRkZjJiYjI0MjUwMjA3OTFhOWY5L3RhYmxlcmFuZ2U6ZGFjMjQ0Mzk5ZTQ1NGRmMmJiMjQyNTAyMDc5MWE5ZjlfMzgtMy0xLTEtMA_eb1a5aba-129e-42e7-8b20-676eef7ffb9c"
      unitRef="usd">1517000</us-gaap:MinorityInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i1e833203be6947b4968aba4d20064ec8_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8xOS9mcmFnOmY3ZTkzYjhjYTJiMDRhYmI4OTA2MDFkZWI3MGNmZTQ4L3RhYmxlOmRhYzI0NDM5OWU0NTRkZjJiYjI0MjUwMjA3OTFhOWY5L3RhYmxlcmFuZ2U6ZGFjMjQ0Mzk5ZTQ1NGRmMmJiMjQyNTAyMDc5MWE5ZjlfMzktMS0xLTEtMA_1e6b9e7a-fe9c-440d-9c22-53edf9d80e1f"
      unitRef="usd">875887000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i87ceb60dc20d4df1b0a97d3514837910_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8xOS9mcmFnOmY3ZTkzYjhjYTJiMDRhYmI4OTA2MDFkZWI3MGNmZTQ4L3RhYmxlOmRhYzI0NDM5OWU0NTRkZjJiYjI0MjUwMjA3OTFhOWY5L3RhYmxlcmFuZ2U6ZGFjMjQ0Mzk5ZTQ1NGRmMmJiMjQyNTAyMDc5MWE5ZjlfMzktMy0xLTEtMA_abeacf05-b668-4925-8e7f-153a2e696118"
      unitRef="usd">810741000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i1e833203be6947b4968aba4d20064ec8_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8xOS9mcmFnOmY3ZTkzYjhjYTJiMDRhYmI4OTA2MDFkZWI3MGNmZTQ4L3RhYmxlOmRhYzI0NDM5OWU0NTRkZjJiYjI0MjUwMjA3OTFhOWY5L3RhYmxlcmFuZ2U6ZGFjMjQ0Mzk5ZTQ1NGRmMmJiMjQyNTAyMDc5MWE5ZjlfNDAtMS0xLTEtMA_27795952-a71e-40b0-a8d7-c343652eeef7"
      unitRef="usd">1599563000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i87ceb60dc20d4df1b0a97d3514837910_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8xOS9mcmFnOmY3ZTkzYjhjYTJiMDRhYmI4OTA2MDFkZWI3MGNmZTQ4L3RhYmxlOmRhYzI0NDM5OWU0NTRkZjJiYjI0MjUwMjA3OTFhOWY5L3RhYmxlcmFuZ2U6ZGFjMjQ0Mzk5ZTQ1NGRmMmJiMjQyNTAyMDc5MWE5ZjlfNDAtMy0xLTEtMA_761d18ad-ddee-4db6-a018-9f9c3d7262e6"
      unitRef="usd">1567198000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions
      contextRef="ib87cee58ccf2448a8d4422101bf61fa0_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yNS9mcmFnOjEyZmVlZDI1M2Y4NjQ2MDk5OTcwNzk2Y2IxODEwNWJiL3RhYmxlOmVjYTIzOWJiNDgzMjQxMDViZDBiYTkwYWE0YjJkMjFlL3RhYmxlcmFuZ2U6ZWNhMjM5YmI0ODMyNDEwNWJkMGJhOTBhYTRiMmQyMWVfMi0xLTEtMS0w_6935b4da-8cea-4160-b52e-892ec31bf483"
      unitRef="usd">564166000</us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions>
    <us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions
      contextRef="i2c8351954d014a1c80a3d8cfc2327ab2_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yNS9mcmFnOjEyZmVlZDI1M2Y4NjQ2MDk5OTcwNzk2Y2IxODEwNWJiL3RhYmxlOmVjYTIzOWJiNDgzMjQxMDViZDBiYTkwYWE0YjJkMjFlL3RhYmxlcmFuZ2U6ZWNhMjM5YmI0ODMyNDEwNWJkMGJhOTBhYTRiMmQyMWVfMi0zLTEtMS0w_2468a13c-c874-4f35-b90a-f49d46658273"
      unitRef="usd">485059000</us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions>
    <us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions
      contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yNS9mcmFnOjEyZmVlZDI1M2Y4NjQ2MDk5OTcwNzk2Y2IxODEwNWJiL3RhYmxlOmVjYTIzOWJiNDgzMjQxMDViZDBiYTkwYWE0YjJkMjFlL3RhYmxlcmFuZ2U6ZWNhMjM5YmI0ODMyNDEwNWJkMGJhOTBhYTRiMmQyMWVfMi01LTEtMS02NQ_ccce66b1-423d-47ac-8ee0-fe20ad615b7a"
      unitRef="usd">1101310000</us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions>
    <us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions
      contextRef="i667fa0996400408f9cb2d7f4d3ee2087_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yNS9mcmFnOjEyZmVlZDI1M2Y4NjQ2MDk5OTcwNzk2Y2IxODEwNWJiL3RhYmxlOmVjYTIzOWJiNDgzMjQxMDViZDBiYTkwYWE0YjJkMjFlL3RhYmxlcmFuZ2U6ZWNhMjM5YmI0ODMyNDEwNWJkMGJhOTBhYTRiMmQyMWVfMi03LTEtMS02NQ_a63f62f0-6371-4cfc-a8d3-f1e6b288d1db"
      unitRef="usd">976744000</us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions>
    <us-gaap:OtherOperatingIncome
      contextRef="ib87cee58ccf2448a8d4422101bf61fa0_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yNS9mcmFnOjEyZmVlZDI1M2Y4NjQ2MDk5OTcwNzk2Y2IxODEwNWJiL3RhYmxlOmVjYTIzOWJiNDgzMjQxMDViZDBiYTkwYWE0YjJkMjFlL3RhYmxlcmFuZ2U6ZWNhMjM5YmI0ODMyNDEwNWJkMGJhOTBhYTRiMmQyMWVfMy0xLTEtMS0w_899628bc-a38e-4257-b568-30cbfaf38479"
      unitRef="usd">4603000</us-gaap:OtherOperatingIncome>
    <us-gaap:OtherOperatingIncome
      contextRef="i2c8351954d014a1c80a3d8cfc2327ab2_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yNS9mcmFnOjEyZmVlZDI1M2Y4NjQ2MDk5OTcwNzk2Y2IxODEwNWJiL3RhYmxlOmVjYTIzOWJiNDgzMjQxMDViZDBiYTkwYWE0YjJkMjFlL3RhYmxlcmFuZ2U6ZWNhMjM5YmI0ODMyNDEwNWJkMGJhOTBhYTRiMmQyMWVfMy0zLTEtMS0w_918dad3f-2303-4be0-b536-ab176b546149"
      unitRef="usd">22780000</us-gaap:OtherOperatingIncome>
    <us-gaap:OtherOperatingIncome
      contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yNS9mcmFnOjEyZmVlZDI1M2Y4NjQ2MDk5OTcwNzk2Y2IxODEwNWJiL3RhYmxlOmVjYTIzOWJiNDgzMjQxMDViZDBiYTkwYWE0YjJkMjFlL3RhYmxlcmFuZ2U6ZWNhMjM5YmI0ODMyNDEwNWJkMGJhOTBhYTRiMmQyMWVfMy01LTEtMS02NQ_b7a6f14f-d0f7-4d8f-a0cf-52afa1409456"
      unitRef="usd">13304000</us-gaap:OtherOperatingIncome>
    <us-gaap:OtherOperatingIncome
      contextRef="i667fa0996400408f9cb2d7f4d3ee2087_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yNS9mcmFnOjEyZmVlZDI1M2Y4NjQ2MDk5OTcwNzk2Y2IxODEwNWJiL3RhYmxlOmVjYTIzOWJiNDgzMjQxMDViZDBiYTkwYWE0YjJkMjFlL3RhYmxlcmFuZ2U6ZWNhMjM5YmI0ODMyNDEwNWJkMGJhOTBhYTRiMmQyMWVfMy03LTEtMS02NQ_b74c78bb-5bea-4910-b1b8-b685c227aea6"
      unitRef="usd">22780000</us-gaap:OtherOperatingIncome>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="ib87cee58ccf2448a8d4422101bf61fa0_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yNS9mcmFnOjEyZmVlZDI1M2Y4NjQ2MDk5OTcwNzk2Y2IxODEwNWJiL3RhYmxlOmVjYTIzOWJiNDgzMjQxMDViZDBiYTkwYWE0YjJkMjFlL3RhYmxlcmFuZ2U6ZWNhMjM5YmI0ODMyNDEwNWJkMGJhOTBhYTRiMmQyMWVfNC0xLTEtMS0w_7ff42579-e33c-4711-b1a7-dc7647beee47"
      unitRef="usd">308691000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i2c8351954d014a1c80a3d8cfc2327ab2_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yNS9mcmFnOjEyZmVlZDI1M2Y4NjQ2MDk5OTcwNzk2Y2IxODEwNWJiL3RhYmxlOmVjYTIzOWJiNDgzMjQxMDViZDBiYTkwYWE0YjJkMjFlL3RhYmxlcmFuZ2U6ZWNhMjM5YmI0ODMyNDEwNWJkMGJhOTBhYTRiMmQyMWVfNC0zLTEtMS0w_9998965b-865f-407d-a360-eb14e8c313c6"
      unitRef="usd">295228000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yNS9mcmFnOjEyZmVlZDI1M2Y4NjQ2MDk5OTcwNzk2Y2IxODEwNWJiL3RhYmxlOmVjYTIzOWJiNDgzMjQxMDViZDBiYTkwYWE0YjJkMjFlL3RhYmxlcmFuZ2U6ZWNhMjM5YmI0ODMyNDEwNWJkMGJhOTBhYTRiMmQyMWVfNC01LTEtMS02NQ_ff45a2f7-ac3d-4cf9-be3f-6cffa57398c5"
      unitRef="usd">605894000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i667fa0996400408f9cb2d7f4d3ee2087_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yNS9mcmFnOjEyZmVlZDI1M2Y4NjQ2MDk5OTcwNzk2Y2IxODEwNWJiL3RhYmxlOmVjYTIzOWJiNDgzMjQxMDViZDBiYTkwYWE0YjJkMjFlL3RhYmxlcmFuZ2U6ZWNhMjM5YmI0ODMyNDEwNWJkMGJhOTBhYTRiMmQyMWVfNC03LTEtMS02NQ_080d054a-bd58-40ee-a2be-587d54c4285a"
      unitRef="usd">580965000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:LaborAndRelatedExpense
      contextRef="ib87cee58ccf2448a8d4422101bf61fa0_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yNS9mcmFnOjEyZmVlZDI1M2Y4NjQ2MDk5OTcwNzk2Y2IxODEwNWJiL3RhYmxlOmVjYTIzOWJiNDgzMjQxMDViZDBiYTkwYWE0YjJkMjFlL3RhYmxlcmFuZ2U6ZWNhMjM5YmI0ODMyNDEwNWJkMGJhOTBhYTRiMmQyMWVfNi0xLTEtMS0w_13ae2050-f256-402b-8564-103a796512e3"
      unitRef="usd">114335000</us-gaap:LaborAndRelatedExpense>
    <us-gaap:LaborAndRelatedExpense
      contextRef="i2c8351954d014a1c80a3d8cfc2327ab2_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yNS9mcmFnOjEyZmVlZDI1M2Y4NjQ2MDk5OTcwNzk2Y2IxODEwNWJiL3RhYmxlOmVjYTIzOWJiNDgzMjQxMDViZDBiYTkwYWE0YjJkMjFlL3RhYmxlcmFuZ2U6ZWNhMjM5YmI0ODMyNDEwNWJkMGJhOTBhYTRiMmQyMWVfNi0zLTEtMS0w_b6c76ba6-3297-4e73-a8ce-4c7d344384ad"
      unitRef="usd">105617000</us-gaap:LaborAndRelatedExpense>
    <us-gaap:LaborAndRelatedExpense
      contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yNS9mcmFnOjEyZmVlZDI1M2Y4NjQ2MDk5OTcwNzk2Y2IxODEwNWJiL3RhYmxlOmVjYTIzOWJiNDgzMjQxMDViZDBiYTkwYWE0YjJkMjFlL3RhYmxlcmFuZ2U6ZWNhMjM5YmI0ODMyNDEwNWJkMGJhOTBhYTRiMmQyMWVfNi01LTEtMS02NQ_13e47f85-cdef-468c-9225-0c3b9bae4e22"
      unitRef="usd">230160000</us-gaap:LaborAndRelatedExpense>
    <us-gaap:LaborAndRelatedExpense
      contextRef="i667fa0996400408f9cb2d7f4d3ee2087_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yNS9mcmFnOjEyZmVlZDI1M2Y4NjQ2MDk5OTcwNzk2Y2IxODEwNWJiL3RhYmxlOmVjYTIzOWJiNDgzMjQxMDViZDBiYTkwYWE0YjJkMjFlL3RhYmxlcmFuZ2U6ZWNhMjM5YmI0ODMyNDEwNWJkMGJhOTBhYTRiMmQyMWVfNi03LTEtMS02NQ_dc797399-e3b6-4630-801d-7485d57a706d"
      unitRef="usd">207183000</us-gaap:LaborAndRelatedExpense>
    <us-gaap:ShareBasedCompensation
      contextRef="ib87cee58ccf2448a8d4422101bf61fa0_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yNS9mcmFnOjEyZmVlZDI1M2Y4NjQ2MDk5OTcwNzk2Y2IxODEwNWJiL3RhYmxlOmVjYTIzOWJiNDgzMjQxMDViZDBiYTkwYWE0YjJkMjFlL3RhYmxlcmFuZ2U6ZWNhMjM5YmI0ODMyNDEwNWJkMGJhOTBhYTRiMmQyMWVfNy0xLTEtMS0w_a58d5cbc-7584-48d4-935e-d52d2e21efc4"
      unitRef="usd">6156000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i2c8351954d014a1c80a3d8cfc2327ab2_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yNS9mcmFnOjEyZmVlZDI1M2Y4NjQ2MDk5OTcwNzk2Y2IxODEwNWJiL3RhYmxlOmVjYTIzOWJiNDgzMjQxMDViZDBiYTkwYWE0YjJkMjFlL3RhYmxlcmFuZ2U6ZWNhMjM5YmI0ODMyNDEwNWJkMGJhOTBhYTRiMmQyMWVfNy0zLTEtMS0w_6d8a0653-9d75-45b8-b16a-4ad6cccab712"
      unitRef="usd">6725000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yNS9mcmFnOjEyZmVlZDI1M2Y4NjQ2MDk5OTcwNzk2Y2IxODEwNWJiL3RhYmxlOmVjYTIzOWJiNDgzMjQxMDViZDBiYTkwYWE0YjJkMjFlL3RhYmxlcmFuZ2U6ZWNhMjM5YmI0ODMyNDEwNWJkMGJhOTBhYTRiMmQyMWVfNy01LTEtMS02NQ_f7268d09-bc22-489f-84c1-72a7d8797741"
      unitRef="usd">13463000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i667fa0996400408f9cb2d7f4d3ee2087_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yNS9mcmFnOjEyZmVlZDI1M2Y4NjQ2MDk5OTcwNzk2Y2IxODEwNWJiL3RhYmxlOmVjYTIzOWJiNDgzMjQxMDViZDBiYTkwYWE0YjJkMjFlL3RhYmxlcmFuZ2U6ZWNhMjM5YmI0ODMyNDEwNWJkMGJhOTBhYTRiMmQyMWVfNy03LTEtMS02NQ_eb30b06f-d138-41d8-a037-325e0ff4b6f6"
      unitRef="usd">12634000</us-gaap:ShareBasedCompensation>
    <us-gaap:OtherGeneralAndAdministrativeExpense
      contextRef="ib87cee58ccf2448a8d4422101bf61fa0_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yNS9mcmFnOjEyZmVlZDI1M2Y4NjQ2MDk5OTcwNzk2Y2IxODEwNWJiL3RhYmxlOmVjYTIzOWJiNDgzMjQxMDViZDBiYTkwYWE0YjJkMjFlL3RhYmxlcmFuZ2U6ZWNhMjM5YmI0ODMyNDEwNWJkMGJhOTBhYTRiMmQyMWVfOC0xLTEtMS0w_3862a77b-78e9-472f-9821-91bdb05d4184"
      unitRef="usd">54731000</us-gaap:OtherGeneralAndAdministrativeExpense>
    <us-gaap:OtherGeneralAndAdministrativeExpense
      contextRef="i2c8351954d014a1c80a3d8cfc2327ab2_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yNS9mcmFnOjEyZmVlZDI1M2Y4NjQ2MDk5OTcwNzk2Y2IxODEwNWJiL3RhYmxlOmVjYTIzOWJiNDgzMjQxMDViZDBiYTkwYWE0YjJkMjFlL3RhYmxlcmFuZ2U6ZWNhMjM5YmI0ODMyNDEwNWJkMGJhOTBhYTRiMmQyMWVfOC0zLTEtMS0w_50fca2a5-4476-46ed-b8b6-f5a77f0a8999"
      unitRef="usd">44003000</us-gaap:OtherGeneralAndAdministrativeExpense>
    <us-gaap:OtherGeneralAndAdministrativeExpense
      contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yNS9mcmFnOjEyZmVlZDI1M2Y4NjQ2MDk5OTcwNzk2Y2IxODEwNWJiL3RhYmxlOmVjYTIzOWJiNDgzMjQxMDViZDBiYTkwYWE0YjJkMjFlL3RhYmxlcmFuZ2U6ZWNhMjM5YmI0ODMyNDEwNWJkMGJhOTBhYTRiMmQyMWVfOC01LTEtMS02NQ_ff3c6879-78a4-4e97-963a-9bc7bf1180af"
      unitRef="usd">103837000</us-gaap:OtherGeneralAndAdministrativeExpense>
    <us-gaap:OtherGeneralAndAdministrativeExpense
      contextRef="i667fa0996400408f9cb2d7f4d3ee2087_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yNS9mcmFnOjEyZmVlZDI1M2Y4NjQ2MDk5OTcwNzk2Y2IxODEwNWJiL3RhYmxlOmVjYTIzOWJiNDgzMjQxMDViZDBiYTkwYWE0YjJkMjFlL3RhYmxlcmFuZ2U6ZWNhMjM5YmI0ODMyNDEwNWJkMGJhOTBhYTRiMmQyMWVfOC03LTEtMS02NQ_ced02e47-7583-422e-be8a-5f977efd40b3"
      unitRef="usd">93268000</us-gaap:OtherGeneralAndAdministrativeExpense>
    <us-gaap:DepreciationAndAmortization
      contextRef="ib87cee58ccf2448a8d4422101bf61fa0_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yNS9mcmFnOjEyZmVlZDI1M2Y4NjQ2MDk5OTcwNzk2Y2IxODEwNWJiL3RhYmxlOmVjYTIzOWJiNDgzMjQxMDViZDBiYTkwYWE0YjJkMjFlL3RhYmxlcmFuZ2U6ZWNhMjM5YmI0ODMyNDEwNWJkMGJhOTBhYTRiMmQyMWVfOS0xLTEtMS0w_ca373865-b601-4105-961e-91e8892ccf07"
      unitRef="usd">6721000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="i2c8351954d014a1c80a3d8cfc2327ab2_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yNS9mcmFnOjEyZmVlZDI1M2Y4NjQ2MDk5OTcwNzk2Y2IxODEwNWJiL3RhYmxlOmVjYTIzOWJiNDgzMjQxMDViZDBiYTkwYWE0YjJkMjFlL3RhYmxlcmFuZ2U6ZWNhMjM5YmI0ODMyNDEwNWJkMGJhOTBhYTRiMmQyMWVfOS0zLTEtMS0w_0384113a-74f4-4e3e-b784-34e2948405de"
      unitRef="usd">6334000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yNS9mcmFnOjEyZmVlZDI1M2Y4NjQ2MDk5OTcwNzk2Y2IxODEwNWJiL3RhYmxlOmVjYTIzOWJiNDgzMjQxMDViZDBiYTkwYWE0YjJkMjFlL3RhYmxlcmFuZ2U6ZWNhMjM5YmI0ODMyNDEwNWJkMGJhOTBhYTRiMmQyMWVfOS01LTEtMS02NQ_13efe110-5e16-4dd6-a958-799d09f5b9a9"
      unitRef="usd">14276000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="i667fa0996400408f9cb2d7f4d3ee2087_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yNS9mcmFnOjEyZmVlZDI1M2Y4NjQ2MDk5OTcwNzk2Y2IxODEwNWJiL3RhYmxlOmVjYTIzOWJiNDgzMjQxMDViZDBiYTkwYWE0YjJkMjFlL3RhYmxlcmFuZ2U6ZWNhMjM5YmI0ODMyNDEwNWJkMGJhOTBhYTRiMmQyMWVfOS03LTEtMS02NQ_692727fe-d0a9-4b7c-8c5b-305f9993c898"
      unitRef="usd">11672000</us-gaap:DepreciationAndAmortization>
    <us-gaap:CostsAndExpenses
      contextRef="ib87cee58ccf2448a8d4422101bf61fa0_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yNS9mcmFnOjEyZmVlZDI1M2Y4NjQ2MDk5OTcwNzk2Y2IxODEwNWJiL3RhYmxlOmVjYTIzOWJiNDgzMjQxMDViZDBiYTkwYWE0YjJkMjFlL3RhYmxlcmFuZ2U6ZWNhMjM5YmI0ODMyNDEwNWJkMGJhOTBhYTRiMmQyMWVfMTAtMS0xLTEtMA_b3d7357d-92c5-44ef-a57c-195f8b83547a"
      unitRef="usd">490634000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i2c8351954d014a1c80a3d8cfc2327ab2_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yNS9mcmFnOjEyZmVlZDI1M2Y4NjQ2MDk5OTcwNzk2Y2IxODEwNWJiL3RhYmxlOmVjYTIzOWJiNDgzMjQxMDViZDBiYTkwYWE0YjJkMjFlL3RhYmxlcmFuZ2U6ZWNhMjM5YmI0ODMyNDEwNWJkMGJhOTBhYTRiMmQyMWVfMTAtMy0xLTEtMA_642e2dd4-1302-4e32-9a74-ce4cf9d0b90c"
      unitRef="usd">457907000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yNS9mcmFnOjEyZmVlZDI1M2Y4NjQ2MDk5OTcwNzk2Y2IxODEwNWJiL3RhYmxlOmVjYTIzOWJiNDgzMjQxMDViZDBiYTkwYWE0YjJkMjFlL3RhYmxlcmFuZ2U6ZWNhMjM5YmI0ODMyNDEwNWJkMGJhOTBhYTRiMmQyMWVfMTAtNS0xLTEtNjU_e1f4a49f-a173-4643-a673-72d77a1eec26"
      unitRef="usd">967630000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i667fa0996400408f9cb2d7f4d3ee2087_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yNS9mcmFnOjEyZmVlZDI1M2Y4NjQ2MDk5OTcwNzk2Y2IxODEwNWJiL3RhYmxlOmVjYTIzOWJiNDgzMjQxMDViZDBiYTkwYWE0YjJkMjFlL3RhYmxlcmFuZ2U6ZWNhMjM5YmI0ODMyNDEwNWJkMGJhOTBhYTRiMmQyMWVfMTAtNy0xLTEtNjU_c8829abc-abbf-402a-8b66-747acf9e5c23"
      unitRef="usd">905722000</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="ib87cee58ccf2448a8d4422101bf61fa0_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yNS9mcmFnOjEyZmVlZDI1M2Y4NjQ2MDk5OTcwNzk2Y2IxODEwNWJiL3RhYmxlOmVjYTIzOWJiNDgzMjQxMDViZDBiYTkwYWE0YjJkMjFlL3RhYmxlcmFuZ2U6ZWNhMjM5YmI0ODMyNDEwNWJkMGJhOTBhYTRiMmQyMWVfMTEtMS0xLTEtMA_9630bf77-3a72-43ea-a706-872c185c1401"
      unitRef="usd">78135000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i2c8351954d014a1c80a3d8cfc2327ab2_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yNS9mcmFnOjEyZmVlZDI1M2Y4NjQ2MDk5OTcwNzk2Y2IxODEwNWJiL3RhYmxlOmVjYTIzOWJiNDgzMjQxMDViZDBiYTkwYWE0YjJkMjFlL3RhYmxlcmFuZ2U6ZWNhMjM5YmI0ODMyNDEwNWJkMGJhOTBhYTRiMmQyMWVfMTEtMy0xLTEtMA_be3beb16-7b02-4cdd-bda5-4f4c5bbe65c5"
      unitRef="usd">49932000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yNS9mcmFnOjEyZmVlZDI1M2Y4NjQ2MDk5OTcwNzk2Y2IxODEwNWJiL3RhYmxlOmVjYTIzOWJiNDgzMjQxMDViZDBiYTkwYWE0YjJkMjFlL3RhYmxlcmFuZ2U6ZWNhMjM5YmI0ODMyNDEwNWJkMGJhOTBhYTRiMmQyMWVfMTEtNS0xLTEtNjU_ff16a029-34bf-49d1-b866-8191eee0adeb"
      unitRef="usd">146984000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i667fa0996400408f9cb2d7f4d3ee2087_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yNS9mcmFnOjEyZmVlZDI1M2Y4NjQ2MDk5OTcwNzk2Y2IxODEwNWJiL3RhYmxlOmVjYTIzOWJiNDgzMjQxMDViZDBiYTkwYWE0YjJkMjFlL3RhYmxlcmFuZ2U6ZWNhMjM5YmI0ODMyNDEwNWJkMGJhOTBhYTRiMmQyMWVfMTEtNy0xLTEtNjU_f862f18f-00f8-4727-84af-0d2baef5e2f0"
      unitRef="usd">93802000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InvestmentIncomeInterestAndDividend
      contextRef="ib87cee58ccf2448a8d4422101bf61fa0_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yNS9mcmFnOjEyZmVlZDI1M2Y4NjQ2MDk5OTcwNzk2Y2IxODEwNWJiL3RhYmxlOmVjYTIzOWJiNDgzMjQxMDViZDBiYTkwYWE0YjJkMjFlL3RhYmxlcmFuZ2U6ZWNhMjM5YmI0ODMyNDEwNWJkMGJhOTBhYTRiMmQyMWVfMTMtMS0xLTEtMA_1dfe27f5-7d13-44c3-becc-58965f377c5d"
      unitRef="usd">25000</us-gaap:InvestmentIncomeInterestAndDividend>
    <us-gaap:InvestmentIncomeInterestAndDividend
      contextRef="i2c8351954d014a1c80a3d8cfc2327ab2_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yNS9mcmFnOjEyZmVlZDI1M2Y4NjQ2MDk5OTcwNzk2Y2IxODEwNWJiL3RhYmxlOmVjYTIzOWJiNDgzMjQxMDViZDBiYTkwYWE0YjJkMjFlL3RhYmxlcmFuZ2U6ZWNhMjM5YmI0ODMyNDEwNWJkMGJhOTBhYTRiMmQyMWVfMTMtMy0xLTEtMA_44643f77-412f-428f-bdc1-b3d0431216af"
      unitRef="usd">214000</us-gaap:InvestmentIncomeInterestAndDividend>
    <us-gaap:InvestmentIncomeInterestAndDividend
      contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yNS9mcmFnOjEyZmVlZDI1M2Y4NjQ2MDk5OTcwNzk2Y2IxODEwNWJiL3RhYmxlOmVjYTIzOWJiNDgzMjQxMDViZDBiYTkwYWE0YjJkMjFlL3RhYmxlcmFuZ2U6ZWNhMjM5YmI0ODMyNDEwNWJkMGJhOTBhYTRiMmQyMWVfMTMtNS0xLTEtNjU_fff9bd41-3e5e-4bd9-9d97-2e16af5ee142"
      unitRef="usd">49000</us-gaap:InvestmentIncomeInterestAndDividend>
    <us-gaap:InvestmentIncomeInterestAndDividend
      contextRef="i667fa0996400408f9cb2d7f4d3ee2087_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yNS9mcmFnOjEyZmVlZDI1M2Y4NjQ2MDk5OTcwNzk2Y2IxODEwNWJiL3RhYmxlOmVjYTIzOWJiNDgzMjQxMDViZDBiYTkwYWE0YjJkMjFlL3RhYmxlcmFuZ2U6ZWNhMjM5YmI0ODMyNDEwNWJkMGJhOTBhYTRiMmQyMWVfMTMtNy0xLTEtNjU_b87a4dff-8ed4-4bf2-9cf5-46e3137ab73b"
      unitRef="usd">227000</us-gaap:InvestmentIncomeInterestAndDividend>
    <us-gaap:InterestExpense
      contextRef="ib87cee58ccf2448a8d4422101bf61fa0_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yNS9mcmFnOjEyZmVlZDI1M2Y4NjQ2MDk5OTcwNzk2Y2IxODEwNWJiL3RhYmxlOmVjYTIzOWJiNDgzMjQxMDViZDBiYTkwYWE0YjJkMjFlL3RhYmxlcmFuZ2U6ZWNhMjM5YmI0ODMyNDEwNWJkMGJhOTBhYTRiMmQyMWVfMTQtMS0xLTEtMA_0b79f306-e3b9-4dbc-9cb6-bbe255e6c6d4"
      unitRef="usd">1932000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i2c8351954d014a1c80a3d8cfc2327ab2_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yNS9mcmFnOjEyZmVlZDI1M2Y4NjQ2MDk5OTcwNzk2Y2IxODEwNWJiL3RhYmxlOmVjYTIzOWJiNDgzMjQxMDViZDBiYTkwYWE0YjJkMjFlL3RhYmxlcmFuZ2U6ZWNhMjM5YmI0ODMyNDEwNWJkMGJhOTBhYTRiMmQyMWVfMTQtMy0xLTEtMA_29136c7f-5c95-4503-8947-179257adbc73"
      unitRef="usd">2752000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yNS9mcmFnOjEyZmVlZDI1M2Y4NjQ2MDk5OTcwNzk2Y2IxODEwNWJiL3RhYmxlOmVjYTIzOWJiNDgzMjQxMDViZDBiYTkwYWE0YjJkMjFlL3RhYmxlcmFuZ2U6ZWNhMjM5YmI0ODMyNDEwNWJkMGJhOTBhYTRiMmQyMWVfMTQtNS0xLTEtNjU_24d35152-1529-4076-957b-110a63f71d14"
      unitRef="usd">4004000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i667fa0996400408f9cb2d7f4d3ee2087_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yNS9mcmFnOjEyZmVlZDI1M2Y4NjQ2MDk5OTcwNzk2Y2IxODEwNWJiL3RhYmxlOmVjYTIzOWJiNDgzMjQxMDViZDBiYTkwYWE0YjJkMjFlL3RhYmxlcmFuZ2U6ZWNhMjM5YmI0ODMyNDEwNWJkMGJhOTBhYTRiMmQyMWVfMTQtNy0xLTEtNjU_b16554f6-8b0a-48cc-8d58-b2e8a5306039"
      unitRef="usd">5983000</us-gaap:InterestExpense>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="ib87cee58ccf2448a8d4422101bf61fa0_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yNS9mcmFnOjEyZmVlZDI1M2Y4NjQ2MDk5OTcwNzk2Y2IxODEwNWJiL3RhYmxlOmVjYTIzOWJiNDgzMjQxMDViZDBiYTkwYWE0YjJkMjFlL3RhYmxlcmFuZ2U6ZWNhMjM5YmI0ODMyNDEwNWJkMGJhOTBhYTRiMmQyMWVfMTUtMS0xLTEtMA_0ba8f945-79f4-4474-abe7-a7922a7b1e5d"
      unitRef="usd">1370000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i2c8351954d014a1c80a3d8cfc2327ab2_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yNS9mcmFnOjEyZmVlZDI1M2Y4NjQ2MDk5OTcwNzk2Y2IxODEwNWJiL3RhYmxlOmVjYTIzOWJiNDgzMjQxMDViZDBiYTkwYWE0YjJkMjFlL3RhYmxlcmFuZ2U6ZWNhMjM5YmI0ODMyNDEwNWJkMGJhOTBhYTRiMmQyMWVfMTUtMy0xLTEtMA_578dae4f-a37a-4b98-9d2f-851435a2184e"
      unitRef="usd">487000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yNS9mcmFnOjEyZmVlZDI1M2Y4NjQ2MDk5OTcwNzk2Y2IxODEwNWJiL3RhYmxlOmVjYTIzOWJiNDgzMjQxMDViZDBiYTkwYWE0YjJkMjFlL3RhYmxlcmFuZ2U6ZWNhMjM5YmI0ODMyNDEwNWJkMGJhOTBhYTRiMmQyMWVfMTUtNS0xLTEtNjU_39903f24-97ae-4eca-a71f-55e5023c07f2"
      unitRef="usd">2488000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i667fa0996400408f9cb2d7f4d3ee2087_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yNS9mcmFnOjEyZmVlZDI1M2Y4NjQ2MDk5OTcwNzk2Y2IxODEwNWJiL3RhYmxlOmVjYTIzOWJiNDgzMjQxMDViZDBiYTkwYWE0YjJkMjFlL3RhYmxlcmFuZ2U6ZWNhMjM5YmI0ODMyNDEwNWJkMGJhOTBhYTRiMmQyMWVfMTUtNy0xLTEtNjU_0539b32c-42ce-471b-8fdd-d212980a188a"
      unitRef="usd">964000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:GainLossOnInvestments
      contextRef="ib87cee58ccf2448a8d4422101bf61fa0_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yNS9mcmFnOjEyZmVlZDI1M2Y4NjQ2MDk5OTcwNzk2Y2IxODEwNWJiL3RhYmxlOmVjYTIzOWJiNDgzMjQxMDViZDBiYTkwYWE0YjJkMjFlL3RhYmxlcmFuZ2U6ZWNhMjM5YmI0ODMyNDEwNWJkMGJhOTBhYTRiMmQyMWVfMTYtMS0xLTEtMzA4MA_be6cf61f-aafc-44ed-84e1-2af518b46298"
      unitRef="usd">31092000</us-gaap:GainLossOnInvestments>
    <us-gaap:GainLossOnInvestments
      contextRef="i2c8351954d014a1c80a3d8cfc2327ab2_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yNS9mcmFnOjEyZmVlZDI1M2Y4NjQ2MDk5OTcwNzk2Y2IxODEwNWJiL3RhYmxlOmVjYTIzOWJiNDgzMjQxMDViZDBiYTkwYWE0YjJkMjFlL3RhYmxlcmFuZ2U6ZWNhMjM5YmI0ODMyNDEwNWJkMGJhOTBhYTRiMmQyMWVfMTYtMy0xLTEtMzA4MA_321845da-b6e1-41a6-be9b-498b1cec4788"
      unitRef="usd">-2980000</us-gaap:GainLossOnInvestments>
    <us-gaap:GainLossOnInvestments
      contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yNS9mcmFnOjEyZmVlZDI1M2Y4NjQ2MDk5OTcwNzk2Y2IxODEwNWJiL3RhYmxlOmVjYTIzOWJiNDgzMjQxMDViZDBiYTkwYWE0YjJkMjFlL3RhYmxlcmFuZ2U6ZWNhMjM5YmI0ODMyNDEwNWJkMGJhOTBhYTRiMmQyMWVfMTYtNS0xLTEtMzA4MA_bd2e553c-03a7-4224-8e4e-7794cd20677d"
      unitRef="usd">31092000</us-gaap:GainLossOnInvestments>
    <us-gaap:GainLossOnInvestments
      contextRef="i667fa0996400408f9cb2d7f4d3ee2087_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yNS9mcmFnOjEyZmVlZDI1M2Y4NjQ2MDk5OTcwNzk2Y2IxODEwNWJiL3RhYmxlOmVjYTIzOWJiNDgzMjQxMDViZDBiYTkwYWE0YjJkMjFlL3RhYmxlcmFuZ2U6ZWNhMjM5YmI0ODMyNDEwNWJkMGJhOTBhYTRiMmQyMWVfMTYtNy0xLTEtMzA4MA_bc0ca2f9-76d7-437e-8c3c-a8a3f95986fa"
      unitRef="usd">-2980000</us-gaap:GainLossOnInvestments>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="ib87cee58ccf2448a8d4422101bf61fa0_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yNS9mcmFnOjEyZmVlZDI1M2Y4NjQ2MDk5OTcwNzk2Y2IxODEwNWJiL3RhYmxlOmVjYTIzOWJiNDgzMjQxMDViZDBiYTkwYWE0YjJkMjFlL3RhYmxlcmFuZ2U6ZWNhMjM5YmI0ODMyNDEwNWJkMGJhOTBhYTRiMmQyMWVfMTYtMS0xLTEtMA_6cfa9949-2f95-4632-a755-9bb18113f7dc"
      unitRef="usd">475000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i2c8351954d014a1c80a3d8cfc2327ab2_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yNS9mcmFnOjEyZmVlZDI1M2Y4NjQ2MDk5OTcwNzk2Y2IxODEwNWJiL3RhYmxlOmVjYTIzOWJiNDgzMjQxMDViZDBiYTkwYWE0YjJkMjFlL3RhYmxlcmFuZ2U6ZWNhMjM5YmI0ODMyNDEwNWJkMGJhOTBhYTRiMmQyMWVfMTYtMy0xLTEtMA_17b79156-9da3-4969-92a3-50b9f74091f3"
      unitRef="usd">277000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yNS9mcmFnOjEyZmVlZDI1M2Y4NjQ2MDk5OTcwNzk2Y2IxODEwNWJiL3RhYmxlOmVjYTIzOWJiNDgzMjQxMDViZDBiYTkwYWE0YjJkMjFlL3RhYmxlcmFuZ2U6ZWNhMjM5YmI0ODMyNDEwNWJkMGJhOTBhYTRiMmQyMWVfMTYtNS0xLTEtNjU_a191f127-cdf2-47bd-905f-cebd4097f8c1"
      unitRef="usd">763000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i667fa0996400408f9cb2d7f4d3ee2087_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yNS9mcmFnOjEyZmVlZDI1M2Y4NjQ2MDk5OTcwNzk2Y2IxODEwNWJiL3RhYmxlOmVjYTIzOWJiNDgzMjQxMDViZDBiYTkwYWE0YjJkMjFlL3RhYmxlcmFuZ2U6ZWNhMjM5YmI0ODMyNDEwNWJkMGJhOTBhYTRiMmQyMWVfMTYtNy0xLTEtNjU_8895a39d-d40d-4550-8fc9-43a6d6f6d492"
      unitRef="usd">540000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="ib87cee58ccf2448a8d4422101bf61fa0_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yNS9mcmFnOjEyZmVlZDI1M2Y4NjQ2MDk5OTcwNzk2Y2IxODEwNWJiL3RhYmxlOmVjYTIzOWJiNDgzMjQxMDViZDBiYTkwYWE0YjJkMjFlL3RhYmxlcmFuZ2U6ZWNhMjM5YmI0ODMyNDEwNWJkMGJhOTBhYTRiMmQyMWVfMTctMS0xLTEtMA_683bfbf2-e026-428f-ad31-b9bebb71e845"
      unitRef="usd">31030000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i2c8351954d014a1c80a3d8cfc2327ab2_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yNS9mcmFnOjEyZmVlZDI1M2Y4NjQ2MDk5OTcwNzk2Y2IxODEwNWJiL3RhYmxlOmVjYTIzOWJiNDgzMjQxMDViZDBiYTkwYWE0YjJkMjFlL3RhYmxlcmFuZ2U6ZWNhMjM5YmI0ODMyNDEwNWJkMGJhOTBhYTRiMmQyMWVfMTctMy0xLTEtMA_94c303de-b3ae-4fb1-97cb-f91acd62419f"
      unitRef="usd">-4754000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yNS9mcmFnOjEyZmVlZDI1M2Y4NjQ2MDk5OTcwNzk2Y2IxODEwNWJiL3RhYmxlOmVjYTIzOWJiNDgzMjQxMDViZDBiYTkwYWE0YjJkMjFlL3RhYmxlcmFuZ2U6ZWNhMjM5YmI0ODMyNDEwNWJkMGJhOTBhYTRiMmQyMWVfMTctNS0xLTEtNjU_fc6416ac-82b8-4006-906c-01d8e7f18158"
      unitRef="usd">30388000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i667fa0996400408f9cb2d7f4d3ee2087_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yNS9mcmFnOjEyZmVlZDI1M2Y4NjQ2MDk5OTcwNzk2Y2IxODEwNWJiL3RhYmxlOmVjYTIzOWJiNDgzMjQxMDViZDBiYTkwYWE0YjJkMjFlL3RhYmxlcmFuZ2U6ZWNhMjM5YmI0ODMyNDEwNWJkMGJhOTBhYTRiMmQyMWVfMTctNy0xLTEtNjU_2958befd-a3e0-44f6-bb10-ba89ed326fd5"
      unitRef="usd">-7232000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="ib87cee58ccf2448a8d4422101bf61fa0_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yNS9mcmFnOjEyZmVlZDI1M2Y4NjQ2MDk5OTcwNzk2Y2IxODEwNWJiL3RhYmxlOmVjYTIzOWJiNDgzMjQxMDViZDBiYTkwYWE0YjJkMjFlL3RhYmxlcmFuZ2U6ZWNhMjM5YmI0ODMyNDEwNWJkMGJhOTBhYTRiMmQyMWVfMTgtMS0xLTEtMA_0b7b255b-8897-4271-91cb-5e607fdfd09d"
      unitRef="usd">109165000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i2c8351954d014a1c80a3d8cfc2327ab2_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yNS9mcmFnOjEyZmVlZDI1M2Y4NjQ2MDk5OTcwNzk2Y2IxODEwNWJiL3RhYmxlOmVjYTIzOWJiNDgzMjQxMDViZDBiYTkwYWE0YjJkMjFlL3RhYmxlcmFuZ2U6ZWNhMjM5YmI0ODMyNDEwNWJkMGJhOTBhYTRiMmQyMWVfMTgtMy0xLTEtMA_20f1c5d1-dac9-4f4a-96fa-a2ab20791b6b"
      unitRef="usd">45178000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yNS9mcmFnOjEyZmVlZDI1M2Y4NjQ2MDk5OTcwNzk2Y2IxODEwNWJiL3RhYmxlOmVjYTIzOWJiNDgzMjQxMDViZDBiYTkwYWE0YjJkMjFlL3RhYmxlcmFuZ2U6ZWNhMjM5YmI0ODMyNDEwNWJkMGJhOTBhYTRiMmQyMWVfMTgtNS0xLTEtNjU_031ccf50-0984-479b-acfb-81f4156e76f4"
      unitRef="usd">177372000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i667fa0996400408f9cb2d7f4d3ee2087_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yNS9mcmFnOjEyZmVlZDI1M2Y4NjQ2MDk5OTcwNzk2Y2IxODEwNWJiL3RhYmxlOmVjYTIzOWJiNDgzMjQxMDViZDBiYTkwYWE0YjJkMjFlL3RhYmxlcmFuZ2U6ZWNhMjM5YmI0ODMyNDEwNWJkMGJhOTBhYTRiMmQyMWVfMTgtNy0xLTEtNjU_5ca78b14-0227-4854-9f2f-15379e42e9f4"
      unitRef="usd">86570000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ib87cee58ccf2448a8d4422101bf61fa0_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yNS9mcmFnOjEyZmVlZDI1M2Y4NjQ2MDk5OTcwNzk2Y2IxODEwNWJiL3RhYmxlOmVjYTIzOWJiNDgzMjQxMDViZDBiYTkwYWE0YjJkMjFlL3RhYmxlcmFuZ2U6ZWNhMjM5YmI0ODMyNDEwNWJkMGJhOTBhYTRiMmQyMWVfMTktMS0xLTEtMA_3a0ae354-e158-4233-abba-ec6a33af0a2c"
      unitRef="usd">28546000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i2c8351954d014a1c80a3d8cfc2327ab2_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yNS9mcmFnOjEyZmVlZDI1M2Y4NjQ2MDk5OTcwNzk2Y2IxODEwNWJiL3RhYmxlOmVjYTIzOWJiNDgzMjQxMDViZDBiYTkwYWE0YjJkMjFlL3RhYmxlcmFuZ2U6ZWNhMjM5YmI0ODMyNDEwNWJkMGJhOTBhYTRiMmQyMWVfMTktMy0xLTEtMA_85fa932f-9b3f-4af3-9a1e-6dc296b5d549"
      unitRef="usd">10031000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yNS9mcmFnOjEyZmVlZDI1M2Y4NjQ2MDk5OTcwNzk2Y2IxODEwNWJiL3RhYmxlOmVjYTIzOWJiNDgzMjQxMDViZDBiYTkwYWE0YjJkMjFlL3RhYmxlcmFuZ2U6ZWNhMjM5YmI0ODMyNDEwNWJkMGJhOTBhYTRiMmQyMWVfMTktNS0xLTEtNjU_e51bdae4-fcd0-48b9-b772-a62acacbaea6"
      unitRef="usd">46461000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i667fa0996400408f9cb2d7f4d3ee2087_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yNS9mcmFnOjEyZmVlZDI1M2Y4NjQ2MDk5OTcwNzk2Y2IxODEwNWJiL3RhYmxlOmVjYTIzOWJiNDgzMjQxMDViZDBiYTkwYWE0YjJkMjFlL3RhYmxlcmFuZ2U6ZWNhMjM5YmI0ODMyNDEwNWJkMGJhOTBhYTRiMmQyMWVfMTktNy0xLTEtNjU_3eb27a6a-2251-45ab-aaee-a857653bb8c4"
      unitRef="usd">19377000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ProfitLoss
      contextRef="ib87cee58ccf2448a8d4422101bf61fa0_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yNS9mcmFnOjEyZmVlZDI1M2Y4NjQ2MDk5OTcwNzk2Y2IxODEwNWJiL3RhYmxlOmVjYTIzOWJiNDgzMjQxMDViZDBiYTkwYWE0YjJkMjFlL3RhYmxlcmFuZ2U6ZWNhMjM5YmI0ODMyNDEwNWJkMGJhOTBhYTRiMmQyMWVfMjAtMS0xLTEtMA_a2a52bc8-f90d-44e0-8356-c0a768c13134"
      unitRef="usd">80619000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i2c8351954d014a1c80a3d8cfc2327ab2_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yNS9mcmFnOjEyZmVlZDI1M2Y4NjQ2MDk5OTcwNzk2Y2IxODEwNWJiL3RhYmxlOmVjYTIzOWJiNDgzMjQxMDViZDBiYTkwYWE0YjJkMjFlL3RhYmxlcmFuZ2U6ZWNhMjM5YmI0ODMyNDEwNWJkMGJhOTBhYTRiMmQyMWVfMjAtMy0xLTEtMA_d143a4a3-679e-427d-af53-1ab5fc2c5670"
      unitRef="usd">35147000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yNS9mcmFnOjEyZmVlZDI1M2Y4NjQ2MDk5OTcwNzk2Y2IxODEwNWJiL3RhYmxlOmVjYTIzOWJiNDgzMjQxMDViZDBiYTkwYWE0YjJkMjFlL3RhYmxlcmFuZ2U6ZWNhMjM5YmI0ODMyNDEwNWJkMGJhOTBhYTRiMmQyMWVfMjAtNS0xLTEtNjU_f9356941-bfeb-4b03-83b7-cc79a7a91e0a"
      unitRef="usd">130911000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i667fa0996400408f9cb2d7f4d3ee2087_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yNS9mcmFnOjEyZmVlZDI1M2Y4NjQ2MDk5OTcwNzk2Y2IxODEwNWJiL3RhYmxlOmVjYTIzOWJiNDgzMjQxMDViZDBiYTkwYWE0YjJkMjFlL3RhYmxlcmFuZ2U6ZWNhMjM5YmI0ODMyNDEwNWJkMGJhOTBhYTRiMmQyMWVfMjAtNy0xLTEtNjU_61880bc8-623f-4995-af66-29fa6fc823c2"
      unitRef="usd">67193000</us-gaap:ProfitLoss>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="ib87cee58ccf2448a8d4422101bf61fa0_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yNS9mcmFnOjEyZmVlZDI1M2Y4NjQ2MDk5OTcwNzk2Y2IxODEwNWJiL3RhYmxlOmVjYTIzOWJiNDgzMjQxMDViZDBiYTkwYWE0YjJkMjFlL3RhYmxlcmFuZ2U6ZWNhMjM5YmI0ODMyNDEwNWJkMGJhOTBhYTRiMmQyMWVfMjEtMS0xLTEtMA_f0a3d7df-aa35-4660-a6cf-1a63dd206386"
      unitRef="usd">470000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i2c8351954d014a1c80a3d8cfc2327ab2_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yNS9mcmFnOjEyZmVlZDI1M2Y4NjQ2MDk5OTcwNzk2Y2IxODEwNWJiL3RhYmxlOmVjYTIzOWJiNDgzMjQxMDViZDBiYTkwYWE0YjJkMjFlL3RhYmxlcmFuZ2U6ZWNhMjM5YmI0ODMyNDEwNWJkMGJhOTBhYTRiMmQyMWVfMjEtMy0xLTEtMA_7edbf1b9-9c91-4593-bd84-33f8b1af990d"
      unitRef="usd">473000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yNS9mcmFnOjEyZmVlZDI1M2Y4NjQ2MDk5OTcwNzk2Y2IxODEwNWJiL3RhYmxlOmVjYTIzOWJiNDgzMjQxMDViZDBiYTkwYWE0YjJkMjFlL3RhYmxlcmFuZ2U6ZWNhMjM5YmI0ODMyNDEwNWJkMGJhOTBhYTRiMmQyMWVfMjEtNS0xLTEtNjU_a03cd9eb-0744-4e12-8cba-0fec103fed4d"
      unitRef="usd">892000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i667fa0996400408f9cb2d7f4d3ee2087_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yNS9mcmFnOjEyZmVlZDI1M2Y4NjQ2MDk5OTcwNzk2Y2IxODEwNWJiL3RhYmxlOmVjYTIzOWJiNDgzMjQxMDViZDBiYTkwYWE0YjJkMjFlL3RhYmxlcmFuZ2U6ZWNhMjM5YmI0ODMyNDEwNWJkMGJhOTBhYTRiMmQyMWVfMjEtNy0xLTEtNjU_44db5d00-cf3f-41cb-a14b-e46109e74cb0"
      unitRef="usd">717000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="ib87cee58ccf2448a8d4422101bf61fa0_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yNS9mcmFnOjEyZmVlZDI1M2Y4NjQ2MDk5OTcwNzk2Y2IxODEwNWJiL3RhYmxlOmVjYTIzOWJiNDgzMjQxMDViZDBiYTkwYWE0YjJkMjFlL3RhYmxlcmFuZ2U6ZWNhMjM5YmI0ODMyNDEwNWJkMGJhOTBhYTRiMmQyMWVfMjItMS0xLTEtMA_fc91ae5f-73a9-4104-af74-853504ad0e52"
      unitRef="usd">80149000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i2c8351954d014a1c80a3d8cfc2327ab2_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yNS9mcmFnOjEyZmVlZDI1M2Y4NjQ2MDk5OTcwNzk2Y2IxODEwNWJiL3RhYmxlOmVjYTIzOWJiNDgzMjQxMDViZDBiYTkwYWE0YjJkMjFlL3RhYmxlcmFuZ2U6ZWNhMjM5YmI0ODMyNDEwNWJkMGJhOTBhYTRiMmQyMWVfMjItMy0xLTEtMA_6960c4ba-c74b-48d7-891c-462aebf75c19"
      unitRef="usd">34674000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yNS9mcmFnOjEyZmVlZDI1M2Y4NjQ2MDk5OTcwNzk2Y2IxODEwNWJiL3RhYmxlOmVjYTIzOWJiNDgzMjQxMDViZDBiYTkwYWE0YjJkMjFlL3RhYmxlcmFuZ2U6ZWNhMjM5YmI0ODMyNDEwNWJkMGJhOTBhYTRiMmQyMWVfMjItNS0xLTEtNjU_7144d208-50dd-40e5-a7e2-cb98f8b04107"
      unitRef="usd">130019000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i667fa0996400408f9cb2d7f4d3ee2087_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yNS9mcmFnOjEyZmVlZDI1M2Y4NjQ2MDk5OTcwNzk2Y2IxODEwNWJiL3RhYmxlOmVjYTIzOWJiNDgzMjQxMDViZDBiYTkwYWE0YjJkMjFlL3RhYmxlcmFuZ2U6ZWNhMjM5YmI0ODMyNDEwNWJkMGJhOTBhYTRiMmQyMWVfMjItNy0xLTEtNjU_8654048c-d400-4ae8-84a8-24b21abe9093"
      unitRef="usd">66476000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="ib87cee58ccf2448a8d4422101bf61fa0_D20210401-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yNS9mcmFnOjEyZmVlZDI1M2Y4NjQ2MDk5OTcwNzk2Y2IxODEwNWJiL3RhYmxlOmVjYTIzOWJiNDgzMjQxMDViZDBiYTkwYWE0YjJkMjFlL3RhYmxlcmFuZ2U6ZWNhMjM5YmI0ODMyNDEwNWJkMGJhOTBhYTRiMmQyMWVfMjQtMS0xLTEtMA_7d40b4be-ad66-4698-a4b8-514f057820f0"
      unitRef="usdPerShare">2.46</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i2c8351954d014a1c80a3d8cfc2327ab2_D20200401-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yNS9mcmFnOjEyZmVlZDI1M2Y4NjQ2MDk5OTcwNzk2Y2IxODEwNWJiL3RhYmxlOmVjYTIzOWJiNDgzMjQxMDViZDBiYTkwYWE0YjJkMjFlL3RhYmxlcmFuZ2U6ZWNhMjM5YmI0ODMyNDEwNWJkMGJhOTBhYTRiMmQyMWVfMjQtMy0xLTEtMA_f3f01c35-efd4-4458-b4e1-6813ff63f3cb"
      unitRef="usdPerShare">1.07</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yNS9mcmFnOjEyZmVlZDI1M2Y4NjQ2MDk5OTcwNzk2Y2IxODEwNWJiL3RhYmxlOmVjYTIzOWJiNDgzMjQxMDViZDBiYTkwYWE0YjJkMjFlL3RhYmxlcmFuZ2U6ZWNhMjM5YmI0ODMyNDEwNWJkMGJhOTBhYTRiMmQyMWVfMjQtNS0xLTEtNjU_13505e1c-9009-494c-9473-96fb2afa8632"
      unitRef="usdPerShare">3.98</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i667fa0996400408f9cb2d7f4d3ee2087_D20200101-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yNS9mcmFnOjEyZmVlZDI1M2Y4NjQ2MDk5OTcwNzk2Y2IxODEwNWJiL3RhYmxlOmVjYTIzOWJiNDgzMjQxMDViZDBiYTkwYWE0YjJkMjFlL3RhYmxlcmFuZ2U6ZWNhMjM5YmI0ODMyNDEwNWJkMGJhOTBhYTRiMmQyMWVfMjQtNy0xLTEtNjU_9041603d-fcb2-4157-8a04-d06ed238f81a"
      unitRef="usdPerShare">2.05</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ib87cee58ccf2448a8d4422101bf61fa0_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yNS9mcmFnOjEyZmVlZDI1M2Y4NjQ2MDk5OTcwNzk2Y2IxODEwNWJiL3RhYmxlOmVjYTIzOWJiNDgzMjQxMDViZDBiYTkwYWE0YjJkMjFlL3RhYmxlcmFuZ2U6ZWNhMjM5YmI0ODMyNDEwNWJkMGJhOTBhYTRiMmQyMWVfMjUtMS0xLTEtMA_9b251a30-efb9-42f7-b66b-c1109bca4361"
      unitRef="shares">32588000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i2c8351954d014a1c80a3d8cfc2327ab2_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yNS9mcmFnOjEyZmVlZDI1M2Y4NjQ2MDk5OTcwNzk2Y2IxODEwNWJiL3RhYmxlOmVjYTIzOWJiNDgzMjQxMDViZDBiYTkwYWE0YjJkMjFlL3RhYmxlcmFuZ2U6ZWNhMjM5YmI0ODMyNDEwNWJkMGJhOTBhYTRiMmQyMWVfMjUtMy0xLTEtMA_a6c9bc6d-bf74-4222-9346-6fabae5b5740"
      unitRef="shares">32412000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yNS9mcmFnOjEyZmVlZDI1M2Y4NjQ2MDk5OTcwNzk2Y2IxODEwNWJiL3RhYmxlOmVjYTIzOWJiNDgzMjQxMDViZDBiYTkwYWE0YjJkMjFlL3RhYmxlcmFuZ2U6ZWNhMjM5YmI0ODMyNDEwNWJkMGJhOTBhYTRiMmQyMWVfMjUtNS0xLTEtNjU_4b2be42d-442f-46e3-a41c-2c8601a8a011"
      unitRef="shares">32684000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i667fa0996400408f9cb2d7f4d3ee2087_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yNS9mcmFnOjEyZmVlZDI1M2Y4NjQ2MDk5OTcwNzk2Y2IxODEwNWJiL3RhYmxlOmVjYTIzOWJiNDgzMjQxMDViZDBiYTkwYWE0YjJkMjFlL3RhYmxlcmFuZ2U6ZWNhMjM5YmI0ODMyNDEwNWJkMGJhOTBhYTRiMmQyMWVfMjUtNy0xLTEtNjU_d5d7d785-5179-45b8-8ef6-5a26130e43f8"
      unitRef="shares">32371000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ib87cee58ccf2448a8d4422101bf61fa0_D20210401-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yNS9mcmFnOjEyZmVlZDI1M2Y4NjQ2MDk5OTcwNzk2Y2IxODEwNWJiL3RhYmxlOmVjYTIzOWJiNDgzMjQxMDViZDBiYTkwYWE0YjJkMjFlL3RhYmxlcmFuZ2U6ZWNhMjM5YmI0ODMyNDEwNWJkMGJhOTBhYTRiMmQyMWVfMjctMS0xLTEtMA_ba7814d4-11f1-4d19-ba15-e77763922b0c"
      unitRef="usdPerShare">2.43</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i2c8351954d014a1c80a3d8cfc2327ab2_D20200401-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yNS9mcmFnOjEyZmVlZDI1M2Y4NjQ2MDk5OTcwNzk2Y2IxODEwNWJiL3RhYmxlOmVjYTIzOWJiNDgzMjQxMDViZDBiYTkwYWE0YjJkMjFlL3RhYmxlcmFuZ2U6ZWNhMjM5YmI0ODMyNDEwNWJkMGJhOTBhYTRiMmQyMWVfMjctMy0xLTEtMA_bb88cb18-e271-484d-97ae-a8b4f3f95331"
      unitRef="usdPerShare">1.04</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yNS9mcmFnOjEyZmVlZDI1M2Y4NjQ2MDk5OTcwNzk2Y2IxODEwNWJiL3RhYmxlOmVjYTIzOWJiNDgzMjQxMDViZDBiYTkwYWE0YjJkMjFlL3RhYmxlcmFuZ2U6ZWNhMjM5YmI0ODMyNDEwNWJkMGJhOTBhYTRiMmQyMWVfMjctNS0xLTEtNjU_f1f18727-6e49-43cc-9e58-ffd8e4bec6b4"
      unitRef="usdPerShare">3.93</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i667fa0996400408f9cb2d7f4d3ee2087_D20200101-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yNS9mcmFnOjEyZmVlZDI1M2Y4NjQ2MDk5OTcwNzk2Y2IxODEwNWJiL3RhYmxlOmVjYTIzOWJiNDgzMjQxMDViZDBiYTkwYWE0YjJkMjFlL3RhYmxlcmFuZ2U6ZWNhMjM5YmI0ODMyNDEwNWJkMGJhOTBhYTRiMmQyMWVfMjctNy0xLTEtNjU_f09e4023-0913-4df3-8f5e-27717b1d85b6"
      unitRef="usdPerShare">2.00</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ib87cee58ccf2448a8d4422101bf61fa0_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yNS9mcmFnOjEyZmVlZDI1M2Y4NjQ2MDk5OTcwNzk2Y2IxODEwNWJiL3RhYmxlOmVjYTIzOWJiNDgzMjQxMDViZDBiYTkwYWE0YjJkMjFlL3RhYmxlcmFuZ2U6ZWNhMjM5YmI0ODMyNDEwNWJkMGJhOTBhYTRiMmQyMWVfMjgtMS0xLTEtMA_646932e8-ff3c-43ea-b510-dfc9cbb4e814"
      unitRef="shares">32981000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i2c8351954d014a1c80a3d8cfc2327ab2_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yNS9mcmFnOjEyZmVlZDI1M2Y4NjQ2MDk5OTcwNzk2Y2IxODEwNWJiL3RhYmxlOmVjYTIzOWJiNDgzMjQxMDViZDBiYTkwYWE0YjJkMjFlL3RhYmxlcmFuZ2U6ZWNhMjM5YmI0ODMyNDEwNWJkMGJhOTBhYTRiMmQyMWVfMjgtMy0xLTEtMA_b0ca2f1f-fa88-46b8-b4bb-5da16d65defd"
      unitRef="shares">33285000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yNS9mcmFnOjEyZmVlZDI1M2Y4NjQ2MDk5OTcwNzk2Y2IxODEwNWJiL3RhYmxlOmVjYTIzOWJiNDgzMjQxMDViZDBiYTkwYWE0YjJkMjFlL3RhYmxlcmFuZ2U6ZWNhMjM5YmI0ODMyNDEwNWJkMGJhOTBhYTRiMmQyMWVfMjgtNS0xLTEtNjU_52873162-7f19-4cb7-9060-f191be232d4e"
      unitRef="shares">33085000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i667fa0996400408f9cb2d7f4d3ee2087_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yNS9mcmFnOjEyZmVlZDI1M2Y4NjQ2MDk5OTcwNzk2Y2IxODEwNWJiL3RhYmxlOmVjYTIzOWJiNDgzMjQxMDViZDBiYTkwYWE0YjJkMjFlL3RhYmxlcmFuZ2U6ZWNhMjM5YmI0ODMyNDEwNWJkMGJhOTBhYTRiMmQyMWVfMjgtNy0xLTEtNjU_2a1672d6-9c37-4d54-80ca-28003416aa5f"
      unitRef="shares">33259000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ieb79ce9f481b42d1ab430d3f3d11be5a_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yOC9mcmFnOjBlNDhiNzZhMTAxZjRjODJiMGUzNzJhYTlhOWNmNDhiL3RhYmxlOmRiMjI3MDg4YTQwODRmYWQ5NGEwMzFlNGMyODIyZTk3L3RhYmxlcmFuZ2U6ZGIyMjcwODhhNDA4NGZhZDk0YTAzMWU0YzI4MjJlOTdfMy0xLTEtMS0w_de78d0e3-c6a0-47c7-b65f-a3310eb1d93b"
      unitRef="usd">789574000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="i6a51d0190d2c46638e83e1dd687ec01c_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yOC9mcmFnOjBlNDhiNzZhMTAxZjRjODJiMGUzNzJhYTlhOWNmNDhiL3RhYmxlOmRiMjI3MDg4YTQwODRmYWQ5NGEwMzFlNGMyODIyZTk3L3RhYmxlcmFuZ2U6ZGIyMjcwODhhNDA4NGZhZDk0YTAzMWU0YzI4MjJlOTdfMy0zLTEtMS0w_97df009e-fe1c-4252-875c-35ea35c5efe3"
      unitRef="shares">37538837</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i6a51d0190d2c46638e83e1dd687ec01c_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yOC9mcmFnOjBlNDhiNzZhMTAxZjRjODJiMGUzNzJhYTlhOWNmNDhiL3RhYmxlOmRiMjI3MDg4YTQwODRmYWQ5NGEwMzFlNGMyODIyZTk3L3RhYmxlcmFuZ2U6ZGIyMjcwODhhNDA4NGZhZDk0YTAzMWU0YzI4MjJlOTdfMy01LTEtMS0w_a32bc23c-769d-4ec6-9886-574cadf639a8"
      unitRef="usd">38000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i505af52860ef4f88b5ff9bd288e4b861_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yOC9mcmFnOjBlNDhiNzZhMTAxZjRjODJiMGUzNzJhYTlhOWNmNDhiL3RhYmxlOmRiMjI3MDg4YTQwODRmYWQ5NGEwMzFlNGMyODIyZTk3L3RhYmxlcmFuZ2U6ZGIyMjcwODhhNDA4NGZhZDk0YTAzMWU0YzI4MjJlOTdfMy03LTEtMS0w_23f5d1dd-18be-41cf-a8b1-defb7461c2d5"
      unitRef="usd">707006000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i74fd298667c64003ab51d64eb7694f4f_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yOC9mcmFnOjBlNDhiNzZhMTAxZjRjODJiMGUzNzJhYTlhOWNmNDhiL3RhYmxlOmRiMjI3MDg4YTQwODRmYWQ5NGEwMzFlNGMyODIyZTk3L3RhYmxlcmFuZ2U6ZGIyMjcwODhhNDA4NGZhZDk0YTAzMWU0YzI4MjJlOTdfMy05LTEtMS0w_55ea7060-d56c-4dd4-9408-0422d9c5ddfa"
      unitRef="usd">-398752000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="idebaf491ed4a4eaa830b4edf82a260af_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yOC9mcmFnOjBlNDhiNzZhMTAxZjRjODJiMGUzNzJhYTlhOWNmNDhiL3RhYmxlOmRiMjI3MDg4YTQwODRmYWQ5NGEwMzFlNGMyODIyZTk3L3RhYmxlcmFuZ2U6ZGIyMjcwODhhNDA4NGZhZDk0YTAzMWU0YzI4MjJlOTdfMy0xMS0xLTEtMA_8fa2300b-276e-40f9-b840-d62e1f984385"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i2abc69b9d9f54af3a54fc8752ccb2ab0_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yOC9mcmFnOjBlNDhiNzZhMTAxZjRjODJiMGUzNzJhYTlhOWNmNDhiL3RhYmxlOmRiMjI3MDg4YTQwODRmYWQ5NGEwMzFlNGMyODIyZTk3L3RhYmxlcmFuZ2U6ZGIyMjcwODhhNDA4NGZhZDk0YTAzMWU0YzI4MjJlOTdfMy0xMy0xLTEtMA_1063b15d-d09a-4438-8efa-c9b37b3eaea4"
      unitRef="usd">479861000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i1f49d2d5c447470d8ad1b0c00a898651_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yOC9mcmFnOjBlNDhiNzZhMTAxZjRjODJiMGUzNzJhYTlhOWNmNDhiL3RhYmxlOmRiMjI3MDg4YTQwODRmYWQ5NGEwMzFlNGMyODIyZTk3L3RhYmxlcmFuZ2U6ZGIyMjcwODhhNDA4NGZhZDk0YTAzMWU0YzI4MjJlOTdfMy0xNS0xLTEtMA_040d6aa0-fa98-4e4e-b569-b7b66717b530"
      unitRef="usd">1421000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="ib87cee58ccf2448a8d4422101bf61fa0_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yOC9mcmFnOjBlNDhiNzZhMTAxZjRjODJiMGUzNzJhYTlhOWNmNDhiL3RhYmxlOmRiMjI3MDg4YTQwODRmYWQ5NGEwMzFlNGMyODIyZTk3L3RhYmxlcmFuZ2U6ZGIyMjcwODhhNDA4NGZhZDk0YTAzMWU0YzI4MjJlOTdfNC0xLTEtMS0w_78019710-a6ec-49b7-8f32-fcc6473cd81f"
      unitRef="usd">913000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="ia839bd0c1e7440a2be8dd89d587ab038_D20210401-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yOC9mcmFnOjBlNDhiNzZhMTAxZjRjODJiMGUzNzJhYTlhOWNmNDhiL3RhYmxlOmRiMjI3MDg4YTQwODRmYWQ5NGEwMzFlNGMyODIyZTk3L3RhYmxlcmFuZ2U6ZGIyMjcwODhhNDA4NGZhZDk0YTAzMWU0YzI4MjJlOTdfNC0zLTEtMS0w_f87c9bd4-2fed-402b-b1ab-5790f8b82cf0"
      unitRef="shares">4060</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="i873536f8b14a43938a68d5f9d661e909_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yOC9mcmFnOjBlNDhiNzZhMTAxZjRjODJiMGUzNzJhYTlhOWNmNDhiL3RhYmxlOmRiMjI3MDg4YTQwODRmYWQ5NGEwMzFlNGMyODIyZTk3L3RhYmxlcmFuZ2U6ZGIyMjcwODhhNDA4NGZhZDk0YTAzMWU0YzI4MjJlOTdfNC03LTEtMS0w_89938d7f-29a7-4c78-808d-153be7ab1128"
      unitRef="usd">913000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="ib87cee58ccf2448a8d4422101bf61fa0_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yOC9mcmFnOjBlNDhiNzZhMTAxZjRjODJiMGUzNzJhYTlhOWNmNDhiL3RhYmxlOmRiMjI3MDg4YTQwODRmYWQ5NGEwMzFlNGMyODIyZTk3L3RhYmxlcmFuZ2U6ZGIyMjcwODhhNDA4NGZhZDk0YTAzMWU0YzI4MjJlOTdfNS0xLTEtMS0w_d36b6b4d-3945-46b3-a15b-775d5a873423"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="ia839bd0c1e7440a2be8dd89d587ab038_D20210401-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yOC9mcmFnOjBlNDhiNzZhMTAxZjRjODJiMGUzNzJhYTlhOWNmNDhiL3RhYmxlOmRiMjI3MDg4YTQwODRmYWQ5NGEwMzFlNGMyODIyZTk3L3RhYmxlcmFuZ2U6ZGIyMjcwODhhNDA4NGZhZDk0YTAzMWU0YzI4MjJlOTdfNS0zLTEtMS0w_67749ce5-7d23-417c-8977-a4ae74973f79"
      unitRef="shares">4068</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="ia839bd0c1e7440a2be8dd89d587ab038_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yOC9mcmFnOjBlNDhiNzZhMTAxZjRjODJiMGUzNzJhYTlhOWNmNDhiL3RhYmxlOmRiMjI3MDg4YTQwODRmYWQ5NGEwMzFlNGMyODIyZTk3L3RhYmxlcmFuZ2U6ZGIyMjcwODhhNDA4NGZhZDk0YTAzMWU0YzI4MjJlOTdfNS01LTEtMS0w_635fef53-af28-45da-b8d8-ce502bf5c21a"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="i873536f8b14a43938a68d5f9d661e909_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yOC9mcmFnOjBlNDhiNzZhMTAxZjRjODJiMGUzNzJhYTlhOWNmNDhiL3RhYmxlOmRiMjI3MDg4YTQwODRmYWQ5NGEwMzFlNGMyODIyZTk3L3RhYmxlcmFuZ2U6ZGIyMjcwODhhNDA4NGZhZDk0YTAzMWU0YzI4MjJlOTdfNS03LTEtMS0w_8a7ebd54-2b40-411c-8dfa-438a997dd8db"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="ib87cee58ccf2448a8d4422101bf61fa0_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yOC9mcmFnOjBlNDhiNzZhMTAxZjRjODJiMGUzNzJhYTlhOWNmNDhiL3RhYmxlOmRiMjI3MDg4YTQwODRmYWQ5NGEwMzFlNGMyODIyZTk3L3RhYmxlcmFuZ2U6ZGIyMjcwODhhNDA4NGZhZDk0YTAzMWU0YzI4MjJlOTdfNi0xLTEtMS0w_70569434-2b27-4051-a30d-56319a91743d"
      unitRef="usd">259000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="ia839bd0c1e7440a2be8dd89d587ab038_D20210401-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yOC9mcmFnOjBlNDhiNzZhMTAxZjRjODJiMGUzNzJhYTlhOWNmNDhiL3RhYmxlOmRiMjI3MDg4YTQwODRmYWQ5NGEwMzFlNGMyODIyZTk3L3RhYmxlcmFuZ2U6ZGIyMjcwODhhNDA4NGZhZDk0YTAzMWU0YzI4MjJlOTdfNi0zLTEtMS0w_40813a25-cd27-436b-a27d-b2d743585a4a"
      unitRef="shares">6390</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i873536f8b14a43938a68d5f9d661e909_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yOC9mcmFnOjBlNDhiNzZhMTAxZjRjODJiMGUzNzJhYTlhOWNmNDhiL3RhYmxlOmRiMjI3MDg4YTQwODRmYWQ5NGEwMzFlNGMyODIyZTk3L3RhYmxlcmFuZ2U6ZGIyMjcwODhhNDA4NGZhZDk0YTAzMWU0YzI4MjJlOTdfNi03LTEtMS0w_2bb5d200-1cd8-4000-80fc-9ca10b7ac021"
      unitRef="usd">259000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ib87cee58ccf2448a8d4422101bf61fa0_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yOC9mcmFnOjBlNDhiNzZhMTAxZjRjODJiMGUzNzJhYTlhOWNmNDhiL3RhYmxlOmRiMjI3MDg4YTQwODRmYWQ5NGEwMzFlNGMyODIyZTk3L3RhYmxlcmFuZ2U6ZGIyMjcwODhhNDA4NGZhZDk0YTAzMWU0YzI4MjJlOTdfNy0xLTEtMS0w_5ae559f6-be98-46b0-a58c-ac146fd4a6db"
      unitRef="usd">6156000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i873536f8b14a43938a68d5f9d661e909_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yOC9mcmFnOjBlNDhiNzZhMTAxZjRjODJiMGUzNzJhYTlhOWNmNDhiL3RhYmxlOmRiMjI3MDg4YTQwODRmYWQ5NGEwMzFlNGMyODIyZTk3L3RhYmxlcmFuZ2U6ZGIyMjcwODhhNDA4NGZhZDk0YTAzMWU0YzI4MjJlOTdfNy03LTEtMS0w_cd36d17e-130a-4de3-9054-35ff24c86786"
      unitRef="usd">6156000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <amed:SurrenderedShares
      contextRef="ib87cee58ccf2448a8d4422101bf61fa0_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yOC9mcmFnOjBlNDhiNzZhMTAxZjRjODJiMGUzNzJhYTlhOWNmNDhiL3RhYmxlOmRiMjI3MDg4YTQwODRmYWQ5NGEwMzFlNGMyODIyZTk3L3RhYmxlcmFuZ2U6ZGIyMjcwODhhNDA4NGZhZDk0YTAzMWU0YzI4MjJlOTdfOC0xLTEtMS0w_aa8d4362-1e30-4cce-8b80-cbfa6925a52d"
      unitRef="usd">170000</amed:SurrenderedShares>
    <amed:SurrenderedShares
      contextRef="iee63e04ff2174c9686bcc42c3eb46125_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yOC9mcmFnOjBlNDhiNzZhMTAxZjRjODJiMGUzNzJhYTlhOWNmNDhiL3RhYmxlOmRiMjI3MDg4YTQwODRmYWQ5NGEwMzFlNGMyODIyZTk3L3RhYmxlcmFuZ2U6ZGIyMjcwODhhNDA4NGZhZDk0YTAzMWU0YzI4MjJlOTdfOC05LTEtMS0w_4ec6cf40-385b-4ee2-8173-38a21289471d"
      unitRef="usd">170000</amed:SurrenderedShares>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="ib87cee58ccf2448a8d4422101bf61fa0_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yOC9mcmFnOjBlNDhiNzZhMTAxZjRjODJiMGUzNzJhYTlhOWNmNDhiL3RhYmxlOmRiMjI3MDg4YTQwODRmYWQ5NGEwMzFlNGMyODIyZTk3L3RhYmxlcmFuZ2U6ZGIyMjcwODhhNDA4NGZhZDk0YTAzMWU0YzI4MjJlOTdfOS0xLTEtMS0w_c7bc2e22-7fdd-45f2-9be4-57a6f0d07bf8"
      unitRef="usd">1188000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="iee63e04ff2174c9686bcc42c3eb46125_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yOC9mcmFnOjBlNDhiNzZhMTAxZjRjODJiMGUzNzJhYTlhOWNmNDhiL3RhYmxlOmRiMjI3MDg4YTQwODRmYWQ5NGEwMzFlNGMyODIyZTk3L3RhYmxlcmFuZ2U6ZGIyMjcwODhhNDA4NGZhZDk0YTAzMWU0YzI4MjJlOTdfOS05LTEtMS0w_6b3a70d5-ccf4-4583-a6b6-e31e27d626ec"
      unitRef="usd">1188000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="ib87cee58ccf2448a8d4422101bf61fa0_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yOC9mcmFnOjBlNDhiNzZhMTAxZjRjODJiMGUzNzJhYTlhOWNmNDhiL3RhYmxlOmRiMjI3MDg4YTQwODRmYWQ5NGEwMzFlNGMyODIyZTk3L3RhYmxlcmFuZ2U6ZGIyMjcwODhhNDA4NGZhZDk0YTAzMWU0YzI4MjJlOTdfMTAtMS0xLTEtMA_d1c143f7-b57c-446e-8b41-25494a806112"
      unitRef="usd">276000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="ib467ac52451749bfb8cdba39aa1441a7_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yOC9mcmFnOjBlNDhiNzZhMTAxZjRjODJiMGUzNzJhYTlhOWNmNDhiL3RhYmxlOmRiMjI3MDg4YTQwODRmYWQ5NGEwMzFlNGMyODIyZTk3L3RhYmxlcmFuZ2U6ZGIyMjcwODhhNDA4NGZhZDk0YTAzMWU0YzI4MjJlOTdfMTAtMTUtMS0xLTA_1b69854a-031b-4bd6-a6c1-28d9f361d5bb"
      unitRef="usd">276000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:ProfitLoss
      contextRef="ib87cee58ccf2448a8d4422101bf61fa0_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yOC9mcmFnOjBlNDhiNzZhMTAxZjRjODJiMGUzNzJhYTlhOWNmNDhiL3RhYmxlOmRiMjI3MDg4YTQwODRmYWQ5NGEwMzFlNGMyODIyZTk3L3RhYmxlcmFuZ2U6ZGIyMjcwODhhNDA4NGZhZDk0YTAzMWU0YzI4MjJlOTdfMTEtMS0xLTEtMA_180960ac-3525-4db2-9c5c-2173421fef8a"
      unitRef="usd">80619000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i6d9970853b6d41799b9af78b866c694b_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yOC9mcmFnOjBlNDhiNzZhMTAxZjRjODJiMGUzNzJhYTlhOWNmNDhiL3RhYmxlOmRiMjI3MDg4YTQwODRmYWQ5NGEwMzFlNGMyODIyZTk3L3RhYmxlcmFuZ2U6ZGIyMjcwODhhNDA4NGZhZDk0YTAzMWU0YzI4MjJlOTdfMTEtMTMtMS0xLTA_16c81076-08df-402b-94d4-4a9e018bdd23"
      unitRef="usd">80149000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="ib467ac52451749bfb8cdba39aa1441a7_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yOC9mcmFnOjBlNDhiNzZhMTAxZjRjODJiMGUzNzJhYTlhOWNmNDhiL3RhYmxlOmRiMjI3MDg4YTQwODRmYWQ5NGEwMzFlNGMyODIyZTk3L3RhYmxlcmFuZ2U6ZGIyMjcwODhhNDA4NGZhZDk0YTAzMWU0YzI4MjJlOTdfMTEtMTUtMS0xLTA_2f60a942-728f-4386-9d92-a473d123cd9b"
      unitRef="usd">470000</us-gaap:ProfitLoss>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i1e833203be6947b4968aba4d20064ec8_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yOC9mcmFnOjBlNDhiNzZhMTAxZjRjODJiMGUzNzJhYTlhOWNmNDhiL3RhYmxlOmRiMjI3MDg4YTQwODRmYWQ5NGEwMzFlNGMyODIyZTk3L3RhYmxlcmFuZ2U6ZGIyMjcwODhhNDA4NGZhZDk0YTAzMWU0YzI4MjJlOTdfMTItMS0xLTEtMA_3bb604cb-fa32-484d-93f4-0f565bfe28e6"
      unitRef="usd">875887000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="i3e59fd3d3cfb4bb7ae9ea1d3af94e290_I20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yOC9mcmFnOjBlNDhiNzZhMTAxZjRjODJiMGUzNzJhYTlhOWNmNDhiL3RhYmxlOmRiMjI3MDg4YTQwODRmYWQ5NGEwMzFlNGMyODIyZTk3L3RhYmxlcmFuZ2U6ZGIyMjcwODhhNDA4NGZhZDk0YTAzMWU0YzI4MjJlOTdfMTItMy0xLTEtMA_addd2ccb-ac64-4be6-81c5-a42c6ca8dcae"
      unitRef="shares">37553355</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i3e59fd3d3cfb4bb7ae9ea1d3af94e290_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yOC9mcmFnOjBlNDhiNzZhMTAxZjRjODJiMGUzNzJhYTlhOWNmNDhiL3RhYmxlOmRiMjI3MDg4YTQwODRmYWQ5NGEwMzFlNGMyODIyZTk3L3RhYmxlcmFuZ2U6ZGIyMjcwODhhNDA4NGZhZDk0YTAzMWU0YzI4MjJlOTdfMTItNS0xLTEtMA_00315127-9504-4aa8-a451-4b51c6c2e35d"
      unitRef="usd">38000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="id0e0b2cc08e747cba20ceed2b5382012_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yOC9mcmFnOjBlNDhiNzZhMTAxZjRjODJiMGUzNzJhYTlhOWNmNDhiL3RhYmxlOmRiMjI3MDg4YTQwODRmYWQ5NGEwMzFlNGMyODIyZTk3L3RhYmxlcmFuZ2U6ZGIyMjcwODhhNDA4NGZhZDk0YTAzMWU0YzI4MjJlOTdfMTItNy0xLTEtMA_64f56586-14f0-4fc7-a728-2051c4029e5b"
      unitRef="usd">714334000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i01768f8d7ebc4cc18d5eb154976ba4d3_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yOC9mcmFnOjBlNDhiNzZhMTAxZjRjODJiMGUzNzJhYTlhOWNmNDhiL3RhYmxlOmRiMjI3MDg4YTQwODRmYWQ5NGEwMzFlNGMyODIyZTk3L3RhYmxlcmFuZ2U6ZGIyMjcwODhhNDA4NGZhZDk0YTAzMWU0YzI4MjJlOTdfMTItOS0xLTEtMA_e0ca2cb9-fa9d-4725-9643-d03dc897745d"
      unitRef="usd">-400110000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i1302a68dd8ef42e6ab76db142d77aae4_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yOC9mcmFnOjBlNDhiNzZhMTAxZjRjODJiMGUzNzJhYTlhOWNmNDhiL3RhYmxlOmRiMjI3MDg4YTQwODRmYWQ5NGEwMzFlNGMyODIyZTk3L3RhYmxlcmFuZ2U6ZGIyMjcwODhhNDA4NGZhZDk0YTAzMWU0YzI4MjJlOTdfMTItMTEtMS0xLTA_2e2afe10-abb6-4051-95f5-eb3eaa3fa9ba"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i90abbd77ace44a6bac4330406a6d4810_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yOC9mcmFnOjBlNDhiNzZhMTAxZjRjODJiMGUzNzJhYTlhOWNmNDhiL3RhYmxlOmRiMjI3MDg4YTQwODRmYWQ5NGEwMzFlNGMyODIyZTk3L3RhYmxlcmFuZ2U6ZGIyMjcwODhhNDA4NGZhZDk0YTAzMWU0YzI4MjJlOTdfMTItMTMtMS0xLTA_04b8a332-b573-42cb-975e-3621076d3b7c"
      unitRef="usd">560010000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ie40ed45ce02a463b81cddfc774673775_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yOC9mcmFnOjBlNDhiNzZhMTAxZjRjODJiMGUzNzJhYTlhOWNmNDhiL3RhYmxlOmRiMjI3MDg4YTQwODRmYWQ5NGEwMzFlNGMyODIyZTk3L3RhYmxlcmFuZ2U6ZGIyMjcwODhhNDA4NGZhZDk0YTAzMWU0YzI4MjJlOTdfMTItMTUtMS0xLTA_196a7934-8710-4f0b-98c8-b22dfcda6d43"
      unitRef="usd">1615000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i7e0bc5dd338e4f46a448f49e5796b04c_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yOC9mcmFnOjBlNDhiNzZhMTAxZjRjODJiMGUzNzJhYTlhOWNmNDhiL3RhYmxlOmRiMjI3MDg4YTQwODRmYWQ5NGEwMzFlNGMyODIyZTk3L3RhYmxlcmFuZ2U6ZGIyMjcwODhhNDA4NGZhZDk0YTAzMWU0YzI4MjJlOTdfMTctMS0xLTEtMA_868e30d7-b001-48e3-9d20-aed815e05b5d"
      unitRef="usd">680144000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="i50eeb2e1fb1c44a38c21b210240eb586_I20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yOC9mcmFnOjBlNDhiNzZhMTAxZjRjODJiMGUzNzJhYTlhOWNmNDhiL3RhYmxlOmRiMjI3MDg4YTQwODRmYWQ5NGEwMzFlNGMyODIyZTk3L3RhYmxlcmFuZ2U6ZGIyMjcwODhhNDA4NGZhZDk0YTAzMWU0YzI4MjJlOTdfMTctMy0xLTEtMA_d6ecd023-43d0-4c26-9478-ba9a68e1be24"
      unitRef="shares">36746554</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i50eeb2e1fb1c44a38c21b210240eb586_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yOC9mcmFnOjBlNDhiNzZhMTAxZjRjODJiMGUzNzJhYTlhOWNmNDhiL3RhYmxlOmRiMjI3MDg4YTQwODRmYWQ5NGEwMzFlNGMyODIyZTk3L3RhYmxlcmFuZ2U6ZGIyMjcwODhhNDA4NGZhZDk0YTAzMWU0YzI4MjJlOTdfMTctNS0xLTEtMA_bcee422d-0175-477e-8851-d2b30ed1db4b"
      unitRef="usd">37000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i293e823d67b246d381d9224a4d88ecb8_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yOC9mcmFnOjBlNDhiNzZhMTAxZjRjODJiMGUzNzJhYTlhOWNmNDhiL3RhYmxlOmRiMjI3MDg4YTQwODRmYWQ5NGEwMzFlNGMyODIyZTk3L3RhYmxlcmFuZ2U6ZGIyMjcwODhhNDA4NGZhZDk0YTAzMWU0YzI4MjJlOTdfMTctNy0xLTEtMA_f9b2abc8-b09e-43bb-94a7-34dc0de3233a"
      unitRef="usd">656266000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ie0f0ea8548294921ad4f0b1603762e12_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yOC9mcmFnOjBlNDhiNzZhMTAxZjRjODJiMGUzNzJhYTlhOWNmNDhiL3RhYmxlOmRiMjI3MDg4YTQwODRmYWQ5NGEwMzFlNGMyODIyZTk3L3RhYmxlcmFuZ2U6ZGIyMjcwODhhNDA4NGZhZDk0YTAzMWU0YzI4MjJlOTdfMTctOS0xLTEtMA_1d09173a-726e-4b0f-a362-97213405e6a8"
      unitRef="usd">-255291000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i259a6cf078e54dd1a1db53e0ddaaf3ee_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yOC9mcmFnOjBlNDhiNzZhMTAxZjRjODJiMGUzNzJhYTlhOWNmNDhiL3RhYmxlOmRiMjI3MDg4YTQwODRmYWQ5NGEwMzFlNGMyODIyZTk3L3RhYmxlcmFuZ2U6ZGIyMjcwODhhNDA4NGZhZDk0YTAzMWU0YzI4MjJlOTdfMTctMTEtMS0xLTA_668b91a2-ed7c-4688-8f94-3b9ebcc0c5fd"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="if8b5cc2263e34d7d829e9025bfd31619_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yOC9mcmFnOjBlNDhiNzZhMTAxZjRjODJiMGUzNzJhYTlhOWNmNDhiL3RhYmxlOmRiMjI3MDg4YTQwODRmYWQ5NGEwMzFlNGMyODIyZTk3L3RhYmxlcmFuZ2U6ZGIyMjcwODhhNDA4NGZhZDk0YTAzMWU0YzI4MjJlOTdfMTctMTMtMS0xLTA_213c9a6a-6fe7-43e4-bd0d-744cac670094"
      unitRef="usd">278185000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i74c16b1d1e794dca817c0cabfec5d055_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yOC9mcmFnOjBlNDhiNzZhMTAxZjRjODJiMGUzNzJhYTlhOWNmNDhiL3RhYmxlOmRiMjI3MDg4YTQwODRmYWQ5NGEwMzFlNGMyODIyZTk3L3RhYmxlcmFuZ2U6ZGIyMjcwODhhNDA4NGZhZDk0YTAzMWU0YzI4MjJlOTdfMTctMTUtMS0xLTA_aedfd1c5-2f13-40b9-824e-8f640e867572"
      unitRef="usd">947000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="i2c8351954d014a1c80a3d8cfc2327ab2_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yOC9mcmFnOjBlNDhiNzZhMTAxZjRjODJiMGUzNzJhYTlhOWNmNDhiL3RhYmxlOmRiMjI3MDg4YTQwODRmYWQ5NGEwMzFlNGMyODIyZTk3L3RhYmxlcmFuZ2U6ZGIyMjcwODhhNDA4NGZhZDk0YTAzMWU0YzI4MjJlOTdfMTgtMS0xLTEtMA_d7cd8022-17ac-41f6-aa66-b14716162d82"
      unitRef="usd">826000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="idfe2bc4b48cf420480bdcedd1afce6c9_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yOC9mcmFnOjBlNDhiNzZhMTAxZjRjODJiMGUzNzJhYTlhOWNmNDhiL3RhYmxlOmRiMjI3MDg4YTQwODRmYWQ5NGEwMzFlNGMyODIyZTk3L3RhYmxlcmFuZ2U6ZGIyMjcwODhhNDA4NGZhZDk0YTAzMWU0YzI4MjJlOTdfMTgtMy0xLTEtMA_4f15a109-4bb7-4af0-824e-c0b9f32a1697"
      unitRef="shares">5295</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="i1667f8e90077426897db77b94e7b94d2_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yOC9mcmFnOjBlNDhiNzZhMTAxZjRjODJiMGUzNzJhYTlhOWNmNDhiL3RhYmxlOmRiMjI3MDg4YTQwODRmYWQ5NGEwMzFlNGMyODIyZTk3L3RhYmxlcmFuZ2U6ZGIyMjcwODhhNDA4NGZhZDk0YTAzMWU0YzI4MjJlOTdfMTgtNy0xLTEtMA_e8f5aebc-ecb9-4e06-84e2-60ad3594ce1d"
      unitRef="usd">826000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="i2c8351954d014a1c80a3d8cfc2327ab2_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yOC9mcmFnOjBlNDhiNzZhMTAxZjRjODJiMGUzNzJhYTlhOWNmNDhiL3RhYmxlOmRiMjI3MDg4YTQwODRmYWQ5NGEwMzFlNGMyODIyZTk3L3RhYmxlcmFuZ2U6ZGIyMjcwODhhNDA4NGZhZDk0YTAzMWU0YzI4MjJlOTdfMjAtMS0xLTEtMA_b212fa02-2315-475d-a500-95c46e88cd45"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="idfe2bc4b48cf420480bdcedd1afce6c9_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yOC9mcmFnOjBlNDhiNzZhMTAxZjRjODJiMGUzNzJhYTlhOWNmNDhiL3RhYmxlOmRiMjI3MDg4YTQwODRmYWQ5NGEwMzFlNGMyODIyZTk3L3RhYmxlcmFuZ2U6ZGIyMjcwODhhNDA4NGZhZDk0YTAzMWU0YzI4MjJlOTdfMjAtMy0xLTEtMA_e308648a-97cf-4288-b475-dfe225360b27"
      unitRef="shares">29461</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="idfe2bc4b48cf420480bdcedd1afce6c9_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yOC9mcmFnOjBlNDhiNzZhMTAxZjRjODJiMGUzNzJhYTlhOWNmNDhiL3RhYmxlOmRiMjI3MDg4YTQwODRmYWQ5NGEwMzFlNGMyODIyZTk3L3RhYmxlcmFuZ2U6ZGIyMjcwODhhNDA4NGZhZDk0YTAzMWU0YzI4MjJlOTdfMjAtNS0xLTEtMA_317a00e6-7bc9-4ee5-af67-21c106a650f6"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="i1667f8e90077426897db77b94e7b94d2_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yOC9mcmFnOjBlNDhiNzZhMTAxZjRjODJiMGUzNzJhYTlhOWNmNDhiL3RhYmxlOmRiMjI3MDg4YTQwODRmYWQ5NGEwMzFlNGMyODIyZTk3L3RhYmxlcmFuZ2U6ZGIyMjcwODhhNDA4NGZhZDk0YTAzMWU0YzI4MjJlOTdfMjAtNy0xLTEtMA_426a8698-d73c-42af-ae9e-7d6881952ab9"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i2c8351954d014a1c80a3d8cfc2327ab2_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yOC9mcmFnOjBlNDhiNzZhMTAxZjRjODJiMGUzNzJhYTlhOWNmNDhiL3RhYmxlOmRiMjI3MDg4YTQwODRmYWQ5NGEwMzFlNGMyODIyZTk3L3RhYmxlcmFuZ2U6ZGIyMjcwODhhNDA4NGZhZDk0YTAzMWU0YzI4MjJlOTdfMjEtMS0xLTEtMA_ffc04aa2-23e9-49b3-b6ea-126f1a51314a"
      unitRef="usd">1763000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="idfe2bc4b48cf420480bdcedd1afce6c9_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yOC9mcmFnOjBlNDhiNzZhMTAxZjRjODJiMGUzNzJhYTlhOWNmNDhiL3RhYmxlOmRiMjI3MDg4YTQwODRmYWQ5NGEwMzFlNGMyODIyZTk3L3RhYmxlcmFuZ2U6ZGIyMjcwODhhNDA4NGZhZDk0YTAzMWU0YzI4MjJlOTdfMjEtMy0xLTEtMA_6deb098b-0925-4233-9caf-4187325c3806"
      unitRef="shares">49988</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i1667f8e90077426897db77b94e7b94d2_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yOC9mcmFnOjBlNDhiNzZhMTAxZjRjODJiMGUzNzJhYTlhOWNmNDhiL3RhYmxlOmRiMjI3MDg4YTQwODRmYWQ5NGEwMzFlNGMyODIyZTk3L3RhYmxlcmFuZ2U6ZGIyMjcwODhhNDA4NGZhZDk0YTAzMWU0YzI4MjJlOTdfMjEtNy0xLTEtMA_10d27b4e-6c50-4d26-844c-f2b673fea2a6"
      unitRef="usd">1763000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i2c8351954d014a1c80a3d8cfc2327ab2_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yOC9mcmFnOjBlNDhiNzZhMTAxZjRjODJiMGUzNzJhYTlhOWNmNDhiL3RhYmxlOmRiMjI3MDg4YTQwODRmYWQ5NGEwMzFlNGMyODIyZTk3L3RhYmxlcmFuZ2U6ZGIyMjcwODhhNDA4NGZhZDk0YTAzMWU0YzI4MjJlOTdfMjItMS0xLTEtMA_17897c74-a118-423b-b4be-8e936eba4b4b"
      unitRef="usd">6725000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i1667f8e90077426897db77b94e7b94d2_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yOC9mcmFnOjBlNDhiNzZhMTAxZjRjODJiMGUzNzJhYTlhOWNmNDhiL3RhYmxlOmRiMjI3MDg4YTQwODRmYWQ5NGEwMzFlNGMyODIyZTk3L3RhYmxlcmFuZ2U6ZGIyMjcwODhhNDA4NGZhZDk0YTAzMWU0YzI4MjJlOTdfMjItNy0xLTEtMA_37db7040-44c4-4c4a-be4b-21ddb27f7470"
      unitRef="usd">6725000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <amed:SurrenderedShares
      contextRef="i2c8351954d014a1c80a3d8cfc2327ab2_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yOC9mcmFnOjBlNDhiNzZhMTAxZjRjODJiMGUzNzJhYTlhOWNmNDhiL3RhYmxlOmRiMjI3MDg4YTQwODRmYWQ5NGEwMzFlNGMyODIyZTk3L3RhYmxlcmFuZ2U6ZGIyMjcwODhhNDA4NGZhZDk0YTAzMWU0YzI4MjJlOTdfMjMtMS0xLTEtMA_6807e8df-8164-4d23-a728-82ea1e8975d2"
      unitRef="usd">2334000</amed:SurrenderedShares>
    <amed:SurrenderedShares
      contextRef="i7b84646fd5a5457ea3426c3891522efe_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yOC9mcmFnOjBlNDhiNzZhMTAxZjRjODJiMGUzNzJhYTlhOWNmNDhiL3RhYmxlOmRiMjI3MDg4YTQwODRmYWQ5NGEwMzFlNGMyODIyZTk3L3RhYmxlcmFuZ2U6ZGIyMjcwODhhNDA4NGZhZDk0YTAzMWU0YzI4MjJlOTdfMjMtOS0xLTEtMA_b5abe414-92fe-496b-9bfe-6cf003e5854c"
      unitRef="usd">2334000</amed:SurrenderedShares>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="i2c8351954d014a1c80a3d8cfc2327ab2_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yOC9mcmFnOjBlNDhiNzZhMTAxZjRjODJiMGUzNzJhYTlhOWNmNDhiL3RhYmxlOmRiMjI3MDg4YTQwODRmYWQ5NGEwMzFlNGMyODIyZTk3L3RhYmxlcmFuZ2U6ZGIyMjcwODhhNDA4NGZhZDk0YTAzMWU0YzI4MjJlOTdfMjQtMS0xLTEtMA_0bbda87b-e518-4096-a832-ae639e2df44c"
      unitRef="usd">12000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="i513740b0a9e54ee1a6565acc0bdf79f2_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yOC9mcmFnOjBlNDhiNzZhMTAxZjRjODJiMGUzNzJhYTlhOWNmNDhiL3RhYmxlOmRiMjI3MDg4YTQwODRmYWQ5NGEwMzFlNGMyODIyZTk3L3RhYmxlcmFuZ2U6ZGIyMjcwODhhNDA4NGZhZDk0YTAzMWU0YzI4MjJlOTdfMjQtMTUtMS0xLTA_c97b5f1c-20b7-493c-959b-0a9cc4919635"
      unitRef="usd">12000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:ProfitLoss
      contextRef="i2c8351954d014a1c80a3d8cfc2327ab2_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yOC9mcmFnOjBlNDhiNzZhMTAxZjRjODJiMGUzNzJhYTlhOWNmNDhiL3RhYmxlOmRiMjI3MDg4YTQwODRmYWQ5NGEwMzFlNGMyODIyZTk3L3RhYmxlcmFuZ2U6ZGIyMjcwODhhNDA4NGZhZDk0YTAzMWU0YzI4MjJlOTdfMjYtMS0xLTEtMA_46c0bd41-6a7a-46f7-9612-c5dd5e47bf98"
      unitRef="usd">35147000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="idb32f2bfc5474a4199e7c84d1720275e_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yOC9mcmFnOjBlNDhiNzZhMTAxZjRjODJiMGUzNzJhYTlhOWNmNDhiL3RhYmxlOmRiMjI3MDg4YTQwODRmYWQ5NGEwMzFlNGMyODIyZTk3L3RhYmxlcmFuZ2U6ZGIyMjcwODhhNDA4NGZhZDk0YTAzMWU0YzI4MjJlOTdfMjYtMTMtMS0xLTA_a6309984-10a4-45a3-892c-bd1cc8fd21c2"
      unitRef="usd">34674000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i513740b0a9e54ee1a6565acc0bdf79f2_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yOC9mcmFnOjBlNDhiNzZhMTAxZjRjODJiMGUzNzJhYTlhOWNmNDhiL3RhYmxlOmRiMjI3MDg4YTQwODRmYWQ5NGEwMzFlNGMyODIyZTk3L3RhYmxlcmFuZ2U6ZGIyMjcwODhhNDA4NGZhZDk0YTAzMWU0YzI4MjJlOTdfMjYtMTUtMS0xLTA_10f164bb-750c-4494-9298-0c61cc354b3a"
      unitRef="usd">473000</us-gaap:ProfitLoss>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i15586f038620443192b7c904beb4ad54_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yOC9mcmFnOjBlNDhiNzZhMTAxZjRjODJiMGUzNzJhYTlhOWNmNDhiL3RhYmxlOmRiMjI3MDg4YTQwODRmYWQ5NGEwMzFlNGMyODIyZTk3L3RhYmxlcmFuZ2U6ZGIyMjcwODhhNDA4NGZhZDk0YTAzMWU0YzI4MjJlOTdfMjctMS0xLTEtMA_ed7f7d5a-3f66-4e18-aac9-517543e14a0e"
      unitRef="usd">722259000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="i6271c5457d114e698b9aa02424c6fba7_I20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yOC9mcmFnOjBlNDhiNzZhMTAxZjRjODJiMGUzNzJhYTlhOWNmNDhiL3RhYmxlOmRiMjI3MDg4YTQwODRmYWQ5NGEwMzFlNGMyODIyZTk3L3RhYmxlcmFuZ2U6ZGIyMjcwODhhNDA4NGZhZDk0YTAzMWU0YzI4MjJlOTdfMjctMy0xLTEtMA_aceaf9ac-b11d-4399-872a-889275cf59b9"
      unitRef="shares">36831298</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i6271c5457d114e698b9aa02424c6fba7_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yOC9mcmFnOjBlNDhiNzZhMTAxZjRjODJiMGUzNzJhYTlhOWNmNDhiL3RhYmxlOmRiMjI3MDg4YTQwODRmYWQ5NGEwMzFlNGMyODIyZTk3L3RhYmxlcmFuZ2U6ZGIyMjcwODhhNDA4NGZhZDk0YTAzMWU0YzI4MjJlOTdfMjctNS0xLTEtMA_3df3bfdb-3ee9-4c7a-8636-91ae64d4d527"
      unitRef="usd">37000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i7f5f7a1bdc904b23a1b3496bf1c343ed_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yOC9mcmFnOjBlNDhiNzZhMTAxZjRjODJiMGUzNzJhYTlhOWNmNDhiL3RhYmxlOmRiMjI3MDg4YTQwODRmYWQ5NGEwMzFlNGMyODIyZTk3L3RhYmxlcmFuZ2U6ZGIyMjcwODhhNDA4NGZhZDk0YTAzMWU0YzI4MjJlOTdfMjctNy0xLTEtMA_bc63077f-42b1-47d0-9801-9258d4e41ab4"
      unitRef="usd">665580000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ic2e9db201a8c41efacbe6c14b48f08c5_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yOC9mcmFnOjBlNDhiNzZhMTAxZjRjODJiMGUzNzJhYTlhOWNmNDhiL3RhYmxlOmRiMjI3MDg4YTQwODRmYWQ5NGEwMzFlNGMyODIyZTk3L3RhYmxlcmFuZ2U6ZGIyMjcwODhhNDA4NGZhZDk0YTAzMWU0YzI4MjJlOTdfMjctOS0xLTEtMA_6a2ed67b-cb31-4e06-b135-7a43d00d5c03"
      unitRef="usd">-257625000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ie2958a3a3c7d4e89970b11fea75ea413_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yOC9mcmFnOjBlNDhiNzZhMTAxZjRjODJiMGUzNzJhYTlhOWNmNDhiL3RhYmxlOmRiMjI3MDg4YTQwODRmYWQ5NGEwMzFlNGMyODIyZTk3L3RhYmxlcmFuZ2U6ZGIyMjcwODhhNDA4NGZhZDk0YTAzMWU0YzI4MjJlOTdfMjctMTEtMS0xLTA_4752a40d-5c38-41f4-9bba-227dead912b1"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i1f8cee8ab0a8499bb9039cd2b585f4be_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yOC9mcmFnOjBlNDhiNzZhMTAxZjRjODJiMGUzNzJhYTlhOWNmNDhiL3RhYmxlOmRiMjI3MDg4YTQwODRmYWQ5NGEwMzFlNGMyODIyZTk3L3RhYmxlcmFuZ2U6ZGIyMjcwODhhNDA4NGZhZDk0YTAzMWU0YzI4MjJlOTdfMjctMTMtMS0xLTA_0f573c7e-cd8e-46ab-a646-95d137868501"
      unitRef="usd">312859000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i0520e88179174d4c983746db6664ff87_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yOC9mcmFnOjBlNDhiNzZhMTAxZjRjODJiMGUzNzJhYTlhOWNmNDhiL3RhYmxlOmRiMjI3MDg4YTQwODRmYWQ5NGEwMzFlNGMyODIyZTk3L3RhYmxlcmFuZ2U6ZGIyMjcwODhhNDA4NGZhZDk0YTAzMWU0YzI4MjJlOTdfMjctMTUtMS0xLTA_2624dd5a-e7cd-4f8b-b001-92047ccc1998"
      unitRef="usd">1408000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i87ceb60dc20d4df1b0a97d3514837910_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yOC9mcmFnOjBlNDhiNzZhMTAxZjRjODJiMGUzNzJhYTlhOWNmNDhiL3RhYmxlOmRiMjI3MDg4YTQwODRmYWQ5NGEwMzFlNGMyODIyZTk3L3RhYmxlcmFuZ2U6ZGIyMjcwODhhNDA4NGZhZDk0YTAzMWU0YzI4MjJlOTdfMzAtMS0xLTEtNzk3_f04a187c-0741-4aae-b545-71bf63143371"
      unitRef="usd">810741000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="i2f9b5ede983b458f9d589f077a9b9885_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yOC9mcmFnOjBlNDhiNzZhMTAxZjRjODJiMGUzNzJhYTlhOWNmNDhiL3RhYmxlOmRiMjI3MDg4YTQwODRmYWQ5NGEwMzFlNGMyODIyZTk3L3RhYmxlcmFuZ2U6ZGIyMjcwODhhNDA4NGZhZDk0YTAzMWU0YzI4MjJlOTdfMzAtMy0xLTEtNzk3_93479e56-4b42-4784-9bae-3dd82c317453"
      unitRef="shares">37470212</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i2f9b5ede983b458f9d589f077a9b9885_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yOC9mcmFnOjBlNDhiNzZhMTAxZjRjODJiMGUzNzJhYTlhOWNmNDhiL3RhYmxlOmRiMjI3MDg4YTQwODRmYWQ5NGEwMzFlNGMyODIyZTk3L3RhYmxlcmFuZ2U6ZGIyMjcwODhhNDA4NGZhZDk0YTAzMWU0YzI4MjJlOTdfMzAtNS0xLTEtNzk3_8a288cae-ff66-4fef-8e3c-0e78b91399b4"
      unitRef="usd">38000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i00022a1a9b074ad09a7448259eb40d7b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yOC9mcmFnOjBlNDhiNzZhMTAxZjRjODJiMGUzNzJhYTlhOWNmNDhiL3RhYmxlOmRiMjI3MDg4YTQwODRmYWQ5NGEwMzFlNGMyODIyZTk3L3RhYmxlcmFuZ2U6ZGIyMjcwODhhNDA4NGZhZDk0YTAzMWU0YzI4MjJlOTdfMzAtNy0xLTEtNzk3_922fc04f-654c-41aa-986b-6de46a11d9b0"
      unitRef="usd">698287000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i3904353da8ce4531bf4ac08cd4d11033_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yOC9mcmFnOjBlNDhiNzZhMTAxZjRjODJiMGUzNzJhYTlhOWNmNDhiL3RhYmxlOmRiMjI3MDg4YTQwODRmYWQ5NGEwMzFlNGMyODIyZTk3L3RhYmxlcmFuZ2U6ZGIyMjcwODhhNDA4NGZhZDk0YTAzMWU0YzI4MjJlOTdfMzAtOS0xLTEtNzk3_144be790-5873-4a12-9e49-e543cab8ce78"
      unitRef="usd">-319092000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ida4c2a7ffda04385afb5f441d707b3cc_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yOC9mcmFnOjBlNDhiNzZhMTAxZjRjODJiMGUzNzJhYTlhOWNmNDhiL3RhYmxlOmRiMjI3MDg4YTQwODRmYWQ5NGEwMzFlNGMyODIyZTk3L3RhYmxlcmFuZ2U6ZGIyMjcwODhhNDA4NGZhZDk0YTAzMWU0YzI4MjJlOTdfMzAtMTEtMS0xLTc5Nw_ec52d92b-5c2c-49a2-8cdf-93a3859a8a69"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i656ece5c7f7e4dff8816621dc7e0455f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yOC9mcmFnOjBlNDhiNzZhMTAxZjRjODJiMGUzNzJhYTlhOWNmNDhiL3RhYmxlOmRiMjI3MDg4YTQwODRmYWQ5NGEwMzFlNGMyODIyZTk3L3RhYmxlcmFuZ2U6ZGIyMjcwODhhNDA4NGZhZDk0YTAzMWU0YzI4MjJlOTdfMzAtMTMtMS0xLTc5Nw_8fcb7a61-14d6-4ead-b4ee-c12bf17b7f7e"
      unitRef="usd">429991000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ic4cd949100864281ac1cb035f36fe501_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yOC9mcmFnOjBlNDhiNzZhMTAxZjRjODJiMGUzNzJhYTlhOWNmNDhiL3RhYmxlOmRiMjI3MDg4YTQwODRmYWQ5NGEwMzFlNGMyODIyZTk3L3RhYmxlcmFuZ2U6ZGIyMjcwODhhNDA4NGZhZDk0YTAzMWU0YzI4MjJlOTdfMzAtMTUtMS0xLTc5Nw_2b4bc0e4-eeb1-4b17-8a25-66f9d662216e"
      unitRef="usd">1517000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yOC9mcmFnOjBlNDhiNzZhMTAxZjRjODJiMGUzNzJhYTlhOWNmNDhiL3RhYmxlOmRiMjI3MDg4YTQwODRmYWQ5NGEwMzFlNGMyODIyZTk3L3RhYmxlcmFuZ2U6ZGIyMjcwODhhNDA4NGZhZDk0YTAzMWU0YzI4MjJlOTdfMzEtMS0xLTEtNzk3_e990cd60-d941-4a39-85f0-75fd24b78077"
      unitRef="usd">1961000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="i4c81959cee2f417b9189bc4e6ad7f42d_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yOC9mcmFnOjBlNDhiNzZhMTAxZjRjODJiMGUzNzJhYTlhOWNmNDhiL3RhYmxlOmRiMjI3MDg4YTQwODRmYWQ5NGEwMzFlNGMyODIyZTk3L3RhYmxlcmFuZ2U6ZGIyMjcwODhhNDA4NGZhZDk0YTAzMWU0YzI4MjJlOTdfMzEtMy0xLTEtNzk3_bfcb3950-4bd9-4bdb-8acf-eb9d41d1a1f2"
      unitRef="shares">8262</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="i3a5e5c59232b4c58b6e84716db6d8973_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yOC9mcmFnOjBlNDhiNzZhMTAxZjRjODJiMGUzNzJhYTlhOWNmNDhiL3RhYmxlOmRiMjI3MDg4YTQwODRmYWQ5NGEwMzFlNGMyODIyZTk3L3RhYmxlcmFuZ2U6ZGIyMjcwODhhNDA4NGZhZDk0YTAzMWU0YzI4MjJlOTdfMzEtNy0xLTEtNzk3_3d14966d-5698-451e-b6e1-33d846fee719"
      unitRef="usd">1961000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yOC9mcmFnOjBlNDhiNzZhMTAxZjRjODJiMGUzNzJhYTlhOWNmNDhiL3RhYmxlOmRiMjI3MDg4YTQwODRmYWQ5NGEwMzFlNGMyODIyZTk3L3RhYmxlcmFuZ2U6ZGIyMjcwODhhNDA4NGZhZDk0YTAzMWU0YzI4MjJlOTdfMzItMS0xLTEtNzk3_a232803c-aaf7-49a8-93e0-c472752f9f2d"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="i4c81959cee2f417b9189bc4e6ad7f42d_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yOC9mcmFnOjBlNDhiNzZhMTAxZjRjODJiMGUzNzJhYTlhOWNmNDhiL3RhYmxlOmRiMjI3MDg4YTQwODRmYWQ5NGEwMzFlNGMyODIyZTk3L3RhYmxlcmFuZ2U6ZGIyMjcwODhhNDA4NGZhZDk0YTAzMWU0YzI4MjJlOTdfMzItMy0xLTEtNzk3_8d64b85a-0b3e-4418-a783-42c80f62024a"
      unitRef="shares">61069</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="i4c81959cee2f417b9189bc4e6ad7f42d_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yOC9mcmFnOjBlNDhiNzZhMTAxZjRjODJiMGUzNzJhYTlhOWNmNDhiL3RhYmxlOmRiMjI3MDg4YTQwODRmYWQ5NGEwMzFlNGMyODIyZTk3L3RhYmxlcmFuZ2U6ZGIyMjcwODhhNDA4NGZhZDk0YTAzMWU0YzI4MjJlOTdfMzItNS0xLTEtNzk3_cdbe8a81-619b-4db5-9018-241cf3191d2a"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="i3a5e5c59232b4c58b6e84716db6d8973_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yOC9mcmFnOjBlNDhiNzZhMTAxZjRjODJiMGUzNzJhYTlhOWNmNDhiL3RhYmxlOmRiMjI3MDg4YTQwODRmYWQ5NGEwMzFlNGMyODIyZTk3L3RhYmxlcmFuZ2U6ZGIyMjcwODhhNDA4NGZhZDk0YTAzMWU0YzI4MjJlOTdfMzItNy0xLTEtNzk3_16b2a7d6-eb9d-4f94-841a-5ae5739634d6"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yOC9mcmFnOjBlNDhiNzZhMTAxZjRjODJiMGUzNzJhYTlhOWNmNDhiL3RhYmxlOmRiMjI3MDg4YTQwODRmYWQ5NGEwMzFlNGMyODIyZTk3L3RhYmxlcmFuZ2U6ZGIyMjcwODhhNDA4NGZhZDk0YTAzMWU0YzI4MjJlOTdfMzMtMS0xLTEtNzk3_18a6c562-80c5-447b-98aa-49f95f145631"
      unitRef="usd">623000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i4c81959cee2f417b9189bc4e6ad7f42d_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yOC9mcmFnOjBlNDhiNzZhMTAxZjRjODJiMGUzNzJhYTlhOWNmNDhiL3RhYmxlOmRiMjI3MDg4YTQwODRmYWQ5NGEwMzFlNGMyODIyZTk3L3RhYmxlcmFuZ2U6ZGIyMjcwODhhNDA4NGZhZDk0YTAzMWU0YzI4MjJlOTdfMzMtMy0xLTEtNzk3_889ffa99-1efe-4e39-889d-ee19494a6862"
      unitRef="shares">13812</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i3a5e5c59232b4c58b6e84716db6d8973_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yOC9mcmFnOjBlNDhiNzZhMTAxZjRjODJiMGUzNzJhYTlhOWNmNDhiL3RhYmxlOmRiMjI3MDg4YTQwODRmYWQ5NGEwMzFlNGMyODIyZTk3L3RhYmxlcmFuZ2U6ZGIyMjcwODhhNDA4NGZhZDk0YTAzMWU0YzI4MjJlOTdfMzMtNy0xLTEtNzk3_4e3cdb13-2428-4113-b268-87a879623623"
      unitRef="usd">623000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yOC9mcmFnOjBlNDhiNzZhMTAxZjRjODJiMGUzNzJhYTlhOWNmNDhiL3RhYmxlOmRiMjI3MDg4YTQwODRmYWQ5NGEwMzFlNGMyODIyZTk3L3RhYmxlcmFuZ2U6ZGIyMjcwODhhNDA4NGZhZDk0YTAzMWU0YzI4MjJlOTdfMzQtMS0xLTEtNzk3_1f02eee7-3770-4a14-be71-4ad316280ae6"
      unitRef="usd">13463000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i3a5e5c59232b4c58b6e84716db6d8973_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yOC9mcmFnOjBlNDhiNzZhMTAxZjRjODJiMGUzNzJhYTlhOWNmNDhiL3RhYmxlOmRiMjI3MDg4YTQwODRmYWQ5NGEwMzFlNGMyODIyZTk3L3RhYmxlcmFuZ2U6ZGIyMjcwODhhNDA4NGZhZDk0YTAzMWU0YzI4MjJlOTdfMzQtNy0xLTEtNzk3_5d88faaa-14aa-4b08-a3c6-99a219fa5e54"
      unitRef="usd">13463000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <amed:SurrenderedShares
      contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yOC9mcmFnOjBlNDhiNzZhMTAxZjRjODJiMGUzNzJhYTlhOWNmNDhiL3RhYmxlOmRiMjI3MDg4YTQwODRmYWQ5NGEwMzFlNGMyODIyZTk3L3RhYmxlcmFuZ2U6ZGIyMjcwODhhNDA4NGZhZDk0YTAzMWU0YzI4MjJlOTdfMzUtMS0xLTEtNzk3_1a374073-d74e-48da-96b1-891d6a5b914c"
      unitRef="usd">6944000</amed:SurrenderedShares>
    <amed:SurrenderedShares
      contextRef="i7299a7a0217a4939aebcf1747818528d_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yOC9mcmFnOjBlNDhiNzZhMTAxZjRjODJiMGUzNzJhYTlhOWNmNDhiL3RhYmxlOmRiMjI3MDg4YTQwODRmYWQ5NGEwMzFlNGMyODIyZTk3L3RhYmxlcmFuZ2U6ZGIyMjcwODhhNDA4NGZhZDk0YTAzMWU0YzI4MjJlOTdfMzUtOS0xLTEtNzk3_d4062570-4498-4138-952b-249f075ba676"
      unitRef="usd">6944000</amed:SurrenderedShares>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yOC9mcmFnOjBlNDhiNzZhMTAxZjRjODJiMGUzNzJhYTlhOWNmNDhiL3RhYmxlOmRiMjI3MDg4YTQwODRmYWQ5NGEwMzFlNGMyODIyZTk3L3RhYmxlcmFuZ2U6ZGIyMjcwODhhNDA4NGZhZDk0YTAzMWU0YzI4MjJlOTdfMzYtMS0xLTEtNzk3_8d629d40-350a-4da8-b506-be30808c23cd"
      unitRef="usd">74074000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i7299a7a0217a4939aebcf1747818528d_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yOC9mcmFnOjBlNDhiNzZhMTAxZjRjODJiMGUzNzJhYTlhOWNmNDhiL3RhYmxlOmRiMjI3MDg4YTQwODRmYWQ5NGEwMzFlNGMyODIyZTk3L3RhYmxlcmFuZ2U6ZGIyMjcwODhhNDA4NGZhZDk0YTAzMWU0YzI4MjJlOTdfMzYtOS0xLTEtNzk3_50cbb854-69cc-4732-9fb1-6659932cb399"
      unitRef="usd">74074000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yOC9mcmFnOjBlNDhiNzZhMTAxZjRjODJiMGUzNzJhYTlhOWNmNDhiL3RhYmxlOmRiMjI3MDg4YTQwODRmYWQ5NGEwMzFlNGMyODIyZTk3L3RhYmxlcmFuZ2U6ZGIyMjcwODhhNDA4NGZhZDk0YTAzMWU0YzI4MjJlOTdfMzctMS0xLTEtNzk3_fd726e83-aa0d-4daa-8037-e734ff46435c"
      unitRef="usd">794000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="i87f87ab13a114dee919b9d2827a73fab_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yOC9mcmFnOjBlNDhiNzZhMTAxZjRjODJiMGUzNzJhYTlhOWNmNDhiL3RhYmxlOmRiMjI3MDg4YTQwODRmYWQ5NGEwMzFlNGMyODIyZTk3L3RhYmxlcmFuZ2U6ZGIyMjcwODhhNDA4NGZhZDk0YTAzMWU0YzI4MjJlOTdfMzctMTUtMS0xLTc5Nw_171d31b2-fe0d-49e2-ba27-d1204b860f9b"
      unitRef="usd">794000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:ProfitLoss
      contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yOC9mcmFnOjBlNDhiNzZhMTAxZjRjODJiMGUzNzJhYTlhOWNmNDhiL3RhYmxlOmRiMjI3MDg4YTQwODRmYWQ5NGEwMzFlNGMyODIyZTk3L3RhYmxlcmFuZ2U6ZGIyMjcwODhhNDA4NGZhZDk0YTAzMWU0YzI4MjJlOTdfMzgtMS0xLTEtNzk3_c5c3d183-1a14-4473-b066-0ce340eadeb2"
      unitRef="usd">130911000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i5ac6fbdda808429998d8987cf9923712_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yOC9mcmFnOjBlNDhiNzZhMTAxZjRjODJiMGUzNzJhYTlhOWNmNDhiL3RhYmxlOmRiMjI3MDg4YTQwODRmYWQ5NGEwMzFlNGMyODIyZTk3L3RhYmxlcmFuZ2U6ZGIyMjcwODhhNDA4NGZhZDk0YTAzMWU0YzI4MjJlOTdfMzgtMTMtMS0xLTc5Nw_e972e9a1-4165-41a5-814a-9131426214d0"
      unitRef="usd">130019000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i87f87ab13a114dee919b9d2827a73fab_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yOC9mcmFnOjBlNDhiNzZhMTAxZjRjODJiMGUzNzJhYTlhOWNmNDhiL3RhYmxlOmRiMjI3MDg4YTQwODRmYWQ5NGEwMzFlNGMyODIyZTk3L3RhYmxlcmFuZ2U6ZGIyMjcwODhhNDA4NGZhZDk0YTAzMWU0YzI4MjJlOTdfMzgtMTUtMS0xLTc5Nw_12f79344-e10a-4121-bbe9-74492062ab15"
      unitRef="usd">892000</us-gaap:ProfitLoss>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i1e833203be6947b4968aba4d20064ec8_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yOC9mcmFnOjBlNDhiNzZhMTAxZjRjODJiMGUzNzJhYTlhOWNmNDhiL3RhYmxlOmRiMjI3MDg4YTQwODRmYWQ5NGEwMzFlNGMyODIyZTk3L3RhYmxlcmFuZ2U6ZGIyMjcwODhhNDA4NGZhZDk0YTAzMWU0YzI4MjJlOTdfMzktMS0xLTEtNzk3_c7364d6c-31af-4179-acae-cc19283ed46c"
      unitRef="usd">875887000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="i3e59fd3d3cfb4bb7ae9ea1d3af94e290_I20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yOC9mcmFnOjBlNDhiNzZhMTAxZjRjODJiMGUzNzJhYTlhOWNmNDhiL3RhYmxlOmRiMjI3MDg4YTQwODRmYWQ5NGEwMzFlNGMyODIyZTk3L3RhYmxlcmFuZ2U6ZGIyMjcwODhhNDA4NGZhZDk0YTAzMWU0YzI4MjJlOTdfMzktMy0xLTEtNzk3_fd06ab77-0e27-484e-a7eb-ba061c51d9d7"
      unitRef="shares">37553355</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i3e59fd3d3cfb4bb7ae9ea1d3af94e290_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yOC9mcmFnOjBlNDhiNzZhMTAxZjRjODJiMGUzNzJhYTlhOWNmNDhiL3RhYmxlOmRiMjI3MDg4YTQwODRmYWQ5NGEwMzFlNGMyODIyZTk3L3RhYmxlcmFuZ2U6ZGIyMjcwODhhNDA4NGZhZDk0YTAzMWU0YzI4MjJlOTdfMzktNS0xLTEtNzk3_a2235016-8856-430a-bfd7-2c59746633e0"
      unitRef="usd">38000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="id0e0b2cc08e747cba20ceed2b5382012_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yOC9mcmFnOjBlNDhiNzZhMTAxZjRjODJiMGUzNzJhYTlhOWNmNDhiL3RhYmxlOmRiMjI3MDg4YTQwODRmYWQ5NGEwMzFlNGMyODIyZTk3L3RhYmxlcmFuZ2U6ZGIyMjcwODhhNDA4NGZhZDk0YTAzMWU0YzI4MjJlOTdfMzktNy0xLTEtNzk3_f8f7d23d-c3f1-4ceb-9545-8e535a771502"
      unitRef="usd">714334000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i01768f8d7ebc4cc18d5eb154976ba4d3_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yOC9mcmFnOjBlNDhiNzZhMTAxZjRjODJiMGUzNzJhYTlhOWNmNDhiL3RhYmxlOmRiMjI3MDg4YTQwODRmYWQ5NGEwMzFlNGMyODIyZTk3L3RhYmxlcmFuZ2U6ZGIyMjcwODhhNDA4NGZhZDk0YTAzMWU0YzI4MjJlOTdfMzktOS0xLTEtNzk3_b42770c8-16b4-4819-b8e9-e53fed467193"
      unitRef="usd">-400110000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i1302a68dd8ef42e6ab76db142d77aae4_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yOC9mcmFnOjBlNDhiNzZhMTAxZjRjODJiMGUzNzJhYTlhOWNmNDhiL3RhYmxlOmRiMjI3MDg4YTQwODRmYWQ5NGEwMzFlNGMyODIyZTk3L3RhYmxlcmFuZ2U6ZGIyMjcwODhhNDA4NGZhZDk0YTAzMWU0YzI4MjJlOTdfMzktMTEtMS0xLTc5Nw_0ae413b5-2701-47d7-a503-15fb17bea399"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i90abbd77ace44a6bac4330406a6d4810_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yOC9mcmFnOjBlNDhiNzZhMTAxZjRjODJiMGUzNzJhYTlhOWNmNDhiL3RhYmxlOmRiMjI3MDg4YTQwODRmYWQ5NGEwMzFlNGMyODIyZTk3L3RhYmxlcmFuZ2U6ZGIyMjcwODhhNDA4NGZhZDk0YTAzMWU0YzI4MjJlOTdfMzktMTMtMS0xLTc5Nw_31804f2c-ed15-448c-97b4-5b4a520107b5"
      unitRef="usd">560010000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ie40ed45ce02a463b81cddfc774673775_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yOC9mcmFnOjBlNDhiNzZhMTAxZjRjODJiMGUzNzJhYTlhOWNmNDhiL3RhYmxlOmRiMjI3MDg4YTQwODRmYWQ5NGEwMzFlNGMyODIyZTk3L3RhYmxlcmFuZ2U6ZGIyMjcwODhhNDA4NGZhZDk0YTAzMWU0YzI4MjJlOTdfMzktMTUtMS0xLTc5Nw_c20c8808-3ce5-4f90-be14-25f308c62cd1"
      unitRef="usd">1615000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ifa673cc4c9af455b97f34a55548dfc84_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yOC9mcmFnOjBlNDhiNzZhMTAxZjRjODJiMGUzNzJhYTlhOWNmNDhiL3RhYmxlOmRiMjI3MDg4YTQwODRmYWQ5NGEwMzFlNGMyODIyZTk3L3RhYmxlcmFuZ2U6ZGIyMjcwODhhNDA4NGZhZDk0YTAzMWU0YzI4MjJlOTdfNDQtMS0xLTEtODAy_7e4707c2-2702-4672-ae84-b4da99f2a250"
      unitRef="usd">641513000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="i34b209949049477791ec23971ce9e445_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yOC9mcmFnOjBlNDhiNzZhMTAxZjRjODJiMGUzNzJhYTlhOWNmNDhiL3RhYmxlOmRiMjI3MDg4YTQwODRmYWQ5NGEwMzFlNGMyODIyZTk3L3RhYmxlcmFuZ2U6ZGIyMjcwODhhNDA4NGZhZDk0YTAzMWU0YzI4MjJlOTdfNDQtMy0xLTEtODAy_127f012e-bc07-486c-ad5d-cf2af3a98e67"
      unitRef="shares">36638021</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i34b209949049477791ec23971ce9e445_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yOC9mcmFnOjBlNDhiNzZhMTAxZjRjODJiMGUzNzJhYTlhOWNmNDhiL3RhYmxlOmRiMjI3MDg4YTQwODRmYWQ5NGEwMzFlNGMyODIyZTk3L3RhYmxlcmFuZ2U6ZGIyMjcwODhhNDA4NGZhZDk0YTAzMWU0YzI4MjJlOTdfNDQtNS0xLTEtODAy_db3dc2b7-7426-44eb-a5ed-cf67e0ecc72c"
      unitRef="usd">37000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ia9b5755043594e6fac0445e663b73395_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yOC9mcmFnOjBlNDhiNzZhMTAxZjRjODJiMGUzNzJhYTlhOWNmNDhiL3RhYmxlOmRiMjI3MDg4YTQwODRmYWQ5NGEwMzFlNGMyODIyZTk3L3RhYmxlcmFuZ2U6ZGIyMjcwODhhNDA4NGZhZDk0YTAzMWU0YzI4MjJlOTdfNDQtNy0xLTEtODAy_8fd7b3cb-0f45-4562-8df1-b05646d7fe61"
      unitRef="usd">645256000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i441145d29ff346a58266e6fa5735a383_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yOC9mcmFnOjBlNDhiNzZhMTAxZjRjODJiMGUzNzJhYTlhOWNmNDhiL3RhYmxlOmRiMjI3MDg4YTQwODRmYWQ5NGEwMzFlNGMyODIyZTk3L3RhYmxlcmFuZ2U6ZGIyMjcwODhhNDA4NGZhZDk0YTAzMWU0YzI4MjJlOTdfNDQtOS0xLTEtODAy_5c487b75-98db-4a41-ab28-7848cc7c95ef"
      unitRef="usd">-251241000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ie9c9163b115847718a0e04afa87d792f_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yOC9mcmFnOjBlNDhiNzZhMTAxZjRjODJiMGUzNzJhYTlhOWNmNDhiL3RhYmxlOmRiMjI3MDg4YTQwODRmYWQ5NGEwMzFlNGMyODIyZTk3L3RhYmxlcmFuZ2U6ZGIyMjcwODhhNDA4NGZhZDk0YTAzMWU0YzI4MjJlOTdfNDQtMTEtMS0xLTgwMg_71656276-6d77-4aa7-bd6d-c8ea5930e3cb"
      unitRef="usd">15000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i2f812fe62e9048c1b51562c9b05a841c_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yOC9mcmFnOjBlNDhiNzZhMTAxZjRjODJiMGUzNzJhYTlhOWNmNDhiL3RhYmxlOmRiMjI3MDg4YTQwODRmYWQ5NGEwMzFlNGMyODIyZTk3L3RhYmxlcmFuZ2U6ZGIyMjcwODhhNDA4NGZhZDk0YTAzMWU0YzI4MjJlOTdfNDQtMTMtMS0xLTgwMg_b95cea43-f132-434f-a10d-462b9adc6155"
      unitRef="usd">246383000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i2fef7471e4c74e2cac75b17f8e455e63_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yOC9mcmFnOjBlNDhiNzZhMTAxZjRjODJiMGUzNzJhYTlhOWNmNDhiL3RhYmxlOmRiMjI3MDg4YTQwODRmYWQ5NGEwMzFlNGMyODIyZTk3L3RhYmxlcmFuZ2U6ZGIyMjcwODhhNDA4NGZhZDk0YTAzMWU0YzI4MjJlOTdfNDQtMTUtMS0xLTgwMg_b53769c0-ef85-4321-9fb5-88ed145645b8"
      unitRef="usd">1063000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="i667fa0996400408f9cb2d7f4d3ee2087_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yOC9mcmFnOjBlNDhiNzZhMTAxZjRjODJiMGUzNzJhYTlhOWNmNDhiL3RhYmxlOmRiMjI3MDg4YTQwODRmYWQ5NGEwMzFlNGMyODIyZTk3L3RhYmxlcmFuZ2U6ZGIyMjcwODhhNDA4NGZhZDk0YTAzMWU0YzI4MjJlOTdfNDUtMS0xLTEtODAy_3fbf4842-f4ff-4a53-ba51-6cc13575f89a"
      unitRef="usd">1686000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="ia6768b0ddf76411381a296ae9d695ae6_D20200101-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yOC9mcmFnOjBlNDhiNzZhMTAxZjRjODJiMGUzNzJhYTlhOWNmNDhiL3RhYmxlOmRiMjI3MDg4YTQwODRmYWQ5NGEwMzFlNGMyODIyZTk3L3RhYmxlcmFuZ2U6ZGIyMjcwODhhNDA4NGZhZDk0YTAzMWU0YzI4MjJlOTdfNDUtMy0xLTEtODAy_fa38fe85-1ca8-4f0b-86d7-1366d82e2dad"
      unitRef="shares">11358</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="i846085ebf1cf4817ac0dd1e9245c242a_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yOC9mcmFnOjBlNDhiNzZhMTAxZjRjODJiMGUzNzJhYTlhOWNmNDhiL3RhYmxlOmRiMjI3MDg4YTQwODRmYWQ5NGEwMzFlNGMyODIyZTk3L3RhYmxlcmFuZ2U6ZGIyMjcwODhhNDA4NGZhZDk0YTAzMWU0YzI4MjJlOTdfNDUtNy0xLTEtODAy_459db252-6018-451f-a1f6-2a41027a9c09"
      unitRef="usd">1686000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <amed:StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch
      contextRef="i667fa0996400408f9cb2d7f4d3ee2087_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yOC9mcmFnOjBlNDhiNzZhMTAxZjRjODJiMGUzNzJhYTlhOWNmNDhiL3RhYmxlOmRiMjI3MDg4YTQwODRmYWQ5NGEwMzFlNGMyODIyZTk3L3RhYmxlcmFuZ2U6ZGIyMjcwODhhNDA4NGZhZDk0YTAzMWU0YzI4MjJlOTdfNDYtMS0xLTEtODAy_2bc678c8-5157-4cb2-b9ad-eecd5f89c1c5"
      unitRef="usd">3057000</amed:StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch>
    <amed:StockIssuedDuringPeriodSharesFourZeroOneKEmployerMatch
      contextRef="ia6768b0ddf76411381a296ae9d695ae6_D20200101-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yOC9mcmFnOjBlNDhiNzZhMTAxZjRjODJiMGUzNzJhYTlhOWNmNDhiL3RhYmxlOmRiMjI3MDg4YTQwODRmYWQ5NGEwMzFlNGMyODIyZTk3L3RhYmxlcmFuZ2U6ZGIyMjcwODhhNDA4NGZhZDk0YTAzMWU0YzI4MjJlOTdfNDYtMy0xLTEtODAy_d5897e3e-48f2-45a3-8b11-b6ea0f302da6"
      unitRef="shares">18312</amed:StockIssuedDuringPeriodSharesFourZeroOneKEmployerMatch>
    <amed:StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch
      contextRef="ia6768b0ddf76411381a296ae9d695ae6_D20200101-20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yOC9mcmFnOjBlNDhiNzZhMTAxZjRjODJiMGUzNzJhYTlhOWNmNDhiL3RhYmxlOmRiMjI3MDg4YTQwODRmYWQ5NGEwMzFlNGMyODIyZTk3L3RhYmxlcmFuZ2U6ZGIyMjcwODhhNDA4NGZhZDk0YTAzMWU0YzI4MjJlOTdfNDYtNS0xLTEtODAy_688dc348-2f67-4ba0-9a4a-a168c6b9295a"
      unitRef="usd">0</amed:StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch>
    <amed:StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch
      contextRef="i846085ebf1cf4817ac0dd1e9245c242a_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yOC9mcmFnOjBlNDhiNzZhMTAxZjRjODJiMGUzNzJhYTlhOWNmNDhiL3RhYmxlOmRiMjI3MDg4YTQwODRmYWQ5NGEwMzFlNGMyODIyZTk3L3RhYmxlcmFuZ2U6ZGIyMjcwODhhNDA4NGZhZDk0YTAzMWU0YzI4MjJlOTdfNDYtNy0xLTEtODAy_231a6e4d-1e47-43ab-a001-37418edf6fc0"
      unitRef="usd">3057000</amed:StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="i667fa0996400408f9cb2d7f4d3ee2087_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yOC9mcmFnOjBlNDhiNzZhMTAxZjRjODJiMGUzNzJhYTlhOWNmNDhiL3RhYmxlOmRiMjI3MDg4YTQwODRmYWQ5NGEwMzFlNGMyODIyZTk3L3RhYmxlcmFuZ2U6ZGIyMjcwODhhNDA4NGZhZDk0YTAzMWU0YzI4MjJlOTdfNDctMS0xLTEtODAy_42a8fd24-8dec-49e0-87a0-319ade08a04f"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="ia6768b0ddf76411381a296ae9d695ae6_D20200101-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yOC9mcmFnOjBlNDhiNzZhMTAxZjRjODJiMGUzNzJhYTlhOWNmNDhiL3RhYmxlOmRiMjI3MDg4YTQwODRmYWQ5NGEwMzFlNGMyODIyZTk3L3RhYmxlcmFuZ2U6ZGIyMjcwODhhNDA4NGZhZDk0YTAzMWU0YzI4MjJlOTdfNDctMy0xLTEtODAy_bbbed47a-bffa-49b5-862c-b3a0a8fe8780"
      unitRef="shares">84884</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="ia6768b0ddf76411381a296ae9d695ae6_D20200101-20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yOC9mcmFnOjBlNDhiNzZhMTAxZjRjODJiMGUzNzJhYTlhOWNmNDhiL3RhYmxlOmRiMjI3MDg4YTQwODRmYWQ5NGEwMzFlNGMyODIyZTk3L3RhYmxlcmFuZ2U6ZGIyMjcwODhhNDA4NGZhZDk0YTAzMWU0YzI4MjJlOTdfNDctNS0xLTEtODAy_3aa0ffd7-7db5-4589-858b-07658c0c9a96"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="i846085ebf1cf4817ac0dd1e9245c242a_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yOC9mcmFnOjBlNDhiNzZhMTAxZjRjODJiMGUzNzJhYTlhOWNmNDhiL3RhYmxlOmRiMjI3MDg4YTQwODRmYWQ5NGEwMzFlNGMyODIyZTk3L3RhYmxlcmFuZ2U6ZGIyMjcwODhhNDA4NGZhZDk0YTAzMWU0YzI4MjJlOTdfNDctNy0xLTEtODAy_a3c51ae0-739e-4ab5-aa94-dc8cb3b0e378"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i667fa0996400408f9cb2d7f4d3ee2087_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yOC9mcmFnOjBlNDhiNzZhMTAxZjRjODJiMGUzNzJhYTlhOWNmNDhiL3RhYmxlOmRiMjI3MDg4YTQwODRmYWQ5NGEwMzFlNGMyODIyZTk3L3RhYmxlcmFuZ2U6ZGIyMjcwODhhNDA4NGZhZDk0YTAzMWU0YzI4MjJlOTdfNDgtMS0xLTEtODAy_fa1b5785-5e8c-473b-8504-d6a1218f1ba8"
      unitRef="usd">2947000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="ia6768b0ddf76411381a296ae9d695ae6_D20200101-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yOC9mcmFnOjBlNDhiNzZhMTAxZjRjODJiMGUzNzJhYTlhOWNmNDhiL3RhYmxlOmRiMjI3MDg4YTQwODRmYWQ5NGEwMzFlNGMyODIyZTk3L3RhYmxlcmFuZ2U6ZGIyMjcwODhhNDA4NGZhZDk0YTAzMWU0YzI4MjJlOTdfNDgtMy0xLTEtODAy_d427cfe9-1ed6-4ec6-965c-664232c51f85"
      unitRef="shares">78723</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i846085ebf1cf4817ac0dd1e9245c242a_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yOC9mcmFnOjBlNDhiNzZhMTAxZjRjODJiMGUzNzJhYTlhOWNmNDhiL3RhYmxlOmRiMjI3MDg4YTQwODRmYWQ5NGEwMzFlNGMyODIyZTk3L3RhYmxlcmFuZ2U6ZGIyMjcwODhhNDA4NGZhZDk0YTAzMWU0YzI4MjJlOTdfNDgtNy0xLTEtODAy_e77d7905-2fd9-499b-bf06-504e845cc824"
      unitRef="usd">2947000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i667fa0996400408f9cb2d7f4d3ee2087_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yOC9mcmFnOjBlNDhiNzZhMTAxZjRjODJiMGUzNzJhYTlhOWNmNDhiL3RhYmxlOmRiMjI3MDg4YTQwODRmYWQ5NGEwMzFlNGMyODIyZTk3L3RhYmxlcmFuZ2U6ZGIyMjcwODhhNDA4NGZhZDk0YTAzMWU0YzI4MjJlOTdfNDktMS0xLTEtODAy_6f5ee9b8-ade6-4176-85b4-257b1f609c90"
      unitRef="usd">12634000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i846085ebf1cf4817ac0dd1e9245c242a_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yOC9mcmFnOjBlNDhiNzZhMTAxZjRjODJiMGUzNzJhYTlhOWNmNDhiL3RhYmxlOmRiMjI3MDg4YTQwODRmYWQ5NGEwMzFlNGMyODIyZTk3L3RhYmxlcmFuZ2U6ZGIyMjcwODhhNDA4NGZhZDk0YTAzMWU0YzI4MjJlOTdfNDktNy0xLTEtODAy_6b1659c7-6ff2-4147-a96e-e1c51b3d9d5d"
      unitRef="usd">12634000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <amed:SurrenderedShares
      contextRef="i667fa0996400408f9cb2d7f4d3ee2087_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yOC9mcmFnOjBlNDhiNzZhMTAxZjRjODJiMGUzNzJhYTlhOWNmNDhiL3RhYmxlOmRiMjI3MDg4YTQwODRmYWQ5NGEwMzFlNGMyODIyZTk3L3RhYmxlcmFuZ2U6ZGIyMjcwODhhNDA4NGZhZDk0YTAzMWU0YzI4MjJlOTdfNTAtMS0xLTEtODAy_993782d3-07cb-41de-8f9e-5562f7d2e6b3"
      unitRef="usd">6384000</amed:SurrenderedShares>
    <amed:SurrenderedShares
      contextRef="ib8af587d580b4f4e9cdf536e3b9b31e6_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yOC9mcmFnOjBlNDhiNzZhMTAxZjRjODJiMGUzNzJhYTlhOWNmNDhiL3RhYmxlOmRiMjI3MDg4YTQwODRmYWQ5NGEwMzFlNGMyODIyZTk3L3RhYmxlcmFuZ2U6ZGIyMjcwODhhNDA4NGZhZDk0YTAzMWU0YzI4MjJlOTdfNTAtOS0xLTEtODAy_320c5d3a-5899-440e-a678-7e1cc5d3b537"
      unitRef="usd">6384000</amed:SurrenderedShares>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="i667fa0996400408f9cb2d7f4d3ee2087_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yOC9mcmFnOjBlNDhiNzZhMTAxZjRjODJiMGUzNzJhYTlhOWNmNDhiL3RhYmxlOmRiMjI3MDg4YTQwODRmYWQ5NGEwMzFlNGMyODIyZTk3L3RhYmxlcmFuZ2U6ZGIyMjcwODhhNDA4NGZhZDk0YTAzMWU0YzI4MjJlOTdfNTEtMS0xLTEtODAy_c33c5b48-c2af-4aec-a120-6e374e36a5b4"
      unitRef="usd">372000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="i917af374eb6a409ebea5c8abe45a5a8e_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yOC9mcmFnOjBlNDhiNzZhMTAxZjRjODJiMGUzNzJhYTlhOWNmNDhiL3RhYmxlOmRiMjI3MDg4YTQwODRmYWQ5NGEwMzFlNGMyODIyZTk3L3RhYmxlcmFuZ2U6ZGIyMjcwODhhNDA4NGZhZDk0YTAzMWU0YzI4MjJlOTdfNTEtMTUtMS0xLTgwMg_5a6b7fae-18a4-44b0-8259-5b5c57a6033a"
      unitRef="usd">372000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <amed:EquityImpactOfWriteOffOfOtherComprehensiveIncome
      contextRef="i667fa0996400408f9cb2d7f4d3ee2087_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yOC9mcmFnOjBlNDhiNzZhMTAxZjRjODJiMGUzNzJhYTlhOWNmNDhiL3RhYmxlOmRiMjI3MDg4YTQwODRmYWQ5NGEwMzFlNGMyODIyZTk3L3RhYmxlcmFuZ2U6ZGIyMjcwODhhNDA4NGZhZDk0YTAzMWU0YzI4MjJlOTdfNTItMS0xLTEtODAy_9078be95-6a53-435c-bbfd-c84fe3db0841"
      unitRef="usd">15000</amed:EquityImpactOfWriteOffOfOtherComprehensiveIncome>
    <amed:EquityImpactOfWriteOffOfOtherComprehensiveIncome
      contextRef="i105f613dfc9b4ea7afdeaf6f08277f25_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yOC9mcmFnOjBlNDhiNzZhMTAxZjRjODJiMGUzNzJhYTlhOWNmNDhiL3RhYmxlOmRiMjI3MDg4YTQwODRmYWQ5NGEwMzFlNGMyODIyZTk3L3RhYmxlcmFuZ2U6ZGIyMjcwODhhNDA4NGZhZDk0YTAzMWU0YzI4MjJlOTdfNTItMTEtMS0xLTgwMg_b8dd2f89-da91-41f4-bd8e-34bb56ac56bb"
      unitRef="usd">15000</amed:EquityImpactOfWriteOffOfOtherComprehensiveIncome>
    <us-gaap:ProfitLoss
      contextRef="i667fa0996400408f9cb2d7f4d3ee2087_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yOC9mcmFnOjBlNDhiNzZhMTAxZjRjODJiMGUzNzJhYTlhOWNmNDhiL3RhYmxlOmRiMjI3MDg4YTQwODRmYWQ5NGEwMzFlNGMyODIyZTk3L3RhYmxlcmFuZ2U6ZGIyMjcwODhhNDA4NGZhZDk0YTAzMWU0YzI4MjJlOTdfNTMtMS0xLTEtODAy_cbdba268-62f3-4510-bfb5-944da4d2b0e3"
      unitRef="usd">67193000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i08ad12ef46cf4d2da58b68346a440ca1_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yOC9mcmFnOjBlNDhiNzZhMTAxZjRjODJiMGUzNzJhYTlhOWNmNDhiL3RhYmxlOmRiMjI3MDg4YTQwODRmYWQ5NGEwMzFlNGMyODIyZTk3L3RhYmxlcmFuZ2U6ZGIyMjcwODhhNDA4NGZhZDk0YTAzMWU0YzI4MjJlOTdfNTMtMTMtMS0xLTgwMg_aa801cbe-be18-4f76-b337-a7336b236f63"
      unitRef="usd">66476000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i917af374eb6a409ebea5c8abe45a5a8e_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yOC9mcmFnOjBlNDhiNzZhMTAxZjRjODJiMGUzNzJhYTlhOWNmNDhiL3RhYmxlOmRiMjI3MDg4YTQwODRmYWQ5NGEwMzFlNGMyODIyZTk3L3RhYmxlcmFuZ2U6ZGIyMjcwODhhNDA4NGZhZDk0YTAzMWU0YzI4MjJlOTdfNTMtMTUtMS0xLTgwMg_e3d1c34f-1192-4eb3-b71d-b522699864c6"
      unitRef="usd">717000</us-gaap:ProfitLoss>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i15586f038620443192b7c904beb4ad54_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yOC9mcmFnOjBlNDhiNzZhMTAxZjRjODJiMGUzNzJhYTlhOWNmNDhiL3RhYmxlOmRiMjI3MDg4YTQwODRmYWQ5NGEwMzFlNGMyODIyZTk3L3RhYmxlcmFuZ2U6ZGIyMjcwODhhNDA4NGZhZDk0YTAzMWU0YzI4MjJlOTdfNTQtMS0xLTEtODAy_1c457ef3-83a2-4d3f-af7d-4453743ad35f"
      unitRef="usd">722259000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="i6271c5457d114e698b9aa02424c6fba7_I20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yOC9mcmFnOjBlNDhiNzZhMTAxZjRjODJiMGUzNzJhYTlhOWNmNDhiL3RhYmxlOmRiMjI3MDg4YTQwODRmYWQ5NGEwMzFlNGMyODIyZTk3L3RhYmxlcmFuZ2U6ZGIyMjcwODhhNDA4NGZhZDk0YTAzMWU0YzI4MjJlOTdfNTQtMy0xLTEtODAy_6a4f6a27-54e8-45b0-a460-165f755f8a38"
      unitRef="shares">36831298</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i6271c5457d114e698b9aa02424c6fba7_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yOC9mcmFnOjBlNDhiNzZhMTAxZjRjODJiMGUzNzJhYTlhOWNmNDhiL3RhYmxlOmRiMjI3MDg4YTQwODRmYWQ5NGEwMzFlNGMyODIyZTk3L3RhYmxlcmFuZ2U6ZGIyMjcwODhhNDA4NGZhZDk0YTAzMWU0YzI4MjJlOTdfNTQtNS0xLTEtODAy_7a9160e4-1973-4154-975e-c0011ac3f613"
      unitRef="usd">37000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i7f5f7a1bdc904b23a1b3496bf1c343ed_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yOC9mcmFnOjBlNDhiNzZhMTAxZjRjODJiMGUzNzJhYTlhOWNmNDhiL3RhYmxlOmRiMjI3MDg4YTQwODRmYWQ5NGEwMzFlNGMyODIyZTk3L3RhYmxlcmFuZ2U6ZGIyMjcwODhhNDA4NGZhZDk0YTAzMWU0YzI4MjJlOTdfNTQtNy0xLTEtODAy_f3c71e79-7872-4e19-86aa-46212d64db05"
      unitRef="usd">665580000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ic2e9db201a8c41efacbe6c14b48f08c5_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yOC9mcmFnOjBlNDhiNzZhMTAxZjRjODJiMGUzNzJhYTlhOWNmNDhiL3RhYmxlOmRiMjI3MDg4YTQwODRmYWQ5NGEwMzFlNGMyODIyZTk3L3RhYmxlcmFuZ2U6ZGIyMjcwODhhNDA4NGZhZDk0YTAzMWU0YzI4MjJlOTdfNTQtOS0xLTEtODAy_8f224139-ee28-4063-9537-c4bdeb2d9d6b"
      unitRef="usd">-257625000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ie2958a3a3c7d4e89970b11fea75ea413_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yOC9mcmFnOjBlNDhiNzZhMTAxZjRjODJiMGUzNzJhYTlhOWNmNDhiL3RhYmxlOmRiMjI3MDg4YTQwODRmYWQ5NGEwMzFlNGMyODIyZTk3L3RhYmxlcmFuZ2U6ZGIyMjcwODhhNDA4NGZhZDk0YTAzMWU0YzI4MjJlOTdfNTQtMTEtMS0xLTgwMg_928ec62d-d5aa-4d7d-9fe4-368fbc1edd49"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i1f8cee8ab0a8499bb9039cd2b585f4be_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yOC9mcmFnOjBlNDhiNzZhMTAxZjRjODJiMGUzNzJhYTlhOWNmNDhiL3RhYmxlOmRiMjI3MDg4YTQwODRmYWQ5NGEwMzFlNGMyODIyZTk3L3RhYmxlcmFuZ2U6ZGIyMjcwODhhNDA4NGZhZDk0YTAzMWU0YzI4MjJlOTdfNTQtMTMtMS0xLTgwMg_fda3b04e-71b4-4b13-9f27-b5dfb16fcee6"
      unitRef="usd">312859000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i0520e88179174d4c983746db6664ff87_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8yOC9mcmFnOjBlNDhiNzZhMTAxZjRjODJiMGUzNzJhYTlhOWNmNDhiL3RhYmxlOmRiMjI3MDg4YTQwODRmYWQ5NGEwMzFlNGMyODIyZTk3L3RhYmxlcmFuZ2U6ZGIyMjcwODhhNDA4NGZhZDk0YTAzMWU0YzI4MjJlOTdfNTQtMTUtMS0xLTgwMg_5b2d7ef2-fdb0-479f-8575-72e35c9df588"
      unitRef="usd">1408000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8zMS9mcmFnOjJjMWUxYzVmMTk4ZTQ1NDNiYzMwZTA3OWU1MjY2ODhhL3RhYmxlOmVlYjE5ZmUzODg2MTQ3NmE5MGJlZDMyODQ0NzUyMDYxL3RhYmxlcmFuZ2U6ZWViMTlmZTM4ODYxNDc2YTkwYmVkMzI4NDQ3NTIwNjFfMy0xLTEtMS0w_688a6ab3-9a38-4cb5-99b1-57a5a64fe66b"
      unitRef="usd">130911000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i667fa0996400408f9cb2d7f4d3ee2087_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8zMS9mcmFnOjJjMWUxYzVmMTk4ZTQ1NDNiYzMwZTA3OWU1MjY2ODhhL3RhYmxlOmVlYjE5ZmUzODg2MTQ3NmE5MGJlZDMyODQ0NzUyMDYxL3RhYmxlcmFuZ2U6ZWViMTlmZTM4ODYxNDc2YTkwYmVkMzI4NDQ3NTIwNjFfMy0zLTEtMS0w_81167009-ba88-4383-ab35-7d7205cc0fe1"
      unitRef="usd">67193000</us-gaap:ProfitLoss>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8zMS9mcmFnOjJjMWUxYzVmMTk4ZTQ1NDNiYzMwZTA3OWU1MjY2ODhhL3RhYmxlOmVlYjE5ZmUzODg2MTQ3NmE5MGJlZDMyODQ0NzUyMDYxL3RhYmxlcmFuZ2U6ZWViMTlmZTM4ODYxNDc2YTkwYmVkMzI4NDQ3NTIwNjFfNS0xLTEtMS0w_3290d2fb-8310-4d66-9337-57a7dfff084a"
      unitRef="usd">14276000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i667fa0996400408f9cb2d7f4d3ee2087_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8zMS9mcmFnOjJjMWUxYzVmMTk4ZTQ1NDNiYzMwZTA3OWU1MjY2ODhhL3RhYmxlOmVlYjE5ZmUzODg2MTQ3NmE5MGJlZDMyODQ0NzUyMDYxL3RhYmxlcmFuZ2U6ZWViMTlmZTM4ODYxNDc2YTkwYmVkMzI4NDQ3NTIwNjFfNS0zLTEtMS0w_f76d7205-2caa-403c-b9cb-5eeffb2281e6"
      unitRef="usd">11672000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:ShareBasedCompensation
      contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8zMS9mcmFnOjJjMWUxYzVmMTk4ZTQ1NDNiYzMwZTA3OWU1MjY2ODhhL3RhYmxlOmVlYjE5ZmUzODg2MTQ3NmE5MGJlZDMyODQ0NzUyMDYxL3RhYmxlcmFuZ2U6ZWViMTlmZTM4ODYxNDc2YTkwYmVkMzI4NDQ3NTIwNjFfNi0xLTEtMS0w_1bc787e4-d589-44bb-85da-ac74bb597a2a"
      unitRef="usd">13463000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i667fa0996400408f9cb2d7f4d3ee2087_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8zMS9mcmFnOjJjMWUxYzVmMTk4ZTQ1NDNiYzMwZTA3OWU1MjY2ODhhL3RhYmxlOmVlYjE5ZmUzODg2MTQ3NmE5MGJlZDMyODQ0NzUyMDYxL3RhYmxlcmFuZ2U6ZWViMTlmZTM4ODYxNDc2YTkwYmVkMzI4NDQ3NTIwNjFfNi0zLTEtMS0w_338b34fe-2cac-4704-9bad-143198ec19ac"
      unitRef="usd">12634000</us-gaap:ShareBasedCompensation>
    <amed:AmortizationandImpairmentofOperatingLeaseRightOfUseAsset
      contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8zMS9mcmFnOjJjMWUxYzVmMTk4ZTQ1NDNiYzMwZTA3OWU1MjY2ODhhL3RhYmxlOmVlYjE5ZmUzODg2MTQ3NmE5MGJlZDMyODQ0NzUyMDYxL3RhYmxlcmFuZ2U6ZWViMTlmZTM4ODYxNDc2YTkwYmVkMzI4NDQ3NTIwNjFfNy0xLTEtMS0w_1ff73ad8-84f7-42f9-9d98-1874657f1685"
      unitRef="usd">19702000</amed:AmortizationandImpairmentofOperatingLeaseRightOfUseAsset>
    <amed:AmortizationandImpairmentofOperatingLeaseRightOfUseAsset
      contextRef="i667fa0996400408f9cb2d7f4d3ee2087_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8zMS9mcmFnOjJjMWUxYzVmMTk4ZTQ1NDNiYzMwZTA3OWU1MjY2ODhhL3RhYmxlOmVlYjE5ZmUzODg2MTQ3NmE5MGJlZDMyODQ0NzUyMDYxL3RhYmxlcmFuZ2U6ZWViMTlmZTM4ODYxNDc2YTkwYmVkMzI4NDQ3NTIwNjFfNy0zLTEtMS0w_f3459e07-64ec-4d2d-8d16-d289402000fa"
      unitRef="usd">18558000</amed:AmortizationandImpairmentofOperatingLeaseRightOfUseAsset>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8zMS9mcmFnOjJjMWUxYzVmMTk4ZTQ1NDNiYzMwZTA3OWU1MjY2ODhhL3RhYmxlOmVlYjE5ZmUzODg2MTQ3NmE5MGJlZDMyODQ0NzUyMDYxL3RhYmxlcmFuZ2U6ZWViMTlmZTM4ODYxNDc2YTkwYmVkMzI4NDQ3NTIwNjFfOC0xLTEtMS0w_925d3093-36bd-40bf-b751-a818b4e3c82a"
      unitRef="usd">-8000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="i667fa0996400408f9cb2d7f4d3ee2087_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8zMS9mcmFnOjJjMWUxYzVmMTk4ZTQ1NDNiYzMwZTA3OWU1MjY2ODhhL3RhYmxlOmVlYjE5ZmUzODg2MTQ3NmE5MGJlZDMyODQ0NzUyMDYxL3RhYmxlcmFuZ2U6ZWViMTlmZTM4ODYxNDc2YTkwYmVkMzI4NDQ3NTIwNjFfOC0zLTEtMS0w_cbb516d6-df00-4cc2-b097-b89ad84f5a9f"
      unitRef="usd">94000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:GainLossOnSaleOfInvestments
      contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8zMS9mcmFnOjJjMWUxYzVmMTk4ZTQ1NDNiYzMwZTA3OWU1MjY2ODhhL3RhYmxlOmVlYjE5ZmUzODg2MTQ3NmE5MGJlZDMyODQ0NzUyMDYxL3RhYmxlcmFuZ2U6ZWViMTlmZTM4ODYxNDc2YTkwYmVkMzI4NDQ3NTIwNjFfOS0xLTEtMS0xMzk_04a63eee-22d5-49cf-934a-8fd347534c65"
      unitRef="usd">31092000</us-gaap:GainLossOnSaleOfInvestments>
    <us-gaap:GainLossOnSaleOfInvestments
      contextRef="i667fa0996400408f9cb2d7f4d3ee2087_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8zMS9mcmFnOjJjMWUxYzVmMTk4ZTQ1NDNiYzMwZTA3OWU1MjY2ODhhL3RhYmxlOmVlYjE5ZmUzODg2MTQ3NmE5MGJlZDMyODQ0NzUyMDYxL3RhYmxlcmFuZ2U6ZWViMTlmZTM4ODYxNDc2YTkwYmVkMzI4NDQ3NTIwNjFfOS0zLTEtMS0xMzk_4e5df52b-534a-44fd-995c-39fba42dac6d"
      unitRef="usd">-2980000</us-gaap:GainLossOnSaleOfInvestments>
    <amed:WriteOffOfOtherComprehensiveIncome
      contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8zMS9mcmFnOjJjMWUxYzVmMTk4ZTQ1NDNiYzMwZTA3OWU1MjY2ODhhL3RhYmxlOmVlYjE5ZmUzODg2MTQ3NmE5MGJlZDMyODQ0NzUyMDYxL3RhYmxlcmFuZ2U6ZWViMTlmZTM4ODYxNDc2YTkwYmVkMzI4NDQ3NTIwNjFfOS0xLTEtMS0w_8ad16adc-cbf8-4e77-83d6-8d7a4423cfc3"
      unitRef="usd">0</amed:WriteOffOfOtherComprehensiveIncome>
    <amed:WriteOffOfOtherComprehensiveIncome
      contextRef="i667fa0996400408f9cb2d7f4d3ee2087_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8zMS9mcmFnOjJjMWUxYzVmMTk4ZTQ1NDNiYzMwZTA3OWU1MjY2ODhhL3RhYmxlOmVlYjE5ZmUzODg2MTQ3NmE5MGJlZDMyODQ0NzUyMDYxL3RhYmxlcmFuZ2U6ZWViMTlmZTM4ODYxNDc2YTkwYmVkMzI4NDQ3NTIwNjFfOS0zLTEtMS0w_257e87db-5f95-49ee-b1e6-82379cf4b03e"
      unitRef="usd">15000</amed:WriteOffOfOtherComprehensiveIncome>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8zMS9mcmFnOjJjMWUxYzVmMTk4ZTQ1NDNiYzMwZTA3OWU1MjY2ODhhL3RhYmxlOmVlYjE5ZmUzODg2MTQ3NmE5MGJlZDMyODQ0NzUyMDYxL3RhYmxlcmFuZ2U6ZWViMTlmZTM4ODYxNDc2YTkwYmVkMzI4NDQ3NTIwNjFfMTAtMS0xLTEtMA_b8b53e7c-5a72-465e-9b2a-2ba2aaff2847"
      unitRef="usd">22716000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="i667fa0996400408f9cb2d7f4d3ee2087_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8zMS9mcmFnOjJjMWUxYzVmMTk4ZTQ1NDNiYzMwZTA3OWU1MjY2ODhhL3RhYmxlOmVlYjE5ZmUzODg2MTQ3NmE5MGJlZDMyODQ0NzUyMDYxL3RhYmxlcmFuZ2U6ZWViMTlmZTM4ODYxNDc2YTkwYmVkMzI4NDQ3NTIwNjFfMTAtMy0xLTEtMA_90dab91b-b649-4988-92e0-4ed9ecf02cd3"
      unitRef="usd">-4036000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8zMS9mcmFnOjJjMWUxYzVmMTk4ZTQ1NDNiYzMwZTA3OWU1MjY2ODhhL3RhYmxlOmVlYjE5ZmUzODg2MTQ3NmE5MGJlZDMyODQ0NzUyMDYxL3RhYmxlcmFuZ2U6ZWViMTlmZTM4ODYxNDc2YTkwYmVkMzI4NDQ3NTIwNjFfMTEtMS0xLTEtMA_f547771f-64fc-4a31-833b-8212782fa6c1"
      unitRef="usd">2488000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i667fa0996400408f9cb2d7f4d3ee2087_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8zMS9mcmFnOjJjMWUxYzVmMTk4ZTQ1NDNiYzMwZTA3OWU1MjY2ODhhL3RhYmxlOmVlYjE5ZmUzODg2MTQ3NmE5MGJlZDMyODQ0NzUyMDYxL3RhYmxlcmFuZ2U6ZWViMTlmZTM4ODYxNDc2YTkwYmVkMzI4NDQ3NTIwNjFfMTEtMy0xLTEtMA_e5f1c13e-e0fb-45d4-ba0d-ce3c8f471594"
      unitRef="usd">964000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8zMS9mcmFnOjJjMWUxYzVmMTk4ZTQ1NDNiYzMwZTA3OWU1MjY2ODhhL3RhYmxlOmVlYjE5ZmUzODg2MTQ3NmE5MGJlZDMyODQ0NzUyMDYxL3RhYmxlcmFuZ2U6ZWViMTlmZTM4ODYxNDc2YTkwYmVkMzI4NDQ3NTIwNjFfMTItMS0xLTEtMA_d5c58e92-4495-4f1a-8874-9c084fbe4b9f"
      unitRef="usd">432000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="i667fa0996400408f9cb2d7f4d3ee2087_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8zMS9mcmFnOjJjMWUxYzVmMTk4ZTQ1NDNiYzMwZTA3OWU1MjY2ODhhL3RhYmxlOmVlYjE5ZmUzODg2MTQ3NmE5MGJlZDMyODQ0NzUyMDYxL3RhYmxlcmFuZ2U6ZWViMTlmZTM4ODYxNDc2YTkwYmVkMzI4NDQ3NTIwNjFfMTItMy0xLTEtMA_073bb366-d8ff-4090-9d79-e3dba1b89b70"
      unitRef="usd">437000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:EquityMethodInvestmentDividendsOrDistributions
      contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8zMS9mcmFnOjJjMWUxYzVmMTk4ZTQ1NDNiYzMwZTA3OWU1MjY2ODhhL3RhYmxlOmVlYjE5ZmUzODg2MTQ3NmE5MGJlZDMyODQ0NzUyMDYxL3RhYmxlcmFuZ2U6ZWViMTlmZTM4ODYxNDc2YTkwYmVkMzI4NDQ3NTIwNjFfMTMtMS0xLTEtMA_724c681a-4270-4494-947a-6df12844616a"
      unitRef="usd">2683000</us-gaap:EquityMethodInvestmentDividendsOrDistributions>
    <us-gaap:EquityMethodInvestmentDividendsOrDistributions
      contextRef="i667fa0996400408f9cb2d7f4d3ee2087_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8zMS9mcmFnOjJjMWUxYzVmMTk4ZTQ1NDNiYzMwZTA3OWU1MjY2ODhhL3RhYmxlOmVlYjE5ZmUzODg2MTQ3NmE5MGJlZDMyODQ0NzUyMDYxL3RhYmxlcmFuZ2U6ZWViMTlmZTM4ODYxNDc2YTkwYmVkMzI4NDQ3NTIwNjFfMTMtMy0xLTEtMA_fec47cd5-7cd4-4db5-99b9-abfc793865e7"
      unitRef="usd">2744000</us-gaap:EquityMethodInvestmentDividendsOrDistributions>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8zMS9mcmFnOjJjMWUxYzVmMTk4ZTQ1NDNiYzMwZTA3OWU1MjY2ODhhL3RhYmxlOmVlYjE5ZmUzODg2MTQ3NmE5MGJlZDMyODQ0NzUyMDYxL3RhYmxlcmFuZ2U6ZWViMTlmZTM4ODYxNDc2YTkwYmVkMzI4NDQ3NTIwNjFfMTUtMS0xLTEtMA_f5136d49-9b6c-4614-ada4-6edad9216593"
      unitRef="usd">22787000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i667fa0996400408f9cb2d7f4d3ee2087_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8zMS9mcmFnOjJjMWUxYzVmMTk4ZTQ1NDNiYzMwZTA3OWU1MjY2ODhhL3RhYmxlOmVlYjE5ZmUzODg2MTQ3NmE5MGJlZDMyODQ0NzUyMDYxL3RhYmxlcmFuZ2U6ZWViMTlmZTM4ODYxNDc2YTkwYmVkMzI4NDQ3NTIwNjFfMTUtMy0xLTEtMA_af052e5c-dcb7-4b1b-9fe9-8b60e4cf1bd0"
      unitRef="usd">-8997000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8zMS9mcmFnOjJjMWUxYzVmMTk4ZTQ1NDNiYzMwZTA3OWU1MjY2ODhhL3RhYmxlOmVlYjE5ZmUzODg2MTQ3NmE5MGJlZDMyODQ0NzUyMDYxL3RhYmxlcmFuZ2U6ZWViMTlmZTM4ODYxNDc2YTkwYmVkMzI4NDQ3NTIwNjFfMTYtMS0xLTEtMA_bd582818-5d3c-4cf0-b8c0-396048eca80c"
      unitRef="usd">-3560000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i667fa0996400408f9cb2d7f4d3ee2087_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8zMS9mcmFnOjJjMWUxYzVmMTk4ZTQ1NDNiYzMwZTA3OWU1MjY2ODhhL3RhYmxlOmVlYjE5ZmUzODg2MTQ3NmE5MGJlZDMyODQ0NzUyMDYxL3RhYmxlcmFuZ2U6ZWViMTlmZTM4ODYxNDc2YTkwYmVkMzI4NDQ3NTIwNjFfMTYtMy0xLTEtMA_4ee9d4c7-8e8e-4feb-9433-4cb80b3508ec"
      unitRef="usd">3469000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8zMS9mcmFnOjJjMWUxYzVmMTk4ZTQ1NDNiYzMwZTA3OWU1MjY2ODhhL3RhYmxlOmVlYjE5ZmUzODg2MTQ3NmE5MGJlZDMyODQ0NzUyMDYxL3RhYmxlcmFuZ2U6ZWViMTlmZTM4ODYxNDc2YTkwYmVkMzI4NDQ3NTIwNjFfMTctMS0xLTEtMA_3b3bdad5-45b0-4f5e-aefe-4b8519b208e9"
      unitRef="usd">52000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="i667fa0996400408f9cb2d7f4d3ee2087_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8zMS9mcmFnOjJjMWUxYzVmMTk4ZTQ1NDNiYzMwZTA3OWU1MjY2ODhhL3RhYmxlOmVlYjE5ZmUzODg2MTQ3NmE5MGJlZDMyODQ0NzUyMDYxL3RhYmxlcmFuZ2U6ZWViMTlmZTM4ODYxNDc2YTkwYmVkMzI4NDQ3NTIwNjFfMTctMy0xLTEtMA_89c0f8fe-d323-49ac-9c4d-90f31b649fce"
      unitRef="usd">675000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8zMS9mcmFnOjJjMWUxYzVmMTk4ZTQ1NDNiYzMwZTA3OWU1MjY2ODhhL3RhYmxlOmVlYjE5ZmUzODg2MTQ3NmE5MGJlZDMyODQ0NzUyMDYxL3RhYmxlcmFuZ2U6ZWViMTlmZTM4ODYxNDc2YTkwYmVkMzI4NDQ3NTIwNjFfMTgtMS0xLTEtMA_2f9b4327-c56f-4f7a-8a98-2e35566fe876"
      unitRef="usd">-6530000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="i667fa0996400408f9cb2d7f4d3ee2087_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8zMS9mcmFnOjJjMWUxYzVmMTk4ZTQ1NDNiYzMwZTA3OWU1MjY2ODhhL3RhYmxlOmVlYjE5ZmUzODg2MTQ3NmE5MGJlZDMyODQ0NzUyMDYxL3RhYmxlcmFuZ2U6ZWViMTlmZTM4ODYxNDc2YTkwYmVkMzI4NDQ3NTIwNjFfMTgtMy0xLTEtMA_061fe00b-8cfb-425b-ba5c-ca931f6808d7"
      unitRef="usd">-6452000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8zMS9mcmFnOjJjMWUxYzVmMTk4ZTQ1NDNiYzMwZTA3OWU1MjY2ODhhL3RhYmxlOmVlYjE5ZmUzODg2MTQ3NmE5MGJlZDMyODQ0NzUyMDYxL3RhYmxlcmFuZ2U6ZWViMTlmZTM4ODYxNDc2YTkwYmVkMzI4NDQ3NTIwNjFfMTktMS0xLTEtMA_60825786-5c8d-489c-adce-059bd4e22505"
      unitRef="usd">-1627000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="i667fa0996400408f9cb2d7f4d3ee2087_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8zMS9mcmFnOjJjMWUxYzVmMTk4ZTQ1NDNiYzMwZTA3OWU1MjY2ODhhL3RhYmxlOmVlYjE5ZmUzODg2MTQ3NmE5MGJlZDMyODQ0NzUyMDYxL3RhYmxlcmFuZ2U6ZWViMTlmZTM4ODYxNDc2YTkwYmVkMzI4NDQ3NTIwNjFfMTktMy0xLTEtMA_189ea338-5f3d-41fc-a0f3-1af9e0bf2f05"
      unitRef="usd">27990000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities
      contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8zMS9mcmFnOjJjMWUxYzVmMTk4ZTQ1NDNiYzMwZTA3OWU1MjY2ODhhL3RhYmxlOmVlYjE5ZmUzODg2MTQ3NmE5MGJlZDMyODQ0NzUyMDYxL3RhYmxlcmFuZ2U6ZWViMTlmZTM4ODYxNDc2YTkwYmVkMzI4NDQ3NTIwNjFfMjAtMS0xLTEtMA_30a1aa32-27eb-4e6f-a050-9378158a76f7"
      unitRef="usd">-1736000</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities
      contextRef="i667fa0996400408f9cb2d7f4d3ee2087_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8zMS9mcmFnOjJjMWUxYzVmMTk4ZTQ1NDNiYzMwZTA3OWU1MjY2ODhhL3RhYmxlOmVlYjE5ZmUzODg2MTQ3NmE5MGJlZDMyODQ0NzUyMDYxL3RhYmxlcmFuZ2U6ZWViMTlmZTM4ODYxNDc2YTkwYmVkMzI4NDQ3NTIwNjFfMjAtMy0xLTEtMA_1b0d7b76-5e10-4b16-a5b1-bac5d97ecbcc"
      unitRef="usd">20746000</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
    <amed:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8zMS9mcmFnOjJjMWUxYzVmMTk4ZTQ1NDNiYzMwZTA3OWU1MjY2ODhhL3RhYmxlOmVlYjE5ZmUzODg2MTQ3NmE5MGJlZDMyODQ0NzUyMDYxL3RhYmxlcmFuZ2U6ZWViMTlmZTM4ODYxNDc2YTkwYmVkMzI4NDQ3NTIwNjFfMjEtMS0xLTEtMA_2e881ece-2ab3-496d-adf2-1273350cb762"
      unitRef="usd">-17955000</amed:IncreaseDecreaseInOperatingLeaseLiability>
    <amed:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="i667fa0996400408f9cb2d7f4d3ee2087_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8zMS9mcmFnOjJjMWUxYzVmMTk4ZTQ1NDNiYzMwZTA3OWU1MjY2ODhhL3RhYmxlOmVlYjE5ZmUzODg2MTQ3NmE5MGJlZDMyODQ0NzUyMDYxL3RhYmxlcmFuZ2U6ZWViMTlmZTM4ODYxNDc2YTkwYmVkMzI4NDQ3NTIwNjFfMjEtMy0xLTEtMA_5c1e33da-c3b6-4a4c-af15-943d94494c32"
      unitRef="usd">-16365000</amed:IncreaseDecreaseInOperatingLeaseLiability>
    <amed:IncreaseDecreaseInOperatingLeaseRightOfUseAsset
      contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8zMS9mcmFnOjJjMWUxYzVmMTk4ZTQ1NDNiYzMwZTA3OWU1MjY2ODhhL3RhYmxlOmVlYjE5ZmUzODg2MTQ3NmE5MGJlZDMyODQ0NzUyMDYxL3RhYmxlcmFuZ2U6ZWViMTlmZTM4ODYxNDc2YTkwYmVkMzI4NDQ3NTIwNjFfMjItMS0xLTEtMA_5d382f5e-64e9-42c1-a8b0-a48c09c55711"
      unitRef="usd">-1524000</amed:IncreaseDecreaseInOperatingLeaseRightOfUseAsset>
    <amed:IncreaseDecreaseInOperatingLeaseRightOfUseAsset
      contextRef="i667fa0996400408f9cb2d7f4d3ee2087_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8zMS9mcmFnOjJjMWUxYzVmMTk4ZTQ1NDNiYzMwZTA3OWU1MjY2ODhhL3RhYmxlOmVlYjE5ZmUzODg2MTQ3NmE5MGJlZDMyODQ0NzUyMDYxL3RhYmxlcmFuZ2U6ZWViMTlmZTM4ODYxNDc2YTkwYmVkMzI4NDQ3NTIwNjFfMjItMy0xLTEtMA_53e62a8c-b1ae-4cce-a47b-782ebb37d80a"
      unitRef="usd">-1924000</amed:IncreaseDecreaseInOperatingLeaseRightOfUseAsset>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8zMS9mcmFnOjJjMWUxYzVmMTk4ZTQ1NDNiYzMwZTA3OWU1MjY2ODhhL3RhYmxlOmVlYjE5ZmUzODg2MTQ3NmE5MGJlZDMyODQ0NzUyMDYxL3RhYmxlcmFuZ2U6ZWViMTlmZTM4ODYxNDc2YTkwYmVkMzI4NDQ3NTIwNjFfMjMtMS0xLTEtMA_2b333b5e-63ba-4453-9cb3-fb9f0bf7bc4a"
      unitRef="usd">121960000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i667fa0996400408f9cb2d7f4d3ee2087_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8zMS9mcmFnOjJjMWUxYzVmMTk4ZTQ1NDNiYzMwZTA3OWU1MjY2ODhhL3RhYmxlOmVlYjE5ZmUzODg2MTQ3NmE5MGJlZDMyODQ0NzUyMDYxL3RhYmxlcmFuZ2U6ZWViMTlmZTM4ODYxNDc2YTkwYmVkMzI4NDQ3NTIwNjFfMjMtMy0xLTEtMA_a9a2e18c-d909-43f1-915e-d633674092bd"
      unitRef="usd">139957000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:ProceedsFromSaleOfRestrictedInvestments
      contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8zMS9mcmFnOjJjMWUxYzVmMTk4ZTQ1NDNiYzMwZTA3OWU1MjY2ODhhL3RhYmxlOmVlYjE5ZmUzODg2MTQ3NmE5MGJlZDMyODQ0NzUyMDYxL3RhYmxlcmFuZ2U6ZWViMTlmZTM4ODYxNDc2YTkwYmVkMzI4NDQ3NTIwNjFfMjUtMS0xLTEtMA_3af3620f-ba8f-4ec0-b6bc-892f6228a9d3"
      unitRef="usd">25000</us-gaap:ProceedsFromSaleOfRestrictedInvestments>
    <us-gaap:ProceedsFromSaleOfRestrictedInvestments
      contextRef="i667fa0996400408f9cb2d7f4d3ee2087_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8zMS9mcmFnOjJjMWUxYzVmMTk4ZTQ1NDNiYzMwZTA3OWU1MjY2ODhhL3RhYmxlOmVlYjE5ZmUzODg2MTQ3NmE5MGJlZDMyODQ0NzUyMDYxL3RhYmxlcmFuZ2U6ZWViMTlmZTM4ODYxNDc2YTkwYmVkMzI4NDQ3NTIwNjFfMjUtMy0xLTEtMA_bbff9e35-3de8-4e0d-876f-d5113206b2df"
      unitRef="usd">21000</us-gaap:ProceedsFromSaleOfRestrictedInvestments>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment
      contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8zMS9mcmFnOjJjMWUxYzVmMTk4ZTQ1NDNiYzMwZTA3OWU1MjY2ODhhL3RhYmxlOmVlYjE5ZmUzODg2MTQ3NmE5MGJlZDMyODQ0NzUyMDYxL3RhYmxlcmFuZ2U6ZWViMTlmZTM4ODYxNDc2YTkwYmVkMzI4NDQ3NTIwNjFfMjYtMS0xLTEtMA_466779a1-99b0-4445-895c-cfb41a7ef5ae"
      unitRef="usd">42000</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment
      contextRef="i667fa0996400408f9cb2d7f4d3ee2087_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8zMS9mcmFnOjJjMWUxYzVmMTk4ZTQ1NDNiYzMwZTA3OWU1MjY2ODhhL3RhYmxlOmVlYjE5ZmUzODg2MTQ3NmE5MGJlZDMyODQ0NzUyMDYxL3RhYmxlcmFuZ2U6ZWViMTlmZTM4ODYxNDc2YTkwYmVkMzI4NDQ3NTIwNjFfMjYtMy0xLTEtMA_883b6537-be22-4096-95d5-4edd4eb02173"
      unitRef="usd">80000</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8zMS9mcmFnOjJjMWUxYzVmMTk4ZTQ1NDNiYzMwZTA3OWU1MjY2ODhhL3RhYmxlOmVlYjE5ZmUzODg2MTQ3NmE5MGJlZDMyODQ0NzUyMDYxL3RhYmxlcmFuZ2U6ZWViMTlmZTM4ODYxNDc2YTkwYmVkMzI4NDQ3NTIwNjFfMjctMS0xLTEtMA_c96ba73e-8f64-47bd-b8bc-28367a05821d"
      unitRef="usd">2943000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i667fa0996400408f9cb2d7f4d3ee2087_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8zMS9mcmFnOjJjMWUxYzVmMTk4ZTQ1NDNiYzMwZTA3OWU1MjY2ODhhL3RhYmxlOmVlYjE5ZmUzODg2MTQ3NmE5MGJlZDMyODQ0NzUyMDYxL3RhYmxlcmFuZ2U6ZWViMTlmZTM4ODYxNDc2YTkwYmVkMzI4NDQ3NTIwNjFfMjctMy0xLTEtMA_89c99a91-c021-45d1-a4d1-e7e3359415fb"
      unitRef="usd">1701000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireInvestments
      contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8zMS9mcmFnOjJjMWUxYzVmMTk4ZTQ1NDNiYzMwZTA3OWU1MjY2ODhhL3RhYmxlOmVlYjE5ZmUzODg2MTQ3NmE5MGJlZDMyODQ0NzUyMDYxL3RhYmxlcmFuZ2U6ZWViMTlmZTM4ODYxNDc2YTkwYmVkMzI4NDQ3NTIwNjFfMjktMS0xLTEtMTQy_9956b72d-67e8-489f-bdd1-57ef85c7de62"
      unitRef="usd">0</us-gaap:PaymentsToAcquireInvestments>
    <us-gaap:PaymentsToAcquireInvestments
      contextRef="i667fa0996400408f9cb2d7f4d3ee2087_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8zMS9mcmFnOjJjMWUxYzVmMTk4ZTQ1NDNiYzMwZTA3OWU1MjY2ODhhL3RhYmxlOmVlYjE5ZmUzODg2MTQ3NmE5MGJlZDMyODQ0NzUyMDYxL3RhYmxlcmFuZ2U6ZWViMTlmZTM4ODYxNDc2YTkwYmVkMzI4NDQ3NTIwNjFfMjktMy0xLTEtMTQy_c05309c8-d00e-41a1-94c3-f7af1c183502"
      unitRef="usd">875000</us-gaap:PaymentsToAcquireInvestments>
    <us-gaap:ProceedsFromSaleOfEquityMethodInvestments
      contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8zMS9mcmFnOjJjMWUxYzVmMTk4ZTQ1NDNiYzMwZTA3OWU1MjY2ODhhL3RhYmxlOmVlYjE5ZmUzODg2MTQ3NmE5MGJlZDMyODQ0NzUyMDYxL3RhYmxlcmFuZ2U6ZWViMTlmZTM4ODYxNDc2YTkwYmVkMzI4NDQ3NTIwNjFfMzAtMS0xLTEtMTQ1_e8d50e1a-6c3d-4a43-95e3-9b745c4fdbb6"
      unitRef="usd">0</us-gaap:ProceedsFromSaleOfEquityMethodInvestments>
    <us-gaap:ProceedsFromSaleOfEquityMethodInvestments
      contextRef="i667fa0996400408f9cb2d7f4d3ee2087_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8zMS9mcmFnOjJjMWUxYzVmMTk4ZTQ1NDNiYzMwZTA3OWU1MjY2ODhhL3RhYmxlOmVlYjE5ZmUzODg2MTQ3NmE5MGJlZDMyODQ0NzUyMDYxL3RhYmxlcmFuZ2U6ZWViMTlmZTM4ODYxNDc2YTkwYmVkMzI4NDQ3NTIwNjFfMzAtMy0xLTEtMTQ1_31914120-4786-4e8b-a964-115b882a925b"
      unitRef="usd">17876000</us-gaap:ProceedsFromSaleOfEquityMethodInvestments>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8zMS9mcmFnOjJjMWUxYzVmMTk4ZTQ1NDNiYzMwZTA3OWU1MjY2ODhhL3RhYmxlOmVlYjE5ZmUzODg2MTQ3NmE5MGJlZDMyODQ0NzUyMDYxL3RhYmxlcmFuZ2U6ZWViMTlmZTM4ODYxNDc2YTkwYmVkMzI4NDQ3NTIwNjFfMjgtMS0xLTEtMA_2c4cf163-7e87-45d9-b0a4-3f2721f924dd"
      unitRef="usd">2503000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="i667fa0996400408f9cb2d7f4d3ee2087_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8zMS9mcmFnOjJjMWUxYzVmMTk4ZTQ1NDNiYzMwZTA3OWU1MjY2ODhhL3RhYmxlOmVlYjE5ZmUzODg2MTQ3NmE5MGJlZDMyODQ0NzUyMDYxL3RhYmxlcmFuZ2U6ZWViMTlmZTM4ODYxNDc2YTkwYmVkMzI4NDQ3NTIwNjFfMjgtMy0xLTEtMA_249489e1-7bd0-498e-adac-1aff3ea8c618"
      unitRef="usd">299723000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8zMS9mcmFnOjJjMWUxYzVmMTk4ZTQ1NDNiYzMwZTA3OWU1MjY2ODhhL3RhYmxlOmVlYjE5ZmUzODg2MTQ3NmE5MGJlZDMyODQ0NzUyMDYxL3RhYmxlcmFuZ2U6ZWViMTlmZTM4ODYxNDc2YTkwYmVkMzI4NDQ3NTIwNjFfMjktMS0xLTEtMA_5d0462a3-ef26-44a2-93b0-04a47ff213fc"
      unitRef="usd">-5379000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i667fa0996400408f9cb2d7f4d3ee2087_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8zMS9mcmFnOjJjMWUxYzVmMTk4ZTQ1NDNiYzMwZTA3OWU1MjY2ODhhL3RhYmxlOmVlYjE5ZmUzODg2MTQ3NmE5MGJlZDMyODQ0NzUyMDYxL3RhYmxlcmFuZ2U6ZWViMTlmZTM4ODYxNDc2YTkwYmVkMzI4NDQ3NTIwNjFfMjktMy0xLTEtMA_9fbe7fb0-706c-4bb4-9c4e-1d3ac156182c"
      unitRef="usd">-284322000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8zMS9mcmFnOjJjMWUxYzVmMTk4ZTQ1NDNiYzMwZTA3OWU1MjY2ODhhL3RhYmxlOmVlYjE5ZmUzODg2MTQ3NmE5MGJlZDMyODQ0NzUyMDYxL3RhYmxlcmFuZ2U6ZWViMTlmZTM4ODYxNDc2YTkwYmVkMzI4NDQ3NTIwNjFfMzEtMS0xLTEtMA_2ca97634-8fbc-4afe-abac-74bc130977df"
      unitRef="usd">623000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="i667fa0996400408f9cb2d7f4d3ee2087_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8zMS9mcmFnOjJjMWUxYzVmMTk4ZTQ1NDNiYzMwZTA3OWU1MjY2ODhhL3RhYmxlOmVlYjE5ZmUzODg2MTQ3NmE5MGJlZDMyODQ0NzUyMDYxL3RhYmxlcmFuZ2U6ZWViMTlmZTM4ODYxNDc2YTkwYmVkMzI4NDQ3NTIwNjFfMzEtMy0xLTEtMA_98802280-a610-4260-9acf-8392dc21b206"
      unitRef="usd">2947000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockPlans
      contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8zMS9mcmFnOjJjMWUxYzVmMTk4ZTQ1NDNiYzMwZTA3OWU1MjY2ODhhL3RhYmxlOmVlYjE5ZmUzODg2MTQ3NmE5MGJlZDMyODQ0NzUyMDYxL3RhYmxlcmFuZ2U6ZWViMTlmZTM4ODYxNDc2YTkwYmVkMzI4NDQ3NTIwNjFfMzItMS0xLTEtMA_191cd716-6de7-416c-b566-c05861f3a8f5"
      unitRef="usd">1961000</us-gaap:ProceedsFromStockPlans>
    <us-gaap:ProceedsFromStockPlans
      contextRef="i667fa0996400408f9cb2d7f4d3ee2087_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8zMS9mcmFnOjJjMWUxYzVmMTk4ZTQ1NDNiYzMwZTA3OWU1MjY2ODhhL3RhYmxlOmVlYjE5ZmUzODg2MTQ3NmE5MGJlZDMyODQ0NzUyMDYxL3RhYmxlcmFuZ2U6ZWViMTlmZTM4ODYxNDc2YTkwYmVkMzI4NDQ3NTIwNjFfMzItMy0xLTEtMA_2133012a-4b68-495d-bb69-ae85d3382136"
      unitRef="usd">1686000</us-gaap:ProceedsFromStockPlans>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8zMS9mcmFnOjJjMWUxYzVmMTk4ZTQ1NDNiYzMwZTA3OWU1MjY2ODhhL3RhYmxlOmVlYjE5ZmUzODg2MTQ3NmE5MGJlZDMyODQ0NzUyMDYxL3RhYmxlcmFuZ2U6ZWViMTlmZTM4ODYxNDc2YTkwYmVkMzI4NDQ3NTIwNjFfMzMtMS0xLTEtMA_9c896b90-ffd9-4011-9efb-c08575027350"
      unitRef="usd">6944000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i667fa0996400408f9cb2d7f4d3ee2087_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8zMS9mcmFnOjJjMWUxYzVmMTk4ZTQ1NDNiYzMwZTA3OWU1MjY2ODhhL3RhYmxlOmVlYjE5ZmUzODg2MTQ3NmE5MGJlZDMyODQ0NzUyMDYxL3RhYmxlcmFuZ2U6ZWViMTlmZTM4ODYxNDc2YTkwYmVkMzI4NDQ3NTIwNjFfMzMtMy0xLTEtMA_72044cf7-b38f-4b2c-a0ca-a8b1e092390a"
      unitRef="usd">6384000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <amed:CashDistributionToNoncontrollingInterest
      contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8zMS9mcmFnOjJjMWUxYzVmMTk4ZTQ1NDNiYzMwZTA3OWU1MjY2ODhhL3RhYmxlOmVlYjE5ZmUzODg2MTQ3NmE5MGJlZDMyODQ0NzUyMDYxL3RhYmxlcmFuZ2U6ZWViMTlmZTM4ODYxNDc2YTkwYmVkMzI4NDQ3NTIwNjFfMzQtMS0xLTEtMA_1c1e149c-830b-438f-b8f0-8871dfd1202a"
      unitRef="usd">794000</amed:CashDistributionToNoncontrollingInterest>
    <amed:CashDistributionToNoncontrollingInterest
      contextRef="i667fa0996400408f9cb2d7f4d3ee2087_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8zMS9mcmFnOjJjMWUxYzVmMTk4ZTQ1NDNiYzMwZTA3OWU1MjY2ODhhL3RhYmxlOmVlYjE5ZmUzODg2MTQ3NmE5MGJlZDMyODQ0NzUyMDYxL3RhYmxlcmFuZ2U6ZWViMTlmZTM4ODYxNDc2YTkwYmVkMzI4NDQ3NTIwNjFfMzQtMy0xLTEtMA_cf52c8db-5041-45df-bd7a-b74f023e4319"
      unitRef="usd">372000</amed:CashDistributionToNoncontrollingInterest>
    <us-gaap:ProceedsFromShortTermDebt
      contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8zMS9mcmFnOjJjMWUxYzVmMTk4ZTQ1NDNiYzMwZTA3OWU1MjY2ODhhL3RhYmxlOmVlYjE5ZmUzODg2MTQ3NmE5MGJlZDMyODQ0NzUyMDYxL3RhYmxlcmFuZ2U6ZWViMTlmZTM4ODYxNDc2YTkwYmVkMzI4NDQ3NTIwNjFfMzUtMS0xLTEtMA_859c4f47-0963-4757-a777-f85e880621fe"
      unitRef="usd">389200000</us-gaap:ProceedsFromShortTermDebt>
    <us-gaap:ProceedsFromShortTermDebt
      contextRef="i667fa0996400408f9cb2d7f4d3ee2087_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8zMS9mcmFnOjJjMWUxYzVmMTk4ZTQ1NDNiYzMwZTA3OWU1MjY2ODhhL3RhYmxlOmVlYjE5ZmUzODg2MTQ3NmE5MGJlZDMyODQ0NzUyMDYxL3RhYmxlcmFuZ2U6ZWViMTlmZTM4ODYxNDc2YTkwYmVkMzI4NDQ3NTIwNjFfMzUtMy0xLTEtMA_fce18d2f-7a74-42f0-9e67-cb224a8dbc5d"
      unitRef="usd">424500000</us-gaap:ProceedsFromShortTermDebt>
    <us-gaap:RepaymentsOfShortTermDebt
      contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8zMS9mcmFnOjJjMWUxYzVmMTk4ZTQ1NDNiYzMwZTA3OWU1MjY2ODhhL3RhYmxlOmVlYjE5ZmUzODg2MTQ3NmE5MGJlZDMyODQ0NzUyMDYxL3RhYmxlcmFuZ2U6ZWViMTlmZTM4ODYxNDc2YTkwYmVkMzI4NDQ3NTIwNjFfMzYtMS0xLTEtMA_d40d0aa0-81f9-44c9-b273-6973fe7e1777"
      unitRef="usd">410200000</us-gaap:RepaymentsOfShortTermDebt>
    <us-gaap:RepaymentsOfShortTermDebt
      contextRef="i667fa0996400408f9cb2d7f4d3ee2087_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8zMS9mcmFnOjJjMWUxYzVmMTk4ZTQ1NDNiYzMwZTA3OWU1MjY2ODhhL3RhYmxlOmVlYjE5ZmUzODg2MTQ3NmE5MGJlZDMyODQ0NzUyMDYxL3RhYmxlcmFuZ2U6ZWViMTlmZTM4ODYxNDc2YTkwYmVkMzI4NDQ3NTIwNjFfMzYtMy0xLTEtMA_f16873f5-abab-4cba-8461-646722d6e599"
      unitRef="usd">259500000</us-gaap:RepaymentsOfShortTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8zMS9mcmFnOjJjMWUxYzVmMTk4ZTQ1NDNiYzMwZTA3OWU1MjY2ODhhL3RhYmxlOmVlYjE5ZmUzODg2MTQ3NmE5MGJlZDMyODQ0NzUyMDYxL3RhYmxlcmFuZ2U6ZWViMTlmZTM4ODYxNDc2YTkwYmVkMzI4NDQ3NTIwNjFfMzctMS0xLTEtMA_11445b5f-273a-4617-bc15-9084430c5efb"
      unitRef="usd">5392000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="i667fa0996400408f9cb2d7f4d3ee2087_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8zMS9mcmFnOjJjMWUxYzVmMTk4ZTQ1NDNiYzMwZTA3OWU1MjY2ODhhL3RhYmxlOmVlYjE5ZmUzODg2MTQ3NmE5MGJlZDMyODQ0NzUyMDYxL3RhYmxlcmFuZ2U6ZWViMTlmZTM4ODYxNDc2YTkwYmVkMzI4NDQ3NTIwNjFfMzctMy0xLTEtMA_0e092680-3622-496c-a8f2-a95621605ec8"
      unitRef="usd">4675000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8zMS9mcmFnOjJjMWUxYzVmMTk4ZTQ1NDNiYzMwZTA3OWU1MjY2ODhhL3RhYmxlOmVlYjE5ZmUzODg2MTQ3NmE5MGJlZDMyODQ0NzUyMDYxL3RhYmxlcmFuZ2U6ZWViMTlmZTM4ODYxNDc2YTkwYmVkMzI4NDQ3NTIwNjFfMzgtMS0xLTEtMA_cb01f206-9232-4c86-bd0c-a6c2d374e67d"
      unitRef="usd">74074000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="i667fa0996400408f9cb2d7f4d3ee2087_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8zMS9mcmFnOjJjMWUxYzVmMTk4ZTQ1NDNiYzMwZTA3OWU1MjY2ODhhL3RhYmxlOmVlYjE5ZmUzODg2MTQ3NmE5MGJlZDMyODQ0NzUyMDYxL3RhYmxlcmFuZ2U6ZWViMTlmZTM4ODYxNDc2YTkwYmVkMzI4NDQ3NTIwNjFfMzgtMy0xLTEtMA_3601a2c2-ccc3-4131-89d8-93e05ee48abb"
      unitRef="usd">0</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <amed:FundsReceivedFromProviderReliefFundAdvance
      contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8zMS9mcmFnOjJjMWUxYzVmMTk4ZTQ1NDNiYzMwZTA3OWU1MjY2ODhhL3RhYmxlOmVlYjE5ZmUzODg2MTQ3NmE5MGJlZDMyODQ0NzUyMDYxL3RhYmxlcmFuZ2U6ZWViMTlmZTM4ODYxNDc2YTkwYmVkMzI4NDQ3NTIwNjFfMzktMS0xLTEtMA_56ab97e1-863b-4a36-99eb-2a1462227d65"
      unitRef="usd">-1672000</amed:FundsReceivedFromProviderReliefFundAdvance>
    <amed:FundsReceivedFromProviderReliefFundAdvance
      contextRef="i667fa0996400408f9cb2d7f4d3ee2087_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8zMS9mcmFnOjJjMWUxYzVmMTk4ZTQ1NDNiYzMwZTA3OWU1MjY2ODhhL3RhYmxlOmVlYjE5ZmUzODg2MTQ3NmE5MGJlZDMyODQ0NzUyMDYxL3RhYmxlcmFuZ2U6ZWViMTlmZTM4ODYxNDc2YTkwYmVkMzI4NDQ3NTIwNjFfMzktMy0xLTEtMA_8cf23786-03ba-481f-a4cb-5814533222b3"
      unitRef="usd">70000000</amed:FundsReceivedFromProviderReliefFundAdvance>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8zMS9mcmFnOjJjMWUxYzVmMTk4ZTQ1NDNiYzMwZTA3OWU1MjY2ODhhL3RhYmxlOmVlYjE5ZmUzODg2MTQ3NmE5MGJlZDMyODQ0NzUyMDYxL3RhYmxlcmFuZ2U6ZWViMTlmZTM4ODYxNDc2YTkwYmVkMzI4NDQ3NTIwNjFfNDAtMS0xLTEtMA_4f27d845-464b-4364-beed-c8c14623d1b6"
      unitRef="usd">-107292000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i667fa0996400408f9cb2d7f4d3ee2087_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8zMS9mcmFnOjJjMWUxYzVmMTk4ZTQ1NDNiYzMwZTA3OWU1MjY2ODhhL3RhYmxlOmVlYjE5ZmUzODg2MTQ3NmE5MGJlZDMyODQ0NzUyMDYxL3RhYmxlcmFuZ2U6ZWViMTlmZTM4ODYxNDc2YTkwYmVkMzI4NDQ3NTIwNjFfNDAtMy0xLTEtMA_12d23d49-b30f-4699-bfa0-4652c030dae3"
      unitRef="usd">228202000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8zMS9mcmFnOjJjMWUxYzVmMTk4ZTQ1NDNiYzMwZTA3OWU1MjY2ODhhL3RhYmxlOmVlYjE5ZmUzODg2MTQ3NmE5MGJlZDMyODQ0NzUyMDYxL3RhYmxlcmFuZ2U6ZWViMTlmZTM4ODYxNDc2YTkwYmVkMzI4NDQ3NTIwNjFfNDEtMS0xLTEtMA_33fea8d8-277d-41fe-b6d0-a5739b20826c"
      unitRef="usd">9289000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="i667fa0996400408f9cb2d7f4d3ee2087_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8zMS9mcmFnOjJjMWUxYzVmMTk4ZTQ1NDNiYzMwZTA3OWU1MjY2ODhhL3RhYmxlOmVlYjE5ZmUzODg2MTQ3NmE5MGJlZDMyODQ0NzUyMDYxL3RhYmxlcmFuZ2U6ZWViMTlmZTM4ODYxNDc2YTkwYmVkMzI4NDQ3NTIwNjFfNDEtMy0xLTEtMA_aba8481e-27eb-4314-9dd3-54a4ae3a620b"
      unitRef="usd">83837000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i87ceb60dc20d4df1b0a97d3514837910_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8zMS9mcmFnOjJjMWUxYzVmMTk4ZTQ1NDNiYzMwZTA3OWU1MjY2ODhhL3RhYmxlOmVlYjE5ZmUzODg2MTQ3NmE5MGJlZDMyODQ0NzUyMDYxL3RhYmxlcmFuZ2U6ZWViMTlmZTM4ODYxNDc2YTkwYmVkMzI4NDQ3NTIwNjFfNDItMS0xLTEtMA_c66eda09-86fb-46d1-a372-fa25f76e1bae"
      unitRef="usd">83357000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ifa673cc4c9af455b97f34a55548dfc84_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8zMS9mcmFnOjJjMWUxYzVmMTk4ZTQ1NDNiYzMwZTA3OWU1MjY2ODhhL3RhYmxlOmVlYjE5ZmUzODg2MTQ3NmE5MGJlZDMyODQ0NzUyMDYxL3RhYmxlcmFuZ2U6ZWViMTlmZTM4ODYxNDc2YTkwYmVkMzI4NDQ3NTIwNjFfNDItMy0xLTEtMA_6909caad-f17a-4552-aba1-380471bb08a5"
      unitRef="usd">96490000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i1e833203be6947b4968aba4d20064ec8_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8zMS9mcmFnOjJjMWUxYzVmMTk4ZTQ1NDNiYzMwZTA3OWU1MjY2ODhhL3RhYmxlOmVlYjE5ZmUzODg2MTQ3NmE5MGJlZDMyODQ0NzUyMDYxL3RhYmxlcmFuZ2U6ZWViMTlmZTM4ODYxNDc2YTkwYmVkMzI4NDQ3NTIwNjFfNDMtMS0xLTEtMA_0e5a0f4f-b396-4fe9-9478-10439950952f"
      unitRef="usd">92646000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i15586f038620443192b7c904beb4ad54_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8zMS9mcmFnOjJjMWUxYzVmMTk4ZTQ1NDNiYzMwZTA3OWU1MjY2ODhhL3RhYmxlOmVlYjE5ZmUzODg2MTQ3NmE5MGJlZDMyODQ0NzUyMDYxL3RhYmxlcmFuZ2U6ZWViMTlmZTM4ODYxNDc2YTkwYmVkMzI4NDQ3NTIwNjFfNDMtMy0xLTEtMA_73877a1f-54d5-4eb7-b41d-fb0c425db7ce"
      unitRef="usd">180327000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:InterestPaidNet
      contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8zMS9mcmFnOjJjMWUxYzVmMTk4ZTQ1NDNiYzMwZTA3OWU1MjY2ODhhL3RhYmxlOmVlYjE5ZmUzODg2MTQ3NmE5MGJlZDMyODQ0NzUyMDYxL3RhYmxlcmFuZ2U6ZWViMTlmZTM4ODYxNDc2YTkwYmVkMzI4NDQ3NTIwNjFfNDUtMS0xLTEtMA_f83f5951-2124-4392-9a68-457d1debaf1e"
      unitRef="usd">1914000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="i667fa0996400408f9cb2d7f4d3ee2087_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8zMS9mcmFnOjJjMWUxYzVmMTk4ZTQ1NDNiYzMwZTA3OWU1MjY2ODhhL3RhYmxlOmVlYjE5ZmUzODg2MTQ3NmE5MGJlZDMyODQ0NzUyMDYxL3RhYmxlcmFuZ2U6ZWViMTlmZTM4ODYxNDc2YTkwYmVkMzI4NDQ3NTIwNjFfNDUtMy0xLTEtMA_6763934d-bfd4-417b-96e9-c5d713c02566"
      unitRef="usd">3292000</us-gaap:InterestPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8zMS9mcmFnOjJjMWUxYzVmMTk4ZTQ1NDNiYzMwZTA3OWU1MjY2ODhhL3RhYmxlOmVlYjE5ZmUzODg2MTQ3NmE5MGJlZDMyODQ0NzUyMDYxL3RhYmxlcmFuZ2U6ZWViMTlmZTM4ODYxNDc2YTkwYmVkMzI4NDQ3NTIwNjFfNDYtMS0xLTEtMA_32fe49ab-9f27-4423-8812-3f34753449b8"
      unitRef="usd">8667000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="i667fa0996400408f9cb2d7f4d3ee2087_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8zMS9mcmFnOjJjMWUxYzVmMTk4ZTQ1NDNiYzMwZTA3OWU1MjY2ODhhL3RhYmxlOmVlYjE5ZmUzODg2MTQ3NmE5MGJlZDMyODQ0NzUyMDYxL3RhYmxlcmFuZ2U6ZWViMTlmZTM4ODYxNDc2YTkwYmVkMzI4NDQ3NTIwNjFfNDYtMy0xLTEtMA_d2908849-79d6-4203-9534-935710c7b5dd"
      unitRef="usd">8153000</us-gaap:IncomeTaxesPaidNet>
    <amed:CashPaidForOperatingLeaseLiabilities
      contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8zMS9mcmFnOjJjMWUxYzVmMTk4ZTQ1NDNiYzMwZTA3OWU1MjY2ODhhL3RhYmxlOmVlYjE5ZmUzODg2MTQ3NmE5MGJlZDMyODQ0NzUyMDYxL3RhYmxlcmFuZ2U6ZWViMTlmZTM4ODYxNDc2YTkwYmVkMzI4NDQ3NTIwNjFfNDctMS0xLTEtMA_9cb5d110-eaea-4ec0-8840-2b1641e16533"
      unitRef="usd">19479000</amed:CashPaidForOperatingLeaseLiabilities>
    <amed:CashPaidForOperatingLeaseLiabilities
      contextRef="i667fa0996400408f9cb2d7f4d3ee2087_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8zMS9mcmFnOjJjMWUxYzVmMTk4ZTQ1NDNiYzMwZTA3OWU1MjY2ODhhL3RhYmxlOmVlYjE5ZmUzODg2MTQ3NmE5MGJlZDMyODQ0NzUyMDYxL3RhYmxlcmFuZ2U6ZWViMTlmZTM4ODYxNDc2YTkwYmVkMzI4NDQ3NTIwNjFfNDctMy0xLTEtMA_44a0e539-6cc3-4b70-a916-d53b5405362d"
      unitRef="usd">18289000</amed:CashPaidForOperatingLeaseLiabilities>
    <amed:CashPaidForFinanceLeaseLiabilities
      contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8zMS9mcmFnOjJjMWUxYzVmMTk4ZTQ1NDNiYzMwZTA3OWU1MjY2ODhhL3RhYmxlOmVlYjE5ZmUzODg2MTQ3NmE5MGJlZDMyODQ0NzUyMDYxL3RhYmxlcmFuZ2U6ZWViMTlmZTM4ODYxNDc2YTkwYmVkMzI4NDQ3NTIwNjFfNDgtMS0xLTEtMA_a4c3efaa-b762-4609-bb2c-3ad3c8cda9f1"
      unitRef="usd">1017000</amed:CashPaidForFinanceLeaseLiabilities>
    <amed:CashPaidForFinanceLeaseLiabilities
      contextRef="i667fa0996400408f9cb2d7f4d3ee2087_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8zMS9mcmFnOjJjMWUxYzVmMTk4ZTQ1NDNiYzMwZTA3OWU1MjY2ODhhL3RhYmxlOmVlYjE5ZmUzODg2MTQ3NmE5MGJlZDMyODQ0NzUyMDYxL3RhYmxlcmFuZ2U6ZWViMTlmZTM4ODYxNDc2YTkwYmVkMzI4NDQ3NTIwNjFfNDgtMy0xLTEtMA_f9bae11d-30bf-4362-929f-f16b23ddc370"
      unitRef="usd">986000</amed:CashPaidForFinanceLeaseLiabilities>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8zMS9mcmFnOjJjMWUxYzVmMTk4ZTQ1NDNiYzMwZTA3OWU1MjY2ODhhL3RhYmxlOmVlYjE5ZmUzODg2MTQ3NmE5MGJlZDMyODQ0NzUyMDYxL3RhYmxlcmFuZ2U6ZWViMTlmZTM4ODYxNDc2YTkwYmVkMzI4NDQ3NTIwNjFfNTAtMS0xLTEtMA_eb409e4b-4952-4695-892f-6105fa4052b2"
      unitRef="usd">20689000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="i667fa0996400408f9cb2d7f4d3ee2087_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8zMS9mcmFnOjJjMWUxYzVmMTk4ZTQ1NDNiYzMwZTA3OWU1MjY2ODhhL3RhYmxlOmVlYjE5ZmUzODg2MTQ3NmE5MGJlZDMyODQ0NzUyMDYxL3RhYmxlcmFuZ2U6ZWViMTlmZTM4ODYxNDc2YTkwYmVkMzI4NDQ3NTIwNjFfNTAtMy0xLTEtMA_b031ec59-4a30-4ec4-8992-e0e92556411b"
      unitRef="usd">18891000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
      contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8zMS9mcmFnOjJjMWUxYzVmMTk4ZTQ1NDNiYzMwZTA3OWU1MjY2ODhhL3RhYmxlOmVlYjE5ZmUzODg2MTQ3NmE5MGJlZDMyODQ0NzUyMDYxL3RhYmxlcmFuZ2U6ZWViMTlmZTM4ODYxNDc2YTkwYmVkMzI4NDQ3NTIwNjFfNTEtMS0xLTEtMA_3ec4acca-be15-4d6e-ad88-2b70c47c6b96"
      unitRef="usd">527000</us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
      contextRef="i667fa0996400408f9cb2d7f4d3ee2087_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8zMS9mcmFnOjJjMWUxYzVmMTk4ZTQ1NDNiYzMwZTA3OWU1MjY2ODhhL3RhYmxlOmVlYjE5ZmUzODg2MTQ3NmE5MGJlZDMyODQ0NzUyMDYxL3RhYmxlcmFuZ2U6ZWViMTlmZTM4ODYxNDc2YTkwYmVkMzI4NDQ3NTIwNjFfNTEtMy0xLTEtMA_637fd1a4-5561-499b-a55d-41b46f03ef1a"
      unitRef="usd">487000</us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability>
    <amed:LesseeOperatingleaseReductionstoROUassetsresultingfromreductionstoleaseobligations
      contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8zMS9mcmFnOjJjMWUxYzVmMTk4ZTQ1NDNiYzMwZTA3OWU1MjY2ODhhL3RhYmxlOmVlYjE5ZmUzODg2MTQ3NmE5MGJlZDMyODQ0NzUyMDYxL3RhYmxlcmFuZ2U6ZWViMTlmZTM4ODYxNDc2YTkwYmVkMzI4NDQ3NTIwNjFfNTItMS0xLTEtMA_51dafcf7-bb4a-4d19-bd17-7175c2df33f0"
      unitRef="usd">904000</amed:LesseeOperatingleaseReductionstoROUassetsresultingfromreductionstoleaseobligations>
    <amed:LesseeOperatingleaseReductionstoROUassetsresultingfromreductionstoleaseobligations
      contextRef="i667fa0996400408f9cb2d7f4d3ee2087_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8zMS9mcmFnOjJjMWUxYzVmMTk4ZTQ1NDNiYzMwZTA3OWU1MjY2ODhhL3RhYmxlOmVlYjE5ZmUzODg2MTQ3NmE5MGJlZDMyODQ0NzUyMDYxL3RhYmxlcmFuZ2U6ZWViMTlmZTM4ODYxNDc2YTkwYmVkMzI4NDQ3NTIwNjFfNTItMy0xLTEtMA_23be7f66-28a1-4f62-bdcb-4188ac9347e1"
      unitRef="usd">407000</amed:LesseeOperatingleaseReductionstoROUassetsresultingfromreductionstoleaseobligations>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock
      contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8zNy9mcmFnOmMxNzYyMDBlMGRjNjRjOGE4NzU4YTM5ZTUxODJhZDk1L3RleHRyZWdpb246YzE3NjIwMGUwZGM2NGM4YTg3NThhMzllNTE4MmFkOTVfNTEwMA_99cc7601-4027-483e-8ac5-01930bb3643f">NATURE OF OPERATIONS, CONSOLIDATION AND PRESENTATION OF FINANCIAL STATEMENTS&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amedisys, Inc., a Delaware corporation, (together with its consolidated subsidiaries, referred to herein as &#x201c;Amedisys,&#x201d; &#x201c;we,&#x201d; &#x201c;us,&#x201d; or &#x201c;our&#x201d;) is a multi-state provider of home health, hospice and personal care services with approximately 75% of our net service revenue derived from Medicare for the three and six-month periods ended June 30, 2021 and approximately 74% of our net service revenue derived from Medicare for the three and six-month periods ended June 30, 2020. As of June&#160;30, 2021, we owned and operated 320 Medicare-certified home health care centers, 180 Medicare-certified hospice care centers and 14 personal-care care centers in 39 states within the United States and the District of Columbia.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In our opinion, the accompanying unaudited condensed consolidated financial statements contain all adjustments (consisting solely of normal recurring adjustments) necessary to present fairly our financial position, our results of operations and our cash flows in accordance with U.S. generally accepted accounting principles (&#x201c;U.S. GAAP&#x201d;) for interim financial reporting. Our results of operations for the interim periods presented are not necessarily indicative of the results of our operations for the entire year and have not been audited by our independent auditors.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;This report should be read in conjunction with our consolidated financial statements and related notes included in our Annual Report on Form 10-K for the year ended December&#160;31, 2020, as filed with the Securities and Exchange Commission (&#x201c;SEC&#x201d;) on February 25, 2021 (the &#x201c;Form 10-K&#x201d;), which includes information and disclosures not included herein. Certain information and footnote disclosures normally included in annual financial statements prepared in accordance with U.S. GAAP have been condensed or omitted from the interim financial information presented, as allowed by SEC rules and regulations. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recently Adopted Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 1, 2021, the Company adopted Accounting Standards Update ("ASU") 2020-10, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Codification Improvements&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, which included minor technical corrections and clarifications to improve consistency and clarify the application of various provisions of the codification by amending the codification to include all disclosure guidance in the appropriate disclosure sections and by amending and adding new headings, cross referencing to other guidance and refining or correcting terminology. Our adoption of this standard did not have a material effect on our condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recently Issued Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2020, the Financial Accounting Standards Board ("FASB") issued ASU 2020-04, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, which provides optional expedients and exceptions for applying U.S. GAAP to contract modifications and hedging relationships that reference the London Inter-Bank Offered Rate ("LIBOR") or another reference rate expected to be discontinued, subject to meeting certain criteria. In January 2021, the FASB issued ASU 2021-01, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Reference Rate Reform (Topic 848)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, which adds implementation guidance to ASU 2020-04 to clarify certain optional expedients in Topic 848. The guidance in ASU 2020-04 and ASU 2021-01 was effective upon issuance and may generally be applied prospectively through December 31, 2022. This standard will not have an effect on our condensed consolidated financial statements. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our accounting and reporting policies conform with U.S. GAAP. In preparing the unaudited condensed consolidated financial statements, we are required to make estimates and assumptions that impact the amounts reported in the condensed consolidated financial statements and accompanying notes. Actual results could differ from those estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Principles of Consolidation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;These unaudited condensed consolidated financial statements include the accounts of Amedisys, Inc. and our wholly owned subsidiaries. All significant intercompany accounts and transactions have been eliminated and business combinations accounted for as purchases have been included from their respective dates of acquisition. In addition to our wholly owned subsidiaries, we also have certain equity investments that are accounted for as set forth below.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Investments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We consolidate investments when the entity is a variable interest entity and we are the primary beneficiary or if we have controlling interests in the entity, which is generally ownership in excess of 50%. Third-party equity interests in our consolidated joint ventures are reflected as noncontrolling interests in our condensed consolidated financial statements. We account for investments in entities in which we have the ability to exercise significant influence under the equity method if we hold 50% or less of the voting stock and the entity is not a variable interest entity in which we are the primary beneficiary. The book value of investments that we account for under the equity method of accounting was $45.1 million and $14.2 million as of June&#160;30, 2021 and December&#160;31, 2020, respectively, and is reflected in other assets within our condensed consolidated balance sheets. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three-month period ended June 30, 2021, a third-party acquired a majority of the issued and outstanding membership interests of one of our equity method investments, Medalogix, for cash, with the remaining membership interests rolling over into a newly formed entity that includes Medalogix as well as another healthcare predictive data and analytics company. We rolled over 100% of our ownership interest in Medalogix to the newly formed entity, and in connection with this transaction, we recognized a $31.1&#160;million gain based on the purchase price of Medalogix which is reflected in gain (loss) on equity method investments within our condensed consolidated statements of operations. &lt;/span&gt;&lt;/div&gt;During the three-month period ended June 30, 2020, we sold our investment in the Heritage Healthcare Innovation Fund, LP via a secondary transaction for $17.9&#160;million which resulted in a $3.0 million loss which is reflected in gain (loss) on equity method investments within our condensed consolidated statements of operations. The Company's original investment was made in 2010 and no longer fit within our strategic areas of focus. Proceeds from the sale were used to pay down debt and fund capital needs.</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i85ce6ba1e58b4b7c883aa1e71fb67e40_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8zNy9mcmFnOmMxNzYyMDBlMGRjNjRjOGE4NzU4YTM5ZTUxODJhZDk1L3RleHRyZWdpb246YzE3NjIwMGUwZGM2NGM4YTg3NThhMzllNTE4MmFkOTVfMzIz_5f9826ef-670b-49f5-8377-3846749c2a0b"
      unitRef="number">0.75</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ib0181bc176d24054b0b4382b5f3a2ef9_D20210401-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8zNy9mcmFnOmMxNzYyMDBlMGRjNjRjOGE4NzU4YTM5ZTUxODJhZDk1L3RleHRyZWdpb246YzE3NjIwMGUwZGM2NGM4YTg3NThhMzllNTE4MmFkOTVfMzIz_cbfdc1c8-4d59-4975-aee8-195726094432"
      unitRef="number">0.75</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="if78f143ce2814015b9ecc0469dc639f1_D20200101-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8zNy9mcmFnOmMxNzYyMDBlMGRjNjRjOGE4NzU4YTM5ZTUxODJhZDk1L3RleHRyZWdpb246YzE3NjIwMGUwZGM2NGM4YTg3NThhMzllNTE4MmFkOTVfMzMw_0cfb9d0a-e2ff-4b00-a391-a80d3b1c7bd4"
      unitRef="number">0.74</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i9d0cb72c37b145799e408add964d0544_D20200401-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8zNy9mcmFnOmMxNzYyMDBlMGRjNjRjOGE4NzU4YTM5ZTUxODJhZDk1L3RleHRyZWdpb246YzE3NjIwMGUwZGM2NGM4YTg3NThhMzllNTE4MmFkOTVfMzMw_230c9191-8bd3-40e7-bea5-fc86b71ab8dc"
      unitRef="number">0.74</us-gaap:ConcentrationRiskPercentage1>
    <amed:OperatingCareCenters
      contextRef="i30a2e3b95ac74ea890c5478c6d00aa9d_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8zNy9mcmFnOmMxNzYyMDBlMGRjNjRjOGE4NzU4YTM5ZTUxODJhZDk1L3RleHRyZWdpb246YzE3NjIwMGUwZGM2NGM4YTg3NThhMzllNTE4MmFkOTVfNDYx_0e766134-c7fd-4c2c-9b45-f1e189545175"
      unitRef="care_center">320</amed:OperatingCareCenters>
    <amed:OperatingCareCenters
      contextRef="i3e0c07dff3444ff8bdeaaddc51231dfe_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8zNy9mcmFnOmMxNzYyMDBlMGRjNjRjOGE4NzU4YTM5ZTUxODJhZDk1L3RleHRyZWdpb246YzE3NjIwMGUwZGM2NGM4YTg3NThhMzllNTE4MmFkOTVfNTA5_f64d70e3-f019-4c54-93ff-75ac788a4315"
      unitRef="care_center">180</amed:OperatingCareCenters>
    <amed:OperatingCareCenters
      contextRef="i7e884a08e6374bbb9ca4c0909fb43265_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8zNy9mcmFnOmMxNzYyMDBlMGRjNjRjOGE4NzU4YTM5ZTUxODJhZDk1L3RleHRyZWdpb246YzE3NjIwMGUwZGM2NGM4YTg3NThhMzllNTE4MmFkOTVfNTU2_403b0d7d-863b-4280-a7cd-9fc1dab90417"
      unitRef="care_center">14</amed:OperatingCareCenters>
    <us-gaap:NumberOfStatesInWhichEntityOperates
      contextRef="i1e833203be6947b4968aba4d20064ec8_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8zNy9mcmFnOmMxNzYyMDBlMGRjNjRjOGE4NzU4YTM5ZTUxODJhZDk1L3RleHRyZWdpb246YzE3NjIwMGUwZGM2NGM4YTg3NThhMzllNTE4MmFkOTVfNTg5_09861249-156c-48f3-92e9-e8672961209a"
      unitRef="state">39</us-gaap:NumberOfStatesInWhichEntityOperates>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8zNy9mcmFnOmMxNzYyMDBlMGRjNjRjOGE4NzU4YTM5ZTUxODJhZDk1L3RleHRyZWdpb246YzE3NjIwMGUwZGM2NGM4YTg3NThhMzllNTE4MmFkOTVfNTEwMQ_a73ffffe-1d54-4434-bba2-bde4fda970a5">&lt;div style="margin-top:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In our opinion, the accompanying unaudited condensed consolidated financial statements contain all adjustments (consisting solely of normal recurring adjustments) necessary to present fairly our financial position, our results of operations and our cash flows in accordance with U.S. generally accepted accounting principles (&#x201c;U.S. GAAP&#x201d;) for interim financial reporting. Our results of operations for the interim periods presented are not necessarily indicative of the results of our operations for the entire year and have not been audited by our independent auditors.&lt;/span&gt;&lt;/div&gt;This report should be read in conjunction with our consolidated financial statements and related notes included in our Annual Report on Form 10-K for the year ended December&#160;31, 2020, as filed with the Securities and Exchange Commission (&#x201c;SEC&#x201d;) on February 25, 2021 (the &#x201c;Form 10-K&#x201d;), which includes information and disclosures not included herein.</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8zNy9mcmFnOmMxNzYyMDBlMGRjNjRjOGE4NzU4YTM5ZTUxODJhZDk1L3RleHRyZWdpb246YzE3NjIwMGUwZGM2NGM4YTg3NThhMzllNTE4MmFkOTVfNTEwOA_958ed32c-110a-4d9c-8cbc-cb3435544819">&lt;div style="margin-top:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recently Adopted Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 1, 2021, the Company adopted Accounting Standards Update ("ASU") 2020-10, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Codification Improvements&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, which included minor technical corrections and clarifications to improve consistency and clarify the application of various provisions of the codification by amending the codification to include all disclosure guidance in the appropriate disclosure sections and by amending and adding new headings, cross referencing to other guidance and refining or correcting terminology. Our adoption of this standard did not have a material effect on our condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recently Issued Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2020, the Financial Accounting Standards Board ("FASB") issued ASU 2020-04, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, which provides optional expedients and exceptions for applying U.S. GAAP to contract modifications and hedging relationships that reference the London Inter-Bank Offered Rate ("LIBOR") or another reference rate expected to be discontinued, subject to meeting certain criteria. In January 2021, the FASB issued ASU 2021-01, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Reference Rate Reform (Topic 848)&lt;/span&gt;, which adds implementation guidance to ASU 2020-04 to clarify certain optional expedients in Topic 848. The guidance in ASU 2020-04 and ASU 2021-01 was effective upon issuance and may generally be applied prospectively through December 31, 2022. This standard will not have an effect on our condensed consolidated financial statements.</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8zNy9mcmFnOmMxNzYyMDBlMGRjNjRjOGE4NzU4YTM5ZTUxODJhZDk1L3RleHRyZWdpb246YzE3NjIwMGUwZGM2NGM4YTg3NThhMzllNTE4MmFkOTVfNTEwOQ_671e73a3-77d1-493e-9de1-a3e7d294317c">&lt;div style="margin-top:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our accounting and reporting policies conform with U.S. GAAP. In preparing the unaudited condensed consolidated financial statements, we are required to make estimates and assumptions that impact the amounts reported in the condensed consolidated financial statements and accompanying notes. Actual results could differ from those estimates.&lt;/span&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:ConsolidationPolicyTextBlock
      contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8zNy9mcmFnOmMxNzYyMDBlMGRjNjRjOGE4NzU4YTM5ZTUxODJhZDk1L3RleHRyZWdpb246YzE3NjIwMGUwZGM2NGM4YTg3NThhMzllNTE4MmFkOTVfNTExNg_aa969598-394e-4698-886d-8c4627dd57af">&lt;div style="margin-top:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Principles of Consolidation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;These unaudited condensed consolidated financial statements include the accounts of Amedisys, Inc. and our wholly owned subsidiaries. All significant intercompany accounts and transactions have been eliminated and business combinations accounted for as purchases have been included from their respective dates of acquisition. In addition to our wholly owned subsidiaries, we also have certain equity investments that are accounted for as set forth below.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:EquityMethodInvestmentsPolicy
      contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8zNy9mcmFnOmMxNzYyMDBlMGRjNjRjOGE4NzU4YTM5ZTUxODJhZDk1L3RleHRyZWdpb246YzE3NjIwMGUwZGM2NGM4YTg3NThhMzllNTE4MmFkOTVfNTExNw_98c88dca-639a-4183-8be7-175206df85d0">&lt;div style="margin-top:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Investments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We consolidate investments when the entity is a variable interest entity and we are the primary beneficiary or if we have controlling interests in the entity, which is generally ownership in excess of 50%. Third-party equity interests in our consolidated joint ventures are reflected as noncontrolling interests in our condensed consolidated financial statements. We account for investments in entities in which we have the ability to exercise significant influence under the equity method if we hold 50% or less of the voting stock and the entity is not a variable interest entity in which we are the primary beneficiary. The book value of investments that we account for under the equity method of accounting was $45.1 million and $14.2 million as of June&#160;30, 2021 and December&#160;31, 2020, respectively, and is reflected in other assets within our condensed consolidated balance sheets. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three-month period ended June 30, 2021, a third-party acquired a majority of the issued and outstanding membership interests of one of our equity method investments, Medalogix, for cash, with the remaining membership interests rolling over into a newly formed entity that includes Medalogix as well as another healthcare predictive data and analytics company. We rolled over 100% of our ownership interest in Medalogix to the newly formed entity, and in connection with this transaction, we recognized a $31.1&#160;million gain based on the purchase price of Medalogix which is reflected in gain (loss) on equity method investments within our condensed consolidated statements of operations. &lt;/span&gt;&lt;/div&gt;During the three-month period ended June 30, 2020, we sold our investment in the Heritage Healthcare Innovation Fund, LP via a secondary transaction for $17.9&#160;million which resulted in a $3.0 million loss which is reflected in gain (loss) on equity method investments within our condensed consolidated statements of operations. The Company's original investment was made in 2010 and no longer fit within our strategic areas of focus. Proceeds from the sale were used to pay down debt and fund capital needs.</us-gaap:EquityMethodInvestmentsPolicy>
    <amed:MinimumPercentOwnershipForControllingInterestPercent
      contextRef="i1e833203be6947b4968aba4d20064ec8_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8zNy9mcmFnOmMxNzYyMDBlMGRjNjRjOGE4NzU4YTM5ZTUxODJhZDk1L3RleHRyZWdpb246YzE3NjIwMGUwZGM2NGM4YTg3NThhMzllNTE4MmFkOTVfNDQ2MQ_c4a57ecf-e9c3-4f5e-9589-f20b148226c8"
      unitRef="number">0.50</amed:MinimumPercentOwnershipForControllingInterestPercent>
    <amed:MaximumPercentOwnershipForEquityMethodPercent
      contextRef="i1e833203be6947b4968aba4d20064ec8_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8zNy9mcmFnOmMxNzYyMDBlMGRjNjRjOGE4NzU4YTM5ZTUxODJhZDk1L3RleHRyZWdpb246YzE3NjIwMGUwZGM2NGM4YTg3NThhMzllNTE4MmFkOTVfNDc2MA_dde61e0f-ce36-499e-8291-2472adfc6778"
      unitRef="number">0.50</amed:MaximumPercentOwnershipForEquityMethodPercent>
    <us-gaap:EquityMethodInvestmentAggregateCost
      contextRef="i1e833203be6947b4968aba4d20064ec8_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8zNy9mcmFnOmMxNzYyMDBlMGRjNjRjOGE4NzU4YTM5ZTUxODJhZDk1L3RleHRyZWdpb246YzE3NjIwMGUwZGM2NGM4YTg3NThhMzllNTE4MmFkOTVfMTA5OTUxMTYzNDc5Nw_6a7f2e11-b4c1-4737-beb1-1df65cc75647"
      unitRef="usd">45100000</us-gaap:EquityMethodInvestmentAggregateCost>
    <us-gaap:EquityMethodInvestmentAggregateCost
      contextRef="i87ceb60dc20d4df1b0a97d3514837910_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8zNy9mcmFnOmMxNzYyMDBlMGRjNjRjOGE4NzU4YTM5ZTUxODJhZDk1L3RleHRyZWdpb246YzE3NjIwMGUwZGM2NGM4YTg3NThhMzllNTE4MmFkOTVfMTA5OTUxMTYzNDgwNQ_6577837f-8d7a-4ec0-9c1a-ad0cd0ca62d4"
      unitRef="usd">14200000</us-gaap:EquityMethodInvestmentAggregateCost>
    <us-gaap:GainLossOnInvestments
      contextRef="i56460531924447ac8bc770856f36964a_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8zNy9mcmFnOmMxNzYyMDBlMGRjNjRjOGE4NzU4YTM5ZTUxODJhZDk1L3RleHRyZWdpb246YzE3NjIwMGUwZGM2NGM4YTg3NThhMzllNTE4MmFkOTVfMTA5OTUxMTYzNTE0Nw_2449c867-9d4c-434c-a2b3-6a6a177e8423"
      unitRef="usd">31100000</us-gaap:GainLossOnInvestments>
    <us-gaap:ProceedsFromSaleOfEquityMethodInvestments
      contextRef="i47cb3be3d5564293b84a6274e71f0a2c_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8zNy9mcmFnOmMxNzYyMDBlMGRjNjRjOGE4NzU4YTM5ZTUxODJhZDk1L3RleHRyZWdpb246YzE3NjIwMGUwZGM2NGM4YTg3NThhMzllNTE4MmFkOTVfMTA5OTUxMTYzMzcxNQ_b22ac94f-c4d8-4c5f-8d27-13d418bcb0ab"
      unitRef="usd">17900000</us-gaap:ProceedsFromSaleOfEquityMethodInvestments>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV80My9mcmFnOjFhYzcyMjM4MzVjYzRiMjFiMWMzNjkwMGJmZjQzMjM3L3RleHRyZWdpb246MWFjNzIyMzgzNWNjNGIyMWIxYzM2OTAwYmZmNDMyMzdfMjIyMTE_fb170d9b-cf20-4dc3-96b7-745fcb63a82d">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We account for revenue from contracts with customers in accordance with Accounting Standards Codification ("ASC") 606, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue from Contracts with Customers&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, and as such, we recognize revenue in the period in which we satisfy our performance obligations under our contracts by transferring our promised services to our customers in amounts that reflect the consideration to which we expect to be entitled in exchange for providing patient care, which are the transaction prices allocated to the distinct services. The Company's cost of obtaining contracts is not material.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues are recognized as performance obligations are satisfied, which varies based on the nature of the services provided. Our performance obligation is the delivery of patient care services in accordance with the nature and frequency of services outlined in physicians' orders, which are determined by a physician based on a patient's specific goals. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's performance obligations relate to contracts with a duration of less than one year; therefore, the Company has elected to apply the optional exemption provided by ASC 606 and is not required to disclose the aggregate amount of the transaction price allocated to performance obligations that are unsatisfied or partially unsatisfied as of the end of the reporting period. The unsatisfied or partially unsatisfied performance obligations are generally completed when the patients are discharged, which generally occurs within days or weeks of the end of the reporting period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We determine the transaction price based on gross charges for services provided, reduced by estimates for contractual and non-contractual revenue adjustments. Contractual revenue adjustments are recorded for the difference between our standard rates and the contracted rates to be realized from patients, third-party payors and others for services provided. Non-contractual revenue adjustments include discounts provided to self-pay, uninsured patients or other payors, adjustments resulting from payment reviews and adjustments arising from our inability to obtain appropriate billing documentation, authorizations or face-to-face documentation. Subsequent changes to the estimate of the transaction price are recorded as adjustments to net service revenue in the period of change. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Non-contractual revenue adjustments are recorded for self-pay, uninsured patients and other payors by major payor class based on our historical collection experience, aged accounts receivable by payor and current economic conditions. The non-contractual revenue adjustments represent the difference between amounts billed and amounts we expect to collect based on our collection history with similar payors. The Company assesses its ability to collect for the healthcare services provided at the time of patient admission based on the Company's verification of the patient's insurance coverage under Medicare, Medicaid, and other commercial or managed care insurance programs. Medicare represents approximately 75% of our net service revenue &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;for the three and six-month periods ended June 30, 2021 and approximately 74% of our net service revenue for the three and six-month periods ended June 30, 2020. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amounts due from third-party payors, primarily commercial health insurers and government programs (Medicare and Medicaid), include variable consideration for retroactive revenue adjustments due to settlements of audits and payment reviews. We determine our estimates for non-contractual revenue adjustments related to audits and payment reviews based on our historical experience and success rates in the claim appeals and adjudication process. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We determine our estimates for non-contractual revenue adjustments related to our inability to obtain appropriate billing documentation, authorizations, or face-to-face documentation based on our historical experience which primarily includes a historical collection rate of over 99% on Medicare claims. Revenue is recorded at amounts we estimate to be realizable for services provided.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue by payor class as a percentage of total net service revenue is as follows:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.923%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three-Month Periods Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Six-Month Periods &lt;br/&gt;Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;Home Health:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Medicare&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Non-Medicare - Episodic-based&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Non-Medicare - Non-episodic based&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;Hospice (1):&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Medicare&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Non-Medicare&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;Personal Care&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="24" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1) Acquired AseraCare Hospice ("AseraCare") on June 1, 2020.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Home Health Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Medicare Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Effective January 1, 2020, the Centers for Medicare and Medicaid Services ("CMS") implemented a revised case-mix adjustment methodology, the Patient-Driven Groupings Model ("PDGM"), to better align payment with patient care needs and ensure that clinically complex and ill beneficiaries have adequate access to home health care. PDGM uses 30-day periods of care rather than 60-day episodes of care as the unit of payment, eliminates the use of the number of therapy visits provided in determining payment and relies more heavily on clinical characteristics and other patient information.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net service revenue is recorded based on the established Federal Medicare home health payment rate for a 30-day period of care. ASC 606 notes that if an entity has a right to consideration from a customer in an amount that corresponds directly with the value of the entity&#x2019;s performance completed to date, the entity may recognize revenue in the amount to which the entity has a right to invoice. We have elected to apply the "right to invoice" practical expedient and therefore, our revenue recognition is based on the reimbursement we are entitled to for each 30-day payment period. We utilize our historical average length of stay for each 30-day period of care as the measure of progress towards the satisfaction of our performance obligation.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;PDGM uses timing, admission source, functional impairment levels and principal and other diagnoses to case-mix adjust payments. The case-mix adjusted payment for a 30-day period of care is subject to additional adjustments based on certain variables, including, but not limited to (a) an outlier payment if our patient's care was unusually costly (capped at 10% of total reimbursement per provider number); (b)&#160;a low utilization payment adjustment (&#x201c;LUPA&#x201d;) if the number of visits provided was less than the established threshold, which ranges from two to six visits and varies for every case-mix group under PDGM; (c)&#160;a partial payment if a patient is transferred to another provider or from another provider before completing the 30-day period of care; and (d) the applicable geographic wage index. Payments for routine and non-routine supplies are included in the 30-day payment rate.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Medicare can also make various adjustments to payments received if we are unable to produce appropriate billing documentation or acceptable authorizations. We estimate the impact of such adjustments based on our historical experience, which primarily includes a historical collection rate of over 99% on Medicare claims, and record this estimate during the period in which services are rendered to revenue with a corresponding reduction to patient accounts receivable.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amounts due from Medicare include variable consideration for retroactive revenue adjustments due to settlements of audits and payment reviews. We determine our estimates for non-contractual revenue adjustments related to audits and payment reviews based on our historical experience and success rates in the claim appeals and adjudication process.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All Medicare contracts are required to have a signed plan of care which represents a single performance obligation, comprised of the delivery of a series of distinct services that are substantially similar and have a similar pattern of transfer to the customer. Accordingly, the Company accounts for the series of services ("episode") as a single performance obligation satisfied over time, as the customer simultaneously receives and consumes the benefits of the goods and services provided. An episode starts the first day a billable visit is performed and ends 60 days later or upon discharge, if earlier, with multiple continuous episodes allowed. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Medicare home health benefit requires that beneficiaries be homebound (meaning that the beneficiary is unable to leave his/her home without a considerable and taxing effort), require intermittent skilled nursing, physical therapy or speech therapy services, and receive treatment under a plan of care established and periodically reviewed by a physician. In order to provide greater flexibility during the novel coronavirus pandemic ("COVID-19"), CMS relaxed the definition of homebound status through the duration of the public health emergency. During the pandemic, a beneficiary is considered homebound if they have been instructed by a physician not to leave their home because of a confirmed or suspected COVID-19 diagnosis or if the patient has a condition that makes them more susceptible to contracting COVID-19. Therefore, if a beneficiary is homebound due to COVID-19 and requires skilled services, the services will be covered under the Medicare home health benefit. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During 2020, 20% of reimbursement from each Medicare episode, referred to as a request for anticipated payment ("RAP"), was billed near the start of each 30-day period of care, and cash was typically received before all services were rendered. Any cash received from Medicare for a RAP for a 30-day period of care that exceeded the associated revenue earned was recorded to accrued expenses within our condensed consolidated balance sheets. CMS fully eliminated all upfront payments associated with RAPs effective January 1, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Non-Medicare Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Episodic-based Revenue.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; We recognize revenue in a similar manner as we recognize Medicare revenue for amounts that are paid by other insurance carriers, including Medicare Advantage programs; however, these amounts can vary based upon the negotiated terms, the majority of which range from 95% to 100% of Medicare rates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Non-episodic based Revenue.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Gross revenue is recorded on an accrual basis based upon the date of service at amounts equal to our established or estimated per-visit rates. Contractual revenue adjustments are recorded for the difference between our standard rates and the contracted rates to be realized from patients, third parties and others for services provided and are deducted from gross revenue to determine net service revenue. We also make non-contractual revenue adjustments to non-episodic revenue based on our historical experience to reflect the estimated transaction price. We receive a minimal amount of our net service revenue from patients who are either self-insured or are obligated for an insurance co-payment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Hospice Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Hospice Medicare Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Gross revenue is recorded on an accrual basis based upon the date of service at amounts equal to the estimated payment rates. The estimated payment rates are predetermined daily or hourly rates for each of the four levels of care we deliver. The four levels of care are routine care, general inpatient care, continuous home care and respite care. Routine care accounted for 97% of our total Medicare hospice service revenue for the three and six-month periods ended June&#160;30, 2021 and June 30, 2020. There are two separate payment rates for routine care: payments for the first 60 days of care and care beyond 60 days. In addition to the two routine rates, we may also receive a service intensity add-on (&#x201c;SIA&#x201d;). The SIA is based on visits made in the last seven days of life by a registered nurse or medical social worker for patients in a routine level of care.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The performance obligation is the delivery of hospice services to the patient, as determined by a physician, each day the patient is on hospice care.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We make adjustments to Medicare revenue for non-contractual revenue adjustments, which include our inability to obtain appropriate billing documentation or acceptable authorizations and other reasons unrelated to credit risk. We estimate the impact of these non-contractual revenue adjustments based on our historical experience, which primarily includes a historical collection rate of over 99% on Medicare claims, and record it during the period services are rendered.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Additionally, our hospice service revenue is subject to certain limitations on payments from Medicare which are considered variable consideration. We are subject to an inpatient cap limit and an overall Medicare payment cap for each provider number. We monitor these caps on a provider-by-provider basis and estimate amounts due back to Medicare if we estimate a cap has been exceeded.&#160;We record these adjustments as a reduction to revenue and an increase in accrued expenses within our condensed consolidated balance sheets. Providers are required to self-report and pay their estimated cap liability by February 28&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;th&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; of the following year. As of June&#160;30, 2021, we have recorded $10.0 million for estimated amounts due back to Medicare in accrued expenses for the Federal cap years ended October&#160;31, 2016 through September 30, 2021; $3.1&#160;million of this balance was acquired with the AseraCare acquisition. As of December&#160;31, 2020, we had recorded $9.3 million for estimated amounts due back to Medicare in accrued expenses for the Federal cap years ended October&#160;31, 2014 through September 30, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Hospice Non-Medicare Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Gross revenue is recorded on an accrual basis based upon the date of service at amounts equal to our established rates or estimated per day rates, as applicable. Contractual revenue adjustments are recorded for the difference between our standard rates and the contractual rates to be realized from patients, third-party payors and others for services provided and are deducted from gross revenue to determine our net service revenue. We also make non-contractual adjustments to non-Medicare revenue based on our historical experience to reflect the estimated transaction price.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Personal Care Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Personal Care Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We generate net service revenues by providing our services directly to patients based on authorized hours, visits or units determined by the relevant agency, at a rate that is either contractual or fixed by legislation. Net service revenue is recognized at the time services are rendered based on gross charges for the services provided, reduced by estimates for contractual and non-contractual revenue adjustments. We receive payment for providing such services from payors, including state and local governmental agencies, managed care organizations, commercial insurers and private consumers. Payors include the following elder service agencies: Aging Services Access Points ("ASAPs"), Senior Care Options ("SCOs"), Program of All-Inclusive Care for the Elderly ("PACE") and the Veterans Administration ("VA"). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Government Grants&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the absence of specific guidance to account for government grants under U.S. GAAP, we have decided to account for government grants in accordance with International Accounting Standard ("IAS") 20, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Accounting for Government Grants and Disclosure of Government Assistance&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, and as such, we recognize grant income on a systematic basis in line with the recognition of expenses or the loss of revenues for which the grants are intended to compensate. We recognize grants once both of the following conditions are met: (1) we are able to comply with the relevant conditions of the grant and (2) the grant will be received. See Note 3 - Novel Coronavirus Pandemic ("COVID-19") for additional information on our accounting for government funds received under the Coronavirus Aid, Relief and Economic Security Act ("CARES Act") and the Mass Home Care ASAP COVID-19 Provider Sustainability Program.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cash, Cash Equivalents and Restricted Cash &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash and cash equivalents include certificates of deposit and all highly liquid debt instruments with maturities of three months or less when purchased. Our cash balance as of June 30, 2021 includes approximately $62&#160;million associated with the CARES Act Provider Relief Fund ("PRF"). We separated the PRF funds into their own account and as of June 30, 2021, we have only transferred funds used through March 31, 2021 to our operating account. We will transfer funds used during the three-month period ended June 30, 2021, totaling approximately $4&#160;million, to our operating account during the third quarter of 2021 and repay the remaining $58&#160;million to the U.S. Department of Health and Human Services ("HHS") by October 30, 2021. Restricted cash includes cash that is not available for ordinary business use. As of June 30, 2021, we had $1&#160;million of restricted cash that was placed into an escrow account related to the indemnity and closing payment adjustment provisions within the Asana Hospice purchase agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the balances related to our cash, cash equivalents and restricted cash (amounts in millions):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.250%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.981%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.739%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;91.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash, cash equivalents and restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;92.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;83.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Patient Accounts Receivable &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We report accounts receivable from services rendered at their estimated transaction price, which includes contractual and non-contractual revenue adjustments based on the amounts expected to be due from payors. Our patient accounts receivable are uncollateralized and consist of amounts due from Medicare, Medicaid, other third-party payors and patients. The Company's non-Medicare third-party payor base is comprised of a diverse group of payors that are geographically dispersed across the country. As of June&#160;30, 2021, there is one payor, other than Medicare, that accounts for 10% of our total outstanding patient receivables. Thus, we believe there are no other significant concentrations of receivables that would subject us to any significant credit risk in the collection of our patient accounts receivable. We write off accounts on a monthly basis once we have exhausted our collection efforts and deem an account to be uncollectible. We believe the collectability risk associated with our Medicare accounts, which represent 66% and 64% of our patient accounts receivable at June&#160;30, 2021 and December&#160;31, 2020, respectively, is limited due to our historical collection rate of over 99% from Medicare and the fact that Medicare is a U.S. government payor. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We do not believe there are any significant concentrations of revenues from any payor that would subject us to any significant credit risk in the collection of our accounts receivable.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Medicare Home Health&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For our home health patients, our pre-billing process includes verifying that we are eligible for payment from Medicare for the services that we provide to our patients. Our Medicare billing begins with a process to ensure that our billings are accurate through the utilization of an electronic Medicare claim review. Prior to January 1, 2021, we submitted a RAP for 20% of our estimated payment for each 30-day period of care. The RAP received was then deducted from our final payment. Effective January 1, 2021, CMS eliminated all upfront payments associated with RAPs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Medicare Hospice&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For our hospice patients, our pre-billing process includes verifying that we are eligible for payment from Medicare for the services that we provide to our patients. Our Medicare billing begins with a process to ensure that our billings are accurate through the utilization of an electronic Medicare claim review. We bill Medicare on a monthly basis for the services provided to the patient.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Non-Medicare Home Health, Hospice and Personal Care&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For our non-Medicare patients, our pre-billing process primarily begins with verifying a patient&#x2019;s eligibility for services with the applicable payor. Once the patient has been confirmed for eligibility, we will provide services to the patient and bill the applicable payor. Our review and evaluation of non-Medicare accounts receivable includes a detailed review of outstanding balances and special consideration to concentrations of receivables from particular payors or groups of payors with similar characteristics that would subject us to any significant credit risk. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:16pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Business Combinations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We account for acquisitions using the acquisition method of accounting in accordance with ASC 805, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Business Combinations&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. Acquisitions are accounted for as purchases and are included in our condensed consolidated financial statements from their respective acquisition dates. Assets acquired and liabilities assumed, if any, are measured at fair value on the acquisition date using the appropriate valuation method. Goodwill generated from acquisitions is recognized for the excess of the purchase price over tangible and identifiable intangible assets. In determining the fair value of identifiable intangible assets, we use various valuation techniques including discounted cash flow analysis, the income approach, the cost approach and the market approach. These valuation methods require us to make estimates and assumptions surrounding projected revenues and costs, growth rates and discount rates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following details our financial instruments where the carrying value and the fair value differ (amounts in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.076%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.954%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.821%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.553%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.821%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.553%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.821%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.553%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.824%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value at Reporting Date Using&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Financial Instrument&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Carrying Value as of June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quoted&#160;Prices&#160;in&#160;Active&lt;br/&gt;Markets for Identical&lt;br/&gt;Items&lt;br/&gt;(Level 1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&#160;Other&lt;br/&gt;Observable&#160;Inputs&lt;br/&gt;(Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Unobservable&#160;Inputs&lt;br/&gt;(Level&#160;3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term obligations&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;189.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;191.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value hierarchy is based on three levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value. The three levels of inputs are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level&#160;1 &#x2013; Quoted prices in active markets for identical assets and liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level&#160;2 &#x2013; Inputs other than Level&#160;1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level&#160;3 &#x2013; Unobservable inputs that are supported by little or no market activity and are significant to the fair value of the assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our deferred compensation plan assets are recorded at fair value and are considered a level 2 measurement. For our other financial instruments, including our cash and cash equivalents, patient accounts receivable, accounts payable, payroll and employee benefits and accrued expenses, we estimate the carrying amounts approximate fair value. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:16pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Weighted-Average Shares Outstanding&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net income per share attributable to Amedisys, Inc. common stockholders, calculated on the treasury stock method, is based on the weighted average number of shares outstanding during the period. The following table sets forth, for the periods indicated, shares used in our computation of the weighted-average shares outstanding, which are used to calculate our basic and diluted net income attributable to Amedisys, Inc. common stockholders (amounts in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.829%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.624%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three-&lt;br/&gt;Month Periods&lt;br/&gt;Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Six-&lt;br/&gt;Month Periods&lt;br/&gt;Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average number of shares outstanding - basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,588&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,412&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,684&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,371&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Effect of dilutive securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;139&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;570&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;145&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;582&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-indent:20.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-vested stock and stock units&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;254&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;303&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;256&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;306&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average number of shares outstanding - diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,981&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,285&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,085&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,259&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Anti-dilutive securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:RevenueRecognitionPolicyTextBlock
      contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV80My9mcmFnOjFhYzcyMjM4MzVjYzRiMjFiMWMzNjkwMGJmZjQzMjM3L3RleHRyZWdpb246MWFjNzIyMzgzNWNjNGIyMWIxYzM2OTAwYmZmNDMyMzdfMjIyMTQ_47f4d174-348c-422f-96c1-299542cfb2af">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We account for revenue from contracts with customers in accordance with Accounting Standards Codification ("ASC") 606, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue from Contracts with Customers&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, and as such, we recognize revenue in the period in which we satisfy our performance obligations under our contracts by transferring our promised services to our customers in amounts that reflect the consideration to which we expect to be entitled in exchange for providing patient care, which are the transaction prices allocated to the distinct services. The Company's cost of obtaining contracts is not material.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues are recognized as performance obligations are satisfied, which varies based on the nature of the services provided. Our performance obligation is the delivery of patient care services in accordance with the nature and frequency of services outlined in physicians' orders, which are determined by a physician based on a patient's specific goals. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's performance obligations relate to contracts with a duration of less than one year; therefore, the Company has elected to apply the optional exemption provided by ASC 606 and is not required to disclose the aggregate amount of the transaction price allocated to performance obligations that are unsatisfied or partially unsatisfied as of the end of the reporting period. The unsatisfied or partially unsatisfied performance obligations are generally completed when the patients are discharged, which generally occurs within days or weeks of the end of the reporting period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We determine the transaction price based on gross charges for services provided, reduced by estimates for contractual and non-contractual revenue adjustments. Contractual revenue adjustments are recorded for the difference between our standard rates and the contracted rates to be realized from patients, third-party payors and others for services provided. Non-contractual revenue adjustments include discounts provided to self-pay, uninsured patients or other payors, adjustments resulting from payment reviews and adjustments arising from our inability to obtain appropriate billing documentation, authorizations or face-to-face documentation. Subsequent changes to the estimate of the transaction price are recorded as adjustments to net service revenue in the period of change. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Non-contractual revenue adjustments are recorded for self-pay, uninsured patients and other payors by major payor class based on our historical collection experience, aged accounts receivable by payor and current economic conditions. The non-contractual revenue adjustments represent the difference between amounts billed and amounts we expect to collect based on our collection history with similar payors. The Company assesses its ability to collect for the healthcare services provided at the time of patient admission based on the Company's verification of the patient's insurance coverage under Medicare, Medicaid, and other commercial or managed care insurance programs. Medicare represents approximately 75% of our net service revenue &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;for the three and six-month periods ended June 30, 2021 and approximately 74% of our net service revenue for the three and six-month periods ended June 30, 2020. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amounts due from third-party payors, primarily commercial health insurers and government programs (Medicare and Medicaid), include variable consideration for retroactive revenue adjustments due to settlements of audits and payment reviews. We determine our estimates for non-contractual revenue adjustments related to audits and payment reviews based on our historical experience and success rates in the claim appeals and adjudication process. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We determine our estimates for non-contractual revenue adjustments related to our inability to obtain appropriate billing documentation, authorizations, or face-to-face documentation based on our historical experience which primarily includes a historical collection rate of over 99% on Medicare claims. Revenue is recorded at amounts we estimate to be realizable for services provided.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue by payor class as a percentage of total net service revenue is as follows:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.923%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three-Month Periods Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Six-Month Periods &lt;br/&gt;Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;Home Health:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Medicare&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Non-Medicare - Episodic-based&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Non-Medicare - Non-episodic based&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;Hospice (1):&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Medicare&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Non-Medicare&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;Personal Care&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="24" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1) Acquired AseraCare Hospice ("AseraCare") on June 1, 2020.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Home Health Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Medicare Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Effective January 1, 2020, the Centers for Medicare and Medicaid Services ("CMS") implemented a revised case-mix adjustment methodology, the Patient-Driven Groupings Model ("PDGM"), to better align payment with patient care needs and ensure that clinically complex and ill beneficiaries have adequate access to home health care. PDGM uses 30-day periods of care rather than 60-day episodes of care as the unit of payment, eliminates the use of the number of therapy visits provided in determining payment and relies more heavily on clinical characteristics and other patient information.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net service revenue is recorded based on the established Federal Medicare home health payment rate for a 30-day period of care. ASC 606 notes that if an entity has a right to consideration from a customer in an amount that corresponds directly with the value of the entity&#x2019;s performance completed to date, the entity may recognize revenue in the amount to which the entity has a right to invoice. We have elected to apply the "right to invoice" practical expedient and therefore, our revenue recognition is based on the reimbursement we are entitled to for each 30-day payment period. We utilize our historical average length of stay for each 30-day period of care as the measure of progress towards the satisfaction of our performance obligation.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;PDGM uses timing, admission source, functional impairment levels and principal and other diagnoses to case-mix adjust payments. The case-mix adjusted payment for a 30-day period of care is subject to additional adjustments based on certain variables, including, but not limited to (a) an outlier payment if our patient's care was unusually costly (capped at 10% of total reimbursement per provider number); (b)&#160;a low utilization payment adjustment (&#x201c;LUPA&#x201d;) if the number of visits provided was less than the established threshold, which ranges from two to six visits and varies for every case-mix group under PDGM; (c)&#160;a partial payment if a patient is transferred to another provider or from another provider before completing the 30-day period of care; and (d) the applicable geographic wage index. Payments for routine and non-routine supplies are included in the 30-day payment rate.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Medicare can also make various adjustments to payments received if we are unable to produce appropriate billing documentation or acceptable authorizations. We estimate the impact of such adjustments based on our historical experience, which primarily includes a historical collection rate of over 99% on Medicare claims, and record this estimate during the period in which services are rendered to revenue with a corresponding reduction to patient accounts receivable.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amounts due from Medicare include variable consideration for retroactive revenue adjustments due to settlements of audits and payment reviews. We determine our estimates for non-contractual revenue adjustments related to audits and payment reviews based on our historical experience and success rates in the claim appeals and adjudication process.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All Medicare contracts are required to have a signed plan of care which represents a single performance obligation, comprised of the delivery of a series of distinct services that are substantially similar and have a similar pattern of transfer to the customer. Accordingly, the Company accounts for the series of services ("episode") as a single performance obligation satisfied over time, as the customer simultaneously receives and consumes the benefits of the goods and services provided. An episode starts the first day a billable visit is performed and ends 60 days later or upon discharge, if earlier, with multiple continuous episodes allowed. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Medicare home health benefit requires that beneficiaries be homebound (meaning that the beneficiary is unable to leave his/her home without a considerable and taxing effort), require intermittent skilled nursing, physical therapy or speech therapy services, and receive treatment under a plan of care established and periodically reviewed by a physician. In order to provide greater flexibility during the novel coronavirus pandemic ("COVID-19"), CMS relaxed the definition of homebound status through the duration of the public health emergency. During the pandemic, a beneficiary is considered homebound if they have been instructed by a physician not to leave their home because of a confirmed or suspected COVID-19 diagnosis or if the patient has a condition that makes them more susceptible to contracting COVID-19. Therefore, if a beneficiary is homebound due to COVID-19 and requires skilled services, the services will be covered under the Medicare home health benefit. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During 2020, 20% of reimbursement from each Medicare episode, referred to as a request for anticipated payment ("RAP"), was billed near the start of each 30-day period of care, and cash was typically received before all services were rendered. Any cash received from Medicare for a RAP for a 30-day period of care that exceeded the associated revenue earned was recorded to accrued expenses within our condensed consolidated balance sheets. CMS fully eliminated all upfront payments associated with RAPs effective January 1, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Non-Medicare Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Episodic-based Revenue.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; We recognize revenue in a similar manner as we recognize Medicare revenue for amounts that are paid by other insurance carriers, including Medicare Advantage programs; however, these amounts can vary based upon the negotiated terms, the majority of which range from 95% to 100% of Medicare rates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Non-episodic based Revenue.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Gross revenue is recorded on an accrual basis based upon the date of service at amounts equal to our established or estimated per-visit rates. Contractual revenue adjustments are recorded for the difference between our standard rates and the contracted rates to be realized from patients, third parties and others for services provided and are deducted from gross revenue to determine net service revenue. We also make non-contractual revenue adjustments to non-episodic revenue based on our historical experience to reflect the estimated transaction price. We receive a minimal amount of our net service revenue from patients who are either self-insured or are obligated for an insurance co-payment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Hospice Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Hospice Medicare Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Gross revenue is recorded on an accrual basis based upon the date of service at amounts equal to the estimated payment rates. The estimated payment rates are predetermined daily or hourly rates for each of the four levels of care we deliver. The four levels of care are routine care, general inpatient care, continuous home care and respite care. Routine care accounted for 97% of our total Medicare hospice service revenue for the three and six-month periods ended June&#160;30, 2021 and June 30, 2020. There are two separate payment rates for routine care: payments for the first 60 days of care and care beyond 60 days. In addition to the two routine rates, we may also receive a service intensity add-on (&#x201c;SIA&#x201d;). The SIA is based on visits made in the last seven days of life by a registered nurse or medical social worker for patients in a routine level of care.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The performance obligation is the delivery of hospice services to the patient, as determined by a physician, each day the patient is on hospice care.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We make adjustments to Medicare revenue for non-contractual revenue adjustments, which include our inability to obtain appropriate billing documentation or acceptable authorizations and other reasons unrelated to credit risk. We estimate the impact of these non-contractual revenue adjustments based on our historical experience, which primarily includes a historical collection rate of over 99% on Medicare claims, and record it during the period services are rendered.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Additionally, our hospice service revenue is subject to certain limitations on payments from Medicare which are considered variable consideration. We are subject to an inpatient cap limit and an overall Medicare payment cap for each provider number. We monitor these caps on a provider-by-provider basis and estimate amounts due back to Medicare if we estimate a cap has been exceeded.&#160;We record these adjustments as a reduction to revenue and an increase in accrued expenses within our condensed consolidated balance sheets. Providers are required to self-report and pay their estimated cap liability by February 28&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;th&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; of the following year. As of June&#160;30, 2021, we have recorded $10.0 million for estimated amounts due back to Medicare in accrued expenses for the Federal cap years ended October&#160;31, 2016 through September 30, 2021; $3.1&#160;million of this balance was acquired with the AseraCare acquisition. As of December&#160;31, 2020, we had recorded $9.3 million for estimated amounts due back to Medicare in accrued expenses for the Federal cap years ended October&#160;31, 2014 through September 30, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Hospice Non-Medicare Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Gross revenue is recorded on an accrual basis based upon the date of service at amounts equal to our established rates or estimated per day rates, as applicable. Contractual revenue adjustments are recorded for the difference between our standard rates and the contractual rates to be realized from patients, third-party payors and others for services provided and are deducted from gross revenue to determine our net service revenue. We also make non-contractual adjustments to non-Medicare revenue based on our historical experience to reflect the estimated transaction price.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Personal Care Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Personal Care Revenue&lt;/span&gt;&lt;/div&gt;We generate net service revenues by providing our services directly to patients based on authorized hours, visits or units determined by the relevant agency, at a rate that is either contractual or fixed by legislation. Net service revenue is recognized at the time services are rendered based on gross charges for the services provided, reduced by estimates for contractual and non-contractual revenue adjustments. We receive payment for providing such services from payors, including state and local governmental agencies, managed care organizations, commercial insurers and private consumers. Payors include the following elder service agencies: Aging Services Access Points ("ASAPs"), Senior Care Options ("SCOs"), Program of All-Inclusive Care for the Elderly ("PACE") and the Veterans Administration ("VA").</us-gaap:RevenueRecognitionPolicyTextBlock>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i85ce6ba1e58b4b7c883aa1e71fb67e40_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV80My9mcmFnOjFhYzcyMjM4MzVjYzRiMjFiMWMzNjkwMGJmZjQzMjM3L3RleHRyZWdpb246MWFjNzIyMzgzNWNjNGIyMWIxYzM2OTAwYmZmNDMyMzdfMTA5OTUxMTY1MDEwNg_5f9826ef-670b-49f5-8377-3846749c2a0b"
      unitRef="number">0.75</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ib0181bc176d24054b0b4382b5f3a2ef9_D20210401-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV80My9mcmFnOjFhYzcyMjM4MzVjYzRiMjFiMWMzNjkwMGJmZjQzMjM3L3RleHRyZWdpb246MWFjNzIyMzgzNWNjNGIyMWIxYzM2OTAwYmZmNDMyMzdfMTA5OTUxMTY1MDEwNg_cbfdc1c8-4d59-4975-aee8-195726094432"
      unitRef="number">0.75</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="if78f143ce2814015b9ecc0469dc639f1_D20200101-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV80My9mcmFnOjFhYzcyMjM4MzVjYzRiMjFiMWMzNjkwMGJmZjQzMjM3L3RleHRyZWdpb246MWFjNzIyMzgzNWNjNGIyMWIxYzM2OTAwYmZmNDMyMzdfMTA5OTUxMTY1MDIyMQ_0cfb9d0a-e2ff-4b00-a391-a80d3b1c7bd4"
      unitRef="number">0.74</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i9d0cb72c37b145799e408add964d0544_D20200401-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV80My9mcmFnOjFhYzcyMjM4MzVjYzRiMjFiMWMzNjkwMGJmZjQzMjM3L3RleHRyZWdpb246MWFjNzIyMzgzNWNjNGIyMWIxYzM2OTAwYmZmNDMyMzdfMTA5OTUxMTY1MDIyMQ_230c9191-8bd3-40e7-bea5-fc86b71ab8dc"
      unitRef="number">0.74</us-gaap:ConcentrationRiskPercentage1>
    <amed:HistoricalCollectionRateFromMedicare
      contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV80My9mcmFnOjFhYzcyMjM4MzVjYzRiMjFiMWMzNjkwMGJmZjQzMjM3L3RleHRyZWdpb246MWFjNzIyMzgzNWNjNGIyMWIxYzM2OTAwYmZmNDMyMzdfMzg5Mw_f47cbdea-9157-4757-a5f2-e4f5e8f77820"
      unitRef="number">0.99</amed:HistoricalCollectionRateFromMedicare>
    <us-gaap:ScheduleOfRevenueSourcesHealthCareOrganizationTableTextBlock
      contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV80My9mcmFnOjFhYzcyMjM4MzVjYzRiMjFiMWMzNjkwMGJmZjQzMjM3L3RleHRyZWdpb246MWFjNzIyMzgzNWNjNGIyMWIxYzM2OTAwYmZmNDMyMzdfMjIxOTk_8f7a3879-bcab-4b1a-af78-f90b51ba33e7">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue by payor class as a percentage of total net service revenue is as follows:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.923%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three-Month Periods Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Six-Month Periods &lt;br/&gt;Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;Home Health:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Medicare&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Non-Medicare - Episodic-based&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Non-Medicare - Non-episodic based&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;Hospice (1):&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Medicare&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Non-Medicare&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;Personal Care&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="24" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1) Acquired AseraCare Hospice ("AseraCare") on June 1, 2020.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfRevenueSourcesHealthCareOrganizationTableTextBlock>
    <amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue
      contextRef="i819d1cc0f63448c9bae946092e2d9634_D20210401-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV80My9mcmFnOjFhYzcyMjM4MzVjYzRiMjFiMWMzNjkwMGJmZjQzMjM3L3RhYmxlOjJkYTM1ZTFhMTg0YzQwYTc5NTZlMzYzMmYwZjU3YzQ3L3RhYmxlcmFuZ2U6MmRhMzVlMWExODRjNDBhNzk1NmUzNjMyZjBmNTdjNDdfMy0xLTEtMS0w_81556ff4-8f40-4452-97f8-d0d938341b26"
      unitRef="number">0.42</amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue>
    <amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue
      contextRef="iab0c4aa1f54048f9bb07ee49f6bb395e_D20200401-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV80My9mcmFnOjFhYzcyMjM4MzVjYzRiMjFiMWMzNjkwMGJmZjQzMjM3L3RhYmxlOjJkYTM1ZTFhMTg0YzQwYTc5NTZlMzYzMmYwZjU3YzQ3L3RhYmxlcmFuZ2U6MmRhMzVlMWExODRjNDBhNzk1NmUzNjMyZjBmNTdjNDdfMy0zLTEtMS0w_e62761d2-9c9d-456a-87ed-77d517ff6f2b"
      unitRef="number">0.40</amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue>
    <amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue
      contextRef="i72044b2a44e74c5591b023a1c6e1f437_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV80My9mcmFnOjFhYzcyMjM4MzVjYzRiMjFiMWMzNjkwMGJmZjQzMjM3L3RhYmxlOjJkYTM1ZTFhMTg0YzQwYTc5NTZlMzYzMmYwZjU3YzQ3L3RhYmxlcmFuZ2U6MmRhMzVlMWExODRjNDBhNzk1NmUzNjMyZjBmNTdjNDdfMy01LTEtMS0yODA_07894343-56ab-4e70-972d-032b54dc1271"
      unitRef="number">0.42</amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue>
    <amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue
      contextRef="iec44149de0804e90a0d618b5aab11df1_D20200101-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV80My9mcmFnOjFhYzcyMjM4MzVjYzRiMjFiMWMzNjkwMGJmZjQzMjM3L3RhYmxlOjJkYTM1ZTFhMTg0YzQwYTc5NTZlMzYzMmYwZjU3YzQ3L3RhYmxlcmFuZ2U6MmRhMzVlMWExODRjNDBhNzk1NmUzNjMyZjBmNTdjNDdfMy03LTEtMS0yODA_b702c777-7c7a-4deb-88e1-6149ff6072fa"
      unitRef="number">0.41</amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue>
    <amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue
      contextRef="iba4b4085e2a44ace9b534d8db3a5cb18_D20210401-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV80My9mcmFnOjFhYzcyMjM4MzVjYzRiMjFiMWMzNjkwMGJmZjQzMjM3L3RhYmxlOjJkYTM1ZTFhMTg0YzQwYTc5NTZlMzYzMmYwZjU3YzQ3L3RhYmxlcmFuZ2U6MmRhMzVlMWExODRjNDBhNzk1NmUzNjMyZjBmNTdjNDdfNC0xLTEtMS0w_bd2aeda9-dafa-4a4a-970b-e8656d61a1b9"
      unitRef="number">0.08</amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue>
    <amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue
      contextRef="i62976d7f48f547f690d30bf5ecdc0c9d_D20200401-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV80My9mcmFnOjFhYzcyMjM4MzVjYzRiMjFiMWMzNjkwMGJmZjQzMjM3L3RhYmxlOjJkYTM1ZTFhMTg0YzQwYTc5NTZlMzYzMmYwZjU3YzQ3L3RhYmxlcmFuZ2U6MmRhMzVlMWExODRjNDBhNzk1NmUzNjMyZjBmNTdjNDdfNC0zLTEtMS0w_7a857ccf-4828-4621-b217-ec436127f2f7"
      unitRef="number">0.06</amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue>
    <amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue
      contextRef="i2b90bd098db34908919842c129b2c275_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV80My9mcmFnOjFhYzcyMjM4MzVjYzRiMjFiMWMzNjkwMGJmZjQzMjM3L3RhYmxlOjJkYTM1ZTFhMTg0YzQwYTc5NTZlMzYzMmYwZjU3YzQ3L3RhYmxlcmFuZ2U6MmRhMzVlMWExODRjNDBhNzk1NmUzNjMyZjBmNTdjNDdfNC01LTEtMS0yODA_5aba69dc-c935-4c37-96b1-aa0fe3c08826"
      unitRef="number">0.08</amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue>
    <amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue
      contextRef="i986914649c744434996e298aed0a55de_D20200101-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV80My9mcmFnOjFhYzcyMjM4MzVjYzRiMjFiMWMzNjkwMGJmZjQzMjM3L3RhYmxlOjJkYTM1ZTFhMTg0YzQwYTc5NTZlMzYzMmYwZjU3YzQ3L3RhYmxlcmFuZ2U6MmRhMzVlMWExODRjNDBhNzk1NmUzNjMyZjBmNTdjNDdfNC03LTEtMS0yODA_43aab793-7d7d-4c0d-b141-4e2d7b5dc947"
      unitRef="number">0.06</amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue>
    <amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue
      contextRef="id3dfc4a215e346f2b62f7a0031e7a1c0_D20210401-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV80My9mcmFnOjFhYzcyMjM4MzVjYzRiMjFiMWMzNjkwMGJmZjQzMjM3L3RhYmxlOjJkYTM1ZTFhMTg0YzQwYTc5NTZlMzYzMmYwZjU3YzQ3L3RhYmxlcmFuZ2U6MmRhMzVlMWExODRjNDBhNzk1NmUzNjMyZjBmNTdjNDdfNS0xLTEtMS0w_5483b0b4-d65f-433f-b57c-08d9ae42347c"
      unitRef="number">0.12</amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue>
    <amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue
      contextRef="i1889f1856fd04eb9a83ad415f13bb6e1_D20200401-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV80My9mcmFnOjFhYzcyMjM4MzVjYzRiMjFiMWMzNjkwMGJmZjQzMjM3L3RhYmxlOjJkYTM1ZTFhMTg0YzQwYTc5NTZlMzYzMmYwZjU3YzQ3L3RhYmxlcmFuZ2U6MmRhMzVlMWExODRjNDBhNzk1NmUzNjMyZjBmNTdjNDdfNS0zLTEtMS0w_c48ce460-0e87-4960-8cb9-4694082e126b"
      unitRef="number">0.14</amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue>
    <amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue
      contextRef="i07bd2c944cf046a189fd4eb6529755d6_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV80My9mcmFnOjFhYzcyMjM4MzVjYzRiMjFiMWMzNjkwMGJmZjQzMjM3L3RhYmxlOjJkYTM1ZTFhMTg0YzQwYTc5NTZlMzYzMmYwZjU3YzQ3L3RhYmxlcmFuZ2U6MmRhMzVlMWExODRjNDBhNzk1NmUzNjMyZjBmNTdjNDdfNS01LTEtMS0yODA_1164f11b-41c4-4a74-b33b-23a77714a309"
      unitRef="number">0.12</amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue>
    <amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue
      contextRef="i584d1976fa4740918795b29a298c07f8_D20200101-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV80My9mcmFnOjFhYzcyMjM4MzVjYzRiMjFiMWMzNjkwMGJmZjQzMjM3L3RhYmxlOjJkYTM1ZTFhMTg0YzQwYTc5NTZlMzYzMmYwZjU3YzQ3L3RhYmxlcmFuZ2U6MmRhMzVlMWExODRjNDBhNzk1NmUzNjMyZjBmNTdjNDdfNS03LTEtMS0yODA_b117d2a8-d576-4677-ae8a-4262a8fa8748"
      unitRef="number">0.14</amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue>
    <amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue
      contextRef="i82e2454c5eed4b28ab058238918f809e_D20210401-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV80My9mcmFnOjFhYzcyMjM4MzVjYzRiMjFiMWMzNjkwMGJmZjQzMjM3L3RhYmxlOjJkYTM1ZTFhMTg0YzQwYTc5NTZlMzYzMmYwZjU3YzQ3L3RhYmxlcmFuZ2U6MmRhMzVlMWExODRjNDBhNzk1NmUzNjMyZjBmNTdjNDdfNy0xLTEtMS0w_af747f1f-946b-43ac-9d10-07e63c0eeb6e"
      unitRef="number">0.33</amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue>
    <amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue
      contextRef="i617f99e1213a4f2094c8432f4837db94_D20200401-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV80My9mcmFnOjFhYzcyMjM4MzVjYzRiMjFiMWMzNjkwMGJmZjQzMjM3L3RhYmxlOjJkYTM1ZTFhMTg0YzQwYTc5NTZlMzYzMmYwZjU3YzQ3L3RhYmxlcmFuZ2U6MmRhMzVlMWExODRjNDBhNzk1NmUzNjMyZjBmNTdjNDdfNy0zLTEtMS0w_3bad2215-95da-44bc-9283-484352f61fda"
      unitRef="number">0.34</amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue>
    <amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue
      contextRef="i7a48258931a748a99b37e6058a5916e4_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV80My9mcmFnOjFhYzcyMjM4MzVjYzRiMjFiMWMzNjkwMGJmZjQzMjM3L3RhYmxlOjJkYTM1ZTFhMTg0YzQwYTc5NTZlMzYzMmYwZjU3YzQ3L3RhYmxlcmFuZ2U6MmRhMzVlMWExODRjNDBhNzk1NmUzNjMyZjBmNTdjNDdfNy01LTEtMS0yODM_1dc38bae-07c7-497b-b564-5b762d39ab35"
      unitRef="number">0.33</amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue>
    <amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue
      contextRef="iff8b2cf9576146db8b00ff2d1d72091f_D20200101-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV80My9mcmFnOjFhYzcyMjM4MzVjYzRiMjFiMWMzNjkwMGJmZjQzMjM3L3RhYmxlOjJkYTM1ZTFhMTg0YzQwYTc5NTZlMzYzMmYwZjU3YzQ3L3RhYmxlcmFuZ2U6MmRhMzVlMWExODRjNDBhNzk1NmUzNjMyZjBmNTdjNDdfNy03LTEtMS0yODM_99fd9cf3-aeea-45c2-bb00-00f3b5be7f2d"
      unitRef="number">0.33</amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue>
    <amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue
      contextRef="i575fb5ffd81f408fb483b5911db2264f_D20210401-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV80My9mcmFnOjFhYzcyMjM4MzVjYzRiMjFiMWMzNjkwMGJmZjQzMjM3L3RhYmxlOjJkYTM1ZTFhMTg0YzQwYTc5NTZlMzYzMmYwZjU3YzQ3L3RhYmxlcmFuZ2U6MmRhMzVlMWExODRjNDBhNzk1NmUzNjMyZjBmNTdjNDdfOC0xLTEtMS0w_7a78ad7d-8a3a-41f6-8b11-439c1547d38a"
      unitRef="number">0.02</amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue>
    <amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue
      contextRef="i79540dc5db374f3e8dad988e2d746e13_D20200401-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV80My9mcmFnOjFhYzcyMjM4MzVjYzRiMjFiMWMzNjkwMGJmZjQzMjM3L3RhYmxlOjJkYTM1ZTFhMTg0YzQwYTc5NTZlMzYzMmYwZjU3YzQ3L3RhYmxlcmFuZ2U6MmRhMzVlMWExODRjNDBhNzk1NmUzNjMyZjBmNTdjNDdfOC0zLTEtMS0w_b20bc85e-e5f5-4d53-af74-c4b16461d56d"
      unitRef="number">0.02</amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue>
    <amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue
      contextRef="i83c28c34df424dba99ce508660059376_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV80My9mcmFnOjFhYzcyMjM4MzVjYzRiMjFiMWMzNjkwMGJmZjQzMjM3L3RhYmxlOjJkYTM1ZTFhMTg0YzQwYTc5NTZlMzYzMmYwZjU3YzQ3L3RhYmxlcmFuZ2U6MmRhMzVlMWExODRjNDBhNzk1NmUzNjMyZjBmNTdjNDdfOC01LTEtMS0yODM_a95366a5-b590-431f-95af-4cbe6c143f4a"
      unitRef="number">0.02</amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue>
    <amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue
      contextRef="ib14de18b4a2d452c831ee77de19f382d_D20200101-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV80My9mcmFnOjFhYzcyMjM4MzVjYzRiMjFiMWMzNjkwMGJmZjQzMjM3L3RhYmxlOjJkYTM1ZTFhMTg0YzQwYTc5NTZlMzYzMmYwZjU3YzQ3L3RhYmxlcmFuZ2U6MmRhMzVlMWExODRjNDBhNzk1NmUzNjMyZjBmNTdjNDdfOC03LTEtMS0yODM_0ea0533e-94fe-4a2e-a01b-a9e7a34e81b3"
      unitRef="number">0.02</amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue>
    <amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue
      contextRef="i9459b4ff31494b3a8001d1ad78d69359_D20210401-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV80My9mcmFnOjFhYzcyMjM4MzVjYzRiMjFiMWMzNjkwMGJmZjQzMjM3L3RhYmxlOjJkYTM1ZTFhMTg0YzQwYTc5NTZlMzYzMmYwZjU3YzQ3L3RhYmxlcmFuZ2U6MmRhMzVlMWExODRjNDBhNzk1NmUzNjMyZjBmNTdjNDdfOS0xLTEtMS0w_babecbd0-5bb1-4ced-b99c-4c01bac3021b"
      unitRef="number">0.03</amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue>
    <amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue
      contextRef="i4720759f4b1249fc9f52ebf7d06b0d2c_D20200401-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV80My9mcmFnOjFhYzcyMjM4MzVjYzRiMjFiMWMzNjkwMGJmZjQzMjM3L3RhYmxlOjJkYTM1ZTFhMTg0YzQwYTc5NTZlMzYzMmYwZjU3YzQ3L3RhYmxlcmFuZ2U6MmRhMzVlMWExODRjNDBhNzk1NmUzNjMyZjBmNTdjNDdfOS0zLTEtMS0w_00c878cb-a743-4a3d-80eb-5df4577ebdee"
      unitRef="number">0.04</amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue>
    <amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue
      contextRef="i913d274664fd48a49b9a53ffbeeb81bd_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV80My9mcmFnOjFhYzcyMjM4MzVjYzRiMjFiMWMzNjkwMGJmZjQzMjM3L3RhYmxlOjJkYTM1ZTFhMTg0YzQwYTc5NTZlMzYzMmYwZjU3YzQ3L3RhYmxlcmFuZ2U6MmRhMzVlMWExODRjNDBhNzk1NmUzNjMyZjBmNTdjNDdfOS01LTEtMS0yODM_33f74912-6faf-4645-a655-ccc806de8091"
      unitRef="number">0.03</amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue>
    <amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue
      contextRef="i2cd2a132976345f995477e91bea1b7a4_D20200101-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV80My9mcmFnOjFhYzcyMjM4MzVjYzRiMjFiMWMzNjkwMGJmZjQzMjM3L3RhYmxlOjJkYTM1ZTFhMTg0YzQwYTc5NTZlMzYzMmYwZjU3YzQ3L3RhYmxlcmFuZ2U6MmRhMzVlMWExODRjNDBhNzk1NmUzNjMyZjBmNTdjNDdfOS03LTEtMS0yODM_0a02f81e-34e9-4ed4-996e-71445afa9ee7"
      unitRef="number">0.04</amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue>
    <amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue
      contextRef="ib87cee58ccf2448a8d4422101bf61fa0_D20210401-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV80My9mcmFnOjFhYzcyMjM4MzVjYzRiMjFiMWMzNjkwMGJmZjQzMjM3L3RhYmxlOjJkYTM1ZTFhMTg0YzQwYTc5NTZlMzYzMmYwZjU3YzQ3L3RhYmxlcmFuZ2U6MmRhMzVlMWExODRjNDBhNzk1NmUzNjMyZjBmNTdjNDdfMTAtMS0xLTEtMA_c4009903-05d8-4232-84e7-9df1805a4198"
      unitRef="number">1</amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue>
    <amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue
      contextRef="i2c8351954d014a1c80a3d8cfc2327ab2_D20200401-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV80My9mcmFnOjFhYzcyMjM4MzVjYzRiMjFiMWMzNjkwMGJmZjQzMjM3L3RhYmxlOjJkYTM1ZTFhMTg0YzQwYTc5NTZlMzYzMmYwZjU3YzQ3L3RhYmxlcmFuZ2U6MmRhMzVlMWExODRjNDBhNzk1NmUzNjMyZjBmNTdjNDdfMTAtMy0xLTEtMA_fa32fdc9-e529-488f-a2e4-932e281d5d5d"
      unitRef="number">1</amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue>
    <amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue
      contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV80My9mcmFnOjFhYzcyMjM4MzVjYzRiMjFiMWMzNjkwMGJmZjQzMjM3L3RhYmxlOjJkYTM1ZTFhMTg0YzQwYTc5NTZlMzYzMmYwZjU3YzQ3L3RhYmxlcmFuZ2U6MmRhMzVlMWExODRjNDBhNzk1NmUzNjMyZjBmNTdjNDdfMTAtNS0xLTEtMjgz_e517b0ca-96c8-4fb1-9e58-12dc7c5a7f72"
      unitRef="number">1</amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue>
    <amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue
      contextRef="i667fa0996400408f9cb2d7f4d3ee2087_D20200101-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV80My9mcmFnOjFhYzcyMjM4MzVjYzRiMjFiMWMzNjkwMGJmZjQzMjM3L3RhYmxlOjJkYTM1ZTFhMTg0YzQwYTc5NTZlMzYzMmYwZjU3YzQ3L3RhYmxlcmFuZ2U6MmRhMzVlMWExODRjNDBhNzk1NmUzNjMyZjBmNTdjNDdfMTAtNy0xLTEtMjgz_2ab619cd-f4c7-4df7-ac08-a4a2f96f5f67"
      unitRef="number">1</amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue>
    <amed:NetServiceRevenuePeriodOfCarePaymentRateDuration
      contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV80My9mcmFnOjFhYzcyMjM4MzVjYzRiMjFiMWMzNjkwMGJmZjQzMjM3L3RleHRyZWdpb246MWFjNzIyMzgzNWNjNGIyMWIxYzM2OTAwYmZmNDMyMzdfNDQ3NA_cf808f76-53a7-400a-85f2-a0394a3e8dfd">P30D</amed:NetServiceRevenuePeriodOfCarePaymentRateDuration>
    <amed:NetServiceRevenueEpisodePaymentRateDuration
      contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV80My9mcmFnOjFhYzcyMjM4MzVjYzRiMjFiMWMzNjkwMGJmZjQzMjM3L3RleHRyZWdpb246MWFjNzIyMzgzNWNjNGIyMWIxYzM2OTAwYmZmNDMyMzdfNDUwOQ_85e895c0-953c-4f4d-a547-a5fdb385dd03">P60D</amed:NetServiceRevenueEpisodePaymentRateDuration>
    <amed:NetServiceRevenuePeriodOfCarePaymentRateDuration
      contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV80My9mcmFnOjFhYzcyMjM4MzVjYzRiMjFiMWMzNjkwMGJmZjQzMjM3L3RleHRyZWdpb246MWFjNzIyMzgzNWNjNGIyMWIxYzM2OTAwYmZmNDMyMzdfNDgyOA_bc2dc7c3-23a6-4159-b465-59e1ee9c83f5">P30D</amed:NetServiceRevenuePeriodOfCarePaymentRateDuration>
    <amed:PercentageOfTotalReimbursementOfOutlierPayment
      contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV80My9mcmFnOjFhYzcyMjM4MzVjYzRiMjFiMWMzNjkwMGJmZjQzMjM3L3RleHRyZWdpb246MWFjNzIyMzgzNWNjNGIyMWIxYzM2OTAwYmZmNDMyMzdfNjQ4NA_5c01dc8b-6269-46ad-bb85-5424aab66ec8"
      unitRef="number">0.10</amed:PercentageOfTotalReimbursementOfOutlierPayment>
    <amed:LowUtilizationPaymentAdjustmentNumberOfVisits
      contextRef="i90c63ef3c03b4a79b0e16bebccfb5aaa_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV80My9mcmFnOjFhYzcyMjM4MzVjYzRiMjFiMWMzNjkwMGJmZjQzMjM3L3RleHRyZWdpb246MWFjNzIyMzgzNWNjNGIyMWIxYzM2OTAwYmZmNDMyMzdfNjY3NA_cac2c2aa-09fd-4c18-9bcb-a0104d0813fa"
      unitRef="visit">2</amed:LowUtilizationPaymentAdjustmentNumberOfVisits>
    <amed:LowUtilizationPaymentAdjustmentNumberOfVisits
      contextRef="iea406e6210c24d67b95bd8bba7ed6315_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV80My9mcmFnOjFhYzcyMjM4MzVjYzRiMjFiMWMzNjkwMGJmZjQzMjM3L3RleHRyZWdpb246MWFjNzIyMzgzNWNjNGIyMWIxYzM2OTAwYmZmNDMyMzdfNjY4MA_c5a9d304-aa8e-4f4b-98e7-189b6d9d9d52"
      unitRef="visit">6</amed:LowUtilizationPaymentAdjustmentNumberOfVisits>
    <amed:HistoricalCollectionRateFromMedicare
      contextRef="i1e89d4343fef486490e1fcdab10c1010_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV80My9mcmFnOjFhYzcyMjM4MzVjYzRiMjFiMWMzNjkwMGJmZjQzMjM3L3RleHRyZWdpb246MWFjNzIyMzgzNWNjNGIyMWIxYzM2OTAwYmZmNDMyMzdfNzMwOA_7f5abd3a-9c5a-4b80-b1da-282483e49cf3"
      unitRef="number">0.99</amed:HistoricalCollectionRateFromMedicare>
    <amed:RateOfRequestForAnticipatedPaymentSubmittedForInitialPeriodOfCare
      contextRef="id4b15251aa8147bcb0b8c78424ea981c_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV80My9mcmFnOjFhYzcyMjM4MzVjYzRiMjFiMWMzNjkwMGJmZjQzMjM3L3RleHRyZWdpb246MWFjNzIyMzgzNWNjNGIyMWIxYzM2OTAwYmZmNDMyMzdfMTA5OTUxMTY1MTI2Mw_04295ca5-6927-4f2b-9a6d-26f441f79f97"
      unitRef="number">0.20</amed:RateOfRequestForAnticipatedPaymentSubmittedForInitialPeriodOfCare>
    <amed:NetServiceRevenuePeriodOfCarePaymentRateDuration
      contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV80My9mcmFnOjFhYzcyMjM4MzVjYzRiMjFiMWMzNjkwMGJmZjQzMjM3L3RleHRyZWdpb246MWFjNzIyMzgzNWNjNGIyMWIxYzM2OTAwYmZmNDMyMzdfOTExNA_b8b43c7e-1458-41d6-8f6c-debaebb42bc9">P30D</amed:NetServiceRevenuePeriodOfCarePaymentRateDuration>
    <amed:NonMedicareRevenueTermRates
      contextRef="i90c63ef3c03b4a79b0e16bebccfb5aaa_D20210101-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV80My9mcmFnOjFhYzcyMjM4MzVjYzRiMjFiMWMzNjkwMGJmZjQzMjM3L3RleHRyZWdpb246MWFjNzIyMzgzNWNjNGIyMWIxYzM2OTAwYmZmNDMyMzdfOTcwMg_d860e34d-b748-4c4e-ada9-2f3ccd49a1fa"
      unitRef="number">0.95</amed:NonMedicareRevenueTermRates>
    <amed:NonMedicareRevenueTermRates
      contextRef="iea406e6210c24d67b95bd8bba7ed6315_D20210101-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV80My9mcmFnOjFhYzcyMjM4MzVjYzRiMjFiMWMzNjkwMGJmZjQzMjM3L3RleHRyZWdpb246MWFjNzIyMzgzNWNjNGIyMWIxYzM2OTAwYmZmNDMyMzdfOTcwOA_e411d502-1af9-45f9-a7b8-095eb39889a7"
      unitRef="number">1</amed:NonMedicareRevenueTermRates>
    <amed:HospiceMedicareRevenueRateAccountedForRoutineCare
      contextRef="i667fa0996400408f9cb2d7f4d3ee2087_D20200101-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV80My9mcmFnOjFhYzcyMjM4MzVjYzRiMjFiMWMzNjkwMGJmZjQzMjM3L3RleHRyZWdpb246MWFjNzIyMzgzNWNjNGIyMWIxYzM2OTAwYmZmNDMyMzdfMTA4ODY_17d0af9c-594d-4b61-9362-9d6608b174e9"
      unitRef="number">0.97</amed:HospiceMedicareRevenueRateAccountedForRoutineCare>
    <amed:HospiceMedicareRevenueRateAccountedForRoutineCare
      contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV80My9mcmFnOjFhYzcyMjM4MzVjYzRiMjFiMWMzNjkwMGJmZjQzMjM3L3RleHRyZWdpb246MWFjNzIyMzgzNWNjNGIyMWIxYzM2OTAwYmZmNDMyMzdfMTA4ODY_ad0c75b8-1fa4-4bcc-bc8c-d06fe291405d"
      unitRef="number">0.97</amed:HospiceMedicareRevenueRateAccountedForRoutineCare>
    <amed:HospiceMedicareRevenueRateAccountedForRoutineCare
      contextRef="i2c8351954d014a1c80a3d8cfc2327ab2_D20200401-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV80My9mcmFnOjFhYzcyMjM4MzVjYzRiMjFiMWMzNjkwMGJmZjQzMjM3L3RleHRyZWdpb246MWFjNzIyMzgzNWNjNGIyMWIxYzM2OTAwYmZmNDMyMzdfMTA4ODY_c073d5cf-287c-469d-bc61-ddb23919deab"
      unitRef="number">0.97</amed:HospiceMedicareRevenueRateAccountedForRoutineCare>
    <amed:HospiceMedicareRevenueRateAccountedForRoutineCare
      contextRef="ib87cee58ccf2448a8d4422101bf61fa0_D20210401-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV80My9mcmFnOjFhYzcyMjM4MzVjYzRiMjFiMWMzNjkwMGJmZjQzMjM3L3RleHRyZWdpb246MWFjNzIyMzgzNWNjNGIyMWIxYzM2OTAwYmZmNDMyMzdfMTA4ODY_e41131a7-e5b5-4a61-97c9-49c6912769ef"
      unitRef="number">0.97</amed:HospiceMedicareRevenueRateAccountedForRoutineCare>
    <amed:HistoricalCollectionRateFromMedicare
      contextRef="i741b04b8cd704e398b27520bf8aea7fc_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV80My9mcmFnOjFhYzcyMjM4MzVjYzRiMjFiMWMzNjkwMGJmZjQzMjM3L3RleHRyZWdpb246MWFjNzIyMzgzNWNjNGIyMWIxYzM2OTAwYmZmNDMyMzdfMTE5MDM_a27c8f2d-17bd-4baa-8731-aeaa5c43ef54"
      unitRef="number">0.99</amed:HistoricalCollectionRateFromMedicare>
    <amed:EstimatedAmountDueBackToMedicareInOtherAccruedLiabilities
      contextRef="i35e97441f2084fc28b554985218499ab_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV80My9mcmFnOjFhYzcyMjM4MzVjYzRiMjFiMWMzNjkwMGJmZjQzMjM3L3RleHRyZWdpb246MWFjNzIyMzgzNWNjNGIyMWIxYzM2OTAwYmZmNDMyMzdfMTI2NTA_b65b673a-12fb-4978-b591-76b27dc27876"
      unitRef="usd">10000000.0</amed:EstimatedAmountDueBackToMedicareInOtherAccruedLiabilities>
    <amed:EstimatedAmountDueBackToMedicareInOtherAccruedLiabilities
      contextRef="i7dc0b5d0b4c04b6ebdca7598a9e533de_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV80My9mcmFnOjFhYzcyMjM4MzVjYzRiMjFiMWMzNjkwMGJmZjQzMjM3L3RleHRyZWdpb246MWFjNzIyMzgzNWNjNGIyMWIxYzM2OTAwYmZmNDMyMzdfMTI3OTM_039486c0-e40b-48ef-b240-09450f7badde"
      unitRef="usd">3100000</amed:EstimatedAmountDueBackToMedicareInOtherAccruedLiabilities>
    <amed:EstimatedAmountDueBackToMedicareInOtherAccruedLiabilities
      contextRef="i4f2f1eaba6994474b883c637fd8bdd09_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV80My9mcmFnOjFhYzcyMjM4MzVjYzRiMjFiMWMzNjkwMGJmZjQzMjM3L3RleHRyZWdpb246MWFjNzIyMzgzNWNjNGIyMWIxYzM2OTAwYmZmNDMyMzdfMTI4ODM_66de6f6f-197a-4d24-8c6d-9425184b5ae0"
      unitRef="usd">9300000</amed:EstimatedAmountDueBackToMedicareInOtherAccruedLiabilities>
    <amed:GovernmentGrantsPolicyTextBlock
      contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV80My9mcmFnOjFhYzcyMjM4MzVjYzRiMjFiMWMzNjkwMGJmZjQzMjM3L3RleHRyZWdpb246MWFjNzIyMzgzNWNjNGIyMWIxYzM2OTAwYmZmNDMyMzdfMjIyMTU_bdff7742-273f-436c-bc08-77b3cf11e81f">&lt;div style="margin-top:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Government Grants&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the absence of specific guidance to account for government grants under U.S. GAAP, we have decided to account for government grants in accordance with International Accounting Standard ("IAS") 20, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Accounting for Government Grants and Disclosure of Government Assistance&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, and as such, we recognize grant income on a systematic basis in line with the recognition of expenses or the loss of revenues for which the grants are intended to compensate. We recognize grants once both of the following conditions are met: (1) we are able to comply with the relevant conditions of the grant and (2) the grant will be received. See Note 3 - Novel Coronavirus Pandemic ("COVID-19") for additional information on our accounting for government funds received under the Coronavirus Aid, Relief and Economic Security Act ("CARES Act") and the Mass Home Care ASAP COVID-19 Provider Sustainability Program.&lt;/span&gt;&lt;/div&gt;</amed:GovernmentGrantsPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy
      contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV80My9mcmFnOjFhYzcyMjM4MzVjYzRiMjFiMWMzNjkwMGJmZjQzMjM3L3RleHRyZWdpb246MWFjNzIyMzgzNWNjNGIyMWIxYzM2OTAwYmZmNDMyMzdfMjIxOTU_df6efdee-7b6d-43e9-ad1b-481812c32b48">&lt;div style="margin-top:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cash, Cash Equivalents and Restricted Cash &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash and cash equivalents include certificates of deposit and all highly liquid debt instruments with maturities of three months or less when purchased. Our cash balance as of June 30, 2021 includes approximately $62&#160;million associated with the CARES Act Provider Relief Fund ("PRF"). We separated the PRF funds into their own account and as of June 30, 2021, we have only transferred funds used through March 31, 2021 to our operating account. We will transfer funds used during the three-month period ended June 30, 2021, totaling approximately $4&#160;million, to our operating account during the third quarter of 2021 and repay the remaining $58&#160;million to the U.S. Department of Health and Human Services ("HHS") by October 30, 2021. Restricted cash includes cash that is not available for ordinary business use. As of June 30, 2021, we had $1&#160;million of restricted cash that was placed into an escrow account related to the indemnity and closing payment adjustment provisions within the Asana Hospice purchase agreement.&lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the balances related to our cash, cash equivalents and restricted cash (amounts in millions):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.250%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.981%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.739%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;91.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash, cash equivalents and restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;92.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;83.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy>
    <amed:CashBalanceAssociatedWithProviderReliefFund
      contextRef="i1e833203be6947b4968aba4d20064ec8_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV80My9mcmFnOjFhYzcyMjM4MzVjYzRiMjFiMWMzNjkwMGJmZjQzMjM3L3RleHRyZWdpb246MWFjNzIyMzgzNWNjNGIyMWIxYzM2OTAwYmZmNDMyMzdfMTU2MDQ_ba3a039b-eb4d-48de-b1ce-18dfcb8d74d5"
      unitRef="usd">62000000</amed:CashBalanceAssociatedWithProviderReliefFund>
    <amed:CARESActProviderReliefFundsUtilized
      contextRef="ib87cee58ccf2448a8d4422101bf61fa0_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV80My9mcmFnOjFhYzcyMjM4MzVjYzRiMjFiMWMzNjkwMGJmZjQzMjM3L3RleHRyZWdpb246MWFjNzIyMzgzNWNjNGIyMWIxYzM2OTAwYmZmNDMyMzdfMTA5OTUxMTY1MTQ1Nw_e2a0598b-11fd-4c8b-8edf-dc11d9f20b6a"
      unitRef="usd">4000000</amed:CARESActProviderReliefFundsUtilized>
    <amed:ProviderReliefFundAdvance
      contextRef="i1e833203be6947b4968aba4d20064ec8_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV80My9mcmFnOjFhYzcyMjM4MzVjYzRiMjFiMWMzNjkwMGJmZjQzMjM3L3RleHRyZWdpb246MWFjNzIyMzgzNWNjNGIyMWIxYzM2OTAwYmZmNDMyMzdfMTA5OTUxMTY1MTQ2OQ_d170182c-e2dd-4192-9deb-809780456433"
      unitRef="usd">58000000</amed:ProviderReliefFundAdvance>
    <us-gaap:RestrictedCash
      contextRef="iab3b21e1071d46c3a8d7f08560252318_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV80My9mcmFnOjFhYzcyMjM4MzVjYzRiMjFiMWMzNjkwMGJmZjQzMjM3L3RleHRyZWdpb246MWFjNzIyMzgzNWNjNGIyMWIxYzM2OTAwYmZmNDMyMzdfMTYwOTI_571a0580-31e6-4491-9277-e827b18052c8"
      unitRef="usd">1000000</us-gaap:RestrictedCash>
    <amed:ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlockTableTextBlock
      contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV80My9mcmFnOjFhYzcyMjM4MzVjYzRiMjFiMWMzNjkwMGJmZjQzMjM3L3RleHRyZWdpb246MWFjNzIyMzgzNWNjNGIyMWIxYzM2OTAwYmZmNDMyMzdfMjIyMjI_1f50dfb4-88bc-48fb-ac47-83b59076881d">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the balances related to our cash, cash equivalents and restricted cash (amounts in millions):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.250%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.981%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.739%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;91.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash, cash equivalents and restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;92.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;83.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</amed:ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlockTableTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i1e833203be6947b4968aba4d20064ec8_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV80My9mcmFnOjFhYzcyMjM4MzVjYzRiMjFiMWMzNjkwMGJmZjQzMjM3L3RhYmxlOjUyYTkwZWRjMDcxNDRjOGRhMDlhODU4ZTQ0MTgyNmMzL3RhYmxlcmFuZ2U6NTJhOTBlZGMwNzE0NGM4ZGEwOWE4NThlNDQxODI2YzNfMS0xLTEtMS0w_15453cf3-9f8c-4991-a680-f20efa99ab81"
      unitRef="usd">91600000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i87ceb60dc20d4df1b0a97d3514837910_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV80My9mcmFnOjFhYzcyMjM4MzVjYzRiMjFiMWMzNjkwMGJmZjQzMjM3L3RhYmxlOjUyYTkwZWRjMDcxNDRjOGRhMDlhODU4ZTQ0MTgyNmMzL3RhYmxlcmFuZ2U6NTJhOTBlZGMwNzE0NGM4ZGEwOWE4NThlNDQxODI2YzNfMS0zLTEtMS0w_5b5796af-a2fc-4157-ad6e-4b1c4750b117"
      unitRef="usd">81800000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCash
      contextRef="i1e833203be6947b4968aba4d20064ec8_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV80My9mcmFnOjFhYzcyMjM4MzVjYzRiMjFiMWMzNjkwMGJmZjQzMjM3L3RhYmxlOjUyYTkwZWRjMDcxNDRjOGRhMDlhODU4ZTQ0MTgyNmMzL3RhYmxlcmFuZ2U6NTJhOTBlZGMwNzE0NGM4ZGEwOWE4NThlNDQxODI2YzNfMi0xLTEtMS0w_4915d956-f142-4862-8306-74db5932c829"
      unitRef="usd">1000000.0</us-gaap:RestrictedCash>
    <us-gaap:RestrictedCash
      contextRef="i87ceb60dc20d4df1b0a97d3514837910_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV80My9mcmFnOjFhYzcyMjM4MzVjYzRiMjFiMWMzNjkwMGJmZjQzMjM3L3RhYmxlOjUyYTkwZWRjMDcxNDRjOGRhMDlhODU4ZTQ0MTgyNmMzL3RhYmxlcmFuZ2U6NTJhOTBlZGMwNzE0NGM4ZGEwOWE4NThlNDQxODI2YzNfMi0zLTEtMS0w_c4e0317f-29dc-40b0-8d8a-81149546fe6f"
      unitRef="usd">1500000</us-gaap:RestrictedCash>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i1e833203be6947b4968aba4d20064ec8_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV80My9mcmFnOjFhYzcyMjM4MzVjYzRiMjFiMWMzNjkwMGJmZjQzMjM3L3RhYmxlOjUyYTkwZWRjMDcxNDRjOGRhMDlhODU4ZTQ0MTgyNmMzL3RhYmxlcmFuZ2U6NTJhOTBlZGMwNzE0NGM4ZGEwOWE4NThlNDQxODI2YzNfMy0xLTEtMS0w_f50a2b4e-3a00-40c2-9e22-6ddc4116dbb6"
      unitRef="usd">92600000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:TradeAndOtherAccountsReceivablePolicy
      contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV80My9mcmFnOjFhYzcyMjM4MzVjYzRiMjFiMWMzNjkwMGJmZjQzMjM3L3RleHRyZWdpb246MWFjNzIyMzgzNWNjNGIyMWIxYzM2OTAwYmZmNDMyMzdfMjIyMjM_45f99aff-36cc-4a95-b609-4ab4f52442da">&lt;div style="margin-top:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Patient Accounts Receivable &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We report accounts receivable from services rendered at their estimated transaction price, which includes contractual and non-contractual revenue adjustments based on the amounts expected to be due from payors. Our patient accounts receivable are uncollateralized and consist of amounts due from Medicare, Medicaid, other third-party payors and patients. The Company's non-Medicare third-party payor base is comprised of a diverse group of payors that are geographically dispersed across the country. As of June&#160;30, 2021, there is one payor, other than Medicare, that accounts for 10% of our total outstanding patient receivables. Thus, we believe there are no other significant concentrations of receivables that would subject us to any significant credit risk in the collection of our patient accounts receivable. We write off accounts on a monthly basis once we have exhausted our collection efforts and deem an account to be uncollectible. We believe the collectability risk associated with our Medicare accounts, which represent 66% and 64% of our patient accounts receivable at June&#160;30, 2021 and December&#160;31, 2020, respectively, is limited due to our historical collection rate of over 99% from Medicare and the fact that Medicare is a U.S. government payor. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We do not believe there are any significant concentrations of revenues from any payor that would subject us to any significant credit risk in the collection of our accounts receivable.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Medicare Home Health&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For our home health patients, our pre-billing process includes verifying that we are eligible for payment from Medicare for the services that we provide to our patients. Our Medicare billing begins with a process to ensure that our billings are accurate through the utilization of an electronic Medicare claim review. Prior to January 1, 2021, we submitted a RAP for 20% of our estimated payment for each 30-day period of care. The RAP received was then deducted from our final payment. Effective January 1, 2021, CMS eliminated all upfront payments associated with RAPs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Medicare Hospice&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For our hospice patients, our pre-billing process includes verifying that we are eligible for payment from Medicare for the services that we provide to our patients. Our Medicare billing begins with a process to ensure that our billings are accurate through the utilization of an electronic Medicare claim review. We bill Medicare on a monthly basis for the services provided to the patient.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Non-Medicare Home Health, Hospice and Personal Care&lt;/span&gt;&lt;/div&gt;For our non-Medicare patients, our pre-billing process primarily begins with verifying a patient&#x2019;s eligibility for services with the applicable payor. Once the patient has been confirmed for eligibility, we will provide services to the patient and bill the applicable payor. Our review and evaluation of non-Medicare accounts receivable includes a detailed review of outstanding balances and special consideration to concentrations of receivables from particular payors or groups of payors with similar characteristics that would subject us to any significant credit risk.</us-gaap:TradeAndOtherAccountsReceivablePolicy>
    <amed:PercentageOfPatientReceivablesOutstanding
      contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV80My9mcmFnOjFhYzcyMjM4MzVjYzRiMjFiMWMzNjkwMGJmZjQzMjM3L3RleHRyZWdpb246MWFjNzIyMzgzNWNjNGIyMWIxYzM2OTAwYmZmNDMyMzdfMTcwMDc_fa445008-a4a8-4c7d-a935-296fe4ae32c8"
      unitRef="number">0.10</amed:PercentageOfPatientReceivablesOutstanding>
    <amed:AccountsReceivablePortionDerivedFromMedicare
      contextRef="i1e833203be6947b4968aba4d20064ec8_I20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV80My9mcmFnOjFhYzcyMjM4MzVjYzRiMjFiMWMzNjkwMGJmZjQzMjM3L3RleHRyZWdpb246MWFjNzIyMzgzNWNjNGIyMWIxYzM2OTAwYmZmNDMyMzdfMTc0NTk_a0de9bb8-b012-4e2d-8c99-d42a99ea45ba"
      unitRef="number">0.66</amed:AccountsReceivablePortionDerivedFromMedicare>
    <amed:AccountsReceivablePortionDerivedFromMedicare
      contextRef="i87ceb60dc20d4df1b0a97d3514837910_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV80My9mcmFnOjFhYzcyMjM4MzVjYzRiMjFiMWMzNjkwMGJmZjQzMjM3L3RleHRyZWdpb246MWFjNzIyMzgzNWNjNGIyMWIxYzM2OTAwYmZmNDMyMzdfMTc0NjY_bebdcb57-32b3-4f3d-9545-924c09b2d3f2"
      unitRef="number">0.64</amed:AccountsReceivablePortionDerivedFromMedicare>
    <amed:HistoricalCollectionRateFromMedicare
      contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV80My9mcmFnOjFhYzcyMjM4MzVjYzRiMjFiMWMzNjkwMGJmZjQzMjM3L3RleHRyZWdpb246MWFjNzIyMzgzNWNjNGIyMWIxYzM2OTAwYmZmNDMyMzdfMTc1ODk_67147559-c19d-46a3-9e5b-32ef2058bc63"
      unitRef="number">0.99</amed:HistoricalCollectionRateFromMedicare>
    <amed:RateOfRequestForAnticipatedPaymentSubmittedForInitialPeriodOfCare
      contextRef="id4b15251aa8147bcb0b8c78424ea981c_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV80My9mcmFnOjFhYzcyMjM4MzVjYzRiMjFiMWMzNjkwMGJmZjQzMjM3L3RleHRyZWdpb246MWFjNzIyMzgzNWNjNGIyMWIxYzM2OTAwYmZmNDMyMzdfMTgyMzU_16c74f5f-66ef-44b8-8b79-7365f17d5cc8"
      unitRef="number">0.20</amed:RateOfRequestForAnticipatedPaymentSubmittedForInitialPeriodOfCare>
    <amed:NetServiceRevenuePeriodOfCarePaymentRateDuration
      contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV80My9mcmFnOjFhYzcyMjM4MzVjYzRiMjFiMWMzNjkwMGJmZjQzMjM3L3RleHRyZWdpb246MWFjNzIyMzgzNWNjNGIyMWIxYzM2OTAwYmZmNDMyMzdfMTgyNzI_c8ec9856-233e-4ffd-8c0e-6ba23a5eb52b">P30D</amed:NetServiceRevenuePeriodOfCarePaymentRateDuration>
    <us-gaap:BusinessCombinationsPolicy
      contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV80My9mcmFnOjFhYzcyMjM4MzVjYzRiMjFiMWMzNjkwMGJmZjQzMjM3L3RleHRyZWdpb246MWFjNzIyMzgzNWNjNGIyMWIxYzM2OTAwYmZmNDMyMzdfMjIyMTc_53883c45-c02b-40eb-9e85-28ea4b2de2c6">&lt;div style="margin-top:16pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Business Combinations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We account for acquisitions using the acquisition method of accounting in accordance with ASC 805, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Business Combinations&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. Acquisitions are accounted for as purchases and are included in our condensed consolidated financial statements from their respective acquisition dates. Assets acquired and liabilities assumed, if any, are measured at fair value on the acquisition date using the appropriate valuation method. Goodwill generated from acquisitions is recognized for the excess of the purchase price over tangible and identifiable intangible assets. In determining the fair value of identifiable intangible assets, we use various valuation techniques including discounted cash flow analysis, the income approach, the cost approach and the market approach. These valuation methods require us to make estimates and assumptions surrounding projected revenues and costs, growth rates and discount rates.&lt;/span&gt;&lt;/div&gt;</us-gaap:BusinessCombinationsPolicy>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy
      contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV80My9mcmFnOjFhYzcyMjM4MzVjYzRiMjFiMWMzNjkwMGJmZjQzMjM3L3RleHRyZWdpb246MWFjNzIyMzgzNWNjNGIyMWIxYzM2OTAwYmZmNDMyMzdfMjIyMDc_d0dd18bc-7d00-48dd-9797-e04fb47acffd">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following details our financial instruments where the carrying value and the fair value differ (amounts in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.076%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.954%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.821%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.553%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.821%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.553%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.821%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.553%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.824%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value at Reporting Date Using&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Financial Instrument&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Carrying Value as of June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quoted&#160;Prices&#160;in&#160;Active&lt;br/&gt;Markets for Identical&lt;br/&gt;Items&lt;br/&gt;(Level 1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&#160;Other&lt;br/&gt;Observable&#160;Inputs&lt;br/&gt;(Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Unobservable&#160;Inputs&lt;br/&gt;(Level&#160;3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term obligations&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;189.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;191.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value hierarchy is based on three levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value. The three levels of inputs are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level&#160;1 &#x2013; Quoted prices in active markets for identical assets and liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level&#160;2 &#x2013; Inputs other than Level&#160;1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level&#160;3 &#x2013; Unobservable inputs that are supported by little or no market activity and are significant to the fair value of the assets or liabilities.&lt;/span&gt;&lt;/div&gt;Our deferred compensation plan assets are recorded at fair value and are considered a level 2 measurement. For our other financial instruments, including our cash and cash equivalents, patient accounts receivable, accounts payable, payroll and employee benefits and accrued expenses, we estimate the carrying amounts approximate fair value.</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <amed:FinancialInstrumentDetailsTableTextBlock
      contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV80My9mcmFnOjFhYzcyMjM4MzVjYzRiMjFiMWMzNjkwMGJmZjQzMjM3L3RleHRyZWdpb246MWFjNzIyMzgzNWNjNGIyMWIxYzM2OTAwYmZmNDMyMzdfMjIyMTg_80157f4e-fbeb-449f-8be1-03fccae02278">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following details our financial instruments where the carrying value and the fair value differ (amounts in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.076%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.954%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.821%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.553%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.821%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.553%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.821%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.553%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.824%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value at Reporting Date Using&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Financial Instrument&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Carrying Value as of June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quoted&#160;Prices&#160;in&#160;Active&lt;br/&gt;Markets for Identical&lt;br/&gt;Items&lt;br/&gt;(Level 1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&#160;Other&lt;br/&gt;Observable&#160;Inputs&lt;br/&gt;(Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Unobservable&#160;Inputs&lt;br/&gt;(Level&#160;3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term obligations&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;189.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;191.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</amed:FinancialInstrumentDetailsTableTextBlock>
    <amed:DebtInstrumentCarryingAmountExcludingFinanceLeases
      contextRef="i1e833203be6947b4968aba4d20064ec8_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV80My9mcmFnOjFhYzcyMjM4MzVjYzRiMjFiMWMzNjkwMGJmZjQzMjM3L3RhYmxlOjQ4OGIwNmJjNTQ0ZjQ0OWY5YTk5YjMxY2NmNjJhMTg5L3RhYmxlcmFuZ2U6NDg4YjA2YmM1NDRmNDQ5ZjlhOTliMzFjY2Y2MmExODlfMi0xLTEtMS0w_e98fe29d-5127-414d-b6ac-93f8e547bd6f"
      unitRef="usd">189700000</amed:DebtInstrumentCarryingAmountExcludingFinanceLeases>
    <us-gaap:LongTermDebtFairValue
      contextRef="ia1dcbe4b6aa344ddad5971d791de6929_I20210630"
      decimals="1"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV80My9mcmFnOjFhYzcyMjM4MzVjYzRiMjFiMWMzNjkwMGJmZjQzMjM3L3RhYmxlOjQ4OGIwNmJjNTQ0ZjQ0OWY5YTk5YjMxY2NmNjJhMTg5L3RhYmxlcmFuZ2U6NDg4YjA2YmM1NDRmNDQ5ZjlhOTliMzFjY2Y2MmExODlfMi0zLTEtMS0w_c79abc11-059e-4740-97ef-d1455e545e42"
      unitRef="usd">0</us-gaap:LongTermDebtFairValue>
    <us-gaap:LongTermDebtFairValue
      contextRef="idd69fb45b72f455583eebe90df674886_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV80My9mcmFnOjFhYzcyMjM4MzVjYzRiMjFiMWMzNjkwMGJmZjQzMjM3L3RhYmxlOjQ4OGIwNmJjNTQ0ZjQ0OWY5YTk5YjMxY2NmNjJhMTg5L3RhYmxlcmFuZ2U6NDg4YjA2YmM1NDRmNDQ5ZjlhOTliMzFjY2Y2MmExODlfMi01LTEtMS0w_7e252d74-ae19-4722-b021-b9629c9c91c7"
      unitRef="usd">191700000</us-gaap:LongTermDebtFairValue>
    <us-gaap:LongTermDebtFairValue
      contextRef="i9c7cadad474d42da9b01844212441bf3_I20210630"
      decimals="1"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV80My9mcmFnOjFhYzcyMjM4MzVjYzRiMjFiMWMzNjkwMGJmZjQzMjM3L3RhYmxlOjQ4OGIwNmJjNTQ0ZjQ0OWY5YTk5YjMxY2NmNjJhMTg5L3RhYmxlcmFuZ2U6NDg4YjA2YmM1NDRmNDQ5ZjlhOTliMzFjY2Y2MmExODlfMi03LTEtMS0w_8fda96c5-7e3a-415a-b9e5-0dd330d3b947"
      unitRef="usd">0</us-gaap:LongTermDebtFairValue>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV80My9mcmFnOjFhYzcyMjM4MzVjYzRiMjFiMWMzNjkwMGJmZjQzMjM3L3RleHRyZWdpb246MWFjNzIyMzgzNWNjNGIyMWIxYzM2OTAwYmZmNDMyMzdfMjIyMDQ_2b80b271-b442-4a5e-a632-8014223cb0c1">Weighted-Average Shares OutstandingNet income per share attributable to Amedisys, Inc. common stockholders, calculated on the treasury stock method, is based on the weighted average number of shares outstanding during the period.</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock
      contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV80My9mcmFnOjFhYzcyMjM4MzVjYzRiMjFiMWMzNjkwMGJmZjQzMjM3L3RleHRyZWdpb246MWFjNzIyMzgzNWNjNGIyMWIxYzM2OTAwYmZmNDMyMzdfMjIxOTc_56b6d27d-bb89-4a68-930e-41be7e1edeca">The following table sets forth, for the periods indicated, shares used in our computation of the weighted-average shares outstanding, which are used to calculate our basic and diluted net income attributable to Amedisys, Inc. common stockholders (amounts in thousands):&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.829%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.624%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three-&lt;br/&gt;Month Periods&lt;br/&gt;Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Six-&lt;br/&gt;Month Periods&lt;br/&gt;Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average number of shares outstanding - basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,588&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,412&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,684&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,371&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Effect of dilutive securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;139&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;570&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;145&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;582&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-indent:20.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-vested stock and stock units&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;254&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;303&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;256&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;306&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average number of shares outstanding - diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,981&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,285&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,085&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,259&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Anti-dilutive securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ib87cee58ccf2448a8d4422101bf61fa0_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV80My9mcmFnOjFhYzcyMjM4MzVjYzRiMjFiMWMzNjkwMGJmZjQzMjM3L3RhYmxlOjY3MDk3MTFjMWQ5ZDRkMzFiM2M0Y2Q5ZWY5NTAwZjBmL3RhYmxlcmFuZ2U6NjcwOTcxMWMxZDlkNGQzMWIzYzRjZDllZjk1MDBmMGZfMi0xLTEtMS0w_489e8a24-51ff-410b-90ca-79fc713c60d4"
      unitRef="shares">32588000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i2c8351954d014a1c80a3d8cfc2327ab2_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV80My9mcmFnOjFhYzcyMjM4MzVjYzRiMjFiMWMzNjkwMGJmZjQzMjM3L3RhYmxlOjY3MDk3MTFjMWQ5ZDRkMzFiM2M0Y2Q5ZWY5NTAwZjBmL3RhYmxlcmFuZ2U6NjcwOTcxMWMxZDlkNGQzMWIzYzRjZDllZjk1MDBmMGZfMi0zLTEtMS0w_c70863ba-f9a5-4201-8d7e-f8f22280f88b"
      unitRef="shares">32412000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV80My9mcmFnOjFhYzcyMjM4MzVjYzRiMjFiMWMzNjkwMGJmZjQzMjM3L3RhYmxlOjY3MDk3MTFjMWQ5ZDRkMzFiM2M0Y2Q5ZWY5NTAwZjBmL3RhYmxlcmFuZ2U6NjcwOTcxMWMxZDlkNGQzMWIzYzRjZDllZjk1MDBmMGZfMi01LTEtMS0zNDY_4382e839-aab0-42d7-8628-715602410fc5"
      unitRef="shares">32684000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i667fa0996400408f9cb2d7f4d3ee2087_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV80My9mcmFnOjFhYzcyMjM4MzVjYzRiMjFiMWMzNjkwMGJmZjQzMjM3L3RhYmxlOjY3MDk3MTFjMWQ5ZDRkMzFiM2M0Y2Q5ZWY5NTAwZjBmL3RhYmxlcmFuZ2U6NjcwOTcxMWMxZDlkNGQzMWIzYzRjZDllZjk1MDBmMGZfMi03LTEtMS0zNDY_e31c9efc-ae8c-499d-b9e5-7fe424086c58"
      unitRef="shares">32371000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="ib87cee58ccf2448a8d4422101bf61fa0_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV80My9mcmFnOjFhYzcyMjM4MzVjYzRiMjFiMWMzNjkwMGJmZjQzMjM3L3RhYmxlOjY3MDk3MTFjMWQ5ZDRkMzFiM2M0Y2Q5ZWY5NTAwZjBmL3RhYmxlcmFuZ2U6NjcwOTcxMWMxZDlkNGQzMWIzYzRjZDllZjk1MDBmMGZfNC0xLTEtMS0w_4acac316-c23c-423f-a6d2-10ba16b51502"
      unitRef="shares">139000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="i2c8351954d014a1c80a3d8cfc2327ab2_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV80My9mcmFnOjFhYzcyMjM4MzVjYzRiMjFiMWMzNjkwMGJmZjQzMjM3L3RhYmxlOjY3MDk3MTFjMWQ5ZDRkMzFiM2M0Y2Q5ZWY5NTAwZjBmL3RhYmxlcmFuZ2U6NjcwOTcxMWMxZDlkNGQzMWIzYzRjZDllZjk1MDBmMGZfNC0zLTEtMS0w_eaf4df70-1946-4e62-a6c1-c31d93a913a0"
      unitRef="shares">570000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV80My9mcmFnOjFhYzcyMjM4MzVjYzRiMjFiMWMzNjkwMGJmZjQzMjM3L3RhYmxlOjY3MDk3MTFjMWQ5ZDRkMzFiM2M0Y2Q5ZWY5NTAwZjBmL3RhYmxlcmFuZ2U6NjcwOTcxMWMxZDlkNGQzMWIzYzRjZDllZjk1MDBmMGZfNC01LTEtMS0zNDY_732c454c-9eb0-4b8a-aa80-4dd2c368bb61"
      unitRef="shares">145000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="i667fa0996400408f9cb2d7f4d3ee2087_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV80My9mcmFnOjFhYzcyMjM4MzVjYzRiMjFiMWMzNjkwMGJmZjQzMjM3L3RhYmxlOjY3MDk3MTFjMWQ5ZDRkMzFiM2M0Y2Q5ZWY5NTAwZjBmL3RhYmxlcmFuZ2U6NjcwOTcxMWMxZDlkNGQzMWIzYzRjZDllZjk1MDBmMGZfNC03LTEtMS0zNDY_ba4f0fbc-a501-4597-ada9-a50243b4e11e"
      unitRef="shares">582000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <amed:NonVestedStockAndStockUnits
      contextRef="ib87cee58ccf2448a8d4422101bf61fa0_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV80My9mcmFnOjFhYzcyMjM4MzVjYzRiMjFiMWMzNjkwMGJmZjQzMjM3L3RhYmxlOjY3MDk3MTFjMWQ5ZDRkMzFiM2M0Y2Q5ZWY5NTAwZjBmL3RhYmxlcmFuZ2U6NjcwOTcxMWMxZDlkNGQzMWIzYzRjZDllZjk1MDBmMGZfNS0xLTEtMS0w_aebb5ddd-5d57-41fe-8728-139fa998de19"
      unitRef="shares">254000</amed:NonVestedStockAndStockUnits>
    <amed:NonVestedStockAndStockUnits
      contextRef="i2c8351954d014a1c80a3d8cfc2327ab2_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV80My9mcmFnOjFhYzcyMjM4MzVjYzRiMjFiMWMzNjkwMGJmZjQzMjM3L3RhYmxlOjY3MDk3MTFjMWQ5ZDRkMzFiM2M0Y2Q5ZWY5NTAwZjBmL3RhYmxlcmFuZ2U6NjcwOTcxMWMxZDlkNGQzMWIzYzRjZDllZjk1MDBmMGZfNS0zLTEtMS0w_bd672d2c-83d3-44a8-a6c6-fddf165075d6"
      unitRef="shares">303000</amed:NonVestedStockAndStockUnits>
    <amed:NonVestedStockAndStockUnits
      contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV80My9mcmFnOjFhYzcyMjM4MzVjYzRiMjFiMWMzNjkwMGJmZjQzMjM3L3RhYmxlOjY3MDk3MTFjMWQ5ZDRkMzFiM2M0Y2Q5ZWY5NTAwZjBmL3RhYmxlcmFuZ2U6NjcwOTcxMWMxZDlkNGQzMWIzYzRjZDllZjk1MDBmMGZfNS01LTEtMS0zNDY_2b86e38a-e494-44d1-a858-68209914f0b5"
      unitRef="shares">256000</amed:NonVestedStockAndStockUnits>
    <amed:NonVestedStockAndStockUnits
      contextRef="i667fa0996400408f9cb2d7f4d3ee2087_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV80My9mcmFnOjFhYzcyMjM4MzVjYzRiMjFiMWMzNjkwMGJmZjQzMjM3L3RhYmxlOjY3MDk3MTFjMWQ5ZDRkMzFiM2M0Y2Q5ZWY5NTAwZjBmL3RhYmxlcmFuZ2U6NjcwOTcxMWMxZDlkNGQzMWIzYzRjZDllZjk1MDBmMGZfNS03LTEtMS0zNDY_7fb5bd72-9174-438a-8673-92de7d837cec"
      unitRef="shares">306000</amed:NonVestedStockAndStockUnits>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ib87cee58ccf2448a8d4422101bf61fa0_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV80My9mcmFnOjFhYzcyMjM4MzVjYzRiMjFiMWMzNjkwMGJmZjQzMjM3L3RhYmxlOjY3MDk3MTFjMWQ5ZDRkMzFiM2M0Y2Q5ZWY5NTAwZjBmL3RhYmxlcmFuZ2U6NjcwOTcxMWMxZDlkNGQzMWIzYzRjZDllZjk1MDBmMGZfNi0xLTEtMS0w_7e962dc4-7cfe-40c6-9df7-f551a603bf59"
      unitRef="shares">32981000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i2c8351954d014a1c80a3d8cfc2327ab2_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV80My9mcmFnOjFhYzcyMjM4MzVjYzRiMjFiMWMzNjkwMGJmZjQzMjM3L3RhYmxlOjY3MDk3MTFjMWQ5ZDRkMzFiM2M0Y2Q5ZWY5NTAwZjBmL3RhYmxlcmFuZ2U6NjcwOTcxMWMxZDlkNGQzMWIzYzRjZDllZjk1MDBmMGZfNi0zLTEtMS0w_5dd212d7-4181-463e-a794-a736b30a2fa7"
      unitRef="shares">33285000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV80My9mcmFnOjFhYzcyMjM4MzVjYzRiMjFiMWMzNjkwMGJmZjQzMjM3L3RhYmxlOjY3MDk3MTFjMWQ5ZDRkMzFiM2M0Y2Q5ZWY5NTAwZjBmL3RhYmxlcmFuZ2U6NjcwOTcxMWMxZDlkNGQzMWIzYzRjZDllZjk1MDBmMGZfNi01LTEtMS0zNDY_41083f01-179c-4ebb-b9ef-52a7218cc7c2"
      unitRef="shares">33085000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i667fa0996400408f9cb2d7f4d3ee2087_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV80My9mcmFnOjFhYzcyMjM4MzVjYzRiMjFiMWMzNjkwMGJmZjQzMjM3L3RhYmxlOjY3MDk3MTFjMWQ5ZDRkMzFiM2M0Y2Q5ZWY5NTAwZjBmL3RhYmxlcmFuZ2U6NjcwOTcxMWMxZDlkNGQzMWIzYzRjZDllZjk1MDBmMGZfNi03LTEtMS0zNDY_2110e176-c79e-47df-a0bb-e7d135536810"
      unitRef="shares">33259000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ib87cee58ccf2448a8d4422101bf61fa0_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV80My9mcmFnOjFhYzcyMjM4MzVjYzRiMjFiMWMzNjkwMGJmZjQzMjM3L3RhYmxlOjY3MDk3MTFjMWQ5ZDRkMzFiM2M0Y2Q5ZWY5NTAwZjBmL3RhYmxlcmFuZ2U6NjcwOTcxMWMxZDlkNGQzMWIzYzRjZDllZjk1MDBmMGZfNy0xLTEtMS0w_f89d5313-5933-419f-9899-3d5bd4f6fdc3"
      unitRef="shares">71000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i2c8351954d014a1c80a3d8cfc2327ab2_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV80My9mcmFnOjFhYzcyMjM4MzVjYzRiMjFiMWMzNjkwMGJmZjQzMjM3L3RhYmxlOjY3MDk3MTFjMWQ5ZDRkMzFiM2M0Y2Q5ZWY5NTAwZjBmL3RhYmxlcmFuZ2U6NjcwOTcxMWMxZDlkNGQzMWIzYzRjZDllZjk1MDBmMGZfNy0zLTEtMS0w_6950040d-9361-4368-be33-7eb845a9177c"
      unitRef="shares">14000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV80My9mcmFnOjFhYzcyMjM4MzVjYzRiMjFiMWMzNjkwMGJmZjQzMjM3L3RhYmxlOjY3MDk3MTFjMWQ5ZDRkMzFiM2M0Y2Q5ZWY5NTAwZjBmL3RhYmxlcmFuZ2U6NjcwOTcxMWMxZDlkNGQzMWIzYzRjZDllZjk1MDBmMGZfNy01LTEtMS0zNDY_12fa0532-7880-4bd3-a457-35f765e6b46e"
      unitRef="shares">58000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i667fa0996400408f9cb2d7f4d3ee2087_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV80My9mcmFnOjFhYzcyMjM4MzVjYzRiMjFiMWMzNjkwMGJmZjQzMjM3L3RhYmxlOjY3MDk3MTFjMWQ5ZDRkMzFiM2M0Y2Q5ZWY5NTAwZjBmL3RhYmxlcmFuZ2U6NjcwOTcxMWMxZDlkNGQzMWIzYzRjZDllZjk1MDBmMGZfNy03LTEtMS0zNDY_38a1f5d8-eabd-4e1a-b437-444d65521ec3"
      unitRef="shares">21000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <amed:COVID19TextBlock
      contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV80OS9mcmFnOjA5MTE3NmEwOTJiMDQ0ODliYjQ5MDRhYTc5ODMyOTlhL3RleHRyZWdpb246MDkxMTc2YTA5MmIwNDQ4OWJiNDkwNGFhNzk4MzI5OWFfNTQzNw_ca6095cf-2e42-48a5-93ae-45b396985747">NOVEL CORONAVIRUS PANDEMIC ("COVID-19")&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2020, the World Health Organization declared COVID-19 a pandemic. As a healthcare at home company, we have been and will continue to be impacted by the effects of COVID-19; however, we remain committed to carrying out our mission of caring for our patients. We will continue to closely monitor the impact of COVID-19 on all aspects of our business, including the impacts to our employees, patients and suppliers; however, at this time, we are unable to estimate the ultimate impact the pandemic will have on our consolidated financial condition, results of operations or cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On March 27, 2020, the CARES Act was signed into legislation. The CARES Act provided for $175&#160;billion to healthcare providers, including hospitals on the front lines of the COVID-19 pandemic. Of this total allocated amount, $30&#160;billion was distributed immediately to providers based on their proportionate share of Medicare fee-for-service reimbursements in 2019. Healthcare providers were required to sign an attestation confirming receipt of the Provider Relief Fund ("PRF") funds and agree to the terms and conditions of payment. Our home health and hospice segments received approximately $100&#160;million from the first $30&#160;billion of funds distributed to healthcare providers in April 2020, which is inclusive of $2&#160;million related to our joint venture care centers (equity method investments). We also acquired approximately $6&#160;million of PRF funds in connection with the acquisition of AseraCare. Under the terms and conditions for receipt of the payment, we are allowed to use the funds to cover lost revenues and health care costs related to COVID-19, and we are required to properly and fully document the use of these funds in reports to the U.S. Department of Health and Human Services ("HHS"). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For our wholly-owned subsidiaries, we have decided to only utilize PRF funds to the extent we have qualifying COVID-19 expenses, which totaled $5&#160;million and $13&#160;million for our home health and hospice segments during the three and six-month periods ended June 30, 2021, respectively, and $21&#160;million and $22&#160;million during the three and six-month periods ended June 30, 2020, respectively. Accordingly, for our wholly-owned subsidiaries, we have not used PRF funds to cover lost revenues resulting from COVID-19. The grant income associated with the COVID-19 expenses incurred during the three and six-month periods ended June 30, 2021 and 2020 is reflected in other operating income within our condensed consolidated statements of operations. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;PRF funds were available for use through June 30, 2021. We did not fully utilize the funds received; therefore, we have recorded a liability for the amount we expect to repay which totaled $58&#160;million at June 30, 2021 and $60&#160;million at December 31, 2020 (see the Provider Relief Fund Advance account in current liabilities within our condensed consolidated balance sheets). We intend to report on our use of the PRF funds to HHS during the three-month period ending September 30, 2021 and to return all unutilized funds by October 30, 2021. In summary, the total funds that we have received from the CARES Act PRF have been accounted for as follows as of June 30, 2021 (amounts in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:87.719%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:76.233%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.567%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Funds utilized through June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Estimated funds to be repaid to the government&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Funds received by unconsolidated joint ventures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;106.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The CARES Act also provided for the temporary suspension of the automatic 2% reduction of Medicare claim reimbursements (sequestration) for the period May 1, 2020 through December 31, 2020. In December 2020, Congress passed additional COVID-19 relief legislation as part of the Consolidated Appropriations Act, 2021. This legislation extended the suspension of sequestration through March 31, 2021. In April 2021, Congress passed H.R. 1868, which among other items, provided for an additional extension of the temporary suspension of sequestration through December 31, 2021. We estimate that the suspension of sequestration will increase our 2021 net service revenue by approximately $36&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Additionally, the CARES Act provided for the deferral of the employer share of social security tax (6.2%), effective for payments due after the enactment date through December 31, 2020. Fifty percent of the deferred payroll taxes are due on December 31, 2021 with the remaining amounts due on December 31, 2022. During 2020, we deferred approximately $55.0&#160;million of social security tax; approximately $28&#160;million is reflected in each of payroll and employee benefits and other long-term obligations within our condensed consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;Our personal care segment did not receive funds under the CARES Act; however, it did receive funds totaling $1&#160;million from the Mass Home Care ASAP COVID-19 Provider Sustainability Program, which were used during 2020 to cover costs related to COVID-19.</amed:COVID19TextBlock>
    <amed:FundingForHealthcareProvidersIncludingHospitals
      contextRef="i0c4514a4ad16425f82d85ae99b3a59c1_I20200327"
      decimals="-9"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV80OS9mcmFnOjA5MTE3NmEwOTJiMDQ0ODliYjQ5MDRhYTc5ODMyOTlhL3RleHRyZWdpb246MDkxMTc2YTA5MmIwNDQ4OWJiNDkwNGFhNzk4MzI5OWFfNzI5_f21de53c-0cbe-465c-b93a-2616006924a1"
      unitRef="usd">175000000000</amed:FundingForHealthcareProvidersIncludingHospitals>
    <amed:FundingImmediatelyDistributedToHealthcareProvidersBasedOnTheir2019MedicareFeeForServiceReimbursements
      contextRef="i0c4514a4ad16425f82d85ae99b3a59c1_I20200327"
      decimals="-9"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV80OS9mcmFnOjA5MTE3NmEwOTJiMDQ0ODliYjQ5MDRhYTc5ODMyOTlhL3RleHRyZWdpb246MDkxMTc2YTA5MmIwNDQ4OWJiNDkwNGFhNzk4MzI5OWFfODU0_4e79cad8-fd84-467b-bf04-f28d4c9b0813"
      unitRef="usd">30000000000</amed:FundingImmediatelyDistributedToHealthcareProvidersBasedOnTheir2019MedicareFeeForServiceReimbursements>
    <amed:FundingReceivedFromCARESAct
      contextRef="iac8bb77409a847a08a3de53000ce0e86_D20200401-20200430"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV80OS9mcmFnOjA5MTE3NmEwOTJiMDQ0ODliYjQ5MDRhYTc5ODMyOTlhL3RleHRyZWdpb246MDkxMTc2YTA5MmIwNDQ4OWJiNDkwNGFhNzk4MzI5OWFfMTIxNA_6408e84e-7741-4dac-96d0-118679ec33c5"
      unitRef="usd">100000000</amed:FundingReceivedFromCARESAct>
    <amed:FundingImmediatelyDistributedToHealthcareProvidersBasedOnTheir2019MedicareFeeForServiceReimbursements
      contextRef="i0c4514a4ad16425f82d85ae99b3a59c1_I20200327"
      decimals="-9"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV80OS9mcmFnOjA5MTE3NmEwOTJiMDQ0ODliYjQ5MDRhYTc5ODMyOTlhL3RleHRyZWdpb246MDkxMTc2YTA5MmIwNDQ4OWJiNDkwNGFhNzk4MzI5OWFfMTIzMg_09d5c8b8-591b-4b60-b051-9779497d69fb"
      unitRef="usd">30000000000</amed:FundingImmediatelyDistributedToHealthcareProvidersBasedOnTheir2019MedicareFeeForServiceReimbursements>
    <amed:FundingReceivedFromCARESAct
      contextRef="i5e57d112c8b243c6ad6311b3c05c5d43_D20200401-20200430"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV80OS9mcmFnOjA5MTE3NmEwOTJiMDQ0ODliYjQ5MDRhYTc5ODMyOTlhL3RleHRyZWdpb246MDkxMTc2YTA5MmIwNDQ4OWJiNDkwNGFhNzk4MzI5OWFfMTMxNw_37792bc1-2796-4378-a17e-2c0b4bed9de2"
      unitRef="usd">2000000</amed:FundingReceivedFromCARESAct>
    <amed:FundingReceivedFromCARESAct
      contextRef="id175698a0fde4ea494dd3ebf050a22e3_D20200401-20200430"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV80OS9mcmFnOjA5MTE3NmEwOTJiMDQ0ODliYjQ5MDRhYTc5ODMyOTlhL3RleHRyZWdpb246MDkxMTc2YTA5MmIwNDQ4OWJiNDkwNGFhNzk4MzI5OWFfMTQyMg_08f2b868-c8a0-4dac-aaad-a6ab70aab71d"
      unitRef="usd">6000000</amed:FundingReceivedFromCARESAct>
    <amed:COVID19ExpensesIncurred
      contextRef="ic7961b340f674cd8b10f0d54284e1eef_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV80OS9mcmFnOjA5MTE3NmEwOTJiMDQ0ODliYjQ5MDRhYTc5ODMyOTlhL3RleHRyZWdpb246MDkxMTc2YTA5MmIwNDQ4OWJiNDkwNGFhNzk4MzI5OWFfMTkzNA_06871c5e-b179-4cd6-adc2-409389f015ea"
      unitRef="usd">5000000</amed:COVID19ExpensesIncurred>
    <amed:COVID19ExpensesIncurred
      contextRef="ia821fd814fc04a678988e6c92ea2a385_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV80OS9mcmFnOjA5MTE3NmEwOTJiMDQ0ODliYjQ5MDRhYTc5ODMyOTlhL3RleHRyZWdpb246MDkxMTc2YTA5MmIwNDQ4OWJiNDkwNGFhNzk4MzI5OWFfMTA5OTUxMTYzNjAwOQ_764df396-af0c-4ccd-8450-4b3b97f6d42c"
      unitRef="usd">13000000</amed:COVID19ExpensesIncurred>
    <amed:COVID19ExpensesIncurred
      contextRef="i1c8d3b2b4c064d6a90ebefef21edaeb5_D20200401-20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV80OS9mcmFnOjA5MTE3NmEwOTJiMDQ0ODliYjQ5MDRhYTc5ODMyOTlhL3RleHRyZWdpb246MDkxMTc2YTA5MmIwNDQ4OWJiNDkwNGFhNzk4MzI5OWFfMTk0MQ_9f927c3b-7dc6-4596-a2fc-c6721b705d9b"
      unitRef="usd">21000000</amed:COVID19ExpensesIncurred>
    <amed:COVID19ExpensesIncurred
      contextRef="ibb3ce40344c74f1581b747ba288ae945_D20200101-20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV80OS9mcmFnOjA5MTE3NmEwOTJiMDQ0ODliYjQ5MDRhYTc5ODMyOTlhL3RleHRyZWdpb246MDkxMTc2YTA5MmIwNDQ4OWJiNDkwNGFhNzk4MzI5OWFfMTA5OTUxMTYzNDU1OQ_c2a64459-41a9-41a5-a605-3487b30e3eac"
      unitRef="usd">22000000</amed:COVID19ExpensesIncurred>
    <amed:ProviderReliefFundAdvance
      contextRef="i1e833203be6947b4968aba4d20064ec8_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV80OS9mcmFnOjA5MTE3NmEwOTJiMDQ0ODliYjQ5MDRhYTc5ODMyOTlhL3RleHRyZWdpb246MDkxMTc2YTA5MmIwNDQ4OWJiNDkwNGFhNzk4MzI5OWFfMjg4OQ_b23476fb-d9f4-4780-8b2f-f94dbb78fa59"
      unitRef="usd">58000000</amed:ProviderReliefFundAdvance>
    <amed:ProviderReliefFundAdvance
      contextRef="i87ceb60dc20d4df1b0a97d3514837910_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV80OS9mcmFnOjA5MTE3NmEwOTJiMDQ0ODliYjQ5MDRhYTc5ODMyOTlhL3RleHRyZWdpb246MDkxMTc2YTA5MmIwNDQ4OWJiNDkwNGFhNzk4MzI5OWFfMjkxNA_7cc28374-d43a-4222-82a1-763eebf9ef75"
      unitRef="usd">60000000</amed:ProviderReliefFundAdvance>
    <amed:ScheduleOfCaresActProviderReliefFundsTableTextBlock
      contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV80OS9mcmFnOjA5MTE3NmEwOTJiMDQ0ODliYjQ5MDRhYTc5ODMyOTlhL3RleHRyZWdpb246MDkxMTc2YTA5MmIwNDQ4OWJiNDkwNGFhNzk4MzI5OWFfNTQ0Mg_99650e62-89b9-4c0f-91f1-9c2f619a91e2">In summary, the total funds that we have received from the CARES Act PRF have been accounted for as follows as of June 30, 2021 (amounts in millions):&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:87.719%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:76.233%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.567%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Funds utilized through June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Estimated funds to be repaid to the government&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Funds received by unconsolidated joint ventures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;106.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</amed:ScheduleOfCaresActProviderReliefFundsTableTextBlock>
    <amed:CARESActProviderReliefFundsUtilized
      contextRef="i8f67ab0074b94f94a94986aa649dde19_D20200327-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV80OS9mcmFnOjA5MTE3NmEwOTJiMDQ0ODliYjQ5MDRhYTc5ODMyOTlhL3RhYmxlOjdhODIwOGY3M2I1MDRiYTNiYjY2NDYyMWUyODZlNGNiL3RhYmxlcmFuZ2U6N2E4MjA4ZjczYjUwNGJhM2JiNjY0NjIxZTI4NmU0Y2JfMS0xLTEtMS0w_d17446eb-284e-475e-8d08-b840da937314"
      unitRef="usd">46600000</amed:CARESActProviderReliefFundsUtilized>
    <amed:EstimatedCARESActProviderReliefFundAmountsToBeRepaid
      contextRef="i1e833203be6947b4968aba4d20064ec8_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV80OS9mcmFnOjA5MTE3NmEwOTJiMDQ0ODliYjQ5MDRhYTc5ODMyOTlhL3RhYmxlOjdhODIwOGY3M2I1MDRiYTNiYjY2NDYyMWUyODZlNGNiL3RhYmxlcmFuZ2U6N2E4MjA4ZjczYjUwNGJhM2JiNjY0NjIxZTI4NmU0Y2JfMy0xLTEtMS0w_f334e61d-c5b9-4117-8115-9c290835e396"
      unitRef="usd">58300000</amed:EstimatedCARESActProviderReliefFundAmountsToBeRepaid>
    <amed:CARESActProviderReliefFundsReceivedByUnconsolidatedJointVentures
      contextRef="i1e833203be6947b4968aba4d20064ec8_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV80OS9mcmFnOjA5MTE3NmEwOTJiMDQ0ODliYjQ5MDRhYTc5ODMyOTlhL3RhYmxlOjdhODIwOGY3M2I1MDRiYTNiYjY2NDYyMWUyODZlNGNiL3RhYmxlcmFuZ2U6N2E4MjA4ZjczYjUwNGJhM2JiNjY0NjIxZTI4NmU0Y2JfNC0xLTEtMS0w_e03d9ff0-2d97-421b-aae0-5463d0a987e5"
      unitRef="usd">1900000</amed:CARESActProviderReliefFundsReceivedByUnconsolidatedJointVentures>
    <amed:TotalCARESActProviderReliefFundsReceived
      contextRef="i1e833203be6947b4968aba4d20064ec8_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV80OS9mcmFnOjA5MTE3NmEwOTJiMDQ0ODliYjQ5MDRhYTc5ODMyOTlhL3RhYmxlOjdhODIwOGY3M2I1MDRiYTNiYjY2NDYyMWUyODZlNGNiL3RhYmxlcmFuZ2U6N2E4MjA4ZjczYjUwNGJhM2JiNjY0NjIxZTI4NmU0Y2JfNS0xLTEtMS0w_e4cdee57-a22d-4149-8e55-9dca55ed1096"
      unitRef="usd">106800000</amed:TotalCARESActProviderReliefFundsReceived>
    <amed:ExtensionOfTemporarySuspensionOfSequestrationRevenueImpact
      contextRef="ia6c66b5559184a299f6fd13a6091fd6c_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV80OS9mcmFnOjA5MTE3NmEwOTJiMDQ0ODliYjQ5MDRhYTc5ODMyOTlhL3RleHRyZWdpb246MDkxMTc2YTA5MmIwNDQ4OWJiNDkwNGFhNzk4MzI5OWFfNDY1OA_7df37985-88e4-4c49-949e-dafba4bb915d"
      unitRef="usd">36000000</amed:ExtensionOfTemporarySuspensionOfSequestrationRevenueImpact>
    <amed:CARESActDeferralOfEmployerShareSocialSecurityTax
      contextRef="i3800e4dbdd2b4b74be666a6efdf57781_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV80OS9mcmFnOjA5MTE3NmEwOTJiMDQ0ODliYjQ5MDRhYTc5ODMyOTlhL3RleHRyZWdpb246MDkxMTc2YTA5MmIwNDQ4OWJiNDkwNGFhNzk4MzI5OWFfNDk4Nw_9eda53bc-13ce-4646-beae-bdb38268ceab"
      unitRef="usd">55000000.0</amed:CARESActDeferralOfEmployerShareSocialSecurityTax>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="ifc0809f18c444433ac13693a115bb6bf_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV80OS9mcmFnOjA5MTE3NmEwOTJiMDQ0ODliYjQ5MDRhYTc5ODMyOTlhL3RleHRyZWdpb246MDkxMTc2YTA5MmIwNDQ4OWJiNDkwNGFhNzk4MzI5OWFfNTAzMA_56b5aa7c-9580-47c8-a77c-1d96a0f4bb69"
      unitRef="usd">28000000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="ifc0809f18c444433ac13693a115bb6bf_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV80OS9mcmFnOjA5MTE3NmEwOTJiMDQ0ODliYjQ5MDRhYTc5ODMyOTlhL3RleHRyZWdpb246MDkxMTc2YTA5MmIwNDQ4OWJiNDkwNGFhNzk4MzI5OWFfNTAzMA_9a16c359-cf63-4963-ae68-9065c9c2243b"
      unitRef="usd">28000000</us-gaap:OtherLiabilitiesNoncurrent>
    <amed:FundingReceivedFromMassHomeCareASAPCOVID19ProviderSustainabilityProgram
      contextRef="ifd83ae148acd4a77824ab56405bb1c41_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV80OS9mcmFnOjA5MTE3NmEwOTJiMDQ0ODliYjQ5MDRhYTc5ODMyOTlhL3RleHRyZWdpb246MDkxMTc2YTA5MmIwNDQ4OWJiNDkwNGFhNzk4MzI5OWFfNTI3OQ_8de58e25-de79-46cd-a430-f7edfe2ce467"
      unitRef="usd">1000000</amed:FundingReceivedFromMassHomeCareASAPCOVID19ProviderSustainabilityProgram>
    <us-gaap:BusinessCombinationDisclosureTextBlock
      contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV81Mi9mcmFnOjE5NzlmNTFhOWI3NDQ1ZTA5ZTI4ODA2YjU2OTg0MzUwL3RleHRyZWdpb246MTk3OWY1MWE5Yjc0NDVlMDllMjg4MDZiNTY5ODQzNTBfMzI4MA_f54d7812-0206-467b-8ea3-30c8b58ea919">ACQUISITIONS&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We complete acquisitions from time to time in order to pursue our strategy of increasing our market presence by expanding our service base and enhancing our position in certain geographic areas as a leading provider of home health, hospice and personal care services. The purchase price paid for acquisitions is negotiated through arm&#x2019;s length transactions, with consideration based on our analysis of, among other things, comparable acquisitions and expected cash flows. Acquisitions are accounted for as purchases and are included in our condensed consolidated financial statements from their respective acquisition dates. Goodwill generated from acquisitions is recognized for the excess of the purchase price over tangible and identifiable intangible assets because of the expected contributions of the acquisitions to our overall corporate strategy. We typically engage outside appraisal firms to assist in the fair value determination of identifiable intangible assets for significant acquisitions. The preliminary purchase price allocation is adjusted, as necessary, up to one year after the acquisition closing date if management obtains more information regarding asset valuations and liabilities assumed.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;2021 Acquisitions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On May 1, 2021, we acquired the regulatory assets of a home health provider in Randolph County, North Carolina for a purchase price of $2.5&#160;million. The purchase price was paid with cash on hand on the date of the transaction. Based on the Company's preliminary valuation, we recorded goodwill of $2.4&#160;million and other intangibles (certificate of need) of $0.1&#160;million in connection with the acquisition.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;2020 Acquisitions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On June 1, 2020, we acquired Homecare Preferred Choice, Inc., doing business as AseraCare Hospice ("AseraCare"), a national hospice care provider with 44 locations, for an estimated purchase price of $230.4&#160;million, net of cash acquired and inclusive of a $32&#160;million tax asset. The closing payment for the purchase price included estimates for cash, working capital and various other items. Under the purchase agreement, the purchase price was subject to a closing payment adjustment for any differences between estimated amounts included in the closing payment and actual amounts at close, not to exceed $1.0&#160;million. The closing payment adjustment, which was finalized in October 2020, reduced the purchase price by $0.8&#160;million, from $230.4&#160;million&#160;to $229.6&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company finalized its valuation of the assets acquired and liabilities assumed during the three-month period ended June 30, 2021. The total consideration of $229.6 million&#160;has been allocated to assets acquired and liabilities assumed as of the acquisition date as follows (amounts in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:79.970%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.037%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.763%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Patient accounts receivable&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease right of use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-indent:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total assets acquired&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payroll and employee benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-indent:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total liabilities assumed&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(29.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net identifiable assets acquired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;212.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total consideration&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;229.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangible assets acquired include licenses ($8.7&#160;million), certificates of need ($0.7&#160;million), acquired names ($5.7&#160;million) and non-compete agreements ($9.2&#160;million). The acquired names will be amortized over a weighted-average period of 2.0 years, and the non-compete agreements will be amortized over a weighted-average period of 1.7 years. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;AseraCare contributed $25.4&#160;million in net service revenue and operating income of $0.5&#160;million (inclusive of acquisition and integration costs totaling $0.6&#160;million and intangibles amortization totaling $2.0&#160;million) during the three-month period ended June 30, 2021 and $50.0&#160;million in net service revenue and an operating loss of $0.1 million (inclusive of acquisition and integration costs totaling $1.2&#160;million and intangibles amortization totaling $4.4&#160;million) during the six-month period ended June 30, 2021. During the three and six-month periods ended June 30, 2020, AseraCare contributed $9.2&#160;million in net service revenue and an operating loss of $3.0 million (inclusive of acquisition and integration costs totaling $3.3&#160;million and intangibles amortization totaling $0.2&#160;million).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We expect the entire amount of goodwill recorded for this acquisition to be deductible for income tax purposes over approximately 15 years.&lt;/span&gt;&lt;/div&gt;</us-gaap:BusinessCombinationDisclosureTextBlock>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="i45e11b09cca8443d838df683d0210fd2_D20210501-20210501"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV81Mi9mcmFnOjE5NzlmNTFhOWI3NDQ1ZTA5ZTI4ODA2YjU2OTg0MzUwL3RleHRyZWdpb246MTk3OWY1MWE5Yjc0NDVlMDllMjg4MDZiNTY5ODQzNTBfMTA5OTUxMTYzMjQwNQ_9d6ad1ea-6557-48de-a04e-779e96e12da9"
      unitRef="usd">2500000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="i535b766678164627a4ddec7a5f2f5950_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV81Mi9mcmFnOjE5NzlmNTFhOWI3NDQ1ZTA5ZTI4ODA2YjU2OTg0MzUwL3RleHRyZWdpb246MTk3OWY1MWE5Yjc0NDVlMDllMjg4MDZiNTY5ODQzNTBfMTA5OTUxMTYzMjQzMw_467bf712-47ef-437c-9f9b-7d8912971759"
      unitRef="usd">2400000</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill
      contextRef="i8bbf534b5cc84c0e8690bc7618aac045_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV81Mi9mcmFnOjE5NzlmNTFhOWI3NDQ1ZTA5ZTI4ODA2YjU2OTg0MzUwL3RleHRyZWdpb246MTk3OWY1MWE5Yjc0NDVlMDllMjg4MDZiNTY5ODQzNTBfMTA5OTUxMTYzMjQxOQ_ca49fb05-a07c-4ad4-8e65-17c435b32dee"
      unitRef="usd">100000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
    <us-gaap:NumberOfBusinessesAcquired
      contextRef="i83f6f6c3fd9a43b9871634c7190f8d34_D20200601-20200601"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV81Mi9mcmFnOjE5NzlmNTFhOWI3NDQ1ZTA5ZTI4ODA2YjU2OTg0MzUwL3RleHRyZWdpb246MTk3OWY1MWE5Yjc0NDVlMDllMjg4MDZiNTY5ODQzNTBfMTQwNQ_78da4dd1-14d9-4871-97a8-981a6933a657"
      unitRef="care_center">44</us-gaap:NumberOfBusinessesAcquired>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="i83f6f6c3fd9a43b9871634c7190f8d34_D20200601-20200601"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV81Mi9mcmFnOjE5NzlmNTFhOWI3NDQ1ZTA5ZTI4ODA2YjU2OTg0MzUwL3RleHRyZWdpb246MTk3OWY1MWE5Yjc0NDVlMDllMjg4MDZiNTY5ODQzNTBfMTQ1NA_9bbb06e1-8186-433b-9ae7-566312d72ad2"
      unitRef="usd">230400000</us-gaap:PaymentsToAcquireBusinessesGross>
    <amed:PaymentsRelatedToTaxAsset
      contextRef="i83f6f6c3fd9a43b9871634c7190f8d34_D20200601-20200601"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV81Mi9mcmFnOjE5NzlmNTFhOWI3NDQ1ZTA5ZTI4ODA2YjU2OTg0MzUwL3RleHRyZWdpb246MTk3OWY1MWE5Yjc0NDVlMDllMjg4MDZiNTY5ODQzNTBfMTQ5OA_2b4e5ab5-786e-4889-beb0-e361290e81b3"
      unitRef="usd">32000000</amed:PaymentsRelatedToTaxAsset>
    <amed:BusinessAcquisitionClosingPaymentAdjustment
      contextRef="i867c8c481181405cacf65820555c0934_D20200601-20200601"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV81Mi9mcmFnOjE5NzlmNTFhOWI3NDQ1ZTA5ZTI4ODA2YjU2OTg0MzUwL3RleHRyZWdpb246MTk3OWY1MWE5Yjc0NDVlMDllMjg4MDZiNTY5ODQzNTBfMTgzOQ_1a18cddf-26dc-4c7f-929c-6e1b0d642f04"
      unitRef="usd">1000000.0</amed:BusinessAcquisitionClosingPaymentAdjustment>
    <amed:BusinessAcquisitionClosingPaymentAdjustment
      contextRef="ifaa721259ce4436aa80fefef62ec970f_D20201001-20201001"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV81Mi9mcmFnOjE5NzlmNTFhOWI3NDQ1ZTA5ZTI4ODA2YjU2OTg0MzUwL3RleHRyZWdpb246MTk3OWY1MWE5Yjc0NDVlMDllMjg4MDZiNTY5ODQzNTBfMTk0Mg_0817bce7-4cd1-4e95-a0e2-6f4f2444480c"
      unitRef="usd">800000</amed:BusinessAcquisitionClosingPaymentAdjustment>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="i83f6f6c3fd9a43b9871634c7190f8d34_D20200601-20200601"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV81Mi9mcmFnOjE5NzlmNTFhOWI3NDQ1ZTA5ZTI4ODA2YjU2OTg0MzUwL3RleHRyZWdpb246MTk3OWY1MWE5Yjc0NDVlMDllMjg4MDZiNTY5ODQzNTBfMTk1MQ_53f4b0f8-6b18-46fb-9449-07c8b79cf415"
      unitRef="usd">230400000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet
      contextRef="i1af2ff078c3a4f71aa611b0e527d319e_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV81Mi9mcmFnOjE5NzlmNTFhOWI3NDQ1ZTA5ZTI4ODA2YjU2OTg0MzUwL3RleHRyZWdpb246MTk3OWY1MWE5Yjc0NDVlMDllMjg4MDZiNTY5ODQzNTBfMTk1Nw_f1655a29-fd3f-4e2e-b079-1dee116c3f9c"
      unitRef="usd">229600000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet>
    <us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock
      contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV81Mi9mcmFnOjE5NzlmNTFhOWI3NDQ1ZTA5ZTI4ODA2YjU2OTg0MzUwL3RleHRyZWdpb246MTk3OWY1MWE5Yjc0NDVlMDllMjg4MDZiNTY5ODQzNTBfMzI5Mw_36722d1b-c689-4bea-8798-d23228105196">The total consideration of $229.6 million&#160;has been allocated to assets acquired and liabilities assumed as of the acquisition date as follows (amounts in millions):&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:79.970%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.037%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.763%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Patient accounts receivable&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease right of use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-indent:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total assets acquired&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payroll and employee benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-indent:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total liabilities assumed&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(29.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net identifiable assets acquired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;212.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total consideration&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;229.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet
      contextRef="i1af2ff078c3a4f71aa611b0e527d319e_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV81Mi9mcmFnOjE5NzlmNTFhOWI3NDQ1ZTA5ZTI4ODA2YjU2OTg0MzUwL3RleHRyZWdpb246MTk3OWY1MWE5Yjc0NDVlMDllMjg4MDZiNTY5ODQzNTBfMjQ4MA_e15460b1-8208-4cb4-b490-2f7a1d8dfc88"
      unitRef="usd">229600000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables
      contextRef="i1af2ff078c3a4f71aa611b0e527d319e_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV81Mi9mcmFnOjE5NzlmNTFhOWI3NDQ1ZTA5ZTI4ODA2YjU2OTg0MzUwL3RhYmxlOmFkNDEzYjNmY2M1NTRlMjE4YzdlMzZjN2RjMmZiOTYzL3RhYmxlcmFuZ2U6YWQ0MTNiM2ZjYzU1NGUyMThjN2UzNmM3ZGMyZmI5NjNfMS0xLTEtMS0w_380c1ba8-dfb6-4950-b8c1-19e21edaebdc"
      unitRef="usd">15300000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables>
    <amed:BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentAssetsPrepaidExpense
      contextRef="i1af2ff078c3a4f71aa611b0e527d319e_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV81Mi9mcmFnOjE5NzlmNTFhOWI3NDQ1ZTA5ZTI4ODA2YjU2OTg0MzUwL3RhYmxlOmFkNDEzYjNmY2M1NTRlMjE4YzdlMzZjN2RjMmZiOTYzL3RhYmxlcmFuZ2U6YWQ0MTNiM2ZjYzU1NGUyMThjN2UzNmM3ZGMyZmI5NjNfMi0xLTEtMS0w_c9b2e68f-0fdd-422f-8db0-3d7bf9597fb5"
      unitRef="usd">700000</amed:BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentAssetsPrepaidExpense>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment
      contextRef="i1af2ff078c3a4f71aa611b0e527d319e_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV81Mi9mcmFnOjE5NzlmNTFhOWI3NDQ1ZTA5ZTI4ODA2YjU2OTg0MzUwL3RhYmxlOmFkNDEzYjNmY2M1NTRlMjE4YzdlMzZjN2RjMmZiOTYzL3RhYmxlcmFuZ2U6YWQ0MTNiM2ZjYzU1NGUyMThjN2UzNmM3ZGMyZmI5NjNfMy0xLTEtMS0w_7650dfc0-445c-448e-80e7-e60e028fd054"
      unitRef="usd">600000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment>
    <amed:BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingleaserightofuseassets
      contextRef="i1af2ff078c3a4f71aa611b0e527d319e_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV81Mi9mcmFnOjE5NzlmNTFhOWI3NDQ1ZTA5ZTI4ODA2YjU2OTg0MzUwL3RhYmxlOmFkNDEzYjNmY2M1NTRlMjE4YzdlMzZjN2RjMmZiOTYzL3RhYmxlcmFuZ2U6YWQ0MTNiM2ZjYzU1NGUyMThjN2UzNmM3ZGMyZmI5NjNfNC0xLTEtMS0w_bde3ab3d-8ace-436b-9a2b-3ab5dc10c374"
      unitRef="usd">5900000</amed:BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingleaserightofuseassets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill
      contextRef="i1af2ff078c3a4f71aa611b0e527d319e_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV81Mi9mcmFnOjE5NzlmNTFhOWI3NDQ1ZTA5ZTI4ODA2YjU2OTg0MzUwL3RhYmxlOmFkNDEzYjNmY2M1NTRlMjE4YzdlMzZjN2RjMmZiOTYzL3RhYmxlcmFuZ2U6YWQ0MTNiM2ZjYzU1NGUyMThjN2UzNmM3ZGMyZmI5NjNfNS0xLTEtMS0w_7c45089e-c60c-4e31-93c1-43df550f532e"
      unitRef="usd">24300000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets
      contextRef="i1af2ff078c3a4f71aa611b0e527d319e_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV81Mi9mcmFnOjE5NzlmNTFhOWI3NDQ1ZTA5ZTI4ODA2YjU2OTg0MzUwL3RhYmxlOmFkNDEzYjNmY2M1NTRlMjE4YzdlMzZjN2RjMmZiOTYzL3RhYmxlcmFuZ2U6YWQ0MTNiM2ZjYzU1NGUyMThjN2UzNmM3ZGMyZmI5NjNfNi0xLTEtMS0w_af5d4966-914f-4894-b07c-18f8f4667300"
      unitRef="usd">100000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets
      contextRef="i1af2ff078c3a4f71aa611b0e527d319e_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV81Mi9mcmFnOjE5NzlmNTFhOWI3NDQ1ZTA5ZTI4ODA2YjU2OTg0MzUwL3RhYmxlOmFkNDEzYjNmY2M1NTRlMjE4YzdlMzZjN2RjMmZiOTYzL3RhYmxlcmFuZ2U6YWQ0MTNiM2ZjYzU1NGUyMThjN2UzNmM3ZGMyZmI5NjNfNy0xLTEtMS0w_02df40f5-97cd-464c-8e10-a0d6117c29c1"
      unitRef="usd">46900000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable
      contextRef="i1af2ff078c3a4f71aa611b0e527d319e_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV81Mi9mcmFnOjE5NzlmNTFhOWI3NDQ1ZTA5ZTI4ODA2YjU2OTg0MzUwL3RhYmxlOmFkNDEzYjNmY2M1NTRlMjE4YzdlMzZjN2RjMmZiOTYzL3RhYmxlcmFuZ2U6YWQ0MTNiM2ZjYzU1NGUyMThjN2UzNmM3ZGMyZmI5NjNfOC0xLTEtMS0w_14562f68-1e51-452a-a46f-4244ca226fa7"
      unitRef="usd">6300000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable>
    <amed:BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesPayrollandEmployeeBenefits
      contextRef="i1af2ff078c3a4f71aa611b0e527d319e_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV81Mi9mcmFnOjE5NzlmNTFhOWI3NDQ1ZTA5ZTI4ODA2YjU2OTg0MzUwL3RhYmxlOmFkNDEzYjNmY2M1NTRlMjE4YzdlMzZjN2RjMmZiOTYzL3RhYmxlcmFuZ2U6YWQ0MTNiM2ZjYzU1NGUyMThjN2UzNmM3ZGMyZmI5NjNfOS0xLTEtMS0w_cf5e555c-7f87-4364-b4f0-bb8858727cf4"
      unitRef="usd">5900000</amed:BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesPayrollandEmployeeBenefits>
    <amed:BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses
      contextRef="i1af2ff078c3a4f71aa611b0e527d319e_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV81Mi9mcmFnOjE5NzlmNTFhOWI3NDQ1ZTA5ZTI4ODA2YjU2OTg0MzUwL3RhYmxlOmFkNDEzYjNmY2M1NTRlMjE4YzdlMzZjN2RjMmZiOTYzL3RhYmxlcmFuZ2U6YWQ0MTNiM2ZjYzU1NGUyMThjN2UzNmM3ZGMyZmI5NjNfMTAtMS0xLTEtMA_0dd21235-5393-4e48-824b-2b84325c7594"
      unitRef="usd">11900000</amed:BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses>
    <amed:BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingLeaseLiabilities
      contextRef="i1af2ff078c3a4f71aa611b0e527d319e_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV81Mi9mcmFnOjE5NzlmNTFhOWI3NDQ1ZTA5ZTI4ODA2YjU2OTg0MzUwL3RhYmxlOmFkNDEzYjNmY2M1NTRlMjE4YzdlMzZjN2RjMmZiOTYzL3RhYmxlcmFuZ2U6YWQ0MTNiM2ZjYzU1NGUyMThjN2UzNmM3ZGMyZmI5NjNfMTEtMS0xLTEtMA_53bd793f-782f-4395-bf64-58e6dba0057d"
      unitRef="usd">5400000</amed:BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingLeaseLiabilities>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities
      contextRef="i1af2ff078c3a4f71aa611b0e527d319e_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV81Mi9mcmFnOjE5NzlmNTFhOWI3NDQ1ZTA5ZTI4ODA2YjU2OTg0MzUwL3RhYmxlOmFkNDEzYjNmY2M1NTRlMjE4YzdlMzZjN2RjMmZiOTYzL3RhYmxlcmFuZ2U6YWQ0MTNiM2ZjYzU1NGUyMThjN2UzNmM3ZGMyZmI5NjNfMTItMS0xLTEtMA_e89b492b-8ad4-4173-b72c-21c6e005d895"
      unitRef="usd">29500000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet
      contextRef="i1af2ff078c3a4f71aa611b0e527d319e_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV81Mi9mcmFnOjE5NzlmNTFhOWI3NDQ1ZTA5ZTI4ODA2YjU2OTg0MzUwL3RhYmxlOmFkNDEzYjNmY2M1NTRlMjE4YzdlMzZjN2RjMmZiOTYzL3RhYmxlcmFuZ2U6YWQ0MTNiM2ZjYzU1NGUyMThjN2UzNmM3ZGMyZmI5NjNfMTMtMS0xLTEtMA_e1153dd5-8fe3-4f2e-b15b-a25f247a7266"
      unitRef="usd">17400000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="ie2776ede445a47be9f24c8e19df8e41a_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV81Mi9mcmFnOjE5NzlmNTFhOWI3NDQ1ZTA5ZTI4ODA2YjU2OTg0MzUwL3RhYmxlOmFkNDEzYjNmY2M1NTRlMjE4YzdlMzZjN2RjMmZiOTYzL3RhYmxlcmFuZ2U6YWQ0MTNiM2ZjYzU1NGUyMThjN2UzNmM3ZGMyZmI5NjNfMTQtMS0xLTEtMA_db6b62e3-e4bd-4cbe-9556-e24acf976be9"
      unitRef="usd">212200000</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet
      contextRef="i1af2ff078c3a4f71aa611b0e527d319e_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV81Mi9mcmFnOjE5NzlmNTFhOWI3NDQ1ZTA5ZTI4ODA2YjU2OTg0MzUwL3RhYmxlOmFkNDEzYjNmY2M1NTRlMjE4YzdlMzZjN2RjMmZiOTYzL3RhYmxlcmFuZ2U6YWQ0MTNiM2ZjYzU1NGUyMThjN2UzNmM3ZGMyZmI5NjNfMTUtMS0xLTEtMA_d35fe7fa-b452-42bd-86c2-bd07e8b8a9ab"
      unitRef="usd">229600000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill
      contextRef="id89f6008c2694e98ab64e39c65f6ad94_I20200601"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV81Mi9mcmFnOjE5NzlmNTFhOWI3NDQ1ZTA5ZTI4ODA2YjU2OTg0MzUwL3RleHRyZWdpb246MTk3OWY1MWE5Yjc0NDVlMDllMjg4MDZiNTY5ODQzNTBfMjY1NQ_ad785999-9688-4890-a108-a7e482b7d1a0"
      unitRef="usd">8700000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill
      contextRef="i529e20e30522490fbfb5f6be349b8c2e_I20200601"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV81Mi9mcmFnOjE5NzlmNTFhOWI3NDQ1ZTA5ZTI4ODA2YjU2OTg0MzUwL3RleHRyZWdpb246MTk3OWY1MWE5Yjc0NDVlMDllMjg4MDZiNTY5ODQzNTBfMjY4Mg_a91b7b51-ba0a-4bb7-b86e-5f83f05e6eee"
      unitRef="usd">700000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill
      contextRef="i012cb8f0777f4308802fe58df675adca_I20200601"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV81Mi9mcmFnOjE5NzlmNTFhOWI3NDQ1ZTA5ZTI4ODA2YjU2OTg0MzUwL3RleHRyZWdpb246MTk3OWY1MWE5Yjc0NDVlMDllMjg4MDZiNTY5ODQzNTBfMjcwMw_bee3d697-43af-4701-a3e4-f154b02c8e54"
      unitRef="usd">5700000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill
      contextRef="i3bd9e093562340059df041fec4f9ea9c_I20200601"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV81Mi9mcmFnOjE5NzlmNTFhOWI3NDQ1ZTA5ZTI4ODA2YjU2OTg0MzUwL3RleHRyZWdpb246MTk3OWY1MWE5Yjc0NDVlMDllMjg4MDZiNTY5ODQzNTBfMjczNQ_f7889589-8095-4cae-96b1-e6c042f2c2e8"
      unitRef="usd">9200000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="ib2a212363aa54dbc9ffb59f71147e64a_D20200601-20200601"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV81Mi9mcmFnOjE5NzlmNTFhOWI3NDQ1ZTA5ZTI4ODA2YjU2OTg0MzUwL3RleHRyZWdpb246MTk3OWY1MWE5Yjc0NDVlMDllMjg4MDZiNTY5ODQzNTBfMjgxMQ_b7150421-e0f9-4dc8-a899-eb83830d4440">P2Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="i203c1416080945b495a673816a335d4a_D20200601-20200601"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV81Mi9mcmFnOjE5NzlmNTFhOWI3NDQ1ZTA5ZTI4ODA2YjU2OTg0MzUwL3RleHRyZWdpb246MTk3OWY1MWE5Yjc0NDVlMDllMjg4MDZiNTY5ODQzNTBfMjg5Nw_d83bd68c-797d-40bc-9ce6-5dd1b9d24c61">P1Y8M12D</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions
      contextRef="id2115fff96eb46a78868c96cf8b1c4a1_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV81Mi9mcmFnOjE5NzlmNTFhOWI3NDQ1ZTA5ZTI4ODA2YjU2OTg0MzUwL3RleHRyZWdpb246MTk3OWY1MWE5Yjc0NDVlMDllMjg4MDZiNTY5ODQzNTBfMjkzOA_d82fd711-0db9-478f-95d4-c621698d6a92"
      unitRef="usd">25400000</us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions>
    <us-gaap:OperatingIncomeLoss
      contextRef="id2115fff96eb46a78868c96cf8b1c4a1_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV81Mi9mcmFnOjE5NzlmNTFhOWI3NDQ1ZTA5ZTI4ODA2YjU2OTg0MzUwL3RleHRyZWdpb246MTk3OWY1MWE5Yjc0NDVlMDllMjg4MDZiNTY5ODQzNTBfMjk4OQ_300d7286-7d76-4b72-a5b4-998f3f579884"
      unitRef="usd">500000</us-gaap:OperatingIncomeLoss>
    <us-gaap:BusinessCombinationIntegrationRelatedCosts
      contextRef="id2115fff96eb46a78868c96cf8b1c4a1_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV81Mi9mcmFnOjE5NzlmNTFhOWI3NDQ1ZTA5ZTI4ODA2YjU2OTg0MzUwL3RleHRyZWdpb246MTk3OWY1MWE5Yjc0NDVlMDllMjg4MDZiNTY5ODQzNTBfMzA0OQ_59601025-afd6-48bb-97da-39b466e8311d"
      unitRef="usd">600000</us-gaap:BusinessCombinationIntegrationRelatedCosts>
    <amed:DepreciationAndAmortizationForContinuingOperations
      contextRef="id2115fff96eb46a78868c96cf8b1c4a1_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV81Mi9mcmFnOjE5NzlmNTFhOWI3NDQ1ZTA5ZTI4ODA2YjU2OTg0MzUwL3RleHRyZWdpb246MTk3OWY1MWE5Yjc0NDVlMDllMjg4MDZiNTY5ODQzNTBfMzA5MA_cbe6eca6-db7e-4152-9a16-38c610bfa36b"
      unitRef="usd">2000000.0</amed:DepreciationAndAmortizationForContinuingOperations>
    <us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions
      contextRef="ie2776ede445a47be9f24c8e19df8e41a_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV81Mi9mcmFnOjE5NzlmNTFhOWI3NDQ1ZTA5ZTI4ODA2YjU2OTg0MzUwL3RleHRyZWdpb246MTk3OWY1MWE5Yjc0NDVlMDllMjg4MDZiNTY5ODQzNTBfMTA5OTUxMTYzMzE3MA_6cf66294-0dbf-44f8-b429-2952e1ad2b5a"
      unitRef="usd">50000000.0</us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions>
    <us-gaap:BusinessCombinationIntegrationRelatedCosts
      contextRef="ie2776ede445a47be9f24c8e19df8e41a_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV81Mi9mcmFnOjE5NzlmNTFhOWI3NDQ1ZTA5ZTI4ODA2YjU2OTg0MzUwL3RleHRyZWdpb246MTk3OWY1MWE5Yjc0NDVlMDllMjg4MDZiNTY5ODQzNTBfMTA5OTUxMTYzMzE4NQ_a2b1af69-b855-4c23-b365-111c45df33f7"
      unitRef="usd">1200000</us-gaap:BusinessCombinationIntegrationRelatedCosts>
    <amed:DepreciationAndAmortizationForContinuingOperations
      contextRef="ie2776ede445a47be9f24c8e19df8e41a_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV81Mi9mcmFnOjE5NzlmNTFhOWI3NDQ1ZTA5ZTI4ODA2YjU2OTg0MzUwL3RleHRyZWdpb246MTk3OWY1MWE5Yjc0NDVlMDllMjg4MDZiNTY5ODQzNTBfMTA5OTUxMTYzMzE5OQ_e498917e-a7e6-4c09-b9eb-b2644d0fb880"
      unitRef="usd">4400000</amed:DepreciationAndAmortizationForContinuingOperations>
    <us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions
      contextRef="i93266b4b1d884fad8c5cb4456e2def79_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV81Mi9mcmFnOjE5NzlmNTFhOWI3NDQ1ZTA5ZTI4ODA2YjU2OTg0MzUwL3RleHRyZWdpb246MTk3OWY1MWE5Yjc0NDVlMDllMjg4MDZiNTY5ODQzNTBfMTA5OTUxMTYzMzIxMw_0f60c6aa-0cfe-445e-a0a0-f4a6e9ac4d1b"
      unitRef="usd">9200000</us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions>
    <us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions
      contextRef="id8f72c421ee54ba2a739418940dde57c_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV81Mi9mcmFnOjE5NzlmNTFhOWI3NDQ1ZTA5ZTI4ODA2YjU2OTg0MzUwL3RleHRyZWdpb246MTk3OWY1MWE5Yjc0NDVlMDllMjg4MDZiNTY5ODQzNTBfMTA5OTUxMTYzMzIxMw_e0d6acd5-8835-4f62-899b-fb94ba757456"
      unitRef="usd">9200000</us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions>
    <us-gaap:BusinessCombinationIntegrationRelatedCosts
      contextRef="i93266b4b1d884fad8c5cb4456e2def79_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV81Mi9mcmFnOjE5NzlmNTFhOWI3NDQ1ZTA5ZTI4ODA2YjU2OTg0MzUwL3RleHRyZWdpb246MTk3OWY1MWE5Yjc0NDVlMDllMjg4MDZiNTY5ODQzNTBfMTA5OTUxMTYzMzIyNw_1f709e7f-23d9-41a5-81d0-6bbbc1c4175d"
      unitRef="usd">3300000</us-gaap:BusinessCombinationIntegrationRelatedCosts>
    <us-gaap:BusinessCombinationIntegrationRelatedCosts
      contextRef="id8f72c421ee54ba2a739418940dde57c_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV81Mi9mcmFnOjE5NzlmNTFhOWI3NDQ1ZTA5ZTI4ODA2YjU2OTg0MzUwL3RleHRyZWdpb246MTk3OWY1MWE5Yjc0NDVlMDllMjg4MDZiNTY5ODQzNTBfMTA5OTUxMTYzMzIyNw_bd505b34-86c4-45b4-994d-a243fa05ac83"
      unitRef="usd">3300000</us-gaap:BusinessCombinationIntegrationRelatedCosts>
    <amed:DepreciationAndAmortizationForContinuingOperations
      contextRef="i93266b4b1d884fad8c5cb4456e2def79_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV81Mi9mcmFnOjE5NzlmNTFhOWI3NDQ1ZTA5ZTI4ODA2YjU2OTg0MzUwL3RleHRyZWdpb246MTk3OWY1MWE5Yjc0NDVlMDllMjg4MDZiNTY5ODQzNTBfMTA5OTUxMTYzMzI0MQ_0fe821b1-d679-48f0-91ee-5e550d33326b"
      unitRef="usd">200000</amed:DepreciationAndAmortizationForContinuingOperations>
    <amed:DepreciationAndAmortizationForContinuingOperations
      contextRef="id8f72c421ee54ba2a739418940dde57c_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV81Mi9mcmFnOjE5NzlmNTFhOWI3NDQ1ZTA5ZTI4ODA2YjU2OTg0MzUwL3RleHRyZWdpb246MTk3OWY1MWE5Yjc0NDVlMDllMjg4MDZiNTY5ODQzNTBfMTA5OTUxMTYzMzI0MQ_bb57a33f-9611-40f2-92a9-44c53d051842"
      unitRef="usd">200000</amed:DepreciationAndAmortizationForContinuingOperations>
    <amed:GoodwillDeductibleForIncomeTaxPurposesPeriod
      contextRef="i83f6f6c3fd9a43b9871634c7190f8d34_D20200601-20200601"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV81Mi9mcmFnOjE5NzlmNTFhOWI3NDQ1ZTA5ZTI4ODA2YjU2OTg0MzUwL3RleHRyZWdpb246MTk3OWY1MWE5Yjc0NDVlMDllMjg4MDZiNTY5ODQzNTBfMzI3Nw_003f4263-1ca5-4c31-a35f-304c1ed8db3f">P15Y</amed:GoodwillDeductibleForIncomeTaxPurposesPeriod>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV81OC9mcmFnOjAyNjBhN2Y0MDYyNzQ1ZTRhZWNlNjk4NThjOTI1ZDkyL3RleHRyZWdpb246MDI2MGE3ZjQwNjI3NDVlNGFlY2U2OTg1OGM5MjVkOTJfNjg4Nw_c57ce018-5cac-49a7-89a7-66e60d702394">LONG-TERM OBLIGATIONS&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Long-term debt consists of the following for the periods indicated (amounts in millions):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.812%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.256%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.596%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.825%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$175.0 million Term Loan; interest rate at Base Rate plus Applicable Rate or Eurodollar Rate plus Applicable Rate (1.4% at June 30, 2021); due February&#160;4, 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;159.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;164.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$550.0 million Revolving Credit Facility; interest only payments; interest rate at Base Rate plus Applicable Rate or Eurodollar Rate plus Applicable Rate (1.3% at June 30, 2021); due February&#160;4, 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Principal amount of long-term obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;191.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;217.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred debt issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;189.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;215.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current portion of long-term obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;179.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;204.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;First Amendment to Amended and Restated Credit Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On February 4, 2019, we entered into the First Amendment to our Credit Agreement (as amended by the First Amendment, the "Amended Credit Agreement"). The Amended Credit Agreement provides for a senior secured credit facility in an initial aggregate principal amount of up to $725.0 million, which includes a $550.0 million Revolving Credit Facility under the Credit Agreement, and a term loan facility with a principal amount of up to $175.0 million (the "Term Loan Facility" and collectively with the Revolving Credit Facility, the "Credit Facility"), which was added by the First Amendment.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The loans issued under the Credit Facility bear interest on a per annum basis, at our election, at either: (i) the Base Rate plus the Applicable Rate or (ii) the Eurodollar Rate plus the Applicable Rate. The &#x201c;Base Rate&#x201d; means a fluctuating rate per annum equal to the highest of (a) the federal funds rate plus 0.50% per annum, (b) the prime rate of interest established by the Administrative Agent, and (c) the Eurodollar Rate plus 1% per annum. The &#x201c;Eurodollar Rate&#x201d; means the quoted rate per annum equal to the London Interbank Offered Rate (&#x201c;LIBOR&#x201d;) or a comparable successor rate approved by the Administrative Agent for an interest period of one, two, three or six months (as selected by us). The &#x201c;Applicable Rate&#x201d; is based on the consolidated leverage ratio and is presented in the table below. As of June&#160;30, 2021, the Applicable Rate is 0.25% per annum for Base Rate loans and 1.25% per annum for Eurodollar Rate loans. We are also subject to a commitment fee and letter of credit fee under the terms of the Amended Credit Agreement, as presented in the table below.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.251%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.151%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:26.158%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.808%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.736%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.808%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.739%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Pricing Tier&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Consolidated Leverage Ratio&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Commitment Fee&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Letter of Credit Fee&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Eurodollar Rate Loans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Base Rate Loans&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;I&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2265; 3.00 to 1.0&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.35%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.75%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.00%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.00%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;II&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&amp;lt; 3.00 to 1.0 but &#x2265; 2.00 to 1.0&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.30%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.50%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.75%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.75%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;III&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&amp;lt; 2.00 to 1.0 but &#x2265; 0.75 to 1.0&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.25%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.25%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.50%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.50%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;IV&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&amp;lt; 0.75 to 1.0&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.20%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.00%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.25%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.25%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The final maturity date of the Credit Facility is February 4, 2024. The Revolving Credit Facility will terminate and be due and payable as of the final maturity date. The Term Loan Facility, however, is subject to quarterly amortization of principal in the amount of (i) 0.625% for the period commencing on February 4, 2019 and ending on March 31, 2020, (ii) 1.250% for the period commencing on April 1, 2020 and ending on March 31, 2023, and (iii) 1.875% for the period commencing on April 1, 2023 and ending on February 4, 2024. The remaining balance of the Term Loan Facility must be paid upon the final maturity date. In addition to the scheduled amortization of the Term Loan Facility, and subject to customary exceptions and reinvestment rights, we are required to prepay the Term Loan Facility first and the Revolving Credit Facility second with 100% of all net cash proceeds received by any loan party or any subsidiary thereof in connection with (a) any asset sale or disposition where such loan party receives net cash proceeds in excess of $5 million or (b) any debt issuance that is not permitted under the Amended Credit Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Amended Credit Agreement requires maintenance of two financial covenants: (i) a consolidated leverage ratio of funded indebtedness to Earnings Before Interest, Taxes, Depreciation and Amortization ("EBITDA"), as defined in the Amended Credit Agreement, and (ii) a consolidated interest coverage ratio of EBITDA to cash interest charges, as defined in the Amended Credit Agreement. Each of these covenants is calculated over rolling four-quarter periods and also is subject to certain exceptions and baskets. The Amended Credit Agreement also contains customary covenants, including, but not limited to, restrictions on: incurrence of liens, incurrence of additional debt, sales of assets and other fundamental corporate changes, investments, and declarations of dividends. These covenants contain customary exclusions and baskets as detailed in the Amended Credit Agreement. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Revolving Credit Facility is guaranteed by substantially all of our wholly-owned direct and indirect subsidiaries. The Amended Credit Agreement requires at all times that we (i) provide guarantees from wholly-owned subsidiaries that in the aggregate represent not less than 95% of our consolidated net revenues and adjusted EBITDA from all wholly-owned subsidiaries and (ii) provide guarantees from subsidiaries that in the aggregate represent not less than 70% of consolidated adjusted EBITDA, subject to certain exceptions.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our weighted average interest rate for borrowings under our $550.0 million Revolving Credit Facility was 1.7% and 1.8% for the three and six-month periods ended June&#160;30, 2021, respectively, and 2.1% and 2.5% for the three and six-month periods ended June 30, 2020, respectively. Our weighted average interest rate for borrowings under our $175.0 million Term Loan Facility was 1.4% and 1.5% for the three and six-month periods ended June&#160;30, 2021, respectively,  and 2.0% and 2.6% for the three and six-month periods ended June 30, 2020, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of June&#160;30, 2021, our consolidated leverage ratio was 0.5, our consolidated interest coverage ratio was 41.9 and we are in compliance with our covenants under the Amended Credit Agreement. In the event we are not in compliance with our debt covenants in the future, we would pursue various alternatives in an attempt to successfully resolve the non-compliance, which might include, among other things, seeking debt covenant waivers or amendments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of June&#160;30, 2021, our availability under our $550.0 million Revolving Credit Facility was $490.3 million as we have $30.0 million outstanding in borrowings and $29.7 million outstanding in letters of credit.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On July 30, 2021, we entered into a Second Amendment to our Credit Agreement (the &#x201c;Second Amended Credit Agreement&#x201d;). See Note 10 - Subsequent Events for additional information on the Second Amended Credit Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Joinder Agreements&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the Compassionate Care Hospice ("CCH") acquisition, we entered into a Joinder Agreement, dated as of February 4, 2019 (the &#x201c;CCH Joinder&#x201d;), pursuant to which CCH and its subsidiaries were made parties to, and became subject to the terms and conditions of, the Amended Credit Agreement, the Amended and Restated Security Agreement, dated as of June 29, 2018 (the &#x201c;Amended and Restated Security Agreement&#x201d;), and the Amended and Restated Pledge Agreement, dated as of June 29, 2018 (the &#x201c;Amended and Restated Pledge Agreement&#x201d;). In connection with the AseraCare acquisition, we entered into a Joinder Agreement, dated as of June 12, 2020, pursuant to which the AseraCare entities were made parties to, and became subject to the terms and conditions of, the Amended Credit Agreement, the Amended and Restated Security Agreement and the Amended and Restated Pledge Agreement (the &#x201c;AseraCare Joinder,&#x201d; and together with the CCH Joinder, the &#x201c;Joinders&#x201d;).  Pursuant to the Joinders, the Amended and Restated Security Agreement and the Amended and Restated Pledge Agreement, CCH and its subsidiaries and the AseraCare entities granted in favor of the Administrative Agent a first lien security interest in substantially all of their personal property assets and pledged to the Administrative Agent each of their respective subsidiaries' issued and outstanding equity interests. CCH and its subsidiaries and the AseraCare entities also guaranteed our obligations, whether now existing or arising after the respective effective dates of the Joinders, under the Amended Credit Agreement pursuant to the terms of the Joinders and the Amended Credit Agreement.&lt;/span&gt;&lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:ScheduleOfDebtInstrumentsTextBlock
      contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV81OC9mcmFnOjAyNjBhN2Y0MDYyNzQ1ZTRhZWNlNjk4NThjOTI1ZDkyL3RleHRyZWdpb246MDI2MGE3ZjQwNjI3NDVlNGFlY2U2OTg1OGM5MjVkOTJfNjg5Mg_a1c220d9-9f3c-4948-aa84-70aa54a9b8e2">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Long-term debt consists of the following for the periods indicated (amounts in millions):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.812%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.256%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.596%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.825%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$175.0 million Term Loan; interest rate at Base Rate plus Applicable Rate or Eurodollar Rate plus Applicable Rate (1.4% at June 30, 2021); due February&#160;4, 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;159.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;164.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$550.0 million Revolving Credit Facility; interest only payments; interest rate at Base Rate plus Applicable Rate or Eurodollar Rate plus Applicable Rate (1.3% at June 30, 2021); due February&#160;4, 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Principal amount of long-term obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;191.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;217.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred debt issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;189.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;215.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current portion of long-term obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;179.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;204.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfDebtInstrumentsTextBlock>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i4f3b5acefd614cc18bfcd62fc3a07ded_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV81OC9mcmFnOjAyNjBhN2Y0MDYyNzQ1ZTRhZWNlNjk4NThjOTI1ZDkyL3RhYmxlOmNhODJmZmZkYTkwNDRkOWE4ZmJmMzM3ZGY1OGRmMDhjL3RhYmxlcmFuZ2U6Y2E4MmZmZmRhOTA0NGQ5YThmYmYzMzdkZjU4ZGYwOGNfMS0wLTEtMS0wL3RleHRyZWdpb246N2M5NjlhYmEwMTQwNGIyNmFlYTQxMjFkY2YxMWQ1M2VfNA_2f3942bc-501f-45c9-9ff0-f959fd079fe3"
      unitRef="usd">175000000.0</us-gaap:DebtInstrumentFaceAmount>
    <amed:DebtInstrumentInterestRateatPeriodEnd
      contextRef="i47d7f0027dea435bbbef8d4d8e234b83_I20210630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV81OC9mcmFnOjAyNjBhN2Y0MDYyNzQ1ZTRhZWNlNjk4NThjOTI1ZDkyL3RhYmxlOmNhODJmZmZkYTkwNDRkOWE4ZmJmMzM3ZGY1OGRmMDhjL3RhYmxlcmFuZ2U6Y2E4MmZmZmRhOTA0NGQ5YThmYmYzMzdkZjU4ZGYwOGNfMS0wLTEtMS0wL3RleHRyZWdpb246N2M5NjlhYmEwMTQwNGIyNmFlYTQxMjFkY2YxMWQ1M2VfMTA3_d1d13bc5-2dbe-45da-a4bf-11b67aa3071f"
      unitRef="number">0.014</amed:DebtInstrumentInterestRateatPeriodEnd>
    <us-gaap:DebtInstrumentMaturityDate
      contextRef="i282996a0cb644ac088b44f613c53cdcb_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV81OC9mcmFnOjAyNjBhN2Y0MDYyNzQ1ZTRhZWNlNjk4NThjOTI1ZDkyL3RhYmxlOmNhODJmZmZkYTkwNDRkOWE4ZmJmMzM3ZGY1OGRmMDhjL3RhYmxlcmFuZ2U6Y2E4MmZmZmRhOTA0NGQ5YThmYmYzMzdkZjU4ZGYwOGNfMS0wLTEtMS0wL3RleHRyZWdpb246N2M5NjlhYmEwMTQwNGIyNmFlYTQxMjFkY2YxMWQ1M2VfMTM0_4759afb2-022d-4377-8e28-1ebd7266b84d">2024-02-04</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i4f3b5acefd614cc18bfcd62fc3a07ded_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV81OC9mcmFnOjAyNjBhN2Y0MDYyNzQ1ZTRhZWNlNjk4NThjOTI1ZDkyL3RhYmxlOmNhODJmZmZkYTkwNDRkOWE4ZmJmMzM3ZGY1OGRmMDhjL3RhYmxlcmFuZ2U6Y2E4MmZmZmRhOTA0NGQ5YThmYmYzMzdkZjU4ZGYwOGNfMS0xLTEtMS0w_a293fa68-50ac-4ba0-aca6-e1bd3a753702"
      unitRef="usd">159700000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i6f0dd8df1d3345b4aa1558de68c7698c_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV81OC9mcmFnOjAyNjBhN2Y0MDYyNzQ1ZTRhZWNlNjk4NThjOTI1ZDkyL3RhYmxlOmNhODJmZmZkYTkwNDRkOWE4ZmJmMzM3ZGY1OGRmMDhjL3RhYmxlcmFuZ2U6Y2E4MmZmZmRhOTA0NGQ5YThmYmYzMzdkZjU4ZGYwOGNfMS0zLTEtMS0w_316c825b-fe01-4ad9-9aa9-9459301f79da"
      unitRef="usd">164100000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i9b034d16545343f69ba28f30d62f22c2_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV81OC9mcmFnOjAyNjBhN2Y0MDYyNzQ1ZTRhZWNlNjk4NThjOTI1ZDkyL3RhYmxlOmNhODJmZmZkYTkwNDRkOWE4ZmJmMzM3ZGY1OGRmMDhjL3RhYmxlcmFuZ2U6Y2E4MmZmZmRhOTA0NGQ5YThmYmYzMzdkZjU4ZGYwOGNfMi0wLTEtMS0wL3RleHRyZWdpb246ZmUxZWIwODY4MGVkNGI3Yjk4Y2U1OGIxNjA3NjkxMTBfNA_4663d741-1888-45e1-9952-0afec6dbcb73"
      unitRef="usd">550000000.0</us-gaap:DebtInstrumentFaceAmount>
    <amed:DebtInstrumentInterestRateatPeriodEnd
      contextRef="i805854b7963a41c7938b322adb3c1278_I20210630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV81OC9mcmFnOjAyNjBhN2Y0MDYyNzQ1ZTRhZWNlNjk4NThjOTI1ZDkyL3RhYmxlOmNhODJmZmZkYTkwNDRkOWE4ZmJmMzM3ZGY1OGRmMDhjL3RhYmxlcmFuZ2U6Y2E4MmZmZmRhOTA0NGQ5YThmYmYzMzdkZjU4ZGYwOGNfMi0wLTEtMS0wL3RleHRyZWdpb246ZmUxZWIwODY4MGVkNGI3Yjk4Y2U1OGIxNjA3NjkxMTBfMTQ3_f8bcea73-a1b6-4af2-8eaf-d0309f7f96a7"
      unitRef="number">0.013</amed:DebtInstrumentInterestRateatPeriodEnd>
    <us-gaap:DebtInstrumentMaturityDate
      contextRef="if607f3cb243b4973902b1d41f80fb10c_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV81OC9mcmFnOjAyNjBhN2Y0MDYyNzQ1ZTRhZWNlNjk4NThjOTI1ZDkyL3RhYmxlOmNhODJmZmZkYTkwNDRkOWE4ZmJmMzM3ZGY1OGRmMDhjL3RhYmxlcmFuZ2U6Y2E4MmZmZmRhOTA0NGQ5YThmYmYzMzdkZjU4ZGYwOGNfMi0wLTEtMS0wL3RleHRyZWdpb246ZmUxZWIwODY4MGVkNGI3Yjk4Y2U1OGIxNjA3NjkxMTBfMTc0_df813017-1d04-487a-b395-5d9b4ee84a2b">2024-02-04</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i9b034d16545343f69ba28f30d62f22c2_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV81OC9mcmFnOjAyNjBhN2Y0MDYyNzQ1ZTRhZWNlNjk4NThjOTI1ZDkyL3RhYmxlOmNhODJmZmZkYTkwNDRkOWE4ZmJmMzM3ZGY1OGRmMDhjL3RhYmxlcmFuZ2U6Y2E4MmZmZmRhOTA0NGQ5YThmYmYzMzdkZjU4ZGYwOGNfMi0xLTEtMS0w_b978315e-9d54-4f31-a14e-f9e90e241185"
      unitRef="usd">30000000.0</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i0eccf63206474ddaa2ee2c286f646d71_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV81OC9mcmFnOjAyNjBhN2Y0MDYyNzQ1ZTRhZWNlNjk4NThjOTI1ZDkyL3RhYmxlOmNhODJmZmZkYTkwNDRkOWE4ZmJmMzM3ZGY1OGRmMDhjL3RhYmxlcmFuZ2U6Y2E4MmZmZmRhOTA0NGQ5YThmYmYzMzdkZjU4ZGYwOGNfMi0zLTEtMS0w_3b93297c-25c3-4c63-bdc5-f2d40da14949"
      unitRef="usd">51000000.0</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="id1083386f2394412b5f29ff8fd11b397_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV81OC9mcmFnOjAyNjBhN2Y0MDYyNzQ1ZTRhZWNlNjk4NThjOTI1ZDkyL3RhYmxlOmNhODJmZmZkYTkwNDRkOWE4ZmJmMzM3ZGY1OGRmMDhjL3RhYmxlcmFuZ2U6Y2E4MmZmZmRhOTA0NGQ5YThmYmYzMzdkZjU4ZGYwOGNfMy0xLTEtMS0w_e912be99-98cf-494e-a7c0-a4dcac10a84b"
      unitRef="usd">2100000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="ibbcbe46ad8ac4ae8a7fd039b14ce5a80_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV81OC9mcmFnOjAyNjBhN2Y0MDYyNzQ1ZTRhZWNlNjk4NThjOTI1ZDkyL3RhYmxlOmNhODJmZmZkYTkwNDRkOWE4ZmJmMzM3ZGY1OGRmMDhjL3RhYmxlcmFuZ2U6Y2E4MmZmZmRhOTA0NGQ5YThmYmYzMzdkZjU4ZGYwOGNfMy0zLTEtMS0w_43dc8fa4-fa27-4ed3-a5c8-b5d591bd5b66"
      unitRef="usd">2600000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i1e833203be6947b4968aba4d20064ec8_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV81OC9mcmFnOjAyNjBhN2Y0MDYyNzQ1ZTRhZWNlNjk4NThjOTI1ZDkyL3RhYmxlOmNhODJmZmZkYTkwNDRkOWE4ZmJmMzM3ZGY1OGRmMDhjL3RhYmxlcmFuZ2U6Y2E4MmZmZmRhOTA0NGQ5YThmYmYzMzdkZjU4ZGYwOGNfNC0xLTEtMS0w_a8ccd835-0d99-4aa6-8fca-9db4b7386a48"
      unitRef="usd">191800000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i87ceb60dc20d4df1b0a97d3514837910_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV81OC9mcmFnOjAyNjBhN2Y0MDYyNzQ1ZTRhZWNlNjk4NThjOTI1ZDkyL3RhYmxlOmNhODJmZmZkYTkwNDRkOWE4ZmJmMzM3ZGY1OGRmMDhjL3RhYmxlcmFuZ2U6Y2E4MmZmZmRhOTA0NGQ5YThmYmYzMzdkZjU4ZGYwOGNfNC0zLTEtMS0w_d5bd4c68-1238-4db6-9126-f2550e22d85b"
      unitRef="usd">217700000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DeferredFinanceCostsNet
      contextRef="i1e833203be6947b4968aba4d20064ec8_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV81OC9mcmFnOjAyNjBhN2Y0MDYyNzQ1ZTRhZWNlNjk4NThjOTI1ZDkyL3RhYmxlOmNhODJmZmZkYTkwNDRkOWE4ZmJmMzM3ZGY1OGRmMDhjL3RhYmxlcmFuZ2U6Y2E4MmZmZmRhOTA0NGQ5YThmYmYzMzdkZjU4ZGYwOGNfNS0xLTEtMS0w_856edc94-4a25-406b-af9c-43da4c4c134e"
      unitRef="usd">2200000</us-gaap:DeferredFinanceCostsNet>
    <us-gaap:DeferredFinanceCostsNet
      contextRef="i87ceb60dc20d4df1b0a97d3514837910_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV81OC9mcmFnOjAyNjBhN2Y0MDYyNzQ1ZTRhZWNlNjk4NThjOTI1ZDkyL3RhYmxlOmNhODJmZmZkYTkwNDRkOWE4ZmJmMzM3ZGY1OGRmMDhjL3RhYmxlcmFuZ2U6Y2E4MmZmZmRhOTA0NGQ5YThmYmYzMzdkZjU4ZGYwOGNfNS0zLTEtMS0w_66595d5e-3794-44de-8678-acc4437bb7c0"
      unitRef="usd">2700000</us-gaap:DeferredFinanceCostsNet>
    <us-gaap:LongTermDebt
      contextRef="i1e833203be6947b4968aba4d20064ec8_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV81OC9mcmFnOjAyNjBhN2Y0MDYyNzQ1ZTRhZWNlNjk4NThjOTI1ZDkyL3RhYmxlOmNhODJmZmZkYTkwNDRkOWE4ZmJmMzM3ZGY1OGRmMDhjL3RhYmxlcmFuZ2U6Y2E4MmZmZmRhOTA0NGQ5YThmYmYzMzdkZjU4ZGYwOGNfNi0xLTEtMS0w_c291234a-2607-404c-8266-3a71b2681a7a"
      unitRef="usd">189600000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i87ceb60dc20d4df1b0a97d3514837910_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV81OC9mcmFnOjAyNjBhN2Y0MDYyNzQ1ZTRhZWNlNjk4NThjOTI1ZDkyL3RhYmxlOmNhODJmZmZkYTkwNDRkOWE4ZmJmMzM3ZGY1OGRmMDhjL3RhYmxlcmFuZ2U6Y2E4MmZmZmRhOTA0NGQ5YThmYmYzMzdkZjU4ZGYwOGNfNi0zLTEtMS0w_5070f531-5498-40b3-9db6-ff361289a298"
      unitRef="usd">215000000.0</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebtCurrent
      contextRef="i1e833203be6947b4968aba4d20064ec8_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV81OC9mcmFnOjAyNjBhN2Y0MDYyNzQ1ZTRhZWNlNjk4NThjOTI1ZDkyL3RhYmxlOmNhODJmZmZkYTkwNDRkOWE4ZmJmMzM3ZGY1OGRmMDhjL3RhYmxlcmFuZ2U6Y2E4MmZmZmRhOTA0NGQ5YThmYmYzMzdkZjU4ZGYwOGNfNy0xLTEtMS0w_55a70a1e-1fd5-48c8-91fb-4dc557b4601b"
      unitRef="usd">10200000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="i87ceb60dc20d4df1b0a97d3514837910_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV81OC9mcmFnOjAyNjBhN2Y0MDYyNzQ1ZTRhZWNlNjk4NThjOTI1ZDkyL3RhYmxlOmNhODJmZmZkYTkwNDRkOWE4ZmJmMzM3ZGY1OGRmMDhjL3RhYmxlcmFuZ2U6Y2E4MmZmZmRhOTA0NGQ5YThmYmYzMzdkZjU4ZGYwOGNfNy0zLTEtMS0w_28293866-9533-4b31-97df-0833c2c0f142"
      unitRef="usd">10500000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i1e833203be6947b4968aba4d20064ec8_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV81OC9mcmFnOjAyNjBhN2Y0MDYyNzQ1ZTRhZWNlNjk4NThjOTI1ZDkyL3RhYmxlOmNhODJmZmZkYTkwNDRkOWE4ZmJmMzM3ZGY1OGRmMDhjL3RhYmxlcmFuZ2U6Y2E4MmZmZmRhOTA0NGQ5YThmYmYzMzdkZjU4ZGYwOGNfOC0xLTEtMS0w_1b5fc7ec-c255-433b-ae14-b3b3a65af8f4"
      unitRef="usd">179400000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i87ceb60dc20d4df1b0a97d3514837910_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV81OC9mcmFnOjAyNjBhN2Y0MDYyNzQ1ZTRhZWNlNjk4NThjOTI1ZDkyL3RhYmxlOmNhODJmZmZkYTkwNDRkOWE4ZmJmMzM3ZGY1OGRmMDhjL3RhYmxlcmFuZ2U6Y2E4MmZmZmRhOTA0NGQ5YThmYmYzMzdkZjU4ZGYwOGNfOC0zLTEtMS0w_e79f21d9-758e-48e2-a4af-13ca83c5eabd"
      unitRef="usd">204500000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i44c7af72d3a34639b4816895619e7f09_I20190204"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV81OC9mcmFnOjAyNjBhN2Y0MDYyNzQ1ZTRhZWNlNjk4NThjOTI1ZDkyL3RleHRyZWdpb246MDI2MGE3ZjQwNjI3NDVlNGFlY2U2OTg1OGM5MjVkOTJfNDU2_015d9e24-c6e7-40ae-814f-9f162b5eea01"
      unitRef="usd">725000000.0</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i24530ac946f344808f972a08211612f0_I20190204"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV81OC9mcmFnOjAyNjBhN2Y0MDYyNzQ1ZTRhZWNlNjk4NThjOTI1ZDkyL3RleHRyZWdpb246MDI2MGE3ZjQwNjI3NDVlNGFlY2U2OTg1OGM5MjVkOTJfNDc3_a7420d25-fd12-433c-890d-4fab98d1dbc1"
      unitRef="usd">550000000.0</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i2d0c143d688b41d490b2ea06ad3046d0_I20190204"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV81OC9mcmFnOjAyNjBhN2Y0MDYyNzQ1ZTRhZWNlNjk4NThjOTI1ZDkyL3RleHRyZWdpb246MDI2MGE3ZjQwNjI3NDVlNGFlY2U2OTg1OGM5MjVkOTJfNTky_f3e44355-7950-4467-97b7-a046e0294cab"
      unitRef="usd">175000000.0</us-gaap:DebtInstrumentFaceAmount>
    <amed:DebtInstrumentInterestAdditionalInterestAboveFederalFundRate
      contextRef="i9ae11ec3a41040829df9de1fe8e7b2bb_D20190204-20190204"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV81OC9mcmFnOjAyNjBhN2Y0MDYyNzQ1ZTRhZWNlNjk4NThjOTI1ZDkyL3RleHRyZWdpb246MDI2MGE3ZjQwNjI3NDVlNGFlY2U2OTg1OGM5MjVkOTJfMTA1MA_a0a2469e-5ad3-47f5-8b34-17ec1a93c170"
      unitRef="number">0.0050</amed:DebtInstrumentInterestAdditionalInterestAboveFederalFundRate>
    <amed:DebtInstrumentInterestAdditionalInterestAboveEurodollarRate
      contextRef="i9ae11ec3a41040829df9de1fe8e7b2bb_D20190204-20190204"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV81OC9mcmFnOjAyNjBhN2Y0MDYyNzQ1ZTRhZWNlNjk4NThjOTI1ZDkyL3RleHRyZWdpb246MDI2MGE3ZjQwNjI3NDVlNGFlY2U2OTg1OGM5MjVkOTJfMTE2OQ_1ff545c4-e545-47d8-9d16-7d17b67f8900"
      unitRef="number">0.01</amed:DebtInstrumentInterestAdditionalInterestAboveEurodollarRate>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="iee6ede9b55994de38f9991f940db59e9_D20210101-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV81OC9mcmFnOjAyNjBhN2Y0MDYyNzQ1ZTRhZWNlNjk4NThjOTI1ZDkyL3RleHRyZWdpb246MDI2MGE3ZjQwNjI3NDVlNGFlY2U2OTg1OGM5MjVkOTJfMTU3MQ_569f6e58-51b4-4df9-b361-c69663912f83"
      unitRef="number">0.0025</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i572c716155d248eeb353108705827f98_D20210101-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV81OC9mcmFnOjAyNjBhN2Y0MDYyNzQ1ZTRhZWNlNjk4NThjOTI1ZDkyL3RleHRyZWdpb246MDI2MGE3ZjQwNjI3NDVlNGFlY2U2OTg1OGM5MjVkOTJfMTYwOA_d3f1a189-a208-4042-bd53-587fb192f534"
      unitRef="number">0.0125</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:ScheduleOfLineOfCreditFacilitiesTextBlock
      contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV81OC9mcmFnOjAyNjBhN2Y0MDYyNzQ1ZTRhZWNlNjk4NThjOTI1ZDkyL3RleHRyZWdpb246MDI2MGE3ZjQwNjI3NDVlNGFlY2U2OTg1OGM5MjVkOTJfNjg4NA_b2651087-2187-40af-8805-6c68fcca5d15">We are also subject to a commitment fee and letter of credit fee under the terms of the Amended Credit Agreement, as presented in the table below.&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.251%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.151%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:26.158%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.808%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.736%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.808%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.739%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Pricing Tier&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Consolidated Leverage Ratio&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Commitment Fee&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Letter of Credit Fee&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Eurodollar Rate Loans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Base Rate Loans&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;I&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2265; 3.00 to 1.0&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.35%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.75%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.00%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.00%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;II&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&amp;lt; 3.00 to 1.0 but &#x2265; 2.00 to 1.0&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.30%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.50%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.75%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.75%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;III&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&amp;lt; 2.00 to 1.0 but &#x2265; 0.75 to 1.0&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.25%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.25%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.50%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.50%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;IV&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&amp;lt; 0.75 to 1.0&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.20%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.00%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.25%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.25%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfLineOfCreditFacilitiesTextBlock>
    <amed:ConsolidatedLeverageRatio
      contextRef="ib51e6cda5b7f4d999f0a54be2194e8fd_D20210101-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV81OC9mcmFnOjAyNjBhN2Y0MDYyNzQ1ZTRhZWNlNjk4NThjOTI1ZDkyL3RhYmxlOmE4ZTYyZDk1ZTQ1YjRjZmJhODhjZjg4Zjg0MThiOTU4L3RhYmxlcmFuZ2U6YThlNjJkOTVlNDViNGNmYmE4OGNmODhmODQxOGI5NThfMS0xLTEtMS0wL3RleHRyZWdpb246MGZkMDZhZGJkOTRlNGVjNWJiMWU1NmJhZGI3NzI4NTRfNg_3bfefe01-e537-4513-9624-9c66f71788a9"
      unitRef="number">3.00</amed:ConsolidatedLeverageRatio>
    <us-gaap:LineOfCreditFacilityCommitmentFeePercentage
      contextRef="ie89771700f0d460f9ee341c9f33ad463_D20210101-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV81OC9mcmFnOjAyNjBhN2Y0MDYyNzQ1ZTRhZWNlNjk4NThjOTI1ZDkyL3RhYmxlOmE4ZTYyZDk1ZTQ1YjRjZmJhODhjZjg4Zjg0MThiOTU4L3RhYmxlcmFuZ2U6YThlNjJkOTVlNDViNGNmYmE4OGNmODhmODQxOGI5NThfMS0yLTEtMS0w_9389ce9f-05e9-48dd-9652-e4064e4863f7"
      unitRef="number">0.0035</us-gaap:LineOfCreditFacilityCommitmentFeePercentage>
    <amed:LetterOfCreditFee
      contextRef="ie89771700f0d460f9ee341c9f33ad463_D20210101-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV81OC9mcmFnOjAyNjBhN2Y0MDYyNzQ1ZTRhZWNlNjk4NThjOTI1ZDkyL3RhYmxlOmE4ZTYyZDk1ZTQ1YjRjZmJhODhjZjg4Zjg0MThiOTU4L3RhYmxlcmFuZ2U6YThlNjJkOTVlNDViNGNmYmE4OGNmODhmODQxOGI5NThfMS0zLTEtMS0w_899d59d4-9423-4f20-a6aa-a71ca01b67a6"
      unitRef="number">0.0175</amed:LetterOfCreditFee>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i8b4a04615e76432ca77412a8ce8c97a7_D20210101-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV81OC9mcmFnOjAyNjBhN2Y0MDYyNzQ1ZTRhZWNlNjk4NThjOTI1ZDkyL3RhYmxlOmE4ZTYyZDk1ZTQ1YjRjZmJhODhjZjg4Zjg0MThiOTU4L3RhYmxlcmFuZ2U6YThlNjJkOTVlNDViNGNmYmE4OGNmODhmODQxOGI5NThfMS00LTEtMS0w_b4e47269-729c-40f6-b3d1-7db843f5c949"
      unitRef="number">0.0200</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i80a16d16af124d8e8088f9cd85a66aa7_D20210101-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV81OC9mcmFnOjAyNjBhN2Y0MDYyNzQ1ZTRhZWNlNjk4NThjOTI1ZDkyL3RhYmxlOmE4ZTYyZDk1ZTQ1YjRjZmJhODhjZjg4Zjg0MThiOTU4L3RhYmxlcmFuZ2U6YThlNjJkOTVlNDViNGNmYmE4OGNmODhmODQxOGI5NThfMS01LTEtMS0w_8b93247c-6e9a-4635-95f8-222b1a84acdb"
      unitRef="number">0.0100</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <amed:ConsolidatedLeverageRatio
      contextRef="i32469c69675f451a93e53e98fcb09d2b_D20210101-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV81OC9mcmFnOjAyNjBhN2Y0MDYyNzQ1ZTRhZWNlNjk4NThjOTI1ZDkyL3RhYmxlOmE4ZTYyZDk1ZTQ1YjRjZmJhODhjZjg4Zjg0MThiOTU4L3RhYmxlcmFuZ2U6YThlNjJkOTVlNDViNGNmYmE4OGNmODhmODQxOGI5NThfMi0xLTEtMS0wL3RleHRyZWdpb246NjAwN2ExYTJiZGFjNGU5ZDk4ZTkxMzA5MjliZmZlYjFfNg_c31b98f5-39a0-4d90-bf76-fd74532b6aa3"
      unitRef="number">3.00</amed:ConsolidatedLeverageRatio>
    <amed:ConsolidatedLeverageRatio
      contextRef="i762c3eb26082484eb8eda66cf8da59d4_D20210101-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV81OC9mcmFnOjAyNjBhN2Y0MDYyNzQ1ZTRhZWNlNjk4NThjOTI1ZDkyL3RhYmxlOmE4ZTYyZDk1ZTQ1YjRjZmJhODhjZjg4Zjg0MThiOTU4L3RhYmxlcmFuZ2U6YThlNjJkOTVlNDViNGNmYmE4OGNmODhmODQxOGI5NThfMi0xLTEtMS0wL3RleHRyZWdpb246NjAwN2ExYTJiZGFjNGU5ZDk4ZTkxMzA5MjliZmZlYjFfMjI_21a21d5a-2608-4b23-bb94-cc8432a9ef3b"
      unitRef="number">2.00</amed:ConsolidatedLeverageRatio>
    <us-gaap:LineOfCreditFacilityCommitmentFeePercentage
      contextRef="i7ec9530f2497489684d4748db38f2068_D20210101-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV81OC9mcmFnOjAyNjBhN2Y0MDYyNzQ1ZTRhZWNlNjk4NThjOTI1ZDkyL3RhYmxlOmE4ZTYyZDk1ZTQ1YjRjZmJhODhjZjg4Zjg0MThiOTU4L3RhYmxlcmFuZ2U6YThlNjJkOTVlNDViNGNmYmE4OGNmODhmODQxOGI5NThfMi0yLTEtMS0w_263862a5-1f75-4b03-8790-5fc3000d0a5e"
      unitRef="number">0.0030</us-gaap:LineOfCreditFacilityCommitmentFeePercentage>
    <amed:LetterOfCreditFee
      contextRef="i7ec9530f2497489684d4748db38f2068_D20210101-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV81OC9mcmFnOjAyNjBhN2Y0MDYyNzQ1ZTRhZWNlNjk4NThjOTI1ZDkyL3RhYmxlOmE4ZTYyZDk1ZTQ1YjRjZmJhODhjZjg4Zjg0MThiOTU4L3RhYmxlcmFuZ2U6YThlNjJkOTVlNDViNGNmYmE4OGNmODhmODQxOGI5NThfMi0zLTEtMS0w_f3cc9c9a-4ff7-4ee1-9566-0969b7201695"
      unitRef="number">0.0150</amed:LetterOfCreditFee>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i9d2fd16e87294dce83ab4611dec95214_D20210101-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV81OC9mcmFnOjAyNjBhN2Y0MDYyNzQ1ZTRhZWNlNjk4NThjOTI1ZDkyL3RhYmxlOmE4ZTYyZDk1ZTQ1YjRjZmJhODhjZjg4Zjg0MThiOTU4L3RhYmxlcmFuZ2U6YThlNjJkOTVlNDViNGNmYmE4OGNmODhmODQxOGI5NThfMi00LTEtMS0w_1784646d-3978-445e-83ea-a778df376294"
      unitRef="number">0.0175</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i38341f6760194d9b94f32fad1615efeb_D20210101-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV81OC9mcmFnOjAyNjBhN2Y0MDYyNzQ1ZTRhZWNlNjk4NThjOTI1ZDkyL3RhYmxlOmE4ZTYyZDk1ZTQ1YjRjZmJhODhjZjg4Zjg0MThiOTU4L3RhYmxlcmFuZ2U6YThlNjJkOTVlNDViNGNmYmE4OGNmODhmODQxOGI5NThfMi01LTEtMS0w_87365ff1-b552-4d51-9670-4f1cb8ae81c0"
      unitRef="number">0.0075</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <amed:ConsolidatedLeverageRatio
      contextRef="i5a18c53bf827477aaee9ccc3df622571_D20210101-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV81OC9mcmFnOjAyNjBhN2Y0MDYyNzQ1ZTRhZWNlNjk4NThjOTI1ZDkyL3RhYmxlOmE4ZTYyZDk1ZTQ1YjRjZmJhODhjZjg4Zjg0MThiOTU4L3RhYmxlcmFuZ2U6YThlNjJkOTVlNDViNGNmYmE4OGNmODhmODQxOGI5NThfMy0xLTEtMS0wL3RleHRyZWdpb246YWM0YjRiYzk3ODc5NGU5MWE0MjFkMjExY2I0OGEwYWVfNg_0db6fab0-f6aa-47d1-b97e-7206b584f061"
      unitRef="number">2.00</amed:ConsolidatedLeverageRatio>
    <amed:ConsolidatedLeverageRatio
      contextRef="ib6f866620dc2459b8f67a5cfdadf6297_D20210101-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV81OC9mcmFnOjAyNjBhN2Y0MDYyNzQ1ZTRhZWNlNjk4NThjOTI1ZDkyL3RhYmxlOmE4ZTYyZDk1ZTQ1YjRjZmJhODhjZjg4Zjg0MThiOTU4L3RhYmxlcmFuZ2U6YThlNjJkOTVlNDViNGNmYmE4OGNmODhmODQxOGI5NThfMy0xLTEtMS0wL3RleHRyZWdpb246YWM0YjRiYzk3ODc5NGU5MWE0MjFkMjExY2I0OGEwYWVfMjI_cb13c6de-2785-4422-9eba-f70721ea165c"
      unitRef="number">0.75</amed:ConsolidatedLeverageRatio>
    <us-gaap:LineOfCreditFacilityCommitmentFeePercentage
      contextRef="i3c46dc14b6294ba49b9a3b6291f5935e_D20210101-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV81OC9mcmFnOjAyNjBhN2Y0MDYyNzQ1ZTRhZWNlNjk4NThjOTI1ZDkyL3RhYmxlOmE4ZTYyZDk1ZTQ1YjRjZmJhODhjZjg4Zjg0MThiOTU4L3RhYmxlcmFuZ2U6YThlNjJkOTVlNDViNGNmYmE4OGNmODhmODQxOGI5NThfMy0yLTEtMS0w_178874de-e07a-4395-a7d4-ba4d9606d6b9"
      unitRef="number">0.0025</us-gaap:LineOfCreditFacilityCommitmentFeePercentage>
    <amed:LetterOfCreditFee
      contextRef="i3c46dc14b6294ba49b9a3b6291f5935e_D20210101-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV81OC9mcmFnOjAyNjBhN2Y0MDYyNzQ1ZTRhZWNlNjk4NThjOTI1ZDkyL3RhYmxlOmE4ZTYyZDk1ZTQ1YjRjZmJhODhjZjg4Zjg0MThiOTU4L3RhYmxlcmFuZ2U6YThlNjJkOTVlNDViNGNmYmE4OGNmODhmODQxOGI5NThfMy0zLTEtMS0w_90cc360b-c701-479a-819d-9b6c6eedb29f"
      unitRef="number">0.0125</amed:LetterOfCreditFee>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i6981eb55a7b7401c865f1b05bd9c637f_D20210101-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV81OC9mcmFnOjAyNjBhN2Y0MDYyNzQ1ZTRhZWNlNjk4NThjOTI1ZDkyL3RhYmxlOmE4ZTYyZDk1ZTQ1YjRjZmJhODhjZjg4Zjg0MThiOTU4L3RhYmxlcmFuZ2U6YThlNjJkOTVlNDViNGNmYmE4OGNmODhmODQxOGI5NThfMy00LTEtMS0w_ef76fcfe-4c1b-4e37-80c8-0b1562915ce4"
      unitRef="number">0.0150</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="ib6892f04dce84842bc5c41b0589b3786_D20210101-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV81OC9mcmFnOjAyNjBhN2Y0MDYyNzQ1ZTRhZWNlNjk4NThjOTI1ZDkyL3RhYmxlOmE4ZTYyZDk1ZTQ1YjRjZmJhODhjZjg4Zjg0MThiOTU4L3RhYmxlcmFuZ2U6YThlNjJkOTVlNDViNGNmYmE4OGNmODhmODQxOGI5NThfMy01LTEtMS0w_d4138093-c180-4440-b9ae-3546dcc040ac"
      unitRef="number">0.0050</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <amed:ConsolidatedLeverageRatio
      contextRef="id9b0d221bc814a0cb3a2f624451a4f31_D20210101-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV81OC9mcmFnOjAyNjBhN2Y0MDYyNzQ1ZTRhZWNlNjk4NThjOTI1ZDkyL3RhYmxlOmE4ZTYyZDk1ZTQ1YjRjZmJhODhjZjg4Zjg0MThiOTU4L3RhYmxlcmFuZ2U6YThlNjJkOTVlNDViNGNmYmE4OGNmODhmODQxOGI5NThfNC0xLTEtMS0wL3RleHRyZWdpb246ZGI2YTJjYWJiMGQ4NDZmZmE2OWFhMTU3MjBjNjkwNjlfNg_ddf21c19-b6a3-4635-a058-38dc9609d835"
      unitRef="number">0.75</amed:ConsolidatedLeverageRatio>
    <us-gaap:LineOfCreditFacilityCommitmentFeePercentage
      contextRef="ieb0d2d2742204b2695d46e6be0103cd6_D20210101-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV81OC9mcmFnOjAyNjBhN2Y0MDYyNzQ1ZTRhZWNlNjk4NThjOTI1ZDkyL3RhYmxlOmE4ZTYyZDk1ZTQ1YjRjZmJhODhjZjg4Zjg0MThiOTU4L3RhYmxlcmFuZ2U6YThlNjJkOTVlNDViNGNmYmE4OGNmODhmODQxOGI5NThfNC0yLTEtMS0w_b0f6b86e-9ca6-4c78-92ff-701adb7eb283"
      unitRef="number">0.0020</us-gaap:LineOfCreditFacilityCommitmentFeePercentage>
    <amed:LetterOfCreditFee
      contextRef="ieb0d2d2742204b2695d46e6be0103cd6_D20210101-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV81OC9mcmFnOjAyNjBhN2Y0MDYyNzQ1ZTRhZWNlNjk4NThjOTI1ZDkyL3RhYmxlOmE4ZTYyZDk1ZTQ1YjRjZmJhODhjZjg4Zjg0MThiOTU4L3RhYmxlcmFuZ2U6YThlNjJkOTVlNDViNGNmYmE4OGNmODhmODQxOGI5NThfNC0zLTEtMS0w_ed3f0abf-9ea7-4963-9227-260e2d8df04e"
      unitRef="number">0.0100</amed:LetterOfCreditFee>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i634fd9a568bf480e98d90ea8e22ee7fd_D20210101-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV81OC9mcmFnOjAyNjBhN2Y0MDYyNzQ1ZTRhZWNlNjk4NThjOTI1ZDkyL3RhYmxlOmE4ZTYyZDk1ZTQ1YjRjZmJhODhjZjg4Zjg0MThiOTU4L3RhYmxlcmFuZ2U6YThlNjJkOTVlNDViNGNmYmE4OGNmODhmODQxOGI5NThfNC00LTEtMS0w_9547d916-a9f4-4d86-8e2d-05992068fa40"
      unitRef="number">0.0125</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i5ab7b8577acf41a4a08641839dff1c5f_D20210101-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV81OC9mcmFnOjAyNjBhN2Y0MDYyNzQ1ZTRhZWNlNjk4NThjOTI1ZDkyL3RhYmxlOmE4ZTYyZDk1ZTQ1YjRjZmJhODhjZjg4Zjg0MThiOTU4L3RhYmxlcmFuZ2U6YThlNjJkOTVlNDViNGNmYmE4OGNmODhmODQxOGI5NThfNC01LTEtMS0w_92ee7d4f-86bd-4d43-9e10-767abbdcf2dd"
      unitRef="number">0.0025</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentMaturityDate
      contextRef="i9d61545dcadf4b1d94a320a38d0b1079_D20190204-20240204"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV81OC9mcmFnOjAyNjBhN2Y0MDYyNzQ1ZTRhZWNlNjk4NThjOTI1ZDkyL3RleHRyZWdpb246MDI2MGE3ZjQwNjI3NDVlNGFlY2U2OTg1OGM5MjVkOTJfMTg0OQ_b8608e8c-38ed-4d5a-9081-ee7828c7d6e5">2024-02-04</us-gaap:DebtInstrumentMaturityDate>
    <amed:DebtInstrumentPeriodicPaymentPercentage
      contextRef="i100ffc02e1834ff6a0bbb7f8fc39dd3d_D20190204-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV81OC9mcmFnOjAyNjBhN2Y0MDYyNzQ1ZTRhZWNlNjk4NThjOTI1ZDkyL3RleHRyZWdpb246MDI2MGE3ZjQwNjI3NDVlNGFlY2U2OTg1OGM5MjVkOTJfMjA1Ng_00155a77-297a-4bde-8440-b7a99ca72e54"
      unitRef="number">0.00625</amed:DebtInstrumentPeriodicPaymentPercentage>
    <amed:DebtInstrumentPeriodicPaymentPercentage
      contextRef="i641e495583ed40d7885721338515e386_D20200401-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV81OC9mcmFnOjAyNjBhN2Y0MDYyNzQ1ZTRhZWNlNjk4NThjOTI1ZDkyL3RleHRyZWdpb246MDI2MGE3ZjQwNjI3NDVlNGFlY2U2OTg1OGM5MjVkOTJfMjE0MA_9fb6d57c-3c60-4ff6-beed-ac6cfe936ab2"
      unitRef="number">0.01250</amed:DebtInstrumentPeriodicPaymentPercentage>
    <amed:DebtInstrumentPeriodicPaymentPercentage
      contextRef="i9f2171b5c0f742c18a35279b1904e320_D20230401-20240204"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV81OC9mcmFnOjAyNjBhN2Y0MDYyNzQ1ZTRhZWNlNjk4NThjOTI1ZDkyL3RleHRyZWdpb246MDI2MGE3ZjQwNjI3NDVlNGFlY2U2OTg1OGM5MjVkOTJfMjIyNg_ce146890-d315-4cbf-bd4a-d6f4b31d8ee0"
      unitRef="number">0.01875</amed:DebtInstrumentPeriodicPaymentPercentage>
    <amed:ProceedsReceivedFromLoanPartyOfSubsidiary
      contextRef="ibc8d6081948b4e9190302d69d2b70231_D20190204-20190204"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV81OC9mcmFnOjAyNjBhN2Y0MDYyNzQ1ZTRhZWNlNjk4NThjOTI1ZDkyL3RleHRyZWdpb246MDI2MGE3ZjQwNjI3NDVlNGFlY2U2OTg1OGM5MjVkOTJfMjgyNA_4e896d6d-75ea-4c83-9a4d-25428cd796ce"
      unitRef="usd">5000000</amed:ProceedsReceivedFromLoanPartyOfSubsidiary>
    <amed:PercentageOfRevenueAndOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromWhollyOwnedSubsidiaries
      contextRef="i9ae11ec3a41040829df9de1fe8e7b2bb_D20190204-20190204"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV81OC9mcmFnOjAyNjBhN2Y0MDYyNzQ1ZTRhZWNlNjk4NThjOTI1ZDkyL3RleHRyZWdpb246MDI2MGE3ZjQwNjI3NDVlNGFlY2U2OTg1OGM5MjVkOTJfNDA3MA_e6f007cd-e004-417c-bb36-1e8f30a89fd3"
      unitRef="number">0.95</amed:PercentageOfRevenueAndOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromWhollyOwnedSubsidiaries>
    <amed:PercentageOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromSubsidiaries
      contextRef="i9ae11ec3a41040829df9de1fe8e7b2bb_D20190204-20190204"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV81OC9mcmFnOjAyNjBhN2Y0MDYyNzQ1ZTRhZWNlNjk4NThjOTI1ZDkyL3RleHRyZWdpb246MDI2MGE3ZjQwNjI3NDVlNGFlY2U2OTg1OGM5MjVkOTJfNDI1Mw_053e783c-cde2-400c-8ae3-7795fac3488c"
      unitRef="number">0.70</amed:PercentageOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromSubsidiaries>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i9b034d16545343f69ba28f30d62f22c2_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV81OC9mcmFnOjAyNjBhN2Y0MDYyNzQ1ZTRhZWNlNjk4NThjOTI1ZDkyL3RleHRyZWdpb246MDI2MGE3ZjQwNjI3NDVlNGFlY2U2OTg1OGM5MjVkOTJfNDM4MQ_391e7c82-8333-417d-844e-46ff4cf2c77c"
      unitRef="usd">550000000.0</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:LongTermDebtWeightedAverageInterestRateOverTime
      contextRef="i21fda464ca064b61a04aca5a4c5e6a99_D20210401-20210630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV81OC9mcmFnOjAyNjBhN2Y0MDYyNzQ1ZTRhZWNlNjk4NThjOTI1ZDkyL3RleHRyZWdpb246MDI2MGE3ZjQwNjI3NDVlNGFlY2U2OTg1OGM5MjVkOTJfNDQxNA_b7cc9088-c55f-41f8-a502-59f3e50b38e9"
      unitRef="number">0.017</us-gaap:LongTermDebtWeightedAverageInterestRateOverTime>
    <us-gaap:LongTermDebtWeightedAverageInterestRateOverTime
      contextRef="if607f3cb243b4973902b1d41f80fb10c_D20210101-20210630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV81OC9mcmFnOjAyNjBhN2Y0MDYyNzQ1ZTRhZWNlNjk4NThjOTI1ZDkyL3RleHRyZWdpb246MDI2MGE3ZjQwNjI3NDVlNGFlY2U2OTg1OGM5MjVkOTJfNDQyMQ_b74028cc-33c9-4308-b5af-94da3170453e"
      unitRef="number">0.018</us-gaap:LongTermDebtWeightedAverageInterestRateOverTime>
    <us-gaap:LongTermDebtWeightedAverageInterestRateOverTime
      contextRef="idb01e853251e464c9326896aad4c2a8f_D20200401-20200630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV81OC9mcmFnOjAyNjBhN2Y0MDYyNzQ1ZTRhZWNlNjk4NThjOTI1ZDkyL3RleHRyZWdpb246MDI2MGE3ZjQwNjI3NDVlNGFlY2U2OTg1OGM5MjVkOTJfMTA5OTUxMTYzNDgwMg_1dbb8534-c0fb-4b9b-a1ae-52bcf1b1b48c"
      unitRef="number">0.021</us-gaap:LongTermDebtWeightedAverageInterestRateOverTime>
    <us-gaap:LongTermDebtWeightedAverageInterestRateOverTime
      contextRef="ib304b65d4507498f9d3f7647d9dbaccd_D20200101-20200630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV81OC9mcmFnOjAyNjBhN2Y0MDYyNzQ1ZTRhZWNlNjk4NThjOTI1ZDkyL3RleHRyZWdpb246MDI2MGE3ZjQwNjI3NDVlNGFlY2U2OTg1OGM5MjVkOTJfMTA5OTUxMTYzNDgwOA_40bab50e-2c46-401d-b617-11aff353152a"
      unitRef="number">0.025</us-gaap:LongTermDebtWeightedAverageInterestRateOverTime>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i4f3b5acefd614cc18bfcd62fc3a07ded_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV81OC9mcmFnOjAyNjBhN2Y0MDYyNzQ1ZTRhZWNlNjk4NThjOTI1ZDkyL3RleHRyZWdpb246MDI2MGE3ZjQwNjI3NDVlNGFlY2U2OTg1OGM5MjVkOTJfNDU0NQ_e5f08446-a11f-4211-ac33-b1971c59560b"
      unitRef="usd">175000000.0</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:LongTermDebtWeightedAverageInterestRateOverTime
      contextRef="ib3b582f4212244b0884fcc031ea6c067_D20210401-20210630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV81OC9mcmFnOjAyNjBhN2Y0MDYyNzQ1ZTRhZWNlNjk4NThjOTI1ZDkyL3RleHRyZWdpb246MDI2MGE3ZjQwNjI3NDVlNGFlY2U2OTg1OGM5MjVkOTJfNDU3MQ_2420680c-4db7-4beb-b8be-3cca0b023f09"
      unitRef="number">0.014</us-gaap:LongTermDebtWeightedAverageInterestRateOverTime>
    <us-gaap:LongTermDebtWeightedAverageInterestRateOverTime
      contextRef="i282996a0cb644ac088b44f613c53cdcb_D20210101-20210630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV81OC9mcmFnOjAyNjBhN2Y0MDYyNzQ1ZTRhZWNlNjk4NThjOTI1ZDkyL3RleHRyZWdpb246MDI2MGE3ZjQwNjI3NDVlNGFlY2U2OTg1OGM5MjVkOTJfNDU3OA_152a097d-1bf2-4fa5-8e47-1b685160a897"
      unitRef="number">0.015</us-gaap:LongTermDebtWeightedAverageInterestRateOverTime>
    <us-gaap:LongTermDebtWeightedAverageInterestRateOverTime
      contextRef="ie080c42adb394ab1aac8bdf81d4f0952_D20200401-20200630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV81OC9mcmFnOjAyNjBhN2Y0MDYyNzQ1ZTRhZWNlNjk4NThjOTI1ZDkyL3RleHRyZWdpb246MDI2MGE3ZjQwNjI3NDVlNGFlY2U2OTg1OGM5MjVkOTJfMTA5OTUxMTYzNDkzMg_24ef27d3-a312-4319-9bba-193e33618b94"
      unitRef="number">0.020</us-gaap:LongTermDebtWeightedAverageInterestRateOverTime>
    <us-gaap:LongTermDebtWeightedAverageInterestRateOverTime
      contextRef="i2b242548637548e5845bd5ec7ebead8c_D20200101-20200630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV81OC9mcmFnOjAyNjBhN2Y0MDYyNzQ1ZTRhZWNlNjk4NThjOTI1ZDkyL3RleHRyZWdpb246MDI2MGE3ZjQwNjI3NDVlNGFlY2U2OTg1OGM5MjVkOTJfMTA5OTUxMTYzNDkzOA_9d7b568f-3dc2-430b-85b9-19c64337a2be"
      unitRef="number">0.026</us-gaap:LongTermDebtWeightedAverageInterestRateOverTime>
    <amed:TotalLeverageRatio
      contextRef="i1e833203be6947b4968aba4d20064ec8_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV81OC9mcmFnOjAyNjBhN2Y0MDYyNzQ1ZTRhZWNlNjk4NThjOTI1ZDkyL3RleHRyZWdpb246MDI2MGE3ZjQwNjI3NDVlNGFlY2U2OTg1OGM5MjVkOTJfNDY4OA_3dd63267-d30e-419a-93e4-47c54c80aa4c"
      unitRef="number">0.5</amed:TotalLeverageRatio>
    <amed:ConsolidatedInterestCoverageRatio
      contextRef="i1e833203be6947b4968aba4d20064ec8_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV81OC9mcmFnOjAyNjBhN2Y0MDYyNzQ1ZTRhZWNlNjk4NThjOTI1ZDkyL3RleHRyZWdpb246MDI2MGE3ZjQwNjI3NDVlNGFlY2U2OTg1OGM5MjVkOTJfNDczNw_5e85bb12-b90b-4ae2-aabc-fffc164b7b20"
      unitRef="number">41.9</amed:ConsolidatedInterestCoverageRatio>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i9b034d16545343f69ba28f30d62f22c2_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV81OC9mcmFnOjAyNjBhN2Y0MDYyNzQ1ZTRhZWNlNjk4NThjOTI1ZDkyL3RleHRyZWdpb246MDI2MGE3ZjQwNjI3NDVlNGFlY2U2OTg1OGM5MjVkOTJfNTExNQ_0becd939-4bf3-4611-9989-65b3ae6ee34d"
      unitRef="usd">550000000.0</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity
      contextRef="i9b034d16545343f69ba28f30d62f22c2_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV81OC9mcmFnOjAyNjBhN2Y0MDYyNzQ1ZTRhZWNlNjk4NThjOTI1ZDkyL3RleHRyZWdpb246MDI2MGE3ZjQwNjI3NDVlNGFlY2U2OTg1OGM5MjVkOTJfNTE0OA_81eff7b6-65ef-4156-ab4e-cf3b50429316"
      unitRef="usd">490300000</us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i9b034d16545343f69ba28f30d62f22c2_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV81OC9mcmFnOjAyNjBhN2Y0MDYyNzQ1ZTRhZWNlNjk4NThjOTI1ZDkyL3RleHRyZWdpb246MDI2MGE3ZjQwNjI3NDVlNGFlY2U2OTg1OGM5MjVkOTJfNTE2Mg_acdf7974-173a-49e5-a1c1-df4c28c90b84"
      unitRef="usd">30000000.0</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LettersOfCreditOutstandingAmount
      contextRef="i123b2ec3b6424cd7858def47d8c592e4_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV81OC9mcmFnOjAyNjBhN2Y0MDYyNzQ1ZTRhZWNlNjk4NThjOTI1ZDkyL3RleHRyZWdpb246MDI2MGE3ZjQwNjI3NDVlNGFlY2U2OTg1OGM5MjVkOTJfNTE5NQ_66413829-4361-4a7a-9ac5-71379762f5b9"
      unitRef="usd">29700000</us-gaap:LettersOfCreditOutstandingAmount>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV82NC9mcmFnOmI1OTRlNTY1YTdjYzQxMDRiMDFlMjQzN2RlNWRhNDMzL3RleHRyZWdpb246YjU5NGU1NjVhN2NjNDEwNGIwMWUyNDM3ZGU1ZGE0MzNfMTA0OTY_3ea6d213-d158-433e-a5a0-ce0abae6cb94">COMMITMENTS AND CONTINGENCIES&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Legal Proceedings - Ongoing&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are involved in legal actions in the normal course of business, some of which seek monetary damages, including claims for punitive damages. Based on information available to us as of the date of this filing, we do not believe that these normal course actions, when finally concluded and determined, will have a material impact on our consolidated financial condition, results of operations or cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Legal fees related to all legal matters are expensed as incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Legal Proceedings - Completed&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Subpoena Duces Tecum and Civil Investigative Demands Issued by the U.S. Department of Justice&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On May 7, 2021, the U.S. Department of Justice notified the Company that they were closing their investigation into the below-referenced Subpoena Duces Tecum ("Subpoena") and civil investigative demands ("CIDs"). As of March 31, 2021, we had recorded a total of $6.5 million to accrued expenses in our condensed consolidated balance sheets related to these matters. During the three-month period ended June 30, 2021, we reversed our accrual related to these matters.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On May&#160;21, 2015, we received a Subpoena issued by the U.S. Department of Justice. The Subpoena requested the delivery of information regarding 53 identified hospice patients to the United States Attorney&#x2019;s Office for the District of Massachusetts. It also requested the delivery of documents relating to our hospice clinical and business operations and related compliance activities. The Subpoena generally covered the period from January&#160;1, 2011 through May&#160;21, 2015.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On November&#160;3, 2015, we received a CID issued by the U.S. Department of Justice pursuant to the federal False Claims Act relating to claims submitted to Medicare and/or Medicaid for hospice services provided through designated facilities in the Morgantown, West Virginia area. The CID requested the delivery of information to the United States Attorney&#x2019;s Office for the Northern District of West Virginia regarding 66 identified hospice patients, as well as documents relating to our hospice clinical and business operations in the Morgantown area. The CID generally covered the period from January&#160;1, 2009 through August 31, 2015.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On June&#160;27, 2016, we received a CID issued by the U.S. Department of Justice pursuant to the federal False Claims Act relating to claims submitted to Medicare and/or Medicaid for hospice services provided through designated facilities in the Parkersburg, West Virginia area. The CID requested the delivery of information to the United States Attorney&#x2019;s Office for the Southern District of West Virginia regarding 68 identified hospice patients, as well as documents relating to our hospice clinical and business operations in the Parkersburg area. The CID generally covered the period from January&#160;1, 2011 through June&#160;20, 2016. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Third Party Audits - Ongoing&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From time to time, in the ordinary course of business, we are subject to audits under various governmental programs in which third party firms engaged by CMS, including Recovery Audit Contractors (&#x201c;RACs&#x201d;), Zone Program Integrity Contractors (&#x201c;ZPICs&#x201d;), Uniform Program Integrity Contractors (&#x201c;UPICs&#x201d;), Program Safeguard Contractors (&#x201c;PSCs&#x201d;), Medicaid Integrity Contractors (&#x201c;MICs&#x201d;), Supplemental Medical Review Contractors (&#x201c;SMRCs&#x201d;) and the Office of Inspector General (&#x201c;OIG&#x201d;), conduct extensive reviews of claims data to identify potential improper payments. We cannot predict the ultimate outcome of any regulatory reviews or other governmental audits and investigations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In July 2010, our subsidiary that provides hospice services in Florence, South Carolina received from a ZPIC a request for records regarding a sample of 30 beneficiaries who received services from the subsidiary during the period of January&#160;1, 2008 through March&#160;31, 2010 (the &#x201c;Review Period&#x201d;) to determine whether the underlying services met pertinent Medicare payment requirements.&#160;We acquired the hospice operations subject to this review on August&#160;1, 2009; the Review Period covers time periods both before and after our ownership of these hospice operations.&#160;Based on the ZPIC&#x2019;s findings for 16 beneficiaries, which were extrapolated to all claims for hospice services provided by the Florence subsidiary billed during the Review Period, on June&#160;6, 2011, the Medicare Administrative Contractor (&#x201c;MAC&#x201d;) for the subsidiary issued a notice of overpayment seeking recovery from our subsidiary of an alleged overpayment. We dispute these findings, and our Florence subsidiary has filed appeals through the Original Medicare Standard Appeals Process, in which we are seeking to have those findings overturned. An administrative law judge ("ALJ") hearing was held in early January 2015. On January&#160;18, 2016, we received a letter dated January&#160;6, 2016 referencing the ALJ hearing decision for the overpayment issued on June&#160;6, 2011. The decision was partially favorable with a new overpayment amount of $3.7 million with a balance owed of $5.6 million, including interest, based on 9 disputed claims (originally 16). We filed an appeal to the Medicare Appeals Council on the remaining 9 disputed claims and also argued that the statistical method used to select the sample was not valid.&#160;No assurances can be given as to the timing or outcome of the Medicare Appeals Council decision. As of June&#160;30, 2021, Medicare has withheld payments of $5.7 million (including additional interest) as part of their standard procedures once this level of the appeal process has been reached. In the event we are not able to recoup this alleged overpayment, we are entitled to be indemnified by the prior owners of the hospice operations for amounts relating to the period prior to August&#160;1, 2009. On January 10, 2019, an arbitration panel from the American Health Lawyers Association determined that the prior owners' liability for their indemnification obligation was $2.8 million. This amount is recorded as an indemnity receivable within other assets in our condensed consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In July 2016, the Company received a request for medical records from SafeGuard Services, L.L.C (&#x201c;SafeGuard&#x201d;), a ZPIC, related to services provided by some of the care centers that the Company acquired from Infinity Home Care, L.L.C. The review period covers time periods both before and after our ownership of the care centers, which were acquired on December&#160;31, 2015. In August 2017, the Company received Requests for Repayment from Palmetto GBA, LLC ("Palmetto") regarding Infinity Home Care of Lakeland, LLC ("Lakeland Care Centers") and Infinity Home Care of Pinellas, LLC ("Clearwater Care Center"). The Palmetto letters are based on a statistical extrapolation performed by SafeGuard which alleged an overpayment of $34.0 million for the Lakeland Care Centers on a universe of 72 Medicare claims totaling $0.2 million in actual claims payments using a 100% error rate and an overpayment of $4.8 million for the Clearwater Care Center on a universe of 70 Medicare claims totaling $0.2 million in actual claims payments using a 100% error rate.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Lakeland Request for Repayment covers claims between January 2, 2014 and September 13, 2016. The Clearwater Request for Repayment covers claims between January 2, 2015 and December 9, 2016. As a result of partially successful Level I and Level II Administrative Appeals, the alleged overpayment for the Lakeland Care Centers has been reduced to $26.0 million and the alleged overpayment for the Clearwater Care Center has been reduced to $3.3 million. The Company has now filed Level III Administrative Appeals, and will continue to vigorously pursue its appeal rights, which include contesting the methodology used by the ZPIC contractor to perform statistical extrapolation. The Company is contractually entitled to indemnification by the prior owners for all claims prior to December 31, 2015, for up to $12.6 million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At this stage of the review, based on the information currently available to the Company, the Company cannot predict the timing or outcome of this review. The Company estimates a low-end potential range of loss related to this review of $6.5 million (assuming the Company is successful in seeking indemnity from the prior owners and unsuccessful in demonstrating that the extrapolation method used by SafeGuard was erroneous). The Company has reduced its high-end potential range of loss from $38.8 million (the maximum amount Palmetto claims has been overpaid for both the Lakeland Care Centers and the Clearwater Care Center, of which amount $12.6 million is subject to indemnification by the prior owners) to $29.3 million based on the partial success achieved by the Company in prosecuting its Level I and II Administrative Appeals.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of June&#160;30, 2021, we have an accrued liability of approximately $17.4 million related to this matter. We expect to be indemnified by the prior owners for approximately $10.9 million of the total $12.6 million available indemnification related to this matter and have recorded this amount within other assets in our condensed consolidated balance sheets. The net of these two amounts, $6.5 million, was recorded as a reduction in net service revenue in our condensed consolidated statements of operations during 2017. As of June&#160;30, 2021, $1.5 million of receivables have been impacted by this payment suspension.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:14pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Insurance&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are obligated for certain costs associated with our insurance programs, including employee health, workers&#x2019; compensation and professional liability. While we maintain various insurance programs to cover these risks, we are self-insured for a substantial portion of our potential claims. We recognize our obligations associated with these costs, up to specified deductible limits in the period in which a claim is incurred, including with respect to both reported claims and claims incurred but not reported. These costs have generally been estimated based on historical data of our claims experience. Such estimates, and the resulting reserves, are reviewed and updated by us on a quarterly basis.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our health insurance has an exposure limit of $1.3 million for any individual covered life. Our workers&#x2019; compensation insurance has a retention limit of $1.0 million per incident and our professional liability insurance has a retention limit of $0.3 million per incident.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:LossContingencyAccrualAtCarryingValue
      contextRef="i64a0980bb9334fcf8d6f808e3e3034e3_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV82NC9mcmFnOmI1OTRlNTY1YTdjYzQxMDRiMDFlMjQzN2RlNWRhNDMzL3RleHRyZWdpb246YjU5NGU1NjVhN2NjNDEwNGIwMWUyNDM3ZGU1ZGE0MzNfMzg0ODI5MDcxMTgzOA_7f3304de-5dd5-486a-9fce-1b3c368a9caa"
      unitRef="usd">6500000</us-gaap:LossContingencyAccrualAtCarryingValue>
    <amed:ReversalOfLossContingencyAccrual
      contextRef="i1743ef92c1a2465ea18877206de3e6eb_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV82NC9mcmFnOmI1OTRlNTY1YTdjYzQxMDRiMDFlMjQzN2RlNWRhNDMzL3RleHRyZWdpb246YjU5NGU1NjVhN2NjNDEwNGIwMWUyNDM3ZGU1ZGE0MzNfMzg0ODI5MDcxMTgzOA_d6ef8e9c-9649-46b2-a7fe-e40ae0c32f2c"
      unitRef="usd">6500000</amed:ReversalOfLossContingencyAccrual>
    <amed:Numberofpatients
      contextRef="icca6ffc5023e4d40ab2f30f7f1376996_D20150521-20150521"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV82NC9mcmFnOmI1OTRlNTY1YTdjYzQxMDRiMDFlMjQzN2RlNWRhNDMzL3RleHRyZWdpb246YjU5NGU1NjVhN2NjNDEwNGIwMWUyNDM3ZGU1ZGE0MzNfMzc2_886cdd18-cebd-4b15-8f07-6a32c1fda5ce"
      unitRef="patient">53</amed:Numberofpatients>
    <amed:Numberofpatients
      contextRef="if9882b4fe5cf46d883f68e6c542f6671_D20151103-20151103"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV82NC9mcmFnOmI1OTRlNTY1YTdjYzQxMDRiMDFlMjQzN2RlNWRhNDMzL3RleHRyZWdpb246YjU5NGU1NjVhN2NjNDEwNGIwMWUyNDM3ZGU1ZGE0MzNfMTI0Mw_48787ff5-19c6-4fe4-bdc9-36a0a19d8405"
      unitRef="patient">66</amed:Numberofpatients>
    <amed:Numberofpatients
      contextRef="i864f8ff014c445d3970f605bf1cf5633_D20160627-20160627"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV82NC9mcmFnOmI1OTRlNTY1YTdjYzQxMDRiMDFlMjQzN2RlNWRhNDMzL3RleHRyZWdpb246YjU5NGU1NjVhN2NjNDEwNGIwMWUyNDM3ZGU1ZGE0MzNfMTk3MQ_daabb267-6d13-4eed-ba97-cfcd4d4a9d2e"
      unitRef="patient">68</amed:Numberofpatients>
    <amed:NumberOfBeneficiaries
      contextRef="i56392e5d72914b00bf5ae116fa9bb7f9_D20080101-20100331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV82NC9mcmFnOmI1OTRlNTY1YTdjYzQxMDRiMDFlMjQzN2RlNWRhNDMzL3RleHRyZWdpb246YjU5NGU1NjVhN2NjNDEwNGIwMWUyNDM3ZGU1ZGE0MzNfNDE0MQ_f00b8a84-52f5-4cc8-9722-71a9ef733899"
      unitRef="beneficiary">30</amed:NumberOfBeneficiaries>
    <amed:NumberOfBeneficiaries
      contextRef="iad1c85c016834639b22c42870630702c_D20110606-20110606"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV82NC9mcmFnOmI1OTRlNTY1YTdjYzQxMDRiMDFlMjQzN2RlNWRhNDMzL3RleHRyZWdpb246YjU5NGU1NjVhN2NjNDEwNGIwMWUyNDM3ZGU1ZGE0MzNfNDU4NQ_f83c007a-2cdf-4f26-b367-d05cdf517a9c"
      unitRef="beneficiary">16</amed:NumberOfBeneficiaries>
    <amed:RecoveryAmountOfOverpaymentMadeToSubsidiary
      contextRef="i417a271b7a39436d9ed178f9bb7bd0c6_I20160118"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV82NC9mcmFnOmI1OTRlNTY1YTdjYzQxMDRiMDFlMjQzN2RlNWRhNDMzL3RleHRyZWdpb246YjU5NGU1NjVhN2NjNDEwNGIwMWUyNDM3ZGU1ZGE0MzNfNTM4OA_e9deb788-ab45-427f-854f-f1a449c8129d"
      unitRef="usd">3700000</amed:RecoveryAmountOfOverpaymentMadeToSubsidiary>
    <amed:RecoveryAmountOfOverpaymentMadeToSubsidiaryIncludingInterest
      contextRef="i417a271b7a39436d9ed178f9bb7bd0c6_I20160118"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV82NC9mcmFnOmI1OTRlNTY1YTdjYzQxMDRiMDFlMjQzN2RlNWRhNDMzL3RleHRyZWdpb246YjU5NGU1NjVhN2NjNDEwNGIwMWUyNDM3ZGU1ZGE0MzNfNTQxNA_ff3b06fb-5dff-44e8-b12a-eca2747b3e59"
      unitRef="usd">5600000</amed:RecoveryAmountOfOverpaymentMadeToSubsidiaryIncludingInterest>
    <amed:NumberOfClaimsSubmittedBySubsidiary
      contextRef="i937449c14ddf4057abd22b9d6ed3e210_D20160118-20160118"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV82NC9mcmFnOmI1OTRlNTY1YTdjYzQxMDRiMDFlMjQzN2RlNWRhNDMzL3RleHRyZWdpb246YjU5NGU1NjVhN2NjNDEwNGIwMWUyNDM3ZGU1ZGE0MzNfNTQ0Nw_b8c0dbbe-e4c1-430e-91b2-321d3cdbadbc"
      unitRef="claim">9</amed:NumberOfClaimsSubmittedBySubsidiary>
    <amed:NumberOfBeneficiaries
      contextRef="iad1c85c016834639b22c42870630702c_D20110606-20110606"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV82NC9mcmFnOmI1OTRlNTY1YTdjYzQxMDRiMDFlMjQzN2RlNWRhNDMzL3RleHRyZWdpb246YjU5NGU1NjVhN2NjNDEwNGIwMWUyNDM3ZGU1ZGE0MzNfNTQ3OA_05797933-11c4-4293-a035-e31b02a1e7db"
      unitRef="beneficiary">16</amed:NumberOfBeneficiaries>
    <amed:NumberOfClaimsSubmittedBySubsidiary
      contextRef="i937449c14ddf4057abd22b9d6ed3e210_D20160118-20160118"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV82NC9mcmFnOmI1OTRlNTY1YTdjYzQxMDRiMDFlMjQzN2RlNWRhNDMzL3RleHRyZWdpb246YjU5NGU1NjVhN2NjNDEwNGIwMWUyNDM3ZGU1ZGE0MzNfNTU1MQ_bdee4d40-09af-4b20-9db4-660c8f4b11e6"
      unitRef="claim">9</amed:NumberOfClaimsSubmittedBySubsidiary>
    <amed:Recoveryamountofoverpaymentmadetosubsidiaryincludinginterestwithheld
      contextRef="i562ae93979ca4fdb8e93e54fc08de2f4_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV82NC9mcmFnOmI1OTRlNTY1YTdjYzQxMDRiMDFlMjQzN2RlNWRhNDMzL3RleHRyZWdpb246YjU5NGU1NjVhN2NjNDEwNGIwMWUyNDM3ZGU1ZGE0MzNfNTc5Ng_a76ac361-5b62-463f-8dc4-c928f7814944"
      unitRef="usd">5700000</amed:Recoveryamountofoverpaymentmadetosubsidiaryincludinginterestwithheld>
    <us-gaap:LossContingencyReceivableNoncurrent
      contextRef="i45b052c3ab1d49c694a0154a1838b1a9_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV82NC9mcmFnOmI1OTRlNTY1YTdjYzQxMDRiMDFlMjQzN2RlNWRhNDMzL3RleHRyZWdpb246YjU5NGU1NjVhN2NjNDEwNGIwMWUyNDM3ZGU1ZGE0MzNfNjMwMQ_03c6b1fc-4c19-4519-baa8-dc91b329b194"
      unitRef="usd">2800000</us-gaap:LossContingencyReceivableNoncurrent>
    <amed:IndemnificationAmount
      contextRef="icf2b127cab17488d81818bf4e3d75ae0_I20190110"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV82NC9mcmFnOmI1OTRlNTY1YTdjYzQxMDRiMDFlMjQzN2RlNWRhNDMzL3RleHRyZWdpb246YjU5NGU1NjVhN2NjNDEwNGIwMWUyNDM3ZGU1ZGE0MzNfNjMwMQ_931e9f03-1cc1-4e1a-af22-a789ccda945e"
      unitRef="usd">2800000</amed:IndemnificationAmount>
    <amed:RecoveryAmountOfOverpaymentMadeToSubsidiary
      contextRef="i4850b525a25f4db491a946f4b9cd5379_I20170831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV82NC9mcmFnOmI1OTRlNTY1YTdjYzQxMDRiMDFlMjQzN2RlNWRhNDMzL3RleHRyZWdpb246YjU5NGU1NjVhN2NjNDEwNGIwMWUyNDM3ZGU1ZGE0MzNfNzE0Ng_29623db1-869b-411a-992e-a76f937ca570"
      unitRef="usd">34000000.0</amed:RecoveryAmountOfOverpaymentMadeToSubsidiary>
    <amed:NumberOfClaimsSubmittedBySubsidiary
      contextRef="ibe7994c4b86d4541b2d0ec37bace16d7_D20170801-20170831"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV82NC9mcmFnOmI1OTRlNTY1YTdjYzQxMDRiMDFlMjQzN2RlNWRhNDMzL3RleHRyZWdpb246YjU5NGU1NjVhN2NjNDEwNGIwMWUyNDM3ZGU1ZGE0MzNfNzE5Ng_1b41b47b-3aab-4aab-8e3e-b4c21483a684"
      unitRef="claim">72</amed:NumberOfClaimsSubmittedBySubsidiary>
    <amed:ActualClaimsPayment
      contextRef="i4850b525a25f4db491a946f4b9cd5379_I20170831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV82NC9mcmFnOmI1OTRlNTY1YTdjYzQxMDRiMDFlMjQzN2RlNWRhNDMzL3RleHRyZWdpb246YjU5NGU1NjVhN2NjNDEwNGIwMWUyNDM3ZGU1ZGE0MzNfNzIyNA_a8bf2910-f77a-4d3c-8d57-3c3fe917372f"
      unitRef="usd">200000</amed:ActualClaimsPayment>
    <amed:ErrorRatePercentage
      contextRef="i4850b525a25f4db491a946f4b9cd5379_I20170831"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV82NC9mcmFnOmI1OTRlNTY1YTdjYzQxMDRiMDFlMjQzN2RlNWRhNDMzL3RleHRyZWdpb246YjU5NGU1NjVhN2NjNDEwNGIwMWUyNDM3ZGU1ZGE0MzNfNzI2MQ_60fdc064-70ce-42f3-8c83-f2896de450bd"
      unitRef="number">1</amed:ErrorRatePercentage>
    <amed:RecoveryAmountOfOverpaymentMadeToSubsidiary
      contextRef="iaab7945d135e446ab572c2d66f2fd19f_I20170831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV82NC9mcmFnOmI1OTRlNTY1YTdjYzQxMDRiMDFlMjQzN2RlNWRhNDMzL3RleHRyZWdpb246YjU5NGU1NjVhN2NjNDEwNGIwMWUyNDM3ZGU1ZGE0MzNfNzI5Nw_564ee170-8c47-4ab3-b359-3940758ab20d"
      unitRef="usd">4800000</amed:RecoveryAmountOfOverpaymentMadeToSubsidiary>
    <amed:NumberOfClaimsSubmittedBySubsidiary
      contextRef="i480a00d19d3d49a99637c18c9b072f05_D20170801-20170831"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV82NC9mcmFnOmI1OTRlNTY1YTdjYzQxMDRiMDFlMjQzN2RlNWRhNDMzL3RleHRyZWdpb246YjU5NGU1NjVhN2NjNDEwNGIwMWUyNDM3ZGU1ZGE0MzNfNzM0OA_4a770240-487c-48dd-91a2-96cebbaa3336"
      unitRef="claim">70</amed:NumberOfClaimsSubmittedBySubsidiary>
    <amed:ActualClaimsPayment
      contextRef="iaab7945d135e446ab572c2d66f2fd19f_I20170831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV82NC9mcmFnOmI1OTRlNTY1YTdjYzQxMDRiMDFlMjQzN2RlNWRhNDMzL3RleHRyZWdpb246YjU5NGU1NjVhN2NjNDEwNGIwMWUyNDM3ZGU1ZGE0MzNfNzM3Ng_ce4e6ade-3966-448b-a598-0f2a01fee56b"
      unitRef="usd">200000</amed:ActualClaimsPayment>
    <amed:ErrorRatePercentage
      contextRef="iaab7945d135e446ab572c2d66f2fd19f_I20170831"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV82NC9mcmFnOmI1OTRlNTY1YTdjYzQxMDRiMDFlMjQzN2RlNWRhNDMzL3RleHRyZWdpb246YjU5NGU1NjVhN2NjNDEwNGIwMWUyNDM3ZGU1ZGE0MzNfNzQxMw_77413e64-0116-496e-b580-cdfffa8cf359"
      unitRef="number">1</amed:ErrorRatePercentage>
    <amed:RecoveryAmountOfOverpaymentMadeToSubsidiary
      contextRef="i1a6de48aaec6424c991ca149df38ebc4_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV82NC9mcmFnOmI1OTRlNTY1YTdjYzQxMDRiMDFlMjQzN2RlNWRhNDMzL3RleHRyZWdpb246YjU5NGU1NjVhN2NjNDEwNGIwMWUyNDM3ZGU1ZGE0MzNfNzc3Nw_f0d34189-2f3e-44b7-8192-4415eda92c67"
      unitRef="usd">26000000.0</amed:RecoveryAmountOfOverpaymentMadeToSubsidiary>
    <amed:RecoveryAmountOfOverpaymentMadeToSubsidiary
      contextRef="i257e928d56124ef98ae9d07b7f7d20e0_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV82NC9mcmFnOmI1OTRlNTY1YTdjYzQxMDRiMDFlMjQzN2RlNWRhNDMzL3RleHRyZWdpb246YjU5NGU1NjVhN2NjNDEwNGIwMWUyNDM3ZGU1ZGE0MzNfNzg1OQ_c5a795e8-76c6-4844-8b7e-688240a775ec"
      unitRef="usd">3300000</amed:RecoveryAmountOfOverpaymentMadeToSubsidiary>
    <amed:IndemnificationAmount
      contextRef="i042d59baaf764eadb82a511fc4630d06_I20170831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV82NC9mcmFnOmI1OTRlNTY1YTdjYzQxMDRiMDFlMjQzN2RlNWRhNDMzL3RleHRyZWdpb246YjU5NGU1NjVhN2NjNDEwNGIwMWUyNDM3ZGU1ZGE0MzNfODIxOA_86e7b815-4e3a-4599-a94d-642b3529e84d"
      unitRef="usd">12600000</amed:IndemnificationAmount>
    <amed:RecoveryAmountOfOverpaymentMadeToSubsidiary
      contextRef="i071a11675b024dfa92b8dd03678270ed_I20170831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV82NC9mcmFnOmI1OTRlNTY1YTdjYzQxMDRiMDFlMjQzN2RlNWRhNDMzL3RleHRyZWdpb246YjU5NGU1NjVhN2NjNDEwNGIwMWUyNDM3ZGU1ZGE0MzNfODQ1OQ_df52e42a-77d4-4eea-9a19-578a9d5879eb"
      unitRef="usd">6500000</amed:RecoveryAmountOfOverpaymentMadeToSubsidiary>
    <amed:RecoveryAmountOfOverpaymentMadeToSubsidiary
      contextRef="i8e89313551f44799b6300c11c9de29b3_I20170831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV82NC9mcmFnOmI1OTRlNTY1YTdjYzQxMDRiMDFlMjQzN2RlNWRhNDMzL3RleHRyZWdpb246YjU5NGU1NjVhN2NjNDEwNGIwMWUyNDM3ZGU1ZGE0MzNfODcwNQ_9a99d883-76ef-4f01-a928-59655ec9a3d7"
      unitRef="usd">38800000</amed:RecoveryAmountOfOverpaymentMadeToSubsidiary>
    <amed:IndemnificationAmount
      contextRef="i042d59baaf764eadb82a511fc4630d06_I20170831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV82NC9mcmFnOmI1OTRlNTY1YTdjYzQxMDRiMDFlMjQzN2RlNWRhNDMzL3RleHRyZWdpb246YjU5NGU1NjVhN2NjNDEwNGIwMWUyNDM3ZGU1ZGE0MzNfODg0NQ_9db27f91-37b9-4a99-931f-ddebda2b05e8"
      unitRef="usd">12600000</amed:IndemnificationAmount>
    <amed:RecoveryAmountOfOverpaymentMadeToSubsidiary
      contextRef="i33ec0cb49c7c45df918d10f6d8b12f6c_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV82NC9mcmFnOmI1OTRlNTY1YTdjYzQxMDRiMDFlMjQzN2RlNWRhNDMzL3RleHRyZWdpb246YjU5NGU1NjVhN2NjNDEwNGIwMWUyNDM3ZGU1ZGE0MzNfODkwMg_242694cb-44de-46d5-9b1c-d019e5c7cc8a"
      unitRef="usd">29300000</amed:RecoveryAmountOfOverpaymentMadeToSubsidiary>
    <us-gaap:LossContingencyAccrualAtCarryingValue
      contextRef="icc9f4a15aebf47b28a9f5ea3e095ade5_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV82NC9mcmFnOmI1OTRlNTY1YTdjYzQxMDRiMDFlMjQzN2RlNWRhNDMzL3RleHRyZWdpb246YjU5NGU1NjVhN2NjNDEwNGIwMWUyNDM3ZGU1ZGE0MzNfOTA3Mg_c35990f2-835c-4536-86af-767cc3bcb598"
      unitRef="usd">17400000</us-gaap:LossContingencyAccrualAtCarryingValue>
    <us-gaap:LossContingencyReceivableNoncurrent
      contextRef="icc9f4a15aebf47b28a9f5ea3e095ade5_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV82NC9mcmFnOmI1OTRlNTY1YTdjYzQxMDRiMDFlMjQzN2RlNWRhNDMzL3RleHRyZWdpb246YjU5NGU1NjVhN2NjNDEwNGIwMWUyNDM3ZGU1ZGE0MzNfOTE2NQ_b3c02c85-88bc-40c2-9bf5-77cbbd793f42"
      unitRef="usd">10900000</us-gaap:LossContingencyReceivableNoncurrent>
    <amed:IndemnificationAmount
      contextRef="i035f004f00fb427aa308a668dff7bb13_I20170831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV82NC9mcmFnOmI1OTRlNTY1YTdjYzQxMDRiMDFlMjQzN2RlNWRhNDMzL3RleHRyZWdpb246YjU5NGU1NjVhN2NjNDEwNGIwMWUyNDM3ZGU1ZGE0MzNfOTE4MQ_8833c8a5-04f4-4b46-a8ae-690b4018dcfb"
      unitRef="usd">12600000</amed:IndemnificationAmount>
    <amed:FloridaZpicRevenueReduction
      contextRef="icd32a02105c3425089f7089841dde5b2_D20170101-20171231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV82NC9mcmFnOmI1OTRlNTY1YTdjYzQxMDRiMDFlMjQzN2RlNWRhNDMzL3RleHRyZWdpb246YjU5NGU1NjVhN2NjNDEwNGIwMWUyNDM3ZGU1ZGE0MzNfOTM1OQ_ef07d295-4bee-45cc-b54b-24359e639dee"
      unitRef="usd">6500000</amed:FloridaZpicRevenueReduction>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="if467e9fca3484710a3ac117350b56dd9_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV82NC9mcmFnOmI1OTRlNTY1YTdjYzQxMDRiMDFlMjQzN2RlNWRhNDMzL3RleHRyZWdpb246YjU5NGU1NjVhN2NjNDEwNGIwMWUyNDM3ZGU1ZGE0MzNfOTQ4MA_91b32b8e-1865-4af3-8326-6ca9a435a454"
      unitRef="usd">1500000</us-gaap:AccountsReceivableNetCurrent>
    <amed:HealthInsuranceRetentionLimit
      contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV82NC9mcmFnOmI1OTRlNTY1YTdjYzQxMDRiMDFlMjQzN2RlNWRhNDMzL3RleHRyZWdpb246YjU5NGU1NjVhN2NjNDEwNGIwMWUyNDM3ZGU1ZGE0MzNfMTAzMDI_59f892d7-f426-4696-b2fa-8e9b148f7dc1"
      unitRef="usd">1300000</amed:HealthInsuranceRetentionLimit>
    <amed:WorkersCompensationInsuranceRetentionLimit
      contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV82NC9mcmFnOmI1OTRlNTY1YTdjYzQxMDRiMDFlMjQzN2RlNWRhNDMzL3RleHRyZWdpb246YjU5NGU1NjVhN2NjNDEwNGIwMWUyNDM3ZGU1ZGE0MzNfMTAzOTk_f00b5e89-2b72-4cef-b8da-5fc8d6b0e615"
      unitRef="usd">1000000.0</amed:WorkersCompensationInsuranceRetentionLimit>
    <amed:ProfessionalLiabilityInsuranceRetentionLimit
      contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV82NC9mcmFnOmI1OTRlNTY1YTdjYzQxMDRiMDFlMjQzN2RlNWRhNDMzL3RleHRyZWdpb246YjU5NGU1NjVhN2NjNDEwNGIwMWUyNDM3ZGU1ZGE0MzNfMTA0ODE_db5c03f2-01f0-4e9b-9d12-9a25c678f920"
      unitRef="usd">300000</amed:ProfessionalLiabilityInsuranceRetentionLimit>
    <us-gaap:SegmentReportingDisclosureTextBlock
      contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV83MC9mcmFnOjVkNDg3NDY3NDZiZDQ1ZWVhZTczY2JkYjNjZTc2MDdhL3RleHRyZWdpb246NWQ0ODc0Njc0NmJkNDVlZWFlNzNjYmRiM2NlNzYwN2FfMTM4Mg_8b3c2175-684d-44d6-94f5-f50482aae4e3">SEGMENT INFORMATIONOur operations involve servicing patients through our three reportable business segments: home health, hospice and personal care. Our home health segment delivers a wide range of services in the homes of individuals who may be recovering from surgery, have a chronic disability or terminal illness or need assistance with completing important personal tasks. Our hospice segment provides palliative care and comfort to terminally ill patients and their families. Our personal care segment provides patients with assistance with the essential activities of daily living. The &#x201c;other&#x201d; column in the following tables consists of costs relating to executive management and administrative support functions, primarily information services, accounting, finance, billing and collections, legal, compliance, risk management, procurement, marketing, clinical administration, training, human resources and administration.&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Management evaluates performance and allocates resources based on the operating income of the reportable segments, which includes an allocation of corporate expenses directly attributable to the specific segment and includes revenues and all other costs directly attributable to the specific segment. Segment assets are not reviewed by the company&#x2019;s chief operating decision maker and therefore are not disclosed below (amounts in millions).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.923%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.713%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three-Month Period Ended June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Home&lt;br/&gt;Health&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Hospice&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Personal&lt;br/&gt;Care&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net service revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;349.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;197.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;564.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other operating income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of service, excluding depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;190.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;105.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;308.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;175.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;272.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;154.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;490.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(47.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three-Month Period Ended June 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Home&lt;br/&gt;Health&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Hospice&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Personal&lt;br/&gt;Care&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net service revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;290.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;177.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;485.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other operating income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of service, excluding depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;184.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;97.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;295.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;156.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;257.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;138.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;457.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(45.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Six-Month Period Ended June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Home&lt;br/&gt;Health&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Hospice&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Personal&lt;br/&gt;Care&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net service revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;677.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;389.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,101.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other operating income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of service, excluding depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;373.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;206.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;605.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;161.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;347.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;537.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;303.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;95.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;967.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;148.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;92.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(95.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;147.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Six-Month Period Ended June 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Home&lt;br/&gt;Health&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Hospice&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Personal&lt;br/&gt;Care&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net service revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;593.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;346.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;976.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other operating income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of service, excluding depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;363.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;189.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;581.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;147.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;313.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;513.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;269.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;905.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;95.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(87.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;93.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:NumberOfReportableSegments
      contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV83MC9mcmFnOjVkNDg3NDY3NDZiZDQ1ZWVhZTczY2JkYjNjZTc2MDdhL3RleHRyZWdpb246NWQ0ODc0Njc0NmJkNDVlZWFlNzNjYmRiM2NlNzYwN2FfODI_016700d1-ddca-4d8c-9f05-ff51cfbf0ba6"
      unitRef="segments">3</us-gaap:NumberOfReportableSegments>
    <us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock
      contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV83MC9mcmFnOjVkNDg3NDY3NDZiZDQ1ZWVhZTczY2JkYjNjZTc2MDdhL3RleHRyZWdpb246NWQ0ODc0Njc0NmJkNDVlZWFlNzNjYmRiM2NlNzYwN2FfMTM4Ng_689ed5df-5ea1-4e7d-aa50-42702a008203">&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.923%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.713%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three-Month Period Ended June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Home&lt;br/&gt;Health&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Hospice&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Personal&lt;br/&gt;Care&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net service revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;349.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;197.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;564.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other operating income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of service, excluding depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;190.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;105.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;308.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;175.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;272.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;154.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;490.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(47.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three-Month Period Ended June 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Home&lt;br/&gt;Health&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Hospice&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Personal&lt;br/&gt;Care&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net service revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;290.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;177.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;485.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other operating income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of service, excluding depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;184.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;97.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;295.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;156.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;257.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;138.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;457.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(45.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Six-Month Period Ended June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Home&lt;br/&gt;Health&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Hospice&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Personal&lt;br/&gt;Care&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net service revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;677.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;389.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,101.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other operating income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of service, excluding depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;373.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;206.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;605.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;161.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;347.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;537.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;303.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;95.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;967.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;148.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;92.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(95.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;147.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Six-Month Period Ended June 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Home&lt;br/&gt;Health&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Hospice&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Personal&lt;br/&gt;Care&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net service revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;593.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;346.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;976.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other operating income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of service, excluding depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;363.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;189.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;581.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;147.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;313.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;513.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;269.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;905.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;95.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(87.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;93.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock>
    <us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions
      contextRef="i39e4f26632264baf9dbebb5fdcfb9311_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV83MC9mcmFnOjVkNDg3NDY3NDZiZDQ1ZWVhZTczY2JkYjNjZTc2MDdhL3RhYmxlOjQ2M2E4NDQ0NmMzOTQ0OWViMTI4Y2VkMzE5MjJmZjYxL3RhYmxlcmFuZ2U6NDYzYTg0NDQ2YzM5NDQ5ZWIxMjhjZWQzMTkyMmZmNjFfMi0xLTEtMS0w_6653b433-23d8-41a7-ac07-68280a3bd55e"
      unitRef="usd">349300000</us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions>
    <us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions
      contextRef="icf5dbb4a4428489fa4c64850e9a5a460_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV83MC9mcmFnOjVkNDg3NDY3NDZiZDQ1ZWVhZTczY2JkYjNjZTc2MDdhL3RhYmxlOjQ2M2E4NDQ0NmMzOTQ0OWViMTI4Y2VkMzE5MjJmZjYxL3RhYmxlcmFuZ2U6NDYzYTg0NDQ2YzM5NDQ5ZWIxMjhjZWQzMTkyMmZmNjFfMi0zLTEtMS0w_6b37ed91-3f26-447b-9ef2-db6ae333083d"
      unitRef="usd">197900000</us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions>
    <us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions
      contextRef="i66723c555afc4c9ab4b0e69183d084cf_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV83MC9mcmFnOjVkNDg3NDY3NDZiZDQ1ZWVhZTczY2JkYjNjZTc2MDdhL3RhYmxlOjQ2M2E4NDQ0NmMzOTQ0OWViMTI4Y2VkMzE5MjJmZjYxL3RhYmxlcmFuZ2U6NDYzYTg0NDQ2YzM5NDQ5ZWIxMjhjZWQzMTkyMmZmNjFfMi01LTEtMS0w_a99790e3-702e-4daf-b6a6-dcf4a0a989e2"
      unitRef="usd">17000000.0</us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions>
    <us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions
      contextRef="ib10fab888a0d4becba7d4378b0313572_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV83MC9mcmFnOjVkNDg3NDY3NDZiZDQ1ZWVhZTczY2JkYjNjZTc2MDdhL3RhYmxlOjQ2M2E4NDQ0NmMzOTQ0OWViMTI4Y2VkMzE5MjJmZjYxL3RhYmxlcmFuZ2U6NDYzYTg0NDQ2YzM5NDQ5ZWIxMjhjZWQzMTkyMmZmNjFfMi03LTEtMS0w_d050b4ee-bf85-4bc7-9158-ae2aaf8d8104"
      unitRef="usd">0</us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions>
    <us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions
      contextRef="ib87cee58ccf2448a8d4422101bf61fa0_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV83MC9mcmFnOjVkNDg3NDY3NDZiZDQ1ZWVhZTczY2JkYjNjZTc2MDdhL3RhYmxlOjQ2M2E4NDQ0NmMzOTQ0OWViMTI4Y2VkMzE5MjJmZjYxL3RhYmxlcmFuZ2U6NDYzYTg0NDQ2YzM5NDQ5ZWIxMjhjZWQzMTkyMmZmNjFfMi05LTEtMS0w_40a6447f-ead9-44ab-92c1-ba55867c6c3a"
      unitRef="usd">564200000</us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions>
    <us-gaap:OtherOperatingIncome
      contextRef="i39e4f26632264baf9dbebb5fdcfb9311_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV83MC9mcmFnOjVkNDg3NDY3NDZiZDQ1ZWVhZTczY2JkYjNjZTc2MDdhL3RhYmxlOjQ2M2E4NDQ0NmMzOTQ0OWViMTI4Y2VkMzE5MjJmZjYxL3RhYmxlcmFuZ2U6NDYzYTg0NDQ2YzM5NDQ5ZWIxMjhjZWQzMTkyMmZmNjFfMy0xLTEtMS0w_14afbb48-ebe8-4423-a8d3-f0580aff910b"
      unitRef="usd">2300000</us-gaap:OtherOperatingIncome>
    <us-gaap:OtherOperatingIncome
      contextRef="icf5dbb4a4428489fa4c64850e9a5a460_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV83MC9mcmFnOjVkNDg3NDY3NDZiZDQ1ZWVhZTczY2JkYjNjZTc2MDdhL3RhYmxlOjQ2M2E4NDQ0NmMzOTQ0OWViMTI4Y2VkMzE5MjJmZjYxL3RhYmxlcmFuZ2U6NDYzYTg0NDQ2YzM5NDQ5ZWIxMjhjZWQzMTkyMmZmNjFfMy0zLTEtMS0w_0416673c-af5e-44ff-ad87-5c6b9a427e2c"
      unitRef="usd">2300000</us-gaap:OtherOperatingIncome>
    <us-gaap:OtherOperatingIncome
      contextRef="i66723c555afc4c9ab4b0e69183d084cf_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV83MC9mcmFnOjVkNDg3NDY3NDZiZDQ1ZWVhZTczY2JkYjNjZTc2MDdhL3RhYmxlOjQ2M2E4NDQ0NmMzOTQ0OWViMTI4Y2VkMzE5MjJmZjYxL3RhYmxlcmFuZ2U6NDYzYTg0NDQ2YzM5NDQ5ZWIxMjhjZWQzMTkyMmZmNjFfMy01LTEtMS0w_3cb659ce-d9f8-4176-b29b-91e21a42c2bd"
      unitRef="usd">0</us-gaap:OtherOperatingIncome>
    <us-gaap:OtherOperatingIncome
      contextRef="ib10fab888a0d4becba7d4378b0313572_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV83MC9mcmFnOjVkNDg3NDY3NDZiZDQ1ZWVhZTczY2JkYjNjZTc2MDdhL3RhYmxlOjQ2M2E4NDQ0NmMzOTQ0OWViMTI4Y2VkMzE5MjJmZjYxL3RhYmxlcmFuZ2U6NDYzYTg0NDQ2YzM5NDQ5ZWIxMjhjZWQzMTkyMmZmNjFfMy03LTEtMS0w_aaef2af8-9d71-4054-8dea-8829c68d1f72"
      unitRef="usd">0</us-gaap:OtherOperatingIncome>
    <us-gaap:OtherOperatingIncome
      contextRef="ib87cee58ccf2448a8d4422101bf61fa0_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV83MC9mcmFnOjVkNDg3NDY3NDZiZDQ1ZWVhZTczY2JkYjNjZTc2MDdhL3RhYmxlOjQ2M2E4NDQ0NmMzOTQ0OWViMTI4Y2VkMzE5MjJmZjYxL3RhYmxlcmFuZ2U6NDYzYTg0NDQ2YzM5NDQ5ZWIxMjhjZWQzMTkyMmZmNjFfMy05LTEtMS0w_3f3e17bf-0629-4660-a9e4-7cec5e1f7d50"
      unitRef="usd">4600000</us-gaap:OtherOperatingIncome>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i39e4f26632264baf9dbebb5fdcfb9311_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV83MC9mcmFnOjVkNDg3NDY3NDZiZDQ1ZWVhZTczY2JkYjNjZTc2MDdhL3RhYmxlOjQ2M2E4NDQ0NmMzOTQ0OWViMTI4Y2VkMzE5MjJmZjYxL3RhYmxlcmFuZ2U6NDYzYTg0NDQ2YzM5NDQ5ZWIxMjhjZWQzMTkyMmZmNjFfNC0xLTEtMS0w_61060087-ddba-4346-8a7d-9576386604e3"
      unitRef="usd">190400000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="icf5dbb4a4428489fa4c64850e9a5a460_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV83MC9mcmFnOjVkNDg3NDY3NDZiZDQ1ZWVhZTczY2JkYjNjZTc2MDdhL3RhYmxlOjQ2M2E4NDQ0NmMzOTQ0OWViMTI4Y2VkMzE5MjJmZjYxL3RhYmxlcmFuZ2U6NDYzYTg0NDQ2YzM5NDQ5ZWIxMjhjZWQzMTkyMmZmNjFfNC0zLTEtMS0w_070ca58a-c521-4239-80d9-74df4420cbf8"
      unitRef="usd">105200000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i66723c555afc4c9ab4b0e69183d084cf_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV83MC9mcmFnOjVkNDg3NDY3NDZiZDQ1ZWVhZTczY2JkYjNjZTc2MDdhL3RhYmxlOjQ2M2E4NDQ0NmMzOTQ0OWViMTI4Y2VkMzE5MjJmZjYxL3RhYmxlcmFuZ2U6NDYzYTg0NDQ2YzM5NDQ5ZWIxMjhjZWQzMTkyMmZmNjFfNC01LTEtMS0w_1f904e19-a8ae-4967-b924-050f2b151858"
      unitRef="usd">13100000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="ib10fab888a0d4becba7d4378b0313572_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV83MC9mcmFnOjVkNDg3NDY3NDZiZDQ1ZWVhZTczY2JkYjNjZTc2MDdhL3RhYmxlOjQ2M2E4NDQ0NmMzOTQ0OWViMTI4Y2VkMzE5MjJmZjYxL3RhYmxlcmFuZ2U6NDYzYTg0NDQ2YzM5NDQ5ZWIxMjhjZWQzMTkyMmZmNjFfNC03LTEtMS0w_5188845f-8465-42ef-81e8-88596b82a95b"
      unitRef="usd">0</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="ib87cee58ccf2448a8d4422101bf61fa0_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV83MC9mcmFnOjVkNDg3NDY3NDZiZDQ1ZWVhZTczY2JkYjNjZTc2MDdhL3RhYmxlOjQ2M2E4NDQ0NmMzOTQ0OWViMTI4Y2VkMzE5MjJmZjYxL3RhYmxlcmFuZ2U6NDYzYTg0NDQ2YzM5NDQ5ZWIxMjhjZWQzMTkyMmZmNjFfNC05LTEtMS0w_8a8b1b40-7b61-4667-82f5-3db96a87dad9"
      unitRef="usd">308700000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i39e4f26632264baf9dbebb5fdcfb9311_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV83MC9mcmFnOjVkNDg3NDY3NDZiZDQ1ZWVhZTczY2JkYjNjZTc2MDdhL3RhYmxlOjQ2M2E4NDQ0NmMzOTQ0OWViMTI4Y2VkMzE5MjJmZjYxL3RhYmxlcmFuZ2U6NDYzYTg0NDQ2YzM5NDQ5ZWIxMjhjZWQzMTkyMmZmNjFfNS0xLTEtMS0w_7012dc8e-1b74-4ea7-9e82-65fb155a4b96"
      unitRef="usd">81300000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="icf5dbb4a4428489fa4c64850e9a5a460_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV83MC9mcmFnOjVkNDg3NDY3NDZiZDQ1ZWVhZTczY2JkYjNjZTc2MDdhL3RhYmxlOjQ2M2E4NDQ0NmMzOTQ0OWViMTI4Y2VkMzE5MjJmZjYxL3RhYmxlcmFuZ2U6NDYzYTg0NDQ2YzM5NDQ5ZWIxMjhjZWQzMTkyMmZmNjFfNS0zLTEtMS0w_5109239f-955a-4ae4-9090-a2afcf994e17"
      unitRef="usd">48400000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i66723c555afc4c9ab4b0e69183d084cf_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV83MC9mcmFnOjVkNDg3NDY3NDZiZDQ1ZWVhZTczY2JkYjNjZTc2MDdhL3RhYmxlOjQ2M2E4NDQ0NmMzOTQ0OWViMTI4Y2VkMzE5MjJmZjYxL3RhYmxlcmFuZ2U6NDYzYTg0NDQ2YzM5NDQ5ZWIxMjhjZWQzMTkyMmZmNjFfNS01LTEtMS0w_fdf9733e-977f-4a17-a622-b1ba6b4657f2"
      unitRef="usd">3200000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="ib10fab888a0d4becba7d4378b0313572_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV83MC9mcmFnOjVkNDg3NDY3NDZiZDQ1ZWVhZTczY2JkYjNjZTc2MDdhL3RhYmxlOjQ2M2E4NDQ0NmMzOTQ0OWViMTI4Y2VkMzE5MjJmZjYxL3RhYmxlcmFuZ2U6NDYzYTg0NDQ2YzM5NDQ5ZWIxMjhjZWQzMTkyMmZmNjFfNS03LTEtMS0w_8cdf236e-78e7-4c1d-ab4f-2f5d5a69e0a0"
      unitRef="usd">42400000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="ib87cee58ccf2448a8d4422101bf61fa0_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV83MC9mcmFnOjVkNDg3NDY3NDZiZDQ1ZWVhZTczY2JkYjNjZTc2MDdhL3RhYmxlOjQ2M2E4NDQ0NmMzOTQ0OWViMTI4Y2VkMzE5MjJmZjYxL3RhYmxlcmFuZ2U6NDYzYTg0NDQ2YzM5NDQ5ZWIxMjhjZWQzMTkyMmZmNjFfNS05LTEtMS0w_0d7644ae-cf36-4944-accd-7e588359c288"
      unitRef="usd">175300000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:DepreciationAndAmortization
      contextRef="i39e4f26632264baf9dbebb5fdcfb9311_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV83MC9mcmFnOjVkNDg3NDY3NDZiZDQ1ZWVhZTczY2JkYjNjZTc2MDdhL3RhYmxlOjQ2M2E4NDQ0NmMzOTQ0OWViMTI4Y2VkMzE5MjJmZjYxL3RhYmxlcmFuZ2U6NDYzYTg0NDQ2YzM5NDQ5ZWIxMjhjZWQzMTkyMmZmNjFfNi0xLTEtMS0w_446f279f-46f6-4608-8532-0f164e431ec7"
      unitRef="usd">1200000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="icf5dbb4a4428489fa4c64850e9a5a460_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV83MC9mcmFnOjVkNDg3NDY3NDZiZDQ1ZWVhZTczY2JkYjNjZTc2MDdhL3RhYmxlOjQ2M2E4NDQ0NmMzOTQ0OWViMTI4Y2VkMzE5MjJmZjYxL3RhYmxlcmFuZ2U6NDYzYTg0NDQ2YzM5NDQ5ZWIxMjhjZWQzMTkyMmZmNjFfNi0zLTEtMS0w_e6413569-0d52-46b5-a109-32392f42fe5a"
      unitRef="usd">700000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="i66723c555afc4c9ab4b0e69183d084cf_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV83MC9mcmFnOjVkNDg3NDY3NDZiZDQ1ZWVhZTczY2JkYjNjZTc2MDdhL3RhYmxlOjQ2M2E4NDQ0NmMzOTQ0OWViMTI4Y2VkMzE5MjJmZjYxL3RhYmxlcmFuZ2U6NDYzYTg0NDQ2YzM5NDQ5ZWIxMjhjZWQzMTkyMmZmNjFfNi01LTEtMS0w_4866906d-af16-4455-9c91-6ed43f0a202f"
      unitRef="usd">0</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="ib10fab888a0d4becba7d4378b0313572_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV83MC9mcmFnOjVkNDg3NDY3NDZiZDQ1ZWVhZTczY2JkYjNjZTc2MDdhL3RhYmxlOjQ2M2E4NDQ0NmMzOTQ0OWViMTI4Y2VkMzE5MjJmZjYxL3RhYmxlcmFuZ2U6NDYzYTg0NDQ2YzM5NDQ5ZWIxMjhjZWQzMTkyMmZmNjFfNi03LTEtMS0w_ce0296c4-18fe-44dc-8bc2-7e30a985c5ae"
      unitRef="usd">4800000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="ib87cee58ccf2448a8d4422101bf61fa0_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV83MC9mcmFnOjVkNDg3NDY3NDZiZDQ1ZWVhZTczY2JkYjNjZTc2MDdhL3RhYmxlOjQ2M2E4NDQ0NmMzOTQ0OWViMTI4Y2VkMzE5MjJmZjYxL3RhYmxlcmFuZ2U6NDYzYTg0NDQ2YzM5NDQ5ZWIxMjhjZWQzMTkyMmZmNjFfNi05LTEtMS0w_d2cc2eaa-5f3b-4115-8ecf-a3e8827e5723"
      unitRef="usd">6700000</us-gaap:DepreciationAndAmortization>
    <us-gaap:CostsAndExpenses
      contextRef="i39e4f26632264baf9dbebb5fdcfb9311_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV83MC9mcmFnOjVkNDg3NDY3NDZiZDQ1ZWVhZTczY2JkYjNjZTc2MDdhL3RhYmxlOjQ2M2E4NDQ0NmMzOTQ0OWViMTI4Y2VkMzE5MjJmZjYxL3RhYmxlcmFuZ2U6NDYzYTg0NDQ2YzM5NDQ5ZWIxMjhjZWQzMTkyMmZmNjFfNy0xLTEtMS0w_b825ea59-307c-4ce8-a535-da30ba67947b"
      unitRef="usd">272900000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="icf5dbb4a4428489fa4c64850e9a5a460_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV83MC9mcmFnOjVkNDg3NDY3NDZiZDQ1ZWVhZTczY2JkYjNjZTc2MDdhL3RhYmxlOjQ2M2E4NDQ0NmMzOTQ0OWViMTI4Y2VkMzE5MjJmZjYxL3RhYmxlcmFuZ2U6NDYzYTg0NDQ2YzM5NDQ5ZWIxMjhjZWQzMTkyMmZmNjFfNy0zLTEtMS0w_d51e99c7-8c16-40fc-8065-9c6e746dd8e1"
      unitRef="usd">154300000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i66723c555afc4c9ab4b0e69183d084cf_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV83MC9mcmFnOjVkNDg3NDY3NDZiZDQ1ZWVhZTczY2JkYjNjZTc2MDdhL3RhYmxlOjQ2M2E4NDQ0NmMzOTQ0OWViMTI4Y2VkMzE5MjJmZjYxL3RhYmxlcmFuZ2U6NDYzYTg0NDQ2YzM5NDQ5ZWIxMjhjZWQzMTkyMmZmNjFfNy01LTEtMS0w_33082975-d02b-426e-9c9b-5020bc801a5a"
      unitRef="usd">16300000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="ib10fab888a0d4becba7d4378b0313572_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV83MC9mcmFnOjVkNDg3NDY3NDZiZDQ1ZWVhZTczY2JkYjNjZTc2MDdhL3RhYmxlOjQ2M2E4NDQ0NmMzOTQ0OWViMTI4Y2VkMzE5MjJmZjYxL3RhYmxlcmFuZ2U6NDYzYTg0NDQ2YzM5NDQ5ZWIxMjhjZWQzMTkyMmZmNjFfNy03LTEtMS0w_0afc32a3-b751-471c-b22f-97d24196ad06"
      unitRef="usd">47200000</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="i39e4f26632264baf9dbebb5fdcfb9311_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV83MC9mcmFnOjVkNDg3NDY3NDZiZDQ1ZWVhZTczY2JkYjNjZTc2MDdhL3RhYmxlOjQ2M2E4NDQ0NmMzOTQ0OWViMTI4Y2VkMzE5MjJmZjYxL3RhYmxlcmFuZ2U6NDYzYTg0NDQ2YzM5NDQ5ZWIxMjhjZWQzMTkyMmZmNjFfOC0xLTEtMS0w_73767906-fa1a-48fc-a969-dafd17907c76"
      unitRef="usd">78700000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="icf5dbb4a4428489fa4c64850e9a5a460_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV83MC9mcmFnOjVkNDg3NDY3NDZiZDQ1ZWVhZTczY2JkYjNjZTc2MDdhL3RhYmxlOjQ2M2E4NDQ0NmMzOTQ0OWViMTI4Y2VkMzE5MjJmZjYxL3RhYmxlcmFuZ2U6NDYzYTg0NDQ2YzM5NDQ5ZWIxMjhjZWQzMTkyMmZmNjFfOC0zLTEtMS0w_c2ea30e0-8ff0-4804-8d45-50182c54e3b3"
      unitRef="usd">45900000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i66723c555afc4c9ab4b0e69183d084cf_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV83MC9mcmFnOjVkNDg3NDY3NDZiZDQ1ZWVhZTczY2JkYjNjZTc2MDdhL3RhYmxlOjQ2M2E4NDQ0NmMzOTQ0OWViMTI4Y2VkMzE5MjJmZjYxL3RhYmxlcmFuZ2U6NDYzYTg0NDQ2YzM5NDQ5ZWIxMjhjZWQzMTkyMmZmNjFfOC01LTEtMS0w_930d50de-d563-47f8-ac76-f02722b17130"
      unitRef="usd">700000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ib10fab888a0d4becba7d4378b0313572_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV83MC9mcmFnOjVkNDg3NDY3NDZiZDQ1ZWVhZTczY2JkYjNjZTc2MDdhL3RhYmxlOjQ2M2E4NDQ0NmMzOTQ0OWViMTI4Y2VkMzE5MjJmZjYxL3RhYmxlcmFuZ2U6NDYzYTg0NDQ2YzM5NDQ5ZWIxMjhjZWQzMTkyMmZmNjFfOC03LTEtMS0w_d77271ff-b507-44d0-90da-ab050726c4a0"
      unitRef="usd">-47200000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ib87cee58ccf2448a8d4422101bf61fa0_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV83MC9mcmFnOjVkNDg3NDY3NDZiZDQ1ZWVhZTczY2JkYjNjZTc2MDdhL3RhYmxlOjQ2M2E4NDQ0NmMzOTQ0OWViMTI4Y2VkMzE5MjJmZjYxL3RhYmxlcmFuZ2U6NDYzYTg0NDQ2YzM5NDQ5ZWIxMjhjZWQzMTkyMmZmNjFfOC05LTEtMS0w_0a3fdeeb-3ead-45d0-b732-a0f3ee4d9c72"
      unitRef="usd">78100000</us-gaap:OperatingIncomeLoss>
    <us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions
      contextRef="i1f0d04b97823461cabfaf4b2dbfbd657_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV83MC9mcmFnOjVkNDg3NDY3NDZiZDQ1ZWVhZTczY2JkYjNjZTc2MDdhL3RhYmxlOjQ2M2E4NDQ0NmMzOTQ0OWViMTI4Y2VkMzE5MjJmZjYxL3RhYmxlcmFuZ2U6NDYzYTg0NDQ2YzM5NDQ5ZWIxMjhjZWQzMTkyMmZmNjFfMTItMS0xLTEtMA_cb67d292-d4f0-4708-a9b6-22a622cbaf47"
      unitRef="usd">290200000</us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions>
    <us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions
      contextRef="if43b4d7c93ab412a9c9070b831320d17_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV83MC9mcmFnOjVkNDg3NDY3NDZiZDQ1ZWVhZTczY2JkYjNjZTc2MDdhL3RhYmxlOjQ2M2E4NDQ0NmMzOTQ0OWViMTI4Y2VkMzE5MjJmZjYxL3RhYmxlcmFuZ2U6NDYzYTg0NDQ2YzM5NDQ5ZWIxMjhjZWQzMTkyMmZmNjFfMTItMy0xLTEtMA_c5737adc-03a1-4122-b947-52bc156a0cc1"
      unitRef="usd">177100000</us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions>
    <us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions
      contextRef="i15797e02165b455389b33741463c1ecd_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV83MC9mcmFnOjVkNDg3NDY3NDZiZDQ1ZWVhZTczY2JkYjNjZTc2MDdhL3RhYmxlOjQ2M2E4NDQ0NmMzOTQ0OWViMTI4Y2VkMzE5MjJmZjYxL3RhYmxlcmFuZ2U6NDYzYTg0NDQ2YzM5NDQ5ZWIxMjhjZWQzMTkyMmZmNjFfMTItNS0xLTEtMA_8bce03a3-55c9-4e9c-8056-131ca009b19a"
      unitRef="usd">17700000</us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions>
    <us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions
      contextRef="i06052fe21e8f47d88c0c73710f1feaa6_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV83MC9mcmFnOjVkNDg3NDY3NDZiZDQ1ZWVhZTczY2JkYjNjZTc2MDdhL3RhYmxlOjQ2M2E4NDQ0NmMzOTQ0OWViMTI4Y2VkMzE5MjJmZjYxL3RhYmxlcmFuZ2U6NDYzYTg0NDQ2YzM5NDQ5ZWIxMjhjZWQzMTkyMmZmNjFfMTItNy0xLTEtMA_3fd9da01-8a4f-4ba3-a635-017263d37065"
      unitRef="usd">0</us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions>
    <us-gaap:OtherOperatingIncome
      contextRef="i1f0d04b97823461cabfaf4b2dbfbd657_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV83MC9mcmFnOjVkNDg3NDY3NDZiZDQ1ZWVhZTczY2JkYjNjZTc2MDdhL3RhYmxlOjQ2M2E4NDQ0NmMzOTQ0OWViMTI4Y2VkMzE5MjJmZjYxL3RhYmxlcmFuZ2U6NDYzYTg0NDQ2YzM5NDQ5ZWIxMjhjZWQzMTkyMmZmNjFfMTMtMS0xLTEtNjkx_88cebb4d-8690-4073-a3a8-361d2af2e775"
      unitRef="usd">15100000</us-gaap:OtherOperatingIncome>
    <us-gaap:OtherOperatingIncome
      contextRef="if43b4d7c93ab412a9c9070b831320d17_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV83MC9mcmFnOjVkNDg3NDY3NDZiZDQ1ZWVhZTczY2JkYjNjZTc2MDdhL3RhYmxlOjQ2M2E4NDQ0NmMzOTQ0OWViMTI4Y2VkMzE5MjJmZjYxL3RhYmxlcmFuZ2U6NDYzYTg0NDQ2YzM5NDQ5ZWIxMjhjZWQzMTkyMmZmNjFfMTMtMy0xLTEtNjkx_b52e5645-1d58-4ca0-8cf4-467fecb089c1"
      unitRef="usd">7200000</us-gaap:OtherOperatingIncome>
    <us-gaap:OtherOperatingIncome
      contextRef="i15797e02165b455389b33741463c1ecd_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV83MC9mcmFnOjVkNDg3NDY3NDZiZDQ1ZWVhZTczY2JkYjNjZTc2MDdhL3RhYmxlOjQ2M2E4NDQ0NmMzOTQ0OWViMTI4Y2VkMzE5MjJmZjYxL3RhYmxlcmFuZ2U6NDYzYTg0NDQ2YzM5NDQ5ZWIxMjhjZWQzMTkyMmZmNjFfMTMtNS0xLTEtNjkx_393a26fe-8242-493c-9988-6232d70847e3"
      unitRef="usd">500000</us-gaap:OtherOperatingIncome>
    <us-gaap:OtherOperatingIncome
      contextRef="i06052fe21e8f47d88c0c73710f1feaa6_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV83MC9mcmFnOjVkNDg3NDY3NDZiZDQ1ZWVhZTczY2JkYjNjZTc2MDdhL3RhYmxlOjQ2M2E4NDQ0NmMzOTQ0OWViMTI4Y2VkMzE5MjJmZjYxL3RhYmxlcmFuZ2U6NDYzYTg0NDQ2YzM5NDQ5ZWIxMjhjZWQzMTkyMmZmNjFfMTMtNy0xLTEtNjkx_858ae600-5196-4182-8a71-1f09da959a8f"
      unitRef="usd">0</us-gaap:OtherOperatingIncome>
    <us-gaap:OtherOperatingIncome
      contextRef="i2c8351954d014a1c80a3d8cfc2327ab2_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV83MC9mcmFnOjVkNDg3NDY3NDZiZDQ1ZWVhZTczY2JkYjNjZTc2MDdhL3RhYmxlOjQ2M2E4NDQ0NmMzOTQ0OWViMTI4Y2VkMzE5MjJmZjYxL3RhYmxlcmFuZ2U6NDYzYTg0NDQ2YzM5NDQ5ZWIxMjhjZWQzMTkyMmZmNjFfMTMtOS0xLTEtNjkx_5ccc1795-0eff-4aed-bf45-b84ebed5ff19"
      unitRef="usd">22800000</us-gaap:OtherOperatingIncome>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i1f0d04b97823461cabfaf4b2dbfbd657_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV83MC9mcmFnOjVkNDg3NDY3NDZiZDQ1ZWVhZTczY2JkYjNjZTc2MDdhL3RhYmxlOjQ2M2E4NDQ0NmMzOTQ0OWViMTI4Y2VkMzE5MjJmZjYxL3RhYmxlcmFuZ2U6NDYzYTg0NDQ2YzM5NDQ5ZWIxMjhjZWQzMTkyMmZmNjFfMTMtMS0xLTEtMA_ab56aef8-4137-4d98-ab20-3f539f6a25fb"
      unitRef="usd">184000000.0</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="if43b4d7c93ab412a9c9070b831320d17_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV83MC9mcmFnOjVkNDg3NDY3NDZiZDQ1ZWVhZTczY2JkYjNjZTc2MDdhL3RhYmxlOjQ2M2E4NDQ0NmMzOTQ0OWViMTI4Y2VkMzE5MjJmZjYxL3RhYmxlcmFuZ2U6NDYzYTg0NDQ2YzM5NDQ5ZWIxMjhjZWQzMTkyMmZmNjFfMTMtMy0xLTEtMA_95c4274e-87ac-47ee-8444-63a4ca8a7c20"
      unitRef="usd">97200000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i15797e02165b455389b33741463c1ecd_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV83MC9mcmFnOjVkNDg3NDY3NDZiZDQ1ZWVhZTczY2JkYjNjZTc2MDdhL3RhYmxlOjQ2M2E4NDQ0NmMzOTQ0OWViMTI4Y2VkMzE5MjJmZjYxL3RhYmxlcmFuZ2U6NDYzYTg0NDQ2YzM5NDQ5ZWIxMjhjZWQzMTkyMmZmNjFfMTMtNS0xLTEtMA_ab8993de-c2fd-4fc8-9429-3a9f47729f36"
      unitRef="usd">14100000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i06052fe21e8f47d88c0c73710f1feaa6_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV83MC9mcmFnOjVkNDg3NDY3NDZiZDQ1ZWVhZTczY2JkYjNjZTc2MDdhL3RhYmxlOjQ2M2E4NDQ0NmMzOTQ0OWViMTI4Y2VkMzE5MjJmZjYxL3RhYmxlcmFuZ2U6NDYzYTg0NDQ2YzM5NDQ5ZWIxMjhjZWQzMTkyMmZmNjFfMTMtNy0xLTEtMA_c021467c-8c34-47d0-b0c2-8c80f8b422ce"
      unitRef="usd">0</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i1f0d04b97823461cabfaf4b2dbfbd657_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV83MC9mcmFnOjVkNDg3NDY3NDZiZDQ1ZWVhZTczY2JkYjNjZTc2MDdhL3RhYmxlOjQ2M2E4NDQ0NmMzOTQ0OWViMTI4Y2VkMzE5MjJmZjYxL3RhYmxlcmFuZ2U6NDYzYTg0NDQ2YzM5NDQ5ZWIxMjhjZWQzMTkyMmZmNjFfMTQtMS0xLTEtMA_305a7939-b832-4fcc-99fa-20b7e7d56dd1"
      unitRef="usd">72200000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="if43b4d7c93ab412a9c9070b831320d17_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV83MC9mcmFnOjVkNDg3NDY3NDZiZDQ1ZWVhZTczY2JkYjNjZTc2MDdhL3RhYmxlOjQ2M2E4NDQ0NmMzOTQ0OWViMTI4Y2VkMzE5MjJmZjYxL3RhYmxlcmFuZ2U6NDYzYTg0NDQ2YzM5NDQ5ZWIxMjhjZWQzMTkyMmZmNjFfMTQtMy0xLTEtMA_bf5cbeda-48c9-4169-a335-df5aa06e6f29"
      unitRef="usd">40900000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i15797e02165b455389b33741463c1ecd_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV83MC9mcmFnOjVkNDg3NDY3NDZiZDQ1ZWVhZTczY2JkYjNjZTc2MDdhL3RhYmxlOjQ2M2E4NDQ0NmMzOTQ0OWViMTI4Y2VkMzE5MjJmZjYxL3RhYmxlcmFuZ2U6NDYzYTg0NDQ2YzM5NDQ5ZWIxMjhjZWQzMTkyMmZmNjFfMTQtNS0xLTEtMA_55cb00d2-457b-40f3-98c2-9b5b3e5fb84a"
      unitRef="usd">2900000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i06052fe21e8f47d88c0c73710f1feaa6_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV83MC9mcmFnOjVkNDg3NDY3NDZiZDQ1ZWVhZTczY2JkYjNjZTc2MDdhL3RhYmxlOjQ2M2E4NDQ0NmMzOTQ0OWViMTI4Y2VkMzE5MjJmZjYxL3RhYmxlcmFuZ2U6NDYzYTg0NDQ2YzM5NDQ5ZWIxMjhjZWQzMTkyMmZmNjFfMTQtNy0xLTEtMA_ecd7742e-8715-439b-98f1-a869aa649935"
      unitRef="usd">40300000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i2c8351954d014a1c80a3d8cfc2327ab2_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV83MC9mcmFnOjVkNDg3NDY3NDZiZDQ1ZWVhZTczY2JkYjNjZTc2MDdhL3RhYmxlOjQ2M2E4NDQ0NmMzOTQ0OWViMTI4Y2VkMzE5MjJmZjYxL3RhYmxlcmFuZ2U6NDYzYTg0NDQ2YzM5NDQ5ZWIxMjhjZWQzMTkyMmZmNjFfMTQtOS0xLTEtMA_08fbf566-2fb9-43fe-a066-6c7e64f0d1f4"
      unitRef="usd">156300000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:DepreciationAndAmortization
      contextRef="i1f0d04b97823461cabfaf4b2dbfbd657_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV83MC9mcmFnOjVkNDg3NDY3NDZiZDQ1ZWVhZTczY2JkYjNjZTc2MDdhL3RhYmxlOjQ2M2E4NDQ0NmMzOTQ0OWViMTI4Y2VkMzE5MjJmZjYxL3RhYmxlcmFuZ2U6NDYzYTg0NDQ2YzM5NDQ5ZWIxMjhjZWQzMTkyMmZmNjFfMTUtMS0xLTEtMA_e9c42d7b-68f0-4109-8fb7-b74a6d708796"
      unitRef="usd">900000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="if43b4d7c93ab412a9c9070b831320d17_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV83MC9mcmFnOjVkNDg3NDY3NDZiZDQ1ZWVhZTczY2JkYjNjZTc2MDdhL3RhYmxlOjQ2M2E4NDQ0NmMzOTQ0OWViMTI4Y2VkMzE5MjJmZjYxL3RhYmxlcmFuZ2U6NDYzYTg0NDQ2YzM5NDQ5ZWIxMjhjZWQzMTkyMmZmNjFfMTUtMy0xLTEtMA_045d5624-281d-492e-84d5-094ba634e11c"
      unitRef="usd">500000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="i15797e02165b455389b33741463c1ecd_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV83MC9mcmFnOjVkNDg3NDY3NDZiZDQ1ZWVhZTczY2JkYjNjZTc2MDdhL3RhYmxlOjQ2M2E4NDQ0NmMzOTQ0OWViMTI4Y2VkMzE5MjJmZjYxL3RhYmxlcmFuZ2U6NDYzYTg0NDQ2YzM5NDQ5ZWIxMjhjZWQzMTkyMmZmNjFfMTUtNS0xLTEtMA_ec9e862c-7904-4ca2-af42-b846c85f54fa"
      unitRef="usd">100000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="i06052fe21e8f47d88c0c73710f1feaa6_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV83MC9mcmFnOjVkNDg3NDY3NDZiZDQ1ZWVhZTczY2JkYjNjZTc2MDdhL3RhYmxlOjQ2M2E4NDQ0NmMzOTQ0OWViMTI4Y2VkMzE5MjJmZjYxL3RhYmxlcmFuZ2U6NDYzYTg0NDQ2YzM5NDQ5ZWIxMjhjZWQzMTkyMmZmNjFfMTUtNy0xLTEtMA_a9b3d18c-7670-4092-b5df-31ec40fa3401"
      unitRef="usd">4800000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="i2c8351954d014a1c80a3d8cfc2327ab2_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV83MC9mcmFnOjVkNDg3NDY3NDZiZDQ1ZWVhZTczY2JkYjNjZTc2MDdhL3RhYmxlOjQ2M2E4NDQ0NmMzOTQ0OWViMTI4Y2VkMzE5MjJmZjYxL3RhYmxlcmFuZ2U6NDYzYTg0NDQ2YzM5NDQ5ZWIxMjhjZWQzMTkyMmZmNjFfMTUtOS0xLTEtMA_b6c8550c-8c61-4373-8585-ec04e2423f02"
      unitRef="usd">6300000</us-gaap:DepreciationAndAmortization>
    <us-gaap:CostsAndExpenses
      contextRef="i1f0d04b97823461cabfaf4b2dbfbd657_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV83MC9mcmFnOjVkNDg3NDY3NDZiZDQ1ZWVhZTczY2JkYjNjZTc2MDdhL3RhYmxlOjQ2M2E4NDQ0NmMzOTQ0OWViMTI4Y2VkMzE5MjJmZjYxL3RhYmxlcmFuZ2U6NDYzYTg0NDQ2YzM5NDQ5ZWIxMjhjZWQzMTkyMmZmNjFfMTYtMS0xLTEtMA_705642ae-9253-43e4-8da6-9549525114da"
      unitRef="usd">257100000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="if43b4d7c93ab412a9c9070b831320d17_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV83MC9mcmFnOjVkNDg3NDY3NDZiZDQ1ZWVhZTczY2JkYjNjZTc2MDdhL3RhYmxlOjQ2M2E4NDQ0NmMzOTQ0OWViMTI4Y2VkMzE5MjJmZjYxL3RhYmxlcmFuZ2U6NDYzYTg0NDQ2YzM5NDQ5ZWIxMjhjZWQzMTkyMmZmNjFfMTYtMy0xLTEtMA_c12b4f63-caf4-4f96-9b85-675d3f33a335"
      unitRef="usd">138600000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i15797e02165b455389b33741463c1ecd_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV83MC9mcmFnOjVkNDg3NDY3NDZiZDQ1ZWVhZTczY2JkYjNjZTc2MDdhL3RhYmxlOjQ2M2E4NDQ0NmMzOTQ0OWViMTI4Y2VkMzE5MjJmZjYxL3RhYmxlcmFuZ2U6NDYzYTg0NDQ2YzM5NDQ5ZWIxMjhjZWQzMTkyMmZmNjFfMTYtNS0xLTEtMA_66d13002-da86-408f-8096-d038c21faa80"
      unitRef="usd">17100000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i06052fe21e8f47d88c0c73710f1feaa6_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV83MC9mcmFnOjVkNDg3NDY3NDZiZDQ1ZWVhZTczY2JkYjNjZTc2MDdhL3RhYmxlOjQ2M2E4NDQ0NmMzOTQ0OWViMTI4Y2VkMzE5MjJmZjYxL3RhYmxlcmFuZ2U6NDYzYTg0NDQ2YzM5NDQ5ZWIxMjhjZWQzMTkyMmZmNjFfMTYtNy0xLTEtMA_e0a761b0-870d-4f3e-a71a-5fef4e240bc0"
      unitRef="usd">45100000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i2c8351954d014a1c80a3d8cfc2327ab2_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV83MC9mcmFnOjVkNDg3NDY3NDZiZDQ1ZWVhZTczY2JkYjNjZTc2MDdhL3RhYmxlOjQ2M2E4NDQ0NmMzOTQ0OWViMTI4Y2VkMzE5MjJmZjYxL3RhYmxlcmFuZ2U6NDYzYTg0NDQ2YzM5NDQ5ZWIxMjhjZWQzMTkyMmZmNjFfMTYtOS0xLTEtMA_9fcfbeef-b769-4196-8357-112f4ce72dbd"
      unitRef="usd">457900000</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="i1f0d04b97823461cabfaf4b2dbfbd657_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV83MC9mcmFnOjVkNDg3NDY3NDZiZDQ1ZWVhZTczY2JkYjNjZTc2MDdhL3RhYmxlOjQ2M2E4NDQ0NmMzOTQ0OWViMTI4Y2VkMzE5MjJmZjYxL3RhYmxlcmFuZ2U6NDYzYTg0NDQ2YzM5NDQ5ZWIxMjhjZWQzMTkyMmZmNjFfMTctMS0xLTEtMA_9c2e9303-472e-4d8c-8a01-f2921098a61e"
      unitRef="usd">48200000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="if43b4d7c93ab412a9c9070b831320d17_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV83MC9mcmFnOjVkNDg3NDY3NDZiZDQ1ZWVhZTczY2JkYjNjZTc2MDdhL3RhYmxlOjQ2M2E4NDQ0NmMzOTQ0OWViMTI4Y2VkMzE5MjJmZjYxL3RhYmxlcmFuZ2U6NDYzYTg0NDQ2YzM5NDQ5ZWIxMjhjZWQzMTkyMmZmNjFfMTctMy0xLTEtMA_87f412bf-a631-4f48-a0d0-93e49aec960d"
      unitRef="usd">45700000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i15797e02165b455389b33741463c1ecd_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV83MC9mcmFnOjVkNDg3NDY3NDZiZDQ1ZWVhZTczY2JkYjNjZTc2MDdhL3RhYmxlOjQ2M2E4NDQ0NmMzOTQ0OWViMTI4Y2VkMzE5MjJmZjYxL3RhYmxlcmFuZ2U6NDYzYTg0NDQ2YzM5NDQ5ZWIxMjhjZWQzMTkyMmZmNjFfMTctNS0xLTEtMA_31b49754-6317-48ee-b075-2aa030edc82f"
      unitRef="usd">1100000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i06052fe21e8f47d88c0c73710f1feaa6_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV83MC9mcmFnOjVkNDg3NDY3NDZiZDQ1ZWVhZTczY2JkYjNjZTc2MDdhL3RhYmxlOjQ2M2E4NDQ0NmMzOTQ0OWViMTI4Y2VkMzE5MjJmZjYxL3RhYmxlcmFuZ2U6NDYzYTg0NDQ2YzM5NDQ5ZWIxMjhjZWQzMTkyMmZmNjFfMTctNy0xLTEtMA_520f6c64-ba48-47e4-a3eb-6e61b585da94"
      unitRef="usd">-45100000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i2c8351954d014a1c80a3d8cfc2327ab2_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV83MC9mcmFnOjVkNDg3NDY3NDZiZDQ1ZWVhZTczY2JkYjNjZTc2MDdhL3RhYmxlOjQ2M2E4NDQ0NmMzOTQ0OWViMTI4Y2VkMzE5MjJmZjYxL3RhYmxlcmFuZ2U6NDYzYTg0NDQ2YzM5NDQ5ZWIxMjhjZWQzMTkyMmZmNjFfMTctOS0xLTEtMA_3b708fdf-3929-4fa3-a30e-5c53d81cd040"
      unitRef="usd">49900000</us-gaap:OperatingIncomeLoss>
    <us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions
      contextRef="i1e89d4343fef486490e1fcdab10c1010_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV83MC9mcmFnOjVkNDg3NDY3NDZiZDQ1ZWVhZTczY2JkYjNjZTc2MDdhL3RhYmxlOjQ2M2E4NDQ0NmMzOTQ0OWViMTI4Y2VkMzE5MjJmZjYxL3RhYmxlcmFuZ2U6NDYzYTg0NDQ2YzM5NDQ5ZWIxMjhjZWQzMTkyMmZmNjFfMjItMS0xLTEtNjk2_4c117c0c-aa67-41bd-85b3-7e3c7558f6f3"
      unitRef="usd">677900000</us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions>
    <us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions
      contextRef="i741b04b8cd704e398b27520bf8aea7fc_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV83MC9mcmFnOjVkNDg3NDY3NDZiZDQ1ZWVhZTczY2JkYjNjZTc2MDdhL3RhYmxlOjQ2M2E4NDQ0NmMzOTQ0OWViMTI4Y2VkMzE5MjJmZjYxL3RhYmxlcmFuZ2U6NDYzYTg0NDQ2YzM5NDQ5ZWIxMjhjZWQzMTkyMmZmNjFfMjItMy0xLTEtNjk2_5f3d0dad-08b8-4136-a2ae-89382cd51462"
      unitRef="usd">389400000</us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions>
    <us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions
      contextRef="ia22ad972b1ec472b9114385ace42cd42_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV83MC9mcmFnOjVkNDg3NDY3NDZiZDQ1ZWVhZTczY2JkYjNjZTc2MDdhL3RhYmxlOjQ2M2E4NDQ0NmMzOTQ0OWViMTI4Y2VkMzE5MjJmZjYxL3RhYmxlcmFuZ2U6NDYzYTg0NDQ2YzM5NDQ5ZWIxMjhjZWQzMTkyMmZmNjFfMjItNS0xLTEtNjk2_c783355a-c643-43a1-9302-40c9de116f37"
      unitRef="usd">34000000.0</us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions>
    <us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions
      contextRef="i91156243b7cb4900b72f0b116d3781c2_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV83MC9mcmFnOjVkNDg3NDY3NDZiZDQ1ZWVhZTczY2JkYjNjZTc2MDdhL3RhYmxlOjQ2M2E4NDQ0NmMzOTQ0OWViMTI4Y2VkMzE5MjJmZjYxL3RhYmxlcmFuZ2U6NDYzYTg0NDQ2YzM5NDQ5ZWIxMjhjZWQzMTkyMmZmNjFfMjItNy0xLTEtNjk2_22d7ec9d-598d-436b-8150-60466355eacc"
      unitRef="usd">0</us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions>
    <us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions
      contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV83MC9mcmFnOjVkNDg3NDY3NDZiZDQ1ZWVhZTczY2JkYjNjZTc2MDdhL3RhYmxlOjQ2M2E4NDQ0NmMzOTQ0OWViMTI4Y2VkMzE5MjJmZjYxL3RhYmxlcmFuZ2U6NDYzYTg0NDQ2YzM5NDQ5ZWIxMjhjZWQzMTkyMmZmNjFfMjItOS0xLTEtNjk2_01fc91cd-7f1d-46fe-a72b-6a13ced29696"
      unitRef="usd">1101300000</us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions>
    <us-gaap:OtherOperatingIncome
      contextRef="i1e89d4343fef486490e1fcdab10c1010_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV83MC9mcmFnOjVkNDg3NDY3NDZiZDQ1ZWVhZTczY2JkYjNjZTc2MDdhL3RhYmxlOjQ2M2E4NDQ0NmMzOTQ0OWViMTI4Y2VkMzE5MjJmZjYxL3RhYmxlcmFuZ2U6NDYzYTg0NDQ2YzM5NDQ5ZWIxMjhjZWQzMTkyMmZmNjFfMjMtMS0xLTEtNjk2_19608c4a-2954-4892-ab56-38b28492e9e0"
      unitRef="usd">7300000</us-gaap:OtherOperatingIncome>
    <us-gaap:OtherOperatingIncome
      contextRef="i741b04b8cd704e398b27520bf8aea7fc_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV83MC9mcmFnOjVkNDg3NDY3NDZiZDQ1ZWVhZTczY2JkYjNjZTc2MDdhL3RhYmxlOjQ2M2E4NDQ0NmMzOTQ0OWViMTI4Y2VkMzE5MjJmZjYxL3RhYmxlcmFuZ2U6NDYzYTg0NDQ2YzM5NDQ5ZWIxMjhjZWQzMTkyMmZmNjFfMjMtMy0xLTEtNjk2_12766b44-f755-4360-94cd-df89977ecac7"
      unitRef="usd">6000000.0</us-gaap:OtherOperatingIncome>
    <us-gaap:OtherOperatingIncome
      contextRef="ia22ad972b1ec472b9114385ace42cd42_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV83MC9mcmFnOjVkNDg3NDY3NDZiZDQ1ZWVhZTczY2JkYjNjZTc2MDdhL3RhYmxlOjQ2M2E4NDQ0NmMzOTQ0OWViMTI4Y2VkMzE5MjJmZjYxL3RhYmxlcmFuZ2U6NDYzYTg0NDQ2YzM5NDQ5ZWIxMjhjZWQzMTkyMmZmNjFfMjMtNS0xLTEtNjk2_90c2ad79-8dd3-480c-bd9a-116657303ad5"
      unitRef="usd">0</us-gaap:OtherOperatingIncome>
    <us-gaap:OtherOperatingIncome
      contextRef="i91156243b7cb4900b72f0b116d3781c2_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV83MC9mcmFnOjVkNDg3NDY3NDZiZDQ1ZWVhZTczY2JkYjNjZTc2MDdhL3RhYmxlOjQ2M2E4NDQ0NmMzOTQ0OWViMTI4Y2VkMzE5MjJmZjYxL3RhYmxlcmFuZ2U6NDYzYTg0NDQ2YzM5NDQ5ZWIxMjhjZWQzMTkyMmZmNjFfMjMtNy0xLTEtNjk2_8f01025e-e4c6-42c0-bf46-7a709e26b9ac"
      unitRef="usd">0</us-gaap:OtherOperatingIncome>
    <us-gaap:OtherOperatingIncome
      contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV83MC9mcmFnOjVkNDg3NDY3NDZiZDQ1ZWVhZTczY2JkYjNjZTc2MDdhL3RhYmxlOjQ2M2E4NDQ0NmMzOTQ0OWViMTI4Y2VkMzE5MjJmZjYxL3RhYmxlcmFuZ2U6NDYzYTg0NDQ2YzM5NDQ5ZWIxMjhjZWQzMTkyMmZmNjFfMjMtOS0xLTEtNjk2_5ff97499-745d-4cd0-a7a0-e03e2b0aed5f"
      unitRef="usd">13300000</us-gaap:OtherOperatingIncome>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i1e89d4343fef486490e1fcdab10c1010_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV83MC9mcmFnOjVkNDg3NDY3NDZiZDQ1ZWVhZTczY2JkYjNjZTc2MDdhL3RhYmxlOjQ2M2E4NDQ0NmMzOTQ0OWViMTI4Y2VkMzE5MjJmZjYxL3RhYmxlcmFuZ2U6NDYzYTg0NDQ2YzM5NDQ5ZWIxMjhjZWQzMTkyMmZmNjFfMjQtMS0xLTEtNjk2_149167fb-38ff-4ec0-a00a-04ad5200c317"
      unitRef="usd">373400000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i741b04b8cd704e398b27520bf8aea7fc_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV83MC9mcmFnOjVkNDg3NDY3NDZiZDQ1ZWVhZTczY2JkYjNjZTc2MDdhL3RhYmxlOjQ2M2E4NDQ0NmMzOTQ0OWViMTI4Y2VkMzE5MjJmZjYxL3RhYmxlcmFuZ2U6NDYzYTg0NDQ2YzM5NDQ5ZWIxMjhjZWQzMTkyMmZmNjFfMjQtMy0xLTEtNjk2_b448160f-904f-4891-884c-7610cb1f29c2"
      unitRef="usd">206800000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="ia22ad972b1ec472b9114385ace42cd42_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV83MC9mcmFnOjVkNDg3NDY3NDZiZDQ1ZWVhZTczY2JkYjNjZTc2MDdhL3RhYmxlOjQ2M2E4NDQ0NmMzOTQ0OWViMTI4Y2VkMzE5MjJmZjYxL3RhYmxlcmFuZ2U6NDYzYTg0NDQ2YzM5NDQ5ZWIxMjhjZWQzMTkyMmZmNjFfMjQtNS0xLTEtNjk2_e7f01e1e-e367-4da8-b4a9-d0c28d183f4f"
      unitRef="usd">25700000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i91156243b7cb4900b72f0b116d3781c2_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV83MC9mcmFnOjVkNDg3NDY3NDZiZDQ1ZWVhZTczY2JkYjNjZTc2MDdhL3RhYmxlOjQ2M2E4NDQ0NmMzOTQ0OWViMTI4Y2VkMzE5MjJmZjYxL3RhYmxlcmFuZ2U6NDYzYTg0NDQ2YzM5NDQ5ZWIxMjhjZWQzMTkyMmZmNjFfMjQtNy0xLTEtNjk2_fd5c5ab9-b162-4cab-aaf9-4c172c8975ba"
      unitRef="usd">0</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV83MC9mcmFnOjVkNDg3NDY3NDZiZDQ1ZWVhZTczY2JkYjNjZTc2MDdhL3RhYmxlOjQ2M2E4NDQ0NmMzOTQ0OWViMTI4Y2VkMzE5MjJmZjYxL3RhYmxlcmFuZ2U6NDYzYTg0NDQ2YzM5NDQ5ZWIxMjhjZWQzMTkyMmZmNjFfMjQtOS0xLTEtNjk2_84e60f78-3b41-42e7-8dfb-1702388d3b13"
      unitRef="usd">605900000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i1e89d4343fef486490e1fcdab10c1010_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV83MC9mcmFnOjVkNDg3NDY3NDZiZDQ1ZWVhZTczY2JkYjNjZTc2MDdhL3RhYmxlOjQ2M2E4NDQ0NmMzOTQ0OWViMTI4Y2VkMzE5MjJmZjYxL3RhYmxlcmFuZ2U6NDYzYTg0NDQ2YzM5NDQ5ZWIxMjhjZWQzMTkyMmZmNjFfMjUtMS0xLTEtNjk2_134e0990-4261-40ee-91b2-3082fb11e4ab"
      unitRef="usd">161400000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i741b04b8cd704e398b27520bf8aea7fc_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV83MC9mcmFnOjVkNDg3NDY3NDZiZDQ1ZWVhZTczY2JkYjNjZTc2MDdhL3RhYmxlOjQ2M2E4NDQ0NmMzOTQ0OWViMTI4Y2VkMzE5MjJmZjYxL3RhYmxlcmFuZ2U6NDYzYTg0NDQ2YzM5NDQ5ZWIxMjhjZWQzMTkyMmZmNjFfMjUtMy0xLTEtNjk2_c1b6e703-0f33-4977-a58f-dd59ad65cba6"
      unitRef="usd">94900000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="ia22ad972b1ec472b9114385ace42cd42_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV83MC9mcmFnOjVkNDg3NDY3NDZiZDQ1ZWVhZTczY2JkYjNjZTc2MDdhL3RhYmxlOjQ2M2E4NDQ0NmMzOTQ0OWViMTI4Y2VkMzE5MjJmZjYxL3RhYmxlcmFuZ2U6NDYzYTg0NDQ2YzM5NDQ5ZWIxMjhjZWQzMTkyMmZmNjFfMjUtNS0xLTEtNjk2_18e3adea-ca1e-4b36-94f1-8439d5e6909f"
      unitRef="usd">6200000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i91156243b7cb4900b72f0b116d3781c2_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV83MC9mcmFnOjVkNDg3NDY3NDZiZDQ1ZWVhZTczY2JkYjNjZTc2MDdhL3RhYmxlOjQ2M2E4NDQ0NmMzOTQ0OWViMTI4Y2VkMzE5MjJmZjYxL3RhYmxlcmFuZ2U6NDYzYTg0NDQ2YzM5NDQ5ZWIxMjhjZWQzMTkyMmZmNjFfMjUtNy0xLTEtNjk2_1c18ae92-b669-44f1-8456-6d84e8856bdf"
      unitRef="usd">84900000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV83MC9mcmFnOjVkNDg3NDY3NDZiZDQ1ZWVhZTczY2JkYjNjZTc2MDdhL3RhYmxlOjQ2M2E4NDQ0NmMzOTQ0OWViMTI4Y2VkMzE5MjJmZjYxL3RhYmxlcmFuZ2U6NDYzYTg0NDQ2YzM5NDQ5ZWIxMjhjZWQzMTkyMmZmNjFfMjUtOS0xLTEtNjk2_b4b3dac7-dc34-4701-91db-d9551f89bc25"
      unitRef="usd">347400000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:DepreciationAndAmortization
      contextRef="i1e89d4343fef486490e1fcdab10c1010_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV83MC9mcmFnOjVkNDg3NDY3NDZiZDQ1ZWVhZTczY2JkYjNjZTc2MDdhL3RhYmxlOjQ2M2E4NDQ0NmMzOTQ0OWViMTI4Y2VkMzE5MjJmZjYxL3RhYmxlcmFuZ2U6NDYzYTg0NDQ2YzM5NDQ5ZWIxMjhjZWQzMTkyMmZmNjFfMjYtMS0xLTEtNjk2_0a72ea1f-71a4-4db0-a52c-b25afb0897bb"
      unitRef="usd">2200000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="i741b04b8cd704e398b27520bf8aea7fc_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV83MC9mcmFnOjVkNDg3NDY3NDZiZDQ1ZWVhZTczY2JkYjNjZTc2MDdhL3RhYmxlOjQ2M2E4NDQ0NmMzOTQ0OWViMTI4Y2VkMzE5MjJmZjYxL3RhYmxlcmFuZ2U6NDYzYTg0NDQ2YzM5NDQ5ZWIxMjhjZWQzMTkyMmZmNjFfMjYtMy0xLTEtNjk2_95f8e699-3425-4c2d-8cc5-9cd5645a09c6"
      unitRef="usd">1300000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="ia22ad972b1ec472b9114385ace42cd42_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV83MC9mcmFnOjVkNDg3NDY3NDZiZDQ1ZWVhZTczY2JkYjNjZTc2MDdhL3RhYmxlOjQ2M2E4NDQ0NmMzOTQ0OWViMTI4Y2VkMzE5MjJmZjYxL3RhYmxlcmFuZ2U6NDYzYTg0NDQ2YzM5NDQ5ZWIxMjhjZWQzMTkyMmZmNjFfMjYtNS0xLTEtNjk2_4b31a23d-7b0a-433a-86ac-39c2e9450ec1"
      unitRef="usd">100000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="i91156243b7cb4900b72f0b116d3781c2_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV83MC9mcmFnOjVkNDg3NDY3NDZiZDQ1ZWVhZTczY2JkYjNjZTc2MDdhL3RhYmxlOjQ2M2E4NDQ0NmMzOTQ0OWViMTI4Y2VkMzE5MjJmZjYxL3RhYmxlcmFuZ2U6NDYzYTg0NDQ2YzM5NDQ5ZWIxMjhjZWQzMTkyMmZmNjFfMjYtNy0xLTEtNjk2_595d715a-e08c-4bbb-9c31-591c82e02e2e"
      unitRef="usd">10700000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV83MC9mcmFnOjVkNDg3NDY3NDZiZDQ1ZWVhZTczY2JkYjNjZTc2MDdhL3RhYmxlOjQ2M2E4NDQ0NmMzOTQ0OWViMTI4Y2VkMzE5MjJmZjYxL3RhYmxlcmFuZ2U6NDYzYTg0NDQ2YzM5NDQ5ZWIxMjhjZWQzMTkyMmZmNjFfMjYtOS0xLTEtNjk2_4fc595f9-96ed-40c8-9254-41a20a6dbb22"
      unitRef="usd">14300000</us-gaap:DepreciationAndAmortization>
    <us-gaap:CostsAndExpenses
      contextRef="i1e89d4343fef486490e1fcdab10c1010_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV83MC9mcmFnOjVkNDg3NDY3NDZiZDQ1ZWVhZTczY2JkYjNjZTc2MDdhL3RhYmxlOjQ2M2E4NDQ0NmMzOTQ0OWViMTI4Y2VkMzE5MjJmZjYxL3RhYmxlcmFuZ2U6NDYzYTg0NDQ2YzM5NDQ5ZWIxMjhjZWQzMTkyMmZmNjFfMjctMS0xLTEtNjk2_3274a1e3-d34a-4952-87a4-0dd42126e416"
      unitRef="usd">537000000.0</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i741b04b8cd704e398b27520bf8aea7fc_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV83MC9mcmFnOjVkNDg3NDY3NDZiZDQ1ZWVhZTczY2JkYjNjZTc2MDdhL3RhYmxlOjQ2M2E4NDQ0NmMzOTQ0OWViMTI4Y2VkMzE5MjJmZjYxL3RhYmxlcmFuZ2U6NDYzYTg0NDQ2YzM5NDQ5ZWIxMjhjZWQzMTkyMmZmNjFfMjctMy0xLTEtNjk2_6c7d5255-1e10-4321-9064-ca54f24cdc24"
      unitRef="usd">303000000.0</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="ia22ad972b1ec472b9114385ace42cd42_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV83MC9mcmFnOjVkNDg3NDY3NDZiZDQ1ZWVhZTczY2JkYjNjZTc2MDdhL3RhYmxlOjQ2M2E4NDQ0NmMzOTQ0OWViMTI4Y2VkMzE5MjJmZjYxL3RhYmxlcmFuZ2U6NDYzYTg0NDQ2YzM5NDQ5ZWIxMjhjZWQzMTkyMmZmNjFfMjctNS0xLTEtNjk2_5139b8aa-9f43-4989-85d2-e85f289e6b72"
      unitRef="usd">32000000.0</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i91156243b7cb4900b72f0b116d3781c2_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV83MC9mcmFnOjVkNDg3NDY3NDZiZDQ1ZWVhZTczY2JkYjNjZTc2MDdhL3RhYmxlOjQ2M2E4NDQ0NmMzOTQ0OWViMTI4Y2VkMzE5MjJmZjYxL3RhYmxlcmFuZ2U6NDYzYTg0NDQ2YzM5NDQ5ZWIxMjhjZWQzMTkyMmZmNjFfMjctNy0xLTEtNjk2_e0a3f566-60f5-4d35-a8a7-91a0111f0f89"
      unitRef="usd">95600000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV83MC9mcmFnOjVkNDg3NDY3NDZiZDQ1ZWVhZTczY2JkYjNjZTc2MDdhL3RhYmxlOjQ2M2E4NDQ0NmMzOTQ0OWViMTI4Y2VkMzE5MjJmZjYxL3RhYmxlcmFuZ2U6NDYzYTg0NDQ2YzM5NDQ5ZWIxMjhjZWQzMTkyMmZmNjFfMjctOS0xLTEtNjk2_d8834325-8596-4874-a896-e79c024cbced"
      unitRef="usd">967600000</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="i1e89d4343fef486490e1fcdab10c1010_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV83MC9mcmFnOjVkNDg3NDY3NDZiZDQ1ZWVhZTczY2JkYjNjZTc2MDdhL3RhYmxlOjQ2M2E4NDQ0NmMzOTQ0OWViMTI4Y2VkMzE5MjJmZjYxL3RhYmxlcmFuZ2U6NDYzYTg0NDQ2YzM5NDQ5ZWIxMjhjZWQzMTkyMmZmNjFfMjgtMS0xLTEtNjk2_372cd4e6-eede-481d-a2f4-608bcfe256ee"
      unitRef="usd">148200000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i741b04b8cd704e398b27520bf8aea7fc_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV83MC9mcmFnOjVkNDg3NDY3NDZiZDQ1ZWVhZTczY2JkYjNjZTc2MDdhL3RhYmxlOjQ2M2E4NDQ0NmMzOTQ0OWViMTI4Y2VkMzE5MjJmZjYxL3RhYmxlcmFuZ2U6NDYzYTg0NDQ2YzM5NDQ5ZWIxMjhjZWQzMTkyMmZmNjFfMjgtMy0xLTEtNjk2_8ca2877c-a071-432a-9e26-ee73fd195f0a"
      unitRef="usd">92400000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ia22ad972b1ec472b9114385ace42cd42_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV83MC9mcmFnOjVkNDg3NDY3NDZiZDQ1ZWVhZTczY2JkYjNjZTc2MDdhL3RhYmxlOjQ2M2E4NDQ0NmMzOTQ0OWViMTI4Y2VkMzE5MjJmZjYxL3RhYmxlcmFuZ2U6NDYzYTg0NDQ2YzM5NDQ5ZWIxMjhjZWQzMTkyMmZmNjFfMjgtNS0xLTEtNjk2_976d9ff1-f11a-41f9-98e7-3d75e3af132f"
      unitRef="usd">2000000.0</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i91156243b7cb4900b72f0b116d3781c2_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV83MC9mcmFnOjVkNDg3NDY3NDZiZDQ1ZWVhZTczY2JkYjNjZTc2MDdhL3RhYmxlOjQ2M2E4NDQ0NmMzOTQ0OWViMTI4Y2VkMzE5MjJmZjYxL3RhYmxlcmFuZ2U6NDYzYTg0NDQ2YzM5NDQ5ZWIxMjhjZWQzMTkyMmZmNjFfMjgtNy0xLTEtNjk2_082e5bc3-0717-4eab-aaaa-d1bf212dae46"
      unitRef="usd">-95600000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV83MC9mcmFnOjVkNDg3NDY3NDZiZDQ1ZWVhZTczY2JkYjNjZTc2MDdhL3RhYmxlOjQ2M2E4NDQ0NmMzOTQ0OWViMTI4Y2VkMzE5MjJmZjYxL3RhYmxlcmFuZ2U6NDYzYTg0NDQ2YzM5NDQ5ZWIxMjhjZWQzMTkyMmZmNjFfMjgtOS0xLTEtNjk2_4f329f65-40eb-4fdf-8f9f-2ffda486cf35"
      unitRef="usd">147000000.0</us-gaap:OperatingIncomeLoss>
    <us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions
      contextRef="i15c3520755c5444cb900d57537639c6c_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV83MC9mcmFnOjVkNDg3NDY3NDZiZDQ1ZWVhZTczY2JkYjNjZTc2MDdhL3RhYmxlOjQ2M2E4NDQ0NmMzOTQ0OWViMTI4Y2VkMzE5MjJmZjYxL3RhYmxlcmFuZ2U6NDYzYTg0NDQ2YzM5NDQ5ZWIxMjhjZWQzMTkyMmZmNjFfMzItMS0xLTEtNzAw_cda28d3e-da5a-45ee-bbb9-25e4488baa5f"
      unitRef="usd">593800000</us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions>
    <us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions
      contextRef="i6ce911e452594105bd0677b242a6a2d3_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV83MC9mcmFnOjVkNDg3NDY3NDZiZDQ1ZWVhZTczY2JkYjNjZTc2MDdhL3RhYmxlOjQ2M2E4NDQ0NmMzOTQ0OWViMTI4Y2VkMzE5MjJmZjYxL3RhYmxlcmFuZ2U6NDYzYTg0NDQ2YzM5NDQ5ZWIxMjhjZWQzMTkyMmZmNjFfMzItMy0xLTEtNzAw_b095b032-8c59-4d07-a824-9f0d6a8f4b77"
      unitRef="usd">346500000</us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions>
    <us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions
      contextRef="i5e461372b93847a4b7c9e1e3e9206b30_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV83MC9mcmFnOjVkNDg3NDY3NDZiZDQ1ZWVhZTczY2JkYjNjZTc2MDdhL3RhYmxlOjQ2M2E4NDQ0NmMzOTQ0OWViMTI4Y2VkMzE5MjJmZjYxL3RhYmxlcmFuZ2U6NDYzYTg0NDQ2YzM5NDQ5ZWIxMjhjZWQzMTkyMmZmNjFfMzItNS0xLTEtNzAw_20fe4431-9fe4-4087-bc9d-f3699d2ddb9f"
      unitRef="usd">36400000</us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions>
    <us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions
      contextRef="i2f63d6ecb3ef4b2f9a0e98f946e6f46e_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV83MC9mcmFnOjVkNDg3NDY3NDZiZDQ1ZWVhZTczY2JkYjNjZTc2MDdhL3RhYmxlOjQ2M2E4NDQ0NmMzOTQ0OWViMTI4Y2VkMzE5MjJmZjYxL3RhYmxlcmFuZ2U6NDYzYTg0NDQ2YzM5NDQ5ZWIxMjhjZWQzMTkyMmZmNjFfMzItNy0xLTEtNzAw_442dc424-e748-4b80-9016-8dd9297b58be"
      unitRef="usd">0</us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions>
    <us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions
      contextRef="i667fa0996400408f9cb2d7f4d3ee2087_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV83MC9mcmFnOjVkNDg3NDY3NDZiZDQ1ZWVhZTczY2JkYjNjZTc2MDdhL3RhYmxlOjQ2M2E4NDQ0NmMzOTQ0OWViMTI4Y2VkMzE5MjJmZjYxL3RhYmxlcmFuZ2U6NDYzYTg0NDQ2YzM5NDQ5ZWIxMjhjZWQzMTkyMmZmNjFfMzItOS0xLTEtNzAw_5b948767-efb6-4bc8-a17c-db5776d7f86d"
      unitRef="usd">976700000</us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions>
    <us-gaap:OtherOperatingIncome
      contextRef="i15c3520755c5444cb900d57537639c6c_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV83MC9mcmFnOjVkNDg3NDY3NDZiZDQ1ZWVhZTczY2JkYjNjZTc2MDdhL3RhYmxlOjQ2M2E4NDQ0NmMzOTQ0OWViMTI4Y2VkMzE5MjJmZjYxL3RhYmxlcmFuZ2U6NDYzYTg0NDQ2YzM5NDQ5ZWIxMjhjZWQzMTkyMmZmNjFfMzMtMS0xLTEtNzAw_bc3dd621-c9b5-4e94-8ab0-332e9b8c600e"
      unitRef="usd">15100000</us-gaap:OtherOperatingIncome>
    <us-gaap:OtherOperatingIncome
      contextRef="i6ce911e452594105bd0677b242a6a2d3_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV83MC9mcmFnOjVkNDg3NDY3NDZiZDQ1ZWVhZTczY2JkYjNjZTc2MDdhL3RhYmxlOjQ2M2E4NDQ0NmMzOTQ0OWViMTI4Y2VkMzE5MjJmZjYxL3RhYmxlcmFuZ2U6NDYzYTg0NDQ2YzM5NDQ5ZWIxMjhjZWQzMTkyMmZmNjFfMzMtMy0xLTEtNzAw_75657600-e039-405c-8674-e6ef2270c5a8"
      unitRef="usd">7200000</us-gaap:OtherOperatingIncome>
    <us-gaap:OtherOperatingIncome
      contextRef="i5e461372b93847a4b7c9e1e3e9206b30_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV83MC9mcmFnOjVkNDg3NDY3NDZiZDQ1ZWVhZTczY2JkYjNjZTc2MDdhL3RhYmxlOjQ2M2E4NDQ0NmMzOTQ0OWViMTI4Y2VkMzE5MjJmZjYxL3RhYmxlcmFuZ2U6NDYzYTg0NDQ2YzM5NDQ5ZWIxMjhjZWQzMTkyMmZmNjFfMzMtNS0xLTEtNzAw_65803e74-4ab4-4e8d-b0d5-6ffa378c11d4"
      unitRef="usd">500000</us-gaap:OtherOperatingIncome>
    <us-gaap:OtherOperatingIncome
      contextRef="i2f63d6ecb3ef4b2f9a0e98f946e6f46e_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV83MC9mcmFnOjVkNDg3NDY3NDZiZDQ1ZWVhZTczY2JkYjNjZTc2MDdhL3RhYmxlOjQ2M2E4NDQ0NmMzOTQ0OWViMTI4Y2VkMzE5MjJmZjYxL3RhYmxlcmFuZ2U6NDYzYTg0NDQ2YzM5NDQ5ZWIxMjhjZWQzMTkyMmZmNjFfMzMtNy0xLTEtMTI5Ng_fe5cbdee-117f-46a5-8d3e-594951211e77"
      unitRef="usd">0</us-gaap:OtherOperatingIncome>
    <us-gaap:OtherOperatingIncome
      contextRef="i667fa0996400408f9cb2d7f4d3ee2087_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV83MC9mcmFnOjVkNDg3NDY3NDZiZDQ1ZWVhZTczY2JkYjNjZTc2MDdhL3RhYmxlOjQ2M2E4NDQ0NmMzOTQ0OWViMTI4Y2VkMzE5MjJmZjYxL3RhYmxlcmFuZ2U6NDYzYTg0NDQ2YzM5NDQ5ZWIxMjhjZWQzMTkyMmZmNjFfMzMtOS0xLTEtNzAw_05023cbc-77c4-446c-ba9b-b8a84f425bb1"
      unitRef="usd">22800000</us-gaap:OtherOperatingIncome>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i15c3520755c5444cb900d57537639c6c_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV83MC9mcmFnOjVkNDg3NDY3NDZiZDQ1ZWVhZTczY2JkYjNjZTc2MDdhL3RhYmxlOjQ2M2E4NDQ0NmMzOTQ0OWViMTI4Y2VkMzE5MjJmZjYxL3RhYmxlcmFuZ2U6NDYzYTg0NDQ2YzM5NDQ5ZWIxMjhjZWQzMTkyMmZmNjFfMzQtMS0xLTEtNzAw_8fb7b402-6e84-47c3-8cc5-c9f06bbbb33d"
      unitRef="usd">363800000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i6ce911e452594105bd0677b242a6a2d3_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV83MC9mcmFnOjVkNDg3NDY3NDZiZDQ1ZWVhZTczY2JkYjNjZTc2MDdhL3RhYmxlOjQ2M2E4NDQ0NmMzOTQ0OWViMTI4Y2VkMzE5MjJmZjYxL3RhYmxlcmFuZ2U6NDYzYTg0NDQ2YzM5NDQ5ZWIxMjhjZWQzMTkyMmZmNjFfMzQtMy0xLTEtNzAw_87208839-0c8e-4a5c-b69c-06a448ac29a4"
      unitRef="usd">189000000.0</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i5e461372b93847a4b7c9e1e3e9206b30_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV83MC9mcmFnOjVkNDg3NDY3NDZiZDQ1ZWVhZTczY2JkYjNjZTc2MDdhL3RhYmxlOjQ2M2E4NDQ0NmMzOTQ0OWViMTI4Y2VkMzE5MjJmZjYxL3RhYmxlcmFuZ2U6NDYzYTg0NDQ2YzM5NDQ5ZWIxMjhjZWQzMTkyMmZmNjFfMzQtNS0xLTEtNzAw_6bcbce4a-0330-4a7e-931e-5eec6c8f7660"
      unitRef="usd">28200000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i2f63d6ecb3ef4b2f9a0e98f946e6f46e_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV83MC9mcmFnOjVkNDg3NDY3NDZiZDQ1ZWVhZTczY2JkYjNjZTc2MDdhL3RhYmxlOjQ2M2E4NDQ0NmMzOTQ0OWViMTI4Y2VkMzE5MjJmZjYxL3RhYmxlcmFuZ2U6NDYzYTg0NDQ2YzM5NDQ5ZWIxMjhjZWQzMTkyMmZmNjFfMzQtNy0xLTEtNzAw_ba2bfb2e-8365-4cac-9b2b-a44be2e61e7d"
      unitRef="usd">0</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i667fa0996400408f9cb2d7f4d3ee2087_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV83MC9mcmFnOjVkNDg3NDY3NDZiZDQ1ZWVhZTczY2JkYjNjZTc2MDdhL3RhYmxlOjQ2M2E4NDQ0NmMzOTQ0OWViMTI4Y2VkMzE5MjJmZjYxL3RhYmxlcmFuZ2U6NDYzYTg0NDQ2YzM5NDQ5ZWIxMjhjZWQzMTkyMmZmNjFfMzQtOS0xLTEtNzAw_4f2c7c41-822d-4b77-ba24-2bdf248e1e82"
      unitRef="usd">581000000.0</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i15c3520755c5444cb900d57537639c6c_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV83MC9mcmFnOjVkNDg3NDY3NDZiZDQ1ZWVhZTczY2JkYjNjZTc2MDdhL3RhYmxlOjQ2M2E4NDQ0NmMzOTQ0OWViMTI4Y2VkMzE5MjJmZjYxL3RhYmxlcmFuZ2U6NDYzYTg0NDQ2YzM5NDQ5ZWIxMjhjZWQzMTkyMmZmNjFfMzUtMS0xLTEtNzAw_057792dc-0081-4434-a36d-ebbac69956c6"
      unitRef="usd">147900000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i6ce911e452594105bd0677b242a6a2d3_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV83MC9mcmFnOjVkNDg3NDY3NDZiZDQ1ZWVhZTczY2JkYjNjZTc2MDdhL3RhYmxlOjQ2M2E4NDQ0NmMzOTQ0OWViMTI4Y2VkMzE5MjJmZjYxL3RhYmxlcmFuZ2U6NDYzYTg0NDQ2YzM5NDQ5ZWIxMjhjZWQzMTkyMmZmNjFfMzUtMy0xLTEtNzAw_8de68702-4ee1-40c6-aa03-73e6112240f8"
      unitRef="usd">79600000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i5e461372b93847a4b7c9e1e3e9206b30_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV83MC9mcmFnOjVkNDg3NDY3NDZiZDQ1ZWVhZTczY2JkYjNjZTc2MDdhL3RhYmxlOjQ2M2E4NDQ0NmMzOTQ0OWViMTI4Y2VkMzE5MjJmZjYxL3RhYmxlcmFuZ2U6NDYzYTg0NDQ2YzM5NDQ5ZWIxMjhjZWQzMTkyMmZmNjFfMzUtNS0xLTEtNzAw_bf2187c4-6386-4ced-9316-0aa75f20a281"
      unitRef="usd">6300000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i2f63d6ecb3ef4b2f9a0e98f946e6f46e_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV83MC9mcmFnOjVkNDg3NDY3NDZiZDQ1ZWVhZTczY2JkYjNjZTc2MDdhL3RhYmxlOjQ2M2E4NDQ0NmMzOTQ0OWViMTI4Y2VkMzE5MjJmZjYxL3RhYmxlcmFuZ2U6NDYzYTg0NDQ2YzM5NDQ5ZWIxMjhjZWQzMTkyMmZmNjFfMzUtNy0xLTEtNzAw_64bd9970-c1d6-4fe5-b52b-d83cea666187"
      unitRef="usd">79200000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i667fa0996400408f9cb2d7f4d3ee2087_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV83MC9mcmFnOjVkNDg3NDY3NDZiZDQ1ZWVhZTczY2JkYjNjZTc2MDdhL3RhYmxlOjQ2M2E4NDQ0NmMzOTQ0OWViMTI4Y2VkMzE5MjJmZjYxL3RhYmxlcmFuZ2U6NDYzYTg0NDQ2YzM5NDQ5ZWIxMjhjZWQzMTkyMmZmNjFfMzUtOS0xLTEtNzAw_5eb9cdee-6b55-4a9b-93c3-581a79d07a1b"
      unitRef="usd">313000000.0</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:DepreciationAndAmortization
      contextRef="i15c3520755c5444cb900d57537639c6c_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV83MC9mcmFnOjVkNDg3NDY3NDZiZDQ1ZWVhZTczY2JkYjNjZTc2MDdhL3RhYmxlOjQ2M2E4NDQ0NmMzOTQ0OWViMTI4Y2VkMzE5MjJmZjYxL3RhYmxlcmFuZ2U6NDYzYTg0NDQ2YzM5NDQ5ZWIxMjhjZWQzMTkyMmZmNjFfMzYtMS0xLTEtNzAw_9616ad43-76ac-48ed-9253-4e8678e6f498"
      unitRef="usd">1900000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="i6ce911e452594105bd0677b242a6a2d3_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV83MC9mcmFnOjVkNDg3NDY3NDZiZDQ1ZWVhZTczY2JkYjNjZTc2MDdhL3RhYmxlOjQ2M2E4NDQ0NmMzOTQ0OWViMTI4Y2VkMzE5MjJmZjYxL3RhYmxlcmFuZ2U6NDYzYTg0NDQ2YzM5NDQ5ZWIxMjhjZWQzMTkyMmZmNjFfMzYtMy0xLTEtNzAw_b7e5cdce-303e-41e6-bca4-0a4a0f69b521"
      unitRef="usd">1100000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="i5e461372b93847a4b7c9e1e3e9206b30_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV83MC9mcmFnOjVkNDg3NDY3NDZiZDQ1ZWVhZTczY2JkYjNjZTc2MDdhL3RhYmxlOjQ2M2E4NDQ0NmMzOTQ0OWViMTI4Y2VkMzE5MjJmZjYxL3RhYmxlcmFuZ2U6NDYzYTg0NDQ2YzM5NDQ5ZWIxMjhjZWQzMTkyMmZmNjFfMzYtNS0xLTEtNzAw_09c8aa96-7e1b-47dc-bfda-621288e799ca"
      unitRef="usd">100000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="i2f63d6ecb3ef4b2f9a0e98f946e6f46e_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV83MC9mcmFnOjVkNDg3NDY3NDZiZDQ1ZWVhZTczY2JkYjNjZTc2MDdhL3RhYmxlOjQ2M2E4NDQ0NmMzOTQ0OWViMTI4Y2VkMzE5MjJmZjYxL3RhYmxlcmFuZ2U6NDYzYTg0NDQ2YzM5NDQ5ZWIxMjhjZWQzMTkyMmZmNjFfMzYtNy0xLTEtNzAw_b0254f81-83c5-4b05-b85a-5c133b4c21a6"
      unitRef="usd">8600000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="i667fa0996400408f9cb2d7f4d3ee2087_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV83MC9mcmFnOjVkNDg3NDY3NDZiZDQ1ZWVhZTczY2JkYjNjZTc2MDdhL3RhYmxlOjQ2M2E4NDQ0NmMzOTQ0OWViMTI4Y2VkMzE5MjJmZjYxL3RhYmxlcmFuZ2U6NDYzYTg0NDQ2YzM5NDQ5ZWIxMjhjZWQzMTkyMmZmNjFfMzYtOS0xLTEtNzAw_9549a1d3-9018-4c90-87d6-51fd173db59c"
      unitRef="usd">11700000</us-gaap:DepreciationAndAmortization>
    <us-gaap:CostsAndExpenses
      contextRef="i15c3520755c5444cb900d57537639c6c_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV83MC9mcmFnOjVkNDg3NDY3NDZiZDQ1ZWVhZTczY2JkYjNjZTc2MDdhL3RhYmxlOjQ2M2E4NDQ0NmMzOTQ0OWViMTI4Y2VkMzE5MjJmZjYxL3RhYmxlcmFuZ2U6NDYzYTg0NDQ2YzM5NDQ5ZWIxMjhjZWQzMTkyMmZmNjFfMzctMS0xLTEtNzAw_c5f048d0-74de-400e-affa-485612fe0b64"
      unitRef="usd">513600000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i6ce911e452594105bd0677b242a6a2d3_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV83MC9mcmFnOjVkNDg3NDY3NDZiZDQ1ZWVhZTczY2JkYjNjZTc2MDdhL3RhYmxlOjQ2M2E4NDQ0NmMzOTQ0OWViMTI4Y2VkMzE5MjJmZjYxL3RhYmxlcmFuZ2U6NDYzYTg0NDQ2YzM5NDQ5ZWIxMjhjZWQzMTkyMmZmNjFfMzctMy0xLTEtNzAw_680ec770-d14b-4805-8d98-0e207a41ec1c"
      unitRef="usd">269700000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i5e461372b93847a4b7c9e1e3e9206b30_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV83MC9mcmFnOjVkNDg3NDY3NDZiZDQ1ZWVhZTczY2JkYjNjZTc2MDdhL3RhYmxlOjQ2M2E4NDQ0NmMzOTQ0OWViMTI4Y2VkMzE5MjJmZjYxL3RhYmxlcmFuZ2U6NDYzYTg0NDQ2YzM5NDQ5ZWIxMjhjZWQzMTkyMmZmNjFfMzctNS0xLTEtNzAw_eadf4455-ace5-48e4-a93a-18c0e5383214"
      unitRef="usd">34600000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i2f63d6ecb3ef4b2f9a0e98f946e6f46e_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV83MC9mcmFnOjVkNDg3NDY3NDZiZDQ1ZWVhZTczY2JkYjNjZTc2MDdhL3RhYmxlOjQ2M2E4NDQ0NmMzOTQ0OWViMTI4Y2VkMzE5MjJmZjYxL3RhYmxlcmFuZ2U6NDYzYTg0NDQ2YzM5NDQ5ZWIxMjhjZWQzMTkyMmZmNjFfMzctNy0xLTEtNzAw_4e1c1b37-e974-4df0-bb05-5efa20adf737"
      unitRef="usd">87800000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i667fa0996400408f9cb2d7f4d3ee2087_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV83MC9mcmFnOjVkNDg3NDY3NDZiZDQ1ZWVhZTczY2JkYjNjZTc2MDdhL3RhYmxlOjQ2M2E4NDQ0NmMzOTQ0OWViMTI4Y2VkMzE5MjJmZjYxL3RhYmxlcmFuZ2U6NDYzYTg0NDQ2YzM5NDQ5ZWIxMjhjZWQzMTkyMmZmNjFfMzctOS0xLTEtNzAw_c3963dce-23a1-4019-8991-4527205dfb6d"
      unitRef="usd">905700000</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="i15c3520755c5444cb900d57537639c6c_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV83MC9mcmFnOjVkNDg3NDY3NDZiZDQ1ZWVhZTczY2JkYjNjZTc2MDdhL3RhYmxlOjQ2M2E4NDQ0NmMzOTQ0OWViMTI4Y2VkMzE5MjJmZjYxL3RhYmxlcmFuZ2U6NDYzYTg0NDQ2YzM5NDQ5ZWIxMjhjZWQzMTkyMmZmNjFfMzgtMS0xLTEtNzAw_c4694c98-3186-4164-a089-2f200947fa94"
      unitRef="usd">95300000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i6ce911e452594105bd0677b242a6a2d3_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV83MC9mcmFnOjVkNDg3NDY3NDZiZDQ1ZWVhZTczY2JkYjNjZTc2MDdhL3RhYmxlOjQ2M2E4NDQ0NmMzOTQ0OWViMTI4Y2VkMzE5MjJmZjYxL3RhYmxlcmFuZ2U6NDYzYTg0NDQ2YzM5NDQ5ZWIxMjhjZWQzMTkyMmZmNjFfMzgtMy0xLTEtNzAw_95cf4d2a-cc5d-4fca-8b60-bead17fb8773"
      unitRef="usd">84000000.0</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i5e461372b93847a4b7c9e1e3e9206b30_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV83MC9mcmFnOjVkNDg3NDY3NDZiZDQ1ZWVhZTczY2JkYjNjZTc2MDdhL3RhYmxlOjQ2M2E4NDQ0NmMzOTQ0OWViMTI4Y2VkMzE5MjJmZjYxL3RhYmxlcmFuZ2U6NDYzYTg0NDQ2YzM5NDQ5ZWIxMjhjZWQzMTkyMmZmNjFfMzgtNS0xLTEtNzAw_e79c00a8-71d2-477b-b828-9faa1f426620"
      unitRef="usd">2300000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i2f63d6ecb3ef4b2f9a0e98f946e6f46e_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV83MC9mcmFnOjVkNDg3NDY3NDZiZDQ1ZWVhZTczY2JkYjNjZTc2MDdhL3RhYmxlOjQ2M2E4NDQ0NmMzOTQ0OWViMTI4Y2VkMzE5MjJmZjYxL3RhYmxlcmFuZ2U6NDYzYTg0NDQ2YzM5NDQ5ZWIxMjhjZWQzMTkyMmZmNjFfMzgtNy0xLTEtNzAw_9afcc6d3-06cb-465c-ba5a-87e5d13979ad"
      unitRef="usd">-87800000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i667fa0996400408f9cb2d7f4d3ee2087_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV83MC9mcmFnOjVkNDg3NDY3NDZiZDQ1ZWVhZTczY2JkYjNjZTc2MDdhL3RhYmxlOjQ2M2E4NDQ0NmMzOTQ0OWViMTI4Y2VkMzE5MjJmZjYxL3RhYmxlcmFuZ2U6NDYzYTg0NDQ2YzM5NDQ5ZWIxMjhjZWQzMTkyMmZmNjFfMzgtOS0xLTEtNzAw_a062857d-e3b2-4d8f-8681-85bc7f6647d7"
      unitRef="usd">93800000</us-gaap:OperatingIncomeLoss>
    <us-gaap:TreasuryStockTextBlock
      contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV83Ni9mcmFnOjNlOTQ3NmZhYTBhNjRiN2RhZjZiNmM2NTQ0NGZlMTJjL3RleHRyZWdpb246M2U5NDc2ZmFhMGE2NGI3ZGFmNmI2YzY1NDQ0ZmUxMmNfMTA2NQ_84e27448-125a-46b9-9b54-127b6349d967">SHARE REPURCHASES &lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;2021 Stock Repurchase Program&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On December 23, 2020, we announced that our Board of Directors authorized a stock repurchase program, under which we may repurchase up to $100&#160;million of our outstanding common stock through December 31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the terms of the program, we are allowed to repurchase shares from time to time through open market purchases, unsolicited or solicited privately negotiated transactions, an accelerated stock repurchase program, and/or a trading plan in compliance with Exchange Act Rule 10b5-1. The timing and the amount of the repurchases will be determined by management based on a number of factors, including but not limited to share price, trading volume and general market conditions, as well as on working capital requirements, general business conditions and other factors. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pursuant to this program, we repurchased 4,757 shares of our common stock at a weighted average price of $249.72 per share and a total cost of approximately $1&#160;million during the three-month period ended June 30, 2021 and 297,105 shares of our common stock at a weighted average price of $249.29 per share and a total cost of approximately $74&#160;million during the six-month period ended June 30, 2021. The repurchased shares are classified as treasury shares. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On August 2, 2021, our Board of Directors authorized a share repurchase program, under which we may repurchase up to $100&#160;million of our outstanding common stock through December 31, 2022, to commence upon the completion of the Company's existing $100&#160;million share repurchase program. See Note 10 - Subsequent Events for additional information on the newly authorized share repurchase program.&lt;/span&gt;&lt;/div&gt;</us-gaap:TreasuryStockTextBlock>
    <us-gaap:StockRepurchaseProgramAuthorizedAmount1
      contextRef="i479f4d0280434d3681861fd2e320cd99_I20201223"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV83Ni9mcmFnOjNlOTQ3NmZhYTBhNjRiN2RhZjZiNmM2NTQ0NGZlMTJjL3RleHRyZWdpb246M2U5NDc2ZmFhMGE2NGI3ZGFmNmI2YzY1NDQ0ZmUxMmNfMTk1_bdad7083-0251-401d-b590-f1ff3203525d"
      unitRef="usd">100000000</us-gaap:StockRepurchaseProgramAuthorizedAmount1>
    <us-gaap:StockRepurchaseProgramExpirationDate
      contextRef="i0d540c3eb0984765b002cd7535b1f472_D20201223-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV83Ni9mcmFnOjNlOTQ3NmZhYTBhNjRiN2RhZjZiNmM2NTQ0NGZlMTJjL3RleHRyZWdpb246M2U5NDc2ZmFhMGE2NGI3ZGFmNmI2YzY1NDQ0ZmUxMmNfMjM4_9788ef35-c1b8-4ece-9b3a-d6c657679bd9">2021-12-31</us-gaap:StockRepurchaseProgramExpirationDate>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="i7d058b3163364b51b7615e3e655ec631_D20210401-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV83Ni9mcmFnOjNlOTQ3NmZhYTBhNjRiN2RhZjZiNmM2NTQ0NGZlMTJjL3RleHRyZWdpb246M2U5NDc2ZmFhMGE2NGI3ZGFmNmI2YzY1NDQ0ZmUxMmNfODk2_f5fba492-f48f-4ce5-8ffa-13ae249b7867"
      unitRef="shares">4757</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockAcquiredAverageCostPerShare
      contextRef="i7d058b3163364b51b7615e3e655ec631_D20210401-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV83Ni9mcmFnOjNlOTQ3NmZhYTBhNjRiN2RhZjZiNmM2NTQ0NGZlMTJjL3RleHRyZWdpb246M2U5NDc2ZmFhMGE2NGI3ZGFmNmI2YzY1NDQ0ZmUxMmNfOTU3_4fede443-2e5c-4c91-bd89-dd66d73f2988"
      unitRef="usdPerShare">249.72</us-gaap:TreasuryStockAcquiredAverageCostPerShare>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="i7d058b3163364b51b7615e3e655ec631_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV83Ni9mcmFnOjNlOTQ3NmZhYTBhNjRiN2RhZjZiNmM2NTQ0NGZlMTJjL3RleHRyZWdpb246M2U5NDc2ZmFhMGE2NGI3ZGFmNmI2YzY1NDQ0ZmUxMmNfMTAwNA_ce7625bd-a712-4553-b1bf-55f0d4040269"
      unitRef="usd">1000000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="ie99fb62084bb4f729ac77ff7dbaed893_D20210101-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV83Ni9mcmFnOjNlOTQ3NmZhYTBhNjRiN2RhZjZiNmM2NTQ0NGZlMTJjL3RleHRyZWdpb246M2U5NDc2ZmFhMGE2NGI3ZGFmNmI2YzY1NDQ0ZmUxMmNfMTA5OTUxMTYyOTcwMA_4dbfe67f-7dd3-40e7-81cb-cdabc7d87988"
      unitRef="shares">297105</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockAcquiredAverageCostPerShare
      contextRef="ie99fb62084bb4f729ac77ff7dbaed893_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV83Ni9mcmFnOjNlOTQ3NmZhYTBhNjRiN2RhZjZiNmM2NTQ0NGZlMTJjL3RleHRyZWdpb246M2U5NDc2ZmFhMGE2NGI3ZGFmNmI2YzY1NDQ0ZmUxMmNfMTA5OTUxMTYyOTcyMg_4e58eec3-7c74-49a2-bc41-66bc97b62535"
      unitRef="usdPerShare">249.29</us-gaap:TreasuryStockAcquiredAverageCostPerShare>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="ie99fb62084bb4f729ac77ff7dbaed893_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV83Ni9mcmFnOjNlOTQ3NmZhYTBhNjRiN2RhZjZiNmM2NTQ0NGZlMTJjL3RleHRyZWdpb246M2U5NDc2ZmFhMGE2NGI3ZGFmNmI2YzY1NDQ0ZmUxMmNfMTA5OTUxMTYyOTcwOQ_39067620-4e44-4689-9070-2a5040ad665c"
      unitRef="usd">74000000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:StockRepurchaseProgramAuthorizedAmount1
      contextRef="i55192f2892ba4410b4d8043c7bd3508f_I20210802"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV83Ni9mcmFnOjNlOTQ3NmZhYTBhNjRiN2RhZjZiNmM2NTQ0NGZlMTJjL3RleHRyZWdpb246M2U5NDc2ZmFhMGE2NGI3ZGFmNmI2YzY1NDQ0ZmUxMmNfMTA5OTUxMTYzMDU0OA_5da2c867-2059-4d11-ae1e-1acb858b3a03"
      unitRef="usd">100000000</us-gaap:StockRepurchaseProgramAuthorizedAmount1>
    <us-gaap:StockRepurchaseProgramExpirationDate
      contextRef="ide446a75729e4d219d7267432d1f1fbc_D20210802-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV83Ni9mcmFnOjNlOTQ3NmZhYTBhNjRiN2RhZjZiNmM2NTQ0NGZlMTJjL3RleHRyZWdpb246M2U5NDc2ZmFhMGE2NGI3ZGFmNmI2YzY1NDQ0ZmUxMmNfMTA5OTUxMTYzMDU3Ng_e4ef915b-3bfe-483c-98f7-cad8ea9a5114">2022-12-31</us-gaap:StockRepurchaseProgramExpirationDate>
    <us-gaap:StockRepurchaseProgramAuthorizedAmount1
      contextRef="i479f4d0280434d3681861fd2e320cd99_I20201223"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV83Ni9mcmFnOjNlOTQ3NmZhYTBhNjRiN2RhZjZiNmM2NTQ0NGZlMTJjL3RleHRyZWdpb246M2U5NDc2ZmFhMGE2NGI3ZGFmNmI2YzY1NDQ0ZmUxMmNfMTA5OTUxMTYzMDU2Mg_38098039-d3d8-469d-a53e-4cbb8b50bdca"
      unitRef="usd">100000000</us-gaap:StockRepurchaseProgramAuthorizedAmount1>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock
      contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV83OS9mcmFnOmQyNWIzMmE1OTBkNDQ2MWJhMDM0MzI3NjQ3Zjk3NmJlL3RleHRyZWdpb246ZDI1YjMyYTU5MGQ0NDYxYmEwMzQzMjc2NDdmOTc2YmVfNDY4_b57917c7-3c04-4907-9709-54484fa9f771">RELATED PARTY TRANSACTIONSWe have an investment in Medalogix, a healthcare predictive data and analytics company, which is accounted for under the equity method. We incurred costs of approximately $1.3 million and $2.6&#160;million during the three and six-month periods ended June&#160;30, 2021, respectively, and approximately $0.7&#160;million and $1.1&#160;million during the three and six-month periods ended June 30, 2020, respectively, in connection with our usage of Medalogix's analytics platforms. We believe that the terms of these transactions are consistent with those negotiated at arm's length.</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction
      contextRef="iad1f6087d55542bd9518895ce038f77e_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV83OS9mcmFnOmQyNWIzMmE1OTBkNDQ2MWJhMDM0MzI3NjQ3Zjk3NmJlL3RleHRyZWdpb246ZDI1YjMyYTU5MGQ0NDYxYmEwMzQzMjc2NDdmOTc2YmVfMjMx_b59401bb-9e37-4a8c-9e41-ab345c15b98a"
      unitRef="usd">1300000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction
      contextRef="i0e79ddec592d4a9286d6d4f8fbd7eebb_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV83OS9mcmFnOmQyNWIzMmE1OTBkNDQ2MWJhMDM0MzI3NjQ3Zjk3NmJlL3RleHRyZWdpb246ZDI1YjMyYTU5MGQ0NDYxYmEwMzQzMjc2NDdmOTc2YmVfMjM4_7f418139-c3ab-49e4-ad8b-d2ab8a0847b8"
      unitRef="usd">2600000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction
      contextRef="i8fb7629dcb544e0686e55cbe211d9a9b_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV83OS9mcmFnOmQyNWIzMmE1OTBkNDQ2MWJhMDM0MzI3NjQ3Zjk3NmJlL3RleHRyZWdpb246ZDI1YjMyYTU5MGQ0NDYxYmEwMzQzMjc2NDdmOTc2YmVfMTA5OTUxMTYyODQxMw_42f6836e-f44a-42cf-bc33-331d49c972c3"
      unitRef="usd">700000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction
      contextRef="i10a4b9a4ae414719a5bbc87698268410_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV83OS9mcmFnOmQyNWIzMmE1OTBkNDQ2MWJhMDM0MzI3NjQ3Zjk3NmJlL3RleHRyZWdpb246ZDI1YjMyYTU5MGQ0NDYxYmEwMzQzMjc2NDdmOTc2YmVfMTA5OTUxMTYyODQyNw_a2c7583b-d77e-4f68-a84d-ca29cb931cc5"
      unitRef="usd">1100000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8xMTg3L2ZyYWc6ZDdkOTI4MzE0YWRmNGRkODkzOTQ1YzVhODBiMWRkMGYvdGV4dHJlZ2lvbjpkN2Q5MjgzMTRhZGY0ZGQ4OTM5NDVjNWE4MGIxZGQwZl8xMDk5NTExNjI4MTQx_1cac0880-8009-445e-8ea9-8336b53eb47a">SUBSEQUENT EVENTS&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Acquisitions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On July 1, 2021, we acquired Visiting Nurse Association ("VNA"), a home health and hospice provider with locations in Nebraska and Iowa for a purchase price of $20.1&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On July 12, 2021, we acquired the regulatory assets of a home health provider in New York for a purchase price of $1.5&#160;million. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On August 1, 2021, we acquired Contessa Health ("Contessa"), a leader in hospital-at-home and skilled nursing facility ("SNF") at-home services for a purchase price of $250.0&#160;million. With the addition of Contessa&#x2019;s risk-based model and claims analytics capabilities, we will be able to bring the essential elements of inpatient hospital and SNF care to patients&#x2019; homes, allowing us to become a risk-bearing, home-based care delivery organization, expanding well beyond traditional Home Health and Hospice. Contessa will operate as a wholly owned division of Amedisys and will be reported as a separate operating segment in our future filings.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Second Amendment to Amended and Restated Credit Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;On July 30, 2021, we entered into the Second Amendment to our Credit Agreement (as amended by the Second Amendment, the "Second Amended Credit Agreement"). The Second Amended Credit Agreement provides for a senior secured credit facility in an initial aggregate principal amount of up to $1.0&#160;billion, which includes a $550.0&#160;million Revolving Credit Facility under the Second Amended Credit Agreement, and a term loan facility with a principal amount of up to $450.0&#160;million (the "Amended Term Loan Facility" and collectively with the Revolving Credit Facility, the "Amended Credit Facility").&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Proceeds from the $450.0&#160;million Amended Term Loan Facility were used to pay off the outstanding Term Loan principal balance as of July 30, 2021, as well as to fund 100% of the Contessa acquisition. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The loans issued under the Amended Credit Facility bear interest on a per annum basis, at our election, at either: (i) the Base Rate plus the Applicable Rate or (ii) the Eurodollar Rate plus the Applicable Rate. We are also subject to a commitment fee and letter of credit fee under the terms of the Second Amended Credit Agreement, as presented in the table below.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.251%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.151%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:26.158%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.808%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.736%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.808%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.739%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Pricing Tier&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Consolidated Leverage Ratio&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Commitment Fee&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Letter of Credit Fee&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Eurodollar Rate Loans and Daily Floating LIBOR Rate Loans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Base Rate Loans&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;I&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&amp;gt; 3.00 to 1.0&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.30%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.75%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.00%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.00%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;II&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"&gt;&amp;lt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; 3.00 to 1.0 but &amp;gt; 2.00 to 1.0&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.25%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.50%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.75%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.75%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;III&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;&amp;lt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt; 2.00 to 1.0 but &amp;gt; 0.75 to 1.0&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.20%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.25%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.50%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.50%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;IV&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;&amp;lt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt; 0.75 to 1.0&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.15%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.00%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.25%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.25%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The final maturity date of the Amended Credit Facility is July 30, 2026. The Revolving Credit Facility will terminate and be due and payable as of the final maturity date. The Amended Term Loan Facility, however, is subject to quarterly amortization of principal in the amount of (i) 0.625% for the period commencing on July 30, 2021 and ending on September 30, 2023, and (ii) 1.250% for the period commencing on October 1, 2023 and ending on July 30, 2026. The remaining balance of the Amended Term Loan Facility must be paid upon the final maturity date. In addition to the scheduled amortization of the Amended Term Loan Facility, and subject to customary exceptions and reinvestment rights, we are required to prepay the Amended Term Loan Facility first and the Revolving Credit Facility second with 100% of all net cash proceeds received by any loan party or any subsidiary thereof in connection with (a) any asset sale or disposition where such loan party receives net cash proceeds in excess of $5&#160;million or (b) any debt issuance that is not permitted under the Second Amended Credit Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Share Repurchase Program&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;On August 2, 2021, our Board of Directors authorized a share repurchase program, under which we may repurchase up to $100&#160;million of our outstanding common stock through December 31, 2022, to commence upon the completion of the Company's existing $100&#160;million share repurchase program, approved by our Board of Directors on December 17, 2020 (the &#x201c;Existing Share Repurchase Program&#x201d;). Repurchases may be made under the Existing Share Repurchase Program through December 31, 2021. See Note 8 &#x2013; Share Repurchases for additional information on the Existing Share Repurchase Program.&lt;/span&gt;&lt;/div&gt;Under the terms of the program, we are allowed to repurchase shares from time to time through open market purchases, unsolicited or solicited privately negotiated transactions, an accelerated stock repurchase program, and/or a trading plan in compliance with Exchange Act Rule 10b5-1. The timing and the amount of the repurchases will be determined by management based on a number of factors, including but not limited to share price, trading volume and general market conditions, as well as on working capital requirements, general business conditions and other factors.</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="i5bf5d306b1c14ff585373333170311d3_D20210701-20210701"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8xMTg3L2ZyYWc6ZDdkOTI4MzE0YWRmNGRkODkzOTQ1YzVhODBiMWRkMGYvdGV4dHJlZ2lvbjpkN2Q5MjgzMTRhZGY0ZGQ4OTM5NDVjNWE4MGIxZGQwZl8xMDk5NTExNjI4OTEw_15d7962f-679f-48a7-a227-176c012a44c5"
      unitRef="usd">20100000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="i1f8587237be448c2bf1c2bbffa581713_D20210712-20210712"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8xMTg3L2ZyYWc6ZDdkOTI4MzE0YWRmNGRkODkzOTQ1YzVhODBiMWRkMGYvdGV4dHJlZ2lvbjpkN2Q5MjgzMTRhZGY0ZGQ4OTM5NDVjNWE4MGIxZGQwZl8xMDk5NTExNjI4OTI1_d727a606-904a-47ad-a381-3d21148969e1"
      unitRef="usd">1500000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="i3fb42087c2d743cca8d759c85d31167b_D20210801-20210801"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8xMTg3L2ZyYWc6ZDdkOTI4MzE0YWRmNGRkODkzOTQ1YzVhODBiMWRkMGYvdGV4dHJlZ2lvbjpkN2Q5MjgzMTRhZGY0ZGQ4OTM5NDVjNWE4MGIxZGQwZl8xMDk5NTExNjI4OTM5_73038d67-826f-4eb9-90ea-1ad2e10790db"
      unitRef="usd">250000000.0</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i37b72216842c4630bdb672d9901858fe_I20210730"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8xMTg3L2ZyYWc6ZDdkOTI4MzE0YWRmNGRkODkzOTQ1YzVhODBiMWRkMGYvdGV4dHJlZ2lvbjpkN2Q5MjgzMTRhZGY0ZGQ4OTM5NDVjNWE4MGIxZGQwZl8xMDk5NTExNjM1NTgy_80a01916-11b1-406b-8d1e-23b71e150f6d"
      unitRef="usd">1000000000.0</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i5f0102c209874abb900b903e54aba58e_I20210730"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8xMTg3L2ZyYWc6ZDdkOTI4MzE0YWRmNGRkODkzOTQ1YzVhODBiMWRkMGYvdGV4dHJlZ2lvbjpkN2Q5MjgzMTRhZGY0ZGQ4OTM5NDVjNWE4MGIxZGQwZl8xMDk5NTExNjM1NTk2_f35a30ee-0428-406a-85b0-2fddd97f70f2"
      unitRef="usd">550000000.0</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i23747c712c2a44b5bf6a948f7a476aab_I20210730"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8xMTg3L2ZyYWc6ZDdkOTI4MzE0YWRmNGRkODkzOTQ1YzVhODBiMWRkMGYvdGV4dHJlZ2lvbjpkN2Q5MjgzMTRhZGY0ZGQ4OTM5NDVjNWE4MGIxZGQwZl8xMDk5NTExNjM1NjEy_640b3141-5a92-44ad-a5fb-9c1b1282aedd"
      unitRef="usd">450000000.0</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i23747c712c2a44b5bf6a948f7a476aab_I20210730"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8xMTg3L2ZyYWc6ZDdkOTI4MzE0YWRmNGRkODkzOTQ1YzVhODBiMWRkMGYvdGV4dHJlZ2lvbjpkN2Q5MjgzMTRhZGY0ZGQ4OTM5NDVjNWE4MGIxZGQwZl8xMDk5NTExNjM1NjMw_36206ad3-fa61-409f-870a-c9f6bc8e162a"
      unitRef="usd">450000000.0</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:ScheduleOfLineOfCreditFacilitiesTextBlock
      contextRef="i013c83768a1e4e0b956e81903f1c8638_D20210730-20210730"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8xMTg3L2ZyYWc6ZDdkOTI4MzE0YWRmNGRkODkzOTQ1YzVhODBiMWRkMGYvdGV4dHJlZ2lvbjpkN2Q5MjgzMTRhZGY0ZGQ4OTM5NDVjNWE4MGIxZGQwZl8xMDk5NTExNjM2Mzk3_c6d58386-3066-4ac6-911e-9dffb24292a4">We are also subject to a commitment fee and letter of credit fee under the terms of the Second Amended Credit Agreement, as presented in the table below.&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.251%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.151%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:26.158%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.808%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.736%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.808%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.739%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Pricing Tier&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Consolidated Leverage Ratio&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Commitment Fee&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Letter of Credit Fee&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Eurodollar Rate Loans and Daily Floating LIBOR Rate Loans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Base Rate Loans&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;I&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&amp;gt; 3.00 to 1.0&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.30%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.75%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.00%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.00%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;II&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"&gt;&amp;lt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; 3.00 to 1.0 but &amp;gt; 2.00 to 1.0&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.25%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.50%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.75%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.75%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;III&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;&amp;lt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt; 2.00 to 1.0 but &amp;gt; 0.75 to 1.0&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.20%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.25%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.50%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.50%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;IV&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;&amp;lt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt; 0.75 to 1.0&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.15%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.00%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.25%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.25%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfLineOfCreditFacilitiesTextBlock>
    <amed:ConsolidatedLeverageRatio
      contextRef="i893fcad73cef4a18a7ab76f16e96f0ad_D20210730-20210730"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8xMTg3L2ZyYWc6ZDdkOTI4MzE0YWRmNGRkODkzOTQ1YzVhODBiMWRkMGYvdGFibGU6MmI4MzdkYjk5NDhjNDg2Zjg0YzBlZjYyYjAzZTFiOWUvdGFibGVyYW5nZToyYjgzN2RiOTk0OGM0ODZmODRjMGVmNjJiMDNlMWI5ZV8xLTEtMS0xLTM2OTQvdGV4dHJlZ2lvbjo4MjM5NDZmNTZhYjU0YmRjYWY4NGU0MzUzMGE2YmRjOF8xMDk5NTExNjI3Nzk3_16014dd5-84f9-4613-9d44-fca011d7bb63"
      unitRef="number">3.00</amed:ConsolidatedLeverageRatio>
    <us-gaap:LineOfCreditFacilityCommitmentFeePercentage
      contextRef="ifa6c63e1eca547f89b708d6f34225a17_D20210730-20210730"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8xMTg3L2ZyYWc6ZDdkOTI4MzE0YWRmNGRkODkzOTQ1YzVhODBiMWRkMGYvdGFibGU6MmI4MzdkYjk5NDhjNDg2Zjg0YzBlZjYyYjAzZTFiOWUvdGFibGVyYW5nZToyYjgzN2RiOTk0OGM0ODZmODRjMGVmNjJiMDNlMWI5ZV8xLTItMS0xLTM5OTE_d69fea0e-4005-4395-8cb9-99febf7594ac"
      unitRef="number">0.0030</us-gaap:LineOfCreditFacilityCommitmentFeePercentage>
    <amed:LetterOfCreditFee
      contextRef="ifa6c63e1eca547f89b708d6f34225a17_D20210730-20210730"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8xMTg3L2ZyYWc6ZDdkOTI4MzE0YWRmNGRkODkzOTQ1YzVhODBiMWRkMGYvdGFibGU6MmI4MzdkYjk5NDhjNDg2Zjg0YzBlZjYyYjAzZTFiOWUvdGFibGVyYW5nZToyYjgzN2RiOTk0OGM0ODZmODRjMGVmNjJiMDNlMWI5ZV8xLTMtMS0xLTM5OTE_d6ca73ff-cf82-4a0e-881d-0cf2a1e7b82c"
      unitRef="number">0.0175</amed:LetterOfCreditFee>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="ibd49c2b0ab464f6ab8d956a502559923_D20210730-20210730"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8xMTg3L2ZyYWc6ZDdkOTI4MzE0YWRmNGRkODkzOTQ1YzVhODBiMWRkMGYvdGFibGU6MmI4MzdkYjk5NDhjNDg2Zjg0YzBlZjYyYjAzZTFiOWUvdGFibGVyYW5nZToyYjgzN2RiOTk0OGM0ODZmODRjMGVmNjJiMDNlMWI5ZV8xLTQtMS0xLTM5OTE_d441d4d8-ad49-4861-9781-629797981d29"
      unitRef="number">0.0200</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i42d092eff4ad4200a0c01193347c59ba_D20210730-20210730"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8xMTg3L2ZyYWc6ZDdkOTI4MzE0YWRmNGRkODkzOTQ1YzVhODBiMWRkMGYvdGFibGU6MmI4MzdkYjk5NDhjNDg2Zjg0YzBlZjYyYjAzZTFiOWUvdGFibGVyYW5nZToyYjgzN2RiOTk0OGM0ODZmODRjMGVmNjJiMDNlMWI5ZV8xLTUtMS0xLTM5OTE_fcaa93b2-7a52-4c26-a904-12312dbfc055"
      unitRef="number">0.0100</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <amed:ConsolidatedLeverageRatio
      contextRef="i399c2067f87f4579a5bf6e8d11ed2b0e_D20210730-20210730"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8xMTg3L2ZyYWc6ZDdkOTI4MzE0YWRmNGRkODkzOTQ1YzVhODBiMWRkMGYvdGFibGU6MmI4MzdkYjk5NDhjNDg2Zjg0YzBlZjYyYjAzZTFiOWUvdGFibGVyYW5nZToyYjgzN2RiOTk0OGM0ODZmODRjMGVmNjJiMDNlMWI5ZV8yLTEtMS0xLTM2OTQvdGV4dHJlZ2lvbjpjY2FkNDllMTc2Yjc0Mzk4YTVmZTBhZWUwZjU5Y2I5NV8xMDk5NTExNjI3ODM4_069886dd-3df8-4e4f-a637-572a3f7fc5ad"
      unitRef="number">3.00</amed:ConsolidatedLeverageRatio>
    <amed:ConsolidatedLeverageRatio
      contextRef="i51a6e6e62aa24e08a1f42edef5dc3362_D20210730-20210730"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8xMTg3L2ZyYWc6ZDdkOTI4MzE0YWRmNGRkODkzOTQ1YzVhODBiMWRkMGYvdGFibGU6MmI4MzdkYjk5NDhjNDg2Zjg0YzBlZjYyYjAzZTFiOWUvdGFibGVyYW5nZToyYjgzN2RiOTk0OGM0ODZmODRjMGVmNjJiMDNlMWI5ZV8yLTEtMS0xLTM2OTQvdGV4dHJlZ2lvbjpjY2FkNDllMTc2Yjc0Mzk4YTVmZTBhZWUwZjU5Y2I5NV8xMDk5NTExNjI3ODQ2_de2a3015-eb6d-4d54-85f3-41bb9eed46bb"
      unitRef="number">2.00</amed:ConsolidatedLeverageRatio>
    <us-gaap:LineOfCreditFacilityCommitmentFeePercentage
      contextRef="i1806f555a63f4ad9be597bfa139ca430_D20210730-20210730"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8xMTg3L2ZyYWc6ZDdkOTI4MzE0YWRmNGRkODkzOTQ1YzVhODBiMWRkMGYvdGFibGU6MmI4MzdkYjk5NDhjNDg2Zjg0YzBlZjYyYjAzZTFiOWUvdGFibGVyYW5nZToyYjgzN2RiOTk0OGM0ODZmODRjMGVmNjJiMDNlMWI5ZV8yLTItMS0xLTM5OTE_4fb691d0-6f2b-4ae7-bbba-3c7c3351bdaa"
      unitRef="number">0.0025</us-gaap:LineOfCreditFacilityCommitmentFeePercentage>
    <amed:LetterOfCreditFee
      contextRef="i1806f555a63f4ad9be597bfa139ca430_D20210730-20210730"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8xMTg3L2ZyYWc6ZDdkOTI4MzE0YWRmNGRkODkzOTQ1YzVhODBiMWRkMGYvdGFibGU6MmI4MzdkYjk5NDhjNDg2Zjg0YzBlZjYyYjAzZTFiOWUvdGFibGVyYW5nZToyYjgzN2RiOTk0OGM0ODZmODRjMGVmNjJiMDNlMWI5ZV8yLTMtMS0xLTM5OTE_a1999e44-8659-4a68-8d9c-bf892cc75ae7"
      unitRef="number">0.0150</amed:LetterOfCreditFee>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="idf8a0386bfef429dac8a61b128e23424_D20210730-20210730"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8xMTg3L2ZyYWc6ZDdkOTI4MzE0YWRmNGRkODkzOTQ1YzVhODBiMWRkMGYvdGFibGU6MmI4MzdkYjk5NDhjNDg2Zjg0YzBlZjYyYjAzZTFiOWUvdGFibGVyYW5nZToyYjgzN2RiOTk0OGM0ODZmODRjMGVmNjJiMDNlMWI5ZV8yLTQtMS0xLTM5OTE_3f7a75dc-90ee-4fa1-af28-2236443121e0"
      unitRef="number">0.0175</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="ibb50673cdce34a36abc32c81bca0b9c2_D20210730-20210730"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8xMTg3L2ZyYWc6ZDdkOTI4MzE0YWRmNGRkODkzOTQ1YzVhODBiMWRkMGYvdGFibGU6MmI4MzdkYjk5NDhjNDg2Zjg0YzBlZjYyYjAzZTFiOWUvdGFibGVyYW5nZToyYjgzN2RiOTk0OGM0ODZmODRjMGVmNjJiMDNlMWI5ZV8yLTUtMS0xLTM5OTE_75ed2715-c829-479a-b364-cbe5289706a1"
      unitRef="number">0.0075</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <amed:ConsolidatedLeverageRatio
      contextRef="ica9a6dd6c4dd4b528399e24681759629_D20210730-20210730"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8xMTg3L2ZyYWc6ZDdkOTI4MzE0YWRmNGRkODkzOTQ1YzVhODBiMWRkMGYvdGFibGU6MmI4MzdkYjk5NDhjNDg2Zjg0YzBlZjYyYjAzZTFiOWUvdGFibGVyYW5nZToyYjgzN2RiOTk0OGM0ODZmODRjMGVmNjJiMDNlMWI5ZV8zLTEtMS0xLTM2OTQvdGV4dHJlZ2lvbjpiZTkxYmRlOTA1YjQ0M2NiOWUxZTk2ZDE0NDdmNzllOV8xMDk5NTExNjI3ODE2_df6bc702-8209-4968-93d1-01044e3d63a8"
      unitRef="number">2.00</amed:ConsolidatedLeverageRatio>
    <amed:ConsolidatedLeverageRatio
      contextRef="ie135590e741545eaba8f6bb70561f7be_D20210730-20210730"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8xMTg3L2ZyYWc6ZDdkOTI4MzE0YWRmNGRkODkzOTQ1YzVhODBiMWRkMGYvdGFibGU6MmI4MzdkYjk5NDhjNDg2Zjg0YzBlZjYyYjAzZTFiOWUvdGFibGVyYW5nZToyYjgzN2RiOTk0OGM0ODZmODRjMGVmNjJiMDNlMWI5ZV8zLTEtMS0xLTM2OTQvdGV4dHJlZ2lvbjpiZTkxYmRlOTA1YjQ0M2NiOWUxZTk2ZDE0NDdmNzllOV8xMDk5NTExNjI3ODIz_d9e3fba6-626b-496f-8ec9-43c7cac41d17"
      unitRef="number">0.75</amed:ConsolidatedLeverageRatio>
    <us-gaap:LineOfCreditFacilityCommitmentFeePercentage
      contextRef="i7ae8c5e5ea3f46338602af709a707586_D20210730-20210730"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8xMTg3L2ZyYWc6ZDdkOTI4MzE0YWRmNGRkODkzOTQ1YzVhODBiMWRkMGYvdGFibGU6MmI4MzdkYjk5NDhjNDg2Zjg0YzBlZjYyYjAzZTFiOWUvdGFibGVyYW5nZToyYjgzN2RiOTk0OGM0ODZmODRjMGVmNjJiMDNlMWI5ZV8zLTItMS0xLTM5OTE_27267ac3-0a93-4166-9ff3-18ca2b03e99e"
      unitRef="number">0.0020</us-gaap:LineOfCreditFacilityCommitmentFeePercentage>
    <amed:LetterOfCreditFee
      contextRef="i7ae8c5e5ea3f46338602af709a707586_D20210730-20210730"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8xMTg3L2ZyYWc6ZDdkOTI4MzE0YWRmNGRkODkzOTQ1YzVhODBiMWRkMGYvdGFibGU6MmI4MzdkYjk5NDhjNDg2Zjg0YzBlZjYyYjAzZTFiOWUvdGFibGVyYW5nZToyYjgzN2RiOTk0OGM0ODZmODRjMGVmNjJiMDNlMWI5ZV8zLTMtMS0xLTM5OTE_97d93d8c-4950-4ca8-948e-12992466965f"
      unitRef="number">0.0125</amed:LetterOfCreditFee>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i0e146a61cc484c3085aa313c3aac07b6_D20210730-20210730"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8xMTg3L2ZyYWc6ZDdkOTI4MzE0YWRmNGRkODkzOTQ1YzVhODBiMWRkMGYvdGFibGU6MmI4MzdkYjk5NDhjNDg2Zjg0YzBlZjYyYjAzZTFiOWUvdGFibGVyYW5nZToyYjgzN2RiOTk0OGM0ODZmODRjMGVmNjJiMDNlMWI5ZV8zLTQtMS0xLTM5OTE_974e9195-a61e-4869-bc16-b12b8fba2e98"
      unitRef="number">0.0150</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i379bc627f4a745e6937f7cc4a2357a7d_D20210730-20210730"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8xMTg3L2ZyYWc6ZDdkOTI4MzE0YWRmNGRkODkzOTQ1YzVhODBiMWRkMGYvdGFibGU6MmI4MzdkYjk5NDhjNDg2Zjg0YzBlZjYyYjAzZTFiOWUvdGFibGVyYW5nZToyYjgzN2RiOTk0OGM0ODZmODRjMGVmNjJiMDNlMWI5ZV8zLTUtMS0xLTM5OTE_4daba372-8eec-422c-b910-aac23aaed5b1"
      unitRef="number">0.0050</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <amed:ConsolidatedLeverageRatio
      contextRef="id407ccb903ff4b5dbcd97f48c071901c_D20210730-20210730"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8xMTg3L2ZyYWc6ZDdkOTI4MzE0YWRmNGRkODkzOTQ1YzVhODBiMWRkMGYvdGFibGU6MmI4MzdkYjk5NDhjNDg2Zjg0YzBlZjYyYjAzZTFiOWUvdGFibGVyYW5nZToyYjgzN2RiOTk0OGM0ODZmODRjMGVmNjJiMDNlMWI5ZV80LTEtMS0xLTM2OTQvdGV4dHJlZ2lvbjoxNTc3NGI1YWYzYjM0MzIzYmM0ZDE0Nzg1NzkyMjNiMV8xMDk5NTExNjI3Nzk4_ed1f1649-5ed2-4e6a-b54f-a5ae6f6d5555"
      unitRef="number">0.75</amed:ConsolidatedLeverageRatio>
    <us-gaap:LineOfCreditFacilityCommitmentFeePercentage
      contextRef="i00349d2687c14dfba218b9ee86bf33b2_D20210730-20210730"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8xMTg3L2ZyYWc6ZDdkOTI4MzE0YWRmNGRkODkzOTQ1YzVhODBiMWRkMGYvdGFibGU6MmI4MzdkYjk5NDhjNDg2Zjg0YzBlZjYyYjAzZTFiOWUvdGFibGVyYW5nZToyYjgzN2RiOTk0OGM0ODZmODRjMGVmNjJiMDNlMWI5ZV80LTItMS0xLTM5OTE_fd3dc4dd-722f-4196-953d-3837d49a6bae"
      unitRef="number">0.0015</us-gaap:LineOfCreditFacilityCommitmentFeePercentage>
    <amed:LetterOfCreditFee
      contextRef="i00349d2687c14dfba218b9ee86bf33b2_D20210730-20210730"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8xMTg3L2ZyYWc6ZDdkOTI4MzE0YWRmNGRkODkzOTQ1YzVhODBiMWRkMGYvdGFibGU6MmI4MzdkYjk5NDhjNDg2Zjg0YzBlZjYyYjAzZTFiOWUvdGFibGVyYW5nZToyYjgzN2RiOTk0OGM0ODZmODRjMGVmNjJiMDNlMWI5ZV80LTMtMS0xLTM5OTE_d6f8f23f-d84d-41a0-b9fa-f0ffa36f5e6c"
      unitRef="number">0.0100</amed:LetterOfCreditFee>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="if952ebf0ec1f4f38950c654b7e9febb8_D20210730-20210730"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8xMTg3L2ZyYWc6ZDdkOTI4MzE0YWRmNGRkODkzOTQ1YzVhODBiMWRkMGYvdGFibGU6MmI4MzdkYjk5NDhjNDg2Zjg0YzBlZjYyYjAzZTFiOWUvdGFibGVyYW5nZToyYjgzN2RiOTk0OGM0ODZmODRjMGVmNjJiMDNlMWI5ZV80LTQtMS0xLTM5OTE_2d758b54-eb10-45da-9467-d130141b280c"
      unitRef="number">0.0125</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="ia0a2cc02f30f44c481140c202f28cf4a_D20210730-20210730"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8xMTg3L2ZyYWc6ZDdkOTI4MzE0YWRmNGRkODkzOTQ1YzVhODBiMWRkMGYvdGFibGU6MmI4MzdkYjk5NDhjNDg2Zjg0YzBlZjYyYjAzZTFiOWUvdGFibGVyYW5nZToyYjgzN2RiOTk0OGM0ODZmODRjMGVmNjJiMDNlMWI5ZV80LTUtMS0xLTM5OTE_73909bb7-2d4b-4475-80a3-191925c2a0ba"
      unitRef="number">0.0025</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentMaturityDate
      contextRef="i8f97846b33b54f368697ed0323cbb2b2_D20210730-20260730"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8xMTg3L2ZyYWc6ZDdkOTI4MzE0YWRmNGRkODkzOTQ1YzVhODBiMWRkMGYvdGV4dHJlZ2lvbjpkN2Q5MjgzMTRhZGY0ZGQ4OTM5NDVjNWE4MGIxZGQwZl8xMDk5NTExNjM1Njcx_43011909-13da-4cb4-81a6-4cb30d1010b6">2026-07-30</us-gaap:DebtInstrumentMaturityDate>
    <amed:DebtInstrumentPeriodicPaymentPercentage
      contextRef="id8e4663758bd4b8c908928b7178d6c4f_D20210730-20230930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8xMTg3L2ZyYWc6ZDdkOTI4MzE0YWRmNGRkODkzOTQ1YzVhODBiMWRkMGYvdGV4dHJlZ2lvbjpkN2Q5MjgzMTRhZGY0ZGQ4OTM5NDVjNWE4MGIxZGQwZl8xMDk5NTExNjM1Njg2_39ebdb14-4503-4414-aef5-2d740b9abef7"
      unitRef="number">0.00625</amed:DebtInstrumentPeriodicPaymentPercentage>
    <amed:DebtInstrumentPeriodicPaymentPercentage
      contextRef="i04246e2f9fa44955a7bdb76cd2520b0b_D20231001-20260730"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8xMTg3L2ZyYWc6ZDdkOTI4MzE0YWRmNGRkODkzOTQ1YzVhODBiMWRkMGYvdGV4dHJlZ2lvbjpkN2Q5MjgzMTRhZGY0ZGQ4OTM5NDVjNWE4MGIxZGQwZl8xMDk5NTExNjM1Njk0_c09b5db1-1816-4996-8747-a61d5989df1d"
      unitRef="number">0.01250</amed:DebtInstrumentPeriodicPaymentPercentage>
    <amed:ProceedsReceivedFromLoanPartyOfSubsidiary
      contextRef="i704e6869254d4b25be00c91be5629417_D20210730-20210730"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8xMTg3L2ZyYWc6ZDdkOTI4MzE0YWRmNGRkODkzOTQ1YzVhODBiMWRkMGYvdGV4dHJlZ2lvbjpkN2Q5MjgzMTRhZGY0ZGQ4OTM5NDVjNWE4MGIxZGQwZl8xMDk5NTExNjM1NzAy_6dadafd4-b84b-4626-a95b-bdde904e5615"
      unitRef="usd">5000000</amed:ProceedsReceivedFromLoanPartyOfSubsidiary>
    <us-gaap:StockRepurchaseProgramAuthorizedAmount1
      contextRef="i55192f2892ba4410b4d8043c7bd3508f_I20210802"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8xMTg3L2ZyYWc6ZDdkOTI4MzE0YWRmNGRkODkzOTQ1YzVhODBiMWRkMGYvdGV4dHJlZ2lvbjpkN2Q5MjgzMTRhZGY0ZGQ4OTM5NDVjNWE4MGIxZGQwZl8xMDk5NTExNjM2NDIy_61d82b8a-869f-4043-84ed-9ea1d14aea0b"
      unitRef="usd">100000000</us-gaap:StockRepurchaseProgramAuthorizedAmount1>
    <us-gaap:StockRepurchaseProgramExpirationDate
      contextRef="ide446a75729e4d219d7267432d1f1fbc_D20210802-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8xMTg3L2ZyYWc6ZDdkOTI4MzE0YWRmNGRkODkzOTQ1YzVhODBiMWRkMGYvdGV4dHJlZ2lvbjpkN2Q5MjgzMTRhZGY0ZGQ4OTM5NDVjNWE4MGIxZGQwZl8xMDk5NTExNjM2NDM2_74b38474-00c4-4f09-9462-51557a6bb1fe">2022-12-31</us-gaap:StockRepurchaseProgramExpirationDate>
    <us-gaap:StockRepurchaseProgramAuthorizedAmount1
      contextRef="i479f4d0280434d3681861fd2e320cd99_I20201223"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8xMTg3L2ZyYWc6ZDdkOTI4MzE0YWRmNGRkODkzOTQ1YzVhODBiMWRkMGYvdGV4dHJlZ2lvbjpkN2Q5MjgzMTRhZGY0ZGQ4OTM5NDVjNWE4MGIxZGQwZl8xMDk5NTExNjM2NDU1_e808e850-b815-448d-9449-e4e129977149"
      unitRef="usd">100000000</us-gaap:StockRepurchaseProgramAuthorizedAmount1>
    <us-gaap:StockRepurchaseProgramExpirationDate
      contextRef="i0d540c3eb0984765b002cd7535b1f472_D20201223-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmNjZDljNjllY2QyYzQyZTU4OTdjZmU5YWI0ZTdlMGI1L3NlYzpjY2Q5YzY5ZWNkMmM0MmU1ODk3Y2ZlOWFiNGU3ZTBiNV8xMTg3L2ZyYWc6ZDdkOTI4MzE0YWRmNGRkODkzOTQ1YzVhODBiMWRkMGYvdGV4dHJlZ2lvbjpkN2Q5MjgzMTRhZGY0ZGQ4OTM5NDVjNWE4MGIxZGQwZl8xMDk5NTExNjM2NDY5_31f9b8de-a3c4-430f-861c-c3121aafa6f4">2021-12-31</us-gaap:StockRepurchaseProgramExpirationDate>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140006524401528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - shares<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jul. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jun. 30,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">0-24260<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">AMEDISYS INC<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">11-3131700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Street Name</a></td>
<td class="text">3854 American Way<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Suite</a></td>
<td class="text">Suite A<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City</a></td>
<td class="text">Baton Rouge<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State</a></td>
<td class="text">LA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">70816<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">225<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">292-2031<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of each class</a></td>
<td class="text">Common Stock, par value $0.001 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">AMED<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Name of each exchange on which registered</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32,631,959<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000896262<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140006524531320">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 91,646<span></span>
</td>
<td class="nump">$ 81,808<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted cash</a></td>
<td class="nump">1,000<span></span>
</td>
<td class="nump">1,549<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Patient accounts receivable</a></td>
<td class="nump">278,216<span></span>
</td>
<td class="nump">255,145<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid expenses</a></td>
<td class="nump">11,979<span></span>
</td>
<td class="nump">10,217<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
<td class="nump">8,124<span></span>
</td>
<td class="nump">13,265<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">390,965<span></span>
</td>
<td class="nump">361,984<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net of accumulated depreciation of $98,552 and $95,024</a></td>
<td class="nump">20,986<span></span>
</td>
<td class="nump">23,719<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right of use assets</a></td>
<td class="nump">95,034<span></span>
</td>
<td class="nump">93,440<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">936,772<span></span>
</td>
<td class="nump">932,685<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net of accumulated amortization of $15,842 and $22,973</a></td>
<td class="nump">66,432<span></span>
</td>
<td class="nump">74,183<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxAssetsNet', window );">Deferred income taxes</a></td>
<td class="nump">25,271<span></span>
</td>
<td class="nump">47,987<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">64,103<span></span>
</td>
<td class="nump">33,200<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">1,599,563<span></span>
</td>
<td class="nump">1,567,198<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">36,668<span></span>
</td>
<td class="nump">42,674<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Payroll and employee benefits</a></td>
<td class="nump">147,017<span></span>
</td>
<td class="nump">146,929<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">166,157<span></span>
</td>
<td class="nump">166,192<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_ProviderReliefFundAdvance', window );">Provider relief fund advance</a></td>
<td class="nump">58,328<span></span>
</td>
<td class="nump">60,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent', window );">Current portion of long-term obligations</a></td>
<td class="nump">10,160<span></span>
</td>
<td class="nump">10,496<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current portion of operating lease liabilities</a></td>
<td class="nump">30,893<span></span>
</td>
<td class="nump">30,046<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">449,223<span></span>
</td>
<td class="nump">456,337<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtAndCapitalLeaseObligations', window );">Long-term obligations, less current portion</a></td>
<td class="nump">179,415<span></span>
</td>
<td class="nump">204,511<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities, less current portion</a></td>
<td class="nump">63,152<span></span>
</td>
<td class="nump">61,987<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term obligations</a></td>
<td class="nump">31,886<span></span>
</td>
<td class="nump">33,622<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">723,676<span></span>
</td>
<td class="nump">756,457<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and Contingencies&#8212;Note 6</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract', window );"><strong>Equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValueOutstanding', window );">Preferred stock, $0.001 par value, 5,000,000 shares authorized; none issued or outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValueOutstanding', window );">Common stock, $0.001 par value, 60,000,000 shares authorized; 37,553,355 and 37,470,212 shares issued; and 32,576,829 and 32,814,278 shares outstanding</a></td>
<td class="nump">38<span></span>
</td>
<td class="nump">38<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">714,334<span></span>
</td>
<td class="nump">698,287<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValue', window );">Treasury stock, at cost 4,976,526 and 4,655,934 shares of common stock</a></td>
<td class="num">(400,110)<span></span>
</td>
<td class="num">(319,092)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Retained earnings</a></td>
<td class="nump">560,010<span></span>
</td>
<td class="nump">429,991<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Amedisys, Inc. stockholders&#8217; equity</a></td>
<td class="nump">874,272<span></span>
</td>
<td class="nump">809,224<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Noncontrolling interests</a></td>
<td class="nump">1,615<span></span>
</td>
<td class="nump">1,517<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Total equity</a></td>
<td class="nump">875,887<span></span>
</td>
<td class="nump">810,741<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and equity</a></td>
<td class="nump">$ 1,599,563<span></span>
</td>
<td class="nump">$ 1,567,198<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_ProviderReliefFundAdvance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payable related to funds received from the government related to COVID-19</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_ProviderReliefFundAdvance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121593590&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121593590&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValueOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of all classes of common stock held by shareholders. May be all or portion of the number of common shares authorized. These shares exclude common shares repurchased by the entity and held as treasury shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValueOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtAndCapitalLeaseObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt and lease obligation, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtAndCapitalLeaseObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt and lease obligation, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValueOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by shareholders, which is net of related treasury stock. May be all or a portion of the number of preferred shares authorized. These shares represent the ownership interest of the preferred shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValueOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6787-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=68074540&amp;loc=d3e5879-108316<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21914-107793<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568740-111683<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21711-107793<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568447-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23315-112656<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29,30)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140006520154520">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Property and equipment, accumulated depreciation</a></td>
<td class="nump">$ 98,552<span></span>
</td>
<td class="nump">$ 95,024<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Intangible assets, accumulated amortization</a></td>
<td class="nump">$ 15,842<span></span>
</td>
<td class="nump">$ 22,973<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (usd per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, authorized (shares)</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, issued (shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, outstanding (shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (usd per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, authorized (shares)</a></td>
<td class="nump">60,000,000<span></span>
</td>
<td class="nump">60,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, issued (shares)</a></td>
<td class="nump">37,553,355<span></span>
</td>
<td class="nump">37,470,212<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, outstanding (shares)</a></td>
<td class="nump">32,576,829<span></span>
</td>
<td class="nump">32,814,278<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockShares', window );">Treasury stock at cost (shares)</a></td>
<td class="nump">4,976,526<span></span>
</td>
<td class="nump">4,655,934<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29,30)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140006604791160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions', window );">Net service revenue</a></td>
<td class="nump">$ 564,166<span></span>
</td>
<td class="nump">$ 485,059<span></span>
</td>
<td class="nump">$ 1,101,310<span></span>
</td>
<td class="nump">$ 976,744<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherOperatingIncome', window );">Other operating income</a></td>
<td class="nump">4,603<span></span>
</td>
<td class="nump">22,780<span></span>
</td>
<td class="nump">13,304<span></span>
</td>
<td class="nump">22,780<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of service, excluding depreciation and amortization</a></td>
<td class="nump">308,691<span></span>
</td>
<td class="nump">295,228<span></span>
</td>
<td class="nump">605,894<span></span>
</td>
<td class="nump">580,965<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpenseAbstract', window );"><strong>General and administrative expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LaborAndRelatedExpense', window );">Salaries and benefits</a></td>
<td class="nump">114,335<span></span>
</td>
<td class="nump">105,617<span></span>
</td>
<td class="nump">230,160<span></span>
</td>
<td class="nump">207,183<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Non-cash compensation</a></td>
<td class="nump">6,156<span></span>
</td>
<td class="nump">6,725<span></span>
</td>
<td class="nump">13,463<span></span>
</td>
<td class="nump">12,634<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherGeneralAndAdministrativeExpense', window );">Other</a></td>
<td class="nump">54,731<span></span>
</td>
<td class="nump">44,003<span></span>
</td>
<td class="nump">103,837<span></span>
</td>
<td class="nump">93,268<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">6,721<span></span>
</td>
<td class="nump">6,334<span></span>
</td>
<td class="nump">14,276<span></span>
</td>
<td class="nump">11,672<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Operating expenses</a></td>
<td class="nump">490,634<span></span>
</td>
<td class="nump">457,907<span></span>
</td>
<td class="nump">967,630<span></span>
</td>
<td class="nump">905,722<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating income</a></td>
<td class="nump">78,135<span></span>
</td>
<td class="nump">49,932<span></span>
</td>
<td class="nump">146,984<span></span>
</td>
<td class="nump">93,802<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterestAndDividend', window );">Interest income</a></td>
<td class="nump">25<span></span>
</td>
<td class="nump">214<span></span>
</td>
<td class="nump">49<span></span>
</td>
<td class="nump">227<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(1,932)<span></span>
</td>
<td class="num">(2,752)<span></span>
</td>
<td class="num">(4,004)<span></span>
</td>
<td class="num">(5,983)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Equity in earnings from equity method investments</a></td>
<td class="nump">1,370<span></span>
</td>
<td class="nump">487<span></span>
</td>
<td class="nump">2,488<span></span>
</td>
<td class="nump">964<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnInvestments', window );">Gain (loss) on equity method investments</a></td>
<td class="nump">31,092<span></span>
</td>
<td class="num">(2,980)<span></span>
</td>
<td class="nump">31,092<span></span>
</td>
<td class="num">(2,980)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Miscellaneous, net</a></td>
<td class="nump">475<span></span>
</td>
<td class="nump">277<span></span>
</td>
<td class="nump">763<span></span>
</td>
<td class="nump">540<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income (expense), net</a></td>
<td class="nump">31,030<span></span>
</td>
<td class="num">(4,754)<span></span>
</td>
<td class="nump">30,388<span></span>
</td>
<td class="num">(7,232)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Income before income taxes</a></td>
<td class="nump">109,165<span></span>
</td>
<td class="nump">45,178<span></span>
</td>
<td class="nump">177,372<span></span>
</td>
<td class="nump">86,570<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="num">(28,546)<span></span>
</td>
<td class="num">(10,031)<span></span>
</td>
<td class="num">(46,461)<span></span>
</td>
<td class="num">(19,377)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">80,619<span></span>
</td>
<td class="nump">35,147<span></span>
</td>
<td class="nump">130,911<span></span>
</td>
<td class="nump">67,193<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net income attributable to noncontrolling interests</a></td>
<td class="num">(470)<span></span>
</td>
<td class="num">(473)<span></span>
</td>
<td class="num">(892)<span></span>
</td>
<td class="num">(717)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income attributable to Amedisys, Inc.</a></td>
<td class="nump">$ 80,149<span></span>
</td>
<td class="nump">$ 34,674<span></span>
</td>
<td class="nump">$ 130,019<span></span>
</td>
<td class="nump">$ 66,476<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAbstract', window );"><strong>Basic earnings per common share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net income attributable to Amedisys, Inc. common stockholders, basic (usd per share)</a></td>
<td class="nump">$ 2.46<span></span>
</td>
<td class="nump">$ 1.07<span></span>
</td>
<td class="nump">$ 3.98<span></span>
</td>
<td class="nump">$ 2.05<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average shares outstanding, basic (shares)</a></td>
<td class="nump">32,588<span></span>
</td>
<td class="nump">32,412<span></span>
</td>
<td class="nump">32,684<span></span>
</td>
<td class="nump">32,371<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDilutedAbstract', window );"><strong>Diluted earnings per common share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net income attributable to Amedisys, Inc. common stockholders, diluted (usd per share)</a></td>
<td class="nump">$ 2.43<span></span>
</td>
<td class="nump">$ 1.04<span></span>
</td>
<td class="nump">$ 3.93<span></span>
</td>
<td class="nump">$ 2.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average shares outstanding, diluted (shares)</a></td>
<td class="nump">32,981<span></span>
</td>
<td class="nump">33,285<span></span>
</td>
<td class="nump">33,085<span></span>
</td>
<td class="nump">33,259<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e4984-109258<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e3842-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1252-109256<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDilutedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDilutedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of realized and unrealized gain (loss) on investment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27405-111563<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(c),9(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of patient service revenue recognized, net of contractual allowances and discounts, less the provision for bad debts related to patient service revenue plus all other revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68072869&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120385591&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterestAndDividend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income and dividend income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(a),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterestAndDividend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LaborAndRelatedExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for salary, wage, profit sharing; incentive and equity-based compensation; and other employee benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(b)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LaborAndRelatedExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of general and administrative expense classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherOperatingIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount of other operating income, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherOperatingIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3000-108585<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140006520049560">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY Statement - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th"><div>Treasury Stock</div></th>
<th class="th"><div>Accumulated Other Comprehensive Income</div></th>
<th class="th"><div>Retained Earnings</div></th>
<th class="th"><div>Noncontrolling Interests</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance, Stockholders Equity at Dec. 31, 2019</a></td>
<td class="nump">$ 641,513<span></span>
</td>
<td class="nump">$ 37<span></span>
</td>
<td class="nump">$ 645,256<span></span>
</td>
<td class="num">$ (251,241)<span></span>
</td>
<td class="nump">$ 15<span></span>
</td>
<td class="nump">$ 246,383<span></span>
</td>
<td class="nump">$ 1,063<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,638,021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of stock - employee stock purchase plan</a></td>
<td class="nump">1,686<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,686<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of stock - employee stock purchase plan (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,358<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch', window );">Issuance of stock - 401(k) plan</a></td>
<td class="nump">3,057<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">3,057<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_StockIssuedDuringPeriodSharesFourZeroOneKEmployerMatch', window );">Issuance of stock - 401(k) plan (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,312<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures', window );">Issuance/(cancellation) of non-vested stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Issuance/(cancellation) of non-vested stock (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">84,884<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">2,947<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,947<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">78,723<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Non-cash compensation</a></td>
<td class="nump">12,634<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,634<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_SurrenderedShares', window );">Surrendered Shares</a></td>
<td class="num">(6,384)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6,384)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders', window );">Noncontrolling interest distribution</a></td>
<td class="num">(372)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(372)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_EquityImpactOfWriteOffOfOtherComprehensiveIncome', window );">Write-off of other comprehensive income</a></td>
<td class="num">(15)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(15)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">67,193<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">66,476<span></span>
</td>
<td class="nump">717<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance, Stockholders Equity at Jun. 30, 2020</a></td>
<td class="nump">722,259<span></span>
</td>
<td class="nump">$ 37<span></span>
</td>
<td class="nump">665,580<span></span>
</td>
<td class="num">(257,625)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">312,859<span></span>
</td>
<td class="nump">1,408<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Jun. 30, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,831,298<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance, Stockholders Equity at Mar. 31, 2020</a></td>
<td class="nump">680,144<span></span>
</td>
<td class="nump">$ 37<span></span>
</td>
<td class="nump">656,266<span></span>
</td>
<td class="num">(255,291)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">278,185<span></span>
</td>
<td class="nump">947<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Mar. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,746,554<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of stock - employee stock purchase plan</a></td>
<td class="nump">826<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">826<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of stock - employee stock purchase plan (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,295<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures', window );">Issuance/(cancellation) of non-vested stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Issuance/(cancellation) of non-vested stock (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29,461<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">1,763<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,763<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49,988<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Non-cash compensation</a></td>
<td class="nump">6,725<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,725<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_SurrenderedShares', window );">Surrendered Shares</a></td>
<td class="num">(2,334)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,334)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders', window );">Noncontrolling interest distribution</a></td>
<td class="num">(12)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(12)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">35,147<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34,674<span></span>
</td>
<td class="nump">473<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance, Stockholders Equity at Jun. 30, 2020</a></td>
<td class="nump">722,259<span></span>
</td>
<td class="nump">$ 37<span></span>
</td>
<td class="nump">665,580<span></span>
</td>
<td class="num">(257,625)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">312,859<span></span>
</td>
<td class="nump">1,408<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Jun. 30, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,831,298<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance, Stockholders Equity at Dec. 31, 2020</a></td>
<td class="nump">810,741<span></span>
</td>
<td class="nump">$ 38<span></span>
</td>
<td class="nump">698,287<span></span>
</td>
<td class="num">(319,092)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">429,991<span></span>
</td>
<td class="nump">1,517<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,470,212<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of stock - employee stock purchase plan</a></td>
<td class="nump">1,961<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,961<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of stock - employee stock purchase plan (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,262<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures', window );">Issuance/(cancellation) of non-vested stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Issuance/(cancellation) of non-vested stock (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">61,069<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">623<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">623<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,812<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Non-cash compensation</a></td>
<td class="nump">13,463<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,463<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_SurrenderedShares', window );">Surrendered Shares</a></td>
<td class="num">(6,944)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6,944)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Shares repurchased</a></td>
<td class="num">(74,074)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(74,074)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders', window );">Noncontrolling interest distribution</a></td>
<td class="num">(794)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(794)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">130,911<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">130,019<span></span>
</td>
<td class="nump">892<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance, Stockholders Equity at Jun. 30, 2021</a></td>
<td class="nump">875,887<span></span>
</td>
<td class="nump">$ 38<span></span>
</td>
<td class="nump">714,334<span></span>
</td>
<td class="num">(400,110)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">560,010<span></span>
</td>
<td class="nump">1,615<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Jun. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,553,355<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance, Stockholders Equity at Mar. 31, 2021</a></td>
<td class="nump">789,574<span></span>
</td>
<td class="nump">$ 38<span></span>
</td>
<td class="nump">707,006<span></span>
</td>
<td class="num">(398,752)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">479,861<span></span>
</td>
<td class="nump">1,421<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Mar. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,538,837<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of stock - employee stock purchase plan</a></td>
<td class="nump">913<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">913<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of stock - employee stock purchase plan (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,060<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures', window );">Issuance/(cancellation) of non-vested stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Issuance/(cancellation) of non-vested stock (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,068<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">259<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">259<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,390<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Non-cash compensation</a></td>
<td class="nump">6,156<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,156<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_SurrenderedShares', window );">Surrendered Shares</a></td>
<td class="num">(170)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(170)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Shares repurchased</a></td>
<td class="num">(1,188)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,188)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders', window );">Noncontrolling interest distribution</a></td>
<td class="num">(276)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(276)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">80,619<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80,149<span></span>
</td>
<td class="nump">470<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance, Stockholders Equity at Jun. 30, 2021</a></td>
<td class="nump">$ 875,887<span></span>
</td>
<td class="nump">$ 38<span></span>
</td>
<td class="nump">$ 714,334<span></span>
</td>
<td class="num">$ (400,110)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 560,010<span></span>
</td>
<td class="nump">$ 1,615<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Jun. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,553,355<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_EquityImpactOfWriteOffOfOtherComprehensiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Impact of Write Off of Other Comprehensive Income</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_EquityImpactOfWriteOffOfOtherComprehensiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_StockIssuedDuringPeriodSharesFourZeroOneKEmployerMatch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period to employees as employer's matching contribution to the company's 401(K) plan</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_StockIssuedDuringPeriodSharesFourZeroOneKEmployerMatch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued during the period to employees as employer's matching contribution to the company's 401(K) plan</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_SurrenderedShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Shares of common stock surrendered by certain employees to satisfy obligations in connection with the vesting of stock. Shares held in Treasury Stock at cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_SurrenderedShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=120383193&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=120383193&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326096&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Decrease in noncontrolling interest balance from payment of dividends or other distributions by the non-wholly owned subsidiary or partially owned entity, included in the consolidation of the parent entity, to the noncontrolling interest holders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3000-108585<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21914-107793<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568740-111683<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21711-107793<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568447-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValueAcquiredCostMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValueAcquiredCostMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140006605028664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash Flows from Operating Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">$ 130,911<span></span>
</td>
<td class="nump">$ 67,193<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net income to net cash provided by operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">14,276<span></span>
</td>
<td class="nump">11,672<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Non-cash compensation</a></td>
<td class="nump">13,463<span></span>
</td>
<td class="nump">12,634<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_AmortizationandImpairmentofOperatingLeaseRightOfUseAsset', window );">Amortization and impairment of operating lease right of use assets</a></td>
<td class="nump">19,702<span></span>
</td>
<td class="nump">18,558<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment', window );">Loss (gain) on disposal of property and equipment</a></td>
<td class="nump">8<span></span>
</td>
<td class="num">(94)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfInvestments', window );">(Gain) loss on equity method investments</a></td>
<td class="num">(31,092)<span></span>
</td>
<td class="nump">2,980<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_WriteOffOfOtherComprehensiveIncome', window );">Write-off of other comprehensive income</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(15)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred income taxes</a></td>
<td class="nump">22,716<span></span>
</td>
<td class="num">(4,036)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Equity in earnings from equity method investments</a></td>
<td class="num">(2,488)<span></span>
</td>
<td class="num">(964)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts', window );">Amortization of deferred debt issuance costs/debt discount</a></td>
<td class="nump">432<span></span>
</td>
<td class="nump">437<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentDividendsOrDistributions', window );">Return on equity method investments</a></td>
<td class="nump">2,683<span></span>
</td>
<td class="nump">2,744<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities, net of impact of acquisitions:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Patient accounts receivable</a></td>
<td class="num">(22,787)<span></span>
</td>
<td class="nump">8,997<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Other current assets</a></td>
<td class="nump">3,560<span></span>
</td>
<td class="num">(3,469)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets', window );">Other assets</a></td>
<td class="num">(52)<span></span>
</td>
<td class="num">(675)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="num">(6,530)<span></span>
</td>
<td class="num">(6,452)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses</a></td>
<td class="num">(1,627)<span></span>
</td>
<td class="nump">27,990<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities', window );">Other long-term obligations</a></td>
<td class="num">(1,736)<span></span>
</td>
<td class="nump">20,746<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_IncreaseDecreaseInOperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="num">(17,955)<span></span>
</td>
<td class="num">(16,365)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_IncreaseDecreaseInOperatingLeaseRightOfUseAsset', window );">Operating lease right of use assets</a></td>
<td class="num">(1,524)<span></span>
</td>
<td class="num">(1,924)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash provided by operating activities</a></td>
<td class="nump">121,960<span></span>
</td>
<td class="nump">139,957<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash Flows from Investing Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfRestrictedInvestments', window );">Proceeds from sale of deferred compensation plan assets</a></td>
<td class="nump">25<span></span>
</td>
<td class="nump">21<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment', window );">Proceeds from sale of property and equipment</a></td>
<td class="nump">42<span></span>
</td>
<td class="nump">80<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(2,943)<span></span>
</td>
<td class="num">(1,701)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireInvestments', window );">Investments in equity method investees</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(875)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfEquityMethodInvestments', window );">Proceeds from sale of equity method investment</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">17,876<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Acquisitions of businesses, net of cash acquired</a></td>
<td class="num">(2,503)<span></span>
</td>
<td class="num">(299,723)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(5,379)<span></span>
</td>
<td class="num">(284,322)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash Flows from Financing Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from issuance of stock upon exercise of stock options</a></td>
<td class="nump">623<span></span>
</td>
<td class="nump">2,947<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockPlans', window );">Proceeds from issuance of stock to employee stock purchase plan</a></td>
<td class="nump">1,961<span></span>
</td>
<td class="nump">1,686<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Shares withheld to pay taxes on non-cash compensation</a></td>
<td class="num">(6,944)<span></span>
</td>
<td class="num">(6,384)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_CashDistributionToNoncontrollingInterest', window );">Noncontrolling interest distribution</a></td>
<td class="num">(794)<span></span>
</td>
<td class="num">(372)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromShortTermDebt', window );">Proceeds from borrowings under revolving line of credit</a></td>
<td class="nump">389,200<span></span>
</td>
<td class="nump">424,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfShortTermDebt', window );">Repayments of borrowings under revolving line of credit</a></td>
<td class="num">(410,200)<span></span>
</td>
<td class="num">(259,500)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Principal payments of long-term obligations</a></td>
<td class="num">(5,392)<span></span>
</td>
<td class="num">(4,675)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Purchase of company stock</a></td>
<td class="num">(74,074)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_FundsReceivedFromProviderReliefFundAdvance', window );">Provider relief fund advance</a></td>
<td class="num">(1,672)<span></span>
</td>
<td class="nump">70,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash (used in) provided by financing activities</a></td>
<td class="num">(107,292)<span></span>
</td>
<td class="nump">228,202<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect', window );">Net increase in cash, cash equivalents and restricted cash</a></td>
<td class="nump">9,289<span></span>
</td>
<td class="nump">83,837<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash at beginning of period</a></td>
<td class="nump">83,357<span></span>
</td>
<td class="nump">96,490<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash at end of period</a></td>
<td class="nump">92,646<span></span>
</td>
<td class="nump">180,327<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental Disclosures of Cash Flow Information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid for interest</a></td>
<td class="nump">1,914<span></span>
</td>
<td class="nump">3,292<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaidNet', window );">Cash paid for income taxes, net of refunds received</a></td>
<td class="nump">8,667<span></span>
</td>
<td class="nump">8,153<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_CashPaidForOperatingLeaseLiabilities', window );">Cash paid for operating lease liabilities</a></td>
<td class="nump">19,479<span></span>
</td>
<td class="nump">18,289<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_CashPaidForFinanceLeaseLiabilities', window );">Cash paid for finance lease liabilities</a></td>
<td class="nump">1,017<span></span>
</td>
<td class="nump">986<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract', window );"><strong>Supplemental Disclosures of Non-Cash Activity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right of use assets obtained in exchange for operating lease liabilities</a></td>
<td class="nump">20,689<span></span>
</td>
<td class="nump">18,891<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability', window );">Right of use assets obtained in exchange for finance lease liabilities</a></td>
<td class="nump">527<span></span>
</td>
<td class="nump">487<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_LesseeOperatingleaseReductionstoROUassetsresultingfromreductionstoleaseobligations', window );">Reductions to right of use assets resulting from reductions to operating lease liabilities</a></td>
<td class="nump">$ 904<span></span>
</td>
<td class="nump">$ 407<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_AmortizationandImpairmentofOperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortization and Impairment of Operating Lease Right Of Use Asset</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_AmortizationandImpairmentofOperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_CashDistributionToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payment of dividends or other distributions to noncontrolling interest holders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_CashDistributionToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_CashPaidForFinanceLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid for finance lease liabilities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_CashPaidForFinanceLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_CashPaidForOperatingLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid for operating lease liabilities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_CashPaidForOperatingLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_FundsReceivedFromProviderReliefFundAdvance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from funds received by the government related to the Novel Coronavirus Pandemic "COVID-19"</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_FundsReceivedFromProviderReliefFundAdvance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating lease liabilities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_IncreaseDecreaseInOperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of increase (decrease) In Operating Lease Right Of Use Asset</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_IncreaseDecreaseInOperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_LesseeOperatingleaseReductionstoROUassetsresultingfromreductionstoleaseobligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating lease, Reductions to ROU assets resulting from reductions to lease obligations</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_LesseeOperatingleaseReductionstoROUassetsresultingfromreductionstoleaseobligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_WriteOffOfOtherComprehensiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Write off of Other Comprehensive Income</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_WriteOffOfOtherComprehensiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCostsAndDiscounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentDividendsOrDistributions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of distribution received from equity method investee for return on investment, classified as operating activities. Excludes distribution for return of investment, classified as investing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 21D<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=SL94080555-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentDividendsOrDistributions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net realized gain (loss) on investments sold during the period, not including gains (losses) on securities separately or otherwise categorized as trading, available-for-sale, or held-to-maturity, which, for cash flow reporting, is a component of proceeds from investing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfPropertyPlantEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4297-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the purchase of all investments (debt, security, other) during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the sale of equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfRestrictedInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the sale of investments that are pledged or subject to withdrawal restrictions during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfRestrictedInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromShortTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a borrowing having initial term of repayment within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromShortTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from the stock plan during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3000-108585<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfShortTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for a borrowing having initial term of repayment within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfShortTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140006518483400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NATURE OF OPERATIONS, CONSOLIDATION AND PRESENTATION OF FINANCIAL STATEMENTS<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">NATURE OF OPERATIONS, CONSOLIDATION AND PRESENTATION OF FINANCIAL STATEMENTS</a></td>
<td class="text">NATURE OF OPERATIONS, CONSOLIDATION AND PRESENTATION OF FINANCIAL STATEMENTS<div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amedisys, Inc., a Delaware corporation, (together with its consolidated subsidiaries, referred to herein as &#8220;Amedisys,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; or &#8220;our&#8221;) is a multi-state provider of home health, hospice and personal care services with approximately 75% of our net service revenue derived from Medicare for the three and six-month periods ended June 30, 2021 and approximately 74% of our net service revenue derived from Medicare for the three and six-month periods ended June 30, 2020. As of June&#160;30, 2021, we owned and operated 320 Medicare-certified home health care centers, 180 Medicare-certified hospice care centers and 14 personal-care care centers in 39 states within the United States and the District of Columbia.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In our opinion, the accompanying unaudited condensed consolidated financial statements contain all adjustments (consisting solely of normal recurring adjustments) necessary to present fairly our financial position, our results of operations and our cash flows in accordance with U.S. generally accepted accounting principles (&#8220;U.S. GAAP&#8221;) for interim financial reporting. Our results of operations for the interim periods presented are not necessarily indicative of the results of our operations for the entire year and have not been audited by our independent auditors.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This report should be read in conjunction with our consolidated financial statements and related notes included in our Annual Report on Form 10-K for the year ended December&#160;31, 2020, as filed with the Securities and Exchange Commission (&#8220;SEC&#8221;) on February 25, 2021 (the &#8220;Form 10-K&#8221;), which includes information and disclosures not included herein. Certain information and footnote disclosures normally included in annual financial statements prepared in accordance with U.S. GAAP have been condensed or omitted from the interim financial information presented, as allowed by SEC rules and regulations. </span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Adopted Accounting Pronouncements</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 1, 2021, the Company adopted Accounting Standards Update ("ASU") 2020-10, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Codification Improvements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which included minor technical corrections and clarifications to improve consistency and clarify the application of various provisions of the codification by amending the codification to include all disclosure guidance in the appropriate disclosure sections and by amending and adding new headings, cross referencing to other guidance and refining or correcting terminology. Our adoption of this standard did not have a material effect on our condensed consolidated financial statements.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Issued Accounting Pronouncements</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, the Financial Accounting Standards Board ("FASB") issued ASU 2020-04, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which provides optional expedients and exceptions for applying U.S. GAAP to contract modifications and hedging relationships that reference the London Inter-Bank Offered Rate ("LIBOR") or another reference rate expected to be discontinued, subject to meeting certain criteria. In January 2021, the FASB issued ASU 2021-01, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reference Rate Reform (Topic 848)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which adds implementation guidance to ASU 2020-04 to clarify certain optional expedients in Topic 848. The guidance in ASU 2020-04 and ASU 2021-01 was effective upon issuance and may generally be applied prospectively through December 31, 2022. This standard will not have an effect on our condensed consolidated financial statements. </span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our accounting and reporting policies conform with U.S. GAAP. In preparing the unaudited condensed consolidated financial statements, we are required to make estimates and assumptions that impact the amounts reported in the condensed consolidated financial statements and accompanying notes. Actual results could differ from those estimates.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Principles of Consolidation</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These unaudited condensed consolidated financial statements include the accounts of Amedisys, Inc. and our wholly owned subsidiaries. All significant intercompany accounts and transactions have been eliminated and business combinations accounted for as purchases have been included from their respective dates of acquisition. In addition to our wholly owned subsidiaries, we also have certain equity investments that are accounted for as set forth below.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investments</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We consolidate investments when the entity is a variable interest entity and we are the primary beneficiary or if we have controlling interests in the entity, which is generally ownership in excess of 50%. Third-party equity interests in our consolidated joint ventures are reflected as noncontrolling interests in our condensed consolidated financial statements. We account for investments in entities in which we have the ability to exercise significant influence under the equity method if we hold 50% or less of the voting stock and the entity is not a variable interest entity in which we are the primary beneficiary. The book value of investments that we account for under the equity method of accounting was $45.1 million and $14.2 million as of June&#160;30, 2021 and December&#160;31, 2020, respectively, and is reflected in other assets within our condensed consolidated balance sheets. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three-month period ended June 30, 2021, a third-party acquired a majority of the issued and outstanding membership interests of one of our equity method investments, Medalogix, for cash, with the remaining membership interests rolling over into a newly formed entity that includes Medalogix as well as another healthcare predictive data and analytics company. We rolled over 100% of our ownership interest in Medalogix to the newly formed entity, and in connection with this transaction, we recognized a $31.1&#160;million gain based on the purchase price of Medalogix which is reflected in gain (loss) on equity method investments within our condensed consolidated statements of operations. </span></div>During the three-month period ended June 30, 2020, we sold our investment in the Heritage Healthcare Innovation Fund, LP via a secondary transaction for $17.9&#160;million which resulted in a $3.0 million loss which is reflected in gain (loss) on equity method investments within our condensed consolidated statements of operations. The Company's original investment was made in 2010 and no longer fit within our strategic areas of focus. Proceeds from the sale were used to pay down debt and fund capital needs.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140006518649128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We account for revenue from contracts with customers in accordance with Accounting Standards Codification ("ASC") 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and as such, we recognize revenue in the period in which we satisfy our performance obligations under our contracts by transferring our promised services to our customers in amounts that reflect the consideration to which we expect to be entitled in exchange for providing patient care, which are the transaction prices allocated to the distinct services. The Company's cost of obtaining contracts is not material.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues are recognized as performance obligations are satisfied, which varies based on the nature of the services provided. Our performance obligation is the delivery of patient care services in accordance with the nature and frequency of services outlined in physicians' orders, which are determined by a physician based on a patient's specific goals. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's performance obligations relate to contracts with a duration of less than one year; therefore, the Company has elected to apply the optional exemption provided by ASC 606 and is not required to disclose the aggregate amount of the transaction price allocated to performance obligations that are unsatisfied or partially unsatisfied as of the end of the reporting period. The unsatisfied or partially unsatisfied performance obligations are generally completed when the patients are discharged, which generally occurs within days or weeks of the end of the reporting period.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We determine the transaction price based on gross charges for services provided, reduced by estimates for contractual and non-contractual revenue adjustments. Contractual revenue adjustments are recorded for the difference between our standard rates and the contracted rates to be realized from patients, third-party payors and others for services provided. Non-contractual revenue adjustments include discounts provided to self-pay, uninsured patients or other payors, adjustments resulting from payment reviews and adjustments arising from our inability to obtain appropriate billing documentation, authorizations or face-to-face documentation. Subsequent changes to the estimate of the transaction price are recorded as adjustments to net service revenue in the period of change. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-contractual revenue adjustments are recorded for self-pay, uninsured patients and other payors by major payor class based on our historical collection experience, aged accounts receivable by payor and current economic conditions. The non-contractual revenue adjustments represent the difference between amounts billed and amounts we expect to collect based on our collection history with similar payors. The Company assesses its ability to collect for the healthcare services provided at the time of patient admission based on the Company's verification of the patient's insurance coverage under Medicare, Medicaid, and other commercial or managed care insurance programs. Medicare represents approximately 75% of our net service revenue </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for the three and six-month periods ended June 30, 2021 and approximately 74% of our net service revenue for the three and six-month periods ended June 30, 2020. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts due from third-party payors, primarily commercial health insurers and government programs (Medicare and Medicaid), include variable consideration for retroactive revenue adjustments due to settlements of audits and payment reviews. We determine our estimates for non-contractual revenue adjustments related to audits and payment reviews based on our historical experience and success rates in the claim appeals and adjudication process. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We determine our estimates for non-contractual revenue adjustments related to our inability to obtain appropriate billing documentation, authorizations, or face-to-face documentation based on our historical experience which primarily includes a historical collection rate of over 99% on Medicare claims. Revenue is recorded at amounts we estimate to be realizable for services provided.</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue by payor class as a percentage of total net service revenue is as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:49.923%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.602%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three-Month Periods Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Six-Month Periods <br/>Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Home Health:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Medicare</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Non-Medicare - Episodic-based</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Non-Medicare - Non-episodic based</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Hospice (1):</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Medicare</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Non-Medicare</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Personal Care</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="24" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1) Acquired AseraCare Hospice ("AseraCare") on June 1, 2020.</span></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Home Health Revenue Recognition</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Medicare Revenue</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective January 1, 2020, the Centers for Medicare and Medicaid Services ("CMS") implemented a revised case-mix adjustment methodology, the Patient-Driven Groupings Model ("PDGM"), to better align payment with patient care needs and ensure that clinically complex and ill beneficiaries have adequate access to home health care. PDGM uses 30-day periods of care rather than 60-day episodes of care as the unit of payment, eliminates the use of the number of therapy visits provided in determining payment and relies more heavily on clinical characteristics and other patient information.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net service revenue is recorded based on the established Federal Medicare home health payment rate for a 30-day period of care. ASC 606 notes that if an entity has a right to consideration from a customer in an amount that corresponds directly with the value of the entity&#8217;s performance completed to date, the entity may recognize revenue in the amount to which the entity has a right to invoice. We have elected to apply the "right to invoice" practical expedient and therefore, our revenue recognition is based on the reimbursement we are entitled to for each 30-day payment period. We utilize our historical average length of stay for each 30-day period of care as the measure of progress towards the satisfaction of our performance obligation.</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">PDGM uses timing, admission source, functional impairment levels and principal and other diagnoses to case-mix adjust payments. The case-mix adjusted payment for a 30-day period of care is subject to additional adjustments based on certain variables, including, but not limited to (a) an outlier payment if our patient's care was unusually costly (capped at 10% of total reimbursement per provider number); (b)&#160;a low utilization payment adjustment (&#8220;LUPA&#8221;) if the number of visits provided was less than the established threshold, which ranges from two to six visits and varies for every case-mix group under PDGM; (c)&#160;a partial payment if a patient is transferred to another provider or from another provider before completing the 30-day period of care; and (d) the applicable geographic wage index. Payments for routine and non-routine supplies are included in the 30-day payment rate.</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medicare can also make various adjustments to payments received if we are unable to produce appropriate billing documentation or acceptable authorizations. We estimate the impact of such adjustments based on our historical experience, which primarily includes a historical collection rate of over 99% on Medicare claims, and record this estimate during the period in which services are rendered to revenue with a corresponding reduction to patient accounts receivable.</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts due from Medicare include variable consideration for retroactive revenue adjustments due to settlements of audits and payment reviews. We determine our estimates for non-contractual revenue adjustments related to audits and payment reviews based on our historical experience and success rates in the claim appeals and adjudication process.</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All Medicare contracts are required to have a signed plan of care which represents a single performance obligation, comprised of the delivery of a series of distinct services that are substantially similar and have a similar pattern of transfer to the customer. Accordingly, the Company accounts for the series of services ("episode") as a single performance obligation satisfied over time, as the customer simultaneously receives and consumes the benefits of the goods and services provided. An episode starts the first day a billable visit is performed and ends 60 days later or upon discharge, if earlier, with multiple continuous episodes allowed. </span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Medicare home health benefit requires that beneficiaries be homebound (meaning that the beneficiary is unable to leave his/her home without a considerable and taxing effort), require intermittent skilled nursing, physical therapy or speech therapy services, and receive treatment under a plan of care established and periodically reviewed by a physician. In order to provide greater flexibility during the novel coronavirus pandemic ("COVID-19"), CMS relaxed the definition of homebound status through the duration of the public health emergency. During the pandemic, a beneficiary is considered homebound if they have been instructed by a physician not to leave their home because of a confirmed or suspected COVID-19 diagnosis or if the patient has a condition that makes them more susceptible to contracting COVID-19. Therefore, if a beneficiary is homebound due to COVID-19 and requires skilled services, the services will be covered under the Medicare home health benefit. </span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2020, 20% of reimbursement from each Medicare episode, referred to as a request for anticipated payment ("RAP"), was billed near the start of each 30-day period of care, and cash was typically received before all services were rendered. Any cash received from Medicare for a RAP for a 30-day period of care that exceeded the associated revenue earned was recorded to accrued expenses within our condensed consolidated balance sheets. CMS fully eliminated all upfront payments associated with RAPs effective January 1, 2021.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Non-Medicare Revenue</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Episodic-based Revenue.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We recognize revenue in a similar manner as we recognize Medicare revenue for amounts that are paid by other insurance carriers, including Medicare Advantage programs; however, these amounts can vary based upon the negotiated terms, the majority of which range from 95% to 100% of Medicare rates.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Non-episodic based Revenue.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Gross revenue is recorded on an accrual basis based upon the date of service at amounts equal to our established or estimated per-visit rates. Contractual revenue adjustments are recorded for the difference between our standard rates and the contracted rates to be realized from patients, third parties and others for services provided and are deducted from gross revenue to determine net service revenue. We also make non-contractual revenue adjustments to non-episodic revenue based on our historical experience to reflect the estimated transaction price. We receive a minimal amount of our net service revenue from patients who are either self-insured or are obligated for an insurance co-payment.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Hospice Revenue Recognition</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Hospice Medicare Revenue</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gross revenue is recorded on an accrual basis based upon the date of service at amounts equal to the estimated payment rates. The estimated payment rates are predetermined daily or hourly rates for each of the four levels of care we deliver. The four levels of care are routine care, general inpatient care, continuous home care and respite care. Routine care accounted for 97% of our total Medicare hospice service revenue for the three and six-month periods ended June&#160;30, 2021 and June 30, 2020. There are two separate payment rates for routine care: payments for the first 60 days of care and care beyond 60 days. In addition to the two routine rates, we may also receive a service intensity add-on (&#8220;SIA&#8221;). The SIA is based on visits made in the last seven days of life by a registered nurse or medical social worker for patients in a routine level of care.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The performance obligation is the delivery of hospice services to the patient, as determined by a physician, each day the patient is on hospice care.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We make adjustments to Medicare revenue for non-contractual revenue adjustments, which include our inability to obtain appropriate billing documentation or acceptable authorizations and other reasons unrelated to credit risk. We estimate the impact of these non-contractual revenue adjustments based on our historical experience, which primarily includes a historical collection rate of over 99% on Medicare claims, and record it during the period services are rendered.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, our hospice service revenue is subject to certain limitations on payments from Medicare which are considered variable consideration. We are subject to an inpatient cap limit and an overall Medicare payment cap for each provider number. We monitor these caps on a provider-by-provider basis and estimate amounts due back to Medicare if we estimate a cap has been exceeded.&#160;We record these adjustments as a reduction to revenue and an increase in accrued expenses within our condensed consolidated balance sheets. Providers are required to self-report and pay their estimated cap liability by February 28</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">th</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of the following year. As of June&#160;30, 2021, we have recorded $10.0 million for estimated amounts due back to Medicare in accrued expenses for the Federal cap years ended October&#160;31, 2016 through September 30, 2021; $3.1&#160;million of this balance was acquired with the AseraCare acquisition. As of December&#160;31, 2020, we had recorded $9.3 million for estimated amounts due back to Medicare in accrued expenses for the Federal cap years ended October&#160;31, 2014 through September 30, 2021.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Hospice Non-Medicare Revenue</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gross revenue is recorded on an accrual basis based upon the date of service at amounts equal to our established rates or estimated per day rates, as applicable. Contractual revenue adjustments are recorded for the difference between our standard rates and the contractual rates to be realized from patients, third-party payors and others for services provided and are deducted from gross revenue to determine our net service revenue. We also make non-contractual adjustments to non-Medicare revenue based on our historical experience to reflect the estimated transaction price.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Personal Care Revenue Recognition</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Personal Care Revenue</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We generate net service revenues by providing our services directly to patients based on authorized hours, visits or units determined by the relevant agency, at a rate that is either contractual or fixed by legislation. Net service revenue is recognized at the time services are rendered based on gross charges for the services provided, reduced by estimates for contractual and non-contractual revenue adjustments. We receive payment for providing such services from payors, including state and local governmental agencies, managed care organizations, commercial insurers and private consumers. Payors include the following elder service agencies: Aging Services Access Points ("ASAPs"), Senior Care Options ("SCOs"), Program of All-Inclusive Care for the Elderly ("PACE") and the Veterans Administration ("VA"). </span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Government Grants</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the absence of specific guidance to account for government grants under U.S. GAAP, we have decided to account for government grants in accordance with International Accounting Standard ("IAS") 20, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounting for Government Grants and Disclosure of Government Assistance</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and as such, we recognize grant income on a systematic basis in line with the recognition of expenses or the loss of revenues for which the grants are intended to compensate. We recognize grants once both of the following conditions are met: (1) we are able to comply with the relevant conditions of the grant and (2) the grant will be received. See Note 3 - Novel Coronavirus Pandemic ("COVID-19") for additional information on our accounting for government funds received under the Coronavirus Aid, Relief and Economic Security Act ("CARES Act") and the Mass Home Care ASAP COVID-19 Provider Sustainability Program.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash, Cash Equivalents and Restricted Cash </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents include certificates of deposit and all highly liquid debt instruments with maturities of three months or less when purchased. Our cash balance as of June 30, 2021 includes approximately $62&#160;million associated with the CARES Act Provider Relief Fund ("PRF"). We separated the PRF funds into their own account and as of June 30, 2021, we have only transferred funds used through March 31, 2021 to our operating account. We will transfer funds used during the three-month period ended June 30, 2021, totaling approximately $4&#160;million, to our operating account during the third quarter of 2021 and repay the remaining $58&#160;million to the U.S. Department of Health and Human Services ("HHS") by October 30, 2021. Restricted cash includes cash that is not available for ordinary business use. As of June 30, 2021, we had $1&#160;million of restricted cash that was placed into an escrow account related to the indemnity and closing payment adjustment provisions within the Asana Hospice purchase agreement.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the balances related to our cash, cash equivalents and restricted cash (amounts in millions):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.250%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.981%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.739%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of June 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92.6&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83.3&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Patient Accounts Receivable </span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We report accounts receivable from services rendered at their estimated transaction price, which includes contractual and non-contractual revenue adjustments based on the amounts expected to be due from payors. Our patient accounts receivable are uncollateralized and consist of amounts due from Medicare, Medicaid, other third-party payors and patients. The Company's non-Medicare third-party payor base is comprised of a diverse group of payors that are geographically dispersed across the country. As of June&#160;30, 2021, there is one payor, other than Medicare, that accounts for 10% of our total outstanding patient receivables. Thus, we believe there are no other significant concentrations of receivables that would subject us to any significant credit risk in the collection of our patient accounts receivable. We write off accounts on a monthly basis once we have exhausted our collection efforts and deem an account to be uncollectible. We believe the collectability risk associated with our Medicare accounts, which represent 66% and 64% of our patient accounts receivable at June&#160;30, 2021 and December&#160;31, 2020, respectively, is limited due to our historical collection rate of over 99% from Medicare and the fact that Medicare is a U.S. government payor. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not believe there are any significant concentrations of revenues from any payor that would subject us to any significant credit risk in the collection of our accounts receivable.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Medicare Home Health</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For our home health patients, our pre-billing process includes verifying that we are eligible for payment from Medicare for the services that we provide to our patients. Our Medicare billing begins with a process to ensure that our billings are accurate through the utilization of an electronic Medicare claim review. Prior to January 1, 2021, we submitted a RAP for 20% of our estimated payment for each 30-day period of care. The RAP received was then deducted from our final payment. Effective January 1, 2021, CMS eliminated all upfront payments associated with RAPs.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Medicare Hospice</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For our hospice patients, our pre-billing process includes verifying that we are eligible for payment from Medicare for the services that we provide to our patients. Our Medicare billing begins with a process to ensure that our billings are accurate through the utilization of an electronic Medicare claim review. We bill Medicare on a monthly basis for the services provided to the patient.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Non-Medicare Home Health, Hospice and Personal Care</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For our non-Medicare patients, our pre-billing process primarily begins with verifying a patient&#8217;s eligibility for services with the applicable payor. Once the patient has been confirmed for eligibility, we will provide services to the patient and bill the applicable payor. Our review and evaluation of non-Medicare accounts receivable includes a detailed review of outstanding balances and special consideration to concentrations of receivables from particular payors or groups of payors with similar characteristics that would subject us to any significant credit risk. </span></div><div style="margin-top:16pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Business Combinations</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We account for acquisitions using the acquisition method of accounting in accordance with ASC 805, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business Combinations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Acquisitions are accounted for as purchases and are included in our condensed consolidated financial statements from their respective acquisition dates. Assets acquired and liabilities assumed, if any, are measured at fair value on the acquisition date using the appropriate valuation method. Goodwill generated from acquisitions is recognized for the excess of the purchase price over tangible and identifiable intangible assets. In determining the fair value of identifiable intangible assets, we use various valuation techniques including discounted cash flow analysis, the income approach, the cost approach and the market approach. These valuation methods require us to make estimates and assumptions surrounding projected revenues and costs, growth rates and discount rates.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value of Financial Instruments</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following details our financial instruments where the carrying value and the fair value differ (amounts in millions):</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.076%"><tr><td style="width:1.0%"/><td style="width:24.954%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.821%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.553%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.821%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.553%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.821%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.553%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.824%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value at Reporting Date Using</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Financial Instrument</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying Value as of June 30, 2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted&#160;Prices&#160;in&#160;Active<br/>Markets for Identical<br/>Items<br/>(Level 1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant&#160;Other<br/>Observable&#160;Inputs<br/>(Level 2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Unobservable&#160;Inputs<br/>(Level&#160;3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term obligations</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">189.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">191.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value hierarchy is based on three levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value. The three levels of inputs are as follows:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level&#160;1 &#8211; Quoted prices in active markets for identical assets and liabilities.</span></div><div style="padding-left:36pt;text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level&#160;2 &#8211; Inputs other than Level&#160;1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.</span></div><div style="padding-left:36pt;text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level&#160;3 &#8211; Unobservable inputs that are supported by little or no market activity and are significant to the fair value of the assets or liabilities.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our deferred compensation plan assets are recorded at fair value and are considered a level 2 measurement. For our other financial instruments, including our cash and cash equivalents, patient accounts receivable, accounts payable, payroll and employee benefits and accrued expenses, we estimate the carrying amounts approximate fair value. </span></div><div style="margin-top:16pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Weighted-Average Shares Outstanding</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net income per share attributable to Amedisys, Inc. common stockholders, calculated on the treasury stock method, is based on the weighted average number of shares outstanding during the period. The following table sets forth, for the periods indicated, shares used in our computation of the weighted-average shares outstanding, which are used to calculate our basic and diluted net income attributable to Amedisys, Inc. common stockholders (amounts in thousands):</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.829%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.624%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three-<br/>Month Periods<br/>Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Six-<br/>Month Periods<br/>Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average number of shares outstanding - basic</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,588&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,412&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,684&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,371&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of dilutive securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">139&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">570&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">145&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">582&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:20.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-vested stock and stock units</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">254&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">303&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">256&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">306&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average number of shares outstanding - diluted</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,981&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,285&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,085&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,259&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Anti-dilutive securities</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140006518638296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NOVEL CORONAVIRUS PANDEMIC "COVID-19"<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ExtraordinaryAndUnusualItemsAbstract', window );"><strong>Unusual or Infrequent Items, or Both [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_COVID19TextBlock', window );">COVID-19</a></td>
<td class="text">NOVEL CORONAVIRUS PANDEMIC ("COVID-19")<div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, the World Health Organization declared COVID-19 a pandemic. As a healthcare at home company, we have been and will continue to be impacted by the effects of COVID-19; however, we remain committed to carrying out our mission of caring for our patients. We will continue to closely monitor the impact of COVID-19 on all aspects of our business, including the impacts to our employees, patients and suppliers; however, at this time, we are unable to estimate the ultimate impact the pandemic will have on our consolidated financial condition, results of operations or cash flows.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 27, 2020, the CARES Act was signed into legislation. The CARES Act provided for $175&#160;billion to healthcare providers, including hospitals on the front lines of the COVID-19 pandemic. Of this total allocated amount, $30&#160;billion was distributed immediately to providers based on their proportionate share of Medicare fee-for-service reimbursements in 2019. Healthcare providers were required to sign an attestation confirming receipt of the Provider Relief Fund ("PRF") funds and agree to the terms and conditions of payment. Our home health and hospice segments received approximately $100&#160;million from the first $30&#160;billion of funds distributed to healthcare providers in April 2020, which is inclusive of $2&#160;million related to our joint venture care centers (equity method investments). We also acquired approximately $6&#160;million of PRF funds in connection with the acquisition of AseraCare. Under the terms and conditions for receipt of the payment, we are allowed to use the funds to cover lost revenues and health care costs related to COVID-19, and we are required to properly and fully document the use of these funds in reports to the U.S. Department of Health and Human Services ("HHS"). </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For our wholly-owned subsidiaries, we have decided to only utilize PRF funds to the extent we have qualifying COVID-19 expenses, which totaled $5&#160;million and $13&#160;million for our home health and hospice segments during the three and six-month periods ended June 30, 2021, respectively, and $21&#160;million and $22&#160;million during the three and six-month periods ended June 30, 2020, respectively. Accordingly, for our wholly-owned subsidiaries, we have not used PRF funds to cover lost revenues resulting from COVID-19. The grant income associated with the COVID-19 expenses incurred during the three and six-month periods ended June 30, 2021 and 2020 is reflected in other operating income within our condensed consolidated statements of operations. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">PRF funds were available for use through June 30, 2021. We did not fully utilize the funds received; therefore, we have recorded a liability for the amount we expect to repay which totaled $58&#160;million at June 30, 2021 and $60&#160;million at December 31, 2020 (see the Provider Relief Fund Advance account in current liabilities within our condensed consolidated balance sheets). We intend to report on our use of the PRF funds to HHS during the three-month period ending September 30, 2021 and to return all unutilized funds by October 30, 2021. In summary, the total funds that we have received from the CARES Act PRF have been accounted for as follows as of June 30, 2021 (amounts in millions):</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:87.719%"><tr><td style="width:1.0%"/><td style="width:76.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.567%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Funds utilized through June 30, 2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Estimated funds to be repaid to the government</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Funds received by unconsolidated joint ventures</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106.8&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:justify"><span><br/></span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The CARES Act also provided for the temporary suspension of the automatic 2% reduction of Medicare claim reimbursements (sequestration) for the period May 1, 2020 through December 31, 2020. In December 2020, Congress passed additional COVID-19 relief legislation as part of the Consolidated Appropriations Act, 2021. This legislation extended the suspension of sequestration through March 31, 2021. In April 2021, Congress passed H.R. 1868, which among other items, provided for an additional extension of the temporary suspension of sequestration through December 31, 2021. We estimate that the suspension of sequestration will increase our 2021 net service revenue by approximately $36&#160;million.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, the CARES Act provided for the deferral of the employer share of social security tax (6.2%), effective for payments due after the enactment date through December 31, 2020. Fifty percent of the deferred payroll taxes are due on December 31, 2021 with the remaining amounts due on December 31, 2022. During 2020, we deferred approximately $55.0&#160;million of social security tax; approximately $28&#160;million is reflected in each of payroll and employee benefits and other long-term obligations within our condensed consolidated balance sheets.</span></div>Our personal care segment did not receive funds under the CARES Act; however, it did receive funds totaling $1&#160;million from the Mass Home Care ASAP COVID-19 Provider Sustainability Program, which were used during 2020 to cover costs related to COVID-19.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_COVID19TextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for Novel Coronavirus Pandemic "COVID-19"</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_COVID19TextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ExtraordinaryAndUnusualItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ExtraordinaryAndUnusualItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140006638119768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACQUISITIONS<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsAbstract', window );"><strong>Business Combinations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationDisclosureTextBlock', window );">ACQUISITIONS</a></td>
<td class="text">ACQUISITIONS<div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We complete acquisitions from time to time in order to pursue our strategy of increasing our market presence by expanding our service base and enhancing our position in certain geographic areas as a leading provider of home health, hospice and personal care services. The purchase price paid for acquisitions is negotiated through arm&#8217;s length transactions, with consideration based on our analysis of, among other things, comparable acquisitions and expected cash flows. Acquisitions are accounted for as purchases and are included in our condensed consolidated financial statements from their respective acquisition dates. Goodwill generated from acquisitions is recognized for the excess of the purchase price over tangible and identifiable intangible assets because of the expected contributions of the acquisitions to our overall corporate strategy. We typically engage outside appraisal firms to assist in the fair value determination of identifiable intangible assets for significant acquisitions. The preliminary purchase price allocation is adjusted, as necessary, up to one year after the acquisition closing date if management obtains more information regarding asset valuations and liabilities assumed.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2021 Acquisitions</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 1, 2021, we acquired the regulatory assets of a home health provider in Randolph County, North Carolina for a purchase price of $2.5&#160;million. The purchase price was paid with cash on hand on the date of the transaction. Based on the Company's preliminary valuation, we recorded goodwill of $2.4&#160;million and other intangibles (certificate of need) of $0.1&#160;million in connection with the acquisition.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2020 Acquisitions</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 1, 2020, we acquired Homecare Preferred Choice, Inc., doing business as AseraCare Hospice ("AseraCare"), a national hospice care provider with 44 locations, for an estimated purchase price of $230.4&#160;million, net of cash acquired and inclusive of a $32&#160;million tax asset. The closing payment for the purchase price included estimates for cash, working capital and various other items. Under the purchase agreement, the purchase price was subject to a closing payment adjustment for any differences between estimated amounts included in the closing payment and actual amounts at close, not to exceed $1.0&#160;million. The closing payment adjustment, which was finalized in October 2020, reduced the purchase price by $0.8&#160;million, from $230.4&#160;million&#160;to $229.6&#160;million.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company finalized its valuation of the assets acquired and liabilities assumed during the three-month period ended June 30, 2021. The total consideration of $229.6 million&#160;has been allocated to assets acquired and liabilities assumed as of the acquisition date as follows (amounts in millions):</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:79.970%"><tr><td style="width:1.0%"/><td style="width:74.037%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.763%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patient accounts receivable</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right of use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total assets acquired</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.3)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payroll and employee benefits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total liabilities assumed</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29.5)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net identifiable assets acquired</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">212.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total consideration</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">229.6&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets acquired include licenses ($8.7&#160;million), certificates of need ($0.7&#160;million), acquired names ($5.7&#160;million) and non-compete agreements ($9.2&#160;million). The acquired names will be amortized over a weighted-average period of 2.0 years, and the non-compete agreements will be amortized over a weighted-average period of 1.7 years. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AseraCare contributed $25.4&#160;million in net service revenue and operating income of $0.5&#160;million (inclusive of acquisition and integration costs totaling $0.6&#160;million and intangibles amortization totaling $2.0&#160;million) during the three-month period ended June 30, 2021 and $50.0&#160;million in net service revenue and an operating loss of $0.1 million (inclusive of acquisition and integration costs totaling $1.2&#160;million and intangibles amortization totaling $4.4&#160;million) during the six-month period ended June 30, 2021. During the three and six-month periods ended June 30, 2020, AseraCare contributed $9.2&#160;million in net service revenue and an operating loss of $3.0 million (inclusive of acquisition and integration costs totaling $3.3&#160;million and intangibles amortization totaling $0.2&#160;million).</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect the entire amount of goodwill recorded for this acquisition to be deductible for income tax purposes over approximately 15 years.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -URI http://asc.fasb.org/topic&amp;trid=2303972<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140006518631592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LONG-TERM OBLIGATIONS<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">LONG-TERM OBLIGATIONS</a></td>
<td class="text">LONG-TERM OBLIGATIONS<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-term debt consists of the following for the periods indicated (amounts in millions):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.812%"><tr><td style="width:1.0%"/><td style="width:66.256%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.823%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.596%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.825%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$175.0 million Term Loan; interest rate at Base Rate plus Applicable Rate or Eurodollar Rate plus Applicable Rate (1.4% at June 30, 2021); due February&#160;4, 2024</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">159.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">164.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$550.0 million Revolving Credit Facility; interest only payments; interest rate at Base Rate plus Applicable Rate or Eurodollar Rate plus Applicable Rate (1.3% at June 30, 2021); due February&#160;4, 2024</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance leases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Principal amount of long-term obligations</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">191.8&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">217.7&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred debt issuance costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">189.6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">215.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of long-term obligations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">179.4&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">204.5&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">First Amendment to Amended and Restated Credit Agreement</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 4, 2019, we entered into the First Amendment to our Credit Agreement (as amended by the First Amendment, the "Amended Credit Agreement"). The Amended Credit Agreement provides for a senior secured credit facility in an initial aggregate principal amount of up to $725.0 million, which includes a $550.0 million Revolving Credit Facility under the Credit Agreement, and a term loan facility with a principal amount of up to $175.0 million (the "Term Loan Facility" and collectively with the Revolving Credit Facility, the "Credit Facility"), which was added by the First Amendment.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The loans issued under the Credit Facility bear interest on a per annum basis, at our election, at either: (i) the Base Rate plus the Applicable Rate or (ii) the Eurodollar Rate plus the Applicable Rate. The &#8220;Base Rate&#8221; means a fluctuating rate per annum equal to the highest of (a) the federal funds rate plus 0.50% per annum, (b) the prime rate of interest established by the Administrative Agent, and (c) the Eurodollar Rate plus 1% per annum. The &#8220;Eurodollar Rate&#8221; means the quoted rate per annum equal to the London Interbank Offered Rate (&#8220;LIBOR&#8221;) or a comparable successor rate approved by the Administrative Agent for an interest period of one, two, three or six months (as selected by us). The &#8220;Applicable Rate&#8221; is based on the consolidated leverage ratio and is presented in the table below. As of June&#160;30, 2021, the Applicable Rate is 0.25% per annum for Base Rate loans and 1.25% per annum for Eurodollar Rate loans. We are also subject to a commitment fee and letter of credit fee under the terms of the Amended Credit Agreement, as presented in the table below.</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.251%"><tr><td style="width:1.0%"/><td style="width:10.151%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:26.158%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.808%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.736%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.808%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.739%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Pricing Tier</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Consolidated Leverage Ratio</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Commitment Fee</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Letter of Credit Fee</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Eurodollar Rate Loans</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Base Rate Loans</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">I</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8805; 3.00 to 1.0</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.35%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.75%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.00%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.00%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">II</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&lt; 3.00 to 1.0 but &#8805; 2.00 to 1.0</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.30%</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.50%</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.75%</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.75%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">III</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&lt; 2.00 to 1.0 but &#8805; 0.75 to 1.0</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.25%</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.25%</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.50%</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.50%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IV</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&lt; 0.75 to 1.0</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.20%</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.00%</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.25%</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.25%</span></td></tr></table></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The final maturity date of the Credit Facility is February 4, 2024. The Revolving Credit Facility will terminate and be due and payable as of the final maturity date. The Term Loan Facility, however, is subject to quarterly amortization of principal in the amount of (i) 0.625% for the period commencing on February 4, 2019 and ending on March 31, 2020, (ii) 1.250% for the period commencing on April 1, 2020 and ending on March 31, 2023, and (iii) 1.875% for the period commencing on April 1, 2023 and ending on February 4, 2024. The remaining balance of the Term Loan Facility must be paid upon the final maturity date. In addition to the scheduled amortization of the Term Loan Facility, and subject to customary exceptions and reinvestment rights, we are required to prepay the Term Loan Facility first and the Revolving Credit Facility second with 100% of all net cash proceeds received by any loan party or any subsidiary thereof in connection with (a) any asset sale or disposition where such loan party receives net cash proceeds in excess of $5 million or (b) any debt issuance that is not permitted under the Amended Credit Agreement.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Amended Credit Agreement requires maintenance of two financial covenants: (i) a consolidated leverage ratio of funded indebtedness to Earnings Before Interest, Taxes, Depreciation and Amortization ("EBITDA"), as defined in the Amended Credit Agreement, and (ii) a consolidated interest coverage ratio of EBITDA to cash interest charges, as defined in the Amended Credit Agreement. Each of these covenants is calculated over rolling four-quarter periods and also is subject to certain exceptions and baskets. The Amended Credit Agreement also contains customary covenants, including, but not limited to, restrictions on: incurrence of liens, incurrence of additional debt, sales of assets and other fundamental corporate changes, investments, and declarations of dividends. These covenants contain customary exclusions and baskets as detailed in the Amended Credit Agreement. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Revolving Credit Facility is guaranteed by substantially all of our wholly-owned direct and indirect subsidiaries. The Amended Credit Agreement requires at all times that we (i) provide guarantees from wholly-owned subsidiaries that in the aggregate represent not less than 95% of our consolidated net revenues and adjusted EBITDA from all wholly-owned subsidiaries and (ii) provide guarantees from subsidiaries that in the aggregate represent not less than 70% of consolidated adjusted EBITDA, subject to certain exceptions.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our weighted average interest rate for borrowings under our $550.0 million Revolving Credit Facility was 1.7% and 1.8% for the three and six-month periods ended June&#160;30, 2021, respectively, and 2.1% and 2.5% for the three and six-month periods ended June 30, 2020, respectively. Our weighted average interest rate for borrowings under our $175.0 million Term Loan Facility was 1.4% and 1.5% for the three and six-month periods ended June&#160;30, 2021, respectively,  and 2.0% and 2.6% for the three and six-month periods ended June 30, 2020, respectively.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2021, our consolidated leverage ratio was 0.5, our consolidated interest coverage ratio was 41.9 and we are in compliance with our covenants under the Amended Credit Agreement. In the event we are not in compliance with our debt covenants in the future, we would pursue various alternatives in an attempt to successfully resolve the non-compliance, which might include, among other things, seeking debt covenant waivers or amendments.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2021, our availability under our $550.0 million Revolving Credit Facility was $490.3 million as we have $30.0 million outstanding in borrowings and $29.7 million outstanding in letters of credit.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 30, 2021, we entered into a Second Amendment to our Credit Agreement (the &#8220;Second Amended Credit Agreement&#8221;). See Note 10 - Subsequent Events for additional information on the Second Amended Credit Agreement.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Joinder Agreements</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Compassionate Care Hospice ("CCH") acquisition, we entered into a Joinder Agreement, dated as of February 4, 2019 (the &#8220;CCH Joinder&#8221;), pursuant to which CCH and its subsidiaries were made parties to, and became subject to the terms and conditions of, the Amended Credit Agreement, the Amended and Restated Security Agreement, dated as of June 29, 2018 (the &#8220;Amended and Restated Security Agreement&#8221;), and the Amended and Restated Pledge Agreement, dated as of June 29, 2018 (the &#8220;Amended and Restated Pledge Agreement&#8221;). In connection with the AseraCare acquisition, we entered into a Joinder Agreement, dated as of June 12, 2020, pursuant to which the AseraCare entities were made parties to, and became subject to the terms and conditions of, the Amended Credit Agreement, the Amended and Restated Security Agreement and the Amended and Restated Pledge Agreement (the &#8220;AseraCare Joinder,&#8221; and together with the CCH Joinder, the &#8220;Joinders&#8221;).  Pursuant to the Joinders, the Amended and Restated Security Agreement and the Amended and Restated Pledge Agreement, CCH and its subsidiaries and the AseraCare entities granted in favor of the Administrative Agent a first lien security interest in substantially all of their personal property assets and pledged to the Administrative Agent each of their respective subsidiaries' issued and outstanding equity interests. CCH and its subsidiaries and the AseraCare entities also guaranteed our obligations, whether now existing or arising after the respective effective dates of the Joinders, under the Amended Credit Agreement pursuant to the terms of the Joinders and the Amended Credit Agreement.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140006518637256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">COMMITMENTS AND CONTINGENCIES</a></td>
<td class="text">COMMITMENTS AND CONTINGENCIES<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Legal Proceedings - Ongoing</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are involved in legal actions in the normal course of business, some of which seek monetary damages, including claims for punitive damages. Based on information available to us as of the date of this filing, we do not believe that these normal course actions, when finally concluded and determined, will have a material impact on our consolidated financial condition, results of operations or cash flows.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Legal fees related to all legal matters are expensed as incurred.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Legal Proceedings - Completed</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Subpoena Duces Tecum and Civil Investigative Demands Issued by the U.S. Department of Justice</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 7, 2021, the U.S. Department of Justice notified the Company that they were closing their investigation into the below-referenced Subpoena Duces Tecum ("Subpoena") and civil investigative demands ("CIDs"). As of March 31, 2021, we had recorded a total of $6.5 million to accrued expenses in our condensed consolidated balance sheets related to these matters. During the three-month period ended June 30, 2021, we reversed our accrual related to these matters.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May&#160;21, 2015, we received a Subpoena issued by the U.S. Department of Justice. The Subpoena requested the delivery of information regarding 53 identified hospice patients to the United States Attorney&#8217;s Office for the District of Massachusetts. It also requested the delivery of documents relating to our hospice clinical and business operations and related compliance activities. The Subpoena generally covered the period from January&#160;1, 2011 through May&#160;21, 2015.  </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November&#160;3, 2015, we received a CID issued by the U.S. Department of Justice pursuant to the federal False Claims Act relating to claims submitted to Medicare and/or Medicaid for hospice services provided through designated facilities in the Morgantown, West Virginia area. The CID requested the delivery of information to the United States Attorney&#8217;s Office for the Northern District of West Virginia regarding 66 identified hospice patients, as well as documents relating to our hospice clinical and business operations in the Morgantown area. The CID generally covered the period from January&#160;1, 2009 through August 31, 2015.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June&#160;27, 2016, we received a CID issued by the U.S. Department of Justice pursuant to the federal False Claims Act relating to claims submitted to Medicare and/or Medicaid for hospice services provided through designated facilities in the Parkersburg, West Virginia area. The CID requested the delivery of information to the United States Attorney&#8217;s Office for the Southern District of West Virginia regarding 68 identified hospice patients, as well as documents relating to our hospice clinical and business operations in the Parkersburg area. The CID generally covered the period from January&#160;1, 2011 through June&#160;20, 2016. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Third Party Audits - Ongoing</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, in the ordinary course of business, we are subject to audits under various governmental programs in which third party firms engaged by CMS, including Recovery Audit Contractors (&#8220;RACs&#8221;), Zone Program Integrity Contractors (&#8220;ZPICs&#8221;), Uniform Program Integrity Contractors (&#8220;UPICs&#8221;), Program Safeguard Contractors (&#8220;PSCs&#8221;), Medicaid Integrity Contractors (&#8220;MICs&#8221;), Supplemental Medical Review Contractors (&#8220;SMRCs&#8221;) and the Office of Inspector General (&#8220;OIG&#8221;), conduct extensive reviews of claims data to identify potential improper payments. We cannot predict the ultimate outcome of any regulatory reviews or other governmental audits and investigations.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2010, our subsidiary that provides hospice services in Florence, South Carolina received from a ZPIC a request for records regarding a sample of 30 beneficiaries who received services from the subsidiary during the period of January&#160;1, 2008 through March&#160;31, 2010 (the &#8220;Review Period&#8221;) to determine whether the underlying services met pertinent Medicare payment requirements.&#160;We acquired the hospice operations subject to this review on August&#160;1, 2009; the Review Period covers time periods both before and after our ownership of these hospice operations.&#160;Based on the ZPIC&#8217;s findings for 16 beneficiaries, which were extrapolated to all claims for hospice services provided by the Florence subsidiary billed during the Review Period, on June&#160;6, 2011, the Medicare Administrative Contractor (&#8220;MAC&#8221;) for the subsidiary issued a notice of overpayment seeking recovery from our subsidiary of an alleged overpayment. We dispute these findings, and our Florence subsidiary has filed appeals through the Original Medicare Standard Appeals Process, in which we are seeking to have those findings overturned. An administrative law judge ("ALJ") hearing was held in early January 2015. On January&#160;18, 2016, we received a letter dated January&#160;6, 2016 referencing the ALJ hearing decision for the overpayment issued on June&#160;6, 2011. The decision was partially favorable with a new overpayment amount of $3.7 million with a balance owed of $5.6 million, including interest, based on 9 disputed claims (originally 16). We filed an appeal to the Medicare Appeals Council on the remaining 9 disputed claims and also argued that the statistical method used to select the sample was not valid.&#160;No assurances can be given as to the timing or outcome of the Medicare Appeals Council decision. As of June&#160;30, 2021, Medicare has withheld payments of $5.7 million (including additional interest) as part of their standard procedures once this level of the appeal process has been reached. In the event we are not able to recoup this alleged overpayment, we are entitled to be indemnified by the prior owners of the hospice operations for amounts relating to the period prior to August&#160;1, 2009. On January 10, 2019, an arbitration panel from the American Health Lawyers Association determined that the prior owners' liability for their indemnification obligation was $2.8 million. This amount is recorded as an indemnity receivable within other assets in our condensed consolidated balance sheets.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2016, the Company received a request for medical records from SafeGuard Services, L.L.C (&#8220;SafeGuard&#8221;), a ZPIC, related to services provided by some of the care centers that the Company acquired from Infinity Home Care, L.L.C. The review period covers time periods both before and after our ownership of the care centers, which were acquired on December&#160;31, 2015. In August 2017, the Company received Requests for Repayment from Palmetto GBA, LLC ("Palmetto") regarding Infinity Home Care of Lakeland, LLC ("Lakeland Care Centers") and Infinity Home Care of Pinellas, LLC ("Clearwater Care Center"). The Palmetto letters are based on a statistical extrapolation performed by SafeGuard which alleged an overpayment of $34.0 million for the Lakeland Care Centers on a universe of 72 Medicare claims totaling $0.2 million in actual claims payments using a 100% error rate and an overpayment of $4.8 million for the Clearwater Care Center on a universe of 70 Medicare claims totaling $0.2 million in actual claims payments using a 100% error rate.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Lakeland Request for Repayment covers claims between January 2, 2014 and September 13, 2016. The Clearwater Request for Repayment covers claims between January 2, 2015 and December 9, 2016. As a result of partially successful Level I and Level II Administrative Appeals, the alleged overpayment for the Lakeland Care Centers has been reduced to $26.0 million and the alleged overpayment for the Clearwater Care Center has been reduced to $3.3 million. The Company has now filed Level III Administrative Appeals, and will continue to vigorously pursue its appeal rights, which include contesting the methodology used by the ZPIC contractor to perform statistical extrapolation. The Company is contractually entitled to indemnification by the prior owners for all claims prior to December 31, 2015, for up to $12.6 million.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At this stage of the review, based on the information currently available to the Company, the Company cannot predict the timing or outcome of this review. The Company estimates a low-end potential range of loss related to this review of $6.5 million (assuming the Company is successful in seeking indemnity from the prior owners and unsuccessful in demonstrating that the extrapolation method used by SafeGuard was erroneous). The Company has reduced its high-end potential range of loss from $38.8 million (the maximum amount Palmetto claims has been overpaid for both the Lakeland Care Centers and the Clearwater Care Center, of which amount $12.6 million is subject to indemnification by the prior owners) to $29.3 million based on the partial success achieved by the Company in prosecuting its Level I and II Administrative Appeals.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2021, we have an accrued liability of approximately $17.4 million related to this matter. We expect to be indemnified by the prior owners for approximately $10.9 million of the total $12.6 million available indemnification related to this matter and have recorded this amount within other assets in our condensed consolidated balance sheets. The net of these two amounts, $6.5 million, was recorded as a reduction in net service revenue in our condensed consolidated statements of operations during 2017. As of June&#160;30, 2021, $1.5 million of receivables have been impacted by this payment suspension.</span></div><div style="margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Insurance</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are obligated for certain costs associated with our insurance programs, including employee health, workers&#8217; compensation and professional liability. While we maintain various insurance programs to cover these risks, we are self-insured for a substantial portion of our potential claims. We recognize our obligations associated with these costs, up to specified deductible limits in the period in which a claim is incurred, including with respect to both reported claims and claims incurred but not reported. These costs have generally been estimated based on historical data of our claims experience. Such estimates, and the resulting reserves, are reviewed and updated by us on a quarterly basis.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our health insurance has an exposure limit of $1.3 million for any individual covered life. Our workers&#8217; compensation insurance has a retention limit of $1.0 million per incident and our professional liability insurance has a retention limit of $0.3 million per incident.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559207&amp;loc=d3e25336-109308<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559207&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140006518661912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SEGMENT INFORMATION<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">SEGMENT INFORMATION</a></td>
<td class="text">SEGMENT INFORMATIONOur operations involve servicing patients through our three reportable business segments: home health, hospice and personal care. Our home health segment delivers a wide range of services in the homes of individuals who may be recovering from surgery, have a chronic disability or terminal illness or need assistance with completing important personal tasks. Our hospice segment provides palliative care and comfort to terminally ill patients and their families. Our personal care segment provides patients with assistance with the essential activities of daily living. The &#8220;other&#8221; column in the following tables consists of costs relating to executive management and administrative support functions, primarily information services, accounting, finance, billing and collections, legal, compliance, risk management, procurement, marketing, clinical administration, training, human resources and administration.<div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management evaluates performance and allocates resources based on the operating income of the reportable segments, which includes an allocation of corporate expenses directly attributable to the specific segment and includes revenues and all other costs directly attributable to the specific segment. Segment assets are not reviewed by the company&#8217;s chief operating decision maker and therefore are not disclosed below (amounts in millions).</span></div><div style="margin-top:10pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:46.923%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.713%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three-Month Period Ended June 30, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Home<br/>Health</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Hospice</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Personal<br/>Care</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net service revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">349.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">197.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">564.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other operating income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of service, excluding depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">190.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">308.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">175.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">272.9&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">154.3&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.3&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47.2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">490.7&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating income (loss)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(47.2)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three-Month Period Ended June 30, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Home<br/>Health</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Hospice</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Personal<br/>Care</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net service revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">290.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">177.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">485.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other operating income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of service, excluding depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">184.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">295.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">156.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">257.1&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">138.6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.1&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45.1&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">457.9&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating income (loss)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(45.1)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Six-Month Period Ended June 30, 2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Home<br/>Health</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Hospice</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Personal<br/>Care</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net service revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">677.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">389.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,101.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other operating income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of service, excluding depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">373.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">206.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">605.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">161.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">347.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">537.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">303.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95.6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">967.6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating income (loss)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(95.6)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">147.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Six-Month Period Ended June 30, 2020</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Home<br/>Health</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Hospice</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Personal<br/>Care</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net service revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">593.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">346.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">976.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other operating income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of service, excluding depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">363.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">189.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">581.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">147.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">313.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">513.6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">269.7&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34.6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87.8&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">905.7&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating income (loss)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95.3&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.3&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(87.8)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93.8&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 34<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8981-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8721-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8844-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8657-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8721-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -URI http://asc.fasb.org/topic&amp;trid=2134510<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140006518839912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHARE REPURCHASE SHARE REPURCHASE<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockTextBlock', window );">SHARE REPURCHASE</a></td>
<td class="text">SHARE REPURCHASES <div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2021 Stock Repurchase Program</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 23, 2020, we announced that our Board of Directors authorized a stock repurchase program, under which we may repurchase up to $100&#160;million of our outstanding common stock through December 31, 2021.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the program, we are allowed to repurchase shares from time to time through open market purchases, unsolicited or solicited privately negotiated transactions, an accelerated stock repurchase program, and/or a trading plan in compliance with Exchange Act Rule 10b5-1. The timing and the amount of the repurchases will be determined by management based on a number of factors, including but not limited to share price, trading volume and general market conditions, as well as on working capital requirements, general business conditions and other factors. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to this program, we repurchased 4,757 shares of our common stock at a weighted average price of $249.72 per share and a total cost of approximately $1&#160;million during the three-month period ended June 30, 2021 and 297,105 shares of our common stock at a weighted average price of $249.29 per share and a total cost of approximately $74&#160;million during the six-month period ended June 30, 2021. The repurchased shares are classified as treasury shares. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 2, 2021, our Board of Directors authorized a share repurchase program, under which we may repurchase up to $100&#160;million of our outstanding common stock through December 31, 2022, to commence upon the completion of the Company's existing $100&#160;million share repurchase program. See Note 10 - Subsequent Events for additional information on the newly authorized share repurchase program.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for treasury stock, including, but not limited to, average cost per share, description of share repurchase program, shares repurchased, shares held for each class of treasury stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -URI http://asc.fasb.org/subtopic&amp;trid=2208821<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140006626713880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RELATED PARTY TRANSACTIONS RELATED PARTY TRANSACTIONS<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">RELATED PARTY TRANSACTIONS</a></td>
<td class="text">RELATED PARTY TRANSACTIONSWe have an investment in Medalogix, a healthcare predictive data and analytics company, which is accounted for under the equity method. We incurred costs of approximately $1.3 million and $2.6&#160;million during the three and six-month periods ended June&#160;30, 2021, respectively, and approximately $0.7&#160;million and $1.1&#160;million during the three and six-month periods ended June 30, 2020, respectively, in connection with our usage of Medalogix's analytics platforms. We believe that the terms of these transactions are consistent with those negotiated at arm's length.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI http://asc.fasb.org/topic&amp;trid=2122745<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140006627154408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUBSEQUENT EVENT<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">SUBSEQUENT EVENT</a></td>
<td class="text">SUBSEQUENT EVENTS<div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Acquisitions</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 1, 2021, we acquired Visiting Nurse Association ("VNA"), a home health and hospice provider with locations in Nebraska and Iowa for a purchase price of $20.1&#160;million.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 12, 2021, we acquired the regulatory assets of a home health provider in New York for a purchase price of $1.5&#160;million. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 1, 2021, we acquired Contessa Health ("Contessa"), a leader in hospital-at-home and skilled nursing facility ("SNF") at-home services for a purchase price of $250.0&#160;million. With the addition of Contessa&#8217;s risk-based model and claims analytics capabilities, we will be able to bring the essential elements of inpatient hospital and SNF care to patients&#8217; homes, allowing us to become a risk-bearing, home-based care delivery organization, expanding well beyond traditional Home Health and Hospice. Contessa will operate as a wholly owned division of Amedisys and will be reported as a separate operating segment in our future filings.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Second Amendment to Amended and Restated Credit Agreement</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On July 30, 2021, we entered into the Second Amendment to our Credit Agreement (as amended by the Second Amendment, the "Second Amended Credit Agreement"). The Second Amended Credit Agreement provides for a senior secured credit facility in an initial aggregate principal amount of up to $1.0&#160;billion, which includes a $550.0&#160;million Revolving Credit Facility under the Second Amended Credit Agreement, and a term loan facility with a principal amount of up to $450.0&#160;million (the "Amended Term Loan Facility" and collectively with the Revolving Credit Facility, the "Amended Credit Facility").</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Proceeds from the $450.0&#160;million Amended Term Loan Facility were used to pay off the outstanding Term Loan principal balance as of July 30, 2021, as well as to fund 100% of the Contessa acquisition. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The loans issued under the Amended Credit Facility bear interest on a per annum basis, at our election, at either: (i) the Base Rate plus the Applicable Rate or (ii) the Eurodollar Rate plus the Applicable Rate. We are also subject to a commitment fee and letter of credit fee under the terms of the Second Amended Credit Agreement, as presented in the table below.</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.251%"><tr><td style="width:1.0%"/><td style="width:10.151%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:26.158%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.808%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.736%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.808%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.739%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Pricing Tier</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Consolidated Leverage Ratio</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Commitment Fee</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Letter of Credit Fee</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Eurodollar Rate Loans and Daily Floating LIBOR Rate Loans</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Base Rate Loans</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">I</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&gt; 3.00 to 1.0</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.30%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.75%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.00%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.00%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">II</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">&lt;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> 3.00 to 1.0 but &gt; 2.00 to 1.0</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.25%</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.50%</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.75%</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.75%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">III</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">&lt;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> 2.00 to 1.0 but &gt; 0.75 to 1.0</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.20%</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.25%</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.50%</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.50%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IV</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">&lt;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> 0.75 to 1.0</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.15%</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.00%</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.25%</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.25%</span></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The final maturity date of the Amended Credit Facility is July 30, 2026. The Revolving Credit Facility will terminate and be due and payable as of the final maturity date. The Amended Term Loan Facility, however, is subject to quarterly amortization of principal in the amount of (i) 0.625% for the period commencing on July 30, 2021 and ending on September 30, 2023, and (ii) 1.250% for the period commencing on October 1, 2023 and ending on July 30, 2026. The remaining balance of the Amended Term Loan Facility must be paid upon the final maturity date. In addition to the scheduled amortization of the Amended Term Loan Facility, and subject to customary exceptions and reinvestment rights, we are required to prepay the Amended Term Loan Facility first and the Revolving Credit Facility second with 100% of all net cash proceeds received by any loan party or any subsidiary thereof in connection with (a) any asset sale or disposition where such loan party receives net cash proceeds in excess of $5&#160;million or (b) any debt issuance that is not permitted under the Second Amended Credit Agreement.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share Repurchase Program</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On August 2, 2021, our Board of Directors authorized a share repurchase program, under which we may repurchase up to $100&#160;million of our outstanding common stock through December 31, 2022, to commence upon the completion of the Company's existing $100&#160;million share repurchase program, approved by our Board of Directors on December 17, 2020 (the &#8220;Existing Share Repurchase Program&#8221;). Repurchases may be made under the Existing Share Repurchase Program through December 31, 2021. See Note 8 &#8211; Share Repurchases for additional information on the Existing Share Repurchase Program.</span></div>Under the terms of the program, we are allowed to repurchase shares from time to time through open market purchases, unsolicited or solicited privately negotiated transactions, an accelerated stock repurchase program, and/or a trading plan in compliance with Exchange Act Rule 10b5-1. The timing and the amount of the repurchases will be determined by management based on a number of factors, including but not limited to share price, trading volume and general market conditions, as well as on working capital requirements, general business conditions and other factors.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI http://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140006605544456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In our opinion, the accompanying unaudited condensed consolidated financial statements contain all adjustments (consisting solely of normal recurring adjustments) necessary to present fairly our financial position, our results of operations and our cash flows in accordance with U.S. generally accepted accounting principles (&#8220;U.S. GAAP&#8221;) for interim financial reporting. Our results of operations for the interim periods presented are not necessarily indicative of the results of our operations for the entire year and have not been audited by our independent auditors.</span></div>This report should be read in conjunction with our consolidated financial statements and related notes included in our Annual Report on Form 10-K for the year ended December&#160;31, 2020, as filed with the Securities and Exchange Commission (&#8220;SEC&#8221;) on February 25, 2021 (the &#8220;Form 10-K&#8221;), which includes information and disclosures not included herein.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Adopted Accounting Pronouncements</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 1, 2021, the Company adopted Accounting Standards Update ("ASU") 2020-10, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Codification Improvements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which included minor technical corrections and clarifications to improve consistency and clarify the application of various provisions of the codification by amending the codification to include all disclosure guidance in the appropriate disclosure sections and by amending and adding new headings, cross referencing to other guidance and refining or correcting terminology. Our adoption of this standard did not have a material effect on our condensed consolidated financial statements.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Issued Accounting Pronouncements</span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, the Financial Accounting Standards Board ("FASB") issued ASU 2020-04, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which provides optional expedients and exceptions for applying U.S. GAAP to contract modifications and hedging relationships that reference the London Inter-Bank Offered Rate ("LIBOR") or another reference rate expected to be discontinued, subject to meeting certain criteria. In January 2021, the FASB issued ASU 2021-01, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reference Rate Reform (Topic 848)</span>, which adds implementation guidance to ASU 2020-04 to clarify certain optional expedients in Topic 848. The guidance in ASU 2020-04 and ASU 2021-01 was effective upon issuance and may generally be applied prospectively through December 31, 2022. This standard will not have an effect on our condensed consolidated financial statements.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our accounting and reporting policies conform with U.S. GAAP. In preparing the unaudited condensed consolidated financial statements, we are required to make estimates and assumptions that impact the amounts reported in the condensed consolidated financial statements and accompanying notes. Actual results could differ from those estimates.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of Consolidation</a></td>
<td class="text"><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Principles of Consolidation</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These unaudited condensed consolidated financial statements include the accounts of Amedisys, Inc. and our wholly owned subsidiaries. All significant intercompany accounts and transactions have been eliminated and business combinations accounted for as purchases have been included from their respective dates of acquisition. In addition to our wholly owned subsidiaries, we also have certain equity investments that are accounted for as set forth below.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsPolicy', window );">Investments</a></td>
<td class="text"><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investments</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We consolidate investments when the entity is a variable interest entity and we are the primary beneficiary or if we have controlling interests in the entity, which is generally ownership in excess of 50%. Third-party equity interests in our consolidated joint ventures are reflected as noncontrolling interests in our condensed consolidated financial statements. We account for investments in entities in which we have the ability to exercise significant influence under the equity method if we hold 50% or less of the voting stock and the entity is not a variable interest entity in which we are the primary beneficiary. The book value of investments that we account for under the equity method of accounting was $45.1 million and $14.2 million as of June&#160;30, 2021 and December&#160;31, 2020, respectively, and is reflected in other assets within our condensed consolidated balance sheets. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three-month period ended June 30, 2021, a third-party acquired a majority of the issued and outstanding membership interests of one of our equity method investments, Medalogix, for cash, with the remaining membership interests rolling over into a newly formed entity that includes Medalogix as well as another healthcare predictive data and analytics company. We rolled over 100% of our ownership interest in Medalogix to the newly formed entity, and in connection with this transaction, we recognized a $31.1&#160;million gain based on the purchase price of Medalogix which is reflected in gain (loss) on equity method investments within our condensed consolidated statements of operations. </span></div>During the three-month period ended June 30, 2020, we sold our investment in the Heritage Healthcare Innovation Fund, LP via a secondary transaction for $17.9&#160;million which resulted in a $3.0 million loss which is reflected in gain (loss) on equity method investments within our condensed consolidated statements of operations. The Company's original investment was made in 2010 and no longer fit within our strategic areas of focus. Proceeds from the sale were used to pay down debt and fund capital needs.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We account for revenue from contracts with customers in accordance with Accounting Standards Codification ("ASC") 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and as such, we recognize revenue in the period in which we satisfy our performance obligations under our contracts by transferring our promised services to our customers in amounts that reflect the consideration to which we expect to be entitled in exchange for providing patient care, which are the transaction prices allocated to the distinct services. The Company's cost of obtaining contracts is not material.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues are recognized as performance obligations are satisfied, which varies based on the nature of the services provided. Our performance obligation is the delivery of patient care services in accordance with the nature and frequency of services outlined in physicians' orders, which are determined by a physician based on a patient's specific goals. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's performance obligations relate to contracts with a duration of less than one year; therefore, the Company has elected to apply the optional exemption provided by ASC 606 and is not required to disclose the aggregate amount of the transaction price allocated to performance obligations that are unsatisfied or partially unsatisfied as of the end of the reporting period. The unsatisfied or partially unsatisfied performance obligations are generally completed when the patients are discharged, which generally occurs within days or weeks of the end of the reporting period.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We determine the transaction price based on gross charges for services provided, reduced by estimates for contractual and non-contractual revenue adjustments. Contractual revenue adjustments are recorded for the difference between our standard rates and the contracted rates to be realized from patients, third-party payors and others for services provided. Non-contractual revenue adjustments include discounts provided to self-pay, uninsured patients or other payors, adjustments resulting from payment reviews and adjustments arising from our inability to obtain appropriate billing documentation, authorizations or face-to-face documentation. Subsequent changes to the estimate of the transaction price are recorded as adjustments to net service revenue in the period of change. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-contractual revenue adjustments are recorded for self-pay, uninsured patients and other payors by major payor class based on our historical collection experience, aged accounts receivable by payor and current economic conditions. The non-contractual revenue adjustments represent the difference between amounts billed and amounts we expect to collect based on our collection history with similar payors. The Company assesses its ability to collect for the healthcare services provided at the time of patient admission based on the Company's verification of the patient's insurance coverage under Medicare, Medicaid, and other commercial or managed care insurance programs. Medicare represents approximately 75% of our net service revenue </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for the three and six-month periods ended June 30, 2021 and approximately 74% of our net service revenue for the three and six-month periods ended June 30, 2020. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts due from third-party payors, primarily commercial health insurers and government programs (Medicare and Medicaid), include variable consideration for retroactive revenue adjustments due to settlements of audits and payment reviews. We determine our estimates for non-contractual revenue adjustments related to audits and payment reviews based on our historical experience and success rates in the claim appeals and adjudication process. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We determine our estimates for non-contractual revenue adjustments related to our inability to obtain appropriate billing documentation, authorizations, or face-to-face documentation based on our historical experience which primarily includes a historical collection rate of over 99% on Medicare claims. Revenue is recorded at amounts we estimate to be realizable for services provided.</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue by payor class as a percentage of total net service revenue is as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:49.923%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.602%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three-Month Periods Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Six-Month Periods <br/>Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Home Health:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Medicare</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Non-Medicare - Episodic-based</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Non-Medicare - Non-episodic based</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Hospice (1):</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Medicare</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Non-Medicare</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Personal Care</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="24" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1) Acquired AseraCare Hospice ("AseraCare") on June 1, 2020.</span></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Home Health Revenue Recognition</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Medicare Revenue</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective January 1, 2020, the Centers for Medicare and Medicaid Services ("CMS") implemented a revised case-mix adjustment methodology, the Patient-Driven Groupings Model ("PDGM"), to better align payment with patient care needs and ensure that clinically complex and ill beneficiaries have adequate access to home health care. PDGM uses 30-day periods of care rather than 60-day episodes of care as the unit of payment, eliminates the use of the number of therapy visits provided in determining payment and relies more heavily on clinical characteristics and other patient information.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net service revenue is recorded based on the established Federal Medicare home health payment rate for a 30-day period of care. ASC 606 notes that if an entity has a right to consideration from a customer in an amount that corresponds directly with the value of the entity&#8217;s performance completed to date, the entity may recognize revenue in the amount to which the entity has a right to invoice. We have elected to apply the "right to invoice" practical expedient and therefore, our revenue recognition is based on the reimbursement we are entitled to for each 30-day payment period. We utilize our historical average length of stay for each 30-day period of care as the measure of progress towards the satisfaction of our performance obligation.</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">PDGM uses timing, admission source, functional impairment levels and principal and other diagnoses to case-mix adjust payments. The case-mix adjusted payment for a 30-day period of care is subject to additional adjustments based on certain variables, including, but not limited to (a) an outlier payment if our patient's care was unusually costly (capped at 10% of total reimbursement per provider number); (b)&#160;a low utilization payment adjustment (&#8220;LUPA&#8221;) if the number of visits provided was less than the established threshold, which ranges from two to six visits and varies for every case-mix group under PDGM; (c)&#160;a partial payment if a patient is transferred to another provider or from another provider before completing the 30-day period of care; and (d) the applicable geographic wage index. Payments for routine and non-routine supplies are included in the 30-day payment rate.</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medicare can also make various adjustments to payments received if we are unable to produce appropriate billing documentation or acceptable authorizations. We estimate the impact of such adjustments based on our historical experience, which primarily includes a historical collection rate of over 99% on Medicare claims, and record this estimate during the period in which services are rendered to revenue with a corresponding reduction to patient accounts receivable.</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts due from Medicare include variable consideration for retroactive revenue adjustments due to settlements of audits and payment reviews. We determine our estimates for non-contractual revenue adjustments related to audits and payment reviews based on our historical experience and success rates in the claim appeals and adjudication process.</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All Medicare contracts are required to have a signed plan of care which represents a single performance obligation, comprised of the delivery of a series of distinct services that are substantially similar and have a similar pattern of transfer to the customer. Accordingly, the Company accounts for the series of services ("episode") as a single performance obligation satisfied over time, as the customer simultaneously receives and consumes the benefits of the goods and services provided. An episode starts the first day a billable visit is performed and ends 60 days later or upon discharge, if earlier, with multiple continuous episodes allowed. </span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Medicare home health benefit requires that beneficiaries be homebound (meaning that the beneficiary is unable to leave his/her home without a considerable and taxing effort), require intermittent skilled nursing, physical therapy or speech therapy services, and receive treatment under a plan of care established and periodically reviewed by a physician. In order to provide greater flexibility during the novel coronavirus pandemic ("COVID-19"), CMS relaxed the definition of homebound status through the duration of the public health emergency. During the pandemic, a beneficiary is considered homebound if they have been instructed by a physician not to leave their home because of a confirmed or suspected COVID-19 diagnosis or if the patient has a condition that makes them more susceptible to contracting COVID-19. Therefore, if a beneficiary is homebound due to COVID-19 and requires skilled services, the services will be covered under the Medicare home health benefit. </span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2020, 20% of reimbursement from each Medicare episode, referred to as a request for anticipated payment ("RAP"), was billed near the start of each 30-day period of care, and cash was typically received before all services were rendered. Any cash received from Medicare for a RAP for a 30-day period of care that exceeded the associated revenue earned was recorded to accrued expenses within our condensed consolidated balance sheets. CMS fully eliminated all upfront payments associated with RAPs effective January 1, 2021.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Non-Medicare Revenue</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Episodic-based Revenue.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We recognize revenue in a similar manner as we recognize Medicare revenue for amounts that are paid by other insurance carriers, including Medicare Advantage programs; however, these amounts can vary based upon the negotiated terms, the majority of which range from 95% to 100% of Medicare rates.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Non-episodic based Revenue.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Gross revenue is recorded on an accrual basis based upon the date of service at amounts equal to our established or estimated per-visit rates. Contractual revenue adjustments are recorded for the difference between our standard rates and the contracted rates to be realized from patients, third parties and others for services provided and are deducted from gross revenue to determine net service revenue. We also make non-contractual revenue adjustments to non-episodic revenue based on our historical experience to reflect the estimated transaction price. We receive a minimal amount of our net service revenue from patients who are either self-insured or are obligated for an insurance co-payment.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Hospice Revenue Recognition</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Hospice Medicare Revenue</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gross revenue is recorded on an accrual basis based upon the date of service at amounts equal to the estimated payment rates. The estimated payment rates are predetermined daily or hourly rates for each of the four levels of care we deliver. The four levels of care are routine care, general inpatient care, continuous home care and respite care. Routine care accounted for 97% of our total Medicare hospice service revenue for the three and six-month periods ended June&#160;30, 2021 and June 30, 2020. There are two separate payment rates for routine care: payments for the first 60 days of care and care beyond 60 days. In addition to the two routine rates, we may also receive a service intensity add-on (&#8220;SIA&#8221;). The SIA is based on visits made in the last seven days of life by a registered nurse or medical social worker for patients in a routine level of care.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The performance obligation is the delivery of hospice services to the patient, as determined by a physician, each day the patient is on hospice care.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We make adjustments to Medicare revenue for non-contractual revenue adjustments, which include our inability to obtain appropriate billing documentation or acceptable authorizations and other reasons unrelated to credit risk. We estimate the impact of these non-contractual revenue adjustments based on our historical experience, which primarily includes a historical collection rate of over 99% on Medicare claims, and record it during the period services are rendered.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, our hospice service revenue is subject to certain limitations on payments from Medicare which are considered variable consideration. We are subject to an inpatient cap limit and an overall Medicare payment cap for each provider number. We monitor these caps on a provider-by-provider basis and estimate amounts due back to Medicare if we estimate a cap has been exceeded.&#160;We record these adjustments as a reduction to revenue and an increase in accrued expenses within our condensed consolidated balance sheets. Providers are required to self-report and pay their estimated cap liability by February 28</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">th</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of the following year. As of June&#160;30, 2021, we have recorded $10.0 million for estimated amounts due back to Medicare in accrued expenses for the Federal cap years ended October&#160;31, 2016 through September 30, 2021; $3.1&#160;million of this balance was acquired with the AseraCare acquisition. As of December&#160;31, 2020, we had recorded $9.3 million for estimated amounts due back to Medicare in accrued expenses for the Federal cap years ended October&#160;31, 2014 through September 30, 2021.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Hospice Non-Medicare Revenue</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gross revenue is recorded on an accrual basis based upon the date of service at amounts equal to our established rates or estimated per day rates, as applicable. Contractual revenue adjustments are recorded for the difference between our standard rates and the contractual rates to be realized from patients, third-party payors and others for services provided and are deducted from gross revenue to determine our net service revenue. We also make non-contractual adjustments to non-Medicare revenue based on our historical experience to reflect the estimated transaction price.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Personal Care Revenue Recognition</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Personal Care Revenue</span></div>We generate net service revenues by providing our services directly to patients based on authorized hours, visits or units determined by the relevant agency, at a rate that is either contractual or fixed by legislation. Net service revenue is recognized at the time services are rendered based on gross charges for the services provided, reduced by estimates for contractual and non-contractual revenue adjustments. We receive payment for providing such services from payors, including state and local governmental agencies, managed care organizations, commercial insurers and private consumers. Payors include the following elder service agencies: Aging Services Access Points ("ASAPs"), Senior Care Options ("SCOs"), Program of All-Inclusive Care for the Elderly ("PACE") and the Veterans Administration ("VA").<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_GovernmentGrantsPolicyTextBlock', window );">Government Grants</a></td>
<td class="text"><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Government Grants</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the absence of specific guidance to account for government grants under U.S. GAAP, we have decided to account for government grants in accordance with International Accounting Standard ("IAS") 20, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounting for Government Grants and Disclosure of Government Assistance</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and as such, we recognize grant income on a systematic basis in line with the recognition of expenses or the loss of revenues for which the grants are intended to compensate. We recognize grants once both of the following conditions are met: (1) we are able to comply with the relevant conditions of the grant and (2) the grant will be received. See Note 3 - Novel Coronavirus Pandemic ("COVID-19") for additional information on our accounting for government funds received under the Coronavirus Aid, Relief and Economic Security Act ("CARES Act") and the Mass Home Care ASAP COVID-19 Provider Sustainability Program.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy', window );">Cash, Cash Equivalents and Restricted Cash</a></td>
<td class="text"><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash, Cash Equivalents and Restricted Cash </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents include certificates of deposit and all highly liquid debt instruments with maturities of three months or less when purchased. Our cash balance as of June 30, 2021 includes approximately $62&#160;million associated with the CARES Act Provider Relief Fund ("PRF"). We separated the PRF funds into their own account and as of June 30, 2021, we have only transferred funds used through March 31, 2021 to our operating account. We will transfer funds used during the three-month period ended June 30, 2021, totaling approximately $4&#160;million, to our operating account during the third quarter of 2021 and repay the remaining $58&#160;million to the U.S. Department of Health and Human Services ("HHS") by October 30, 2021. Restricted cash includes cash that is not available for ordinary business use. As of June 30, 2021, we had $1&#160;million of restricted cash that was placed into an escrow account related to the indemnity and closing payment adjustment provisions within the Asana Hospice purchase agreement.</span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the balances related to our cash, cash equivalents and restricted cash (amounts in millions):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.250%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.981%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.739%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of June 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92.6&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83.3&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TradeAndOtherAccountsReceivablePolicy', window );">Patient Accounts Receivable</a></td>
<td class="text"><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Patient Accounts Receivable </span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We report accounts receivable from services rendered at their estimated transaction price, which includes contractual and non-contractual revenue adjustments based on the amounts expected to be due from payors. Our patient accounts receivable are uncollateralized and consist of amounts due from Medicare, Medicaid, other third-party payors and patients. The Company's non-Medicare third-party payor base is comprised of a diverse group of payors that are geographically dispersed across the country. As of June&#160;30, 2021, there is one payor, other than Medicare, that accounts for 10% of our total outstanding patient receivables. Thus, we believe there are no other significant concentrations of receivables that would subject us to any significant credit risk in the collection of our patient accounts receivable. We write off accounts on a monthly basis once we have exhausted our collection efforts and deem an account to be uncollectible. We believe the collectability risk associated with our Medicare accounts, which represent 66% and 64% of our patient accounts receivable at June&#160;30, 2021 and December&#160;31, 2020, respectively, is limited due to our historical collection rate of over 99% from Medicare and the fact that Medicare is a U.S. government payor. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not believe there are any significant concentrations of revenues from any payor that would subject us to any significant credit risk in the collection of our accounts receivable.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Medicare Home Health</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For our home health patients, our pre-billing process includes verifying that we are eligible for payment from Medicare for the services that we provide to our patients. Our Medicare billing begins with a process to ensure that our billings are accurate through the utilization of an electronic Medicare claim review. Prior to January 1, 2021, we submitted a RAP for 20% of our estimated payment for each 30-day period of care. The RAP received was then deducted from our final payment. Effective January 1, 2021, CMS eliminated all upfront payments associated with RAPs.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Medicare Hospice</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For our hospice patients, our pre-billing process includes verifying that we are eligible for payment from Medicare for the services that we provide to our patients. Our Medicare billing begins with a process to ensure that our billings are accurate through the utilization of an electronic Medicare claim review. We bill Medicare on a monthly basis for the services provided to the patient.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Non-Medicare Home Health, Hospice and Personal Care</span></div>For our non-Medicare patients, our pre-billing process primarily begins with verifying a patient&#8217;s eligibility for services with the applicable payor. Once the patient has been confirmed for eligibility, we will provide services to the patient and bill the applicable payor. Our review and evaluation of non-Medicare accounts receivable includes a detailed review of outstanding balances and special consideration to concentrations of receivables from particular payors or groups of payors with similar characteristics that would subject us to any significant credit risk.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsPolicy', window );">Business Combinations</a></td>
<td class="text"><div style="margin-top:16pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Business Combinations</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We account for acquisitions using the acquisition method of accounting in accordance with ASC 805, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business Combinations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Acquisitions are accounted for as purchases and are included in our condensed consolidated financial statements from their respective acquisition dates. Assets acquired and liabilities assumed, if any, are measured at fair value on the acquisition date using the appropriate valuation method. Goodwill generated from acquisitions is recognized for the excess of the purchase price over tangible and identifiable intangible assets. In determining the fair value of identifiable intangible assets, we use various valuation techniques including discounted cash flow analysis, the income approach, the cost approach and the market approach. These valuation methods require us to make estimates and assumptions surrounding projected revenues and costs, growth rates and discount rates.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value of Financial Instruments</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following details our financial instruments where the carrying value and the fair value differ (amounts in millions):</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.076%"><tr><td style="width:1.0%"/><td style="width:24.954%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.821%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.553%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.821%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.553%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.821%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.553%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.824%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value at Reporting Date Using</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Financial Instrument</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying Value as of June 30, 2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted&#160;Prices&#160;in&#160;Active<br/>Markets for Identical<br/>Items<br/>(Level 1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant&#160;Other<br/>Observable&#160;Inputs<br/>(Level 2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Unobservable&#160;Inputs<br/>(Level&#160;3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term obligations</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">189.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">191.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value hierarchy is based on three levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value. The three levels of inputs are as follows:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level&#160;1 &#8211; Quoted prices in active markets for identical assets and liabilities.</span></div><div style="padding-left:36pt;text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level&#160;2 &#8211; Inputs other than Level&#160;1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.</span></div><div style="padding-left:36pt;text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level&#160;3 &#8211; Unobservable inputs that are supported by little or no market activity and are significant to the fair value of the assets or liabilities.</span></div>Our deferred compensation plan assets are recorded at fair value and are considered a level 2 measurement. For our other financial instruments, including our cash and cash equivalents, patient accounts receivable, accounts payable, payroll and employee benefits and accrued expenses, we estimate the carrying amounts approximate fair value.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Weighted-Average Shares Outstanding</a></td>
<td class="text">Weighted-Average Shares OutstandingNet income per share attributable to Amedisys, Inc. common stockholders, calculated on the treasury stock method, is based on the weighted average number of shares outstanding during the period.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_GovernmentGrantsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accounting policy disclosure text block for government grants</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_GovernmentGrantsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -Subparagraph (a)-(d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6909625&amp;loc=d3e227-128457<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Entity's cash and cash equivalents accounting policy with respect to restricted balances.  Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for equity method of accounting for investments and other interests. Investment includes, but is not limited to, unconsolidated subsidiary, corporate joint venture, noncontrolling interest in real estate venture, limited partnership, and limited liability company. Information includes, but is not limited to, ownership percentage, reason equity method is or is not considered appropriate, and accounting policy election for distribution received.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 21D<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=SL94080555-108585<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 60<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=7493716&amp;loc=d3e21868-110260<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13279-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18823-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18823-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TradeAndOtherAccountsReceivablePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121611835&amp;loc=d3e4975-111524<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121611835&amp;loc=d3e5212-111524<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121611835&amp;loc=SL6953423-111524<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121611835&amp;loc=d3e5093-111524<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121611835&amp;loc=d3e5033-111524<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=84159169&amp;loc=d3e10133-111534<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TradeAndOtherAccountsReceivablePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140006604838440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTableTextBlock', window );">Schedule of Revenue by Payor Class</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue by payor class as a percentage of total net service revenue is as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:49.923%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.602%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three-Month Periods Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Six-Month Periods <br/>Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Home Health:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Medicare</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Non-Medicare - Episodic-based</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Non-Medicare - Non-episodic based</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Hospice (1):</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Medicare</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Non-Medicare</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Personal Care</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="24" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1) Acquired AseraCare Hospice ("AseraCare") on June 1, 2020.</span></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlockTableTextBlock', window );">Schedule of Cash Cash Equivalents and Restricted Cash</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the balances related to our cash, cash equivalents and restricted cash (amounts in millions):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.250%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.981%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.739%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of June 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92.6&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83.3&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_FinancialInstrumentDetailsTableTextBlock', window );">Schedule of Fair Value of Financial Instruments</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following details our financial instruments where the carrying value and the fair value differ (amounts in millions):</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.076%"><tr><td style="width:1.0%"/><td style="width:24.954%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.821%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.553%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.821%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.553%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.821%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.553%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.824%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value at Reporting Date Using</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Financial Instrument</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying Value as of June 30, 2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted&#160;Prices&#160;in&#160;Active<br/>Markets for Identical<br/>Items<br/>(Level 1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant&#160;Other<br/>Observable&#160;Inputs<br/>(Level 2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Unobservable&#160;Inputs<br/>(Level&#160;3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term obligations</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">189.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">191.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock', window );">Schedule of Weighted-Average Shares Outstanding</a></td>
<td class="text">The following table sets forth, for the periods indicated, shares used in our computation of the weighted-average shares outstanding, which are used to calculate our basic and diluted net income attributable to Amedisys, Inc. common stockholders (amounts in thousands):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.829%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.624%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three-<br/>Month Periods<br/>Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Six-<br/>Month Periods<br/>Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average number of shares outstanding - basic</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,588&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,412&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,684&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,371&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of dilutive securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">139&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">570&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">145&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">582&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:20.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-vested stock and stock units</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">254&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">303&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">256&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">306&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average number of shares outstanding - diluted</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,981&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,285&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,085&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,259&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Anti-dilutive securities</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_FinancialInstrumentDetailsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Financial instrument details, table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_FinancialInstrumentDetailsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlockTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of Cash, Cash Equivalents and Restricted Cash Table Text Block</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlockTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of patient service revenue (net of contractual allowances and discounts), by major payor source of revenue for health care organizations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the weighted average number of shares used in calculating basic net earnings per share (or unit) and diluted earnings per share (or unit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140006517210344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NOVEL CORONAVIRUS PANDEMIC "COVID-19" (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ExtraordinaryAndUnusualItemsAbstract', window );"><strong>Unusual or Infrequent Items, or Both [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_ScheduleOfCaresActProviderReliefFundsTableTextBlock', window );">Schedule of Cares Act Provider Relief Funds</a></td>
<td class="text">In summary, the total funds that we have received from the CARES Act PRF have been accounted for as follows as of June 30, 2021 (amounts in millions):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:87.719%"><tr><td style="width:1.0%"/><td style="width:76.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.567%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Funds utilized through June 30, 2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Estimated funds to be repaid to the government</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Funds received by unconsolidated joint ventures</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106.8&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_ScheduleOfCaresActProviderReliefFundsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of Cares Act Provider Relief Funds</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_ScheduleOfCaresActProviderReliefFundsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ExtraordinaryAndUnusualItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ExtraordinaryAndUnusualItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140006518583240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACQUISITIONS (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsAbstract', window );"><strong>Business Combinations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock', window );">Schedule of Business Acquisitions</a></td>
<td class="text">The total consideration of $229.6 million&#160;has been allocated to assets acquired and liabilities assumed as of the acquisition date as follows (amounts in millions):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:79.970%"><tr><td style="width:1.0%"/><td style="width:74.037%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.763%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patient accounts receivable</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right of use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total assets acquired</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.3)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payroll and employee benefits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total liabilities assumed</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29.5)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net identifiable assets acquired</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">212.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total consideration</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">229.6&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of a material business combination completed during the period, including background, timing, and recognized assets and liabilities. This table  does not include leveraged buyouts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1486-128463<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140006517211176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LONG-TERM OBLIGATIONS LONG-TERM OBLIGATIONS (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock', window );">Schedule of Long-Term Debt</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-term debt consists of the following for the periods indicated (amounts in millions):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.812%"><tr><td style="width:1.0%"/><td style="width:66.256%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.823%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.596%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.825%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$175.0 million Term Loan; interest rate at Base Rate plus Applicable Rate or Eurodollar Rate plus Applicable Rate (1.4% at June 30, 2021); due February&#160;4, 2024</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">159.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">164.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$550.0 million Revolving Credit Facility; interest only payments; interest rate at Base Rate plus Applicable Rate or Eurodollar Rate plus Applicable Rate (1.3% at June 30, 2021); due February&#160;4, 2024</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance leases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Principal amount of long-term obligations</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">191.8&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">217.7&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred debt issuance costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">189.6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">215.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of long-term obligations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">179.4&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">204.5&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock', window );">Schedule of Commitment Fee Under Credit Facilities</a></td>
<td class="text">We are also subject to a commitment fee and letter of credit fee under the terms of the Amended Credit Agreement, as presented in the table below.<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.251%"><tr><td style="width:1.0%"/><td style="width:10.151%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:26.158%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.808%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.736%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.808%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.739%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Pricing Tier</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Consolidated Leverage Ratio</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Commitment Fee</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Letter of Credit Fee</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Eurodollar Rate Loans</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Base Rate Loans</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">I</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8805; 3.00 to 1.0</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.35%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.75%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.00%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.00%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">II</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&lt; 3.00 to 1.0 but &#8805; 2.00 to 1.0</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.30%</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.50%</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.75%</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.75%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">III</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&lt; 2.00 to 1.0 but &#8805; 0.75 to 1.0</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.25%</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.25%</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.50%</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.50%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IV</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&lt; 0.75 to 1.0</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.20%</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.00%</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.25%</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.25%</span></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28541-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21506-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(e),(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28551-108399<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21521-112644<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21538-112644<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=75038535&amp;loc=d3e64711-112823<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtInstrumentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of short-term or long-term contractual arrangements with lenders, including letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(e),(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140006518515736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SEGMENT INFORMATION (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock', window );">Schedule of Operating Income of Reportable Segments</a></td>
<td class="text"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:46.923%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.713%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three-Month Period Ended June 30, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Home<br/>Health</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Hospice</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Personal<br/>Care</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net service revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">349.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">197.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">564.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other operating income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of service, excluding depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">190.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">308.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">175.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">272.9&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">154.3&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.3&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47.2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">490.7&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating income (loss)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(47.2)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three-Month Period Ended June 30, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Home<br/>Health</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Hospice</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Personal<br/>Care</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net service revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">290.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">177.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">485.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other operating income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of service, excluding depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">184.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">295.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">156.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">257.1&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">138.6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.1&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45.1&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">457.9&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating income (loss)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(45.1)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Six-Month Period Ended June 30, 2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Home<br/>Health</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Hospice</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Personal<br/>Care</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net service revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">677.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">389.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,101.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other operating income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of service, excluding depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">373.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">206.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">605.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">161.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">347.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">537.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">303.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95.6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">967.6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating income (loss)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(95.6)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">147.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Six-Month Period Ended June 30, 2020</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Home<br/>Health</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Hospice</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Personal<br/>Care</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net service revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">593.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">346.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">976.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other operating income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of service, excluding depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">363.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">189.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">581.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">147.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">313.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">513.6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">269.7&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34.6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87.8&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">905.7&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating income (loss)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95.3&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.3&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(87.8)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93.8&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8813-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140006523260984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUBSEQUENT EVENT (Tables)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock', window );">Schedule of Commitment Fee Under Credit Facilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">We are also subject to a commitment fee and letter of credit fee under the terms of the Amended Credit Agreement, as presented in the table below.<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.251%"><tr><td style="width:1.0%"/><td style="width:10.151%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:26.158%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.808%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.736%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.808%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.739%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Pricing Tier</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Consolidated Leverage Ratio</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Commitment Fee</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Letter of Credit Fee</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Eurodollar Rate Loans</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Base Rate Loans</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">I</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8805; 3.00 to 1.0</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.35%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.75%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.00%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.00%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">II</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&lt; 3.00 to 1.0 but &#8805; 2.00 to 1.0</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.30%</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.50%</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.75%</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.75%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">III</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&lt; 2.00 to 1.0 but &#8805; 0.75 to 1.0</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.25%</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.25%</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.50%</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.50%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IV</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&lt; 0.75 to 1.0</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.20%</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.00%</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.25%</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.25%</span></td></tr></table><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock', window );">Schedule of Commitment Fee Under Credit Facilities</a></td>
<td class="text">We are also subject to a commitment fee and letter of credit fee under the terms of the Second Amended Credit Agreement, as presented in the table below.<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.251%"><tr><td style="width:1.0%"/><td style="width:10.151%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:26.158%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.808%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.736%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.808%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.739%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Pricing Tier</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Consolidated Leverage Ratio</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Commitment Fee</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Letter of Credit Fee</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Eurodollar Rate Loans and Daily Floating LIBOR Rate Loans</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Base Rate Loans</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">I</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&gt; 3.00 to 1.0</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.30%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.75%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.00%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.00%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">II</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">&lt;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> 3.00 to 1.0 but &gt; 2.00 to 1.0</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.25%</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.50%</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.75%</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.75%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">III</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">&lt;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> 2.00 to 1.0 but &gt; 0.75 to 1.0</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.20%</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.25%</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.50%</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.50%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IV</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">&lt;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> 0.75 to 1.0</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.15%</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.00%</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.25%</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.25%</span></td></tr></table><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of short-term or long-term contractual arrangements with lenders, including letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(e),(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140006604808296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NATURE OF OPERATIONS, CONSOLIDATION AND PRESENTATION OF FINANCIAL STATEMENTS - Narrative (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($) </div>
<div>care_center </div>
<div>state</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($) </div>
<div>care_center </div>
<div>state</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfStatesInWhichEntityOperates', window );">Number of states with facilities | state</a></td>
<td class="nump">39<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_MinimumPercentOwnershipForControllingInterestPercent', window );">Minimum ownership percentage for controlling interest (percent)</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_MaximumPercentOwnershipForEquityMethodPercent', window );">Maximum ownership percentage for equity method investment (percent)</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentAggregateCost', window );">Equity method investment, aggregate cost</a></td>
<td class="nump">$ 45,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 45,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,200<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfEquityMethodInvestments', window );">Proceeds from sale of equity method investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 17,876<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnInvestments', window );">Gain (loss) on equity method investments</a></td>
<td class="nump">31,092<span></span>
</td>
<td class="num">$ (2,980)<span></span>
</td>
<td class="nump">$ 31,092<span></span>
</td>
<td class="num">$ (2,980)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_TypeofEquityMethodInvestmentAxis=amed_HeritageHealthcareInnovationFundLPMember', window );">Heritage Healthcare Innovation Fund, LP [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfEquityMethodInvestments', window );">Proceeds from sale of equity method investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnInvestments', window );">Gain (loss) on equity method investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_TypeofEquityMethodInvestmentAxis=amed_MedalogixMember', window );">Medalogix [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnInvestments', window );">Gain (loss) on equity method investments</a></td>
<td class="nump">$ 31,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=amed_HomeHealthMember', window );">Home Health [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_OperatingCareCenters', window );">Number of owned and operated care centers | care_center</a></td>
<td class="nump">320<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">320<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=amed_HospiceMember', window );">Hospice [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_OperatingCareCenters', window );">Number of owned and operated care centers | care_center</a></td>
<td class="nump">180<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">180<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=amed_PersonalCareMember', window );">Personal Care [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_OperatingCareCenters', window );">Number of owned and operated care centers | care_center</a></td>
<td class="nump">14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember', window );">Revenue from Contract with Customer [Member] | Product Concentration Risk | Medicare Revenue [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percent of net services revenue</a></td>
<td class="nump">75.00%<span></span>
</td>
<td class="nump">74.00%<span></span>
</td>
<td class="nump">75.00%<span></span>
</td>
<td class="nump">74.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_MaximumPercentOwnershipForEquityMethodPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description containing the percentage ownership required in order for an investment to be treated under the equity method of accounting in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_MaximumPercentOwnershipForEquityMethodPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_MinimumPercentOwnershipForControllingInterestPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description containing the percentage ownership required in order for a variable interest entity (VIE) to be consolidated in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_MinimumPercentOwnershipForControllingInterestPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_OperatingCareCenters">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description containing the number of care centers owned by the entity as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_OperatingCareCenters</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13531-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13537-108611<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentAggregateCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents the aggregate cost of investments accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentAggregateCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of realized and unrealized gain (loss) on investment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27405-111563<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(c),9(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfStatesInWhichEntityOperates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of states the entity operates in as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfStatesInWhichEntityOperates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the sale of equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_TypeofEquityMethodInvestmentAxis=amed_HeritageHealthcareInnovationFundLPMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_TypeofEquityMethodInvestmentAxis=amed_HeritageHealthcareInnovationFundLPMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_TypeofEquityMethodInvestmentAxis=amed_MedalogixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_TypeofEquityMethodInvestmentAxis=amed_MedalogixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=amed_HomeHealthMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=amed_HomeHealthMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=amed_HospiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=amed_HospiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=amed_PersonalCareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=amed_PersonalCareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_ProductConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_ProductConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=amed_MedicareRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=amed_MedicareRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140006524406680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Revenue Recognition Narrative (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($) </div>
<div>visit</div>
</th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems', window );"><strong>Revenue Recognition, Multiple-deliverable Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_NetServiceRevenuePeriodOfCarePaymentRateDuration', window );">Net service revenue period of care payment rate (days)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_PercentageOfTotalReimbursementOfOutlierPayment', window );">Percentage of total reimbursement of outlier payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_HistoricalCollectionRateFromMedicare', window );">Historical collection rate from Medicare</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">99.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_HospiceMedicareRevenueRateAccountedForRoutineCare', window );">Hospice Medicare revenue rate accounted for routine care</a></td>
<td class="nump">97.00%<span></span>
</td>
<td class="nump">97.00%<span></span>
</td>
<td class="nump">97.00%<span></span>
</td>
<td class="nump">97.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_NetServiceRevenueEpisodePaymentRateDuration', window );">Net service revenue episode payment rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">60 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_RateOfRequestForAnticipatedPaymentSubmittedForInitialPeriodOfCare', window );">Rate of request for anticipated payment submitted for the initial episode of care</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=amed_HomeHealthMember', window );">Home Health [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems', window );"><strong>Revenue Recognition, Multiple-deliverable Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_HistoricalCollectionRateFromMedicare', window );">Historical collection rate from Medicare</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">99.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=amed_HomeHealthMember', window );">Home Health [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems', window );"><strong>Revenue Recognition, Multiple-deliverable Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_LowUtilizationPaymentAdjustmentNumberOfVisits', window );">Low utilization payment adjustment, maximum number of visits | visit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_NonMedicareRevenueTermRates', window );">Non-Medicare revenue term rates</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">95.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=amed_HomeHealthMember', window );">Home Health [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems', window );"><strong>Revenue Recognition, Multiple-deliverable Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_LowUtilizationPaymentAdjustmentNumberOfVisits', window );">Low utilization payment adjustment, maximum number of visits | visit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_NonMedicareRevenueTermRates', window );">Non-Medicare revenue term rates</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=amed_HospiceMember', window );">Hospice [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems', window );"><strong>Revenue Recognition, Multiple-deliverable Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_HistoricalCollectionRateFromMedicare', window );">Historical collection rate from Medicare</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">99.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_CapYearAxis=amed_CapYearTwoThousandFourteenThroughTwoThousandTwentyOneMember', window );">Cap Year 2014 Through 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems', window );"><strong>Revenue Recognition, Multiple-deliverable Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_EstimatedAmountDueBackToMedicareInOtherAccruedLiabilities', window );">Estimated amounts due back to Medicare</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_CapYearAxis=amed_CapYearTwoThousandSixteenThroughTwoThousandTwentyOneMember', window );">Cap Year 2016 Through 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems', window );"><strong>Revenue Recognition, Multiple-deliverable Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_EstimatedAmountDueBackToMedicareInOtherAccruedLiabilities', window );">Estimated amounts due back to Medicare</a></td>
<td class="nump">$ 10.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_ProductConcentrationRiskMember', window );">Product Concentration Risk | Revenue from Contract with Customer [Member] | Medicare Revenue [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems', window );"><strong>Revenue Recognition, Multiple-deliverable Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percent of net services revenue</a></td>
<td class="nump">75.00%<span></span>
</td>
<td class="nump">74.00%<span></span>
</td>
<td class="nump">75.00%<span></span>
</td>
<td class="nump">74.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=amed_AseraCareHospiceMember', window );">AseraCare Hospice [Member] | Cap Year 2016 Through 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems', window );"><strong>Revenue Recognition, Multiple-deliverable Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_EstimatedAmountDueBackToMedicareInOtherAccruedLiabilities', window );">Estimated amounts due back to Medicare</a></td>
<td class="nump">$ 3.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_EstimatedAmountDueBackToMedicareInOtherAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Estimate of obligations due Medicare upon demand due to overages for the inpatient cap and/or overall payment cap.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_EstimatedAmountDueBackToMedicareInOtherAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_HistoricalCollectionRateFromMedicare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Historical collection rate from Medicare.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_HistoricalCollectionRateFromMedicare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_HospiceMedicareRevenueRateAccountedForRoutineCare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description containing the percentage of the entity's Hospice net Medicare service revenue that is derived from routine care.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_HospiceMedicareRevenueRateAccountedForRoutineCare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_LowUtilizationPaymentAdjustmentNumberOfVisits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description containing the visit threshold for a low utilization payment adjustment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_LowUtilizationPaymentAdjustmentNumberOfVisits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_NetServiceRevenueEpisodePaymentRateDuration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description containing the number of days from the date the request for anticipated payment was received in which the final bill must be submitted to Medicare.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_NetServiceRevenueEpisodePaymentRateDuration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_NetServiceRevenuePeriodOfCarePaymentRateDuration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description containing the number of days from the date the request for anticipated payment was received in which the final bill must be submitted to Medicare.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_NetServiceRevenuePeriodOfCarePaymentRateDuration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_NonMedicareRevenueTermRates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Non-Medicare Revenue Term Rates as a percentage of Medicare Term Rates</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_NonMedicareRevenueTermRates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_PercentageOfTotalReimbursementOfOutlierPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage at which total reimbursement is capped if cost of care is unusually costly.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_PercentageOfTotalReimbursementOfOutlierPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_RateOfRequestForAnticipatedPaymentSubmittedForInitialPeriodOfCare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description containing the percentage of estimated payment that is requested at the start of care for an initial period of care.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_RateOfRequestForAnticipatedPaymentSubmittedForInitialPeriodOfCare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13531-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13537-108611<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=amed_HomeHealthMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=amed_HomeHealthMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=amed_HospiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=amed_HospiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_CapYearAxis=amed_CapYearTwoThousandFourteenThroughTwoThousandTwentyOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_CapYearAxis=amed_CapYearTwoThousandFourteenThroughTwoThousandTwentyOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_CapYearAxis=amed_CapYearTwoThousandSixteenThroughTwoThousandTwentyOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_CapYearAxis=amed_CapYearTwoThousandSixteenThroughTwoThousandTwentyOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_ProductConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_ProductConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=amed_MedicareRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=amed_MedicareRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=amed_AseraCareHospiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=amed_AseraCareHospiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140006612525688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Revenue by Payor Class (Details)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems', window );"><strong>Revenue Recognition, Multiple-deliverable Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_Revenuebypayorclassasapercentageoftotalnetservicerevenue', window );">Revenue by payor class as a percentage of total net service revenue</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_PayorClassAxis=amed_HomeHealthMedicareMember', window );">Home Health Medicare [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems', window );"><strong>Revenue Recognition, Multiple-deliverable Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_Revenuebypayorclassasapercentageoftotalnetservicerevenue', window );">Revenue by payor class as a percentage of total net service revenue</a></td>
<td class="nump">42.00%<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
<td class="nump">42.00%<span></span>
</td>
<td class="nump">41.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_PayorClassAxis=amed_HomeHealthNonMedicareEpisodicBasedMember', window );">Home Health Non-Medicare - Episodic Based [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems', window );"><strong>Revenue Recognition, Multiple-deliverable Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_Revenuebypayorclassasapercentageoftotalnetservicerevenue', window );">Revenue by payor class as a percentage of total net service revenue</a></td>
<td class="nump">8.00%<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_PayorClassAxis=amed_HomeHealthNonMedicareNonEpisodicBasedMember', window );">Home Health Non-Medicare - Non-Episodic Based [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems', window );"><strong>Revenue Recognition, Multiple-deliverable Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_Revenuebypayorclassasapercentageoftotalnetservicerevenue', window );">Revenue by payor class as a percentage of total net service revenue</a></td>
<td class="nump">12.00%<span></span>
</td>
<td class="nump">14.00%<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
<td class="nump">14.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_PayorClassAxis=amed_HospiceMedicareMember', window );">Hospice Medicare [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems', window );"><strong>Revenue Recognition, Multiple-deliverable Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_Revenuebypayorclassasapercentageoftotalnetservicerevenue', window );">Revenue by payor class as a percentage of total net service revenue</a></td>
<td class="nump">33.00%<span></span>
</td>
<td class="nump">34.00%<span></span>
</td>
<td class="nump">33.00%<span></span>
</td>
<td class="nump">33.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_PayorClassAxis=amed_HospiceNonMedicareMember', window );">Hospice Non-Medicare [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems', window );"><strong>Revenue Recognition, Multiple-deliverable Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_Revenuebypayorclassasapercentageoftotalnetservicerevenue', window );">Revenue by payor class as a percentage of total net service revenue</a></td>
<td class="nump">2.00%<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_PayorClassAxis=amed_PersonalCareMember', window );">Personal Care [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems', window );"><strong>Revenue Recognition, Multiple-deliverable Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_Revenuebypayorclassasapercentageoftotalnetservicerevenue', window );">Revenue by payor class as a percentage of total net service revenue</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_Revenuebypayorclassasapercentageoftotalnetservicerevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue by payor class as a percentage of total net service revenue</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_Revenuebypayorclassasapercentageoftotalnetservicerevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_PayorClassAxis=amed_HomeHealthMedicareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_PayorClassAxis=amed_HomeHealthMedicareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_PayorClassAxis=amed_HomeHealthNonMedicareEpisodicBasedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_PayorClassAxis=amed_HomeHealthNonMedicareEpisodicBasedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_PayorClassAxis=amed_HomeHealthNonMedicareNonEpisodicBasedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_PayorClassAxis=amed_HomeHealthNonMedicareNonEpisodicBasedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_PayorClassAxis=amed_HospiceMedicareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_PayorClassAxis=amed_HospiceMedicareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_PayorClassAxis=amed_HospiceNonMedicareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_PayorClassAxis=amed_HospiceNonMedicareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_PayorClassAxis=amed_PersonalCareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_PayorClassAxis=amed_PersonalCareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140006524510296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Cash and Cash Equivalents (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">15 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems', window );"><strong>Restricted Cash and Cash Equivalents Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 91,646<span></span>
</td>
<td class="nump">$ 91,646<span></span>
</td>
<td class="nump">$ 81,808<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted cash</a></td>
<td class="nump">1,000<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="nump">1,549<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, Cash Equivalents and Restricted Cash</a></td>
<td class="nump">92,646<span></span>
</td>
<td class="nump">92,646<span></span>
</td>
<td class="nump">83,357<span></span>
</td>
<td class="nump">$ 180,327<span></span>
</td>
<td class="nump">$ 96,490<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_CashBalanceAssociatedWithProviderReliefFund', window );">Cash Balance Associated with Provider Relief Fund</a></td>
<td class="nump">62,000<span></span>
</td>
<td class="nump">62,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_ProviderReliefFundAdvance', window );">Provider relief fund advance</a></td>
<td class="nump">58,328<span></span>
</td>
<td class="nump">58,328<span></span>
</td>
<td class="nump">$ 60,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_CARESActProviderReliefFundsUtilized', window );">CARES Act Provider Relief Funds Utilized</a></td>
<td class="nump">4,000<span></span>
</td>
<td class="nump">46,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=amed_AsanaHospiceMember', window );">Asana Hospice [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems', window );"><strong>Restricted Cash and Cash Equivalents Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted cash</a></td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_CARESActProviderReliefFundsUtilized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>CARES Act Provider Relief Funds Utilized</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_CARESActProviderReliefFundsUtilized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_CashBalanceAssociatedWithProviderReliefFund">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash Balance Associated with the CARES Act Provider Relief Fund</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_CashBalanceAssociatedWithProviderReliefFund</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_ProviderReliefFundAdvance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payable related to funds received from the government related to COVID-19</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_ProviderReliefFundAdvance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=amed_AsanaHospiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=amed_AsanaHospiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140006612639816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Patient Accounts Receivable Narrative (Details)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_AccountsReceivablePortionDerivedFromMedicare', window );">Accounts receivable derived from Medicare</a></td>
<td class="nump">66.00%<span></span>
</td>
<td class="nump">64.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_NetServiceRevenuePeriodOfCarePaymentRateDuration', window );">Net service revenue period of care payment rate (days)</a></td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_PercentageOfPatientReceivablesOutstanding', window );">Percentage of patient receivables outstanding</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_HistoricalCollectionRateFromMedicare', window );">Historical collection rate from Medicare</a></td>
<td class="nump">99.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_RateOfRequestForAnticipatedPaymentSubmittedForInitialPeriodOfCare', window );">Rate of request for anticipated payment submitted for the initial episode of care</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_AccountsReceivablePortionDerivedFromMedicare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accounts Receivable, Portion Derived From Medicare</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_AccountsReceivablePortionDerivedFromMedicare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_HistoricalCollectionRateFromMedicare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Historical collection rate from Medicare.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_HistoricalCollectionRateFromMedicare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_NetServiceRevenuePeriodOfCarePaymentRateDuration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description containing the number of days from the date the request for anticipated payment was received in which the final bill must be submitted to Medicare.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_NetServiceRevenuePeriodOfCarePaymentRateDuration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_PercentageOfPatientReceivablesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of patient receivables outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_PercentageOfPatientReceivablesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_RateOfRequestForAnticipatedPaymentSubmittedForInitialPeriodOfCare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description containing the percentage of estimated payment that is requested at the start of care for an initial period of care.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_RateOfRequestForAnticipatedPaymentSubmittedForInitialPeriodOfCare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140006523872504">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Fair Value of Financial Instruments (Details)<br></strong></div></th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_DebtInstrumentCarryingAmountExcludingFinanceLeases', window );">Debt Instrument Carrying Amount Excluding Finance Leases</a></td>
<td class="nump">$ 189,700,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Fair Value, Inputs, Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtFairValue', window );">Long-term Debt, Fair Value</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Fair Value, Inputs, Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtFairValue', window );">Long-term Debt, Fair Value</a></td>
<td class="nump">191,700,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Fair Value, Inputs, Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtFairValue', window );">Long-term Debt, Fair Value</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_DebtInstrumentCarryingAmountExcludingFinanceLeases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument Carrying Amount Excluding Finance Leases</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_DebtInstrumentCarryingAmountExcludingFinanceLeases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fair value amount of long-term debt whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140006520755144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Weighted-Average Shares Outstanding (Details) - shares<br> shares in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average number of shares outstanding - basic (shares)</a></td>
<td class="nump">32,588<span></span>
</td>
<td class="nump">32,412<span></span>
</td>
<td class="nump">32,684<span></span>
</td>
<td class="nump">32,371<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract', window );"><strong>Effect of dilutive securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements', window );">Stock options (shares)</a></td>
<td class="nump">139<span></span>
</td>
<td class="nump">570<span></span>
</td>
<td class="nump">145<span></span>
</td>
<td class="nump">582<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_NonVestedStockAndStockUnits', window );">Non-vested stock and stock units (shares)</a></td>
<td class="nump">254<span></span>
</td>
<td class="nump">303<span></span>
</td>
<td class="nump">256<span></span>
</td>
<td class="nump">306<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average number of shares outstanding - diluted (shares)</a></td>
<td class="nump">32,981<span></span>
</td>
<td class="nump">33,285<span></span>
</td>
<td class="nump">33,085<span></span>
</td>
<td class="nump">33,259<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities (shares)</a></td>
<td class="nump">71<span></span>
</td>
<td class="nump">14<span></span>
</td>
<td class="nump">58<span></span>
</td>
<td class="nump">21<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_NonVestedStockAndStockUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Non vested stock and stock units.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_NonVestedStockAndStockUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1707-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28A<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1500-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1757-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140006605255160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NOVEL CORONAVIRUS PANDEMIC "COVID-19" (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1">15 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Apr. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Mar. 27, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnusualOrInfrequentItemLineItems', window );"><strong>NOVEL CORONAVIRUS PANDEMIC "COVID-19" [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_FundingForHealthcareProvidersIncludingHospitals', window );">Funding for Healthcare Providers, Including Hospitals</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 175,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_FundingImmediatelyDistributedToHealthcareProvidersBasedOnTheir2019MedicareFeeForServiceReimbursements', window );">Funding Immediately Distributed to Healthcare Providers Based on Their 2019 Medicare Fee-For-Service Reimbursements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_FundingReceivedFromCARESAct', window );">Funding Received From CARES Act</a></td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_ProviderReliefFundAdvance', window );">Provider relief fund advance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 58,328<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 58,328<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 60,000<span></span>
</td>
<td class="nump">$ 58,328<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_CARESActProviderReliefFundsUtilized', window );">CARES Act Provider Relief Funds Utilized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">46,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_EstimatedCARESActProviderReliefFundAmountsToBeRepaid', window );">Estimated CARES Act Provider Relief Fund Amounts to be Repaid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">58,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">58,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">58,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_CARESActProviderReliefFundsReceivedByUnconsolidatedJointVentures', window );">CARES Act Provider Relief Funds Received by Unconsolidated Joint Ventures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_TotalCARESActProviderReliefFundsReceived', window );">Total CARES Act Provider Relief Funds Received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">106,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">106,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">106,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Payroll and employee benefits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">147,017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">147,017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">146,929<span></span>
</td>
<td class="nump">147,017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31,886<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31,886<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33,622<span></span>
</td>
<td class="nump">31,886<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnusualOrInfrequentItemLineItems', window );"><strong>NOVEL CORONAVIRUS PANDEMIC "COVID-19" [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_ExtensionOfTemporarySuspensionOfSequestrationRevenueImpact', window );">Extension of Temporary Suspension of Sequestration, Revenue Impact</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 36,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnusualOrInfrequentItemAxis=amed_COVID19DeferralOfSocialSecurityMember', window );">COVID-19 Deferral of Social Security</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnusualOrInfrequentItemLineItems', window );"><strong>NOVEL CORONAVIRUS PANDEMIC "COVID-19" [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_CARESActDeferralOfEmployerShareSocialSecurityTax', window );">CARES Act Deferral of Employer Share Social Security Tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">55,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Payroll and employee benefits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 28,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=amed_HomeHealthAndHospiceMember', window );">Home Health and Hospice [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnusualOrInfrequentItemLineItems', window );"><strong>NOVEL CORONAVIRUS PANDEMIC "COVID-19" [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_COVID19ExpensesIncurred', window );">COVID-19 Expenses Incurred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="nump">$ 21,000<span></span>
</td>
<td class="nump">$ 13,000<span></span>
</td>
<td class="nump">$ 22,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=amed_PersonalCareMember', window );">Personal Care [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnusualOrInfrequentItemLineItems', window );"><strong>NOVEL CORONAVIRUS PANDEMIC "COVID-19" [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_FundingReceivedFromMassHomeCareASAPCOVID19ProviderSustainabilityProgram', window );">Funding Received From Mass Home Care ASAP COVID-19 Provider Sustainability Program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=amed_AseraCareHospiceMember', window );">AseraCare Hospice [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnusualOrInfrequentItemLineItems', window );"><strong>NOVEL CORONAVIRUS PANDEMIC "COVID-19" [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_FundingReceivedFromCARESAct', window );">Funding Received From CARES Act</a></td>
<td class="nump">6,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_EquityMethodInvestmentsMember', window );">Equity Method Investments [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnusualOrInfrequentItemLineItems', window );"><strong>NOVEL CORONAVIRUS PANDEMIC "COVID-19" [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_FundingReceivedFromCARESAct', window );">Funding Received From CARES Act</a></td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_CARESActDeferralOfEmployerShareSocialSecurityTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The deferral of the employer's share social security tax provided by the CARES Act</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_CARESActDeferralOfEmployerShareSocialSecurityTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_CARESActProviderReliefFundsReceivedByUnconsolidatedJointVentures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>CARES Act Provider Relief Funds Received by Unconsolidated Joint Ventures</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_CARESActProviderReliefFundsReceivedByUnconsolidatedJointVentures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_CARESActProviderReliefFundsUtilized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>CARES Act Provider Relief Funds Utilized</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_CARESActProviderReliefFundsUtilized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_COVID19ExpensesIncurred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expenses incurred as a result of the Novel Coronavirus Pandemic "COVID-19"</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_COVID19ExpensesIncurred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_EstimatedCARESActProviderReliefFundAmountsToBeRepaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Estimated CARES Act Provider Relief Fund Amounts to be Repaid</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_EstimatedCARESActProviderReliefFundAmountsToBeRepaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_ExtensionOfTemporarySuspensionOfSequestrationRevenueImpact">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The impact on revenue due to the extension of the temporary suspension of sequestration as a result of the novel coronavrius pandemic ("COVID-19").</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_ExtensionOfTemporarySuspensionOfSequestrationRevenueImpact</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_FundingForHealthcareProvidersIncludingHospitals">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Funding for healthcare providers, including hospitals provided by the Coronavirus Aid, Relief and Economic Security (CARES) Act</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_FundingForHealthcareProvidersIncludingHospitals</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_FundingImmediatelyDistributedToHealthcareProvidersBasedOnTheir2019MedicareFeeForServiceReimbursements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Funding immediately distributed to healthcare providers based on their 2019 Medicare Fee-For-Service reimbursements provided by the Coronavirus Aid, Relief and Economic Security (CARES) Act</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_FundingImmediatelyDistributedToHealthcareProvidersBasedOnTheir2019MedicareFeeForServiceReimbursements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_FundingReceivedFromCARESAct">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Funding received by the Company from the Coronavirus Aid Relief and Economic Security (CARES) Act</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_FundingReceivedFromCARESAct</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_FundingReceivedFromMassHomeCareASAPCOVID19ProviderSustainabilityProgram">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Funding Received From Mass Home Care ASAP COVID-19 Provider Sustainability Program</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_FundingReceivedFromMassHomeCareASAPCOVID19ProviderSustainabilityProgram</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_ProviderReliefFundAdvance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payable related to funds received from the government related to COVID-19</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_ProviderReliefFundAdvance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_TotalCARESActProviderReliefFundsReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total CARES Act Provider Relief Funds Received</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_TotalCARESActProviderReliefFundsReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnusualOrInfrequentItemLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnusualOrInfrequentItemLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnusualOrInfrequentItemAxis=amed_COVID19DeferralOfSocialSecurityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnusualOrInfrequentItemAxis=amed_COVID19DeferralOfSocialSecurityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=amed_HomeHealthAndHospiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=amed_HomeHealthAndHospiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=amed_PersonalCareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=amed_PersonalCareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=amed_AseraCareHospiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=amed_AseraCareHospiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_EquityMethodInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_EquityMethodInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140006512968296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACQUISITIONS - Narrative (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>May 01, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 01, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 01, 2020 </div>
<div>USD ($) </div>
<div>care_center</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions', window );">Net service revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 564,166<span></span>
</td>
<td class="nump">$ 485,059<span></span>
</td>
<td class="nump">$ 1,101,310<span></span>
</td>
<td class="nump">$ 976,744<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating Income (Loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">78,135<span></span>
</td>
<td class="nump">49,932<span></span>
</td>
<td class="nump">146,984<span></span>
</td>
<td class="nump">93,802<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=amed_HospiceMember', window );">Hospice [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions', window );">Net service revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">197,900<span></span>
</td>
<td class="nump">177,100<span></span>
</td>
<td class="nump">389,400<span></span>
</td>
<td class="nump">346,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating Income (Loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45,900<span></span>
</td>
<td class="nump">45,700<span></span>
</td>
<td class="nump">92,400<span></span>
</td>
<td class="nump">84,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=amed_HospiceMember', window );">Hospice [Member] | AseraCare Hospice [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Payments to acquire business</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 230,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfBusinessesAcquired', window );">Acquisition, number of care centers acquired | care_center</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_PaymentsRelatedToTaxAsset', window );">Payments related to tax asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 32,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables', window );">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentAssetsPrepaidExpense', window );">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment', window );">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingleaserightofuseassets', window );">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Operating lease right of use assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Acquisition, other intangibles recorded</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets', window );">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets', window );">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">46,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">46,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable', window );">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6,300)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6,300)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesPayrollandEmployeeBenefits', window );">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Payroll and Employee Benefits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,900)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,900)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses', window );">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accrued Expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(11,900)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(11,900)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingLeaseLiabilities', window );">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Operating Lease Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,400)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,400)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities', window );">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(29,500)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(29,500)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet', window );">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Goodwill recorded during period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">212,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet', window );">Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">229,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">229,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions', window );">Net service revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,400<span></span>
</td>
<td class="nump">9,200<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="nump">9,200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating Income (Loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500<span></span>
</td>
<td class="num">(3,000)<span></span>
</td>
<td class="num">(100)<span></span>
</td>
<td class="num">(3,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationIntegrationRelatedCosts', window );">Business Combination, Integration Related Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600<span></span>
</td>
<td class="nump">3,300<span></span>
</td>
<td class="nump">1,200<span></span>
</td>
<td class="nump">3,300<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_BusinessAcquisitionClosingPaymentAdjustment', window );">Business Acquisition Closing Payment Adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_DepreciationAndAmortizationForContinuingOperations', window );">Depreciation and amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="nump">4,400<span></span>
</td>
<td class="nump">200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_GoodwillDeductibleForIncomeTaxPurposesPeriod', window );">GoodwillDeductibleForIncomeTaxPurposesPeriod</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=amed_HospiceMember', window );">Hospice [Member] | AseraCare Hospice [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_BusinessAcquisitionClosingPaymentAdjustment', window );">Business Acquisition Closing Payment Adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=amed_HomeHealthMember', window );">Home Health [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions', window );">Net service revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">349,300<span></span>
</td>
<td class="nump">290,200<span></span>
</td>
<td class="nump">677,900<span></span>
</td>
<td class="nump">593,800<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating Income (Loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">78,700<span></span>
</td>
<td class="nump">$ 48,200<span></span>
</td>
<td class="nump">148,200<span></span>
</td>
<td class="nump">$ 95,300<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=stpr_NC', window );">NORTH CAROLINA | Home Health [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Payments to acquire business</a></td>
<td class="nump">$ 2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Goodwill recorded during period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_NoncompeteAgreementsMember', window );">Noncompete Agreements [Member] | Hospice [Member] | AseraCare Hospice [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Weighted-average amortization period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 8 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Acquisition, other intangibles recorded</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=amed_AcquiredNamesMember', window );">Acquired Names [Member] | Hospice [Member] | AseraCare Hospice [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Weighted-average amortization period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Acquisition, other intangibles recorded</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=amed_MedicareLicenseMember', window );">Medicare licenses [Member] | Hospice [Member] | AseraCare Hospice [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Acquisition, other intangibles recorded</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=amed_CertificatesOfNeedMember', window );">Certificates Of Need | Hospice [Member] | AseraCare Hospice [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Acquisition, other intangibles recorded</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=amed_CertificateOfNeedMember', window );">Certificate of Need [Member] | NORTH CAROLINA | Home Health [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Acquisition, other intangibles recorded</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_BusinessAcquisitionClosingPaymentAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Acquisition Closing Payment Adjustment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_BusinessAcquisitionClosingPaymentAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentAssetsPrepaidExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentAssetsPrepaidExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accrued Expenses</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesPayrollandEmployeeBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Payroll and Employee Benefits</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesPayrollandEmployeeBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Operating Lease Liabilities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingleaserightofuseassets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Operating lease right of use assets</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingleaserightofuseassets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_DepreciationAndAmortizationForContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Depreciation And Amortization For Continuing Operations</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_DepreciationAndAmortizationForContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_GoodwillDeductibleForIncomeTaxPurposesPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The period of time that goodwill is deductible for income tax purposes</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_GoodwillDeductibleForIncomeTaxPurposesPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_PaymentsRelatedToTaxAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments related to tax asset</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_PaymentsRelatedToTaxAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationIntegrationRelatedCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Costs incurred to effect a business combination which have been expensed during the period. Such costs could include business integration costs, systems integration and conversion costs, and severance and other employee-related costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationIntegrationRelatedCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of assets acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121647850&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount due from customers or clients for goods or services, including trade receivables, that have been delivered or sold in the normal course of business, and amounts due from others, including related parties expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121647850&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred for goods and services received that are used in an entity's business and related party payables, assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121647850&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of intangible assets, excluding goodwill, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121647850&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121647850&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI http://asc.fasb.org/extlink&amp;oid=121600890&amp;loc=d3e2207-128464<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121647850&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of other assets expected to be realized or consumed after one year or the normal operating cycle, if longer, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121647850&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of property, plant, and equipment recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI http://asc.fasb.org/extlink&amp;oid=121600890&amp;loc=d3e2207-128464<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121647850&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121647850&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAcquiredDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAcquiredDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of patient service revenue recognized, net of contractual allowances and discounts, less the provision for bad debts related to patient service revenue plus all other revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfBusinessesAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of businesses acquired by the entity during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfBusinessesAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=amed_HospiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=amed_HospiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=amed_AseraCareHospiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=amed_AseraCareHospiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=amed_HomeHealthMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=amed_HomeHealthMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_NC">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_NC</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_NoncompeteAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_NoncompeteAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=amed_AcquiredNamesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=amed_AcquiredNamesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=amed_MedicareLicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=amed_MedicareLicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=amed_CertificatesOfNeedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=amed_CertificatesOfNeedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=amed_CertificateOfNeedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=amed_CertificateOfNeedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140006604740312">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>LONG-TERM OBLIGATIONS - Schedule of Long-Term Debt (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal amount</a></td>
<td class="nump">$ 191.8<span></span>
</td>
<td class="nump">$ 217.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Deferred debt issuance costs</a></td>
<td class="num">(2.2)<span></span>
</td>
<td class="num">(2.7)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term obligations, including current portion</a></td>
<td class="nump">189.6<span></span>
</td>
<td class="nump">215.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Current portion of long-term obligations</a></td>
<td class="num">(10.2)<span></span>
</td>
<td class="num">(10.5)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term obligations, less current portion</a></td>
<td class="nump">179.4<span></span>
</td>
<td class="nump">204.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LoansPayableMember', window );">Term Loan [Member] | One Hundred Seventy Five Million Term Loan Facility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal amount</a></td>
<td class="nump">159.7<span></span>
</td>
<td class="nump">164.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility [Member] | Five Hundred Fifty Million Revolving Credit Facility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal amount</a></td>
<td class="nump">30.0<span></span>
</td>
<td class="nump">51.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_CapitalLeaseObligationsMember', window );">Finance leases [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal amount</a></td>
<td class="nump">$ 2.1<span></span>
</td>
<td class="nump">$ 2.6<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520924&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520924&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LoansPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_LoansPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amed_OneHundredSeventyFiveMillionTermLoanFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amed_OneHundredSeventyFiveMillionTermLoanFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_RevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_RevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_CapitalLeaseObligationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_CapitalLeaseObligationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140006605508840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LONG-TERM OBLIGATIONS - Schedule of Long-Term Debt Additional Information (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($)</div>
</th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LoansPayableMember', window );">Term Loan [Member] | One Hundred Seventy Five Million Term Loan Facility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument, face amount</a></td>
<td class="nump">$ 175.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Maturity Date</a></td>
<td class="text">Feb.  04,  2024<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LoansPayableMember', window );">Term Loan [Member] | One Hundred Seventy Five Million Term Loan Facility [Member] | Eurodollar [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_DebtInstrumentInterestRateatPeriodEnd', window );">Debt Instrument Interest Rate at Period End</a></td>
<td class="nump">1.40%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility [Member] | Five Hundred Fifty Million Revolving Credit Facility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument, face amount</a></td>
<td class="nump">$ 550.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Maturity Date</a></td>
<td class="text">Feb.  04,  2024<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility [Member] | Five Hundred Fifty Million Revolving Credit Facility [Member] | Eurodollar [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_DebtInstrumentInterestRateatPeriodEnd', window );">Debt Instrument Interest Rate at Period End</a></td>
<td class="nump">1.30%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_DebtInstrumentInterestRateatPeriodEnd">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument Interest Rate at Period End</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_DebtInstrumentInterestRateatPeriodEnd</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28551-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date when the debt instrument is scheduled to be fully repaid, in CCYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LoansPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_LoansPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amed_OneHundredSeventyFiveMillionTermLoanFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amed_OneHundredSeventyFiveMillionTermLoanFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_EurodollarMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_EurodollarMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_RevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_RevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140006520937912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LONG-TERM OBLIGATIONS - Fees and Rates Under Credit Facilities (Details)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=amed_DebtInstrumentByLeverageRatioTrancheOneMember', window );">Consolidated Leverage Ratio: Greater Than Equal To 3.00 to 1.0</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityCommitmentFeePercentage', window );">Commitment fee percentage</a></td>
<td class="nump">0.35%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_LetterOfCreditFee', window );">Letter Of Credit Fee</a></td>
<td class="nump">1.75%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=amed_DebtInstrumentByLeverageRatioTrancheOneMember', window );">Consolidated Leverage Ratio: Greater Than Equal To 3.00 to 1.0 | Eurodollar [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate</a></td>
<td class="nump">2.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=amed_DebtInstrumentByLeverageRatioTrancheOneMember', window );">Consolidated Leverage Ratio: Greater Than Equal To 3.00 to 1.0 | Base Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate</a></td>
<td class="nump">1.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=amed_DebtInstrumentByLeverageRatioTrancheTwoMember', window );">Consolidated Leverage Ratio: Less Than 3.00 to 1.0 but Greater Than Equal To 2.00 to 1.0</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityCommitmentFeePercentage', window );">Commitment fee percentage</a></td>
<td class="nump">0.30%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_LetterOfCreditFee', window );">Letter Of Credit Fee</a></td>
<td class="nump">1.50%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=amed_DebtInstrumentByLeverageRatioTrancheTwoMember', window );">Consolidated Leverage Ratio: Less Than 3.00 to 1.0 but Greater Than Equal To 2.00 to 1.0 | Eurodollar [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate</a></td>
<td class="nump">1.75%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=amed_DebtInstrumentByLeverageRatioTrancheTwoMember', window );">Consolidated Leverage Ratio: Less Than 3.00 to 1.0 but Greater Than Equal To 2.00 to 1.0 | Base Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate</a></td>
<td class="nump">0.75%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=amed_DebtInstrumentByLeverageRatioTrancheThreeMember', window );">Consolidated Leverage Ratio: Less Than 2.00 to 1.0 but Greater Than Equal To 0.75 to 1.0</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityCommitmentFeePercentage', window );">Commitment fee percentage</a></td>
<td class="nump">0.25%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_LetterOfCreditFee', window );">Letter Of Credit Fee</a></td>
<td class="nump">1.25%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=amed_DebtInstrumentByLeverageRatioTrancheThreeMember', window );">Consolidated Leverage Ratio: Less Than 2.00 to 1.0 but Greater Than Equal To 0.75 to 1.0 | Eurodollar [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate</a></td>
<td class="nump">1.50%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=amed_DebtInstrumentByLeverageRatioTrancheThreeMember', window );">Consolidated Leverage Ratio: Less Than 2.00 to 1.0 but Greater Than Equal To 0.75 to 1.0 | Base Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate</a></td>
<td class="nump">0.50%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=amed_DebtInstrumentByLeverageRatioTrancheFourMember', window );">Consolidated Leverage Ratio: Less Than 0.75 to 1.0</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityCommitmentFeePercentage', window );">Commitment fee percentage</a></td>
<td class="nump">0.20%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_LetterOfCreditFee', window );">Letter Of Credit Fee</a></td>
<td class="nump">1.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=amed_DebtInstrumentByLeverageRatioTrancheFourMember', window );">Consolidated Leverage Ratio: Less Than 0.75 to 1.0 | Eurodollar [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate</a></td>
<td class="nump">1.25%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=amed_DebtInstrumentByLeverageRatioTrancheFourMember', window );">Consolidated Leverage Ratio: Less Than 0.75 to 1.0 | Base Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate</a></td>
<td class="nump">0.25%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | Consolidated Leverage Ratio: Greater Than Equal To 3.00 to 1.0</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_ConsolidatedLeverageRatio', window );">Consolidated Leverage Ratio</a></td>
<td class="nump">3.00<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | Consolidated Leverage Ratio: Less Than 3.00 to 1.0 but Greater Than Equal To 2.00 to 1.0</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_ConsolidatedLeverageRatio', window );">Consolidated Leverage Ratio</a></td>
<td class="nump">2.00<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | Consolidated Leverage Ratio: Less Than 2.00 to 1.0 but Greater Than Equal To 0.75 to 1.0</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_ConsolidatedLeverageRatio', window );">Consolidated Leverage Ratio</a></td>
<td class="nump">0.75<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Consolidated Leverage Ratio: Less Than 3.00 to 1.0 but Greater Than Equal To 2.00 to 1.0</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_ConsolidatedLeverageRatio', window );">Consolidated Leverage Ratio</a></td>
<td class="nump">3.00<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Consolidated Leverage Ratio: Less Than 2.00 to 1.0 but Greater Than Equal To 0.75 to 1.0</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_ConsolidatedLeverageRatio', window );">Consolidated Leverage Ratio</a></td>
<td class="nump">2.00<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Consolidated Leverage Ratio: Less Than 0.75 to 1.0</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_ConsolidatedLeverageRatio', window );">Consolidated Leverage Ratio</a></td>
<td class="nump">0.75<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_ConsolidatedLeverageRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Consolidated Leverage Ratio</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_ConsolidatedLeverageRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_LetterOfCreditFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fee, expressed as a percentage of the letters of credit, for the letters of credit</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_LetterOfCreditFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityCommitmentFeePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fee, expressed as a percentage of the line of credit facility, for the line of credit facility regardless of whether the facility has been used.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityCommitmentFeePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amed_DebtInstrumentByLeverageRatioTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amed_DebtInstrumentByLeverageRatioTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_EurodollarMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_EurodollarMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_BaseRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_BaseRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amed_DebtInstrumentByLeverageRatioTrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amed_DebtInstrumentByLeverageRatioTrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amed_DebtInstrumentByLeverageRatioTrancheThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amed_DebtInstrumentByLeverageRatioTrancheThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amed_DebtInstrumentByLeverageRatioTrancheFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amed_DebtInstrumentByLeverageRatioTrancheFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140006522239144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LONG-TERM OBLIGATIONS - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1">10 Months Ended</th>
<th class="th" colspan="1">14 Months Ended</th>
<th class="th" colspan="1">36 Months Ended</th>
<th class="th" colspan="1">60 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Feb. 04, 2019</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Feb. 04, 2024</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Feb. 04, 2024</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_TotalLeverageRatio', window );">Consolidated leverage ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_ConsolidatedInterestCoverageRatio', window );">Consolidated interest coverage ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 191.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 191.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 217.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LoansPayableMember', window );">Term Loan [Member] | One Hundred Seventy Five Million Term Loan Facility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument, face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 175.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 175.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtWeightedAverageInterestRateOverTime', window );">Weighted average interest rate (percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.40%<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="nump">1.50%<span></span>
</td>
<td class="nump">2.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Maturity Date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Feb.  04,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 159.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 159.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">164.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility [Member] | Five Hundred Fifty Million Revolving Credit Facility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument, face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 550.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 550.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtWeightedAverageInterestRateOverTime', window );">Weighted average interest rate (percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.70%<span></span>
</td>
<td class="nump">2.10%<span></span>
</td>
<td class="nump">1.80%<span></span>
</td>
<td class="nump">2.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Maturity Date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Feb.  04,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity', window );">Remaining availability under revolving credit facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 490.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 490.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 51.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember', window );">Line of Credit [Member] | Five Hundred Fifty Million Revolving Credit Facility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LettersOfCreditOutstandingAmount', window );">Outstanding letters of credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 29.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 29.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=amed_AmendedCreditAgreementMember', window );">Amended Credit Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Credit facility, maximum borrowing capacity</a></td>
<td class="nump">$ 725.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_DebtInstrumentInterestAdditionalInterestAboveFederalFundRate', window );">Additional interest rate above Federal Fund rate</a></td>
<td class="nump">0.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_DebtInstrumentInterestAdditionalInterestAboveEurodollarRate', window );">Additional interest rate above Eurodollar rate</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_PercentageOfRevenueAndOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromWhollyOwnedSubsidiaries', window );">Percentage of consolidated revenue and adjusted EBITDA that guarantor wholly-owned subsidiaries represent</a></td>
<td class="nump">95.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_PercentageOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromSubsidiaries', window );">Percentage of adjusted EBITDA that guarantor subsidiaries represent</a></td>
<td class="nump">70.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=amed_AmendedCreditAgreementMember', window );">Amended Credit Agreement [Member] | Five Hundred Fifty Million Revolving Credit Facility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument, face amount</a></td>
<td class="nump">$ 550.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=amed_AmendedCreditAgreementMember', window );">Amended Credit Agreement [Member] | One Hundred Seventy Five Million Term Loan Facility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_DebtInstrumentPeriodicPaymentPercentage', window );">Debt Instrument Periodic Payment Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.625%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument, face amount</a></td>
<td class="nump">$ 175.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableRateAxis=us-gaap_BaseRateMember', window );">Base Rate [Member] | Amended Credit Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis', window );">Description of variable rate basis</a></td>
<td class="text">Fluctuating rate per annum equal to the highest of (a)&#160;the federal funds rate plus 0.50% per annum, (b)&#160;the prime rate of interest established by the Administrative Agent, and (c)&#160;the Eurodollar Rate for an interest period of one month plus 1% per annum.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableRateAxis=us-gaap_BaseRateMember', window );">Base Rate [Member] | Amended Credit Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableRateAxis=us-gaap_EurodollarMember', window );">Eurodollar [Member] | Amended Credit Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis', window );">Description of variable rate basis</a></td>
<td class="text">Rate at which Eurodollar deposits in the London interbank market for an interest period of one, two, three or six months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableRateAxis=us-gaap_EurodollarMember', window );">Eurodollar [Member] | Term Loan [Member] | One Hundred Seventy Five Million Term Loan Facility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_DebtInstrumentInterestRateatPeriodEnd', window );">Debt Instrument Interest Rate at Period End</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableRateAxis=us-gaap_EurodollarMember', window );">Eurodollar [Member] | Revolving Credit Facility [Member] | Five Hundred Fifty Million Revolving Credit Facility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_DebtInstrumentInterestRateatPeriodEnd', window );">Debt Instrument Interest Rate at Period End</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableRateAxis=us-gaap_EurodollarMember', window );">Eurodollar [Member] | Amended Credit Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | Amended Credit Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_ProceedsReceivedFromLoanPartyOfSubsidiary', window );">Proceeds Received From Loan Party Of Subsidiary</a></td>
<td class="nump">$ 5.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Amended Credit Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Maturity Date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Feb.  04,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Amended Credit Agreement [Member] | One Hundred Seventy Five Million Term Loan Facility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_DebtInstrumentPeriodicPaymentPercentage', window );">Debt Instrument Periodic Payment Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.875%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_ConsolidatedInterestCoverageRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Ratio of adjusted earnings before interest, taxes, depreciation and amortization to cash interest charges</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_ConsolidatedInterestCoverageRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_DebtInstrumentInterestAdditionalInterestAboveEurodollarRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument Interest Additional Interest Above Eurodollar Rate</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_DebtInstrumentInterestAdditionalInterestAboveEurodollarRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_DebtInstrumentInterestAdditionalInterestAboveFederalFundRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument Interest Additional Interest Above Federal Fund Rate</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_DebtInstrumentInterestAdditionalInterestAboveFederalFundRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_DebtInstrumentInterestRateatPeriodEnd">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument Interest Rate at Period End</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_DebtInstrumentInterestRateatPeriodEnd</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_DebtInstrumentPeriodicPaymentPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of the Term Loan that is required as periodic payments including both interest and principal payments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_DebtInstrumentPeriodicPaymentPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_PercentageOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromSubsidiaries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of adjusted EBITDA that guarantor subsidiaries represent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_PercentageOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromSubsidiaries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_PercentageOfRevenueAndOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromWhollyOwnedSubsidiaries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of consolidated net revenues and adjusted EBITDA that guarantor wholly-owned subsidiaries represent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_PercentageOfRevenueAndOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromWhollyOwnedSubsidiaries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_ProceedsReceivedFromLoanPartyOfSubsidiary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds Received From Loan Party Of Subsidiary</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_ProceedsReceivedFromLoanPartyOfSubsidiary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_TotalLeverageRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Ratio of debt to earnings before interest, taxes, depreciation and amortization.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_TotalLeverageRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520924&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The reference rate for the variable rate of the debt instrument, such as LIBOR or the US Treasury rate and the maturity of the reference rate used, such as three months or six months LIBOR.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentDescriptionOfVariableRateBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28551-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date when the debt instrument is scheduled to be fully repaid, in CCYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LettersOfCreditOutstandingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount of the contingent obligation under letters of credit outstanding as of the reporting date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LettersOfCreditOutstandingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of borrowing capacity currently available under the credit facility (current borrowing capacity less the amount of borrowings outstanding).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtWeightedAverageInterestRateOverTime">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average interest rate of long-term debt outstanding calculated over time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtWeightedAverageInterestRateOverTime</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LoansPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_LoansPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amed_OneHundredSeventyFiveMillionTermLoanFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amed_OneHundredSeventyFiveMillionTermLoanFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_RevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_RevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=amed_AmendedCreditAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=amed_AmendedCreditAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_BaseRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_BaseRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amed_AmendedCreditAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amed_AmendedCreditAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_EurodollarMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_EurodollarMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140006514879720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES - Narrative (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1">27 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jun. 27, 2016 </div>
<div>patient</div>
</th>
<th class="th">
<div>Jan. 18, 2016 </div>
<div>USD ($) </div>
<div>claim</div>
</th>
<th class="th">
<div>Nov. 03, 2015 </div>
<div>patient</div>
</th>
<th class="th">
<div>May 21, 2015 </div>
<div>patient</div>
</th>
<th class="th">
<div>Jun. 06, 2011 </div>
<div>beneficiary</div>
</th>
<th class="th">
<div>Aug. 31, 2017 </div>
<div>USD ($) </div>
<div>claim</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2010 </div>
<div>beneficiary</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 10, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Patient accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 278,216<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 255,145<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_HealthInsuranceRetentionLimit', window );">Health insurance retention limit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_WorkersCompensationInsuranceRetentionLimit', window );">Workers compensation insurance retention limit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_ProfessionalLiabilityInsuranceRetentionLimit', window );">Professional liability insurance retention limit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=stpr_SC', window );">South Carolina | Hospice [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_NumberOfBeneficiaries', window );">Number of beneficiaries | beneficiary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyReceivableNoncurrent', window );">Indemnity receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_IndemnificationAmount', window );">Indemnification amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,800<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=stpr_SC', window );">South Carolina | Hospice [Member] | Extrapolated [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_NumberOfBeneficiaries', window );">Number of beneficiaries | beneficiary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=stpr_SC', window );">South Carolina | Hospice [Member] | Unfavorable [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_RecoveryAmountOfOverpaymentMadeToSubsidiary', window );">Recovery amount of overpayment made to subsidiary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_RecoveryAmountOfOverpaymentMadeToSubsidiaryIncludingInterest', window );">Recovery amount of overpayment made to subsidiary including interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_NumberOfClaimsSubmittedBySubsidiary', window );">Number of claims submitted by subsidiary | claim</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_Recoveryamountofoverpaymentmadetosubsidiaryincludinginterestwithheld', window );">Recovery amount of over payment made to subsidiary including interest withheld</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=amed_UsDepartmentOfJusticeMember', window );">US Department of Justice | Hospice [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualAtCarryingValue', window );">Loss contingency accrual</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_ReversalOfLossContingencyAccrual', window );">Reversal of Loss Contingency Accrual</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=amed_UsDepartmentOfJusticeMember', window );">US Department of Justice | Massachusetts | Hospice [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_Numberofpatients', window );">Number of patients | patient</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">53<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=amed_UsDepartmentOfJusticeMember', window );">US Department of Justice | Morgantown, West Virginia | Hospice [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_Numberofpatients', window );">Number of patients | patient</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">66<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=amed_UsDepartmentOfJusticeMember', window );">US Department of Justice | Parkersburg, West Virginia | Hospice [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_Numberofpatients', window );">Number of patients | patient</a></td>
<td class="nump">68<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=amed_SafeguardZoneProgramIntegrityContractorMember', window );">Safeguard Zone Program Integrity Contractor | Florida</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualAtCarryingValue', window );">Loss contingency accrual</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyReceivableNoncurrent', window );">Indemnity receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_IndemnificationAmount', window );">Indemnification amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=amed_SafeguardZoneProgramIntegrityContractorMember', window );">Safeguard Zone Program Integrity Contractor | Florida | Infinity HomeCare</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_IndemnificationAmount', window );">Indemnification amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=amed_SafeguardZoneProgramIntegrityContractorMember', window );">Safeguard Zone Program Integrity Contractor | Florida | Home Health [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_FloridaZpicRevenueReduction', window );">Florida ZPIC revenue reduction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=amed_SafeguardZoneProgramIntegrityContractorMember', window );">Safeguard Zone Program Integrity Contractor | Florida | Home Health [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_RecoveryAmountOfOverpaymentMadeToSubsidiary', window );">Recovery amount of overpayment made to subsidiary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=amed_SafeguardZoneProgramIntegrityContractorMember', window );">Safeguard Zone Program Integrity Contractor | Florida | Home Health [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_RecoveryAmountOfOverpaymentMadeToSubsidiary', window );">Recovery amount of overpayment made to subsidiary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38,800<span></span>
</td>
<td class="nump">29,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=amed_SafeguardZoneProgramIntegrityContractorMember', window );">Safeguard Zone Program Integrity Contractor | Florida | Home Health [Member] | Infinity HomeCare</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Patient accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=amed_SafeguardZoneProgramIntegrityContractorMember', window );">Safeguard Zone Program Integrity Contractor | Lakeland, Florida | Home Health [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_RecoveryAmountOfOverpaymentMadeToSubsidiary', window );">Recovery amount of overpayment made to subsidiary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 34,000<span></span>
</td>
<td class="nump">26,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_NumberOfClaimsSubmittedBySubsidiary', window );">Number of claims submitted by subsidiary | claim</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">72<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_ActualClaimsPayment', window );">Actual claims payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_ErrorRatePercentage', window );">Error rate (percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=amed_SafeguardZoneProgramIntegrityContractorMember', window );">Safeguard Zone Program Integrity Contractor | Clearwater, Florida | Home Health [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_RecoveryAmountOfOverpaymentMadeToSubsidiary', window );">Recovery amount of overpayment made to subsidiary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,800<span></span>
</td>
<td class="nump">$ 3,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_NumberOfClaimsSubmittedBySubsidiary', window );">Number of claims submitted by subsidiary | claim</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_ActualClaimsPayment', window );">Actual claims payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_ErrorRatePercentage', window );">Error rate (percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_ActualClaimsPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Actual Claims Payment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_ActualClaimsPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_ErrorRatePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Error Rate Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_ErrorRatePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_FloridaZpicRevenueReduction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reduction in revenue as a result of the Florida ZPIC audit</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_FloridaZpicRevenueReduction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_HealthInsuranceRetentionLimit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum potential amount of future payments the entity could be required to make related to a specific Health Insurance Claim.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_HealthInsuranceRetentionLimit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_IndemnificationAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount to be reimbursed if and when certain assumed liabilities are paid</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_IndemnificationAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_NumberOfBeneficiaries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of beneficiaries who received services</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_NumberOfBeneficiaries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_NumberOfClaimsSubmittedBySubsidiary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of claims submitted by subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_NumberOfClaimsSubmittedBySubsidiary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_Numberofpatients">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of patients</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_Numberofpatients</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_ProfessionalLiabilityInsuranceRetentionLimit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum potential amount of future payments the entity could be required to make related to a specific Professional Liability Claim.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_ProfessionalLiabilityInsuranceRetentionLimit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_RecoveryAmountOfOverpaymentMadeToSubsidiary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Recovery amount of the overpayment made to the subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_RecoveryAmountOfOverpaymentMadeToSubsidiary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_RecoveryAmountOfOverpaymentMadeToSubsidiaryIncludingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Recovery amount of overpayment made to subsidiary including interest</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_RecoveryAmountOfOverpaymentMadeToSubsidiaryIncludingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_Recoveryamountofoverpaymentmadetosubsidiaryincludinginterestwithheld">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Recovery amount of over payment made to subsidiary including interest withheld</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_Recoveryamountofoverpaymentmadetosubsidiaryincludinginterestwithheld</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_ReversalOfLossContingencyAccrual">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reversal of Loss Contingency Accrual</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_ReversalOfLossContingencyAccrual</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_WorkersCompensationInsuranceRetentionLimit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum potential amount of future payments the entity could be required to make related to a specific Workers' Compensation Insurance Claim.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_WorkersCompensationInsuranceRetentionLimit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121593590&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121593590&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyAccrualAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss contingency liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyAccrualAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyReceivableNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of receivable related to a loss contingency accrual that is expected to be collected after one year or beyond the normal operating cycle, if longer. For example, an insurance recovery receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121555522&amp;loc=d3e12053-110248<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyReceivableNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_SC">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_SC</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=amed_HospiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=amed_HospiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=amed_ExtrapolatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesByNatureOfContingencyAxis=amed_ExtrapolatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=amed_UnfavorableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesByNatureOfContingencyAxis=amed_UnfavorableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=amed_UsDepartmentOfJusticeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=amed_UsDepartmentOfJusticeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_MA">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_MA</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=amed_MorgantownWestVirginiaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=amed_MorgantownWestVirginiaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=amed_ParkersburgWestVirginiaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=amed_ParkersburgWestVirginiaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=amed_SafeguardZoneProgramIntegrityContractorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=amed_SafeguardZoneProgramIntegrityContractorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_FL">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_FL</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=amed_InfinityHomeCareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=amed_InfinityHomeCareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=amed_HomeHealthMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=amed_HomeHealthMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=amed_LakelandFloridaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=amed_LakelandFloridaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=amed_ClearwaterFloridaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=amed_ClearwaterFloridaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140006518666792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SEGMENT INFORMATION - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2021 </div>
<div>Segments</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of reportable business segments</a></td>
<td class="nump">3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140006523946520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SEGMENT INFORMATION - Operating Income of Reportable Segments (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions', window );">Net service revenue</a></td>
<td class="nump">$ 564,166<span></span>
</td>
<td class="nump">$ 485,059<span></span>
</td>
<td class="nump">$ 1,101,310<span></span>
</td>
<td class="nump">$ 976,744<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherOperatingIncome', window );">Other operating income</a></td>
<td class="nump">4,603<span></span>
</td>
<td class="nump">22,780<span></span>
</td>
<td class="nump">13,304<span></span>
</td>
<td class="nump">22,780<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of service, excluding depreciation and amortization</a></td>
<td class="nump">308,691<span></span>
</td>
<td class="nump">295,228<span></span>
</td>
<td class="nump">605,894<span></span>
</td>
<td class="nump">580,965<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="nump">175,300<span></span>
</td>
<td class="nump">156,300<span></span>
</td>
<td class="nump">347,400<span></span>
</td>
<td class="nump">313,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">6,721<span></span>
</td>
<td class="nump">6,334<span></span>
</td>
<td class="nump">14,276<span></span>
</td>
<td class="nump">11,672<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Operating expenses</a></td>
<td class="nump">490,634<span></span>
</td>
<td class="nump">457,907<span></span>
</td>
<td class="nump">967,630<span></span>
</td>
<td class="nump">905,722<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating income (loss)</a></td>
<td class="nump">78,135<span></span>
</td>
<td class="nump">49,932<span></span>
</td>
<td class="nump">146,984<span></span>
</td>
<td class="nump">93,802<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=amed_HomeHealthMember', window );">Home Health [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions', window );">Net service revenue</a></td>
<td class="nump">349,300<span></span>
</td>
<td class="nump">290,200<span></span>
</td>
<td class="nump">677,900<span></span>
</td>
<td class="nump">593,800<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherOperatingIncome', window );">Other operating income</a></td>
<td class="nump">2,300<span></span>
</td>
<td class="nump">15,100<span></span>
</td>
<td class="nump">7,300<span></span>
</td>
<td class="nump">15,100<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of service, excluding depreciation and amortization</a></td>
<td class="nump">190,400<span></span>
</td>
<td class="nump">184,000<span></span>
</td>
<td class="nump">373,400<span></span>
</td>
<td class="nump">363,800<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="nump">81,300<span></span>
</td>
<td class="nump">72,200<span></span>
</td>
<td class="nump">161,400<span></span>
</td>
<td class="nump">147,900<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">1,200<span></span>
</td>
<td class="nump">900<span></span>
</td>
<td class="nump">2,200<span></span>
</td>
<td class="nump">1,900<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Operating expenses</a></td>
<td class="nump">272,900<span></span>
</td>
<td class="nump">257,100<span></span>
</td>
<td class="nump">537,000<span></span>
</td>
<td class="nump">513,600<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating income (loss)</a></td>
<td class="nump">78,700<span></span>
</td>
<td class="nump">48,200<span></span>
</td>
<td class="nump">148,200<span></span>
</td>
<td class="nump">95,300<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=amed_HospiceMember', window );">Hospice [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions', window );">Net service revenue</a></td>
<td class="nump">197,900<span></span>
</td>
<td class="nump">177,100<span></span>
</td>
<td class="nump">389,400<span></span>
</td>
<td class="nump">346,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherOperatingIncome', window );">Other operating income</a></td>
<td class="nump">2,300<span></span>
</td>
<td class="nump">7,200<span></span>
</td>
<td class="nump">6,000<span></span>
</td>
<td class="nump">7,200<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of service, excluding depreciation and amortization</a></td>
<td class="nump">105,200<span></span>
</td>
<td class="nump">97,200<span></span>
</td>
<td class="nump">206,800<span></span>
</td>
<td class="nump">189,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="nump">48,400<span></span>
</td>
<td class="nump">40,900<span></span>
</td>
<td class="nump">94,900<span></span>
</td>
<td class="nump">79,600<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">700<span></span>
</td>
<td class="nump">500<span></span>
</td>
<td class="nump">1,300<span></span>
</td>
<td class="nump">1,100<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Operating expenses</a></td>
<td class="nump">154,300<span></span>
</td>
<td class="nump">138,600<span></span>
</td>
<td class="nump">303,000<span></span>
</td>
<td class="nump">269,700<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating income (loss)</a></td>
<td class="nump">45,900<span></span>
</td>
<td class="nump">45,700<span></span>
</td>
<td class="nump">92,400<span></span>
</td>
<td class="nump">84,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=amed_PersonalCareMember', window );">Personal Care [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions', window );">Net service revenue</a></td>
<td class="nump">17,000<span></span>
</td>
<td class="nump">17,700<span></span>
</td>
<td class="nump">34,000<span></span>
</td>
<td class="nump">36,400<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherOperatingIncome', window );">Other operating income</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">500<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of service, excluding depreciation and amortization</a></td>
<td class="nump">13,100<span></span>
</td>
<td class="nump">14,100<span></span>
</td>
<td class="nump">25,700<span></span>
</td>
<td class="nump">28,200<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="nump">3,200<span></span>
</td>
<td class="nump">2,900<span></span>
</td>
<td class="nump">6,200<span></span>
</td>
<td class="nump">6,300<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="nump">100<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Operating expenses</a></td>
<td class="nump">16,300<span></span>
</td>
<td class="nump">17,100<span></span>
</td>
<td class="nump">32,000<span></span>
</td>
<td class="nump">34,600<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating income (loss)</a></td>
<td class="nump">700<span></span>
</td>
<td class="nump">1,100<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
<td class="nump">2,300<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=us-gaap_AllOtherSegmentsMember', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions', window );">Net service revenue</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherOperatingIncome', window );">Other operating income</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of service, excluding depreciation and amortization</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="nump">42,400<span></span>
</td>
<td class="nump">40,300<span></span>
</td>
<td class="nump">84,900<span></span>
</td>
<td class="nump">79,200<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">4,800<span></span>
</td>
<td class="nump">4,800<span></span>
</td>
<td class="nump">10,700<span></span>
</td>
<td class="nump">8,600<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Operating expenses</a></td>
<td class="nump">47,200<span></span>
</td>
<td class="nump">45,100<span></span>
</td>
<td class="nump">95,600<span></span>
</td>
<td class="nump">87,800<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating income (loss)</a></td>
<td class="num">$ (47,200)<span></span>
</td>
<td class="num">$ (45,100)<span></span>
</td>
<td class="num">$ (95,600)<span></span>
</td>
<td class="num">$ (87,800)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of patient service revenue recognized, net of contractual allowances and discounts, less the provision for bad debts related to patient service revenue plus all other revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherOperatingIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount of other operating income, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherOperatingIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=amed_HomeHealthMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=amed_HomeHealthMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=amed_HospiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=amed_HospiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=amed_PersonalCareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=amed_PersonalCareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=us-gaap_AllOtherSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=us-gaap_AllOtherSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140006605038616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHARE REPURCHASE Narrative (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1">17 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Aug. 02, 2021</div></th>
<th class="th"><div>Dec. 23, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_ShareRepurchaseLineItems', window );"><strong>Share Repurchase [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Purchase of company stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 74,074<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareRepurchaseProgramAxis=amed_A2021ShareRepurchaseProgramMember', window );">2021 Share Repurchase Program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_ShareRepurchaseLineItems', window );"><strong>Share Repurchase [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1', window );">Stock Repurchase Program, Authorized Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Shares repurchased (shares)</a></td>
<td class="nump">4,757<span></span>
</td>
<td class="nump">297,105<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Purchase of company stock</a></td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="nump">$ 74,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockAcquiredAverageCostPerShare', window );">Treasury Stock Acquired, Average Cost Per Share</a></td>
<td class="nump">$ 249.72<span></span>
</td>
<td class="nump">$ 249.29<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareRepurchaseProgramAxis=amed_A2021ShareRepurchaseProgramMember', window );">2021 Share Repurchase Program | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_ShareRepurchaseLineItems', window );"><strong>Share Repurchase [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramExpirationDate', window );">Stock Repurchase Program Expiration Date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Dec. 31,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareRepurchaseProgramAxis=amed_ShareRepurchaseProgramMember', window );">Share Repurchase Program | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_ShareRepurchaseLineItems', window );"><strong>Share Repurchase [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1', window );">Stock Repurchase Program, Authorized Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramExpirationDate', window );">Stock Repurchase Program Expiration Date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Dec. 31,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_ShareRepurchaseLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>[Line Items] for Share Repurchase [Table]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_ShareRepurchaseLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stock repurchase plan authorized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchaseProgramAuthorizedAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchaseProgramExpirationDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expiration date for the purchase of an entity's own shares under a stock repurchase plan, in the CCYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchaseProgramExpirationDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockAcquiredAverageCostPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total cost of shares repurchased divided by the total number of shares repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockAcquiredAverageCostPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockSharesAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and are being held in treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockSharesAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareRepurchaseProgramAxis=amed_A2021ShareRepurchaseProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareRepurchaseProgramAxis=amed_A2021ShareRepurchaseProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareRepurchaseProgramAxis=amed_ShareRepurchaseProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareRepurchaseProgramAxis=amed_ShareRepurchaseProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140006517255160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RELATED PARTY TRANSACTIONS Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=amed_MedalogixMember', window );">Medalogix [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction', window );">Related Party Transaction, Amounts of Transaction</a></td>
<td class="nump">$ 1.3<span></span>
</td>
<td class="nump">$ 0.7<span></span>
</td>
<td class="nump">$ 2.6<span></span>
</td>
<td class="nump">$ 1.1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transactions with related party during the financial reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39603-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAmountsOfTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=amed_MedalogixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=amed_MedalogixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140006519936648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUBSEQUENT EVENT - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1">17 Months Ended</th>
<th class="th" colspan="1">26 Months Ended</th>
<th class="th" colspan="1">34 Months Ended</th>
<th class="th" colspan="1">60 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Aug. 01, 2021</div></th>
<th class="th"><div>Jul. 30, 2021</div></th>
<th class="th"><div>Jul. 12, 2021</div></th>
<th class="th"><div>Jul. 01, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Jul. 30, 2026</div></th>
<th class="th"><div>Jul. 30, 2026</div></th>
<th class="th"><div>Aug. 02, 2021</div></th>
<th class="th"><div>Dec. 23, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareRepurchaseProgramAxis=amed_A2021ShareRepurchaseProgramMember', window );">2021 Share Repurchase Program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1', window );">Stock Repurchase Program, Authorized Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | 2021 Share Repurchase Program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramExpirationDate', window );">Stock Repurchase Program Expiration Date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Dec. 31,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Share Repurchase Program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1', window );">Stock Repurchase Program, Authorized Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramExpirationDate', window );">Stock Repurchase Program Expiration Date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Dec. 31,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Second Amended Credit Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Credit facility, maximum borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Maturity Date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jul. 30,  2026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Second Amended Credit Agreement | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_ProceedsReceivedFromLoanPartyOfSubsidiary', window );">Proceeds Received From Loan Party Of Subsidiary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Second Amended Credit Agreement | Five Hundred Fifty Million Revolving Credit Facility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument, face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">550.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Second Amended Credit Agreement | Four Hundred Fifty Million Term Loan Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument, face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 450.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_DebtInstrumentPeriodicPaymentPercentage', window );">Debt Instrument Periodic Payment Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.625%<span></span>
</td>
<td class="nump">1.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Contessa Health</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Payments to acquire business</a></td>
<td class="nump">$ 250.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Home Health [Member] | NEW YORK</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Payments to acquire business</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Home Health [Member] | Visiting Nurse Association</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Payments to acquire business</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_DebtInstrumentPeriodicPaymentPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of the Term Loan that is required as periodic payments including both interest and principal payments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_DebtInstrumentPeriodicPaymentPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_ProceedsReceivedFromLoanPartyOfSubsidiary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds Received From Loan Party Of Subsidiary</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_ProceedsReceivedFromLoanPartyOfSubsidiary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28551-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date when the debt instrument is scheduled to be fully repaid, in CCYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stock repurchase plan authorized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchaseProgramAuthorizedAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchaseProgramExpirationDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expiration date for the purchase of an entity's own shares under a stock repurchase plan, in the CCYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchaseProgramExpirationDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareRepurchaseProgramAxis=amed_A2021ShareRepurchaseProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareRepurchaseProgramAxis=amed_A2021ShareRepurchaseProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareRepurchaseProgramAxis=amed_ShareRepurchaseProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareRepurchaseProgramAxis=amed_ShareRepurchaseProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=amed_SecondAmendmentToAmendedCreditAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=amed_SecondAmendmentToAmendedCreditAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amed_FourHundredFiftyMillionTermLoanFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amed_FourHundredFiftyMillionTermLoanFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=amed_ContessaHealthMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=amed_ContessaHealthMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=amed_HomeHealthMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=amed_HomeHealthMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_NY">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_NY</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=amed_VisitingNurseAssociationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=amed_VisitingNurseAssociationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140006523268632">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SUBSEQUENT EVENT- Fees and Rates Under Credit Facilities (Details) - Subsequent Event<br></strong></div></th>
<th class="th"><div>Jul. 30, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=amed_AmendedDebtInstrumentByLeverageRatioTrancheOneMember', window );">Consolidated Leverage Ratio: Greater Than 3.00 to 1.0</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityCommitmentFeePercentage', window );">Commitment fee percentage</a></td>
<td class="nump">0.30%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_LetterOfCreditFee', window );">Letter Of Credit Fee</a></td>
<td class="nump">1.75%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=amed_AmendedDebtInstrumentByLeverageRatioTrancheOneMember', window );">Consolidated Leverage Ratio: Greater Than 3.00 to 1.0 | Eurodollar [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate</a></td>
<td class="nump">2.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=amed_AmendedDebtInstrumentByLeverageRatioTrancheOneMember', window );">Consolidated Leverage Ratio: Greater Than 3.00 to 1.0 | Base Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate</a></td>
<td class="nump">1.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=amed_AmendedDebtInstrumentByLeverageRatioTrancheTwoMember', window );">Consolidated Leverage Ratio: Less Than Equal 3.00 to 1.0 but Greater Than 2.00 to 1.0</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityCommitmentFeePercentage', window );">Commitment fee percentage</a></td>
<td class="nump">0.25%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_LetterOfCreditFee', window );">Letter Of Credit Fee</a></td>
<td class="nump">1.50%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=amed_AmendedDebtInstrumentByLeverageRatioTrancheTwoMember', window );">Consolidated Leverage Ratio: Less Than Equal 3.00 to 1.0 but Greater Than 2.00 to 1.0 | Eurodollar [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate</a></td>
<td class="nump">1.75%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=amed_AmendedDebtInstrumentByLeverageRatioTrancheTwoMember', window );">Consolidated Leverage Ratio: Less Than Equal 3.00 to 1.0 but Greater Than 2.00 to 1.0 | Base Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate</a></td>
<td class="nump">0.75%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=amed_AmendedDebtInstrumentByLeverageRatioTrancheThreeMember', window );">Consolidated Leverage Ratio: Less Than Equal To 2.00 to 1.0 but Greater Than 0.75 to 1.0</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityCommitmentFeePercentage', window );">Commitment fee percentage</a></td>
<td class="nump">0.20%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_LetterOfCreditFee', window );">Letter Of Credit Fee</a></td>
<td class="nump">1.25%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=amed_AmendedDebtInstrumentByLeverageRatioTrancheThreeMember', window );">Consolidated Leverage Ratio: Less Than Equal To 2.00 to 1.0 but Greater Than 0.75 to 1.0 | Eurodollar [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate</a></td>
<td class="nump">1.50%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=amed_AmendedDebtInstrumentByLeverageRatioTrancheThreeMember', window );">Consolidated Leverage Ratio: Less Than Equal To 2.00 to 1.0 but Greater Than 0.75 to 1.0 | Base Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate</a></td>
<td class="nump">0.50%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=amed_AmendedDebtInstrumentByLeverageRatioTrancheFourMember', window );">Consolidated Leverage Ratio: Less Than Equal To 0.75 to 1.0</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityCommitmentFeePercentage', window );">Commitment fee percentage</a></td>
<td class="nump">0.15%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_LetterOfCreditFee', window );">Letter Of Credit Fee</a></td>
<td class="nump">1.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=amed_AmendedDebtInstrumentByLeverageRatioTrancheFourMember', window );">Consolidated Leverage Ratio: Less Than Equal To 0.75 to 1.0 | Eurodollar [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate</a></td>
<td class="nump">1.25%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=amed_AmendedDebtInstrumentByLeverageRatioTrancheFourMember', window );">Consolidated Leverage Ratio: Less Than Equal To 0.75 to 1.0 | Base Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate</a></td>
<td class="nump">0.25%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | Consolidated Leverage Ratio: Greater Than 3.00 to 1.0</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_ConsolidatedLeverageRatio', window );">Consolidated Leverage Ratio</a></td>
<td class="nump">3.00<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | Consolidated Leverage Ratio: Less Than Equal 3.00 to 1.0 but Greater Than 2.00 to 1.0</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_ConsolidatedLeverageRatio', window );">Consolidated Leverage Ratio</a></td>
<td class="nump">2.00<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | Consolidated Leverage Ratio: Less Than Equal To 2.00 to 1.0 but Greater Than 0.75 to 1.0</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_ConsolidatedLeverageRatio', window );">Consolidated Leverage Ratio</a></td>
<td class="nump">0.75<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Consolidated Leverage Ratio: Less Than Equal 3.00 to 1.0 but Greater Than 2.00 to 1.0</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_ConsolidatedLeverageRatio', window );">Consolidated Leverage Ratio</a></td>
<td class="nump">3.00<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Consolidated Leverage Ratio: Less Than Equal To 2.00 to 1.0 but Greater Than 0.75 to 1.0</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_ConsolidatedLeverageRatio', window );">Consolidated Leverage Ratio</a></td>
<td class="nump">2.00<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Consolidated Leverage Ratio: Less Than Equal To 0.75 to 1.0</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_ConsolidatedLeverageRatio', window );">Consolidated Leverage Ratio</a></td>
<td class="nump">0.75<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_ConsolidatedLeverageRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Consolidated Leverage Ratio</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_ConsolidatedLeverageRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_LetterOfCreditFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fee, expressed as a percentage of the letters of credit, for the letters of credit</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_LetterOfCreditFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityCommitmentFeePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fee, expressed as a percentage of the line of credit facility, for the line of credit facility regardless of whether the facility has been used.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityCommitmentFeePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amed_AmendedDebtInstrumentByLeverageRatioTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amed_AmendedDebtInstrumentByLeverageRatioTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_EurodollarMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_EurodollarMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_BaseRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_BaseRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amed_AmendedDebtInstrumentByLeverageRatioTrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amed_AmendedDebtInstrumentByLeverageRatioTrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amed_AmendedDebtInstrumentByLeverageRatioTrancheThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amed_AmendedDebtInstrumentByLeverageRatioTrancheThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amed_AmendedDebtInstrumentByLeverageRatioTrancheFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amed_AmendedDebtInstrumentByLeverageRatioTrancheFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>56
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MB4+;B##*9P*8'!0F7H5?M1'%*Q0FULU9BM.CNP\:'6:<I$GH%ID>1*8O/&7
M96VV_<KN%O4& &8"5 %>]:I+U+9L"]&MIEP"13,E>C;!;R=I$D01[4>>I%&
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M-18O$='$-L=':\3]UJAY<S*]CW/7GL14LL1FZ\)$R )[<2,P)B!E'+(N3D;
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M'>?I25ULVR]W?"OJNMBTOZZ36-1%(Q"OWQ5%_?RD^;[(_DM1Y_\'4$L#!!0
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M]_SI3[8S*)+S%;QJU%_TM),-3E#1-2U?[P:#!NNR[O_GSSM'C ; //8!>#<
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M4:[22XWEGL6#;1,$)(P]%).#5PX$K_0W,Z?)7O32=GC9WP$X[?Y)L,>#V[!
M*M\93=+-PPNB0ZMG&NE )Q5IAVI2%PLM1^)$>LT*;^242\/6MJ4V#'LZ+Y/$
M%J4TC]JL1&UDG3(7P#]%M0Q/72 L8TKR74K"CDI2$.2YD.E7U)FPOD5'(1Y1
M!@GR.20R5/]RN#FIG:-7O2/O@02 U:.B4W"507BQE-K18<C>"5!:KT/TTCIV
M(E!8Y>!'O E&HK>)])E8HF=@ZY+*+@49%:+B;C0?B94R.):##5ZKDI2E?;5A
M\4M(FN@RA^&WFDCE4W^>S6YBO!(V-?E0%STYG4*>(2(C<?VJH"VLV^,ME!L+
MD#! B+%5-)"&I-H0YJ@3(7)TOD^=/?V, ZAID'I4TK%Y,GD?""^4@FD:]R^"
MM<% E11.< *_LLZ/Q.<,V IJ"9_9.L=^8BU3LBZ<_K4VH4UB\[(#_B6(2!:'
MY$P;((XB3R5Y39&L VQGQM0X<QL8@SIU4F(RWOYK5(ZU"N%_!CL5"^3*W4E(
M 4-*TDN=XQV+1?OG!$*@J(FG\X<DDV:E$$A%H3WWBJV[Y^>GT='$6RU<33"=
M[C<);HL(-INC9.T1I)I,)UFK$RD7>N"V]J-F)+GU-1S(WHC*AP(S$J=(*Q1D
M3P\NK:W(7D\H4(PQ0CH;RF"_%ZT/G)72-?M>"@\">L *XZ1+#["\+715M9FZ
MC^*.55_JB&GV",2TZX XF%BX.E<M&%9U'L [@M,I.T*A66HY-F==;-XX:_"<
M-*I<&_&+-.R;29OG2:C3D.:0;IY10$HUJ72(M[N2("JV!K/YW> ]XV9[,J9F
M+45.3YHT6E A;M@]\6Q*?36A4269P8&<&@T7IH:@5Y(C>%M:GM*<#O1$DRZ5
M21Y[.Q]#FB[+O.6/X+['&UO[T!%X)M1D@*0O*8PJ(69*2CY[29R#T)RY._R(
M5:V#_YO*PW4;*5!NP P5NZ=6GQ77^I0?#48IU$QZ1J%,G/4^]$_0DJ6RPG+C
M%7D&WP,Z]-JZ:#_:K!Q9-[>KQY!,V9>-22K*2K[Q),3D-!(@BRY*$B+A#;5<
MJH2S1Y.6OK?*]3!XZ7W])@119S])!U"$O$,F['KY%W%W8DGHK<'%;'XRH,XO
M<)C?!0B.]X9@'ZRFQ"WY 3\IR6Q]1C5/Q,'>P?L/XD(F.M?= $&,SUEAAL?+
M%"B91>%NVV(5<=WTG"# EB83/I3H=6+25@]4+F.-(:!R+]&E#?B86@0:6D31
M0V XGZET1?LY^=-JIDN$12:K"!3%FGR$L[B)@2NW3Z3Y)JZ7]#X-ZFP-/EZ>
M7-_">B2%":CJ*%!KQZ(G5>C<%P'+EEQ14S)"D_^5L(%W!29@DBEIDFZ"(D'X
M&9%KV^S2I1;RVA.?3;;'D^_P630SPL53(L@90L&#,20@40\*;,\F-;0"ON0<
M+$=&5+0WX[I/D-S0DUNLD9=#H%!K49>0A;2+X5G(QUZ_M&BR$Y0'6'P9CN64
MMYRM5]FS4CQM6H@8K&N-_--%J_E/HO3.<S-TCK:SX$:9\T07<R&]M"@O02VA
M\@_*[)O-BL?^#K6Q3:&_JT7F28,Z.*=^K74S.A;R&Q 9Y>2D"2L733!Q!  1
M%#6<A M2H6V\0JD..?W[.W7FT6_XN=/"<)14-;>JH7M,N*=#H *];56WOB?L
M"!DO-L0\>/3O,@ U_SL-%2M2.YJPRN"P.<G'QGZ=68)@&.+Z4SIT J:\7AE.
M-Z8*34G2-@$M:1ZCG#1>-K6LZW%4KE%M6%0N<+77!JTWE,",9=H,%@B1.I1V
M4)%K)'[I59]2[ W:#DGS'-!$BDC9_U!2)D!'F&H8>51#VU+]IK8!7[FW@6F;
M%0AL%36!]ZJ=R1A5A,1G@GO,X'@$_!=TNTH"=,>^J+[O-BBN,V7B9$'<Z-:"
M^A.YR)M6$'O;MV3))A;H#)H*NKX%2X.2#S#@F::H)6T*NE#E@-J$UI:8;[$?
MB,86S/>R$AG)42VAO52C/)MX?_P#9Q^7;B.H(5"T48_TLXGEJ\5[<0]VW%Z'
M2%[FH99(ZK?-JW+^VQGL2W1.,U%VMB952&7-$T2C=FLI#ID%-0 \/*L'P%TC
M$#>#8)G77)!J0Q=);,1@@4(AR-/6]!8) +8B9^2-Z6COO0W3?&63;_$*HG,\
MY? WG-\7^0T$A&)%E^\@!7&)^3,,KS>M])HZ'%4Q^5-A>[>W/YJ@2X>KFA'J
MW61O-.U6GE\4\:X7!LHNAG. D#;Q8-P"@YS/70C2NJKB7<X;@%C(G(LL7\$#
M"F=UK#M\X;5QT?72-1M=<58]='-&H7I#+?!7Z\@RC2N;?B5DTHIK,?$J6,DF
M<%H8TW6"4>VMPA/ =)X9TBV81'NN'X;L%;IW&7;CME/T9>=5+FWX8!;BBQ0+
MJ3$_()BI-*NTA5&HC.TD'5F2Y]:*[J!\[/_"=1U?KZ&,ISHF7!EJ(5JFQTHG
MG-2I,'#TD1PTV9(8D_$XWE+V4TH#;+BSXP^!2<L71&[ P7.S4;V[$1Y:>O6'
M$SG&'8N0_8W=]FYWTH/KBM(Z?3A*J3GB^&GJ#052PB[J!(II<0.33&,+,YSG
MFXQ7O?D=>.T5[HW[K)%XZ>/$3N_+4J'<BK^?<;=AJO"1*:[&3W2S\&6JVQZ^
M[V&\PM#@D9N6.#H>_;0_$"Y\,PL_*EOR=ZJ%K2I;\".-H<K1!KRG:Y/V!S&(
M'RZ/_PE02P,$%     @ *4 %4S_-'P=N'@  8&$  !@   !X;"]W;W)K<VAE
M971S+W-H965T."YX;6SM7?MSVT:2_E=0NN36KJ)H49)EV4Y2Q<@O;<6QSK+C
MNKJZ'X; D$0,8K@80!+WK[_^NN<%$I2=;+*W/VQ5++Z F9Z>?GS]&.2[6]-\
MMDNMV^QN5=7V^X-EVZZ?/7ID\Z5>*3LV:UW3+W/3K%1+'YO%([MNM"KXIE7U
MZ/CHZ.S12I7UP0_?\7=7S0_?F:ZMREI?-9GM5BO5;'[4E;G]_F!RX+]X7RZ6
M+;YX],-W:[70U[K]N+YJZ-.C,$I1KG1M2U-GC9Y_?S"=//OQ%-?S!;^4^M8F
M[S.L9&;,9WRX++X_. )!NM)YBQ$4O=SH"UU5&(C(^)L;\R!,B1O3]W[T5[QV
M6LM,67UAJD]ET2Z_/S@_R H]5UW5OC>W;[1;SV.,EYO*\M_L5JX]/3G(\LZV
M9N5N)@I692VOZL[Q(;GA_&C/#<?NAF.F6R9B*E^H5OWP76-NLP97TVAXPTOE
MNXFXLL:F7+<-_5K2?>T/UQ_?OIV^_^_LW:OL^O+USY>O+B^F/W_(IA<7[S[^
M_.'RY]?9U;N?+B\N7UY_]ZBE^7#7H]R-_:.,?;QG[+/LK:G;I<U>UH4N^O<_
M(CH#L<>>V!^/[QWPKUT]SDZ.1MGQT?'DGO%.PN)/>+R3/>--\]QT=5O6B^S*
M5&5>:IO]SW1FVX:$Y7_OF> T3'#*$YS^*=R]=VQHZS.[5KG^_H#4T>KF1A_\
MA@FS]_I&UYVFU]PLZI)UY),F-6&>9*3OI'1RR;PQJRRGO01?+$EHNW2RJ1N;
ME37?U!2JSK7\F##VNE5UH9K"9A>F*.=EKGBF!P?3ZXN#A]G9T=DHD,+S7/3G
MN0CSC#(:*5.6#$B^'&6WFNACTO^N Z5$2[O4V5HWI2GPZ799YDM<:VE>.]]D
MIFOP,YLST&MF5;E@FFS6D9PV?$5<[&R3T;O:SG738#U\/]%96EUDX'J9D]2T
M1F[K,64%'M!O2]7"?L$0,74TN"UI)N$$W1J(U'=KOLAD,_I #&PKS<O0=_E2
MU0O-VT+3WY0%B%G3$'19EJM&C]PP])9G8:J5V+YUPU2JJC+$?QJ29L U16EI
MDVA&OY!Q]H&^OC"KM:HW?[%$JFTS,R<NM63@,67D3&FSVK1DC%KBMJK&?ALM
MDQ#VAK=L'\=QI>Q,J0N_@AO50!-A;(O,R([6JNWH6B(%GP+?A16Z&&?O]NXK
M".7%ZHH<0+/!("GCXF@#DIS,#>F;-_IOG:YS'B3<YYP=[]1ZN;%D28CW?\EH
M))*%=&,*3<Q:\;4D6"I>'5>K/''$?DOB )W)%D95.YNSCZF-KFA/L,=;.JNR
MHG-21^17VK)PTH=:9QNMFN=8+DFJ@32U<:YL25O(CE1$1ZW7U88O,&N,IBH2
M4+U:.UF3+<$"2<>AX<PZ)RY@8-G(."1^>66LR*M:+!J] .&B.'ZO=^2X+\;[
MF,!:!Y9W=1"P#,JCFI:DE>A/?Z#UN>DTD>K>-GIM&C9B8D^$_U\UWGWROM U
MZ3[NR(F]E<9";I?:62[9>[D2_%FJ9A%5(]YK\KQK9%])Z@JUL:#F5NO/7[>4
M3XDP[N%S$,E%8TA4A!3+)FA' 4<T1='ELNV:K K,@ESKA; C,8$@U*8^3+_S
MMEL5OY+Y7&'UX^ %]EP03$P#2<,L8L[F9*8UF#[3+?&B9JMLG0O*&J8)-#@S
MS%-H_X.878*V%9LM]D9^/Z /95,<8KLW].W&-#*2@<KL8<HX^_G+:R6CD5==
M(;LM'B.H$%%$ '9.LVY&)%]E;3NH3A 2FI3G=P2->N,2*"!HBCUW*]G@>Y
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M$Q9Q.RT !B!GUX[*U;"N[0T]1G]*[#%R2  ^&B&VC1077>,%8+N,%N(-R4%
M/D72O&=P58;H,S$2)X9]J2OD6W9S6 /!?Z#ZW['Y/QJ;3ZL$:<6ZD.QD+,D(
M]"53M4"-:EVI.C@/9]>2U%.&A'&E]SC*$=N3A@,!AY#2$IR".)4"@W?JD+%\
M0_X*^7M78_'I0:PSD.HSA@@-)#?G[*!/)7MX-^;"= .IK#;]"E>01Y^YBL39
M&.LXZ$[QCOKB\K.D3 1%1,9QY.%( )Q$?5?1^C19K6KC[9-L)&2<C([<(1%*
M&XH["V-<B#.0!9C6/LH 1FI:&6)>-H0C8$L5VS56)'9(<!YN%2Z3JX%WSXZD
ML 099N_1D4['JM0(5E2K!LY^)+J/Q91KT4_:T0ZV.,0[J-O=:E=&&T3];I%>
M(IT8](.SF=PRH^TB/T2XKA9SY1*[\>(-5A6M>Z4A+Z1=C^#Z>%:03!Z(+98S
M)VS/ 7W5'8;5<^))^W#D*2*M8X- HD;Z:S]+ZKLF9,*82,JYI+D^+$.29JVU
MP';^QN]6L,#8;Y)8K02<B-=7?=5+D08;$#;,+I85*[)341YGE[54H)UO@VP0
MM-"\F7.*?DN76DLL?DVB"E_2$"J\*1O:/=*.0J.&0)'^NU\N7QQ.GB(6IZB?
MC=N=+IQFSTL7$A#1<8.(\+;#/I*K7TCPDM:@V<MTM+3<BP"99A*M.M^,LQ>)
M)W)4C""Z_1WV6T>$Q&D%S6W$1LQ0K2AKVS8=AT-;E7> V" ?=%?II&.F<^5B
M;A:0><G:@2WM4)C'4)XE'KJ77/ J>^4!%Z:%&HS(*N *J^5*(G$:$X"B=-+J
M+308X"=AQ?$!&6._+5;$]3MG%\@367-*Y<4VBF*OI^)6$B)2R:#+1"+;+^AL
MV"Y)(QT+>N_C=O;I'*N%D9QQ@((EP)7#6I0%K8MGR)@@6$KCG <'[Z=7$$4
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M2#9P ?T^-^2VW =,$/ZG"C_\'U!+ P04    "  I0 53/5GH%1@)  "I%@
M&    'AL+W=O<FMS:&5E=',O<VAE970Y+GAM;)U8V6[<N!+]%:+A 1S 5B]>
MXB2.@8X3PQ[<Q(8]21X&]X$M42W>D42%I+KM^?I[JDBIU5XRRT/BED36<NK4
M0IZNC?W#%4IY<5^5M7L_*KQOWH['+BU4)5UB&E7C2VYL)3T>[7+L&JMDQINJ
M<CR;3(['E=3UZ.R4W]W8LU/3^E+7ZL8*UU:5M \?5&G6[T?34??B5B\+3R_&
M9Z>-7*H[Y;\V-Q9/XUY*IBM5.VUJ857^?C2?OOUP2.MYP3>MUF[P6Y G"V/^
MH(>K[/UH0@:I4J6>)$C\6:ES598D"&;\B#)'O4K:./S=2;]@W^'+0CIU;LKO
M.O/%^]')2&0JEVWI;\WZ4D5_CDA>:DK'_XMU6'N(Q6GKO*GB9EA0Z3K\E?<1
MA\&&D\D+&V9QPXSM#HK8RH_2R[-3:];"TFI(HQ_L*N^&<;JFH-QYBZ\:^_S9
ME^MOG_XCSJ]OK[_,OUW=?KT3-_,O'S]]OCH7H_/K;U<?]Z=O1J=C#U6T89Q&
ML1^"V-D+8H_%9U/[PHE/=::R[?UCF-C;.>OL_##[J<!?VSH1!Y,],9O,IC^1
M=]#[?<#R#EZ0][5N72M+8:RXJG.K?K2J]N+*J\KMT<L/QA?B]_G">0OB_/<G
M&@][C8>L\? %C1V:SX'Y\YT_B='N)DBOX(CX+&U:$$9 RA=*?#>VS,2EDB7<
MN;9+6>L_):=#IM)26I6)3H"0HI&(5J731,P='@O>EF*5D%X4IE(B-146/>R)
MM1*%7"FQ4 JI56>@;5GB<^UUW2KA#;X(C<6IAX[% UNC\AS)Z(3)>ZWO('>M
M5LJR2*NHCI"62GO:"#G0;Q]TO10H*?AGD06.2P*DX!M]06WB+PU<0QA=(KZK
MIP:EI4$U>!"5J;7'#K(H6#@T2%"IP$[IFLY6$KUH':+B0 Y=IV6;D=J- $?R
M:9FJFM(\*(5UG3&,CFN;IM3*NH&_P-07&EM1Y-A[ KJMY:)D<Y7#!^D5JT&-
M"0_18'K712MXRM$@5& %O':FU)DD"'-=RSK5DL'(- 5_#T [B S>-<HR)1SQ
M/I6N$#E*-4"\[OGT>F_ J?/Y[:<[,8<5:^F$T\L:6G0-DTNUU*YD88GX;6MI
M8\U*9V0.E.Q,7Q^)!:RF,&+?@&AQG=T"NC"NT5Z6CAPD$W*+N K*$W:!K>KB
MMR'Q=1X!-MA+034I(R(KT]9^3^P<3'HKR)5,(]OUHJ4UNJI4IK$<A(&%O5G<
M K)HA[;TH3&6/*;HN()\@$6?L9G]R97:A\O[3MF53HGANEJTUJF*N0&RSR;3
M-TE,T6T(P E+.WZTVH9<(+#!)U#'@QXAD1'57-N*<+(J5;KQ'20W49"X5>!>
M+BY:,'%W='-[@6*1XR%P4RZM8L;1'J]L%5[W;&&(&_E %@-4\(M+00@:+^7X
MP#FGEL$M-F1%4#?PYIZI"R!WII,)TC<@CAA6(9C:.K\5#.@+Y@TC\@)/",)Y
M8W49&;HN-!BK7:"/TRN.Q\ZLUVM5*:,\RI7_&5!7K&!V"[$L.\4#2=XEY#T*
MAO*%(8JO #H[^(HK# AI,%;$\#QR];A7"/6 /'K$U:VNXTRRUD"0,& ICN&F
M]7/019[#ED1\K2F"+X:&TNE1V&.H^I)"Q%\'AUL7RDFPA6JB02D2*(P>4@!"
MJX*&&-P ![ZZ(6Q=JNV%PA^T#&E*2:$L4*#O>5OB5V;2EJP*U<RI:*Q3&URL
MHDQR'1._)G>)^*@::1ESVG"YH=QE6R$/[D)6(52CR\N[$<)R$5O!NC!0NV_6
M5)Q<NW :V6PU%>:N=:$#<D4B(M0PL?6ZU'^J0;"B)>K>DP'=OA^8&W3.+:DO
M.NH>4[)CZ<P_+CF0O7/4TX"LWID>;/@?+?W+9,I:VW4;7U"J<D/1]_L5C5@"
M2&L#8Q5-6@)SDNKG)*[SU,:0!>5#"-?.;+IMTFR3&O]:TV1;$^:'-#66:C>I
MS?]^3&KCB1W9=A">8VGH8-S]J9!TD0A]9VDE H8*0-A*YTRJF;Q]OCT)'"UN
M+?'WW\/-*PD-*C\X7-#)@UNCP# )!V*GA?!H&9FC^Y:=D2'9=O.F(A];Q5:K
M3@8 <9>0*ZE+'AT([9#GUK3+8MM$KEN9SACHD)D=[3=UH:O>[^@=_#!6;2*$
MCX@LU3OT7XF*314RC^-4Z*RTEG"E.<506LN')VEQLB&A?P;%G>/)<,%'6%0M
M .'!-/!-[#JE7FYR\VR%F8?*:LH&4=6EZ/+0$(P&[?X&_@M9LB ^8,6RCWZ!
MX$?74+&ZJ6M3U;;9B\KTA%1;9"(NT=<[U?CHYA +5H3N%.;2MHX!RZ(&S-;7
MJ3?#;0D=!>(Q.\QL802*)A72#\,9.G7?CC<S&WDQ&/(#EG&$D]1ZJ+$X^@FW
MMV.X&YC =3W&T;UZ*^:!'Q=L1^_'LTP5.^+P.#D6G^(8G&T 72@FE<ZZ KVD
M^E!SES@Z20ZB_-XU(-366V'=:OI.3),W4#>='"<GC\96;O%;LVOHQ!4"#W !
MLFOB#44,O6QQ9$>2IF+V"TS(VK1KZOU,B(.7KAY/@B TSJ!TW*3UKWI=D2*?
MD4,=]SN\GF0%Q[U_&^KRN:DQWSF'L< 1O6461@?0H2^"-J3.8'RGH%+G[:?K
M(7ISFG0P<L53 W#J:/<;C=M#,=PZN<E"R#986_[V/H4#1W0H$+F?[J9/O;E,
M;A,Q/3D^Z1HO>$='1:ZW.ISFM\)'P_,& 39O&+V7(ON\L8\#$,KKX. F_5\Z
MSH<W] .K)-6/U@;VU\J+S9F!>Q[Q^-&0>=!/F6BYO5OEP^.#VA,&9RI7UM+]
M1_ [GEOMY@3#/;.$#2B<5.*]O!>[Q\GLEU=[\1Q/HS7)B_,F#2J@?^[CN*IJ
M'%0Y)[, QHNDO= Y%(#H:9SS-A;"9(BWJ#1D  VGL([TF/HI^IOV'NX1J*9V
M=>B%/3.,F*$TQ]/#0/$CK(^.DLEPIG\&H'>/]\PV;>[Q2* DV!H.5NP>5?KN
M]@ 5KE:YCG<'@<PE>+U/1P!A%J5>QMS[IQTL>>XB:SRX/JR47?(EJ1-<[L--
M8O^VOX>=A^O'S?)PB8OT7>J::D".K9/D]=%(V' Q&AZ\:?@R<F$\ZB3_Q.R+
M_DT+\#TWQG</I*"_G3[[/U!+ P04    "  I0 53'Z$*$&,(  "B%0  &0
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M1 (C8P7-8,48*G)Q,_&"..^_J.ETQ>XH;(!/S%18"#*5YBBXD2\ 52JSG*=
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M4QY*)G;+-(P?Z@1 V:Z"5YOR.]ST*8V@2B<4;_<:A"^;^KTI]7O'^KVL6?P
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M28W":>UNQT\EW8G<<(E%WO4M]+<IWS^!]J-YG" O]"JO/'!AV+'@V7"N!"@
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M=_!]$NI+B^<E%KO;@[$G;LF:/&6GS3'5M"=V!"I&QEH>B+J8UDE9SQZ&T.@
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MY+L39G[EC3=S_MO.R'BTU7PY54@WEA;@][%!-8\W=$#U/ZYW_P-02P,$%
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MMTVIRO'\(XB6Y5LD^5XO[EWPAZZ9BN/91"QFB_D]ZQWG\Q[S>L=WG=?4M?9
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M -R&C"HHPBIF6:6>)*'T<#%]EB# U89+3LVQ.G4,R3'24GX7R2HS S4).:D
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M:[TV* D<%,F]581]:AV$E,/2&PZ9#T.*HW@Z-15B#AWR.5.9]2XD=3%7X!9
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ME@;@]Y6!B\4OM$%^V?K5OP%02P,$%     @ *4 %4_Z>%E+.!@  EQ$  !D
M  !X;"]W;W)K<VAE971S+W-H965T,3,N>&ULO5AK;]LX%OTKA+=89 "/K;>L
M-@G0=OH:($W09F8_+/8#+=$V$8KTD%32S*^?<ZE'W$Z2/A:['VR1(N^YCW/O
MI:3C&V.OW$X(SSZU2KN3V<[[_=/ETM4[T7*W,'NAL;(QMN4>4[M=NKT5O E"
MK5HF450L6R[U[/0XW+NPI\>F\TIJ<6&9Z]J6V]L70IF;DUD\&V]\D-N=IQO+
MT^,]WXJ/PO^VO["8+2>41K9".VDTLV)S,GL>/WV1T?ZPX7<I;MS!F)$G:V.N
M:/*N.9E%9)!0HO:$P'&Y%B^%4@0$,_X8,&>32A(\'(_HKX/O\&7-G7AIU+]D
MXW<GL]6,-6+#.^4_F)NW8O G)[S:*!?^V4V_-ZEFK.Z<-^T@# M:J?LK_S3$
MX4!@%3T@D P"2;"[5Q2L_(5[?GILS0VSM!MH- BN!FD8)S61\M%;K$K(^=./
MK]Z<O7I_R=Z]?WW^X>SYY;OS]\=+#V!:7M8#R(L>)'D I&!G1ON=8Z]T(YK/
MY9<P:+(J&:UZD3P*^&NG%RR-YBR)DO@1O'3R,@UXZ4->BBT2R;,/8F^LEWK+
M_OU\[;Q%3OSG$?AL@L\"?/;?!?%1$*J^IV[/:W$R0WDY8:_%[#[D\\XRU*3E
ME-6.27UMU+5@)"!K<FV/%3CKF-]9TVUWS$ "8R%01>0_7RO!UIV# <Y!,,3&
M/64[TPJV$USYW1P3MY>U8%PW#-J<T5RQFENQ8&3!P=X1 <6@4&'6,4Y)#&U<
M;P4SF\$V0<;"$!&$'2U(W<AKV71<.7:S,TCL6[8F,VL#(')F8TV+CF&WPM["
M* Y/.:OAF)8U:Z3C:ZFDOV4&+@J+ H&54JG@&>YI(1K&G9/.<PUO;B3LK4V[
M5R*D@6Q#0&#\Y*/G[LJ-3O8Q&!W<6P-K8?J>*R4Y]9,0DA DH*)'>N;-9(FZ
M)5ON"*%M\%]:MN$M[!:#GL_B>Y^V03Y8_Z4W%%!XBPT2"*'+2>P/\6VXA U@
M!;XNV"5V_O,?JR2)GAE(V3".G\%RU;5Z)&=C%#HU!2<DBL.R)HT!L#8TL$+Q
M$#[X*CZ)N@N1:+E&&P^FDZ.\00PD%5E8==V>0LTVG0[]V,WAH,1!0!9*W1\O
MU*?'9)G#E]ITFA3-V0;QA,MS!KX5J>Y#KH;NCMU*;+F:]^3*?J^5[NK +-)H
MZLX.$^B^$CUZ#4A94_@.C#9ZSC# G+;L.@#!<X=JHE3^TD6#CG5V%P%QS57'
M/;$G;'!.#\6$M#!U6+D#HW.E8:8G8"ANRDY=4YDA[G3_H'C'FIVC:F2]HXVJ
M:X)5(SZ%,A!F(05U( H'N<.>1J*^/*+.O;=RW?60E+90XO:BEAO4UIB%9/($
M;\6UT-WH/5([Y-&0%=^%NV!C3T8^"ZH-9+XVGE3@Y$4TUK=!D/CD^I9R-2Z?
M(1MW4FP.8M0 -SPAM/P*I@PEAJ/=4%T.H&@4M3(4XS4]AK CWE)FA8;44D(A
M@WY:L-?41:#SDIKES^%,8Q?H0Z;I3S:&<TE,YQ)[2^2\'7K$Q5C#YR$DE\9C
M_!Y/54,^C[%C3UB:58L4U[@J%Q5=RT6$2W Q>8917F2+9 #Z6S8DD*7?N'V\
M9HN"O001!PUW#M*)N3Y..%5JV2=&H*^EH_#/_D9<18N,Q5$.O7&ZB"?4-%HM
M2O9&:%BA[JOK*:U6,8S*5H!) 9(EA%?FN/?+XYJQ.8**.S=6K,#\?/)[TI"4
M">(5YQE XX*TE:2IBC[;/H3I"'R[GQ#,DAQXPK(\Q#H*DR.2'!;C[Z,]^F':
M$QB:!+I+* VTEY_1GJUR),(#M,<YA,H0K'R221)$Z\=)7V705Q%HG!UPGE1$
MV[=P#D) 0(3($C,8@)B\^"KG)$!N1%#:\YW>RW=.@8K3%3([IF&6AS^JFH?Y
M1@HF/=\4W3B$^H@DPV(%V9'OC_+3_Z[(B[(O[G15H1*HZ+\H\G@>1U0R#_!=
M8JF R)=ECNI,?YSRM$QA31(5B'J2'Y1=$5%]? OG<1$#HLJPO4"D5S1(44_9
M5TBG5"%_B?28RC#.[J<]3ZD?IE%*_PEE:(X$J(H2_P_3'@^\5TD(=Q*B?42B
M_2IA?@?Q/U[F>94BN$1X@13'M0@&W1%?E:&__=_*/"W(H!AY&+&$@C3"YFC9
MT;=QGE$REQ48H%K%(&%I3 1]K;E7H0*)\U#%\?V=/0=6P9*BPG)*!]FJA,E5
ME#_:V4.;>L)6?64E87)$DF&1G+[OW6YY\++<"KQ8T"<!>LK% T'_WCS=G;XZ
M/.]?MN^V]Y\LSKC=2KR#*;&!*'(ZG^&9,WP&Z"?>[,.K]]IXO,B'(=Z9&F%I
M ]8WQOAQ0@JF;S&G?P%02P,$%     @ *4 %4]4M&AN$!   U@H  !D   !X
M;"]W;W)K<VAE971S+W-H965T,30N>&ULQ59-;^,V$/TK R- +XX_9&>]63@&
MG,1%6F"WAMVTAZ('6AI+1"A2RX_8[J_O#"4K3A&GN^BAAT0B-?/FS>/,F-.=
ML4^N0/2P+Y5V-YW"^^I3O^_2 DOA>J9"35^VQI;"T]+F?5=9%%ET*E4_&0P^
M]$LA=6<VC7M+.YN:X)74N+3@0ED*>[A%978WG6'GN+&2>>%YHS^;5B+'-?K'
M:FEIU6]1,EFB=M)HL+B]Z<R'GV[';!\-?I.X<R?OP)ELC'GBQ4_936? A%!A
MZAE!T.,9[U I!B(:7QO,3AN2'4_?C^@_QMPIEXUP>&?4[S+SQ4WG8P<RW(J@
M_,KL'K#)YXKQ4J-<_ ^[VG8T[D :G#=EXTP,2JGKI]@W.IPX?!R<<4@:AR3R
MK@-%EO?"B]G4FAU8MB8T?HFI1F\B)S4?RMI;^BK)S\_6#_/5 E:+Y>/J[F&^
M7L _-Z9]3V'8N)\VD+<U9'(&\@-\-MH7#A8ZP^RU?Y_HM1R3(\?;Y%W GX/N
MP6C0A620#-_!&[4YCR+>Z S>XFN0_@!_S#?.6RJ+/]_!'+>8XX@Y_D8=WY+M
M^Q#6,5U8>Y,^P0JK8-."R@^6UN16E/"+AGM,L=R@A604Q2&)=@A":Q-TBAGX
M0G@PP<*M$38#LX5[::D=C'4@@B^,E7^1F0 7@]B7(%4=I N!SM#"KI!IP=BE
M.)R:A0J\@8OA8$"UJ12W&07AB-3_S@N=29U#:LJ2OM1!?&%-R(L7[J-A?; ]
M>(RQ?('@T9:.H7C1<N'<+/TIFB2<G3FEX@KZYF!K30F>Q@9_KI]-0)YCQ-\^
MT:0[>CE.T!DE4^D)T="T:A>5E<_"HSJ QMQX*7B3ZD4[$0<*^0J>*BE-&!L_
MGE>1A.@3N&#_*$FER%=JEJ924M!I4=_[ A9[\M0YPCSUL H*83C87%V2.+^R
M++)D9T*+PHB2SMD?97J)ZPA+*=@@C2=6D@HM@\V!DM<T9VFB^CC(*%_B#SK$
M8R"4K8BET25BJ0J1YR9XT,:#HLB^UCP*S>JDV&WS>38JE!B9Y:A)#W64.C54
M!$>]B!G-7WY2:![7L3Q$)3TY6*2^M)$?V1YA-L$1?^=.@&(80SG;(^4>+(-U
M05!F?.R%=*^JYD6:#,;=R=7D6"U-L;XJ4&H904X\S;DWGHE%WN3+]A?)^+HW
M2:"BZ+44S(9.UG .J7'Q0$1%\?>RK OH8MBV1Q8LYQR+O+"(ER7/2D:3)@/D
MB0DT[["==Q$^N9YTAX.K_TH[N?X^VI/Q6[R=W/\KZ[I>3W5OJ'/D5 GGY%8R
M3T<EA,(%>V@L>CS8YB&GGSY(:K#NM\VPF-7_.L.(+T&Q*7)'AXH\6+'8Y>@;
M:-ZYHQVA#S\XP+UTGB.\8G NF1ZL$>&+\3P8X!+68>.H;;BE%\_<.+#E.9/5
MG4(G*W5]<8NQ:S8:=W2X)]J=#?;6[V+_Y*Y1HLWCC8J[DT91?>UH=]M+V[R^
MJ[R8US>^S\+FDMI9X99<![W)50=L?8NJ%]Y4\>:R,9[N0?&UH(LG6C:@[UM#
M0C0+#M!>96=_ U!+ P04    "  I0 53CJ7H1Q$#  #6!@  &0   'AL+W=O
M<FMS:&5E=',O<VAE970Q-2YX;6RE56UOTS 0_BNG@.#+:-*T&PC:2MT+8HB-
MJBL@A/C@)M?$FF,'^[*V_YZSTX8.L4G A[8^^^YY[LZ/KZ.UL;>N1"385$J[
M<502U:_CV&4E5L+U3(V:3U;&5H+8M$7L:HLB#T&5BM,D.8DK(74T&86]F9V,
M3$-*:IQ9<$U5";L]1676XZ@?[3?FLBC);\2342T*O$'Z5,\L6W&'DLL*M9-&
M@\75.)KV7Y\.O7]P^"QQ[0[6X"M9&G/KC<M\'"4^(528D4<0_'.'9ZB4!^(T
M?NPPHX[2!QZN]^AO0^U<RU(X/#/JB\RI'$>O(LAQ)1I%<[-^A[MZCCU>9I0+
MW[!N?8^'$62-(U/M@CF#2NKV5VQV?3@(>)4\$)#N M*0=TL4LCP7)"8C:]9@
MO3>C^44H-41S<E+[2[DARZ>2XV@RO_@P75R<PVPZ7WR%Q7QZ?3,]6UQ^O+Z!
MAX]&,3&U!XBS'<UI2Y,^0',"5T93Z>!"YYC?CX\YY2[O=)_W:?HHX/M&]V"0
M'$&:I/U'\ 9='P8!;_!0'U )PAQFPM(6%E9H)X)N''R;+AU9MKX_PC/L>(:!
M9_C7_?Y34_\5ZPM"*>X0A :I[] 1/R/B)5QA+I0IY.8(!)0H%)69L C\H',9
M'@CD+",.S/DCU)9DYB S52WT]@C6I<Q*D(X?4V8:[1O&<P$:OE0+5"+@CT9R
M_RJDTN0]X#RDSAK+Z SBR(%9@:AK:S:27Q2J+3SM]P8L;*7"&V7:IVGOY-F3
M_DGR9K^;-U;J(N!3:1&#FY.;%Y77%-1HI<D=H)<6L#"P#=^KXXB'AZLQ5*>X
MB%#;_1R2WLO[E"&1?J__GXGL%9K\G@-?16:TWHVFM>1HTW C'0]"WZ/NGIZ[
M@WNH6:-^#KO0V24JB7<^%4%M3LA'/IH-Q^:AB/TE,Z.3CKP4 B/?$;MI+ S)
M('[&$;9B2H6ZH++W)[W'![.F0EN$B>HEPG)HQTZWVPWM:3NK?KFW$_]*V$)J
MS[;B4+Z#XPAL.T5;@TP=)M?2$,_!L&3-LM:\ Y^OC*&]X0FZO[+)3U!+ P04
M    "  I0 536&&8)E@(   +%0  &0   'AL+W=O<FMS:&5E=',O<VAE970Q
M-BYX;6RE6&MSV[@5_2L8-;NU9QR)DNTDC1\S=F*/O>-U4COQ3J?3#R )B:A)
M@ % *]I?WW,O2$I6)*>=?I'X ,X]]WW!X[EUC[Y0*HCO56G\R: (H7X_&OFL
M4)7T0ULK@S=3ZRH9<.MF(U\[)7/>5)6C29*\&552F\'I,3_[[$Z/;1-*;=1G
M)WQ35=(MSE5IYR>#\:![<*=G1: 'H]/C6L[4O0I?Z\\.=Z,>)=>5,EY;(YR:
MG@S.QN_/#V@]+WC0:NY7K@5IDEK[2#?7^<D@(4*J5%D@!(F_)_5!E24!@<:W
M%G/0BZ2-J]<=^B7K#EU2Z=4'6_ZA\U"<#-X-1*ZFLBG#G9U?J5:?0\++;.GY
M5\SCVLG?!B)K?+!5NQD,*FWBO_S>VF%EP[MDRX9)NV'"O*,@9OE1!GEZ[.Q<
M.%H--+I@57DWR&E#3KD/#F\U]H73^Z_G]Q=__WIQ^T5</.#W>!2 2N]&68MP
M'A$F6Q#>B-^M"847%R97^?/]([#I*4TZ2N>3%P%_:\Q0["=[8I),QB_@[?<J
M[C/>_C85F]2K;XTR05P\X=>+?YZE/C@$Q+]>@#_HX0\8_N#_L.#_AG OSK)O
MC?::XM:+3T;\UI0+,8X6V1-SA6#& J=R\<#+S$S<-LXK<>:]S;3D@-\9/-R>
M#7;WA!2%K90HE"Q#(:3)<>]KG2E1._ND<^40='A3VDQ&D=J(6Y4ZZ1\EK[^V
M<RE0 0!5-RXKD ;82PAV*EY-DN$8L5F6V#M<TIULXAL*A5R>-:4,UBV$]%[!
M(4!Y3K(GQDSFXA]([>T$QL/#9_+/FADR9[/!/B!8E?=27$5).X/N2315B<H6
MY;*1@BQ?R_":N9$E_"/D ,; W&3VJ<QTJ<,"./>WEX-=T2WVRCV!GW_!;(?)
M,%GR_H-<0.:1><Z>IT4=MU__\FXR?GODA=/^\365H5Q4-E<ED\I*J2N/2UDN
M@LZ\R&0M4^*EE6?UYY B4F"GI1+!BM01>9(&=.2$EJ5 I:PX/2!7FQJA0"G3
M68$%045@.X9H%_B6&KL/PF2).D_@C6=!*F/3M<25),%[O+A5@_&@"8HS @+M
M11K])\?AGE#?:X@EM+EB!186+)"ZT4)@=47H5\O(OHJ1/5SZF55'$W,R@ >L
M).:%+1&@=FX@/M=/VK?6/JM4KOW",U)G,J=JZP)6\EZO:LE($9&H>34CNU'(
MV,:):1,::#2%^<W,#\4]+  X8)N<U\$J?$.0>'&G?)"$_P'AJ8,XFSG%CN@S
MJ:N%[$F\4!3'V@"''+@)GWC\ +=#"K2"T\7&O7O\=+#Z> .QP>Y0?%G;O8E_
MF\1="B#.-"Z\RAI2((O+^P2"^:3!K^9@E#/ S,C02!B3Z9J>5;8!+!S5U*0E
M\CX1:<P?V*;068']6=F03"E>':XF&.S\9,LG<EA+]+*3W!C*^'5[;-!HCQTF
M!3Q0H5J";L^>"ZA\B>S!,S8[;.A.T!<"O"' CM0@)C8"5?'<4K8B:-M635KW
MK='O(>&VS\YF2N5PB;,5KU[CM9T1@@]AW5#*<O8C@:93AL"LAQ".>;K<MS1%
M*DMI,DX^F&,MI/&0<UMRN9C"%V*<)+_02L+NTU@N6V*,/K(_.I7W#1@M7;A%
M>4&EAY(&2J UT#PHD,&PLFDJFNLTU:[ F=.-C/Q P>K*O1<[>I?QSZF(WW%@
MEE3B2&1=ESKCTLHO$.0[NEU^T3B;PXL0_N(FU'\8" :6I;<8D=-_@P-91"((
MJDH'SJBIBEVH5 &*D(VZ+,*+I0TH/GUGP9_'M(>O%'4!+BL1@8FE-+-3T.B,
M?:N!#X=X6^J<2]:-0M'&[$XJ:(MW/=-+$+KI67;.4#\:Y(;=2$I]E!J1<0F_
M<EF]N3[_=+>Z9FGY>'\M?IV%([$_3!(R%!6#9+B/T!D/WQ[^(B;#A*_I]QIK
MR[6U:1,BP.09P.20-AWV, G_7G<(DTT(M&8%@?<N<1+^O7Z( ,_7C@\[BG%'
ME$_A/=74WG#L:!R%;\Z!-7TQQ+5_EEQO8IYLKWO<X2A6("K$P$*_RYMXB0SG
M()!])&V@%$5L+QK4Z><4)'O$;B6LOS423=6!+0JE"VW')TG+NM'&XK*24@XF
MPS=D(FHI]!(YK&W..:(,1ZE=ZYJLC(K5">_N51U4E2(NVP7[L:ISQI(3DI^
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MG-]Z<W%QS=\GSX\24GXT?&N:8AG!V9A5W6"0<?)N)Z!X%=1PK].=HLZMPP"
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MWE]<@Q7AF&L-JL*6,5X,M!X V!T9B@#RMCN,T*Y77I[41U2O&!N+ G),Y/I
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MS7;B?HNR#\XV#M(+A0W9>O@N]*P.+DJ:!Y$-0T>%QDBN;Z>0<Q/271UM\7[
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M]OA5:ZLW*&1,#)3@B8?ZI3C%;BFA<*_1J-U0N4:]4^O">\\='JDM1[WV,\6
MOX]2>)6W&EM1J=:_X>7,>V!ZS:4!@2FEUFN?K@/0Y1PI#:LV7KLK96D2^&U&
MHQ>U"Z#S5"E[,%R!:I@/_@!02P,$%     @ *4 %4U@H';@Q P  O08  !D
M  !X;"]W;W)K<VAE971S+W-H965T,C N>&UL?559;]LX$/XK R$/-K#09=EM
M ]N G;U<H(VW3MN'Q3[0TL@B2I$J2<7QO]\A==0MDKQ8Y'#F.WB,EV>EOYD*
MT<)3+:19!96US6T4F;S"FIE0-2AII52Z9I:F^A291B,K?%$MHC2.%U'-N S6
M2Q_;Z_52M59PB7L-IJUKIB];%.J\"I)@"'SBI\JZ0+1>-NR$![2?F[VF632B
M%+Q&:;B2H+%<!9OD=INY?)_PA>/97(W!.3DJ]<U-=L4JB)T@%)A;A\#H\XAW
M*(0#(AG?>\Q@I'2%U^,!_4_OG;P<F<$[);[RPE:KX&T !9:L%?:3.O^-O9^Y
MP\N5,/X7SEWN+ L@;XU5=5],"FHNNR][ZO?AJN!M_$)!VA>D7G='Y%7^SBQ;
M+[4Z@W;9A.8&WJJO)G%<ND,Y6$VKG.KL>G/WS^?=8?>PN_]X@,D#.PHTTV5D
M"=HE1'D/L^U@TA=@%O!!25L9^$,66/Q<'Y&D45<ZZ-JFKP*^;V4(L_@W2.,T
M>05O-OJ<>;S9"WC;UE#$&+A3]9%+YJZ$@7\W1V,UW8S_7J'(1HK,4V0O4!SH
MP12M0% EC'2;_'O+#?=TSVWKJY#N1=Z:AN6X"NC)&=2/&*P?*@2K+!.0$R@O
M4'LWCO8F3=^%"[HG0KA(Q0P<$>GN"Z%R9K&@0F#&H#7T'DB9IA"3!0C.CER0
M3#1NO:U=W#A(2VSLAPDH",8ME8HPSP8FK%:M)#PN!UXSO86-C\*>I"%]69YW
M61ISY(_NFL$-)/-P!GN-#>,%X!,U&D/\<?B&@M1VM+UX<4CL3>U@8C)WWWC#
M\@0"Z3F"=N_.*6T-#M[FX3O82<ODB3NF/IIF1'=/AO00B<,$'OQ6_KHIV8(@
M-H/JAEV\Y,DBG$W)U$63^TY;W0AU0:1]EEARRIT0^=25ZA:O7$V2Q,5_57^]
M\52937L]SQW(A YW/H6/U*KIU*7E)6=7]D;MR9LP@[^4*LYT'I F:9CVJ#]?
MF!OHKLMS=S^Z:BDUZI-OG ;\?G3=98R.O7G3M:0?Z5UC_\#TB=-C$UA2*9WN
M/.@.;9A8U?@&=526VIT?5O3_@MHET'JIE!TFCF#\QUK_#U!+ P04    "  I
M0 53I#SKACT$  #8"0  &0   'AL+W=O<FMS:&5E=',O<VAE970R,2YX;6RU
M5MMNVS@0_96!-EW$0"M+LA4[J6W SJ7K1=($2=H^+/:!EL8VMY2H):FD^?N=
MH6S5"1*C+_M"D2/.F3,WDJ-';;[;-:*#'X4J[3A8.U>==+LV6V,A;*@K+.G/
M4IM".%J:5==6!D7NE0K53:+HJ%L(60:3D9?=F,E(UT[)$F\,V+HHA'F:H=*/
MXR .MH);N5H[%G0GHTJL\ [=E^K&T*K;HN2RP-)*78+!Y3B8QB>SE/?[#5\E
M/MJ=.; G"ZV_\V*>CX.(":'"S#&"H,\#GJ)2#$0T_MU@!JU)5MR=;]$OO._D
MRT)8/-7JF\S=>AP, \AQ*6KE;O7C'[CQQQ/,M+)^A,=F;]H+(*NMT\5&F1@4
MLFR^XL<F#CL*P^@-A62CD'C>C2'/\DPX,1D9_0B&=Q,:3[RK7IO(R9*3<N<,
M_96DYR:7UY\_?;@_O[V"Z]GE_-/T?G[]^0Y>EQ[>BX5"VQEU'5EF_6ZVL3)K
MK"1O6#F"*UVZM87S,L?\N7Z7&+>TDRWM6;(7\,^Z#*$7O8<D2N(]>+TV##V/
MUWL#[PP7#LZDS92VM4'X:[JPSE#)_+T'O-^"]SUX_PWP.^JDO%8(>@F7NEQ]
MN$=3 )M\+9)[L;A'3VPE,AP'U(06S0,&$P_J&#1G/S)-/6.=97MNC;#4BGI/
MEBN:&2^IT$B=6Y!E+C/A,(=#4>BZ="RB,E.*.L9V3H#BC&V<B7*&Q0(-]&(O
MB> @'J1AM-4 []BE%N5'PB%":!T8P@?A8$:] [>\J%1M85I5BFQ3035"8G9>
M&YT35V'V[#N,P_X[QGM&K?,1\AKA A>FIK,%^E[<AP.(T^-PP-^C?AC#09I&
M.WQO\4&K!X[,J<%<.K@0F532/>WPUZ5Z@DH\T4GD[/_J5^_7_>JQ%VE,PX4L
M19DA*"0>%A)R,@F/X,;(,I.54- DEFM!M66B%TJN!!^+%N+C.!Q"$@\H3&>X
M1$.1:.I(6EM[[$QS-1TF8=+A<="!>'A,1I*8DW]:DPI9J+3Q!^V;E@[CR"/0
M)^W O7;$CA(S. XY44G4#U/8TVYIVV[I+[?;J2X*Z3AU%$.$+W3\F!>YEFA?
M:\/]-KY1ZNF8$,IJNL\6_] = TZ#H%"U!I=D4)0Y9<91*)A-UACF'[5GPKW(
M86I;=4J:=$)N*4Y7!I'!WH.PX!N^Y&ZE)O6JOGP6?+.&G/&,*_E>LHL4;ZUD
M[GO[$A_0T W+A2;URYA<MO2V<2'ARY+EGK8[I=ZLY_#[;\-AE'Z$7AA%' "N
MR"CLI>]H-J Q(3G/>9S3=N6>[UW4KL5(GF-XO33:(D5^G&]!DC= >-M/D,03
M:4:&BOPX_]I@O-C;$FTTO/9KY=C=N6T+-"O_IK"4>6JSYN)MI>VS9=K<UC^W
M-V^>*V%6D@*I<$FJS"< T[PCFH73E;^[%]K12\!/U_3T0L,;Z/]2:[==L('V
M,3?Y#U!+ P04    "  I0 53PNOY3W@$  !3#   &0   'AL+W=O<FMS:&5E
M=',O<VAE970R,BYX;6R]5UEOXS80_BN$&A1>(+5XZ$QM TDVN\D".9"X[4/1
M!T6B;6$ET27I.-U?WQE*5IQ%[&0#M \1KYEOCF^&9D9KI;^:A926/-958\;>
MPMKED>^;?"'KS S54C9P,E.ZSBPL]=PW2RVSPBG5E<\IC?PZ*QMO,G)[-WHR
M4BM;E8V\T<2LZCK3_YS(2JW''O,V&[?E?&%QPY^,EME<WDG[V_)&P\KO48JR
MEHTI54.TG(V]8W9T$J"\$_B]E&NS-2<8R;U27W%Q48P]B@[)2N86$3(8'N2I
MK"H$ C?^[C"]WB0J;L\WZ)]<[!#+?6;DJ:K^* N[&'N)1PHYRU:5O57K<]G%
M$R)>KBKCOF3=RH;<(_G*6%5WRN!!73;MF#UV>=A22.@.!=XI<.=W:\AY^3&S
MV62DU9IHE 8TG+A0G38X5S9(RIW5<%J"GIW<G7V^/+N:DHNK3]>WE\?3B^LK
M,IAF]Y4T'T:^!0LHY^<=VDF+QG>@1>12-79AR%E3R.*YO@^>]>[QC7LG?"_@
MEU4S)((>$DXYVX,G^G"%PQ.[PI5SJ"A+;N52:5LV<_+G\;VQ&HKCKSWP00\?
M./A@%SST3+&J)%$S<KV4.G,F+II<U6ZO-8O9)9TGYJ4D[S6";7IDEEDNQQ[T
MH9'Z07H3 C5*[$*2Z4)+^8NC@=Q(7:JB)8- *F6?2G*.'ITKLRQSB7)&-5E%
MK@%!DZFR,+^"&P'!44#+!]FL)#D@(DB' D:6QL,4QWA(8?CYIX0S_BO,PB@8
M\@Y(]2DHVQ1PT,6_C?AF#(81.57&8HXZFX=$/N;5JD#M0D*@>9FU?=P4)*N1
MO6_M!DOI,"",AF"7B2'K405-AC'Y+!OPHFKU"FBA$OG&NP LP-UFI"$) Z>"
M!& $@ 0<\>(0]C[NMPS"%$P\A9&0"-9/U/<6>,PA7RP, )1%:"U&2RE])MZE
M:5 I8SY ,F,,X( $H<LU=8L!:G:'[,=HI^^FG8.CW-$=@U%'>_R,]B )H1!V
MT,Y"4(I=LL)>AW/(UOM)3P*PER(H"[8XYRG2]A;.@1 @@$)FD1F8 #%A]"KG
MJ(!A4##:\BU>Y#O$1#&10&4SG :A^V#7[.8;2I"W?&-VF4OU #7=80JZ&[[O
MRL?_KLFCN&UND:30"=CTWS4Y.V046V8'WS$<1:#R?9M#=XKW4RYB =YP&D'6
M>;C5=A'%_G@+YRQB )$&(!Y!IA.<".BGX!72L50P7B2=81NRX&7:0X'WH: "
MOQPK-(0"2*,8OKMI9QWO*7?IYB[; U1M3Q'S!XA_?YN'J8#D(N$1E#B,D7/H
MB?@T=O?;_];F(D*'&-0A)1R3M($-X<JF;^,\P&*.4V  >Q4FG B&!+UVN:>N
M Y%SU\7LY9L]!*R(\"B%8X$_9$D,+J<TW'NSNVOJ@"1M9W&W&*"F.\2@7WJ.
M^%L/O5KJN7O.&I*K56/;-U^_V[^8C]N'XI-X^]R^S/2\; RIY Q4H:9#C^CV
M"=LNK%JZ9^.]LO (==,%O/JE1@$XGREE-PLTT/\?,?D74$L#!!0    ( "E
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M$V=H51+.]287_<GPZ\7P\SD,+]F^/A=3A?9-)W1$ST%ALJ+J5U3Q%JJ/I6I
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M+AD-F30#X/Y<")V=F GR[TK=_P%02P,$%     @ *4 %4X.'^_?< P  5!4
M !D   !X;"]W;W)K<VAE971S+W-H965T,C8N>&ULQ5AACZ)($/TK'9)+[I*=
M@6[4<29JHLCLN%D=HSMWN6SN0PNED@6:ZV['G7]_#2CH1D"Y#R1&NYM^]:J+
M1Q56;\_X#[$%D.AGX(>BKVVEC)YT73A;"*BX9Q&$ZLJ:\8!*->4;740<J)N
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M)V;2W)H["DH[P8ROA=#/ACTV\UM/^R]02P,$%     @ *4 %4WE%TW5Y P
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MQ#39_,<O>2"V $J/&8!R *H+<'. NP]H'0"T<D"KKH5V#FC7M>#E &\?X!T
M=') IZZ%;@[HUK70RP&]NA:@\Y8Y)UM!FY1GZV6();XXX^P9<"VO].F+;-%E
M>+5,:*+WQU1R]2M5.'GQX_;)_PX&M_>W/_I/X_O'*;CK_QCZD_$ - :W3^/A
M"50^?AX2B6DDOH 3\#@=@L^?OH!/@";@8<E2@9-0G#6E\D;K; :YY<N-973
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M>9&F(7LY(0E].NS!WNL7M_%\P>47_:.#93@G=X1_6]XP\=1?>XGBE&1Y3#/
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MNDY7<)/-O5B"._N0L4S?.Y:^*+%UG:%UG:'2K=OB]J3(Q3=Y#HYG?Q5Q'I?
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M6GY<D# B3!J(WQ\HY:\/\E7H]?O^1_\ 4$L#!!0    ( "E !5.U'H*9D@,
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MFL%;% 8A+H&/Z^$3&@$<.WAP#O?!C]R4,#<E='S-2CY(<R:T42GL6(.^S2$
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MHZ\7]/52DST]*^B/8$HG"#25F3#[ IVS-3R;ZP_+-CFI-\/E'@F-0D*C5,*
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MT'/])!*@+SF"OL>YMA>7"7"9-,IE EPFGKGLT M=I@&7B1<NDYU,*\-R<YD
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M.(_%(UM\)%6' FDO9'%6_$6+JJW=0V&>"9948(@@H6GY/_Y6#407@%L!W#6
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M ^K[*6/R^4:_N[5Z._/P?U!+ P04    "  I0 53-QA_EQL"  !D!   &0
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M(S2)WZ$D3L9[J.QL&'V%.QEZ,/'<R:4>!!3:02.5H:)"/^:Y-LI.S,\K^.F
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MZ=K#@'8H2X&R-"!E/5IQ%S="C0)E:1C*>F1\=T$4*$O#4O80D%( *6T'I!1
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MR!/:=;#?3Y0RKSONQ7W]OXO^OU!+ P04    "  I0 53 '1"AB8#   ,$P
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M_N@;!/F^;TI#@4C).ZXK9)"W> 91HC")IL&0IOZ0W-,I#3V?)!/?3Q, Z""
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M(2I'02I'82I'@2I'H2I'P2I'X2I' 2M'(:M (:M (:M (:M (:M (:M (:M
M(:M (:M (:M (:M$(:M$(:M$(:M$(:M$(:M$(:M$(:M$(:M$(:M$(6N"0M8$
MA:P)"EF3_R3KN]:KO_ZIT:YQK<KFZ,^Z/T?S3U!+ 0(4 Q0    ( "E !5,'
M04UB@0   +$    0              "  0    !D;V-0<F]P<R]A<' N>&UL
M4$L! A0#%     @ *4 %4XB,Y</N    *P(  !$              ( !KP
M &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @ *4 %4YE<G",0!@  G"<
M !,              ( !S $  'AL+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4
M    "  I0 53$'BNZ"\%  #@%0  &               @($-"   >&PO=V]R
M:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%     @ *4 %4^<H."E'!P  A!P
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M965T-BYX;6Q02P$"% ,4    "  I0 53@E$;J?H*  #$'   &
M    @(%I,P  >&PO=V]R:W-H965T<R]S:&5E=#<N>&UL4$L! A0#%     @
M*4 %4S_-'P=N'@  8&$  !@              ("!F3X  'AL+W=O<FMS:&5E
M=',O<VAE970X+GAM;%!+ 0(4 Q0    ( "E !5,]6>@5& D  *D6   8
M          " @3U=  !X;"]W;W)K<VAE971S+W-H965T.2YX;6Q02P$"% ,4
M    "  I0 53'Z$*$&,(  "B%0  &0              @(&+9@  >&PO=V]R
M:W-H965T<R]S:&5E=#$P+GAM;%!+ 0(4 Q0    ( "E !5,4L_X&70P  -,E
M   9              " @25O  !X;"]W;W)K<VAE971S+W-H965T,3$N>&UL
M4$L! A0#%     @ *4 %4_S5%$ZS#P  >"T  !D              ("!N7L
M 'AL+W=O<FMS:&5E=',O<VAE970Q,BYX;6Q02P$"% ,4    "  I0 53_IX6
M4LX&  "7$0  &0              @(&CBP  >&PO=V]R:W-H965T<R]S:&5E
M=#$S+GAM;%!+ 0(4 Q0    ( "E !5/5+1H;A 0  -8*   9
M  " @:B2  !X;"]W;W)K<VAE971S+W-H965T,30N>&UL4$L! A0#%     @
M*4 %4XZEZ$<1 P  U@8  !D              ("!8Y<  'AL+W=O<FMS:&5E
M=',O<VAE970Q-2YX;6Q02P$"% ,4    "  I0 536&&8)E@(   +%0  &0
M            @(&KF@  >&PO=V]R:W-H965T<R]S:&5E=#$V+GAM;%!+ 0(4
M Q0    ( "E !5-5Y6<0ER$  .EN   9              " @3JC  !X;"]W
M;W)K<VAE971S+W-H965T,3<N>&UL4$L! A0#%     @ *4 %4_1,\H"-!0
M=PT  !D              ("!",4  'AL+W=O<FMS:&5E=',O<VAE970Q."YX
M;6Q02P$"% ,4    "  I0 53;[Y'J.4"  #8!0  &0              @(',
MR@  >&PO=V]R:W-H965T<R]S:&5E=#$Y+GAM;%!+ 0(4 Q0    ( "E !5-8
M*!VX,0,  +T&   9              " @>C-  !X;"]W;W)K<VAE971S+W-H
M965T,C N>&UL4$L! A0#%     @ *4 %4Z0\ZX8]!   V D  !D
M     ("!4-$  'AL+W=O<FMS:&5E=',O<VAE970R,2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( "E !5.#A_OWW ,  %05   9              "
M@2KI  !X;"]W;W)K<VAE971S+W-H965T,C8N>&UL4$L! A0#%     @ *4 %
M4SMTO2JA P  IPP  !D              ("!/>T  'AL+W=O<FMS:&5E=',O
M<VAE970R-RYX;6Q02P$"% ,4    "  I0 53S2CLC1,#  !="   &0
M        @($5\0  >&PO=V]R:W-H965T<R]S:&5E=#(X+GAM;%!+ 0(4 Q0
M   ( "E !5,W=9^!U (   $)   9              " @5_T  !X;"]W;W)K
M<VAE971S+W-H965T,CDN>&UL4$L! A0#%     @ *4 %4WE%TW5Y P  2PL
M !D              ("!:O<  'AL+W=O<FMS:&5E=',O<VAE970S,"YX;6Q0
M2P$"% ,4    "  I0 536%:*UU0&   \'   &0              @($:^P
M>&PO=V]R:W-H965T<R]S:&5E=#,Q+GAM;%!+ 0(4 Q0    ( "E !5.3/F>!
MBP@  /LO   9              " @:4! 0!X;"]W;W)K<VAE971S+W-H965T
M,S(N>&UL4$L! A0#%     @ *4 %4[4>@IF2 P  ]PL  !D
M ("!9PH! 'AL+W=O<FMS:&5E=',O<VAE970S,RYX;6Q02P$"% ,4    "  I
M0 53#3CB 4D#  !-"P  &0              @($P#@$ >&PO=V]R:W-H965T
M<R]S:&5E=#,T+GAM;%!+ 0(4 Q0    ( "E !5.J8SC'WP0  )$B   9
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M970S.2YX;6Q02P$"% ,4    "  I0 53S:-#E.$#   C#P  &0
M    @($G,0$ >&PO=V]R:W-H965T<R]S:&5E=#0P+GAM;%!+ 0(4 Q0    (
M "E !5,Q14F]E (  !$'   9              " @3\U 0!X;"]W;W)K<VAE
M971S+W-H965T-#$N>&UL4$L! A0#%     @ *4 %4[H?.8P5!0  ^A<  !D
M             ("!"C@! 'AL+W=O<FMS:&5E=',O<VAE970T,BYX;6Q02P$"
M% ,4    "  I0 53AJO0C+L$  "#(0  &0              @(%6/0$ >&PO
M=V]R:W-H965T<R]S:&5E=#0S+GAM;%!+ 0(4 Q0    ( "E !5, =$*&)@,
M  P3   -              "  4A" 0!X;"]S='EL97,N>&UL4$L! A0#%
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K 0!;0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@     S #, W T  $5. 0    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.21.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>270</ContextCount>
  <ElementCount>359</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>78</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>11</UnitCount>
  <MyReports>
    <Report instance="amed-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="amed-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001002 - Statement - CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="amed-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1002003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETSParenthetical</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="amed-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1003004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF OPERATIONS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="amed-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1004005 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY Statement</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYStatement</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY Statement</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="amed-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1005006 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="amed-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>2101101 - Disclosure - NATURE OF OPERATIONS, CONSOLIDATION AND PRESENTATION OF FINANCIAL STATEMENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTS</Role>
      <ShortName>NATURE OF OPERATIONS, CONSOLIDATION AND PRESENTATION OF FINANCIAL STATEMENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="amed-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>2103102 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="amed-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2112103 - Disclosure - NOVEL CORONAVIRUS PANDEMIC "COVID-19"</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/NOVELCORONAVIRUSPANDEMICCOVID19</Role>
      <ShortName>NOVEL CORONAVIRUS PANDEMIC "COVID-19"</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="amed-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2115104 - Disclosure - ACQUISITIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/ACQUISITIONS</Role>
      <ShortName>ACQUISITIONS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="amed-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2119105 - Disclosure - LONG-TERM OBLIGATIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/LONGTERMOBLIGATIONS</Role>
      <ShortName>LONG-TERM OBLIGATIONS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="amed-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2125106 - Disclosure - COMMITMENTS AND CONTINGENCIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIES</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="amed-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2127107 - Disclosure - SEGMENT INFORMATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/SEGMENTINFORMATION</Role>
      <ShortName>SEGMENT INFORMATION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="amed-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2131108 - Disclosure - SHARE REPURCHASE SHARE REPURCHASE</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/SHAREREPURCHASESHAREREPURCHASE</Role>
      <ShortName>SHARE REPURCHASE SHARE REPURCHASE</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="amed-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2133109 - Disclosure - RELATED PARTY TRANSACTIONS RELATED PARTY TRANSACTIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/RELATEDPARTYTRANSACTIONSRELATEDPARTYTRANSACTIONS</Role>
      <ShortName>RELATED PARTY TRANSACTIONS RELATED PARTY TRANSACTIONS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="amed-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2135110 - Disclosure - SUBSEQUENT EVENT</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/SUBSEQUENTEVENT</Role>
      <ShortName>SUBSEQUENT EVENT</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="amed-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2204201 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="amed-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2305301 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES</ParentRole>
      <Position>18</Position>
    </Report>
    <Report instance="amed-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2313302 - Disclosure - NOVEL CORONAVIRUS PANDEMIC "COVID-19" (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/NOVELCORONAVIRUSPANDEMICCOVID19Tables</Role>
      <ShortName>NOVEL CORONAVIRUS PANDEMIC "COVID-19" (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.amedisys.com/role/NOVELCORONAVIRUSPANDEMICCOVID19</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="amed-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2316303 - Disclosure - ACQUISITIONS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/ACQUISITIONSTables</Role>
      <ShortName>ACQUISITIONS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.amedisys.com/role/ACQUISITIONS</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="amed-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2320304 - Disclosure - LONG-TERM OBLIGATIONS LONG-TERM OBLIGATIONS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/LONGTERMOBLIGATIONSLONGTERMOBLIGATIONSTables</Role>
      <ShortName>LONG-TERM OBLIGATIONS LONG-TERM OBLIGATIONS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="amed-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2328305 - Disclosure - SEGMENT INFORMATION (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/SEGMENTINFORMATIONTables</Role>
      <ShortName>SEGMENT INFORMATION (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.amedisys.com/role/SEGMENTINFORMATION</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="amed-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2336306 - Disclosure - SUBSEQUENT EVENT (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/SUBSEQUENTEVENTTables</Role>
      <ShortName>SUBSEQUENT EVENT (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.amedisys.com/role/SUBSEQUENTEVENT</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="amed-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2402401 - Disclosure - NATURE OF OPERATIONS, CONSOLIDATION AND PRESENTATION OF FINANCIAL STATEMENTS - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails</Role>
      <ShortName>NATURE OF OPERATIONS, CONSOLIDATION AND PRESENTATION OF FINANCIAL STATEMENTS - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTS</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="amed-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2406402 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Revenue Recognition Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Revenue Recognition Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="amed-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2407403 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Revenue by Payor Class (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenuebyPayorClassDetails</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Revenue by Payor Class (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="amed-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2408404 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Cash and Cash Equivalents (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESCashandCashEquivalentsDetails</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Cash and Cash Equivalents (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="amed-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2409405 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Patient Accounts Receivable Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPatientAccountsReceivableNarrativeDetails</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Patient Accounts Receivable Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="amed-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2410406 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Fair Value of Financial Instruments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESFairValueofFinancialInstrumentsDetails</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Fair Value of Financial Instruments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="amed-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2411407 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Weighted-Average Shares Outstanding (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESWeightedAverageSharesOutstandingDetails</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Weighted-Average Shares Outstanding (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="amed-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2414408 - Disclosure - NOVEL CORONAVIRUS PANDEMIC "COVID-19" (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/NOVELCORONAVIRUSPANDEMICCOVID19Details</Role>
      <ShortName>NOVEL CORONAVIRUS PANDEMIC "COVID-19" (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.amedisys.com/role/NOVELCORONAVIRUSPANDEMICCOVID19Tables</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="amed-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2417409 - Disclosure - ACQUISITIONS - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails</Role>
      <ShortName>ACQUISITIONS - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="amed-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2421411 - Disclosure - LONG-TERM OBLIGATIONS - Schedule of Long-Term Debt (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtDetails</Role>
      <ShortName>LONG-TERM OBLIGATIONS - Schedule of Long-Term Debt (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="amed-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2422412 - Disclosure - LONG-TERM OBLIGATIONS - Schedule of Long-Term Debt Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtAdditionalInformationDetails</Role>
      <ShortName>LONG-TERM OBLIGATIONS - Schedule of Long-Term Debt Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="amed-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2423413 - Disclosure - LONG-TERM OBLIGATIONS - Fees and Rates Under Credit Facilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/LONGTERMOBLIGATIONSFeesandRatesUnderCreditFacilitiesDetails</Role>
      <ShortName>LONG-TERM OBLIGATIONS - Fees and Rates Under Credit Facilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="amed-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2424414 - Disclosure - LONG-TERM OBLIGATIONS - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails</Role>
      <ShortName>LONG-TERM OBLIGATIONS - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="amed-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2426415 - Disclosure - COMMITMENTS AND CONTINGENCIES - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="amed-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2429416 - Disclosure - SEGMENT INFORMATION - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/SEGMENTINFORMATIONNarrativeDetails</Role>
      <ShortName>SEGMENT INFORMATION - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="amed-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>2430417 - Disclosure - SEGMENT INFORMATION - Operating Income of Reportable Segments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/SEGMENTINFORMATIONOperatingIncomeofReportableSegmentsDetails</Role>
      <ShortName>SEGMENT INFORMATION - Operating Income of Reportable Segments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="amed-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>2432418 - Disclosure - SHARE REPURCHASE Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/SHAREREPURCHASENarrativeDetails</Role>
      <ShortName>SHARE REPURCHASE Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="amed-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>2434419 - Disclosure - RELATED PARTY TRANSACTIONS Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/RELATEDPARTYTRANSACTIONSNarrativeDetails</Role>
      <ShortName>RELATED PARTY TRANSACTIONS Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="amed-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>2437420 - Disclosure - SUBSEQUENT EVENT - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/SUBSEQUENTEVENTNarrativeDetails</Role>
      <ShortName>SUBSEQUENT EVENT - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="amed-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>2438421 - Disclosure - SUBSEQUENT EVENT- Fees and Rates Under Credit Facilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/SUBSEQUENTEVENTFeesandRatesUnderCreditFacilitiesDetails</Role>
      <ShortName>SUBSEQUENT EVENT- Fees and Rates Under Credit Facilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="amed-20210630.htm">amed-20210630.htm</File>
    <File>amed-20210630.xsd</File>
    <File>amed-20210630_cal.xml</File>
    <File>amed-20210630_def.xml</File>
    <File>amed-20210630_lab.xml</File>
    <File>amed-20210630_pre.xml</File>
    <File>amed-20213006xexx311.htm</File>
    <File>amed-20213006xexx312.htm</File>
    <File>amed-20213006xexx321.htm</File>
    <File>amed-20213006xexx322.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>amed-20210630_g1.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy>http://fasb.org/us-gaap/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/stpr/2018-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/srt/2020-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>62
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "amed-20210630.htm": {
   "axisCustom": 3,
   "axisStandard": 20,
   "contextCount": 270,
   "dts": {
    "calculationLink": {
     "local": [
      "amed-20210630_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "amed-20210630_def.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml",
      "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml"
     ]
    },
    "inline": {
     "local": [
      "amed-20210630.htm"
     ]
    },
    "labelLink": {
     "local": [
      "amed-20210630_lab.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-doc-2020-01-31.xml",
      "https://xbrl.sec.gov/dei/2020/dei-doc-2020-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "amed-20210630_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "https://xbrl.sec.gov/dei/2020/dei-ref-2020-01-31.xml",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-ref-2020-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "amed-20210630.xsd"
     ],
     "remote": [
      "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd",
      "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd",
      "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd",
      "https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-parts-codification-2020-01-31.xsd"
     ]
    }
   },
   "elementCount": 572,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2020-01-31": 10,
    "http://xbrl.sec.gov/dei/2020-01-31": 6,
    "total": 16
   },
   "keyCustom": 82,
   "keyStandard": 277,
   "memberCustom": 47,
   "memberStandard": 28,
   "nsprefix": "amed",
   "nsuri": "http://www.amedisys.com/20210630",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20210630.htm",
      "contextRef": "id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Cover",
     "role": "http://www.amedisys.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20210630.htm",
      "contextRef": "id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20210630.htm",
      "contextRef": "id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2115104 - Disclosure - ACQUISITIONS",
     "role": "http://www.amedisys.com/role/ACQUISITIONS",
     "shortName": "ACQUISITIONS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20210630.htm",
      "contextRef": "id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20210630.htm",
      "contextRef": "id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2119105 - Disclosure - LONG-TERM OBLIGATIONS",
     "role": "http://www.amedisys.com/role/LONGTERMOBLIGATIONS",
     "shortName": "LONG-TERM OBLIGATIONS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20210630.htm",
      "contextRef": "id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20210630.htm",
      "contextRef": "id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2125106 - Disclosure - COMMITMENTS AND CONTINGENCIES",
     "role": "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIES",
     "shortName": "COMMITMENTS AND CONTINGENCIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20210630.htm",
      "contextRef": "id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20210630.htm",
      "contextRef": "id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2127107 - Disclosure - SEGMENT INFORMATION",
     "role": "http://www.amedisys.com/role/SEGMENTINFORMATION",
     "shortName": "SEGMENT INFORMATION",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20210630.htm",
      "contextRef": "id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20210630.htm",
      "contextRef": "id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:TreasuryStockTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2131108 - Disclosure - SHARE REPURCHASE SHARE REPURCHASE",
     "role": "http://www.amedisys.com/role/SHAREREPURCHASESHAREREPURCHASE",
     "shortName": "SHARE REPURCHASE SHARE REPURCHASE",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20210630.htm",
      "contextRef": "id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:TreasuryStockTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20210630.htm",
      "contextRef": "id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2133109 - Disclosure - RELATED PARTY TRANSACTIONS RELATED PARTY TRANSACTIONS",
     "role": "http://www.amedisys.com/role/RELATEDPARTYTRANSACTIONSRELATEDPARTYTRANSACTIONS",
     "shortName": "RELATED PARTY TRANSACTIONS RELATED PARTY TRANSACTIONS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20210630.htm",
      "contextRef": "id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20210630.htm",
      "contextRef": "id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2135110 - Disclosure - SUBSEQUENT EVENT",
     "role": "http://www.amedisys.com/role/SUBSEQUENTEVENT",
     "shortName": "SUBSEQUENT EVENT",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20210630.htm",
      "contextRef": "id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20210630.htm",
      "contextRef": "id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2204201 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "role": "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20210630.htm",
      "contextRef": "id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20210630.htm",
      "contextRef": "id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRevenueSourcesHealthCareOrganizationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2305301 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)",
     "role": "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20210630.htm",
      "contextRef": "id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRevenueSourcesHealthCareOrganizationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20210630.htm",
      "contextRef": "id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "amed:ScheduleOfCaresActProviderReliefFundsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2313302 - Disclosure - NOVEL CORONAVIRUS PANDEMIC \"COVID-19\" (Tables)",
     "role": "http://www.amedisys.com/role/NOVELCORONAVIRUSPANDEMICCOVID19Tables",
     "shortName": "NOVEL CORONAVIRUS PANDEMIC \"COVID-19\" (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20210630.htm",
      "contextRef": "id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "amed:ScheduleOfCaresActProviderReliefFundsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20210630.htm",
      "contextRef": "i1e833203be6947b4968aba4d20064ec8_I20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001002 - Statement - CONSOLIDATED BALANCE SHEETS",
     "role": "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS",
     "shortName": "CONSOLIDATED BALANCE SHEETS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20210630.htm",
      "contextRef": "i1e833203be6947b4968aba4d20064ec8_I20210630",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:PrepaidExpenseCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20210630.htm",
      "contextRef": "id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2316303 - Disclosure - ACQUISITIONS (Tables)",
     "role": "http://www.amedisys.com/role/ACQUISITIONSTables",
     "shortName": "ACQUISITIONS (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20210630.htm",
      "contextRef": "id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20210630.htm",
      "contextRef": "id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2320304 - Disclosure - LONG-TERM OBLIGATIONS LONG-TERM OBLIGATIONS (Tables)",
     "role": "http://www.amedisys.com/role/LONGTERMOBLIGATIONSLONGTERMOBLIGATIONSTables",
     "shortName": "LONG-TERM OBLIGATIONS LONG-TERM OBLIGATIONS (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20210630.htm",
      "contextRef": "id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20210630.htm",
      "contextRef": "id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2328305 - Disclosure - SEGMENT INFORMATION (Tables)",
     "role": "http://www.amedisys.com/role/SEGMENTINFORMATIONTables",
     "shortName": "SEGMENT INFORMATION (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20210630.htm",
      "contextRef": "id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20210630.htm",
      "contextRef": "id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfLineOfCreditFacilitiesTextBlock",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2336306 - Disclosure - SUBSEQUENT EVENT (Tables)",
     "role": "http://www.amedisys.com/role/SUBSEQUENTEVENTTables",
     "shortName": "SUBSEQUENT EVENT (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20210630.htm",
      "contextRef": "i013c83768a1e4e0b956e81903f1c8638_D20210730-20210730",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfLineOfCreditFacilitiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20210630.htm",
      "contextRef": "i1e833203be6947b4968aba4d20064ec8_I20210630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfStatesInWhichEntityOperates",
      "reportCount": 1,
      "unitRef": "state",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402401 - Disclosure - NATURE OF OPERATIONS, CONSOLIDATION AND PRESENTATION OF FINANCIAL STATEMENTS - Narrative (Details)",
     "role": "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails",
     "shortName": "NATURE OF OPERATIONS, CONSOLIDATION AND PRESENTATION OF FINANCIAL STATEMENTS - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:EquityMethodInvestmentsPolicy",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20210630.htm",
      "contextRef": "i87ceb60dc20d4df1b0a97d3514837910_I20201231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:EquityMethodInvestmentAggregateCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20210630.htm",
      "contextRef": "id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "amed:NetServiceRevenuePeriodOfCarePaymentRateDuration",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2406402 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Revenue Recognition Narrative (Details)",
     "role": "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Revenue Recognition Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20210630.htm",
      "contextRef": "id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630",
      "decimals": "INF",
      "lang": "en-US",
      "name": "amed:PercentageOfTotalReimbursementOfOutlierPayment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfRevenueSourcesHealthCareOrganizationTableTextBlock",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20210630.htm",
      "contextRef": "ib87cee58ccf2448a8d4422101bf61fa0_D20210401-20210630",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2407403 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Revenue by Payor Class (Details)",
     "role": "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenuebyPayorClassDetails",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Revenue by Payor Class (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfRevenueSourcesHealthCareOrganizationTableTextBlock",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20210630.htm",
      "contextRef": "ib87cee58ccf2448a8d4422101bf61fa0_D20210401-20210630",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20210630.htm",
      "contextRef": "i1e833203be6947b4968aba4d20064ec8_I20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2408404 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Cash and Cash Equivalents (Details)",
     "role": "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESCashandCashEquivalentsDetails",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Cash and Cash Equivalents (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:TradeAndOtherAccountsReceivablePolicy",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20210630.htm",
      "contextRef": "i1e833203be6947b4968aba4d20064ec8_I20210630",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "amed:AccountsReceivablePortionDerivedFromMedicare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2409405 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Patient Accounts Receivable Narrative (Details)",
     "role": "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPatientAccountsReceivableNarrativeDetails",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Patient Accounts Receivable Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:TradeAndOtherAccountsReceivablePolicy",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20210630.htm",
      "contextRef": "i1e833203be6947b4968aba4d20064ec8_I20210630",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "amed:AccountsReceivablePortionDerivedFromMedicare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "amed:FinancialInstrumentDetailsTableTextBlock",
       "us-gaap:FairValueOfFinancialInstrumentsPolicy",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20210630.htm",
      "contextRef": "i1e833203be6947b4968aba4d20064ec8_I20210630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "amed:DebtInstrumentCarryingAmountExcludingFinanceLeases",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2410406 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Fair Value of Financial Instruments (Details)",
     "role": "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESFairValueofFinancialInstrumentsDetails",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Fair Value of Financial Instruments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "amed:FinancialInstrumentDetailsTableTextBlock",
       "us-gaap:FairValueOfFinancialInstrumentsPolicy",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20210630.htm",
      "contextRef": "i1e833203be6947b4968aba4d20064ec8_I20210630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "amed:DebtInstrumentCarryingAmountExcludingFinanceLeases",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20210630.htm",
      "contextRef": "i1e833203be6947b4968aba4d20064ec8_I20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "role": "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETSParenthetical",
     "shortName": "CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20210630.htm",
      "contextRef": "i1e833203be6947b4968aba4d20064ec8_I20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20210630.htm",
      "contextRef": "ib87cee58ccf2448a8d4422101bf61fa0_D20210401-20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:WeightedAverageNumberOfSharesOutstandingBasic",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2411407 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Weighted-Average Shares Outstanding (Details)",
     "role": "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESWeightedAverageSharesOutstandingDetails",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Weighted-Average Shares Outstanding (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20210630.htm",
      "contextRef": "ib87cee58ccf2448a8d4422101bf61fa0_D20210401-20210630",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20210630.htm",
      "contextRef": "i0c4514a4ad16425f82d85ae99b3a59c1_I20200327",
      "decimals": "-9",
      "first": true,
      "lang": "en-US",
      "name": "amed:FundingForHealthcareProvidersIncludingHospitals",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2414408 - Disclosure - NOVEL CORONAVIRUS PANDEMIC \"COVID-19\" (Details)",
     "role": "http://www.amedisys.com/role/NOVELCORONAVIRUSPANDEMICCOVID19Details",
     "shortName": "NOVEL CORONAVIRUS PANDEMIC \"COVID-19\" (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20210630.htm",
      "contextRef": "i0c4514a4ad16425f82d85ae99b3a59c1_I20200327",
      "decimals": "-9",
      "first": true,
      "lang": "en-US",
      "name": "amed:FundingForHealthcareProvidersIncludingHospitals",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20210630.htm",
      "contextRef": "ib87cee58ccf2448a8d4422101bf61fa0_D20210401-20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2417409 - Disclosure - ACQUISITIONS - Narrative (Details)",
     "role": "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails",
     "shortName": "ACQUISITIONS - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20210630.htm",
      "contextRef": "i83f6f6c3fd9a43b9871634c7190f8d34_D20200601-20200601",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:PaymentsToAcquireBusinessesGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20210630.htm",
      "contextRef": "i1e833203be6947b4968aba4d20064ec8_I20210630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentCarryingAmount",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2421411 - Disclosure - LONG-TERM OBLIGATIONS - Schedule of Long-Term Debt (Details)",
     "role": "http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtDetails",
     "shortName": "LONG-TERM OBLIGATIONS - Schedule of Long-Term Debt (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20210630.htm",
      "contextRef": "i1e833203be6947b4968aba4d20064ec8_I20210630",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:DeferredFinanceCostsNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20210630.htm",
      "contextRef": "i4f3b5acefd614cc18bfcd62fc3a07ded_I20210630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentFaceAmount",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2422412 - Disclosure - LONG-TERM OBLIGATIONS - Schedule of Long-Term Debt Additional Information (Details)",
     "role": "http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtAdditionalInformationDetails",
     "shortName": "LONG-TERM OBLIGATIONS - Schedule of Long-Term Debt Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20210630.htm",
      "contextRef": "ie89771700f0d460f9ee341c9f33ad463_D20210101-20210630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LineOfCreditFacilityCommitmentFeePercentage",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2423413 - Disclosure - LONG-TERM OBLIGATIONS - Fees and Rates Under Credit Facilities (Details)",
     "role": "http://www.amedisys.com/role/LONGTERMOBLIGATIONSFeesandRatesUnderCreditFacilitiesDetails",
     "shortName": "LONG-TERM OBLIGATIONS - Fees and Rates Under Credit Facilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20210630.htm",
      "contextRef": "ie89771700f0d460f9ee341c9f33ad463_D20210101-20210630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LineOfCreditFacilityCommitmentFeePercentage",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20210630.htm",
      "contextRef": "i1e833203be6947b4968aba4d20064ec8_I20210630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "amed:TotalLeverageRatio",
      "reportCount": 1,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2424414 - Disclosure - LONG-TERM OBLIGATIONS - Narrative (Details)",
     "role": "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails",
     "shortName": "LONG-TERM OBLIGATIONS - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20210630.htm",
      "contextRef": "ib3b582f4212244b0884fcc031ea6c067_D20210401-20210630",
      "decimals": "3",
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtWeightedAverageInterestRateOverTime",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20210630.htm",
      "contextRef": "i1e833203be6947b4968aba4d20064ec8_I20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsReceivableNetCurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2426415 - Disclosure - COMMITMENTS AND CONTINGENCIES - Narrative (Details)",
     "role": "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails",
     "shortName": "COMMITMENTS AND CONTINGENCIES - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20210630.htm",
      "contextRef": "id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630",
      "decimals": "-5",
      "lang": "en-US",
      "name": "amed:HealthInsuranceRetentionLimit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20210630.htm",
      "contextRef": "id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfReportableSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segments",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2429416 - Disclosure - SEGMENT INFORMATION - Narrative (Details)",
     "role": "http://www.amedisys.com/role/SEGMENTINFORMATIONNarrativeDetails",
     "shortName": "SEGMENT INFORMATION - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20210630.htm",
      "contextRef": "id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfReportableSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segments",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20210630.htm",
      "contextRef": "ib87cee58ccf2448a8d4422101bf61fa0_D20210401-20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2430417 - Disclosure - SEGMENT INFORMATION - Operating Income of Reportable Segments (Details)",
     "role": "http://www.amedisys.com/role/SEGMENTINFORMATIONOperatingIncomeofReportableSegmentsDetails",
     "shortName": "SEGMENT INFORMATION - Operating Income of Reportable Segments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20210630.htm",
      "contextRef": "ib87cee58ccf2448a8d4422101bf61fa0_D20210401-20210630",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:GeneralAndAdministrativeExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20210630.htm",
      "contextRef": "ib87cee58ccf2448a8d4422101bf61fa0_D20210401-20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS",
     "role": "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
     "shortName": "CONSOLIDATED STATEMENTS OF OPERATIONS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20210630.htm",
      "contextRef": "ib87cee58ccf2448a8d4422101bf61fa0_D20210401-20210630",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:LaborAndRelatedExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20210630.htm",
      "contextRef": "id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PaymentsForRepurchaseOfCommonStock",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2432418 - Disclosure - SHARE REPURCHASE Narrative (Details)",
     "role": "http://www.amedisys.com/role/SHAREREPURCHASENarrativeDetails",
     "shortName": "SHARE REPURCHASE Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20210630.htm",
      "contextRef": "i7d058b3163364b51b7615e3e655ec631_D20210401-20210630",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:TreasuryStockSharesAcquired",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20210630.htm",
      "contextRef": "iad1f6087d55542bd9518895ce038f77e_D20210401-20210630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionAmountsOfTransaction",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2434419 - Disclosure - RELATED PARTY TRANSACTIONS Narrative (Details)",
     "role": "http://www.amedisys.com/role/RELATEDPARTYTRANSACTIONSNarrativeDetails",
     "shortName": "RELATED PARTY TRANSACTIONS Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20210630.htm",
      "contextRef": "iad1f6087d55542bd9518895ce038f77e_D20210401-20210630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionAmountsOfTransaction",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20210630.htm",
      "contextRef": "i479f4d0280434d3681861fd2e320cd99_I20201223",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockRepurchaseProgramAuthorizedAmount1",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2437420 - Disclosure - SUBSEQUENT EVENT - Narrative (Details)",
     "role": "http://www.amedisys.com/role/SUBSEQUENTEVENTNarrativeDetails",
     "shortName": "SUBSEQUENT EVENT - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20210630.htm",
      "contextRef": "i37b72216842c4630bdb672d9901858fe_I20210730",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20210630.htm",
      "contextRef": "ifa6c63e1eca547f89b708d6f34225a17_D20210730-20210730",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LineOfCreditFacilityCommitmentFeePercentage",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2438421 - Disclosure - SUBSEQUENT EVENT- Fees and Rates Under Credit Facilities (Details)",
     "role": "http://www.amedisys.com/role/SUBSEQUENTEVENTFeesandRatesUnderCreditFacilitiesDetails",
     "shortName": "SUBSEQUENT EVENT- Fees and Rates Under Credit Facilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20210630.htm",
      "contextRef": "ifa6c63e1eca547f89b708d6f34225a17_D20210730-20210730",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LineOfCreditFacilityCommitmentFeePercentage",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20210630.htm",
      "contextRef": "ifa673cc4c9af455b97f34a55548dfc84_I20191231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004005 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY Statement",
     "role": "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYStatement",
     "shortName": "CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY Statement",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20210630.htm",
      "contextRef": "ifa673cc4c9af455b97f34a55548dfc84_I20191231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20210630.htm",
      "contextRef": "id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005006 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "role": "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
     "shortName": "CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20210630.htm",
      "contextRef": "id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20210630.htm",
      "contextRef": "id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101101 - Disclosure - NATURE OF OPERATIONS, CONSOLIDATION AND PRESENTATION OF FINANCIAL STATEMENTS",
     "role": "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTS",
     "shortName": "NATURE OF OPERATIONS, CONSOLIDATION AND PRESENTATION OF FINANCIAL STATEMENTS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20210630.htm",
      "contextRef": "id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20210630.htm",
      "contextRef": "id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2103102 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
     "role": "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20210630.htm",
      "contextRef": "id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20210630.htm",
      "contextRef": "id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "amed:COVID19TextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2112103 - Disclosure - NOVEL CORONAVIRUS PANDEMIC \"COVID-19\"",
     "role": "http://www.amedisys.com/role/NOVELCORONAVIRUSPANDEMICCOVID19",
     "shortName": "NOVEL CORONAVIRUS PANDEMIC \"COVID-19\"",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20210630.htm",
      "contextRef": "id2de9452c37d4a59836fd8ad57a139e4_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "amed:COVID19TextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 78,
   "tag": {
    "amed_A2019ShareRepurchaseProgramMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2019 Share Repurchase Program",
        "label": "2019 Share Repurchase Program [Member]",
        "terseLabel": "2019 Share Repurchase Program"
       }
      }
     },
     "localname": "A2019ShareRepurchaseProgramMember",
     "nsuri": "http://www.amedisys.com/20210630",
     "presentation": [
      "http://www.amedisys.com/role/SHAREREPURCHASENarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_A2021ShareRepurchaseProgramMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2021 Share Repurchase Program",
        "label": "2021 Share Repurchase Program [Member]",
        "terseLabel": "2021 Share Repurchase Program"
       }
      }
     },
     "localname": "A2021ShareRepurchaseProgramMember",
     "nsuri": "http://www.amedisys.com/20210630",
     "presentation": [
      "http://www.amedisys.com/role/SHAREREPURCHASENarrativeDetails",
      "http://www.amedisys.com/role/SUBSEQUENTEVENTNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_AccountsReceivablePortionDerivedFromMedicare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounts Receivable, Portion Derived From Medicare",
        "label": "Accounts Receivable, Portion Derived From Medicare",
        "terseLabel": "Accounts receivable derived from Medicare"
       }
      }
     },
     "localname": "AccountsReceivablePortionDerivedFromMedicare",
     "nsuri": "http://www.amedisys.com/20210630",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPatientAccountsReceivableNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "amed_AcquiredNamesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Acquired Names",
        "label": "Acquired Names [Member]",
        "terseLabel": "Acquired Names [Member]"
       }
      }
     },
     "localname": "AcquiredNamesMember",
     "nsuri": "http://www.amedisys.com/20210630",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_ActualClaimsPayment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Actual Claims Payment",
        "label": "Actual Claims Payment",
        "terseLabel": "Actual claims payment"
       }
      }
     },
     "localname": "ActualClaimsPayment",
     "nsuri": "http://www.amedisys.com/20210630",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_AdditionalFundingDistributedToHealthcareProviders": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional funding distributed to healthcare providers provided by the Coronavirus Aid, Relief and Economic Security (CARES) Act",
        "label": "Additional Funding Distributed to Healthcare Providers",
        "terseLabel": "Additional Funding Distributed to Healthcare Providers"
       }
      }
     },
     "localname": "AdditionalFundingDistributedToHealthcareProviders",
     "nsuri": "http://www.amedisys.com/20210630",
     "presentation": [
      "http://www.amedisys.com/role/NOVELCORONAVIRUSPANDEMICCOVID19Details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_AmedisysCIAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amedisys CIA [Member]",
        "label": "Amedisys CIA [Member]",
        "terseLabel": "Amedisys CIA"
       }
      }
     },
     "localname": "AmedisysCIAMember",
     "nsuri": "http://www.amedisys.com/20210630",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_AmendedCreditAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amended Credit Agreement [Member]",
        "label": "Amended Credit Agreement [Member]",
        "terseLabel": "Amended Credit Agreement [Member]"
       }
      }
     },
     "localname": "AmendedCreditAgreementMember",
     "nsuri": "http://www.amedisys.com/20210630",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_AmendedDebtInstrumentByLeverageRatioTrancheFourMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amended Debt Instrument, By Leverage Ratio, Tranche Four",
        "label": "Amended Debt Instrument, By Leverage Ratio, Tranche Four [Member]",
        "terseLabel": "Consolidated Leverage Ratio: Less Than Equal To 0.75 to 1.0"
       }
      }
     },
     "localname": "AmendedDebtInstrumentByLeverageRatioTrancheFourMember",
     "nsuri": "http://www.amedisys.com/20210630",
     "presentation": [
      "http://www.amedisys.com/role/SUBSEQUENTEVENTFeesandRatesUnderCreditFacilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_AmendedDebtInstrumentByLeverageRatioTrancheOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amended Debt Instrument, By Leverage Ratio, Tranche One",
        "label": "Amended Debt Instrument, By Leverage Ratio, Tranche One [Member]",
        "terseLabel": "Consolidated Leverage Ratio: Greater Than 3.00 to 1.0"
       }
      }
     },
     "localname": "AmendedDebtInstrumentByLeverageRatioTrancheOneMember",
     "nsuri": "http://www.amedisys.com/20210630",
     "presentation": [
      "http://www.amedisys.com/role/SUBSEQUENTEVENTFeesandRatesUnderCreditFacilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_AmendedDebtInstrumentByLeverageRatioTrancheThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amended Debt Instrument, By Leverage Ratio, Tranche Three",
        "label": "Amended Debt Instrument, By Leverage Ratio, Tranche Three [Member]",
        "terseLabel": "Consolidated Leverage Ratio: Less Than Equal To 2.00 to 1.0 but Greater Than 0.75 to 1.0"
       }
      }
     },
     "localname": "AmendedDebtInstrumentByLeverageRatioTrancheThreeMember",
     "nsuri": "http://www.amedisys.com/20210630",
     "presentation": [
      "http://www.amedisys.com/role/SUBSEQUENTEVENTFeesandRatesUnderCreditFacilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_AmendedDebtInstrumentByLeverageRatioTrancheTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amended Debt Instrument, By Leverage Ratio, Tranche Two",
        "label": "Amended Debt Instrument, By Leverage Ratio, Tranche Two [Member]",
        "terseLabel": "Consolidated Leverage Ratio: Less Than Equal 3.00 to 1.0 but Greater Than 2.00 to 1.0"
       }
      }
     },
     "localname": "AmendedDebtInstrumentByLeverageRatioTrancheTwoMember",
     "nsuri": "http://www.amedisys.com/20210630",
     "presentation": [
      "http://www.amedisys.com/role/SUBSEQUENTEVENTFeesandRatesUnderCreditFacilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_AmortizationandImpairmentofOperatingLeaseRightOfUseAsset": {
     "auth_ref": [],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortization and Impairment of Operating Lease Right Of Use Asset",
        "label": "Amortization and Impairment of Operating Lease Right Of Use Asset",
        "terseLabel": "Amortization and impairment of operating lease right of use assets"
       }
      }
     },
     "localname": "AmortizationandImpairmentofOperatingLeaseRightOfUseAsset",
     "nsuri": "http://www.amedisys.com/20210630",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_AsanaHospiceAquisitionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asana Hospice Aquisition",
        "label": "Asana Hospice Aquisition [Member]",
        "terseLabel": "Asana Hospice Aquisition [Member]"
       }
      }
     },
     "localname": "AsanaHospiceAquisitionMember",
     "nsuri": "http://www.amedisys.com/20210630",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESCashandCashEquivalentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_AsanaHospiceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asana Hospice",
        "label": "Asana Hospice [Member]",
        "terseLabel": "Asana Hospice [Member]"
       }
      }
     },
     "localname": "AsanaHospiceMember",
     "nsuri": "http://www.amedisys.com/20210630",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESCashandCashEquivalentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_AseraCareHospiceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "AseraCare Hospice",
        "label": "AseraCare Hospice [Member]",
        "terseLabel": "AseraCare Hospice [Member]"
       }
      }
     },
     "localname": "AseraCareHospiceMember",
     "nsuri": "http://www.amedisys.com/20210630",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails",
      "http://www.amedisys.com/role/ACQUISITIONSProFormaDetails",
      "http://www.amedisys.com/role/NOVELCORONAVIRUSPANDEMICCOVID19Details",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESCashandCashEquivalentsDetails",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_BusinessAcquisitionClosingPaymentAdjustment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Acquisition Closing Payment Adjustment",
        "label": "Business Acquisition Closing Payment Adjustment",
        "terseLabel": "Business Acquisition Closing Payment Adjustment"
       }
      }
     },
     "localname": "BusinessAcquisitionClosingPaymentAdjustment",
     "nsuri": "http://www.amedisys.com/20210630",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_BusinessAcquisitionWorkingCapitalAdjustment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Acquisition, Working Capital Adjustment",
        "label": "Business Acquisition Working Capital Adjustment",
        "terseLabel": "Business Acquisition Working Capital Adjustment"
       }
      }
     },
     "localname": "BusinessAcquisitionWorkingCapitalAdjustment",
     "nsuri": "http://www.amedisys.com/20210630",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherCurrentAsset": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, acquired at the acquisition date.",
        "label": "Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Other Current Asset",
        "terseLabel": "Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Other Current Asset"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherCurrentAsset",
     "nsuri": "http://www.amedisys.com/20210630",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentAssetsPrepaidExpense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense",
        "terseLabel": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentAssetsPrepaidExpense",
     "nsuri": "http://www.amedisys.com/20210630",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accrued Expenses",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accrued Expenses",
        "negatedLabel": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accrued Expenses"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses",
     "nsuri": "http://www.amedisys.com/20210630",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesPayrollandEmployeeBenefits": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Payroll and Employee Benefits",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Payroll and Employee Benefits",
        "negatedLabel": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Payroll and Employee Benefits"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesPayrollandEmployeeBenefits",
     "nsuri": "http://www.amedisys.com/20210630",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingLeaseLiabilities": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Operating Lease Liabilities",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Operating Lease Liabilities",
        "negatedLabel": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Operating Lease Liabilities"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingLeaseLiabilities",
     "nsuri": "http://www.amedisys.com/20210630",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingleaserightofuseassets": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Operating lease right of use assets",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Operating lease right of use assets",
        "terseLabel": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Operating lease right of use assets"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingleaserightofuseassets",
     "nsuri": "http://www.amedisys.com/20210630",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_Businessacquisitionproformaoperatingincomeloss": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The pro forma operating income (loss) for the period as if the business combination or combinations had been completed at the beginning of a period.",
        "label": "Business acquisition pro forma operating income loss",
        "terseLabel": "Operating income"
       }
      }
     },
     "localname": "Businessacquisitionproformaoperatingincomeloss",
     "nsuri": "http://www.amedisys.com/20210630",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSProFormaDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_CARESActDeferralOfEmployerShareSocialSecurityTax": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The deferral of the employer's share social security tax provided by the CARES Act",
        "label": "CARES Act Deferral of Employer Share Social Security Tax",
        "terseLabel": "CARES Act Deferral of Employer Share Social Security Tax"
       }
      }
     },
     "localname": "CARESActDeferralOfEmployerShareSocialSecurityTax",
     "nsuri": "http://www.amedisys.com/20210630",
     "presentation": [
      "http://www.amedisys.com/role/NOVELCORONAVIRUSPANDEMICCOVID19Details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_CARESActProviderReliefFundsReceivedByUnconsolidatedJointVentures": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "CARES Act Provider Relief Funds Received by Unconsolidated Joint Ventures",
        "label": "CARES Act Provider Relief Funds Received by Unconsolidated Joint Ventures",
        "terseLabel": "CARES Act Provider Relief Funds Received by Unconsolidated Joint Ventures"
       }
      }
     },
     "localname": "CARESActProviderReliefFundsReceivedByUnconsolidatedJointVentures",
     "nsuri": "http://www.amedisys.com/20210630",
     "presentation": [
      "http://www.amedisys.com/role/NOVELCORONAVIRUSPANDEMICCOVID19Details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_CARESActProviderReliefFundsUtilized": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "CARES Act Provider Relief Funds Utilized",
        "label": "CARES Act Provider Relief Funds Utilized",
        "terseLabel": "CARES Act Provider Relief Funds Utilized"
       }
      }
     },
     "localname": "CARESActProviderReliefFundsUtilized",
     "nsuri": "http://www.amedisys.com/20210630",
     "presentation": [
      "http://www.amedisys.com/role/NOVELCORONAVIRUSPANDEMICCOVID19Details",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESCashandCashEquivalentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_COVID19DeferralOfSocialSecurityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "COVID-19 Deferral of Social Security",
        "label": "COVID-19 Deferral of Social Security [Member]",
        "terseLabel": "COVID-19 Deferral of Social Security"
       }
      }
     },
     "localname": "COVID19DeferralOfSocialSecurityMember",
     "nsuri": "http://www.amedisys.com/20210630",
     "presentation": [
      "http://www.amedisys.com/role/NOVELCORONAVIRUSPANDEMICCOVID19Details"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_COVID19ExpensesIncurred": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expenses incurred as a result of the Novel Coronavirus Pandemic \"COVID-19\"",
        "label": "COVID-19 Expenses Incurred",
        "terseLabel": "COVID-19 Expenses Incurred"
       }
      }
     },
     "localname": "COVID19ExpensesIncurred",
     "nsuri": "http://www.amedisys.com/20210630",
     "presentation": [
      "http://www.amedisys.com/role/NOVELCORONAVIRUSPANDEMICCOVID19Details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_COVID19PPEMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "COVID-19 PPE",
        "label": "COVID-19 PPE [Member]",
        "terseLabel": "COVID-19 PPE [Member]"
       }
      }
     },
     "localname": "COVID19PPEMember",
     "nsuri": "http://www.amedisys.com/20210630",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESCashandCashEquivalentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_COVID19TextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for Novel Coronavirus Pandemic \"COVID-19\"",
        "label": "COVID-19 [Text Block]",
        "terseLabel": "COVID-19"
       }
      }
     },
     "localname": "COVID19TextBlock",
     "nsuri": "http://www.amedisys.com/20210630",
     "presentation": [
      "http://www.amedisys.com/role/NOVELCORONAVIRUSPANDEMICCOVID19"
     ],
     "xbrltype": "textBlockItemType"
    },
    "amed_CapYearAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cap Year [Axis]",
        "label": "Cap Year [Axis]",
        "terseLabel": "Cap Year [Axis]"
       }
      }
     },
     "localname": "CapYearAxis",
     "nsuri": "http://www.amedisys.com/20210630",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "amed_CapYearDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cap Year [Domain]",
        "label": "Cap Year [Domain]",
        "terseLabel": "Cap Year [Domain]"
       }
      }
     },
     "localname": "CapYearDomain",
     "nsuri": "http://www.amedisys.com/20210630",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_CapYearTwoThousandFourteenThroughTwoThousandTwentyOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cap Year Two Thousand Fourteen Through Two Thousand Twenty One[Member]",
        "label": "Cap Year Two Thousand Fourteen Through Two Thousand Twenty One [Member]",
        "terseLabel": "Cap Year 2014 Through 2021"
       }
      }
     },
     "localname": "CapYearTwoThousandFourteenThroughTwoThousandTwentyOneMember",
     "nsuri": "http://www.amedisys.com/20210630",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_CapYearTwoThousandSixteenThroughTwoThousandTwentyOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cap Year Two Thousand Sixteen Through Two Thousand Twenty One",
        "label": "Cap Year Two Thousand Sixteen Through Two Thousand Twenty One [Member]",
        "terseLabel": "Cap Year 2016 Through 2021"
       }
      }
     },
     "localname": "CapYearTwoThousandSixteenThroughTwoThousandTwentyOneMember",
     "nsuri": "http://www.amedisys.com/20210630",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_CashBalanceAssociatedWithProviderReliefFund": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash Balance Associated with the CARES Act Provider Relief Fund",
        "label": "Cash Balance Associated with Provider Relief Fund",
        "terseLabel": "Cash Balance Associated with Provider Relief Fund"
       }
      }
     },
     "localname": "CashBalanceAssociatedWithProviderReliefFund",
     "nsuri": "http://www.amedisys.com/20210630",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESCashandCashEquivalentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_CashDistributionToNoncontrollingInterest": {
     "auth_ref": [],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payment of dividends or other distributions to noncontrolling interest holders.",
        "label": "Cash Distribution To Noncontrolling Interest",
        "negatedLabel": "Noncontrolling interest distribution"
       }
      }
     },
     "localname": "CashDistributionToNoncontrollingInterest",
     "nsuri": "http://www.amedisys.com/20210630",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_CashPaidForFinanceLeaseLiabilities": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid for finance lease liabilities",
        "label": "Cash paid for finance lease liabilities",
        "terseLabel": "Cash paid for finance lease liabilities"
       }
      }
     },
     "localname": "CashPaidForFinanceLeaseLiabilities",
     "nsuri": "http://www.amedisys.com/20210630",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_CashPaidForOperatingLeaseLiabilities": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid for operating lease liabilities",
        "label": "Cash paid for operating lease liabilities",
        "terseLabel": "Cash paid for operating lease liabilities"
       }
      }
     },
     "localname": "CashPaidForOperatingLeaseLiabilities",
     "nsuri": "http://www.amedisys.com/20210630",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_CertificateOfNeedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Certificate of Need",
        "label": "Certificate of Need [Member]",
        "terseLabel": "Certificate of Need [Member]"
       }
      }
     },
     "localname": "CertificateOfNeedMember",
     "nsuri": "http://www.amedisys.com/20210630",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_CertificatesOfNeedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Certificates Of Need",
        "label": "Certificates Of Need [Member]",
        "terseLabel": "Certificates Of Need"
       }
      }
     },
     "localname": "CertificatesOfNeedMember",
     "nsuri": "http://www.amedisys.com/20210630",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_ClearwaterFloridaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Clearwater, Florida [Member]",
        "label": "Clearwater, Florida [Member]",
        "terseLabel": "Clearwater, Florida"
       }
      }
     },
     "localname": "ClearwaterFloridaMember",
     "nsuri": "http://www.amedisys.com/20210630",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_CompanysinsurancecarriersMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Company's insurance carriers [Member]",
        "label": "Company's insurance carriers [Member]",
        "terseLabel": "Company's insurance carriers [Member]"
       }
      }
     },
     "localname": "CompanysinsurancecarriersMember",
     "nsuri": "http://www.amedisys.com/20210630",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_CompassionateCareHospiceCIAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Compassionate Care Hospice CIA [Member]",
        "label": "Compassionate Care Hospice CIA [Member]",
        "terseLabel": "Compassionate Care Hospice CIA"
       }
      }
     },
     "localname": "CompassionateCareHospiceCIAMember",
     "nsuri": "http://www.amedisys.com/20210630",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_CompassionateCareHospiceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Compassionate Care Hospice [Member]",
        "label": "Compassionate Care Hospice [Member]",
        "terseLabel": "Compassionate Care Hospice [Member]"
       }
      }
     },
     "localname": "CompassionateCareHospiceMember",
     "nsuri": "http://www.amedisys.com/20210630",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSProFormaDetails",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPatientAccountsReceivableNarrativeDetails",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_ConsolidatedInterestCoverageRatio": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ratio of adjusted earnings before interest, taxes, depreciation and amortization to cash interest charges",
        "label": "Consolidated Interest Coverage Ratio",
        "terseLabel": "Consolidated interest coverage ratio"
       }
      }
     },
     "localname": "ConsolidatedInterestCoverageRatio",
     "nsuri": "http://www.amedisys.com/20210630",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "amed_ConsolidatedLeverageRatio": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Consolidated Leverage Ratio",
        "label": "Consolidated Leverage Ratio",
        "terseLabel": "Consolidated Leverage Ratio"
       }
      }
     },
     "localname": "ConsolidatedLeverageRatio",
     "nsuri": "http://www.amedisys.com/20210630",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSFeesandRatesUnderCreditFacilitiesDetails",
      "http://www.amedisys.com/role/SUBSEQUENTEVENTFeesandRatesUnderCreditFacilitiesDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "amed_ContessaHealthMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contessa Health",
        "label": "Contessa Health [Member]",
        "terseLabel": "Contessa Health"
       }
      }
     },
     "localname": "ContessaHealthMember",
     "nsuri": "http://www.amedisys.com/20210630",
     "presentation": [
      "http://www.amedisys.com/role/SUBSEQUENTEVENTNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_CorporateIntegrityAgreementTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Corporate Integrity Agreement Term",
        "label": "Corporate Integrity Agreement Term",
        "terseLabel": "Corporate integrity agreement term (years)"
       }
      }
     },
     "localname": "CorporateIntegrityAgreementTerm",
     "nsuri": "http://www.amedisys.com/20210630",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "amed_CreditFacilityMaximumAllowableConsolidatedLeverageRatioMultiple": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Credit Facility, Maximum Allowable Consolidated Leverage Ratio Multiple",
        "label": "Credit Facility Maximum Allowable Consolidated Leverage Ratio Multiple",
        "terseLabel": "Credit Facility Maximum Allowable Consolidated Leverage Ratio Multiple"
       }
      }
     },
     "localname": "CreditFacilityMaximumAllowableConsolidatedLeverageRatioMultiple",
     "nsuri": "http://www.amedisys.com/20210630",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "amed_Creditfacilitymaximumallowableconsolidatedleverageratio": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Credit facility maximum allowable consolidated leverage ratio as defined in the Company's Credit Agreement",
        "label": "Credit facility maximum allowable consolidated leverage ratio",
        "terseLabel": "Credit facility, maximum allowable consolidated leverage ratio"
       }
      }
     },
     "localname": "Creditfacilitymaximumallowableconsolidatedleverageratio",
     "nsuri": "http://www.amedisys.com/20210630",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "amed_DebtInstrumentByLeverageRatioTrancheFourMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, By Leverage Ratio, Tranche Four [Member]",
        "label": "Debt Instrument, By Leverage Ratio, Tranche Four [Member]",
        "terseLabel": "Consolidated Leverage Ratio: Less Than 0.75 to 1.0"
       }
      }
     },
     "localname": "DebtInstrumentByLeverageRatioTrancheFourMember",
     "nsuri": "http://www.amedisys.com/20210630",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSFeesandRatesUnderCreditFacilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_DebtInstrumentByLeverageRatioTrancheOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, By Leverage Ratio, Tranche One [Member]",
        "label": "Debt Instrument, By Leverage Ratio, Tranche One [Member]",
        "terseLabel": "Consolidated Leverage Ratio: Greater Than Equal To 3.00 to 1.0"
       }
      }
     },
     "localname": "DebtInstrumentByLeverageRatioTrancheOneMember",
     "nsuri": "http://www.amedisys.com/20210630",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSFeesandRatesUnderCreditFacilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_DebtInstrumentByLeverageRatioTrancheThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, By Leverage Ratio, Tranche Three [Member]",
        "label": "Debt Instrument, By Leverage Ratio, Tranche Three [Member]",
        "terseLabel": "Consolidated Leverage Ratio: Less Than 2.00 to 1.0 but Greater Than Equal To 0.75 to 1.0"
       }
      }
     },
     "localname": "DebtInstrumentByLeverageRatioTrancheThreeMember",
     "nsuri": "http://www.amedisys.com/20210630",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSFeesandRatesUnderCreditFacilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_DebtInstrumentByLeverageRatioTrancheTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, By Leverage Ratio, Tranche Two [Member]",
        "label": "Debt Instrument, By Leverage Ratio, Tranche Two [Member]",
        "terseLabel": "Consolidated Leverage Ratio: Less Than 3.00 to 1.0 but Greater Than Equal To 2.00 to 1.0"
       }
      }
     },
     "localname": "DebtInstrumentByLeverageRatioTrancheTwoMember",
     "nsuri": "http://www.amedisys.com/20210630",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSFeesandRatesUnderCreditFacilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_DebtInstrumentCarryingAmountExcludingFinanceLeases": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument Carrying Amount Excluding Finance Leases",
        "label": "Debt Instrument Carrying Amount Excluding Finance Leases",
        "terseLabel": "Debt Instrument Carrying Amount Excluding Finance Leases"
       }
      }
     },
     "localname": "DebtInstrumentCarryingAmountExcludingFinanceLeases",
     "nsuri": "http://www.amedisys.com/20210630",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESFairValueofFinancialInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_DebtInstrumentInterestAdditionalInterestAboveEurodollarRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument Interest Additional Interest Above Eurodollar Rate",
        "label": "Debt Instrument Interest Additional Interest Above Eurodollar Rate",
        "terseLabel": "Additional interest rate above Eurodollar rate"
       }
      }
     },
     "localname": "DebtInstrumentInterestAdditionalInterestAboveEurodollarRate",
     "nsuri": "http://www.amedisys.com/20210630",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails",
      "http://www.amedisys.com/role/SUBSEQUENTEVENTNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "amed_DebtInstrumentInterestAdditionalInterestAboveFederalFundRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument Interest Additional Interest Above Federal Fund Rate",
        "label": "Debt Instrument Interest Additional Interest Above Federal Fund Rate",
        "terseLabel": "Additional interest rate above Federal Fund rate"
       }
      }
     },
     "localname": "DebtInstrumentInterestAdditionalInterestAboveFederalFundRate",
     "nsuri": "http://www.amedisys.com/20210630",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails",
      "http://www.amedisys.com/role/SUBSEQUENTEVENTNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "amed_DebtInstrumentInterestRateatPeriodEnd": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument Interest Rate at Period End",
        "label": "Debt Instrument Interest Rate at Period End",
        "terseLabel": "Debt Instrument Interest Rate at Period End"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateatPeriodEnd",
     "nsuri": "http://www.amedisys.com/20210630",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "amed_DebtInstrumentPeriodicPaymentPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage of the Term Loan that is required as periodic payments including both interest and principal payments",
        "label": "Debt Instrument Periodic Payment Percentage",
        "terseLabel": "Debt Instrument Periodic Payment Percentage"
       }
      }
     },
     "localname": "DebtInstrumentPeriodicPaymentPercentage",
     "nsuri": "http://www.amedisys.com/20210630",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails",
      "http://www.amedisys.com/role/SUBSEQUENTEVENTNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "amed_DepreciationAndAmortizationForContinuingOperations": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Depreciation And Amortization For Continuing Operations",
        "label": "Depreciation And Amortization For Continuing Operations",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationAndAmortizationForContinuingOperations",
     "nsuri": "http://www.amedisys.com/20210630",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_Discountedclosingstockprice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discounted closing stock price",
        "label": "Discounted closing stock price",
        "terseLabel": "Discounted closing stock price"
       }
      }
     },
     "localname": "Discountedclosingstockprice",
     "nsuri": "http://www.amedisys.com/20210630",
     "presentation": [
      "http://www.amedisys.com/role/SHAREREPURCHASENarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "amed_EpisodeOfCareAsEpisodicBasedRevenueDuration": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description containing the number of days in a home health episode of care.",
        "label": "Episode Of Care As Episodic Based Revenue Duration",
        "terseLabel": "Episode of care as episodic-based revenue (days)"
       }
      }
     },
     "localname": "EpisodeOfCareAsEpisodicBasedRevenueDuration",
     "nsuri": "http://www.amedisys.com/20210630",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "amed_EquityImpactOfWriteOffOfOtherComprehensiveIncome": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Impact of Write Off of Other Comprehensive Income",
        "label": "Equity Impact of Write Off of Other Comprehensive Income",
        "negatedLabel": "Write-off of other comprehensive income"
       }
      }
     },
     "localname": "EquityImpactOfWriteOffOfOtherComprehensiveIncome",
     "nsuri": "http://www.amedisys.com/20210630",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_EquityImpactofRepurchaseofNoncontrollingInterest": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Impact of Repurchase of Noncontrolling Interest",
        "label": "Equity Impact of Repurchase of Noncontrolling Interest",
        "negatedLabel": "Repurchase of noncontrolling interest"
       }
      }
     },
     "localname": "EquityImpactofRepurchaseofNoncontrollingInterest",
     "nsuri": "http://www.amedisys.com/20210630",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_ErrorRatePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Error Rate Percentage",
        "label": "Error Rate Percentage",
        "terseLabel": "Error rate (percent)"
       }
      }
     },
     "localname": "ErrorRatePercentage",
     "nsuri": "http://www.amedisys.com/20210630",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "amed_EstimatedAmountDueBackToMedicareInOtherAccruedLiabilities": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Estimate of obligations due Medicare upon demand due to overages for the inpatient cap and/or overall payment cap.",
        "label": "Estimated Amount Due Back To Medicare In Other Accrued Liabilities",
        "terseLabel": "Estimated amounts due back to Medicare"
       }
      }
     },
     "localname": "EstimatedAmountDueBackToMedicareInOtherAccruedLiabilities",
     "nsuri": "http://www.amedisys.com/20210630",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_EstimatedCARESActProviderReliefFundAmountsToBeRepaid": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Estimated CARES Act Provider Relief Fund Amounts to be Repaid",
        "label": "Estimated CARES Act Provider Relief Fund Amounts to be Repaid",
        "terseLabel": "Estimated CARES Act Provider Relief Fund Amounts to be Repaid"
       }
      }
     },
     "localname": "EstimatedCARESActProviderReliefFundAmountsToBeRepaid",
     "nsuri": "http://www.amedisys.com/20210630",
     "presentation": [
      "http://www.amedisys.com/role/NOVELCORONAVIRUSPANDEMICCOVID19Details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_EstimatedCARESActProviderReliefFundsExpectedToBeUtilized": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Estimated CARES Act Provider Relief Funds Expected to be Utilized",
        "label": "Estimated CARES Act Provider Relief Funds Expected to be Utilized",
        "terseLabel": "Estimated CARES Act Provider Relief Funds Expected to be Utilized"
       }
      }
     },
     "localname": "EstimatedCARESActProviderReliefFundsExpectedToBeUtilized",
     "nsuri": "http://www.amedisys.com/20210630",
     "presentation": [
      "http://www.amedisys.com/role/NOVELCORONAVIRUSPANDEMICCOVID19Details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_EstimatedFutureCOVID19RelatedExpenses": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Estimated expenses as a result of the Novel Coronavirus Pandemic \"COVID-19\"",
        "label": "Estimated Future COVID-19 related expenses",
        "terseLabel": "Estimated Future COVID-19 related expenses"
       }
      }
     },
     "localname": "EstimatedFutureCOVID19RelatedExpenses",
     "nsuri": "http://www.amedisys.com/20210630",
     "presentation": [
      "http://www.amedisys.com/role/NOVELCORONAVIRUSPANDEMICCOVID19Details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_ExtensionOfTemporarySuspensionOfSequestrationRevenueImpact": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The impact on revenue due to the extension of the temporary suspension of sequestration as a result of the novel coronavrius pandemic (\"COVID-19\").",
        "label": "Extension of Temporary Suspension of Sequestration, Revenue Impact",
        "terseLabel": "Extension of Temporary Suspension of Sequestration, Revenue Impact"
       }
      }
     },
     "localname": "ExtensionOfTemporarySuspensionOfSequestrationRevenueImpact",
     "nsuri": "http://www.amedisys.com/20210630",
     "presentation": [
      "http://www.amedisys.com/role/NOVELCORONAVIRUSPANDEMICCOVID19Details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_ExtrapolatedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Extrapolated [Member]",
        "label": "Extrapolated [Member]",
        "terseLabel": "Extrapolated [Member]"
       }
      }
     },
     "localname": "ExtrapolatedMember",
     "nsuri": "http://www.amedisys.com/20210630",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_FinancialInstrumentDetailsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financial instrument details, table.",
        "label": "Financial Instrument Details [Table Text Block]",
        "terseLabel": "Schedule of Fair Value of Financial Instruments"
       }
      }
     },
     "localname": "FinancialInstrumentDetailsTableTextBlock",
     "nsuri": "http://www.amedisys.com/20210630",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "amed_FirstThresholdOfTherapyServicesRequired": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description containing the number of visits related to the first threshold of therapy services required.",
        "label": "First Threshold Of Therapy Services Required",
        "terseLabel": "First threshold of therapy services required (visits)"
       }
      }
     },
     "localname": "FirstThresholdOfTherapyServicesRequired",
     "nsuri": "http://www.amedisys.com/20210630",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Five Hundred Fifty Million Revolving Credit Facility [Member]",
        "label": "Five Hundred Fifty Million Revolving Credit Facility [Member]",
        "terseLabel": "Five Hundred Fifty Million Revolving Credit Facility [Member]"
       }
      }
     },
     "localname": "FiveHundredFiftyMillionRevolvingCreditFacilityMember",
     "nsuri": "http://www.amedisys.com/20210630",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtAdditionalInformationDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtDetails",
      "http://www.amedisys.com/role/SUBSEQUENTEVENTNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_FloridaZpicRevenueReduction": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reduction in revenue as a result of the Florida ZPIC audit",
        "label": "Florida Zpic Revenue Reduction",
        "terseLabel": "Florida ZPIC revenue reduction"
       }
      }
     },
     "localname": "FloridaZpicRevenueReduction",
     "nsuri": "http://www.amedisys.com/20210630",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_FourHundredFiftyMillionTermLoanFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Four Hundred Fifty Million Term Loan Facility",
        "label": "Four Hundred Fifty Million Term Loan Facility [Member]",
        "terseLabel": "Four Hundred Fifty Million Term Loan Facility"
       }
      }
     },
     "localname": "FourHundredFiftyMillionTermLoanFacilityMember",
     "nsuri": "http://www.amedisys.com/20210630",
     "presentation": [
      "http://www.amedisys.com/role/SUBSEQUENTEVENTNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_FundingForHealthcareProvidersIncludingHospitals": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Funding for healthcare providers, including hospitals provided by the Coronavirus Aid, Relief and Economic Security (CARES) Act",
        "label": "Funding for Healthcare Providers, Including Hospitals",
        "terseLabel": "Funding for Healthcare Providers, Including Hospitals"
       }
      }
     },
     "localname": "FundingForHealthcareProvidersIncludingHospitals",
     "nsuri": "http://www.amedisys.com/20210630",
     "presentation": [
      "http://www.amedisys.com/role/NOVELCORONAVIRUSPANDEMICCOVID19Details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_FundingImmediatelyDistributedToHealthcareProvidersBasedOnTheir2019MedicareFeeForServiceReimbursements": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Funding immediately distributed to healthcare providers based on their 2019 Medicare Fee-For-Service reimbursements provided by the Coronavirus Aid, Relief and Economic Security (CARES) Act",
        "label": "Funding Immediately Distributed to Healthcare Providers Based on Their 2019 Medicare Fee-For-Service Reimbursements",
        "terseLabel": "Funding Immediately Distributed to Healthcare Providers Based on Their 2019 Medicare Fee-For-Service Reimbursements"
       }
      }
     },
     "localname": "FundingImmediatelyDistributedToHealthcareProvidersBasedOnTheir2019MedicareFeeForServiceReimbursements",
     "nsuri": "http://www.amedisys.com/20210630",
     "presentation": [
      "http://www.amedisys.com/role/NOVELCORONAVIRUSPANDEMICCOVID19Details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_FundingReceivedFromCARESAct": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Funding received by the Company from the Coronavirus Aid Relief and Economic Security (CARES) Act",
        "label": "Funding Received From CARES Act",
        "terseLabel": "Funding Received From CARES Act"
       }
      }
     },
     "localname": "FundingReceivedFromCARESAct",
     "nsuri": "http://www.amedisys.com/20210630",
     "presentation": [
      "http://www.amedisys.com/role/NOVELCORONAVIRUSPANDEMICCOVID19Details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_FundingReceivedFromMassHomeCareASAPCOVID19ProviderSustainabilityProgram": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Funding Received From Mass Home Care ASAP COVID-19 Provider Sustainability Program",
        "label": "Funding Received From Mass Home Care ASAP COVID-19 Provider Sustainability Program",
        "terseLabel": "Funding Received From Mass Home Care ASAP COVID-19 Provider Sustainability Program"
       }
      }
     },
     "localname": "FundingReceivedFromMassHomeCareASAPCOVID19ProviderSustainabilityProgram",
     "nsuri": "http://www.amedisys.com/20210630",
     "presentation": [
      "http://www.amedisys.com/role/NOVELCORONAVIRUSPANDEMICCOVID19Details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_FundsReceivedFromProviderReliefFundAdvance": {
     "auth_ref": [],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from funds received by the government related to the Novel Coronavirus Pandemic \"COVID-19\"",
        "label": "Funds received from Provider relief fund advance",
        "terseLabel": "Provider relief fund advance"
       }
      }
     },
     "localname": "FundsReceivedFromProviderReliefFundAdvance",
     "nsuri": "http://www.amedisys.com/20210630",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_GoodwillDeductibleForIncomeTaxPurposesPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The period of time that goodwill is deductible for income tax purposes",
        "label": "GoodwillDeductibleForIncomeTaxPurposesPeriod",
        "terseLabel": "GoodwillDeductibleForIncomeTaxPurposesPeriod"
       }
      }
     },
     "localname": "GoodwillDeductibleForIncomeTaxPurposesPeriod",
     "nsuri": "http://www.amedisys.com/20210630",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "amed_GovernmentGrantsPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounting policy disclosure text block for government grants",
        "label": "Government Grants [Policy Text Block]",
        "terseLabel": "Government Grants"
       }
      }
     },
     "localname": "GovernmentGrantsPolicyTextBlock",
     "nsuri": "http://www.amedisys.com/20210630",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "amed_HealthInsuranceRetentionLimit": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum potential amount of future payments the entity could be required to make related to a specific Health Insurance Claim.",
        "label": "Health Insurance Retention Limit",
        "terseLabel": "Health insurance retention limit"
       }
      }
     },
     "localname": "HealthInsuranceRetentionLimit",
     "nsuri": "http://www.amedisys.com/20210630",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_HeritageHealthcareInnovationFundLPMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Heritage Healthcare Innovation Fund, LP",
        "label": "Heritage Healthcare Innovation Fund, LP [Member]",
        "terseLabel": "Heritage Healthcare Innovation Fund, LP [Member]"
       }
      }
     },
     "localname": "HeritageHealthcareInnovationFundLPMember",
     "nsuri": "http://www.amedisys.com/20210630",
     "presentation": [
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_HistoricalCollectionRateFromMedicare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Historical collection rate from Medicare.",
        "label": "Historical Collection Rate From Medicare",
        "terseLabel": "Historical collection rate from Medicare"
       }
      }
     },
     "localname": "HistoricalCollectionRateFromMedicare",
     "nsuri": "http://www.amedisys.com/20210630",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPatientAccountsReceivableNarrativeDetails",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "amed_HomeHealthAndHospiceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Home Health and Hospice",
        "label": "Home Health and Hospice [Member]",
        "terseLabel": "Home Health and Hospice [Member]"
       }
      }
     },
     "localname": "HomeHealthAndHospiceMember",
     "nsuri": "http://www.amedisys.com/20210630",
     "presentation": [
      "http://www.amedisys.com/role/NOVELCORONAVIRUSPANDEMICCOVID19Details"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_HomeHealthMedicareMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Home Health Medicare [Member]",
        "label": "Home Health Medicare [Member]",
        "terseLabel": "Home Health Medicare [Member]"
       }
      }
     },
     "localname": "HomeHealthMedicareMember",
     "nsuri": "http://www.amedisys.com/20210630",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenuebyPayorClassDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_HomeHealthMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Home Health [Member]",
        "label": "Home Health [Member]",
        "terseLabel": "Home Health [Member]"
       }
      }
     },
     "localname": "HomeHealthMember",
     "nsuri": "http://www.amedisys.com/20210630",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails",
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails",
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails",
      "http://www.amedisys.com/role/NOVELCORONAVIRUSPANDEMICCOVID19Details",
      "http://www.amedisys.com/role/SEGMENTINFORMATIONOperatingIncomeofReportableSegmentsDetails",
      "http://www.amedisys.com/role/SUBSEQUENTEVENTNarrativeDetails",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_HomeHealthNonMedicareEpisodicBasedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Home Health Non-Medicare - Episodic Based [Member]",
        "label": "Home Health Non-Medicare - Episodic Based [Member]",
        "terseLabel": "Home Health Non-Medicare - Episodic Based [Member]"
       }
      }
     },
     "localname": "HomeHealthNonMedicareEpisodicBasedMember",
     "nsuri": "http://www.amedisys.com/20210630",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenuebyPayorClassDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_HomeHealthNonMedicareNonEpisodicBasedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Home Health Non-Medicare - Non-Episodic Based [Member]",
        "label": "Home Health Non-Medicare - Non-Episodic Based [Member]",
        "terseLabel": "Home Health Non-Medicare - Non-Episodic Based [Member]"
       }
      }
     },
     "localname": "HomeHealthNonMedicareNonEpisodicBasedMember",
     "nsuri": "http://www.amedisys.com/20210630",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenuebyPayorClassDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_HospiceMedicareMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Hospice Medicare [Member]",
        "label": "Hospice Medicare [Member]",
        "terseLabel": "Hospice Medicare [Member]"
       }
      }
     },
     "localname": "HospiceMedicareMember",
     "nsuri": "http://www.amedisys.com/20210630",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenuebyPayorClassDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_HospiceMedicareRevenueRateAccountedForRoutineCare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description containing the percentage of the entity's Hospice net Medicare service revenue that is derived from routine care.",
        "label": "Hospice Medicare Revenue Rate Accounted For Routine Care",
        "terseLabel": "Hospice Medicare revenue rate accounted for routine care"
       }
      }
     },
     "localname": "HospiceMedicareRevenueRateAccountedForRoutineCare",
     "nsuri": "http://www.amedisys.com/20210630",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "amed_HospiceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Hospice [Member]",
        "label": "Hospice [Member]",
        "terseLabel": "Hospice [Member]"
       }
      }
     },
     "localname": "HospiceMember",
     "nsuri": "http://www.amedisys.com/20210630",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails",
      "http://www.amedisys.com/role/ACQUISITIONSProFormaDetails",
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails",
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails",
      "http://www.amedisys.com/role/SEGMENTINFORMATIONOperatingIncomeofReportableSegmentsDetails",
      "http://www.amedisys.com/role/SUBSEQUENTEVENTNarrativeDetails",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_HospiceNonMedicareMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Hospice Non-Medicare [Member]",
        "label": "Hospice Non-Medicare [Member]",
        "terseLabel": "Hospice Non-Medicare [Member]"
       }
      }
     },
     "localname": "HospiceNonMedicareMember",
     "nsuri": "http://www.amedisys.com/20210630",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenuebyPayorClassDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_IncreaseDecreaseInOperatingLeaseLiability": {
     "auth_ref": [],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 18.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating lease liabilities",
        "label": "Increase (Decrease) In Operating Lease Liability",
        "terseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "nsuri": "http://www.amedisys.com/20210630",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_IncreaseDecreaseInOperatingLeaseRightOfUseAsset": {
     "auth_ref": [],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 19.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of increase (decrease) In Operating Lease Right Of Use Asset",
        "label": "Increase (Decrease) In Operating Lease Right Of Use Asset",
        "terseLabel": "Operating lease right of use assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLeaseRightOfUseAsset",
     "nsuri": "http://www.amedisys.com/20210630",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_IncreaseInEstimatedFutureCOVID19RelatedExpenses": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase in Estimated Future COVID-19 Related Expenses",
        "label": "Increase in Estimated Future COVID-19 Related Expenses",
        "terseLabel": "Increase in Estimated Future COVID-19 Related Expenses"
       }
      }
     },
     "localname": "IncreaseInEstimatedFutureCOVID19RelatedExpenses",
     "nsuri": "http://www.amedisys.com/20210630",
     "presentation": [
      "http://www.amedisys.com/role/NOVELCORONAVIRUSPANDEMICCOVID19Details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_IndemnificationAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount to be reimbursed if and when certain assumed liabilities are paid",
        "label": "Indemnification Amount",
        "terseLabel": "Indemnification amount"
       }
      }
     },
     "localname": "IndemnificationAmount",
     "nsuri": "http://www.amedisys.com/20210630",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_InfinityHomeCareMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Infinity HomeCare [Member]",
        "label": "Infinity HomeCare [Member]",
        "terseLabel": "Infinity HomeCare"
       }
      }
     },
     "localname": "InfinityHomeCareMember",
     "nsuri": "http://www.amedisys.com/20210630",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_InternalAuditComplianceReviewMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Internal Audit Compliance Review [Member]",
        "label": "Internal Audit Compliance Review [Member]",
        "terseLabel": "Internal Audit Compliance Review [Member]"
       }
      }
     },
     "localname": "InternalAuditComplianceReviewMember",
     "nsuri": "http://www.amedisys.com/20210630",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_LakelandFloridaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lakeland, Florida [Member]",
        "label": "Lakeland, Florida [Member]",
        "terseLabel": "Lakeland, Florida"
       }
      }
     },
     "localname": "LakelandFloridaMember",
     "nsuri": "http://www.amedisys.com/20210630",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_LesseeOperatingleaseReductionstoROUassetsresultingfromreductionstoleaseobligations": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating lease, Reductions to ROU assets resulting from reductions to lease obligations",
        "label": "Lessee, Operating lease, Reductions to ROU assets resulting from reductions to lease obligations",
        "terseLabel": "Reductions to right of use assets resulting from reductions to operating lease liabilities"
       }
      }
     },
     "localname": "LesseeOperatingleaseReductionstoROUassetsresultingfromreductionstoleaseobligations",
     "nsuri": "http://www.amedisys.com/20210630",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_LetterOfCreditFee": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The fee, expressed as a percentage of the letters of credit, for the letters of credit",
        "label": "Letter Of Credit Fee",
        "terseLabel": "Letter Of Credit Fee"
       }
      }
     },
     "localname": "LetterOfCreditFee",
     "nsuri": "http://www.amedisys.com/20210630",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSFeesandRatesUnderCreditFacilitiesDetails",
      "http://www.amedisys.com/role/SUBSEQUENTEVENTFeesandRatesUnderCreditFacilitiesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "amed_LineOfCreditFacilityAdditionalBorrowingCapacity": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line Of Credit Facility Additional Borrowing Capacity",
        "label": "Line Of Credit Facility Additional Borrowing Capacity",
        "terseLabel": "Credit facility, maximum additional borrowing capacity"
       }
      }
     },
     "localname": "LineOfCreditFacilityAdditionalBorrowingCapacity",
     "nsuri": "http://www.amedisys.com/20210630",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_LossContingencyReceivableNoncurrentRelatedToAmountsWithheldPriorToAugust2009": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss Contingency, Receivable, Noncurrent, Related To Amounts Withheld Prior To August 2009",
        "label": "Loss Contingency, Receivable, Noncurrent, Related To Amounts Withheld Prior To August 2009",
        "terseLabel": "Indemnity receivable related to amounts withheld prior to August 2009"
       }
      }
     },
     "localname": "LossContingencyReceivableNoncurrentRelatedToAmountsWithheldPriorToAugust2009",
     "nsuri": "http://www.amedisys.com/20210630",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_LowUtilizationPaymentAdjustmentNumberOfVisits": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description containing the visit threshold for a low utilization payment adjustment.",
        "label": "Low Utilization Payment Adjustment Number Of Visits",
        "terseLabel": "Low utilization payment adjustment, maximum number of visits"
       }
      }
     },
     "localname": "LowUtilizationPaymentAdjustmentNumberOfVisits",
     "nsuri": "http://www.amedisys.com/20210630",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "amed_MajorSinglePayorCustomerMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Major Single Payor Customer [Member]",
        "label": "Major Single Payor Customer [Member]",
        "terseLabel": "Single Payor"
       }
      }
     },
     "localname": "MajorSinglePayorCustomerMember",
     "nsuri": "http://www.amedisys.com/20210630",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPatientAccountsReceivableNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_MaximumDaysToSubmitFinalBillFromDateRequestForAnticipatedPaymentWasPaid": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description containing the number of days from the date the request for anticipated payment was received in which the final bill must be submitted to Medicare.",
        "label": "Maximum Days To Submit Final Bill From Date Request For Anticipated Payment Was Paid",
        "terseLabel": "Maximum days to submit final bill from the date the request for anticipated payment was paid"
       }
      }
     },
     "localname": "MaximumDaysToSubmitFinalBillFromDateRequestForAnticipatedPaymentWasPaid",
     "nsuri": "http://www.amedisys.com/20210630",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPatientAccountsReceivableNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "amed_MaximumDaysToSubmitFinalBillFromStartOfPeriodOfCare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description containing the number of days from the start of the period of care in which the final bill must be submitted to Medicare.",
        "label": "Maximum Days To Submit Final Bill From Start Of Period of Care",
        "terseLabel": "Maximum days to submit final bill from the start of episode"
       }
      }
     },
     "localname": "MaximumDaysToSubmitFinalBillFromStartOfPeriodOfCare",
     "nsuri": "http://www.amedisys.com/20210630",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPatientAccountsReceivableNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "amed_MaximumPercentOwnershipForCostMethodPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description containing the percentage ownership required in order for an investment to be treated under the cost method of accounting in the entity's financial statements.",
        "label": "Maximum Percent Ownership For Cost Method Percent",
        "terseLabel": "Maximum ownership percentage for cost method investment (percent)"
       }
      }
     },
     "localname": "MaximumPercentOwnershipForCostMethodPercent",
     "nsuri": "http://www.amedisys.com/20210630",
     "presentation": [
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "amed_MaximumPercentOwnershipForEquityMethodPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description containing the percentage ownership required in order for an investment to be treated under the equity method of accounting in the entity's financial statements.",
        "label": "Maximum Percent Ownership For Equity Method Percent",
        "terseLabel": "Maximum ownership percentage for equity method investment (percent)"
       }
      }
     },
     "localname": "MaximumPercentOwnershipForEquityMethodPercent",
     "nsuri": "http://www.amedisys.com/20210630",
     "presentation": [
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "amed_MedalogixMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Medalogix [Member]",
        "label": "Medalogix [Member]",
        "terseLabel": "Medalogix [Member]"
       }
      }
     },
     "localname": "MedalogixMember",
     "nsuri": "http://www.amedisys.com/20210630",
     "presentation": [
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails",
      "http://www.amedisys.com/role/RELATEDPARTYTRANSACTIONSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_MedicareLicenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Medicare license",
        "label": "Medicare license [Member]",
        "terseLabel": "Medicare licenses [Member]"
       }
      }
     },
     "localname": "MedicareLicenseMember",
     "nsuri": "http://www.amedisys.com/20210630",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_MedicareRevenueMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Medicare Revenue [Member]",
        "label": "Medicare Revenue [Member]",
        "terseLabel": "Medicare Revenue [Member]"
       }
      }
     },
     "localname": "MedicareRevenueMember",
     "nsuri": "http://www.amedisys.com/20210630",
     "presentation": [
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_MinimumPercentOwnershipForControllingInterestPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description containing the percentage ownership required in order for a variable interest entity (VIE) to be consolidated in the entity's financial statements.",
        "label": "Minimum Percent Ownership For Controlling Interest Percent",
        "terseLabel": "Minimum ownership percentage for controlling interest (percent)"
       }
      }
     },
     "localname": "MinimumPercentOwnershipForControllingInterestPercent",
     "nsuri": "http://www.amedisys.com/20210630",
     "presentation": [
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "amed_MorgantownWestVirginiaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Morgantown, West Virginia [Member]",
        "label": "Morgantown, West Virginia [Member]",
        "terseLabel": "Morgantown, West Virginia"
       }
      }
     },
     "localname": "MorgantownWestVirginiaMember",
     "nsuri": "http://www.amedisys.com/20210630",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_NetServiceRevenueEpisodePaymentRateDuration": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description containing the number of days from the date the request for anticipated payment was received in which the final bill must be submitted to Medicare.",
        "label": "Net Service Revenue, Episode Payment Rate Duration",
        "terseLabel": "Net service revenue episode payment rate"
       }
      }
     },
     "localname": "NetServiceRevenueEpisodePaymentRateDuration",
     "nsuri": "http://www.amedisys.com/20210630",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "amed_NetServiceRevenuePeriodOfCarePaymentRateDuration": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description containing the number of days from the date the request for anticipated payment was received in which the final bill must be submitted to Medicare.",
        "label": "Net Service Revenue, Period of Care Payment Rate Duration",
        "terseLabel": "Net service revenue period of care payment rate (days)"
       }
      }
     },
     "localname": "NetServiceRevenuePeriodOfCarePaymentRateDuration",
     "nsuri": "http://www.amedisys.com/20210630",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPatientAccountsReceivableNarrativeDetails",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "amed_NonMedicareRevenueTermRates": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non-Medicare Revenue Term Rates as a percentage of Medicare Term Rates",
        "label": "Non-Medicare Revenue Term Rates",
        "terseLabel": "Non-Medicare revenue term rates"
       }
      }
     },
     "localname": "NonMedicareRevenueTermRates",
     "nsuri": "http://www.amedisys.com/20210630",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "amed_NonVestedStockAndStockUnits": {
     "auth_ref": [],
     "calculation": {
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESWeightedAverageSharesOutstandingDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non vested stock and stock units.",
        "label": "Non Vested Stock And Stock Units",
        "terseLabel": "Non-vested stock and stock units (shares)"
       }
      }
     },
     "localname": "NonVestedStockAndStockUnits",
     "nsuri": "http://www.amedisys.com/20210630",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESWeightedAverageSharesOutstandingDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "amed_NumberOfBeneficiaries": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of beneficiaries who received services",
        "label": "Number of beneficiaries",
        "terseLabel": "Number of beneficiaries"
       }
      }
     },
     "localname": "NumberOfBeneficiaries",
     "nsuri": "http://www.amedisys.com/20210630",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "amed_NumberOfClaimsSubmittedBySubsidiary": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of claims submitted by subsidiary.",
        "label": "Number Of Claims Submitted By Subsidiary",
        "terseLabel": "Number of claims submitted by subsidiary"
       }
      }
     },
     "localname": "NumberOfClaimsSubmittedBySubsidiary",
     "nsuri": "http://www.amedisys.com/20210630",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "amed_Numberofpatients": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of patients",
        "label": "Number of patients",
        "terseLabel": "Number of patients"
       }
      }
     },
     "localname": "Numberofpatients",
     "nsuri": "http://www.amedisys.com/20210630",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "amed_OneHundredMillionTermLoanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "100 Million Term Loan [Member]",
        "label": "One Hundred Million Term Loan [Member]",
        "terseLabel": "100 Million Term Loan"
       }
      }
     },
     "localname": "OneHundredMillionTermLoanMember",
     "nsuri": "http://www.amedisys.com/20210630",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_OneHundredSeventyFiveMillionTermLoanFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "One Hundred Seventy Five Million Term Loan Facility [Member]",
        "label": "One Hundred Seventy Five Million Term Loan Facility [Member]",
        "terseLabel": "One Hundred Seventy Five Million Term Loan Facility [Member]"
       }
      }
     },
     "localname": "OneHundredSeventyFiveMillionTermLoanFacilityMember",
     "nsuri": "http://www.amedisys.com/20210630",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtAdditionalInformationDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_OperatingCareCenters": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description containing the number of care centers owned by the entity as of the balance sheet date.",
        "label": "Operating Care Centers",
        "terseLabel": "Number of owned and operated care centers"
       }
      }
     },
     "localname": "OperatingCareCenters",
     "nsuri": "http://www.amedisys.com/20210630",
     "presentation": [
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "amed_ParkersburgWestVirginiaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Parkersburg, West Virginia [Member]",
        "label": "Parkersburg, West Virginia [Member]",
        "terseLabel": "Parkersburg, West Virginia"
       }
      }
     },
     "localname": "ParkersburgWestVirginiaMember",
     "nsuri": "http://www.amedisys.com/20210630",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_PaymentsRelatedToTaxAsset": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments related to tax asset",
        "label": "Payments related to tax asset",
        "terseLabel": "Payments related to tax asset"
       }
      }
     },
     "localname": "PaymentsRelatedToTaxAsset",
     "nsuri": "http://www.amedisys.com/20210630",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails",
      "http://www.amedisys.com/role/SUBSEQUENTEVENTNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_PayorClassAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payor Class [Axis]",
        "label": "Payor Class [Axis]",
        "terseLabel": "Payor Class [Axis]"
       }
      }
     },
     "localname": "PayorClassAxis",
     "nsuri": "http://www.amedisys.com/20210630",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenuebyPayorClassDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "amed_PayorClassDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "[Domain] for Payor Class [Axis]",
        "label": "Payor Class [Domain]",
        "terseLabel": "Payor Class [Domain]"
       }
      }
     },
     "localname": "PayorClassDomain",
     "nsuri": "http://www.amedisys.com/20210630",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenuebyPayorClassDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_PayorsAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payors [Axis]",
        "label": "Payors [Axis]",
        "terseLabel": "Payors [Axis]"
       }
      }
     },
     "localname": "PayorsAxis",
     "nsuri": "http://www.amedisys.com/20210630",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "amed_PayorsDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "[Domain] for Payors [Axis]",
        "label": "Payors [Domain]",
        "terseLabel": "Payors [Domain]"
       }
      }
     },
     "localname": "PayorsDomain",
     "nsuri": "http://www.amedisys.com/20210630",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_PercentageOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromSubsidiaries": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of adjusted EBITDA that guarantor subsidiaries represent",
        "label": "Percentage Of Earnings Before Interest Taxes Depreciation And Amortization From Subsidiaries",
        "terseLabel": "Percentage of adjusted EBITDA that guarantor subsidiaries represent"
       }
      }
     },
     "localname": "PercentageOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromSubsidiaries",
     "nsuri": "http://www.amedisys.com/20210630",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails",
      "http://www.amedisys.com/role/SUBSEQUENTEVENTNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "amed_PercentageOfPatientReceivablesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of patient receivables outstanding.",
        "label": "Percentage Of Patient Receivables Outstanding",
        "terseLabel": "Percentage of patient receivables outstanding"
       }
      }
     },
     "localname": "PercentageOfPatientReceivablesOutstanding",
     "nsuri": "http://www.amedisys.com/20210630",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPatientAccountsReceivableNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "amed_PercentageOfRevenueAndOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromWhollyOwnedSubsidiaries": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of consolidated net revenues and adjusted EBITDA that guarantor wholly-owned subsidiaries represent",
        "label": "Percentage Of Revenue And Of Earnings Before Interest Taxes Depreciation And Amortization From Wholly Owned Subsidiaries",
        "terseLabel": "Percentage of consolidated revenue and adjusted EBITDA that guarantor wholly-owned subsidiaries represent"
       }
      }
     },
     "localname": "PercentageOfRevenueAndOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromWhollyOwnedSubsidiaries",
     "nsuri": "http://www.amedisys.com/20210630",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails",
      "http://www.amedisys.com/role/SUBSEQUENTEVENTNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "amed_PercentageOfTotalReimbursementOfOutlierPayment": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage at which total reimbursement is capped if cost of care is unusually costly.",
        "label": "Percentage Of Total Reimbursement Of Outlier Payment",
        "terseLabel": "Percentage of total reimbursement of outlier payment"
       }
      }
     },
     "localname": "PercentageOfTotalReimbursementOfOutlierPayment",
     "nsuri": "http://www.amedisys.com/20210630",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "amed_PercentageofSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of Shares Outstanding",
        "label": "Percentage of Shares Outstanding",
        "terseLabel": "Percentage of shares outstanding"
       }
      }
     },
     "localname": "PercentageofSharesOutstanding",
     "nsuri": "http://www.amedisys.com/20210630",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails",
      "http://www.amedisys.com/role/SHAREREPURCHASENarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "amed_Percentageofclosingstockprice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of closing stock price",
        "label": "Percentage of closing stock price",
        "terseLabel": "Percentage of closing stock price"
       }
      }
     },
     "localname": "Percentageofclosingstockprice",
     "nsuri": "http://www.amedisys.com/20210630",
     "presentation": [
      "http://www.amedisys.com/role/SHAREREPURCHASENarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "amed_PeriodOfCareAsEpisodicBasedRevenueDuration": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description containing the number of days in a home health period of care using PDGM",
        "label": "Period of Care As Episodic Based Revenue Duration",
        "terseLabel": "Period of care as episodic-based revenue (days)"
       }
      }
     },
     "localname": "PeriodOfCareAsEpisodicBasedRevenueDuration",
     "nsuri": "http://www.amedisys.com/20210630",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "amed_PersonalCareMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Personal Care [Member]",
        "label": "Personal Care [Member]",
        "terseLabel": "Personal Care [Member]"
       }
      }
     },
     "localname": "PersonalCareMember",
     "nsuri": "http://www.amedisys.com/20210630",
     "presentation": [
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails",
      "http://www.amedisys.com/role/NOVELCORONAVIRUSPANDEMICCOVID19Details",
      "http://www.amedisys.com/role/SEGMENTINFORMATIONOperatingIncomeofReportableSegmentsDetails",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenuebyPayorClassDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_PriorCreditAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Prior Credit Agreement [Member]",
        "label": "Prior Credit Agreement [Member]",
        "terseLabel": "Prior Credit Agreement [Member]"
       }
      }
     },
     "localname": "PriorCreditAgreementMember",
     "nsuri": "http://www.amedisys.com/20210630",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_ProceedsReceivedFromLoanPartyOfSubsidiary": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds Received From Loan Party Of Subsidiary",
        "label": "Proceeds Received From Loan Party Of Subsidiary",
        "terseLabel": "Proceeds Received From Loan Party Of Subsidiary"
       }
      }
     },
     "localname": "ProceedsReceivedFromLoanPartyOfSubsidiary",
     "nsuri": "http://www.amedisys.com/20210630",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails",
      "http://www.amedisys.com/role/SUBSEQUENTEVENTNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_ProfessionalLiabilityInsuranceRetentionLimit": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum potential amount of future payments the entity could be required to make related to a specific Professional Liability Claim.",
        "label": "Professional Liability Insurance Retention Limit",
        "terseLabel": "Professional liability insurance retention limit"
       }
      }
     },
     "localname": "ProfessionalLiabilityInsuranceRetentionLimit",
     "nsuri": "http://www.amedisys.com/20210630",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_PromissoryNotesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Promissory Notes [Member]",
        "label": "Promissory Notes [Member]",
        "terseLabel": "Promissory Notes [Member]"
       }
      }
     },
     "localname": "PromissoryNotesMember",
     "nsuri": "http://www.amedisys.com/20210630",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_ProviderReliefFundAdvance": {
     "auth_ref": [],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payable related to funds received from the government related to COVID-19",
        "label": "Provider relief fund advance",
        "terseLabel": "Provider relief fund advance"
       }
      }
     },
     "localname": "ProviderReliefFundAdvance",
     "nsuri": "http://www.amedisys.com/20210630",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.amedisys.com/role/NOVELCORONAVIRUSPANDEMICCOVID19Details",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESCashandCashEquivalentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_RateOfRequestForAnticipatedPaymentSubmittedForInitialPeriodOfCare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description containing the percentage of estimated payment that is requested at the start of care for an initial period of care.",
        "label": "Rate Of Request For Anticipated Payment Submitted For Initial Period Of Care",
        "terseLabel": "Rate of request for anticipated payment submitted for the initial episode of care"
       }
      }
     },
     "localname": "RateOfRequestForAnticipatedPaymentSubmittedForInitialPeriodOfCare",
     "nsuri": "http://www.amedisys.com/20210630",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPatientAccountsReceivableNarrativeDetails",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "amed_RateOfRequestForAnticipatedPaymentSubmittedForSubsequentEpisodesOfCare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description containing the percentage of estimated payment that is requested at the start of care for any subsequent episodes of care.",
        "label": "Rate Of Request For Anticipated Payment Submitted For Subsequent Episodes Of Care",
        "terseLabel": "Rate of request for anticipated payment submitted for subsequent episodes of care"
       }
      }
     },
     "localname": "RateOfRequestForAnticipatedPaymentSubmittedForSubsequentEpisodesOfCare",
     "nsuri": "http://www.amedisys.com/20210630",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPatientAccountsReceivableNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "amed_RecoveryAmountOfOverpaymentMadeToSubsidiary": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Recovery amount of the overpayment made to the subsidiary.",
        "label": "Recovery Amount Of Overpayment Made To Subsidiary",
        "terseLabel": "Recovery amount of overpayment made to subsidiary"
       }
      }
     },
     "localname": "RecoveryAmountOfOverpaymentMadeToSubsidiary",
     "nsuri": "http://www.amedisys.com/20210630",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_RecoveryAmountOfOverpaymentMadeToSubsidiaryIncludingInterest": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Recovery amount of overpayment made to subsidiary including interest",
        "label": "Recovery Amount of Overpayment Made To Subsidiary Including Interest",
        "terseLabel": "Recovery amount of overpayment made to subsidiary including interest"
       }
      }
     },
     "localname": "RecoveryAmountOfOverpaymentMadeToSubsidiaryIncludingInterest",
     "nsuri": "http://www.amedisys.com/20210630",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_Recoveryamountofoverpaymentmadetosubsidiaryincludinginterestwithheld": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Recovery amount of over payment made to subsidiary including interest withheld",
        "label": "Recovery Amount Of Over Payment Made To Subsidiary Including Interest Withheld",
        "terseLabel": "Recovery amount of over payment made to subsidiary including interest withheld"
       }
      }
     },
     "localname": "Recoveryamountofoverpaymentmadetosubsidiaryincludinginterestwithheld",
     "nsuri": "http://www.amedisys.com/20210630",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_RevenueAdjustmentToMedicareRevenue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of the provisions that reduce the amount of Medicare revenue recognized by the entity.",
        "label": "Revenue Adjustment To Medicare Revenue",
        "terseLabel": "Revenue adjustment to Medicare revenue"
       }
      }
     },
     "localname": "RevenueAdjustmentToMedicareRevenue",
     "nsuri": "http://www.amedisys.com/20210630",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPatientAccountsReceivableNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_Revenuebypayorclassasapercentageoftotalnetservicerevenue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue by payor class as a percentage of total net service revenue",
        "label": "Revenue by payor class as a percentage of total net service revenue",
        "terseLabel": "Revenue by payor class as a percentage of total net service revenue"
       }
      }
     },
     "localname": "Revenuebypayorclassasapercentageoftotalnetservicerevenue",
     "nsuri": "http://www.amedisys.com/20210630",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenuebyPayorClassDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "amed_ReversalOfLossContingencyAccrual": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reversal of Loss Contingency Accrual",
        "label": "Reversal of Loss Contingency Accrual",
        "terseLabel": "Reversal of Loss Contingency Accrual"
       }
      }
     },
     "localname": "ReversalOfLossContingencyAccrual",
     "nsuri": "http://www.amedisys.com/20210630",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_RevolvingCreditFacilityTotal": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Revolving Credit Facility Total",
        "terseLabel": "Revolving Credit Facility Total"
       }
      }
     },
     "localname": "RevolvingCreditFacilityTotal",
     "nsuri": "http://www.amedisys.com/20210630",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_SafeguardZoneProgramIntegrityContractorMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Safeguard Zone Program Integrity Contractor [Member]",
        "label": "Safeguard Zone Program Integrity Contractor [Member]",
        "terseLabel": "Safeguard Zone Program Integrity Contractor"
       }
      }
     },
     "localname": "SafeguardZoneProgramIntegrityContractorMember",
     "nsuri": "http://www.amedisys.com/20210630",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_ScheduleOfCaresActProviderReliefFundsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of Cares Act Provider Relief Funds",
        "label": "Schedule of Cares Act Provider Relief Funds [Table Text Block]",
        "terseLabel": "Schedule of Cares Act Provider Relief Funds"
       }
      }
     },
     "localname": "ScheduleOfCaresActProviderReliefFundsTableTextBlock",
     "nsuri": "http://www.amedisys.com/20210630",
     "presentation": [
      "http://www.amedisys.com/role/NOVELCORONAVIRUSPANDEMICCOVID19Tables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "amed_ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlockTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of Cash, Cash Equivalents and Restricted Cash Table Text Block",
        "label": "ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlock [Table Text Block]",
        "terseLabel": "Schedule of Cash Cash Equivalents and Restricted Cash"
       }
      }
     },
     "localname": "ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlockTableTextBlock",
     "nsuri": "http://www.amedisys.com/20210630",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "amed_SecondAmendmentToAmendedCreditAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Second Amendment to Amended Credit Agreement",
        "label": "Second Amendment to Amended Credit Agreement [Member]",
        "terseLabel": "Second Amended Credit Agreement"
       }
      }
     },
     "localname": "SecondAmendmentToAmendedCreditAgreementMember",
     "nsuri": "http://www.amedisys.com/20210630",
     "presentation": [
      "http://www.amedisys.com/role/SUBSEQUENTEVENTNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_SecondThresholdOfServicesRequired": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description containing the number of visits related to the second threshold of therapy services required.",
        "label": "Second Threshold Of Services Required",
        "terseLabel": "Second threshold of therapy services required (visits)"
       }
      }
     },
     "localname": "SecondThresholdOfServicesRequired",
     "nsuri": "http://www.amedisys.com/20210630",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "amed_SecuritiesClassActionLawsuitMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities Class Action Lawsuit [Member]",
        "label": "Securities Class Action Lawsuit [Member]",
        "terseLabel": "Securities Class Action Lawsuit [Member]"
       }
      }
     },
     "localname": "SecuritiesClassActionLawsuitMember",
     "nsuri": "http://www.amedisys.com/20210630",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_SecuritiesClassActionLawsuitsettlement": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Charge related to Securities Class Action Lawsuit settlement",
        "label": "Securities Class Action Lawsuit settlement",
        "terseLabel": "Securities Class Action Lawsuit settlement, net"
       }
      }
     },
     "localname": "SecuritiesClassActionLawsuitsettlement",
     "nsuri": "http://www.amedisys.com/20210630",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_ShareRepurchaseLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "[Line Items] for Share Repurchase [Table]",
        "label": "Share Repurchase [Line Items]",
        "terseLabel": "Share Repurchase [Line Items]"
       }
      }
     },
     "localname": "ShareRepurchaseLineItems",
     "nsuri": "http://www.amedisys.com/20210630",
     "presentation": [
      "http://www.amedisys.com/role/SHAREREPURCHASENarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "amed_ShareRepurchaseProgramMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share Repurchase Program",
        "label": "Share Repurchase Program [Member]",
        "terseLabel": "Share Repurchase Program"
       }
      }
     },
     "localname": "ShareRepurchaseProgramMember",
     "nsuri": "http://www.amedisys.com/20210630",
     "presentation": [
      "http://www.amedisys.com/role/SHAREREPURCHASENarrativeDetails",
      "http://www.amedisys.com/role/SUBSEQUENTEVENTNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_ShareRepurchaseTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share Repurchase [Table]",
        "label": "Share Repurchase [Table]",
        "terseLabel": "Share Repurchase [Table]"
       }
      }
     },
     "localname": "ShareRepurchaseTable",
     "nsuri": "http://www.amedisys.com/20210630",
     "presentation": [
      "http://www.amedisys.com/role/SHAREREPURCHASENarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "amed_StockIssuedDuringPeriodSharesFourZeroOneKEmployerMatch": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period to employees as employer's matching contribution to the company's 401(K) plan",
        "label": "Stock Issued During Period Shares Four Zero One K Employer Match",
        "terseLabel": "Issuance of stock - 401(k) plan (shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesFourZeroOneKEmployerMatch",
     "nsuri": "http://www.amedisys.com/20210630",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYStatement"
     ],
     "xbrltype": "sharesItemType"
    },
    "amed_StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued during the period to employees as employer's matching contribution to the company's 401(K) plan",
        "label": "Stock Issued During Period Value Four Zero One K Employer Match",
        "terseLabel": "Issuance of stock - 401(k) plan"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch",
     "nsuri": "http://www.amedisys.com/20210630",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_SurrenderedShares": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares of common stock surrendered by certain employees to satisfy obligations in connection with the vesting of stock. Shares held in Treasury Stock at cost.",
        "label": "Surrendered Shares",
        "negatedLabel": "Surrendered Shares"
       }
      }
     },
     "localname": "SurrenderedShares",
     "nsuri": "http://www.amedisys.com/20210630",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_SwingLineLoanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Swing Line Loan [Member]",
        "label": "Swing Line Loan [Member]",
        "terseLabel": "Swing Line Loan [Member]"
       }
      }
     },
     "localname": "SwingLineLoanMember",
     "nsuri": "http://www.amedisys.com/20210630",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_ThirdThresholdOfTherapyServicesRequired": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description containing the number of visits related to the third threshold of therapy services required.",
        "label": "Third Threshold Of Therapy Services Required",
        "terseLabel": "Third threshold of therapy services required (visits)"
       }
      }
     },
     "localname": "ThirdThresholdOfTherapyServicesRequired",
     "nsuri": "http://www.amedisys.com/20210630",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "amed_TotalCARESActProviderReliefFundsReceived": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total CARES Act Provider Relief Funds Received",
        "label": "Total CARES Act Provider Relief Funds Received",
        "terseLabel": "Total CARES Act Provider Relief Funds Received"
       }
      }
     },
     "localname": "TotalCARESActProviderReliefFundsReceived",
     "nsuri": "http://www.amedisys.com/20210630",
     "presentation": [
      "http://www.amedisys.com/role/NOVELCORONAVIRUSPANDEMICCOVID19Details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_TotalLeverageRatio": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ratio of debt to earnings before interest, taxes, depreciation and amortization.",
        "label": "Total Leverage Ratio",
        "terseLabel": "Consolidated leverage ratio"
       }
      }
     },
     "localname": "TotalLeverageRatio",
     "nsuri": "http://www.amedisys.com/20210630",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "amed_TwoHundredMillionRevolvingCreditFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two Hundred Million Revolving Credit Facility [Member]",
        "label": "Two Hundred Million Revolving Credit Facility [Member]",
        "terseLabel": "200 Million Revolving Credit Facility"
       }
      }
     },
     "localname": "TwoHundredMillionRevolvingCreditFacilityMember",
     "nsuri": "http://www.amedisys.com/20210630",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_TypeOfEquityMethodInvestmentDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of Equity Method Investment [Domain]",
        "label": "Type of Equity Method Investment [Domain]",
        "terseLabel": "Type of Equity Method Investment [Domain]"
       }
      }
     },
     "localname": "TypeOfEquityMethodInvestmentDomain",
     "nsuri": "http://www.amedisys.com/20210630",
     "presentation": [
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_TypeofEquityMethodInvestmentAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of Equity Method Investment [Axis]",
        "label": "Type of Equity Method Investment [Axis]",
        "terseLabel": "Type of Equity Method Investment [Axis]"
       }
      }
     },
     "localname": "TypeofEquityMethodInvestmentAxis",
     "nsuri": "http://www.amedisys.com/20210630",
     "presentation": [
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "amed_UnfavorableMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unfavorable [Member]",
        "terseLabel": "Unfavorable [Member]"
       }
      }
     },
     "localname": "UnfavorableMember",
     "nsuri": "http://www.amedisys.com/20210630",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_UsDepartmentOfJusticeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "US Department of Justice",
        "label": "US Department of Justice [Member]",
        "terseLabel": "US Department of Justice"
       }
      }
     },
     "localname": "UsDepartmentOfJusticeMember",
     "nsuri": "http://www.amedisys.com/20210630",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_VisitingNurseAssociationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Visiting Nurse Association",
        "label": "Visiting Nurse Association [Member]",
        "terseLabel": "Visiting Nurse Association"
       }
      }
     },
     "localname": "VisitingNurseAssociationMember",
     "nsuri": "http://www.amedisys.com/20210630",
     "presentation": [
      "http://www.amedisys.com/role/SUBSEQUENTEVENTNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_WorkersCompensationInsuranceRetentionLimit": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum potential amount of future payments the entity could be required to make related to a specific Workers' Compensation Insurance Claim.",
        "label": "Workers Compensation Insurance Retention Limit",
        "terseLabel": "Workers compensation insurance retention limit"
       }
      }
     },
     "localname": "WorkersCompensationInsuranceRetentionLimit",
     "nsuri": "http://www.amedisys.com/20210630",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_WriteOffOfOtherComprehensiveIncome": {
     "auth_ref": [],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Write off of Other Comprehensive Income",
        "label": "Write off of Other Comprehensive Income",
        "negatedLabel": "Write-off of other comprehensive income"
       }
      }
     },
     "localname": "WriteOffOfOtherComprehensiveIncome",
     "nsuri": "http://www.amedisys.com/20210630",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover page."
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r465"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r466"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Street Name"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Suite"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r467"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r467"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r467"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r468"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r467"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r467"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r467"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r467"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers",
        "terseLabel": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer",
        "terseLabel": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r463"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of each class"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r464"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Name of each exchange on which registered"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "srt_LitigationCaseAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Litigation Case [Axis]",
        "terseLabel": "Litigation Case [Axis]"
       }
      }
     },
     "localname": "LitigationCaseAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_LitigationCaseTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Litigation Case [Domain]",
        "terseLabel": "Litigation Case [Domain]"
       }
      }
     },
     "localname": "LitigationCaseTypeDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MajorCustomersAxis": {
     "auth_ref": [
      "r184",
      "r255",
      "r258",
      "r438"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Axis]",
        "terseLabel": "Customer [Axis]"
       }
      }
     },
     "localname": "MajorCustomersAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPatientAccountsReceivableNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r270",
      "r272",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r435",
      "r439"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum [Member]"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails",
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSFeesandRatesUnderCreditFacilitiesDetails",
      "http://www.amedisys.com/role/SUBSEQUENTEVENTFeesandRatesUnderCreditFacilitiesDetails",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r270",
      "r272",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r435",
      "r439"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum [Member]"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSFeesandRatesUnderCreditFacilitiesDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails",
      "http://www.amedisys.com/role/SUBSEQUENTEVENTFeesandRatesUnderCreditFacilitiesDetails",
      "http://www.amedisys.com/role/SUBSEQUENTEVENTNarrativeDetails",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_NameOfMajorCustomerDomain": {
     "auth_ref": [
      "r184",
      "r255",
      "r258",
      "r438"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Domain]",
        "terseLabel": "Customer [Domain]"
       }
      }
     },
     "localname": "NameOfMajorCustomerDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPatientAccountsReceivableNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_OwnershipAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ownership [Axis]",
        "terseLabel": "Ownership [Axis]"
       }
      }
     },
     "localname": "OwnershipAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSProFormaDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_OwnershipDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ownership [Domain]",
        "terseLabel": "Ownership [Domain]"
       }
      }
     },
     "localname": "OwnershipDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSProFormaDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r180",
      "r255",
      "r256",
      "r384",
      "r434",
      "r436"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r180",
      "r255",
      "r256",
      "r384",
      "r434",
      "r436"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r259",
      "r270",
      "r272",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r435",
      "r439"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Range [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails",
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSFeesandRatesUnderCreditFacilitiesDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails",
      "http://www.amedisys.com/role/SUBSEQUENTEVENTFeesandRatesUnderCreditFacilitiesDetails",
      "http://www.amedisys.com/role/SUBSEQUENTEVENTNarrativeDetails",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r259",
      "r270",
      "r272",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r435",
      "r439"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Range [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails",
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSFeesandRatesUnderCreditFacilitiesDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails",
      "http://www.amedisys.com/role/SUBSEQUENTEVENTFeesandRatesUnderCreditFacilitiesDetails",
      "http://www.amedisys.com/role/SUBSEQUENTEVENTNarrativeDetails",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r181",
      "r182",
      "r255",
      "r257",
      "r437",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]",
        "terseLabel": "Geographical [Domain]"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails",
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails",
      "http://www.amedisys.com/role/SUBSEQUENTEVENTNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r181",
      "r182",
      "r255",
      "r257",
      "r437",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]",
        "terseLabel": "Geographical [Axis]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails",
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails",
      "http://www.amedisys.com/role/SUBSEQUENTEVENTNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "stpr_FL": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "FLORIDA",
        "terseLabel": "Florida"
       }
      }
     },
     "localname": "FL",
     "nsuri": "http://xbrl.sec.gov/stpr/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "stpr_KY": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "KENTUCKY",
        "terseLabel": "KENTUCKY"
       }
      }
     },
     "localname": "KY",
     "nsuri": "http://xbrl.sec.gov/stpr/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "stpr_MA": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "MASSACHUSETTS",
        "terseLabel": "Massachusetts"
       }
      }
     },
     "localname": "MA",
     "nsuri": "http://xbrl.sec.gov/stpr/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "stpr_NC": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "NORTH CAROLINA",
        "terseLabel": "NORTH CAROLINA"
       }
      }
     },
     "localname": "NC",
     "nsuri": "http://xbrl.sec.gov/stpr/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "stpr_NY": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "NEW YORK",
        "terseLabel": "NEW YORK"
       }
      }
     },
     "localname": "NY",
     "nsuri": "http://xbrl.sec.gov/stpr/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SUBSEQUENTEVENTNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "stpr_SC": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "SOUTH CAROLINA",
        "terseLabel": "South Carolina"
       }
      }
     },
     "localname": "SC",
     "nsuri": "http://xbrl.sec.gov/stpr/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "stpr_TN": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "TENNESSEE",
        "terseLabel": "Tennessee [Member]"
       }
      }
     },
     "localname": "TN",
     "nsuri": "http://xbrl.sec.gov/stpr/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "stpr_WA": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "WASHINGTON",
        "terseLabel": "WASHINGTON"
       }
      }
     },
     "localname": "WA",
     "nsuri": "http://xbrl.sec.gov/stpr/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]",
        "terseLabel": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingStandardsUpdate201602Member": {
     "auth_ref": [
      "r358"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounting Standards Update 2016-02 Leases (Topic 842).",
        "label": "Accounting Standards Update 2016-02 [Member]",
        "terseLabel": "Accounting Standards Update 2016-02 [Member]"
       }
      }
     },
     "localname": "AccountingStandardsUpdate201602Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r29"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Due from customers or clients for goods or services that have been delivered or sold.",
        "label": "Accounts Receivable [Member]",
        "terseLabel": "Accounts Receivable"
       }
      }
     },
     "localname": "AccountsReceivableMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPatientAccountsReceivableNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r4",
      "r18",
      "r186",
      "r187"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "terseLabel": "Patient accounts receivable"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails",
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r33"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Accrued expenses"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r26",
      "r223"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "terseLabel": "Property and equipment, accumulated depreciation"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r44",
      "r45",
      "r46",
      "r100",
      "r101",
      "r102",
      "r324",
      "r442",
      "r443"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Income"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYStatement"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife": {
     "auth_ref": [
      "r214"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Acquired Finite-lived Intangible Assets, Weighted Average Useful Life",
        "terseLabel": "Weighted-average amortization period"
       }
      }
     },
     "localname": "AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Cash Flow Elements and Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental Disclosures of Non-Cash Activity:"
       }
      }
     },
     "localname": "AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "auth_ref": [
      "r19"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.",
        "label": "Additional Paid in Capital, Common Stock",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r100",
      "r101",
      "r102",
      "r281",
      "r282",
      "r283"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-in Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYStatement"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": {
     "auth_ref": [
      "r103",
      "r104",
      "r105",
      "r106",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r291",
      "r292",
      "r293",
      "r294",
      "r386",
      "r387",
      "r388",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by amendment to accounting standards.",
        "label": "Accounting Standards Update [Axis]",
        "terseLabel": "Adjustments for New Accounting Pronouncements [Axis]"
       }
      }
     },
     "localname": "AdjustmentsForNewAccountingPronouncementsAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r273",
      "r274",
      "r285",
      "r286"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Non-cash compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net income to net cash provided by operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllOtherSegmentsMember": {
     "auth_ref": [
      "r149",
      "r167",
      "r168",
      "r169",
      "r170",
      "r172"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating segments classified as other. Excludes intersegment elimination and reconciling items.",
        "label": "Other Segments [Member]",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "AllOtherSegmentsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SEGMENTINFORMATIONOperatingIncomeofReportableSegmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AmortizationOfFinancingCostsAndDiscounts": {
     "auth_ref": [
      "r85",
      "r354"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.",
        "label": "Amortization of Debt Issuance Costs and Discounts",
        "terseLabel": "Amortization of deferred debt issuance costs/debt discount"
       }
      }
     },
     "localname": "AmortizationOfFinancingCostsAndDiscounts",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r127"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Anti-dilutive securities (shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESWeightedAverageSharesOutstandingDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AociAttributableToNoncontrollingInterestMember": {
     "auth_ref": [
      "r44",
      "r45",
      "r324"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the noncontrolling interest. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Noncontrolling Interest [Member]",
        "terseLabel": "AOCI Attributable to Noncontrolling Interest"
       }
      }
     },
     "localname": "AociAttributableToNoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYStatement"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r95",
      "r162",
      "r169",
      "r176",
      "r199",
      "r318",
      "r325",
      "r342",
      "r405",
      "r420"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r6",
      "r8",
      "r43",
      "r95",
      "r199",
      "r318",
      "r325",
      "r342"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BaseRateMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum rate investor will accept.",
        "label": "Base Rate [Member]",
        "terseLabel": "Base Rate [Member]"
       }
      }
     },
     "localname": "BaseRateMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSFeesandRatesUnderCreditFacilitiesDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails",
      "http://www.amedisys.com/role/SUBSEQUENTEVENTFeesandRatesUnderCreditFacilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "auth_ref": [
      "r269",
      "r271"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.",
        "label": "Business Acquisition, Acquiree [Domain]",
        "terseLabel": "Business Acquisition, Acquiree [Domain]"
       }
      }
     },
     "localname": "BusinessAcquisitionAcquireeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails",
      "http://www.amedisys.com/role/ACQUISITIONSProFormaDetails",
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails",
      "http://www.amedisys.com/role/NOVELCORONAVIRUSPANDEMICCOVID19Details",
      "http://www.amedisys.com/role/SUBSEQUENTEVENTNarrativeDetails",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESCashandCashEquivalentsDetails",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPatientAccountsReceivableNarrativeDetails",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "auth_ref": [
      "r269",
      "r271",
      "r304",
      "r305"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business combination or series of individually immaterial business combinations.",
        "label": "Business Acquisition [Axis]",
        "terseLabel": "Business Acquisition [Axis]"
       }
      }
     },
     "localname": "BusinessAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails",
      "http://www.amedisys.com/role/ACQUISITIONSProFormaDetails",
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails",
      "http://www.amedisys.com/role/NOVELCORONAVIRUSPANDEMICCOVID19Details",
      "http://www.amedisys.com/role/SUBSEQUENTEVENTNarrativeDetails",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESCashandCashEquivalentsDetails",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPatientAccountsReceivableNarrativeDetails",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Business Acquisition [Line Items]",
        "terseLabel": "Business Acquisition [Line Items]"
       }
      }
     },
     "localname": "BusinessAcquisitionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails",
      "http://www.amedisys.com/role/ACQUISITIONSProFormaDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionNameOfAcquiredEntity": {
     "auth_ref": [
      "r301"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the acquired entity.",
        "label": "Business Acquisition, Name of Acquired Entity",
        "terseLabel": "Business Acquisition, Name of Acquired Entity"
       }
      }
     },
     "localname": "BusinessAcquisitionNameOfAcquiredEntity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic": {
     "auth_ref": [
      "r302",
      "r303"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The pro forma basic net income per share for a period as if the business combination or combinations had been completed at the beginning of a period.",
        "label": "Business Acquisition, Pro Forma Earnings Per Share, Basic",
        "terseLabel": "Basic earnings per share"
       }
      }
     },
     "localname": "BusinessAcquisitionProFormaEarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSProFormaDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted": {
     "auth_ref": [
      "r302",
      "r303"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The pro forma diluted net income per share for a period as if the business combination or combinations had been completed at the beginning of a period.",
        "label": "Business Acquisition, Pro Forma Earnings Per Share, Diluted",
        "terseLabel": "Diluted earnings per share"
       }
      }
     },
     "localname": "BusinessAcquisitionProFormaEarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSProFormaDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_BusinessAcquisitionProFormaInformationTextBlock": {
     "auth_ref": [
      "r302",
      "r303"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of pro forma results of operations for a material business acquisition or series of individually immaterial business acquisitions that are material in the aggregate.",
        "label": "Business Acquisition, Pro Forma Information [Table Text Block]",
        "terseLabel": "Business Acquisition, Pro Forma Information"
       }
      }
     },
     "localname": "BusinessAcquisitionProFormaInformationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss": {
     "auth_ref": [
      "r302",
      "r303"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The pro forma net Income or Loss for the period as if the business combination or combinations had been completed at the beginning of a period.",
        "label": "Business Acquisition, Pro Forma Net Income (Loss)",
        "terseLabel": "Net income"
       }
      }
     },
     "localname": "BusinessAcquisitionsProFormaNetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSProFormaDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessAcquisitionsProFormaRevenue": {
     "auth_ref": [
      "r302",
      "r303"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The pro forma revenue for a period as if the business combination or combinations had been completed at the beginning of the period.",
        "label": "Business Acquisition, Pro Forma Revenue",
        "terseLabel": "Net service revenue"
       }
      }
     },
     "localname": "BusinessAcquisitionsProFormaRevenue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSProFormaDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationConsiderationTransferred1": {
     "auth_ref": [
      "r310",
      "r311",
      "r312"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.",
        "label": "Business Combination, Consideration Transferred",
        "terseLabel": "Total purchase price for acquisition"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationTransferred1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SUBSEQUENTEVENTNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationDisclosureTextBlock": {
     "auth_ref": [
      "r314"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).",
        "label": "Business Combination Disclosure [Text Block]",
        "terseLabel": "ACQUISITIONS"
       }
      }
     },
     "localname": "BusinessCombinationDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessCombinationIntegrationRelatedCosts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Costs incurred to effect a business combination which have been expensed during the period. Such costs could include business integration costs, systems integration and conversion costs, and severance and other employee-related costs.",
        "label": "Business Combination, Integration Related Costs",
        "terseLabel": "Business Combination, Integration Related Costs"
       }
      }
     },
     "localname": "BusinessCombinationIntegrationRelatedCosts",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets": {
     "auth_ref": [
      "r307"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of assets acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets",
        "terseLabel": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables": {
     "auth_ref": [
      "r307"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount due from customers or clients for goods or services, including trade receivables, that have been delivered or sold in the normal course of business, and amounts due from others, including related parties expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer, acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables",
        "terseLabel": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable": {
     "auth_ref": [
      "r307"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities incurred for goods and services received that are used in an entity's business and related party payables, assumed at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable",
        "negatedLabel": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities": {
     "auth_ref": [
      "r307"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences assumed at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities",
        "negatedLabel": "Business Combination Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill": {
     "auth_ref": [
      "r307"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of intangible assets, excluding goodwill, acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill",
        "terseLabel": "Acquisition, other intangibles recorded"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities": {
     "auth_ref": [
      "r307"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities assumed at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities",
        "negatedLabel": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet": {
     "auth_ref": [
      "r306",
      "r307"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net",
        "terseLabel": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt": {
     "auth_ref": [
      "r307"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt due after one year or the normal operating cycle, if longer, assumed at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Long-term Debt",
        "negatedLabel": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Long-term Debt"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther": {
     "auth_ref": [
      "r307"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of other liabilities due after one year or the normal operating cycle, if longer, assumed at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Other",
        "negatedTerseLabel": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Other"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets": {
     "auth_ref": [
      "r307"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of other assets expected to be realized or consumed after one year or the normal operating cycle, if longer, acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets",
        "terseLabel": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment": {
     "auth_ref": [
      "r306",
      "r307"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of property, plant, and equipment recognized as of the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment",
        "terseLabel": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet": {
     "auth_ref": [
      "r307"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net",
        "terseLabel": "Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combinations [Abstract]",
        "terseLabel": "Business Combinations [Abstract]"
       }
      }
     },
     "localname": "BusinessCombinationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationsPolicy": {
     "auth_ref": [
      "r91",
      "r300"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.",
        "label": "Business Combinations Policy [Policy Text Block]",
        "terseLabel": "Business Combinations"
       }
      }
     },
     "localname": "BusinessCombinationsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CapitalLeaseObligationsMember": {
     "auth_ref": [
      "r357"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A borrowing recorded for a lease meeting the criteria for capitalization. A lease is defined as an agreement conveying the right to use property, plant, or equipment (land or depreciable assets) usually for a stated period of time.",
        "label": "Capital Lease Obligations [Member]",
        "terseLabel": "Finance leases [Member]"
       }
      }
     },
     "localname": "CapitalLeaseObligationsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CashAcquiredFromAcquisition": {
     "auth_ref": [
      "r66"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the acquisition of business during the period (for example, cash that was held by the acquired business).",
        "label": "Cash Acquired from Acquisition",
        "terseLabel": "Cash Acquired from Acquisition"
       }
      }
     },
     "localname": "CashAcquiredFromAcquisition",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r3",
      "r24",
      "r87"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESCashandCashEquivalentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": {
     "auth_ref": [
      "r9",
      "r88",
      "r91",
      "r403"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances.  Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.",
        "label": "Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash, Cash Equivalents and Restricted Cash"
       }
      }
     },
     "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r80",
      "r87",
      "r90"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash, cash equivalents and restricted cash at end of period",
        "periodStartLabel": "Cash, cash equivalents and restricted cash at beginning of period",
        "terseLabel": "Cash, Cash Equivalents and Restricted Cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESCashandCashEquivalentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": {
     "auth_ref": [
      "r80",
      "r343"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect",
        "totalLabel": "Net increase in cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r94",
      "r95",
      "r117",
      "r121",
      "r122",
      "r124",
      "r126",
      "r133",
      "r134",
      "r135",
      "r199",
      "r342"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class of Stock [Domain]",
        "terseLabel": "Class of Stock [Domain]"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSProFormaDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r38",
      "r232",
      "r410",
      "r427"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and Contingencies\u2014Note 6"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]",
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r229",
      "r230",
      "r231",
      "r239"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "COMMITMENTS AND CONTINGENCIES"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIES"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r100",
      "r101"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYStatement"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (usd per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, authorized (shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, issued (shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r17",
      "r246"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common stock, outstanding (shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValueOutstanding": {
     "auth_ref": [
      "r17"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of all classes of common stock held by shareholders. May be all or portion of the number of common shares authorized. These shares exclude common shares repurchased by the entity and held as treasury shares.",
        "label": "Common Stock, Value, Outstanding",
        "terseLabel": "Common stock, $0.001 par value, 60,000,000 shares authorized; 37,553,355 and 37,470,212 shares issued; and 32,576,829 and 32,814,278 shares outstanding"
       }
      }
     },
     "localname": "CommonStockValueOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "auth_ref": [
      "r143",
      "r144",
      "r184",
      "r339",
      "r340"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.",
        "label": "Concentration Risk Benchmark [Domain]",
        "terseLabel": "Concentration Risk Benchmark [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskBenchmarkDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPatientAccountsReceivableNarrativeDetails",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "auth_ref": [
      "r143",
      "r144",
      "r184",
      "r339",
      "r340",
      "r452"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by benchmark of concentration risk.",
        "label": "Concentration Risk Benchmark [Axis]",
        "terseLabel": "Concentration Risk Benchmark [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPatientAccountsReceivableNarrativeDetails",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "auth_ref": [
      "r143",
      "r144",
      "r184",
      "r339",
      "r340",
      "r452"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.",
        "label": "Concentration Risk Type [Axis]",
        "terseLabel": "Concentration Risk Type [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPatientAccountsReceivableNarrativeDetails",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Concentration Risk [Line Items]",
        "terseLabel": "Concentration Risk [Line Items]",
        "verboseLabel": "Organization, Consolidation and Presentation of Financial Statements [Line Items]"
       }
      }
     },
     "localname": "ConcentrationRiskLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPatientAccountsReceivableNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "auth_ref": [
      "r143",
      "r144",
      "r184",
      "r339",
      "r340"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.",
        "label": "Concentration Risk, Percentage",
        "terseLabel": "Percent of net services revenue",
        "verboseLabel": "Concentration risk (percent)"
       }
      }
     },
     "localname": "ConcentrationRiskPercentage1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPatientAccountsReceivableNarrativeDetails",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ConcentrationRiskTable": {
     "auth_ref": [
      "r140",
      "r143",
      "r144",
      "r145",
      "r339",
      "r341"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Describes the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.",
        "label": "Concentration Risk [Table]",
        "terseLabel": "Concentration Risk [Table]"
       }
      }
     },
     "localname": "ConcentrationRiskTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPatientAccountsReceivableNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "auth_ref": [
      "r143",
      "r144",
      "r184",
      "r339",
      "r340"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.",
        "label": "Concentration Risk Type [Domain]",
        "terseLabel": "Concentration Risk Type [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPatientAccountsReceivableNarrativeDetails",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "auth_ref": [
      "r91",
      "r320"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.",
        "label": "Consolidation, Policy [Policy Text Block]",
        "terseLabel": "Principles of Consolidation"
       }
      }
     },
     "localname": "ConsolidationPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "auth_ref": [
      "r59",
      "r384"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.",
        "label": "Cost of Goods and Services Sold",
        "terseLabel": "Cost of service, excluding depreciation and amortization"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSold",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.amedisys.com/role/SEGMENTINFORMATIONOperatingIncomeofReportableSegmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostsAndExpenses": {
     "auth_ref": [
      "r57"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 3.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total costs of sales and operating expenses for the period.",
        "label": "Costs and Expenses",
        "terseLabel": "Operating expenses",
        "totalLabel": "Operating expenses"
       }
      }
     },
     "localname": "CostsAndExpenses",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.amedisys.com/role/SEGMENTINFORMATIONOperatingIncomeofReportableSegmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CreditFacilityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Axis]",
        "terseLabel": "Credit Facility [Axis]"
       }
      }
     },
     "localname": "CreditFacilityAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSFeesandRatesUnderCreditFacilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CreditFacilityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Domain]",
        "terseLabel": "Credit Facility [Domain]"
       }
      }
     },
     "localname": "CreditFacilityDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSFeesandRatesUnderCreditFacilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "auth_ref": [
      "r141",
      "r184"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.",
        "label": "Customer Concentration Risk [Member]",
        "terseLabel": "Customer Concentration Risk"
       }
      }
     },
     "localname": "CustomerConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPatientAccountsReceivableNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]",
        "terseLabel": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r245"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Debt Disclosure [Text Block]",
        "terseLabel": "LONG-TERM OBLIGATIONS"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r12",
      "r13",
      "r14",
      "r406",
      "r407",
      "r419"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSFeesandRatesUnderCreditFacilitiesDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtAdditionalInformationDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtDetails",
      "http://www.amedisys.com/role/SUBSEQUENTEVENTFeesandRatesUnderCreditFacilitiesDetails",
      "http://www.amedisys.com/role/SUBSEQUENTEVENTNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument.",
        "label": "Debt Instrument, Basis Spread on Variable Rate",
        "terseLabel": "Basis spread on variable rate"
       }
      }
     },
     "localname": "DebtInstrumentBasisSpreadOnVariableRate1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSFeesandRatesUnderCreditFacilitiesDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails",
      "http://www.amedisys.com/role/SUBSEQUENTEVENTFeesandRatesUnderCreditFacilitiesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentCarryingAmount": {
     "auth_ref": [
      "r14",
      "r243",
      "r407",
      "r419"
     ],
     "calculation": {
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtDetails_1": {
       "order": 1.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.",
        "label": "Long-term Debt, Gross",
        "terseLabel": "Principal amount"
       }
      }
     },
     "localname": "DebtInstrumentCarryingAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentDescriptionOfVariableRateBasis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The reference rate for the variable rate of the debt instrument, such as LIBOR or the US Treasury rate and the maturity of the reference rate used, such as three months or six months LIBOR.",
        "label": "Debt Instrument, Description of Variable Rate Basis",
        "terseLabel": "Description of variable rate basis"
       }
      }
     },
     "localname": "DebtInstrumentDescriptionOfVariableRateBasis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "auth_ref": [
      "r353",
      "r355"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face (par) amount of debt instrument at time of issuance.",
        "label": "Debt Instrument, Face Amount",
        "terseLabel": "Debt instrument, face amount"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtAdditionalInformationDetails",
      "http://www.amedisys.com/role/SUBSEQUENTEVENTNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]",
        "terseLabel": "Debt Instrument [Line Items]"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtAdditionalInformationDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentMaturityDate": {
     "auth_ref": [
      "r35",
      "r334"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date when the debt instrument is scheduled to be fully repaid, in CCYY-MM-DD format.",
        "label": "Debt Instrument, Maturity Date",
        "terseLabel": "Maturity Date"
       }
      }
     },
     "localname": "DebtInstrumentMaturityDate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtAdditionalInformationDetails",
      "http://www.amedisys.com/role/SUBSEQUENTEVENTNarrativeDetails"
     ],
     "xbrltype": "dateItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r36"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]",
        "terseLabel": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSFeesandRatesUnderCreditFacilitiesDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtAdditionalInformationDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtDetails",
      "http://www.amedisys.com/role/SUBSEQUENTEVENTFeesandRatesUnderCreditFacilitiesDetails",
      "http://www.amedisys.com/role/SUBSEQUENTEVENTNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r36",
      "r98",
      "r247",
      "r248",
      "r249",
      "r250",
      "r352",
      "r353",
      "r355",
      "r418"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Schedule of Long-term Debt Instruments [Table]",
        "terseLabel": "Schedule of Long-term Debt Instruments [Table]"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtAdditionalInformationDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtIssuanceCostsLineOfCreditArrangementsGross": {
     "auth_ref": [
      "r356"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before accumulated amortization, of debt issuance costs related to line of credit arrangements. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.",
        "label": "Debt Issuance Costs, Line of Credit Arrangements, Gross",
        "terseLabel": "Deferred debt issuance cost"
       }
      }
     },
     "localname": "DebtIssuanceCostsLineOfCreditArrangementsGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredFinanceCostsNet": {
     "auth_ref": [
      "r28",
      "r354"
     ],
     "calculation": {
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtDetails_1": {
       "order": 2.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.",
        "label": "Debt Issuance Costs, Net",
        "negatedTerseLabel": "Deferred debt issuance costs"
       }
      }
     },
     "localname": "DeferredFinanceCostsNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxAssetsNet": {
     "auth_ref": [
      "r287",
      "r288"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 6.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.",
        "label": "Deferred Income Tax Assets, Net",
        "terseLabel": "Deferred income taxes"
       }
      }
     },
     "localname": "DeferredIncomeTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r85",
      "r96",
      "r290",
      "r296",
      "r297",
      "r298"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Income Tax Expense (Benefit)",
        "terseLabel": "Deferred income taxes"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationAndAmortization": {
     "auth_ref": [
      "r85",
      "r222"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 5.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.",
        "label": "Depreciation, Depletion and Amortization, Nonproduction",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.amedisys.com/role/SEGMENTINFORMATIONOperatingIncomeofReportableSegmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r85",
      "r157"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r53",
      "r107",
      "r108",
      "r109",
      "r110",
      "r111",
      "r115",
      "r117",
      "r124",
      "r125",
      "r126",
      "r130",
      "r131",
      "r415",
      "r430"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Net income attributable to Amedisys, Inc. common stockholders, basic (usd per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareBasicAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Basic [Abstract]",
        "terseLabel": "Basic earnings per common share:"
       }
      }
     },
     "localname": "EarningsPerShareBasicAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r53",
      "r107",
      "r108",
      "r109",
      "r110",
      "r111",
      "r117",
      "r124",
      "r125",
      "r126",
      "r130",
      "r131",
      "r415",
      "r430"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Net income attributable to Amedisys, Inc. common stockholders, diluted (usd per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDilutedAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Diluted [Abstract]",
        "terseLabel": "Diluted earnings per common share:"
       }
      }
     },
     "localname": "EarningsPerShareDilutedAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r91",
      "r127",
      "r129"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Weighted-Average Shares Outstanding"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r33"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Payroll and employee benefits"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.amedisys.com/role/NOVELCORONAVIRUSPANDEMICCOVID19Details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]",
        "terseLabel": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r100",
      "r101",
      "r102",
      "r104",
      "r112",
      "r114",
      "r132",
      "r203",
      "r246",
      "r251",
      "r281",
      "r282",
      "r283",
      "r293",
      "r294",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r442",
      "r443",
      "r444"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYStatement"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityMethodInvestmentAggregateCost": {
     "auth_ref": [
      "r25"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents the aggregate cost of investments accounted for under the equity method of accounting.",
        "label": "Equity Method Investment, Aggregate Cost",
        "terseLabel": "Equity method investment, aggregate cost"
       }
      }
     },
     "localname": "EquityMethodInvestmentAggregateCost",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquityMethodInvestmentDividendsOrDistributions": {
     "auth_ref": [
      "r51",
      "r79",
      "r85",
      "r428"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of distribution received from equity method investee for return on investment, classified as operating activities. Excludes distribution for return of investment, classified as investing activities.",
        "label": "Proceeds from Equity Method Investment, Distribution",
        "terseLabel": "Return on equity method investments"
       }
      }
     },
     "localname": "EquityMethodInvestmentDividendsOrDistributions",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquityMethodInvestments": {
     "auth_ref": [
      "r25",
      "r163",
      "r197"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.",
        "label": "Equity Method Investments",
        "terseLabel": "Equity Method Investments"
       }
      }
     },
     "localname": "EquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquityMethodInvestmentsMember": {
     "auth_ref": [
      "r196"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investment in the stock of an investee which is adjusted for the investor's share of the earnings or losses of the investee after the date of acquisition.",
        "label": "Equity Method Investments [Member]",
        "terseLabel": "Equity Method Investments [Member]"
       }
      }
     },
     "localname": "EquityMethodInvestmentsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/NOVELCORONAVIRUSPANDEMICCOVID19Details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityMethodInvestmentsPolicy": {
     "auth_ref": [
      "r25",
      "r79",
      "r91",
      "r198",
      "r342"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for equity method of accounting for investments and other interests. Investment includes, but is not limited to, unconsolidated subsidiary, corporate joint venture, noncontrolling interest in real estate venture, limited partnership, and limited liability company. Information includes, but is not limited to, ownership percentage, reason equity method is or is not considered appropriate, and accounting policy election for distribution received.",
        "label": "Equity Method Investments [Policy Text Block]",
        "terseLabel": "Investments"
       }
      }
     },
     "localname": "EquityMethodInvestmentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EurodollarMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest rate based on U.S. dollar denominated deposits at foreign banks or foreign branches of U.S. banks.",
        "label": "Eurodollar [Member]",
        "terseLabel": "Eurodollar [Member]"
       }
      }
     },
     "localname": "EurodollarMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSFeesandRatesUnderCreditFacilitiesDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtAdditionalInformationDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtDetails",
      "http://www.amedisys.com/role/SUBSEQUENTEVENTFeesandRatesUnderCreditFacilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ExtraordinaryAndUnusualItemsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unusual or Infrequent Items, or Both [Abstract]"
       }
      }
     },
     "localname": "ExtraordinaryAndUnusualItemsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESFairValueofFinancialInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r331",
      "r332",
      "r333",
      "r336"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value Measurements, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESFairValueofFinancialInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": {
     "auth_ref": [
      "r335"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of asset.",
        "label": "Asset Class [Domain]",
        "terseLabel": "Asset Class [Domain]"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/NOVELCORONAVIRUSPANDEMICCOVID19Details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueByAssetClassAxis": {
     "auth_ref": [
      "r331",
      "r336"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by class of asset.",
        "label": "Asset Class [Axis]",
        "terseLabel": "Asset Class [Axis]"
       }
      }
     },
     "localname": "FairValueByAssetClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/NOVELCORONAVIRUSPANDEMICCOVID19Details"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r268",
      "r332",
      "r374",
      "r375",
      "r376"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESFairValueofFinancialInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r260",
      "r261",
      "r266",
      "r268",
      "r332",
      "r374"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Fair Value, Inputs, Level 1 [Member]"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESFairValueofFinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r260",
      "r261",
      "r266",
      "r268",
      "r332",
      "r375"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Fair Value, Inputs, Level 2 [Member]"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESFairValueofFinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r268",
      "r332",
      "r376"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Fair Value, Inputs, Level 3 [Member]"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESFairValueofFinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r268",
      "r374",
      "r375",
      "r376"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESFairValueofFinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "auth_ref": [
      "r91",
      "r337",
      "r338"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.",
        "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]",
        "terseLabel": "Fair Value of Financial Instruments"
       }
      }
     },
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "auth_ref": [
      "r219"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization",
        "terseLabel": "Intangible assets, accumulated amortization"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r213",
      "r216",
      "r219",
      "r221",
      "r385",
      "r389"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by major type or class of finite-lived intangible assets.",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r213",
      "r218"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.",
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GainLossOnInvestments": {
     "auth_ref": [
      "r62",
      "r85",
      "r195"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 4.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of realized and unrealized gain (loss) on investment.",
        "label": "Gain (Loss) on Investments",
        "terseLabel": "Gain (loss) on equity method investments"
       }
      }
     },
     "localname": "GainLossOnInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainLossOnSaleOfInvestments": {
     "auth_ref": [
      "r85"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net realized gain (loss) on investments sold during the period, not including gains (losses) on securities separately or otherwise categorized as trading, available-for-sale, or held-to-maturity, which, for cash flow reporting, is a component of proceeds from investing activities.",
        "label": "Gain (Loss) on Sale of Investments",
        "negatedLabel": "(Gain) loss on equity method investments"
       }
      }
     },
     "localname": "GainLossOnSaleOfInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainLossOnSaleOfPropertyPlantEquipment": {
     "auth_ref": [
      "r85"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.",
        "label": "Gain (Loss) on Disposition of Property Plant Equipment",
        "negatedLabel": "Loss (gain) on disposal of property and equipment"
       }
      }
     },
     "localname": "GainLossOnSaleOfPropertyPlantEquipment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainOnSaleOfInvestments": {
     "auth_ref": [
      "r55",
      "r56",
      "r85",
      "r412",
      "r431"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the carrying value and the sale price of an investment.  A gain would be recognized when the sale price of the investment is greater than the carrying value of the investment.  This element refers to the Gain included in earnings and not to the cash proceeds of the sale.",
        "label": "Gain on Sale of Investments",
        "terseLabel": "Gain on Sale of Investments"
       }
      }
     },
     "localname": "GainOnSaleOfInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r60"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "terseLabel": "General and administrative expenses"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SEGMENTINFORMATIONOperatingIncomeofReportableSegmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and Administrative Expense [Abstract]",
        "terseLabel": "General and administrative expenses:"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r208",
      "r209",
      "r404"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAcquiredDuringPeriod": {
     "auth_ref": [
      "r210"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination.",
        "label": "Goodwill, Acquired During Period",
        "terseLabel": "Goodwill recorded during period"
       }
      }
     },
     "localname": "GoodwillAcquiredDuringPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions": {
     "auth_ref": [],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of patient service revenue recognized, net of contractual allowances and discounts, less the provision for bad debts related to patient service revenue plus all other revenue.",
        "label": "Health Care Organization, Revenue Net of Patient Service Revenue Provisions",
        "terseLabel": "Net service revenue"
       }
      }
     },
     "localname": "HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails",
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.amedisys.com/role/SEGMENTINFORMATIONOperatingIncomeofReportableSegmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r50",
      "r162",
      "r168",
      "r172",
      "r175",
      "r178",
      "r402",
      "r413",
      "r417",
      "r432"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "Income before income taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromEquityMethodInvestments": {
     "auth_ref": [
      "r51",
      "r85",
      "r159",
      "r197",
      "r411",
      "r428"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 3.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) for proportionate share of equity method investee's income (loss).",
        "label": "Income (Loss) from Equity Method Investments",
        "negatedLabel": "Equity in earnings from equity method investments",
        "terseLabel": "Equity in earnings from equity method investments"
       }
      }
     },
     "localname": "IncomeLossFromEquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r225"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSProFormaDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSProFormaDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r96",
      "r113",
      "r114",
      "r160",
      "r289",
      "r295",
      "r299",
      "r433"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "negatedLabel": "Income tax expense"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxesPaidNet": {
     "auth_ref": [
      "r89"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.",
        "label": "Income Taxes Paid, Net",
        "terseLabel": "Cash paid for income taxes, net of refunds received"
       }
      }
     },
     "localname": "IncomeTaxesPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r84"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 15.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r84"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Patient accounts receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "auth_ref": [
      "r84"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 16.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.",
        "label": "Increase (Decrease) in Accrued Liabilities",
        "terseLabel": "Accrued expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities, net of impact of acquisitions:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 17.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in noncurrent operating liabilities classified as other.",
        "label": "Increase (Decrease) in Other Noncurrent Liabilities",
        "terseLabel": "Other long-term obligations"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherNoncurrentLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingAssets": {
     "auth_ref": [
      "r84"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating assets classified as other.",
        "label": "Increase (Decrease) in Other Operating Assets",
        "negatedLabel": "Other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r84"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Other current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": {
     "auth_ref": [
      "r118",
      "r119",
      "r120",
      "r126"
     ],
     "calculation": {
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESWeightedAverageSharesOutstandingDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.",
        "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements",
        "terseLabel": "Stock options (shares)"
       }
      }
     },
     "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESWeightedAverageSharesOutstandingDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r215",
      "r220"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type or class of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.",
        "label": "Indefinite-lived Intangible Assets [Axis]",
        "terseLabel": "Indefinite-lived Intangible Assets [Axis]"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r215",
      "r220"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of indefinite-lived intangible asset (for example, trade names, etc. but not all-inclusive), excluding goodwill. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company.",
        "label": "Indefinite-lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Indefinite-lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "auth_ref": [
      "r212",
      "r217"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.",
        "label": "Intangible Assets, Net (Excluding Goodwill)",
        "terseLabel": "Intangible assets, net of accumulated amortization of $15,842 and $22,973"
       }
      }
     },
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r49",
      "r156",
      "r351",
      "r354",
      "r416"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "negatedLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r77",
      "r81",
      "r89"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "terseLabel": "Cash paid for interest"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentIncomeInterestAndDividend": {
     "auth_ref": [
      "r61"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income and dividend income on nonoperating securities.",
        "label": "Investment Income, Interest and Dividend",
        "terseLabel": "Interest income"
       }
      }
     },
     "localname": "InvestmentIncomeInterestAndDividend",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LaborAndRelatedExpense": {
     "auth_ref": [
      "r54"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for salary, wage, profit sharing; incentive and equity-based compensation; and other employee benefit.",
        "label": "Labor and Related Expense",
        "terseLabel": "Salaries and benefits"
       }
      }
     },
     "localname": "LaborAndRelatedExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LetterOfCreditMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A document typically issued by a financial institution which acts as a guarantee of payment to a beneficiary, or as the source of payment for a specific transaction (for example, wiring funds to a foreign exporter if and when specified merchandise is accepted pursuant to the terms of the letter of credit).",
        "label": "Letter of Credit [Member]",
        "terseLabel": "Letter of Credit [Member]"
       }
      }
     },
     "localname": "LetterOfCreditMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LettersOfCreditOutstandingAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount of the contingent obligation under letters of credit outstanding as of the reporting date.",
        "label": "Letters of Credit Outstanding, Amount",
        "terseLabel": "Outstanding letters of credit"
       }
      }
     },
     "localname": "LettersOfCreditOutstandingAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r32",
      "r95",
      "r170",
      "r199",
      "r319",
      "r325",
      "r326",
      "r342"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r23",
      "r95",
      "r199",
      "r342",
      "r409",
      "r425"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "LIABILITIES AND EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r34",
      "r95",
      "r199",
      "r319",
      "r325",
      "r326",
      "r342"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditFacilityAxis": {
     "auth_ref": [
      "r30",
      "r98"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by name of lender, which may be a single entity (for example, but not limited to, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit.",
        "label": "Lender Name [Axis]",
        "terseLabel": "Lender Name [Axis]"
       }
      }
     },
     "localname": "LineOfCreditFacilityAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSFeesandRatesUnderCreditFacilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditFacilityCommitmentFeePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The fee, expressed as a percentage of the line of credit facility, for the line of credit facility regardless of whether the facility has been used.",
        "label": "Line of Credit Facility, Commitment Fee Percentage",
        "terseLabel": "Commitment fee percentage"
       }
      }
     },
     "localname": "LineOfCreditFacilityCommitmentFeePercentage",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSFeesandRatesUnderCreditFacilitiesDetails",
      "http://www.amedisys.com/role/SUBSEQUENTEVENTFeesandRatesUnderCreditFacilitiesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_LineOfCreditFacilityLenderDomain": {
     "auth_ref": [
      "r30"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the lender, which may be a single entity (for example, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit, including a letter of credit facility.",
        "label": "Line of Credit Facility, Lender [Domain]",
        "terseLabel": "Line of Credit Facility, Lender [Domain]"
       }
      }
     },
     "localname": "LineOfCreditFacilityLenderDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSFeesandRatesUnderCreditFacilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LineOfCreditFacilityLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Line of Credit Facility [Line Items]",
        "terseLabel": "Line of Credit Facility [Line Items]"
       }
      }
     },
     "localname": "LineOfCreditFacilityLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSFeesandRatesUnderCreditFacilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": {
     "auth_ref": [
      "r30"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.",
        "label": "Line of Credit Facility, Maximum Borrowing Capacity",
        "terseLabel": "Credit facility, maximum borrowing capacity"
       }
      }
     },
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails",
      "http://www.amedisys.com/role/SUBSEQUENTEVENTNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity": {
     "auth_ref": [
      "r30"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of borrowing capacity currently available under the credit facility (current borrowing capacity less the amount of borrowings outstanding).",
        "label": "Line of Credit Facility, Remaining Borrowing Capacity",
        "terseLabel": "Remaining availability under revolving credit facility"
       }
      }
     },
     "localname": "LineOfCreditFacilityRemainingBorrowingCapacity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditFacilityTable": {
     "auth_ref": [
      "r30",
      "r98"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to short-term or long-term contractual arrangements with lenders, including letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line.",
        "label": "Line of Credit Facility [Table]",
        "terseLabel": "Line of Credit Facility [Table]"
       }
      }
     },
     "localname": "LineOfCreditFacilityTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSFeesandRatesUnderCreditFacilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A contractual arrangement with a lender under which borrowings can be made up to a specific amount at any point in time, and under which borrowings outstanding may be either short-term or long-term, depending upon the particulars.",
        "label": "Line of Credit [Member]",
        "terseLabel": "Line of Credit [Member]"
       }
      }
     },
     "localname": "LineOfCreditMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LoansPayableMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Borrowing supported by a written promise to pay an obligation.",
        "label": "Loans Payable [Member]",
        "terseLabel": "Term Loan [Member]"
       }
      }
     },
     "localname": "LoansPayableMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtAdditionalInformationDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LongTermDebt": {
     "auth_ref": [
      "r14",
      "r244",
      "r407",
      "r421"
     ],
     "calculation": {
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt",
        "totalLabel": "Long-term obligations, including current portion"
       }
      }
     },
     "localname": "LongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtAndCapitalLeaseObligations": {
     "auth_ref": [
      "r14"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt and lease obligation, classified as noncurrent.",
        "label": "Long-term Debt and Lease Obligation",
        "terseLabel": "Long-term obligations, less current portion"
       }
      }
     },
     "localname": "LongTermDebtAndCapitalLeaseObligations",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent": {
     "auth_ref": [
      "r33"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt and lease obligation, classified as current.",
        "label": "Long-term Debt and Lease Obligation, Current",
        "terseLabel": "Current portion of long-term obligations"
       }
      }
     },
     "localname": "LongTermDebtAndCapitalLeaseObligationsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtCurrent": {
     "auth_ref": [
      "r31"
     ],
     "calculation": {
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt, Current Maturities",
        "negatedTerseLabel": "Current portion of long-term obligations"
       }
      }
     },
     "localname": "LongTermDebtCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtFairValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The fair value amount of long-term debt whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission.",
        "label": "Long-term Debt, Fair Value",
        "terseLabel": "Long-term Debt, Fair Value"
       }
      }
     },
     "localname": "LongTermDebtFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESFairValueofFinancialInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtNoncurrent": {
     "auth_ref": [
      "r36"
     ],
     "calculation": {
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt, Excluding Current Maturities",
        "terseLabel": "Long-term obligations, less current portion"
       }
      }
     },
     "localname": "LongTermDebtNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtWeightedAverageInterestRateOverTime": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average interest rate of long-term debt outstanding calculated over time.",
        "label": "Long-term Debt, Weighted Average Interest Rate, over Time",
        "terseLabel": "Weighted average interest rate (percent)"
       }
      }
     },
     "localname": "LongTermDebtWeightedAverageInterestRateOverTime",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "auth_ref": [
      "r36"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-term debt.",
        "label": "Long-term Debt, Type [Axis]",
        "terseLabel": "Long-term Debt, Type [Axis]"
       }
      }
     },
     "localname": "LongtermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtAdditionalInformationDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtDetails",
      "http://www.amedisys.com/role/SUBSEQUENTEVENTNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "auth_ref": [
      "r36",
      "r242"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Long-term Debt, Type [Domain]",
        "terseLabel": "Long-term Debt, Type [Domain]"
       }
      }
     },
     "localname": "LongtermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtAdditionalInformationDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtDetails",
      "http://www.amedisys.com/role/SUBSEQUENTEVENTNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LossContingenciesByNatureOfContingencyAxis": {
     "auth_ref": [
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r240",
      "r241"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur.",
        "label": "Loss Contingency Nature [Axis]",
        "terseLabel": "Loss Contingency Nature [Axis]"
       }
      }
     },
     "localname": "LossContingenciesByNatureOfContingencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingenciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Loss Contingencies [Line Items]",
        "terseLabel": "Loss Contingencies [Line Items]"
       }
      }
     },
     "localname": "LossContingenciesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingenciesTable": {
     "auth_ref": [
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r240",
      "r241"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations.",
        "label": "Loss Contingencies [Table]",
        "terseLabel": "Loss Contingencies [Table]"
       }
      }
     },
     "localname": "LossContingenciesTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingencyAccrualAtCarryingValue": {
     "auth_ref": [
      "r232"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of loss contingency liability.",
        "label": "Loss Contingency Accrual",
        "terseLabel": "Loss contingency accrual"
       }
      }
     },
     "localname": "LossContingencyAccrualAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LossContingencyAccrualCarryingValuePeriodIncreaseDecrease": {
     "auth_ref": [
      "r232"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in loss contingency liability.",
        "label": "Loss Contingency Accrual, Period Increase (Decrease)",
        "terseLabel": "Loss contingency accrual, period increase (decrease)"
       }
      }
     },
     "localname": "LossContingencyAccrualCarryingValuePeriodIncreaseDecrease",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LossContingencyNatureDomain": {
     "auth_ref": [
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r240",
      "r241"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur. Resolution of the uncertainty may confirm the incurrence of a loss or impairment of an asset or the incurrence of a liability.",
        "label": "Loss Contingency, Nature [Domain]",
        "terseLabel": "Loss Contingency, Nature [Domain]"
       }
      }
     },
     "localname": "LossContingencyNatureDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LossContingencyReceivableCurrent": {
     "auth_ref": [
      "r241"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of receivable related to a loss contingency accrual that is expected to be collected within one year or the normal operating cycle, if longer. For example, an insurance recovery receivable.",
        "label": "Loss Contingency, Receivable, Current",
        "terseLabel": "Settlement amount to be paid by company's insurance carriers"
       }
      }
     },
     "localname": "LossContingencyReceivableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LossContingencyReceivableNoncurrent": {
     "auth_ref": [
      "r241"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of receivable related to a loss contingency accrual that is expected to be collected after one year or beyond the normal operating cycle, if longer. For example, an insurance recovery receivable.",
        "label": "Loss Contingency, Receivable, Noncurrent",
        "terseLabel": "Indemnity receivable"
       }
      }
     },
     "localname": "LossContingencyReceivableNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MinorityInterest": {
     "auth_ref": [
      "r41",
      "r95",
      "r199",
      "r342",
      "r408",
      "r424"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).",
        "label": "Stockholders' Equity Attributable to Noncontrolling Interest",
        "terseLabel": "Noncontrolling interests"
       }
      }
     },
     "localname": "MinorityInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders": {
     "auth_ref": [
      "r251"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Decrease in noncontrolling interest balance from payment of dividends or other distributions by the non-wholly owned subsidiary or partially owned entity, included in the consolidation of the parent entity, to the noncontrolling interest holders.",
        "label": "Noncontrolling Interest, Decrease from Distributions to Noncontrolling Interest Holders",
        "negatedLabel": "Noncontrolling interest distribution"
       }
      }
     },
     "localname": "MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r80"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash (used in) provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash Flows from Financing Activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r80"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash Flows from Investing Activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r80",
      "r83",
      "r86"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash provided by operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Cash Flows from Operating Activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r1",
      "r47",
      "r48",
      "r52",
      "r86",
      "r95",
      "r103",
      "r107",
      "r108",
      "r109",
      "r110",
      "r113",
      "r114",
      "r123",
      "r162",
      "r168",
      "r172",
      "r175",
      "r178",
      "r199",
      "r342",
      "r414",
      "r429"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "totalLabel": "Net income attributable to Amedisys, Inc."
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r47",
      "r48",
      "r113",
      "r114",
      "r322",
      "r328"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest.",
        "label": "Net Income (Loss) Attributable to Noncontrolling Interest",
        "negatedTerseLabel": "Net income attributable to noncontrolling interests"
       }
      }
     },
     "localname": "NetIncomeLossAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recent Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NoncompeteAgreementsMember": {
     "auth_ref": [
      "r309"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agreement in which one party agrees not to pursue a similar trade in competition with another party.",
        "label": "Noncompete Agreements [Member]",
        "terseLabel": "Noncompete Agreements [Member]"
       }
      }
     },
     "localname": "NoncompeteAgreementsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NoncontrollingInterestMember": {
     "auth_ref": [
      "r100",
      "r101",
      "r102",
      "r251",
      "r315"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest.",
        "label": "Noncontrolling Interest [Member]",
        "terseLabel": "Noncontrolling Interests"
       }
      }
     },
     "localname": "NoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYStatement"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r63"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "totalLabel": "Total other income (expense), net"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonoperating Income (Expense) [Abstract]",
        "terseLabel": "Other income (expense):"
       }
      }
     },
     "localname": "NonoperatingIncomeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NumberOfBusinessesAcquired": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of businesses acquired by the entity during the period.",
        "label": "Number of Businesses Acquired",
        "terseLabel": "Acquisition, number of care centers acquired"
       }
      }
     },
     "localname": "NumberOfBusinessesAcquired",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails",
      "http://www.amedisys.com/role/SUBSEQUENTEVENTNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_NumberOfReportableSegments": {
     "auth_ref": [
      "r150"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.",
        "label": "Number of Reportable Segments",
        "terseLabel": "Number of reportable business segments"
       }
      }
     },
     "localname": "NumberOfReportableSegments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SEGMENTINFORMATIONNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_NumberOfStatesInWhichEntityOperates": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of states the entity operates in as of the balance sheet date.",
        "label": "Number of States in which Entity Operates",
        "terseLabel": "Number of states with facilities"
       }
      }
     },
     "localname": "NumberOfStatesInWhichEntityOperates",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OffMarketFavorableLeaseMember": {
     "auth_ref": [
      "r27"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifiable intangible asset established upon acquisition based on a favorable difference between the terms of an acquired lease and the current market terms for that lease.",
        "label": "Off-Market Favorable Lease [Member]",
        "terseLabel": "Favorable Lease Contract [Member]"
       }
      }
     },
     "localname": "OffMarketFavorableLeaseMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OffMarketLeaseUnfavorable": {
     "auth_ref": [
      "r37"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents a liability associated with the acquisition of an off-market lease when the terms of the lease are unfavorable to the market terms for the lease at the date of acquisition.",
        "label": "Off-market Lease, Unfavorable",
        "terseLabel": "Off-market Lease, Unfavorable"
       }
      }
     },
     "localname": "OffMarketLeaseUnfavorable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r162",
      "r168",
      "r172",
      "r175",
      "r178"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "terseLabel": "Operating income (loss)",
        "totalLabel": "Operating income",
        "verboseLabel": "Operating Income (Loss)"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails",
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.amedisys.com/role/SEGMENTINFORMATIONOperatingIncomeofReportableSegmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r360"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 6.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Current portion of operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r360"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Operating lease liabilities, less current portion"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r359"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating lease right of use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "auth_ref": [
      "r2",
      "r330"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "terseLabel": "NATURE OF OPERATIONS, CONSOLIDATION AND PRESENTATION OF FINANCIAL STATEMENTS"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAssetsCurrent": {
     "auth_ref": [
      "r42"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current assets classified as other.",
        "label": "Other Assets, Current",
        "terseLabel": "Other current assets"
       }
      }
     },
     "localname": "OtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r28"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 7.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r60"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 4.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of general and administrative expense classified as other.",
        "label": "Other General and Administrative Expense",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r37"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other long-term obligations"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.amedisys.com/role/NOVELCORONAVIRUSPANDEMICCOVID19Details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r64"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 5.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "terseLabel": "Miscellaneous, net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherOperatingIncome": {
     "auth_ref": [
      "r58"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount of other operating income, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operation.",
        "label": "Other Operating Income",
        "terseLabel": "Other operating income"
       }
      }
     },
     "localname": "OtherOperatingIncome",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.amedisys.com/role/SEGMENTINFORMATIONOperatingIncomeofReportableSegmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForLegalSettlements": {
     "auth_ref": [
      "r82"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid for the settlement of litigation or for other legal issues during the period.",
        "label": "Payments for Legal Settlements",
        "terseLabel": "Payments for legal settlements"
       }
      }
     },
     "localname": "PaymentsForLegalSettlements",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForRepurchaseOfCommonStock": {
     "auth_ref": [
      "r74"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow to reacquire common stock during the period.",
        "label": "Payments for Repurchase of Common Stock",
        "negatedLabel": "Purchase of company stock",
        "terseLabel": "Purchase of company stock"
       }
      }
     },
     "localname": "PaymentsForRepurchaseOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.amedisys.com/role/SHAREREPURCHASENarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfFinancingCosts": {
     "auth_ref": [
      "r76"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for loan and debt issuance costs.",
        "label": "Payments of Financing Costs",
        "terseLabel": "Debt issuance costs"
       }
      }
     },
     "localname": "PaymentsOfFinancingCosts",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "auth_ref": [
      "r74"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.",
        "label": "Payment, Tax Withholding, Share-based Payment Arrangement",
        "negatedLabel": "Shares withheld to pay taxes on non-cash compensation"
       }
      }
     },
     "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireBusinessesGross": {
     "auth_ref": [
      "r69",
      "r313"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.",
        "label": "Payments to Acquire Businesses, Gross",
        "terseLabel": "Payments to acquire business"
       }
      }
     },
     "localname": "PaymentsToAcquireBusinessesGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails",
      "http://www.amedisys.com/role/SUBSEQUENTEVENTNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": {
     "auth_ref": [
      "r69"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.",
        "label": "Payments to Acquire Businesses, Net of Cash Acquired",
        "negatedLabel": "Acquisitions of businesses, net of cash acquired"
       }
      }
     },
     "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireInvestments": {
     "auth_ref": [
      "r71"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the purchase of all investments (debt, security, other) during the period.",
        "label": "Payments to Acquire Investments",
        "negatedTerseLabel": "Investments in equity method investees"
       }
      }
     },
     "localname": "PaymentsToAcquireInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r70"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value (usd per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, authorized (shares)"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock, issued (shares)"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock, outstanding (shares)"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValueOutstanding": {
     "auth_ref": [
      "r16"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by shareholders, which is net of related treasury stock. May be all or a portion of the number of preferred shares authorized. These shares represent the ownership interest of the preferred shareholders.",
        "label": "Preferred Stock, Value, Outstanding",
        "terseLabel": "Preferred stock, $0.001 par value, 5,000,000 shares authorized; none issued or outstanding"
       }
      }
     },
     "localname": "PreferredStockValueOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseCurrent": {
     "auth_ref": [
      "r5",
      "r7",
      "r206",
      "r207"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense, Current",
        "terseLabel": "Prepaid expenses"
       }
      }
     },
     "localname": "PrepaidExpenseCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfEquityMethodInvestments": {
     "auth_ref": [
      "r66"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the sale of equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence.",
        "label": "Proceeds from Sale of Equity Method Investments",
        "terseLabel": "Proceeds from sale of equity method investment"
       }
      }
     },
     "localname": "ProceedsFromSaleOfEquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment": {
     "auth_ref": [
      "r67"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.",
        "label": "Proceeds from Sale of Property, Plant, and Equipment",
        "terseLabel": "Proceeds from sale of property and equipment"
       }
      }
     },
     "localname": "ProceedsFromSaleOfPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfRestrictedInvestments": {
     "auth_ref": [
      "r68"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the sale of investments that are pledged or subject to withdrawal restrictions during the period.",
        "label": "Proceeds from Sale of Restricted Investments",
        "terseLabel": "Proceeds from sale of deferred compensation plan assets"
       }
      }
     },
     "localname": "ProceedsFromSaleOfRestrictedInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromShortTermDebt": {
     "auth_ref": [
      "r73"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from a borrowing having initial term of repayment within one year or the normal operating cycle, if longer.",
        "label": "Proceeds from Short-term Debt",
        "terseLabel": "Proceeds from borrowings under revolving line of credit"
       }
      }
     },
     "localname": "ProceedsFromShortTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r72",
      "r276"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds from Stock Options Exercised",
        "terseLabel": "Proceeds from issuance of stock upon exercise of stock options"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockPlans": {
     "auth_ref": [
      "r72"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from the stock plan during the period.",
        "label": "Proceeds from Stock Plans",
        "terseLabel": "Proceeds from issuance of stock to employee stock purchase plan"
       }
      }
     },
     "localname": "ProceedsFromStockPlans",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProductConcentrationRiskMember": {
     "auth_ref": [
      "r142"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the percentage that revenues during the period from a specified product are to a specified benchmark, such as total net revenues, segment revenues or product line revenues. May also reflect the percentage contribution the product made to operating results. Risk is materially adverse effects of a loss of sales of a significant product or line of products, which could occur upon loss of rights to sell, distribute or license others; loss of patent or copyright protection; or technological obsolescence.",
        "label": "Product Concentration Risk [Member]",
        "terseLabel": "Product Concentration Risk"
       }
      }
     },
     "localname": "ProductConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r1",
      "r47",
      "r48",
      "r78",
      "r95",
      "r103",
      "r113",
      "r114",
      "r162",
      "r168",
      "r172",
      "r175",
      "r178",
      "r199",
      "r317",
      "r321",
      "r323",
      "r328",
      "r329",
      "r342",
      "r417"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net income",
        "totalLabel": "Net income"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r10",
      "r11",
      "r224",
      "r426"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net of accumulated depreciation of $98,552 and $95,024"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyDomain": {
     "auth_ref": [
      "r267",
      "r365",
      "r366"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Domain]",
        "terseLabel": "Related Party [Domain]"
       }
      }
     },
     "localname": "RelatedPartyDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/RELATEDPARTYTRANSACTIONSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionAmountsOfTransaction": {
     "auth_ref": [
      "r365",
      "r368"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transactions with related party during the financial reporting period.",
        "label": "Related Party Transaction, Amounts of Transaction",
        "terseLabel": "Related Party Transaction, Amounts of Transaction"
       }
      }
     },
     "localname": "RelatedPartyTransactionAmountsOfTransaction",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/RELATEDPARTYTRANSACTIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyTransactionAxis": {
     "auth_ref": [
      "r267",
      "r365",
      "r366",
      "r368"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party transaction.",
        "label": "Related Party Transaction [Axis]",
        "terseLabel": "Related Party Transaction [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/RELATEDPARTYTRANSACTIONSNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionDomain": {
     "auth_ref": [
      "r267"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Transaction between related party.",
        "label": "Related Party Transaction [Domain]",
        "terseLabel": "Related Party Transaction [Domain]"
       }
      }
     },
     "localname": "RelatedPartyTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/RELATEDPARTYTRANSACTIONSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Related Party Transaction [Line Items]",
        "terseLabel": "Related Party Transaction [Line Items]"
       }
      }
     },
     "localname": "RelatedPartyTransactionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/RELATEDPARTYTRANSACTIONSNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Abstract]",
        "terseLabel": "Related Party Transactions [Abstract]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "auth_ref": [
      "r267",
      "r365",
      "r368",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Axis]",
        "terseLabel": "Related Party [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/RELATEDPARTYTRANSACTIONSNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "auth_ref": [
      "r363",
      "r364",
      "r366",
      "r369",
      "r370"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "terseLabel": "RELATED PARTY TRANSACTIONS"
       }
      }
     },
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/RELATEDPARTYTRANSACTIONSRELATEDPARTYTRANSACTIONS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RepaymentsOfLongTermDebt": {
     "auth_ref": [
      "r75"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.",
        "label": "Repayments of Long-term Debt",
        "negatedLabel": "Principal payments of long-term obligations"
       }
      }
     },
     "localname": "RepaymentsOfLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RepaymentsOfShortTermDebt": {
     "auth_ref": [
      "r75"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for a borrowing having initial term of repayment within one year or the normal operating cycle, if longer.",
        "label": "Repayments of Short-term Debt",
        "negatedLabel": "Repayments of borrowings under revolving line of credit"
       }
      }
     },
     "localname": "RepaymentsOfShortTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCash": {
     "auth_ref": [
      "r90",
      "r403",
      "r422"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash",
        "terseLabel": "Restricted cash"
       }
      }
     },
     "localname": "RestrictedCash",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESCashandCashEquivalentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis": {
     "auth_ref": [
      "r24"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by category of cash or cash equivalent items which are restricted as to withdrawal or usage.",
        "label": "Restricted Cash and Cash Equivalents [Axis]",
        "terseLabel": "Restricted Cash and Cash Equivalents [Axis]"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESCashandCashEquivalentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents [Domain]",
        "terseLabel": "Cash and Cash Equivalents [Domain]"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESCashandCashEquivalentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Restricted Cash and Cash Equivalents Items [Line Items]",
        "terseLabel": "Restricted Cash and Cash Equivalents Items [Line Items]"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsItemsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESCashandCashEquivalentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r20",
      "r251",
      "r284",
      "r423",
      "r446",
      "r451"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Retained earnings"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r100",
      "r101",
      "r102",
      "r104",
      "r112",
      "r114",
      "r203",
      "r281",
      "r282",
      "r283",
      "r293",
      "r294",
      "r442",
      "r444"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Retained Earnings"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYStatement"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerMember": {
     "auth_ref": [
      "r143",
      "r184"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue from satisfaction of performance obligation by transferring promised product and service to customer, when it serves as benchmark in concentration of risk calculation.",
        "label": "Revenue from Contract with Customer Benchmark [Member]",
        "terseLabel": "Revenue from Contract with Customer [Member]"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueRecognitionAndDeferredRevenueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue Recognition and Deferred Revenue [Abstract]",
        "terseLabel": "Revenue Recognition and Deferred Revenue [Abstract]"
       }
      }
     },
     "localname": "RevenueRecognitionAndDeferredRevenueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Revenue Recognition, Multiple-deliverable Arrangements [Line Items]",
        "terseLabel": "Revenue Recognition, Multiple-deliverable Arrangements [Line Items]"
       }
      }
     },
     "localname": "RevenueRecognitionMultipleDeliverableArrangementsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenuebyPayorClassDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summarization of information required and determined to be disclosed concerning the recognition of revenue arrangements under which the entity does or will perform multiple revenue-generating activities, categorized by type of arrangement, including certain revenue arrangements that include software elements. This item does not include multiple-deliverable arrangements for industries that prepare disclosures under specific requirements (for instance, construction-type and production-type contracts) otherwise provided for in the taxonomy.",
        "label": "Revenue Recognition, Multiple-deliverable Arrangements [Table]",
        "terseLabel": "Revenue Recognition, Multiple-deliverable Arrangements [Table]"
       }
      }
     },
     "localname": "RevenueRecognitionMultipleDeliverableArrangementsTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueRecognitionPolicyTextBlock": {
     "auth_ref": [
      "r92",
      "r93"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.",
        "label": "Revenue [Policy Text Block]",
        "terseLabel": "Revenue Recognition"
       }
      }
     },
     "localname": "RevenueRecognitionPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevolvingCreditFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount.",
        "label": "Revolving Credit Facility [Member]",
        "terseLabel": "Revolving Credit Facility [Member]"
       }
      }
     },
     "localname": "RevolvingCreditFacilityMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtAdditionalInformationDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability": {
     "auth_ref": [
      "r361",
      "r362"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for finance lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Finance Lease Liability",
        "terseLabel": "Right of use assets obtained in exchange for finance lease liabilities"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r361",
      "r362"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "Right of use assets obtained in exchange for operating lease liabilities"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": {
     "auth_ref": [
      "r304",
      "r305"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.",
        "label": "Schedule of Business Acquisitions, by Acquisition [Table]",
        "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]"
       }
      }
     },
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails",
      "http://www.amedisys.com/role/ACQUISITIONSProFormaDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock": {
     "auth_ref": [
      "r304",
      "r305"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of a material business combination completed during the period, including background, timing, and recognized assets and liabilities. This table  does not include leveraged buyouts.",
        "label": "Schedule of Business Acquisitions, by Acquisition [Table Text Block]",
        "terseLabel": "Schedule of Business Acquisitions"
       }
      }
     },
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDebtInstrumentsTextBlock": {
     "auth_ref": [
      "r36",
      "r98",
      "r247",
      "r248",
      "r249",
      "r250",
      "r352",
      "r353",
      "r355",
      "r418"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.",
        "label": "Schedule of Long-term Debt Instruments [Table Text Block]",
        "terseLabel": "Schedule of Long-Term Debt"
       }
      }
     },
     "localname": "ScheduleOfDebtInstrumentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSLONGTERMOBLIGATIONSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock": {
     "auth_ref": [
      "r30",
      "r98"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of short-term or long-term contractual arrangements with lenders, including letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line.",
        "label": "Schedule of Line of Credit Facilities [Table Text Block]",
        "terseLabel": "Schedule of Commitment Fee Under Credit Facilities"
       }
      }
     },
     "localname": "ScheduleOfLineOfCreditFacilitiesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSLONGTERMOBLIGATIONSTables",
      "http://www.amedisys.com/role/SUBSEQUENTEVENTTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "auth_ref": [
      "r97",
      "r367",
      "r368"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Schedule of Related Party Transactions, by Related Party [Table]",
        "terseLabel": "Schedule of Related Party Transactions, by Related Party [Table]"
       }
      }
     },
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/RELATEDPARTYTRANSACTIONSNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable": {
     "auth_ref": [
      "r9",
      "r90",
      "r403",
      "r422"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about cash and cash equivalents restricted as to withdrawal or usage.",
        "label": "Restrictions on Cash and Cash Equivalents [Table]",
        "terseLabel": "Restrictions on Cash and Cash Equivalents [Table]"
       }
      }
     },
     "localname": "ScheduleOfRestrictedCashAndCashEquivalentsTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESCashandCashEquivalentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of the major payor source of revenue for health care organizations.",
        "label": "Schedule of Revenue Sources, Health Care Organization [Table]",
        "terseLabel": "Schedule of Revenue Sources, Health Care Organization [Table]"
       }
      }
     },
     "localname": "ScheduleOfRevenueSourcesHealthCareOrganizationTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenuebyPayorClassDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of patient service revenue (net of contractual allowances and discounts), by major payor source of revenue for health care organizations.",
        "label": "Schedule of Revenue Sources, Health Care Organization [Table Text Block]",
        "terseLabel": "Schedule of Revenue by Payor Class"
       }
      }
     },
     "localname": "ScheduleOfRevenueSourcesHealthCareOrganizationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": {
     "auth_ref": [
      "r162",
      "r165",
      "r171",
      "r211"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table disclosing the profit or loss and total assets for each reportable segment of the entity. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.",
        "label": "Schedule of Segment Reporting Information, by Segment [Table]",
        "terseLabel": "Schedule of Segment Reporting Information, by Segment [Table]"
       }
      }
     },
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SEGMENTINFORMATIONOperatingIncomeofReportableSegmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": {
     "auth_ref": [
      "r162",
      "r165",
      "r171",
      "r211"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.",
        "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]",
        "terseLabel": "Schedule of Operating Income of Reportable Segments"
       }
      }
     },
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SEGMENTINFORMATIONTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock": {
     "auth_ref": [
      "r128"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the weighted average number of shares used in calculating basic net earnings per share (or unit) and diluted earnings per share (or unit).",
        "label": "Schedule of Weighted Average Number of Shares [Table Text Block]",
        "terseLabel": "Schedule of Weighted-Average Shares Outstanding"
       }
      }
     },
     "localname": "ScheduleOfWeightedAverageNumberOfSharesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentDomain": {
     "auth_ref": [
      "r149",
      "r153",
      "r154",
      "r155",
      "r156",
      "r157",
      "r158",
      "r159",
      "r160",
      "r161",
      "r162",
      "r163",
      "r164",
      "r167",
      "r168",
      "r169",
      "r170",
      "r172",
      "r173",
      "r174",
      "r175",
      "r176",
      "r178",
      "r184",
      "r434"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.",
        "label": "Segments [Domain]",
        "terseLabel": "Segments [Domain]"
       }
      }
     },
     "localname": "SegmentDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails",
      "http://www.amedisys.com/role/ACQUISITIONSProFormaDetails",
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails",
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails",
      "http://www.amedisys.com/role/NOVELCORONAVIRUSPANDEMICCOVID19Details",
      "http://www.amedisys.com/role/SEGMENTINFORMATIONOperatingIncomeofReportableSegmentsDetails",
      "http://www.amedisys.com/role/SUBSEQUENTEVENTNarrativeDetails",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SegmentReportingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting [Abstract]",
        "terseLabel": "Segment Reporting [Abstract]"
       }
      }
     },
     "localname": "SegmentReportingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "auth_ref": [
      "r149",
      "r151",
      "r152",
      "r162",
      "r166",
      "r172",
      "r176",
      "r177",
      "r178",
      "r179",
      "r180",
      "r183",
      "r184",
      "r185"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.",
        "label": "Segment Reporting Disclosure [Text Block]",
        "terseLabel": "SEGMENT INFORMATION"
       }
      }
     },
     "localname": "SegmentReportingDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SEGMENTINFORMATION"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentReportingInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Segment Reporting Information [Line Items]",
        "terseLabel": "Segment Reporting Information [Line Items]"
       }
      }
     },
     "localname": "SegmentReportingInformationLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SEGMENTINFORMATIONOperatingIncomeofReportableSegmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r84"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 3.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Noncash Expense",
        "terseLabel": "Non-cash compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareRepurchaseProgramAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by share repurchase program.",
        "label": "Share Repurchase Program [Axis]",
        "terseLabel": "Share Repurchase Program [Axis]"
       }
      }
     },
     "localname": "ShareRepurchaseProgramAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SHAREREPURCHASENarrativeDetails",
      "http://www.amedisys.com/role/SUBSEQUENTEVENTNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareRepurchaseProgramDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the share repurchase program.",
        "label": "Share Repurchase Program [Domain]",
        "terseLabel": "Share Repurchase Program [Domain]"
       }
      }
     },
     "localname": "ShareRepurchaseProgramDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SHAREREPURCHASENarrativeDetails",
      "http://www.amedisys.com/role/SUBSEQUENTEVENTNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Balance (in shares)",
        "periodStartLabel": "Balance (in shares)"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYStatement"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r99"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StatementBusinessSegmentsAxis": {
     "auth_ref": [
      "r0",
      "r149",
      "r153",
      "r154",
      "r155",
      "r156",
      "r157",
      "r158",
      "r159",
      "r160",
      "r161",
      "r162",
      "r163",
      "r164",
      "r167",
      "r168",
      "r169",
      "r170",
      "r172",
      "r173",
      "r174",
      "r175",
      "r176",
      "r178",
      "r184",
      "r211",
      "r226",
      "r227",
      "r228",
      "r434"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business segments.",
        "label": "Segments [Axis]",
        "terseLabel": "Segments [Axis]"
       }
      }
     },
     "localname": "StatementBusinessSegmentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails",
      "http://www.amedisys.com/role/ACQUISITIONSProFormaDetails",
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails",
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails",
      "http://www.amedisys.com/role/NOVELCORONAVIRUSPANDEMICCOVID19Details",
      "http://www.amedisys.com/role/SEGMENTINFORMATIONOperatingIncomeofReportableSegmentsDetails",
      "http://www.amedisys.com/role/SUBSEQUENTEVENTNarrativeDetails",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r15",
      "r16",
      "r17",
      "r94",
      "r95",
      "r117",
      "r121",
      "r122",
      "r124",
      "r126",
      "r133",
      "r134",
      "r135",
      "r199",
      "r246",
      "r342"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]",
        "terseLabel": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSProFormaDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r40",
      "r100",
      "r101",
      "r102",
      "r104",
      "r112",
      "r114",
      "r132",
      "r203",
      "r246",
      "r251",
      "r281",
      "r282",
      "r283",
      "r293",
      "r294",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r442",
      "r443",
      "r444"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYStatement"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYStatement"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r100",
      "r101",
      "r102",
      "r132",
      "r384"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYStatement"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": {
     "auth_ref": [
      "r16",
      "r17",
      "r246",
      "r251"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan.",
        "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans",
        "terseLabel": "Issuance of stock - employee stock purchase plan (shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYStatement"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures": {
     "auth_ref": [
      "r16",
      "r17",
      "r246",
      "r251"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.",
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures",
        "terseLabel": "Issuance/(cancellation) of non-vested stock (shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYStatement"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r16",
      "r17",
      "r246",
      "r251",
      "r275"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period",
        "terseLabel": "Exercise of stock options (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYStatement"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": {
     "auth_ref": [
      "r16",
      "r17",
      "r246",
      "r251"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.",
        "label": "Stock Issued During Period, Value, Employee Stock Purchase Plan",
        "terseLabel": "Issuance of stock - employee stock purchase plan"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures": {
     "auth_ref": [
      "r246",
      "r251"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited.",
        "label": "Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures",
        "terseLabel": "Issuance/(cancellation) of non-vested stock"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r40",
      "r246",
      "r251"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Exercise of stock options"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRepurchaseProgramAuthorizedAmount1": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of stock repurchase plan authorized.",
        "label": "Stock Repurchase Program, Authorized Amount",
        "terseLabel": "Stock Repurchase Program, Authorized Amount"
       }
      }
     },
     "localname": "StockRepurchaseProgramAuthorizedAmount1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SHAREREPURCHASENarrativeDetails",
      "http://www.amedisys.com/role/SUBSEQUENTEVENTNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRepurchaseProgramExpirationDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expiration date for the purchase of an entity's own shares under a stock repurchase plan, in the CCYY-MM-DD format.",
        "label": "Stock Repurchase Program Expiration Date",
        "terseLabel": "Stock Repurchase Program Expiration Date"
       }
      }
     },
     "localname": "StockRepurchaseProgramExpirationDate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SHAREREPURCHASENarrativeDetails",
      "http://www.amedisys.com/role/SUBSEQUENTEVENTNarrativeDetails"
     ],
     "xbrltype": "dateItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r17",
      "r21",
      "r22",
      "r95",
      "r193",
      "r199",
      "r342"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "totalLabel": "Total Amedisys, Inc. stockholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r95",
      "r100",
      "r101",
      "r102",
      "r104",
      "r112",
      "r199",
      "r203",
      "r251",
      "r281",
      "r282",
      "r283",
      "r293",
      "r294",
      "r315",
      "r316",
      "r327",
      "r342",
      "r344",
      "r345",
      "r349",
      "r443",
      "r444"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.",
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest",
        "periodEndLabel": "Balance, Stockholders Equity",
        "periodStartLabel": "Balance, Stockholders Equity",
        "totalLabel": "Total equity"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]",
        "terseLabel": "Equity:"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.",
        "label": "Subsequent Event [Line Items]",
        "terseLabel": "Subsequent Event [Line Items]"
       }
      }
     },
     "localname": "SubsequentEventLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SUBSEQUENTEVENTFeesandRatesUnderCreditFacilitiesDetails",
      "http://www.amedisys.com/role/SUBSEQUENTEVENTNarrativeDetails",
      "http://www.amedisys.com/role/SUBSEQUENTEVENTTables"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r350",
      "r372"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails",
      "http://www.amedisys.com/role/NOVELCORONAVIRUSPANDEMICCOVID19Details",
      "http://www.amedisys.com/role/SHAREREPURCHASENarrativeDetails",
      "http://www.amedisys.com/role/SUBSEQUENTEVENTFeesandRatesUnderCreditFacilitiesDetails",
      "http://www.amedisys.com/role/SUBSEQUENTEVENTNarrativeDetails",
      "http://www.amedisys.com/role/SUBSEQUENTEVENTTables"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTable": {
     "auth_ref": [
      "r350",
      "r372"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.",
        "label": "Subsequent Event [Table]",
        "terseLabel": "Subsequent Event [Table]"
       }
      }
     },
     "localname": "SubsequentEventTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SUBSEQUENTEVENTFeesandRatesUnderCreditFacilitiesDetails",
      "http://www.amedisys.com/role/SUBSEQUENTEVENTNarrativeDetails",
      "http://www.amedisys.com/role/SUBSEQUENTEVENTTables"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r350",
      "r372"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]",
        "terseLabel": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails",
      "http://www.amedisys.com/role/NOVELCORONAVIRUSPANDEMICCOVID19Details",
      "http://www.amedisys.com/role/SHAREREPURCHASENarrativeDetails",
      "http://www.amedisys.com/role/SUBSEQUENTEVENTFeesandRatesUnderCreditFacilitiesDetails",
      "http://www.amedisys.com/role/SUBSEQUENTEVENTNarrativeDetails",
      "http://www.amedisys.com/role/SUBSEQUENTEVENTTables"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r350",
      "r372"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]",
        "terseLabel": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails",
      "http://www.amedisys.com/role/NOVELCORONAVIRUSPANDEMICCOVID19Details",
      "http://www.amedisys.com/role/SHAREREPURCHASENarrativeDetails",
      "http://www.amedisys.com/role/SUBSEQUENTEVENTFeesandRatesUnderCreditFacilitiesDetails",
      "http://www.amedisys.com/role/SUBSEQUENTEVENTNarrativeDetails",
      "http://www.amedisys.com/role/SUBSEQUENTEVENTTables"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]",
        "terseLabel": "Subsequent Events [Abstract]"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r371",
      "r373"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "SUBSEQUENT EVENT"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SUBSEQUENTEVENT"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental Disclosures of Cash Flow Information:"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TradeAndOtherAccountsReceivablePolicy": {
     "auth_ref": [
      "r188",
      "r189",
      "r190",
      "r191",
      "r192",
      "r194"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for accounts receivable.",
        "label": "Accounts Receivable [Policy Text Block]",
        "terseLabel": "Patient Accounts Receivable"
       }
      }
     },
     "localname": "TradeAndOtherAccountsReceivablePolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_TradeNamesMember": {
     "auth_ref": [
      "r308"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rights acquired through registration of a business name to gain or protect exclusive use thereof.",
        "label": "Trade Names [Member]",
        "terseLabel": "Trade Names [Member]"
       }
      }
     },
     "localname": "TradeNamesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TreasuryStockAcquiredAverageCostPerShare": {
     "auth_ref": [
      "r252"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total cost of shares repurchased divided by the total number of shares repurchased.",
        "label": "Treasury Stock Acquired, Average Cost Per Share",
        "terseLabel": "Treasury Stock Acquired, Average Cost Per Share"
       }
      }
     },
     "localname": "TreasuryStockAcquiredAverageCostPerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SHAREREPURCHASENarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_TreasuryStockMember": {
     "auth_ref": [
      "r39",
      "r252"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares of an entity that have been repurchased by the entity. This stock has no voting rights and receives no dividends. Note that treasury stock may be recorded at its total cost or separately as par (or stated) value and additional paid in capital. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.",
        "label": "Treasury Stock [Member]",
        "terseLabel": "Treasury Stock"
       }
      }
     },
     "localname": "TreasuryStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYStatement"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TreasuryStockShares": {
     "auth_ref": [
      "r39",
      "r252"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.",
        "label": "Treasury Stock, Shares",
        "terseLabel": "Treasury stock at cost (shares)"
       }
      }
     },
     "localname": "TreasuryStockShares",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TreasuryStockSharesAcquired": {
     "auth_ref": [
      "r17",
      "r246",
      "r251"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares that have been repurchased during the period and are being held in treasury.",
        "label": "Treasury Stock, Shares, Acquired",
        "terseLabel": "Shares repurchased (shares)"
       }
      }
     },
     "localname": "TreasuryStockSharesAcquired",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SHAREREPURCHASENarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TreasuryStockTextBlock": {
     "auth_ref": [
      "r254"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for treasury stock, including, but not limited to, average cost per share, description of share repurchase program, shares repurchased, shares held for each class of treasury stock.",
        "label": "Treasury Stock [Text Block]",
        "terseLabel": "SHARE REPURCHASE"
       }
      }
     },
     "localname": "TreasuryStockTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SHAREREPURCHASESHAREREPURCHASE"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_TreasuryStockValue": {
     "auth_ref": [
      "r39",
      "r252",
      "r253"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.",
        "label": "Treasury Stock, Value",
        "negatedLabel": "Treasury stock, at cost 4,976,526 and 4,655,934 shares of common stock"
       }
      }
     },
     "localname": "TreasuryStockValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TreasuryStockValueAcquiredCostMethod": {
     "auth_ref": [
      "r246",
      "r251",
      "r252"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.",
        "label": "Treasury Stock, Value, Acquired, Cost Method",
        "negatedLabel": "Shares repurchased"
       }
      }
     },
     "localname": "TreasuryStockValueAcquiredCostMethod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TypeOfAdoptionMember": {
     "auth_ref": [
      "r103",
      "r104",
      "r105",
      "r106",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r291",
      "r292",
      "r293",
      "r294",
      "r386",
      "r387",
      "r388",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amendment to accounting standards.",
        "label": "Accounting Standards Update [Domain]",
        "terseLabel": "Type of Adoption [Domain]"
       }
      }
     },
     "localname": "TypeOfAdoptionMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UnusualOrInfrequentItemAxis": {
     "auth_ref": [
      "r65"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by an event or transaction that is unusual in nature or infrequent in occurrence, or both.",
        "label": "Unusual or Infrequent Item, or Both [Axis]",
        "terseLabel": "Unusual or Infrequent Item, or Both [Axis]"
       }
      }
     },
     "localname": "UnusualOrInfrequentItemAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/NOVELCORONAVIRUSPANDEMICCOVID19Details"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_UnusualOrInfrequentItemDomain": {
     "auth_ref": [
      "r65"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event or transaction that is unusual in nature or infrequent in occurrence, or both.",
        "label": "Unusual or Infrequent Item, or Both [Domain]",
        "terseLabel": "Unusual or Infrequent Item, or Both [Domain]"
       }
      }
     },
     "localname": "UnusualOrInfrequentItemDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/NOVELCORONAVIRUSPANDEMICCOVID19Details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UnusualOrInfrequentItemLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Unusual or Infrequent Item, or Both [Line Items]",
        "terseLabel": "NOVEL CORONAVIRUS PANDEMIC \"COVID-19\" [Line Items]"
       }
      }
     },
     "localname": "UnusualOrInfrequentItemLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/NOVELCORONAVIRUSPANDEMICCOVID19Details"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_UnusualOrInfrequentItemTable": {
     "auth_ref": [
      "r65"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about the nature and financial statement effect of an event or transaction that is unusual in nature or infrequent in occurrence, or both.",
        "label": "Unusual or Infrequent Item, or Both [Table]",
        "terseLabel": "NOVEL CORONAVIRUS PANDEMIC \"COVID-19\" [Table]"
       }
      }
     },
     "localname": "UnusualOrInfrequentItemTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/NOVELCORONAVIRUSPANDEMICCOVID19Details"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r136",
      "r137",
      "r138",
      "r139",
      "r146",
      "r147",
      "r148"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_VariableRateAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of variable rate.",
        "label": "Variable Rate [Axis]",
        "terseLabel": "Variable Rate [Axis]"
       }
      }
     },
     "localname": "VariableRateAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSFeesandRatesUnderCreditFacilitiesDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtAdditionalInformationDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtDetails",
      "http://www.amedisys.com/role/SUBSEQUENTEVENTFeesandRatesUnderCreditFacilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VariableRateDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index.",
        "label": "Variable Rate [Domain]",
        "terseLabel": "Variable Rate [Domain]"
       }
      }
     },
     "localname": "VariableRateDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSFeesandRatesUnderCreditFacilitiesDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtAdditionalInformationDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtDetails",
      "http://www.amedisys.com/role/SUBSEQUENTEVENTFeesandRatesUnderCreditFacilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Incremental Weighted Average Shares Attributable to Dilutive Effect [Abstract]",
        "terseLabel": "Effect of dilutive securities:"
       }
      }
     },
     "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESWeightedAverageSharesOutstandingDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r116",
      "r126"
     ],
     "calculation": {
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESWeightedAverageSharesOutstandingDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Weighted average shares outstanding, diluted (shares)",
        "totalLabel": "Weighted average number of shares outstanding - diluted (shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESWeightedAverageSharesOutstandingDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r115",
      "r126"
     ],
     "calculation": {
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESWeightedAverageSharesOutstandingDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted average shares outstanding, basic (shares)",
        "verboseLabel": "Weighted average number of shares outstanding - basic (shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESWeightedAverageSharesOutstandingDetails"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 11
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21914-107793"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21930-107793"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21711-107793"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(4)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1448-109256"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1505-109256"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1252-109256"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1707-109256"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1757-109256"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1500-109256"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1278-109256"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e2626-109256"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1337-109256"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=120380238&loc=d3e3842-109258"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=120380238&loc=d3e4984-109258"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70191-108054"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70229-108054"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6327-108592"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6442-108592"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8657-108599"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8672-108599"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8721-108599"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8721-108599"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(j)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8813-108599"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8813-108599"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8813-108599"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "26",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8844-108599"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "34",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8981-108599"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "280",
   "URI": "http://asc.fasb.org/topic&trid=2134510"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4428-111522"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4531-111522"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121611835&loc=d3e4975-111524"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121611835&loc=SL6953423-111524"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121611835&loc=d3e5212-111524"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121611835&loc=d3e5033-111524"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121611835&loc=d3e5093-111524"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=84159169&loc=d3e10133-111534"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27405-111563"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=75018788&loc=d3e30768-111565"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=109237563&loc=d3e33749-111570"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "http://asc.fasb.org/topic&trid=2122149"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(4)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=68074540&loc=d3e5879-108316"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=120320667&loc=SL49117168-202975"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "((a)(1),(b))",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(d))",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14394-108349"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14453-108349"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14472-108349"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=121555522&loc=d3e12021-110248"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=121555522&loc=d3e12053-110248"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=6802200&loc=SL6230698-112601"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=120520924&loc=SL6031897-161870"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=120520924&loc=SL6031897-161870"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "http://asc.fasb.org/topic&trid=2208564"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21521-112644"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.12)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21538-112644"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "http://asc.fasb.org/subtopic&trid=2208821"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130545-203045"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.14)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.15)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121326096&loc=d3e4534-113899"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11149-113907"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11178-113907"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e31917-109318"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e31931-109318"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32672-109319"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120385591&loc=d3e38679-109324"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(b),22(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Subparagraph": "(a)-(d)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=6909625&loc=d3e227-128457"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(3)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "37",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=121600890&loc=d3e2207-128464"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=121647850&loc=d3e4845-128472"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=121598580&loc=d3e5263-128473"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=121598580&loc=d3e5263-128473"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859721&loc=d3e6578-128477"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859721&loc=d3e6613-128477"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(1)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "805",
   "URI": "http://asc.fasb.org/topic&trid=2303972"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4568447-111683"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4568740-111683"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "http://asc.fasb.org/topic&trid=2197479"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19279-110258"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "60",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13279-108611"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13531-108611"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13537-108611"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13537-108611"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(2))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28541-108399"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28551-108399"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28555-108399"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=68176171&loc=SL68176184-208336"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=121616839&loc=d3e45280-112737"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121329987&loc=SL77916155-209984"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121568110&loc=SL77918982-209971"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "850",
   "URI": "http://asc.fasb.org/topic&trid=2122745"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "http://asc.fasb.org/topic&trid=2122774"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=119991564&loc=SL119991595-234733"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "928",
   "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29,30)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61929-109447"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61929-109447"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62059-109447"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62059-109447"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62395-109447"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62395-109447"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62479-109447"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62479-109447"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=SL6807758-109447"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=SL6807758-109447"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(1)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61872-109447"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(2)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61872-109447"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "http://asc.fasb.org/extlink&oid=68072869&loc=d3e41242-110953"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(13)(f))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(13))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.8)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(24))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(10))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(3)(a))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121643868&loc=SL117782755-158439"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117819544-158441"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iv)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669686-108580"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=99380617&loc=SL75241803-196195"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "http://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL34724394-108580"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r463": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r464": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r465": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r466": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r467": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r468": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(12))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(b)(4))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(b)(7)(c))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(b)(9)(a))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.1)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(a),(b))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(c),9(a))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=114868883&loc=SL114871943-224233"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3179-108585"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3179-108585"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3179-108585"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6787-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3367-108585"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3000-108585"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21D",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=SL94080555-108585"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6801-107765"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3521-108585"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3044-108585"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4273-108586"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4297-108586"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=SL98516268-108586"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18823-107790"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18823-107790"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(k))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(e),(f))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>63
<FILENAME>0000896262-21-000104-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000896262-21-000104-xbrl.zip
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M-"C&@A)6KKQXRR8HVLT6>I"KW7A<=K/CZ]7PR%*JWY*JN*6RBD=-P106DBW
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MKH5B7B&)$"(PT#$Z+CB&4(H(S50R>B&0,ZF4WD^&'2=HE#Y8X52"@!8G$2O
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M1W=Y<#$W-Q$2DY(S)L'99(*+SHD4?'(8P=,Y6K]OK+![I$&<SK)Y/HG@'%@
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MUJCY5YZ?IUDKTJC''[RU?[DN3<((OU]D;W\TF4]SBS7XUAXL.]FAG#0&AP_
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M8:38!DF$4S9GGH"DFVQII;@*,Q9FK-/ YV!&*17XRL9(GHU"G8QW-*C$ XL
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M6]N&-:FLTRG21[7#O[OT4A6/(CJYROC K(@R3<T(J+#3/.QT/!,6\)8IIJ5
M3H*,.,$"# X2D2%1:T-!KEB-]@H7C@J478;ZXGB548&"XZ7A>!H,P$QS0L!3
M4#QEQX&!C:$T1XQ':KCF6(28<<QJM<]0<+S&L8""XZ7A^)N\_A0)P4A$(A$/
M02)KA$;*F(!-$LY8L[5->).JDH&WP5!>902@0'EI4)YU_*6ABJH44<#6(.Z4
M1]H+AQ@&U]\8YK71^;AL4RI:(RAO?,G*RZJLEW4I%LD 6*R[T%ISU*HK5>8R
M.N. 9&F:,U<MW9.=3$HCOW_GG6-!,:$" @\_[Q_&A*P =@(/,&D'KB#/[<2X
MP<O(2UJS9F(%^K6+&!3H+PK]BTOH2TXC#8$CPC#-@0**C%4<^9B+X@7L#/8
M?:&:!B]KA[% ?Z.@O^IJF 7Z"T#_<+SJ'WYX_2Z2Q"TWL-@3Q1"7G"$KX94"
MQQ)D%Z.G<FO;2 7+_F/K(5JP7[NH1,'^HMB_F&+?:TV-S7WHG,NUK*E%VDF)
M5&XFG$P48+@!]K%H*KIP,*+TR5QZI&+Q#IF/F+56>HSA:LN?/[O]0ESS$=?>
M;*C"@"Q<4@HQJ\!?8=&B7!,%:44]T<(3$-K6MM)-LGC%P7F!LD9[)8\8_"L]
M\5# OSCXI\$*%YF+CH"5XG*PPH> 7,@G'A+WPKDH1:[:STW3L&5MH!3P;Q3X
M5WHXHH!_8?#/ABM2(M)B:A#CV64Q@2"GP671Q) 8([8ANIP)(9M&+RNKJ<!_
MH^"_TF,4!?Z+PW\F8I&TI(GHA#!..I]85DAS"W\&ZFQ,(M*$JV,3&J_-XK_Y
MJ17Y+-$X6-'X99Q>\<_[M?VX:\2V7*,^UUCUH:&'T_1]6&9ZL3]80F1NL]?@
M)03?KBZT^YU/,.]GL3,8K;032>QTPF[K4RO$3NFO-=_">S ;<2,A1:J20"H0
MACCW#+GH/1*Y%V9B2GF1*Q*7VH$;C-DEQ,P*9G\Z9J>!,IXW\W.4G!,*KC(%
MJ]D%#_XR"Y@S0L&13H!94@[_;#!HEQ#K*J#]V:"]&N!*Q@5.$(LB(NZ"0288
MA6C,>!4Q$DYS>+N =G-!NX0(50'M3P?M3%@*W!G+0TI(Q\ !M(DBX\%:YC(R
MPL X4LS!4DL73IZMWXF>=?+*QZ&G1U;:\Y>:)L5,Q%*J"=V'@%[.NN?8*9,8
MEKEAD$$\. _\XR1R+E(AHO0R\*UM<N.6^#]+;;!-0.XJ,UH*<A=$[M1)IX8P
MZ55"PIO<EP,SI U7B"A#P4<#)"L&ED-3B8+<#47N*M-1"G(70^ZLIT[!'Q-$
M4 3_AT47*XF,4 X1@JUD29% 8-'-I7:O1]@*=#<"NJM,)2G071"ZL_XZD4+P
M))%VV"(.[@[206CD:-16@"&-F=G:%DUS0WO-!X'NX]E"W_OOL#6X:+0ZC6A[
M'7CV?B/UNF>-.'K_+ Y.NP$^G@2T[E>FXU&$$5?KS$_RVYZ!M$9"/*AD-8T]
MEM2W^3CK]547W\+ZP@4"3Y_G\OX<61<5LN H4*L<B7D'GC296OB4;MD:J"^F
M?\(F? 'N3P#NU,,72@<;>4*6*; UG-'(!)J0%H0S82G1/(*;H.NT-U!@6[]M
M^+(4/RBB9SU_9@QF8%,AHVQ$//I\_I0D)$04F#*/5:(Y:,?UPK7["ZCK"^J?
ML$U?D/L3D#OC^&/!C&/4(TX](%<1AW0* 05*J %;BFAM<[6;.N7$/9Z-^N<6
MW/Y?VJ#__VP ]);K\J]O1+*F+G^65N:JHTYAI_NRTYNIB_]UAU>GVZ7/HD+6
M)I^K< 8$_@%(RR9!M..2YO+ C#2Q659%GK*U4,>MA24X^GT8,+PJD%XUI"^N
M0)IE%U\$BYR,N9V.E<A%XQ WVA$?/5=:9V\![(]Z;#84,*^Q]U\@O P('WZS
M*@<:A6 >8695[M;'D8X\(J4,]X%BJ50HJ_*: GG%&_YE57X@2%]=E9W'WM)D
MD)(!(,U41-H#PJVV+!G@:)ELK5;EQY,"<-#J^]ANVT[L#OO-1B<.RA[_R@[2
M5\4Z#KN=[M7*-27K:$'W?N<=./;6&&X0L$X^&L0HLDH(9)PCFA"65,A5]E4Y
M1+_!>%WZ_GW!Z\_QW7?>$>64(4(B$RP#;UT:9"B\$MB9I#@V).74?%4V[C<8
MKTL_/U_P^E,<];RY9PE DE"%?$@4<>4",E@DY*,+ %>5M,]EH>7UG-X"V(T!
M[-(WY0M@?XH;G@&KM1&6F8  G@%Q(3#2R1OPQJT,,LG #=W:%KQ.&:W+W(UG
MJLYN^$EW8-N-[HW%&^_OE9=V.:O<HR^\M1S>\E<<><U<RC4^(J9R5%C+!D:0
M,RXZITC47(QV TK'K$=$ ;7?W2]DL#0RF$8)#/<,LQ"18SD7.#F"C/(.)4.L
M#Y)R8E(^!:S$$DX!%QJH/PW4-"^@@']9X+]2K<]+3J3U2%.G$2B$1 9+CS )
M.JI$-!$Y70\WV>)' 0H'K T'U#ZEH+#!TMA@)IY!C= NIH LBQCQ7&# .8*1
ML]K$P"BP.S@&JDF748:K?GTI;HZRU#? ,5+\!DBLVXN3$,? ?HD+U138-"ZK
M:63CZEFII_ 8K<X0IG;<<:?;Z?]>R77TO9,LU;TO@YX%Z;0ZMG>Q/XAG?:#!
M/(!>M]VNB'!48:5PX%P<^/Z;2H2."N&0UB9G2BIPAPBX0R)*K%)( 9M<I@";
M)I&E-V=AD0>O9%A8I#8L,E,5$2?B12 HV+P=E+A%1B:++ 7Y8V6(DVYKFXLF
M4<LZ85U(9*-(Y.$*+A02>4@2F0W.8$; $A488:,YXLHX9'T"TX0D3H2,2J9<
M%5FI)E-KTRVPT,B:99,4&EE'&IF)Z@AOE7:$(TPIN#1:<&0238@(IF EH=%D
M&M&R*996>JU^L9UUZSFZ?QG-*5T?:ABW ?8:!YQ_CYV86H6AYF.HC[,Q%V:Q
MC0QH*1*A$:>,(>N<1=%+RYA-V%*_M4UU4W!9C[-LY6!J#1-*"H17#>%IP$.+
M9 T#H\(XEA"WB2%C240R>&JD$T%PD\.F3?!I"H0W$\*K#UD4""\*X=EP0Q3$
MY4JO*/F P4]P!CFE*+*26F^]L]'*K6TNFUP6#&\HAE<?+R@87AC#,[X^BP[,
M)6D1I8(@+JQ#UL:(K!9*"N:<]CED:)KLAF.?ZUP6HKZ>_&$<C',S2E9&[;,R
M7O2Z0$$YAEEH:!X:^K SZ]!;:@5U7J-D\KDX'C$"[TXBCZV2VA-&6(XXXJ8D
MR^H#7?8M-@KSJPP'%,S?'_/3"$ @G%EN&9+*Q)PX%9!-@B%BG0"Q>2$5WMIF
MHDGXL@I.%,QO%.97&3\HF+\WYJ\<'S&PK!M.D$O1(>YR]U?F%/)>&:NL(1%;
M<#<8;AIR/6904%]0O]*(0T']_5$_$V201&N<S7M)<[#?& %+O92(FF1E\IHR
M3[>VI6H2LZQ2-26A8'EAB(8=#'HM-QQ8UXZ-0;?1N9)S ]\:)=T\MC85*\XX
M^.9 6QQ,\Z=V9@1TTBTI44M@L+W9^$3*WJ0*N4D%RY4L)496^@2^BF0AE\-F
M.N]TW) .5;8Y-@*^2Z]B6>#[T^$[#36H&%PBSB#C3=[D, RYH#EB+&E';#(&
MAPS?FO2^+O"M8:9!@>]JX7NESB5F/ICH$%:<(QX)1=H[BW"*GF"68N" 7WU#
M*XJ"WXW [])K7!;\_G3\SOC_G <G L;(I^S_Y^/1EG"'(I<$FZBX=WAK6Y&2
M8?#@KOW.60RM_D6_V0!\//EI49<;.>JF27I0BOK'SQM_O;FYILD65UB[,/)<
MC+Q_)9X!?I"-(B'%K %"QAS9I#C2@@G,;<!1T"K?@O#'EF]1**Y0W /FEA2*
M6XCBIC$?:23V')Q$K\#2Y#HHI WQB$MJHTM*>&*VMAEO2K6LWN>%X@K%U6G@
M-4VE*12W",7-QL44 <^:8HT$#@%QL-J059$B[XQ.VF$P[-0HFP8_NKS90G*%
MY!XP<ZB0W$(D-]LS1PJ.N?:Y9PY&W$:--+<:4>XHL2X:;-C6MI1-KJX?]J\I
MQVU\\M#OMM_RC6A['7C<?N,\]F"<9V> S_ZI[<5?;\T4NL,DS$B'P?R'[C#'
M+K\5SZV[*<O8D2E/6?>G?#S-H^\<S+]$X*#K/YYVVS"EUS+VYIF>#36,-L3V
M>1%[QYEJEQNNI]_:.7MCBI_<KB+^2WL'%WOG#O;.R]G0//C?V'$7D0U2(BZ-
M1I8[</$(3U@H37'"6]OTR0V5C=:^J6=AGPUGGP4CZ85]?@[[3*/FB25,/!,H
MIL 1YT(CQR-!4A.6DF2)>;>U39[@#>P!7MAGP]EGP2!W89^?PCZS 6W"!!:1
M>&0P-H@;#J^X8KD6OJ,V62T9W=IF3\RRBN 7^BGTLRKZ63#\7.CGY]#/3*C9
M8 XDP@)*(!K$B5!(6\Q1P#(&RG32Q&;?"R^KD4^-8LEK$.GZN_HCAH:%1[+O
MXRB6W&]TAX/^P';R:![9"=1;66@T,P^8JCF1U<Y(5(?#,Q=[1ZDBJO[15&!7
M2:OLC]V%M%[/QHN,HX)8AL%C<V RT:20D](A3P@VSEO.) &3B3;%TAJREC,R
M]<3W*O,4"[Y_*KZG$1DK/<!8!N1R@C;P-46&<8EDLLY&X83BN,(W)PNW]"GX
MKC6^5YFD5_#],_$]&_/@CKK(:2Y[21/B,C)D.?$(V%QB8L$!(:,%7.J%$Y4+
MP&L-\%4FJ!6 _U2 ST05@@@J*"V0( HL=.$TTC%))"R5A.'(6=(5P)E:N.1=
M.05[=VSNMMK#'$U8<I;:#\*\Y1HUO,;CB:&M)EOLK@OV&F]9W#3$-;5%'BY;
M;$S!9=-B+O/"S\;_G%6:\, 1(8D@'HA!SA*!HE)*,D.IP[[*%UNXLF;]G(?"
M/QO./S\[7ZSPSSWY9QJ?=$YK[XA&D2K@'\T#,LKF!D*.)Y:,8(Q4&6,;&+PH
M_+/A_/.S,\8*_]R/?ZZT% "[1RNJD(S<(,Z\1P9,5I1 4I&[Z*7C5<Y8,8 *
M :T; ?WLG+%"0/<DH)GX;L*P$F#*$#:$@0>6&-))1$25(LJ1H(635=;8]>K@
M:Q_=78.(U\_*&KMK6NX:\5!=L\;&+'5M;ZIL2\U%6^]GXT:22\-HS'82\V V
M18N<(!B%Y&&1<3QJPJM=*:.7U8BI1LGV!>'URALK"%\6PF<B,]A;"MX1J)C6
MB$N7S_(YAT2P1 8I0DP!$,Z:5-<IG[T@?",SQPK"EX3PV=B'H%HQ(BE2B1C$
MO5/(8(D1_$5<!/H./%80QP7B&P[Q&N2.%8@O"^(ST04*B[6B02(#Y(UX$!QI
M6-@1U1@S3J2U(HU6<;&L$H]+BR_\J\HM@7]#Z]/V_\!_)K<^L[WWK<ZHP!J]
MBD,?<\>-U4..9LB=G,:&];Y[!O>^R*T-.]T!7!WTN0$/D_L<ON_9=N/<]@:-
M;FH,3F,_9AB&V.G'3$B=JE:<S>&&U.K8CF_!UP$'@W@&X^I/&RI\.R/CQ^#T
MB1+PJ.?=?BM+\-=>;-M!ZU/\[7,K#$XGS##SP]&T_XJG/[$.'@* >.M/ZC+;
M[.ILS/XW/VU%%=X'XZ6)/E#/:13:*)^BL>"@JHB=>$?UUN1'I[W)",Z!E9#K
M1?L1V00#_-6V/]N+_M:_KFHAJ.!DWI_D6?]VPD;3LOT_K@<_O.%9'W1.U8US
MVM@YV-O=/WYSW&SL'SY]TM@YW&T<O_[]>']W?^?5_M[QK0I8EP$\/0)V/#S>
MVVW J^.C/_=W=T[@C^,3^.=@[_#DN''T#/XZ>OJ__S[Z<W?OU?'__3^:$O5;
M8^_EZ_V3-[4?WR\[9T"Y@SZP"?!'=PC7"OUF(W[Q$:AV-NEN'*C\9_V']+IC
MAZ$%I'?YK*.DPDN*JLKWP>.T[7D__CIY\5MH]<_;]N+75J>Z:/6CW\9KPYC7
M,BR_#27G88\^GB+V"1ZA=AS2'M]Y_/&3ZJ-OEK_19]0\X4+<^C%^0F[]['N7
M%4^$E/>ZZO<_XX8O_5GE$\'TFCRK>$+$[9_6ZUGE$TW61P<(I6ORK 3 3N[[
M0*M76*/9FCRK>2+QW9[G![N'/W38N;CVW1M<\M&BMAJ?7/]HI:N6EV?=7C;Z
M&R>GO1C1 7S_M-_8 _,_-/X8=F*#X68C!]"N>%SCR?K&TC?5S'PS?[WNYV\C
M&G<Y\W##S^8I85WO.3_I#FS[>R=Q[COZ6V?4;. L/AT9EL?9L+S+L::%)G#3
M57('GC6[VJ"7V35\85L!M3K5ZZ?VO+5J?=WTZ3X!1[X_[%U4$_Q##2[3.Z\V
M>S\\&[9ST*J:X2-8X7HC9>Z>G??B:>ST6Y]B8]3/HDS]$J?^51Q8>',T[Y/<
MO$:9XB5.\=5VSM5$3WHZ]^]@IE%VDYVV<;,TVK-9A6&P<5,WBN?=8>I^YLGC
M!TB__'9V;FL$T[8='YN- ]OSIPU&;G"0[I#RNB[=NNXV*7,GN=>^6=?=QCU'
MKZ[HE/'1)*Z)XS00ZSC#@246"'%1V'?[5:)*/EQVWUWLXYF3[7O_';8&%V#A
MM(=Y+E]T>_D!=V9.R)]TKZXDDT6D-IO;1T\GF]N_MP]W3UN'7]^>'ISL?'G[
MX=6'H]T_6@?/7W\]_/K'Z9N3]NG1WX=G^3O3S>U7K8,/^^Q@]SU_<_+R\]'N
MJ[,W?[\4A\_W/A]\?=8^?'YP<;2[#\_[D5W;W'Z^?W'PP<-O3D\/=W?XX?.W
MIV]W/^(W)SM?#_Y^C=]\W><''_YHPSC397;:,?[\+D2E XX,>6DQXLKGRH4B
M(0M"Q=&18)C;VE;:-,7B+5KG!=(:E45:C!O7AR1N3GNQ@@1,#,[[PU(R'36+
M) 2I5?28^)MY L]#$[>FLSST89DU0?S72\0;%1+&)J*4:[QS*BC22GC$1+1,
M>!%39%O;3#4%TTW-%NXQL6:@+T90,8*60&[9""J6SL/S'KGD/<NH\Y1YI*0)
MB$<OD=%:(K!KO U),F-S!;AEU6<N?%?XKC[CGH/O!!8V":HECHDGK9U(R;A
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MO@P)#>^AS/C7(@*+R.V-&=#CK[<R7**$V+BAVSG+_M;H'D/W/5[6YAQCW<6
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M$@U@.54\HR:WMHU]<!.FFFIV;\OZQ75=+V"[]8]Q#UN9'5O%*A:-N?K^(.*
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M-[K'T'V/E[7V-=6N3E+N8L SCX.68,6#*J?-%SNW^E(#WPO?_J8$OI-36H0
MP;H$4GJKDP GI0034S!-?@2SC M6 ]_K$_@^W/WGU6G*H]V=B_<:05,=>$F1
MX 24YL2A >(A.FL3=US2K6T%K"V96-(9^)79#%QB_8J7?9H2/*?6@J5@06MM
M&08NK&8!+0+(V[FBGJ9\4JN_F+%ZQG6BC"/Q@9;3E"H0%V6>T]G@DW#6H"JG
M*55;"=-N:B^\*,.O8JB*H2407#U-N2+<=SBK>*(7,7"OB0:N" !ZXB06[E,:
M*8:@>2@GR2OG5<Y[R9SGK)=:2@I"6D"57*"9Z5 IX;40]BN<5QW %:?#62EH
M4M1>!$]H=O,)2,5)=O 9\50J4%$G5*PX@++-I:J<6#EQXSAQD=.4 (R!C-RF
M)$ Y:;A2A1NE%M()(^XFQ7J:<DW8\6A6+,H 1GLMB371$W# B//<$&W 9*48
MK,2TM<TE:W.XZ24OW'J]$F,EQM6Y[T72Y&VP+"M#QJ3)#C(SCB(%EYS145N>
MJH.\TIQW?6[RPZ>##^\U4UD':D6R_M.9]9PF/JH\RPTZ:07%K!>WMA^>"%]9
MK[+>.K,>3X;Q["!QM#3K >8ERW83;/:=G $6JHN\OH1X,$N(WLJ #@1)3' "
M A)QK#0-5-Q;%X-B4F89"*J=?8#*BI457S8K8M*@&4+0@#RXH*5G.AD$*5%]
MQ4>NK+CJK/ANCA6ET,H&2C 9F5F1,V*3E\08C RD NE-.3))U=IPXJ:W5M@?
M#L<E([#53_F;LQ&UFNHG[*\M/#OO]B\0IP^?CP?AU VQ==YUO>]JR'K+R*QY
M[LM-JE-*)T>M5?F3@)ID@^=1)X@"D5.CF\8N]+*Q"WWX,?&"'\;=\: P7;Z[
M?OR7ZXYQ;PI>\YHW4^C>9.0JQ2U$<>_FD^-$\@D,<)(@I>P'2T&\DXRH$)B0
M6B9C77,FW#QX9^1V'EF77@(;9.2W)K@YI97Q-,:D%3 F#'/<*H<V*BL=JF_8
M^4*9;K>;^20![DX[']9\N$4-?783-#EA$F81PX(S!!+UQ*BH"1-*1<.11Q>S
MH;.VD,NJLETM_8DL_?MZ85:45H2/;^FF!XH:B3ZQD%=GIEW(Q,S0<I"! W=5
M=*T;%\\EI("TT7/)B:(L<[%D)=:6%.$.&.7:98?35M&UED9>J;BB5%&J*%64
MG@RE33_A?'= $RC[X8\?OS]^^1(:4S]%_#+_B%_5T:_[X\%_<- _ZN'_FVKJ
MP8$;A=.JHQ?2T;_-!R^Y#TJ;8(AD4A/(R)*R5TT00RR1R\""W-H6;2J7==1E
MA3:E7ZB%/U?P\FLV/HE<?MO(:^#RGD8^ZRQ'::Q&@01,XME9=H(8SQCQ"AU-
M@O+H5':635NP5>I@7ZU\R6>U'F;B1'V]JTE=PI_,NN>.JBIC8A!@"$\J+^'>
M46(=..*8,D%YRS.X2^M?4LU[9<W[*2+>U<:?SL9G5W NF%,(D3"$;./">>(R
ME$1H8 9C4BG0*M/7TL*_+_A34:HH590J2A6EFK][9[C[+S^$\D^WZXH0^+%$
MO[,P(!]Q.,(X"837I-VG"7I_M07H'5KZ;<9IT D9J^95.Y_<(![BZ"B][@\2
M=D;C)HI79?4"LCK,1[^S5V12Y$!,1HZ 14J,SOZS8-9%I,912,MN_5EW59_;
MV%<Z>7<AHZ_1\'L:_:PO[;W'"-H1GY++1E_.(BD>B!>.NI+@JTWVI0VTC8%J
M\QMB\T\>#:\+_#/9^EQL7#A'4XJ:Z.A+W3)CB9'&$ZJ5-($&ZZRJ"_SF&_N2
M8^/5V%?%V&<7=B>"9"YK>"TL$G#9XIVS0&(PP0M/46A3C7U-C?W9<R0K2A6E
MBE)%Z>6@M.E9X7N?<1 ZPYFL\/YYD0)W]UC;R.V8%<L$OX^6;IX[FH!UB6*L
MXGDA\?QA/A2>'/-2&TDDFD! "Y\]99K%LW*,,Y.8=UD\\[:%FF&R*0:^TH'P
MK]MXC7S?T\;G\L"!ZY#0$H91$<"@B%4R$*6 "YZ=YV3DUK8V;<V758NK&OE*
MJ\6*THI0\>H6L*A::QD\/!>H1%WJG5-)>(J6@+6>^$05R7H+388W& Y5:ZVE
M@5<:KBA5E"I*%:6:S;ND 3[L]TAPP]-\<V?GV!LVR;PU;W<%0I0[\??Q<'2&
MO='PI+^3![5<G.N^<9VXWWOESCLCUVV"&=YES?QJ!KZW^-]Q9]@9X3$./G8"
M3O3V6PS]#[WF4QKI757V0BK[C_F(IDH2T7I#7$1%@&E%C/1 N-2>)45ML'1K
MF_&V$C7/;\T(X=GWQBI*%:4-06E%8U)U<5VQQ74NA*4\4](&350J)648:.*L
M0H(L2.9%M%'&NKBN)R%4VJXH590J2A6EFFJWI $^'@\&V(LX*.?.F_2.EY5C
MMTCW^*<KMWH-RO$T$ZA*XOM+XI.=^7B3M4(;'@6A.O@LB2.2#!X2*15/.G)4
M7FQME^:?-Q7QPCW@Z_;&2B\-%:6*4D6IHK2.*"VB5;QQ21H=I:$>$J -,4FA
M4'CK!?OV(?JJ59Y,JQS-G8OG-,@H')'&6@) D3BE#='(0GFB-.VM6F7=++?R
M:T6IHK0A*+V M*8B)0;];G[N0ZN3545>UD>MV"EU,OSXY64Y/7&0:'Z[]:#3
MZP\ZHXO]*0Z[& ;HAOAZT#_;G8%D>-*?1^[R#7_O=[,\J[IL,5VV-Q]#"D($
MZ<&0P%WI)8Z!.,8IR8I: PKE\I-;VT+?;--Q?U56-Q?6826I*%64*DH5I8I2
M1:FB5%&J**TR2HNX;I9IEXJ<]\H!M>C1R6"<1Y!..H/5=5L;U^WDW=1]^_#I
MX,-[Z93/7CD29AP0 $^)X=(2Z660VBDJA%LAYVW3<X[^G6T"23^E4M^K/SK%
M07.";H"GV!MV/F*KDVWA#&LBTJ/'F)H=O+W_C@M'G9WG+SY*#3A'*1VEHX+,
MJUE@]AM<*ALMQ$;[7R0C46T\6DF4DX* D(%XG_+\-9!01$\-L*UM)NONWMJ8
M[K/O2%24*DH5I8I21:FB])V2DE&9%!,Q!>L!77:$([JD$C5<Z\1EE92K)2FO
M]B<;!]>;&'DRED1G&0&6@/AHD CP7BH7I/*^BLJU,MY*L16EFHRT?8BCAX2#
MUC9NO6+'TBXCVF\&_=09_=H?UICT8DOVP1?I1#YZQY4ABB=!0#)*?/*26(#H
M(/+2$VEK6^DVLP\N^%RWG-9A3:@H590J2A6EBE)%J:+T<E%:0/A3XR+CF$"%
MK/9Y=-)X900H!T"#8U7XKX;POQ+_3:S..4-9\$@\,D,@:46\$)HX+83R7*BD
MBO17;="J2O^--=ZE)YM5"WV A<ZEBZ&(+ A(A#'+249($*]9)%YRKJPU"H+:
MVM;LP3U :L[8O2WK%]=UO8#MUC_&/6P)VFX5JU@TXNK[@X@#,AFZGT4>Z]@?
M^RZV+J]_^H)\FS\7)(;];B=>/?E-/KIMQ)Z3CO[G&<=G4WB:26E4HL(H3@%$
M9@2O@Z7@T8.+$M[O+Z?)T^DDU7>Z<]H+W7$9RS?]0;G G=$D5]AE+.[*%:ZL
MOQ#K_W,^(,L"2(U)$"-<YOPH$G%)1P(@\R(M7!0R9<[GO,VE75+OI^59VQKM
M\3TR!:\/U=S:XU-QS8+,4S$R!JBL\=8YRH%GR9&\T[>SS4*M/9NO/1J/AB/7
M*V-9.W<NRAMSY;8=).6X)A(P>W/24^) 4<*43%K*9)PP6]M"M8U@;6Y-I8YY
MZJB*K2JV9>^'?Q>'WG2HJRQ[%GH]G)5EVME,CPB$62T(, G$:HDD4,J8"Z+D
M+):36Y56*ZU66GU46M4I*QK'?&R\7R[RKP*L*BUG! B,U1%>6\:=%;1)!,U0
M6Z*-+L%/9HE1SA%0G/&H('HJR_:$;$M#*^U6VJVT^[@G,P)'&SVGS)D #),+
M'E5@X,$D:H*\FW>'^3;S;Y6 5YV YRH F\0Y,&$)(C<$,K#$2J%) !_1\VBC
M\EO;7.JVXDLXT%&YMW+OB^+>!:@7N97&"9<E400TUFKJ&4OHL@OJLHW>0;UJ
MGG'_Q$$_NN%I)=N5(-LOCLY9;C H'DF41>5&'8E-"$0HDWQ@&"/8J]RYJG<K
MYU;.?=S]]F3RV!CGJ3-@K?>6"ALB]]+(!!YKF&%]B7<N#S)%)SP%))IY(.!9
MUKF):^)E3)ZIE&>!VMH6C+=-W7&OQ%N)][&SR26G: S3EFF($*P1&E3T2BE(
MR7QEVZP2[ZH3[WPUQ'(\&!,G*7I*0-M$C-22:(Y"!AN3-&9KF[6!;DZV0I,>
M^Y=F6N5_8^?C]O_F'Y<7/O-9 <LL6[:Q,OHM:^7%6D].L>5"J87H>A>E]T:O
M/\J?[@;YX5[3B./#P'5;YVXP*J431Z<XQ&+$$7M#+ M+KQDY-\I_I$[/]4(G
MOWPXR@^<Y?L:_G0%W)<C,+T,^$GF"SWO#SL%[9\'V'6CSD?\ZZ=.')U>4LK,
MVZ:(TNNW.)\O83RZ^RVK,M8P/Q:S/\O5-L020K1!6<SR,P!'::P.":WS@!JI
ME^\%V[I\T^G@\@[.W0<D?H#N#^)2OL&?7?>3NQAN_65N',XZO<L+ OZ3+N/^
MY9!-!F;[?_T@O_66JWW64=6WCNK.P=[N_O%OQ^W6_N&KGUH[A[NMXW>_'._O
M[N^\W=\[OG/^K<KUOSHZW-T[/-[;;>7?CH]^W=_=.<E_')_D?P[V#D^.6T>O
M6Z]VCO_>>OWKT;]7_WY^V#G+?#P:9O+(=-$?Y\^*PQ]7_[+?]5R6!9G'%K_6
MV^SE&V]KUH5K3FO6HGRK77<^Q)\O?_EK[ S/N^[BYTZON>#F37\]<X,/V9*G
M1%BL^,L3$^7[)D]/#1PT_TG21LY/#VQ,OWEJ_S_1VZ3^Y$DA]4]<WOW\5]_\
MU2?EA(26_\'LD3YWD0N>GH[Y8K7C$Y_J=I=LP8,QSWNP]S91=G5/]C[W-+&%
MY[FK&QS0W-7K_F!R8UGF3'XY[GPF!_E]I],;+G;^)G]V/PXGC^QE)12O3@C-
M#<CM,X#Q%S$#9@(-"PCMU9X>V1EER[KA.\\S;.C T8>:Q@H?)_RVPFA&X94;
MGK9>=_N?AJTTZ)^UCLYQD'V=['/M9$_W8W9F</CS?>;7-WS>AT^\[SZ,\R@7
MN93)LC(UZ+[M*WZC"-V#C[ _W4IRSWN]?RCUMEM\IF#H/>]M@6AHY!$M2!Z$
MCN"D-4*E:%R4VC%A$9KC^>SR>#[;L-H:?QX<7X8V__'[P;_???[MSW^='9S\
M ?\Y^2<[W#WL_/;GP:?_G.R(HW^_8P?YDTLH\CJT^:_N;[_OR7P=?Q[M?N '
M)_\4AV=[\N!O_^C^9[>$-?])#_]\=W&P^]OG&Z'-?_^K<W#2/?O/R0$<Y></
M=P/_[>2/3[^=_>N/@S_WX7 W?];)_J?#WU^GRW-8!\?TTWMEC%/."V*=, 1"
MJ:5G/2,9+^D4)%0E:XIE66@96Z%S^TLJJU%Y:$-YZ&47]UP7'OKSBH<,8RHK
M3DN\,YF'A!$DLY(D.FI.90@T(5O!PIX;[@/<;H8[\??Q<-3LC+1&_=8 L^6%
M3A=;O2N]5QXO?X7B+IP/^A\[)<+@+UK]*W_!+<=?6!67X*E5_V0QLJL\3W;Q
M/,^-CFNXVO5BRYV5W>H_FP<VI2SU>DOH68CR[UULD@EZ<6<&J;JH+;"H79["
M;18UP2V-/'EB!*,$HE+$EI)U&4D=\T2F!EP6U]#FM63=)EOT4XK1:M'+M^AK
MF9JT:@0IX:%DO5,1B,]H$EDT@.?<L))\R5A;W=(4=2-EZAKHD,-^CS1"M&0(
M86_X_?IC!?NMK+?^:*HJ_>*&&%_-8%/Y:1%^ZLPH#N:#-AJ!1&ELZ=B<M8>,
MCKB@2TLKJQTOBD.T03W8C:X]DU;7AI]2<50;7H8-7VL,(8P7D+!HC$! 4R#6
MNTA8J:)I,##K0K9AWE8"5LB&7W:L8U9>-[&.SMFYZPQ*D*SIUGX5]NIBMI16
M,Y[EB7'^PPV'.!K6@,AS"I*F_>8LB!G#_2L(^^DJS^'7@M_;<B-'Z=T0=PIV
ME>L6X;K9[4>6DA8N&F(@:0(\66*C-809#4KJQ)21F>ML6]-5\J=JA&0-]4HU
M\2<T\9F0B0!ID6JB +.<R61.3&2*1&XL%"QI*BZ):4OYX'-3-62R)-,MF]FM
M'SZX3N_'5K;<DL+?'[IN42SG@R)F1A>-RL'_CCOGQ7QJ..41U<M50:IYQ^MO
M&9X"U%'O.%/347HS1>9-U_5&>Y?(5.9:@+F.7LV($\ME%-0*(I2/!*A/Q&O)
MB#/,>$ 13 FF+.NP9XVC/)7Q+E)%;@G"I!KMXQOMM=P(WDNF8M87B5("(7#B
MJ=7$&YO]#$C2V;2U;6]&3A:N +<R*F-M@R8__*T1&-TB-K(98E/:H'6&H]-^
M;'5Z'W&:9?3"0B.+\--3;M9\25W[UPA5OEJ$KZYS1#X?_/G'>PI.Y>4$">=1
M$K A$2O $9.B "T%!"5+19\VM3>#(/>GK1K_6%TG80DR8_&JM=6>EV;/?\[:
M,Z",27)/9+%B@!2)M3(089-WP*,+*FYM\[9]>"'P&O!8DJW^>] 9(>FGU.S6
MC$YQT&2+#/ 4>\/.1[SC'-N&>TK/)T2^+/[:!&\;D(Y2.DI'!:%7LP#M-_A4
MWOH^'?+I?>F)K5P,)/AD"*#6Q(CL1IFH'0 7(06Q['JN->2QBB[%TD(>U68?
M56M\>L^E1J-C%AK)%L<ANQ">8;99+G3V(L!3@5O;; G5[E=&8*QMK&,7$PX&
M&*\.2+G/^-("&RL:U[B$9D)')^[SWN>2QH:_8 ]3I\9B%SK4>;)SU2#X8.>]
M-UX*U(%(5[HB*8G$>NX(]XX[EQ(WH+,KQ-N:U1,PZV;.3RPJ%@]P5,->LF%?
M7!FVI=%YRSSQ"FR6'L80RY%FQR%:#(GR$+.[ &TJ;MKULX0L7W9X8U(UNE2S
M1#?HY6N?EF]:[I;+R_"/GE*:3)BK!&E?9[@F*!XT8-5@[??RV-ZL0$D2M-8L
M$04I$'""$2.$)R7,H0U/3@568K5@;N9Y/(L75>,=*RA-JM$^@=%>BP^4B04F
MD"!-GH",0+RC>=J6G*P$FDD+6]L9T-4PV9<=^)@[&=-/V7*F@9"(?M3J#(=C
MUPNE'/]P-/Q+\UCL#$.IOEVC(X\H0>8I:Q:DH_1ZT@.A]^%5 66G%W>GB%36
M6HRU]F>E1I1!&K2< )1H;6*.&*.!V$ -)(_@2V8:B'K098,M=^EBHUKN8UGN
MM=Z@6G@OE"+1I$2 6DILU):@B-XQ;ZS7M%BN7B'+?=GQCK<X&@]ZRT\J75^/
M:$4#'+=[1[N=4C"P%X='@TQ@D]9F^:(KB2U&8@>S\D-S",IDT0%<TZ)!LO(
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MA"OQRFZWY6*YQ<GC/Y2W9H,OGYP_HKC_>01[Y4ABM[2'& \&Y:F9M_R8G8Z
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MK:>43-GH9N32H-_+OX;).%7Q-!%/1SOOK308!0^$,5J2DFT@)OA @A<@,G^
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M3H%I@ R.K0_SC8M:MC;0%, F1'C4&5O1_R0;<2L'(N+\3$@ZF">$_"]<+ >
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M(/COQ;LWHOV9JCS/FD9!Y*D:8:4AHDMPJTL#Z'+KS 8>LJJ$]:+ "$\.+WV
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M4=B<T$*HS CX;\K6GE>#+^<)H$82Y.>?@Q702X\@6)[-^36Z.TXB;PGVIC\
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M/.B!6.DHKW>E.4(UW2Z&1JGP$X5AG]&3D97CP+_DM+.Q>/,9;L-<BAM:)'"
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M+]O;H\DTG!W486JQ;R0_3DK4 @ +.B$I5T2DK*[\^'TA*<M!5$#QS?1KLCB
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MF2RGH4E5FPI4VCI4"3Z-9&C_>I_0^3PM^<)'VO:4%"B)[;TY-#2/:<$TL<P
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M%P-M0'VNG.YU!<=F0,K"JM85:60[//BM]74VPU/Q.?4/0@TQ(,A971DUU.K
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M:I/'Q^#,+V9P7I$QK\B85V3,MTK&?*-(]O58U 5=NWS@=P5I%B\._VE%%6/
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MK,I(0TS*U#$S,HF9K<SO+Q?8[6_-DWV<)/;26H1]BKDY X@NMA@E;F4TUO-
MW%*YG4$G13VG)$;!G:56,<.)-AR'$(7RM23PE23<,TF(.$CK<_F/9F#[DJ1(
M&^-0<@;640D%NWGQ"<]M S.VCN\6F-VE]EH!LV6%\[1ULD^2PB:JA"@+!CQ1
M"V)* D;2.><!FQ$EPKU54ZLEO\F2NR"P<(SG_'&.>!7OY %9REFR6%BOV=IS
MMH!@\,[!^5WHCQ4X_R&)PLUW@'6BIL01%*0"):(31@;V/\ID;S@P!JMX_[#.
M:MU_>-V=$\J"ZXZ,) 1QG"@RU(($<"]8P()H3G/L>UED\W3]P9TM_Q,+@YX?
M%D<QITCU2^+$J%N:?AW4V4ZY6W8NG E9/N&K[<$<]!KV<KX%_'D$LY+3J?.W
MZI/%H?W6.![UCWLYB[I*Q#@^[O>^@4P/8^?TTLP+S9),TK,4C.7,&:V(9-PK
M8G#2@?&;9%Z4_3/.XMJ<#!FV376^N&N_O:V'.R[O?5S[Y3O<&_Q S!*GDB'B
M;8Y\L9Q *!)BF'L2@PZ.I:KJ9F&6Q9E*@H453V5:O0_&2Q-]R(HS"FT4.)[&
M.AY5Q$[L"[UV^7XB^M=LJ,6U&V+]4HD.   ,%]0S%;@51C.9@K8!%!+)M1,+
MPW;SZ'$SNN%F>^#!/1KUXR[<^D6GY[_\8C'=>3D6TXW3UN<7ARVZAYN;>Z>M
M[UE,WQ_"/3JMSU]X:_?P\\[N-OFT^>7TG)AN;M/FZRWVZ?.[D];G+.)_=UJO
M7\%XBVB3G==-T?S\]Y>=W;]2"T07Q-2#58V8:"2\]8@;J\!)A7^DC!('A2D8
MX,I(@^S%L)'U@K%":$:$%R!EEDF;I$L2@X(!G,8#&.$(MO(X5\OT1W'M^9N=
MUFNTN_6^V=AY\6;[]<;N]D[KPUFYGQ?XA44S5S]W?IQ6TABLI83$G%(I=8(7
MP@0,5Z+1T7!9D<T$MOPL*?S@#T%W=N).RO*XW1W 7)7TNT<LD"*G\Q-/*0:?
MU"26!9)K9*WF2.&<>VJ-TY&>%;!?8OG?]+H':!C[1V"WW; J],\!$[#Z&0JD
M7J?3.\F.3V7QXR1BW.Z&4K\2&D\JH) _&L=G!D__&.^$4@4[K2PM9;<^,U,?
M#^(?XQ_^#.W!<<>>_M'NEB&6B_ZL9;DN1\TUK&>J;HNZK_Y<5V<:LJX)S06:
M-2]#_>"Z=G.]U&Z>*2&N_B;E.A7RPC_C=7+AWRZ[+>'KFK(;W?;ROPGSDP8K
MKG7;*[@OQE74.-=0S]SODJ\N('BH:A/OALY 7XL.8^YTY4+BG=]_'C:CCT<.
M4#PCU6G1W%S<$3$*&+EYXU=?C_*7,S?FG[-<F>@NR#(OX@6Y?O" )^:$]3$%
M2;CW1+OD@Z3),XL5^%87DV!<._ X;ZI?P<,VB@:_-\&!&QKMFN"B=;BS^=?1
MIZ-/7_9VOYRT-M]_V?EGBW\Z^NNH^3V35.R!P7Y_U-P\_'R.X()N\6:^\NC]
MX<[N!FZ]AC'O'A[M'>6@0?CRZ?-'#M>?[+QNI=P18-P9X"Q@:-&F@+F!>V^=
M-'<!-+S>/FT= 6#8??>M^?G5ESVZ]ZWYSSO2I'^GUL8^30!/J?-(8)(0%S[#
MAH11,L*D@)5)D66&-;$@V65R(K*;;?B;GNW^68X_^G$P;/1M+HD8-EYDMNGW
M^9?CSFC0V#@^[L VRG:Y? B6?6O4[X5LC/N7?.]B+E,0-U &9R59!94PIB"U
MX+8+YUP$=YT'@#Z,.\T62S([$^&:%=7M^L7R:.RP\LNWNE/F+417@GMG@MO<
MW6#[@03"G!>(!A=!=$-N]^,2(L1)92W#BN3XP(+$AO_.@CEG3I_^V0BC>'D-
MCJ;&2(N]DYQ;C[5VG"=)F!?,!^\6>BRS>C& Y)3,AV!/<X@B=B]7CDT['/7;
MP]--N&XE6W<H6TV\SY4P-CF*,*4!<:; J8\T=Y9R(9-..LW!^7T577]D^Z=5
M")874>*7N^4_W$'O<;&37>/]?QL*LINCK\NTR$O;[Y_"9*U@UDTTRDQO8&I8
MLE(#4,IA/F<QLCD//1(7F%6"*4QS--I<6-#^T[; 3:G";N@AG?4G5ZILI<K.
MJ#*9< @Z)!(8RVD2UA(A=(A2>R6-KJD6"&7GJ!96JNQGJ;+O$U7&B/2:"H=2
M!+#*;0X56PO_<&$8N('*! NJ3/(?;W1^5ZKLCCBW?\NHCW&8\4"DX()QEJ1Q
MENK$<,8>E'JZBOK<DSW<OMC!@3GX]NF?[9.=S3W>?/WW%W!PV!Z,=X_".[_>
M_M;ZO,%@_-^:NR]RU(=+R8+B!!&=V<1$),@8 =Z.3='+X+Q3;.VY6%CB-(GZ
MO(]?>YVO^7SF93^&]K !ZYHI;$YGHD"];N<TM[ NYW+W)CJDL="".V4DLYQX
M99AVC%(;'/.$*KV*#CUH 0</G^TG[7RTBB%+G 0CERAX\#:A@!DV224C;:F;
M.I^K>:/H4))8)>9AJ,QQHYC!U)' 2=(X.8+]*CKTN\B6Q_LA:0) 22$2,$=<
M*XM<[AHG@G$\1LTM=3\4'5JUT?AQ<++R)'[61IH&19Q1.9TH(A,$;(244_0(
MCRB9:'"DG! MUIZSBRNE?T7KC!NZ"!<>HS_Z/8JC]TDRBB57/.1\L1AA:VJ9
M))=!D96W?_=[=,;;=X91HSRBPC/$O63(!2]0HH'C -O5< -8G]RK/7JG61R_
M8GN]:G=MU\>J&_-C:\&\3#T+P9HQ4"4YC983ZD2B)B6= B& N=3*_M^U;CF=
ML?_1P(K$S$JN?<JIIIEEP&-D>?#6$VPU+VP\MQ5'O$>G'JLM.J&V==Y%+FW0
MUG,;M54)G&SC"/=16(U7YO_NM^C4_',6O$Z6@YA0A7@,#%GA-7(B"$-<$"ZW
MT*2WUOOHP47S?\7N>MMO=WW[V'9F"MTZDVSXGH/A5363/])?\\?.71^T2B(1
M0 /%S$5IN'+<2&T=&*5<H,>COR# NU))/TTEM5[.IE)H[T-F], !H .W5B*=
MO$4F..X4@#W+]=ISDNLI;LDEN3>I%+<84WC$VULK'YW$P5,<>$C$86M48()P
MS90A*\3Q"[;W%'$ I C<2XU@ 33BP4D$;H)$B0J!(Z5!B^P4$/7CF5)WM;U_
M^W#$9DRQG[M?E$J\]F P*M&)0F#TR((3%Y\E_TR<44U_'14JQ#OWJ>OK@]!!
ML]F:6L@8O.& +JA '$N';#(>@3=DN>>>,!ZSUW.>7^/I*B;Q.^S,VX,(JYUY
M"SMSB@ZD%$8$$1$L VQ/'B+24FEDO>><*>>4+ZUWSF.#7[(S?S04L4+XO]2!
MSQ0#N3HQ(_W5GEUFS\X>\WL* )YQBZC$"JPI]TA3*1&SBC@J-;$J)PSK6^B@
MOG+8?\?M?%O6>+6=;[Z=IR988(638 0);G3N7\9RZ T<],0DH=I8:G1VT!?5
M?-_3[?S;.^@O1X!"N\/&<:99A,UVJP<&C\,E^!F8HEZ6E2Y:1A?-9A (816V
M)"*2 CCJVFMD2'*Y)Z<0L$@29[)WLH@)<^6I_Q;;\F=@@]6VO-&VG$*$3';!
M-$!\(QA#W %8@$5)*"=C>>IQ(IF?EBSJ[_<@W?399Q-SGX' ;F8#OR'^JMGL
M&+QHZ(UR]=1XO(^V1OOV)^A^:^9?C)=:O:Y?Z>:E=?/.;/H$<2)Y%3WR-'<$
M8\PA&PE'CCEFI;!))YXIN\R%+9U^W>[XQ>&:E9Y<Z<D'$=Q:Z<F;ZLDIAHW*
M)$J"04KH"*YEI,ARFQ!AWFKF1;0NK#VGF%_8I/KAZ<F"@_]5*(R?GR\U/4MA
M?X[FM=YLS__/]?]UIC1U\64_G>F^W/&/=NZ XZ_!??^JW1\,&QM'L1MR2E=N
M"U%^B:'TV'D?!\/"&UTS%FP<]&/,7US^7>_1'%U*LKW3;8P+D1NE!IF89XV3
MTF@CYH2?=A?F*)-K+YBZWJA_;J8:3VSN3U3-J3M==.FS\N':>.+/WF'MZ7IC
M%[YPT=\;Q[D97H IR+S?MC&(W3;\,(B@$>'KOOIZJLDF,O.WS1W=VL-VSJ<^
M@-L<%**(!3G6H^/\6DM1XG*O;%(T,,NXS*W)-9':"$ER[R]LLG(G!O0[OS$Y
MRAM8LYU4S<*80J-IO[6/1D<O>OU^H4!_:8_A+\/3AVX-;LYMO_F1[F,B@HF4
M(R]C/H>T$6G"$S*)2.I$C!:3M>>*7D96"\)_V/:'C=+$+PN974H>*!<,6V^X
M3(QSC74RBEJL*2&2T(1O01Y^5[*<'UA[S_:MXH"OJ$ I$)J]'H^TP0'Q9)W1
M@03GR<TI:V#)P3 7O756'3VKVD(VRDE+IP>Z9J)Z3MK#0_C+[6@:&K GG 69
MB65)X 8["@(M;6"8R["2K)\A6;M?3O<3BYPS<*65$1AQ+A4RRBED8=HCIH9[
MZZZDP'Y23-Z$"'LB6&M%>G*OB0A7?,WMIHK4Y*]?*(VU 3WSZ=K3L>XZR28X
M7&R SS<!>UB8):.#O-,&)1,97O/<[ISL6Q=M?Y9N*F_'W."K"QNAX>R@/7B6
MZ7PRDHEE";(%@ \B+$+L_]%XTGY:[GN&B"I_M(",ZDF[_OI"5JH%%U5(YW_^
M2U.*_YP\H_Q._FP<Q?R.MI$Z(S\<52UG"S/6]!7B?T:@5VJ(=@AS5%XS 0JK
M!I(BS Q\(\$4#>J+\UB6(\0R-A(2?6;#PAR,F0G)A$A2U%$YZ@JW=:5[T"(E
MM-UZ=0UNK UP;_)8;&?RB>M]C:^J-W@%+_"^<!D]<,JL&RNCYNX&:6[L6VSA
M0A.1 ,V/N$H"Z=QSE*CHB37,$X5S:T!Q7AO]]U1PGC6>N$I"P#H=Q4HR0&XF
M6R5[0J[3'AQ.M<A&. (8#<MFLZ8""SBQ?D_\)6+_<$1M.OS'+FE;=.?=/DE)
M<.$YBO ?D+2@D0E$(A6(<E(EP%<@:>=K]V?$;$Z_G9&.>2V7Q><_HUYVOB]3
M<6]ZW0 R5);-V>Z7QDY*Q4^M>/[J)[W9?K'SOK[_TT;Q$GWOZ-CVJX9/(^_C
M8  ?5S2#N=GCU\O%O'(UN]/M4;6:RCNFUXU@CT]ZV2@#),Q/&[2_-0I7VZ!X
MPX-B6:H'C 9/Y^;DC#T8STE[D(T37));5Q[&TOLJ!X-*<*(3OX)&/"B;MMVK
MF@,/8!_'07;:L\M>KJFZ6[G8Z9VL-S9*VZS,6E>%KL;4=<\6FK+VLKLV1@EJ
MVC@A<L/CR,#M,8:DW%;6"1/-0GJ[A;MV,19]D2WU!WA%&W:Z?]M^.X\U#Y4\
MYEWZD37?[0MIDHQ"(T$<1QS4)7),$O"!C93,@-.9FT[C=7H^BCFS48N 3T%.
MA:ZR9"TG!T)1K\#3%2)0KF-T3#""M<)"4Y6,7LG!SY"#O9.=C?W $K%$&V0I
MSEF;G"(7!$-"J^2(H4FP?.QW'3DX:\:+-/STKJ'3?HT+(E[M^)C;-O+6QKZC
M4N2MA"C1);B5D-98(.FE3MY;$<CY_IQ1TT"]B<* "VN5X3$%:ZP"O9PR3CS3
MYO$?L(:YNW)GT ,KZ3Z7KLN]RGH>M8<E^IK QF7%T(E#L(79JHPCKO"'J2.6
MPR&35HT7A7(!/5YAN*[@PUS8M;?V1FN7D>?FC,>]J@_T'_W8*6:][LE8'^;-
M7%4?SN#I)=:!Z1T-+[[DHF.2NW:+B3PS.S/_'O:GE.0'$3G0H%^033#8/VSG
MQ)X.UOXUWZNUW1W?7.=3ZF7?_?JAA#N:LL7G01O-K<WM#WL?GC6V6R\!);4V
M&Q\^OOBPO;F]\7Y[Z\.]'W]K9W?K0V-WI['[[ZW&RYW6YE;KP]9F_NG#SIOM
MS8U=^.75=FNC]7)[XTWCPRY\T-QJ[=[_%WORL6M'H"MB>+KT6&\H>XLNNZ17
M\I6]C\_H8AE5)C51VK#(HS5:<RV85,HQ[(,T5^^KQ<.X2L7?>9M;"A"#W*3-
M+<'K1-RLY^QEMZ42;JMOOR&M7-?X)]R6K"OV$]KG_L31FMOLROL@6LR^!2B2
M@[&[[=A?HM/N@WBWE[.AAC?C4,/[K')^OU>=H-I7,?YN;_=F M#'AR*_WSN>
M]53SV=K%-6X/]"6G89GSKW?3PL9E,LU^U>Q<,Q5S^QKK?>OS<&FJ[OWR#<LD
M_<]_Y6#!GTN&\YP@4?I@A5.)!V-,PE9P%RD!F F ]_KAO'(8,VM:QI:E&)9)
M\ X_S-A.G<2ZQ3_M[IW"9_#==V3O\WL8TU^'.YN'GS]]/N#P?]S</6SOP'C/
M);'N'L)]__JRL_MWI[7Y-XRI=;0']]N!_\+U\/]WWW9>;PMX[ES;R7-QI=>?
MOC0W/QU^>IWO];[3>OWWY]8_?[6;_WPD+1C+I]?;K/5]&\;_/K4.]IE+L31Y
MBX(IQ 5AR$C*D?%2)D64UA;\$K:.%V0V#'N-P@E_:7^2QZ6)ECPST4;!'&.<
M<. 2)Q,CX\2;Q)B%#]CRL?)%F8)3C /F_VWLYVF#;??@P^5WO>5.)WGCAFGC
MHTD(BV@0UR' IA$419[KGKB6+*E\X,(6!-I_A:E:;91Y*U3AXLD^B:N]L.Q>
MF-90:&.", $L!J<,\40QLM):9!7Q%A,GE97YT$FM]L+M[ 7M>,X[)"(JR1GU
M5BE.J-4^:F^45:L#UGNS2_"T#1:8!46E08IFCDF<)'(L$*2"TYPEX4N+';H(
M9JUVR8UV";9$!B)M(I0''376.AD?M+ 2U--JE]R?74*FMB0WHN+*(QF-16#7
M!3(B:40I=<1J;GW(>=97[Y*?T![B'NZ([9O%/6[6"N->AS8ZPV7C&BQGT.8$
M*242>+W6,'" H]').VP"=:NXQJ]0!NV+XQJMSQLG+;KU;6_WK_:GUZ\^P[L)
M& ^,Z\NWYO<-T?S<:7\Z^M39^_PJQS4\(PY64R!F+$8\&(Q<4A*EH+A@U($-
M8)?'-1IN-&S<+&BF)/4L.BJQIESSZ'0,8'9\TL%FK+P2K@<L7,W/V_N46$J"
M*'2G&G$'GH]SAB/O <U1:V)B[@(X]^-1LP=IJY;<0-$;P7"BW"BNC=0\</@A
M.*;!P90W2")=!<9^WK::!L:H9%I2*Q!)2L"^P QI!:I7),] O@*V(I; V&VY
M.:N]L,1>6,6^;D7<I[&OQ+PW/KLJ*>7.>9& OR(EPD8:IR@FTHCLKRPJQ%J)
M^P757X$F\-NC5M3PX*-FUG%)2,C;@)(EL-/*<?_)&V$:WB)*\]S)&]"V CS$
M142:Q1P$5CHD!GC8\%L- C^"C< TXR1))3&!C6  7B9&DPVYMB:FN(2'NMH(
M/WDCS$2P%),B)8*<$!3<3@$602IP0!/Q3MNHB2^EN5=NA)] 5WX/=\3V#4-8
M-^-F_\U"6,(2[05S25/%E;(V1N.]9R%)2H4BJRC#K] &IQ='&?;^:6)X;GOO
M^Q>VL^E%CC(T_]G"S<^OOC0_;WW;H]MXY_76R=X_?^<0%@Y.)NLP2OD\E:L
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M%I.W3Z"*4XJYH]*(P&64+L*683[<P+ZN8@P_;U=-8PP.)^FTC,AX*P%P*HT
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MIKR7"_W65^O%0]M;K1>W6W\W!ZSF'FNUJF\Z&39_'.?&LO75SWK1SCUTW@:
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M4RYRKCUUB<"_7$I6:*+(##&$HNF+@IC[1\P6.0B**BNQ1 9GET[9@"S3!+$
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MA$V._%(DB!#*2N=(BBMK&Z#0:R>G-E[I^2C :F7TU>9N/+,[X9V37IRW(?^
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MJ]_3V08GML41F1OL&H/ME<2?>-,9%HD)MGM/+>/-]?7EQ\LWY[*9%<J7Y?'
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M">OLB&0V&F&?9SVT).R1A5))6? 6B2BVVY7>*<B03(B' E[D0^*?RL0E]LP
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M5'<@#C*[8MMA3,!JXC(Q;@?TI1W!4Y:WJ%*[K43L]^!7<",0ZI*#KX3B #8
MWO[ 0&6":U$_3[7@[$D"9[Z5*V0F1@D!U][V,I\*J;7,Y$PN<?U]98X% N?^
M,,XX8\;OX# ;IG%A_&Y%L8!ESB"-6@JL>>+S7",46H(:"U=_!K?/)[CBV\R+
M22 BB]V=:7J+XO@0%E@&3ZBLDNTBD2HA1&T"#")?^E>A0FZ%\UWEZ>T,'%24
M/"[$#])(01HI2",%::0@C13T8M8V%/!&(P75"2DHG7,:2+^B\R541>I??LF\
MR(04QZ@",0[\\K5'0HKI<Z8"-;X.78H'LN3Z[5*BM;=UO_.!@X,,LO%U\Q"&
MNIB*><F1K*85QQ5-L=KE;=U>_Y@()7NJT]<R5R>9,R?=TDUS=#>N$D<( O]B
MG79N>-,#T^R71C/0G2E>F4F340. ;JK1\OBEN*NG?,"MUY_LVA2R,L=<]/G%
M]9[MI+-KUPA]BK%"^)SUM7/=8YHY[8IL![]PL+;WNK?""CYG\YIA/1/G=MK]
MVN=6FLZD<7_7[JC:$]B"OBKLIF[HI,C=T-P5+:,RT8?NZ+2>O5US5^^O>M%'
MW=P.#0 G^GSLC.RJW8_7XM&H=[#VJ-K[>!Z8Y+!FJ<:[BJ7G7_%E-GYA%Y?*
M.UM:DD]#DOOCRH8-#?(KBZO=;JTY,VXC;!/RBSRY9IZ_7^M5;C%UA2<%#:)>
M5+FVK5]UF%$VWK-("BR:BR#[3$OV!B%]:FS8O6./G(YXY'OD-L@&/E]<MH^J
MDAI*MWFH@MGJ";>&+RFO^YH$57)0U5<WET^<^<>6$]1P8;=T<GV->K?L-FE]
M;;IV^<JKO1UA<&LH'2?F\0FU]Q!X,0+L=L^-L^&+X'5K*-REPYGZVG3M\957
M?3M6D==0.DJIOJ2#BA]@VYQ-$O5:5S9MP'7RJ8M3ZO]D3]1VRN4T'N.3%5G&
MA2%LSEEOQ^SZ'D]^'^P9C?<;+E\6*-77'HPGK=[HB%4=VFIO51+0;_6Z98L"
M=.W-]@2^838.90J#$4UU=XT;ZAL4]X>MCEGV"( ^!/3Z7!H-RN;T]3&@73,(
M+\L>-*Y0O#=H]<8[UNE6ICAMCZY$XQC<-5N=RC)8ZIYD('+D0^)>52*EJCSC
ME?3T4:4UW=K'+N >PV;/;.'RP#FYTQ.C2<L<U[\U5L.Y-!RWAD-]?O. 61P)
M7;A<\X.M[5>5A'%6 C-\VXBA<DJR=/%YC>K+NZW)>%C[B%7+7+UD;ERZID['
MWSLX=1EZ:Y'J'IS<MGY_UPY1VL%[-1X-CME#18?'E0N/CZ=&_T4H6OZ]\3$%
M(J<&1ZA.Z3?="KO.;8DG9KM;_W9-6N9J)7.]MJGWH ]'7Z&I+<_X:OG6/0(+
M[Z:P==A8Q<73[AVQ>:/.5)RDR/4/=;)5)RJ20H&7.=4GV^BD]/RKO=3@W_:@
MJMOFK^2L:UENBBQWVX,=(6^JU[:G;D$ F9%3.ZUKML:3?JO3J?]>7N,9-9KT
M6L/!L?W*GPCA^N=5$&_YA@M<U._[@SP])8JY^,I%L/CH_05"G;\^-;NB\\RY
M06VZ.+7I4D#HC9 M0D*^YP1## XF0KX:]LSR[_%* CU/MLI:1J[1B>4[\DR2
M+']H*7T C"!,BENG$N-X0;C&AL4-*WU1,*6?7O@&^90%/#^4KVGG9LP-ATV!
M+O1V4<I%R+8X:RLR'IDQLQZ8[(X+5^&0X7N/6>!UXZ,]^O#(/+AJ#@2?<1H<
MCZPPBA?R,6+(V%D7F(74A7%9!L_&H;RYO18?OEZBU3TW<I7,KF][L0,OL#RU
M+011*UPZ_+ M#2;M;:C0[>)EQZ)#+Z%#1@#[KY@V1V"F+2$I%R@J2 D8<? 0
M;$V 3D: E.>]8\ZV?VZ4K(%RA8*QUMW%K-"7"X]9]LQ87W.)JPI_:9<=0LBF
M'K.EIHM"7*.D Z/ N/[TRU<#+ ?\[,(*_X?EQU;X9)@M _&FB65X$X\Y-LV6
M2YNSOV+&HU!HTNSNKU9Z9]M8RV%)T'ZW/4+F+@(QFO<A\RQ\S(='UXEFTAZJ
M-PHS];Z3W6+=@0,<1^MO49:.T#Y'DION> D:6?EW%F:R?\\N[D)F_7EA36&P
M[RWOT7KB;W[*S6GN^A=+-%R>OICDS_]]%\*M!2^NSWH;G!O;U:O@!2BILP!T
M\8Q97C1;N1.$=;60V0!BN Y\<?>T_@'IQ=G]3ASB[F]FWVNKTX;GQC4Y$$^@
MBPQK#GXE$(O\@CO&T%6RR0D(8/;D0>%'G+<=AR'Z,G0?N)-V[)%*6$\)@?PA
MPM=^H6D["A'$.!QF!T*GO0?/FH5XE=HT_(;QV%-"QPV3&U9G;C #M!:>UR*7
M=AF%#?\#&H>#1+_MF0F./"X5RW@[F*1?))>A:^RO0DFVC>\@$"0( ;Q.?$KN
MX;0ZP4D%"L'T#-+T\$(I1NY\8=GD$7_\]J\OGR[,";Y^D8KDWSC<0:1OH9>I
MCD1UTG-&4"[8EO$X<\&HDA_,[="]@]?"?7-T2AT66:X',NX%C^"G,"23;Q-%
M4+#IPFP4ZJCAQ]@6QUA=9*<UG2)%T5H:'!A.GAXL#)A9".28XR*1H\WH#Q\H
M',%7.B$8/A]5D'(+3^ZQTPJ3.'(]]S_"[I([Y7+;72#+@5$_6@:8R!D24LR:
MEC"LV0CF'<NA+['H7@'DR?QWXB92.&)S#D$"<@^\.!>DZ D>/^4@ ##6)68@
M+V..?@DZ*OA:9&LZ>(ZOY_$"]"<1!&>6DLX#ZGO"12Q@<; &PF,K15.MM9@3
M 2G6@L*6QP.Y%H0UL@,><57LTN41H<.-#WC;31<HDNZMV4__3H+/:!8R=D&A
MFS14W& ^&KQ_Q" VO0XY;";=CYY;"T>U$!Z=]Y0L(!IAQGE\,)B% $0]DDZA
M5"<6YP%P&T?\Z,(K\<J/ES=7M\8E",/US><-GJ%J'<;5X=HFZX"HNK=2%=XL
M]3^MDTP6J'35,BB&X SN.1?VP>R^RRL -1ZFI6P,\U=LTM7"A,B[[T5']4>+
M*[K1 @'-/R^+LW."JNA@[RFWIM(EE-/MXM7;#C0)Z<3J%;D.LSW)CRQD[OPN
M#CGI.K!;QC3V/.,OB*XB5&73W<(J?! ((BE\>,EO?UQ?)L81U<$T#.8&4@0F
M*WW>(O61F_N*3<6!36.?[!N&]4 ]-YS+G!5JXP4,D,R38'&6,J,IP14V^RER
MYXE%O&?!?6@M@#MHKH".R7S59S5+*PC(J<QS_)*'FZF-8BC$[473SETT35**
MEPP!R([#*>4%PNL(F2RP E]@]=I /(<<H-16P.J8"\F"USA)$BDB=T0\&58U
M^&S@:0BIMLF9\;!*0*Y5CKG.1X9I."Z-J./">% 76)%PAC"[K:Z)MO$9U@-*
MY.,L "_G(GC$K R/[[CKN."V,M0P,EO*,)LBWBX<,I8L&H=G0TJ76[($Q5 "
M'ZVJ3*R$#,PT>*GT6$G'_Y#G293..\J<R4>L-_^#]&\E/'V9!R!T8SH9,0)*
M^!98^@4L_AGJ$9"#Z^LK=$C]& , T"$TC9P["R1=A&SNQO/L@B*_$51+^OX9
MR">HP#GI'M19+<4]ACOAHW_?(D4+VA_UY,)ZHJEEWA,H6;BH<&*I[[^1?H7D
M*^)*+HC&K5LYQQP0+I$O<?4#3 EPDA:?=G>)P. G1S(F0,4I5B0FDHUO8@VJ
MK%<#J:59226M:G_59T1SNVF@9V_-GK@8IEF60ATIH]N)J'S 5PL$RNA)\W>^
M_(CE :\+%%Y"XB89I@2"6;JL+>/J!R;MD52?<$,,UW.B32XA2(YDL%D_TT6,
MSDNO:K>D&EM28<),* J%7$"Y:# QR%=]H,S44$I,OM-.2HWGHM28HUW!#30W
MDG%9(+(RH,L\T+/A4Y;=S^5KA$^]/)7,->^]4Q(K3DQ&;<7MEHZYS)\61?(&
MN/(@,KFH6WDU>K]TNU":FQZ/J99D&!L#A*)Q+&<_"C,?+20VPZ0M> Z.&'[B
M% .-S'9W<ZHXGP(1MCA8H,<J,ROPD'QB1<QZ2Q+E*)"[8TM?1)6I9[-2]%C?
M9^2N"RFVLOQ4+CU51/"%9_GHZ#Q:]YE4@4U%,\O"-<N$$CU*)DI)]P3A%FF>
MEI(9I'3B([POS"RU?+E,PKL^CP4):#3-CA2NEL%I:Z-PUUE>)8N0)1$*5!;W
M@D<'O.XE^<8 V2F*8EO/R6ZQ^+3$;JSCI/$*.+L4LZ:""V9O*0UQ=A=SF#''
M+#((<+ @R6:@6((GQF2XDI4X4%K"=T4H_\"$^ O?Q?4?P/L4^DV9%&W#%JU/
M($JZ#+<(8O2FJ[KI.JGJIFL%%-5* ^9G%-6O 5^@YW'+[E%Z:Z>?T(!/(;(/
M'BGFH*7#XSEJH?^@6P=6:B:GR,44T^Q\+AQXOW;FAQ?[[E8SS5<.RIDFBYFJ
MAV$DGK7@['WRX4/2;=SUZ7ETTP?)2JD!4.27BWAQQN)GN1K&@_9PU,4%(4N(
MY8OE6FG36EDJ9A2_C3KM4;^W]N=.VUS[VZ;'FMWV8+#^UDV/W?S;<'"@P6[W
MV&?*M"O19&Z\5<5K<:%K.J?)-G,2Z^TXLRKN9/]91GG?*;'QE1(;US+W1A;B
M*I<?*0.DT!S>*F7@)8XU5)OQF K<UX2W:<K1),)UCH$@E\XY=>%>T>D2NL+U
M(3X!S]_XDA6H)Z0XQB$$X\ OIR>^=S%=;F]!GS,LV!&!(S]?\K]V.5JRM[5W
MR*8ZY0?9^// R9Z\;JQ3YR8GYGC8WO'P8XW.ZFJ9J]+<S.&HK=L"'XZ^ZMFU
M4SM9:Y:6+'VH]M4/W+>/V!IH3WZ9(/6DTFI@M8A4@[LH8C@9[>KYU*6%R4FS
M=S0JK69T5X\]$;^X5/7$?)%NNRSVL'9%7IE%H](]QJOGB517"WS,E\F=6@/[
MSD!WL*\ZDR;E-8#.1&Q/WE^4\ZPOL?Y-<TXG@UW3%)4)/?;H.#2-N^/RD<=K
M<;?Q/L>ZPM<3<S[ZDUV#7^U[O!J/S J@YS37]_CV3/;AL%:IQAN*I>=?\64V
M*)WFK9FOI27Y9"2Y+!Z-]BOW5!5(75QOJ7OJ+_(4DJE4O^W@]2@\Z0'5G2#&
MHP%[*7S;UJ\ZS"@;[UDL=Z,YM7V- Z7,*V=HWNVTO$][1Z5L1-,0X6B0_2N>
M;G+@,&OQ=6(9E4-M$U1<L'4J9QN:G1TJV58]Z3A_F=ZKFZ^7]'9W+&R/8#.?
MQZ>&5G-VJ#*6J@NW]OBV.U4Z[IK=#R<C(TWU^XKS'O]D3\9M9$4NI_$8GZS(
M,BXDQLA9]V4ID*HD.4XSC;$GE[Z^FLOLMH:CLBB6ND;SU8_TM/IF_0^,5%</
M[,W%K6_\9O9:W<$1-^-UE+VEOAZ898,173*Q/8%OE.[ZCO740AR"%P'&-W,_
MN49;QN:PWS;K?R)6"UVMA&XP: ^TQ_9J!VL2?:T[L=2Y*P96C9<M[ZF>"ZIE
MKE8R-VCW= WR*X36+K=G5@B?/.;?"U! 'JUJ[(:G<B8[EB]6R!-M.H<.5;^S
MK3;XB9H=__P,:F^ON)EUE6!\S7.#:D8YU8RZ62M)(T1H%TX]YR5<,;;_5(#;
MBF!46\9JNMX(PA3(7"3O9/8N19N4X#T6-ZST/1(F;+<7R.?+9PA@ (FWG)LN
MMN:?N@@'@*!?62]^G+(5I=!=XIR6Q%N'[SU&T,;P:(\^/#(/KB(@(M'6G^#K
M$;V>'D.X5PI0J@#_X]DXE#=OB0== \GJGLOM-]='M" $/+#_BEV>H+,1C2Z0
M2(1)R_S@(6@6;E(#0* +@6?7@\060IQ)_BOHE^G*5"0"O[J$85H?<3' W_00
M">%EG/7[::=]=9V>MXU+1:H,@;Q$[W.,S=!=T[2!K@+BE> .NJ$"9Y<;)M[,
MX:V<$'-P-JU"'(!BLN4@\VBT?A 1RN<380Y9(=J5&B(4;T0+#]G<(BT[]4 =
M"I3PKLR\E($*YYD Y84*WLZ!D:17WXXR>$/;#F/X'@S9@QO$G%#$)>Y; 002
M9U$D\8?0$XZE=4G1B_YHW[81\0ST5H)L^@^DNLT^H*E(P2N!I3AR!:F.,Q1"
M%<A5@/^A==C\9#! 8)F\ ,67@+(("L:]%S;ZC#-F_!Y$S!@:%\;'8#YW)4P,
M81<&B&5XST#*!4Y-Z=6 YDZ"WI B3[T#6'>H&Q)N"!1JR9)BU%I:0XA$E:%B
MY)>\$'^)R.=+<UJ$/2@@>\6K!2,S8"BXMPB46(!U+4EE!KUH#O.(F+WDSV50
MR\N4& C'&:R'Y9Y:#P$NY3R.L/"=^ K2K\3$W0O8;P$*NXK8IN  X_"+W*85
M;-^@ !8O06 "QYH3F' 4NA+<_H[1B79$;WH&5ND@R.UU\0Y.! 1\2<_G]<8+
M5894#@1Q!ZN(H+^V5",%6D05Q#5Z!-ZN*(LB?9!<F?A(R900<U2 8:$FR6F%
M: E%/*\:LD7^S8Z".WA4ZA.]S3!868K(B4_+**1X+N?[U#((ZEKJY0G?I3YV
M4&ZEI4+;D0 >.DLXBXF>V<K, XGQD? 5!G1W\) "95@,9+F56A0B(W'<-6B:
MH@=ZG3PY*@F:5BG-B0ZQX80(XHKRG$0/J;>+JT7)$!2F-U"G$/AA[]WRLBF
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MDSM=G%#_)WNBME,NI_$8GZS(,BX,86[.>COFUO=X]OM@SVB\RW#YLABIOO;
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MKO9<6^B%!4+0TS$J'^-3OF4""*0G>+1"$7PB6K<TBU,W!&HGCJ=0^&$0W\-
MHH+<*)D7VA\2TH+^V-+4Y$#@Q]3!A&\ANIH94\L&0Q2Y<DXBGS\#&Y)S\XID
M@+1FD0?'"R>.<N6Y4QRD]/%P*GLD>LBB./1IDB&[2,7*0^3Q9FGE92_Q:KDA
M9FVT[II<9D[E#G,J%SR@Q2(,?D!@%V'&Z*W9R[9)IEER0O& UNHVH;Y#-A<^
MA+)DLB5L<%!3%%["BE'T+J:*'/4MB<"UUJ@KX7QLTE@:7#Z70!G5((%2%W#Y
M:Q9RVI"B)=!@B/E%,E':^=9 \QIH7@/-5P2.7 /--Y6S#<5+UT#S&FA> \UK
MH'D--*^!YO49L]?MC*A/-FJIJZ34-?YLXPF#S?=V!F/0)QE?C4?#7:%?*M2"
M0H/-UQT0< =54982-6HZUCCNEE<RK\7=QOL?&FK^X'@LVAG9$YLZ[2-VOFA\
MGNC$X>8'QX02U9U+M^+1^)B0O(UW!338_)KV7NT=6W]6)O;04/,;F*N!YBL2
M>IPHT/RPM'K1CL>KLVC'_(3V.[;1 QIF_D4]K9L"SMVM+#;W*_5?UX+<%$&N
M:L#0()]R%Z UC3=_HB!M?W<]C\YSX$''4P-H,UM=<]@:]31&6^49U9OT6Z/)
MCAD);2"VV>7PQ(%LW.5@SHFE&LQ.:](Y(E*!SC9L"= VZ97M(*\3#ML3^';F
M3J-3\P(&YK@UZ!P1F$#[ %NE&LU!:S@RM0=P, JK\(P8#NAS,74^H= =M4NC
MK53/H]$R5RN9&[9-78CR.AJ:HZ^FT7/K#&0Z'+2']3_HHV6N3C(WF+1-G48[
M''U_Q3SZ>@7=\ Q-^0V^ZKF<FD4']M"VQ&"<M+=!R^MV\;(C-8(C',;#(>9A
M=[8\38@DR5>A&-D:,AV%)'L'UAO4C@2K95O+/4#7]0;$]I_8;QXNEDAKW:RG
M,7L>8^VYBY1VHH1I(U$5IEGK8PF".9WBX/D,>Q7?L^)>R(0IH2)XR;[.RUU1
MTQGD(3'$@ N&@. /U!4]>^G<)=0TT907$?R<V):MK9,NRMR8RT,ZJP1F\X47
M/#$F6O]2*W?J%)[T]KVSN,NK#=]0MLWFQR!<X-?U0VS8HK6FG4SNF7::^QW^
M+ITR2U ][>^INVOJ[IIU[L'8M.Z:NKEFLWM$ZN::NKFF;JZIFVOJYIK'.<.H
M-WCKM'LP[K<GM4_P:I&KD\B-)KJWQ0')NP*?9Q7!YYU&B:'9V;7G086VXQO.
MHW'[B)6ZC??:Q$[6R[TVZ1#+5.32:;OU[O(IF-Z]D*;::W0R*+U(]TB<BGN7
M>FF<\M(8C]H['C,[YM+87+:Q7+)0F<W$=!O4")X'^%S:N!YN@T1>!$3>-M:B
MB2YCCJ\%!$U@BYWU&^B( 8J[HC!6N:<O,3W5QZ _[_H1NP]5S&&8,R(\.WDD
M416%.5J')MU2=E^WH*F"Y[XT>CGF=8C**+/X/G!&IK%ORX\\7B!^\K. R]D
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MU73V=,?]=N\H##H-?_-,ZH+SG.<Y%<78+U<,]:V'.3,[HS*2IPN67IE!W1W
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M27++->YDH66N5C*W<Z&^%CDM<KN)G)8X+7&O+'%EC^-JB=,2][(#<%V-RG=
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M#X1K%KV>NU-61VL6U<+=T6QZ;64WW+6^N4(']QK78Z8,7%6#=TR:<G1V5!Z
MJ2P%*KZ]IR6Y&9(\UH*L!;D)@MS;M6Y,"[(6Y"I-_$5I92W,6IBK-/%)IS3J
MR&M)<N-KD@[38Z;I!2IZE)4;Y7Y&UD1K49X U387W<%@5V3KHW=GJ/^!OKWW
MF-ECARO]C)H^8XNB$KETQ6HK6KW-:T+3>6$KK7W0ZD5Z\*<(/4CXK^,^_/S?
M\$\R<N59_QOSR)T^[9W&W>=HW"UH0?/ZXQSN8YB281=H*=[WAGG!E@,77[F^
M W[^^PMS3 OQE<6:YJ+8B==__8<<J8;M7A_I\"T.#1!D._8@#@I\(Y@:SCHS
MYW(#EH[[P!SC[LD )KCT=0"/8.**#<&4847&/V*?"7[V.M0'PS3@T6EW#/F3
M;)&![\!'6[#8K'L&PP**&#Z+TK< &1Y<FZ5CG0:A$<T8_"]D[&(.])@9"QAP
MX' <( R[U !:\&"^8'8$,_:>VFM%<&Z%]ZXO(O%QH0 >3MSHB>]="&1=.R<!
M*ZU(2 "_ !7N(N;XC/.MYM.MRGR*%]1G-^21<3D'[LY1(J) _ &L1K[>,)!=
MF*[Q,62."Q?>@V#@A96<^\:9?O.-S^PNC*WPR>BC?)J3EO'(#&KP S-T?9@[
M"G\!27 5+5/ .+.X84E:P4HKN+5%7[Y)"+K\A#?G;>,[7+#N=V,1!J A@ 2X
M+BU8K;X+'SBS8QRP+2Z?6K;KN=$33 !8!O^ZD6MYAG4/C[D'WL%37-]V%_C=
M''4*:JAX@=-Z.^H.VAT#B.V!Y@)JS%Q[!D^PO1C?:AEO!X-.=@%(PT/@/:":
MDD/]G+P;W @F5,?*)%",+ -H/#>\  :8CO?1!>UB;1J>.5*&9YP1,;_C@W[#
M!R4O?T.O #'R$DTC'HV7KQVQ9,W2MV_.$R(\(G.=]:Q=K\S6"OS/_WT7_O3S
M$=V%;1<*"+NX )6 M!TNK1*@0(@BA?((;F 8/ )IN>0^+I*M!0;I:[9'[XAW
M9GO\+F][Z&ON_MC2!N4-38ON[K;-=_+#8+NGKV6-) \V=AP "1<!=]'4OP\9
MVOP']N'1=:*9]+S5&Z43W<ENL>YXX,71^EM6>H\=20KZG3PYU']G8>8\WK.+
MNY!9?UY84QCL>\M[!.?GS4]YFP &88F&R]-?OT2JNU R:32D("Y[/,:+UE)>
M_:TJ/KF(^LDBVE+,RRVB3K*(AF6?OHXH]7,=+CD:I2**(9_LP*>](_*3/":9
M'&(T0!SJM <%%Z9"8 <K=_3-]H3("^X)MK\"RVX'\X7G6CXXZV3<Q// :[<P
M2,C,[SI?HG%4MQX@FK'N5/<C,T#BANVLT-O^I-/NI<L,O@&JSV"M&F][JBW+
MQ7&^NF214V^[D_9HW;4>BX#9-!WAM-60&[>PXG\/0%\-C M00S Q4DC?[F!L
M%/@*.M E9@>NN8WO./LK1A?P"N04I%0ZTK ,'.9S]&#5!3%U099M=%TIY)C3
M+>3X0M"-+X!?'!8!UX&0/CU));,'0[H@+S/(AE1-.I<,.6]GJ -NV"(.[9G%
MV59Q9W$>IS)A)R4.;J/ _E.9F'$=!O>A-:_B_)X++=/^I-U>8O10>?L^A#0V
M2'<TLR*2V;\'5NB@)OCDAF 2 U +5AS-@A#>AX$2)Z*$&5$6@B@MJ>1D>,*,
MN?6D7I:$3)TEY0=O6EXJ8$O 9LLW@2T/XOM9<0;'W&H!58H7?Z2F$)4!Z5S\
M(Z6B-*F6YP6/R)= )2+'I09:)PSF1@2CPI_%?R65@@7S@?+AGYA$2]8CL@;U
MF.VB'L,(/?UC(8XL4MKM/H# '+^,0IB?99.&0C<+DWW,8R']N)[_P+V?* \
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M'6;#S/4V5%(BK3C.I.T+[EU.L<SUJ<2$,U)[7_&MX2)D9ZLW_Q3(]G+(*9[
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M-&0_ L2Q7.)8&A?'C>6P<1PZB/V"1),<"0!V^[9(AX):;V;L[M2F;NYN%%E
M^$?Q#;B%2@1+#K@:[PL-8 TE_ZIMX+>'0'R?!1(/?A-_MURZOL.B+^ KY.0/
M"3N/J)-(^YU#;H_,D/]\(-SBS,L1,*=+SI:4!RX5Z0-2(IASZGP\0>%>2X3Z
M'QZ9OH&1)$UV.MC>D_CS*8!0K[>920*+[/GQ1  ]/!JM394GON2TZ,0!1,")
M*@G]T\_?(E[1^0.(%7K_/Z9O4Z?H] '$]=T#9H_0$_C=<$$_;3'0[D\,_.YV
MU,U6NV274>,$6X)O,Y!/=5"<X3^CMC$$:H:$^O7T<=M'6$)![8'_2?[]F+-C
MX+B) O 12VC#;:_E7K#XRV3Q5$LZZ(\'O>ZU.6E?7YD]L]]JC[^TVY.Q]C)G
M(E L?4,N_1FL]Q@6CB9KGT)EQ+B,"-DK12;C(>$PJSD-7!CGT>39QJ:F%>YC
M?5H9?]G"_7\OE';C"?S_3;L_&0\Z@V%[9$ZZ\.LA=,O I*;9>;W>5-%L@]08
M=(P-VE=J=<:30>L?7P:]Z_9HW/[G;7?RVWH5CR6?"K6:GDTP'O3IF>[G?XVH
MIPWL*XT[+7/\I=,;?#MZ0VX0J>GWMEZ_T*<?8C4DVA=$J[XYN1VUTS)NLT+P
MR>Q?#T?M,2R1_#CH=+KP7:MK]C9KITO-I^A*06]0E!N-2+5TA>4Q$7(*'Z)>
MM^7M7XVMG@WHVDCWC:W7O:>XY)4OBA"K3SB'6=S1:QH0UQ,_D$]VNE;Q3;,.
M_STKWR"Z9$3&7^(QO20=;7Q[<V..?H.SN/NYW^UT6R:L6*LUN.U/NOW/0UC1
M5K>M+4@TL:EEQ7E#VD);-(\1R\-\@]K8X#82Y*^T>[3:0^:YEDNU-WE!K"I:
MGM6;9[O[5Y^68#O%W;QNR<<$F)"I]]1$C7&J2'I>?WM^'$FC3EX)^GCQ1_2.
M^B$=48O-HJX//::?K#_UV7S1/$9.0^-X!$9J"*^GL3[EIJLA63'>\H@0S\DA
M^_I1<\:[IO20'<\9TY4A^S9DYZ\LD4FJ%A%SXMOX3_O/T+TC'LSX>;A"W96:
M,=XWI1ON<,; 7@WH/?HCU?\K;V2K:C!*F*-I62R$E0)I2V'5X!!^WO-%OULU
MSUPVI:OO<)Z)!V(D(S$V0WD];C0(V2$N_TJ\D#*GX_K$MUSB=7T1<!DE?!XA
MH]FGDG,:]:9T,A[..3@*0P[#8(ZQ'HB1&LDKWV32\!O%[%!JFW>4DQD=SPE,
M>A &F N&6:C/PCBZG:HYIP$ZS%&<DPRC%H_#B 9BI$;R(CFG/_C:[K4&HT'?
M_-H=W8Z'9O^Z?=.%-?S:O6Y<:CLB<] H'4P-]#'M.!41HY%":20XC1.)M09H
M7PF5K' Q[X,>,J7;H7%^OFMM:A'M)7H<<A:\J-M?#YM:I#9!^S^0?B]03IJM
M?]YVQ]U"21);,&H)^+:Q:X>EP5_H2A>3:GL@U2+LXGSWW$DC>8F2*CW_0^U1
M)0ZU5'H']J62)"\]/IA>C"%G> >('$&>QRC4U'D/-EP.=0"A(3&^2.KT!OW/
MD_;H9G#5ZWXNEE*W#U1]:%PV=ATQB*6&:(P4GI=-@#U?%3M7"N%4GCAG]?/=
M<WXOR3*^?8$'TIZEQKND=NA1YO28/YM0O 8Y#0I*P<)XE:+QK-%L[$1A]].P
M9B3]H!,+>ZIA5P;V]2HT-2CQ1^.Y: R87ZE<-I5-VY9]HH/904T"/SS7YE9V
MIN8%T(=V'" '\,)F!$9J"*\L$JU=AU)!?'M$ BIN?9OR%@=:!QUBN9Z+5\*.
M9PSM+M3L<-YL[!B36>R 7<JHJ>S4D+T:4;?&IM]7'C"/,D-U4*EIVFPV--6U
MEVZ6M@8W-]V)3.$U^]>M@0S M/M%<E55*)2&T-G;QFY<,85-)A]OX7LE#*["
MH?NJ"$KU_KIH-G8L6"7A7OP^&[<_X])T^YW!Z$;*'NUP[2ZD>E>]:^R)N49(
MC!26%[WX!9-^L^#53H/WYWL2;G8)\1*= [LK>G .53XFM2R[;#9VDUOV4.E5
M@CU>Z,&2XGKXLZX/Y  #;42Q[@LR\YC.#LII.J8/)9G/Z\V&CE2$;]==&E&?
M:/MM>C62;E\F$WPQ1^U1>W@[:GTQQ^U''[7)K,:B/-[.&XW=^+?$8&Q0['SQ
M<DETL%S-0:/>;1ASRB72RY:GHW8/;V@/S='DM\G([(_-EC1)L[[7)5QAO.KM
M=M[8#>S&J R)RT@C4_ST2MJ##3=M?.I-V6PVBI#R96_/\>T5EM( ]:#]%?Y/
M/[EV&TR]N=XV=N/R&PR&1/%RU[SHS<Q]P$H+[?SB?%]B^_;ZOTCS;'LM#[_?
MHD:C%E?OFF>YF^/5*MM>XJ<.NQR*7DW9]\VS/3>?MRG[&FR)OO[U=+MR:?1Y
MJ[HIUC:-2TM+GD R_M%^"*B/)<L'SH1B/5;"5^-0+),OQ_3/D(J 2RSQ-='N
M8DDL+&4]Q1^LX..)0SPLVHB57#^>'(/2=ST/Q>C'DX"'6 82:WU_ $O;9?9$
M%FJTPP@P^6U*/"QU_/'$DB0_,40(PW*#$!M]YBQ<?CR)6KH!79P84;G'Z)L%
M\X$I^*H+OR#V35W8G77JA/(22725C=H=SA8W1(@O8/BW"*?FV!S&Z=E#SNY<
MX$&8,C"<3Z;(@2OX=L;)(G/1G@S_$2MHT^GS+:"\D#.BRY!;<R)H/-X;NIAB
M4<W-JD2CCA9%#5-DIEISB@K%?[#9 M958TJ3N<OMR1Q$Q)QY-G#[G'*R7(TI
MOW,M*D; YR['BNT9-->&?_*9QM_X 9U1KC%3D$5TX&Q)\=4FL>&*<<[N@7M;
M!'8Q_)0YX\)X\F<>U3H/?K XN"'_9GP,0_5H=%D?-B-L5:[FYSRHTCFZQ4 .
M"Q33<):BW/G"Q!)X43VM/*C2IX52] LE7C"_ ::P8(3J"66W+WTJZQH12V0@
M"\LT$$%@ !:J*3/*G ".? \8641BA$< F5OR<(1/OQ:P$'''A8C:9WY")_BS
MO70%@T]7<&+8NG360%$ZZ6]]A]R!-@5C4$]K3\/2![\6"7K[;V_CTB<!0EO&
M=$;4PQ=[)FQ"'DPA:+8NK("HK*J+53Z"5:21RT!:K'XQ![:&Q?P + ]/AMH"
M$ 9"80@41E15Y77@TR^@H,.RW\ ( 37F=_88\=5\G M6.D?'.RTE_K1VYI[V
MI4\%*]0,B6MW&(\J1] >!6;KN9&%)"OR93"J#FAEM^OZ5K!#.2<>V-<,BV:,
MJ15RV'XYJIL><.G$Q9)E=Y2OR )+RC '/RPCV;H@-@T8]NK:+BR9ZUM>B+:T
M&XL5?%=M3KUL.^QID!]NJCRKZ$*OV, 913X78'#3#US+7>)I%!].XW"Z< /X
M#+]VT?=$O*$<-5AJL,&SE^UXS"6KD-^ QV$*SL 9!&![HQW#Z1S]5'<T2NK(
MG+P.:&5%ABF(3V)1;L(A+:0!KI84:IC2!03ZST3:>Y:XR4#S<JF#/YOV7?28
MFL(%IXNBJHK*!&VU'HV*X(QP -G>ISU-"\BP N,'O8]J^50>W$6X&$;;=W#O
M4R[F[A)D1XN)X(8&<V;'/V9.JA".IYYM,>&#MX,VA:U 'N+I,C/E&=1^B(^9
MM#J2K;\<@JJJGK7)/=O6F4?TCGEWZ!7<<ANJI551+*7+KQ;S!?-<&T_/Q!Z2
MKT'E[F,-R%*W]9@X=!82;O\.3!"[\'&<,U0P6V@%HGF8XSDMB*1T<D9>)=B3
MT ULFA$-X&<9U%NXV=(K!ZJJA\X0!A"'>,T9I_)7-3E5$*73KD66OU'"S0=7
M9)I-Z29/,& [^&"[BRA VMTA!8P O20:6RV^AAJIU\*T@ET51L@TE0E]"*X\
M9GW/Y,6#<#T7[8*D"YU8%;N_#4"X_T?V$ULBIOWO4 3X5S]$-ALX7U&#S3Y2
M"V(I/4+WR&6:%!N'0R$NPRJ-L!&#7GVJ-.L.P%2R&;>)(,91]&M7Q(]LVQ,6
M"56<2L+ V50_ %-%S?Z$?#T@I2]RO'H9C4N7Q&:<:-3JFCG&Z6[#T@<_QD@V
M!KSS_<1[FY8^@=B6NB8K,6&1*P=M".\*!H;F\1A8,1@X6KZB@W"5+E0?R4"]
M3?2H<>EDW#8.HQ5VK?A$&Z[CO)K&I0*^Y%, ?QXX4<PI,O2[_AV-CNMKN5B9
MQJ(&9.ED3#2.*^I3Q[5<PE41C8S6I>^H,;68;X.X]FW\8<+DG]0N9#T41%(Z
MZ7HT") 8L>N!9N^U/2W+UJVBI=T6 E>K+;_A!*W5.>VP,,>*/Q!9Z00L,&Y,
MY\LY* [%5OHR7(4"=!0A6FPQA<,[2M^53PG]A]I=&WT5CHLCE!D.8#)&^8O$
MMU.15/@-)FRW0HZO-*=_L"R8EMU^P$1AA6C[P:.HJI\48]9745<P&8S:@HWR
MS0WFNV:Z,NZMC:.JADZ.9GD-<U+%*+\1@:'_@S57;?REG[VI5Z64ZM!NN](E
M3W3BIU*EM7.L-2!+)TR?^5^!?:@]#ICUW?2C?V]]E7]*"?-,,Q+R38T"NBHP
MD;L0ZRR J]5XG4B1J[DJ84LGF;E@/(B=@W"R8(Z;R[$)<]9U(62D;83OD@R<
M6T'5B8*'(ZQJ5 !_9AE6E<JWG@]7'8=[$57NGCV=6KC!5;IH[OJ@YP!?7M/H
MWZZ_S:^);I6]XPM@J"JOW[A^9MK!3IIK;@[#0<C*36;89-+#4:1U:40%43I3
M#PG_#JL^#?GL&RSR5Y?/@"@D)ZBI!BI]4L7R]?"XQ:9^$-V&H.))TP&ST9?L
M\-"1OP,_A[D+(BF=-9[&O?/S^77.ZHW+0RZF:@"6/CF\-A^%:_'V/!P9 BV$
M)7<5*9!*F.?:F'(=-2;TF3'['L9P3>W0"EP8B4PKQES;"7D8AGS)!!51@")S
MAL60/).=D0#I9_<G_B@8*;JL%"Z=K/9559W:#S"-)9/7H]2;;E_+TG=9GP:Q
M1R&.^\7'67SDX:%XO1Y!ELE;!$?Y+ F";N$*P?BJSP(J\C*]]C8NG6Z/A+=,
M9-(L0Q"W?1HK=+Y"U22<TF.LT+/Z6>/ 8RP/L'1"M2A'A[XEM<L^S1,2F<U+
MGT@;4"Y0=K7,47N\-Y\NRM@6$W:%!%%YI0]#5E$7OG0X"Y5/*-VB.MZ?+] G
MICYL\L*ZOL_N9-](@=XPQP36AB^=>;-*/.1F9FD ECZY;TP:[CA4X(GH&"R8
MN5T$154UL3BI61T<>M2H=-IU/,9=F_P./)5DJD::O4+?4L)4E3K#5$4.?8,N
M!ZID7XO,GH8A]4,NUA%H-^\F8AY4Z3SY&6_?^/C=9Q  @1@RS[56^2GWN7!5
M2*]?^^91F+<HNJ&SHY3[&S_/=23]X%U22&W8UKH<GVI7.FL]2:3IYPLQR9J(
MJZ08GGIV6:U+GT:2B=2'3SE6\]ZFI4_@FBXYC86M*0V,=<@Z#DZY?@B;/=[U
MS%?=6"V.JJHG<W2QUL4G!I,]%=<:U;QJI8^@"@? MO1(XI#IAQ;C;Z9PG'4H
MV*31;1IT8VDFF1=%6K(:LZ=V9V*6%ZGWN8&I*J?OIQ+2@,07 ]J*;$--Z+(#
MV5JQZVJ%J[^XH-2#1D^\%O,\*BT97%=913:^EI)]WT\+N.0M)K/;ND*$U+X.
MT3T3,8ST70J,*?Y..1OX]!_MQ=)C*\IO2&#-L[,"#T17=F)=U[?IPH_\FWAR
M2A>?(K%F;^N*>@$S:/*5>"%],@KG8:MLR9Z-(3]PVH3[:,A?48>ASS 2I!/R
M@(75L_4JO&:7Y%"J[@X]1U<EBX_BQ8".JOU3SHT 4!U"$.(R;S8.'6:GF^YK
M6U7!D*I$(.;X/TP.O2,>M!+ >2,L)N]:& R!W[95Y@.*'1S;115T=-C" M7F
M?&MY7\O2]9FX_"!(#GD-P90Z28_<B]#-OQJ8"UGZ]*)HEL8EC.I<P$A7Q-:M
MG%V1U5:QA*!!$+5772#1 J^JS991^$I6?U,5!5< 5?4 ;#&.KXT$=%T9:GT7
M& OO*BIHY<"5GW-3R#_2#CFSP98C_.E\+H]QEJS0M3EG<B0:!0SVMBW7RR W
M4G;JQKH*I;IXHQ:"BBIUD6!Q8L&RB"Y9$L]C]SA8*U73SHNC$UQ=!>]0?*76
MQMO[ ,&Q#QA4\_6"M%491]U!L3[&POPV!WFTPOLQ=F&[]IE'4+:YFYJIE!0C
MZBZF&"['=@-G$ 8@*7B>D5@4337<\-T%%H."G>ZM\JIWR1TR\"=SZG+,Z$]V
M4(=B5O@Z)S<UZ6SN^D&]5U2<PZ0<&J5Y>>O[>D63J(HAJ:K"K9&:*3 ]WY)\
M<46C,H.*L_YPA%5EEE124N1R!TF"X\ -I)7*M ?JYZF3DWM[[#!<I9_P&+6'
M[4MT_ 3[VY8^A8[+X>0__$4_;?C2"QA$91:8LX1.E.?:;L/2Q[YY5F>,:ERP
MZH"I\^B%';TRX8=@*I])6<CC47=<!P9VR,P+(BE]TFE==!BQ8F3CXJ@*GA^Y
M&'Z"*\@:=<9^O@)C/89EO3#W:T9]:[4A#[X7%I7J6C^D%E]O^1:_OR,KBL.W
MX2P4P5F]?JFH[/R4G514Q3(%D%K[ <^LUJ4S!)KI7."[5(^H)LNTJ1W8.8 5
M)=PS5+>+6@ZYO 067PS^D=7U]O=?T?7/*T:C6\^I,)ZJFK.Q,5*H0*L:IG2I
MLC:H(_%^'=(K8GV?L,0! [3"-[WB4I Z#P@>@;&JP;0#!8&Y3Q!$3Z2EI,%3
MBQ_=7BLJ=#85%W,OP:9:5><B;/* 8L3] V>P>4#QAMA4ULW,J_M7"$=%Z;@6
M YTP"#F-[P_%VF1N85M-Z*H>%&.YTVR*QK1TSV6G5.RVK.JD8J]^A_$]#OQN
M\ABH5)L#F&)>=$ ?3T4Y/&;*_(RZW895R(N[Q8@>X4$4O_H[6'&YMI$2I'Q5
M)O7$]L YXCW3XH@JNV5AC'L\6P<](W@8KM*Y(E4$110LFB(J5C5EIS;2,/5$
MS%%%EG(1E9_UE?V::;H\[O#@-U'W8BDW,RJ)<6Y>)$]N:$A58?MY\@EYR#Z
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M1/"Y!E,J(@2?(ZT=)S6/R3J!/61^&ZAUTG\-*-!L_CO%'A_J-.Z6WV>X&.R
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M!RG'+(1,$*PB_6--)OVC%*#51J,VW,LNF=$;MZ*;E'0;[KA0%+%8[@I%F%:
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M&*6B5KH$[TT3NCR@$H7[_R#2K"*8WE7%IZFSRQ.A9%).%U]/A=9#[#%!8")
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M;1E(E5D!D9+W)#NC=VT-=0'^9,GV*)J[S3S;U$;J- $#2107)"M21IH%[<*
M.K%8<HRQ<!E"WKFU]"-SKY'N;I//M5SV9K\[^505,GGQ!<=I,*'E7:8HI0_
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M5Q+2R7 .\2HLI]""EI9EK>K25LL.>8],^F1=@F)";G*IX0X\!T.,/N3=H)!
MA56O7YP,KX$*&;G0A:GB/=,I.+)V:)U+:%3,2JADFZ0OKT1S4!383M9]WK>_
M<[+S+&V?,9C";3T),TPCV3G!D?VKE":WJ90L3)/;M:OA[.J>PZ["UNO+>%_N
M/5RI/T&F\1O\_2BET>6PAG!I[QO2EVDVX#R)UQL>N'"2>5T3KZP2+,KL6:V0
MXIP$KJ%U&9&'43[6O8@^6'%W=9">M=,B&9(^=U*.\FA67&=Q-MX%4\OK$JM
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M=U>5[!\I#6('.MR72OC+Z^)'Z5^7-<I=E3A+R+0I@R73,06T3,OD6*BMY31
ML<(7;TJ7W-2U^7@'GL=*3]\%$T;]:Z1!H855L-(LB+6L/],%8,OB&P\B?)R"
M'+WHLP-'ME?&H[#&:JO!0LWMK?Z$JOZ$ULB2+T4+6[3V^H#8\D 9C\<ARSHZ
MZ#M7Z]GHXA-,JG!JETJRX*X71J!]N]2FE2P#IY4TN'JVEB.STCD37.')=O/B
M[A]G]]9USUH9M1%IWWF<1Q/:,F]#$JAH1EXR2#&S>IK.8B&G49&#6/L[9"ZZ
MW5A=_?R#TFX/(MQ)"?'O]2<--R)9+EG1]3*?,H9%*VSEGR(C/1B5FO@V>UC@
M]Q'LR;XTLXN>!5>J&7:!]D<!X$WTN$:%UTV4L.,"P#):IS0"L]S6 *,4=3<S
MS#ENI-5:%/[#%P!N18]U9+^;.Y8J)NY1(BO%U3Z49.5$(6HK(*\+63I9ZFZ&
MQ"/?L>Q=^@_?M%Q'=+LO ,QSMCX'S@+*68<$S@"QL&2EC-QS&TP3-_$I%0#>
MA! -Q+\;Z_)ZRY4DG),R!%8[K]1>]HKP&5WAEL@3MP9WU*!F/QI@[8>=N;F.
M>KRI<3>^&TU8NN#[HT'6=FI=M]O1)CK9R?IS Z<J&# [QSAWY-)[I5@T2I W
M#RD5E;W331H>/<T&64TILXXJ&E"E6SNF E(';Q-3)=0+CK.T")E9R)!UYBZH
MV/*X]\DUR%I+J1LUR%I'(WU'19_!I_]&&,\C_>!LCH0C\\C)#(^9^2!(D1#H
M%[YDW['T[I6'_@!6R%9R[/N"WP+'TBSO@&2MNJS7'O\()5@W%O,*76TAH]Y/
MHJXA@F"R]@%82M69TL6RVNR7&4=^L)..1]>M?/(.M'5?N=0&REI'-(V4=/K[
MZ/3CZ'("P_QR=#F>(@Y//XY'EQ\^7OG-Z>^TIGP]&2XC'($P\^QI2=%U^J)V
M$"]!,+ JF^)L%<(Z*MT$Q(Y+:FZAN!7Z;R[U1AOK%73O!U^ZP98"?+*!,Q5*
MA:T]"U9*ED)6R0H7HUYK']X PZ%PI8G,6_22N;>'BA;DMD3B<4JFU,8!]4:%
MDK4XJ2E>)(VV36^9?6PS]0CQI?ZTT^/=_-4])KJ ^:';4*VEK7O[$6TBZA9+
MQS50JG CLY5,VEI<6NG(0DB"&6,\MPERZE38=1_UOE4;JO[4OHZ$>Z_#?[/'
M$B3G0[&>8:YU0434+-0Z1%P4+J0J2M_,;[GS]N-^M:%:2\KWMJ%:1T1]&X$W
M.BT1ZI@"6190*PU[C@P,;48R.2.T@Y!#UYYA>]2&:@M-;2J<GLMDOZNFPKQ=
M<42R!;1FBMM82R)D%AQP,@6SM-$2'K =5L].9;&_C?H#&%*;2[GGHO@S$,MD
MU XP^BZ#?V7\W1>^WU #-W6XA?A:O+C+)%2I(ZWDDA4YN^WI0BWC;LEIM&"#
MX=%P]62T>$\-^WZ5N([4>E;>:Y+4Q>7%MWYVMD@@@XRG6FR]5MSTX(&199:X
M2A*%[I)+UTE]UT;>;?'ZC64_ZD-P/9HW,R#PY0H08X+(H("YVO9*6Y*Y3Y+V
M!1V$R4%$D;KTPNZFP:LC/T$-;BRX7?0#XCDX+= RKP,9=+Q>#Q!.,Y.CM3(!
MH.J2T/3D^@'MV![:6O8]5FV[OZ]&%U _6K^@M135J6O,)E+>6;\@+#[Q6NI8
MAEJS-CJR-=![YHJQ0=,6I$67"/0^JG[=?D']:WX=X>XFEQT0HRNAL.@U(3+%
MLXB)UC0N:V% +%%WN_JXU_V"UI+[PUGLZPAM#_L%Q:]OX>MH_.P<)I-=]0E:
M->:N^P,]..\;?8%4D=*F8B0/9&(G]+3-^^P]H,DJEK)>7Z!5HS]:/R!M2R1K
M4S%T"9CV 9FW*C#MZ#7Q:(4W31K@[+X?T+SBSU(%GZH*4E4!3.#3MVKNHS*M
MU=R'.)W,%X[Q_ _.%"0R\5&QJ.<M(A/S60*CU5^G+$R2-YW5NTHS;8C@255D
M6H=5URLR[4(_#>X3O4\?,5^>SZI)S0"]'UT2YLG\6*+>GSX9?X#AHO3[W(L(
M6!0/4K' 4^TE40MYUZ^*YR:Z(+C.7<)7ZY_;K8_U"51@VH1RN]+>8Y=?FK>L
M^+;IS&S:(J,RCD?FI>),@S+,<P$U!28Z$U EV:W6W/7G/I8GWUR%HWY$V;<Q
M?\64F%NX7<"LE?][<X1'2 '>1MZK];:%L)IKT! 'K0F)Z1P$TP$-^2A.L*B*
M,5)H^JW8(\W=EP[<3''KR*AE1L;<*5QX@\ZHH(IR#)PA&R1HFID!QR1FVHZX
M10G=7.B[1MAQBN9V4K\K0V-CD?6?J;$$=:4V^K7N7\MHO4M*FL*9U9EH&PS-
M.(K".-0.*\45E[I=\^\ZX@'HN4>1MGM_KX"D+U?A5(#.)9=9=BHS':UDL6C+
MBI4I)Y-YP([]*+H/>EC:[T&P??=<O%'??IF-I*)2M3=*L<G1YI3(&@3G&3>2
M-BGC.;F1ZZ5J'<C2O:VP^NZ#N$!TA6/?SL6=-.3K,]1@6>VYQT(NGBGT@2R+
MD-5ZR7:W1GCJ2MQ.9'W?6WR+X\EH".?/KI@#*1BOBF8FU?P62(%,1>T81E^"
MY#F8FW57[C)];SW[R>IN2S'=>?W@$8X=GL'D(PQS_<^+?UT./L-YC>$T/WFX
M?]B='3ZL,?L;YP\E0/9&&8QH-;?>0XXHC:R6$NV?H>/YP_T MCV"F$S'@S3%
MV>./;HTR"])]C]:!D %TX*R(1&\#BEHC3'H&.I)O6""ZW"5S:(-CAW5@;EW(
M8^481U-ZE<=?!\,/?X?S2SP3PGERBRT3/M#;'#DGK]A:YGVV2?L@BFA3S:,+
MNL<X=FC&I%O5/7K73X.CA>OR.$-#?I)QP+@OM&.K4)@W')@!#(3'"^!-;OM<
MAW'0M-A"XBVJ 1&&&W.])8OK/[CRR3/IT-L4.3-">*:Y1A83&):*"A9B29B@
MU>*R,>J#9M?N]-FWWURQ_ KG,$QX-)F,TJ VRJG%;=Z.1Y\'-, [/!]@>7DY
MS&<E08B6/,+DI2$3-0<2CDM,"*&S*4EEV^V\?(U!#Y(V327?MVM^&\Y1_EQ1
MGY$C:9#S6BU254=3S$+_2-Z0(?_%  ^ZXZ'&74,<KO;[D6KO98>.WKUX?Y2F
MM]%-YEWN:[]A*TNL>Z7 &B;"K&FU0L]R;6Q?@E?JIIE_URKP\&"'J_^^)=VB
M(L&5X_?[A3(_>H\!+-0*+1R-K?V&:P2C5@.VT2I=,F0H+<R2-7'N+N]E9^9'
M2TT]=IY+5W'>X??-B@;H$I&6569R+15@$!B$HIA% 4&%$(ML0LS-(>]#QDWO
M1+K7(VNFT"8%.C=!OHCS=L'>LK++-N ?IQ#,KHC2"S^WT/*^,94;KYWAAG%=
M;\35JG^!2W(Z,G?T&RY4C#\&0Q\H6?,4";J.<OM.UCB:P! 6QY='W[I;+8"A
MD]P%'EE1'LC5Q7J-UEKF7(XE\Q*5[%8U[[Y1]L^OZ$]9HQ:2[KVLXLG?CY^+
M\/;MBP48FQP&GA7SJ&*]@TV6KQ&%7!]G2PE:2]FQ6.J-)_\HJMY*HOV_X2L[
MS)4@M4D*:I$#7\-8BH'*-$/I8^#66]Y1R?O2I.^QWNJMI=N@%=M=C4<5<E.2
M-C2OZB,(KYGWM.-9IY/6$(Q5H849L6=]H'?I6O6ABATQY'I+RRX _V@ O9D^
MU^[INXDR&O@P#P,M''RM2\X,M[7H+R0607B6E 1,/B7CFM35?5H-H-N291T=
MM/0GEGLK )!Y2R"<%+7V=*J7^ VS7BN9?+ Z=DLZO/WL?6P%O);T[W(0-A#=
M/M4_> O3 6V?1RF-+F?G[PEI1Z6M] V,:UN8S]@\*;$[A)TE*&XHE1O)BL:
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M4N6\H@F[H)E+SE4+ME9")#,V611<(H*Q36X^[5G*<H,(0A\2[['H0?<,NRX
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MRJ*]* \M<MV'>]KJ;B36YM'1US"]').S_9Q GAD?M0_$0:EJ;W:G.%EU0')
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M!E7H;E$K>F<.VC]A^.GS#-+%(K?B[JRA2_S51S3B!S:G*#D3I'3Q*QQ$!)Z
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MBT X.&ZBL4[P#35 _=GIC?S)D@[J:=MZ .>XTFQP"W$Y^PR3M:]_8+3GG--
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M:Z6"XX/''MZGX?MGW +0Z;J9Q,]^"G<<?4.=LKH,,L6M7!H62.#&$@ K;#2
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M["W7QI5EGIFQV4N?G8P&1>N ,>>EID(+G]?'E75>M-$8LP2&.ZK0?XL*=4\
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M:.VU!X8N;YX/RN2"6.\$\8$KY$Z@>]5MGNY!R_]DJG(@[T>XMEDUQ4!EE<R
M)KQ,_I40D04O%5KZ26?K*!7J6,-VSLJ#K<'W<=1@E9S> =B_9G+M)[_.XY<.
M(;_]&*8[ -%VSD%[4:XS'1I%SA,OI2:@HXVY? GR)Y[)U48I]N&\O3(LCS&G
M;516":)XZ9$0"B@>#/$L!5#"*FZ;!#N?_4RNO:35:2;7/E0WR ^\FW6R*$OT
M60MIT+B%8-'6!;1@YE7IECL&EI;J]Q:B7P=R-C9"+X8K=@/>A&=54MP!44NK
MX"&DIS$'^HEJA]Q[\-Q@S]^ C*F@5!EF+RT D1)5W27'$)Y4E&8;*#3I)G@L
MR3]RY+<6_#[T-A#XJYO).(VOKOS*3<5="UWA,IMB/L!:>8IX,B<1SQ]>9HM&
MW:1V81W(\8_VOL(95V2VP7'^PD_GK[8*1W#(3CM'6 QH7#B$5$;%$>J5E)DQ
MQD.3P_P^C).7<@]6MW[-6ZK.EK\N/P*N^G__QW\#4$L#!!0    ( "E !5-Y
M: /XZ&4  %FG   4    86UE9"TR,#(Q,#8S,%]G,2YJ<&?LO =84]O6+KQ4
M%,6"*$%$( A20U&:@$ V*B @8&BA!NF]]QH%$8@4 0$% 2'T%NG2E2((2.]-
M>N\02B#)'SW[[+W//N=[[O??_S[?/O\]#IZA:ZW,K+GFF&.^XQUSSA7B('$"
MN"@O(R<#'#MV#'A,^@.(DQ??2;M;F * HB+ !0# :8#LV!W@..F(DG0B'V@!
MD)&.CY&.M=\F?/\?8 2 BYY+]  YZ=HYTKDD20'ZI1_?_2D_Y:?\E)_R4W[*
M?Z@HF)B8&=CR*KA9.!K8.I,N'/N=+9RV_E[B)UOX*3_EI_R4G_)3_M-% 3 A
M_9D!!H MP$LZ<P,L ,<?9]_) W&2PLS<V=E>C(_/UHG7P-C.T(37R,Z&S]W
MGN\6[TT^0!SJ;F]@9&7BS&1H8F9A*\&^7EG+SF1A+,$.%U*\J6A_S\3<XH&G
MHXFJIY*:D:>5D:@Q.U3R/(6XNYB[C;V-B;,!D[N-M:V3F+L$\X^[BY&.OU_F
M8Y84=S0V%5.Y+_-K"=*9!/.OS^+FYL;K)L!KYVC&=TM45)3O)C\?/S\/J02/
MDX>MLX$[CZT3RZ\WN&_B9.1H8>]L86?+]/W<P-#.Q5F"V<7%PEC,U,!4R-#8
M6(C'T$# F.?6+6,#'@-C@5L\Q@("QK>%;HGPF]XR9/ZU>F.CWVJW=W&T_E&W
ML1&?B;6)C8FMLQ/)&K?XF/G^@CHEQ8V-Q(P<30R<[1S_5KVJB</_-YM96TC^
M(XT4Y_OU\M\.2!60^O#,F3/B?'^LF^]/;?_U"JD+24>_=3CIFTS_ _*SDI^5
M_*SD9R4_*_E9R<]*_KTJ^9TTFMB2F*(;B1(21X![ /G)DZ=.DI&?.GGJ-#GY
M:0JJLR2.00&BO'B.BA9$=Y461'OE&B/[]6L,K Q7:)EYF5DY."'<$#HF/@$^
M+GYV+@C7]YL<(S]]FN(,!?79L]1<]+3T7/^OA?@1H#I]W(ZL^,0Q9N XU;$3
M5,>(#0 8 (Z=//9#_LZ<CQT_07;R%/GI,Q1G205*+@+'CYTX<9SLQ,F39&2D
M3WU(GP-D5"<O7;\E=>HRS("<V8&:_VE$\FF6NP6?0"I=&S<$#!W]SE#07*&]
M2L?*QL[!R24H)'Q;1%3LWGUI&=D'<O*J:NH:<$TM;2-C$U,S<PM+)V<75S=W
M#T__9P'/ X."49%1KZ)C8E^_B4M!IZ:E9V1F91<6%9>4EGTHKZBK;VC\W-3\
MI:6[I[>O?V!P:'AR:GIF=FY^87%I<VM[![N[MW^ ^]ZN8\")8W^7?]DN*E*[
MCI.1G2 C_]ZN8\?=OA>@(CMY_=:I2U(P<@.'R\S\3T]3WXU(+OATAD5 90-D
MZ-A%07-#<))U\WO3?K3LO]<PO_^MEOW6L-_;-0R<.W&,U'DGJ  H@)-!<;P[
M_E-_ZD_]J?^D3;6;B-",R"($^@/A=(T3SAY*-\_GR\K1W)-[9L=C!+R_0 3H
MVM4-&(;>9M^]4U294I4]WQ0W<[ UAQIE[+H/W;7N-QYGZEN#]B_![S/6J9#/
M0*Z@ N^;;E(M>$F#)I]O+=9@VYJ6KZ=>$0B+>@"=,$4O*Q1 -;<DNE$;^UC(
M0OPMA.YUK)8F4KN6'(5M];;N3;=&=CR$;G]5:93-IFO@S=RE@[2MUC O%3S6
MK;<367.--MKW#^\N6_%EMHB:M#.,ZZI\:P?;#T/*=PLMUJ2CBL&J>2G90Y:N
MVBC;@@J4O=@S6]E>%Y!EJ:)$J)U]"HKS"4R:&OBI?U-5DQ@19@LVES"AJZ9.
M3\C[RXG 1?>Z5NDQ,LWR2B*0:.FNO!>^L[R#$>US&;NG%>^S,_N*/E>ACJ\3
MB2CI4*DR2.E[W5YLE*%:UD>XKJU#\T+^Q:K*!?'/D^18:$;_AVKE!L_TO @W
MYW$M(A CMY4Q(T80BI5V4,J=KQ2955$9Y4A!-;>1_@'^J,Z.7\[Y/=!#NXB>
MRR#S%>JQ\)7HXY9/FQL9##S:F6PZ.GODI%L-@KU%%W'Q.PSNG@<WBIF6///3
MYW(B MPFD[47FC;RXC8>/Q"EIUMRAC+H6S0:]MY&Z.RT@L<Y=B6( +B]DG-*
MM=M,[1;##<\ D*IB'X^0%<S!Z&;$G; EG],KEF,NZ7$58E$UGZ2I58$4%,=_
ML%H7IE()%HFEFM\6N/7Q1/\3T)B1C <M5V:K #T@8=51I3B=D>23&#3+LK#'
M\MQNSX>\5KMC$_["I/^&E0Z;^8H:_EQ&[Z$GY98H:B(/05A1$BO!I/X2J:3,
MAN+(O_?JSSW_9RW)L(1[J@^/:K9U-8M-HRGOWD%A*2^XYX_HA=S?]]N4_4HE
M?KL"AQ<+[Z^*2:(NE.)O/5OL>+VE\.U%*VT7$\4#NI[,B0[7E'+DF?T2H:#&
MM$VU&MBG!59&]+=>9$0O/.,J)P1=PZ\"EY*F5J>FADD#_XE*%D 6]43TQB[F
MYF8@*BQ/M+# D1LM_IXT8!O<<)Z^+ICIVDL>#X:EHXY6H-WTC/Z'M>%(NSP/
MK/T4%_Z90W_6[B.8-.BS8P U[)>3_PV]$";[7#V2S=A95$/5CS+/$_/L2"EN
M%A/E>/?;_5J1Q3G*=<IE!$QU"*&<,2[M8CG+&ER8@?.!:*LSW)ZQ4D+[2[2@
MVCNQ02[5O'<^^&H<%K+Y3KN!T(@4BQQTIZ*0,ZE%M_Z[C_)_C1KO1VGK4<I&
M3OL+>+_,6FO"72C)0RA.\Y@=ZNBZ!!?9V+R>;KJ+#*Z]C#NFV9_U!2S 5303
M',"-$>_@;D/(&K8U;,FM/TQ!;76(_,N1F.__<$,#DR53>*!@<_E<X-MIED&7
MG#WP!1>1:9Z37ZO:H/ZL<CACPV*U]+YN0;6YOA5':O47(V?SA"<^^9RH9YJW
MNH#N99S*Z?>B>D\*.J?_?/^QC9@*9T4][_[&W'VYP RT+[A5:/G)C+$CY%-.
MK_B9/*3Y(M@HH4@BG=HLA]UHW_DHI^B\ZHI _C-"JU@<1TIEV/N_'B?_1_7$
MY<8*S*YR8+JSM>+MM10L&1;ZY OF>G[9%$W:;IX-=^<LCVK2WD@4S@B;+U_5
M=O\@P[;II(630B?)VA\__MG\D$YQ\,0Z-UM:3M,V?N&QP1YRV&!YX0Z2Y1.!
M<JNJ6D$C?/ZP\V/]&A$HKA_H="7H?77M2MY-=>E.VTVE5F6+N^..L!@S"CTU
M9RH":$B^F,HY;[MDY>78U?QL!3[=IK].N9%?=B/A3>],5!&/E39/?KFAS5KL
M.=&P1Y+F'9E$@&)+3T>NH@LSW+]Y4Y9K>NT#%K3JDI1G7EHQ^[2T@I;E]<R)
MN1!<^$:N%4P5KO-&/34]OTQ<&U6=8W%;6^A0>YSM]*RNSP!C2N9 7(]2VX1%
MABFU>AY_\Y)V0G7<AY"V23>JMW!]4C7==K@S&?@#Z#2<SC&N"@9[EE8H8@G)
M[1<_RQ:1VN$]L,SQ[,3[^S*.ORPG><XLRE_R+P[@^%!Y,P7%)4?!D?*$HF]C
M/-,YU'-\YNU]I2_(40DD;VV "4Q1.*&SQV*,<>N"C"PSJG[#%XU/F\QQ-7IS
MG5$!#\]81(UB$'QO]!A3]?KJ4!S9M'\UX?L?(Y;&$0;!,R\GJ11N[1Q/T*SA
MK3P$!]AIT@L&SU+Z-)'OL*4K1PMSWH$D*OLX#PP_VU/Q64PUDQP2S>1(J?+I
MX";Y)=D?8Q1H@9%R QD]NZ1=C*SZ!V^4]3\"SWIXQN2!UR5W;MX\K%V]B=UA
MJ(UUTBLVQV<QO,KRR3K);X$N"YA+Z!?IM#4U>G+RLB)#%9_@6L%G?R<2BX&T
M>JM/90F5AU9GF:\\VJ@^%WC8A*-8R(*IRO1Q<3!MPE&I_7/"NVGH@GMU._S@
M=? ")/&Y!<^<W#O7L/MWHE]-^#],J?HB]V4LT3MU9JU#?0.#0O=/TNQ)&]5(
M-2_< (^#>^%RB,OGNG7:HGY9I0]R@W!^.E6M4%?#%:[S3&<,%'9 SO+N)=(=
M"=/KM7+R*AQ=28/'C\7,I9>D#"_'G!I?M)>]U4S^]2H6/(F0^[/35^<78?-H
M!G3?"^_=(W.B?^+=E00C@-0SLW+R6G+D%/5L/<P"B,",10\16'Z/,<)P]CC'
MYUUKHA$N"WY^^7B^Y'(X#)&G^EQ1.EV1K-OBM:\ $8BX>[B0A*,;B(#G[W<0
MI,^NIR 7K!#2FE,U@B9!^WXDWJ;Z^N_0L5IS[9MU366!44/F#?W,"4+@#N8>
MAF$C[]O@$<SHNLAY]ACDA#X?%F.(D3T/J1L+PUW8($4 4+?M7\UY_J<4U.3]
MX,-0RL@OE/S*'PX#5 G,E73;1"#8<<Y'DF\MIVP.?@2A6^L=BC8S%WB>@H*T
MBD_\$>LQOVP@_8\P?"I]:/S\^/-38#=\.F.-?]F6/OD^],L6ED<;.N[S.V3[
M>+J!1F0"AR,&Y&.'7_X)FF&"72-UVTK+]#^H_/&JLD8$5Y3.ZY$1FK!&RI8_
MNCWV#V[?2'+[+<R]ZX1-@E]Y!0>&7\71S2R)4_3.^Q_ Z"T@9\>O>()$ND=S
M,\CH3*B/+=6 -M4\1YG'%W+=FD41?E)+T,S\R"JVJZEE;]B>#HM>7"/1OO.>
ML0'>ZHQEI\LJ( Q;%V2EF @;A)1J"J'RZB%;-Y6<KVNM3JY3+>-K#Q#N]>(7
M&(77TC-24$MBYZ!7B4!SLL^.,OZ\57/.@+<9$6 .V.N"[@AAF#%0T";Z!=4F
MB1'I9MS\.Q#MF]SLH,_:B_"GS!1:B_@0*>0\JWE<,GH2M!K'7>/J;\#N6AJ2
ME-^E]QJ>(XM@6.IR)3GX=.[_*C'YOT4A[;XWDO;CAL)QCY$[+(A0A-LF)W+*
MQ'C\?02."&"7S\EN#(4BGTQEIJ"V*<5_9PS>X DBP-[:6V).!#SVDI\&CNV8
M_G!,\7_Z@ A8!&+>K6(71^$V=%!+61,N?4NIAW'FJY,>&2YA@M?>O)XX=K]'
MUN[LUSNY#N]&VYI(C. ;R#U;T=;(SEK[#C64ZU?434F35KRFEOG._X?COOU'
MQYU;^ ,(DR)MUHV_/RSGQE?6JB^"%[J: QU)B:'%JT?DV?OP1MBR_0NOE()O
M3+.>9\CW K&@;OBS>L&8[1OO[\@R,[2TV$MA5#8R4-._0_F/M!&>+%-VNY*G
M?4G=@^2JUDL5WI[YL1*OVIJC>&_S/9)JAK[&@/MV7N31X//LKI!GBQSF2TA[
MZ9DMBPGEES^VR1_X':1=LKRD7<K5+;9S\CIH4C"6..G^%[[]92_\1&7!+DV9
MV4)S@CU%(G060]^S&;_ODW75476KM77#'D0@G<E7%QXZ4+"OY[JOHPS>::!;
MKCMZN%A_]+"?!")5JS\(RW^"3A#8I(D TZ(L7E"5"(1%X*VJ\A6F>&K?3.Z;
MGGAM=A5W47:[T4@+$<^?C3GED4 -0VC-_\B8/"E)O&'FX,^\H:::\E\B*Y)W
MJM*\ZU#E#J?*H0J%\3^ZZS_B+#QF/Z=1Q<KIFI=AUV#R 3SY)1%P)P)2>B N
M+O/A-&DR1JY-M;C1N?'!8E<.7_4%8^@XM!-^6QHT)Z^DM+(]R\[N2HH<<M>E
MJ1\=DW:MN;IAFY2[X#"NI^@8*7"36?B1B,A:>@D1F-2U &]O>Q$!GPPB<%DG
M^[+EPA L'B[[IDN[YD;W9!?VBW6>MFPHZ '_164FQH\:ZH8D=OPE/>$U"12?
M4>^;1HX;QY&;S]PKUU(Z+=C"<:+/FW/J _:#='67YOI+1[$SLIE[_WMCPM+J
MAZ_W#RCX]XL"!R])U!USX[<A0>88]H-T#&CAVD.M\C6O695\HF]B @N:]2(#
MU"VY+)<=L[M)/#^11QKQYR^I67TEL7M[TK @]?W3DUZF+ZY$O1N4';.9)E\N
MAK_X=%G9@9YS+]4>O:0$&>TB<\CFHWAW;">_C:NO"'.AQ-J%&J;7I/E7$^/_
M*=501O%(CDS&+SQI/?T"T^=KMZC=&Y+\*N><WTVI=7GYI3K+I2;_+@VL#DN&
MY8!P*!'@-N82&'6%QG"EN7_5&MP:?XKP)T$Y^8$D(BU']K"C^MPYR?G#AQ(^
MY':8>]\S0^_OF>%>DB<MK4_'[FM/W(5OB(1&UR[TWS/#+^EAP^1Q;IK34N5O
MP@!J14'73O&>BB:Z\VUM]@"&^SO!&&"_J?-/[./OI'N [4_LH^6?V,>O*""A
M\Q&YQ5E/!/3 1.!N?EAYQS$22\B@Q#LC\1058M@L[],[BT>GM\(9D,UC3H0I
MY )S^?!"E0L18''I. PF N]0\U9M69M%'5F;WV]\^L>-_S6UT?V-VC"0H7N]
M<*A%2)U!G()'I#D#.N+"K(D(TT"6.[S1X>_19<;Y4CAL?0G2B=8AD?IY%ZZJ
M\94R(:$$.A)GM[)*^[3\]W P$U<3X9+RK21O:B(,UC3FL 097H9J=>6YM)XJ
MK=!E+/@U!5#71L55C&87O^KKGW\!@Y?X,"]+UUKI-'ZB1X=73/>JTVUK6PR]
M/2^X\A5S>@A?U"C\0$;C]K;.B!T+]GBU[P?*Y_U7X]8?&=0]I0 [M2)9CY9K
M,;*4U^[BVY>HBGE)N.,<_Y\T><;HM'GEX98+K1!M4ZM])3TIIZR&WCK*"?LQ
M12G,M>"8*^:_C&B:4N2PHJ/>_6CZZ';CRG3&?,\FAH[)3XJ6)5-H;HJE]<Z>
M"$0V!KYF003JY'*)0*?*,H$0!YV\T8]<X"1Y&5+1%*:YK5 >*U@9:UL2*K\+
M9EO#>:#;Y<6?^5E&4ZN5CD_95),XRSNI[YBOIUS_[>!J/*%ZY  UFY.Q<:Z@
M?DK&0L](__ISS0D74!I?*)WJ?M>2FCJR;(@(=/2"]S9@NX?0 YP_@4"!M0V7
M62B0%A:]I/;M<@XF^RW*Y58 B#K6=5-4SBR8UD7#_KS ZBYR&TN./Z+.#W"^
MK48$7DK,X^V1>+*!('BQI5M_:.I80,6SJ!-/R/R37@V\&+@ <78TO$UZ-/CU
MEA]IS7Y:Y)D833V2NZO_2'Z?")*BT>]M!6]$6D%WJ"N(0&UZ$4?V7*QC>=IH
MF4>VON7I'"\W[J4,KAO64]DPG42J;F1)E11%Q=QIJ!??!P;R*0=<9]3;W#.B
M=QC#)T,%#B'U_?TKMR!\;]@/O[9#+R0%6,&D/1=OY(8K0B!,*2C.D+^://^/
M$O56;Z<4(F"Z?&H)U%@]Q'OKB._H'HX@V;>DGI2W>,M*^V&IXP3-U=#-/5IG
MZ'R)B4:2N+69"OUFP52O6IEP]]"8G)U] &LPJC"Q04U]EM'^7\W#8NW^ 3?G
MQ<E)V=5;*+:+".QP+2SWIVVP]&1LL+2(_R-RIFP.'(4.0-?8"7Z0! Q_QN<.
MR8S/)'?.9/JG1O2+7R4UPG@AYT;KB_A<.3;/3 +HJ%;%*G1#XRD^+]LG?5+
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M9_$):Q3%9N5-$('3H?=YD[,R<!S0RA BT'IOR:<VP?,N\V=41*;ZC_9Y_MI
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MM=7'*K9, CI]N:3=?;R^>E"^$(SI]I82"V@0N,PM2_\8"WXZO94OKN:L(NI
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M3B6FK;"JGM1O1D[<Y#6?/T)AG7V6D,15:Z." 1*[H!*BO5FVT>A:/>@=BG/
MP94S]N=EJNM:(=JBJ_P3R&_WPCM LX(:FPU*DJ8%>8)>Q:JRXH8/;LA=W#%^
M+'4D+5DEUO&HLF=VFSO_QM/*%6NSI3L#)FCO^_:M-"4731;G&V[*]B'KM_)?
M&QKNQ 3>MVI<3_[6!=,>D_*R+1J6+[H_'7COI:7V'S"ERK_1$[XK4ROXX-:Y
MVNH7"UZ^Y,S5ON7*X$5]FRZ-+:&VTD!VADXL(7 [WW-C+N"0MC]<T(?R5@Z=
MSTR<;_+)4:COE7,2>-DID>P=>%RQB# IDDWRYAE^>#;+^LN23U"6U<M]KVR?
M#+G(SS)M,7G1'7N4^_0$PPH<=I+7/=W3/E90E=0[N>\PK)N)6?BT*<Z[PH9E
M^&ZGQ5X"LJ6:I8'N93<IR\Z=[!-N(FQ.(,,G$?QRIJQA<J)L'S95N^[/-B@H
MP;BL%"SX^)A+GYG*Z3+CY3*M"O8]TO!HU=A'$8XQRR4"^&W""6B"XUWQK0=S
MSSQ2(Q9H:!P&+3:TZVZ^? =;7]<@Y=4^X<H_-NBE,O&__'A1YK3$HOD[2IY-
MLP#6;E[&M2]G!\L[Z ]N[$K^/^U]9U136[MN+(B"@@60'A&0$@$IH4-$! 2$
M" *1%D00I L8.D1%0".A(PH$I$DGTKN(:&C22RC2BW1"$P@A.<'][>_3??:Y
M9]PS[KCG_#AC9/Y88R0K:ZTYY_L\;WO6: @IZ5[M1)?UM;"4V&"ZR BUA\3M
MAC7>4ERPX8GI8;F/%,#CI#'57?PI,X516BXM,:\DI%9>4WU$[%VWX[(7WU47
M5KU/;/ ]&G$#$H1G(_KT,C<6MA769NYTF+S_N <=.HVD^:.\+K.'S#ND'=3K
M9/VDKHYMM"Y.CXC'Z)G@2J:*I=#&C=G+K^3;,=GAFQQ-[R CIX*IUA4*]JCA
M/)M'%T6E6D-5IP1P566O#?GBEB/"QU]/AZ<AR(@>3OV]&Z.R03\B%YF,I$,F
MT1"S6^\AL:ZA)6?]5QMZC=H0."VMN?F_2(-R?@\MW4BSNP>R^3+2;GA\(; :
M&4(!F-2D1VD*1/G$#ZTYIR+$SHXHNW/J3#=NPB&WHW?Z1;P1F1V2[;G*=C1V
M<_$T*]7N,T.7!GK)ZS9[V62!H;?=C^;!3OKT@EX29?16*V'I9,.E,A9IHE.,
M1]GSLX(XP(I_1ZTA.[QK9,E0V(]8&ZHD^7%(YVEP1>AHZ\B[O;JGFZ0-\Y.W
MOARUO/#BHDJ7WE5@AC)JDY>UT=H#)ZQ O6B#6T&J)Z\<]3EC:--=LA?Y\B6'
M'63T!70S]Y%^D2^J^?7M'4F59+Z!9\J%U6+SB48Z8PV^;!*.JY>>$6\<"9\W
MQS SQ'#/A>@RIDP/?0]<+5&XC>![WP:X6QT1H>Z/=M]:^*!$-6'Z%L2YY/::
MG!IBYZW8R$8C88FBOV,* O]B"B4'3"$/@G.ATNLYKOJ#P 7J-VI02W5AFY"W
M* #L&\@FKX$#[M72>M)WG7'&7?9H<D6M#\;;]C%DVAY*G-Q:0,Q9?CA2S4B@
M^<E'?VU8#O4*(:OKJ)(_ '?[G>Q^/?!:WWDST^KQ"$Y#O?ZRX?W& ^_%I]9;
MXPERVHG*HEVIH'P.CC7?<7E,90?4D\$T?V<'%,#+NFF'#U30)=+A\I//(YOP
M_F3JCYC1<#4H.LF:?,G%2X"L02_V!S] _)4?>$S\R@\:UN+9%'G\ ,V'.-81
MX&G#Y:K2PIHNK$C,_8R@OH"*J2WLV8*3^MO1LH7THS=!_8JG+B"/#SWI8^NE
M,@!KZAI<]Z&:_6W+S=;J:]XHO0O$*XWD5F*O)2;GG,K0S_1TNF?0_ZF'Z:'%
MN7.S/<F]-Z@0LDHU5&BGV0<19HR[5M*,7=0U?L<(W#=?+-Q"L(WO9#@N=:"(
MQ#US_TK%^_+7CZ+X77=">[=>C._5>T\XJ":6:,]<V1S^N"]NBEA2&Q5*2C?O
MMOP[J637NK-\1]1+PZO-G$DQ% #:^XL'Y SV:%5I;6KRUID5RY6Q_;N@,*QH
M=:VZ]Q9F]C]LU,#3KTD0_O]$FO\<7WO]%#+L*V5>N9:$D$W$6L9>+^[@Q;+\
MI&E%,D:GNA6>4 #%C(2"%52[08I(U]E,-N=PSEY%\=SY2AD6?0G&7;OS[769
M4%R1PZB#C![A1US.4Y?+4Z+(F51T_FY8'=I=FYZ4]_T5<-=XB@EF4;!#-_O%
MQ%\H?N5,<VCXJ-C,=AV#?VX$+RUMOIO6V<!BN8SSYVWL'_ALC09Y\9<Y=8GO
M3_.1"B IVUCC[BUM)PNH=K5TB\Q1[BS?P%4XO_GYIUMEW:7IP>H4@'H5#R<W
M:NS36#)0U;0S9W(7CNNUEZU6"H>EHD!="D\/0#'ALIV4&%.@FWSL7=] W=3'
MBM [/0E:_:*7Q\C&=2W^!NN,,Z@,^),U#JT1)O9$[9: !7TER#.R-_ Y%H*]
ME"=WJ6NV-_QRGJ.7J0&Y>>WH.<E[ LIF=2M)%,"3>JPE]AC6@D!%N]R) 3Z;
MKX6,PM"LU9U0]OE/'5X)$S,_='($WVD+J]"W@IRNZW^%W@65+,H"GP\E[;WT
MEY:>%)]M4NI0V;7=*.#.7_#LR%Z(.Q]E*REWE]%R(.!P#BQ2WVS=<4- U$X:
M8#T.*]IQT28W=>8OOW$5E6DEKRV2@4'>'8%2=<N0,]?-W4_5K5H0YB#R6SD+
MGQJ\N62]]M]2GT')PJ\D[V)E:7G-LR^>)]W5D<%J)R$FLZ6,(43#?I.N]&+W
M_9Y*)"\9W*>G)ZANFGJ?M?61MW/*.!>\1\21MX;*W!2'3^T"Y^._.XMDEL8T
M(DY&5"P4"=TFXJL,8"QEVZZL*REAUI"&B\' ?/=6^O.$XA.6/0.$*E#WEDM(
MOXQ6MUVH$__2LU>J^QJ[DQ6GM+5JND71M:1+,N1SO5>V:&O==&-2*MODW8)G
M##S"U+P&TK)_ZIEW^_%,4@#+2F7LT8<\:%>FY_A_'&3 -[0>N2E*Y$6*:UQC
MN\.MPC67J5<_<O32^$JX9VH122$7[7 ]>&Y<>YO_2'%87;(%KA341T5"'Z%W
M!=0E\>Y*U@K_NE-&'-M 4!V/OH',<^M"#*T1.F1><XDVN)CEWE<WS6;EDA@]
MN/@TIJ[!U-!W>/@=)^XE.P7P\84 E9$RSQE^])-Z<WWH&1_I:V$%=\-#R%<8
M$IX$W'FP*4@Z$!CYI?":.F9)OE3BFUZWU07!>!LB/LBL"2_ @(,_H EW3$7'
MUWBI/(,"4,J-PDK4Q&2F?.^/BMG\$WSN_SWX8.G7ZJY1=SQ;+=4POO7\&=$1
M^AUO['_\7@**93<M;O'%R/P+<V:2_EG_F8U/"=YA6()\_'=:2-SBD\!=-C C
M<0?YW;@TX]>#J=9)VSB1P2ZO\V3U89=MX$$=TL+6#/?O>.0Y\>%(\1_()G#U
MU^ZV*;(H]8L%>_L4P!R(O<S/G +@-=_>H_[*".S-K"SM';WSIG8\>9?S<MTX
MDG@$EH^/^@V.AH-VE&WAP''JPJX*>XQE6^-.>M1QVGQXZCC?Y>25<M[=R=KX
MBN3G\1H)#BS9=#,I^]\JR/.*P(^) >".YR%28@.?:EPX?BBNE]=PY9P2^ZS'
MQG&Z73%.^<T<4C&@-%#-NROZ995LZC?SKE4I&'B\XS3:0I<%+Y;0BFBPWKCX
MPV4.2=SJQF,/M/2[0V-B.ZDT0.T_!">;G>"/"R8T(T6AU>I:C#]">'>-8IGB
MJ]['5Q6.]QIUH#;3TG>>>L6ZG@QI>QDFG33VI"G/?FTZT?S-3$E/L0(R1/YU
MV,*43N3CL^$2BA2 %P(8!PGR8?:ZC_E6)E-H;EHV>/%NB\-@"5J?R^HF:OT;
M8>IDY0Q'1<&2U"JWD<<M#%[H0-^S./W712D4W<956A-]<]@*K2VN]#@33SNU
M>CH4:6T"4>0(IEVW6$#2H:)OH0?/13US=JW*V%OPR?@RG<B6^)YM+^T]B<8@
M%;7.45TY6WOM/T*U VW&N=_Z#R5)?W$ :S-_]Q #F==XP\]4T?WN &+E?W<0
M.QA)U]480Y>I=['93OBC_48=H79YB5E#7Q?PEB8UM;RJO%K=UWCJC6'9*W0#
MP%^6V%ORS_@9#$-2Z>(M35+2'SQ\>;GH+BT',9CT$"GFLZGUW<\CQX__H6E.
M%3-Q!=@#1C_(5GECB'IH&W.+05Y/S=LVT=<YW,.EQ%3AG9R=I9'+=F''8GSE
MG8"3]T9/%XK@&2"GEDUCEU1^4H;)UW^N".92>L$M+GE?S0_333#EI! "EJFR
M/*I[P=0;[Q@II\[]C'U;:P/YW 0Z6"JX=3SNA)OT!P59*G*3<J//T3<F%+8]
M1^/%&V'&5(I@L'>IJ%]?FK>*U>R':Q,)IS%CAM$\NNKDRDG %*G7]Q)/NX%0
M9V>B;/GNMX*2%LWJPA&0P@<0&W0A_[ CU<R$U^[33ID2$0OV\H[G7?T'(Z0/
MVA_PK[WPM\E=:YPYZ-?Y(5&OMX!>9&]2;E>^PNV>[!$CCV",K@]*F/SB75E^
MWO!@P</EC<A!#3ZRX6SZ<)'LV>K"N:2CW>3ZMR*?7[YP[GCM/HA\AK3 5=E?
M5PL#7S]D>)6.UE(;7F/5RA2N*SYC1%T(66__V3>5XCM\9X6%MO*%C7M0:,7)
M@*?O_M4;65PZPLWEHAW5?TMF2ER.?&S)01VE<RGO<[?]5T*(>IBZ!H>QYDE&
M*YU\L3/"V!>(TQCESN];>4-K0\6%,Z6V5I4[#EYJ;<MO%"5.&/C<':< Q'=A
M;V%Q)*5[BKI7Y^X^#'C#O, \-S$RC^GE&C^P>QQ!/\UHWB"7@DEU*>]AN1L6
MVS[AG:@T\^W/2LP)K7UOS8(.RZT-[^7O0X3''9JS&32EO$MY6T'L25Q][2_S
M53W<[NU%/1EAM&@-W($5JDIYGD[OE/6:OM72XG4!_PRO.M'!,O+ HB(RH,M&
M]Z;U>&95\KQ)9WYSVD W&F[.W9BG9^SC\GRSUA"V5/Z SV7W/L_0%$$)2=>+
M59'JZQJ*]Z4NIIN6:KQ5N"#,TZSIJ(<T[D-8= E&SM@R;CF:X<6))I)IYDS\
M&RUQF&,</U=[T!L]>@4:0S:^1 "HH\9T2L6=8YZHD"Q(*FJ'A/J(E=?Y?,(K
M&F8YO-%\K>J2="'\<4!F[3T\LYF&=*2<L-&'2#J0R?#U*.BIT86-PX5JI3Q4
M*'KY&-IY6 ,_;PQNZ3%-7 97_ .6@'_ 4DU4K4L]9%W@#@4P#-UG[>L)VAE+
M^0"<DLFB;E6& XWG(U_ OY9YP?LI@&E(%A+_-9EX)@<\I>WA#75_1Z EH:DT
MUPQ>JUM3_!&X#A;8=_79DM^\,G9HY ]W(_KA+]UW1W"*JE3LN)1" 5@PDA:E
M2VI^.ZSQ]KNY/E,M+W:8BH_#3N0I*MY<JH77I'VL6Y<>1E90 %2"#2L@R7ST
ML"13SP=*G_N5,RDBOXRM@\>0=?LT5D8=OWA,V(N9N)]!U)ISU+\+BB,Q4@!7
M[;>JUJ$'R#U!1>XC5"QCKW6N?EA'^W7Q#Q=,KY.9Z_.9$=/FHW/<<DRY0BNG
M-*F>&*XVK375OLBD-2K91X!,_ %.@#=.BASC0NJNF_TCPJ4<,H"/'!V$9HYJ
M.GBRA=UI9X-N$&%Q)M&!/58=N=#(71K,--%_VE,ZBG4F=.8.,BEVX0/GFDY!
M]?%K1AQ?@(I\6]L6>J3<IOFF54[46C'O3WIE=SMGOH[G=M9XAV=JS93Z3J"[
M8RX#EJTR]"'_35H@O'&SH$=WC3LV!R BQCN*G$G Y.]RUP7YG,X]L=0^T!M:
M)C67BNKM_(DH6:+8?$>K,6]W)OI%WJ V=_;,SUS*O4P]>E@^\MKNK0"_Y-:U
MK)@IKL&#!F#YRG=A?[:S8L( 0).-,2:O$2QSWJ;-@W%%Q7VV_9"W^PZ8OM)]
M#9-HF>*HQS/W=,\@&1>\\X8F<Y^[=0OP:[6;7-^TH/6J6[:4&M&';C[Y+"E.
M 1@O^5, R7BL'9SAQ$DZ@N^]VI<-8MF:*9\0L9\I@$_04=! >=WNHLG$0J5O
M7C=:0PP1WZNGAL <J,[2RDWIG-LS59?XF%#@5#0?EE>+)Y*99\"KX-E1,*'Z
MSC?ES'MORB*+A0^1\\.1*06*:@I[<S-87?*Z+'&(@'_^KE.LW.U']VG^</PW
MWWX1YB]LLM5ID=*8KA4C6!D1G6HVV%+T>2H8V$1D3ZJQT,"[/%)(EFZ!QGX@
MZ;34]2)--D4$&DW@;U-$$Y9N>QHS&.QSD%SA:/FU5T3)*N8TD6UY>Z'LBUHI
M:0B$$EUBH&Y!('4+R".HEK*UMT8SP\X^H,<CJ)%4'+IBM<.0C'XX]#UL%0SH
MM&MQNJ#(TM'>L#A,("T*]3^3D8R]\WG.SWAR9[-IM%47X8MCM>5\CMP3<^Z;
M=5[F+:YFL9&[K*LI]>Q[/O3^?>44;Z[\5#;^B F-+2(,HY^><V,B\=L@"VZ]
M=5GA4+VC:[*6DR<WJ/MBER*'E1T+O7^Z5 'MF%-^M)F24'W]($IOQL,2WCP1
MOLN\2=UFDR#<XJ B=9XN?DBF;F^U1Y8!EYQ"=M[D'M1+#!UXU+9_2<7Z0G]/
MU1X#36IP\SYB_BT7"T?\EJFETO#G*"#;$!5^YS$'L13:Q)VX+SXSKPK=[T5E
M5*D/W.:TNIP9X>8^W%VID+M8W3_B[2[UG1POYQB &/-3Z1R:' 2;(EH_2M\$
M+&#"QY')I=Y]WK&5,4..&PL;0L88L:>DJU7*Z7>KG,KB^([="YCR<,FTH@#Z
ML09'3Q^7HTUA'N_KW7''E;-?X\]?*&U+)51 %*V&>WW9JYAC_ <=S=EK/BR%
MWTK-LJL:Q>2JL^/F^1RM&Q-EB=FS6+R/76Y:H=26BAI3:+U!\6D &U]2#$[D
M8=V94L/3]1F?!]U&'2N6Y 5)WI#'N<3M,,>\BP]*&DVK"Y[$Q4#=?/=IO$O;
MON(]Q5S=>34OA[@K("Y5+/8;S;QH-<DI%[Z8BAH@?(@8:J\\>;GRJ>3L35\G
MKCKNV"],TTMAUQ,\-+*\ GH'O3QPQUCO!VDS7O.&9.>S"V(M02#N5*,#U'[]
M4[RAB*21@;:X5E%V1,+*#_Y5#I@,Q94*IE,Q6<?<.(E!Q8@G^+CLA6Z8VI03
M:$_F\UEY49XJ;GM?X"0P&8)V+YW6$I6P2[*.?EF(W['Z/'63L)+B B*O\X\Y
M,[I]LR+(0C!NE[\,%'-&N6FN:JJ=38C2W.2(MA/H!'4&<,[[7JCHG8%;*QL8
M;W(6DM9V830N1^-@>J:?9#1!S_16=$'#4HN"F\O2]#<"E@3/+_@FMU==Z:RI
MK&;O1,\$?(D73*T]4O$G_:U?\\A%ILV#$)F7;;>?\(E6#AT?#_/W(CFTK2IJ
MYHY-FRV<8U8RY+A'5F5>K H*-7F%44JD -RLA:&9*21&\!1[4.B0$ZD_#E1V
M(X%VK#/<JK_"5;%YE,@9NQM=NWDQV%MDA3?I$HC/D<NT,S 17_A _IO\RNLX
M\=-%#/SABFG(D RO-K/N+=-:;H+90'-AXTE&X89.% YM84,*S3:8#M HZS)K
M1T^A9?0,P]:"8G%R9X$1R384 "=,*Z\@)2)87^*XW+%:P18)F,8CZ_2"H%24
M,(HN/VOLRSN['K@9)Y^6*7?F>Q*4F2$S?YYXW1=;H"^-NWYW9GB.%CP+YUM3
MPM7)WCHI'9G8R.*3O"I3MYYGWW<+;F,H+"@FR3[I65GYREL7#A-M_)88'W;P
M?H:IXAT7>PN#ZBK>F;#3;[:MDO=?U;*_K^%)Y^*]BKYD7OS5;U!EX<0<Y%!X
M([@:GL^Z7L_;G<%]AX^ZJ>T?'.QLB3MI2>=1UHP<V49&G*=]8;$[:9^*'[B_
M&3\E\C(YEOB: AAT65N%8W6BI.(OA1G -%CO6T9H9-S7C\\*7;A]6^.9GCFY
MDK"I($7D"%+2J0D)WZ%'JN[BS_EFPNVZ=SW[NZ^.E!<<(G)O?==-3*FL%W8+
MF['O+,5OF?+3.V7IHN1%24]VN$'*J&=# S%# V-0#@>JQR(V'+*G)[!SFW_M
M5>T5GM)C>N3/]G5-1ES,\&[_EN]Q;FW]:;Y4UQT8YPX->ZI);[61TVN8("*_
MH9?04E@>Y;E:Z 6\W1D EB_3S8_-32%T!#F#F_OM M7N9<Y&A)[_8;&V;,X0
M2-CGN5_1/WC?LJE<=3U\.QQ)A;:RZW>Z],%T.5>8U0',>&V&T6)YNT[?IN]^
M5D>-1H]7/ATYZJK.:V@X=VP+*X0U66LDO=A.OO,SR<J?]9GDT)FH\9EY,> @
M'"O?2AY"SN&P?%A3 I3THA_RHX<"4 <KBN'VC_QG:>PK]K^7V\_7'*(R&7TD
M_CSV-O;R+RRL]J3,1\]_D*/?&GS7PD]3N4XSE<!1'37YMGRQWPZQW!;G%"N=
MVU_^QK2P@@0Q$KJ, EB!4)V^OL6#[/CKG]GQ^=^SX\ U3Q+:<VR5Z@+>Z?M'
M]GHQ\[\8GO[9CBQ@05A^5^M09CG3GK;MGC7C'Y[U(]]>2"K]IU.QYF^E^J%+
MU"]WX'TZ*0HK3 &H[H/D:_LGAS@JV#E>1]U)R)&?9I_<0H:X-K6)HF5B?';/
M1L$(SFEK'?T5]I;Q_0*<<^ \J'(JUIY=.B6C\'Q_U'5)]/1]:%<(LWHENX.Z
M>TG_3+4_[%;)Y!!QDF<NZCWPE<,U,5:'KI.BJ=_W-XW(]PH%<_2C!M%:VC8N
M=>C2;=8]C['M>RK[PC'DB_VBA\XNP/BX4ZR%&<=!TBC.Z>V[WP6JF3&8EPHL
M5KW147:"V7?+DA;TN$HD='CF"K.M=NDBSQB4]1>/?KO,$JG87:ZF$FVN&TT@
M$N?RXA->RM95*-M".I%)H-KN35,N=D;A3X W>^W>-L3XN<R0F%(?CFNA&1]"
M(!/A-!KOBN#V3^Y7<:;[&_'N0]?W'0JH?)Z7AN8@1?.SB/L/7:X$/KO+3IPY
M7*R6L<$J3 N"1[Z2],:;'\WZMHFSF^KFL\ZD4KU:LUC?-K>J[2?Y8&F[);HA
MLRCMDWYA_HTN6:1<5 $PCT$K1O[S!AU(0[\3+'+IFIB(F>#\1703DKV]0#K>
MPQ:D\Z!Y>=4YG\%)U.8Q!= C1T<!"/>$?R$N/6!&L!T'CAH*;%PL?)!"?8+@
M2V4V$VMA->J0$@Z"&@5 E^:>;^]Y]V7"W@NFK=L'XC)973KM4 \&?=_WJ;&&
MF*>IKZPZ#R7BH6D[Y_1ZZ9J]R2&'OHM*3/N*[72QMN@V'[U'!4J?]I:I6]7:
M#K+QQF:$7-)^D$]FL*(X2Z C_!I_383?NH?>?M<R:>%'9,K 7(2WA[CE\]UI
M9V/RNQ+0AUB:4_#O3O+"\K7M?ZOX,_8/Q9\"1XTU!I__&QF)?U?0MD@!_#\(
MJQSB8KENC3B9=T6%[2@LSJOX4]2##?!(5/% Y7+S<R+0194,S=:7O_R\^6*P
M^K^L==[7@Q8BV\ N>% !23GL7L]<Z,6 =R,=+0$AY9WDV ;X/#[><=1PJR8"
MXC05N*G$. %_--_"D2B1*>@,,Q*NCXE0:;JPF<^JJ)%G*CI0"HI08K\V0'7C
M#BPW]3-$ 3RK@X/"E]D@J['424U!Y(R-'183$W@-G/ ^ 8S3RE:3$5(:^):^
M;:G&W&G'?:H/K%^PQG&#D53Z^F[D4BUT?3N#M5+A@IZ;A[I(1OHV7M/)CD/[
M<@A=#@BO*/-6[:U=*D](1?1L_%7EM4WN3^E=4O0B=&/W4YTC0U8ON5"?W;A2
MKFXMG90WV!=3DNUFOWT0?M3Y5=>*P1U'A/V("QF]@9<T20;[WR#S[+KOP&+P
M-:?9;EA&J!\'3RGS]""+$(L):GNHX30*X-$Z) D4PGS*($SQ.F)6\D$J:DI.
MMVYB)>X'QGAUVJS1OL+"$S(N281E&&D$2]4M80Z/'C/3:O@:MS\U3)C?,:KU
M*;%L/AJN%>-M=9=JHF]?_=,Y+O#\$G!>QV.XO?P3_'/%-2\&2!75<T&AWJAI
M&D<+9H,D/]D$F]J-LOTIB=L#&D!TG!QP*)R=\*M^?*4X<Y2[L1>&6>0^W2<5
M;"/.D>#:_4#=:YM+8WT;*Y_!IMK&*9DA2&0UM,'KUQ91 .$*E>/<D4T& 88F
MJ$_+CO<+BSZ(X&'O,L0FF2@ +13RG ,,] (!"O7A72;?R:L2KISYYM>] JJ^
M,8-Y*2['EQBMJ6;ZOGL5H>E736]WR7E&X\B"#UU,@@^]D4%!3SV<V?=-6A^8
M=>TP5R>N8=]R:0SZW<2$]G%J":*RG\V9GS,/U"*T3=Y>)^)MCAVC\>AJJ-ZX
MN9"A-KI.G:)JW=_>EOA.F\D=9Q4/CF0T1#1!@I11@(\U!*,0#VW_Z":K4180
M\=$^2-0BN%^$G$J<@(S1C4V88Y@3,FBK)!^-$SEY=FRJ*_ITE90[J*S%H,L/
M7')2<?F:+=>G"Q9K!?VH9$OH^]I0!5:6 +K.)4) BS,KDFFY>G.>:#1]Z\O1
M>[*\-SH?&=P"D&B44=WBH1YJ61D'K6=9J7++$U5!J94O+J&KTE%LT''[S!\L
MD13 U5PQ$BV4D+NI;Z?TQ;H%.&"BL7\XKX[ !?F47W]4NC-/NHM/7&SD0#QT
MGT93[03_>^-_ZL1G7$*_:^75Y \JKH[ZVG8V2G-5A]S073?'X4 !!,!(POM,
ME3!+MX(OIOX2N&ZH1'_[<0O6$4Y+7>74?#TU%FW+I;^6"@FUIMOUM'2W63JN
MB[=*7C\AL'CS;TZ8FO\ASM)!+,')]JB$%4?4%<99X3XF/>LR[K^^6OAP^I N
MQE526PE=$R4SZOG\+)(]?(]1BPK@3MC]78N#FYXQ#[(V"-3J67YGG+^4/QD9
ML)A^]<Q.7Y5@"E\95]Y?K^],C$3LW>.*IS5,FJL(!2\\HT4Q9Z-'%3/)@2A\
M:C3*]T7ZMAPH/,3$X,T5'?<3F]]8 ](@^?HNP:X4 $-6P^(QY _[E:P\#+M+
M2G)1X-S#7$(;[5C?G?T+C>0V(YX=I[MU:VN^K@)[3V!$]J6LM(';2]PXKE .
M"YH'1@,0JXW7GK&M 1B(UF!YZ=-NB&C_\0GH"NZ)QKQ^EXD@3N%BK_[@SWJ&
MOZOJ/'W\0FA@+WM3+:$ ': 9CP.[K*JM WOR';HTORA][O9-]*MCD.KG^X)P
M!Q8*7]T7/D+H'MM!"-'V\Y#!PUW&ONS^H?LQ"IPF?N!BX*+8=Y?M6W35+N.G
M6,[LS<2/4P#E/$ B R@S-3Y-YQ%[!DUGIFWZ/-'K<$L[ZPTROTKUQB),,+5$
M4^1ED>E!D-%:QL@#7_A\]4+8(]J'QDQ7:/')^8;D^F[D'_-L5"*88;W-'"U)
M ;R7"B<>.RCBB\WMPD7@"C^CGJ=1:2T@4^^:IB/+C9^=)M1I89^+PG4UY<Q]
M##9B.^ISQ@ Y >RB .;.VU+/=IX$NH;2$:B(A[I#R&?V@>0G'LCM">2G/*JQ
M'T@3P908+31>OGBU$A($5>/,=GS:_$<8]!\U$C?CCQ?PBG^['I6R4)#RA'2*
MNI7K:PCP$ _-/8&(QIK+L(-]9Y9\*N^$LN%R2]CPT^0Y4%%J\:.WV^K.B4#5
MY\!3(AL;]A*1RZS _OQZPNJ-T$"I\MO :^.,G;9;!44H+32X4RGFO*IR@TKW
MYE<.D&"::U?3M['MKMF2GT_LC!W_@3 [[J^U =*:+(+QF@R]5XU?+-%X%11F
M2>?F?AM51OI,9RG%O06^ G7Y>>?XAZCL23F]<&[OV#F^-T;U)&9*ZU]@QH0:
MG[^J23']<+J[KE11]3CBZY6 '[JRLG.0<ZA/V%L$EK@?(O3+^J+\U4YCUSD/
MD3JFC/5"%+]F:\1KW%9C@F7Y\/Q%]?Y@'$.LAFSF7XWVM*0O1CRLOD/F/58H
MJLPU+U%F^6H6>'<B9$&2B#=64\T\X?S\X<L13E4_J3*!Z=[[1T:O(/.USS<X
M )#^OFY4TAYD,>=0E)HVT+,$+0JQ.MQ1;\*5=FQ/"!/B_;I\OF<S?V RC/7S
MPU3<RX^&K$<(F7HFZN)A35UJ(A%Z:LRJ_^UOSOIO'7D=9Q:0@_*GVCIEHYV;
M*(!11<8UDI!T5/4Y#YAMXDZ' ;E[C2F%0]R4/'_%9RJ;1 '$NF\>E&;Q;4G%
M3K7HZI1Y1_FUSXP H4XP6'DQ=/<!!2"^"4\G&R[KJ4=\BE273A4T//*>N<%/
MKIM0SIZ8B]_6.S??%[X.Q'@BYBPG6CFV%035N^H>_KL@]_^.OQD;V.=5F1A_
M!@S'_;L<T\!E[N0(,F+N/$Q\<$C;7?RS*X^'\D?8"_A(,](?W#L68"OJ7SQ4
MZ2I9XNV;N#7S8.!I\E$Q5U?.*P7S?'=12IJR3"V+RL!Y"X=^DQ]J7SW20)%]
M'=#6Z%W82=XVOC#9QG@C)<:;A3J2-Y^VBT9>T/>'NN_VY0ABS0_B;SU41B?T
M^'^ ).W_Y'&HD:3:I]SQ3B,3-Q UO>+GH4(6V(4EP%PG+4XY5+57*[68ICRS
MO/@U=UMC:C%ZIQ]&NA"_3=K3H "0<22']ERV=J>!B:Q,(7BC'+Q^0D=L#]30
M>;WUA36W8]WM80(K,,B5"'F"X.];'M,/8AGD<"<3I%V'C_377BIMZ'%UUE>/
M$2K-I:Z;:H:WJ?]U8?O_'?_Y.$(9_#=02P,$%     @ *4 %4],0ER;D$P$
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M\X(47!D+M2[_?BWA?%FDY1O(5]+^ZZ]K!?L!>OXCX)L/BYR2%FR(>P'6 E^
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M0@$3Q!-($]=CD7#]T#/*V&DNPM1XMQ$+\$9<E=X6%$I@N]H !H.A9_T-"_'
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M=P#3LS'M81B8GVO!!BG/>ECG/JW$G1Y&M0@/:[=K_1UYRL+2^[*Z['TGFLP
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M!'9[]\?'&W!U=W]W>_G']?WO#^#+Y>V'CY^OK\!/5W=_7'^ ;O+3&6E>3PZ
M'HGU">O Q-6(JC:ZU\)6V%VHW[W/RN>!<KCJ@M0G4YWL<U1VTD5@EY&TW[,)
M@WQ-BXRIL$IIIUT6]3]3*MF-LWO^E2^6_,,RK_T'XD:"QF$"L<HT@GRDKD$A
M%T8H#%W7]SS?UV(CTXZGQDJ-Z%44MA0>X +P1GQ(E/P@KQ4 [QA^TRTS;#P<
M&F[R0" /?337X'LG@)(;7!:@E1Q4HH-&=M */Q#")@&/PR#]XTLE+):JQI7Z
MUM6WK$H;8/"LJD0_<SR7BP7?G@Q]^=D6>';'/AJT-V+8H[F6VQ&/%N_;EBQ0
M'P5G;>F?2RH_S.5<A9E_X"*E:3E#2>1SPA/(B*_*35>7ZZ7G+5@4$Q%A@N/0
MK$S!J2ZGMC"T$J_*D)D6'3B)L9X]VB]R [/]"K15%;%W&_*"1N >R]'KH]-O
M 8&3O8Y<-$ 7A?U" =IOVG'-W2M7G+5XNN&2R.[3I^?R3OQ>\"HD=";B(,8.
MHY)AA">M4 _#&+,8,A'%/$'8#<RR"W?V-C6&60D+YDI:D"MQU=J[+)0=JD)F
MS3BG&VL]NND-P8&99@U>)>@%J$2%F8!26%!)VQ_+:('2)\%T=S@JMVCIODLK
M>B]9N+CJSNF'5%U$)<LJ^V]V)+^)YXO "7$ HX!( T;$TH!!3@(CGP72V?5\
M-W -,OSH]JLU0T;-['-[.)</8!O:&+A<V@.@X='V"NJ(M^DW90:/60_I>[11
M-?!BAT!WK)CO.EM8Y:BF7U/&%ZQ0.YJ9=&+SK2^W4/<>CZ2KDJ[M7-)*;]7Y
M3 'M]&&U&QO/@375;\M[-7[9YJ9/]L+_6NU4R+;;\VCYXY:KW!2+E_:C[WB(
M0%>$""+N,*@*:D./4X?C@".4Z)>3->AX:D:F$AW4LBN>@JWT %;_W-F+.UEJ
M_KQ!T5@3!H)ZX&5A4BB;7!0:!NVQ[@OUB[KAY2%SZ+KO$!FT-^)5(G,MMV\4
M6;QO>P&\2220+M*2WZ1?.9-KCOQ<4C*O_8[B;UPY(IQ=?I7>R1.7_HA8SF]2
MH:Z'B@@%+("Q2Z6W$(<4QE%((/58Z$4^QZ'02A;5AS!36T%:02&N)07X)<O+
M]+^JR:VJ+Z<9,[U@?L90Z6UCC#4  Z\KJWPEM1YPKA0!:TWJC8[B K3*@$8;
M4*L#E#Y]7FP_']5^K[^?(<_(E^3/1V[_*GT/;9Z=4?^&/^'Y R_+>5T+?<80
MBP(A?)@$TNA&PDD@"7P$/9<F1&#A><PH'4)'7U.CRJVTY',E+"C6TEHG=M^#
M6(\#>P)N8(K;PJR2$SQH8'9.!O=C: R4NGVONQ^5L_V8WAW)VH^^8AW1RY:T
MO%*B+\KZ,/L^+?[>>"Z)X\<QY2[$1!6;]!B%6!6)\)Q$T!@+3)A958C.[B;'
M'K6T8$M<H.0U#M[M EF3/'J#;FC^.(I:CQZ?&2H]A_=V]3AVF*^&]@?"?77>
MLB.4QYSC8IF_57'$#\_2N2Q:LVA&A!=3@1!T1"P-$103F/ (01Q+!R\AB >(
MF;!)1U]3HY):.I"OTJ8S\*ZH?J=Y@5$'7STBZ0FU@5FDE;+.!G !:D$O5@DC
M^Z,0#3SZY(^N[D8E#PV]=YE#YQ6K,^37_^ X_Y"]X'0Q\R,1LI QZ 1A!!%W
M0X@#'D"4Q FA7LPIT3\HV&IZ:J0@A0-*.O!G+9_)_O,V9EIGNY9(#'Z VQ<(
M1D>QEF",M)&N#XKIB>D!O4\<BVZ^,>;9YP%)=PXX#SUA9[6T1:VOLA>2+FJ+
MB-/L:9'^%V?73 YX*JK@M*9P0D-ZEPMV(W^=SM-2I;XL"OEM,&E>O?*\?%-)
M5$KYA,K(]JJ^F9F@&"$72X/'I0E$1! 8\\B%C#F<L="/HM H3](H4D^--%>E
MYC>T5ID36[W!IN+-=NPZS;3*J+BA/&BTOP"M_A=5XJ'RHGIR!8*9C3;.UZ1G
M[4WN&QEX.9G6YV%LC(XZ7'V:M>,(/JJ!/.I8[)K:XW9^1HGUYDY74QYL0>=+
M5J6#SI7(EV5]_T@)>NP"TBI/N>-['DDB(K\N5QK^/HD@]GP74H8P\J@(.'*,
M"Z[W)M[4UL%:H[]8E%;O;\3TEJ ?-PX#KS6;BOT+J%6[ "OE0*,=V%1/78\\
M<CUUD$SVPX#?>T7V_B0<OSY[[^@>K-;>?R]VI'^3+9X>>?ZB,GE4.:=?TQ+/
MJ["".S)/GZJEJIA1Z@6()BHIM& 0N2Z77H\;0M<E+))_\OW *)!(K]NID;22
M&LJ.7D"V%O("S)6!2NM,>^"U'D(S(M<<!3V"[A_;@8EW#6N5*JBRVJN(K;6X
M_3&H&3I],J-FSZ,RGAD:NTQF^+890Q5Y.?N,_S/+KY9%F;W(Z7WY/2UFA$1(
M_C^!$6*JM+C*3DU] 843>Y0RABC68J+#S4^-<5KAI#$AI=/<3#V"7#=[G(_'
MT#O+FE!H,T*WQATS7[ZX,>OEOW9G_)&61YG9W5JU,_C$4Y8.9'6$M%E#TY>#
M&I.80NGL"15_S&#L4P8#$0DF5+U8UYO55UP?2IR7FI[@;C\F7^EN;P/N7>%Y
ME4+^7;H 5H?#^WC2*$D<'R$8)%CZU+$@D."$0Q%[H4.HP%[$&CP_+D[$7?:(
M9MO7_U98:GJ[YZ SM,/:'*+K5,(U]S2/*=ZKL[C7R;C^WC$=]URVHP]:A=D5
MKRGE;;1&DWM&Y4ELDG=S]BG+[[-EF2ZX2E8S\R(N8B)\2),00R1$ &,6<ACX
M$2<(41_Y6MEB[+J?FDW4*+!*5[S*(%:E:L6M$M6%U[Q6 Y@FC#8>(HTC^T&!
M'YAJ]C!OLXI5.5M7\@.I &@TJ/*1#8JY42#>@-C_^,1CKUM%O-5O>%4VZ%\*
MT([<@I?KT2MX_E7]LITYY3,N05H R6!5!$R5#GQS[O26$MQV'$[$]IFV.F:$
MGZ7&.W%^MJU8+% WO"@X7^48J;+GW'-UR52Y\V5V?_=[G3Y'?MW+N7I$Z9QO
M/%&]LK%'-HL3ESC413!B)("()A%,/,YA$B)7."(*6*P5M#*0?%-;XM;:J .&
M XF+P$JU9JYNO9#M9#Z:K\\0#0AY@,] 8Y7\L8,[]$YGI9RTV+<'2-UHV!P_
MJ:/6.->CNZ'JCQU=@_7XQX[R2 OV#QMMLS5YN+'H7+0'Z':\57TXS+:6_0&[
ML2SDG;V\9(NZJAS.[_*J("7[ \^7_ O/*S=Y%O(XBGS!H1=)CQ\AC*%<_0GT
M/.S%'%/&?*U:4 9]3FW]KD6NZT1>@%><@Z]*7/!N63!EK-=[6(9;6#K8ZVUJ
M]8SHT!O_-9A-Y(@46*6JJD4&E<Q "EU'E/18,5L?HEX+8VMT.V[]:WT<]LI<
M&[QZ7IC\G?B4+O""2OZ[RHJRF F7<@=S'Q(?2W>#^1AB-Q+0QY@(%*'81484
M=*RCJ?%.=7Z^JEU+E8AV4?%[B.H12Q\X#<PFJWAXZ4^MA 17G5!9!\,?PV&(
M2/B]OGY(&/PQC8_%P!]]WC(=LLI@N'%E5MV=:NJK!IB$!%$$'4>5JDU<%Y+
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M-4'KH,1)AR,:(F.^P3U*,.*/#D/4#T#L+?2P<I'O%FW1@ <54%>^J3("3>F
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M5!KT>S7)'+F^;RP92##Z129S= [=;[)HQ2+PY+-LD58G")7%V=SNQ9@R3*(
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M2;E!*[BA\6@V"+J;&CU#._AVQFE4W\LI\?R"\[_W6+;""J]^-S-T.AYY&\,
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MQ?><\O2KNGRW#H-O3LX>LSJVL5!6YS.?LR_27<[E;Y=/T@15-]AF-" ^(5$
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MO 3B&$70"UT)JBK9(8SJ)AWM:6J\L))U+WMN):Y9P9_C^&K8;GVA-OR% "O
MC&OZG 3C5#V?XPV,6LOGI!Z[=7Q.OV Q^^\6_*_+!9.-?D[G<VEH/O+\Y2;#
MB^:@T<6$8JQ.X2D6$&%'F@6)Y-* < ]S*E"(]!.!GNAL:AS@.@YH! 5*4J!$
M-9CYI[#5F/P](C;P_)>2@D;4?=!L#L1/H6?@G?6(XDA.V<%/K^^C;4U8.OGT
M5!OC4:JF-ENLJON.!;%>\5PE-Y0#P._$+9<]U)\M#JETJ=Q(&J2^ Y%#?9A$
M/((!8QA[7H!\P;4)]4@G4R/2#3'5SI@2U(81CD&JP:,] #4P?PZ,D0%;]H#5
M2"QY +.>J/$$!IV4>.S=\:CPA/1;%'CJ60OJJXS2J\O[CP^7M&R*KN7W?)YR
M\4FR;5$?;<@''>)'/"0.#'$8JO!4%R8D\J' 3A2+,(BB@&ASH6ZO4R/'.C%&
M);BJ.]C6)LQ!+3NHA >M] 94H#T,&OPY!+@#$^J/Q]6 <X? =R02[@EG,WXV
MQ:N3L+4;&X_!3?7;HG3CE^U.$JX7DAYY4;:)_'U,(^''%$8XC%7RE 1B1F*8
M^*%4/_3BQ'',DI_M]*#U\8^:\*P5$'"3\@K' -0[*; !9:QRD@T:IXI-&)\*
M'-&YS]. W2Y&/04XHM_N[O^QQRQLM,^<X7GVE'YO_ /?"6**5*T?Q@A$G >0
MA$):9J[O>PD+0Q;K%Z'=:7QJ%M=*/!L':Q<X#>/I##@&GK&](F%@[IR!R$A6
MC0$R9I;+$=4[#93==\:S0XY(NV5N''O&JG2VG/\+/+]<LK2\REY>YZE*VW[/
MOZ;\6WLBX0=!+%P*8X\AB )!(2$)@S[WHD@DA/B^_I&D1H=38Z]69%#)#-9"
M@UIJFZFL@[L&T?6,YACFR@\ TJC(=:^ CE;8^EQ@36M9:Z-THG[UZ7;&K%FM
MK=5.G6K]]^P<OP_\-><TK;XB^?.<JQ\N%^SR155*^:_ZNW89PV&4$(@C%$'D
MQ0XD"78A9P$* Y:PA&@=')MT.C6JWI2Y*MF'-X0U\Q6U,-=S(/M&<F":WA3W
M JP$KO"\U,'3V-LT :A/%U2KWU']4A,D=IU5HW=M4F)26@5!K ,EOJB&56>Y
MVMU2&2VD:9I2G/,98C2)F1=#K$K9(D$P3 )"H4?]0*#0PZ[!J:M)SU.CI%;V
MS0A!5HM=YW)I!3?)HV@R$AIFY%#X#DQ4*V@W([P:R4$C.O@T!L8F&2H'PGJL
MO)3]86Z8D-("M^XTE"8-CIA\TD+/[923-@V8+0=%7LZ^Y!E;TO(N?^#YUY36
M5^\]GSJ1[P;0C_T$(L)]F @40\*Y)QS&O"!R=%C_6 =3(_=&QLHT:L0T"F4X
M"F0W:?<!S\#<;(&,-A^<4K_#1)2O;IB'\E^[IN'1MD=A@%.:M1/]Y'.6B6/7
M-8!GKA]BQ$4 68)#B!(>P81S#)$K HX3%#.,3(JD;+1M-(M'JY0R7PMHF+EU
M S4]A] 2BX&G[(T& .9)4_=5[34-ZD;SXR8VW==K+U7I@4<LW*[;I=I!NA-7
M<YR^% ]+\I*6)6?OWU1H4LI2G+_-0A\%))0^EG")D%/4]V$<.0'T.$DHCUG(
M*=;VMC0ZG-HZ7(NLKB322FA0M%(#\J;^T<AM8/_KP*[A6O4,YL 4T.!X)T M
M+U@)K)+ /0R%HX'[U#.>(WE-NM]G7W'?!BAU^D@Z[8SG&AEHM>41F;QG65AN
M/K\KGWG>E# OFH,GA"3S.DD$/95""[$H@A@Y/B01BVGDQHQBK>NVW=U,C8PK
M$0TKSAW&3\^:.A^5@5FUD@ZTX@V0F[D;@5Y+UAWN:=P2=IW:[I6TZW[:)M (
MO_X'Q_GCM^SQ.5L6TL-]2+^7G"\>G_-L^?2\\8?';[++M[M%6\D&(X89=3$,
M<$@A\B(')F'B0,8#3"-&O81K[8^<*<?4&$-J I0JP'/<$#3B [4<F03BV ^+
MAATW#M@#$]$*9Y6VMQ47-(JL<-_Z8ZT,4,&F-L%1]F-B$C\URMB,%6)USACU
M%8QU-J#=\5KVS8\8TG4V!MM17^<W9YE^J,F7=B>.54Y\_[;U%W5B,/,I8L1%
M+O2$[T&D4CL3QW6AFP0^)TZ Y')EE)S(1HJI+5.;J>>.5Q>]4"[=]I_K[&FF
MZ8VL!D[/9!Y\. 9>R 8;"?/T2><@V6MR)2M!QDV]= Y6>XF9SFK,)L,V_KML
M;L$^S;,\9;@Q4TB8B!"'JHP\01 Y",$8QPP*GSB"418RIE_P]6 74V/!5L@+
MT(AIDO/X((8:YO?9R Q]=K(+BHVU?!@=D]3.YZ(T5HYF<[0,<RQW =&=+/G@
MFR-F/>Z2?#M]<>>3=L;B5?;RDI;5/LGE@JV3(Z=\H[[V)2FJJE4S@J+ 0TX
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M^1:LD.QU))BU-)W7P$JS/1>!W9L7GK'?RH_9BB@;D2RW0=OEUWR9L9<%\>*
MA G2F4,BB'R"E9&&"21A%$@9^ +%1JGAK'J=&\'O7-17$V0C]\Z5 LNP'S/L
M+0_FAT)T9'XW %,7X]-2@]_:_S]*+*,5<*.<[O=V_#8G_298G#SU-WK9P1"]
M4^_<R@__6F?52W.2]VGU+)HM[OO\D62KA>]Q/PK#!,8\T#M*I#:3/B4P2CR.
MHT3&,N7&5NCY_N;&4%IB/9T:F=LC:K"5&OS6R&V3R=$ =0/S<U@LQPX >!L8
M+>S.8>&<R.B\'%8[D](<I%Y[TJ"9Z8Q)<YWV+$F+U]S,R.--EXN QC+DH0\Y
MY@PBG$J(]:69@ CJ>3@6(K"Z?WNBG[D1\:E/W-) /(6JF4DX %9C;_*M8;(V
M[\Z ,*1!=ZJK24VX,_H>&FWG'G?/O9NOZABL)@SQ=EV5%5GQ;'6_2 )!PU!9
M9G&,8XBX]"#F@80128,X%E[ [.[I]G4V-UYH9 5E$UB8;P4%/Y2U[#_:)](]
M";092PP%W\A4T2+7AF0VDEZ!'5F'38I[#I&A<^">[&_RE+?G-#^6X?;L.VXT
M4A<[VYQ&-L>6B\A+8\_S*<2L#O(F$4RQ^D\8>0E)$ETUUNJVV;%.YD8;3=6]
M;=1'$QYB1Q5'P32CB$LA&ID:&G2VT1*?^M&QYH,^]8?D@:/]3#K_^S0]G/>]
MS[K-]V_B.5\^J]9N"L&SZF.3>>^E33XAI1]ZJ<\A"J0N#)UR2%!$H0R9VF*H
MGP)L%636V]O<&& C+&BD!9VXCBFL^Z$VHX7! !R9'R[ SIHKC# 9DC3Z.YR4
M/8QT/Z01LY<<O,4_Y>53QL3/JE6FS)+VR_9IFB0TTB%'J=I\!(C!-$"!SAE$
M T81XHD1B9SN8F[,T0H).BE=JOD<Q]+ [7LQ0B-3PWC@6#AS+P9I(O^M/5AV
M_MI>''I=M,??G,XKVROYGB.V_TD'FCN2"N37O/A=$VJ3,&D;!KJ()(IC+T"0
M-O&6D;*@?($A"]+(3X2/<6@4;VG;\=PH\5@"'= *OTD!MA7?@@ML1L. /D?"
M>&12G0>\%@0\$LP3T?(QN*]<\+9C:P?0>CG<IKWIF-U!RSV^=WG?817XDJ_^
M(<I*\-H/=[UJ_O\OJZPJ%S()4C])U>:!!8$R>7T"<4P#B!//$T' /#\QC\SM
MZ6AN+*]$A<^UK(V_O;XYV?RTUO):NMS/XFS YP.A-S)_*RE!(V;C;@?7J^ZG
M6M2!\+(@Z(%PFXB0-7Y]'][?!V)@ U1Z&;?O_>D8UD"+/48U>=Z!0;\*-?KJ
MT[@7N7Q]E,91+#P<)Y ':0H15^8S22($@X 3&M @B+EGS*&]7<V-1;?"UH51
MFJ0RN<&QFRW$!O0Y&' C$^@^9FTB'I.C2NO/TIQ"!\-N(A)UQM".0XU@Z671
M_A:FXU$C3?:8U.P-Y\2A[1W3CTK,IN[I6C7;'ACI?*5"YH5HGKLC?XKRPY]5
M050?V8H4+Y\J\5@JJE>:5PJ"97W$I/A.,?^"ISQ(/,EA'"04HB3Q8!JK_W"4
MD(APB84N594KX]KL(&A$6:W8?"/Q>+.JO7Y.:WTV60:T1M8)2T<;7K/#IYD,
MVL@KR7ZZ #WCP595L-6U&]'V^5K=*["O'NCT&S23ZMB#,' "UM'$G3IOZ]BX
M'TGW.GJ7;DN-EFFOL/:[ER]$WY>[E=M?O]3WY6D8!4R$# :4A!"%3*T<0<0@
MI7&<A"%+2&Q5D]:\Z[F9]5KRG5+S+Z"1VRFGK,4 F''[.+".3-6.B%ISKCTX
M0U*H1>^3,J(]*H<$Y]""&U]U+N&;_)$J:M3<J9GPOJ'1]G:OSE99+@(I<9S$
M(221[T$4^Q$D/A)0IF&*HC@686C%5^9=SXVO-H<<.Z)?@1WA02M]G9S5TIJU
M&!$S AL'YZF.[2Z$V)K1[-$:DM$L>I^4T>Q1.60TAQ:<XS;%:BUTCJG[57W&
M]?-Z665/2_%>++-G92#2I;@N"O6U-;7MFRKR08ACS!"'--))!8*80IP2M8]7
M;)<2@H((^Y8!G0YBS(WI6BW CAI7H%,$\JTF8%>5LQ7GAQPX,Q(<?SA&)L21
M1L(EIO0"( <.-G619.HHU O0.A*>>DEKCN7IUK04_UJKYCZHWJLVHE @$8<>
MIM##J0\1"WU(9<353VI'ZV/LD\2*+H_V,C<VW H):BDMZ\D=!=*,OBZ&9V1V
M.D1FA&#V7@@&K>-VM*-I"[7UZ?JJ$EOOPPZGS_7QR[=-J8ZO1:ZLM,<NE#CE
MG@Q)J- C J(HB93%Q"(H4DY%XD72\XTF_MF>9C?YM:Q@*RQHI;4X/^T%UN#(
M>2BXQB:#$TBYQ+/W?XOF)\Y#03?1@;/UQV9WT&R"1N\Y<V\#TQTSF^BQ=\IL
M](*CYU]4FH9N97-W:.?T^OHQ7Z^J!8E83.(80T*(,ID0CB".O 0R/XD]&B(_
M2:RRCYSK<&X$NB,@6#:RZV@*5DMOZ>0_A[6A:W] !,=VZ&\!:^\-[DA[!1IY
M!_3K&R(SJ#?_7)_3^O -$7CEN3=]SXUEOI*7-HEZ6TJJ\ZN)\HNH5*^D?.B*
M3"V8,LR8'U-(DC"$2&"L;#6B]VPD2G2R3 ];5I^SZ=YH]DQ:A6ZW0K&>270C
M_%5=VD*SD:Z 0%H-[$C):FC,"&IPN"<*.6S%UB4E6O' NQVLOS18U]4FKL]A
M;<U=+J -R6-6_4_*:2[('/*;4QL.F]#7%7WW"Q%UA7U?%A&3) RP!S$3RJX*
MJ0^)ER0P2(-$LM@C06Q4?M>NV]E95P?EZ98&Q:HO0=U@NSH*EB-3U[$2X)]6
MKZJ:;40?!5N+?>TH&$]726[=%(W+-JCSW<+KAR473;YINXVP-7R]NV+SUJ;;
M(EMKN+=?MG][H!Q]U^OJ(2^R?RL9, W\E D"&:4ZQY94.V@>^1"'2 0\Y![B
M5D<-/7W-C=3W,_21C9Q#)>C;0=G,(!T(NY%)_%AZ/K"5=,3D?*_A&#4WWTYW
M;YN:[[7>9S/S'7G%E3M6^N9(&TB2E;^_>]$9ANL03QG%$:>Q#ZD748@PX>HG
MM2$.,$4^#CT_#HT*'1OT-3_NV!$5:%E!G?/:):BV#V)3XA@$N-&)PPDS!]XX
MB\:PO'&ZNXEYXZS>KWGC_"O.M\**.DR"+%MR:GBIJHJ,KBL=.G&7U[][IRP=
MWFY\=\,K%B3&@NC$P2E*$40!CY55$NA\@(IWXB3U8F$5$GNY2'-CH>:F?O[4
M^-S<S)8!!LJ,I*:%?XJ=;*,,Z RBUA+:T4>[Z-YGRW65/0OP04K!JLT55TBU
MEJ!5<R^N;-!;6P-A/O#EK$NEFOH.UD H'KEJ-53+CB<>1<Z$X/5-KYI-;ALR
M^?"G*%BFNEPD::H+.P302WBBC#P90>J'BH65]8?3D$3J;S8L?+;'N9%L)W!S
M)S,KRS517TV=(J%)]/&D)K]HI=_^NF5ERU..L\-A>+0Q),ACGV?LX=LL::VX
M8"/O@ <8IM ,>FIQMM-ICRI,,7AU/F'\HNL%S]7]G2@>WPM:7:]XFSBK=H;=
MTF5;Z;:\61>%SOL6!R((*0X@DU&D""GQ(>8T@EAR+X[3Q$^D40DPI][G1E.M
M6. I+^K]E2*BI=('JKX?0;X5W_;"I\V F)'3:#"/3%2?-W!JR>M43\UYQ5;J
M*]"*/>0E4 >TAKT':B/ Q%=!';!Y?1O4I9&AKD\UM1)UN<NZVN4B0CR@@2]A
M$@JA.8W!E!(!8T5V:1P&/&!&*?R,>YP;CQVYBG/I3:=#C,UH:E#D1J:F#K11
MRZ<: S+N/:3#3M_XRM$)#,[?+CKUHN-%(O8@^'HI;N5W<:]WAM]$;0GHW!LR
M+QYK%GOWTOYQ.Q<$\<+4#S@441I"1%BHMW<AE(C[<4QB+GPK&\I1CKFQ4*>&
M-J,.R\WHWS5:U3Z>5A5+P\IUO,RX:X)1&)G1=@>@%1-LE  [6EP!^K)YHKF0
M.0[]78CIH)>H'$69]IK597B]NHAU87,.47(?RBI[U)&S32S-^[5X1]CO=WF7
MTO_3JJZ,=,U8L1;\\S9^9I$@WP_\6$#L:5>9H!2J?2J&41C%,F0B%-@\$;.S
M&',CU8TB@-2:E( KFX4J9;2CO%/'(NC+?8#Z:70ZV$=FT2WB;3B8T@)H-<#=
M%O Z!*\NK-;J CX[A3>ZCX9%2-XDHS)1B%ZGBU[C=CPT]:S8#$[M7N;B4;L;
M]!_43,GU9?1[40+%>T!I"[+5DWI5+X",/&G'Q'^J/]1/+9?@J3UA4G\:*AWU
MQ8/0&^CGWOIT@7\7([ 7"'AY:W:K6UD]%8LO_UP0FM(PD3[TZES7RMR'E 0$
M<IH$L2!I&DNC7-=M>W-;;[Y\^!7\\_;;?YMQ6 =*_]+@H.K('']62^.Y?:#;
MUF(M.Y.U%.SO]_GS?^HGE88^KG^"^J<=,[5K9Y+I>"!T-Z\.?^V6)[[,5V1Y
MLUM3CGHB]#R(*:[S&$F8^H+ &",2RS2*1(QLDL,?M#^W"=1)"&X<"Z8=@=#
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MY\8N.TNWCO^&V0JP1FC+0X#S8!L>!PP*X=@' UOTM+3Z!E4K;^.VRU>@%GG
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MC= 9CXG<Q!:X6%;_.ZIY?WV__5<FK.!W5-;]&GW''W'@HK;"8QM)</O'2K'
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M(3RPMSL3X>'E/::N_U;D*WFGU)VZTQYM82(B"ODH%V7^7=:5!&=<4,Y")F!
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MH!J>+3/#5> ^TN8;UN$^S4!W->Z.^_J*T.*;_I:?S#E)DX.I.CZ"99Q$69I
M@2*N78-00"H)@R*,B* 1)3AP.M1SK)&IB8W!" U(8%!>@2IK6I^S.D<9M=6/
MRW@:7#/<*>JA%*<Y\*L.1]H961%.6WJH AW7]DR/5BW!M0-<'*8DR"B'29I)
M_<FG!.*(4*BBD(929 &+A<M6],[3I[85_6#: +P&UZQ%.F8HVR'/[NON3<G
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M!:;,D0::($AB&<),I!$1"8M39K76T]G*U#[J!F@51] @==SPZB:U^T/W1M7
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MK*)$<B_QK!&*4"7 4,,X0)7,\-.D#9M9:0B0/6NQ 5R>S\$OKN;?OF^R4:)
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M)'$A&V\="I8]V9-AKY6[8>J'N'2I*O0F#MZ;#7L=H&? &,F6TN(T).( :>?
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MF&],,G CA):<1&;+O7!TQ#*6B$C)ZAQ=N4BK<EW:A;K6T'8((.[U.^A;.PU
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M#VD?QU^[L<F9MU%C%"I<+FQ*2QP&H"2Z)*)F)@3YK,-G#QH&'+=<#6=5Y-^
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M/NZ[]5P/[V?7Z!D/NVMMVKX(^T;"9_K,= (7]3A=D\^=0XB>@LF@@,Y1JUE
MR\F4VF)%"$*G9F[)TV_W&P&UI/D]1=:WQN^ >S/34CHC !/349 ?)A/Y85(
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M/0BY@RSU:0_' ]+U0-"_&O&[?OQ\\N7MUY.T&,6@1=++9GJ"Q)S(NX$H%3-
MSK!/%IQIUK#CA44&>2??'M+VEFO?^'CZ!.PD_ZS]/D<V*\MC$,Q+T,2%RA0Q
M07T.;PR&HH1OF,]Z=HE!)M-;P$8[,NT;&2<Y+\NBX&*-]==,Z2AKG81$R4H
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MABN=F9&9Z(]2,N#DN')O'7FLVD/HQ$MY3,A@T;6_UJ<MJF  $*IW8-/+'[C
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M.T\ YS>,C6+6"6.,+&BOR94T@H&WF7%/_)GBLI>A"SP]3U*_M_6=P:DE'0P
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M3],%SM<<%)3D[]&6$+86+8I,![GGEG$$:T"60,:Y4>7*QL_W6R/0(AQ:DN
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M/-W&ZKL)?7#8.879[)J<L9/+Z=5D,5IVSHT>F$VUW#>0D$ 6RX)R"53.!O$
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MV6Q:2_-/X0?]R>)Z9+QWUCE5.QE8XDTBL:4*X_2K@I2SXIW4;VQ#9"/ ^6,
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M]U?NKUBS%>WO+,3!A9-T\GVX;=9I3?0FH65%QT)^4$06?30L8?'*"G)GA6T
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MJ\5\ 9,Z[FZDG>4\J,A"MJYFL@0+'@0CLYM%5(K\RF9S+5]<II\ZXO:QT;)
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M_)?7".OY'<M0+-ENBAHN\%8UB/.S<N]GHU+^?WM7UB1%CJ3?Y[_XK.[C9<R
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M@VOEYT33;=7^K$(6F&V5O%_EOJO+O7?4W;.^,>N[^]G?4$L#!!0    ( "E
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M,#(Q,#8S,"YX<V102P$"% ,4    "  I0 536&I'L#\9  #][   %0
M        @ &&:P( 86UE9"TR,#(Q,#8S,%]C86PN>&UL4$L! A0#%     @
M*4 %4P.J[KNO?P  +%8% !4              ( !^(0" &%M960M,C R,3 V
M,S!?9&5F+GAM;%!+ 0(4 Q0    ( "E !5-Y: /XZ&4  %FG   4
M      "  =H$ P!A;65D+3(P,C$P-C,P7V<Q+FIP9U!+ 0(4 Q0    ( "E
M!5/3$)<FY!,! $TK"P 5              "  ?1J P!A;65D+3(P,C$P-C,P
M7VQA8BYX;6Q02P$"% ,4    "  I0 53\4D;_Z&M   K@0< %0
M    @ $+?P0 86UE9"TR,#(Q,#8S,%]P<F4N>&UL4$L! A0#%     @ *4 %
M4ZWIOEC/!P  9A\  !@              ( !WRP% &%M960M,C R,3,P,#9X
M97AX,S$Q+FAT;5!+ 0(4 Q0    ( "E !5,;U]O5RP<  &4?   8
M      "  >0T!0!A;65D+3(P,C$S,# V>&5X>#,Q,BYH=&U02P$"% ,4
M"  I0 53#';_SLX$   6$   &               @ 'E/ 4 86UE9"TR,#(Q
M,S P-GAE>'@S,C$N:'1M4$L! A0#%     @ *4 %4YFN"%[6!   1Q   !@
M             ( !Z4$% &%M960M,C R,3,P,#9X97AX,S(R+FAT;5!+!08
1    "P + .0"  #U1@4    !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
